<SEC-DOCUMENT>0001213900-21-057373.txt : 20211108
<SEC-HEADER>0001213900-21-057373.hdr.sgml : 20211108
<ACCEPTANCE-DATETIME>20211108165402
ACCESSION NUMBER:		0001213900-21-057373
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		99
CONFORMED PERIOD OF REPORT:	20210930
FILED AS OF DATE:		20211108
DATE AS OF CHANGE:		20211108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Clene Inc.
		CENTRAL INDEX KEY:			0001822791
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39834
		FILM NUMBER:		211388691

	BUSINESS ADDRESS:	
		STREET 1:		6550 SOUTH MILLROCK DRIVE, SUITE G50
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84121
		BUSINESS PHONE:		801-676-9695

	MAIL ADDRESS:	
		STREET 1:		6550 SOUTH MILLROCK DRIVE, SUITE G50
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Chelsea Worldwide Inc.
		DATE OF NAME CHANGE:	20200827
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>f10q0921_cleneinc.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Nov 08 18:21:47 UTC 2021 -->
<html xmlns:clnn="http://www.cleaninccom/20210930" xmlns:compsci="http://compsciresources.com" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:xml="http://www.w3.org/XML/1998/namespace"><head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type" />
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>UNITED STATES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Washington, D.C. 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType">10-Q</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric>&#160;QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the quarterly period ended <b><span style="text-decoration:underline"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate">September
30, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus">2021</ix:nonNumeric></ix:nonNumeric></span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">or</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric>&#160;TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the transition period from _____________ to
_____________</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Commission file number: <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber"><b><span style="text-decoration:underline">01-39834</span></b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName"><b>Clene Inc.</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in its charter)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; width: 49%; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Delaware</b></span></ix:nonNumeric></td> <td style="width: 2%; text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 49%; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityTaxIdentificationNumber"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>85-2828339</b></span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction of <br/>
incorporation or organization)</span></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer<br/>
Identification No.)</span></td></tr> </table><div>
</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center; width: 49%; border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1">6550 South Millrock Drive</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine2">Suite G50</ix:nonNumeric></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown">Salt Lake City</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Utah</ix:nonNumeric></b></p></td> <td style="width: 2%; text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 49%; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>84121</b></span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive offices)</span></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Registrant&#8217;s telephone number, including
area code: <b><ix:nonNumeric contextRef="c0" name="dei:CityAreaCode">(801)</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:LocalPhoneNumber">676-9695</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Former name, former address, and former fiscal
year, if changed since last report.): <b>N/A</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Securities registered pursuant to Section 12(b)
of the Act:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of each class</b></span></td> <td style="width: 2%">&#160;</td> <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading Symbol(s)</b></span></td> <td style="width: 2%">&#160;</td> <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: center"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock, $0.0001 par value</span></ix:nonNumeric></td> <td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CLNN</span></ix:nonNumeric></td> <td>&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <ix:nonNumeric contextRef="c0" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric> Capital Market</span></td></tr> <tr> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants, to acquire one-half of one share of Common Stock for $11.50 per share</span></td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CLNNW</span></td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Nasdaq Capital Market</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days. <ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric>&#160;&#9746;&#160;No&#160;&#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric>&#160;&#9746;&#160;No&#160;&#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221;
and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="white-space: nowrap; width: 25%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer</span></td> <td style="white-space: nowrap; width: 25%; text-align: justify">&#9744;</td> <td style="white-space: nowrap; width: 25%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</span></td> <td style="white-space: nowrap; width: 25%; text-align: justify">&#9744;</td></tr> <tr> <td style="white-space: nowrap; text-align: justify"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer</span></ix:nonNumeric></td> <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td> <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company</span></td> <td style="white-space: nowrap; text-align: justify"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></td></tr> <tr> <td style="white-space: nowrap; text-align: justify">&#160;</td> <td style="white-space: nowrap; text-align: justify">&#160;</td> <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</span></td> <td style="white-space: nowrap; text-align: justify"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntityEmergingGrowthCompany"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes&#160;&#9744;&#160;<ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany">No</ix:nonNumeric>&#160;&#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The number of shares outstanding of the registrant&#8217;s Common Stock
as of November 4, 2021 was <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares">62,203,532</ix:nonFraction>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><div><a id="toc"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>CLENE INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Quarterly Report on Form 10-Q for the Period
Ended September 30, 2021</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 90%; padding-left: 9pt; text-indent: -9pt"><a href="#a_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART I &#8211; FINANCIAL INFORMATION</b></span></a></td>
    <td style="width: 10%; text-align: center">1</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -9pt"><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 1. UNAUDITED FINANCIAL STATEMENTS</span></a></td>
    <td style="text-align: center">2</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.5in; text-indent: -9pt"><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONDENSED CONSOLIDATED BALANCE SHEETS</span></a></td>
    <td style="text-align: center">2</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0.5in; text-indent: -9pt"><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)</span></a></td>
    <td style="text-align: center">3</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.5in; text-indent: -9pt"><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (DEFICIT)</span></a></td>
    <td style="text-align: center">4</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.5in; text-indent: -9pt"><a href="#a_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></a></td>
    <td style="text-align: center">5</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.5in; text-indent: -9pt"><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></a></td>
    <td style="text-align: center">6</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0.25in; text-indent: -9pt"><a href="#a_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></a></td>
    <td style="text-align: center">42</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -9pt"><a href="#a_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></a></td>
    <td style="text-align: center">58</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -9pt"><a href="#a_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 4. CONTROLS AND PROCEDURES</span></a></td>
    <td style="text-align: center">58</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><a href="#a_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART II &#8211; OTHER INFORMATION</b></span></a></td>
    <td style="text-align: center">61</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -9pt"><a href="#a_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 1. LEGAL PROCEEDINGS</span></a></td>
    <td style="text-align: center">61</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -9pt"><a href="#a_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 1A. RISK FACTORS</span></a></td>
    <td style="text-align: center">61</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -9pt"><a href="#a_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></a></td>
    <td style="text-align: center">100</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -9pt"><a href="#a_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 3. DEFAULTS UPON SENIOR SECURITIES</span></a></td>
    <td style="text-align: center">101</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -9pt"><a href="#a_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 4. MINE SAFETY DISCLOSURES</span></a></td>
    <td style="text-align: center">101</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -9pt"><a href="#a_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 5. OTHER INFORMATION</span></a></td>
    <td style="text-align: center">101</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -9pt"><a href="#a_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 6. EXHIBITS</span></a></td>
    <td style="text-align: center">101</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><a href="#a_019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></a></td>
    <td style="text-align: center">102</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>PART I&#8212;FINANCIAL INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Throughout this Quarterly
Report on Form 10-Q (the &#8220;Quarterly Report&#8221;), the &#8220;Company,&#8221; and references to &#8220;we,&#8221; &#8220;us,&#8221;
or similar such references should be understood to be references to the combined company, Clene Inc. When this Quarterly Report references
&#8220;Clene&#8221; and describes the business of Clene, it refers to the business of Clene Nanomedicine, Inc. and its subsidiaries, prior
to the consummation of the business combination (referred to throughout as the &#8220;Reverse Recapitalization&#8221;). Following the
date of the Reverse Recapitalization, references to &#8220;Clene&#8221; should be understood to reference Clene Inc. Given that the business
combination is accounted for as a Reverse Recapitalization, as described in more detail below, and the accounting acquirer is Clene Nanomedicine,
Inc., the post-Reverse Recapitalization financial statements included in this Quarterly Report show the condensed consolidated balances
and transactions of the Company and Clene as well as comparative financial information of Clene (the acquirer for accounting purposes).</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 1. FINANCIAL STATEMENTS&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>CLENE INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>CONDENSED CONSOLIDATED BALANCE SHEETS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(Amounts in thousands, except share and per
share amounts)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; padding-left: 0.25in">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="3" unitRef="usd">60,552</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="3" unitRef="usd">59,275</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" unitRef="usd">68</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" unitRef="usd">21</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in">Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" unitRef="usd">41</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" unitRef="usd">191</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd">4,732</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd">3,502</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 27pt">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd">65,393</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd">62,989</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" unitRef="usd">58</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-0">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd">3,340</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd">1,029</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Property and equipment, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">4,246</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">4,225</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">TOTAL ASSETS</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd">73,037</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd">68,243</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" unitRef="usd">1,023</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" unitRef="usd">1,124</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in">Accrued liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitRef="usd">3,117</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitRef="usd">3,960</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Income tax payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrent" scale="3" unitRef="usd">164</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrent" scale="3" unitRef="usd">164</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in">Deferred revenue from related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueCurrent" scale="3" unitRef="usd">112</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueCurrent" scale="3" unitRef="usd">112</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Operating lease obligations, current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd">262</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd">194</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in">Finance lease obligations, current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" unitRef="usd">153</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" unitRef="usd">190</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Clene Nanomedicine contingent earn-out, current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="3" unitRef="usd">5,924</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 27pt">Total current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd">4,831</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd">11,668</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease obligations, net of current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd">4,068</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd">1,785</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Finance lease obligations, net of current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" unitRef="usd">125</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" unitRef="usd">205</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Convertible notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleLongTermNotesPayable" scale="3" unitRef="usd">4,559</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermNotesPayable" scale="3" unitRef="usd">14,613</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermNotesPayable" scale="3" unitRef="usd">1,949</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred income tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" unitRef="usd">68</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" unitRef="usd">260</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="clnn:WarrantLiabilityNoncurrent" scale="3" unitRef="usd">910</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Clene Nanomedicine contingent earn-out, net of current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" unitRef="usd">33,981</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" unitRef="usd">46,129</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Initial Shareholders contingent earn-out</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="clnn:InitialShareholdersContingentEarnout" scale="3" unitRef="usd">4,196</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="clnn:InitialShareholdersContingentEarnout" scale="3" unitRef="usd">5,906</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">TOTAL LIABILITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd">67,351</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd">67,902</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Commitments and contingencies (Note 13)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-5">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stockholders&#8217; equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 0.25in">Common stock, $<ix:nonFraction contextRef="c2" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c3" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.0001</ix:nonFraction></ix:nonFraction> par value: <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">150,000,000</ix:nonFraction> and <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">100,000,000</ix:nonFraction> shares authorized at September 30, 2021 and December 31, 2020, respectively; <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">62,177,020</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">59,526,171</ix:nonFraction></ix:nonFraction> shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd">6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd">6</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 0.25in">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd">173,203</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd">153,571</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 0.25in">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd">167,724</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd">153,561</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 0.25in">Accumulated other comprehensive income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" unitRef="usd">201</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" unitRef="usd">325</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">TOTAL STOCKHOLDERS&#8217; EQUITY</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">5,686</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">341</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd">73,037</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd">68,243</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><i>See accompanying notes to the condensed consolidated
financial statements.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><i>&#160;</i></p><div>


</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>CLENE INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE
INCOME (LOSS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(Amounts in thousands, except share and per
share amounts)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>



</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Revenue:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Product revenue</td><td>&#160;</td>
    <td style="text-align: right">$</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd">63</ix:nonFraction></td><td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">$</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd">81</ix:nonFraction></td><td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">$</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd">400</ix:nonFraction></td><td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">$</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd">160</ix:nonFraction></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 52%; text-align: left; padding-bottom: 1.5pt">Royalty revenue</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd">47</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd">17</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd">124</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd">17</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd">110</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd">98</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd">524</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd">177</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cost of revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" unitRef="usd">14</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-6">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" unitRef="usd">812</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" unitRef="usd">58</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">6,146</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">3,994</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">18,893</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">10,750</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">4,400</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">1,795</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">16,739</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">3,623</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd">10,560</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd">5,789</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd">36,444</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd">14,431</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">10,450</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">5,691</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">35,920</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">14,254</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other income (expense), net:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest income (expense)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="clnn:InterestIncomeexpense" scale="3" sign="-" unitRef="usd">80</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="clnn:InterestIncomeexpense" scale="3" unitRef="usd">367</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="clnn:InterestIncomeexpense" scale="3" unitRef="usd">497</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="clnn:InterestIncomeexpense" scale="3" unitRef="usd">608</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Gain on extinguishment of notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="clnn:GainOnExtinguishmentOfNotesPayable" scale="3" sign="-" unitRef="usd">647</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-9">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss on extinguishment of convertible notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="clnn:LossOnExtinguishmentOfConvertibleNotesPayable" scale="3" unitRef="usd">540</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-11">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="clnn:LossOnExtinguishmentOfConvertibleNotesPayable" scale="3" unitRef="usd">540</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Gain on termination of lease</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-12">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-13">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-14">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnContractTermination" scale="3" unitRef="usd">51</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value of preferred stock warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-15">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="clnn:ChangeInFairValueOfPreferredStockWarrantLiability" scale="3" sign="-" unitRef="usd">5,071</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-16">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="clnn:ChangeInFairValueOfPreferredStockWarrantLiability" scale="3" sign="-" unitRef="usd">7,378</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Change in fair value of derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="clnn:ChangeInFairValueOfDerivativeLiability" scale="3" unitRef="usd">15</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="clnn:ChangeInFairValueOfDerivativeLiability" scale="3" unitRef="usd">29</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value of Clene Nanomedicine contingent earn-out</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="clnn:ChangeInFairValueOfContingentEarnout" scale="3" unitRef="usd">35,042</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="clnn:ChangeInFairValueOfContingentEarnout" scale="3" unitRef="usd">18,072</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Change in fair value of Initial Shareholders contingent earn-out</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="clnn:ChangeInFairValueOfInitialShareholdersContingentEarnout" scale="3" unitRef="usd">3,439</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="clnn:ChangeInFairValueOfInitialShareholdersContingentEarnout" scale="3" unitRef="usd">1,710</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-22">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value of common stock warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="clnn:ChangeInFairValueOfCommonStockWarrantLiability" scale="3" unitRef="usd">414</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-23">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="clnn:ChangeInFairValueOfCommonStockWarrantLiability" scale="3" unitRef="usd">547</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-24">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Australia research and development credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="clnn:AustraliaResearchAndDevelopmentCredit" scale="3" sign="-" unitRef="usd">364</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="clnn:AustraliaResearchAndDevelopmentCredit" scale="3" sign="-" unitRef="usd">1,343</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="clnn:AustraliaResearchAndDevelopmentCredit" scale="3" sign="-" unitRef="usd">1,078</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="clnn:AustraliaResearchAndDevelopmentCredit" scale="3" sign="-" unitRef="usd">2,611</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other income (expense), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" sign="-" unitRef="usd">14</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" unitRef="usd">16</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" sign="-" unitRef="usd">13</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" unitRef="usd">34</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total other income (expense), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd">39,325</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" sign="-" unitRef="usd">4,604</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd">21,544</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" sign="-" unitRef="usd">5,801</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net income (loss) before income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" unitRef="usd">28,875</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd">10,295</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd">14,376</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd">20,055</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Income tax benefit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" sign="-" unitRef="usd">69</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" sign="-" unitRef="usd">213</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net income (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" unitRef="usd">28,944</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">10,295</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">14,163</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">20,055</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other comprehensive income (loss):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign currency translation adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" sign="-" unitRef="usd">87</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" unitRef="usd">2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" sign="-" unitRef="usd">124</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" unitRef="usd">18</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total other comprehensive income (loss)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="3" unitRef="usd">87</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="3" sign="-" unitRef="usd">2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="3" unitRef="usd">124</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="3" sign="-" unitRef="usd">18</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Comprehensive income (loss)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" unitRef="usd">28,857</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" sign="-" unitRef="usd">10,293</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" sign="-" unitRef="usd">14,287</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" sign="-" unitRef="usd">20,037</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net income (loss) per common share attributable to common shareholders (Note 19)<sup>(1)</sup>:</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Basic </td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="2" format="ixt:num-dot-decimal" id="ix_0_fact" name="us-gaap:EarningsPerShareBasic" scale="0" unitRef="usdPershares">0.47</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c13" decimals="2" format="ixt:num-dot-decimal" id="ix_1_fact" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">0.59</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" id="ix_2_fact" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">0.23</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="2" format="ixt:num-dot-decimal" id="ix_3_fact" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">1.16</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Diluted </td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="2" format="ixt:num-dot-decimal" id="ix_4_fact" name="us-gaap:EarningsPerShareDiluted" scale="0" unitRef="usdPershares">0.42</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c13" decimals="2" format="ixt:num-dot-decimal" id="ix_5_fact" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares">0.59</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" id="ix_6_fact" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares">0.23</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="2" format="ixt:num-dot-decimal" id="ix_7_fact" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares">1.16</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average number of common shares outstanding<sup>(1)</sup>:&#160;</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Basic</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="INF" format="ixt:num-dot-decimal" id="ix_8_fact" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">62,071,754</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="INF" format="ixt:num-dot-decimal" id="ix_9_fact" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">17,358,159</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" id="ix_10_fact" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">61,307,699</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="INF" format="ixt:num-dot-decimal" id="ix_11_fact" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">17,358,159</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><ix:nonFraction contextRef="c12" decimals="INF" format="ixt:num-dot-decimal" id="ix_12_fact" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares">70,038,634</ix:nonFraction></p></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c13" decimals="INF" format="ixt:num-dot-decimal" id="ix_13_fact" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares">17,358,159</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" id="ix_14_fact" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares">61,307,699</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c14" decimals="INF" format="ixt:num-dot-decimal" id="ix_15_fact" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares">17,358,159</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><ix:footnote id="ix_0_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retroactively restated for the three and nine months ended September 30, 2020 for the Reverse Recapitalization as described in Note 3</span></ix:footnote></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>See accompanying notes to the condensed consolidated
financial statements.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>


</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>CLENE INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY
(DEFICIT)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(Amounts in thousands, except share and per
share amounts)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">Redeemable</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">Accumulated</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">Total</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">Convertible</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">Additional</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">Other</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">Stockholders&#8217;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 8pt">Preferred
    Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 8pt">Common
    Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">Paid-In</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">Accumulated</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">Comprehensive</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">Equity</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 8pt">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 8pt">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 8pt">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 8pt">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 8pt">Capital</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 8pt">Deficit</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 8pt">Income</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 8pt">(Deficit)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; font-weight: bold; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 8pt">Balances at December
    31, 2020</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 5%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-27"><span style="font-size: 8pt">-</span></div></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-28"><span style="font-size: 8pt">-</span></div></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c16" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">59,526,171</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">6</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">153,571</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">153,561</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">)</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">325</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">341</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="font-size: 8pt">Exercise of stock options</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-29"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-30"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c21" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares">48,211</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-31"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd">50</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-32"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-33"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd">50</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 8pt">Stock-based compensation expense</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-34"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-35"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd">3,265</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd">3,265</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 8pt">Foreign currency translation adjustment</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-38"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-39"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="clnn:ForeignCurrencyTranslationAdjustment" scale="3" unitRef="usd">24</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="clnn:ForeignCurrencyTranslationAdjustment" scale="3" unitRef="usd">24</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 8pt">Net loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-42"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-43"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-44"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c23" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd">39,756</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-45"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd">39,756</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 8pt">Balances at
    March 31, 2021</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-46"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-47"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c27" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">59,574,382</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">6</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">156,886</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">193,317</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">349</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">36,076</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 8pt">Issuance of common stock upon the
    private offering</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-49"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c33" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">960,540</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-50"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">9,250</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-51"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-52"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">9,250</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="font-size: 8pt">Exercise of stock options</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-53"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c33" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares">124,680</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-55"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd">58</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd">58</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 8pt">Issuance of common stock upon vesting
    of restricted stock awards</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c33" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares">21,989</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-62"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-63"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-64"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 8pt">Stock-based compensation expense</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-65"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-66"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd">4,255</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-67"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-68"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd">4,255</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 8pt">Foreign currency translation adjustment</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-69"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-70"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-71"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-72"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="clnn:ForeignCurrencyTranslationAdjustment" scale="3" sign="-" unitRef="usd">61</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="clnn:ForeignCurrencyTranslationAdjustment" scale="3" sign="-" unitRef="usd">61</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 8pt">Net loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-73"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-74"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-75"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd">3,351</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-76"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd">3,351</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 8pt">Balances at
    June 30, 2021</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-77"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-78"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c39" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">60,681,591</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">6</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">170,449</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c41" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">196,668</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c42" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">288</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">25,925</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="font-size: 8pt">Exercise of stock options</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-79"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-80"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c45" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares">236,976</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-81"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd">319</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-82"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-83"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd">319</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="font-size: 8pt">Exercise of warrants</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-84"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-85"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c45" decimals="INF" format="ixt:num-dot-decimal" name="clnn:StockIssueDuringPeriodSharesExerciseOfWarrants" scale="0" unitRef="shares">1,002,250</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-86"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="clnn:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="3" unitRef="usd">10</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-87"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-88"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="clnn:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="3" unitRef="usd">10</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="font-size: 8pt">Exercise of underwriter&#8217;s option</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-89"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-90"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c45" decimals="INF" format="ixt:num-dot-decimal" name="clnn:StockIssuedDuringPeriodExerciseOfUnderwritersOptioninShares" scale="0" unitRef="shares">54,083</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-91"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-92"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 8pt">Stock-based compensation expense</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-96"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-97"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd">2,425</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-98"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-99"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd">2,425</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 8pt">Issuance of common stock upon vesting
    of restricted stock awards</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-100"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-101"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c45" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares">202,120</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-102"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-104"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-105"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-106"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 8pt">Foreign currency translation adjustment</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-107"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-108"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-109"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-110"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="clnn:ForeignCurrencyTranslationAdjustment" scale="3" sign="-" unitRef="usd">87</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="clnn:ForeignCurrencyTranslationAdjustment" scale="3" sign="-" unitRef="usd">87</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 8pt">Net income</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-111"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-112"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-113"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c47" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" unitRef="usd">28,944</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-114"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" unitRef="usd">28,944</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 8pt">Balances at
    September 30, 2021</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-115"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c50" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">62,177,020</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">6</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c51" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">173,203</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">167,724</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">201</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">5,686</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Balances
    at December 31, 2019<sup>(1)</sup></b></span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c54" decimals="INF" format="ixt:num-dot-decimal" id="ix_16_fact" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">27,499,837</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c54" decimals="-3" format="ixt:num-dot-decimal" id="ix_17_fact" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">72,661</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c55" decimals="INF" format="ixt:num-dot-decimal" id="ix_18_fact" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">17,357,505</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" id="ix_19_fact" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">2</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" id="ix_20_fact" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">1,754</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" id="ix_21_fact" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">69,571</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" id="ix_22_fact" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">41</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" id="ix_23_fact" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">67,774</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 8pt">Stock-based compensation expense</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-116"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-117"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd">171</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-118"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-119"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c65" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd">171</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 8pt">Foreign currency translation adjustment</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-120"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-121"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-122"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-123"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="clnn:ForeignCurrencyTranslationAdjustment" scale="3" unitRef="usd">6</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c65" decimals="-3" format="ixt:num-dot-decimal" name="clnn:ForeignCurrencyTranslationAdjustment" scale="3" unitRef="usd">6</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 8pt">Net loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-124"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-125"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-126"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c63" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd">3,941</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-127"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c65" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd">3,941</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Balances
    at March 31, 2020<sup>(1)</sup></b></span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c66" decimals="INF" format="ixt:num-dot-decimal" id="ix_24_fact" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">27,499,837</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c66" decimals="-3" format="ixt:num-dot-decimal" id="ix_25_fact" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">72,661</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c67" decimals="INF" format="ixt:num-dot-decimal" id="ix_26_fact" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">17,357,505</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c67" decimals="-3" format="ixt:num-dot-decimal" id="ix_27_fact" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">2</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c68" decimals="-3" format="ixt:num-dot-decimal" id="ix_28_fact" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">1,925</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" id="ix_29_fact" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">73,512</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c70" decimals="-3" format="ixt:num-dot-decimal" id="ix_30_fact" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">47</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" id="ix_31_fact" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">71,538</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 8pt">Stock-based compensation expense</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-128"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-129"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c74" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd">174</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-130"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-131"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c77" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd">174</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 8pt">Foreign currency translation adjustment</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-132"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-133"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-134"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-135"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c76" decimals="-3" format="ixt:num-dot-decimal" name="clnn:ForeignCurrencyTranslationAdjustment" scale="3" unitRef="usd">10</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c77" decimals="-3" format="ixt:num-dot-decimal" name="clnn:ForeignCurrencyTranslationAdjustment" scale="3" unitRef="usd">10</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 8pt">Net loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-136"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-137"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-138"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c75" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd">5,819</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-139"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c77" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd">5,819</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Balances
    at June 30, 2020<sup>(1)</sup></b></span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c78" decimals="INF" format="ixt:num-dot-decimal" id="ix_32_fact" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">27,499,837</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c78" decimals="-3" format="ixt:num-dot-decimal" id="ix_33_fact" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">72,661</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c79" decimals="INF" format="ixt:num-dot-decimal" id="ix_34_fact" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">17,357,505</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c79" decimals="-3" format="ixt:num-dot-decimal" id="ix_35_fact" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">2</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c80" decimals="-3" format="ixt:num-dot-decimal" id="ix_36_fact" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">2,099</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c81" decimals="-3" format="ixt:num-dot-decimal" id="ix_37_fact" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">79,331</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c82" decimals="-3" format="ixt:num-dot-decimal" id="ix_38_fact" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">57</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c83" decimals="-3" format="ixt:num-dot-decimal" id="ix_39_fact" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">77,173</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance of Series D Preferred Stock, net of issuance costs of $<ix:nonFraction contextRef="c13" decimals="-2" format="ixt:num-dot-decimal" name="clnn:NetOfIssuanceCosts" scale="3" unitRef="usd">1.3</ix:nonFraction> million<b><sup>(1)</sup></b></span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c84" decimals="INF" format="ixt:num-dot-decimal" id="ix_40_fact" name="clnn:StockIssuedDuringPeriodSharesSeriesDPreferredStock" scale="0" unitRef="shares">7,896,922</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c84" decimals="-3" format="ixt:num-dot-decimal" id="ix_41_fact" name="clnn:StockIssuedDuringPeriodOfSeriesDPreferredStock" scale="3" unitRef="usd">35,051</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-140"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-141"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-142"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-143"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-144"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-145"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance
    of Series D Preferred Stock in connection with the extinguishment of convertible promissory notes<b><sup>(1)</sup></b></span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c84" decimals="INF" format="ixt:num-dot-decimal" id="ix_42_fact" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="0" unitRef="shares">1,497,135</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c84" decimals="-3" format="ixt:num-dot-decimal" id="ix_43_fact" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="3" unitRef="usd">6,891</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-146"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-147"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-148"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-149"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-150"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-151"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Exercise
    of stock options<b><sup>(1)</sup></b></span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-152"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-153"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c85" decimals="INF" format="ixt:num-dot-decimal" id="ix_44_fact" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares">2,663</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-154"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c86" decimals="-3" format="ixt:num-dot-decimal" id="ix_45_fact" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd">2</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-155"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-156"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" id="ix_46_fact" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd">2</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 8pt">Stock-based compensation expense</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-157"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-158"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c86" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd">209</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-159"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-160"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd">209</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 8pt">Foreign currency translation adjustment</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-161"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-162"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-163"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-164"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c88" decimals="-3" format="ixt:num-dot-decimal" name="clnn:ForeignCurrencyTranslationAdjustment" scale="3" unitRef="usd">2</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="clnn:ForeignCurrencyTranslationAdjustment" scale="3" unitRef="usd">2</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 8pt">Net loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-165"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-166"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-167"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c87" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd">10,295</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-168"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd">10,295</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Balances
    at September 30, 2020<sup>(1)</sup></b></span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c89" decimals="INF" format="ixt:num-dot-decimal" id="ix_47_fact" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">36,893,894</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c89" decimals="-3" format="ixt:num-dot-decimal" id="ix_48_fact" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">114,603</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c90" decimals="INF" format="ixt:num-dot-decimal" id="ix_49_fact" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">17,360,168</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c90" decimals="-3" format="ixt:num-dot-decimal" id="ix_50_fact" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">2</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c91" decimals="-3" format="ixt:num-dot-decimal" id="ix_51_fact" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">2,310</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c92" decimals="-3" format="ixt:num-dot-decimal" id="ix_52_fact" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">89,626</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c93" decimals="-3" format="ixt:num-dot-decimal" id="ix_53_fact" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">59</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c94" decimals="-3" format="ixt:num-dot-decimal" id="ix_54_fact" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">87,255</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><ix:footnote id="ix_1_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retroactively restated for the Reverse Recapitalization as described in Note 3</span></ix:footnote></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><i>See accompanying notes to the condensed consolidated
financial statements.</i></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><i>&#160;</i></p><div>


</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>CLENE INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(Amounts in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Nine Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cash flows from operating activities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">14,163</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">20,055</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSoldDepreciation" scale="3" unitRef="usd">734</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSoldDepreciation" scale="3" unitRef="usd">696</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in">Non-cash lease expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashExpense" scale="3" unitRef="usd">81</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashExpense" scale="3" unitRef="usd">87</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Change in fair value of preferred stock warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" unitRef="usd">7,378</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in">Change in fair value of Clene Nanomedicine contingent earn-out</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="clnn:ChangeInFairValueOfCleneNanomedicineContingentEarnouts" scale="3" unitRef="usd">18,072</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-170">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Change in fair value of Initial Shareholders contingent earn-out</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="clnn:ChangesInFairValueOfInitialShareholdersContingentEarnout" scale="3" unitRef="usd">1,710</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-171">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in">Change in fair value of derivative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-172">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="3" unitRef="usd">29</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Change in fair value of common stock warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="clnn:ChangeInFairValueOfCommonStockWarrantLiabilitys" scale="3" unitRef="usd">547</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-173">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in">Gain on termination of lease</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-174">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnTerminationOfLease" scale="3" unitRef="usd">51</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd">9,945</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd">554</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in">Gain on extinguishment of notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" unitRef="usd">647</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-175">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Loss on extinguishment of convertible notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-176">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" scale="3" sign="-" unitRef="usd">540</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in">Accretion of debt discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-177">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" unitRef="usd">179</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Increase (decrease) in interest accrued on notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="clnn:IncreaseInInterestAccruedOnNotesPayable" scale="3" sign="-" unitRef="usd">134</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="clnn:IncreaseInInterestAccruedOnNotesPayable" scale="3" unitRef="usd">399</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 27pt">Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" sign="-" unitRef="usd">150</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" unitRef="usd">32</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 27pt">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" unitRef="usd">48</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" unitRef="usd">21</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 27pt">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" unitRef="usd">1,230</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" unitRef="usd">2,112</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 27pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" unitRef="usd">446</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" sign="-" unitRef="usd">242</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 27pt">Accrued liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" unitRef="usd">511</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" sign="-" unitRef="usd">335</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 27pt">Payable to related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-178">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDueToRelatedParties" scale="3" sign="-" unitRef="usd">131</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 27pt">Deferred revenue from related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-179">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" unitRef="usd">112</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 27pt">Deferred income tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="3" unitRef="usd">192</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-180">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 27pt">Operating lease obligations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" sign="-" unitRef="usd">142</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" sign="-" unitRef="usd">58</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in">Net cash used in operating activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd">25,018</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd">13,121</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Cash flows from investing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Purchases of property and equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd">661</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd">269</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in">Net cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd">661</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd">269</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Proceeds from exercise of stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" unitRef="usd">427</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" unitRef="usd">2</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Proceeds from issuance of convertible notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-181">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" unitRef="usd">6,125</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Proceeds from warrants exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" unitRef="usd">10</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-182">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Payments of finance lease obligations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" unitRef="usd">117</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" unitRef="usd">156</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Proceeds from the private placement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="3" unitRef="usd">9,250</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-183">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Proceeds from the issuance of notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromOtherDebt" scale="3" unitRef="usd">20,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromOtherDebt" scale="3" unitRef="usd">652</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Payments of debt issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" unitRef="usd">534</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-184">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Payments of notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfNotesPayable" scale="3" unitRef="usd">5</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-185">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Payments of deferred transaction costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfFinancingCosts" scale="3" unitRef="usd">1,901</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfFinancingCosts" scale="3" unitRef="usd">310</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Proceeds from issuance of Series D Preferred Stock, net of issuance costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-186">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="3" unitRef="usd">35,051</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Net cash provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd">27,130</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd">41,364</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Effect of foreign exchange rate changes on cash</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="3" sign="-" unitRef="usd">116</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="3" unitRef="usd">19</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net increase in cash and restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" unitRef="usd">1,335</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" unitRef="usd">27,993</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash and restricted cash &#8211; beginning of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd">59,275</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd">8,788</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Cash and restricted cash &#8211; end of period</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd">60,610</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c94" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd">36,781</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Reconciliation of cash and restricted cash to the condensed consolidated balance sheets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Cash</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="3" unitRef="usd">60,552</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c94" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="3" unitRef="usd">36,781</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Restricted cash</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCash" scale="3" unitRef="usd">58</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-187">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.25in">Cash and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">60,610</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c94" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">36,781</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Supplemental disclosure of non-cash investing and financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Warrant liability recorded at issuance of notes payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="clnn:WarrantLiabilityRecordedAtIssuanceOfNotesPayable" scale="3" unitRef="usd">1,457</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-188">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Lease liability arising from obtaining right-of-use assets, leasehold improvements, and lease incentives</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" unitRef="usd">2,492</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" unitRef="usd">820</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Lease liability settled through termination of lease</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-189">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="clnn:LeaseLiabilitySettledThroughTerminationOfLease" scale="3" unitRef="usd">349</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Issuance of derivative instrument related to convertible notes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-190">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="3" unitRef="usd">705</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Issuance of Series D Preferred Stock upon extinguishment of convertible promissory notes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-191">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="clnn:IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes" scale="3" unitRef="usd">5,675</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Extinguishment of derivative liability in connection with extinguishment of convertible promissory notes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-192">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="clnn:ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN" scale="3" unitRef="usd">676</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Deferred offering costs in accrued liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-193">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="clnn:DeferredOfferingCostsInAccruedLiabilities" scale="3" unitRef="usd">2,011</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Supplemental disclosure:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Cash paid for interest expense</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="clnn:CashPaidForInterestExpense" scale="3" unitRef="usd">631</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="clnn:CashPaidForInterestExpense" scale="3" unitRef="usd">30</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><i>See accompanying notes to the condensed consolidated
financial statements.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><i>&#160;</i></p><div>


</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>CLENE INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_1" escape="true" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. Nature of the Business</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_2" id="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clene Inc. (formerly Chelsea
Worldwide Inc.) (the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or similar such references) is a clinical-stage pharmaceutical
company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. We have developed
an electro-crystal-chemistry drug development platform which enables production of concentrated, stable, highly active, clean-surfaced
nanocrystal suspensions. We have multiple drug assets currently in development for applications in neurology, infectious disease, and
oncology. Our efforts are currently focused on addressing the high unmet medical needs in two areas: first, those related to central nervous
system disorders including Multiple Sclerosis (&#8220;MS&#8221;), Parkinson&#8217;s Disease (&#8220;PD&#8221;) and Amyotrophic Lateral
Sclerosis (&#8220;ALS&#8221;); and second, those related to COVID-19, a highly infectious viral respiratory disease with serious and sometimes
fatal co-morbidities. Our patented electro-crystal-chemistry manufacturing platform further enables us to develop very low concentration
dietary supplements to advance the health and well-being of broad populations. These dietary supplements can vary greatly and include
nanocrystals of varying composition, shapes and sizes as well as ionic solutions with diverse metallic constituents. Dietary supplements
are marketed and distributed through our wholly owned subsidiary, dOrbital, Inc. (&#8220;dOrbital&#8221;), or through an exclusive license
with 4Life Research LLC (&#8220;4Life&#8221;), a related party (see Note 20).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_3" id="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying condensed
consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Clene Nanomedicine, Inc. (&#8220;Clene
Nanomedicine&#8221;), a subsidiary incorporated in Delaware, Clene Australia Pty Ltd (&#8220;Clene Australia&#8221;), a subsidiary incorporated
in Australia, and dOrbital, Inc., a subsidiary incorporated in Delaware, after elimination of all intercompany accounts and transactions.
The wholly-owned subsidiary, Clene Netherlands B.V. (&#8220;Clene Netherlands&#8221;) was established on April 21, 2021 and has no financial
positions or operations to date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_4" id="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Registration Statements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_5" id="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 16, 2021, we filed
a registration statement on Form S-1 (file number 333-253173) to register <ix:nonFraction contextRef="c95" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares">4,541,481</ix:nonFraction> shares of Clene Inc. common stock (&#8220;Common Stock&#8221;)
underlying outstanding warrants that we have previously issued, among which <ix:nonFraction contextRef="c96" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares">2,517,500</ix:nonFraction> warrants (the &#8220;Public Warrants&#8221;) and
<ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares">904,231</ix:nonFraction> warrants (the &#8220;Kensington Warrants&#8221;) were originally issued by Tottenham Acquisition I Limited (&#8220;Tottenham&#8221;)
and Clene Nanomedicine, respectively, prior to the closing of the Reverse Recapitalization, and <ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares">2,239,500</ix:nonFraction> warrants (the &#8220;December
2020 PIPE Warrants&#8221;) were issued as part of a private placement (the &#8220;December 2020 PIPE&#8221;) in connection with the closing
of the Reverse Recapitalization. We will receive aggregate proceeds of $<ix:nonFraction contextRef="c99" decimals="-5" format="ixt:num-dot-decimal" name="clnn:AggregateFutureProceedsWarrantsExercised" scale="6" unitRef="usd">30.7</ix:nonFraction> million if all of these warrants are exercised. On April
19, 2021, the registration statement was declared effective by the Securities and Exchange Commission (the &#8220;SEC&#8221;). In connection
with the registration statement on Form S-1, we incurred $<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="clnn:OfferingCost" scale="0" unitRef="usd">0</ix:nonFraction> and $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="clnn:OfferingCost" scale="3" unitRef="usd">27</ix:nonFraction> thousand of certain offering costs during the three and nine months
ended September 30, 2021, respectively, recognized as an expense within general and administrative expenses in the condensed consolidated
statement of operations and comprehensive income (loss) during the three and nine months ended September 30, 2021. As of September 30,
2021, the Company received aggregate proceeds of $<ix:nonFraction contextRef="c2" decimals="-2" format="ixt:num-dot-decimal" name="clnn:AggregateProceedsReceived" scale="3" unitRef="usd">10.0</ix:nonFraction> thousand from the exercise of certain warrants, representing <ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares">2,004,500</ix:nonFraction> December
2020 PIPE Warrants at an offering price per share of $<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="clnn:OfferingPricePerShare" scale="0" unitRef="usdPershares">0.01</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_6" id="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_5"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On July 22, 2021, we
filed a registration statement on Form S-1 (file number 333-258098) to register <ix:nonFraction contextRef="c101" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares">1,140,731</ix:nonFraction> shares of Common Stock underlying
outstanding warrants that we have previously issued, among which <ix:nonFraction contextRef="c102" decimals="0" format="ixt:num-dot-decimal" name="clnn:CommonStockUnderlyingWarrantOutstanding" scale="0" unitRef="shares">1,024,880</ix:nonFraction> warrants (the &#8220;AK Warrants&#8221;, and collectively
with the Kensington Warrants, the &#8220;Founder Warrants&#8221;) were originally issued by Clene Nanomedicine prior to the Reverse
Recapitalization in April 2013 and <ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="clnn:CommonStockUnderlyingWarrantOutstanding" scale="0" unitRef="shares">115,851</ix:nonFraction> warrants (the &#8220;Avenue Warrants&#8221;) were issued pursuant to a loan agreement
(the &#8220;2021 Avenue Loan&#8221;) with Avenue Venture Opportunities Fund, L.P. (&#8220;Avenue&#8221;) (see Note 8). We will
receive aggregate proceeds of $<ix:nonFraction contextRef="c102" decimals="-5" format="ixt:num-dot-decimal" name="clnn:AggregateFutureProceedsWarrantsExercised" scale="6" unitRef="usd">3.0</ix:nonFraction> million if all of these warrants are exercised. In addition, the registration statement on Form
S-1 registered <ix:nonFraction contextRef="c104" decimals="0" format="ixt:num-dot-decimal" name="clnn:ShareIssuanceOfCommonStockPrivateOffering" scale="0" unitRef="shares">960,540</ix:nonFraction> shares of Common Stock, issued in a private placement in May 2021 (the &#8220;May 2021 PIPE&#8221;). We will
not receive any proceeds from the possible sale of these shares by the selling shareholders. On August 2, 2021, the registration
statement was declared effective by the SEC. In connection with the registration statement on Form S-1, we incurred an immaterial
amount of certain offering costs, which were recognized as an expense within general and administrative expenses in the condensed
consolidated statements of operations and comprehensive income (loss) during the three and nine months ended September 30, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_7" id="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Liquidity</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_8" id="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have incurred significant losses and negative cash flows from operations
since our inception. We incurred a net loss of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" sign="-" unitRef="usd">14.2</ix:nonFraction> million for the nine months ended September 30, 2021. We incurred net losses of $<ix:nonFraction contextRef="c13" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" sign="-" unitRef="usd">10.3</ix:nonFraction>
million and $<ix:nonFraction contextRef="c14" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" sign="-" unitRef="usd">20.1</ix:nonFraction> million for the three and nine months ended September 30, 2020, respectively. As of September 30, 2021, our cash totaled
$<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="6" unitRef="usd">60.6</ix:nonFraction> million, and our accumulated deficit was $<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" sign="-" unitRef="usd">167.7</ix:nonFraction> million. As of December 31, 2020, our cash totaled $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="6" unitRef="usd">59.3</ix:nonFraction> million, and our accumulated
deficit was $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" sign="-" unitRef="usd">153.6</ix:nonFraction> million. We had net cash used in operating activities of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" sign="-" unitRef="usd">25.0</ix:nonFraction> million and $<ix:nonFraction contextRef="c14" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" sign="-" unitRef="usd">13.1</ix:nonFraction> million for the nine months ended
September 30, 2021 and 2020, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_9" id="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the Reverse Recapitalization,
Clene Nanomedicine&#8217;s operations were financed through the issuance of equity instruments and the issuance of convertible promissory
notes. Subsequent to the Reverse Recapitalization, we have obtained additional liquidity through a term loan and private placements of
equity instruments. We have not generated significant revenues to date and do not anticipate generating any significant revenues unless
we successfully complete development and obtain regulatory approval for our drugs or for our COVID-19 study. We expect to incur additional
losses in the future to fund our operations and conduct product research and development and we recognize the need to raise additional
capital to fully implement our business plan. Additionally, we may attempt to negotiate a collaboration agreement with a third party for
development and commercialization of a drug candidate, which may provide upfront and milestone payments to reduce our spending going forward.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_10" id="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to continue investing
in product development, sales and marketing and customer support for our products. The long-term continuation of our business plan is
dependent upon the generation of sufficient revenues from our products to offset expenses and capital expenditures. In the event that
we do not generate sufficient revenues and are unable to obtain funding, we will be forced to delay, reduce, or eliminate some or all
of our research and development programs, product portfolio expansion, commercialization efforts, or capital expenditures, which could
adversely affect our business prospects, ability to meet long-term liquidity needs, or we may be unable to continue operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_11" id="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that the cash on
hand as of September 30, 2021 will be sufficient to fund our operations for a period extending beyond twelve months from the date these
condensed consolidated financial statements for the three and nine months ended September 30, 2021 were issued.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_12" id="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Impact of the COVID-19 Pandemic</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_13" id="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The COVID-19 pandemic, which
began in December&#160;2019 and has spread worldwide, has caused many governments to implement measures to slow the spread of the outbreak.
The outbreak and government measures taken in response have had a significant impact, both direct and indirect, on businesses and commerce,
as worker shortages have occurred, supply chains have been disrupted, and facilities and production have been suspended. The future progression
of the pandemic and its effects on our business and operations remains uncertain. The COVID-19 pandemic may affect our ability to initiate
and complete preclinical studies, delay the initiation of future clinical trials, disrupt regulatory activities, or have other adverse
effects on our business and operations. In particular, the Company and our clinical research organizations (&#8220;CROs&#8221;) may face
disruptions that may affect our ability to initiate and complete preclinical studies, manufacturing disruptions, and delays at clinical
trial sites. The pandemic has already caused significant disruptions in the financial markets, and may continue to cause such disruptions,
which could impact our ability to raise additional funds to support our operations. Moreover, the pandemic has significantly impacted
economies worldwide and could result in adverse effects on our business and operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are monitoring the potential
impact of the COVID-19 pandemic on our business and financial statements. While the COVID-19 pandemic has led to various research restrictions
and paused certain of our clinical trials, these impacts have been temporary and to date we have not experienced material business disruptions
or incurred impairment losses in the carrying values of our assets as a result of the pandemic and we are not aware of any specific related
event or circumstance that would require us to revise the estimates reflected in these condensed consolidated financial statements. The
extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations, cash flows, and financial
condition, including planned and future clinical trials and research and development costs, will depend on future developments that are
highly uncertain, including as a result of new information that may emerge concerning COVID-19, the actions taken to contain or treat
it, and the duration and intensity of the related effects.&#160;</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>2. Summary of Significant Accounting Policies</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Basis of Presentation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:continuation continuedAt="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_2" id="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have prepared the accompanying
condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States of America
(&#8220;GAAP&#8221;) for interim financial reporting and as required by Regulation S-X, Rule 10-01. The condensed consolidated financial
statements have been prepared on the same basis as our audited annual consolidated financial statements and, in the opinion of management,
reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of our financial condition as
of September 30, 2021, the results of our operations for the three and nine months ended September 30, 2021, our cash flows for the nine
months ended September 30, 2021 and 2020, and the condensed consolidated statement of stockholders&#8217; equity (deficit) for the three
and nine months ended September 30, 2021 and 2020. The financial data and other information disclosed in these notes related to the three
and nine months ended September 30, 2021 and 2020 are unaudited. The results of operations for the three and nine months ended September
30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021, any other interim periods,
or any future year or period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_4" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:continuation id="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior period balances for
accounts receivable have been reclassified to conform to the current year presentation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_5" id="_SignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_6" id="_SignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:continuation continuedAt="_UseOfEstimates-c0_cont_2" id="_UseOfEstimates-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of condensed
consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets, liabilities, and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial
statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying
condensed consolidated financial statements include, but are not limited to, the valuation of common stock, stock options, contingent
earn-out liabilities, Preferred Stock warrants, and Common Stock warrants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_7" id="_SignificantAccountingPoliciesTextBlock-c0_cont_6"><ix:continuation id="_UseOfEstimates-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We base our estimates on historical
experience and on various other assumptions that are believed to be reasonable. Actual results may differ from those estimates or assumptions.
Estimates are periodically reviewed in light of changes in circumstances, facts, and experience. Changes in estimates will be recorded
in future periods as they develop.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_8" id="_SignificantAccountingPoliciesTextBlock-c0_cont_7"><ix:nonNumeric contextRef="c0" continuedAt="_RiskAndUncertaintiesPolicyTextBlock-c0_cont_1" escape="true" name="clnn:RiskAndUncertaintiesPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Risks and Uncertainties</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_9" id="_SignificantAccountingPoliciesTextBlock-c0_cont_8"><ix:continuation continuedAt="_RiskAndUncertaintiesPolicyTextBlock-c0_cont_2" id="_RiskAndUncertaintiesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The product candidates we
develop require approvals from the U.S. Food and Drug Administration or foreign regulatory agencies prior to commercial sales. There can
be no assurance that our current and future product candidates will receive the necessary approvals or be commercially successful. If
we are denied approval or approval is delayed, it will have a material adverse impact on our business and our condensed consolidated financial
statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_10" id="_SignificantAccountingPoliciesTextBlock-c0_cont_9"><ix:continuation continuedAt="_RiskAndUncertaintiesPolicyTextBlock-c0_cont_3" id="_RiskAndUncertaintiesPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to risks common
to companies in the development stage including, but not limited to, dependency on the need for substantial additional financing to achieve
our goals, uncertainty of broad adoption of our approved products, if any, by physicians and patients, significant competition, and untested
manufacturing capabilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_11" id="_SignificantAccountingPoliciesTextBlock-c0_cont_10"><ix:continuation id="_RiskAndUncertaintiesPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to certain
risks and uncertainties and believe that changes in any of the following areas could have a material adverse effect on future financial
condition or results of operations: ability to obtain additional financing; regulatory approval and market acceptance of, and reimbursement
for, product candidates; performance of third-party CROs and manufacturers upon which we rely; protection of our intellectual property;
litigation or claims against us based on intellectual property, patent, product, regulatory, or other factors; and our ability to attract
and retain employees necessary to support our growth.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_12" id="_SignificantAccountingPoliciesTextBlock-c0_cont_11"><ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskCreditRisk-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Concentrations of Credit Risk</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_13" id="_SignificantAccountingPoliciesTextBlock-c0_cont_12"><ix:continuation id="_ConcentrationRiskCreditRisk-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial instruments which
potentially subject us to significant concentrations of credit risk consist primarily of cash. Our cash is mainly held in financial institutions.
Amounts on deposit may at times exceed federally insured limits. We have not experienced any losses on our deposits of cash and do not
believe that we are subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_14" id="_SignificantAccountingPoliciesTextBlock-c0_cont_13"><ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cash and Cash Equivalents</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_15" id="_SignificantAccountingPoliciesTextBlock-c0_cont_14"><ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We consider all short-term
investments with an original maturity of three months or less when purchased to be cash equivalents. As of September 30, 2021 and December
31, 2020, we had no cash equivalents.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_16" id="_SignificantAccountingPoliciesTextBlock-c0_cont_15"><ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Restricted Cash</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_17" id="_SignificantAccountingPoliciesTextBlock-c0_cont_16"><ix:continuation id="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We classify cash as restricted when it is unavailable for withdrawal
or use in our general operating activities. Restricted cash and investments are classified as current and noncurrent on the consolidated
balance sheets based on the nature of the restriction. Our restricted cash balance includes contractually restricted deposits related
to our corporate credit card. As of September 30, 2021 and December 31, 2020, we had restricted cash of $<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RestrictedInvestments" scale="6" unitRef="usd">0.1</ix:nonFraction> million and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedInvestments" scale="0" unitRef="usd">0</ix:nonFraction>, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_18" id="_SignificantAccountingPoliciesTextBlock-c0_cont_17"><ix:nonNumeric contextRef="c0" continuedAt="_TradeAndOtherAccountsReceivablePolicy-c0_cont_1" escape="true" name="us-gaap:TradeAndOtherAccountsReceivablePolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Accounts Receivable</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_19" id="_SignificantAccountingPoliciesTextBlock-c0_cont_18"><ix:continuation id="_TradeAndOtherAccountsReceivablePolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Accounts receivable are stated
at invoice value less estimated allowances for sales returns and doubtful accounts. We estimate the allowance for sales returns based
on historical percentage of returns over a 12-month trailing average of sales. We continually monitor customer payments and maintain a
reserve for estimated losses resulting from our customers&#8217; inability to make required payments. We consider factors when estimating
the allowance for doubtful accounts such as historical experience, age of the accounts receivable balances, geographic related risks,
and economic conditions that may affect a customer&#8217;s ability to pay. In cases where there are circumstances that may impair a specific
customer&#8217;s ability to meet its financial obligations, a specific allowance is recorded against amounts due, thereby reducing the
net recognized receivable to the amount reasonably believed to be collectible. Accounts receivable are written off when deemed uncollectible.
Recoveries of accounts receivable previously written off are recorded when received. Historically, there have been no sales returns, no
written-off accounts receivable, and no allowance for doubtful accounts reducing the balance of the accounts receivable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_20" id="_SignificantAccountingPoliciesTextBlock-c0_cont_19"><ix:nonNumeric contextRef="c0" continuedAt="_InventoryPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:InventoryPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Inventory</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_21" id="_SignificantAccountingPoliciesTextBlock-c0_cont_20"><ix:continuation id="_InventoryPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Inventory is stated at historic
cost on a first-in first-out basis. Our inventory consisted of $<ix:nonFraction contextRef="c2" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterials" scale="6" unitRef="usd">26</ix:nonFraction> thousand in raw materials and $<ix:nonFraction contextRef="c2" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="6" unitRef="usd">14</ix:nonFraction> thousand in finished goods as of
September 30, 2021. Our inventory consisted of $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterials" scale="6" unitRef="usd">0.1</ix:nonFraction> million in raw material and $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="6" unitRef="usd">0.1</ix:nonFraction> million in finished goods as of December 31, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_22" id="_SignificantAccountingPoliciesTextBlock-c0_cont_21"><ix:nonNumeric contextRef="c0" continuedAt="_DebtDiscountAndIssuanceCostsPolicyTextBlock-c0_cont_1" escape="true" name="clnn:DebtDiscountAndIssuanceCostsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Debt Discounts, Debt Premiums, and Debt
Issuance Costs</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_23" id="_SignificantAccountingPoliciesTextBlock-c0_cont_22"><ix:continuation id="_DebtDiscountAndIssuanceCostsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">When debt is issued and a
derivative is required to be bifurcated (e.g., bifurcated conversion option) or another separate freestanding financial instrument (e.g.,
warrant) is issued, costs and fees incurred are allocated to the instruments issued (or bifurcated) in proportion to the allocation of
proceeds. When some portions of the costs and fees relate to a bifurcated derivative or freestanding financial instrument that is being
subsequently measured at fair value, those allocated costs are expensed immediately. Debt discounts, debt premiums, and debt issuance
costs related to convertible loans are recorded as deductions that net against the principal value of the debt and are amortized to interest
expense over the contractual term of the debt using the effective interest method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_24" id="_SignificantAccountingPoliciesTextBlock-c0_cont_23"><ix:nonNumeric contextRef="c0" continuedAt="_DeferredChargesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:DeferredChargesPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Deferred Offering Costs</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_25" id="_SignificantAccountingPoliciesTextBlock-c0_cont_24"><ix:continuation continuedAt="_DeferredChargesPolicyTextBlock-c0_cont_2" id="_DeferredChargesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We capitalize certain legal,
professional accounting. and other third-party fees that are directly associated with in-process equity financings, including the Reverse
Recapitalization and the December 2020 PIPE, as deferred offering costs until such financings are consummated. After consummation of the
equity financing, these costs are recorded in stockholders&#8217; equity (deficit) as a reduction of proceeds generated as a result of
the offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge
to operating expenses in the condensed consolidated statements of operations and comprehensive income (loss).&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_26" id="_SignificantAccountingPoliciesTextBlock-c0_cont_25"><ix:continuation id="_DeferredChargesPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the three and nine
months ended September 30, 2021, we did not incur any offering costs.&#160;During the three and nine months ended September 30, 2020,
we incurred $<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredOfferingCosts" scale="6" unitRef="usd">2.3</ix:nonFraction> million of deferred offering costs related to the Reverse Recapitalization that were comprised of legal and professional
accounting fees and other costs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_27" id="_SignificantAccountingPoliciesTextBlock-c0_cont_26"><ix:nonNumeric contextRef="c0" continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Leases</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_28" id="_SignificantAccountingPoliciesTextBlock-c0_cont_27"><ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_2" id="_LesseeLeasesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At inception of a contract,
we determine if a contract meets the definition of a lease. A lease is a contract, or part of a contract, that conveys the right to control
the use of identified property, plant, or equipment for a period of time in exchange for consideration. We determine if the contract conveys
the right to control the use of an identified asset for a period of time. We assess throughout the period of use whether we have both
of the following: (i)&#160;the right to obtain substantially all of the economic benefits from use of the identified asset, and (ii)&#160;the
right to direct the use of the identified asset. This determination is reassessed if the terms of the contract are changed. Leases are
classified as operating or finance leases based on the terms of the lease agreement and certain characteristics of the identified asset.
Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of the future lease
payments less any lease incentives received. At the lease commencement date, the discount rate implicit in the lease is used to discount
the lease liability if readily determinable. If not readily determinable or leases do not contain an implicit rate, our incremental borrowing
rate is used as the discount rate.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_29" id="_SignificantAccountingPoliciesTextBlock-c0_cont_28"><ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_3" id="_LesseeLeasesPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We lease laboratory and office
space and certain equipment under non-cancellable operating and finance leases. The carrying value of our right-of-use lease assets is
substantially concentrated in our real estate leases, while the volume of lease agreements is primarily concentrated in equipment leases.
Our policy is to not record leases with an original term of twelve months or less within the condensed consolidated balance sheets. We
recognize lease expense for these short-term leases on a straight-line basis over the lease term in the condensed consolidated statements
of operations and comprehensive income (loss).&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_30" id="_SignificantAccountingPoliciesTextBlock-c0_cont_29"><ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_4" id="_LesseeLeasesPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain lease agreements may
require us to pay additional amounts for taxes, insurance, maintenance, and other expenses, which are generally referred to as non-lease
components. Such variable non-lease components are treated as variable lease payments and recognized in the period in which the obligation
for these payments is incurred. Variable lease components and variable non-lease components are not measured as part of the right-of-use
asset and liability. Only when lease components and their associated non-lease components are fixed are they accounted for as a single
lease component and are recognized as part of a right-of-use asset and liability. Total contract consideration is allocated to the combined
fixed lease and non-lease component. This policy election applies consistently to all asset classes under lease agreements.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_31" id="_SignificantAccountingPoliciesTextBlock-c0_cont_30"><ix:continuation id="_LesseeLeasesPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Leases may contain clauses
for renewal at our option. Payments to be made in option periods are recognized as part of the right-of-use lease assets and lease liabilities
when it is reasonably certain that the option to extend the lease will be exercised, or is not at our option. We determine whether the
reasonably certain threshold is met by considering contract-, asset-, market-, and entity-based factors. In the condensed consolidated
statements of operations and comprehensive income (loss), operating lease expense, which is recognized on a straight-line basis over the
lease term, and the amortization of finance lease right-of-use assets, which are included in property and equipment and depreciated, are
included in research and development or general and administrative expenses consistent with the leased assets&#8217; primary use. Accretion
on the liabilities for finance leases is included in interest expense.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_32" id="_SignificantAccountingPoliciesTextBlock-c0_cont_31"><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Property and Equipment</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_33" id="_SignificantAccountingPoliciesTextBlock-c0_cont_32"><ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Property and equipment are
stated at cost less accumulated depreciation. Property and equipment consist of laboratory and office equipment and leasehold improvements.
Depreciation is calculated using the straight-line method over the estimated economic useful lives of the assets, which are <ix:nonNumeric contextRef="c105" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric>-<ix:nonNumeric contextRef="c106" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric>&#160;years
for laboratory equipment and <ix:nonNumeric contextRef="c107" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric>-<ix:nonNumeric contextRef="c108" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">7</ix:nonNumeric>&#160;years for furniture and fixtures. Leasehold improvements are amortized over the lesser of the estimated
lease term or the estimated useful life of the assets. Costs for capital assets not yet placed into service are capitalized as construction
in progress and depreciated or amortized in accordance with the above useful lives once placed into service. Upon retirement or sale,
the related cost and accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included
in the condensed consolidated statements of operations and comprehensive income (loss). Maintenance and repairs that do not improve or
extend the lives of the respective assets are expensed to operations as incurred.&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_34" id="_SignificantAccountingPoliciesTextBlock-c0_cont_33"><ix:nonNumeric contextRef="c0" continuedAt="_ConvertibleNotespolicytextblock-c0_cont_1" escape="true" name="clnn:ConvertibleNotespolicytextblock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Convertible Notes</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_35" id="_SignificantAccountingPoliciesTextBlock-c0_cont_34"><ix:continuation continuedAt="_ConvertibleNotespolicytextblock-c0_cont_2" id="_ConvertibleNotespolicytextblock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with ASU 2020-06,
<i>Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own
Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</i>, when we issue notes
with conversion features, we evaluate if the conversion features are freestanding or embedded. If the conversion feature is embedded,
we do not separate the conversion feature from the host contract for convertible notes that are not required to be accounted for as derivatives,
or that do not result in substantial premiums accounted for as paid-in-capital. Consequently, we account for a convertible note as a single
liability measured at its amortized cost, and we account for a convertible preferred stock as a single equity instrument measured at its
historical cost, as long as no other features require bifurcation and recognition as derivatives.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_36" id="_SignificantAccountingPoliciesTextBlock-c0_cont_35"><ix:continuation id="_ConvertibleNotespolicytextblock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the conversion feature
is freestanding, or is embedded and meets the requirements to be bifurcated, we account for the conversion feature as a derivative under
ASC 815, <i>Derivatives and Hedging</i> (&#8220;ASC 815&#8221;). We record the derivative instrument at fair value at inception, and subsequently
re-measure to fair value at each reporting period and immediately prior to the extinguishment of the derivative instrument, with any changes
recorded in the condensed consolidated statements of operations and comprehensive income (loss).&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_37" id="_SignificantAccountingPoliciesTextBlock-c0_cont_36"><ix:nonNumeric contextRef="c0" continuedAt="_DebtWithWarrantsPolicyTextBlock-c0_cont_1" escape="true" name="clnn:DebtWithWarrantsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Debt With Warrants</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_38" id="_SignificantAccountingPoliciesTextBlock-c0_cont_37"><ix:continuation id="_DebtWithWarrantsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with ASC 470-20, <i>Debt with Conversion and Other Options</i>,
when we issue debt with warrants, we treat the warrants as a debt discount, recorded as a contra-liability against the debt, and amortize
the balance over the life of the underlying debt as amortization of debt discount expense in the condensed consolidated statements of
operations and comprehensive income (loss). The offset to the contra-liability is recorded as additional paid-in capital in the condensed
consolidated balance sheets if the warrants are not treated as a derivative or liability under ASC 480, <i>Distinguishing Liabilities
from Equity</i> (&#8220;ASC 480&#8221;). Otherwise, the offset to the contra-liability is recorded as a warrant liability in the condensed
consolidated balance sheets and is subject to re-measurement to fair value at each balance sheet date, with any changes in fair value
recognized in the condensed consolidated statements of operations and comprehensive income (loss). If the debt is retired early, the associated
debt discount is then recognized immediately as amortization of debt discount expense in the condensed consolidated statements of operations
and comprehensive income (loss).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_39" id="_SignificantAccountingPoliciesTextBlock-c0_cont_38"><ix:nonNumeric contextRef="c0" continuedAt="_ContingentEarnoutPolicyTextBlock-c0_cont_1" escape="true" name="clnn:ContingentEarnoutPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Contingent Earn-Out Liabilities</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_40" id="_SignificantAccountingPoliciesTextBlock-c0_cont_39"><ix:continuation id="_ContingentEarnoutPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the Reverse
Recapitalization, certain shareholders are entitled to receive additional shares of Common Stock (the &#8220;Contingent Earn-outs&#8221;)
upon us achieving certain milestones (see Notes 3 and 12). In accordance with ASC 815, the Contingent Earn-outs are not indexed to our
own stock and therefore are accounted for as a liability at the Reverse Recapitalization date and subsequently remeasured at each reporting
date with changes in fair value recorded as a component of other income (expense), net in the condensed consolidated statements of operations
and comprehensive income (loss).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_41" id="_SignificantAccountingPoliciesTextBlock-c0_cont_40"><ix:nonNumeric contextRef="c0" continuedAt="_CommonStockWarrantsPolicyTextBlock-c0_cont_1" escape="true" name="clnn:CommonStockWarrantsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Common Stock Warrants</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_42" id="_SignificantAccountingPoliciesTextBlock-c0_cont_41"><ix:continuation id="_CommonStockWarrantsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We account for common stock
warrants as either equity-classified instruments or liability-classified instruments based on an assessment of the warrant terms and applicable
authoritative guidance in accordance with ASC 480 and ASC 815. The assessment considers whether the warrants are freestanding financial
instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements
for equity classification under ASC 815, including whether the warrants are indexed to our Common Stock, among other conditions for equity
classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and, for
liability-classified warrants, as of each subsequent quarterly period end date while the warrants are outstanding.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_43" id="_SignificantAccountingPoliciesTextBlock-c0_cont_42"><ix:nonNumeric contextRef="c0" continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue Recognition</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_44" id="_SignificantAccountingPoliciesTextBlock-c0_cont_43"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_2" id="_RevenueRecognitionPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under ASC 606, <i>Revenue
from Contracts with Customers</i> (&#8220;ASC 606&#8221;), an entity recognizes revenue when its customer obtains control of promised
goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services.
To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following
five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine
the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations
in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the five-step
model to contracts when it is probable that we will collect the consideration to which we are entitled in exchange for the goods or services
we transfer to the customer.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_45" id="_SignificantAccountingPoliciesTextBlock-c0_cont_44"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_3" id="_RevenueRecognitionPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Once a contract is determined
to be within the scope of ASC 606 at contract inception, we review the contract to determine which performance obligations we must deliver,
and which performance obligations are distinct. We recognize as revenue the amount of the transaction price that is allocated to each
performance obligation when that performance obligation is satisfied or as it is satisfied. We typically satisfy our performance obligations
via delivery of dietary supplements to the customer. Payments are due upon receipt for commercial transactions, or a prepayment is collected
for online retail sales. Our revenue for the three and nine months ended September 30, 2021 and 2020 was comprised of sales of dietary
supplements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_46" id="_SignificantAccountingPoliciesTextBlock-c0_cont_45"><ix:continuation id="_RevenueRecognitionPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recorded deferred revenue of $<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenue" scale="6" unitRef="usd">0.1</ix:nonFraction> and $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenue" scale="6" unitRef="usd">0.1</ix:nonFraction> million as of September
30, 2021 and December 31, 2020 from the dietary supply agreement with the related party (see Note 20).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_47" id="_SignificantAccountingPoliciesTextBlock-c0_cont_46"><ix:nonNumeric contextRef="c0" continuedAt="_GrantFundingPolicyTextBlock-c0_cont_1" escape="true" name="clnn:GrantFundingPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Grant Funding</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_48" id="_SignificantAccountingPoliciesTextBlock-c0_cont_47"><ix:continuation continuedAt="_GrantFundingPolicyTextBlock-c0_cont_2" id="_GrantFundingPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may submit applications
to receive grant funding from governmental and non-governmental entities. Grant funding received that involves no conditions or continuing
performance obligations of the Company is recognized upon receipt. Grant funding with conditions or obligations of the Company is recognized
as the conditions or obligations are fulfilled. We have made an accounting policy election to record such unconditional grants, such as
the Australian Research and Development Credit, as other income in the condensed consolidated statements of operations and comprehensive
income (loss). Income from grants is recognized in the period during which the related qualifying expenses are incurred, provided that
the conditions under which the grants were provided have been met. We recognize the Australian Research and Development Credit in an amount
equal to the qualifying expenses incurred in each period multiplied by the applicable reimbursement percentage. During the three and nine
months ended September 30, 2021, we recognized $<ix:nonFraction contextRef="c109" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" unitRef="usd">0.4</ix:nonFraction> million and $<ix:nonFraction contextRef="c110" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" unitRef="usd">1.1</ix:nonFraction> million, respectively, of Australian Research and Development Credit
within other income (expense), net in the condensed consolidated statements of operations and comprehensive income (loss). During the
three and nine months ended September 30, 2020, we recognized $<ix:nonFraction contextRef="c111" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" unitRef="usd">1.3</ix:nonFraction> million and $<ix:nonFraction contextRef="c112" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" unitRef="usd">2.6</ix:nonFraction> million, respectively, of Australian Research and
Development Credit within other income (expense), net in the condensed consolidated statements of operations and comprehensive income
(loss). As of September 30, 2021, and December 31, 2020, we recorded $<ix:nonFraction contextRef="c113" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" scale="6" unitRef="usd">1.2</ix:nonFraction> million and $<ix:nonFraction contextRef="c114" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" scale="6" unitRef="usd">2.1</ix:nonFraction> million, respectively, of Australian Research
and Development Credit receivable in prepaid expenses and other current assets on the condensed consolidated balance sheets.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_49" id="_SignificantAccountingPoliciesTextBlock-c0_cont_48"><ix:continuation continuedAt="_GrantFundingPolicyTextBlock-c0_cont_3" id="_GrantFundingPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any amount received in advance
of fulfilling such conditions or obligations is recorded in accrued liabilities on the condensed consolidated balance sheets if the conditions
or obligations are expected to be met within the next twelve months. As of September 30, 2021 and December 31, 2020, we recorded $<ix:nonFraction contextRef="c115" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="6" unitRef="usd">0.6</ix:nonFraction>
million and $<ix:nonFraction contextRef="c114" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="6" unitRef="usd">0.3</ix:nonFraction> million, respectively, of deferred grant funds received in advance in accrued liabilities.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_50" id="_SignificantAccountingPoliciesTextBlock-c0_cont_49"><ix:continuation id="_GrantFundingPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Grant funding recognized on
conditional grants is included as a reduction in research and development expenses in the condensed consolidated statements of operations
and comprehensive income (loss) as the conditions are tied to our research and development efforts, and as the arrangement between us
and the organizations are not part of our ongoing, major, or central operations. During the three and nine months ended September 30,
2021, we recorded a grant of $<ix:nonFraction contextRef="c12" decimals="-6" format="ixt:num-dot-decimal" name="clnn:GrantFundingRecognizedOnConditionalGrants" scale="6" unitRef="usd">0</ix:nonFraction> and $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="clnn:GrantFundingRecognizedOnConditionalGrants" scale="6" unitRef="usd">0.2</ix:nonFraction> million, respectively, as a reduction of research and development expenses in the condensed consolidated
statements of operations and comprehensive income (loss). During the three and nine months ended September 30, 2020, we recorded a grant
of $<ix:nonFraction contextRef="c13" decimals="-5" format="ixt:num-dot-decimal" name="clnn:GrantFundingRecognizedOnConditionalGrants" scale="6" unitRef="usd">0.2</ix:nonFraction> million and $<ix:nonFraction contextRef="c14" decimals="-5" format="ixt:num-dot-decimal" name="clnn:GrantFundingRecognizedOnConditionalGrants" scale="6" unitRef="usd">0.7</ix:nonFraction> million, respectively, as a reduction of research and development expenses in the condensed consolidated statements
of operations and comprehensive income (loss).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_51" id="_SignificantAccountingPoliciesTextBlock-c0_cont_50"><ix:nonNumeric contextRef="c0" continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Fair Value of Financial Instruments</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_52" id="_SignificantAccountingPoliciesTextBlock-c0_cont_51"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain assets and liabilities
are carried at fair value under GAAP. Fair value is defined as the price that would be received for an asset or paid to transfer a liability
(an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants
on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use
of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following
three levels of the fair value hierarchy:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_53" id="_SignificantAccountingPoliciesTextBlock-c0_cont_52"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Level 1</b><i>&#8212;</i>Inputs
based upon quoted market prices for identical assets or liabilities in active markets at the measurement date.&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_54" id="_SignificantAccountingPoliciesTextBlock-c0_cont_53"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Level 2</b><i>&#8212;</i>Observable
inputs other than quoted market prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets;
quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can
be corroborated by observable market data.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_55" id="_SignificantAccountingPoliciesTextBlock-c0_cont_54"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Level 3</b><i>&#8212;</i>Inputs
that are management&#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date.
The inputs are unobservable in the market and significant to the instrument&#8217;s valuation.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_56" id="_SignificantAccountingPoliciesTextBlock-c0_cont_55"><ix:continuation id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We review the fair value hierarchy
classification of our applicable assets and liabilities on a quarterly basis. Changes in the observability of valuation inputs may result
in a reclassification for certain financial assets or liabilities. Reclassifications impacting all levels of the fair value hierarchy
are reported as transfers in or out of the Level 1, 2, or 3 categories as of the beginning of the quarter during which the reclassifications
occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_57" id="_SignificantAccountingPoliciesTextBlock-c0_cont_56"><ix:nonNumeric contextRef="c0" continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Foreign Currency Translation and Transactions</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_58" id="_SignificantAccountingPoliciesTextBlock-c0_cont_57"><ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_2" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our functional currency is
the U.S. dollar. Our Australian subsidiary determined its functional currency to be the Australian dollar and our Netherlands subsidiary
determined its functional currency to be the Euro. We use the U.S. dollar as our reporting currency for the condensed consolidated financial
statements. The results of our non-U.S. dollar based functional currency operations are translated to U.S. dollars at the average exchange
rates during the period. Our assets and liabilities are translated using the current exchange rate as of the balance sheet date and shareholders&#8217;
equity is translated using historical rates.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_59" id="_SignificantAccountingPoliciesTextBlock-c0_cont_58"><ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_3" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Adjustments resulting from
the translation of the condensed consolidated financial statements of our foreign functional currency subsidiaries into U.S. dollars are
excluded from the determination of net loss and are accumulated in a separate component of shareholders&#8217; equity. These foreign currency
translation gains and losses are currently the only component of other comprehensive income (loss).&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_60" id="_SignificantAccountingPoliciesTextBlock-c0_cont_59"><ix:continuation id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also incur foreign exchange
transaction gains and losses for purchases denominated in foreign currencies. Foreign exchange transaction gains and losses are included
in other income (expense) in the condensed consolidated statements of operations and comprehensive income (loss) as incurred.&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_61" id="_SignificantAccountingPoliciesTextBlock-c0_cont_60"><ix:nonNumeric contextRef="c0" continuedAt="_ComprehensiveIncomePolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Comprehensive Income (Loss</i></b>)</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_62" id="_SignificantAccountingPoliciesTextBlock-c0_cont_61"><ix:continuation id="_ComprehensiveIncomePolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Comprehensive income (loss)
includes net income (loss) as well as other changes in stockholders&#8217; equity (deficit) that result from transactions and economic
events other than those with stockholders. The only element of other comprehensive income (loss) in any period presented was translation
of Australian dollar denominated balances of our Australian subsidiary to U.S. dollars for consolidation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_63" id="_SignificantAccountingPoliciesTextBlock-c0_cont_62"><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Net Income (Loss) Per Share Attributable
to Common Shareholders</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_64" id="_SignificantAccountingPoliciesTextBlock-c0_cont_63"><ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Basic net income (loss) per share attributable to common shareholders
is calculated using our weighted-average outstanding common shares. Diluted net income (loss) per share attributable to common shareholders
is calculated using our weighted-average outstanding common shares including the dilutive effect of securities as determined under the
treasury stock method, except for the dilutive effect of convertible notes payable, which is calculated under the if-converted method,
even if the embedded conversion option is out-of-the-money. In periods in which we report a net loss attributable to common shareholders,
diluted net loss per share attributable to common shareholders is the same as basic net loss per share attributable to common shareholders,
since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_65" id="_SignificantAccountingPoliciesTextBlock-c0_cont_64"><ix:nonNumeric contextRef="c0" continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Segment Information</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_66" id="_SignificantAccountingPoliciesTextBlock-c0_cont_65"><ix:continuation id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have determined that our
chief executive officer is the chief operating decision maker (&#8220;CODM&#8221;). Operating segments are identified as components of
an enterprise about which separate discrete financial information is available for evaluation by the CODM in making decisions regarding
resource allocation and assessing performance. We view our operations and manage our business in two operating segments: (1) the development
and commercialization of proprietary nanotechnology drug suspensions (&#8220;Drugs&#8221;), and (2) the development and commercialization
of dietary supplements (&#8220;Supplements&#8221;). Our operating segment profit measure is segment loss from operations, which is calculated
as revenue less cost of revenue, research and development, and general and administrative expenses (see Note 21).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_67" id="_SignificantAccountingPoliciesTextBlock-c0_cont_66"><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Income Taxes</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_68" id="_SignificantAccountingPoliciesTextBlock-c0_cont_67"><ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_2" id="_IncomeTaxPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We account for income taxes
using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax
consequences of events that have been recognized in the condensed consolidated financial statements or in our tax returns. Deferred tax
assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities
using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities
are recorded in the provision for income taxes. We assess the likelihood that our deferred tax assets will be recovered from future taxable
income and, to the extent we believe, based upon the weight of available evidence, that it is more likely than not that all or a portion
of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential
for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible
tax planning strategies.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_69" id="_SignificantAccountingPoliciesTextBlock-c0_cont_68"><ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We account for uncertainty
in income taxes recognized in the condensed consolidated financial statements by applying a two-step process to determine the amount of
tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external
examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed
to determine the amount of benefit to recognize in the condensed consolidated financial statements. The amount of the benefit that may
be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for
income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well
as the related net interest and penalties.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_70" id="_SignificantAccountingPoliciesTextBlock-c0_cont_69"><ix:nonNumeric contextRef="c0" continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock-Based Compensation</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_71" id="_SignificantAccountingPoliciesTextBlock-c0_cont_70"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We account for stock-based
compensation arrangements with employees using a fair value-based method for costs related to all share-based payments including stock
options and stock awards. Stock-based compensation expense is recorded in research and development and general and administrative expenses
based on the classification of the work performed by the grantees.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_72" id="_SignificantAccountingPoliciesTextBlock-c0_cont_71"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_3" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair value is recognized
over the period during which a grantee was required to provide services in exchange for the option award and service-based stock awards,
known as the requisite service period (usually the vesting period), on a straight-line basis. For stock awards with market conditions,
the fair value is recognized over the period based on the expected milestone achievement dates as the derived service period (usually
the vesting period), on a straight-line basis. For stock awards with performance conditions, the grant-date fair value of these awards
is the market price on the applicable grant date, and compensation expense will be recognized when the conditions become probable of
being satisfied. We will recognize a cumulative true-up adjustment once the conditions become probable of being satisfied as the related
service period had been completed in a prior period.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_73" id="_SignificantAccountingPoliciesTextBlock-c0_cont_72"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_4" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stock-based compensation expense
is recognized at fair value. We elect to account for forfeitures as they occur, rather than estimating expected forfeitures.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_74" id="_SignificantAccountingPoliciesTextBlock-c0_cont_73"><ix:continuation id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After the closing of the Reverse
Recapitalization, we determine the fair value of each share of Common Stock underlying stock-based awards based on the closing price of
our Common Stock as reported by the Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) on the date of grant. The fair value of stock awards
with market conditions are determined using a Monte Carlo valuation model.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_75" id="_SignificantAccountingPoliciesTextBlock-c0_cont_74"><ix:nonNumeric contextRef="c0" continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_76" id="_SignificantAccountingPoliciesTextBlock-c0_cont_75"><ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development costs
are charged to expense as incurred. We account for nonrefundable advance payments for goods and services that will be used in future research
and development activities as expenses when the goods have been received or when the service has been performed. Research and development
expenses consist of costs incurred for the discovery and development of our product candidates. Research and development costs include,
but are not limited to, payroll and personnel expenses including stock-based compensation, clinical trial supplies, fees for clinical
trial services, consulting costs, and allocated overhead, including rent, equipment, and utilities.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_77" id="_SignificantAccountingPoliciesTextBlock-c0_cont_76"><ix:nonNumeric contextRef="c0" continuedAt="_ClinicalTrialAccrualPolicyTextBlock-c0_cont_1" escape="true" name="clnn:ClinicalTrialAccrualPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Clinical Trial Accrual</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_78" id="_SignificantAccountingPoliciesTextBlock-c0_cont_77"><ix:continuation continuedAt="_ClinicalTrialAccrualPolicyTextBlock-c0_cont_2" id="_ClinicalTrialAccrualPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our clinical trial accrual
process accounts for expenses resulting from obligations under contracts with CROs, consultants, and under clinical site agreements in
connection with conducting clinical trials. Clinical trial costs are charged to research and development expense as incurred. The financial
terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not
match the periods over which materials or services are provided to us under such contracts. We reflect the appropriate clinical trial
expense in the condensed consolidated financial statements by matching the appropriate expenses with the period in which services and
efforts are expended. In the event advance payments are made to a CRO, the payments will be recorded as a prepaid asset which will be
amortized to research and development expense over the period the contracted services are performed. In addition to pass-through costs,
we generally incur costs in clinical trials in four distinct groups as follows:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_79" id="_SignificantAccountingPoliciesTextBlock-c0_cont_78"><ix:continuation continuedAt="_ClinicalTrialAccrualPolicyTextBlock-c0_cont_3" id="_ClinicalTrialAccrualPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">CRO Start-up&#8212;These costs
include the initial set-up of the clinical trial and usually occur within a few months after the contract has been executed and includes
costs which are expensed ratably over the start-up period when such period is identifiable and expensed as incurred when no such period
exists. Start-up phase activities include study initiation, site recruitment, regulatory applications, investigator meetings, screening,
preparation, pre-study visits, and training.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_80" id="_SignificantAccountingPoliciesTextBlock-c0_cont_79"><ix:continuation continuedAt="_ClinicalTrialAccrualPolicyTextBlock-c0_cont_4" id="_ClinicalTrialAccrualPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">CRO Site and Study Management&#8212;These
costs include medical and safety monitoring, patient administration and data management. These costs are usually calculated on a per-patient
basis and expensed ratably over the treatment period beginning on the date that the patient enrolls.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_81" id="_SignificantAccountingPoliciesTextBlock-c0_cont_80"><ix:continuation continuedAt="_ClinicalTrialAccrualPolicyTextBlock-c0_cont_5" id="_ClinicalTrialAccrualPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">CRO Close-Down and Reporting&#8212;These
costs include analyzing the data obtained and reporting results, which occurs after patients have ceased treatment and the database of
information collected is locked. These costs are expensed as incurred over the course of any close-down and reporting period.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_82" id="_SignificantAccountingPoliciesTextBlock-c0_cont_81"><ix:continuation continuedAt="_ClinicalTrialAccrualPolicyTextBlock-c0_cont_6" id="_ClinicalTrialAccrualPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Third-Party Contracts&#8212;These
costs include fees charged by third parties for various support services which are not provided by CROs and include such items as laboratory
fees, data quality review costs, and fees incurred for investigational product monitoring and inventory control. These items are expensed
ratably over any identifiable service period with the engaged third-party vendors.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_83" id="_SignificantAccountingPoliciesTextBlock-c0_cont_82"><ix:continuation id="_ClinicalTrialAccrualPolicyTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The CRO contracts generally
include pass-through fees including, but not limited to, regulatory expenses, investigator fees, travel costs, and other miscellaneous
costs, including shipping and printing fees. We determine accrual estimates through reports from and discussion with applicable personnel
and outside service providers as to the progress or state of completion of trials or the services completed. We estimate accrued expenses
as of each balance sheet date in the condensed consolidated financial statements based on the facts and circumstances known to us at that
time.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_84" id="_SignificantAccountingPoliciesTextBlock-c0_cont_83"><ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Recently Adopted Accounting Pronouncements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_85" id="_SignificantAccountingPoliciesTextBlock-c0_cont_84"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2020, the FASB issued
ASU 2020-06, <i>Debt</i>&#8212;<i>Debt with Conversion and Other Options (Subtopic 470-20) </i>and <i>Derivatives and Hedging</i>&#8212;<i>Contracts
in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</i>
to simplify accounting for certain financial instruments by removing certain separation models for convertible instruments. Under the
amendments in ASU 2020-06, the embedded conversion features no longer are separated from the host contract for convertible instruments
with conversion features that are not required to be accounted for as derivatives, or that do not result in substantial premiums accounted
for as paid-in-capital. Consequently, a convertible debt instrument will be accounted as a single liability measured at its amortized
cost, and a convertible preferred stock will be accounted for as a single equity instrument measured at its historical cost, as long as
no other features require bifurcation and recognition as derivatives. The new standard also introduces additional disclosures for convertible
debt and freestanding instruments that are indexed to and settled in an entity&#8217;s own equity. ASU 2020-06 amends the diluted earnings
per share guidance, including the requirements to use the if-converted method for all convertible instruments. For smaller reporting companies,
the new guidance is effective for fiscal years beginning after December 15, 2023, and should be applied on a full or modified retrospective
basis, with early adoption permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods with
those fiscal years. We early adopted ASU 2020-06 on January 1, 2021. The adoption of this guidance did not have a material impact on our
condensed consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_86" id="_SignificantAccountingPoliciesTextBlock-c0_cont_85"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2020, the FASB issued
ASU 2020-04, <i>Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</i>, which
provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions in which the
reference LIBOR or another reference rate is expected to be discontinued as a result of the Reference Rate Reform. This ASU is intended
to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The new guidance
was effective immediately and through December 31, 2022. We adopted this guidance on March 1, 2020. The adoption of this guidance did
not have a material impact on our condensed consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_87" id="_SignificantAccountingPoliciesTextBlock-c0_cont_86"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_4" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2019, the FASB
issued ASU 2019-12, <i>Income Taxes (Topic 740)</i>, which amends the existing guidance relating to the accounting for income taxes. This
ASU is intended to simplify the accounting for income taxes by removing certain exceptions to the general principles of accounting for
income taxes and to improve the consistent application of GAAP for other areas of accounting for income taxes by clarifying and amending
existing guidance. The new guidance was effective for our fiscal year, and interim periods within our fiscal year, beginning after December
15, 2020. The adoption of this guidance did not have a material impact on our condensed consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_88" id="_SignificantAccountingPoliciesTextBlock-c0_cont_87"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_5" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2018, the FASB issued
ASU 2018-15, <i>Intangibles</i>&#8212;<i>Goodwill and Other</i>&#8212;<i>Internal-Use Software (Subtopic 350-40): Customer&#8217;s Accounting
for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract</i>. The new guidance provides for the deferral
of implementation costs for cloud computing arrangements and expensing those costs over the term of the cloud services arrangement. The
new guidance was effective for our fiscal year beginning after December 15, 2020. The adoption of this guidance did not have a material
impact on our condensed consolidated financial statements.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_89" id="_SignificantAccountingPoliciesTextBlock-c0_cont_88"><ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">In&#160;August
2018,&#160;the FASB issued ASU&#160;2018-13,&#160;<i>Fair Value Measurement (Topic&#160;</i></span><i>820<span style="font-size: 10pt">)</span></i><span style="font-size: 10pt">.
The new guidance improves the effectiveness of disclosures about fair value measurements required under ASC&#160;820.&#160;The new guidance&#160;amends
the disclosure requirements for recurring and nonrecurring fair value measurements by removing, modifying, and adding certain disclosures.
The new guidance was effective for our fiscal year, and interim periods with our fiscal year, beginning after December 15, 2019. The adoption
of this guidance&#160;did&#160;not&#160;have a material impact on our condensed consolidated financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_90" id="_SignificantAccountingPoliciesTextBlock-c0_cont_89"><ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock-c0_cont_1" escape="true" name="clnn:NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Recent Accounting Pronouncements Not Yet
Adopted</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_90"><ix:continuation id="_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2016, the FASB issued
ASU 2016-13, <i>Financial Instruments</i>&#8212;<i>Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>.
The amendments in this ASU, among other things, require the measurement of all expected credit losses for financial assets held at the
reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions and
other organizations will now use forward-looking information to better inform their credit loss estimates. As a smaller reporting company,
the guidance is effective for our fiscal years beginning after December 15, 2022. We are currently evaluating the expected impact of the
new guidance as a result of this extended deadline of implementation for smaller reporting companies.&#160;&#160;</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock-c0_cont_1" escape="true" name="clnn:ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>3. Reverse Recapitalization with Tottenham
and Clene Nanomedicine</b>&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock-c0_cont_2" id="_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 30, 2020 (the
&#8220;Closing Date&#8221;), Chelsea Worldwide Inc., our predecessor company, consummated the previously announced business combination
(referred to as the &#8220;Reverse Recapitalization&#8221;) pursuant to a merger agreement, dated as of September 1, 2020 (the &#8220;Merger
Agreement&#8221;), by and among Clene Nanomedicine, Tottenham, Chelsea Worldwide Inc. (&#8220;PubCo&#8221;), a Delaware corporation and
wholly-owned subsidiary of Tottenham, Creative Worldwide Inc. (&#8220;Merger Sub&#8221;), a Delaware corporation and wholly-owned subsidiary
of PubCo, and Fortis Advisors LLC, a Delaware limited liability company as the representative of our shareholders. Prior to the Reincorporation
Merger discussed below, Tottenham was incorporated in the British Virgin Islands as a blank check company for the purpose of entering
into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination
with one or more businesses or entities. Prior to the Reverse Recapitalization, there was not a public market for the shares of Clene
Nanomedicine common stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock-c0_cont_3" id="_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Reverse Recapitalization
was effected in two steps: (i) Tottenham was reincorporated to the state of Delaware by merging with and into PubCo (the &#8220;Reincorporation
Merger&#8221;); and (ii) promptly following the Reincorporation Merger, Merger Sub was merged with and into Clene Nanomedicine, resulting
in Clene Nanomedicine becoming a wholly-owned subsidiary of PubCo (the &#8220;Acquisition Merger&#8221;). On the Closing Date, PubCo
changed its name from Chelsea Worldwide Inc. to Clene Inc. and listed its shares of Common Stock, par value $<ix:nonFraction contextRef="c116" decimals="4" format="ixt:num-dot-decimal" name="clnn:CommonStockParOrStatedValuesPerShare" scale="0" unitRef="usdPershares">0.0001</ix:nonFraction> per share on Nasdaq
under the symbol &#8220;CLNN.&#8221;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock-c0_cont_4" id="_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the consummation of the
Reverse Recapitalization, each Tottenham ordinary share issued and outstanding immediately prior to the effective time of the Reincorporation
Merger, which totaled <ix:nonFraction contextRef="c117" decimals="0" format="ixt:num-dot-decimal" name="clnn:SharesCancelledUponReverseRecapitalization" scale="0" unitRef="shares">2,303,495</ix:nonFraction> shares held by the Initial Shareholders and Tottenham public shareholders (excluding certain shares that
were canceled pursuant to the Merger Agreement, any redeemed shares, and any dissenting shares), was automatically cancelled and ceased
to exist and (i) for each Tottenham ordinary share, we issued to each shareholder one validly-issued share of our Common Stock; (ii) each
warrant to purchase one-half (1/2) of one Tottenham Ordinary Share converted into a warrant to purchase one-half (1/2) of one share of
our Common Stock; (iii) each right exchangeable into one-tenth (1/10) of one Tottenham ordinary share converted into a right exchangeable
for one-tenth (1/10) of one share of our Common Stock; provided, however, that no fractional shares were issued and all fractional shares
were rounded down to the nearest whole share. In addition, pursuant to the Merger Agreement, the Initial Shareholders are entitled to
receive up to <ix:nonFraction contextRef="c118" decimals="0" format="ixt:num-dot-decimal" name="clnn:InitialShareholdersContingentsEarnout" scale="0" unitRef="shares">750,000</ix:nonFraction> shares of Common Stock as earn-out shares upon the achievement of certain milestones described below. &#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock-c0_cont_5" id="_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On the Closing Date, each
share of Clene Nanomedicine common stock then issued and outstanding was cancelled and the holders thereof in exchange received <ix:nonFraction contextRef="c118" decimals="0" format="ixt:num-dot-decimal" name="clnn:ExchangeOfSharesReceived" scale="0" unitRef="shares">54,339,012</ix:nonFraction>
shares of Clene Inc. Common Stock, which is equal to <ix:nonFraction contextRef="c117" decimals="4" format="ixt:num-dot-decimal" name="clnn:ReverseRecapitalizationExchangeRatio" scale="0" unitRef="pure">0.1389</ix:nonFraction> newly-issued shares of Clene Inc. Common Stock for each single share of Clene
Nanomedicine common stock (the &#8220;Exchange Ratio&#8221;). Pursuant to the Merger Agreement, <ix:nonFraction contextRef="c117" decimals="2" format="ixt:num-dot-decimal" name="clnn:SharesHeldInEscrowPercentage" scale="-2" unitRef="pure">5</ix:nonFraction>% of the aggregate amount of the closing
payment shares, or <ix:nonFraction contextRef="c117" decimals="0" format="ixt:num-dot-decimal" name="clnn:SharesHeldInEscrow" scale="0" unitRef="shares">2,716,958</ix:nonFraction> shares were held in escrow to satisfy any indemnification obligation incurred and were released six months
after the closing of the Reverse Recapitalization. In addition, each share of Clene Nanomedicine&#8217;s preferred stock outstanding immediately
prior to the closing of the Reverse Recapitalization was converted into the right to receive our Common Stock based on the same Exchange
Ratio. All outstanding warrants exercisable for common stock in Clene Nanomedicine (other than warrants that expired, were exercised or
were deemed automatically net exercised immediately prior to the Acquisition Merger) were exchanged for warrants exercisable for our Common
Stock with the same terms and conditions except adjusted by the Exchange Ratio.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock-c0_cont_6" id="_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All outstanding stock options
of Clene Nanomedicine common stock, totaling <ix:nonFraction contextRef="c119" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" scale="0" unitRef="usd">53,286,115</ix:nonFraction> stock options, was cancelled and the holders thereof in exchange received <ix:nonFraction contextRef="c119" decimals="4" format="ixt:num-dot-decimal" name="clnn:ReverseRecapitalizationExchangeRatio" scale="0" unitRef="pure">0.1320</ix:nonFraction>
newly issued stock options of our Common Stock for a total of <ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" scale="0" unitRef="shares">7,032,591</ix:nonFraction> stock options, which is <ix:nonFraction contextRef="c120" decimals="2" format="ixt:num-dot-decimal" name="clnn:ExchangeRatioPercentage" scale="-2" unitRef="pure">95</ix:nonFraction>% of the Exchange Ratio. Pursuant to
the Merger Agreement, we agreed to issue rights to <ix:nonFraction contextRef="c121" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" scale="0" unitRef="shares">370,101</ix:nonFraction> restricted stock awards to the option holders which complements the <ix:nonFraction contextRef="c122" decimals="2" format="ixt:num-dot-decimal" name="clnn:SharesHeldInEscrowPercentage" scale="-2" unitRef="pure">5</ix:nonFraction>% closing
payment shares held in escrow for Clene Nanomedicine common shareholders. The modification of the stock options did not result in a material
incremental compensation expense upon closing of the Reverse Recapitalization.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock-c0_cont_7" id="_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we issued rights
to <ix:nonFraction contextRef="c123" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" scale="0" unitRef="shares">1,136,961</ix:nonFraction> restricted stock awards to option holders to complement the earn-out payments that would contingently be issued to certain
current Clene Nanomedicine shareholders upon the achievement of milestones described below.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock-c0_cont_8" id="_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The proceeds received from
the Reverse Recapitalization were $<ix:nonFraction contextRef="c124" decimals="-5" format="ixt:num-dot-decimal" name="clnn:ProceedsFromReverseRecapitalization" scale="6" unitRef="usd">3.7</ix:nonFraction> million, net of offering costs of $<ix:nonFraction contextRef="c125" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredOfferingCosts" scale="6" unitRef="usd">5.9</ix:nonFraction> million which excludes the fair value of common shares issued
as a payment of related offering costs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock-c0_cont_9" id="_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with Tottenham&#8217;s
initial public offering in August 2018, Tottenham issued to Chardan Capital Markets, LLC (&#8220;Chardan&#8221;), options to purchase
<ix:nonFraction contextRef="c126" decimals="0" format="ixt:num-dot-decimal" name="clnn:SaleOfUnitsNumberOfUnitsIssued" scale="0" unitRef="shares">220,000</ix:nonFraction> units at $<ix:nonFraction contextRef="c127" decimals="2" format="ixt:num-dot-decimal" name="clnn:UnitsIssuedPricePerUnit" scale="0" unitRef="usdPershares">11.50</ix:nonFraction> per unit. Each of the units consists of one and one-tenth shares of Tottenham&#8217;s ordinary shares and one
warrant to purchase one-half of one of Tottenham&#8217;s ordinary shares at an exercise price of $<ix:nonFraction contextRef="c127" decimals="2" format="ixt:num-dot-decimal" name="clnn:ExercisePrice" scale="0" unitRef="usdPershares">11.50</ix:nonFraction> per share (the &#8220;Chardan
Unit Purchase Option&#8221;). In connection with the Reverse Recapitalization, the Chardan Unit Purchase Option was converted into one
Company unit purchase option. The warrants included in the Chardan Unit Purchase Option (the &#8220;Chardan Unit Purchase Option Warrants&#8221;)
are exercisable upon the completion of the Reverse Recapitalization and will expire on December 30, 2025, five years after the consummation
of the Reverse Recapitalization (see Note 10).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock-c0_cont_10" id="_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Also, in connection with the
Reverse Recapitalization, Clene Nanomedicine entered into a letter agreement with LifeSci Capital LLC (&#8220;LifeSci&#8221;) on July
2, 2020, according to which LifeSci was engaged to act as Clene Nanomedicine&#8217;s financial advisor with respect to identifying and
soliciting special purpose acquisition companies for the purpose of entering into a merger or similar transaction with Clene Nanomedicine
and its shareholders. Under this agreement, Clene Nanomedicine agreed that if it consummated a merger with Tottenham, LifeSci would receive
consideration of <ix:nonNumeric contextRef="c128" name="clnn:ServicesLetterAgreementDescription">(i) 3% of the amount by which the total transaction consideration exceeded $350 million, plus (ii) 7% of cash and cash-equivalents
received by Clene Nanomedicine from the Tottenham&#8217;s trust account. Clene Nanomedicine could elect to pay LifeSci either in cash,
equity interests of the surviving company, or a combination of the two. Upon the consummation of the Reverse Recapitalization, <ix:nonFraction contextRef="c129" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">644,164</ix:nonFraction>
shares of Common Stock were issued to LifeSci as consideration for its services as pursuant to the letter agreement (see Note 18).</ix:nonNumeric>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock-c0_cont_11" id="_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Immediately after giving effect
to the Reverse Recapitalization, there were <ix:nonFraction contextRef="c116" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockOtherSharesOutstanding" scale="0" unitRef="shares">59,526,171</ix:nonFraction> shares of Common Stock issued and outstanding and warrants to purchase <ix:nonFraction contextRef="c130" decimals="0" format="ixt:num-dot-decimal" name="clnn:WarrantsToPurchaseCommonStockIssuedAndOutstanding" scale="0" unitRef="shares">5,566,363</ix:nonFraction>
shares of Common Stock issued and outstanding (see Note 10).&#160;Based on the number of shares of Common Stock outstanding on December
30, 2020 (in each case, not giving effect to any shares issuable upon exercise of warrants, options, or earn-out shares), Clene Nanomedicine&#8217;s
shareholders owned approximately <ix:nonFraction contextRef="c131" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">91</ix:nonFraction>% of the Common Stock of the Company, Tottenham shareholders owned approximately <ix:nonFraction contextRef="c132" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">4</ix:nonFraction>% of the Common Stock
of the Company, and investors from the December 2020 PIPE owned approximately <ix:nonFraction contextRef="c133" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">4</ix:nonFraction>% of the Common Stock of the Company.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock-c0_cont_12" id="_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During Tottenham&#8217;s IPO,
Tottenham incurred deferred underwriters&#8217; fees which were payable to Chardan from the amounts held in the trust account upon completion
of the Reverse Recapitalization. Upon the closing of the Reverse Recapitalization, we paid $<ix:nonFraction contextRef="c124" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherUnderwritingExpense" scale="6" unitRef="usd">2.1</ix:nonFraction> million to Chardan as settlement of the
deferred underwriting fees, which amount was included in the total offering costs of the Reverse Recapitalization.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock-c0_cont_13" id="_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2020, we recorded $<ix:nonFraction contextRef="c134" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" scale="6" unitRef="usd">5.9</ix:nonFraction> million of offering costs related to third-party legal, accounting, and other professional services to consummate
the Reverse Recapitalization, excluding the fair value of common shares issued as a payment of related offering costs and Chardan underwriting
fees discussed above. These offering costs are recorded as a reduction of additional paid-in capital upon the close of the Reverse Recapitalization
in our condensed consolidated balance sheets.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock-c0_cont_14" id="_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The transaction was accounted for as a &#8220;reverse recapitalization&#8221;
in accordance with GAAP. Under this method of accounting, Tottenham was treated as the &#8220;acquired&#8221; company for financial reporting
purposes. This determination was primarily based on the fact that subsequent to the Reverse Recapitalization, Clene Nanomedicine&#8217;s
shareholders have a majority of the voting power of the combined company, Clene Nanomedicine comprises all of the ongoing operations of
the combined entity, Clene Nanomedicine comprises a majority of the governing body of the combined company, and Clene Nanomedicine&#8217;s
senior management comprises all of the senior management of the combined company. Accordingly, for accounting purposes, this transaction
was treated as the equivalent of Clene Nanomedicine issuing shares for the net assets of Tottenham, accompanied by a recapitalization.
The shares and net loss per common share in historical periods prior to the Reverse Recapitalization have been retroactively restated
using the Exchange Ratio established in the Reverse Recapitalization. The net assets of Tottenham were recorded at historical costs, with
no goodwill or other intangible assets recorded. Operations prior to the Reverse Recapitalization are those of Clene Nanomedicine.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock-c0_cont_15" id="_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Between July 1, 2021 and September
15, 2021, various investors exercised December 2020 PIPE Warrants for <ix:nonFraction contextRef="c135" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">1,002,250</ix:nonFraction> shares of Common Stock at an exercise price of $<ix:nonFraction contextRef="c136" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceIncrease" scale="0" unitRef="usdPershares">0.01</ix:nonFraction> per
share. The December 2020 PIPE Warrants were issued prior to the completion of the Reverse Recapitalization on December 30, 2020, and were
subject to a 180-day holding period which expired on June 28, 2021. We received cash proceeds of $<ix:nonFraction contextRef="c137" decimals="-2" format="ixt:num-dot-decimal" name="clnn:AggregateGrossProceedWarrantsExercised" scale="3" unitRef="usdPershares">10.0</ix:nonFraction> thousand.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock-c0_cont_16" id="_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 15, 2021, Chardan
exercised the Chardan Unit Purchase Option for <ix:nonFraction contextRef="c138" decimals="0" format="ixt:num-dot-decimal" name="clnn:ChardanUnitPurchaseOption" scale="0" unitRef="shares">220,000</ix:nonFraction> units, each unit consisting of one and one-tenth shares of Common Stock and one
warrant to purchase one-half of one share of Common Stock at an exercise price of $<ix:nonFraction contextRef="c139" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">11.50</ix:nonFraction> per share. Chardan elected to perform a cashless
or net exercise, which resulted in a net issuance of <ix:nonFraction contextRef="c138" decimals="0" format="ixt:num-dot-decimal" name="clnn:NetIssuanceSharesOfCommonStock" scale="0" unitRef="shares">54,083</ix:nonFraction> shares of Common Stock and <ix:nonFraction contextRef="c138" decimals="0" format="ixt:num-dot-decimal" name="clnn:WarrantsToPurchaseSharesOfCommonStock" scale="0" unitRef="shares">49,166</ix:nonFraction> warrants to purchase one-half of one share
of Common Stock. The Chardan Unit Purchase Option was originally issued in connection with Tottenham&#8217;s initial public offering in
August 2018. We received no cash proceeds.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock-c0_cont_17" id="_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Earn-Out Shares</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock-c0_cont_18" id="_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock-c0_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain of Clene Nanomedicine&#8217;s
current shareholders are entitled to receive earn-out shares as follows (the &#8220;Clene Nanomedicine Contingent Earn-out&#8221;): (i)
<ix:nonFraction contextRef="c134" decimals="0" format="ixt:num-dot-decimal" name="clnn:CleneNanomedicineContingentEarnOutMilestone1Shares" scale="0" unitRef="shares">3,333,333</ix:nonFraction> shares of Common Stock if (A) the volume-weighted average price (&#8220;VWAP&#8221;) of the shares of our Common Stock equals
or exceeds $<ix:nonFraction contextRef="c134" decimals="2" format="ixt:num-dot-decimal" name="clnn:CleneNanomedicineContingentEarnoutMilestone1Price" scale="0" unitRef="usdPershares">15.00</ix:nonFraction> (or any foreign currency equivalent) (the &#8220;Milestone 1 Price&#8221;) in any twenty trading days within a thirty
trading day period within the three years following the closing of the Reverse Recapitalization on any securities exchange or securities
market on which the shares of our Common Stock are then traded or (B) the change of control price equals or exceeds the Milestone 1 Price
if a change of control transaction occurs within the three years following the closing of the Reverse Recapitalization (the requirements
set forth in clause (A) and (B), &#8220;Milestone 1&#8221;); (ii) <ix:nonFraction contextRef="c134" decimals="0" format="ixt:num-dot-decimal" name="clnn:CleneNanomedicineContingentEarnoutMilestone2Shares" scale="0" unitRef="shares">2,500,000</ix:nonFraction> shares of Common Stock if (A) the VWAP of the shares of our
Common Stock equals or exceeds $<ix:nonFraction contextRef="c134" decimals="2" format="ixt:num-dot-decimal" name="clnn:CleneNanomedicineContingentEarnoutMilestone2Price" scale="0" unitRef="usdPershares">20.00</ix:nonFraction> (or any foreign currency equivalent) (the &#8220;Milestone 2 Price&#8221;) in any twenty trading
days within a thirty trading day period within the five years following the closing of the Reverse Recapitalization on any securities
exchange or securities market on which the shares of our Common Stock are then traded or (B) the change of control price equals or exceeds
the Milestone 2 Price if a change of control transaction occurs within the five years following the closing of the Reverse Recapitalization
(the requirements set forth in clause (A) or (B), &#8220;Milestone 2&#8221;); and (iii) <ix:nonFraction contextRef="c134" decimals="0" format="ixt:num-dot-decimal" name="clnn:CleneNanomedicineContingentEarnoutMilestone3Shares" scale="0" unitRef="shares">2,500,000</ix:nonFraction> shares of Common Stock if Clene Nanomedicine
completes a randomized placebo-controlled study for treatment of COVID-19 which results in a statistically significant finding of clinical
efficacy within twelve months after the closing of the Reverse Recapitalization (&#8220;Milestone 3&#8221;). If Milestone 1 is not achieved
but Milestone 2 is achieved, the Clene Nanomedicine shareholders will receive a catch-up issuance equal to the shares issued upon satisfaction
of Milestone 1. Upon the consummation of the Reverse Recapitalization, the Clene Nanomedicine Contingent Earn-out shares increased by
<ix:nonFraction contextRef="c134" decimals="0" format="ixt:num-dot-decimal" name="clnn:IncreaseInCleneNanomedicineContingentEarnoutSharesUponReverseRecapitalization" scale="0" unitRef="shares">12,852</ix:nonFraction> as a result of the exercise of stock options during November 2020. Therefore, the total Clene Nanomedicine Contingent Earn-out
shares has increased to <ix:nonFraction contextRef="c134" decimals="0" format="ixt:num-dot-decimal" name="clnn:TotalCleneNanomedicineContingentEarnoutShares" scale="0" unitRef="shares">8,346,185</ix:nonFraction> shares of Common Stock.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock-c0_cont_19" id="_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock-c0_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Initial Shareholders of
Tottenham may be entitled to receive earn-out shares as follows (the &#8220;Initial Shareholders Contingent Earn-out&#8221;): (i) <ix:nonFraction contextRef="c134" decimals="0" format="ixt:num-dot-decimal" name="clnn:InitialShareholdersContingentEarnoutMilestone1Shares" scale="0" unitRef="shares">375,000</ix:nonFraction>
shares of Common Stock upon satisfaction of the requirements of Milestone 1; and (ii) another <ix:nonFraction contextRef="c134" decimals="0" format="ixt:num-dot-decimal" name="clnn:InitialShareholdersContingentEarnoutMilestone2Shares" scale="0" unitRef="shares">375,000</ix:nonFraction> shares of the Company&#8217;s Common
Stock upon satisfaction of the requirements of Milestone 2. If Milestone 1 is not achieved but Milestone 2 is achieved, the Initial Shareholders
shall receive a catch-up issuance equal to the shares granted upon satisfaction of the requirements of Milestone 1.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock-c0_cont_19"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Clene Nanomedicine Contingent
Earn-out and Initial Shareholders Contingent Earn-out (collectively, the &#8220;Contingent Earn-out<b>s</b>&#8221;) have been classified
as liabilities in the condensed consolidated balance sheets and were initially measured at fair value on the date of the Reverse Recapitalization
and are subsequently remeasured to fair value at each reporting date (see Note 16).&#160;</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_PrepaidExpensesAndOtherCurrentAssetsTextBlock-c0_cont_1" escape="true" name="clnn:PrepaidExpensesAndOtherCurrentAssetsTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>4. Prepaid Expenses and Other Current Assets</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_PrepaidExpensesAndOtherCurrentAssetsTextBlock-c0_cont_2" id="_PrepaidExpensesAndOtherCurrentAssetsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prepaid expenses and other
current assets consisted of the following as of September 30, 2021 and December 31, 2020:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_PrepaidExpensesAndOtherCurrentAssetsTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="clnn:PrepaidExpensesAndOtherCurrentAssetsTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">September&#160;30,</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">December&#160;31,</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Australia research and development credit receivable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="clnn:AustraliaResearchAndDevelopmentCreditReceivable" scale="3" sign="-" unitRef="usd">1,212</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="clnn:AustraliaResearchAndDevelopmentCreditReceivable" scale="3" sign="-" unitRef="usd">2,148</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">CRO prepayments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="clnn:CROPrepayments" scale="3" unitRef="usd">693</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="clnn:CROPrepayments" scale="3" unitRef="usd">1,211</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Metals to be used in research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="clnn:MetalsToBeUsedInResearchAndDevelopment" scale="3" unitRef="usd">1,691</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="clnn:MetalsToBeUsedInResearchAndDevelopment" scale="3" unitRef="usd">31</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Directors &amp; Officers Insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="clnn:DirectorsOfficersInsurance" scale="3" unitRef="usd">934</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-194">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" unitRef="usd">202</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" unitRef="usd">112</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" unitRef="usd">4,732</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" unitRef="usd">3,502</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>5. Property and Equipment, Net</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Property and equipment, net
consisted of the following as of September 30, 2021 and December 31, 2020:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_3" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">September&#160;30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Laboratory equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MachineryAndEquipmentGross" scale="3" unitRef="usd">3,183</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MachineryAndEquipmentGross" scale="3" unitRef="usd">3,077</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FurnitureAndFixturesGross" scale="3" unitRef="usd">147</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FurnitureAndFixturesGross" scale="3" unitRef="usd">147</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseholdImprovementsGross" scale="3" unitRef="usd">3,927</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseholdImprovementsGross" scale="3" unitRef="usd">3,889</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Construction in progress</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ConstructionInProgressGross" scale="3" unitRef="usd">1,061</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ConstructionInProgressGross" scale="3" unitRef="usd">490</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">8,318</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">7,603</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd">4,072</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd">3,378</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">4,246</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">4,225</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>



</div><div>

</div><ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_4" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Depreciation expense related
to property and equipment, net for the three and nine months ended September 30, 2021 was approximately $<ix:nonFraction contextRef="c140" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="6" unitRef="usd">0.2</ix:nonFraction> million and $<ix:nonFraction contextRef="c141" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="6" unitRef="usd">0.7</ix:nonFraction> million,
respectively. Depreciation expense is reported in research and development expense and in general and administrative expense for $<ix:nonFraction contextRef="c110" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="6" unitRef="usd">0.6</ix:nonFraction>
million and $<ix:nonFraction contextRef="c142" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="6" unitRef="usd">0.1</ix:nonFraction> million, respectively, for the nine months ended September 30, 2021; and in research and development expense and in general
and administrative expense for $<ix:nonFraction contextRef="c109" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="6" unitRef="usd">0.2</ix:nonFraction> million and $<ix:nonFraction contextRef="c143" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd">29</ix:nonFraction> thousand, respectively, for the three months ended September 30, 2021, in the condensed
consolidated statements of operations and comprehensive income (loss).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Depreciation expense related
to property and equipment, net for the three and nine months ended September 30, 2020 was approximately $<ix:nonFraction contextRef="c144" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="6" unitRef="usd">0.2</ix:nonFraction> million and $<ix:nonFraction contextRef="c145" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="6" unitRef="usd">0.7</ix:nonFraction> million,
respectively. Depreciation expense is reported in research and development expense and in general and administrative expense for $<ix:nonFraction contextRef="c112" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="6" unitRef="usd">0.6</ix:nonFraction>
million and $<ix:nonFraction contextRef="c146" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd">47</ix:nonFraction> thousand, respectively, for the nine months ended September 30, 2020; and in research and development expense and in general
and administrative expense for $<ix:nonFraction contextRef="c111" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="6" unitRef="usd">0.2</ix:nonFraction> million and $<ix:nonFraction contextRef="c147" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd">34</ix:nonFraction> thousand, respectively, for the three months ended September 30, 2020, in the condensed
consolidated statements of operations and comprehensive income (loss).</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock-c0_cont_1" escape="true" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>6. Accrued Liabilities</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock-c0_cont_2" id="_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Accrued liabilities consisted
of the following as of September 30, 2021 and December 31, 2020:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">September&#160;30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accrued professional fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-195">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" unitRef="usd">189</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued compensation and benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" unitRef="usd">1,744</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" unitRef="usd">1,225</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued CRO fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="clnn:AccruedCROFees" scale="3" unitRef="usd">675</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="clnn:AccruedCROFees" scale="3" unitRef="usd">788</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Deferred grant funds</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="clnn:DeferredGrantFunds" scale="3" unitRef="usd">601</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="clnn:DeferredGrantFunds" scale="3" unitRef="usd">301</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued expense reimbursements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="clnn:AccruedExpenseReimbursements" scale="3" unitRef="usd">33</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="clnn:AccruedExpenseReimbursements" scale="3" unitRef="usd">33</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued transaction costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-196">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="clnn:AccruedTransactionCosts" scale="3" unitRef="usd">1,354</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd">64</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd">70</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" unitRef="usd">3,117</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" unitRef="usd">3,960</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_LeasesOfLesseeDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:LeasesOfLesseeDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>7. Leases</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_LeasesOfLesseeDisclosureTextBlock-c0_cont_2" id="_LeasesOfLesseeDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We adopted ASC 842, <i>Leases</i>
(&#8220;ASC 842&#8221;) on January 1, 2019 using the modified retrospective approach. &#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LeasesOfLesseeDisclosureTextBlock-c0_cont_3" id="_LeasesOfLesseeDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April&#160;2020, we terminated
an existing operating lease for office space. At the time of termination, we removed the remaining right-of-use asset of $<ix:nonFraction contextRef="c148" decimals="-5" format="ixt:num-dot-decimal" name="clnn:RemainingRightofuseAsset" scale="6" unitRef="usd">0.3</ix:nonFraction> million,
lease liability of $<ix:nonFraction contextRef="c148" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="6" unitRef="usd">0.3</ix:nonFraction> million, and recognized a gain of $<ix:nonFraction contextRef="c149" decimals="-5" format="ixt:num-dot-decimal" name="clnn:RecognizedGainOnOperatingLease" scale="6" unitRef="usd">0.1</ix:nonFraction> million. Further, in April&#160;2020, we commenced a new operating lease.
At the time of commencement, we recorded the right-of-use asset value of $<ix:nonFraction contextRef="c148" decimals="-5" format="ixt:num-dot-decimal" name="clnn:RightOfUseAssets" scale="6" unitRef="usd">0.4</ix:nonFraction> million, leasehold improvements of $<ix:nonFraction contextRef="c148" decimals="-5" format="ixt:num-dot-decimal" name="clnn:LeaseholdImprovements" scale="6" unitRef="usd">0.4</ix:nonFraction> million, and a lease
liability of $<ix:nonFraction contextRef="c148" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" unitRef="usd">0.8</ix:nonFraction> million. The net effect of the change in leases being an increase in right-of-use assets of $<ix:nonFraction contextRef="c149" decimals="-5" format="ixt:num-dot-decimal" name="clnn:IncreaseInRightOfUseAssets" scale="6" unitRef="usd">0.1</ix:nonFraction> million, an increase
in leasehold improvements of $<ix:nonFraction contextRef="c149" decimals="-5" format="ixt:num-dot-decimal" name="clnn:IncreaseInLeaseholdImprovements" scale="6" unitRef="usd">0.5</ix:nonFraction> million, an increase in lease liability of $<ix:nonFraction contextRef="c149" decimals="-5" format="ixt:num-dot-decimal" name="clnn:IncreaseInLeaseLiability" scale="6" unitRef="usd">0.4</ix:nonFraction> million, and a gain on termination of $<ix:nonFraction contextRef="c149" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnTerminationOfLease" scale="6" unitRef="usd">0.1</ix:nonFraction> million.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LeasesOfLesseeDisclosureTextBlock-c0_cont_4" id="_LeasesOfLesseeDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2021, we entered into an operating lease for laboratory space.
At the time of commencement, we recorded a right-of-use asset value of $<ix:nonFraction contextRef="c150" decimals="-5" format="ixt:num-dot-decimal" name="clnn:OperatingLeaseRightofUseAssets" scale="6" unitRef="usd">2.4</ix:nonFraction> million and a lease liability of $<ix:nonFraction contextRef="c150" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" unitRef="usd">2.4</ix:nonFraction> million, net of a lease
incentive of $<ix:nonFraction contextRef="c150" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncentiveToLessee" scale="6" unitRef="usd">1.0</ix:nonFraction> million. The lease incentive represents an allowance from the lessor for facility alterations. As the lease incentive
is payable based on events within our control and are deemed reasonably certain to occur, we recorded the lease incentive as a reduction
of the right-of-use asset and lease liability at the lease commencement. As of September 30, 2021, we incurred $<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="clnn:LeaseIncentiveRecordedConstructionInProgress" scale="6" unitRef="usd">0.1</ix:nonFraction> million of costs related
to the lease incentive which we recorded as construction in progress, with a corresponding increase to the lease liability, and the construction
in progress will be capitalized as leasehold improvements when the facility is placed into service. <ix:nonNumeric contextRef="c0" name="us-gaap:LessorOperatingLeaseDescription">The lease has an initial ten-year
term and provides us the right and option to extend or renew for two periods of five years each. In accordance with ASC 842, the payments
to be made in option periods have not been recognized as part of the right-of-use asset or lease liability because we do not assess the
exercise of the option to be reasonably certain.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LeasesOfLesseeDisclosureTextBlock-c0_cont_5" id="_LeasesOfLesseeDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, in August 2021, we entered into an operating lease for
laboratory space that will replace a previous operating lease for the same facility. The commencement of the new lease and the termination
of the previous lease will be effective as of December 1, 2021, and had no impact on the condensed consolidated financial statements for
the three and nine months ended September 30, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LeasesOfLesseeDisclosureTextBlock-c0_cont_6" id="_LeasesOfLesseeDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have noncancelable operating
lease arrangements primarily for office and laboratory space. We also have noncancelable finance leases for certain laboratory equipment.
The maturity analysis of finance and operating lease liabilities as of September 30, 2021 are as follows:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LeasesOfLesseeDisclosureTextBlock-c0_cont_7" id="_LeasesOfLesseeDisclosureTextBlock-c0_cont_6"><ix:nonNumeric contextRef="c0" escape="true" name="clnn:FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Finance<br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Operating<br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c151" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear" scale="3" unitRef="usd">43</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c152" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" scale="3" unitRef="usd">870</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c151" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent" scale="3" unitRef="usd">136</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c152" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" scale="3" unitRef="usd">960</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c151" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears" scale="3" unitRef="usd">82</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c152" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" scale="3" unitRef="usd">982</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c151" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears" scale="3" unitRef="usd">20</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c152" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" scale="3" unitRef="usd">1,007</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-197">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c152" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" scale="3" unitRef="usd">1,031</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-198">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c152" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter" scale="3" unitRef="usd">2,887</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Total undiscounted cash flows</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c151" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CapitalLeasesFutureMinimumPaymentsDue" scale="3" unitRef="usd">281</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c152" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" scale="3" unitRef="usd">7,737</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Less amount representing interest/discounting</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c151" decimals="-3" format="ixt:num-dot-decimal" name="clnn:CapitalLeasesAmountRepresentingInterestdiscounting" scale="3" unitRef="usd">3</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c152" decimals="-3" format="ixt:num-dot-decimal" name="clnn:OperatingLeasesAmountRepresentingInterestdiscounting" scale="3" unitRef="usd">2,507</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Present value of future lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c151" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" scale="3" unitRef="usd">278</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c152" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" unitRef="usd">5,230</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Less future lease incentives</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-199">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c152" decimals="-3" format="ixt:num-dot-decimal" name="clnn:OperatingLeasesLessFutureLeaseIncentives" scale="3" sign="-" unitRef="usd">900</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Less lease obligations, current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c151" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CapitalLeaseObligationsCurrent" scale="3" unitRef="usd">153</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c152" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd">262</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Lease obligations&#160;&#8211; long term portion</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c151" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CapitalLeaseObligationsNoncurrent" scale="3" unitRef="usd">125</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c152" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd">4,068</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><ix:continuation continuedAt="_LeasesOfLesseeDisclosureTextBlock-c0_cont_8" id="_LeasesOfLesseeDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that, in the normal
course of business, the existing leases will be renewed or replaced by similar leases.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_LeasesOfLesseeDisclosureTextBlock-c0_cont_9" id="_LeasesOfLesseeDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Finance Leases</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LeasesOfLesseeDisclosureTextBlock-c0_cont_10" id="_LeasesOfLesseeDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Assets recorded under finance
lease obligations and included with property and equipment as of September 30, 2021 and December 31, 2020 are summarized as follows:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LeasesOfLesseeDisclosureTextBlock-c0_cont_11" id="_LeasesOfLesseeDisclosureTextBlock-c0_cont_10"><ix:nonNumeric contextRef="c0" escape="true" name="clnn:FinanceLeaseByMajorClassPropertyAndEquipmentTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">September&#160;30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Laboratory equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="clnn:FinanceLeaseLaboratoryEquipmentGross" scale="3" unitRef="usd">1,148</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="clnn:FinanceLeaseLaboratoryEquipmentGross" scale="3" unitRef="usd">920</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="clnn:FinanceLeaseFurnitureAndFixturesGross" scale="3" unitRef="usd">46</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="clnn:FinanceLeaseFurnitureAndFixturesGross" scale="3" unitRef="usd">46</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Work in process</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-200">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="clnn:FinanceLeaseWorkInProcessGross" scale="3" unitRef="usd">228</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="clnn:FinanceLeaseLiabilityGross" scale="3" unitRef="usd">1,194</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="clnn:FinanceLeaseLiabilityGross" scale="3" unitRef="usd">1,194</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="clnn:AccumulatedDepreciationDepletionAndAmortizationLeases" scale="3" sign="-" unitRef="usd">629</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="clnn:AccumulatedDepreciationDepletionAndAmortizationLeases" scale="3" sign="-" unitRef="usd">593</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="clnn:FinanceLeaseLiabilityNet" scale="3" unitRef="usd">565</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="clnn:FinanceLeaseLiabilityNet" scale="3" unitRef="usd">601</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_LeasesOfLesseeDisclosureTextBlock-c0_cont_12" id="_LeasesOfLesseeDisclosureTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of September 30, 2021, our finance lease obligations had a weighted-average
interest rate of <ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="clnn:FinanceLeaseObligationsWeightedaverageInterestRate" scale="-2" unitRef="pure">8.6</ix:nonFraction>% and had a weighted-average remaining term of <ix:nonNumeric contextRef="c2" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1">2.2</ix:nonNumeric> years. As of December 31, 2020, our finance lease obligations had
a weighted-average interest rate of <ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="clnn:FinanceLeaseObligationsWeightedaverageInterestRate" scale="-2" unitRef="pure">8.1</ix:nonFraction>% and had a weighted-average remaining term of <ix:nonNumeric contextRef="c3" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1">2.7</ix:nonNumeric> years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LeasesOfLesseeDisclosureTextBlock-c0_cont_13" id="_LeasesOfLesseeDisclosureTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Operating Leases</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LeasesOfLesseeDisclosureTextBlock-c0_cont_14" id="_LeasesOfLesseeDisclosureTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our balance of right-of-use assets on the face of the balance sheet
pertain to operating leases. As of September 30, 2021, our operating lease obligations had a weighted-average discount rate of <ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="clnn:OperatingLeaseObligationsWeightedAverageInterestRate" scale="-2" unitRef="pure">9.6</ix:nonFraction>% and
had a weighted-average remaining term of <ix:nonNumeric contextRef="c2" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">8.3</ix:nonNumeric> years. As of December 31, 2020, our operating lease obligations had a weighted-average discount
rate of <ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="clnn:OperatingLeaseObligationsWeightedAverageInterestRate" scale="-2" unitRef="pure">9.6</ix:nonFraction>% and a weighted-average remaining term of <ix:nonNumeric contextRef="c3" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">6.3</ix:nonNumeric> years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LeasesOfLesseeDisclosureTextBlock-c0_cont_15" id="_LeasesOfLesseeDisclosureTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Components of Lease Cost</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LeasesOfLesseeDisclosureTextBlock-c0_cont_16" id="_LeasesOfLesseeDisclosureTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The components of finance
and operating lease costs for the three and nine months ended September 30, 2021 and 2020 were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LeasesOfLesseeDisclosureTextBlock-c0_cont_17" id="_LeasesOfLesseeDisclosureTextBlock-c0_cont_16"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LeaseCostTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Finance lease costs:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 52%">Amortization</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" unitRef="usd">37</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" unitRef="usd">41</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" unitRef="usd">110</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" unitRef="usd">137</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Interest on lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" unitRef="usd">6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" unitRef="usd">9</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" unitRef="usd">21</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" unitRef="usd">30</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" unitRef="usd">107</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" unitRef="usd">95</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" unitRef="usd">247</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" unitRef="usd">308</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Short-term lease costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermLeaseCost" scale="3" unitRef="usd">98</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermLeaseCost" scale="3" unitRef="usd">66</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermLeaseCost" scale="3" unitRef="usd">214</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermLeaseCost" scale="3" unitRef="usd">203</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Variable lease costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:VariableLeaseCost" scale="3" unitRef="usd">32</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:VariableLeaseCost" scale="3" unitRef="usd">22</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:VariableLeaseCost" scale="3" unitRef="usd">71</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:VariableLeaseCost" scale="3" unitRef="usd">70</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total lease costs</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" unitRef="usd">280</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" unitRef="usd">233</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" unitRef="usd">663</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" unitRef="usd">748</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LeasesOfLesseeDisclosureTextBlock-c0_cont_18" id="_LeasesOfLesseeDisclosureTextBlock-c0_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Supplemental Cash Flow Information</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_LeasesOfLesseeDisclosureTextBlock-c0_cont_18"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating cash flows from operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="clnn:OperatingCashFlowsFromOperatingLeases" scale="3" sign="-" unitRef="usd">533</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c94" decimals="-3" format="ixt:num-dot-decimal" name="clnn:OperatingCashFlowsFromOperatingLeases" scale="3" sign="-" unitRef="usd">497</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating cash flows from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="clnn:OperatingCashFlowsFromFinanceLeases" scale="3" sign="-" unitRef="usd">21</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c94" decimals="-3" format="ixt:num-dot-decimal" name="clnn:OperatingCashFlowsFromFinanceLeases" scale="3" sign="-" unitRef="usd">30</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financing cash flows from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="clnn:FinanceCashFlowsFromFinanceLeases" scale="3" sign="-" unitRef="usd">117</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c94" decimals="-3" format="ixt:num-dot-decimal" name="clnn:FinanceCashFlowsFromFinanceLeases" scale="3" sign="-" unitRef="usd">156</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DebtDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>8. Notes Payable</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_2" id="_DebtDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our long-term debt, net of
original issue discount and unamortized debt issuance costs, consisted of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_3" id="_DebtDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">September&#160;30,</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Rate</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Term Loans:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 9pt">Maryland Department of Housing &amp; Community Development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c180" decimals="4" format="ixt:num-dot-decimal" name="clnn:InterestRate" scale="-2" unitRef="pure">8.00</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c181" decimals="-3" format="ixt:num-dot-decimal" name="clnn:TotalTermLoans" scale="3" unitRef="usd">819</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c182" decimals="-3" format="ixt:num-dot-decimal" name="clnn:TotalTermLoans" scale="3" unitRef="usd">1,080</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Advance Cecil, Inc.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c183" decimals="4" format="ixt:num-dot-decimal" name="clnn:InterestRate" scale="-2" unitRef="pure">8.00</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c184" decimals="-3" format="ixt:num-dot-decimal" name="clnn:TotalTermLoans" scale="3" unitRef="usd">164</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c185" decimals="-3" format="ixt:num-dot-decimal" name="clnn:TotalTermLoans" scale="3" unitRef="usd">216</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Paycheck Protection Program</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c186" decimals="4" format="ixt:num-dot-decimal" name="clnn:InterestRate" scale="-2" unitRef="pure">1.00</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-201">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c188" decimals="-3" format="ixt:num-dot-decimal" name="clnn:TotalTermLoans" scale="3" unitRef="usd">647</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Avenue Venture Opportunities Fund, L.P.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c189" decimals="4" format="ixt:num-dot-decimal" name="clnn:InterestRate" scale="-2" unitRef="pure">9.85</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c190" decimals="-3" format="ixt:num-dot-decimal" name="clnn:TotalTermLoans" scale="3" unitRef="usd">20,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-202">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c192" decimals="4" format="ixt:num-dot-decimal" name="clnn:InterestRate" scale="-2" unitRef="pure">0.00</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-203">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c194" decimals="-3" format="ixt:num-dot-decimal" name="clnn:TotalTermLoans" scale="3" unitRef="usd">6</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="clnn:TotalTermLoans" scale="3" unitRef="usd">20,983</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="clnn:TotalTermLoans" scale="3" unitRef="usd">1,949</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Unamortized debt issuance costs and original issue discounts</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:UnamortizedDebtIssuanceExpense" scale="3" unitRef="usd">1,811</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-204">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Less convertible notes payable, net of unamortized debt discount and issuance costs (see Note 11)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" sign="-" unitRef="usd">4,559</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-205">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Total notes payable</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="clnn:TotalNotesPayableAndConvertibleNotesPayable" scale="3" unitRef="usd">14,613</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c134" decimals="-3" format="ixt:num-dot-decimal" name="clnn:TotalNotesPayableAndConvertibleNotesPayable" scale="3" unitRef="usd">1,949</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_4" id="_DebtDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Maryland Loan</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_5" id="_DebtDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February&#160;2019, we
entered into a loan agreement (the &#8220;2019 MD Loan&#8221;) with the Department of Housing and Community Development, a principal department
of the State of Maryland (&#8220;Maryland&#8221;). Pursuant to the 2019 MD Loan, Maryland agreed to provide a $<ix:nonFraction contextRef="c153" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" unitRef="usd">0.5</ix:nonFraction> million term loan.
Amounts outstanding under the 2019 MD Loan bear simple interest at an annual rate of <ix:nonFraction contextRef="c153" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure">8.00</ix:nonFraction>%. Under the 2019 MD Loan, we agreed to affirmative
and negative covenants to which we will remain subject until maturity. These covenants include providing information about the Company
and our operations; limitations on our ability to retire, repurchase, or redeem our common or preferred stock, options, and warrants other
than per the terms of the securities; and limitations on our ability to pay dividends of cash or property. There are no financial covenants
associated with the 2019 MD Loan. Events of default under the 2019 MD Loan include failure to make payments when due, insolvency events,
and failure to comply with covenants. We are not in violation of any affirmative covenants. Repayment of the full balance outstanding
is due on <ix:nonNumeric contextRef="c154" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate">February 22, 2034</ix:nonNumeric>. <ix:nonNumeric contextRef="c154" name="us-gaap:DebtInstrumentDescription">The 2019 MD Loan establishes &#8220;Phantom Shares,&#8221; based on 119,906 shares of Common Stock (based
on 863,110 Series C Preferred Shares prior to the Reverse Recapitalization), determined at issuance.</ix:nonNumeric> The 2019 MD Loan states the repayment
amount is to be the greater of the balance of principal and accrued interest or the Phantom Shares value. We determined that the note
should be accounted for at fair value. We record the fair value of the debt at the end of each reporting period. In order to value the
note, we consider the amount of the simple interest expense that would be due and the value of Phantom Shares. Upon the closing of the
Reverse Recapitalization and as of December 31, 2020, the fair value of the 2019 MD Loan is determined based on the closing price of CLNN
shares listed on Nasdaq.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_6" id="_DebtDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Income of $<ix:nonFraction contextRef="c155" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeOther" scale="6" unitRef="usd">0.5</ix:nonFraction> million and
$<ix:nonFraction contextRef="c156" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeOther" scale="6" unitRef="usd">0.3</ix:nonFraction> million were recognized during the three and nine months ended September 30, 2021, respectively. Expense of $<ix:nonFraction contextRef="c157" decimals="-5" format="ixt:num-dot-decimal" name="clnn:SimpleInterestExpense" scale="6" unitRef="usd">0.2</ix:nonFraction> million and $<ix:nonFraction contextRef="c158" decimals="-5" format="ixt:num-dot-decimal" name="clnn:SimpleInterestExpense" scale="6" unitRef="usd">0.3</ix:nonFraction>
million was recognized during the three and nine months ended September 30, 2020, respectively. The fair value of $<ix:nonFraction contextRef="c159" decimals="-5" format="ixt:num-dot-decimal" name="clnn:FairValueOfLongTermNotesPayable" scale="6" unitRef="usd">0.8</ix:nonFraction> million and $<ix:nonFraction contextRef="c160" decimals="-5" format="ixt:num-dot-decimal" name="clnn:FairValueOfLongTermNotesPayable" scale="6" unitRef="usd">1.1</ix:nonFraction>
million of principal and accrued interest is included in long-term notes payable as of September 30, 2021 and December 31, 2020, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_7" id="_DebtDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cecil County Loan</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_8" id="_DebtDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April&#160;2019, we entered
into a loan agreement (the &#8220;2019 Cecil Loan&#8221;) with Advance Cecil Inc., a non-stock corporation formed under the laws of the
state of Maryland with application for 501(c)(3) non-profit status pending before the United States Internal Revenue Service at the time
of execution of the 2019 Cecil Loan. Pursuant to the 2019 Cecil Loan, Cecil agreed to provide a $<ix:nonFraction contextRef="c161" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" unitRef="usd">0.1</ix:nonFraction> million term loan. Amounts outstanding
under the 2019 Cecil Loan bear simple interest at an annual rate of <ix:nonFraction contextRef="c161" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure">8.00</ix:nonFraction>%. Under the 2019 Cecil Loan, we agreed to affirmative covenants
to which we will remain subject until maturity. These covenants include providing information about the Company and our operations. There
are no financial covenants associated with the 2019 Cecil Loan. Events of default under the 2019 Cecil Loan include failure to make payments
when due, insolvency events, failure to comply with covenants, and material adverse effects with respect to the Company. We are not in
violation of any affirmative covenants. Repayment of the full balance outstanding is due on <ix:nonNumeric contextRef="c162" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate">April 30, 2034</ix:nonNumeric>. <ix:nonNumeric contextRef="c162" name="us-gaap:DebtInstrumentDescription">The 2019 Cecil Loan establishes
&#8220;Phantom Shares,&#8221; based on 23,981 shares of Common Stock (based on 172,622 Series C Preferred Shares prior to the Reverse
Recapitalization), determined at issuance.</ix:nonNumeric> The 2019 Cecil Loan states the repayment amount is to be the greater of the balance of principal
and accrued interest or the Phantom Share value. We determined that the note should be accounted for at fair value. We record the fair
value of the debt at the end of each reporting period. In order to value the note, we consider the amount of the simple interest expense
that would be due and the value of Phantom Shares. Upon the closing of the Reverse Recapitalization and as of December 31, 2020, the fair
value of the 2019 Cecil Loan is determined based on the closing price of CLNN shares listed on Nasdaq.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_9" id="_DebtDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Income of $<ix:nonFraction contextRef="c163" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="6" unitRef="usd">0.1</ix:nonFraction> million and
expense of $<ix:nonFraction contextRef="c164" decimals="-3" format="ixt:num-dot-decimal" name="clnn:SimpleInterestExpense" scale="3" unitRef="usd">52</ix:nonFraction> thousand were recognized during the three and <ix:nonFraction contextRef="c163" decimals="-3" format="ixt-sec:numwordsen" name="clnn:SimpleInterestExpense" scale="3" unitRef="usd">nine</ix:nonFraction> months ended September 30, 2021, respectively. Expense of $<ix:nonFraction contextRef="c165" decimals="-3" format="ixt:num-dot-decimal" name="clnn:SimpleInterestExpense" scale="3" unitRef="usd">42</ix:nonFraction> thousand
and $<ix:nonFraction contextRef="c166" decimals="-3" format="ixt:num-dot-decimal" name="clnn:SimpleInterestExpense" scale="3" unitRef="usd">55</ix:nonFraction> thousand was recognized during the three and nine months ended September 30, 2020, respectively. The fair value of $<ix:nonFraction contextRef="c167" decimals="-5" format="ixt:num-dot-decimal" name="clnn:FairValueOfLongTermNotesPayable" scale="6" unitRef="usd">0.2</ix:nonFraction> million
and $<ix:nonFraction contextRef="c168" decimals="-5" format="ixt:num-dot-decimal" name="clnn:FairValueOfLongTermNotesPayable" scale="6" unitRef="usd">0.2</ix:nonFraction> million of principal and accrued interest is included in long-term notes payable as of September 30, 2021 and December 31, 2020,
respectively.&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_10" id="_DebtDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>PPP Loan</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_11" id="_DebtDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May&#160;2020, we entered
into a note payable in the amount of $<ix:nonFraction contextRef="c169" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NotesAndLoansPayable" scale="6" unitRef="usd">0.6</ix:nonFraction> million (the &#8220;PPP Note&#8221;) under the Paycheck Protection Program of the CARES Act
(the &#8220;PPP&#8221;). As amended, the PPP permits forgiveness of amounts loaned for payments of payroll and other qualifying expenses
within 24 weeks of receipt of loaned funds, given that at least <ix:nonFraction contextRef="c170" decimals="2" format="ixt:num-dot-decimal" name="clnn:PercentageOfLoanAmountUsedToPayrollExpenses" scale="-2" unitRef="pure">60</ix:nonFraction>% of the total loan is used for payroll. Amounts not forgiven have a
repayment period of five years. In January 2021, the full $<ix:nonFraction contextRef="c171" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ExtinguishmentOfDebtAmount" scale="6" unitRef="usd">0.6</ix:nonFraction> million balance of the PPP Note was forgiven and has been recorded as a
gain on extinguishment of debt during the nine months ended September 30, 2021. There was no gain on extinguishment of debt recorded during
the three months ended September 30, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_12" id="_DebtDisclosureTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Avenue Loan</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_13" id="_DebtDisclosureTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2021, we entered into the 2021 Avenue Loan with Avenue. The
agreement provides for a 42-month term loan of up to $<ix:nonFraction contextRef="c172" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" unitRef="usd">30.0</ix:nonFraction> million. The first tranche is $<ix:nonFraction contextRef="c173" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" unitRef="usd">20.0</ix:nonFraction> million (&#8220;Tranche 1&#8221;), of which
$<ix:nonFraction contextRef="c173" decimals="-5" format="ixt:num-dot-decimal" name="clnn:FundedAmountAtClosing" scale="6" unitRef="usd">15.0</ix:nonFraction> million was funded at close. We incurred issuance costs for a total of $<ix:nonFraction contextRef="c174" decimals="-5" format="ixt:num-dot-decimal" name="clnn:AccruedDebtIssuanceCosts" scale="6" unitRef="usd">0.5</ix:nonFraction> million of which $<ix:nonFraction contextRef="c174" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCosts" scale="3" unitRef="usd">35</ix:nonFraction> thousand has been expensed immediately.
The remaining balance from Tranche 1 of $<ix:nonFraction contextRef="c173" decimals="-5" format="ixt:num-dot-decimal" name="clnn:DebtInstrumentUnfundedBalance" scale="6" unitRef="usd">5.0</ix:nonFraction> million was funded on September 28, 2021 and an additional tranche of $<ix:nonFraction contextRef="c175" decimals="-5" format="ixt:num-dot-decimal" name="clnn:SecondLoanAmount" scale="6" unitRef="usd">10.0</ix:nonFraction> million (&#8220;Tranche
2&#8221;) is available at the Company&#8217;s request until June 30, 2022. Pursuant to the 2021 Avenue Loan, <ix:nonNumeric contextRef="c174" name="clnn:ConditionsForFutureFundingDescription">funding of Tranche 2 is subject
to evidence reasonably satisfactory to Avenue of receipt of an additional $5.0 million financing through Maryland&#8217;s State Incentive
Programs and/or other Maryland State programs and mutual agreement of the Company and Avenue. On September 27, 2021, we obtained a waiver
from this additional financing requirement for the funding of the remaining $5.0 million of Tranche 1 and exercised the option to postpone
principal repayment by one year. We incurred additional issuance costs of $<ix:nonFraction contextRef="c176" decimals="-3" format="ixt:num-dot-decimal" name="clnn:AccruedDebtIssuanceCosts" scale="3" unitRef="usd">75</ix:nonFraction> thousand upon funding the remaining $5.0 million of Tranche
1, of which $<ix:nonFraction contextRef="c176" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" unitRef="usd">12</ix:nonFraction> thousand has been expensed immediately. Funding of Tranche 2 is also subject to (a) our achievement of a statistically
significant result on the primary endpoint as defined within the statistical analysis plan for each respective study, or the totality
of the results for any study warrant advancement into a subsequent clinical efficacy study, as reasonably determined by the Company and
Avenue with respect to at least two of the following studies: (i) RESCUE-ALS or the Healey ALS Platform Trial; (ii) REPAIR-PD; or (iii)
REPAIR-MS (&#8220;Performance Milestone 1&#8221;); and (b) our receipt of net proceeds of at least $30 million from the sale and issuance
of our equity securities (including any private placement or follow-on offering) between May 2, 2021 and June 30, 2022.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_14" id="_DebtDisclosureTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="c176" name="clnn:RateOfInterestDescription">The loans bear interest at
a variable rate per annum equal to the sum of (i) the greater of (A) the prime rate, as published by the Wall Street Journal from time
to time or (B) 3.25%, plus (ii) 6.60%. Payments for the loan are interest only for the initial 12 months and can be extended to (i) 12
months (the &#8220;First Interest-only Period Extension&#8221;) if we achieve Performance Milestone 1 and (ii) up to 36 months if (a)
we achieve the First Interest-only Period Extension and (b) have drawn from Tranche 2. On August 16, 2021, we mutually confirmed with
Avenue that Performance Milestone 1 and the First Interest-only Period Extension had been achieved.</ix:nonNumeric> The loan will amortize in equal payments
of principal from the end of the interest period to the expiration of the 42-month term on December 1, 2024. <ix:nonNumeric contextRef="c177" name="clnn:AdditionalPaymentUponMaturityDescription">On the maturity date, an
additional payment equal to 4.25% of the funded loans, or $0.6 million, is due in addition to the remaining unpaid principal and accrued
interest.</ix:nonNumeric> The final payment is recorded as a debt premium and is being amortized over the contractual term using the effective interest
method. The final payment provision is related to the loan host and is not bifurcated pursuant to ASC 815.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_15" id="_DebtDisclosureTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the agreement, we granted to Avenue the Avenue Warrants
for the purchase of <ix:nonFraction contextRef="c174" decimals="0" format="ixt:num-dot-decimal" name="clnn:WarrantToPurchaseShares" scale="0" unitRef="shares">115,851</ix:nonFraction> shares of Common Stock at an exercise price equal to the lower of (i) $<ix:nonFraction contextRef="c174" decimals="2" format="ixt:num-dot-decimal" name="clnn:CommonStockAtAnExercisePrice" scale="0" unitRef="usdPershares">8.63</ix:nonFraction> (which is equal to the five-day
volume weighted average price (&#8220;VWAP&#8221;) per share, determined as of the end of trading on the last trading day prior to execution
of the loan agreement), or (ii) the lowest price per share paid by cash investors for our Common Stock issued in the next bona fide round
of equity financing prior to March 31, 2022 (the &#8220;Next Round Price&#8221;) (see Note 10). <ix:nonNumeric contextRef="c174" name="clnn:Tranche2WarrantAdjustmentDescription">Upon the funding of Tranche 2, the Avenue
Warrant shall be automatically adjusted to include an additional estimated 86,679 shares of Common Stock, which is equal to 5% of the
principal amount of Tranche 2, divided by the lower of (i) the five (5)-day VWAP per share; determined as of the end of trading on the
last trading day before the date of issuance of Tranche 2; or (ii) the Next Round Price.</ix:nonNumeric> We accounted for the Tranche 2 warrants at inception
of the 2021 Avenue Loan in accordance with ASC 815 and the fair value and issuable shares will be remeasured at each reporting period
(see Note 10). Avenue also has the right, in its discretion, but not the obligation, at any time from time to time from the first through
the third-year anniversary of the agreement, while the loan is outstanding, to convert an amount of up to $<ix:nonFraction contextRef="c172" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayable" scale="6" unitRef="usd">5.0</ix:nonFraction> million of the principal
amount of the outstanding loan into Common Stock (the &#8220;Conversion Feature&#8221;) at a price per share equal to <ix:nonFraction contextRef="c174" decimals="2" format="ixt:num-dot-decimal" name="clnn:ConversionPercentageOfCommonStockPriceForConvertibleNotePayable" scale="-2" unitRef="pure">120</ix:nonFraction>% of the stock
purchase price set forth in the warrant. The Conversion Feature is subject to (i) the closing price of our Common Stock for each of the
seven consecutive trading days immediately preceding the conversion being greater than or equal to the conversion price and (ii) the Common
Stock issued in connection with any such conversion not exceeding <ix:nonFraction contextRef="c174" decimals="2" format="ixt:num-dot-decimal" name="clnn:TradingVolumeLimitForConversionOfConvertibleNotePayable" scale="-2" unitRef="pure">20</ix:nonFraction>% of the total trading volume of our Common Stock for the twenty-two
consecutive trading days immediately prior to and including the effective date of such conversion.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_16" id="_DebtDisclosureTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the 2021 Avenue Loan, we agreed to affirmative and negative covenants
to which we will remain subject upon maturity in the absence of prepayments. These covenants include providing information about the Company
and our operations; limitation on our ability to retire, repurchase, or redeem our Common Stock, options, and warrants other than per
the terms of the securities; and limitations on our ability to pay dividends of cash or property. <ix:nonNumeric contextRef="c176" name="clnn:ThresholdForRemovalOfFinancialCovenantsDescription">The financial covenant associated with
the loan agreement includes maintaining minimum unrestricted cash and cash equivalents of at least $<ix:nonFraction contextRef="c176" decimals="-5" format="ixt:num-dot-decimal" name="clnn:MinimumCashBalanceForLoanCovenant" scale="6" unitRef="usd">5.0</ix:nonFraction> million; provided that upon our
(i) achievement of Performance Milestone 1, and (ii) receiving of net proceeds of at least $30.0 million from the sale and issuance of
our equity securities (including any PIPE or follow-on offering) between May 1, 2021 and June 30, 2022, we shall no longer be subject
to financial covenants.</ix:nonNumeric> We are not in violation of the covenants. The agreement provides for events of default customary for loans of
this type, including but not limited to non-payment, breaches, the occurrence of a material adverse change, or defaults in the performance
of covenants, insolvency, and bankruptcy. The 2021 Avenue Loan is collateralized by substantially all of our assets other than intellectual
property, including capital stock of the Company and its subsidiaries, in which Avenue is granted a continuing security interest. The
net proceeds from the issuance of the loan were initially allocated to the warrant at an amount equal to their fair value of $<ix:nonFraction contextRef="c174" decimals="-5" format="ixt:num-dot-decimal" name="clnn:FairValueOfWarrant" scale="6" unitRef="usd">1.0</ix:nonFraction> million
and the remainder to the loan. The allocation of incurred financing costs of $<ix:nonFraction contextRef="c174" decimals="-5" format="ixt:num-dot-decimal" name="clnn:DebtInstrumentFinancingCosts" scale="6" unitRef="usd">0.5</ix:nonFraction> million and the fair value of the warrant, together
with the final payment, are recorded as a debt discount and debt premium, respectively, and are being amortized over the contractual term
using the effective interest method. During the three and nine months ended September 30, 2021, we recorded interest expense of $<ix:nonFraction contextRef="c178" decimals="-5" format="ixt:num-dot-decimal" name="clnn:SimpleInterestExpense" scale="6" unitRef="usd">0.6</ix:nonFraction> million
and $<ix:nonFraction contextRef="c176" decimals="-5" format="ixt:num-dot-decimal" name="clnn:SimpleInterestExpense" scale="6" unitRef="usd">0.8</ix:nonFraction> million, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_17" id="_DebtDisclosureTextBlock-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following is a schedule of
future payments, net of unamortized debt discounts, if Avenue does not convert up to $<ix:nonFraction contextRef="c179" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleDebt" scale="6" unitRef="usd">5.0</ix:nonFraction> million of the loan into Common Stock between
May 21, 2022 through May 21, 2024:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_DebtDisclosureTextBlock-c0_cont_17"><ix:nonNumeric contextRef="c0" escape="true" name="clnn:ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscounts"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>2021 (remainder)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-206">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-207">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="clnn:DebtInstrumentUnamortizedDiscountYearTwo" scale="3" unitRef="usd">6,667</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="clnn:DebtInstrumentUnamortizedDiscountYearThree" scale="3" unitRef="usd">13,333</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-208">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-209">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-210">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Subtotal of future principal payments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="clnn:FuturePrincipalPayments" scale="3" unitRef="usd">20,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Unamortized debt discount associated with issuance date warrant fair value and financing costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedPremium" scale="3" unitRef="usd">1,811</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecurities" scale="3" unitRef="usd">18,189</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_PreferredStockTextBlock-c0_cont_1" escape="true" name="us-gaap:PreferredStockTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>9. Preferred Stock Warrant Liability</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_PreferredStockTextBlock-c0_cont_2" id="_PreferredStockTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the Reverse Recapitalization,
we issued Series A Preferred Stock Warrants in 2013 pursuant to certain note purchase agreements. The warrants expire <span style="-sec-ix-hidden: hidden-fact-211">ten&#160;years</span> from
issuance. These warrants are exercisable at a fixed exercise price of $<ix:nonFraction contextRef="c196" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceDecrease" scale="0" unitRef="usdPershares">1.97</ix:nonFraction>, which is equal to the price per share of the Series A Preferred
Stock. As of December 31, 2019, these warrants were exercisable into <ix:nonFraction contextRef="c196" decimals="0" format="ixt:num-dot-decimal" name="clnn:SharesOfWarrantsExercisable" scale="0" unitRef="shares">1,608,670</ix:nonFraction> shares of the Series A Preferred Stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_PreferredStockTextBlock-c0_cont_3" id="_PreferredStockTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the Reverse Recapitalization,
on April 8, 2013, we issued ten-year warrants to purchase units of our most senior equity equal to <ix:nonFraction contextRef="c197" decimals="4" format="ixt:num-dot-decimal" name="clnn:PercentOfFullydilutedEquityPurchasableUponExercise" scale="-2" unitRef="pure">0.25</ix:nonFraction>% of our fully diluted equity at
the time of exercise pursuant to certain note purchase agreements. As of December 31, 2019, these warrants were exercisable into <ix:nonFraction contextRef="c198" decimals="0" format="ixt:num-dot-decimal" name="clnn:SharesOfWarrantsExercisable" scale="0" unitRef="shares">271,439</ix:nonFraction>
shares of our most senior equity, Series C Preferred Stock, at a fixed exercise price of $<ix:nonFraction contextRef="c198" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceDecrease" scale="0" unitRef="usdPershares">1.97</ix:nonFraction> per share. On August 11, 2020, in connection
with our issuance of Series D Preferred Stock, these warrants became exercisable into <ix:nonFraction contextRef="c199" decimals="0" format="ixt:num-dot-decimal" name="clnn:SharesOfWarrantsExercisable" scale="0" unitRef="shares">320,441</ix:nonFraction> shares of our most senior equity, Series
D Preferred Stock, at a fixed exercise price of $<ix:nonFraction contextRef="c199" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceDecrease" scale="0" unitRef="usdPershares">1.97</ix:nonFraction> per share.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_PreferredStockTextBlock-c0_cont_4" id="_PreferredStockTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the Reverse Recapitalization,
we classified Preferred Stock warrants as a liability on the condensed consolidated balance sheets because the warrants are freestanding
financial instruments that may have required us to transfer assets upon exercise. The liability associated with each of these warrants
was initially recorded at fair value upon the issuance date of each warrant and is subsequently remeasured to fair value as a component
of other income (expense), net in the condensed consolidated statements of operations and comprehensive income (loss). Upon the closing
of the Reverse Recapitalization (see Note 3), and pursuant to the Merger Agreement, all of the outstanding Clene Nanomedicine Preferred
Stock was converted into Common Stock and the Clene Nanomedicine Preferred Stock warrants to purchase Clene Nanomedicine Preferred Stock
were converted to warrants to purchase Common Stock (see Note 10). Upon conversion, we assessed the features of the warrants and determined
that they qualify for classification as permanent equity upon the closing of the Reverse Recapitalization. Accordingly, we remeasured
the warrants to fair value one final time upon the close of the Reverse Recapitalization, and recognized a loss of $<ix:nonFraction contextRef="c134" decimals="-5" format="ixt:num-dot-decimal" name="clnn:LossInFairValueOfWarrantLiability" scale="6" unitRef="usd">14.6</ix:nonFraction> million for the
year ended December 31, 2020, within other income, (expense), net on the condensed consolidated statements of operations and comprehensive
income (loss). Upon the closing of the Reverse Recapitalization, the warrant liability was reclassified to additional paid-in capital
(see Note 17).&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_PreferredStockTextBlock-c0_cont_5" id="_PreferredStockTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of September 30, 2021 and
December 31, 2020, we do not have any Preferred Stock warrants outstanding.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_PreferredStockTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recognized a change in
fair value of the outstanding warrants of $<ix:nonFraction contextRef="c13" decimals="-5" format="ixt:num-dot-decimal" name="clnn:FairValueAdjustmentOfWarrantsOutstanding" scale="6" unitRef="usd">5.1</ix:nonFraction> million during the three months ended September 30, 2020 and $<ix:nonFraction contextRef="c14" decimals="-5" format="ixt:num-dot-decimal" name="clnn:FairValueAdjustmentOfWarrantsOutstanding" scale="6" unitRef="usd">7.4</ix:nonFraction> million during the nine
months ended September 30, 2020 in the condensed consolidated statements of operations and comprehensive&#160;income (loss).&#160;</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CommonStockWarrantsDisclosureTextBlock-c0_cont_1" escape="true" name="clnn:CommonStockWarrantsDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>10. Common Stock Warrants</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_CommonStockWarrantsDisclosureTextBlock-c0_cont_2" id="_CommonStockWarrantsDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of September 30, 2021,
outstanding warrants to purchase shares of Common Stock consisted of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommonStockWarrantsDisclosureTextBlock-c0_cont_3" id="_CommonStockWarrantsDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1.5pt solid">Date Exercisable</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Shares<br/>
 Issuable</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercise Price</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercisable for</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Classification</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Expiration</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%">June 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><ix:nonFraction contextRef="c212" decimals="0" format="ixt:num-dot-decimal" name="clnn:NumberOfSharesIssuable" scale="0" unitRef="shares">117,500</ix:nonFraction></td><td style="white-space: nowrap; width: 2%; text-align: left"><sup>(1)</sup></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction contextRef="c212" decimals="2" format="ixt:num-dot-decimal" name="clnn:CommonStockWarrantsExercisePrice" scale="0" unitRef="usdPershares">0.01</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: center"><ix:nonNumeric contextRef="c213" name="clnn:CommonStockWarrantsExercisable">Common Stock</ix:nonNumeric></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: center"><ix:nonNumeric contextRef="c213" name="clnn:CommonStockWarrantsClassification"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: center"><ix:nonNumeric contextRef="c213" name="clnn:CommonStockWarrantsExpiration"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 2021</span></ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>December 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c214" decimals="0" format="ixt:num-dot-decimal" name="clnn:NumberOfSharesIssuable" scale="0" unitRef="shares">2,407,500</ix:nonFraction></td><td style="white-space: nowrap; text-align: left"><sup>(2)</sup></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c214" decimals="2" format="ixt:num-dot-decimal" name="clnn:CommonStockWarrantsExercisePrice" scale="0" unitRef="usdPershares">11.50</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c215" name="clnn:CommonStockWarrantsExercisable">Common Stock</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><ix:nonNumeric contextRef="c215" name="clnn:CommonStockWarrantsClassification"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><ix:nonNumeric contextRef="c215" name="clnn:CommonStockWarrantsExpiration"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 2025</span></ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>December 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c216" decimals="0" format="ixt:num-dot-decimal" name="clnn:NumberOfSharesIssuable" scale="0" unitRef="shares">24,583</ix:nonFraction></td><td style="white-space: nowrap; text-align: left"><sup>(3)</sup></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c216" decimals="2" format="ixt:num-dot-decimal" name="clnn:CommonStockWarrantsExercisePrice" scale="0" unitRef="usdPershares">11.50</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c217" name="clnn:CommonStockWarrantsExercisable">Common Stock</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><ix:nonNumeric contextRef="c217" name="clnn:CommonStockWarrantsClassification"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><ix:nonNumeric contextRef="c217" name="clnn:CommonStockWarrantsExpiration"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 2025</span></ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>December 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c218" decimals="0" format="ixt:num-dot-decimal" name="clnn:NumberOfSharesIssuable" scale="0" unitRef="shares">1,929,111</ix:nonFraction></td><td style="white-space: nowrap; text-align: left"><sup>(4)</sup></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c218" decimals="2" format="ixt:num-dot-decimal" name="clnn:CommonStockWarrantsExercisePrice" scale="0" unitRef="usdPershares">1.97</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c219" name="clnn:CommonStockWarrantsExercisable">Common Stock</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><ix:nonNumeric contextRef="c219" name="clnn:CommonStockWarrantsClassification"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><ix:nonNumeric contextRef="c219" name="clnn:CommonStockWarrantsExpiration"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2023</span></ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">May 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c220" decimals="0" format="ixt:num-dot-decimal" name="clnn:NumberOfSharesIssuable" scale="0" unitRef="shares">115,851</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><sup>(5)(6)</sup></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c220" decimals="2" format="ixt:num-dot-decimal" name="clnn:CommonStockWarrantsExercisePrice" scale="0" unitRef="usdPershares">8.63</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c221" name="clnn:CommonStockWarrantsExercisable">Common Stock</ix:nonNumeric></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center"><ix:nonNumeric contextRef="c221" name="clnn:CommonStockWarrantsClassification"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liability</span></ix:nonNumeric></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center"><ix:nonNumeric contextRef="c221" name="clnn:CommonStockWarrantsExpiration"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2026</span></ix:nonNumeric></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="clnn:NumberOfSharesIssuable" scale="0" unitRef="shares">4,594,545</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_CommonStockWarrantsDisclosureTextBlock-c0_cont_4" id="_CommonStockWarrantsDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2020, outstanding
warrants to purchase shares of Common Stock consisted of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommonStockWarrantsDisclosureTextBlock-c0_cont_5" id="_CommonStockWarrantsDisclosureTextBlock-c0_cont_4"><ix:continuation continuedAt="_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-c0_cont_2" id="_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1.5pt solid">Date Exercisable</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Shares Issuable</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercise Price</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercisable for</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Classification</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Expiration</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%">June 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><ix:nonFraction contextRef="c222" decimals="0" format="ixt:num-dot-decimal" name="clnn:NumberOfSharesIssuable" scale="0" unitRef="shares">1,119,750</ix:nonFraction></td><td style="width: 2%; text-align: left"><sup>(1)</sup></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction contextRef="c222" decimals="2" format="ixt:num-dot-decimal" name="clnn:CommonStockWarrantsExercisePrice" scale="0" unitRef="usdPershares">0.01</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: center"><ix:nonNumeric contextRef="c223" name="clnn:CommonStockWarrantsExercisable">Common Stock</ix:nonNumeric></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: center"><ix:nonNumeric contextRef="c223" name="clnn:CommonStockWarrantsClassification"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: center"><ix:nonNumeric contextRef="c223" name="clnn:CommonStockWarrantsExpiration"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 2021</span></ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>December 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c224" decimals="0" format="ixt:num-dot-decimal" name="clnn:NumberOfSharesIssuable" scale="0" unitRef="shares">2,407,500</ix:nonFraction></td><td style="text-align: left"><sup>(2)</sup></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c224" decimals="2" format="ixt:num-dot-decimal" name="clnn:CommonStockWarrantsExercisePrice" scale="0" unitRef="usdPershares">11.50</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c225" name="clnn:CommonStockWarrantsExercisable">Common Stock</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><ix:nonNumeric contextRef="c225" name="clnn:CommonStockWarrantsClassification"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><ix:nonNumeric contextRef="c225" name="clnn:CommonStockWarrantsExpiration"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 2025</span></ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>December 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c226" decimals="0" format="ixt:num-dot-decimal" name="clnn:NumberOfSharesIssuable" scale="0" unitRef="shares">110,000</ix:nonFraction></td><td style="text-align: left"><sup>(3)</sup></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c226" decimals="2" format="ixt:num-dot-decimal" name="clnn:CommonStockWarrantsExercisePrice" scale="0" unitRef="usdPershares">11.50</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c227" name="clnn:CommonStockWarrantsExercisable">Common Stock</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><ix:nonNumeric contextRef="c227" name="clnn:CommonStockWarrantsClassification"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><ix:nonNumeric contextRef="c227" name="clnn:CommonStockWarrantsExpiration"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 2025</span></ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">December 2020</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c228" decimals="0" format="ixt:num-dot-decimal" name="clnn:NumberOfSharesIssuable" scale="0" unitRef="shares">1,929,111</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left"><sup>(4)</sup></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c228" decimals="2" format="ixt:num-dot-decimal" name="clnn:CommonStockWarrantsExercisePrice" scale="0" unitRef="usdPershares">1.97</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c229" name="clnn:CommonStockWarrantsExercisable">Common Stock</ix:nonNumeric></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center"><ix:nonNumeric contextRef="c229" name="clnn:CommonStockWarrantsClassification"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></ix:nonNumeric></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center"><ix:nonNumeric contextRef="c229" name="clnn:CommonStockWarrantsExpiration"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2023</span></ix:nonNumeric></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="clnn:NumberOfSharesIssuable" scale="0" unitRef="shares">5,566,361</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation id="_CommonStockWarrantsDisclosureTextBlock-c0_cont_5"><ix:continuation id="_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consisted of <ix:nonFraction contextRef="c200" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">1,119,750</ix:nonFraction> shares of Common Stock underlying <ix:nonFraction contextRef="c200" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares">2,239,500</ix:nonFraction> December 2020 PIPE Warrants issued on December 30, 2020, in connection with the December 2020 PIPE (see Note 18). A holder of the December 2020 PIPE Warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than <ix:nonNumeric contextRef="c201" name="clnn:PIPEWarrantsOwnershipLimit">9.99%</ix:nonNumeric> of the number of shares of the Company&#8217;s Common Stock outstanding immediately after giving effect to such exercise. As of September 30, 2021, <ix:nonFraction contextRef="c202" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" unitRef="shares">2,004,500</ix:nonFraction> December 2020 PIPE Warrants were exercised into <ix:nonFraction contextRef="c203" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">1,002,250</ix:nonFraction> shares of Common Stock. The outstanding balance as of September 30, 2021 consists of <ix:nonFraction contextRef="c202" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">117,500</ix:nonFraction> shares of Common Stock underlying <ix:nonFraction contextRef="c202" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares">235,000</ix:nonFraction> December 2020 PIPE Warrants. As of December 31, 2020, none of the warrants had been exercised.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">2,407,500</ix:nonFraction> shares of Common Stock underlying <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares">4,815,000</ix:nonFraction> warrants issued in connection with Tottenham&#8217;s initial public offering. <ix:nonNumeric contextRef="c0" name="clnn:CompanyWarrantRedemptionRight">The Company may redeem the outstanding warrants, in whole and not in part, at a price of $0.01 per warrant if, and only if, the last sales price of the Company&#8217;s Common Stock equals or exceeds $16.50 per share for any 20 trading days within a 30-trading day period ending three business days before the Company sends the notice of redemption.</ix:nonNumeric> As of September 30, 2021, and December 31, 2020, none of the warrants had been exercised.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consisted of <ix:nonFraction contextRef="c204" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">110,000</ix:nonFraction> shares of Common Stock underlying <ix:nonFraction contextRef="c204" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares">220,000</ix:nonFraction> warrants issued as part of the Chardan Unit Purchase Option (see Note 3). On July 15, 2021 the Chardan Unit Purchase Option was net exercised, resulting in the issuance of <ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">54,083</ix:nonFraction> shares of Common Stock and <ix:nonFraction contextRef="c206" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">49,166</ix:nonFraction> warrants to purchase one-half of one share of Common Stock, or <ix:nonFraction contextRef="c207" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">24,583</ix:nonFraction> shares of Common Stock. As of September 30, 2021, none of the warrants had been exercised. As of December 31, 2020, the Chardan Unit Purchase Option had not been exercised.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of <ix:nonFraction contextRef="c208" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">1,929,111</ix:nonFraction> shares of Common Stock underlying <ix:nonFraction contextRef="c208" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares">1,929,111</ix:nonFraction> warrants originally issued by Clene Nanomedicine as Series A and Series D Preferred Stock Warrants (see Note 9). As of September 30, 2021, and December 31, 2020, none of the warrants had been exercised.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><ix:nonNumeric contextRef="c209" continuedAt="_ExercisePriceOfWarrantsDescription-c209_cont_1" name="clnn:ExercisePriceOfWarrantsDescription"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></ix:nonNumeric></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:continuation id="_ExercisePriceOfWarrantsDescription-c209_cont_1">Consists of <ix:nonFraction contextRef="c210" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">115,851</ix:nonFraction> shares of Common Stock underlying <ix:nonFraction contextRef="c210" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares">115,851</ix:nonFraction> Avenue Warrants issued pursuant to Tranche 1 of the 2021 Avenue Loan at an exercise price equal to the lower of (i) $8.63 (which is equal to the five-day VWAP per share, determined as of the end of trading on the last trading day prior to execution of the loan agreement), or (ii) the Next Round Price.</ix:continuation> (see Note 8). As of September 30, 2021, the Avenue Warrant had not been exercised.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the 2021 Avenue Loan, an additional estimated <ix:nonFraction contextRef="c211" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">86,679</ix:nonFraction> shares
of Common Stock underlying warrants are issuable pursuant to our draw of Tranche 2 between January 1, 2022 and June 30, 2022 (see Note
8). In accordance with ASC 815, we recognized these warrants at the inception of the 2021 Avenue Loan and classified them as a warrant
liability and the fair value and issuable shares will be remeasured at each reporting period (see Note 16). As of September 30, 2021,
the warrants are not issued or outstanding.</span></td></tr> </table></ix:continuation></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_ConvertibleNotesDisclosureTextBlock-c0_cont_1" escape="true" name="clnn:ConvertibleNotesDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>11. Convertible Notes</b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_ConvertibleNotesDisclosureTextBlock-c0_cont_2" id="_ConvertibleNotesDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>2020 Convertible Notes</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ConvertibleNotesDisclosureTextBlock-c0_cont_3" id="_ConvertibleNotesDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February through July 2020,
we issued convertible promissory notes (the &#8220;2020 Convertible Notes&#8221;) in an aggregate principal amount of $<ix:nonFraction contextRef="c230" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayable" scale="6" unitRef="usd">6.1</ix:nonFraction> million, bearing
interest at an annual rate of <ix:nonFraction contextRef="c231" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure">5</ix:nonFraction>%. <ix:nonNumeric contextRef="c231" name="clnn:DescriptionOfConvertibleNotes">The 2020 Convertible Notes were convertible at the earlier of (i)&#160;one year, at which point the
notes would be convertible into Series C Preferred Shares at the Series C Preferred Share issuance price, and (ii)&#160;next equity financing
of no less than $10.0 million, at which point the notes would be convertible into shares issued in the next equity financing at 90% of
the per share issuance price of the next equity financing. The 2020 Convertible Notes contained embedded features that provide the lenders
with multiple settlement alternatives. Certain of these settlement features provided the lenders with a right to a fixed number of our
shares upon conversion of the notes. Other settlement features provided the lenders with the right or the obligation to receive cash or
a variable number of shares upon the completion of a capital raising transaction, change of control, or default of the Company (the &#8220;Redemption
Features&#8221;). The Redemption Features of the 2020 Convertible Notes met the requirements for separate accounting and were accounted
for as a single derivative instrument (the &#8220;2020 Derivative Instrument&#8221;). Accordingly, the 2020 Derivative Instrument of $0.7
million was recorded at fair value at inception as redeemable convertible preferred stock derivative liability in the condensed consolidated
balance sheets (see Note 12).</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_ConvertibleNotesDisclosureTextBlock-c0_cont_4" id="_ConvertibleNotesDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recognized interest expense
of $<ix:nonFraction contextRef="c232" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="3" unitRef="usd">34</ix:nonFraction> thousand, including amortization of debt discount of $<ix:nonFraction contextRef="c232" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" unitRef="usd">0.1</ix:nonFraction> million during the three months ended September 30, 2020, in connection
with the 2020 Convertible Notes. We recognized interest expense of $<ix:nonFraction contextRef="c233" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" unitRef="usd">0.1</ix:nonFraction> million, including amortization of debt discount of $<ix:nonFraction contextRef="c233" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="6" unitRef="usd">0.2</ix:nonFraction> million
during the nine months ended September 30, 2020, in connection with the 2020 Convertible Notes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ConvertibleNotesDisclosureTextBlock-c0_cont_5" id="_ConvertibleNotesDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 11, 2020, in connection
with our issuance and sale of Series D Preferred Stock, all of the outstanding principal and accrued interest under the 2020 Convertible
Notes, totaling $<ix:nonFraction contextRef="c234" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ExtinguishmentOfDebtAmount" scale="6" unitRef="usd">6.9</ix:nonFraction> million, was automatically converted into <ix:nonFraction contextRef="c234" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" unitRef="shares">1,497,135</ix:nonFraction> shares of Series D Preferred Stock at a price equal to <ix:nonFraction contextRef="c234" decimals="2" format="ixt:num-dot-decimal" name="clnn:PercentageOfStockPrice" scale="-2" unitRef="pure">90</ix:nonFraction>% of
$<ix:nonFraction contextRef="c235" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" unitRef="usdPershares">4.60</ix:nonFraction> per share, the per share price paid in cash by investors in the Series D Preferred Stock financing.&#160;Upon the closing of the
Reverse Recapitalization (see Note 3), and pursuant to the Merger Agreement, all outstanding Clene Nanomedicine Series D Preferred Stock
was converted to Clene Inc. Common Stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ConvertibleNotesDisclosureTextBlock-c0_cont_6" id="_ConvertibleNotesDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We accounted for the conversion
of the 2020 Convertible Notes as a debt extinguishment and recognized a loss on extinguishment of debt of $<ix:nonFraction contextRef="c236" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" scale="6" unitRef="usd">0.5</ix:nonFraction> million within other income
(expense), net in the consolidated statements of operations and comprehensive income (loss) for the year ended December 31, 2020. As of
the date of conversion, the unamortized discount on the 2020 Convertible Notes was $<ix:nonFraction contextRef="c237" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" unitRef="usd">0.5</ix:nonFraction> million. <ix:nonNumeric contextRef="c236" name="clnn:DescriptionOfLossOnExtinguishment">The loss on extinguishment was calculated
as the difference between (i) the fair value of the 1,497,135 shares of Series D Preferred Stock issued to settle the 2020 Convertible
Notes of $6.9 million and (ii) the carrying value of the 2020 Convertible Notes of $5.7 million, which includes the principal balance
of the 2020 Convertible Notes of $6.1 million and accrued but unpaid interest of $0.1 million, net of the unamortized debt discount of
$0.5 million, plus the then-current fair value of derivative liability associated with the 2020 Convertible Notes at the time of the extinguishment
of $0.7 million.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ConvertibleNotesDisclosureTextBlock-c0_cont_7" id="_ConvertibleNotesDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Convertible Notes Payable</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ConvertibleNotesDisclosureTextBlock-c0_cont_8" id="_ConvertibleNotesDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="c238" name="clnn:ConvertibleNotesPayableDescription">In May 2021, we entered into
the 2021 Avenue Loan from which we granted to Avenue the right, in its discretion, but not the obligation, at any time from time to time
from May 21, 2022 through May 21, 2024, while the loan is outstanding, to convert an amount of up to $<ix:nonFraction contextRef="c238" decimals="-5" format="ixt:num-dot-decimal" name="clnn:LoanOutstanding" scale="6" unitRef="usd">5.0</ix:nonFraction> million of the principal amount
of the outstanding loan into shares of Common Stock at a price per share equal to <ix:nonFraction contextRef="c238" decimals="2" format="ixt:num-dot-decimal" name="clnn:ConversionPercentageOfCommonStockPriceForConvertibleNotePayable" scale="-2" unitRef="pure">120</ix:nonFraction>% of the stock purchase price set forth in the Avenue
Warrant (see Note 8).</ix:nonNumeric> The Conversion Feature is subject to (i) the closing price of our Common Stock for each of the seven consecutive
trading days immediately preceding the conversion being greater than or equal to the conversion price and (ii) the Common Stock issued
in connection with any such conversion not exceeding 20% of the total trading volume of our Common Stock for the twenty-two consecutive
trading days immediately prior to and including the effective date of such conversion. The Conversion Feature did not meet the requirements
for separate accounting and is not accounted for as a derivative instrument. As of September 30, 2021, the number of shares of Common
Stock potentially issuable upon conversion was <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares">482,703</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ConvertibleNotesDisclosureTextBlock-c0_cont_9" id="_ConvertibleNotesDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We classified $<ix:nonFraction contextRef="c239" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayable" scale="6" unitRef="usd">5.0</ix:nonFraction> million of the 2021 Avenue Loan as convertible notes
payable in the condensed consolidated balance sheets as of September 30, 2021, with unamortized debt discount and issuance costs of $<ix:nonFraction contextRef="c239" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscountCurrent" scale="6" unitRef="usd">0.4</ix:nonFraction>
million.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_ConvertibleNotesDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the three and nine months ended September 30, 2021, we recognized
(i) total interest expense of $<ix:nonFraction contextRef="c240" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="6" unitRef="usd">0.2</ix:nonFraction> million and $<ix:nonFraction contextRef="c241" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="6" unitRef="usd">0.3</ix:nonFraction> million, respectively; (ii) coupon interest expense of $<ix:nonFraction contextRef="c240" decimals="-5" format="ixt:num-dot-decimal" name="clnn:CouponInterestExpense" scale="6" unitRef="usd">0.1</ix:nonFraction> million and $<ix:nonFraction contextRef="c241" decimals="-5" format="ixt:num-dot-decimal" name="clnn:CouponInterestExpense" scale="6" unitRef="usd">0.2</ix:nonFraction> million,
respectively; and (iii) amortization of debt discount and issuance costs of $<ix:nonFraction contextRef="c240" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" unitRef="usd">41</ix:nonFraction> thousand and $<ix:nonFraction contextRef="c241" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" unitRef="usd">64</ix:nonFraction> thousand, respectively, in connection
with the convertible notes payable. During the three and nine months ended September 30, 2020, we did not recognize any interest expense
or amortization in connection with the convertible notes payable. <ix:nonNumeric contextRef="c0" name="us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate">The effective interest rate was <ix:nonNumeric contextRef="c240" name="us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate">15.46%</ix:nonNumeric> for the three and nine months
ended September 30, 2021.</ix:nonNumeric></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>12. Derivative Instruments</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock-c0_cont_2" id="_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Derivative Instrument in Connection with
the 2020 Convertible Notes</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock-c0_cont_3" id="_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">One of the redemption features
of the 2020 Convertible Notes met the requirements for separate accounting and was accounted for as a derivative instrument. The 2020
Derivative Instrument was recorded at fair value, which was $<ix:nonFraction contextRef="c242" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DerivativeFairValueOfDerivativeNet" scale="6" unitRef="usd">0.7</ix:nonFraction> million at issuance. In August 2020, in connection with our issuance
and sale of Series D Preferred Stock, all of the outstanding principal and accrued interest under the 2020 Convertible Notes was automatically
converted into shares of Series D Preferred Stock and the derivative liability was extinguished. Prior to the extinguishment of derivative
liability, the 2020 Derivative Instrument was marked to fair value and we recorded the change in the 2020 Derivative Instrument of ($<ix:nonFraction contextRef="c134" decimals="-3" format="ixt:num-dot-decimal" name="clnn:LossOnDerivativeInstruments" scale="3" sign="-" unitRef="usd">29</ix:nonFraction>)
thousand in the consolidated statements of operations and comprehensive income (loss) for the year ended December 31, 2020 (see Note 11).
For the three and nine months ended September 30, 2020, we recorded the change in the 2020 Derivative Instrument of $<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="clnn:LossOnDerivativeInstruments" scale="3" unitRef="usd">15</ix:nonFraction> thousand and $<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="clnn:LossOnDerivativeInstruments" scale="3" unitRef="usd">29</ix:nonFraction>
thousand, respectively, in the condensed consolidated statements of operations and comprehensive income (loss). Upon the closing of the
Reverse Recapitalization (see Note 3), and pursuant to the Merger Agreement, all outstanding Clene Nanomedicine Preferred Stock was converted
to Clene Inc. Common Stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock-c0_cont_4" id="_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Derivative Instruments in Connection with
the Contingent Earn-Outs</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock-c0_cont_5" id="_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The earn-out shares issued
in connection with the Reverse Recapitalization met the requirements for separate accounting and are therefore accounted for as derivative
instruments. Accordingly, upon the consummation of the Reverse Recapitalization, we recorded a liability in the condensed consolidated
balance sheets and a debit to additional paid-in capital for the earn-out provision associated with the Initial Shareholders Contingent
Earn-out and a debit to accumulated deficit for the earn-out provisions associated with the Clene Nanomedicine Contingent Earn-out. The
contingent shares to be issued to the Clene Nanomedicine shareholders immediately prior to the Reverse Capitalization were treated as
a deemed distribution. The Contingent Earn-outs were subsequently remeasured to fair value at each reporting date as a component of other
income (expense), net in the condensed consolidated statements of operations and comprehensive income (loss).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock-c0_cont_6" id="_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the closing of the Reverse
Recapitalization, we recognized the Clene Nanomedicine Contingent Earn-out and Initial Shareholders Contingent Earn-out liabilities at
their fair value of $<ix:nonFraction contextRef="c124" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquityFairValueAdjustment" scale="6" unitRef="usd">64.7</ix:nonFraction> million and $<ix:nonFraction contextRef="c243" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure" scale="6" unitRef="usd">7.4</ix:nonFraction> million, respectively, in the condensed consolidated balance sheets. As of December 31, 2020,
the carrying values of the Clene Nanomedicine Contingent Earn-out and Initial Shareholders Contingent Earn-out were $<ix:nonFraction contextRef="c134" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquityFairValueAdjustment" scale="6" unitRef="usd">52.1</ix:nonFraction> million and
$<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure" scale="6" unitRef="usd">5.9</ix:nonFraction> million, respectively. As of September 30, 2021, the carrying values of the Clene Nanomedicine Contingent Earn-out and Initial Shareholders
Contingent Earn-out were $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquityFairValueAdjustment" scale="6" unitRef="usd">34.0</ix:nonFraction> million and $<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure" scale="6" unitRef="usd">4.2</ix:nonFraction> million, respectively. For the three months ended September 30, 2021, we recognized gains
of $<ix:nonFraction contextRef="c12" decimals="-5" format="ixt:num-dot-decimal" name="clnn:GainlossOnCleneNanomedicineContingentEarnout" scale="6" unitRef="usd">35.0</ix:nonFraction> million in change in fair value of the Clene Nanomedicine Contingent Earn-out and $<ix:nonFraction contextRef="c12" decimals="-5" format="ixt:num-dot-decimal" name="clnn:GainlossOnInitialShareholdersContingentEarnout" scale="6" unitRef="usd">3.4</ix:nonFraction> million in change in fair value of the
Initial Shareholders Contingent Earn-out as components of other income (expense), net in the condensed consolidated statements of operations
and comprehensive income (loss). For the nine months ended September 30, 2021, we recognized gains of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="clnn:GainlossOnCleneNanomedicineContingentEarnout" scale="6" sign="-" unitRef="usd">18.1</ix:nonFraction> million in change in fair
value of the Clene Nanomedicine Contingent Earn-out and $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="clnn:GainlossOnInitialShareholdersContingentEarnout" scale="6" sign="-" unitRef="usd">1.7</ix:nonFraction> million in change in fair value of the Initial Shareholders Contingent Earn-out
as components of other income (expense), net in the condensed consolidated statements of operations and comprehensive income (loss). To
date, none of the milestones have been achieved.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock-c0_cont_7" id="_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Derivative Instrument in Connection with
the 2021 Avenue Loan</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock-c0_cont_8" id="_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Avenue Warrants issued
pursuant to Tranche 1 of the 2021 Avenue Loan and the warrants issuable pursuant to the draw of Tranche 2 (see Note 8) met the requirements
for separate accounting and are therefore accounted for as derivative instruments. The 2021 Avenue Loan has the following features: (i)
prepayment provision, (ii) final payment provision, (iii) event of default redemption provision, and (iv) event of default interest provision.
The provisions (i) to (iii) are related to the loan host and are not bifurcated pursuant to ASC 815. For the provision (iv), we have not
experienced an event of default in the past and believe the probability of triggering one in the future is remote. Therefore, we determined
the value of this feature to be de minimis on the remote probability of occurrence of a triggering event.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the closing of the 2021
Avenue Loan, we recognized the warrant liability as a debt discount based on its fair value of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="clnn:WarrantLiabilityFairValue" scale="6" unitRef="usd">1.5</ix:nonFraction> million. The debt discount is being
amortized over the contractual term using the effective interest method. Our determination of the fair value of the warrant utilized the
Black-Scholes option-pricing valuation model. Additionally, a Monte Carlo simulation was used to simulate the exercise price as an input
in the Black-Scholes valuation model (see Note 10). For the three and nine months ended September 30, 2021, we recognized income of $<ix:nonFraction contextRef="c12" decimals="-5" format="ixt:num-dot-decimal" name="clnn:Changeinfairvaluewarrants" scale="6" unitRef="usd">0.4</ix:nonFraction>
million and $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="clnn:Changeinfairvaluewarrants" scale="6" unitRef="usd">0.5</ix:nonFraction> million, respectively, in change in fair value of the warrant as a component of other income (expense), net in the condensed
consolidated statements of operations and comprehensive income (loss). To date, the warrants have not been exercised.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>13. Commitments and Contingencies</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Litigation</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may
have certain contingent liabilities that arise in the ordinary course of business activities. We accrue a liability for such matters when
it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. We are not aware of any current
pending legal matters or claims.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>14. Income Taxes</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_2" id="_IncomeTaxDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recorded income tax benefits
of $<ix:nonFraction contextRef="c12" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" unitRef="usd">0.1</ix:nonFraction> million and $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" unitRef="usd">0.2</ix:nonFraction> million for the net operating losses incurred for the three and nine months ended September 30, 2021. We have
not recorded income tax benefits for the net operating losses incurred during the three and nine months ended September 30, 2020. We have
not recorded income tax benefits for research and development tax credits and other deferred tax assets generated, due to its uncertainty
of realizing a benefit from those items.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_3" id="_IncomeTaxDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The components of income (loss)
before income taxes for the three and nine months ended September 30, 2021 and 2020 were as follows:&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_4" id="_IncomeTaxDisclosureTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">United States</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" unitRef="usd">29,860</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" sign="-" unitRef="usd">11,370</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" sign="-" unitRef="usd">11,435</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" sign="-" unitRef="usd">20,724</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" sign="-" unitRef="usd">985</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" unitRef="usd">1,075</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" sign="-" unitRef="usd">2,941</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" unitRef="usd">669</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total loss before income taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="clnn:TotalLossBeforeIncomeTaxes" scale="3" unitRef="usd">28,875</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="clnn:TotalLossBeforeIncomeTaxes" scale="3" sign="-" unitRef="usd">10,295</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="clnn:TotalLossBeforeIncomeTaxes" scale="3" sign="-" unitRef="usd">14,376</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="clnn:TotalLossBeforeIncomeTaxes" scale="3" sign="-" unitRef="usd">20,055</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation id="_IncomeTaxDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is subject to
taxation in the United States, Australia, and various state jurisdictions. The Company computes its quarterly income tax provision by
using a forecasted annual effective tax rate and adjusts for any discrete items arising during the quarter. The primary difference between
the effective tax rate and the federal statutory tax rate relates to the full valuation allowance on the Company&#8217;s U.S. net operating
losses and other deferred tax assets.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>15. Stock-Based Compensation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>2020 Stock Plan</i>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_3" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2020, in connection
with the Reverse Recapitalization, the Company&#8217;s Board of Directors approved the 2020 Stock Plan (the &#8220;2020 Stock Plan&#8221;)
and reserved <ix:nonFraction contextRef="c244" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares">12,000,000</ix:nonFraction> shares of Common Stock for issuance thereunder, all of which may be issued pursuant to incentive stock options
or any other type of award under the 2020 Stock Plan. The 2020 Stock Plan became effective immediately upon the closing of the Reverse
Recapitalization. The maximum number of shares of Common Stock that may be issued pursuant to the exercise of incentive stock options
under the 2020 Stock Plan is <ix:nonFraction contextRef="c244" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares">12,000,000</ix:nonFraction>. Selected employees, officers, directors, and consultants are eligible to participate in the traditional
stock option grants, stock appreciation rights, restricted stock awards, restricted stock units, other stock awards, and performance awards
under the 2020 Stock Plan. The purpose of this 2020 Stock Plan is to enable us to offer competitive equity compensation packages in order
to attract and retain the talent necessary for the combined company.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_4" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The 2020 Stock Plan is administered
by the Company&#8217;s Board of Directors. <ix:nonNumeric contextRef="c245" name="clnn:MinimumFairMarketValueOfOptionGrantDescription">The exercise prices, vesting periods, and other restrictions are determined at the discretion
of the Company&#8217;s Board of Directors, except that the exercise price per share of options may not be less than 100% of the fair market
value of the Common Stock on the date of grant.</ix:nonNumeric> Stock options awarded under the 2020 Stock Plan expire ten years after the grant date,
unless the Company&#8217;s Board of Directors sets a shorter term. Stock options and restricted stock granted to employees, officers,
members of the Company&#8217;s Board of Directors, and consultants generally vest over a four-year period. If an option or other award
granted under the 2020 Stock Plan expires, terminates, or is cancelled, the unissued shares subject to that option or award shall again
be available under the 2020 Stock Plan. If shares awarded pursuant to the 2020 Stock Plan are forfeited to or repurchased at original
cost by the Company, the number of shares forfeited or repurchased at original cost shall again be available under the 2020 Stock Plan.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_5" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of September 30, 2021, the Company&#8217;s Board of Directors granted
rights to <ix:nonFraction contextRef="c246" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" unitRef="shares">3,819,930</ix:nonFraction> restricted stock awards and stock options under the 2020 Stock Plan. As of September 30, 2021, <ix:nonFraction contextRef="c246" decimals="0" format="ixt:num-dot-decimal" name="clnn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants" scale="0" unitRef="shares">8,180,070</ix:nonFraction> shares remained
available for future grant.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_6" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2020, the
Company&#8217;s Board of Directors granted rights to <ix:nonFraction contextRef="c247" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" unitRef="shares">1,507,062</ix:nonFraction> restricted stock awards under the 2020 Stock Plan. As of December 31, 2020,
<ix:nonFraction contextRef="c247" decimals="0" format="ixt:num-dot-decimal" name="clnn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants" scale="0" unitRef="shares">10,492,938</ix:nonFraction> shares remained available for future grant.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_7" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>2014 Stock Plan</i>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_8" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the closing of the
Reverse Recapitalization, the 2014 Stock Plan is administered by the Company&#8217;s Board of Directors. Stock options awarded under the
2014 Stock Plan expire ten years after the grant date. Stock options and restricted stock granted to employees, officers, members of the
Company&#8217;s Board of Directors, and consultants typically vest over a four-year period.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_9" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the Reverse
Recapitalization (see Note 3), stock options outstanding under the 2014 Stock Plan of <ix:nonFraction contextRef="c248" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockOtherSharesOutstanding" scale="0" unitRef="shares">53,286,115</ix:nonFraction> were converted into <ix:nonFraction contextRef="c249" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" unitRef="shares">7,032,591</ix:nonFraction> of stock
options of the Company based on the Exchange Ratio determined in accordance with the terms of the Merger Agreement. The exchange of Clene
Nanomedicine&#8217;s stock options for Clene Inc. stock options was treated as a modification of the awards. The modification of the stock
options did not result in a material incremental compensation expense to be recognized at the closing of the Reverse Recapitalization.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_10" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2020, the Company&#8217;s Board of Directors granted stock options for <ix:nonFraction contextRef="c250" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" unitRef="shares">270,555</ix:nonFraction> shares under the 2014 Stock Plan. Effective as of the
closing of the Reverse Recapitalization on December 30, 2020, no additional awards may be made under the 2014 Stock Plan and as a result,
(i) any shares in respect of stock options that are expired or terminated under the 2014 Stock Plan without having been fully exercised
will not be available for future awards; (ii) any shares in respect of restricted stock that are forfeited to, or otherwise repurchased
by the Company, will not be available for future awards; and (iii) any shares of Common Stock that are tendered to the Company by a participant
to exercise an award will not be available for future awards.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_11" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stock-based compensation expense for the three months ended September
30, 2021 and 2020 was approximately $<ix:nonFraction contextRef="c12" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockOptionPlanExpense" scale="6" unitRef="usd">2.4</ix:nonFraction> million and $<ix:nonFraction contextRef="c13" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockOptionPlanExpense" scale="6" unitRef="usd">0.2</ix:nonFraction> million, respectively, and approximately $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockOptionPlanExpense" scale="6" unitRef="usd">9.9</ix:nonFraction> million and $<ix:nonFraction contextRef="c14" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockOptionPlanExpense" scale="6" unitRef="usd">0.6</ix:nonFraction> million for the
nine months ended September 30, 2021 and 2020, respectively. Stock-based compensation is recorded in research and development and general
and administrative expenses in the condensed consolidated statements of operations and comprehensive income (loss) as follows:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_12" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_11"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c109" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd">858</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c111" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd">134</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c110" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd">3,861</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c112" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd">364</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c143" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd">1,567</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c147" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd">75</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c142" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd">6,084</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c146" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd">190</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total stock-based compensation</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd">2,425</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd">209</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd">9,945</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd">554</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_13" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock Options</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_14" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following sets forth the
outstanding stock options and related activity for the nine months ended September 30, 2021 (in thousands, except share and per share
data):&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_15" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_14"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Equity</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/> Average <br/> Exercise <br/> Price <br/> Per Share</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/> Average <br/> Remaining <br/> Term <br/> (Years)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Intrinsic <br/> Value</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -10pt; padding-left: 10pt">Outstanding - December&#160;31, 2020</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">7,032,591</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">0.97</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">5.34</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="clnn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValue" scale="3" unitRef="usd">62,462</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares">2,574,441</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">8.85</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="clnn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted">9.61</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-212">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="clnn:ShareBasedCompensationArrangementNumberOfOptionsExercised" scale="0" unitRef="shares">409,867</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">1.04</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-213">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="clnn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue" scale="3" unitRef="usd">2,373</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 0.125in">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" unitRef="shares">133,742</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">8.66</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-214">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-215">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Outstanding - September 30, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">9,063,423</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">3.09</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">5.90</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="clnn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValue" scale="3" unitRef="usd">38,863</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Options vested and exercisable - September 30, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="clnn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber" scale="0" unitRef="shares">6,000,723</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="clnn:WeightedAverageExercisePricePerShareOptionVestedAndExercisable" scale="0" unitRef="usdPershares">0.82</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="clnn:WeightedAverageExercisePriceWeightedAverageRemainingTermYearsOptionsVestedAndEexercisableEnding">4.33</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="clnn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueIntrinsicValueOptionsVestedAndExercisableEnding" scale="3" unitRef="usd">36,247</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Stock options vested and expected to vest - September 30, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" unitRef="shares">9,063,423</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">3.09</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="clnn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm1">5.90</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="clnn:IntrinsicValueStockOptionsVestedAndExpectedToVestIntrinsicValueOptionsV" scale="3" unitRef="usd">38,863</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_16" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of September 30, 2021 and December 31, 2020, we had approximately
$<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="clnn:UnrecognizedStockbasedCompensation" scale="6" unitRef="usd">15.2</ix:nonFraction> million and $<ix:nonFraction contextRef="c134" decimals="-5" format="ixt:num-dot-decimal" name="clnn:UnrecognizedStockbasedCompensation" scale="6" unitRef="usd">2.4</ix:nonFraction> million of unrecognized stock-based compensation costs related to non-vested stock options which is expected to
be recognized over a weighted-average period of <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="clnn:SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm">2.33</ix:nonNumeric> years and <ix:nonNumeric contextRef="c134" format="ixt-sec:duryear" name="clnn:SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm">2.04</ix:nonNumeric> years, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_17" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the consummation
of the Reverse Recapitalization, the exercise price of the stock options granted was based on the fair market value of the common shares
of the Company as of the grant date as determined by the Board of Directors, with input from management. The Board of Directors determined
the fair value of the common stock at the time of grant of the options by considering a number of objective and subjective factors, including
third-party valuation reports, valuations of comparable companies, sales of redeemable convertible Preferred Stock, sales of common stock
to unrelated third parties, operating and financial performance, the lack of liquidity of the Company&#8217;s capital stock, and general
and industry-specific economic outlook.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_18" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stock options are valued using
the Black-Scholes valuation model. Since we have limited trading history of our Common Stock, the expected volatility is derived from
the average historical stock volatilities of several unrelated public companies within our industry that we consider to be comparable
to its own business over a period equivalent to the expected term of the stock option grants. The risk-free interest rate for periods
within the contractual life of the stock options is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected
dividend is assumed to be zero as we have never paid dividends and have no current plans to do so. The expected term represents the period
that stock-based awards are expected to be outstanding. For option grants that are considered to be &#8220;plain vanilla,&#8221; we determine
the expected term using the simplified method. The simplified method deems the term to be the average of the time-to-vesting and the contractual
life of the options. For other option grants, we estimate the expected term using historical data on employee exercises and post-vesting
employment termination behavior taking into account the contractual life of the award.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_19" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the nine months ended
September 30, 2021, we granted stock options for <ix:nonFraction contextRef="c251" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" unitRef="shares">2,574,441</ix:nonFraction> shares under the 2020 Stock Plan. The assumptions used to calculate the value
of the stock option awards granted for the nine months ended September 30, 2021 are presented as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_20" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_19"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; white-space: nowrap; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; white-space: nowrap; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">Nine months ended<br/> September 30,<br/>
 2021</td><td style="padding-bottom: 1.5pt; white-space: nowrap; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected stock price volatility</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c257" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">84.8</ix:nonFraction>
&#8211; <ix:nonFraction contextRef="c258" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">87.4</ix:nonFraction>% </span></td><td style="text-align: left"></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c257" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">0.59</ix:nonFraction> &#8211; <ix:nonFraction contextRef="c258" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">0.94</ix:nonFraction>%</span></td><td style="text-align: left"></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Expected dividend yield</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center"><ix:nonFraction contextRef="c259" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0.00</ix:nonFraction>%</td><td style="width: 1%; text-align: left"></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected term</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c259" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.00</ix:nonNumeric> years &#160;</span></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_21" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_20"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The weighted-average grant-date
fair value of options granted during the nine months ended September 30, 2021 was $<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="clnn:weightedAverageFairValuesOfOptionsGranted" scale="0" unitRef="usdPershares">8.85</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_22" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_21"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Restricted Stock Awards</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_23" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_22"><ix:nonNumeric contextRef="c252" continuedAt="_RestrictedStockUnitsDescription-c252_cont_1" name="clnn:RestrictedStockUnitsDescription"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 30, 2020, we granted
rights to awards of the following shares of restricted stock under the 2020 Stock Plan:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_24" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_23"><ix:continuation continuedAt="_RestrictedStockUnitsDescription-c252_cont_2" id="_RestrictedStockUnitsDescription-c252_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in">&#9679;</td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">370,101 shares to various employees and non-employee directors, which
vest on various dates between June 30, 2021 and January 15, 2022, subject to the employee&#8217;s continuous employment through such vesting
date. The restricted stock awards convert to shares of Common Stock on a one-for-one basis upon vesting. The award represents 5% of the
converted stock options under 2014 Stock Plan as a result of the Reverse Recapitalization and complements the 5% closing payment shares
held in escrow for Clene Nanomedicine common shareholders (see Note 3). The grant-date fair value of these awards was $4.0 million based
on the closing price of CLNN shares listed on Nasdaq of $10.82 per share on December 30, 2020, the date of the Reverse Recapitalization.
As of September 30, 2021, there were 224,109 shares of Common Stock issued upon the vesting of restricted stock awards. As of December
31, 2020 no shares were vested.</p></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_25" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_24"><ix:continuation continuedAt="_RestrictedStockUnitsDescription-c252_cont_3" id="_RestrictedStockUnitsDescription-c252_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">454,781 shares to various employees and non-employee directors, which were eligible to vest based on certain market conditions, subject to the employee&#8217;s continuous employment through such vesting date. The award complements the Milestone 1 earn-out share entitlement of Clene Nanomedicine shareholders and vests based on the same market condition (see Note 3). The grant-date fair value of these awards, using a Monte Carlo simulation, was $4.3 million. Based on the outcome of the market condition as of the September 30, 2021 and December 31, 2020 measurement dates, no shares were vested.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_26" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_25"><ix:continuation continuedAt="_RestrictedStockUnitsDescription-c252_cont_4" id="_RestrictedStockUnitsDescription-c252_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">341,090 shares to various employees and non-employee directors, which were eligible to vest based on certain market conditions, subject to the employee&#8217;s continuous employment through such vesting date. The award complements the Milestone 2 earn-out share entitlement of Clene Nanomedicine. shareholders and vests based on the same market condition (see Note 3). The grant-date fair value of these awards, using a Monte Carlo simulation, was $3.5 million. Based on the outcome of the market condition as of the September 30, 2021 and December 31, 2020 measurement dates, no shares were vested.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_27" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_26"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.5in"><ix:continuation continuedAt="_RestrictedStockUnitsDescription-c252_cont_5" id="_RestrictedStockUnitsDescription-c252_cont_4">&#160;</ix:continuation></td> <td style="width: 0.25in"><ix:continuation continuedAt="_RestrictedStockUnitsDescription-c252_cont_6" id="_RestrictedStockUnitsDescription-c252_cont_5"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></ix:continuation></td> <td style="text-align: justify"><ix:continuation id="_RestrictedStockUnitsDescription-c252_cont_6"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">341,090 shares to various employees and non-employee directors, which were eligible to vest based on certain performance conditions tied to the completion of the COVID-19 coronavirus treatment study, subject to the employee&#8217;s continuous employment through such vesting date. The award complements the Milestone 3 earn-out share entitlement of Clene Nanomedicine shareholders and vests based on the same performance condition (see Note 3). The grant-date fair value of these awards was $3.7 million, based on the closing price of CLNN shares listed on Nasdaq of $10.82 per share on December 30, 2020, the date of the Reverse Recapitalization. We did not recognize compensation expense because the occurrence of achieving this milestone was not probable. As of the September 30, 2021 and December 31, 2020 measurement dates, no shares were vested.</span></ix:continuation></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_28" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_27"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes
the restricted stock award activity during the nine months ended September 30, 2021:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_29" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_28"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Restricted Stock Awards</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-<br/> Average<br/> Grant <br/> Date Fair <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Outstanding and unvested balance as of December 31, 2020</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c256" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" unitRef="shares">1,507,062</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c256" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">10.30</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Converted to shares of Common Stock upon vesting</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c252" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares">224,109</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-216">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c252" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" unitRef="shares">37,464</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c252" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">10.82</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Outstanding and unvested balance as of September 30, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c255" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" unitRef="shares">1,245,489</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c255" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">10.14</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_30" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_29"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The assumptions used to calculate
the value of the rights to restricted stock awards granted in 2020 in the Monte Carlo valuation model include projected stock price, volatility,
and risk-free rate based on the achievement of certain stock price milestones. Our significant unobservable inputs as of December 31,
2020 were as follows: (i) <ix:nonFraction contextRef="c253" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" scale="-2" unitRef="pure">85</ix:nonFraction>% of expected stock price volatility, (ii) risk-free interest rate of <ix:nonFraction contextRef="c253" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">0.4</ix:nonFraction>%, and (iii) expected term of <ix:nonNumeric contextRef="c253" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">five
years</ix:nonNumeric>. The weighted average grant-date fair value of rights to restricted stock awards granted as of December 31, 2020 was $<ix:nonFraction contextRef="c253" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">10.3034</ix:nonFraction>.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_30"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The stock-based compensation expense associated with the rights to
restricted stock awards was $<ix:nonFraction contextRef="c254" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RestrictedStockExpense" scale="6" unitRef="usd">0.8</ix:nonFraction> million and $<ix:nonFraction contextRef="c252" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RestrictedStockExpense" scale="6" unitRef="usd">6.8</ix:nonFraction> million for the three and nine months ended September 30, 2021. As of September 30,
2021 and December 31, 2020, total unrecognized compensation cost related to the unvested stock-based awards was $<ix:nonFraction contextRef="c255" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" unitRef="usd">0.9</ix:nonFraction> million and $<ix:nonFraction contextRef="c256" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" unitRef="usd">15.5</ix:nonFraction>
million, respectively, which is expected to be recognized over a weighted average period of less than <ix:nonNumeric contextRef="c252" format="ixt-sec:durmonth" name="clnn:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm">1</ix:nonNumeric> month and <ix:nonNumeric contextRef="c253" format="ixt-sec:durmonth" name="clnn:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm">6</ix:nonNumeric> months, respectively.
We did not issue any restricted stock awards during the nine months ended September 30, 2020.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_FairValueDisclosuresTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueDisclosuresTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>16. Fair Value</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_2" id="_FairValueDisclosuresTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cash is carried at fair
value. Financial instruments, including accounts receivable, accounts payable, and accrued expenses are carried at cost, which
approximates fair value given their short-term nature. The 2019 MD Loan, the 2019 Cecil Loan, the derivative instruments associated
with the 2021 Avenue Loan, and the derivative instruments associated with the Contingent Earn-outs are carried at fair value. The
2021 Avenue Loan, related convertible notes payable, and Conversion Feature are carried at amortized cost, which approximate fair value due to our credit
risk and market interest rates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_3" id="_FairValueDisclosuresTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Liabilities with Fair Value Measurements on a Recurring Basis</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_4" id="_FairValueDisclosuresTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following tables present
our fair value hierarchy for liabilities measured at fair value on a recurring basis as of September 30, 2021 and December 31, 2020:&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_5" id="_FairValueDisclosuresTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair Value Measurements on a Recurring Basis <br/> September 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Notes payable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c261" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="3" unitRef="usd">983</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-217">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-218">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="3" unitRef="usd">983</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-219">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-220">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c263" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilities" scale="3" unitRef="usd">910</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilities" scale="3" unitRef="usd">910</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Clene Nanomedicine contingent earn-out</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-221">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-222">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c263" decimals="-3" format="ixt:num-dot-decimal" name="clnn:CleneNanomedicineContingentEarnoutFairValueDisclosure" scale="3" unitRef="usd">33,981</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="clnn:CleneNanomedicineContingentEarnoutFairValueDisclosure" scale="3" unitRef="usd">33,981</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Initial Shareholders contingent earn-out</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-223">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-224">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c263" decimals="-3" format="ixt:num-dot-decimal" name="clnn:InitialShareholdersContingentEarnoutFairValueDisclosure" scale="3" unitRef="usd">4,196</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="clnn:InitialShareholdersContingentEarnoutFairValueDisclosure" scale="3" unitRef="usd">4,196</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_6" id="_FairValueDisclosuresTextBlock-c0_cont_5"><ix:continuation id="_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair Value Measurements on a Recurring Basis <br/> December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Notes payable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c264" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="3" unitRef="usd">1,296</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-225">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-226">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="3" unitRef="usd">1,296</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Clene Nanomedicine contingent earn-out</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-227">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-228">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c266" decimals="-3" format="ixt:num-dot-decimal" name="clnn:CleneNanomedicineContingentEarnoutFairValueDisclosure" scale="3" unitRef="usd">52,053</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="clnn:CleneNanomedicineContingentEarnoutFairValueDisclosure" scale="3" unitRef="usd">52,053</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Initial Shareholders contingent earn-out</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-229">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-230">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c266" decimals="-3" format="ixt:num-dot-decimal" name="clnn:InitialShareholdersContingentEarnoutFairValueDisclosure" scale="3" unitRef="usd">5,906</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="clnn:InitialShareholdersContingentEarnoutFairValueDisclosure" scale="3" unitRef="usd">5,906</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_7" id="_FairValueDisclosuresTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There were no transfers between
levels in the fair value hierarchy as of September 30, 2021 and December 31, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_8" id="_FairValueDisclosuresTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Valuation of Notes Payable and Convertible
Notes Payable</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_9" id="_FairValueDisclosuresTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The carrying value of notes payable and convertible notes payable includes
certain notes carried at amortized cost, and certain notes remeasured at fair value on a recurring basis in the condensed consolidated
balance sheets as of September 30, 2021 and December 31, 2020. In order to value the notes, we considered the amount of simple interest
expense that would be due and the value of our Common Stock.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_10" id="_FairValueDisclosuresTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of September 30, 2021 and
December 31, 2020, the fair value of the 2019 MD Loan and the 2019 Cecil Loan was determined based on the closing prices of $<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="clnn:NotesPayableBasedOnClosingPrice" scale="0" unitRef="usdPershares">6.83</ix:nonFraction> and
$<ix:nonFraction contextRef="c134" decimals="2" format="ixt:num-dot-decimal" name="clnn:NotesPayableBasedOnClosingPrice" scale="0" unitRef="usdPershares">9.01</ix:nonFraction> per share, respectively, as reported by Nasdaq.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_11" id="_FairValueDisclosuresTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of September 30, 2021,
the amortized cost of the 2021 Avenue Loan was $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="clnn:FairValueAmortizedCost" scale="6" unitRef="usd">18.2</ix:nonFraction> million, which includes the notes payable, carried at $<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayable" scale="6" unitRef="usd">13.6</ix:nonFraction> million;
and the convertible notes payable and embedded Conversion Feature, carried at $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature" scale="6" unitRef="usd">4.6</ix:nonFraction> million. The valuation of the Conversion Feature is
discussed below. The 2021 Avenue Loan was not outstanding as of December 31, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_12" id="_FairValueDisclosuresTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Valuation of Conversion Feature</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_13" id="_FairValueDisclosuresTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Conversion Feature of the convertible notes payable from the 2021
Avenue Loan is carried at amortized cost and did not meet the requirements for separate accounting and is not accounted for as a derivative
instrument. The estimated fair value of the Conversion Feature was $<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="clnn:FairValueOfConvertibleNotesPayable" scale="6" unitRef="usd">2.0</ix:nonFraction> million and was determined using a Black-Scholes valuation model,
with a Monte Carlo analysis performed in order to simulate the Next Round Price as an input in the Black-Scholes valuation model. The
unobservable inputs to the model were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_14" id="_FairValueDisclosuresTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Black-Scholes Valuation Model</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_15" id="_FairValueDisclosuresTextBlock-c0_cont_14"><ix:nonNumeric contextRef="c0" continuedAt="_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2020</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Expected stock price volatility</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c267" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">85.00</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-231">N/A</div></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c267" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">0.50</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-232">N/A</div></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c267" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0.00</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-233">N/A</div></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c267" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">2.56</ix:nonNumeric> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-234">N/A</div></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_16" id="_FairValueDisclosuresTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Monte Carlo Simulation</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_17" id="_FairValueDisclosuresTextBlock-c0_cont_16"><ix:continuation continuedAt="_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock-c0_cont_2" id="_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September&#160;30,<br/> 2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, <br/> 2020</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Expected stock price volatility</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c269" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">35.00</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-235">N/A</div></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c269" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">0.07</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-236">N/A</div></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c269" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0.00</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-237">N/A</div></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c269" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">0.09</ix:nonNumeric> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-238">N/A</div></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p></ix:continuation></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_18" id="_FairValueDisclosuresTextBlock-c0_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Valuation of Warrants to Purchase Preferred
Stock</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_19" id="_FairValueDisclosuresTextBlock-c0_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;Our Preferred Stock
warrant liabilities contain unobservable inputs that reflect our own assumptions. Accordingly, the Preferred Stock warrant liabilities
were measured at fair value on a recurring basis using unobservable inputs. Prior to the extinguishment of the Preferred Stock warrant
liabilities on December 30, 2020, the Preferred Stock warrant liability was valued using a Black-Scholes valuation model.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_20" id="_FairValueDisclosuresTextBlock-c0_cont_19"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board of Directors determined
the fair value of the Preferred Stock by considering a number of objective and subjective factors, including third-party valuations, valuations
of comparable companies, sales of redeemable convertible Preferred Stock, sales of common stock to unrelated third parties, operating
and financial performance, the lack of liquidity of our capital stock, and general and industry-specific economic outlook. We estimated
the volatility of our Preferred Stock based on comparable peer companies&#8217; historical volatility. The risk-free interest rate for
periods within the contractual life of the warrants was based on the U.S. Treasury yield curve in effect at the valuation date. We have
no plans to declare any future dividends. The determination of the fair value of the Preferred Stock warrant liability could change in
future periods based upon changes in the value of our Preferred Stock and other assumptions as presented above. We record any such change
in fair value to the change in fair value of Preferred Stock warrant liability expense line in the condensed consolidated statements of
operations and comprehensive income (loss).&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_21" id="_FairValueDisclosuresTextBlock-c0_cont_20"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the closing of the Reverse
Recapitalization (see Note 3), all of the outstanding Clene Nanomedicine Preferred Stock was converted to Clene Inc. Common Stock and
the Clene Nanomedicine Preferred Stock warrants were converted to warrants for the purchase of Clene Inc. Common Stock. Accordingly, the
Preferred Stock warrant liabilities were extinguished in connection with the conversion of Clene Nanomedicine Preferred Stock on December
30, 2020 (see Note 9).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_22" id="_FairValueDisclosuresTextBlock-c0_cont_21"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Valuation of the Warrant Liability</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_23" id="_FairValueDisclosuresTextBlock-c0_cont_22"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the 2021 Avenue Loan, we issued the Avenue Warrants to
purchase <ix:nonFraction contextRef="c210" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">115,851</ix:nonFraction> shares of Common Stock pursuant to Tranche 1 of the 2021 Avenue Loan. In accordance with ASC 815, we recognized an additional
warrant to purchase an estimated <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="clnn:AdditionalWarrantToPurchaseShares" scale="0" unitRef="shares">86,679</ix:nonFraction> shares of Common Stock that will be issued pursuant to the draw of Tranche 2 of the 2021 Avenue
Loan (see Note 10). The warrants were recorded at fair value at the closing of the 2021 Avenue Loan on May 21, 2021, and the fair value
and issuable shares will be remeasured at each reporting period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_24" id="_FairValueDisclosuresTextBlock-c0_cont_23"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The estimated fair value of
the warrant liability was determined using a Black-Scholes valuation model, with a Monte Carlo analysis performed in order to simulate
the Next Round Price as an input in the Black-Scholes valuation model. The carrying amount of the liability may fluctuate significantly
and actual amounts may be materially different from the liabilities&#8217; estimated value. As of September 30, 2021, the warrant was
revalued using a similar Black-Scholes valuation model. The unobservable inputs to the model were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_25" id="_FairValueDisclosuresTextBlock-c0_cont_24"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Black-Scholes Valuation Model</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_26" id="_FairValueDisclosuresTextBlock-c0_cont_25"><ix:continuation continuedAt="_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock-c0_cont_3" id="_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,<br/> 2021</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2020</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Expected stock price volatility</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><ix:nonFraction contextRef="c271" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">95.00</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-239">N/A</div></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c271" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">0.90</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-240">N/A</div></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c271" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0.00</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-241">N/A</div></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c273" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">3.89</ix:nonNumeric> years &#8211; <ix:nonNumeric contextRef="c274" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">4.56</ix:nonNumeric> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-242">N/A</div></td>
    <td>&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_27" id="_FairValueDisclosuresTextBlock-c0_cont_26"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Monte Carlo Simulation</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_28" id="_FairValueDisclosuresTextBlock-c0_cont_27"><ix:continuation continuedAt="_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock-c0_cont_4" id="_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,<br/> 2021</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2020</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected stock price volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c275" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">40.00</ix:nonFraction> &#8211; <ix:nonFraction contextRef="c276" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">70.00</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-243">N/A</div></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 78%; text-align: left">Risk-free interest rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><ix:nonFraction contextRef="c278" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">0.07</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-244">N/A</div></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c278" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0.00</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-245">N/A</div></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c275" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">0.09</ix:nonNumeric> years &#8211; <ix:nonNumeric contextRef="c276" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">0.66</ix:nonNumeric> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-246">N/A</div></td>
    <td>&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_29" id="_FairValueDisclosuresTextBlock-c0_cont_28"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Valuation of the Contingent Earn-Outs</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_30" id="_FairValueDisclosuresTextBlock-c0_cont_29"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="c260" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsDescription">Pursuant to the Merger Agreement,
Clene Nanomedicine&#8217;s common shareholders immediately prior to the Reverse Recapitalization and Initial Shareholders of Tottenham
were entitled to receive additional shares of up to 8,333,333 shares and 750,000 shares of Common Stock, respectively, upon us achieving
certain milestones (see Note 3). Upon the consummation of the Reverse Recapitalization, Clene Nanomedicine and the Initial Shareholders
are entitled to receive up to 8,346,185 additional shares as a result of the exercise of the stock options in November 2020, and 750,000
shares of Common Stock</ix:nonNumeric>. The Contingent Earn-outs were recorded at fair value on the closing of the Reverse Recapitalization on December
30, 2020 and will be remeasured at each reporting period. As of September 30, 2021 and December 31, 2020, no milestone has been achieved.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_31" id="_FairValueDisclosuresTextBlock-c0_cont_30"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The estimated fair value of
the initial Contingent Earn-outs was determined using a Monte Carlo analysis in order to simulate the future path of our stock price over
the earn-out periods. The carrying amount of the liabilities may fluctuate significantly and actual amounts paid may be materially different
from the liabilities&#8217; estimated value. As of September 30, 2021 and December 31, 2020, the Contingent Earn-outs were revalued using
a similar Monte Carlo analysis. The unobservable inputs to the models were as follows:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_32" id="_FairValueDisclosuresTextBlock-c0_cont_31"><ix:continuation id="_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,<br/> 2021</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2020</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Expected stock price volatility</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c279" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">95.00</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c280" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">85.00</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c279" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">0.80</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c280" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">0.40</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c279" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0.00</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c280" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0.00</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c279" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">4.2</ix:nonNumeric> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c280" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.00</ix:nonNumeric> years</span></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_33" id="_FairValueDisclosuresTextBlock-c0_cont_32"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of changes in the fair value of our financial liabilities related to the notes payable, the derivative instrument, the Preferred Stock
warrants, the warrant liability, and the Contingent Earn-outs measured at fair value for the nine months ended September 30, 2021 and
2020:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_34" id="_FairValueDisclosuresTextBlock-c0_cont_33"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Notes <br/> Payable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Clene Nanomedicine<br/> Contingent <br/> Earn-out</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Initial Shareholders<br/> Contingent <br/> Earn-out</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Warrant<br/> Liability</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Balance - December 31, 2020</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c281" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" unitRef="usd">1,296</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c282" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" unitRef="usd">52,053</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c283" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" unitRef="usd">5,906</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-247">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10pt">Initial fair value of instrument</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-248">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-249">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-250">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c288" decimals="-3" format="ixt:num-dot-decimal" name="clnn:InitialFairValueOfInstrument" scale="3" unitRef="usd">1,457</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c285" decimals="-3" format="ixt:num-dot-decimal" name="clnn:IncreseDecreaseInFairValue" scale="3" sign="-" unitRef="usd">313</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c286" decimals="-3" format="ixt:num-dot-decimal" name="clnn:IncreseDecreaseInFairValue" scale="3" sign="-" unitRef="usd">18,072</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c287" decimals="-3" format="ixt:num-dot-decimal" name="clnn:IncreseDecreaseInFairValue" scale="3" sign="-" unitRef="usd">1,710</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c288" decimals="-3" format="ixt:num-dot-decimal" name="clnn:IncreseDecreaseInFairValue" scale="3" sign="-" unitRef="usd">547</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Balance - September 30, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c289" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" unitRef="usd">983</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c290" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" unitRef="usd">33,981</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c291" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" unitRef="usd">4,196</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c292" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" unitRef="usd">910</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation id="_FairValueDisclosuresTextBlock-c0_cont_34"><ix:continuation id="_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Notes <br/> Payable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Derivative<br/> Instrument</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Preferred<br/> Stock<br/> Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Balance - December 31, 2019</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c293" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" unitRef="usd">640</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-251">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c295" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" unitRef="usd">3,213</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 10pt">Issuance of convertible promissory notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-252">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c297" decimals="-3" format="ixt:num-dot-decimal" name="clnn:FairValueIssuanceOfConvertiblePromissoryNotes" scale="3" unitRef="usd">705</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-253">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c296" decimals="-3" format="ixt:num-dot-decimal" name="clnn:IncreseDecreaseInFairValue" scale="3" unitRef="usd">323</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c297" decimals="-3" format="ixt:num-dot-decimal" name="clnn:IncreseDecreaseInFairValue" scale="3" sign="-" unitRef="usd">29</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c298" decimals="-3" format="ixt:num-dot-decimal" name="clnn:IncreseDecreaseInFairValue" scale="3" unitRef="usd">7,378</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Extinguishment of derivative liability in connection with extinguishment of convertible promissory notes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-254">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c297" decimals="-3" format="ixt:num-dot-decimal" name="clnn:FairValueMeasurementExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN" scale="3" sign="-" unitRef="usd">676</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-255">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance - September 30, 2020</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c299" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" unitRef="usd">963</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-256">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c301" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" unitRef="usd">10,591</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_RedeemableConvertiblePreferredStockDisclosureTextBlock-c0_cont_1" escape="true" name="clnn:RedeemableConvertiblePreferredStockDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>17. Redeemable Convertible Preferred Stock</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_RedeemableConvertiblePreferredStockDisclosureTextBlock-c0_cont_2" id="_RedeemableConvertiblePreferredStockDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the closing
of the Reverse Recapitalization, the Preferred Stock converted into <ix:nonFraction contextRef="c302" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares">36,893,894</ix:nonFraction> shares of Common Stock on a 1:0.1389 basis (see Note 3).
As of September 30, 2021 and December 31, 2020, there were no Preferred Stock outstanding.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_RedeemableConvertiblePreferredStockDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The redeemable convertible
preferred stock is described in Note 17, Redeemable Convertible Preferred Stock in Part II, Item 8 of our 2020 Annual Report on Form 10-K
for the year ended December 31, 2020 (&#8220;2020 Annual Report&#8221;) which was filed with the SEC on March 29, 2021. There have been
no changes since our 2020 Annual Report.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>18. Common Stock</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of September 30, 2021 and
December 31, 2020, our certificate of incorporation, as amended and restated, authorized us to issue <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">150,000,000</ix:nonFraction> and <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">100,000,000</ix:nonFraction> shares
of Common Stock, respectively, par value $<ix:nonFraction contextRef="c2" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.0001</ix:nonFraction> per share and <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="clnn:PreferredStockShares" scale="0" unitRef="shares">1,000,000</ix:nonFraction> shares of Preferred Stock, par value $<ix:nonFraction contextRef="c2" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.0001</ix:nonFraction> per share. At our
2021 Annual Meeting of Stockholders on May 18, 2021, our stockholders approved an amendment to the Amended and Restated Certificate of
Incorporation to increase the number of authorized shares of Common Stock from <ix:nonFraction contextRef="c303" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">100,000,000</ix:nonFraction> to <ix:nonFraction contextRef="c304" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">150,000,000</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common shareholders are
entitled to one vote per share and to notice of any shareholders&#8217; meeting. Voting, dividend, and liquidation rights of the holders
of Common Stock are subject to the prior rights of holders of all classes of stock and are qualified by the rights, powers, preferences,
and privileges of the holders of Preferred Stock. No distributions shall be made with respect to Common Stock until all declared dividends
to Preferred Shares have been paid or set aside for payment to the holders of Preferred Stock. Common Stock is not redeemable at the option
of the holder.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On the closing of the Reverse
Recapitalization, the total outstanding <ix:nonFraction contextRef="c124" decimals="0" format="ixt:num-dot-decimal" name="clnn:IssuanceOfCommonStockUponReverseRecapitalization" scale="0" unitRef="shares">2,303,495</ix:nonFraction> Tottenham ordinary shares held by the Initial Shareholders and public shareholders were
converted into the same number of Common Stock (see Note 3).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On the closing of the Reverse
Recapitalization, <ix:nonFraction contextRef="c124" decimals="0" format="ixt:num-dot-decimal" name="clnn:RecapitalizationShare" scale="0" unitRef="shares">644,164</ix:nonFraction> shares of Common Stock were issued to LifeSci as financial advisor to the Reverse Recapitalization (see Note
3).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the completion of
the Reverse Recapitalization on December 30, 2020, the Company entered into a subscription agreement on December 28, 2020, with various
investors. Pursuant to the subscription agreements, the Company issued <ix:nonFraction contextRef="c305" decimals="0" format="ixt:num-dot-decimal" name="clnn:InvestorsPurchasedShares" scale="0" unitRef="shares">2,239,500</ix:nonFraction> shares of Common Stock (the &#8220;December 2020 PIPE
Shares&#8221;) at a price of $<ix:nonFraction contextRef="c306" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares">10.00</ix:nonFraction> per share with net proceeds of $<ix:nonFraction contextRef="c305" decimals="-5" format="ixt:num-dot-decimal" name="clnn:NetProceeds" scale="6" unitRef="usd">22.2</ix:nonFraction> million. The purpose of the December 2020 PIPE was to fund general
corporate expenses. <ix:nonNumeric contextRef="c134" name="clnn:PrivatePlacementWarrantsDescription">In addition, investors in the December 2020 PIPE offering also received warrants to purchase a number of shares equal
to one-half (1/2) of the number of December 2020 PIPE Shares, totaling 1,119,750 shares of Common Stock, at an exercise price of $0.01
per share, subject to a 180-day holding period (see Note 10).</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 21, 2021, the Company
entered into the May 2021 PIPE subscription agreements with various investors. Pursuant to the subscription agreements, the Company issued
<ix:nonFraction contextRef="c307" decimals="0" format="ixt:num-dot-decimal" name="clnn:CommonStockSharesPurchased" scale="0" unitRef="shares">960,540</ix:nonFraction> shares of Common Stock at a price of $<ix:nonFraction contextRef="c307" decimals="2" format="ixt:num-dot-decimal" name="clnn:CommonStockPricePerShare" scale="0" unitRef="usdPershares">9.63</ix:nonFraction> per share with net proceeds of $<ix:nonFraction contextRef="c307" decimals="-5" format="ixt:num-dot-decimal" name="clnn:NetProceeds" scale="6" unitRef="usd">9.3</ix:nonFraction> million. The closing of the May 2021 PIPE occurred
substantially concurrently with, and was conditioned upon, the closing of the 2021 Avenue Loan (see Note 8). The purpose of the May 2021
PIPE was to fund the expansion of manufacturing capabilities in the state of Maryland and to fund general corporate expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_8" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Between July 1, 2021 and September
15, 2021, various investors exercised December 2020 PIPE Warrants for <ix:nonFraction contextRef="c308" decimals="0" format="ixt:num-dot-decimal" name="clnn:WarrantsShares" scale="0" unitRef="shares">1,002,250</ix:nonFraction> shares of Common Stock at an exercise price of $<ix:nonFraction contextRef="c308" decimals="2" format="ixt:num-dot-decimal" name="clnn:ExercisePricePerShare" scale="0" unitRef="usdPershares">0.01</ix:nonFraction> per
share. The December 2020 PIPE Warrants were issued prior to the completion of the Reverse Recapitalization on December 30, 2020, and were
subject to a 180-day holding period which expired on June 28, 2021. We received cash proceeds of $<ix:nonFraction contextRef="c308" decimals="-2" format="ixt:num-dot-decimal" name="clnn:CashProceedsReceived" scale="3" unitRef="usd">10.0</ix:nonFraction> thousand.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_9" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 15, 2021, Chardan
exercised the Chardan Unit Purchase Option for <ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="clnn:PurchaseOptionUnits" scale="0" unitRef="shares">220,000</ix:nonFraction> units, each unit consisting of one and one-tenth shares of Common Stock and one
warrant to purchase one-half of one share of Common Stock at an exercise price of $<ix:nonFraction contextRef="c309" decimals="2" format="ixt:num-dot-decimal" name="clnn:ExercisePricePerShare" scale="0" unitRef="usdPershares">11.50</ix:nonFraction> per share. Chardan elected to perform a cashless
or net exercise, which resulted in a net issuance of <ix:nonFraction contextRef="c309" decimals="0" format="ixt:num-dot-decimal" name="clnn:NetIssuanceShares" scale="0" unitRef="shares">54,083</ix:nonFraction> shares of Common Stock and <ix:nonFraction contextRef="c309" decimals="0" format="ixt:num-dot-decimal" name="clnn:NetIssuanceWarrants" scale="0" unitRef="shares">49,166</ix:nonFraction> warrants to purchase one-half of one share
of Common Stock. The Chardan Unit Purchase Option was originally issued in connection with Tottenham&#8217;s initial public offering in
August 2018. We received no cash proceeds.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of September 30, 2021 and
December 31, 2020, our common shares issued and outstanding were <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares">62,177,020</ix:nonFraction> and <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">59,526,171</ix:nonFraction>, respectively. As of September 30, 2021 and
December 31, 2020, there were no preferred shares issued and outstanding (see Note 17).</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerShareTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerShareTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>19. Net Income (Loss) Per Share Attributable
to Common Shareholders</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_EarningsPerShareTextBlock-c0_cont_2" id="_EarningsPerShareTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
the computation of basic and diluted net income (loss) per share attributable to common shareholders (in thousands, except share and per
share data):&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_EarningsPerShareTextBlock-c0_cont_3" id="_EarningsPerShareTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="text-decoration:underline">Numerator&#160;:</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -9pt; padding-left: 0.25in">Net income (loss) attributable to common shareholders &#8211; Basic</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c312" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" unitRef="usd">28,944</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c313" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" sign="-" unitRef="usd">10,295</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c314" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" sign="-" unitRef="usd">14,163</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c315" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" sign="-" unitRef="usd">20,055</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Less interest expense on potentially dilutive convertible notes payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c312" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestOnConvertibleDebtNetOfTax" scale="3" unitRef="usd">196</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Net income (loss) attributable to common shareholders - Diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c312" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" unitRef="usd">29,140</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c313" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" sign="-" unitRef="usd">10,295</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c314" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" sign="-" unitRef="usd">14,163</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c315" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" sign="-" unitRef="usd">20,055</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="text-decoration:underline">Denominator:</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 0.25in">Weighted average common shares outstanding &#8211;Basic</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c312" decimals="INF" format="ixt:num-dot-decimal" name="clnn:WeightedAverageSharesOutstanding" scale="0" unitRef="shares">62,071,754</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c313" decimals="INF" format="ixt:num-dot-decimal" name="clnn:WeightedAverageSharesOutstanding" scale="0" unitRef="shares">17,358,159</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c314" decimals="INF" format="ixt:num-dot-decimal" name="clnn:WeightedAverageSharesOutstanding" scale="0" unitRef="shares">61,307,699</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c315" decimals="INF" format="ixt:num-dot-decimal" name="clnn:WeightedAverageSharesOutstanding" scale="0" unitRef="shares">17,358,159</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 0.25in">Weighted average effect of potentially dilutive securities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Effect of potentially dilutive stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c312" decimals="INF" format="ixt:num-dot-decimal" name="clnn:EffectOfPotentiallyDilutiveStockOptionsinDollars" scale="0" unitRef="shares">5,791,023</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-257">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-258">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-259">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Effect of potentially dilutive common stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c312" decimals="INF" format="ixt:num-dot-decimal" name="clnn:EffectOfPotentiallyDilutiveRestrictedStockAwards" scale="0" unitRef="shares">1,485,049</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-260">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-261">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-262">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Effect of potentially dilutive convertible notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c312" decimals="INF" format="ixt:num-dot-decimal" name="clnn:EffectOfPotentiallyDilutiveConvertibleNotesPayable" scale="0" unitRef="shares">482,703</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-263">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-264">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-265">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Effect of potentially dilutive restricted stock awards</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c312" decimals="INF" format="ixt:num-dot-decimal" name="clnn:EffectOfPotentiallyDilutiveUnvestedRestrictedStockAwardsShares" scale="0" unitRef="shares">208,105</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-266">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-267">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-268">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Weighted average common shares outstanding &#8211;Diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c312" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" unitRef="shares">70,038,634</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c313" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" unitRef="shares">17,358,159</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c314" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" unitRef="shares">61,307,699</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c315" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" unitRef="shares">17,358,159</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Net income (loss) per share attributable to common shareholders:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 0.25in">Basic</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c312" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" unitRef="usdPershares">0.47</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c313" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">0.59</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c314" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">0.23</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c315" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">1.16</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 0.25in">Diluted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c312" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" unitRef="usdPershares">0.42</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c313" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares">0.59</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c314" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares">0.23</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c315" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares">1.16</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>




</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_EarningsPerShareTextBlock-c0_cont_4" id="_EarningsPerShareTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Included within weighted average common shares outstanding are the
remaining <ix:nonFraction contextRef="c310" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" unitRef="shares">117,500</ix:nonFraction> (originally <ix:nonFraction contextRef="c311" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" unitRef="shares">1,119,750</ix:nonFraction>) common shares issuable upon the exercise of the December 2020 PIPE Warrants, as these warrants
are exercisable at any time for nominal consideration, and as such, the shares are considered outstanding for the purpose of calculating
basic and diluted net loss per share attributable to common shareholders.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_EarningsPerShareTextBlock-c0_cont_5" id="_EarningsPerShareTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following shares of potentially dilutive securities were excluded
from the computation of diluted net income (loss) per share attributable to common shareholders for the periods presented because including
them would have been antidilutive, or issuance of such shares is contingent upon the satisfaction of certain conditions which were not
satisfied by the end of the period, or they were out-of-the money:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_EarningsPerShareTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Series D redeemable convertible preferred stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-269">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="clnn:SeriesDRedeemableConvertiblePreferredStock" scale="0" unitRef="shares">9,394,057</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-270">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="clnn:SeriesDRedeemableConvertiblePreferredStock" scale="0" unitRef="shares">9,394,057</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Series C redeemable convertible preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-271">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="clnn:SeriesCRedeemableConvertiblePreferredStock" scale="0" unitRef="shares">7,264,519</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-272">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="clnn:SeriesCRedeemableConvertiblePreferredStock" scale="0" unitRef="shares">7,264,519</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Series B redeemable convertible preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-273">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="clnn:SeriesBRedeemableConvertiblePreferredStock" scale="0" unitRef="shares">4,168,815</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-274">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="clnn:SeriesBRedeemableConvertiblePreferredStock" scale="0" unitRef="shares">4,168,815</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Series A redeemable convertible preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-275">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="clnn:SeriesARedeemableConvertiblePreferredStock" scale="0" unitRef="shares">16,066,503</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-276">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="clnn:SeriesARedeemableConvertiblePreferredStock" scale="0" unitRef="shares">16,066,503</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Series D redeemable convertible preferred stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-277">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="clnn:SeriesDRedeemableConvertiblePreferredStockWarrants" scale="0" unitRef="shares">320,441</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-278">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="clnn:SeriesDRedeemableConvertiblePreferredStockWarrants" scale="0" unitRef="shares">320,441</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Series A redeemable convertible preferred stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-279">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="clnn:SeriesARedeemableConvertiblePreferredStockWarrantsinShares" scale="0" unitRef="shares">1,608,670</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-280">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="clnn:SeriesARedeemableConvertiblePreferredStockWarrantsinShares" scale="0" unitRef="shares">1,608,670</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Convertible notes payable (see Note 11)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-281">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-282">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="clnn:ConvertibleNotesPayables" scale="0" unitRef="shares">482,703</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-283">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Common stock warrants (see Note 10)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="clnn:CommonStockWarrants" scale="0" unitRef="shares">2,523,351</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-284">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="clnn:CommonStockWarrants" scale="0" unitRef="shares">4,569,962</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-285">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Options to purchase common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="clnn:OptionsToPurchaseCommonStockinShares" scale="0" unitRef="shares">2,685,575</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="clnn:OptionsToPurchaseCommonStockinShares" scale="0" unitRef="shares">7,509,810</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="clnn:OptionsToPurchaseCommonStockinShares" scale="0" unitRef="shares">9,063,423</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="clnn:OptionsToPurchaseCommonStockinShares" scale="0" unitRef="shares">7,509,810</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Restricted stock awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="clnn:UnvestedRestrictedStockAwardsShares" scale="0" unitRef="shares">1,100,050</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-286">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="clnn:UnvestedRestrictedStockAwardsShares" scale="0" unitRef="shares">1,245,489</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-287">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Chardan Unit Purchase Option Warrants (see Notes 3 and 10)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="clnn:ChardanUnitPurchaseOptionWarrants" scale="0" unitRef="shares">24,583</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-288">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="clnn:ChardanUnitPurchaseOptionWarrants" scale="0" unitRef="shares">24,583</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-289">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Clene Nanomedicine contingent earn-out shares (see Note 3 and 12)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="clnn:CleneNanomedicineContingentEarnoutShares" scale="0" unitRef="shares">8,346,185</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-290">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="clnn:CleneNanomedicineContingentEarnoutShares" scale="0" unitRef="shares">8,346,185</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-291">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Initial Shareholders contingent earn-out shares (see Note 3 and 12)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="clnn:InitialShareholdersContingentEarnoutShares" scale="0" unitRef="shares">750,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-292">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="clnn:InitialShareholdersContingentEarnoutShares" scale="0" unitRef="shares">750,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-293">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="clnn:TotalDilutiveSecurities" scale="0" unitRef="shares">15,429,744</ix:nonFraction></p></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="clnn:TotalDilutiveSecurities" scale="0" unitRef="shares">46,332,815</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="clnn:TotalDilutiveSecurities" scale="0" unitRef="shares">24,482,345</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="clnn:TotalDilutiveSecurities" scale="0" unitRef="shares">46,332,815</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>20. Related Party Transactions</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_2" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the three and nine months
ended September 30, 2020, we incurred $<ix:nonFraction contextRef="c13" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="6" unitRef="usd">0</ix:nonFraction> and $<ix:nonFraction contextRef="c14" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="6" unitRef="usd">0.1</ix:nonFraction> million, respectively, of expenses for compensation for consulting services provided
by a member of the Board of Directors. These expenses were paid in their entirety and as of September 30, 2020 and December 30, 2020,
there was no outstanding balance due to this related party.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_3" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>License and Supply Agreements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_4" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August&#160;2018, in conjunction
with an investment made in our Series C Preferred Stock and Series C Preferred Stock Warrants by 4Life Research, LLC, an investor, we
entered into a supply agreement with the investor. Under the terms of this agreement, we granted the investor an exclusive license to
pursue development of dietary supplements using certain of our intellectual property (&#8220;IP&#8221;). The exclusive rights to the IP
is for a term of <span style="-sec-ix-hidden: hidden-fact-294">five</span>&#160;years from the commencement of sales of licensed product by the investor, with a deemed commencement date of
January 1, 2023 if sales have not yet commenced, and is subject to annual minimum sales. The agreement may be renewed for additional five-year
terms. If the investor fails to meet the annual minimum sales requirements, the investor may pay an additional fee to maintain exclusivity
or have the investor&#8217;s license converted to non-exclusive rights. As part of this agreement, we will provide non-pharmaceutical
product to the investor for development efforts and potential future production, and the investor is to pay royalties of <ix:nonFraction contextRef="c317" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure">3</ix:nonFraction>% of incremental
sales, as defined in the agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_5" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the three and nine months
ended September 30, 2021, we sold $<ix:nonFraction contextRef="c12" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsSoldSalesTypeLease" scale="6" unitRef="usd">0.1</ix:nonFraction> million and $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsSoldSalesTypeLease" scale="6" unitRef="usd">0.4</ix:nonFraction> million of product, respectively, under this agreement. We did not sell any products
outside of this agreement. For the three and nine months ended September 30, 2021, the investor has made commercial sales of their products
under the agreement which we recognized as royalty revenues of $<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRoyaltiesReceived" scale="3" unitRef="usd">47</ix:nonFraction> thousand and $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRoyaltiesReceived" scale="6" unitRef="usd">0.1</ix:nonFraction> million, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the nine months ended September 30, 2020, we sold $<ix:nonFraction contextRef="c13" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsSoldSalesTypeLease" scale="6" unitRef="usd">0.1</ix:nonFraction> million
of product under this agreement, as well as $<ix:nonFraction contextRef="c14" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsSoldSalesTypeLease" scale="6" unitRef="usd">0.1</ix:nonFraction> million of product not under this agreement, and received $<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AdvancesToAffiliate" scale="6" unitRef="usd">0.1</ix:nonFraction> million in advance to
be applied against future sales of product under this agreement. We recorded this advanced amount as deferred revenue as of September
30, 2020. The investor did not make sales of their products under the agreement, and as such we did not recognize any royalty revenues
for the nine months ended September 30, 2020. For the three months ended September 30, 2020, we did not sell any product under this agreement,
we sold $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsSoldDirectFinancingLease" scale="3" unitRef="usd">2</ix:nonFraction> thousand of product not under this agreement, and there were no balances outstanding due to or from the investor.&#160;</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SegmentReportingDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:SegmentReportingDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>21. Geographic and Segment Information</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_SegmentReportingDisclosureTextBlock-c0_cont_2" id="_SegmentReportingDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Geographic Information</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SegmentReportingDisclosureTextBlock-c0_cont_3" id="_SegmentReportingDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our long-lived assets, which
were composed of property and equipment, net by location were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SegmentReportingDisclosureTextBlock-c0_cont_4" id="_SegmentReportingDisclosureTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">As of<br/> September&#160;30,<br/>
</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">As of<br/> December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">United States</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c318" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">4,193</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c319" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">3,997</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Australia</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c320" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">53</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c321" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">228</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">4,246</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">4,225</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_SegmentReportingDisclosureTextBlock-c0_cont_5" id="_SegmentReportingDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Segment Information</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SegmentReportingDisclosureTextBlock-c0_cont_6" id="_SegmentReportingDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The operating results of the
Drugs and Supplements segments were as follows:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SegmentReportingDisclosureTextBlock-c0_cont_7" id="_SegmentReportingDisclosureTextBlock-c0_cont_6"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfSegmentReportingInformationBySegmentTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Three Months ended <br/> September 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Nine Months ended <br/> September 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Drugs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Supplements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Drugs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Supplements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; text-indent: -9pt; padding-left: 9pt">Revenue from external customers</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-295">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c323" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd">110</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd">110</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-296">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c325" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd">524</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd">524</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Income (loss) from operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c322" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">10,546</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c323" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" unitRef="usd">96</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">10,450</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c324" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">35,632</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c325" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">288</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">35,920</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SegmentReportingDisclosureTextBlock-c0_cont_8" id="_SegmentReportingDisclosureTextBlock-c0_cont_7"><ix:continuation id="_ScheduleOfSegmentReportingInformationBySegmentTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Three Months ended <br/> September 30, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Nine Months ended <br/> September 30, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Drugs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Supplements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Drugs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Supplements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; text-indent: -9pt; padding-left: 9pt">Revenue from external customers</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-297">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c327" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd">98</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd">98</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-298">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c329" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd">177</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd">177</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Income (loss) from operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c326" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">5,789</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c327" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" unitRef="usd">98</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">5,691</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c328" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">14,373</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c329" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" unitRef="usd">119</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">14,254</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SegmentReportingDisclosureTextBlock-c0_cont_9" id="_SegmentReportingDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our long-lived assets, which
were composed of property and equipment, net by segment were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_SegmentReportingDisclosureTextBlock-c0_cont_9"><ix:nonNumeric contextRef="c0" escape="true" name="clnn:ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">As of <br/> September 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">As of <br/> December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Drugs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-299">4, 038</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c331" decimals="-3" format="ixt:num-dot-decimal" name="clnn:TotalPropertyAndEquipmentNet" scale="3" unitRef="usd">3,990</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Supplements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c332" decimals="-3" format="ixt:num-dot-decimal" name="clnn:TotalPropertyAndEquipmentNet" scale="3" unitRef="usd">208</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c333" decimals="-3" format="ixt:num-dot-decimal" name="clnn:TotalPropertyAndEquipmentNet" scale="3" unitRef="usd">235</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="clnn:TotalPropertyAndEquipmentNet" scale="3" unitRef="usd">4,246</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="clnn:TotalPropertyAndEquipmentNet" scale="3" unitRef="usd">4,225</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SubsequentEventsTextBlock-c0_cont_1" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>22. Subsequent Events</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation id="_SubsequentEventsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 1, 2021, various
investors exercised December 2020 PIPE Warrants for <ix:nonFraction contextRef="c334" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">25,000</ix:nonFraction> shares of Common Stock at an exercise price of $<ix:nonFraction contextRef="c334" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">0.01</ix:nonFraction> per share. <ix:nonNumeric contextRef="c335" name="us-gaap:SubsequentEventDescription">The December
2020 PIPE Warrants were issued prior to the completion of the Reverse Recapitalization on December 30, 2020, and were subject to a 180-day
holding period which expired on June 28, 2021.</ix:nonNumeric> We received cash proceeds of $<ix:nonFraction contextRef="c335" decimals="0" format="ixt:num-dot-decimal" name="clnn:AggregateGrossProceedWarrantsExercised" scale="0" unitRef="usdPershares">250</ix:nonFraction>.&#160;&#160;</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>The following discussion
and analysis of our financial condition and results of operations contain forward-looking statements within the meaning of Section 27A
of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934,
as amended (the &#8220;Exchange Act&#8221;). The forward-looking statements include, but are not limited to, our expectations, hopes,
beliefs, intentions, strategies, estimates, and assumptions concerning events and financial trends that may affect our future results
of operations or financial condition. In addition, any statements that refer to projections, forecasts, or other characterizations of
future events or circumstances, including any underlying assumptions, are forward-looking statements. The words &#8220;anticipate,&#8221;
&#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221;
&#8220;intends,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221;
&#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and similar expressions may identify forward-looking
statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are
based on information available as of the date of this Quarterly Report and our management&#8217;s current expectations, forecasts, and
assumptions, and involve a number of judgments, risks, and uncertainties. Accordingly, forward-looking statements should not be relied
upon as representing our views as of any subsequent date. We disclaim any obligation to update forward-looking statements to reflect
events or circumstances after the date they were made, whether as a result of new information, future events, or otherwise, except as
specifically required under applicable securities laws.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>As a result of a number
of known and unknown risks and uncertainties, our actual results and the timing of events may differ materially from those expressed or
implied by these forward-looking statements due to a number of factors, including those discussed in the section titled &#8220;Risk Factors&#8221;
appearing elsewhere in this Quarterly Report. </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>The following discussion
and analysis of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial
statements and the related notes appearing in Part I, Item I of this Quarterly Report on Form 10-Q and with our Annual Report on Form
10-K for the year ended December 31, 2020 (the &#8220;2020 Annual Report&#8221;), which was filed with the SEC on March 29, 2021.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Business Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a clinical-stage pharmaceutical
company pioneering the discovery, development, and commercialization of novel, clean-surfaced nanocrystal (&#8220;CSN<sup>&#174;</sup>&#8221;)
therapeutics. CSN<sup>&#174;</sup> therapeutics are comprised of atoms of transition elements that, when assembled in nanocrystal form,
possess unusually high, unique catalytic activities not present in those same elements in bulk form. These catalytic activities drive,
support, and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed, and damaged cells.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our patent-protected, proprietary
position affords us the potential to develop a broad and deep pipeline of novel&#160;CSN<sup>&#174;</sup> therapeutics to address a range
of diseases with high impact on human health. We began in 2013 by innovating an electro-crystal-chemistry drug development platform that
draws from advances in nanotechnology, plasma and quantum physics, material science, and biochemistry. Our platform process results in
nanocrystals with faceted structures and surfaces that are free of the chemical surface modifications that accompany other production
methods. Many traditional methods of nanoparticle synthesis involve the unavoidable deposition of potentially toxic organic residues and
stabilizing surfactants on the particle surfaces. Synthesizing stable nanocrystals that are both nontoxic and highly catalytic has overcome
this significant hurdle in harnessing transition metal catalytic activity for human therapeutic use.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our clean-surfaced nanocrystals
exhibit catalytic activities many-fold higher than multiple other commercially available nanoparticles, produced using various techniques,
that we have comparatively evaluated. We now have multiple drug assets currently in development and/or clinical trials for applications
in neurology, infectious disease, and oncology. Our development and clinical efforts are currently focused on addressing the high unmet
medical needs in two areas: first, those related to central nervous system disorders including Multiple Sclerosis (&#8220;MS&#8221;),
Parkinson&#8217;s Disease (&#8220;PD&#8221;), and Amyotrophic Lateral Sclerosis (&#8220;ALS&#8221;); and second, those related to COVID-19,
a highly infectious viral respiratory disease with serious and sometimes fatal co-morbidities.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently have no drugs
approved by the FDA for commercial sale and have not generated any revenue from drug sales. We have never been profitable and have incurred
operating losses in each year since inception. We began supplying low-dose dietary supplements to 4Life Research, LLC, one of our shareholders,
and had minimal direct sales of our rMetx<sup>&#8482; </sup>ZnAg Immune Boost dietary supplement product. Our total loss from operations
was $10.5 million and $35.9 million for the three and nine months ended September 30, 2021. Our total loss from operations was $5.7 million
and $14.3 million for the three and nine months ended September 30, 2020. Substantially all of our losses from operations resulted from
research and development expenses and administrative expenses. As of September 30, 2021 and December 31, 2020, we had an accumulated deficit
of $167.7 million and $153.6 million, respectively.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to continue investing
in product development, sales and marketing, and customer support for our products and expect to incur additional losses in the future
to fund our operations and conduct product research and development. We also recognize the need to raise additional capital to fully implement
our business plan. The long-term continuation of our business plan is dependent upon the generation of sufficient revenues from our products
to offset expenses and capital expenditures. In the event that we do not generate sufficient revenues and are unable to obtain funding,
we will be forced to delay, reduce, or eliminate some or all of our research and development programs, product portfolio expansion, commercialization
efforts, or capital expenditures, which could adversely affect our business prospects, ability to meet long-term liquidity needs, or we
may be unable to continue operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Impact of the COVID-19 Pandemic</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;The COVID-19 pandemic,
which began in December&#160;2019 and has spread worldwide, has caused many governments to implement measures to slow the spread of the
COVID-19 outbreak. The COVID-19 pandemic and government measures taken in response have had a significant impact, both direct and indirect,
on businesses and commerce, as worker shortages have occurred, supply chains have been disrupted, and facilities and production have been
suspended. The future progression of the COVID-19 pandemic and its effects on our business and operations remain uncertain. The COVID-19
pandemic may affect our ability to initiate and complete preclinical studies, delay the initiation of future clinical trials, disrupt
regulatory activities, or have other adverse effects on our business and operations. In particular, we and our third-party clinical research
organizations (&#8220;CROs&#8221;) may face disruptions that may affect our ability to initiate and complete preclinical studies, cause
manufacturing disruptions, or create delays at clinical trial sites. The COVID-19 pandemic has already caused significant disruptions
in the financial markets, and may continue to cause such disruptions, which could impact our ability to raise additional funds to support
our operations. Moreover, the COVID-19 pandemic has significantly impacted economies worldwide and could result in adverse effects on
our business and operations.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are monitoring the potential
impact of the COVID-19 pandemic on our business and financial statements. While the COVID-19 pandemic has led to various research restrictions
and paused certain of our clinical trials, these impacts have been temporary and to date we have not experienced material business disruptions
or incurred impairment losses in the carrying values of our assets as a result of the COVID-19 pandemic. We are not aware of any specific
related event or circumstance that would require us to revise the estimates reflected in our financial statements. The extent to which
the COVID-19 pandemic will directly or indirectly impact our business, results of operations, and financial condition, including planned
and future clinical trials and research and development costs, will depend on future developments that are highly uncertain, including
as a result of new information that may emerge concerning COVID-19, the actions taken to contain or treat it, and the duration and intensity
of the related effects.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Reverse Recapitalization with Tottenham and
Clene Nanomedicine</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 30, 2020, we completed
the previously announced Reverse Recapitalization (see &#8220;Business Overview&#8221; above).&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the closing of the Reverse
Recapitalization, Clene Inc. acquired 100% of the issued and outstanding Clene Nanomedicine common stock, in exchange for 54,339,012 shares
of Clene Inc. Common Stock issued to the Clene Nanomedicine common shareholders, of which 2,716,958 shares of the Clene Inc. Common Stock
were to be issued and held in escrow to satisfy any indemnification obligations incurred under the Merger Agreement.&#160;The escrowed
shares were released without restrictions following the six month anniversary of the completion of the Reverse Recapitalization.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the closing of the Reverse
Recapitalization, each stock option of Clene Nanomedicine common stock was cancelled and the holders thereof in exchange received 0.1320
newly-issued stock options of our Common Stock, which is 95% of the exchange ratio determined in the Merger Agreement. Pursuant to the
Merger Agreement, we agreed to issue rights to 370,101 restricted stock awards under the 2020 Plan to the option holders which complements
the 5% closing payment shares held in escrow for Clene Nanomedicine common shareholders discussed above. In addition, we issued rights
to 1,136,961 restricted stock awards to option holders to complement the earn-out payments that would contingently be issued to certain
current Clene Nanomedicine shareholders upon the achievement of milestones. See &#8220;Earn-out Shares&#8221; for the milestones detail.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Immediately after giving effect
to the Reverse Recapitalization and the December 2020 PIPE offering discussed below, there were 59,526,171 shares of Common Stock issued
and outstanding and warrants to purchase 5,566,361 shares of Common Stock issued and outstanding.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The transaction was accounted
for as a &#8220;reverse recapitalization&#8221; and Tottenham was treated as the &#8220;acquired&#8221; company for accounting purposes.
Accordingly, for accounting purposes, the Reverse Recapitalization was treated as the equivalent of Clene Nanomedicine issuing shares
for the net assets of Tottenham, accompanied by a recapitalization. The net assets of Tottenham were recorded at historical costs, with
no goodwill or other intangible assets recorded. Reported amounts from operations included herein prior to the Reverse Recapitalization
are those of Clene Nanomedicine.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The PIPE Offerings</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the completion of
the Reverse Recapitalization on December 30, 2020, we entered into subscription agreements on December 28, 2020, with various investors
(the &#8220;December 2020 PIPE&#8221;). Pursuant to the subscription agreements, we issued 2,239,500 shares of Common Stock (the &#8220;December
2020 PIPE Shares&#8221;) at a price of $10.00 per share with net proceeds of $22.2 million. The purpose of the December 2020 PIPE was
to fund general corporate expenses. In addition, investors in the December 2020 PIPE offering also received warrants to purchase a number
of shares equal to one-half (1/2) of the number of December 2020 PIPE Shares, for an aggregate total of 1,119,750 shares of Common Stock,
at an exercise price of $0.01 per share (the &#8220;December 2020 PIPE Warrants&#8221;), subject to a 180-day holding period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 21, 2021, the Company
entered into the May 2021 PIPE subscription agreements with various investors. Pursuant to the subscription agreements, the Company issued
960,540 shares of Common Stock at a price of $9.63 per share with net proceeds of approximately $9.3 million. The closing of the May 2021
PIPE occurred substantially concurrently with, and was conditioned upon, the closing of a loan agreement with Avenue (see Note 8 to our
condensed consolidated financial statements as of September 30, 2021 included in Part I, Item 1 of this Quarterly Report). The purpose
of the May 2021 PIPE was to fund the expansion of manufacturing capabilities in the state of Maryland and to fund general corporate expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Between July 1, 2021 and September
15, 2021, various investors exercised December 2020 PIPE Warrants for 1,002,250 shares of Common Stock at an exercise price of $0.01 per
share. The December 2020 PIPE Warrants were issued prior to the completion of the Reverse Recapitalization on December 30, 2020, and were
subject to a 180-day holding period which expired on June 28, 2021. We received cash proceeds of $10.0 thousand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Key Factors Affecting Our Results of Operations</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our results of operations,
financial condition, and the period-to-period comparability of our financial results are principally affected by the following factors:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Earn-Out Shares</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the Reverse
Recapitalization, certain of Clene Nanomedicine&#8217;s current shareholders and Tottenham&#8217;s former officers and directors and the
Sponsor (collectively, the &#8220;Initial Shareholders&#8221;) are entitled to receive earn-out payments (the &#8220;Contingent Earn-Outs&#8221;)
based on achieving milestones discussed below. The Contingent Earn-Outs have been classified as liabilities in the condensed consolidated
balance sheets and were initially measured at fair value on the date of the Reverse Recapitalization and are subsequently remeasured to
fair value at each reporting date. The change in fair value of the Contingent Earn-Outs has been recorded in the condensed consolidated
statements of operations and comprehensive income (loss) for the three and nine months ended September 30, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Contingent Earn-Out provision
for Clene Nanomedicine&#8217;s common shareholders (the &#8220;Clene Nanomedicine Contingent Earn-Out&#8221;) includes (i) Milestone 1
that is based on achieving a certain volume-weighted average price (&#8220;VWAP&#8221;) of the shares of our Common Stock within three
years after the closing of the Reverse Recapitalization or the change of control price equaling or exceeding a certain price if a change
of control transaction occurs within the three years following the closing of the Reverse Recapitalization, (ii) Milestone 2 that is based
on achieving a certain VWAP of the shares of our Common Stock within five years after the closing of the Reverse Recapitalization or the
change of control price equaling or exceeding a certain price if a change of control transaction occurs within the five years following
the closing of the Reverse Recapitalization, and (iii) Milestone 3 that is based on completing by December 30, 2021 a randomized placebo-controlled
study for treatment of COVID-19 which results in a statistically significant finding of clinical efficacy within twelve months after the
closing of the Reverse Recapitalization.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Contingent Earn-Out provision
for the Initial Shareholders (the &#8220;Initial Shareholders Contingent Earn-Out&#8221;) includes Milestone 1 and Milestone 2 listed
above. Upon the consummation of the Reverse Recapitalization, Clene Nanomedicine and the Initial Shareholders are entitled to receive
up to 8,346,185 and 750,000 shares of Common Stock, respectively, if the milestones described above are achieved.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The estimated fair values
of the contingent consideration were determined using Monte Carlo simulations that simulated the future path of our Common Stock price
over the earn-out periods. The assumptions utilized in the calculations are based on the achievement of certain stock price milestones
including projected stock price, volatility, and risk-free rate. For potential payments related to a product development milestone, the
fair value was determined based on our expectations of achieving such a milestone and the simulated estimated stock price on the expected
date of achievement.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Contingent Earn-Out payments involve certain assumptions
requiring significant judgment and actual results may differ from assumed and estimated amounts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development Expenses</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The discovery and development
of novel drug candidates require a significant investment of resources over a prolonged period of time, and a core part of our strategy
is to continue making sustained investments in this area. As a result of this commitment, our pipeline of drug candidates has been advancing
and expanding, with two clinical-stage drug candidates currently being investigated.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We anticipate that our research
and development expenses will increase significantly due to the increase in clinical trial expenses incurred to develop our drug candidates,
expenses incurred for payments to CROs, principal investigators and clinical trial sites, costs of materials to support our clinical trials
and preclinical studies, costs associated with preclinical activities, share awards granted to our research and development personnel,
and salaries for our expanding research and development personnel. Our research and development expenses are affected by the timing and
advancement of our existing product pipeline as well as the timing and quantity of new drug programs commenced.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Funding for Our Operations</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since our inception, we have
dedicated substantially all of our resources to the development of our drug candidates. We have financed our operations principally through
proceeds from the issuance of preferred stock, issuance of Common Stock upon exercise of common stock options, convertible promissory
notes, issuances of notes payable, the consummation of the Reverse Recapitalization, and the consummation of PIPE offerings.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since our inception and through
the date of this Quarterly Report, we have funded our operations primarily with proceeds from the following sources:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">gross proceeds of $87.2 million from sales of our preferred stock and other equity financing;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">gross proceeds of $28.1 million from borrowings under convertible promissory notes;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">gross proceeds of $0.6 million through government lending; </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">gross cash proceeds of $31.7 million from the Reverse Recapitalization and the December 2020 PIPE offering; </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">gross cash proceeds of $0.6 million from a Program Paycheck Protection loan obtained through the U.S. Small Business Administration, which was forgiven in January 2021;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">gross cash proceeds of approximately $9.3 million from the May 2021 PIPE offering; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">gross cash proceeds of $20.0 million through the 2021 Avenue Loan.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have also been awarded
grants from various other organizations, including the National Multiple Sclerosis Society; FightMND, a not-for-profit registered charity
in Australia; and the Michael J. Fox Foundation, who together have issued us grants totaling approximately $1.9 million. We also receive
indirect financial support for one of the clinical trials in which we participate, the Healey ALS Platform Trial, administered by the
Massachusetts General Hospital, which is conducting a study of our CNM-Au8<sup>&#174;</sup> drug candidate along with other drugs in a
platform trial, at significantly lower costs to us than we would otherwise incur if we were to conduct a comparably designed study on
our own at reasonable market rates.&#160;In December 2019, we were awarded a grant from the U.S. Congressionally Directed Medical Research
Program administered by the Department of Defense for $1.3 million, which as of June 17, 2021, we have determined not to accept. We communicated
that decision to the Department of Defense and the awarded grant was terminated effective July 19, 2021. No amounts relating to this award
were recognized in the financial statements of any period and therefore there will be no impact to our financial condition or to the results
of our operations or our cash flows for any period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The net cash used in our operating
activities was $25.0 million and $13.1 million for the nine months ended September 30, 2021 and 2020, respectively. As of September 30,
2021, we had cash of $60.6 million. We expect that the cash on hand as of September 30, 2021 will be sufficient to fund our operations
for a period extending beyond twelve months from the date the condensed consolidated financial statements for the three and nine months
ended September 30, 2021 were issued. We have based this estimate on assumptions that may prove to be wrong, and we may exhaust our available
capital resources sooner than we anticipate. See &#8220;Liquidity and Capital Resources.&#8221; We expect our expenses to increase significantly
in connection with our ongoing activities, particularly as we advance the clinical development of our clinical-stage drug products and
continue research and development of our preclinical drug products and initiate additional clinical trials of, and seek regulatory approval
for, these and other future drug products. As we continue to grow and expand, we will incur more expenses relating to regulatory compliance
and sales and marketing personnel as we prepare to commence commercialization once we obtain regulatory approval of our drug products.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>General and Administrative Expenses</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our general and administrative
expenses consist primarily of staff costs, agency and consulting fees, utilities, rent and general office expenses, share grants, and
restricted stock award grants. We anticipate that our general and administrative expenses will increase in future periods to support increases
in our research and development activities and as we continue to rapidly advance the clinical programs of our drug products and expect
to commercialize our products once we receive regulatory approval. These increases will likely include increased headcount, increased
share compensation charges, expanded infrastructure, and increased insurance expenses. We also anticipate increasing legal, compliance,
accounting, and investor and public relations expenses associated with being a public company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Grants and Government Tax Incentives</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We received grants issued
by non-government entities related to income which have future related costs expected to be incurred and require us to comply with conditions
attached to the grants. These non-government grants related to income are recognized in profit or loss as an offset to research and development
expenses when funding has been received and related costs have been incurred. We received tax incentives from the Australian government
in the form of cash subsidies for research and development activities related to clinical trial activities conducted by our Australian
subsidiary, which are recognized as other income upon compliance with certain conditions. We recognized $0 and $0.2 million of grant funding
against research and development expenses for the three and nine months ended September 30, 2021, respectively. We recognized $0.2 million
and $0.7 million of grant funding against research and development expenses for the three and nine months ended September 30, 2020. We
recognized $0.4 million and $1.1 million of other income for the three and nine months ended September 30, 2021 that we classified as
Australia research and development credit. We recognized $2.6 million of other income for the three and nine months ended September 30,
2020 that we classified as Australia research and development credit.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Commercialization of Our Drug Candidates</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business and results of
operations depend on our ability to commercialize our drug candidates, if approved for marketing. Our pipeline is comprised of four drug
candidates ranging from preclinical to late-stage clinical programs, including two drug candidates at the clinical stage or IND stage.
Although we currently do not have any drug candidates approved for commercial sale and have not generated any revenue from drug product
sales, we expect to commercialize one or more of our drug products in the coming years as they move toward the final stages of development.
While we began selling our ZnAg Immune Boost product online in May&#160;2020, we anticipate revenue generated from sales of this dietary
supplement will be small compared to our operating expenses as well as the revenue we expect to generate from future sales of our drug
candidates for which we are currently conducting clinical trials.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Components of Results of Operations</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Comparison of the Three Months Ended September
30, 2021 and 2020</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes
our results of operations for the three months ended September 30, 2021 and 2020:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Three Months ended</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-style: italic">&#160;</td>
    <td colspan="6" style="font-style: italic; text-align: center">(in thousands)</td><td style="text-align: center; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Product revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">63</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">81</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Royalty revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">47</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Total revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">110</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">98</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Cost of revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,146</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,994</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,400</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,795</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Total operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,560</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,789</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10.450</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,691</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Other income (expenses):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Interest income (expense)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(367</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Loss on extinguishment of convertible notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(540</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Change in fair value of preferred stock warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,071</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Change in fair value of derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Change in fair value of Clene Nanomedicine contingent earn-out</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,042</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Change in fair value of Initial Shareholders contingent earn-out</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,439</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Change in fair value of common stock warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">414</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Australia research and development credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">364</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,343</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Other income, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total other income (expense), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">39,325</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,604</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net income (loss) before income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,875</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,295</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Income tax benefit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">69</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net income (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,944</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,295</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other comprehensive income (loss):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Foreign currency translation adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(87</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total other comprehensive income (loss)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(87</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Comprehensive income (loss)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">28,857</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(10,293</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Comparison of the Nine Months Ended September
30, 2021 and 2020</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes
our results of operations for the nine months ended September 30, 2021 and 2020:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Nine Months ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-style: italic">&#160;</td>
    <td colspan="6" style="font-style: italic; text-align: center">(in thousands)</td><td style="font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Product revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">400</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">160</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Royalty revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">124</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Total revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">524</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">177</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Cost of revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">812</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">58</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,893</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,750</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,739</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,623</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Total operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36,444</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,431</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(35,920</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14,254</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Other income (expenses):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(497</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(608</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Gain on extinguishment of notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">647</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Loss on extinguishment of convertible notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(540</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Gain on termination of lease</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Change in fair value of preferred stock warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,378</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Change in fair value of derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Change in fair value of Clene Nanomedicine contingent earn-out</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,072</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Change in fair value of Initial Shareholders contingent earn-out</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,710</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Change in fair value of common stock warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">547</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Australia research and development credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,078</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,611</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Other income, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">34</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total other income (expense), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,544</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,801</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss before income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14,376</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(20,055</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Income tax benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">213</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14,163</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(20,055</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other comprehensive income (loss):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Foreign currency translation adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(124</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total other comprehensive income (loss)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(124</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Comprehensive loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(14,287</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(20,037</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We generated revenue of $0.1
million and $0.5 million for the three and nine months ended September 30, 2021. Product revenue of $0.1 million and $0.4 million was
recognized in our dietary supplement segment under a supply agreement with 4Life Research, LLC, a related party, for KHC46 and a low dose
zinc-silver solution, two dietary (mineral) supplements that we began supplying during those periods.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We generated revenue of $0.1
million and $0.2 million for the three and nine months ended September 30, 2020. All of our revenue was product revenue from our supply
agreement with 4Life Research, LLC, a related party, for KHC46 and a low dose zinc-silver solution, two dietary (mineral) supplements
that we began supplying during those periods.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also generated minimal
product revenue from sales of rMetx<sup>&#8482; </sup>ZnAg Immune Boost during those periods. In addition, $47 thousand and $0.1 million
of our revenue during the three and nine months ended September 30, 2021 was paid to us by 4Life Research, LLC under an exclusive and
royalty-bearing license agreement relating to the sale of KHC46. We generated royalty revenue under the same license agreement of $17
thousand for the three and nine months ended September 30, 2020. For more details on the license agreement, see Note 20 to our condensed
consolidated financial statements included in Part I, Item 1 of this Quarterly Report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Operating Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Cost of Sales</i>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We incurred cost of sales
of $14 thousand and $0.8 million for the three and nine months ended September 30, 2021, relating to production and distribution costs
for the sales of our KHC46 and low dose zinc-silver solution dietary supplement products.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We incurred insignificant
cost of sales for the three and nine months ended September 30, 2020, relating to production and distribution costs for the sales of our
KHC46 and low dose zinc-silver solution dietary supplement products.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Research and Development Expenses</i>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development expenses
were (i) $6.1 million and $4.0 million for the three months ended September 30, 2021 and 2020, respectively, and (ii) $18.9 million and
$10.8 million for the nine months ended September 30, 2021 and 2020, respectively. During these periods, substantially all of our research
and development expenses were related to the development and clinical trials of our lead drug candidate, CNM-Au8<sup>&#174;</sup>. The
increases for the three and nine months ended September 30, 2021 of $2.2 million, or 53.9% and $8.1 million, or 75.7%, respectively, were
primarily due to the progression of our drug candidates through the clinical development process, including increased enrollment into
the REPAIR-PD and the REPAIR-MS studies, and calendar payments due for our participation in the Healey ALS Platform Trial. These efforts
resulted in greater associated costs and manufacturing expenses in support of these trials. Also, during the three months ended September
30, 2021 and 2020, research and development expenses included $0.9 million and $0.1 million, respectively of share-based compensation
expense related to stock options and restricted stock awards. During the nine months ended September 30, 2021 and 2020, research and development
expenses included $3.9 million and $0.3 million, respectively of share-based compensation expense related to stock options and restricted
stock awards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Historically, substantially
all of our research and development expenses relate to CNM-Au8<sup>&#174;</sup>, our lead asset. Drug candidates in later stages of clinical
development generally have higher development costs than those in earlier stages of clinical development, primarily due to per patient
clinical trial site fees for larger studies, the costs of opening and monitoring clinical sites, CRO activity, and manufacturing expenses.
We expect that our research and development expenses will increase in connection with our clinical development activities in the near
term and in the future.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development costs
are charged to operations as incurred. Research and development costs include payroll and personnel expenses, including salaries and related
benefits and stock-based compensation for employees engaged in research and development functions; clinical trial supplies; fees for clinical
trial services; consulting costs; and allocated overhead, including rent, equipment, utilities, depreciation, insurance, and facilities
maintenance costs. We account for nonrefundable advance payments for goods and services that will be used in future research and development
activities initially as an asset and then as expenses when the goods have been received or when the service has been performed rather
than when the payment is made.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our clinical trial accrual
process seeks to account for expenses resulting from obligations under contracts with CROs, consultants, and under clinical site agreements
in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract
to contract and may result in payment flows that do not match the periods over which materials or services are provided to us under such
contracts. We reflect the appropriate trial expenses in the condensed consolidated financial statements by matching the appropriate expenses
with the period in which services and efforts are expended. In the event advance payments are made to a CRO, the payments will be recorded
as a prepaid asset, which will be expensed over the period of time the contracted services are performed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>General and Administrative Expenses</i>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses consist of employee salary and benefits; share-based compensation expenses; professional fees for legal, consulting, and audit
services; fees for business development activities; facility expenses; travel expenses; rental fees; and other administrative expenses.
We expect our general and administrative expenses to increase as we continue to grow and expand. General and administrative expenses were
(i) $4.4 million and $1.8 million for the three months ended September 30, 2021 and 2020, respectively, and (ii) $16.7 million and $3.6
million for the nine months ended September 30, 2021 and 2020, respectively. The increases for the three and nine months ended September
30, 2021 of $2.6 million or 145.1% and $13.1 million or 362.0%, respectively, were primarily due to (i) increased professional expenses,
public company expenses, legal fees, accounting fees, tax fees, and director and officer insurance expenses as a result of becoming a
public company on December 30, 2020 to support our efforts to comply with SEC rules and regulations, and (ii) $1.6 million and $6.1 million
of share-based compensation expense related to stock options and restricted stock awards during the three and nine months ended September
30, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Other Income (Expenses)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other income (expenses) consists
of interest expense, loss on extinguishment of convertible notes payable, gain on termination of leases, changes in fair value of preferred
stock warrant liability, changes in fair value of Clene Nanomedicine contingent earn-out, changes in fair value of Initial Shareholders
contingent earn-out, changes in fair value of common stock warrant liability, a research and development credit received from the Australian
government, and gain (loss) on extinguishment of notes payable. Other income (expenses), net for the three months ended September 30,
2021 and 2020 included the following:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i) recognized interest income
of $0.1 million and interest expense of $0.4 million, respectively, due to a decrease in the fair value of the 2019 MD Loan and 2019 Cecil
Loan, partially offset by the interest on the 2021 Avenue Loan of $0.5 million. As of September 30, 2021, the fair value of notes payable
was determined based on the closing price of our Common Stock on Nasdaq of $6.83 per share;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ii) recognized a loss on
extinguishment of convertible notes payable of $0.5 million for the three months ended September 30, 2020;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(iii) recognized expense of
$5.1 million relating to the changes in fair value of preferred stock warrant liability for the three months ended September 30, 2020.
There was no preferred stock warrant liability as a result of the Reverse Recapitalization on December 30, 2020. Upon the consummation
of the Reverse Recapitalization, we determined that the warrants qualify for classification as permanent equity and we reclassified the
resulting warrant liability to additional paid-in capital. No change in fair value of preferred stock warrant liability is recorded going
forward;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(iv) recognized income for
the change in fair value of the Clene Nanomedicine contingent earn-out liability of $35.0 million for the three months ended September
30, 2021. The change in fair value was primarily a result of the decrease of the closing price of our Common Stock on Nasdaq from $11.24
per share on June 30, 2021 to $6.83 per share on September 30, 2021 when we remeasured the Clene Nanomedicine contingent earn-out liability.&#160;There
was no Clene Nanomedicine contingent earn-out liability for the three months ended September 30, 2020;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(v) recognized income for
the change in fair value of the Initial Shareholders contingent earn-out liability of $3.4 million for the three months ended September
30, 2021. The change in fair value was primarily a result of the decrease of the closing price of our Common Stock on Nasdaq from $11.24
per share on June 30, 2021 to $6.83 per share on September 30, 2021 when we remeasured the Initial Shareholders contingent earn-out liability.
There was no Initial Shareholders contingent earn-out liability for the three months ended September 30, 2020;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(vi) recognized income of
$0.4 million and $1.3 million, respectively, relating to a research and development credit received from the Australian government. We
recognized Australian research and development credit in an amount equal to the qualifying expenses incurred in each period multiplied
by the applicable reimbursement percentage. The decrease in research and development credit is the result of decreased research and development
activities during the three months ended September 30, 2021; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(vii) recognized the change in fair value of the Avenue Warrants of
$0.4 million for the three months ended September 30, 2021. The change in fair value was primarily a result of the decrease of the expected
term ranging from 3.89 years to 4.56 years on September 30, 2021 from 4.89 years on June 30, 2021, partially offset by the decrease of
the closing price of our Common Stock on Nasdaq from $11.24 per share on June 30, 2021 to $6.83 per share on September 30, 2021 when we
remeasured the Avenue Warrants. There were no Avenue Warrants for the three months ended September 30, 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other income (expenses), net
for the nine months ended September 30, 2021 and 2020 included the following:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i) recognized interest
expense of $0.5 million and $0.6 million, respectively, due to a decrease in the fair value of the 2019 MD Loan and 2019 Cecil Loan and
the interest expense on the 2021 Avenue Loan of $0.8 million. As of September 30, 2021, the fair value of notes payable was determined
based on the closing price of our Common Stock on Nasdaq of $6.83 per share;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ii) recognized gain on termination
of leases of $51 thousand due to the termination of an operating lease for office space for the nine months ended September 30, 2020;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(iii) recognized gain on extinguishment
of notes payable of $0.6 million for the nine months ended September 30, 2021, due to the forgiveness of the PPP Note by the U.S. Small
Business Administration. We recognized a loss on extinguishment of convertible notes payable of $0.5 million for the nine months ended
September 30, 2020;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(iv) recognized expense of
$7.4 million relating to the changes in fair value of preferred stock warrant liability for the nine months ended September 30, 2020.
There was no preferred stock warrant liability as a result of the Reverse Recapitalization on December 30, 2020. Upon the consummation
of the Reverse Recapitalization, we determined that the warrants qualify for classification as permanent equity and we reclassified the
resulting warrant liability to additional paid-in capital. No change in fair value of preferred stock warrant liability is recorded going
forward;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(v) recognized income for
the change in fair value of the Clene Nanomedicine contingent earn-out liability of $18.1 million for the nine months ended September
30, 2021. The change in fair value was primarily a result of the decrease of the closing price of our Common Stock on Nasdaq from $9.01
per share on December 31, 2020 to $6.83 per share on September 30, 2021 when we remeasured the Clene Nanomedicine contingent earn-out
liability.&#160;There was no Clene Nanomedicine contingent earn-out liability for the nine months ended September 30, 2020;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(vi) recognized income for
the change in fair value of the Initial Shareholders contingent earn-out liability of $1.7 million for the nine months ended September
30, 2021. The change in fair value was primarily a result of the decrease of the closing price of our Common Stock on Nasdaq from $9.01
per share on December 31, 2020 to $6.83 per share on September 30, 2021 when we remeasured the Initial Shareholders contingent earn-out
liability. There was no Initial Shareholders contingent earn-out liability for the nine months ended September 30, 2020;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(vii) recognized income of
$1.1 million and $2.6 million, respectively, relating to a research and development credit received from the Australian government. We
recognized Australian research and development credit in an amount equal to the qualifying expenses incurred in each period multiplied
by the applicable reimbursement percentage. The decrease in research and development credit is the result of decreased research and development
activities in Clene Australia during the nine months ended September 30, 2021; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(vii) recognized the change
in fair value of the Avenue warrants of $0.6 million for the nine months ended September 30, 2021. The change in fair value was primarily
a result of the decrease of the expected term ranging from 3.89 years to 4.56 years on September 30, 2021 from 5.0 years on May 21, 2021,
partially offset by the decrease of the closing price of our Common Stock on Nasdaq from $9.63 per share on May 21, 2021 to $6.83 per
share on September 30, 2021 when we remeasured the Avenue Warrants. There were no Avenue Warrants for the nine months ended September
30, 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Comprehensive Income (Loss)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the foregoing,
we (i) generated comprehensive income of $28.9 million and incurred a comprehensive loss of $10.3 million for the three months ended September
30, 2021 and 2020, respectively, and (ii) incurred a comprehensive loss of $14.3 million and $20.0 million for the nine months ended September
30, 2021 and 2020, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Taxation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>United&#160;States</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are incorporated in Delaware
in the U.S. and subject to statutory U.S. federal corporate income tax at a rate of 21% for the three and nine months ended September
30, 2021 and 2020. We are also subject to state income tax in Utah and Maryland, at a rate of 4.95% and 8.25%, respectively, for the nine
months ended September 30, 2021 and 2020. As of September 30, 2021 and December 31, 2020, we recorded a full valuation allowance against
our net deferred tax assets due to the uncertainty as to whether such assets will be realized resulting from our three-year cumulative
loss position and the uncertainty surrounding our ability to generate pre-tax income in the foreseeable future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Australia</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our wholly-owned subsidiary,
Clene Australia Pty Ltd (&#8220;Clene Australia&#8221;), was established in Australia on March 5, 2018 and is subject to corporate income
tax at a rate of 25.0% and 27.5% for the three and nine months ended September 30, 2021 and 2020, respectively. Clene Australia total
income tax expense was $0.1 million and $0.2 million for the three and nine months ended September 30, 2021, respectively. During the
three and nine months ended September 30, 2020, Clene Australia had no taxable income no provision for income taxes. We recorded $0.4
million and $1.1 million as other income during the three and nine months ended September 30, 2021 for a refund of research and development
credits pertaining to Clene Australia for the 2021 tax year. We recorded $2.6 million as other income during the three and nine months
ended September 30, 2020 for a refund of research and development credits pertaining to Clene Australia for the 2020 tax year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Netherlands</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our wholly-owned subsidiary,
Clene Netherlands B.V. (&#8220;Clene Netherlands&#8221;), was established in the Netherlands on April 21, 2021 and will be subject to
corporate income tax at a rate of 15% up to &#8364;245,000 of taxable income and 25% for taxable income in excess of &#8364;245,000. During
the three and nine months ended September 30, 2021, Clene Netherlands had no taxable income and no provision for income taxes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>JOBS Act</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We qualify as an &#8220;emerging
growth company&#8221; as defined in Section 2(a)(19) of the Securities Act, as modified by the JOBS Act. As such, we are eligible for
and may take advantage of certain exemptions from various reporting requirements applicable to other public companies that are not emerging
growth companies for as long as we continue to be an emerging growth company, including (i) the exemption from the auditor attestation
requirements with respect to internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act, (ii) the exemptions
from say-on-pay, say-on-frequency and say-on-golden parachute voting requirements, and (iii) reduced disclosure obligations regarding
executive compensation in our periodic reports and proxy statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will remain an emerging
growth company until the earlier of: (i) the last day of the fiscal year (a) following the fifth anniversary of the closing of the initial
public offering of Tottenham, (b) in which we have total annual gross revenue of at least $1.07 billion, or (c) in which we are deemed
to be a &#8220;large accelerated filer&#8221; under the Exchange Act of 1934, which would occur if the market value of the shares of our
Common Stock held by non-affiliates exceeds $700.0 million as of the last business day of our most recently completed second fiscal quarter;
or (ii) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the JOBS Act
provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting
standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise
apply to private companies. We have elected to avail ourselves of this extended transition period and, as a result, we may adopt new or
revised accounting standards on the relevant dates on which adoption of such standards is required for non-public companies instead of
the dates required for other public companies. As a result, our financial statements may not be comparable to companies that comply with
new or revised accounting pronouncements as of public company effective dates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Smaller Reporting Company Status</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also a &#8220;smaller
reporting company&#8221; because the market value of our stock held by non-affiliates is less than $700 million as of June 30, 2021 and
our annual revenue was less than $100 million during the fiscal year ended December 31, 2020. We may continue to be a smaller reporting
company in any given year if either (i) the market value of our stock held by non-affiliates is less than $250 million as of June 30 in
the most recently completed fiscal year or (ii) our annual revenue is less than $100 million during the most recently completed fiscal
year and the market value of our stock held by non-affiliates is less than $700 million as of June 30 in the most recently completed fiscal
year. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions
from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we
may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and, similar
to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Liquidity and Capital Resources</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since inception, we have incurred annual net losses from our operations.
Substantially all of our losses have resulted from the funding of our research and development programs and general and administrative
expenses associated with our operations. We incurred a net loss of $14.2 million for the nine months ended September 30, 2021. We incurred
net losses of $10.3 million and $20.1 million for the three and nine months ended September 30, 2020. Our loss from operations was $10.5
million and $35.9 million for the three and nine months ended September 30, 2021. Our loss from operations was $5.7 million and $14.3
million for the three and nine months ended September 30, 2020. We have financed our operations principally through proceeds from the
sale of preferred stock, the sale of preferred stock warrants, the sale of convertible notes that have converted into shares of preferred
stock, the sale of shares of Common Stock underlying outstanding warrants, and through the funds we raised from the consummation of the
Reverse Recapitalization and the December 2020 PIPE. During the three months ended September 30, 2021, we raised $5.0 million under the
2021 Avenue Loan. During the nine months ended September 30, 2021, we raised $9.3 million from the May 2021 PIPE and $20.0 million under
the 2021 Avenue Loan. During the nine months ended September 30, 2020, we raised an aggregate of $41.9 million, consisting of net proceeds
from issuance of notes payable, convertible notes payable, and Series D preferred stock.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The net cash used in our operating
activities was $25.0 million and $13.1 million for the nine months ended September 30, 2021 and 2020, respectively. As of September 30,
2021, we had cash and restricted cash of $60.6 million. We expect that the cash on hand as of September 30, 2021 will be sufficient to
fund our operations for a period extending beyond twelve months from the date the condensed consolidated financial statements for the
three and nine months ended September 30, 2021 were issued. We have based this estimate on assumptions that may prove to be wrong, and
we may exhaust our available capital resources sooner than we anticipate. We expect our expenses to increase significantly in connection
with our ongoing activities, particularly as we advance the clinical development of our clinical-stage drug products and continue research
and development of our preclinical drug products and initiate additional clinical trials of, and seek regulatory approval for, these and
other future drug products. As we continue to grow and expand, we will incur more expenses relating to regulatory compliance and sales
and marketing personnel as we prepare to commence commercialization if we obtain regulatory approval of our drug products.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to continue as
a going concern may require obtaining additional funding to finance operations. As part of our ongoing business plans, we will continue
seeking funding through equity financing and may seek debt financing or other capital sources. We may not be able to obtain financing
on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of our shareholders. If we
are unable to raise capital when needed or on acceptable terms, we would be forced to delay, reduce or eliminate research and development
programs and commercialization efforts.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table provides
information regarding our cash flows for the relevant periods:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Nine Months ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net cash used in operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(25,018</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(13,121</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(661</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(269</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,130</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41,364</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Effect of foreign exchange rate changes on cash</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(116</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net increase in cash and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,335</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">27,993</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Funds</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our primary use of cash in
all periods presented was to fund our research and development, regulatory and other clinical trial costs, and related supporting administration.
Our prepaid expenses and other current assets, accounts payable, and accrued expense balances in all periods presented were affected by
the timing of vendor invoicing and payments, and impacted the cash provided by, or used in, operations. We have no commitments for capital
expenditures as of the end of the latest fiscal period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Operating Activities</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in operating
activities was $25.0 million of cash for the nine months ended September 30, 2021, which resulted from a net loss of $14.2 million, adjusted
for (i)&#160;non-cash items of $10.3 million, which primarily consisted of depreciation expense of $0.7 million, non-cash lease expense
of $0.1 million, stock-based compensation expense of $9.9 million, changes in fair value of the Clene Nanomedicine contingent earn-out
of $18.1 million, changes in fair value of the Initial Shareholders contingent earn-out of $1.7 million, changes in fair value of the
common stock warrant liability of $0.5 million, gain on extinguishment of debt of $0.6 million, and increase in interest accrued on notes
payable and accretion of debt discount of $0.1 million; and (ii)&#160;a net change in operating assets and liabilities of $0.5 million.
The net change in operating assets and liabilities was primarily attributable to a decrease in inventory of $0.1 million; an increase
in accounts receivable of $48 thousand, an increase in prepaid expenses and other current assets of $1.2 million due to the increase in
Australia research and development credit receivable and prepayments to CROs and other vendors, $0.4 million increase in accounts payable,
$0.1 million decrease in operating lease obligations, $0.2 million increase in deferred income tax, and $0.5 million increase in accrued
liabilities due to the timing of vendor invoicing and payments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in operating
activities was $13.1 million of cash for the nine months ended September 30, 2020, which resulted from a net loss of $20.1 million, adjusted
for (i) non-cash items of $9.8 million, which primarily consisted of depreciation expense of $0.7 million, stock-based compensation expenses
of $0.6 million, changes in the fair value of preferred stock warrant liability of $7.4 million, accretion of debt discount of $0.2 million,
loss on extinguishment of convertible notes of $0.5 million, and increase in interest accrued on notes payable of $0.4 million; and (ii)
a net change in operating assets and liabilities of $2.8 million. The net change in operating assets and liabilities was primarily attributable
to a $2.1 million increase in prepaid expenses and other current assets, $0.3 million decrease in accounts payable, $0.4 million decrease
in accrued liabilities due to the timing of vendor invoicing and payments, $0.1 million increase in deferred revenue from related parties,
and $0.1 million decrease in payable to related parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Investing Activities</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in investing
activities was $0.7 million and $0.3 million for the nine months ended September 30, 2021 and 2020, respectively, which in each instance
was related to purchases of property and equipment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Financing Activities</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash provided by financing activities was $27.1 million for the
nine months ended September 30, 2021, which primarily resulted from (i) proceeds from the May 2021 PIPE of $9.3 million, (ii) proceeds
from the issuance of notes payable of $20.0 million, (iii) proceeds from exercise of stock options of $0.4 million, and (iiii) proceeds
from warrants exercised of $10 thousand, partially offset by (i) payments of notes payable issuance costs of $0.5 million, (ii) payments
of our finance lease obligations of $0.1 million, (iii) payments of notes payable of $5 thousand, and (iv) payments of deferred transaction
costs of $1.9 million.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash provided by financing
activities was $41.4 million for the nine months ended September 30, 2020, which primarily resulted from proceeds from the issuance of
Series D Preferred Stock of $35.1 million, the issuance of notes payable of $0.7 million and the issuance of convertible notes payable
of 6.1 million, partially offset by payments on our finance lease obligations of $0.2 million as well as the deferred offering costs of
$0.3 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Debt Obligations</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Maryland Loan&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February&#160;2019, we
entered into a loan agreement (the &#8220;2019 MD Loan&#8221;) with the Department of Housing and Community Development, a principal department
of the State of Maryland (&#8220;Maryland&#8221;). Pursuant to the 2019 MD Loan, Maryland agreed to provide a $0.5 million term loan.
Amounts outstanding under the 2019 MD Loan bear simple interest at an annual rate of 8.00%. Under the 2019 MD Loan, we agreed to affirmative
and negative covenants to which we will remain subject until maturity. These covenants include providing information about the Company
and our operations; limitations on our ability to retire, repurchase, or redeem our common or preferred stock, options, and warrants other
than per the terms of the securities; and limitations on our ability to pay dividends of cash or property. There are no financial covenants
associated with the 2019 MD Loan. Events of default under the 2019 MD Loan include failure to make payments when due, insolvency events,
and failure to comply with covenants. We are not in violation of any affirmative covenants. Repayment of the full balance outstanding
is due on February 22, 2034. The 2019 MD Loan establishes &#8220;Phantom Shares,&#8221; based on 119,906 shares of Common Stock (based
on 863,110 Series C Preferred Shares prior to the Reverse Recapitalization), determined at issuance. The 2019 MD Loan states the repayment
amount is to be the greater of the balance of principal and accrued interest or the Phantom Shares value. We determined that the note
should be accounted for at fair value. We record the fair value of the debt at the end of each reporting period. In order to value the
note, we consider the amount of the simple interest expense that would be due and the value of Phantom Shares. Upon the closing of the
Reverse Recapitalization and as of December 31, 2020, the fair value of the 2019 MD Loan is determined based on the closing price of CLNN
shares listed on Nasdaq.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Income of $0.5 million and
$0.3 million were recognized during the three and nine months ended September 30, 2021, respectively. Expense of $0.2 million and $0.3
million was recognized during the three and nine months ended September 30, 2020, respectively. The fair value of $0.8 million and $1.1
million of principal and accrued interest is included in long-term notes payable as of September 30, 2021 and December 31, 2020, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Cecil County Loan&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April&#160;2019, we entered
into a loan agreement (the &#8220;2019 Cecil Loan&#8221;) with Advance Cecil Inc., a non-stock corporation formed under the laws of the
State of Maryland with application for 501(c)(3) non-profit status pending before the United States Internal Revenue Service at the time
of execution of the 2019 Cecil Loan. Pursuant to the 2019 Cecil Loan, Cecil agreed to provide a $0.1 million term loan. Amounts outstanding
under the 2019 Cecil Loan bear simple interest at an annual rate of 8.00%. Under the 2019 Cecil Loan, we agreed to affirmative covenants
to which we will remain subject until maturity. These covenants include providing information about the Company and our operations. There
are no financial covenants associated with the 2019 Cecil Loan. Events of default under the 2019 Cecil Loan include failure to make payments
when due, insolvency events, and failure to comply with covenants. We are not in violation of any affirmative covenants. Repayment of
the full balance outstanding is due on April 30, 2034. The 2019 Cecil Loan establishes &#8220;Phantom Shares,&#8221; based on 23,981 shares
of Common Stock (based on 172,622 Series C Preferred Shares prior to the Reverse Recapitalization), determined at issuance. The 2019 Cecil
Loan states the repayment amount is to be the greater of the balance of principal and accrued interest or the Phantom Share value. We
determined that the note should be accounted for at fair value. We record the fair value of the debt at the end of each reporting period.
In order to value the note, we consider the amount of the simple interest expense that would be due and the value of Phantom Shares. Upon
the closing of the Reverse Recapitalization and as of December 31, 2020, the fair value of the 2019 Cecil Loan is determined based on
the closing price of CLNN shares listed on Nasdaq.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Income of $0.1 million and
$52 thousand were recognized during the three and nine months ended September 30, 2021, respectively. Expense of $42 thousand and $55
thousand was recognized during the three and nine months ended September 30, 2020, respectively. The fair value of $0.2 million and $0.2
million of principal and accrued interest is included in long-term notes payable as of September 30, 2021 and December 31, 2020, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>PPP Loan</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May&#160;2020, we entered
into a note payable in the amount of $0.6 million (the &#8220;PPP Note&#8221;) under the Paycheck Protection Program of the CARES Act
(the &#8220;PPP&#8221;). As amended, the PPP permits forgiveness of amounts loaned for payments of payroll and other qualifying expenses
within 24 weeks of receipt of loaned funds, given that at least 60% of the total loan is used for payroll. Amounts not forgiven have a
repayment period of five years. In January 2021, the full $0.6 million balance of the PPP Note was forgiven and has been recorded as a
gain on extinguishment of debt during the nine months ended September 30, 2021. There was no gain on extinguishment of debt recorded during
the three months ended September 30, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Avenue Loan</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2021, we entered into the 2021 Avenue Loan with Avenue. The
agreement provides for a 42-month term loan of up to $30.0 million. The first tranche is $20.0 million (&#8220;Tranche 1&#8221;), of which
$15.0 million was funded at close. We incurred issuance costs for a total of $0.5 million of which $35 thousand has been expensed immediately.
The remaining balance from Tranche 1 of $5.0 million was funded on September 28, 2021 and an additional tranche of $10.0 million (&#8220;Tranche
2&#8221;) is available at the Company&#8217;s request until June 30, 2022. Pursuant to the 2021 Avenue Loan, funding of Tranche 2 is subject
to evidence reasonably satisfactory to Avenue of receipt of an additional $5.0 million financing through Maryland&#8217;s State Incentive
Programs and/or other Maryland State programs and mutual agreement of the Company and Avenue. On September 27, 2021, we obtained a waiver
from this additional financing requirement for the funding of the remaining $5.0 million of Tranche 1 and exercised the option to postpone
principal repayment by one year. We incurred additional issuance costs of $75 thousand upon funding the remaining $5.0 million of Tranche
1, of which $12 thousand has been expensed immediately. Funding of Tranche 2 is also subject to (a) our achievement of a statistically
significant result on the primary endpoint as defined within the statistical analysis plan for each respective study, or the totality
of the results for any study warrant advancement into a subsequent clinical efficacy study, as reasonably determined by the Company and
Avenue with respect to at least two of the following studies: (i) RESCUE-ALS or the Healey ALS Platform Trial; (ii) REPAIR-PD; or (iii)
REPAIR-MS (&#8220;Performance Milestone 1&#8221;); and (b) our receipt of net proceeds of at least $30 million from the sale and issuance
of our equity securities (including any private placement or follow-on offering) between May 2, 2021 and June 30, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The loans bear interest at
a variable rate per annum equal to the sum of (i) the greater of (A) the prime rate, as published by the Wall Street Journal from time
to time or (B) 3.25%, plus (ii) 6.60%. Payments for the loan are interest only for the initial 12 months and can be extended to (i) 12
months (the &#8220;First Interest-only Period Extension&#8221;) if we achieve Performance Milestone 1 and (ii) up to 36 months if (a)
we achieve the First Interest-only Period Extension and (b) have drawn from Tranche 2. On August 16, 2021, we mutually confirmed with
Avenue that Performance Milestone 1 and the First Interest-only Period Extension had been achieved. The loan will amortize in equal payments
of principal from the end of the interest period to the expiration of the 42-month term on December 1, 2024. On the maturity date, an
additional payment equal to 4.25% of the funded loans, or $0.6 million, is due in addition to the remaining unpaid principal and accrued
interest. The final payment is recorded as a debt premium and is being amortized over the contractual term using the effective interest
method. The final payment provision is related to the loan host and is not bifurcated pursuant to ASC 815.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the agreement, we granted to Avenue the Avenue Warrants
for the purchase of 115,851 shares of Common Stock at an exercise price equal to the lower of (i) $8.63 (which is equal to the five-day
volume weighted average price (&#8220;VWAP&#8221;) per share, determined as of the end of trading on the last trading day prior to execution
of the loan agreement), or (ii) the lowest price per share paid by cash investors for our Common Stock issued in the next bona fide round
of equity financing prior to March 31, 2022 (the &#8220;Next Round Price&#8221;) (see Note 10 to our condensed consolidated financial
statements included in Part I, Item 1 of this Quarterly Report). Upon the funding of Tranche 2, the Avenue Warrant shall be automatically
adjusted to include an additional estimated 86,679 shares of Common Stock, which is equal to 5% of the principal amount of Tranche 2,
divided by the lower of (i) the five (5)-day VWAP per share; determined as of the end of trading on the last trading day before the date
of issuance of Tranche 2; or (ii) the Next Round Price. We accounted for the Tranche 2 warrants at inception of the 2021 Avenue Loan in
accordance with ASC 815 and the fair value and issuable shares will be remeasured at each reporting period (see Note 10 to our condensed
consolidated financial statements included in Part I, Item 1 of this Quarterly Report). Avenue also has the right, in its discretion,
but not the obligation, at any time from time to time from the first- through the third-year anniversary of the agreement, while the loan
is outstanding, to convert an amount of up to $5.0 million of the principal amount of the outstanding loan into Common Stock (the &#8220;Conversion
Feature&#8221;) at a price per share equal to 120% of the stock purchase price set forth in the warrant. The Conversion Feature is subject
to (i) the closing price of our Common Stock for each of the seven consecutive trading days immediately preceding the conversion being
greater than or equal to the conversion price and (ii) the Common Stock issued in connection with any such conversion not exceeding 20%
of the total trading volume of our Common Stock for the twenty-two consecutive trading days immediately prior to and including the effective
date of such conversion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the 2021 Avenue Loan, we agreed to affirmative and negative covenants
to which we will remain subject upon maturity in the absence of prepayments. These covenants include providing information about the Company
and our operations; limitation on our ability to retire, repurchase, or redeem our Common Stock, options, and warrants other than per
the terms of the securities; and limitations on our ability to pay dividends of cash or property. The financial covenant associated with
the loan agreement includes maintaining minimum unrestricted cash and cash equivalents of at least $5.0 million; provided that upon our
(i) achievement of Performance Milestone 1, and (ii) receiving of net proceeds of at least $30.0 million from the sale and issuance of
our equity securities (including any PIPE or follow-on offering) between May 1, 2021 and June 30, 2022, we shall no longer be subject
to financial covenants. We are not in violation of the covenants. The agreement provides for events of default customary for loans of
this type, including but not limited to non-payment, breaches, the occurrence of a material adverse change, or defaults in the performance
of covenants, insolvency, and bankruptcy. The 2021 Avenue Loan is collateralized by substantially all of our assets other than intellectual
property, including capital stock of the Company and its subsidiaries, in which Avenue is granted continuing security interest. The net
proceeds from the issuance of the loan were initially allocated to the warrant at an amount equal to their fair value of $1.5 million
and the remainder to the loan. The allocation of incurred financing costs of $0.5 million, which together with the fair value of the warrant
and the final payment, are recorded as a debt discount and debt premium, respectively, and are being amortized over the contractual term
using the effective interest method. During the three and nine months ended September 30, 2021, we recorded interest expense of $0.6 million
and $0.8 million, respectively.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Contractual Obligations and Commitments</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as set forth in Note
8, <i>Notes Payable</i>, to the condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report, there
have been no material changes to our contractual obligations and other commitments as of September 30, 2021, as compared to those disclosed
in Part II, Item 7 <i>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</i> of our 2020 Annual
Report which was filed with the SEC on March 29, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have made an accounting
policy election not to recognize leases with an initial term of 12 months or less within our consolidated balance sheet and to recognize
those lease payments on a straight-line basis in our consolidated statements of operations and comprehensive income (loss) over the lease
term.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We enter into agreements
in the normal course of business with CROs for clinical trials and with vendors for preclinical studies and other services and products
for operating purposes, which are cancelable at any time by us, subject to payment of our remaining obligations under binding purchase
orders and, in certain cases, nominal early termination fees. These commitments are not deemed significant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Off-Balance Sheet Arrangements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the period presented,
we did not have, and we currently do not have, any off-balance sheet arrangements, such as relationships with unconsolidated entities
or financial partnerships, which are often referred to as structured finance or special purpose entities, established for the purpose
of facilitating financing transactions that are not required to be reflected on our balance sheets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Critical Accounting Policies</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our discussion and analysis
of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared
in accordance with GAAP. The preparation of these financial statements requires us to make estimates, assumptions, and judgments that
affect the reported amounts of assets, liabilities, revenues, costs, and expenses. We evaluate our estimates and judgments on an ongoing
basis, and our actual results may differ from these estimates. We base our estimates on historical experience, known trends and events,
contractual milestones, and other various factors that are believed to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our most critical accounting
policies are described under the heading <i>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8211;Critical
Accounting Policies</i> in Part II, Item 7 of our 2020 Annual Report which was filed with the SEC on March 29, 2021. There were no material
changes to our critical accounting policies through September 30, 2021 from those discussed in our 2020 Annual Report.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recent Accounting Pronouncements</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See Note 2 to our condensed
consolidated financial statements included in Part I, Item 1 of this Quarterly Report for a description of recent accounting pronouncements
applicable to our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Information required by this
Item is not applicable as we are electing scaled disclosure requirements available to&#160;Smaller&#160;Reporting Companies with respect
to this Item.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 4. CONTROLS AND PROCEDURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Evaluation of Disclosure Controls and Procedures</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the supervision and
with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation
of the effectiveness of our disclosure controls and procedures as of September 30, 2021, as such term is defined in Rules 13a-15(e) and
15d-15(e) under the Exchange Act. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that,
as of September 30, 2021, our disclosure controls and procedures were not effective due to the material weaknesses in internal control
over financial reporting described below. Notwithstanding the identified material weaknesses, management, including our Chief Executive
Officer and Chief Financial Officer, believes the condensed consolidated financial statements included in this Quarterly Report on Form
10-Q fairly represent in all material respects our financial condition, results of operations, and cash flows at and for the periods presented
in accordance with U.S. GAAP.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Disclosure controls and procedures
are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is
recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information
is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to
allow timely decisions regarding required disclosure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Material Weaknesses in Internal Control over
Financial Reporting </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the audit
of our financial statements as of and for the years ended December 31, 2020 and 2019, our management identified material weaknesses in
our internal control over financial reporting. A material weakness is a deficiency, or combination of deficiencies, in internal control
over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial
statements will not be prevented or detected on a timely basis. The material weaknesses identified relate to the fact that we did not
design or maintain an effective control environment commensurate with our financial reporting requirements, including (a) lack of a sufficient
number of trained professionals with an appropriate level of accounting knowledge, training, and experience to appropriately analyze,
record, and disclose accounting matters timely and accurately; and (b) lack of structures, reporting lines, and appropriate authorities
and responsibilities to achieve financial reporting objectives. This deficiency in our control environment contributed to the following
additional deficiencies (each of which individually represents a material weakness) in our internal control over financial reporting:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we did not design and maintain formal accounting policies, procedures, and controls to achieve complete, accurate, and timely financial accounting, reporting, and disclosures, including controls over the preparation and review of account reconciliations and journal entries;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we did not design and maintain effective controls over segregation of duties related to manual journal entries. Specifically, certain personnel have the ability to both prepare and post manual journal entries without an independent review by someone without the ability to prepare and post manual journal entries;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we did not design and maintain formal accounting policies, processes, and controls to analyze, account for, and disclose complex transactions. Specifically, we did not design and maintain controls to analyze, account for, and disclose warrants to purchase preferred stock and convertible promissory notes with embedded derivatives, including ensuring complete and accurate data was used in the valuations; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we did not design and maintain effective controls over certain information technology (&#8220;IT&#8221;) general controls for IT systems that are relevant to the preparation of the financial statements. Specifically, we did not design and maintain: (a) user access controls to ensure appropriate segregation of duties and that adequately restrict user and privileged access to financial applications, programs, and data to our appropriate personnel; (b) program change management controls to ensure that IT program and data changes affecting financial IT applications and underlying accounting records are identified, tested, authorized, and implemented appropriately; (c) computer operations controls to ensure that data backups are authorized and monitored; and (d) testing and approval controls for program development to ensure that new software development is aligned with business and IT requirements.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The control deficiencies described
above resulted in the misstatement of our redeemable convertible preferred stock warrant liability, accrued liabilities, general and administrative
expenses, Australian research and development credit, and amounts and classification within our statement of cash flows, and related financial
disclosures as of and for the year ended December 31, 2019 and in the misstatement of our prepaid expenses and other current assets, accrued
liabilities, earn-out liabilities, redeemable convertible preferred stock warrant liability, general and administrative expenses, amounts
and classification within our statement of equity, and amounts and classification within our statement of cash flows, and related financial
disclosures as of and for the year ended December 31, 2020. Additionally, each of the control deficiencies described above could result
in a misstatement of one or more account balances or disclosures that would result in a material misstatement to the annual or interim
consolidated financial statements that would not be prevented or detected. Accordingly, our management has determined that each of the
control deficiencies described above constitute material weaknesses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Material Weakness Remediation </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Management is actively engaged
and committed to taking the steps necessary to remediate the control deficiencies that constituted the above material weakness. During
2020, we made the following enhancements to our control environment:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we added finance personnel to the organization to strengthen our internal accounting team, to provide oversight, structure and reporting lines, and to provide additional review over our disclosures to include a Chief Financial Officer and a Manager of SEC Reporting;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we engaged outside consultants to assist in the design, implementation, and documentation of internal controls that address the relevant risks, are properly designed, and provide for appropriate evidence of performance of the internal control; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we engaged outside consultants to assist us in the evaluation of a new Enterprise Resource Planning (&#8220;ERP&#8221;) system in order to mitigate the internal control gaps and limitations that cannot be addressed by the current ERP around segregation of duties, and to enhance the information technology general controls environment.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our remediation activities
are continuing during 2021. In addition to the above actions, we expect to engage in additional activities, including, but not limited
to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adding more technical accounting resources to enhance our control environment;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">until we have sufficient technical accounting resources, engaging external consultants to provide support and to assist us in our evaluation of more complex applications of GAAP, and to assist us with documenting and assessing our accounting policies and procedures; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">implementing a new ERP to enhance the accuracy of our financial records, enable the enforcement of systematic segregation of duties, and improve our information technology general controls environment.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We continue to enhance corporate
oversight over process-level controls and structures to ensure that there is appropriate assignment of authority, responsibility, and
accountability to enable remediation of our material weaknesses. We believe that our remediation plan will be sufficient to remediate
the identified material weakness and strengthen our internal control over financial reporting. As we continue to evaluate, and work to
improve, our internal control over financial reporting, management may determine that additional measures to address control deficiencies
or modifications to the remediation plan are necessary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Changes in Internal Control over Financial
Reporting</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are engaged in the process
of the design and implementation of our internal control over financial reporting in a manner commensurate with the scale of our operations
following the Reverse Recapitalization. During the quarter ended September 30, 2021, we continued the process to implement a new ERP to
enhance the accuracy of our financial records, enable the enforcement of systematic segregation of duties, and improve our information
technology general controls environment; and we continued to engage outside consultants to assist in the design, implementation, and documentation
of internal controls that address our relevant risks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART II&#8212;OTHER INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 1. LEGAL PROCEEDINGS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be subject to legal
proceedings, investigations, and claims incidental to the conduct of our business from time to time. There are no material pending legal
proceedings to which we are a party or of which any of our property is the subject.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 1A. RISK FACTORS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Investing in our securities
involves a high degree of risk. You should carefully consider the risks and uncertainties described below, together with the other information
in this Quarterly Report, including our condensed consolidated financial statements and the related notes appearing in this Quarterly
Report and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before deciding
whether to invest in our securities. The occurrence of one or more of the events or circumstances described in these risk factors, alone
or in combination with other events or circumstances, may have a material adverse effect on our business, reputation, revenue, financial
condition, results of operations and future prospects, in which event the market price of our Common Stock could decline, and you could
lose part or all of your investment. Unless otherwise indicated, reference in this section and elsewhere in this Quarterly Report to our
business being adversely affected, negatively impacted or harmed will include an adverse effect on, or a negative impact or harm to, our
business, reputation, financial condition, results of operations, revenue and prospects. The material and other risks and uncertainties
summarized above and described below are not intended to be exhaustive and are not the only ones we face. Additional risks and uncertainties
not presently known to us or that we currently deem immaterial may also impair our business operations. This Quarterly Report also contains
forward-looking statements that involve risks and uncertainties. Our actual results could differ materially and adversely from those anticipated
in the forward-looking statements as a result of a number of factors, including the risks described below.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risk Factors Summary</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business is subject to
numerous material and other risks that you should be aware of before making an investment decision. These risks include, among others,
the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We depend substantially on the successful commercialization of our drug candidates in the future, which may fail to materialize or may experience significant delays.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We currently do not generate any revenue from the commercial sales of drug candidates and we may not become profitable when expected, or at all.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have incurred significant net losses since our inception and expect to continue to incur significant net losses for the foreseeable future.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ability to continue as a going concern requires that we obtain sufficient funding to finance our operations, which may not be available on acceptable terms, or at all. A failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our drug development or commercialization efforts.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have a limited operating history, which may make it difficult to evaluate our current business and predict our future performance.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may encounter difficulties in managing our growth and expanding our operations successfully, which could adversely affect our business, financial condition, results of operations and prospects.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in government regulation or in practices relating to the pharmaceutical and biotechnology industries, including potential healthcare reform, could decrease the need for our drug candidates, or make it more difficult to obtain regulatory approvals for our drug candidates and commercialize them.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we, or any contract research organization (&#8220;CRO&#8221;) we may engage, fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business, financial conditions, results of operations and prospects.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our internal computer systems, or those used by any CROs or other third-party contractors or consultants we may engage, may fail or suffer security breaches.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We manufacture all of our drug candidates ourselves, and intend to manufacture most, if not all, of any approved drugs ourselves as well, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delays in completing and receiving regulatory approvals for our manufacturing facilities could delay our development plans or commercialization efforts, which could harm our business.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may fail to get regulatory approval for our products or such approval could be significantly delayed.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Damage to, destruction of or interruption of production at our manufacturing facilities would negatively affect our business and prospects.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our future success depends on our ability to retain key executives and to attract, train, retain and motivate qualified and highly skilled personnel.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Relating to Our Business and Industry</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We depend substantially on the successful
commercialization of our drug candidates in the future, which may fail to materialize or may experience significant delays.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a new biopharmaceutical
business, we currently do not have any drugs available for commercial sales nor do we have any drugs that have been approved for sale
by the regulatory authorities. We have invested a significant portion of our efforts and financial resources in research and development
of our leading drug candidate, CNM-Au8<sup>&#174;</sup>, a catalytically-active gold nanocrystal suspension, which in early-stage studies
has shown potential for the treatment of patients with multiple sclerosis (&#8220;MS&#8221;), amyotrophic lateral sclerosis (&#8220;ALS&#8221;)
and Parkinson&#8217;s disease (&#8220;PD&#8221;). Our ability to generate revenue and become profitable in the future depends substantially
on the future sales generated by CNM-Au8<sup>&#174;</sup> and our drug candidates, which in turn depends on the successful research and
development (&#8220;R&amp;D&#8221;), regulatory approval, commercialization and sale of our drug candidates presently under clinical development
for the treatment of patients with neurological disorders. We are also developing new drugs based on our technology that have not yet
entered into human studies. The ultimate success of our drug candidates is subject to us achieving certain milestones, including without
limitation:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying, assessing, acquiring and obtaining evidence of biological activity of new drug candidates to treat certain diseases;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining satisfactory evidence of safety of these drug candidates in animal toxicology studies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining regulatory approval for the conduct of, enrollment in, and completion of, clinical trials of our drug candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining satisfactory proof of the clinical efficacy and safety of our drug candidates from these clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining approvals and marketing authorizations from regulatory authorities for our drug candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing sustainable and scalable manufacturing processes to produce these drug candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully expanding manufacturing processes to support global commercialization capacity of our drug candidates; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">launching and commercializing any drug candidates for which we may obtain regulatory approvals and marketing authorizations, either directly or with a collaborator or distributor.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we do not achieve one or
more of these milestones in a timely manner, or at all, we could experience significant delays in our ability to obtain approval for and/or
to successfully commercialize our drug candidates, which would materially harm our business and we may not be able to generate sufficient
revenues and cash flows to continue our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we are able to generate
revenues from any future sales of our drug candidates, we may not become profitable and may need to obtain additional funding to continue
operations. Any required funding may not be available on favorable terms or at all. If we fail to become profitable or are unable to sustain
profitability on a continuing basis, then we may be unable to continue our operations at planned levels and may be forced to reduce our
operations. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis.
Our failure to become and remain profitable would decrease our value significantly and could impair our ability to raise capital, expand
our business or continue our operations, which in turn may adversely affect our business, financial condition, and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We currently do not generate any revenue
from the commercial sales of drug candidates and we may not become profitable when expected, or at all.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our main business is R&amp;D,
and if successful, the sales of drug candidates. As all of our drug candidates are still in the R&amp;D stage, we currently do not generate
revenue from the sale of drug candidates, and we have recorded continued significant net losses. We generate an immaterial amount of revenue
related to supply agreements for dietary (mineral) supplements and from sales of another product; however, such revenue is not expected
to be a material contributor to our revenue in the future. If we fail to commercialize our drug candidates as planned due to failures
to complete clinical trials, obtain regulatory approval, conduct commercial scale manufacturing or for any other reason, we may experience
significant delays or failure in generating revenue and realizing profit from the commercial sale of our drug candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, we expect to incur
significant costs in the future, in particular for R&amp;D and the commercialization of our drug candidates. Our R&amp;D expenses were
$15.2&#160;million, $9.6&#160;million and $6.6&#160;million in 2020, 2019 and 2018, respectively. For the three and nine&#160;months ended
September 30, 2021, our R&amp;D expenses were $6.1&#160;million and $18.9&#160;million, respectively. For the three and nine months ended
September 30, 2020, our R&amp;D expenses were $4.0&#160;million and $10.8&#160;million, respectively. As drug candidates presently undergoing
preclinical research enter into the clinical trial stage, costs associated with such drug candidates may increase significantly. In the
future, as we move more drug candidates into the clinical trial stage, conduct more clinical trials for commercialized products to broaden
their use, and carry out commercial production of our drug candidates, the costs associated with such operations may increase significantly.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As we operate in the highly
competitive pharmaceutical market, we compete to commercialize our drug candidates ahead of our competitors, putting us under pressure
to incur R&amp;D and other expenses with a potential negative impact on our profitability. On the other hand, our commercialized drug
candidates, if any are approved, may fail to realize their sales potential due to competition, insufficient market demand, product defects,
or any other reason. Therefore, even if we ever start to generate revenue from the sales of our commercialized drug candidates in the
future, we may still not be profitable for an extended period of time or at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have incurred significant net losses
and net operating cash outflows since our inception and expect to continue to incur significant net losses for the foreseeable future.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Investment in biopharmaceutical
drug development is highly speculative. It entails substantial upfront capital expenditures and significant risk that a drug candidate
might fail to gain regulatory approval or become commercially viable. We continue to incur significant expenses related to our ongoing
operations. We have incurred substantial losses since our inception. During 2020, 2019 and 2018, we recorded a net loss for the year of
$19.3&#160;million, $16.2&#160;million and $11.7&#160;million, respectively. We incurred net income of $28.9 million and net loss of $14.2&#160;million
for the three and nine months ended September 30, 2021, respectively. We incurred net losses of $10.3&#160;million and $20.1 million for
the three and nine months ended September 30, 2020, respectively. As of September 30, 2021 and December&#160;31, 2020, we had an accumulated
deficit of $167.7 million and $153.6&#160;million, respectively. For details, see &#8220;Management&#8217;s Discussion and Analysis of
Financial Condition and Results of Operations.&#8221; Substantially all of our operating losses have resulted from costs incurred in connection
with our R&amp;D programs and administrative expenses associated with our operations, and we expect that our R&amp;D expenses will continue
to increase in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>


</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to continue to incur
losses for the foreseeable future, and we expect these losses to increase as we continue to expand our development of, and seek regulatory
approvals for, our drug candidates, and we continue to build up our commercialization and sales workforce in anticipation of the potential
future roll-out of our late-stage drug candidates. Typically, it takes many&#160;years to develop one new drug from the drug discovery
stage to the time it is available for treating patients. In addition, we will continue to incur costs associated with operating as a public
company and in support of our growth as a development-stage or commercial-stage pharmaceutical company. The size of our future net losses
will depend, in part, on the number and scope of our drug development programs and the associated costs of those programs, the cost of
commercializing any approved products, our ability to generate revenues and the timing and amount of milestones and other payments we
make or receive through arrangements with third parties. If any of our drug candidates fails in clinical trials or does not gain regulatory
approval, or if approved, fails to achieve market acceptance, we may never become profitable. Our failure to become and remain profitable
would decrease our value significantly and impair our ability to raise capital, maintain our R&amp;D efforts, expand our business or continue
our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our ability to continue as a going concern
requires that we obtain sufficient funding to finance our operations, which may not be available on acceptable terms, or at all. A failure
to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our drug development or commercialization
efforts.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December&#160;31, 2020,
we had cash totaling $59.3&#160;million and an accumulated deficit of $153.6&#160;million. As of September&#160;30, 2021, we had cash
and restricted cash totaling $60.6&#160;million and an accumulated deficit of $167.7&#160;million. During the nine months ended September
30, 2021 and 2020, we used net cash in operating activities of $25.0&#160;million and $13.1&#160;million, respectively. We expect to continue
to incur losses and use cash in operating activities in 2021 and for the foreseeable future. We expect that the cash on hand as of September
30, 2021 will be sufficient to fund our planned operations for a period extending beyond twelve&#160;months from the date of this Quarterly
Report. For details, please see &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Liquidity
and Capital Resources.&#8221; Our ability to continue as a going concern requires that we obtain sufficient funding to finance our operations
until our drug candidates begin generating sufficient revenue. As part of our ongoing business plans, we will continue seeking funding
through equity financing and may seek debt financing or other capital sources. We may not be able to obtain financing on acceptable terms,
or at all. The terms of any financing may adversely affect the holdings or the rights of our shareholders. If we are unable to raise capital
when needed or on acceptable terms, we would be forced to delay, reduce or eliminate R&amp;D programs and commercialization efforts. These
factors, among others, may raise substantial doubt about our ability to continue as a going concern.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have a limited operating history, which
may make it difficult to evaluate our current business and predict our future performance.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a biopharmaceutical
company formed in December&#160;2012 focusing on the discovery and development of innovative drugs for the treatment of neurological diseases
and other disorders. Our limited operating history, particularly in light of the rapidly evolving nanocrystal therapies field, may make
it difficult to evaluate our current business and predict our future performance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Investment in biopharmaceutical
product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential
drug candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval and become commercially
viable. As a relatively new business, we have not yet demonstrated an ability to manufacture drugs at a commercial scale, to arrange for
a third party to do so on our behalf, or to conduct sales and marketing activities necessary for successful commercialization. We have
not had any product approved for commercial sale and have not generated any revenue from product sales. In addition, as a business with
a limited operating history, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors
and risks frequently experienced by early-stage biopharmaceutical companies in rapidly evolving fields. Consequently, any assessment you
make about our current business or future success or viability may not be as accurate as it could be if we had a longer operating history
and had been able to reduce some of the uncertainties as set out above. Further, our limited financial track record, without any revenue
yet from our expected future principal business, may be of limited reference value for your assessment of our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"></p><div>

</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may encounter difficulties in managing
our growth and expanding our operations successfully, which could adversely affect our business, financial condition, results of operations
and prospects.</i></b></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As we seek to advance our
drug candidates through clinical trials, we will need to expand our development, regulatory, compliance, manufacturing, marketing and
sales capabilities or contract with third parties to provide these capabilities for us. As our operations expand, we expect that we will
need to manage additional relationships with various strategic partners, suppliers and other third parties. Future growth will impose
significant added responsibilities on members of our management. Our future financial performance and our ability to commercialize our
drug candidates, if approved, and to compete effectively will depend, in part, on our ability to manage any future growth effectively.
To that end, we must be able to manage our development efforts and clinical trials effectively and hire, train and integrate additional
clinical, regulatory, manufacturing, financial, legal, managerial, administrative, and sales and marketing personnel. We may not be able
to accomplish these tasks, and our failure to accomplish any of them could prevent us from successful growth and could harm our business,
financial condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Changes in government regulation or in practices
relating to the pharmaceutical and biotechnology industries, including potential healthcare reform, could decrease the need for our drug
candidates, or make it more difficult to obtain regulatory approvals for our drug candidates and commercialize them.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In recent&#160;years, the
U.S.&#160;Congress, the President, executive branch agencies, and state legislatures have considered various types of healthcare reform
to control growing healthcare costs. Similar reform movements have occurred in parts of Europe and Asia. Healthcare reform legislation
could also increase the costs of drug development and commercialization or limit reimbursement for marketed drugs that could limit the
profits to be made from the development of new drugs. This could adversely affect R&amp;D expenditures by pharmaceutical and biotechnology
companies, which could in turn decrease the business opportunities available to us in the U.S.&#160;and other countries. We are unable
to predict what reform proposals will be adopted in the future, if any.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we, or any CRO we may engage, fail to
comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could
have a material adverse effect on our business, financial condition, results of operations and prospects.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We and certain of the third
parties we contract with, such as our third-party clinical research organizations (&#8220;CROs&#8221;), are subject to numerous environmental,
health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment, and
disposal of hazardous materials and wastes. In addition, our future construction projects may necessitate that certain regulatory procedures
be completed with the relevant administrative authorities in charge of environmental protection, health and safety before the project
can be put into operation. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials.
Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and
wastes. We cannot entirely eliminate the risk of contamination or injury from these materials. In the event of contamination or injury
resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we maintain workers&#8217;
compensation insurance to cover the costs and expenses we may incur due to injuries to our employees resulting from the use of or exposure
to hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for
environmental liability or toxic tort claims that may be asserted against us in connection with our storage, use or disposal of biological
or hazardous materials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the environmental,
health and safety laws and regulations applicable to us and our third-party contractors may change and impose stricter requirements in
the future. As a result, we may be required to incur substantial costs to comply with future environmental, health and safety laws and
regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply
with these laws and regulations also may result in substantial fines, penalties or other sanctions, which could have a material adverse
effect on our business, financial condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our internal computer systems, or those
used by any CROs or other third-party contractors or consultants we may engage, may fail or suffer security breaches.</i></b></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Despite the implementation
of security measures, our internal computer systems and those of our CROs and other contractors and consultants are vulnerable to damage
from computer viruses and unauthorized access. Although, to our knowledge, we have not experienced any material system failure or security
breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of
our development programs and business operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the ordinary course of
our business, we collect and store sensitive data, including, among other things, legally protected patient health information, personally
identifiable information about our employees, intellectual property, and proprietary business information. We manage and maintain our
applications and data utilizing on-site systems and outsourced vendors. These applications and data encompass a wide variety of business-critical
information including research and development information, commercial information, and business and financial information. Because information
systems, networks and other technologies are critical to many of our operating activities, shutdowns or service disruptions of our systems
or those of the vendors that provide information systems, networks or other services to us pose increasing risks. Such disruptions may
be caused by events such as computer hacking, phishing attacks, ransomware, dissemination of computer viruses, worms and other destructive
or disruptive software, denial-of-service attacks and other malicious activity, as well as security incidents from inadvertent or intentional
actions (such as error or theft) by our employees, contractors, consultants, business partners, and/or other third parties, supply chain
attacks, power outages, natural disasters (including extreme weather), terrorist attacks or other similar events. Such events could have
an adverse impact on us and our business, including loss of data and damage to equipment and data. In addition, system redundancy may
be ineffective or inadequate, and our disaster recovery planning may not be sufficient to cover all eventualities. Significant events
could result in a disruption of our operations, damage to our reputation or a loss of revenues. In addition, we may not have adequate
insurance coverage to compensate for any losses associated with such events.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We could be subject to risks
caused by misappropriation, misuse, leakage, falsification or intentional or accidental release or loss of information maintained in our
information systems and networks and those of our vendors, including personal information of our employees and patients, and company and
vendor confidential data. In addition, outside parties may attempt to penetrate our systems or those of our vendors or fraudulently induce
our personnel or the personnel of our vendors to disclose sensitive information in order to gain access to our data and/or systems. Like
other companies, we have on occasion experienced, and will continue to experience, threats to our data and systems, including malicious
codes and viruses, phishing and other cyber-attacks. The number and complexity of these threats continue to increase over time. If a material
breach of our information technology systems or those of our vendors occurs, the market perception of the effectiveness of our security
measures could be harmed and our reputation and credibility could be damaged. We could be required to expend significant amounts of money
and other resources to repair or replace information systems or networks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, despite our efforts,
the possibility of these events occurring cannot be eliminated entirely. As we outsource more of our information systems to vendors, engage
in more electronic transactions with payors and patients and rely more on cloud-based information systems, the related security risks
will increase and we will need to expend additional resources to protect our technology and information systems.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may also be required to
comply with laws, regulations, rules, industry standards, and other legal obligations that require us to maintain the security of personal
data. We may also have contractual and other legal obligations to notify customers, collaborators, or other relevant stakeholders of security
incidents. Failure to prevent or mitigate cyberattacks could result in unauthorized access to data, including proprietary and personal
information. Most jurisdictions have enacted laws requiring companies to notify individuals, regulatory authorities, and others of security
breaches involving certain types of data. Such disclosures are costly, could lead to negative publicity, may cause our customer or collaborators
or other relevant stakeholders to lose confidence in the effectiveness of our security measures and require us to expend significant capital
and other resources to respond to and/or alleviate problems caused by the actual or perceived security incident. In addition, the costs
to respond to a cybersecurity event or to mitigate any identified security vulnerabilities could be significant, including costs for remediating
the effects of such an event, paying a ransom, restoring data from backups, and conducting data analysis to determine what data may have
been affected by the breach. In addition, our efforts to contain or remediate a security incident or any vulnerability exploited to cause
an incident may be unsuccessful, and efforts and any related failures to contain or remediate them could result in interruptions, delays,
harm to our reputation, and increases to our insurance coverage.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, regulatory response
or litigation resulting from security breaches may adversely affect our business. Unauthorized access to our information technology systems
could result in litigation with our customers, collaborators, or other relevant stakeholders, or regulatory actions by government entities.
These proceedings could force us to spend money in defense or settlement, divert management&#8217;s time and attention, increase our costs
of doing business, or adversely affect our reputation. We could be required to fundamentally change our business activities and practices
in response to such litigation, which could have an adverse effect on our business. If a security breach were to occur and the confidentiality,
integrity or availability of our data or the data of our collaborators were disrupted, we could incur significant liability, which could
negatively affect our business and damage our reputation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, our insurance
may not be adequate to cover losses associated with such events, and in any case, such insurance may not cover all of the types of costs,
expenses, or at all, and losses we could incur to respond to and remediate a security breach. The successful assertion of one or more
large claims against us that exceeds our available insurance coverage, or results in changes to our insurance policies (including premium
increases or the imposition of large deductible or co-insurance requirements), could have an adverse effect on our business. In addition,
we cannot be sure that our existing insurance coverage and coverage for errors and omissions will continue to be available on acceptable
terms or that our insurers will not deny coverage as to any future claim.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We manufacture all of our drug candidates
ourselves, and intend to manufacture most, if not all, of any approved drugs ourselves as well, which could have a material adverse effect
on our business, financial condition, results of operations and prospects.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently have manufacturing
facilities in the U.S.&#160;and may build additional manufacturing facilities in other markets to expand our manufacturing capacity. These
facilities may encounter unanticipated delays and expenses due to a number of factors, including regulatory requirements. If construction,
regulatory evaluation, and/or approval of our new facilities is delayed, we may not be able to manufacture sufficient quantities of our
drug candidates, if approved, which would limit our development and commercialization activities and our opportunities for growth. Cost
overruns associated with constructing or maintaining our facilities could require us to raise additional funds from other sources, which
may not be available on favorable terms or at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Much of the equipment used
in our manufacturing process was developed and built by us, and it would be difficult or even impossible to purchase or create suitable
replacements in a short period of time. Further, for much of this equipment we have an insufficient amount of or no spare parts available.
Were certain equipment, some of which is critical to the production of our drug candidates, to become damaged, lost, or otherwise unusable,
we would have to construct new parts, which could take a considerable amount of time, causing a temporary halt to at least a portion of
our production operations. Additionally, we are constantly seeking to further fine-tune and develop our advanced manufacturing techniques
and process controls to fully utilize our facilities. Advances in manufacturing techniques may render our facilities and equipment inadequate,
in which case we may lose any competitive advantage.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To produce our drug candidates
in the quantities that we believe will be required to meet anticipated market demand, if approved, we will need to increase or &#8220;scale
up&#8221; the production process by a significant factor over current levels of production. A significant part of the scaling up process
will include seeking ways to increase the automation and semi-automation of our production process, which will require additional research
and development, investment, potential new regulatory approvals, and cooperation with third parties, some of which may not be successful.
If we are unable or are delayed in scaling up, or if the cost of doing so is not economically feasible for us, we may not be able to produce
our approved drug candidates in a sufficient quantity to meet any future demand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Delays in completing and receiving regulatory
approvals for our manufacturing facilities could delay our development plans or commercialization efforts, which could harm our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our manufacturing facilities
will be subject to ongoing, periodic inspection by various regulatory authorities, including the U.S.&#160;Food and Drug Administration
(&#8220;FDA&#8221;), European Medicines Agency (&#8220;EMA&#8221;), China&#8217;s National Medical Products Administration (&#8220;NMPA&#8221;),
Health Canada, and the Australian Therapeutics Goods Administration (&#8220;TGA&#8221;) or other comparable regulatory agencies to ensure
compliance with good manufacturing practices (&#8220;GMP&#8221;). Our failure to follow and document our adherence to such GMP or other
regulatory requirements may lead to significant delays in the availability of products for clinical or, if approved, commercial use, and
may result in the termination of or a hold on a clinical trial, or may delay or prevent filing or approval of marketing applications for
our drug candidates or the commercialization of our drugs, if approved. We also may encounter problems with the following:</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">achieving adequate or clinical-grade materials that meet FDA, EMA, NMPA, Health Canada, TGA or other comparable regulatory agency standards or specifications with consistent and acceptable production yield and costs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shortages of qualified personnel, raw materials or key contractors; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ongoing compliance with GMP and other requirements of the FDA, EMA, NMPA, Health Canada, TGA or other comparable regulatory agencies.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Failure to comply with applicable
regulations could also result in sanctions being imposed on us, including fines, injunctions, civil penalties, a requirement to suspend
or put on hold one or more of our clinical trials, failure of regulatory authorities to grant marketing approval of our drug candidates,
delays, suspension or withdrawal of approvals, supply disruptions, license revocation, seizures, or recalls of our drug candidates, operating
restrictions and civil or criminal prosecutions, any of which could harm our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Damage to, destruction of or interruption
of production at our manufacturing facilities would negatively affect our business and prospects.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our manufacturing facilities
or the equipment in them is damaged or destroyed, we may not be able to quickly or inexpensively replace our manufacturing capacity or
replace it at all. In the event of a temporary or protracted loss of the facilities or equipment, we might not be able to transfer manufacturing
to a third party. Even if we could transfer manufacturing to a third party, the shift would likely be expensive and time-consuming, particularly
since the new facility would need to comply with the necessary regulatory requirements and we would need regulatory agency approval before
selling any of our drugs, if approved, manufactured at that new facility. Such an event could delay our clinical trials or reduce our
product sales if any of our drug candidates are approved and successfully commercialized. Any interruption in manufacturing operations
at our manufacturing facilities could result in our inability to satisfy the demands of our clinical trials or commercialization. Any
disruption that impedes our ability to manufacture our drug candidates in a timely manner could materially harm our business, financial
condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Currently, we maintain insurance
coverage against damage to our property and equipment in amounts we believe are reasonable. However, our insurance coverage may not reimburse
us, or may not be sufficient to reimburse us, for any expenses or losses we may suffer. We may be unable to meet the requirements for
our drug candidates if there were a catastrophic event or failure of our manufacturing facilities or processes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our future success depends on our ability
to retain key executives and to attract, train, retain and motivate qualified and highly skilled personnel.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are highly dependent on
Mark Mortenson, our co-founder and Chief Science Officer, Rob Etherington, our Chief Executive Officer and President, and the other principal
members of our management and scientific teams. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other
employees. The loss of the services of any of our executive officers, other key employees, and other scientific advisors, and our inability
to find suitable replacements could result in delays in product development and harm our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Recruiting and retaining qualified
scientific, technical, clinical, manufacturing, sales, and marketing personnel in the future will also be critical to our success. In
addition, we rely on third-party consultants and advisors, including scientific and clinical advisors, to assist us in formulating our
discovery, clinical development, operations, and commercialization strategy. The loss of the services of our executive officers or other
key employees and consultants could impede the achievement of our research, development, and commercialization objectives and seriously
harm our ability to successfully implement our business strategy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We benefit from certain tax and financial
incentives, the expiration of or changes to which could adversely affect our profitability.</i></b></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We benefit from certain tax
treatments, as well as tax concessions in relation to our research and development costs. We receive refundable tax credits through the
R&amp;D tax credits in the United&#160;States, Australia, and the state of Maryland. In the United&#160;States, the R&amp;D credit is
used to offset federal employment taxes on our United&#160;States payroll. In Australia, we receive a refundable tax offset of 43.5% of
R&amp;D deductions. In Maryland, we receive the Basic Research and Development Tax credit of 3% of the lesser of eligible R&amp;D expenses
and the Maryland Base Amount, which is used to offset state income taxes and may be applied against following&#160;years&#8217; taxes
until the credit is used or the credit may be carried forward for seven&#160;years. We also receive a tax exemption in Maryland for state
personal property and sales tax, as well as the Maryland enterprise zone hiring and job creation tax credits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, current or future
tax treatments, tax concessions, tax allowances and financial incentives applicable to us may be changed, terminated, or otherwise become
unavailable due to many factors, including changes in government policy or administrative decisions by the relevant government authorities.
Due to potential changes in government policies, we cannot be certain of the level of government grants we will receive in the future.
Our post-tax profitability and cash flows may be adversely affected as a result of one or more of these or other factors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our ability to use net operating losses
to offset future taxable income may be subject to certain limitations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have incurred substantial
losses since inception and do not expect to become profitable in the near future, if ever. To the extent that we continue to generate
taxable losses, unused losses will carry forward to offset future taxable income, if any. As of December&#160;31, 2020, we had U.S.&#160;federal
net operating loss, or NOL, carryforwards of $72.2&#160;million, which may be available to reduce future taxable income and have an indefinite
carryforward period but are limited in their usage to an annual deduction equal to 80% of annual taxable income. In addition, as of December&#160;31,
2020, we had state NOL carryforwards of $59.8&#160;million, which may be available to reduce future taxable income, of which $39.4&#160;million
have an indefinite carryforward period while the remaining $20.4&#160;million begin to expire after 2032. As of December&#160;31, 2020,
we also had research and development tax credit carryforwards of $1.7&#160;million, which may be available to reduce future tax liabilities
and expire at various dates beginning after 2032.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under U.S.&#160;federal tax
legislation commonly referred to as the Tax Cuts and Jobs Act (&#8220;TCJA&#8221;), as modified by the Coronavirus Aid, Relief and Economic
Security Act, or the CARES Act, U.S.&#160;federal NOLs incurred in taxable&#160;years beginning after December&#160;31, 2017 and in future
taxable&#160;years may carry forward indefinitely, but the deductibility of such U.S.&#160;federal NOLs incurred in taxable&#160;years
beginning after December&#160;31, 2020 are limited. It is uncertain how various states will respond to the TCJA and CARES Act. In addition,
under Section&#160;382 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes
an &#8220;ownership change,&#8221; which is generally defined as a greater than 50% change, by value, in its equity ownership over a three-year
period, the corporation&#8217;s ability to use its pre-change NOL carryforwards and other pre-change tax attributes to offset its post-change
income or taxes may be limited. Any future offerings of equity securities, together with other transactions that have occurred since our
inception, may trigger such an ownership change pursuant to Section&#160;382 of the Code. We have not conducted a study to assess whether
any such ownership changes have occurred. We may experience ownership changes as a result of subsequent shifts in our stock ownership,
some of which may be outside of our control. If an ownership change occurs and our ability to use our NOL carryforwards is materially
limited, it would harm our financial condition and results of operations by effectively increasing our future tax obligations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Changes in tax laws may adversely affect
us, and the Internal Revenue Service or a court may disagree with tax positions taken by us, which may result in adverse effects in our
financial condition or the value of our Common Stock.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The TCJA, enacted on December&#160;22,
2017, significantly affected U.S.&#160;tax law, including by changing how the United&#160;States imposes tax on certain types of income
of corporations and by reducing the U.S.&#160;federal corporate income tax rate to 21%. It also imposed new limitations on a number of
tax benefits, including deductions or business interest, use of net operating loss carry forwards, taxation of foreign income and the
foreign tax credit, among others.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>


</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The CARES Act, enacted on
March&#160;27, 2020, in response to the COVID-19 pandemic, further amended the Internal Revenue Code of 1986 (the &#8220;Code&#8221;),
including in respect of certain changes that were made by the TCJA, generally on a temporary basis. In addition, the Internal Revenue
Service (&#8220;IRS&#8221;) has yet to issue guidance on a number of important issues regarding the changes made by the TCJA and the CARES
Act. In the absence of such guidance, we will take positions with respect to a number of unsettled issues. There is no assurance that
the IRS or a court will agree with the positions taken by us, in which case tax penalties and interest may be imposed that could adversely
affect our business, cash flows or financial performance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, the current
administration may propose significant changes to U.S.&#160;tax law, some or all of which may be enacted. The passage of such legislation,
as well as changes or modifications in existing judicial decisions or in the current positions of the IRS, could substantially modify
the tax treatment described in this Quarterly Report, possibly on a retroactive basis. We cannot predict whether the U.S.&#160;Congress
or any other legislative body will enact new tax legislation or whether the IRS or any other tax authority will issue new regulations
or other guidance, nor can we predict what effect such legislation or regulations might have on us or our financial condition. There can
be no assurance that future tax law changes will not increase the rate of the corporate income tax significantly, impose new limitations
on deductions, credits or other tax benefits, or make other changes that may adversely affect our business, cash flows or financial performance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our financial position and operations may
be adversely affected by the COVID-19 pandemic.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An outbreak of the respiratory
illness COVID-19 caused by a strain of novel coronavirus, SARS-Cov-2, has spread worldwide, causing many governments to implement measures
to slow the spread of the outbreak through quarantines, strict travel restrictions, heightened border scrutiny, and other measures. The
outbreak and government measures taken in response to the COVID-19 pandemic have had a significant impact, both direct and indirect, on
businesses and commerce. The future progression of the COVID-19 pandemic and its effects on our business and operations are uncertain.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We, our CROs, clinical investigators,
third-party vendors and clinical sites may experience disruptions in supply of drug candidates and/or procuring items that are essential
for our R&amp;D activities, including raw materials used in the manufacturing of our drug candidates, medical and laboratory supplies
used in our clinical trials or preclinical studies or animals that are used for preclinical testing, in each case, for which there may
be shortages because of ongoing efforts to address the COVID-19 pandemic. Any disruption in the supply chain from the COVID-19 pandemic,
or any potential future outbreak, could have a material adverse effect on our clinical trial plans and business operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, we have enrolled,
and will seek to enroll, patients in our clinical trials at sites located in many areas affected by the COVID-19 pandemic and, as a result,
our trials have been impacted. In addition, even if sites are actively recruiting, we may face difficulties recruiting or retaining patients
in our ongoing and planned clinical trials if patients are affected by the COVID-19 virus or are fearful of visiting or traveling to clinical
trial sites because of the COVID-19 pandemic. Prolonged delays or closure to enrollment in our trials or patient discontinuations could
have a material adverse impact on our clinical trial plans and timelines.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The response to the COVID-19
pandemic may redirect the Company&#8217;s resources with respect to regulatory and intellectual property matters in a way that would adversely
affect our ability to obtain regulatory approvals and protect our intellectual property. In addition, we may face impediments to regulatory
meetings and approvals due to measures intended to limit in-person interactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any negative impact that the
COVID-19 pandemic has on the ability of our suppliers to provide materials for our drug candidates or on recruiting or retaining patients
in our clinical trials or our ability to collect patient data could cause costly delays to clinical trial activities, which could adversely
affect our ability to obtain regulatory approval for and, if approved, to commercialize our drug candidates, increase our operating expenses,
and have a material adverse effect on our financial results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>


</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The COVID-19 pandemic has
significantly impacted economies worldwide. The extent to which the COVID-19 pandemic impacts our business, preclinical studies and clinical
trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic
spread of the disease, the duration of the COVID-19 pandemic, travel restrictions and social distancing in the United&#160;States and
other countries, business closures or business disruptions and the effectiveness of actions taken in the United&#160;States and other
countries to contain and treat the disease. The global outbreak of the COVID-19 pandemic continues to evolve and the conduct of our clinical
trials may continue to be adversely affected, despite any efforts to mitigate this impact. The COVID-19 pandemic has the potential to
adversely affect our business, financial condition, results of operations, and prospects. For details, please see &#8220;Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations&#8212;Impact of COVID-19 Pandemic.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have identified material weaknesses in
our internal control over financial reporting. If we fail to remediate these material weaknesses, or if we experience additional material
weaknesses in the future or otherwise fail to maintain an effective system of internal controls, we may not be able to accurately or timely
report our financial condition or results of operations, which may adversely affect investor confidence in us and, as a result, the value
of our Common Stock.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective internal control
over financial reporting is necessary for us to provide reliable financial reports and, together with adequate disclosure controls and
procedures, is designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their
implementation, could cause us to fail to meet our reporting obligations. In addition, any testing by us, as and when required, conducted
in connection with Section&#160;404 of the Sarbanes-Oxley Act or any subsequent testing by our independent registered public accounting
firm, as and when required, may reveal deficiencies in our internal control over financial reporting that are deemed to be significant
deficiencies or material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other
areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial
information, which could have a negative effect on the trading price of our Common Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the audit
of our financial statements as of and for the&#160;years ended December&#160;31, 2020 and 2019, our management identified material weaknesses
in our internal control over financial reporting. A material weakness is a deficiency, or combination of deficiencies, in internal control
over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial
statements will not be prevented or detected on a timely basis. The material weaknesses identified relate to the fact that we did not
design or maintain an effective control environment commensurate with our financial reporting requirements, including (a)&#160;lack of
a sufficient number of trained professionals with an appropriate level of accounting knowledge, training and experience to appropriately
analyze, record and disclose accounting matters in a timely and accurately fashion, and (b)&#160;lack of structures, reporting lines and
appropriate authorities and responsibilities to achieve financial reporting objectives. This deficiency in our control environment contributed
to the following additional deficiencies (each of which individually represents a material weakness) in our internal control over financial
reporting:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we did not design and maintain formal accounting policies, procedures and controls to achieve complete, accurate and timely financial accounting, reporting and disclosures, including controls over the preparation and review of account reconciliations and journal entries;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we did not design and maintain effective controls over segregation of duties related to manual journal entries; specifically, certain personnel have the ability to both prepare and post manual journal entries without an independent review by someone without the ability to prepare and post manual journal entries;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we did not design and maintain formal accounting policies, processes and controls to analyze, account for and disclose complex transactions; specifically, we did not design and maintain controls to analyze, account for and disclose warrants to purchase preferred stock and convertible promissory notes with embedded derivatives, including ensuring that complete and accurate data was used in the valuations; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we did not design and maintain effective controls over certain information technology (&#8220;IT&#8221;) general controls for IT systems that are relevant to the preparation of the financial statements; specifically, we did not design and maintain: (i) user access controls to ensure appropriate segregation of duties and that adequately restrict user and privileged access to financial applications, programs, and data to our appropriate personnel, (ii) program change management controls to ensure that IT program and data changes affecting financial IT applications and underlying accounting records are identified, tested, authorized and implemented appropriately, (iii) computer operations controls to ensure that data backups are authorized and monitored, and (iv) testing and approval controls for program development to ensure that new software development is aligned with business and IT requirements.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"></p><div>

</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The control deficiencies described
above resulted in the misstatement of our redeemable convertible preferred stock warrant liability, accrued liabilities, general and administrative
expenses, Australian research and development credit, and amounts and classification within our statement of cash flows and related financial
disclosures as of and for the year ended December&#160;31, 2019 and in the misstatement of our prepaid expenses and other current assets,
accrued liabilities, earn-out liabilities, redeemable convertible preferred stock warrant liability, general and administrative expenses,
amounts and classification within our statement of equity, and amounts and classification within our statement of cash flows and related
financial disclosures as of and for the year ended December&#160;31, 2020. Additionally, each of the control deficiencies described above
could result in a misstatement of one or more account balances or disclosures that would result in a material misstatement to the annual
or interim consolidated financial statements that would not be prevented or detected. Accordingly, our management has determined that
each of the control deficiencies described above constitute a material weakness.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we have begun to
implement measures to address the material weaknesses, the implementation of these measures may not fully address the material weaknesses
and deficiencies in our internal control over financial reporting, and we cannot conclude that these matters have been fully remedied.
As we continue to evaluate, and work to improve, our internal control over financial reporting, management may determine that additional
or different measures to address control deficiencies or modifications to the remediation plan are necessary. Further, in the future we
may determine that we have additional material weaknesses. Our failure to remediate the material weaknesses or failure to identify and
address any other material weaknesses or control deficiencies could result in inaccuracies in our financial statements and could also
impair our ability to comply with applicable financial reporting requirements and related regulatory filings on a timely basis, which
could cause investors to lose confidence in our reported financial information, which may result in volatility in and a decline in the
market price of our Common Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to Section&#160;404,
after the Reverse Recapitalization, we, as the surviving entity, are required to furnish a report by our management on the effectiveness
of our internal control over financial reporting, including an attestation report on internal control over financial reporting issued
by our independent registered public accounting firm. However, while we remain an emerging growth company, we will not be required to
include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm.
To achieve compliance with Section&#160;404 within the prescribed period, we will be engaged in a process to document and evaluate our
internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate
internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal
control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are
functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting.
Despite our efforts, there is a risk that neither we nor our independent registered public accounting firm will be able to conclude within
the prescribed timeframe that our internal control over financial reporting is effective as required by Section&#160;404. This could adversely
affect investor confidence in us and, as a result, the value of our Common Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>There is significant uncertainty associated
with our drug candidates and their viability as a commercial product.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Metallic nanocrystal therapeutic
candidates, such as our lead product, CNM-Au8<sup>&#174;</sup>, are considered emerging and novel investigational products for the potential
treatment of neurological diseases and other disorders. We are developing CNM-Au8<sup>&#174;</sup> for the treatment of neurological disorders
such as MS, ALS, and PD through remyelination and/or neuroprotection mechanisms related to catalysis of certain biological reactions.
There are currently no approved remyelination therapies and the evidence for an effect of neuroprotection treatments on these indications
is thus far limited. Since there is limited clinical trial data and precedent for the development of nanocrystal therapies that promote
remyelination and neuroprotection to treat these indications, there is a substantial risk that the design or outcomes of our clinical
trials will not be satisfactory to support regulatory approval. In addition, there are generally limited or no regulatory precedents concerning
metallic nanocrystal drug marketing authorization, or a regulatory framework to appropriately differentiate approved nanocrystal product
labeling. Our lead metallic nanocrystal drug candidate, CNM-Au8<sup>&#174;</sup>, contains nanocrystals made entirely of high purity gold
alone. It is unclear how regulatory authorities will identify or classify the active moiety of CNM-Au8<sup>&#174;</sup>, including whether
it is classified as a new chemical entity or comparable designation. The inability to obtain sufficiently differentiated active moiety
classification from gold generically could potentially limit CNM-Au8<sup>&#174;</sup> and our drug candidates from ever achieving profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, the mechanisms of
action for nanocrystal therapies are not thoroughly understood, and adverse events or side effects may be observed in clinical trials
and reported by medical practitioners in connection with patient usage in the future. If those adverse events or side effects prove significant,
they may hamper the ability of our drug candidates to pass through clinical trials or they may outweigh the benefits that patients derive
from using our drug candidates, both of which could potentially prevent our drug candidates from ever achieving profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our drug candidates are not
metabolized and may accumulate in the body following long-term usage, making the long-term effects of taking our drug candidates for substantial
periods of time uncertain. While all of the current toxicology studies of our drug candidates have resulted in no-adverse-effect levels
as of the date of this Quarterly Report, we have not completed reproductive or carcinogenicity studies, which we are required to complete
in the future. Any negative results from these studies could materially and adversely affect our business, results of operations, financial
condition and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, the results of clinical
trials for nanocrystal therapies could reveal a high and unacceptable severity and prevalence of undesirable side effects. Any such side
effects could adversely impact our ability to obtain regulatory approvals. For example, the FDA, NMPA, Health Canada, TGA, EMA or other
comparable authorities could order us to suspend or terminate our studies or to cease further clinical development of or deny approval
of our drug candidates. In addition, any adverse drug-related side effects could affect patient recruitment or the ability of enrolled
patients to complete trials or may result in potential product liability claims. Any of these occurrences may harm our business, financial
condition, results of operations, and prospects significantly.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have not previously obtained any regulatory
approval for a drug candidate and we may be unable to obtain or may be delayed in obtaining regulatory approval for any of our drug candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business is substantially
dependent on our ability to complete the development of, obtain regulatory approval for and successfully commercialize drug candidates
in a timely manner. We cannot commercialize drug candidates without obtaining regulatory approval to market each drug from the FDA, NMPA,
Health Canada, TGA, EMA and other comparable regulatory authorities. The time required to obtain approval from regulatory authorities
is unpredictable but typically takes&#160;years following the commencement of preclinical studies and clinical trials and depends upon
numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations or the
type and amount of clinical data necessary to gain approval may change during the course of a drug candidate&#8217;s clinical development
and may vary among jurisdictions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our drug candidates could
fail to receive regulatory approval for many reasons, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to begin or complete clinical trials due to disagreements with regulatory authorities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to begin or complete clinical trials due to inability to recruit sufficient numbers of study participants;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to demonstrate that a drug candidate is safe and effective or is safe, pure and potent for our proposed indication;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure of clinical trial results to meet the level of statistical significance required for approval;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">data integrity issues related to our clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disagreement with our interpretation of data from preclinical studies or clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in approval policies or regulations that render our preclinical and clinical data insufficient for approval or require us to amend our clinical trial protocols;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory requests for additional analysis, reports, data, nonclinical studies and clinical trials, or questions regarding interpretations of data and results and the emergence of new information regarding our drug candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">insufficient data from the clinical trials of our drug candidates to obtain regulatory approval;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure by us or our investigators to conduct a clinical trial in accordance with regulatory requirements or our clinical trial protocols; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical sites, investigators or other participants in our clinical trials deviating from a trial protocol, failing to conduct the trial in accordance with regulatory requirements, or dropping out of a trial.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA, NMPA, TGA, Health
Canada, EMA or a comparable regulatory authority may require more information, including additional preclinical or clinical data, to support
approval, which may delay or prevent approval and our commercialization plans, or we may decide to abandon the development program.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">New or unexpected adverse
events, or changes in regulatory requirements and guidance may also occur, and we may need to amend clinical trial protocols submitted
to applicable regulatory authorities to reflect these changes. Amendments may require us to resubmit clinical trial protocols to institutional
review boards (&#8220;IRBs&#8221;) or human research ethics committees (&#8220;HRECs&#8221;) for re-examination, which may impact the
costs, timing or successful completion of a clinical trial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we experience delays in
the completion of, or the termination of, a clinical trial of any of our drug candidates, the commercial prospects of that drug candidate
will be harmed, and our ability to generate product sales revenues from any of those drug candidates will be delayed. In addition, any
delays in completing our clinical trials will increase our costs, slow down our drug candidate development and approval process, and jeopardize
our ability to commence product sales and generate related revenues for that product. Any of these occurrences may harm our business,
financial condition, results of operations and prospects significantly. In addition, many of the factors that cause, or lead to, a delay
in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our drug candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be able to successfully identify,
discover, develop or in-license new drug candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot guarantee that we
will be successful in identifying potential drug candidates for clinical development for a number of reasons. For example, our research
methodology may be unsuccessful in identifying potential drug candidates or those we identify may be shown to have harmful side effects
or other characteristics that make them unmarketable or unlikely to receive regulatory approval. We have devoted significant resources
to discovery efforts through our proprietary electro-crystal-chemistry drug development platform, however, we cannot guarantee that we
will be successful in identifying additional potential drug candidates, or that we will be able to successfully identify and in-license
new drug candidates with high potential from other parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"></p><div>

</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research programs to pursue
the development of our drug candidates for additional indications and to identify new drug candidates and drug targets require substantial
technical, financial, and human resources. Our research programs may initially show promise in identifying potential indications and/or
drug candidates, yet fail to yield results for clinical development for a number of reasons, including:&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the research methodology used may not be successful in identifying potential indications, and/or drug candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential drug candidates may, after further study, be shown to have harmful adverse effects or other characteristics that indicate they are unlikely to be effective drugs; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">it may take greater human and financial resources to identify additional therapeutic opportunities for our drug candidates or to develop suitable potential drug candidates through internal research programs than we will possess, thereby limiting our ability to diversify and expand our drug portfolio.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Accordingly, there is no assurance
that we will ever be able to identify additional therapeutic opportunities for our drug candidates or to develop suitable potential drug
candidates through internal research programs, which could materially and adversely affect our future growth, business, financial condition,
results of operations and prospects. We may focus our efforts and resources on potential drug candidates or other potential programs that
ultimately prove to be unsuccessful.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Preclinical and clinical development of
drug candidates involves a lengthy and expensive process with an uncertain outcome, and we are unable to predict if or when we will successfully
develop or commercialize any of our drug candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is a risk of failure
for each of our drug candidates. Before obtaining regulatory approval for the sale of any of our drug candidates, we must complete preclinical
studies and then conduct extensive clinical trials to demonstrate the safety and efficacy of our drug candidates in humans. It is difficult
to predict when or if any of our drug candidates will prove effective and safe in humans or receive regulatory approval. Our internal
discovery programs for some of our drug candidates are at an early stage of development and will require significant investment and regulatory
approvals prior to commercialization. We are not permitted to market or promote any of our drug candidates until we receive regulatory
approval from the FDA, NMPA, TGA, Health Canada, EMA or comparable regulatory authorities, and we may never receive such regulatory approval
for any of our drug candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We could encounter regulatory
delays if a clinical trial is suspended or terminated by us or, as applicable, by the institutional review boards or the ethics committees
of the institutions in which such trials are being conducted, by the data safety monitoring board, which is an independent group of experts
that is formed to monitor clinical trials while ongoing, or by the FDA, NMPA, TGA, Health Canada, EMA or other regulatory authorities.
Such authorities may impose a suspension or termination due to a number of factors, including: (1)&#160;a failure to conduct the clinical
trial in accordance with regulatory requirements or the applicable clinical protocols, (2)&#160;inspection of the clinical trial operations
or trial site by the FDA, NMPA, TGA, Health Canada, EMA or other regulatory authorities that results in the imposition of a clinical hold,
unforeseen safety issues or adverse side effects, (3)&#160;failure to demonstrate a benefit from using a drug, (4)&#160;changes in governmental
regulations or administrative actions, or (5)&#160;lack of adequate funding to continue the clinical trial. Many of the factors that cause
a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our drug
candidates. Further, the FDA, NMPA, TGA, Health Canada, EMA or other regulatory authorities may disagree with our clinical trial design
or our interpretation of data from clinical trials, or may change the requirements for approval even after any regulatory authority has
reviewed and commented on the design for our clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Preclinical studies and clinical
trials are expensive, difficult to design and implement, and can take many&#160;years to complete. Moreover, preclinical and clinical
data are often susceptible to varying interpretations and analysis, and many companies that have believed their drug candidates performed
satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain regulatory approval of their drug candidates.
Future clinical trials of our drug candidates may not be successful.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Commencement of clinical trials
is subject to finalizing the trial design based on ongoing discussions with the FDA, NMPA, TGA, Health Canada, EMA and/or other regulatory
authorities. The FDA, NMPA, TGA, Health Canada, EMA and other regulatory authorities could change their position on the acceptability
of trial designs or clinical endpoints, which could require us to complete additional clinical trials or impose approval conditions that
we do not currently expect. Successful completion of our clinical trials is a prerequisite to submitting a New Drug Application (&#8220;NDA&#8221;)
(or analogous filing) to the FDA, NMPA, TGA, Health Canada, EMA and/or other regulatory authorities for each drug candidate and, consequently,
the ultimate approval and commercial marketing of our drug candidates. We do not know whether the clinical trials for our drug candidates
will be completed on schedule, if at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Results of earlier clinical trials may not
be predictive of results of later-stage clinical trials.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The results of preclinical
studies and early clinical trials of our drug candidates may not be predictive of the results of later-stage clinical trials. Drug candidates
in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical
studies and initial clinical trials. Future clinical trial results may not be favorable for these and other reasons.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In some cases, there can be
significant variability in the safety and/or efficacy results between different trials of the same drug candidate due to numerous factors,
including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, including genetic
differences, patient adherence to the dosing regimen, and the rate of dropout among clinical trial participants. As drug candidates are
developed through preclinical to early- to late-stage clinical trials towards approval and commercialization, it is customary that various
aspects of the development program, such as manufacturing and formulation, are altered along the way in an effort to optimize processes
and results. Such changes carry the risk that they will not achieve these intended objectives. In the case of any trials we conduct, results
may differ from earlier trials due to the larger number of clinical trial sites and additional countries and languages involved in such
trials. Any of these changes could make the results of planned clinical trials or other future clinical trials we may initiate less predictable
and could cause our drug candidates to perform differently, which could delay completion of clinical trials, delay approval of our drug
candidates, and/or jeopardize our ability to commence commercialization of our drug candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Clinical trials of our drug candidates may
fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities, or may not otherwise produce positive results,
which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete, the development
and commercialization of our drug candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before obtaining regulatory
approval for the sale of our drug candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of our
drug candidates in humans. We may experience numerous unexpected events during, or as a result of, clinical trials that could delay or
prevent us from receiving regulatory approval or commercializing our drug candidates, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulators, IRBs, or HRECs may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our inability to reach agreements on acceptable terms with prospective CROs, clinical trial vendors, and trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing issues, including problems with manufacturing, supply quality, compliance with GMP, or obtaining from third parties sufficient quantities of a drug candidate for use in a clinical trial;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical trials of our drug candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon drug development programs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of patients required for clinical trials of our drug candidates may be larger than we anticipate;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our third-party contractors, including clinical investigators, may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not investigate, may not be able to license, or may be unable to properly conduct companion diagnostic tests to identify patients who are likely to benefit from treatment with our drug candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we might have to suspend or terminate clinical trials of our drug candidates for various reasons, including a finding of a lack of clinical response or other unexpected characteristics or a finding that participants are being exposed to unacceptable health risks;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulators, IRBs or HRECs may require that we or our investigators suspend or terminate clinical research or not rely on the results of clinical research for various reasons, including non-compliance with regulatory requirements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost of clinical trials of our drug candidates may be greater than we anticipate;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the supply or quality of our drug candidates or other materials necessary to conduct clinical trials of our drug candidates may be insufficient or inadequate; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our drug candidates may have undesirable side effects or unexpected characteristics, causing us or our investigators, regulators, institutional review boards or ethics committees to suspend or terminate the clinical trials, or reports may arise from preclinical studies or clinical trials of other therapies that raise safety or efficacy concerns about our drug candidates.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are required to conduct
additional clinical trials or other testing of our drug candidates beyond those that we currently contemplate, if we are unable to successfully
complete clinical trials of our drug candidates or other testing, if the results of these trials or tests are not positive or are only
modestly positive or if they raise safety concerns, we may (i)&#160;be delayed in obtaining regulatory approval for our drug candidates;
(ii)&#160;not obtain regulatory approval at all; (iii)&#160;obtain approval for indications that are not as broad as intended; (iv)&#160;have
the drug removed from the market after obtaining regulatory approval; (v)&#160;be subject to additional post-market testing requirements;
(vi)&#160;be subject to restrictions on how the drug is distributed or used; or (vii)&#160;be unable to obtain reimbursement for use of
the drug.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Significant clinical trial
delays may also increase our development costs and could shorten any periods during which we have the exclusive right to commercialize
our drug candidates or allow our competitors to bring drugs to market before we do. This could impair our ability to commercialize our
drug candidates and may harm our business and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we encounter difficulties enrolling patients
in clinical trials, clinical trials of our drug candidates may be delayed or otherwise adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The timely completion of clinical
trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain
in the trial until our conclusion. We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons,
including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the COVID-19 pandemic;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the size and nature of the patient population;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the design of the trial, including the patient eligibility criteria defined in the protocol;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the size of the study population required for analysis of the trial&#8217;s primary endpoints;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the proximity of patients to trial sites;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competing clinical trials for similar therapies or other new therapeutics;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages and side effects of the drug candidate being studied in relation to other available therapies, including any new drugs or treatments that may be approved for the indications we are investigating;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain and maintain patient consents;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the risk that patients enrolled in clinical trials will not complete a clinical trial; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the availability of approved therapies that are similar in mechanism to our drug candidates.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Failure of our timely completion
of clinical trials would delay the approval and commercialization of our drug candidates, impair the commercial performance of our drug
candidates, and consequently harm our business and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are not able to obtain, or experiences
delays in obtaining, required regulatory approvals, we will not be able to commercialize our drug candidates, and our ability to generate
revenue will be materially impaired.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before obtaining regulatory
approvals for the commercial sale of any drug candidate for a target indication, we must demonstrate in preclinical studies and well-controlled
clinical trials, and, with respect to approval in the U.S., to the satisfaction of the FDA, that the drug candidate is safe and effective
for use for that target indication and that the manufacturing facilities, processes and controls are adequate. In addition to preclinical
and clinical data, the NDA must include significant information regarding the chemistry, manufacturing, and controls for the drug candidate.
Obtaining approval of an NDA is a lengthy, expensive and uncertain process, and approval may not be obtained. After we submit an NDA to
the FDA, the FDA decides whether to accept or reject the submission for filing. We cannot be certain that any submissions will be accepted
for filing and review by the&#160;FDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not yet demonstrated
an ability to file for or receive regulatory approval for our drug candidates. For example, we do not have experience in preparing the
required materials for regulatory submission or navigating the regulatory approval process. As a result, our ability to successfully submit
an NDA and obtain regulatory approval for our drug candidates may involve more inherent risk, take longer, and cost more than it would
if we were a company with experience in obtaining regulatory approvals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Regulatory authorities outside
of the U.S., such as the NMPA, TGA, Health Canada and EMA, also have requirements for approval of drugs for commercial sale with which
we must comply prior to marketing in those areas. Regulatory requirements can vary widely from country to country and could delay or prevent
the introduction of our drug candidates. Clinical trials conducted in one country may not be accepted by regulatory authorities in other
countries, and obtaining regulatory approval in one country does not mean that regulatory approval will be obtained in any other country.
Approval processes vary among countries and can involve additional product testing and validation, and additional administrative review
periods. Seeking non-U.S.&#160;regulatory approval could require additional nonclinical studies or clinical trials, which could be costly
and time consuming. The non-U.S.&#160;regulatory approval process may include all of the risks associated with obtaining FDA approval.
For all of these reasons, we may not obtain non-U.S.&#160;regulatory approvals on a timely basis, if at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The process to develop, obtain
regulatory approval for and commercialize drug candidates is long, complex and costly both inside and outside the United&#160;States,
and approval is never guaranteed. Even if our drug candidates were to successfully obtain approval from the regulatory authorities, any
approval might significantly limit the approved indications for use, or require that precautions, contraindications or warnings be included
on the product labeling, or require expensive and time-consuming post-approval clinical trials or surveillance as conditions of approval.
Following any approval for commercial sale of our drug candidates, certain changes to the drug, such as changes in manufacturing processes
and additional labeling claims, may be subject to additional review and approval by the FDA, NMPA, TGA, Health Canada, EMA and comparable
regulatory authorities. Also, regulatory approval for any of our drug candidates may be withdrawn. If we are unable to obtain regulatory
approval for our drug candidates in one or more jurisdictions, or any approval contains significant limitations, our target market will
be reduced and our ability to realize the full market potential of our drug candidates will be harmed. Furthermore, we may not be able
to obtain sufficient funding or generate sufficient revenue and cash flows to continue the development of any other drug candidate in
the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Favorable designations may not be granted,
or if granted, may be withdrawn later, for any of our drug candidates, and may not lead to faster development or regulatory review or
approval.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not currently have Fast
Track Designation or Breakthrough Therapy Designation, but may seek one or more of such designations in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a drug is intended for
the treatment of a serious or life-threatening condition and the drug demonstrates the potential to address unmet medical need for that
condition, the drug sponsor may apply for FDA Fast Track Designation. The FDA has broad discretion in deciding whether or not to grant
this designation. Even if we believe a particular drug candidate is eligible for this designation, we cannot assure that the FDA would
decide to grant it. Even if we do receive Fast Track Designation, we may not experience a development, review or approval process faster
than conventional FDA procedures. The FDA may withdraw a Fast Track Designation if it believes that the designation is no longer supported
by data from our clinical development program. Many drugs that have received Fast Track Designation have failed to obtain approval from
the FDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A Breakthrough Therapy is
defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease
or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies
on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs
that have been designated as Breakthrough Therapies, interaction and communication between the FDA and the sponsor can help to identify
the most efficient path for development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Designation as a Breakthrough
Therapy is within the discretion of the FDA.&#160;Accordingly, even if we believe, after completing early clinical trials, that one of
our drug candidates meets the criteria for designation as a Breakthrough Therapy, the FDA may disagree and instead decide not to grant
that designation. In any event, the receipt of a Breakthrough Therapy Designation for a drug candidate may not result in a faster development,
review or approval process compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval
by the FDA.&#160;In addition, even if one or more of our drug candidates qualify as Breakthrough Therapies, the FDA may later decide that
such drug candidates no longer meet the conditions for qualification.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Although we have obtained FDA orphan drug
designation for CNM-Au8&#174; for the treatment of ALS, we may not realize any benefit from such designation and it does not increase the
chance of approval.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA granted orphan drug
designation to our lead drug candidate, CNM-Au8<sup>&#174;</sup>, for the treatment of ALS in May&#160;2019. Regulatory authorities in
some jurisdictions, including the U.S.&#160;and the European Union, may designate drugs for relatively small patient populations as orphan
drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition,
which is generally defined as a disease with a patient population of fewer than 200,000 individuals in the U.S., or that affects more
than 200,000 individuals in the U.S.&#160;and for which there is no reasonable expectation that costs of research and development of the
product for the indication can be recovered by sales of the product in the U.S.&#160;Generally, if a drug with an orphan drug designation
subsequently receives the first regulatory approval for the indication for which it has such designation, the drug is entitled to a period
of marketing exclusivity, which precludes the FDA or EMA, from approving another marketing application for the same drug for the same
indication during the period of exclusivity. The applicable period is seven&#160;years in the United&#160;States and 10&#160;years in
the European Union. The European exclusivity period can be reduced to six&#160;years if a drug no longer meets the criteria for orphan
drug designation or if the drug is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity
may be lost if the FDA or the EMA determines that the request for designation was materially defective or if the manufacturer is unable
to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we have obtained
orphan drug designation for CNM-Au8<sup>&#174;</sup> for the treatment of ALS in the U.S., and may obtain the same designation for other
drug candidates or indications, that designation may not effectively protect the drug candidate from competition, if approved, because
different drugs can be approved for the same condition and the same drugs can be approved for a different condition but used off-label
for any orphan indication we may obtain. Even after an orphan drug is approved, the FDA can subsequently approve a drug that is otherwise
the same drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer,
more effective, or makes a major contribution to patient care.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"></p><div>

</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Any of our drug candidates, if approved,
would continue to be subject to ongoing or additional regulatory obligations and regulatory review, which may result in significant additional
expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with
our drug candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of our drug candidates,
if approved, will be subject to ongoing or additional regulatory requirements for manufacturing, labeling, packaging, storage, advertising,
promotion, sampling, record-keeping, conduct of post-market studies, and submission of safety, efficacy, and other post-market information,
including both federal and state requirements in the U.S.&#160;and requirements of comparable regulatory authorities in the European Union,
China, Australia and other markets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Manufacturers and manufacturers&#8217;
facilities are required to comply with extensive FDA, NMPA, TGA, Health Canada, EMA and other comparable regulatory authority requirements
ensuring that quality control and manufacturing procedures conform to GMP.&#160;As such, we will be subject to continual review and inspections
to assess compliance with GMP and adherence to commitments made in any NDA, other marketing applications, and previous responses to any
inspection observations if we were to build manufacturing facilities in the future. Accordingly, we and others with whom we work must
continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, and quality control.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any approvals that we receive
for our drug candidates may be subject to limitations on the approved indicated uses for which the drug may be marketed or to the conditions
of approval, which could adversely affect the drug&#8217;s commercial potential or contain requirements for potentially costly post-market
testing and surveillance to monitor the safety and efficacy of the drug candidate. The FDA, NMPA, TGA, Health Canada, EMA or a comparable
regulatory authority may also require a risk evaluation mitigation strategy program as a condition of approval of our drug candidates
or following approval. In addition, if the FDA, NMPA, TGA, Health Canada, EMA or a comparable regulatory authority approves our drug candidates,
we will have to comply with requirements, including, for example, submissions of safety and other post-market information and reports,
registration, as well as continued compliance with GMP and GCP, for any clinical trials that we conduct post-approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA and other regulatory
authorities strictly regulate the marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may
be promoted only for their approved indications and for use in accordance with the provisions of the approved label. The FDA, NMPA, TGA,
Health Canada, EMA and other regulatory authorities actively enforce the laws and regulations prohibiting the promotion of off-label uses,
and a company that is found to have improperly promoted off-label uses may be subject to significant penalties and enforcement actions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Even if we are able to commercialize any
approved drug candidates, the drugs may become subject to national or other third-party reimbursement practices or unfavorable pricing
regulations, which could harm our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The regulations that govern
regulatory approvals, pricing and reimbursement for new therapeutic products vary widely from country to country. In Europe, Canada, Australia,
China, and some markets outside China, prescription pharmaceutical pricing remains subject to continuing governmental control even after
initial approval is granted. As a result, we might obtain regulatory approval for a drug in a particular country, but then be subject
to price regulations that delay our commercial launch of the drug and negatively impact our revenues.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to commercialize
any approved drug candidates successfully also will depend in part on the extent to which reimbursement for these drugs and related treatments
will be available from government health administration authorities, private health insurers, and other organizations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A primary trend in the global
healthcare industry is cost containment. Government authorities and these third-party payors have attempted to control costs by limiting
coverage and the amount of reimbursement for particular medications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the U.S., no uniform policy
of coverage and reimbursement for drugs exists among third-party payors. As a result, obtaining coverage and reimbursement approval of
a drug from a government or other third-party payor is a time-consuming and costly process that could require us to provide to each payor
supporting scientific, clinical, and cost-effectiveness data for the use of our future approved drugs on a payor-by-payor basis, with
no assurance that coverage and adequate reimbursement will be obtained. Even if we obtain coverage for a given drug, the resulting reimbursement
rates might not be adequate for us to achieve or sustain profitability or may require co-payments that patients find unacceptably high.
Additionally, third-party payors may not cover, or provide adequate reimbursement for, long-term follow-up evaluations required following
the use of our future approved drug candidates. Patients are unlikely to use any of our future approved drugs unless coverage is provided
and reimbursement is adequate to cover a significant portion of the cost of the drug. Because some of our drug candidates may have a higher
cost of goods than conventional small molecule therapies, and may require long-term follow-up evaluations, the risk that coverage and
reimbursement rates may be inadequate for us to achieve profitability may be greater.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"></p><div>

</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Increasingly, third-party
payors are requiring that companies provide them with predetermined discounts from list prices and are challenging the prices charged
for medical products. We cannot assure that reimbursement will be available for any approved drug candidate that we commercialize and,
if reimbursement is available, what the level of reimbursement will be. Reimbursement may impact the demand for, or the price of, any
approved drug candidate that we commercialize. If reimbursement is not available or is available only to limited levels, we may not be
able to successfully commercialize any drug candidate that we successfully develop.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There may be significant delays
in obtaining reimbursement for approved drug candidates, and coverage may be more limited than the purposes for which the drug candidates
are approved by the FDA, NMPA, TGA, Health Canada, EMA or other comparable regulatory authorities. Moreover, eligibility for reimbursement
does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture,
sale and distribution. Interim payments for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made
permanent. Payment rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on payments
allowed for lower cost drugs that are already reimbursed, and may be incorporated into existing payments for other services. Net prices
for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future
weakening of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the U.S.&#160;Our
inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any future approved
drug candidates and any new drugs that we develop could have a material adverse effect on our business, operating results and overall
financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to seek approval
alone or in conjunction with partners to market our drug candidates in the U.S., China, the European Union, Australia, Canada, and other
jurisdictions. In China, Australia, Canada, and the European Union, the pricing of drugs is subject to governmental control, and it can
take considerable time after obtaining marketing regulatory approval to get the future approved drugs reimbursed. Market acceptance and
sales of any of our future approved drug candidates will depend significantly on the availability of adequate coverage and reimbursement
from third-party payors for drugs and may be affected by existing and future healthcare reform measures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our drug candidates, if approved in the
future, may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community
necessary for commercial success and the market opportunity for the drug candidate may be smaller than we estimate.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our drug candidates, if approved
in the future, may fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community.
For example, current MS treatments are well established in the medical community, and physicians may continue to rely on these treatments
to the exclusion of our drug candidates that are in clinical trials for the same or similar indications. In addition, physicians, patients,
and third-party payors may prefer other novel products to ours. If our drug candidates do not achieve an adequate level of acceptance,
we may not generate significant product sales revenues and we may not become profitable. The degree of market acceptance of our drug candidates,
if approved for commercial sale, will depend on a number of factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the clinical indications for which our drug candidates are approved;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether physicians, hospitals, treatment centers and patients consider our drug candidates as a safe and effective treatment;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential and perceived advantages of our drug candidates over alternative treatments;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the prevalence and severity of any side effects;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product labeling or product insert requirements of regulatory authorities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations or warnings contained in the labeling approved by regulatory authorities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing of market introduction of our drug candidates as well as competitive drugs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost of treatment in relation to alternative treatments;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the availability of adequate coverage, reimbursement and pricing by third-party payors and government authorities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the willingness of patients to pay out-of-pocket in the absence of coverage and reimbursement by third-party payors and government authorities; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the effectiveness of our sales and marketing efforts.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any approved drug candidates
that we commercialize fail to achieve market acceptance among physicians, patients, hospitals, treatment centers or others in the medical
community, we will not be able to generate significant revenue. Even if any future approved drug candidates achieve market acceptance,
we may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably
received than our drug candidates, are more cost-effective or render our drug candidates obsolete.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If our drug candidates cause, or are perceived
to cause, undesirable side effects, it can result in delays or failure to receive regulatory approval or limitations on the commercial
profile of an approved label.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Undesirable side effects caused
by our drug candidates could cause either us or regulatory authorities to interrupt, delay or halt clinical trials and could result in
a more restrictive label or the delay or denial of regulatory approval by the FDA, NMPA, TGA, Health Canada, EMA or other regulatory authorities.
If the results of the ongoing clinical trials of our drug candidates reveal a high and unacceptable severity and prevalence of undesirable
side effects, the clinical trials of our drug candidates could be suspended or terminated and the FDA, NMPA, TGA, Health Canada, EMA or
comparable regulatory authorities could order us to cease further development of or deny approval of our drug candidates for any or all
targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the
clinical trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and
prospects significantly.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical trials assess a sample
of the potential patient population. With a limited number of patients and a limited duration of exposure, rare and severe side effects
of our drug candidates may only be uncovered with a significantly larger number of patients exposed to the drug candidates. If our drug
candidates receive regulatory approval and we or others discover undesirable side effects caused by such drugs (or any other similar drugs)
or that such drug candidates are less effective than previously believed, a number of potentially significant negative consequences could
result, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA, NMPA, TGA, Health Canada, EMA or other comparable regulatory authorities may withdraw or limit their approval of such drug candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA, NMPA, TGA, Health Canada, EMA or other comparable regulatory authorities may require the addition of labeling statements, such as a &#8220;boxed&#8221; warning or a contra-indication;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be required to change the way such drug candidates are distributed or administered, conduct additional clinical trials or change the labeling of our drug candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA, NMPA, TGA, Health Canada, EMA or other comparable regulatory authorities may require the development of risk evaluation and mitigation strategies and plans to mitigate risks, which could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be subject to regulatory investigations and government enforcement actions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may decide to, or be required to, remove such drug candidates from the marketplace;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we could be sued and held liable for injury caused to individuals exposed to or taking our drugs; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our reputation may suffer.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of these events could
prevent us from achieving or maintaining market acceptance of the affected drug candidates and could substantially increase the costs
of commercializing our drugs, if approved, and significantly impact our ability to successfully commercialize our drugs and generate revenue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Adverse drug reactions and negative results
from off-label use of our products could materially harm our business reputation, product brand name, commercial operations, financial
condition, including the value of our Common Stock, and expose us to liability.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Products distributed or sold
in the pharmaceutical market may be subject to off-label drug use. Off-label drug use is prescribing a product for an indication, patient
population, dosage strength or frequency, or other condition of use that is not in accordance with regulatory approved usage and labeling.
Even though the FDA, NMPA, TGA, Health Canada, EMA and other comparable regulatory authorities actively enforce the laws and regulations
prohibiting the promotion of off-label use, there remains the risk that our products are subject to off-label drug use and are prescribed
in a patient population or dosage that has not been approved by competent authorities. Off-label use of our products may be less effective
or entirely ineffective and may cause adverse drug reactions. Any of these occurrences can create negative publicity and significantly
harm our business reputation, product brand name, commercial operations, and financial condition, including the value of our Common Stock.
In addition, this may negatively impact our  ability to commercialize our products because it could influence third party
payers reimbursement and formulary placement decisions about our products. These occurrences may also expose us to liability and cause,
or lead to, a delay in the progress of our clinical trials and may also ultimately result in failure to obtain regulatory approval for
our drug candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Off-label use of our products could expose
us to government investigation or prosecution.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin: 0pt 0">Regulatory bodies that enforce laws and regulations to prohibit off-label
use may investigate whether our products are being used off-label. Even though we take steps to prevent off-label promotion of our products,
this would not necessarily prevent regulatory or prosecuting agencies from investigating and taking action against us as if we were engaged
in off-label promotion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>As a company, we have no experience in launching
and marketing drugs. If we are unable to develop sales, marketing and distribution capabilities or enter into sales, marketing and distribution
agreements or arrangements with third parties, we may not be successful in commercializing any drugs, if approved, or generating drug
candidate sales revenue.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not yet demonstrated
an ability to launch and commercialize any of our drug candidates, if approved. As a result, our ability to successfully commercialize
any approved drugs may involve more inherent risk, take longer, and cost more than it would if we were a company with prior experience
launching and marketing drugs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will have to compete with
other pharmaceutical and biopharmaceutical companies to recruit, hire, train and retain marketing and sales personnel. We must either
develop internal sales, marketing, and commercial distribution capabilities for any or all of our approved drugs or pursue collaborative
arrangements regarding the sales and marketing of our approved drugs. However, there can be no assurance that we will be able to develop
such distribution capabilities or establish or maintain such collaborative arrangements, or if we are able to do so, that they will have
effective sales forces. Any revenue we receive will depend upon the efforts of such third parties. We would have little or no control
over the marketing and sales efforts of such third parties, and our revenue from product sales, if approved, may be lower than if we had
commercialized any approved drugs by ourselves or we may fail to generate any product sales revenue in the future at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"></p><div>

</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We face substantial competition from other
pharmaceutical and biotechnology companies, and our operating results may suffer if we fail to compete effectively.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The development and commercialization
of new drugs is highly competitive. We face competition from major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology
companies worldwide. There are a number of large pharmaceutical and biotechnology companies that currently market and sell drugs or are
pursuing the development of drugs for the treatment of neurological diseases and other disorders for which we are commercializing our
drugs or developing our drug candidates. Potential competitors also include academic institutions, government agencies, and other public
and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research,
development, manufacturing, and commercialization.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial opportunity
could be reduced or eliminated if our competitors develop and commercialize drugs that are safer, more effective, have fewer or less severe
side effects, are more convenient, or are less expensive than any drugs that we may commercialize or may develop. Our competitors may
also obtain approval from the FDA, NMPA, TGA, Health Canada, EMA or other comparable regulatory authorities for their drugs more rapidly
than we may obtain approval for our drugs, which could result in our competitors establishing a strong market position before we are able
to enter the market and/or could slow our regulatory approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many of our current or future
competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing,
conducting clinical trials, obtaining regulatory approvals, and marketing approved drugs than we do. Mergers and acquisitions in the pharmaceutical
and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and
other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and
established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel,
establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to,
or necessary for, our programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject, directly or indirectly,
to applicable anti-kickback, false claims laws, physician payment transparency laws, privacy and security laws, fraud and abuse laws or
similar healthcare and security laws and regulations in the U.S.&#160;and other jurisdictions, which could expose us to criminal sanctions,
civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Healthcare providers, physicians
and others play a primary role in the recommendation and prescription of any products for which we obtain regulatory approval. If we obtain
FDA approval for any of our drug candidates and begin commercializing those drugs in the U.S., our operations may be subject to various
federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, the federal False Claims Act,
and physician payment sunshine laws and regulations. These laws may impact, among other things, our proposed sales, marketing, and education
programs. In addition, we may be subject to patient privacy regulation by both the federal government and the states in which we conduct
our business. Restrictions under applicable federal and state healthcare laws and regulations include the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal false claims and civil monetary penalties laws, including the civil False Claims Act and the Civil Monetary Penalties Law, which can be enforced by private citizens through civil whistleblower or qui tam actions, prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) prohibits, among other things, executing or attempting to execute a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;), and their implementing regulations, also imposes obligations, including mandatory contractual terms, certain covered healthcare providers, health plans, and healthcare clearinghouses and their respective business associates and covered subcontractors that perform services for them that involve the use, or disclosure of, individually identifiable health information with respect to safeguarding the privacy, security and transmission of individually identifiable health information; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal Physician Payments Sunshine Act requires applicable manufacturers of covered drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) information regarding payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as information regarding ownership and investment interests held by physicians and their immediate family members. Beginning in 2022, applicable manufacturers also will be required to report such information regarding payments and transfers of value provided during the previous year to physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified nurse anesthetists and certified nurse-midwives. The information reported is publicly available on a searchable website, with disclosure required annually.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, we are subject
to state and non-U.S.&#160;equivalents of each of the healthcare laws described above, among others, some of which may be broader in scope
and may apply to healthcare services reimbursed by any source, not just governmental payors, including private insurers. In addition,
some states have passed laws that require pharmaceutical companies to comply with the April&#160;2003 Office of Inspector General Compliance
Program Guidance for Pharmaceutical Manufacturers and/or other voluntary industry codes of conduct. Several states also impose other marketing
restrictions or require pharmaceutical companies to make marketing or price disclosures to the state. There are ambiguities as to what
is required to comply with these state requirements, and if we fail to comply with applicable state law requirements, we could be subject
to penalties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Violations of fraud and abuse
laws may be punishable by criminal and/or civil sanctions, including penalties, fines and/or exclusion or suspension from federal and
state healthcare programs such as Medicare and Medicaid and debarment from contracting with the U.S.&#160;government.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Neither the U.S.&#160;government
nor the U.S.&#160;courts have provided definitive guidance on limitations to potential liability under the fraud and abuse laws as they
may apply to our business. Law enforcement authorities are increasingly focused on enforcing these laws, often using new and creative
legal theories, and it is possible that some of our practices may be challenged under these laws. Efforts to ensure that our business
arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Regardless
of the compliance efforts, it is possible that governmental authorities will conclude that our business practices may not comply with
current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. In
addition, private individuals have the ability to bring actions on behalf of the U.S.&#160;government under the federal False Claims Act
as well as under the false claims laws of several states. If any such actions are instituted against us, defending against such actions,
even if successful, would distract the Company and key personnel from our core mission and impose potentially significant costs. If we
are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including
the imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation
in Medicare, Medicaid, and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings,
and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.
In addition, the approval and commercialization of any of our approved drugs outside the U.S.&#160;will also likely subject us to non-U.S.&#160;equivalents
of the healthcare laws mentioned above, among other non-U.S.&#160;laws, as well as the U.S.&#160;Foreign Corrupt Practices Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"></p><div>

</div><!-- Field: Page; Sequence: 87; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any of the physicians or
other providers or entities with whom we expect to do business are found to be not in compliance with applicable laws, they may be subject
to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs, which may also adversely
affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may face difficulties from changes to
current regulations and future legislation.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United&#160;States
and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding
the healthcare system that could prevent or delay marketing approval of drug candidates, restrict or regulate post-approval activities,
and affect the ability to profitably sell drug candidates for which marketing approval is obtained. Among policy makers and payors in
the United&#160;States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of
containing healthcare costs, improving quality and/or expanding access. In the United&#160;States, the pharmaceutical industry has been
a particular focus of these efforts and has been significantly affected by major legislative initiatives.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For example, the Patient Protection
and Affordable Care Act&#160;of&#160;2010, as amended by the Health Care and Education Reconciliation Act&#160;of&#160;2010 (collectively,
the &#8220;Affordable Care Act&#8221;), has substantially changed healthcare financing and delivery by both governmental and private insurers.
Among the Affordable Care Act provisions of importance to the pharmaceutical and biotechnology industries are the following: among other
things, subjected biological products to potential competition by lower-cost biosimilars, created a new methodology by which rebates owed
by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected,
increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to
individuals enrolled in Medicaid managed care organizations, established annual fees and taxes on manufacturers of certain branded prescription
drugs, and created a new Medicare Part&#160;D coverage gap discount program, in which manufacturers must agree to offer 70% point-of-sale
discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for
the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part&#160;D.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Some of the provisions of
the Affordable Care Act have yet to be implemented, and there have been legal and political challenges to certain aspects of the Affordable
Care Act. For example, on June&#160;17, 2021 the U.S.&#160;Supreme Court dismissed a challenge on procedural grounds that argued the Affordable
Care Act is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the Affordable
Care Act will remain in effect in its current form. Further, prior to the U.S.&#160;Supreme Court ruling, on January&#160;28, 2021, President
Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through
the Affordable Care Act marketplace, which began on February&#160;15, 2021 and remained open through August&#160;15, 2021. The executive
order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare,
including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that
create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the Affordable Care Act. It is possible
that the Affordable Care Act will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges
and the healthcare reform measures of the Biden administration will impact the Affordable Care Act and our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further legislation or regulation
could be passed that could harm our business, financial condition and results of operations. Other legislative changes have been proposed
and adopted since the Affordable Care Act was enacted. For example, in August&#160;2011, President Obama signed into law the Budget Control
Act&#160;of&#160;2011, which, among other things, included aggregate reductions to Medicare payments to providers of 2% per fiscal year,
which went into effect beginning on April&#160;1, 2013. However, COVID-19 relief legislation suspended the 2% Medicare sequester from
May&#160;1, 2020 through December&#160;31, 2021. In January&#160;2013, the American Taxpayer Relief Act&#160;of&#160;2012 was signed into
law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers
and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers
from three to five&#160;years. Additionally, on March&#160;11, 2021, President Biden signed the American Rescue Plan Act&#160;of&#160;2021
into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price,
for single source and innovator multiple source drugs, beginning January&#160;1, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"></p><div>

</div><!-- Field: Page; Sequence: 88; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, there has been
increasing legislative and enforcement interest in the United&#160;States with respect to specialty drug pricing practices. Specifically,
there have been several recent U.S.&#160;Congressional inquiries and proposed federal legislation designed to, among other things, bring
more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer
patient programs, and reform government program reimbursement methodologies for drugs. Congress has indicated that it will continue to
seek new legislative and/or administrative measures to control drug costs. Additionally, based on a recent executive order, the Biden
administration expressed its intent to pursue certain policy initiatives to reduce drug prices. In response to Biden&#8217;s executive
order, on September&#160;9, 2021, the Department of Health and Human Services (&#8220;HHS&#8221;) released a Comprehensive Plan for Addressing
High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress
could pursue as well as potential administrative actions HHS can take to advance these principles. No legislation or administrative actions
have been finalized to implement these principles. In addition, Congress is considering drug pricing as part of the budget reconciliation
process. Individual states in the United&#160;States have also become increasingly active in passing legislation and implementing regulations
designed to control biopharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on
certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation
from other countries and bulk purchasing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We anticipate that the Affordable Care Act, if substantially maintained
in its current form, will continue to result in additional downward pressure on coverage and the price that we receive for any approved
product, and could seriously harm our business. Any reduction in reimbursement from Medicare and other government programs may result
in a similar reduction in payments from private payors. Further, the implementation of cost containment measures or other healthcare reforms
may prevent us from being able to generate revenue, attain profitability, or commercialize our products. Such reforms could have an adverse
effect on anticipated revenue from drug candidates that we may successfully develop and for which we may obtain regulatory approval and
may affect our overall financial condition and ability to develop drug candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Any failure to perform proper quality control
and quality assurance would have a material adverse effect on our business and financial results.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The manufacturing of our drug
candidates and any drugs, if approved, is subject to applicable laws, regulations, and GMP.&#160;These regulations govern manufacturing
processes and procedures, including record keeping and the implementation and operation of quality management systems to control and assure
the quality of investigational products and products approved for sale. We apply stringent quality controls at each stage of our production
process to comply with these requirements. We perform extensive tests throughout the manufacturing processes to ensure the safety and
effectiveness of our drug candidates. We may, however, detect instances in which an unreleased product was produced without adherence
to our manufacturing procedures or the raw material used in our production process was not collected to store in accordance with the GMP
or other regulations, resulting in a determination that the implicated products should be destroyed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, if we fail to
comply with relevant quality control requirements under laws, regulations, and GMP, we could experience a disruption in the supply of
our products, which could delay or prevent further sales of such products, which could have a material adverse effect on our business
and financial results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, quality issues
may arise during scale-up activities. If we are unable to successfully ensure consistent and high quality of our products during large-volume
production, the sales of our products may not be able to be promoted, which could have a material adverse effect on our business and financial
results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"></p><div>

</div><!-- Field: Page; Sequence: 89; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may explore the licensing of commercialization
rights or other forms of collaboration worldwide, which will expose us to additional risks.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Non-U.S.&#160;markets are
an important component of our growth strategy. We initially intend to focus on opportunities in the U.S., the European Union, Canada,
Australia, Japan, Korea and China, in particular. If we fail to obtain licenses or enter into collaboration arrangements with third parties
in these or other markets, or if these arrangements are not successful, our revenue-generating growth potential will be adversely affected.
Moreover, international business relationships subject us to additional risks that may materially adversely affect our ability to attain
or sustain profitable operations, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">efforts to enter into collaboration or licensing arrangements with third parties in connection with our international sales, marketing, and distribution efforts may increase our expenses or divert our management&#8217;s attention from the development of our drug candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty of effective enforcement of contractual provisions in foreign jurisdictions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">differing regulatory requirements for drug approvals and marketing internationally, including differing product reimbursement regimes;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in a specific market&#8217;s political and cultural climate or economic condition;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential third-party patent rights or potentially reduced protection for intellectual property rights;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unexpected changes in tariffs, trade barriers, and regulatory requirements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">economic weakness, including inflation;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance with tax, employment, immigration, and labor laws for employees traveling abroad;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the effects of applicable non-U.S. tax structures and potentially adverse tax consequences;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">currency fluctuations, which could result in increased operating expenses and reduced revenue;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">workforce uncertainty and labor unrest;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure of our employees and contracted third parties to comply with Office of Foreign Assets Control rules and regulations and the Foreign Corrupt Practices Act; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">business interruptions resulting from geo-political actions, including war and terrorism, or natural disasters, including earthquakes, volcanoes, typhoons, floods, hurricanes, and fires.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These and other risks may
materially and adversely affect our ability to attain or sustain revenue from international markets and could have a material adverse
effect on our business, financial condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Illegal and/or parallel imports and counterfeit
pharmaceutical products may reduce demand for our future approved drug candidates and could have a negative impact on our reputation and
business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The imports, whether authorized
by governmental policy or illegal, of competing products from countries where government price controls or other market dynamics result
in lower prices may adversely affect the demand for any of our future drugs, if approved, and, in turn, may adversely affect our sales
and profitability if we commercialize our products. Unapproved foreign imports of prescription drugs are illegal under the current laws
of the U.S., China, the European Union, Australia and other jurisdictions. However, illegal imports may continue to occur or even increase
as the ability of patients to obtain these lower priced imports continues to grow. Furthermore, cross-border imports from lower-priced
markets (parallel imports) into higher-priced markets could harm sales of our future drugs, if approved, and exert commercial pressure
on pricing within one or more markets. In addition, competent government authorities may expand consumers&#8217; ability to import lower-priced
versions of our future drugs, if approved, or competing products from outside the countries where we operate. Any future legislation or
regulations that increase consumer access to lower-priced medicines from outside the countries where we operate could have a material
adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"></p><div>

</div><!-- Field: Page; Sequence: 90; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain products distributed
or sold in the pharmaceutical market may be manufactured without proper licenses or approvals, or may be fraudulently mislabeled with
respect to their content or manufacturers. These products are generally referred to as counterfeit pharmaceutical products. The counterfeit
pharmaceutical product control and enforcement system, particularly in developing markets such as China, may be inadequate to discourage
or eliminate the manufacturing and sale of counterfeit pharmaceutical products imitating our products. Since counterfeit pharmaceutical
products in many cases have very similar appearances to the authentic pharmaceutical products but are generally sold at lower prices,
counterfeits of our products can quickly erode the demand for our future drugs, if approved. Our reputation and business could suffer
harm as a result of counterfeit pharmaceutical products sold under our or our collaborators&#8217; brand names. In addition, theft of
inventory at warehouses, plants or while in-transit, which are not properly stored and which are sold through unauthorized channels, could
adversely impact patient safety, as well as our reputation and business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We rely on third parties to conduct our
preclinical studies and clinical trials and we must work effectively with collaborators to develop our drug candidates. If these third
parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval
for or commercialize our drug candidates and our business could be substantially harmed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We rely on and plan to continue
to rely on third-party CROs and third-party vendors to monitor, collect samples, analyze samples, report data, and manage data for our
ongoing preclinical and clinical programs. We&#160;rely on these third parties for execution of our preclinical studies and clinical trials.
While we control only certain aspects of their activities, we are responsible for ensuring that each of our studies is conducted in accordance
with the applicable protocol, legal and regulatory requirements, and scientific standards, and our reliance on the CROs does not relieve
us of our regulatory responsibilities. We, our CROs, third-party vendors supporting our clinical programs, and our clinical investigators,
are required to comply with GCPs, which are regulations and guidelines enforced by the FDA, NMPA, TGA, Health Canada, EMA, and other comparable
regulatory authorities for all of our drugs in clinical development. If we, any of our CROs, third-party vendors, or clinical investigators
fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, NMPA, TGA,
Health Canada, EMA or comparable regulatory authorities may require us to perform additional clinical trials before approving our marketing
applications. In addition, our pivotal clinical trials must be conducted with products produced under GMP.&#160;Our failure, or the failure
of any third party, to comply with these regulations may results in our having to repeat clinical trials, which would delay the regulatory
approval process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any of our relationships
with these third parties terminates, we may not be able to enter into arrangements with alternative CROs, vendors or clinical investigators,
or to do so on commercially reasonable terms. In addition, our CROs are not our employees, and except for remedies available to us under
our agreements with such CROs, we cannot control whether or not they devote sufficient time and resources to our ongoing clinical and
other programs. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need
to be replaced or if the quality or accuracy of the clinical data they or our clinical investigators obtain is compromised due to the
failure to adhere to our clinical protocols, regulatory requirements, or for other reasons, our clinical trials may be extended, delayed
or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our drug candidates. As a result,
our results of operations and any commercial prospects for our drugs would be harmed, our costs would increase and our ability to generate
revenues would be delayed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Switching or adding additional
CROs or clinical investigators involves additional cost and delays, which can materially affect our ability to meet our desired clinical
development timelines. There can be no assurance that we will not encounter these delays in the future or that these delays or challenges
will not have a material adverse effect on our business, financial condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"></p><div>

</div><!-- Field: Page; Sequence: 91; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>
</div><p style="margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to generate future
revenues is dependent on our ability to work effectively with collaborators to develop our drug candidates, including to obtain regulatory
approval. Our arrangements with collaborators will be critical to successfully bringing products to market and commercializing them, if
approved. We rely on collaborators in various respects, including to undertake research and development programs, to conduct clinical
trials, to manage or assist with the regulatory filings and approval process, and to assist with our commercialization efforts. We do
not control our collaborators and we cannot ensure that these third parties will adequately and timely perform all of their obligations
to us. If they fail to complete the remaining studies successfully, or at all, it would delay, adversely affect or prevent regulatory
approval. We cannot guarantee the satisfactory performance of any of our collaborators&#8217; obligations and if any of our collaborators
breach or terminate their agreements with us, we may not be able to successfully commercialize the drug candidates which could materially
and adversely affect our business, financial condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our CROs, clinical investigators
and third-party vendors may also be impacted by the COVID-19 outbreak. See &#8220;&#8212;Our financial condition and results of operations
may be adversely affected by the COVID-19 pandemic.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have entered into research collaborations
and may form or seek collaborations, joint ventures or strategic alliances or enter into licensing arrangements in the future, and we
may not realize the benefits of such collaborations, alliances, or licensing arrangements.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may form or seek strategic
alliances, create joint ventures or collaborations, or enter into licensing arrangements with third parties that we believe will complement
or augment our development and commercialization efforts with respect to our drug candidates and any future drug candidates that we may
develop. Any of these relationships may require us to incur non-recurring and other costs, increase our near and long-term expenditures,
disrupt our management and business, or issue securities that dilute our existing shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While we have entered into
collaborative research arrangements with some of the world&#8217;s leading academic institutions and research centers and are working
with key scientists in the field of central nervous system disorders, we face significant competition in seeking appropriate strategic
partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic
partnership or other alternative arrangements for our drug candidates because they may be deemed to be at too early of a stage of development
for collaborative effort and third parties may not view our drug candidates as having the requisite potential to demonstrate safety and
efficacy or commercial viability. If and when we collaborate with a third party for development and commercialization of a drug candidate,
if approved, we can expect to relinquish some or all of the control over the future success of that drug candidate to the third party.
For any drug candidates that we may seek to in-license from third parties, we may face significant competition from other pharmaceutical
or biotechnology companies with greater resources or capabilities than we have, and any agreement that we do enter into may not result
in the anticipated benefits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, collaborations involving
our drug candidates are subject to numerous risks, which may include the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators have significant discretion in determining the efforts and resources that they will apply to a collaboration;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators may not pursue development and commercialization of our drug candidates, if approved, or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in their strategic focus due to the acquisition of competitive drugs, availability of funding, or other external factors outside of our control, such as a business combination that diverts resources or creates competing priorities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial, stop a clinical trial, abandon a drug candidate, repeat or conduct new clinical trials, or require a new formulation of a drug candidate for clinical testing;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators could independently develop, or develop with third parties, drugs that compete directly or indirectly with our drugs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 92; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators with marketing and distribution rights to one or more drugs may not commit sufficient resources to their marketing and distribution;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators may not properly develop, maintain, or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes may arise between us and a collaborator that cause the delay or termination of the research, development, or commercialization of our drug candidates, if approved, or that result in costly litigation or arbitration that diverts management attention and resources;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of our drug candidates, if approved; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators may own or co-own intellectual property covering our drugs that results from our collaborating with them, and in such cases, we would not have the exclusive right to commercialize such intellectual property.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result, we may not be
able to realize the benefit of any current or future research collaborations, strategic partnerships, or the potential licensing of third-party
drugs if we are unable to successfully integrate such products with our existing operations and company culture, which could delay our
timelines or otherwise adversely affect our business. We also cannot be certain that, following a strategic transaction or license, we
will achieve the revenue or net income that justifies such transaction. If we are unable to reach agreements with suitable collaborators
on a timely basis, on acceptable terms, or at all, we may have to curtail the development of one of more of our drug candidates, reduce
or delay our development program or one or more of our future development programs, delay our potential commercialization or reduce the
scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at
our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional
expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations
and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able
to further develop our drug candidates or, if approved, bring them to market and generate product sales revenue, which would harm our
business, financial condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our business depends on the use of raw materials,
and a decrease in the supply or an increase in the cost of these raw materials or any quality issues in such raw materials could materially
and adversely affect our business, financial condition, results of operations and prospects.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to manufacture our
products, we must obtain sufficient quantities of high-quality raw materials at commercially acceptable prices and in a timely manner.
Certain critical raw materials, such as wires made of high-purity gold and other transition elements, are available from a limited number
of suppliers in the market. As a result, any disruption in production or inability of our suppliers to produce adequate quantities to
meet our needs could impair our ability to operate our business on a&#160;day-to-day basis and to continue our research and development
of future drug candidates. Moreover, we expect our demand for such materials to increase as we expand our business scale and commercialize
our products, if approved, and we cannot guarantee that current suppliers have the capacity to meet our demand. We are also exposed to
the risk of increased material costs, which we may not be able to pass on to customers and as a result, we could have lower profitability.
In addition, although we have implemented quality inspection procedures on such materials before they are used in our manufacturing processes
and also require our suppliers to maintain high quality standards, we cannot guarantee that we will be able to secure sufficient quantities
of raw materials at high quality standards, nor detect all quality issues in the supplies we use. For example, should the highly purified
water that we utilize be compromised in any way, it could render entire batches unusable or, depending on the nature of the impurity,
could be dangerous to patients. Further, we cannot assure you that third parties will be able to maintain and renew all licenses, permits,
and approvals necessary for their operations or comply with all applicable laws and regulations. Failure to do so by them may lead to
interruption in their business operations, which in turn may result in shortages of the raw materials utilized by us. If we are unable
to obtain adequate raw materials and the quality of our products suffers as a result, we may have to delay clinical trials and regulatory
filings, recall our products, be subject to product liability claims, fail to comply with continuing regulatory requirements, and incur
significant costs to rectify such issues, which may have a material and adverse effect on our business, financial condition, results of
operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"></p><div>

</div><!-- Field: Page; Sequence: 93; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are unable to obtain and maintain
sufficient patent protection for our drug candidates through intellectual property rights, or if the scope of such intellectual property
rights obtained is not sufficiently broad, third parties could develop and commercialize products similar or identical to our products,
and our ability to commercialize our approved drugs successfully may be adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success depends in large
part on our ability to protect our proprietary technology, drug candidates in clinical trials, and approved drugs on market (if approved)
from competition by obtaining, maintaining and enforcing our intellectual property rights, including patent rights. We seek to protect
the drug candidates and technology that we consider commercially important by filing patent applications in most important commercial
markets, including the U.S., China, Europe, Canada, Japan, Korea, and other countries, relying on trade secrets or pharmaceutical regulatory
protection or employing a combination of these methods. However, the patent prosecution process is expensive, time-consuming and complex,
and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent applications at a reasonable
cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output
before it is too late to obtain patent protection. As a result, we may not be able to prevent competitors from developing and commercializing
competitive drugs in all such fields and territories.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Patents may be invalidated
and patent applications may not be granted for a number of reasons, including known or unknown prior art, deficiencies in the patent application
or the lack of novelty of the underlying invention or technology. Although we enter into non-disclosure and confidentiality agreements
with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate
collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and any other third parties, any of these
parties may breach such agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to
seek patent protection. In addition, publications of discoveries in the scientific literature often lag behind the actual discoveries,
and patent applications in the U.S.&#160;and other jurisdictions are typically not published until 18&#160;months after filing, or in
some cases, not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patents or pending
patent applications or that we were the first to file for patent protection of such inventions. Furthermore, China, EPO, and the U.S.&#160;have
adopted the &#8220;first-to-file&#8221; system under which whoever first files a patent application will be awarded the patent if all
other patentability requirements are met. Under the first-to-file system, third parties may be granted a patent relating to a technology
which we invented.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The coverage sought by the
claims in a patent application can be significantly reduced before the patent is issued, and the scope of the claims can be reinterpreted
after issuance. Even if patent applications we license or own currently or in the future issue as patents, they may not issue in a form
that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide
us with any competitive advantage. In addition, the patent position of biotechnology and pharmaceutical companies generally is highly
uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent&#160;years. As a result,
the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The issuance of a patent is
not conclusive as to our inventorship, scope, validity, or enforceability, and our patents may be challenged in the courts or patent offices
in any country. We may be subject to a third-party preissuance submission of prior art to the U.S.&#160;Patent and Trademark Office (&#8220;USPTO&#8221;),
or become involved in opposition, derivation, revocation, re-examination, post-grant and <i>inter partes</i> review, or interference proceedings
or similar proceedings in foreign jurisdictions challenging our patent rights or the patent rights of others. An adverse determination
in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize
our technology or approved drugs and compete directly with us without payment, or result in our inability to manufacture or commercialize
drug candidates and approved drugs without infringing, misappropriating or otherwise violating third-party patent rights. Moreover, we
may have to participate in interference proceedings declared by the USPTO to determine priority of invention or in post-grant challenge
proceedings, such as oppositions in a foreign patent office, that challenge the priority of our invention or other features of patentability
of our patents and patent applications. Such challenges may result in loss of patent rights, loss of exclusivity, or in patent claims
being narrowed, invalidated, or held unenforceable, which could limit our ability to stop others from using or commercializing similar
or identical technology and products, or limit the duration of the patent protection of our technology and drug candidates. Such proceedings
also may result in substantial costs and require significant time from our scientists and management, even if the eventual outcome is
favorable to us. Consequently, we do not know whether any of our technology or drug candidates will be protectable or remain protected
by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our patents by developing similar or
alternative technologies or products in a non-infringing manner.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"></p><div>

</div><!-- Field: Page; Sequence: 94; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, although various
extensions may be available, the life of a patent and the protection it affords, are limited. For example, approved therapies may face
competition from generic medications after the related patents have expired, or if they are challenged and invalidated even before their
expiry. Manufacturers of generic drugs may challenge the scope, validity or enforceability of our patents in court, and we may not be
successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant
product exclusively, which would have a material adverse effect on any potential sales of that product. The issued patents and pending
patent applications, if issued, for our drug candidates are expected to expire on various dates as described in &#8220;Business&#8212;Intellectual
Property&#8221; of our Annual Report on Form 10-K filed with the SEC on March 29, 2021. Upon the expiration of our issued patents or patents
that may issue from our pending patent applications, we will not be able to assert such patent rights against potential competitors and
our business and results of operations may be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Given the amount of time required
for the development, testing and regulatory review of new drug candidates, patents protecting such drug candidates might expire before
or shortly after such drugs are commercialized. As a result, our patents and patent applications may not provide us with sufficient rights
to exclude others from commercializing products similar or identical to our products. Moreover, some of our patents and patent applications
may in the future be co-owned with third parties. If we are unable to obtain an exclusive license to any such third-party co-owners&#8217;
interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including
our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such
co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of
the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations
and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be able to protect our intellectual
property rights throughout the world or prevent unfair competition by third parties.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Filing, prosecuting, maintaining,
and defending patents on drug candidates in all countries throughout the world could be prohibitively expensive for us, and our intellectual
property rights in some non-U.S.&#160;countries can have a different scope and strength than do those in the U.S.&#160;In addition, the
laws of certain non-U.S.&#160;countries do not protect intellectual property rights to the same extent as the laws of the U.S.&#160;Consequently,
we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling or importing
drugs made using our inventions in and into the U.S.&#160;or non-U.S.&#160;jurisdictions. Competitors may use our technologies in jurisdictions
where we have not obtained patent protection to develop their own drugs and further, may export otherwise infringing drugs to non-U.S.&#160;jurisdictions
where we have patent protection, but where enforcement rights are not as strong as those in the U.S.&#160;These drugs may compete with
our future approved drugs and our patent rights or other intellectual property rights may not be effective or adequate to prevent them
from competing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may become involved in lawsuits to protect
or enforce our intellectual property, which could be expensive, time consuming and unsuccessful. Our patent rights relating to our drugs
could be found invalid or unenforceable if challenged in court or before the U.S.&#160;Patent and Trademark Office or comparable non-U.S.&#160;authority.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Competitors may infringe our
patent rights or misappropriate or otherwise violate our intellectual property rights. To counter infringement or unauthorized use, litigation
may be necessary in the future to enforce or defend our intellectual property rights, protect our trade secrets or determine the validity
and scope of our own intellectual property rights or the proprietary rights of others. Enforcement or defense of intellectual property
rights can be expensive and time consuming. Any claims that we assert against perceived infringers could also provoke these parties to
assert counterclaims against us alleging that we infringe their intellectual property rights. Many of our current and potential competitors
have the ability to dedicate substantially greater resources to enforce and/or defend their intellectual property rights than we can.
Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating our intellectual
property. An adverse result in any litigation proceeding could put our patents, as well as any patents that may issue in the future from
our pending patent applications, at risk of being invalidated, held unenforceable or interpreted narrowly. Furthermore, because of the
substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential
information could be compromised by disclosure during this type of litigation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"></p><div>

</div><!-- Field: Page; Sequence: 95; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In patent litigation in the
U.S., defendant counterclaims in district courts or in the Patent Trademark and Appeal Board alleging invalidity or unenforceability are
commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Third parties
may also raise similar claims before administrative bodies in the U.S.&#160;or abroad, even outside the context of litigation. Such mechanisms
include ex parte re-examination, <i>inter partes</i> review, post-grant review, derivation and equivalent proceedings in non-U.S.&#160;jurisdictions,
such as opposition proceedings. Such proceedings could result in revocation or amendment to our patents in such a way that they no longer
cover and protect our drug candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With
respect to the validity of our patents, for example, we cannot be certain that there is no invalidating prior art of which we, our patent
counsel, and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or
unenforceability, we would lose at least part, and perhaps all, of the patent protection on our drug candidates. Such a loss of patent
protection could have a material adverse impact on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may not be able to prevent
misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights
as fully as in the U.S.&#160;Furthermore, because of the substantial amount of discovery required in connection with intellectual property
litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are sued for infringing the intellectual
property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or
commercializing our drug candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial success depends
in part on our avoiding infringement of the patents and other intellectual property rights of third parties. We are aware of other issued
patents belonging to third parties that exist in fields in which we are developing our drug candidates. There may also be third-party
patents or patent applications of which we are currently unaware, and given the dynamic area in which we operate, additional patents are
likely to be issued that relate to some aspects of our business. There is a substantial amount of litigation and other claims and proceedings
involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries generally. As the biotechnology
and pharmaceutical industries expand and more patents are issued, the risk increases that our drug candidates may give rise to claims
of infringement of the patent rights of others.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Third parties may assert that
we are using technology in violation of their patent or other proprietary rights. Defense of these claims, regardless of their merit,
could involve substantial litigation expense and divert our technical personnel, management personnel, or both from their normal responsibilities.
If third parties bring successful claims against us for infringement of their intellectual property rights, we may be subject to injunctive
or other equitable relief, which could prevent us from developing and commercializing one or more of our drug candidates. We may also
have to pay substantial damages, including treble damages and attorneys&#8217; fees in the case of willful infringement, or redesign our
infringing drug candidates, which may be impossible or require substantial time and cost. In the event of an adverse result in any such
litigation, or even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization
of our drug candidates. Any such license might not be available on reasonable terms or at all. In the event that we are unable to obtain
such a license, we would be unable to further develop and commercialize one or more of our drug candidates, which could harm our business
significantly. We may also elect to enter into license agreements in order to settle patent infringement claims or to resolve disputes
prior to litigation, and any such license agreements may require us to pay royalties and other fees that could significantly harm our
business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"></p><div>

</div><!-- Field: Page; Sequence: 96; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Intellectual property litigation may lead
to unfavorable publicity that harms our reputation and increases our operating losses, causing the market price of our Common Stock to
decline.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the course of any intellectual
property litigation, there could be public announcements of the results of hearings, motions or other interim proceedings or developments,
and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the market
price of our Common Stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available
for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources
to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings
more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation
of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Obtaining and maintaining our patent protection
depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent
agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Periodic maintenance fees
on any issued patent are due to be paid to the USPTO and most foreign jurisdictions either annually or in several stages over the lifetime
of the patent. The USPTO and various non-U.S.&#160;governmental patent agencies require compliance with a number of procedural, documentary,
fee payment, and other similar provisions during the patent application process. Although an inadvertent lapse can in many cases be cured
by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result
in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.
Noncompliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official
actions within prescribed time limits, non-payment of fees, and failure to properly legalize and submit formal documents. In any such
event, our competitors might be able to enter the market, which would have a material adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we do not obtain patent term extension
and data exclusivity for any drug candidates we may develop, our business may be materially harmed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Depending upon the timing,
duration, and specifics of any FDA marketing approval of any drug candidates we may develop, one or more of our U.S.&#160;patents may
be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Action of 1984, or Hatch Waxman
Amendments. The Hatch Waxman Amendments permit a patent extension term of up to five&#160;years as compensation for patent term lost during
clinical trials and the FDA regulatory review process. A comparable extension right may exist in other foreign jurisdictions as well.
A patent term extension cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of drug approval, only
one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may
be extended. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing
phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents,
or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded
could be less than we request. In addition, no patent term extension system has been established in China beyond the new pilot program,
and implementation of the pilot program may not occur quickly. As a result, the patents we have in China are not yet eligible to be extended
for patent term lost during clinical trials and the regulatory review process. If we are unable to obtain patent term extension or if
the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent
expiration, and our business, financial condition, results of operations, and prospects could be materially harmed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Changes in patent law could diminish the
value of patents in general, thereby impairing our ability to protect our drug candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The U.S.&#160;has recently
enacted and is currently implementing wide-ranging patent reform legislation. Recent U.S.&#160;Supreme Court rulings have narrowed the
scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition
to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty
with respect to the value of patents once obtained, if any. Depending on decisions by the U.S.&#160;Congress, the federal courts and the
USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents
or to enforce our existing patents and patents that we might obtain in the future. There could be similar changes in the laws of foreign
jurisdictions that may impact the value of our patent rights or other intellectual property rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 97; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are unable to protect the confidentiality
of our trade secrets, our business and competitive position would be harmed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to our issued
patents and pending patent applications, we rely on trade secrets, including unpatented know-how, technology, and other proprietary information,
to maintain our competitive position and to protect our drug candidates. We seek to protect these trade secrets, in part, by entering
into non-disclosure and confidentiality agreements with parties that have access to them, such as our employees, corporate collaborators,
outside scientific collaborators, sponsored researchers, consultants, advisors and other third parties. We also enter into confidentiality
and invention or patent assignment agreements with our employees and consultants. However, any of these parties may breach such agreements
and disclose our proprietary information, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that
a party illegally disclosed or misappropriated a trade secret can be difficult, expensive, time-consuming, and the outcome is unpredictable.
If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent
the competitor from using that technology or information to compete with us and our competitive position would be harmed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject to claims that our employees
have wrongfully used or disclosed the alleged trade secrets of their former employers.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many of our employees, including
our senior management, were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential
competitors. Some of these employees, including each member of our senior management, executed proprietary rights, non-disclosure and
non-competition agreements in connection with such previous employment. Although we try to ensure that our employees do not use the proprietary
information or know-how of others in their work for us, we may be subject to claims that we or these employees have used or disclosed
intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employer. We are
not aware of any threatened or pending claims related to these matters or concerning the agreements with our senior management, but in
the future litigation may be necessary to defend against such claims. If we fail in defending any such claims, in addition to paying monetary
damages, we may lose valuable intellectual property rights, or personnel. Even if we are successful in defending against such claims,
litigation could result in substantial costs and be a distraction to management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Intellectual property rights do not necessarily
protect us from all potential threats to our competitive advantages.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The degree of future protection
afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately
protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others may be able to make compounds that are similar to our drug candidates but that are not covered by the claims of the patents that we own or may in the future exclusively license;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own or may in the future exclusively license, which could result in the patent applications not issuing or being invalidated after issuing;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we might not have been the first to file patent applications covering certain of our inventions, which could prevent the issuance of the patent applications or cause them to be invalidated after issuance;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">it is possible that our pending patent applications will not lead to issued patents;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issued patents that we own or have exclusively licensed may not provide us with any competitive advantages, or may be held invalid or unenforceable, as a result of legal challenges by our competitors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 98; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may obtain patents for certain drug candidates many years before we receive NDA approval for these drugs, and because patents have a limited life, which may begin to run prior to the commercial sale of the related drugs, limiting the commercial value of our patents;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive drugs for commercialization in our major markets;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may fail to develop additional proprietary technologies that are patentable;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may fail to apply for or obtain adequate intellectual property protection in all the jurisdictions in which we operate;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the patents of others may have an adverse effect on our business, for example by preventing us from commercializing one or more of our drug candidates for one or more indications; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any of the aforementioned threats to our competitive advantage could have a material adverse effect on our business.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to the Reverse Recapitalization
and Integration of Businesses</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have incurred significant increased expenses
and administrative burdens as a public company, which could have an adverse effect on our business, financial condition and results of
operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a newly public company,
and particularly after we are no longer an emerging growth company or smaller reporting company, we have faced and will continue to face
increased legal, accounting, administrative and other costs and expenses as a public company that we did not incur as a private company.
The Sarbanes-Oxley Act, including the requirements of Section&#160;404, as well as rules and regulations subsequently implemented by the
SEC, the Dodd-Frank Wall Street Reform and Consumer Protection Act&#160;of&#160;2010 and the rules and regulations promulgated and to
be promulgated thereunder, the Public Company Accounting Oversight Board and the securities exchanges, impose additional reporting and
other obligations on public companies. Compliance with public company requirements has increased costs and made certain activities more
time-consuming. A number of those requirements has required us to carry out activities we have not done previously. Our management and
other personnel also have devoted and will continue to devote a substantial amount of time to these compliance initiatives. In addition,
additional expenses associated with SEC reporting requirements have been incurred. Furthermore, if any issues in complying with those
requirements are identified (for example, if the auditors identify a material weakness or significant deficiency in the internal control
over financial reporting), we could incur additional costs rectifying those issues, and the existence of those issues could adversely
affect our reputation or investor perceptions of it. It is also more expensive to obtain director and officer liability insurance. Risks
associated with our status as a public company may make it more difficult to attract and retain qualified persons to serve on the board
of directors or as executive officers. The additional reporting and other obligations imposed by these rules and regulations has increased
legal and financial compliance costs and the costs of related legal, accounting and administrative activities. These increased costs require
us to divert a significant amount of money that could otherwise be used to expand our business and achieve strategic objectives. Advocacy
efforts by shareholders and third parties may also prompt additional changes in governance and reporting requirements, which could further
increase costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"></p><div>

</div><!-- Field: Page; Sequence: 99; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We qualify as an emerging growth company
and smaller reporting company within the meaning of the Securities Act, and if we take advantage of certain exemptions from disclosure
requirements available to emerging growth companies, it could make our Common Stock less attractive to investors and may make it more
difficult to compare our performance to the performance of other public companies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We qualify as an &#8220;emerging
growth company&#8221; as defined in Section&#160;2(a)(19)&#160;of the Securities Act, as modified by the JOBS Act. As such, we are eligible
for and may take advantage of certain exemptions from various reporting requirements applicable to other public companies that are not
emerging growth companies for as long as we continue to be an emerging growth company, including (i)&#160;the exemption from the auditor
attestation requirements with respect to internal control over financial reporting under Section&#160;404(b)&#160;of the Sarbanes-Oxley
Act, (ii)&#160;the exemptions from say-on-pay, say-on-frequency and say-on-golden parachute voting requirements and (iii)&#160;reduced
disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We will remain an emerging growth
company until the earlier of: (i)&#160;the last&#160;day of the fiscal year (a)&#160;following the fifth anniversary of the closing of
the initial public offering of Tottenham, (b)&#160;in which we have total annual gross revenue of at least $1.07&#160;billion, or (c)&#160;in
which we are deemed to be a &#8220;large accelerated filer&#8221; under the Exchange&#160;Act, which would occur if the market value of
the shares of our Common Stock held by non-affiliates exceeds $700.0&#160;million as of the last business&#160;day of our most recently
completed second fiscal quarter; or (ii)&#160;the date on which we have issued more than $1.0&#160;billion in non-convertible debt securities
during the prior three-year period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the JOBS Act
provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting
standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise
apply to private companies. We have elected to avail ourselves of this extended transition period and, as a result, we may adopt new or
revised accounting standards on the relevant dates on which adoption of such standards is required for non-public companies instead of
the dates required for other public companies. As a result, our financial statements may not be comparable to companies that comply with
new or revised accounting pronouncements as of public company effective dates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we are also a
&#8220;smaller reporting company&#8221; because the market value of our stock held by non-affiliates is less than $700&#160;million as
of June&#160;30, 2021 and our annual revenue was less than $100&#160;million during the fiscal year ended December&#160;31, 2020. We may
continue to be a smaller reporting company in any given year if either (i)&#160;the market value of our stock held by non-affiliates is
less than $250&#160;million as of June&#160;30 in the most recently completed fiscal year or (ii)&#160;our annual revenue is less than
$100&#160;million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than
$700&#160;million as of June&#160;30 in the most recently completed fiscal year. If we are a smaller reporting company at the time we
cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available
to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal&#160;years
of audited financial statements in our Annual Report on Form&#160;10-K and, similar to emerging growth companies, smaller reporting companies
have reduced disclosure obligations regarding executive compensation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot predict if investors
will find our Common Stock less attractive because we rely on these exemptions. If some investors find our Common Stock less attractive
as a result, there may be a less active trading market for our Common Stock and our stock price may be more volatile.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Common Stock</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Provisions in our amended and restated certificate
of incorporation and amended and restated bylaws could make a merger, tender offer or proxy contest difficult, thereby depressing the
trading price of our Common Stock.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Provisions in our amended
and restated certificate of incorporation and amended and restated bylaws may discourage, delay or prevent a merger, acquisition or other
change in control that shareholders may consider favorable, including transactions in which shareholders might otherwise receive a premium
for their shares of our Common Stock. These provisions could also limit the price that investors might be willing to pay in the future
for shares of our Common Stock, thereby depressing the market price of our Common Stock. Such provisions include the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a classified board of directors with three-year staggered terms, which could delay the ability of shareholders to change the membership of a majority of our board of directors (the &#8220;Board&#8221;);</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the ability of our Board to approve the issuance shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without shareholder approval, which could be used to significantly dilute the ownership of a hostile acquiror and/or existing stockholders;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the requirement for the affirmative vote of holders of at least 66&#8532;% of the voting power of all of the then-outstanding shares of the Common Stock, voting together as a single class, to amend certain provisions of our amended and restated certificate of incorporation or our amended and restated bylaws, which may inhibit the ability of an acquiror to effect such amendments to facilitate an unsolicited takeover attempt;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 100; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the exclusive right of our Board to elect a director to fill a vacancy created by the expansion of our Board or the resignation, retirement death, disqualification or removal of a director, which prevents shareholders from being able to fill vacancies on our Board for a period of time; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the requirement that a special meeting of shareholders may be called only by our Board, the chairman of our Board or our Chief Executive Officer, which could delay the ability of our shareholders to force consideration of a proposal or to take action, including the removal of directors.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These and other provisions
in our amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for shareholders
or potential acquirors to obtain control of our Board or initiate actions that are opposed by our then-current&#160;Board, including the
ability to delay or impede a merger, tender offer or proxy contest. The existence of these provisions could negatively affect the price
of our Common Stock and limit opportunities for shareholders to realize value in a corporate transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>General Risk Factors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>There can be no assurance that we will be
able to comply with the continued listing standards of Nasdaq.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If Nasdaq delists our shares
of Common Stock or warrants from trading on its exchange for failure to meet Nasdaq&#8217;s listing standards, we and our shareholders
could face significant material adverse consequences including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a limited availability of market quotations for our securities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced liquidity for our securities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a determination that our Common Stock is a &#8220;penny stock&#8221; which will require brokers trading in our Common Stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a limited amount of news and analyst coverage; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a decreased ability to issue additional securities or obtain additional financing in the future.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The price of our Common Stock may be volatile.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The stock markets in general
and the markets for biotechnology stocks have experienced extreme volatility. The market for the common stock of smaller companies such
as ours is characterized by significant price volatility when compared to the shares of larger, more established companies that trade
on a national securities exchange and have large public floats, and the share price of our Common Stock is more volatile than the price
of the shares of such larger, more established companies and will continue to be for the indefinite future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The price of our Common Stock
may fluctuate due to a variety of factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in the industries in which we operate;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">variations in our operating performance and the performance of our competitors in general;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">material and adverse impact of the COVID-19 pandemic on the markets and the broader global economy;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual or anticipated fluctuations in our quarterly or annual operating results;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">publication of research reports by securities analysts about us or our competitors or our industry;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 101; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the public&#8217;s reaction to our press releases, our other public announcements and our filings with the SEC;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our failure or the failure of our competitors to meet analysts&#8217; projections or guidance that we or our competitors may give to the market;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions and departures of key personnel;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in laws and regulations affecting our business;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">commencement of, or involvement in, litigation involving us;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in our capital structure, such as future issuances of securities or the incurrence of additional debt;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the volume of shares of our Common Stock available for public sale; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general economic and political conditions such as recessions, interest rates, fuel prices, foreign currency fluctuations, international tariffs, social, political and economic risks, pandemics and acts of war or terrorism.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These market and industry
factors may materially reduce the market price of our Common Stock regardless of our operating performance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Future offerings of debt or equity securities
by us may adversely affect the market price of our Common Stock.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the future, we may attempt
to obtain financing or to further increase our capital resources by issuing additional shares of our Common Stock or offering debt or
other equity securities, including commercial paper, medium-term notes, senior or subordinated notes, debt securities convertible into
equity or shares of preferred stock. Future clinical trials, commercialization efforts, and acquisitions could require substantial additional
capital in excess of cash from operations. We would expect to obtain the capital required for acquisitions through a combination of additional
issuances of equity, corporate indebtedness and/or cash from operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Issuing additional shares
of our Common Stock or other equity securities or securities convertible into equity may dilute the economic and voting rights of our
existing shareholders or reduce the market price of our Common Stock or both. Upon liquidation, holders of such debt securities and preferred
shares, if issued, and lenders with respect to other borrowings would receive a distribution of our available assets prior to the holders
of our Common Stock. Debt securities convertible into equity could be subject to adjustments in the conversion ratio pursuant to which
certain events may increase the number of equity securities issuable upon conversion. Preferred shares, if issued, could have a preference
with respect to liquidating distributions or a preference with respect to dividend payments that could limit our ability to pay dividends
to the holders of our Common Stock. Our decision to issue securities in any future offering will depend on market conditions and other
factors beyond our control, which may adversely affect the amount, timing and nature of our future offerings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(a) Recent Sales of Unregistered Securities&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 15, 2021, Chardan exercised a Unit Purchase Option for 220,000
units, each unit consisting of one and one-tenth shares of Common Stock and one warrant to purchase one-half of one share of Common Stock
at an exercise price of $11.50 per share. Chardan elected to perform a cashless or net exercise, which resulted in a net issuance of 54,083
shares of Common Stock and 49,166 warrants to purchase one-half of one share of Common Stock. We received no cash proceeds. This issuance
was made in reliance upon the exemption to the registration requirements of the Securities Act provided by Rule 506(b) of Regulation D.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(b) Use of Proceeds</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(c) Purchases of Equity Securities by the Issuer
and Affiliated Purchasers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 102; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 3. DEFAULTS UPON SENIOR SECURITIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 4. MINE SAFETY DISCLOSURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not Applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 5. OTHER INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 6. EXHIBITS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%; border-bottom: black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="width: 2%; text-align: justify">&#160;</td>
    <td style="width: 88%; border-bottom: black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1822791/000121390021037232/ea144299ex3-1_cleneinc.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline;text-decoration: none">Third Amended and Restated Certificate of Incorporation of Clene Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed by the Registrant on July 16, 2021).</span></span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1822791/000121390021000487/ea132520ex3-2_cleneinc.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline;text-decoration: none">Bylaws of Clene Inc. (incorporated by reference to Exhibit 3.2 to the Current Report on Form&#160;8-K filed by the Registrant on January 5, 2021).</span></span></a></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1822791/000121390021041493/ea145537ex10-1_cleneinc.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease Agreement, dated as of August 10, 2021, between Clene Nanomedicine, Inc. and 100 Chesapeake Blvd LLC (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by the Registrant on August 11, 2021).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1822791/000121390021041493/ea145537ex10-2_cleneinc.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease Agreement, dated as of August 10, 2021, between Clene Nanomedicine, Inc. and Upper Chesapeake Flex One, LLC (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed by the Registrant on August 11, 2021).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="f10q0921ex31-1_cleneinc.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline;text-decoration: none">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934, as amended.</span></span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="f10q0921ex31-2_cleneinc.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline;text-decoration: none">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934, as amended.</span></span></a></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="f10q0921ex32-1_cleneinc.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline;text-decoration: none">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="f10q0921ex32-2_cleneinc.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline;text-decoration: none">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></span></a></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Instance Document.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 103; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"><a href="#toc">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_019"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CLENE INC.</b></span></td></tr>
  <tr>
    <td style="width: 60%">&#160;</td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 35%">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: November 8, 2021</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Robert Etherington</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&#160;&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert Etherington</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President, Chief Executive Officer and&#160;Director</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: November 8, 2021</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Ted (Tae Heum) Jeong</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ted (Tae Heum) Jeong</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>
</div><p style="margin: 0">&#160;</p><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0">102</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c3" id="hidden-fact-0" name="us-gaap:RestrictedCashNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-1" name="us-gaap:DerivativeLiabilitiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-2" name="us-gaap:ConvertibleLongTermNotesPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-3" name="clnn:WarrantLiabilityNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-4" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-5" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-6" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-7" name="clnn:GainOnExtinguishmentOfNotesPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-8" name="clnn:GainOnExtinguishmentOfNotesPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-9" name="clnn:GainOnExtinguishmentOfNotesPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-10" name="clnn:LossOnExtinguishmentOfConvertibleNotesPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-11" name="clnn:LossOnExtinguishmentOfConvertibleNotesPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-12" name="us-gaap:GainLossOnContractTermination" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-13" name="us-gaap:GainLossOnContractTermination" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-14" name="us-gaap:GainLossOnContractTermination" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-15" name="clnn:ChangeInFairValueOfPreferredStockWarrantLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-16" name="clnn:ChangeInFairValueOfPreferredStockWarrantLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-17" name="clnn:ChangeInFairValueOfDerivativeLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-18" name="clnn:ChangeInFairValueOfDerivativeLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-19" name="clnn:ChangeInFairValueOfContingentEarnout" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-20" name="clnn:ChangeInFairValueOfContingentEarnout" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-21" name="clnn:ChangeInFairValueOfInitialShareholdersContingentEarnout" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-22" name="clnn:ChangeInFairValueOfInitialShareholdersContingentEarnout" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-23" name="clnn:ChangeInFairValueOfCommonStockWarrantLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-24" name="clnn:ChangeInFairValueOfCommonStockWarrantLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-25" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-26" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c15" id="hidden-fact-27" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c15" id="hidden-fact-28" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-29" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-30" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-31" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-32" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-33" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-34" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-35" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-36" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-37" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-38" name="clnn:ForeignCurrencyTranslationAdjustment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-39" name="clnn:ForeignCurrencyTranslationAdjustment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-40" name="clnn:ForeignCurrencyTranslationAdjustment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-41" name="clnn:ForeignCurrencyTranslationAdjustment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-42" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-43" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-44" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-45" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-46" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-47" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-48" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-49" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-50" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-51" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-52" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-53" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-54" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-55" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-56" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-57" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-58" name="us-gaap:StockIssuedDuringPeriodSharesOther" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-59" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-60" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-61" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-62" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-63" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c37" id="hidden-fact-64" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-65" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-66" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-67" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-68" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-69" name="clnn:ForeignCurrencyTranslationAdjustment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-70" name="clnn:ForeignCurrencyTranslationAdjustment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-71" name="clnn:ForeignCurrencyTranslationAdjustment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-72" name="clnn:ForeignCurrencyTranslationAdjustment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-73" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-74" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-75" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-76" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c38" id="hidden-fact-77" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c38" id="hidden-fact-78" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c44" id="hidden-fact-79" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c44" id="hidden-fact-80" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c45" id="hidden-fact-81" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-82" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c48" id="hidden-fact-83" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c44" id="hidden-fact-84" name="clnn:StockIssueDuringPeriodSharesExerciseOfWarrants" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c44" id="hidden-fact-85" name="clnn:StockIssuedDuringPeriodValueExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c45" id="hidden-fact-86" name="clnn:StockIssuedDuringPeriodValueExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-87" name="clnn:StockIssuedDuringPeriodValueExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c48" id="hidden-fact-88" name="clnn:StockIssuedDuringPeriodValueExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c44" id="hidden-fact-89" name="clnn:StockIssuedDuringPeriodExerciseOfUnderwritersOptioninShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c44" id="hidden-fact-90" name="clnn:StockIssuedDuringPeriodExerciseOfUnderwritersOption" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c45" id="hidden-fact-91" name="clnn:StockIssuedDuringPeriodExerciseOfUnderwritersOption" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c46" id="hidden-fact-92" name="clnn:StockIssuedDuringPeriodExerciseOfUnderwritersOption" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-93" name="clnn:StockIssuedDuringPeriodExerciseOfUnderwritersOption" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c48" id="hidden-fact-94" name="clnn:StockIssuedDuringPeriodExerciseOfUnderwritersOption" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-95" name="clnn:StockIssuedDuringPeriodExerciseOfUnderwritersOption" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c44" id="hidden-fact-96" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c45" id="hidden-fact-97" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-98" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c48" id="hidden-fact-99" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c44" id="hidden-fact-100" name="us-gaap:StockIssuedDuringPeriodSharesOther" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c44" id="hidden-fact-101" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c45" id="hidden-fact-102" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c46" id="hidden-fact-103" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-104" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c48" id="hidden-fact-105" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-106" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c44" id="hidden-fact-107" name="clnn:ForeignCurrencyTranslationAdjustment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c45" id="hidden-fact-108" name="clnn:ForeignCurrencyTranslationAdjustment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c46" id="hidden-fact-109" name="clnn:ForeignCurrencyTranslationAdjustment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-110" name="clnn:ForeignCurrencyTranslationAdjustment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c44" id="hidden-fact-111" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c45" id="hidden-fact-112" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c46" id="hidden-fact-113" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c48" id="hidden-fact-114" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-115" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c60" id="hidden-fact-116" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c61" id="hidden-fact-117" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c63" id="hidden-fact-118" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c64" id="hidden-fact-119" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c60" id="hidden-fact-120" name="clnn:ForeignCurrencyTranslationAdjustment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c61" id="hidden-fact-121" name="clnn:ForeignCurrencyTranslationAdjustment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c62" id="hidden-fact-122" name="clnn:ForeignCurrencyTranslationAdjustment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c63" id="hidden-fact-123" name="clnn:ForeignCurrencyTranslationAdjustment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c60" id="hidden-fact-124" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c61" id="hidden-fact-125" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c62" id="hidden-fact-126" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c64" id="hidden-fact-127" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c72" id="hidden-fact-128" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c73" id="hidden-fact-129" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c75" id="hidden-fact-130" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c76" id="hidden-fact-131" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c72" id="hidden-fact-132" name="clnn:ForeignCurrencyTranslationAdjustment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c73" id="hidden-fact-133" name="clnn:ForeignCurrencyTranslationAdjustment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c74" id="hidden-fact-134" name="clnn:ForeignCurrencyTranslationAdjustment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c75" id="hidden-fact-135" name="clnn:ForeignCurrencyTranslationAdjustment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c72" id="hidden-fact-136" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c73" id="hidden-fact-137" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c74" id="hidden-fact-138" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c76" id="hidden-fact-139" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c85" id="hidden-fact-140" name="clnn:StockIssuedDuringPeriodSharesSeriesDPreferredStock" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c85" id="hidden-fact-141" name="clnn:StockIssuedDuringPeriodOfSeriesDPreferredStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c86" id="hidden-fact-142" name="clnn:StockIssuedDuringPeriodOfSeriesDPreferredStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c87" id="hidden-fact-143" name="clnn:StockIssuedDuringPeriodOfSeriesDPreferredStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c88" id="hidden-fact-144" name="clnn:StockIssuedDuringPeriodOfSeriesDPreferredStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-145" name="clnn:StockIssuedDuringPeriodOfSeriesDPreferredStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c85" id="hidden-fact-146" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c85" id="hidden-fact-147" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c86" id="hidden-fact-148" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c87" id="hidden-fact-149" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c88" id="hidden-fact-150" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-151" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c84" id="hidden-fact-152" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c84" id="hidden-fact-153" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c85" id="hidden-fact-154" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c87" id="hidden-fact-155" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c88" id="hidden-fact-156" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c84" id="hidden-fact-157" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c85" id="hidden-fact-158" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c87" id="hidden-fact-159" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c88" id="hidden-fact-160" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c84" id="hidden-fact-161" name="clnn:ForeignCurrencyTranslationAdjustment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c85" id="hidden-fact-162" name="clnn:ForeignCurrencyTranslationAdjustment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c86" id="hidden-fact-163" name="clnn:ForeignCurrencyTranslationAdjustment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c87" id="hidden-fact-164" name="clnn:ForeignCurrencyTranslationAdjustment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c84" id="hidden-fact-165" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c85" id="hidden-fact-166" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c86" id="hidden-fact-167" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c88" id="hidden-fact-168" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-169" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-170" name="clnn:ChangeInFairValueOfCleneNanomedicineContingentEarnouts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-171" name="clnn:ChangesInFairValueOfInitialShareholdersContingentEarnout" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-172" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-173" name="clnn:ChangeInFairValueOfCommonStockWarrantLiabilitys" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-174" name="us-gaap:GainLossOnTerminationOfLease" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-175" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-176" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-177" name="us-gaap:AmortizationOfDebtDiscountPremium" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-178" name="us-gaap:IncreaseDecreaseInDueToRelatedParties" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-179" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-180" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-181" name="us-gaap:ProceedsFromConvertibleDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-182" name="us-gaap:ProceedsFromWarrantExercises" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-183" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-184" name="us-gaap:PaymentsOfDebtIssuanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-185" name="us-gaap:RepaymentsOfNotesPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-186" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c94" id="hidden-fact-187" name="us-gaap:RestrictedCash" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-188" name="clnn:WarrantLiabilityRecordedAtIssuanceOfNotesPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-189" name="clnn:LeaseLiabilitySettledThroughTerminationOfLease" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-190" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-191" name="clnn:IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-192" name="clnn:ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-193" name="clnn:DeferredOfferingCostsInAccruedLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-194" name="clnn:DirectorsOfficersInsurance" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-195" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-196" name="clnn:AccruedTransactionCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c151" id="hidden-fact-197" name="us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFourYears" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c151" id="hidden-fact-198" name="us-gaap:CapitalLeasesFutureMinimumPaymentsDueThereafter" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c151" id="hidden-fact-199" name="clnn:CapitalLeasesFutureLeaseIncentives" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-200" name="clnn:FinanceLeaseWorkInProcessGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c187" id="hidden-fact-201" name="clnn:TotalTermLoans" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c191" id="hidden-fact-202" name="clnn:TotalTermLoans" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c193" id="hidden-fact-203" name="clnn:TotalTermLoans" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-204" name="us-gaap:UnamortizedDebtIssuanceExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-205" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-206" name="clnn:DebtInstrumentUnamortizedDiscountRemainderOfFiscalYear" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-207" name="clnn:DebtInstrumentUnamortizedDiscountYearOne" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-208" name="clnn:DebtInstrumentUnamortizedDiscountYearFour" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-209" name="clnn:DebtInstrumentUnamortizedDiscountYearFive" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-210" name="clnn:DebtInstrumentThereafter" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c195" id="hidden-fact-211" name="us-gaap:WarrantsAndRightsOutstandingTerm">P10Y</ix:nonNumeric>
<ix:nonFraction contextRef="c0" id="hidden-fact-212" name="clnn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueGranted" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" id="hidden-fact-213" name="clnn:WeightedAverageRemainingTermYearsExercised" xsi:nil="true"></ix:nonNumeric>
<ix:nonNumeric contextRef="c0" id="hidden-fact-214" name="clnn:WeightedAverageRemainingTermYearsForfeited" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c0" id="hidden-fact-215" name="clnn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c252" id="hidden-fact-216" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c262" id="hidden-fact-217" name="us-gaap:NotesPayableFairValueDisclosure" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c263" id="hidden-fact-218" name="us-gaap:NotesPayableFairValueDisclosure" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c261" id="hidden-fact-219" name="us-gaap:DerivativeLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c262" id="hidden-fact-220" name="us-gaap:DerivativeLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c261" id="hidden-fact-221" name="clnn:CleneNanomedicineContingentEarnoutFairValueDisclosure" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c262" id="hidden-fact-222" name="clnn:CleneNanomedicineContingentEarnoutFairValueDisclosure" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c261" id="hidden-fact-223" name="clnn:InitialShareholdersContingentEarnoutFairValueDisclosure" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c262" id="hidden-fact-224" name="clnn:InitialShareholdersContingentEarnoutFairValueDisclosure" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c265" id="hidden-fact-225" name="us-gaap:NotesPayableFairValueDisclosure" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c266" id="hidden-fact-226" name="us-gaap:NotesPayableFairValueDisclosure" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c264" id="hidden-fact-227" name="clnn:CleneNanomedicineContingentEarnoutFairValueDisclosure" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c265" id="hidden-fact-228" name="clnn:CleneNanomedicineContingentEarnoutFairValueDisclosure" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c264" id="hidden-fact-229" name="clnn:InitialShareholdersContingentEarnoutFairValueDisclosure" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c265" id="hidden-fact-230" name="clnn:InitialShareholdersContingentEarnoutFairValueDisclosure" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c268" id="hidden-fact-231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c268" id="hidden-fact-232" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c268" id="hidden-fact-233" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c268" id="hidden-fact-234" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c270" id="hidden-fact-235" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c270" id="hidden-fact-236" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c270" id="hidden-fact-237" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c270" id="hidden-fact-238" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c272" id="hidden-fact-239" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c272" id="hidden-fact-240" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c272" id="hidden-fact-241" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c272" id="hidden-fact-242" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c277" id="hidden-fact-243" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c277" id="hidden-fact-244" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c277" id="hidden-fact-245" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c277" id="hidden-fact-246" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c284" id="hidden-fact-247" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c285" id="hidden-fact-248" name="clnn:InitialFairValueOfInstrument" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c286" id="hidden-fact-249" name="clnn:InitialFairValueOfInstrument" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c287" id="hidden-fact-250" name="clnn:InitialFairValueOfInstrument" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c294" id="hidden-fact-251" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c296" id="hidden-fact-252" name="clnn:FairValueIssuanceOfConvertiblePromissoryNotes" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c298" id="hidden-fact-253" name="clnn:FairValueIssuanceOfConvertiblePromissoryNotes" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c296" id="hidden-fact-254" name="clnn:FairValueMeasurementExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c298" id="hidden-fact-255" name="clnn:FairValueMeasurementExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c300" id="hidden-fact-256" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c313" id="hidden-fact-257" name="clnn:EffectOfPotentiallyDilutiveStockOptionsinDollars" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c314" id="hidden-fact-258" name="clnn:EffectOfPotentiallyDilutiveStockOptionsinDollars" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c315" id="hidden-fact-259" name="clnn:EffectOfPotentiallyDilutiveStockOptionsinDollars" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c313" id="hidden-fact-260" name="clnn:EffectOfPotentiallyDilutiveRestrictedStockAwards" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c314" id="hidden-fact-261" name="clnn:EffectOfPotentiallyDilutiveRestrictedStockAwards" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c315" id="hidden-fact-262" name="clnn:EffectOfPotentiallyDilutiveRestrictedStockAwards" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c313" id="hidden-fact-263" name="clnn:EffectOfPotentiallyDilutiveConvertibleNotesPayable" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c314" id="hidden-fact-264" name="clnn:EffectOfPotentiallyDilutiveConvertibleNotesPayable" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c315" id="hidden-fact-265" name="clnn:EffectOfPotentiallyDilutiveConvertibleNotesPayable" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c313" id="hidden-fact-266" name="clnn:EffectOfPotentiallyDilutiveUnvestedRestrictedStockAwardsShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c314" id="hidden-fact-267" name="clnn:EffectOfPotentiallyDilutiveUnvestedRestrictedStockAwardsShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c315" id="hidden-fact-268" name="clnn:EffectOfPotentiallyDilutiveUnvestedRestrictedStockAwardsShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-269" name="clnn:SeriesDRedeemableConvertiblePreferredStock" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-270" name="clnn:SeriesDRedeemableConvertiblePreferredStock" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-271" name="clnn:SeriesCRedeemableConvertiblePreferredStock" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-272" name="clnn:SeriesCRedeemableConvertiblePreferredStock" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-273" name="clnn:SeriesBRedeemableConvertiblePreferredStock" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-274" name="clnn:SeriesBRedeemableConvertiblePreferredStock" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-275" name="clnn:SeriesARedeemableConvertiblePreferredStock" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-276" name="clnn:SeriesARedeemableConvertiblePreferredStock" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-277" name="clnn:SeriesDRedeemableConvertiblePreferredStockWarrants" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-278" name="clnn:SeriesDRedeemableConvertiblePreferredStockWarrants" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-279" name="clnn:SeriesARedeemableConvertiblePreferredStockWarrantsinShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-280" name="clnn:SeriesARedeemableConvertiblePreferredStockWarrantsinShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-281" name="clnn:ConvertibleNotesPayables" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-282" name="clnn:ConvertibleNotesPayables" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-283" name="clnn:ConvertibleNotesPayables" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-284" name="clnn:CommonStockWarrants" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-285" name="clnn:CommonStockWarrants" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-286" name="clnn:UnvestedRestrictedStockAwardsShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-287" name="clnn:UnvestedRestrictedStockAwardsShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-288" name="clnn:ChardanUnitPurchaseOptionWarrants" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-289" name="clnn:ChardanUnitPurchaseOptionWarrants" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-290" name="clnn:CleneNanomedicineContingentEarnoutShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-291" name="clnn:CleneNanomedicineContingentEarnoutShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-292" name="clnn:InitialShareholdersContingentEarnoutShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-293" name="clnn:InitialShareholdersContingentEarnoutShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c316" id="hidden-fact-294" name="clnn:ExclusiveRightsIntellectualPropertyTerm">P5Y</ix:nonNumeric>
<ix:nonFraction contextRef="c322" id="hidden-fact-295" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c324" id="hidden-fact-296" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c326" id="hidden-fact-297" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c328" id="hidden-fact-298" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c330" decimals="-3" id="hidden-fact-299" name="clnn:TotalPropertyAndEquipmentNet" unitRef="usd">4038000</ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus">Q3</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey">0001822791</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="clnn-20210930.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><ix:relationship fromRefs="ix_0_fact ix_1_fact ix_2_fact ix_3_fact ix_4_fact ix_5_fact ix_6_fact ix_7_fact ix_8_fact ix_9_fact ix_10_fact ix_11_fact ix_12_fact ix_13_fact ix_14_fact ix_15_fact" toRefs="ix_0_footnote"></ix:relationship>
<ix:relationship fromRefs="ix_16_fact ix_17_fact ix_18_fact ix_19_fact ix_20_fact ix_21_fact ix_22_fact ix_23_fact ix_24_fact ix_25_fact ix_26_fact ix_27_fact ix_28_fact ix_29_fact ix_30_fact ix_31_fact ix_32_fact ix_33_fact ix_34_fact ix_35_fact ix_36_fact ix_37_fact ix_38_fact ix_39_fact ix_40_fact ix_41_fact hidden-fact-140 hidden-fact-141 hidden-fact-142 hidden-fact-143 hidden-fact-144 hidden-fact-145 ix_42_fact ix_43_fact hidden-fact-146 hidden-fact-147 hidden-fact-148 hidden-fact-149 hidden-fact-150 hidden-fact-151 hidden-fact-152 hidden-fact-153 ix_44_fact hidden-fact-154 ix_45_fact hidden-fact-155 hidden-fact-156 ix_46_fact ix_47_fact ix_48_fact ix_49_fact ix_50_fact ix_51_fact ix_52_fact ix_53_fact ix_54_fact" toRefs="ix_1_footnote"></ix:relationship>
<xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-11-04</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:CleneIncMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-02-16</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:TottenhamMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-02-16</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:CleneNanomedicineMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-02-16</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:PIPEMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-16</xbrli:startDate>
    <xbrli:endDate>2021-02-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:PIPEMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-07-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2021-07-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-05-18</xbrli:startDate>
    <xbrli:endDate>2021-05-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-05-18</xbrli:startDate>
    <xbrli:endDate>2021-05-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:CleneIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:CleneIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-12-01</xbrli:startDate>
    <xbrli:endDate>2020-12-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:CleneNanomedicineMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-12-01</xbrli:startDate>
    <xbrli:endDate>2020-12-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:CleneIncMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-12-01</xbrli:startDate>
    <xbrli:endDate>2020-12-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis">us-gaap:ExchangeClearedMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:CleneIncMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-12-01</xbrli:startDate>
    <xbrli:endDate>2020-12-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:CleneIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-12-01</xbrli:startDate>
    <xbrli:endDate>2020-12-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis">us-gaap:ExchangeClearedMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:CleneIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-12-01</xbrli:startDate>
    <xbrli:endDate>2020-12-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:CleneIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-12-01</xbrli:startDate>
    <xbrli:endDate>2020-12-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-12-01</xbrli:startDate>
    <xbrli:endDate>2020-12-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">clnn:ReverseRecapitalizationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:ChardanCapitalMarketsLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-07-15</xbrli:startDate>
    <xbrli:endDate>2018-08-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:ChardanCapitalMarketsLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-08-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:LifeSciCapitalLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-15</xbrli:startDate>
    <xbrli:endDate>2020-07-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:LifeSciCapitalLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:CleneIncMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:CleneNanomedicineMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:TottenhamMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:PIPEMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:PIPEMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:PIPEMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-09-01</xbrli:startDate>
    <xbrli:endDate>2021-09-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-09-01</xbrli:startDate>
    <xbrli:endDate>2021-09-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-10</xbrli:startDate>
    <xbrli:endDate>2021-07-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-07-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-01</xbrli:startDate>
    <xbrli:endDate>2020-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">clnn:FinanceLeasesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">clnn:OperatingLeasesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandNineteenMDLoanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-02-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandNineteenMDLoanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-02-01</xbrli:startDate>
    <xbrli:endDate>2019-02-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandNineteenMDLoanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandNineteenMDLoanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandNineteenMDLoanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSraqWjSnTNF4jeT3oaMW8W5R0MkiIXXy8k2PQbBklJ1lYSX00RI6mU1NUjmu2Z8DGiLsvWC/Nx+2e5I3XA4/waZZD17aBEHbiQmUEtZYNMriew3bFfu2eViLA2wfQ1rEEEBO8y7g2agPYYHRPjjYinU2cKZ+amGrmBSyV0SZoKs9f3ak4+Lf8OT2] CSR-->
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandNineteenMDLoanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandNineteenMDLoanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandNineteenMDLoanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandNineteenCecilLoanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandNineteenCecilLoanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-04-01</xbrli:startDate>
    <xbrli:endDate>2019-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandNineteenCecilLoanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandNineteenCecilLoanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandNineteenCecilLoanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandNineteenCecilLoanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c167">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandNineteenCecilLoanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c168">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandNineteenCecilLoanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c169">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:PaycheckProtectionProgramNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c170">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:PaycheckProtectionProgramNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-05-01</xbrli:startDate>
    <xbrli:endDate>2020-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c171">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:PaycheckProtectionProgramNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-15</xbrli:startDate>
    <xbrli:endDate>2021-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c172">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandtwentyoneAvenueLoanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c173">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandtwentyoneAvenueLoanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c174">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandtwentyoneAvenueLoanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-05-01</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c175">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandtwentyoneAvenueLoanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c176">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandtwentyoneAvenueLoanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c177">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandtwentyoneAvenueLoanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c178">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandtwentyoneAvenueLoanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c179">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandtwentyoneAvenueLoanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c180">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="clnn:TermLoansAxis">clnn:MarylandDepartmentOfHousingCommunityDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c181">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="clnn:TermLoansAxis">clnn:MarylandDepartmentOfHousingCommunityDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c182">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="clnn:TermLoansAxis">clnn:MarylandDepartmentOfHousingCommunityDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c183">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="clnn:TermLoansAxis">clnn:AdvanceCecilIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c184">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="clnn:TermLoansAxis">clnn:AdvanceCecilIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c185">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="clnn:TermLoansAxis">clnn:AdvanceCecilIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c186">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="clnn:TermLoansAxis">clnn:PaycheckProtectionProgramMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c187">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="clnn:TermLoansAxis">clnn:PaycheckProtectionProgramMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c188">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="clnn:TermLoansAxis">clnn:PaycheckProtectionProgramMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c189">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="clnn:TermLoansAxis">clnn:AvenueVentureOpportunitiesFundsLPMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c190">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="clnn:TermLoansAxis">clnn:AvenueVentureOpportunitiesFundsLPMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c191">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="clnn:TermLoansAxis">clnn:AvenueVentureOpportunitiesFundsLPMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c192">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="clnn:TermLoansAxis">clnn:OtherTermLoanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c193">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="clnn:TermLoansAxis">clnn:OtherTermLoanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c194">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="clnn:TermLoansAxis">clnn:OtherTermLoanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c195">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2013-04-08</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c196">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-01-01</xbrli:startDate>
    <xbrli:endDate>2019-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c197">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2013-04-08</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c198">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-01-01</xbrli:startDate>
    <xbrli:endDate>2019-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c199">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-08-04</xbrli:startDate>
    <xbrli:endDate>2020-08-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c200">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:PIPEWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c201">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:PIPEWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-12-01</xbrli:startDate>
    <xbrli:endDate>2020-12-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c202">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:PIPEWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c203">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:PIPEWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c204">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clnn:ChardanUnitPurchaseOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c205">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clnn:ChardanUnitPurchaseOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-07-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c206">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clnn:ChardanUnitPurchaseOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-07-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c207">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clnn:ChardanUnitPurchaseOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-07-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c208">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:CommonStockWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c209">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:AvenueLoanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c210">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:AvenueLoanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c211">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandtwentyoneAvenueLoanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c212">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantsDateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c213">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantsDateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c214">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantsDate1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c215">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantsDate1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c216">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:December20201Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c217">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:December20201Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c218">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantsDate2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c219">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantsDate2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c220">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:May2021Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c221">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:May2021Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c222">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantsDateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c223">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantsDateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c224">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantsDate1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c225">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantsDate1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c226">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:December20201Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c227">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:December20201Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c228">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantsDate2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c229">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantsDate2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c230">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-07-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c231">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2020-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c232">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c233">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c234">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-08-01</xbrli:startDate>
    <xbrli:endDate>2020-08-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c235">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-08-11</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c236">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c237">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c238">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandtwentyoneAvenueLoanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-05-01</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c239">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandtwentyoneAvenueLoanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c240">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandtwentyoneAvenueLoanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c241">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandtwentyoneAvenueLoanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c242">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-07-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c243">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c244">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:StockPlan2020Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c245">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:StockPlan2020Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c246">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clnn:StockPlan2020Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c247">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clnn:StockPlan2020Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c248">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:StockPlan2014Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c249">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:StockPlan2014Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c250">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clnn:StockPlan2014Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c251">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clnn:StockPlan2020Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c252">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c253">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c254">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c255">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c256">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c257">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c258">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c259">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c260">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c261">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c262">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c263">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c264">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c265">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c266">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c267">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">clnn:BlackScholesValuationModelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c268">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">clnn:BlackScholesValuationModelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c269">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">clnn:MonteCarloSimulationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c270">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">clnn:MonteCarloSimulationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c271">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantLiabilityMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">clnn:BlackScholesValuationModelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c272">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantLiabilityMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">clnn:BlackScholesValuationModelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c273">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantLiabilityMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">clnn:BlackScholesValuationModelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c274">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantLiabilityMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">clnn:BlackScholesValuationModelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c275">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantLiabilityMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">clnn:MonteCarloSimulationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c276">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantLiabilityMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">clnn:MonteCarloSimulationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c277">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantLiabilityMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">clnn:MonteCarloSimulationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c278">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantLiabilityMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">clnn:MonteCarloSimulationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c279">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">clnn:ContingentEarnOutMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c280">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">clnn:ContingentEarnOutMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c281">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c282">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:CleneNanomedicineContingentEarnoutMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c283">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:InitialShareholdersContingentEarnoutMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c284">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:WarrantLiabilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c285">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c286">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:CleneNanomedicineContingentEarnoutMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c287">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:InitialShareholdersContingentEarnoutMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c288">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:WarrantLiabilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c289">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c290">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:CleneNanomedicineContingentEarnoutMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c291">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:InitialShareholdersContingentEarnoutMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c292">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:WarrantLiabilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c293">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c294">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:DerivativeInstrumentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c295">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:PreferredStockWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c296">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c297">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:DerivativeInstrumentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c298">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:PreferredStockWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c299">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c300">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:DerivativeInstrumentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c301">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:PreferredStockWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c302">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertibleCommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c303">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-05-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c304">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-05-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c305">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-12-01</xbrli:startDate>
    <xbrli:endDate>2020-12-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c306">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c307">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">clnn:InvestorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-05-01</xbrli:startDate>
    <xbrli:endDate>2021-05-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c308">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2021-09-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c309">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-02</xbrli:startDate>
    <xbrli:endDate>2021-07-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c310">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:PIPEWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c311">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:PIPEWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c312">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">clnn:NetIncomeLossPerShareAttributableToCommonShareholdersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c313">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">clnn:NetIncomeLossPerShareAttributableToCommonShareholdersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c314">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">clnn:NetIncomeLossPerShareAttributableToCommonShareholdersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c315">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">clnn:NetIncomeLossPerShareAttributableToCommonShareholdersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c316">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-08-02</xbrli:startDate>
    <xbrli:endDate>2018-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c317">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c318">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c319">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c320">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c321">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c322">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">clnn:DrugsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c323">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">clnn:SupplementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c324">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">clnn:DrugsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c325">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">clnn:SupplementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c326">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">clnn:DrugsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c327">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">clnn:SupplementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c328">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">clnn:DrugsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c329">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">clnn:SupplementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c330">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">clnn:DrugsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c331">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">clnn:DrugsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c332">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">clnn:SupplementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c333">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">clnn:SupplementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c334">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:PIPEWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-10-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c335">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001822791</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-09-25</xbrli:startDate>
    <xbrli:endDate>2021-10-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>f10q0921ex31-1_cleneinc.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0in; text-align: right; background-color: white"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">I, Robert Etherington, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">I have reviewed this Quarterly Report on Form&nbsp;10-Q&nbsp;of Clene Inc.;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.25in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-size: 10pt">Date: November 8, 2021</FONT></TD>
    <TD STYLE="width: 40%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Robert Etherington</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Robert Etherington</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>f10q0921ex31-2_cleneinc.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><B>Exhibit
31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">I, Ted (Tae Heum) Jeong, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">I have reviewed this Quarterly Report on Form&nbsp;10-Q&nbsp;of Clene Inc.;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and&nbsp;15d-15(e))&nbsp;and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.25in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-size: 10pt">Date: November 8, 2021</FONT></TD>
    <TD STYLE="width: 40%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Ted (Tae Heum) Jeong</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Ted (Tae Heum) Jeong</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>f10q0921ex32-1_cleneinc.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Pursuant to the requirement set forth in Rule&nbsp;13a-14(b)&nbsp;of
the Securities Exchange Act of 1934, as amended, (the &ldquo;Exchange Act&rdquo;) and Section&nbsp;1350 of Chapter 63 of Title 18 of the
United States Code (18 U.S.C. &sect;1350),<B>&nbsp;</B>Robert Etherington, Chief Executive Officer of Clene Inc. (the &ldquo;Company&rdquo;),
hereby certifies that, to the best of his knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>1.</B></FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">The Company&rsquo;s Quarterly Report on Form&nbsp;10-Q&nbsp;for the period ended September 30, 2021, to which this Certification is attached as Exhibit 32.1 (the &ldquo;Quarterly Report&rdquo;), fully complies with the requirements of Section&nbsp;13(a) or Section&nbsp;15(d) of the Exchange Act; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>2.</B></FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-size: 10pt">Dated: November 8, 2021</FONT></TD>
    <TD STYLE="width: 40%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Robert Etherington</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Robert Etherington</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">A signed original of this written statement
required by Section&nbsp;906 of 18 U.S.C. &sect;&nbsp;1350 has been provided to the Company, and will be retained by the Company and furnished
to the Securities and Exchange Commission or its staff upon request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">This certification accompanies the Form&nbsp;10-Q&nbsp;to
which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any
filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the
Form&nbsp;10-Q),&nbsp;irrespective of any general incorporation language contained in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>f10q0921ex32-2_cleneinc.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><B>Exhibit
32.2&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Pursuant to the requirement set forth in Rule&nbsp;13a-14(b)&nbsp;of
the Securities Exchange Act of 1934, as amended, (the &ldquo;Exchange Act&rdquo;) and Section&nbsp;1350 of Chapter 63 of Title 18 of the
United States Code (18 U.S.C. &sect;1350),<B>&nbsp;</B>Ted (Tae Heum) Jeong, Chief Financial Officer of Clene Inc. (the &ldquo;Company&rdquo;),
hereby certifies that, to the best of his knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>1.</B></FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">The Company&rsquo;s Quarterly Report on Form&nbsp;10-Q&nbsp;for the period ended September 30, 2021, to which this Certification is attached as Exhibit 32.2 (the &ldquo;Quarterly Report&rdquo;), fully complies with the requirements of Section&nbsp;13(a) or Section&nbsp;15(d) of the Exchange Act; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>2.</B></FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-size: 10pt">Dated: November 8, 2021</FONT></TD>
    <TD STYLE="width: 40%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Ted (Tae Heum) Jeong</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Ted (Tae Heum) Jeong</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4in; text-indent: -12.25pt; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">A signed original of this written statement
required by Section&nbsp;906 of 18 U.S.C. &sect;&nbsp;1350 has been provided to the Company, and will be retained by the Company and furnished
to the Securities and Exchange Commission or its staff upon request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">This certification accompanies the Form&nbsp;10-Q&nbsp;to
which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any
filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the
Form&nbsp;10-Q),&nbsp;irrespective of any general incorporation language contained in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>clnn-20210930.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Nov 08 18:21:45 UTC 2021 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" targetNamespace="http://www.cleaninccom/20210930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:clnn="http://www.cleaninccom/20210930" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="clnn-20210930_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="clnn-20210930_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="clnn-20210930_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="clnn-20210930_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.cleaninccom/role/ConsolidatedBalanceSheet" id="clnn_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ConsolidatedBalanceSheet_Parentheticals" id="clnn_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ConsolidatedIncomeStatement" id="clnn_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ShareholdersEquityType2or3" id="clnn_r_ShareholdersEquityType2or3">
        <link:definition>004 - Statement - Condensed Consolidated Statements Of Stockholders' Equity (Deficit) (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ShareholdersEquityType2or3_Parentheticals" id="clnn_r_ShareholdersEquityType2or3_Parentheticals">
        <link:definition>005 - Statement - Condensed Consolidated Statements Of Stockholders' Equity (Deficit) (Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ConsolidatedCashFlow" id="clnn_r_ConsolidatedCashFlow">
        <link:definition>006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/NatureoftheBusiness" id="clnn_r_NatureoftheBusiness">
        <link:definition>007 - Disclosure - Nature of the Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/SummaryofSignificantAccountingPolicies" id="clnn_r_SummaryofSignificantAccountingPolicies">
        <link:definition>008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicine" id="clnn_r_ReverseRecapitalizationwithTottenhamandCleneNanomedicine">
        <link:definition>009 - Disclosure - Reverse Recapitalization with Tottenham and Clene Nanomedicine</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/PrepaidExpensesandOtherCurrentAssets" id="clnn_r_PrepaidExpensesandOtherCurrentAssets">
        <link:definition>010 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/PropertyandEquipmentNet" id="clnn_r_PropertyandEquipmentNet">
        <link:definition>011 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/AccruedLiabilities" id="clnn_r_AccruedLiabilities">
        <link:definition>012 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/Leases" id="clnn_r_Leases">
        <link:definition>013 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/NotesPayable" id="clnn_r_NotesPayable">
        <link:definition>014 - Disclosure - Notes Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/PreferredStockWarrantLiability" id="clnn_r_PreferredStockWarrantLiability">
        <link:definition>015 - Disclosure - Preferred Stock Warrant Liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/CommonStockWarrants" id="clnn_r_CommonStockWarrants">
        <link:definition>016 - Disclosure - Common Stock Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ConvertibleNotes" id="clnn_r_ConvertibleNotes">
        <link:definition>017 - Disclosure - Convertible Notes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/DerivativeInstruments" id="clnn_r_DerivativeInstruments">
        <link:definition>018 - Disclosure - Derivative Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/CommitmentsandContingencies" id="clnn_r_CommitmentsandContingencies">
        <link:definition>019 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/IncomeTaxes" id="clnn_r_IncomeTaxes">
        <link:definition>020 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/StockBasedCompensation" id="clnn_r_StockBasedCompensation">
        <link:definition>021 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/FairValue" id="clnn_r_FairValue">
        <link:definition>022 - Disclosure - Fair Value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/RedeemableConvertiblePreferredStock" id="clnn_r_RedeemableConvertiblePreferredStock">
        <link:definition>023 - Disclosure - Redeemable Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/CommonStock" id="clnn_r_CommonStock">
        <link:definition>024 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/NetIncomeLossPerShareAttributabletoCommonShareholders" id="clnn_r_NetIncomeLossPerShareAttributabletoCommonShareholders">
        <link:definition>025 - Disclosure - Net Income (Loss) Per Share Attributable to Common Shareholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/RelatedPartyTransactions" id="clnn_r_RelatedPartyTransactions">
        <link:definition>026 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/GeographicandSegmentInformation" id="clnn_r_GeographicandSegmentInformation">
        <link:definition>027 - Disclosure - Geographic and Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/SubsequentEvents" id="clnn_r_SubsequentEvents">
        <link:definition>028 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/AccountingPoliciesByPolicy" id="clnn_r_AccountingPoliciesByPolicy">
        <link:definition>029 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/PrepaidExpensesandOtherCurrentAssetsTables" id="clnn_r_PrepaidExpensesandOtherCurrentAssetsTables">
        <link:definition>030 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/PropertyandEquipmentNetTables" id="clnn_r_PropertyandEquipmentNetTables">
        <link:definition>031 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/AccruedLiabilitiesTables" id="clnn_r_AccruedLiabilitiesTables">
        <link:definition>032 - Disclosure - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/LeasesTables" id="clnn_r_LeasesTables">
        <link:definition>033 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/NotesPayableTables" id="clnn_r_NotesPayableTables">
        <link:definition>034 - Disclosure - Notes Payable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/CommonStockWarrantsTables" id="clnn_r_CommonStockWarrantsTables">
        <link:definition>035 - Disclosure - Common Stock Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/IncomeTaxesTables" id="clnn_r_IncomeTaxesTables">
        <link:definition>036 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/StockBasedCompensationTables" id="clnn_r_StockBasedCompensationTables">
        <link:definition>037 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/FairValueTables" id="clnn_r_FairValueTables">
        <link:definition>038 - Disclosure - Fair Value (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/NetIncomeLossPerShareAttributabletoCommonShareholdersTables" id="clnn_r_NetIncomeLossPerShareAttributabletoCommonShareholdersTables">
        <link:definition>039 - Disclosure - Net Income (Loss) Per Share Attributable to Common Shareholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/GeographicandSegmentInformationTables" id="clnn_r_GeographicandSegmentInformationTables">
        <link:definition>040 - Disclosure - Geographic and Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/NatureoftheBusinessDetails" id="clnn_r_NatureoftheBusinessDetails">
        <link:definition>041 - Disclosure - Nature of the Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/SummaryofSignificantAccountingPoliciesDetails" id="clnn_r_SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>042 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails" id="clnn_r_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails">
        <link:definition>043 - Disclosure - Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleofprepaidexpensesandothercurrentassetsTable" id="clnn_r_ScheduleofprepaidexpensesandothercurrentassetsTable">
        <link:definition>044 - Disclosure - Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/PropertyandEquipmentNetDetails" id="clnn_r_PropertyandEquipmentNetDetails">
        <link:definition>045 - Disclosure - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetTable" id="clnn_r_ScheduleofpropertyandequipmentnetTable">
        <link:definition>046 - Disclosure - Property and Equipment, Net (Details) - Schedule of property and equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleofaccruedliabilitiesTable" id="clnn_r_ScheduleofaccruedliabilitiesTable">
        <link:definition>047 - Disclosure - Accrued Liabilities (Details) - Schedule of accrued liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/LeasesDetails" id="clnn_r_LeasesDetails">
        <link:definition>048 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable" id="clnn_r_ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable">
        <link:definition>049 - Disclosure - Leases (Details) - Schedule of noncancelable finance and operating lease liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleoffinanceleaseobligationsincludedinpropertyandequipmentTable" id="clnn_r_ScheduleoffinanceleaseobligationsincludedinpropertyandequipmentTable">
        <link:definition>050 - Disclosure - Leases (Details) - Schedule of finance lease obligations included in property and equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleoffinanceandoperatingleasecostsTable" id="clnn_r_ScheduleoffinanceandoperatingleasecostsTable">
        <link:definition>051 - Disclosure - Leases (Details) - Schedule of finance and operating lease costs</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleofsupplementalcashflowinformationTable" id="clnn_r_ScheduleofsupplementalcashflowinformationTable">
        <link:definition>052 - Disclosure - Leases (Details) - Schedule of supplemental cash flow information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/NotesPayableDetails" id="clnn_r_NotesPayableDetails">
        <link:definition>053 - Disclosure - Notes Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleoflongtermdebtnetoforiginalissuediscountandunamortizeddebtissuancecostsTable" id="clnn_r_ScheduleoflongtermdebtnetoforiginalissuediscountandunamortizeddebtissuancecostsTable">
        <link:definition>054 - Disclosure - Notes Payable (Details) - Schedule of long-term debt, net of original issue discount and unamortized debt issuance costs</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleoffuturepaymentsnetofunamortizeddebtdiscountsTable" id="clnn_r_ScheduleoffuturepaymentsnetofunamortizeddebtdiscountsTable">
        <link:definition>055 - Disclosure - Notes Payable (Details) - Schedule of future payments, net of unamortized debt discounts</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/PreferredStockWarrantLiabilityDetails" id="clnn_r_PreferredStockWarrantLiabilityDetails">
        <link:definition>056 - Disclosure - Preferred Stock Warrant Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/CommonStockWarrantsDetails" id="clnn_r_CommonStockWarrantsDetails">
        <link:definition>057 - Disclosure - Common Stock Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleofoutstandingwarrantstopurchasesharesofcommonstockTable" id="clnn_r_ScheduleofoutstandingwarrantstopurchasesharesofcommonstockTable">
        <link:definition>058 - Disclosure - Common Stock Warrants (Details) - Schedule of outstanding warrants to purchase shares of common stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ConvertibleNotesDetails" id="clnn_r_ConvertibleNotesDetails">
        <link:definition>059 - Disclosure - Convertible Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/DerivativeInstrumentsDetails" id="clnn_r_DerivativeInstrumentsDetails">
        <link:definition>060 - Disclosure - Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/IncomeTaxesDetails" id="clnn_r_IncomeTaxesDetails">
        <link:definition>061 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleofcomponentsofincomelossbeforeincometaxesTable" id="clnn_r_ScheduleofcomponentsofincomelossbeforeincometaxesTable">
        <link:definition>062 - Disclosure - Income Taxes (Details) - Schedule of components of income (loss) before income taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/StockBasedCompensationDetails" id="clnn_r_StockBasedCompensationDetails">
        <link:definition>063 - Disclosure - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleofstockbasedcompensationexpenseTable" id="clnn_r_ScheduleofstockbasedcompensationexpenseTable">
        <link:definition>064 - Disclosure - Stock-Based Compensation (Details) - Schedule of stock-based compensation expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleofoutstandingcommonstockoptionsandrelatedactivityTable" id="clnn_r_ScheduleofoutstandingcommonstockoptionsandrelatedactivityTable">
        <link:definition>065 - Disclosure - Stock-Based Compensation (Details) - Schedule of outstanding common stock options and related activity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsTable" id="clnn_r_ScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsTable">
        <link:definition>066 - Disclosure - Stock-Based Compensation (Details) - Schedule of assumptions used to calculate the fair value of stock options</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleofrestrictedcommonstockactivityTable" id="clnn_r_ScheduleofrestrictedcommonstockactivityTable">
        <link:definition>067 - Disclosure - Stock-Based Compensation (Details) - Schedule of restricted common stock activity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/FairValueDetails" id="clnn_r_FairValueDetails">
        <link:definition>068 - Disclosure - Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable" id="clnn_r_ScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable">
        <link:definition>069 - Disclosure - Fair Value (Details) - Schedule of fair value hierarchy of liabilities measured at fair value on recurring basis</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleofunobservableinputstotheconversionfeaturewarrantliabilityandcontingentearnoutvaluationmodelsTable" id="clnn_r_ScheduleofunobservableinputstotheconversionfeaturewarrantliabilityandcontingentearnoutvaluationmodelsTable">
        <link:definition>070 - Disclosure - Fair Value (Details) - Schedule of unobservable inputs to the conversion feature, warrant liability, and contingent earn-out valuation models</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsTable" id="clnn_r_ScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsTable">
        <link:definition>071 - Disclosure - Fair Value (Details) - Schedule of changes in fair value of financial liabilities related to the notes payable, the derivative instrument, the preferred stock warrants, and the contingent earn-outs</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSraqWjSnTNF4jeT3oaMW8W5R0MkiIXXy8k2PQbBklJ1lYSX00RI6mU1NUjmu2Z8DGiLsvWC/Nx+2e5I3XA4/waZZD17aBEHbiQmUEtZYNMriew3bFfu2eViLA2wfQ1rEEEBO8y7g2agPYYHRPjjYinU2diXExMT0U6XA9oDN2WtM4mvPR7Lhu4ZV] CSR-->
      <link:roleType roleURI="http://www.cleaninccom/role/RedeemableConvertiblePreferredStockDetails" id="clnn_r_RedeemableConvertiblePreferredStockDetails">
        <link:definition>072 - Disclosure - Redeemable Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/CommonStockDetails" id="clnn_r_CommonStockDetails">
        <link:definition>073 - Disclosure - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/NetIncomeLossPerShareAttributabletoCommonShareholdersDetails" id="clnn_r_NetIncomeLossPerShareAttributabletoCommonShareholdersDetails">
        <link:definition>074 - Disclosure - Net Income (Loss) Per Share Attributable to Common Shareholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleofbasicanddilutednetlosspershareTable" id="clnn_r_ScheduleofbasicanddilutednetlosspershareTable">
        <link:definition>075 - Disclosure - Net Income (Loss) Per Share Attributable to Common Shareholders (Details) - Schedule of basic and diluted net loss per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleofsecuritiesexcludedfromcomputationofdilutednetincomelosspershareTable" id="clnn_r_ScheduleofsecuritiesexcludedfromcomputationofdilutednetincomelosspershareTable">
        <link:definition>076 - Disclosure - Net Income (Loss) Per Share Attributable to Common Shareholders (Details) - Schedule of securities excluded from computation of diluted net income (loss) per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/RelatedPartyTransactionsDetails" id="clnn_r_RelatedPartyTransactionsDetails">
        <link:definition>077 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetbylocationTable" id="clnn_r_ScheduleofpropertyandequipmentnetbylocationTable">
        <link:definition>078 - Disclosure - Geographic and Segment Information (Details) - Schedule of property and equipment, net by location</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleofdrugsandsupplementssegmentsTable" id="clnn_r_ScheduleofdrugsandsupplementssegmentsTable">
        <link:definition>079 - Disclosure - Geographic and Segment Information (Details) - Schedule of drugs and supplements segments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetbysegmentTable" id="clnn_r_ScheduleofpropertyandequipmentnetbysegmentTable">
        <link:definition>080 - Disclosure - Geographic and Segment Information (Details) - Schedule of property and equipment, net by segment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/SubsequentEventsDetails" id="clnn_r_SubsequentEventsDetails">
        <link:definition>081 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cleaninccom/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2021" schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd"/>
  <xs:element name="ReverseRecapitalizationWithTottenhamAndCleneNanomedicineAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineAbstract"/>
  <xs:element name="PrepaidExpensesAndOtherCurrentAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_PrepaidExpensesAndOtherCurrentAssetsAbstract"/>
  <xs:element name="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfPropertyAndEquipmentNetAbstract"/>
  <xs:element name="ScheduleOfAccruedLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfAccruedLiabilitiesAbstract"/>
  <xs:element name="ScheduleOfNoncancelableFinanceAndOperatingLeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfNoncancelableFinanceAndOperatingLeaseLiabilitiesAbstract"/>
  <xs:element name="ScheduleOfFinanceLeaseObligationsIncludedInPropertyAndEquipmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfFinanceLeaseObligationsIncludedInPropertyAndEquipmentAbstract"/>
  <xs:element name="ScheduleOfFinanceAndOperatingLeaseCostsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfFinanceAndOperatingLeaseCostsAbstract"/>
  <xs:element name="ScheduleOfSupplementalCashFlowInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfSupplementalCashFlowInformationAbstract"/>
  <xs:element name="ScheduleOfLongTermDebtNetOfOriginalIssueDiscountAndUnamortizedDebtIssuanceCostsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfLongTermDebtNetOfOriginalIssueDiscountAndUnamortizedDebtIssuanceCostsAbstract"/>
  <xs:element name="ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscountsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscountsAbstract"/>
  <xs:element name="CommonStockWarrantsDisclosureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_CommonStockWarrantsDisclosureAbstract"/>
  <xs:element name="ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockAbstract"/>
  <xs:element name="ConvertibleNotesDisclosureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ConvertibleNotesDisclosureAbstract"/>
  <xs:element name="ScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesAbstract"/>
  <xs:element name="ScheduleOfStockBasedCompensationExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfStockBasedCompensationExpenseAbstract"/>
  <xs:element name="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract"/>
  <xs:element name="ScheduleOfAssumptionsUsedToCalculateTheFairValueOfStockOptionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfAssumptionsUsedToCalculateTheFairValueOfStockOptionsAbstract"/>
  <xs:element name="ScheduleOfRestrictedCommonStockActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfRestrictedCommonStockActivityAbstract"/>
  <xs:element name="ScheduleOfFairValueHierarchyOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfFairValueHierarchyOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract"/>
  <xs:element name="ScheduleOfUnobservableInputsToTheConversionFeatureWarrantLiabilityAndContingentEarnOutValuationModelsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfUnobservableInputsToTheConversionFeatureWarrantLiabilityAndContingentEarnOutValuationModelsAbstract"/>
  <xs:element name="ScheduleOfChangesInFairValueOfFinancialLiabilitiesRelatedToTheNotesPayableTheDerivativeInstrumentThePreferredStockWarrantsAndTheContingentEarnOutsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfChangesInFairValueOfFinancialLiabilitiesRelatedToTheNotesPayableTheDerivativeInstrumentThePreferredStockWarrantsAndTheContingentEarnOutsAbstract"/>
  <xs:element name="RedeemableConvertiblePreferredStockDisclosureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_RedeemableConvertiblePreferredStockDisclosureAbstract"/>
  <xs:element name="ScheduleOfBasicAndDilutedNetLossPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfBasicAndDilutedNetLossPerShareAbstract"/>
  <xs:element name="ScheduleOfSecuritiesExcludedFromComputationOfDilutedNetIncomeLossPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfSecuritiesExcludedFromComputationOfDilutedNetIncomeLossPerShareAbstract"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentNetByLocationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfPropertyAndEquipmentNetByLocationAbstract"/>
  <xs:element name="ScheduleOfDrugsAndSupplementsSegmentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfDrugsAndSupplementsSegmentsAbstract"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentNetBySegmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfPropertyAndEquipmentNetBySegmentAbstract"/>
  <xs:element name="NetIncomeLossPerCommonShareAttributableToCommonShareholdersNote191Abstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_NetIncomeLossPerCommonShareAttributableToCommonShareholdersNote191Abstract"/>
  <xs:element name="WeightedAverageNumberOfCommonSharesOutstanding1Abstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_WeightedAverageNumberOfCommonSharesOutstanding1Abstract"/>
  <xs:element name="TermLoansAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_TermLoansAbstract"/>
  <xs:element name="NumeratorAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_NumeratorAbstract"/>
  <xs:element name="DenominatorAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_DenominatorAbstract"/>
  <xs:element name="WeightedAverageEffectOfPotentiallyDilutiveSecuritiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_WeightedAverageEffectOfPotentiallyDilutiveSecuritiesAbstract"/>
  <xs:element name="NetIncomeLossPerShareAttributableToCommonShareholdersAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_NetIncomeLossPerShareAttributableToCommonShareholdersAbstract"/>
  <xs:element name="WarrantLiabilityNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_WarrantLiabilityNoncurrent"/>
  <xs:element name="InitialShareholdersContingentEarnout" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_InitialShareholdersContingentEarnout"/>
  <xs:element name="InterestIncomeexpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_InterestIncomeexpense"/>
  <xs:element name="GainOnExtinguishmentOfNotesPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_GainOnExtinguishmentOfNotesPayable"/>
  <xs:element name="LossOnExtinguishmentOfConvertibleNotesPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_LossOnExtinguishmentOfConvertibleNotesPayable"/>
  <xs:element name="ChangeInFairValueOfPreferredStockWarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_ChangeInFairValueOfPreferredStockWarrantLiability"/>
  <xs:element name="ChangeInFairValueOfDerivativeLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_ChangeInFairValueOfDerivativeLiability"/>
  <xs:element name="ChangeInFairValueOfContingentEarnout" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_ChangeInFairValueOfContingentEarnout"/>
  <xs:element name="ChangeInFairValueOfInitialShareholdersContingentEarnout" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout"/>
  <xs:element name="ChangeInFairValueOfCommonStockWarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_ChangeInFairValueOfCommonStockWarrantLiability"/>
  <xs:element name="AustraliaResearchAndDevelopmentCredit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_AustraliaResearchAndDevelopmentCredit"/>
  <xs:element name="ForeignCurrencyTranslationAdjustment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_ForeignCurrencyTranslationAdjustment"/>
  <xs:element name="StockIssuedDuringPeriodValueExerciseOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_StockIssuedDuringPeriodValueExerciseOfWarrants"/>
  <xs:element name="StockIssueDuringPeriodSharesExerciseOfWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_StockIssueDuringPeriodSharesExerciseOfWarrants"/>
  <xs:element name="StockIssuedDuringPeriodExerciseOfUnderwritersOption" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_StockIssuedDuringPeriodExerciseOfUnderwritersOption"/>
  <xs:element name="StockIssuedDuringPeriodExerciseOfUnderwritersOptioninShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_StockIssuedDuringPeriodExerciseOfUnderwritersOptioninShares"/>
  <xs:element name="StockIssuedDuringPeriodOfSeriesDPreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_StockIssuedDuringPeriodOfSeriesDPreferredStock"/>
  <xs:element name="StockIssuedDuringPeriodSharesSeriesDPreferredStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_StockIssuedDuringPeriodSharesSeriesDPreferredStock"/>
  <xs:element name="NetOfIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_NetOfIssuanceCosts"/>
  <xs:element name="ChangeInFairValueOfCleneNanomedicineContingentEarnouts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_ChangeInFairValueOfCleneNanomedicineContingentEarnouts"/>
  <xs:element name="ChangesInFairValueOfInitialShareholdersContingentEarnout" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_ChangesInFairValueOfInitialShareholdersContingentEarnout"/>
  <xs:element name="ChangeInFairValueOfCommonStockWarrantLiabilitys" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_ChangeInFairValueOfCommonStockWarrantLiabilitys"/>
  <xs:element name="IncreaseInInterestAccruedOnNotesPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_IncreaseInInterestAccruedOnNotesPayable"/>
  <xs:element name="WarrantLiabilityRecordedAtIssuanceOfNotesPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_WarrantLiabilityRecordedAtIssuanceOfNotesPayable"/>
  <xs:element name="LeaseLiabilitySettledThroughTerminationOfLease" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_LeaseLiabilitySettledThroughTerminationOfLease"/>
  <xs:element name="IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes"/>
  <xs:element name="ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN"/>
  <xs:element name="DeferredOfferingCostsInAccruedLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_DeferredOfferingCostsInAccruedLiabilities"/>
  <xs:element name="CashPaidForInterestExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_CashPaidForInterestExpense"/>
  <xs:element name="ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock"/>
  <xs:element name="PrepaidExpensesAndOtherCurrentAssetsTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
  <xs:element name="CommonStockWarrantsDisclosureTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_CommonStockWarrantsDisclosureTextBlock"/>
  <xs:element name="ConvertibleNotesDisclosureTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ConvertibleNotesDisclosureTextBlock"/>
  <xs:element name="RedeemableConvertiblePreferredStockDisclosureTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_RedeemableConvertiblePreferredStockDisclosureTextBlock"/>
  <xs:element name="RiskAndUncertaintiesPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_RiskAndUncertaintiesPolicyTextBlock"/>
  <xs:element name="DebtDiscountAndIssuanceCostsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_DebtDiscountAndIssuanceCostsPolicyTextBlock"/>
  <xs:element name="ConvertibleNotespolicytextblock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ConvertibleNotespolicytextblock"/>
  <xs:element name="DebtWithWarrantsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_DebtWithWarrantsPolicyTextBlock"/>
  <xs:element name="ContingentEarnoutPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ContingentEarnoutPolicyTextBlock"/>
  <xs:element name="CommonStockWarrantsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_CommonStockWarrantsPolicyTextBlock"/>
  <xs:element name="GrantFundingPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_GrantFundingPolicyTextBlock"/>
  <xs:element name="ClinicalTrialAccrualPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ClinicalTrialAccrualPolicyTextBlock"/>
  <xs:element name="NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock"/>
  <xs:element name="PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
  <xs:element name="AccruedLiabilitiesTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_AccruedLiabilitiesTablesTable"/>
  <xs:element name="AccruedLiabilitiesTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_AccruedLiabilitiesTablesLineItems"/>
  <xs:element name="FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock"/>
  <xs:element name="FinanceLeaseByMajorClassPropertyAndEquipmentTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_FinanceLeaseByMajorClassPropertyAndEquipmentTableTextBlock"/>
  <xs:element name="ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscounts" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscounts"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock"/>
  <xs:element name="AustraliaResearchAndDevelopmentCreditReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_AustraliaResearchAndDevelopmentCreditReceivable"/>
  <xs:element name="CROPrepayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_CROPrepayments"/>
  <xs:element name="MetalsToBeUsedInResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_MetalsToBeUsedInResearchAndDevelopment"/>
  <xs:element name="DirectorsOfficersInsurance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_DirectorsOfficersInsurance"/>
  <xs:element name="AccruedCROFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_AccruedCROFees"/>
  <xs:element name="DeferredGrantFunds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_DeferredGrantFunds"/>
  <xs:element name="AccruedExpenseReimbursements" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_AccruedExpenseReimbursements"/>
  <xs:element name="AccruedTransactionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_AccruedTransactionCosts"/>
  <xs:element name="LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable"/>
  <xs:element name="LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems"/>
  <xs:element name="CapitalLeasesAmountRepresentingInterestdiscounting" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_CapitalLeasesAmountRepresentingInterestdiscounting"/>
  <xs:element name="OperatingLeasesAmountRepresentingInterestdiscounting" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_OperatingLeasesAmountRepresentingInterestdiscounting"/>
  <xs:element name="CapitalLeasesFutureLeaseIncentives" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_CapitalLeasesFutureLeaseIncentives"/>
  <xs:element name="OperatingLeasesLessFutureLeaseIncentives" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_OperatingLeasesLessFutureLeaseIncentives"/>
  <xs:element name="FinanceLeaseLaboratoryEquipmentGross" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_FinanceLeaseLaboratoryEquipmentGross"/>
  <xs:element name="FinanceLeaseFurnitureAndFixturesGross" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_FinanceLeaseFurnitureAndFixturesGross"/>
  <xs:element name="FinanceLeaseWorkInProcessGross" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_FinanceLeaseWorkInProcessGross"/>
  <xs:element name="FinanceLeaseLiabilityGross" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_FinanceLeaseLiabilityGross"/>
  <xs:element name="AccumulatedDepreciationDepletionAndAmortizationLeases" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_AccumulatedDepreciationDepletionAndAmortizationLeases"/>
  <xs:element name="FinanceLeaseLiabilityNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_FinanceLeaseLiabilityNet"/>
  <xs:element name="OperatingCashFlowsFromOperatingLeases" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_OperatingCashFlowsFromOperatingLeases"/>
  <xs:element name="OperatingCashFlowsFromFinanceLeases" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_OperatingCashFlowsFromFinanceLeases"/>
  <xs:element name="FinanceCashFlowsFromFinanceLeases" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_FinanceCashFlowsFromFinanceLeases"/>
  <xs:element name="TermLoansDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_TermLoansDomain"/>
  <xs:element name="InterestRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_InterestRate"/>
  <xs:element name="TotalTermLoans" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_TotalTermLoans"/>
  <xs:element name="TotalNotesPayableAndConvertibleNotesPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_TotalNotesPayableAndConvertibleNotesPayable"/>
  <xs:element name="DebtInstrumentUnamortizedDiscountRemainderOfFiscalYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_DebtInstrumentUnamortizedDiscountRemainderOfFiscalYear"/>
  <xs:element name="DebtInstrumentUnamortizedDiscountYearOne" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_DebtInstrumentUnamortizedDiscountYearOne"/>
  <xs:element name="DebtInstrumentUnamortizedDiscountYearTwo" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_DebtInstrumentUnamortizedDiscountYearTwo"/>
  <xs:element name="DebtInstrumentUnamortizedDiscountYearThree" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_DebtInstrumentUnamortizedDiscountYearThree"/>
  <xs:element name="DebtInstrumentUnamortizedDiscountYearFour" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_DebtInstrumentUnamortizedDiscountYearFour"/>
  <xs:element name="DebtInstrumentUnamortizedDiscountYearFive" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_DebtInstrumentUnamortizedDiscountYearFive"/>
  <xs:element name="DebtInstrumentThereafter" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_DebtInstrumentThereafter"/>
  <xs:element name="FuturePrincipalPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_FuturePrincipalPayments"/>
  <xs:element name="NumberOfSharesIssuable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="clnn_NumberOfSharesIssuable"/>
  <xs:element name="CommonStockWarrantsExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="clnn_CommonStockWarrantsExercisePrice"/>
  <xs:element name="CommonStockWarrantsExercisable" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_CommonStockWarrantsExercisable"/>
  <xs:element name="CommonStockWarrantsClassification" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_CommonStockWarrantsClassification"/>
  <xs:element name="CommonStockWarrantsExpiration" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_CommonStockWarrantsExpiration"/>
  <xs:element name="TotalLossBeforeIncomeTaxes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_TotalLossBeforeIncomeTaxes"/>
  <xs:element name="StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable"/>
  <xs:element name="StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValue"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueGranted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueGranted"/>
  <xs:element name="ShareBasedCompensationArrangementNumberOfOptionsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ShareBasedCompensationArrangementNumberOfOptionsExercised"/>
  <xs:element name="WeightedAverageRemainingTermYearsExercised" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_WeightedAverageRemainingTermYearsExercised"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue"/>
  <xs:element name="WeightedAverageRemainingTermYearsForfeited" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_WeightedAverageRemainingTermYearsForfeited"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber"/>
  <xs:element name="WeightedAverageExercisePricePerShareOptionVestedAndExercisable" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="clnn_WeightedAverageExercisePricePerShareOptionVestedAndExercisable"/>
  <xs:element name="WeightedAverageExercisePriceWeightedAverageRemainingTermYearsOptionsVestedAndEexercisableEnding" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_WeightedAverageExercisePriceWeightedAverageRemainingTermYearsOptionsVestedAndEexercisableEnding"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueIntrinsicValueOptionsVestedAndExercisableEnding" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueIntrinsicValueOptionsVestedAndExercisableEnding"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm1" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm1"/>
  <xs:element name="IntrinsicValueStockOptionsVestedAndExpectedToVestIntrinsicValueOptionsV" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_IntrinsicValueStockOptionsVestedAndExpectedToVestIntrinsicValueOptionsV"/>
  <xs:element name="StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsTable"/>
  <xs:element name="StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsLineItems"/>
  <xs:element name="StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityTable"/>
  <xs:element name="StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems"/>
  <xs:element name="FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable"/>
  <xs:element name="FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems"/>
  <xs:element name="CleneNanomedicineContingentEarnoutFairValueDisclosure" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_CleneNanomedicineContingentEarnoutFairValueDisclosure"/>
  <xs:element name="InitialShareholdersContingentEarnoutFairValueDisclosure" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_InitialShareholdersContingentEarnoutFairValueDisclosure"/>
  <xs:element name="FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsTable"/>
  <xs:element name="FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsLineItems"/>
  <xs:element name="InitialFairValueOfInstrument" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_InitialFairValueOfInstrument"/>
  <xs:element name="IncreseDecreaseInFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_IncreseDecreaseInFairValue"/>
  <xs:element name="FairValueIssuanceOfConvertiblePromissoryNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_FairValueIssuanceOfConvertiblePromissoryNotes"/>
  <xs:element name="FairValueMeasurementExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_FairValueMeasurementExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN"/>
  <xs:element name="NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareTable"/>
  <xs:element name="NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareLineItems"/>
  <xs:element name="WeightedAverageSharesOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_WeightedAverageSharesOutstanding"/>
  <xs:element name="EffectOfPotentiallyDilutiveStockOptionsinDollars" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_EffectOfPotentiallyDilutiveStockOptionsinDollars"/>
  <xs:element name="EffectOfPotentiallyDilutiveRestrictedStockAwards" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_EffectOfPotentiallyDilutiveRestrictedStockAwards"/>
  <xs:element name="EffectOfPotentiallyDilutiveConvertibleNotesPayable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_EffectOfPotentiallyDilutiveConvertibleNotesPayable"/>
  <xs:element name="EffectOfPotentiallyDilutiveUnvestedRestrictedStockAwardsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_EffectOfPotentiallyDilutiveUnvestedRestrictedStockAwardsShares"/>
  <xs:element name="SeriesDRedeemableConvertiblePreferredStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_SeriesDRedeemableConvertiblePreferredStock"/>
  <xs:element name="SeriesCRedeemableConvertiblePreferredStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_SeriesCRedeemableConvertiblePreferredStock"/>
  <xs:element name="SeriesBRedeemableConvertiblePreferredStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_SeriesBRedeemableConvertiblePreferredStock"/>
  <xs:element name="SeriesARedeemableConvertiblePreferredStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_SeriesARedeemableConvertiblePreferredStock"/>
  <xs:element name="SeriesDRedeemableConvertiblePreferredStockWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_SeriesDRedeemableConvertiblePreferredStockWarrants"/>
  <xs:element name="SeriesARedeemableConvertiblePreferredStockWarrantsinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_SeriesARedeemableConvertiblePreferredStockWarrantsinShares"/>
  <xs:element name="ConvertibleNotesPayables" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ConvertibleNotesPayables"/>
  <xs:element name="CommonStockWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_CommonStockWarrants"/>
  <xs:element name="OptionsToPurchaseCommonStockinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_OptionsToPurchaseCommonStockinShares"/>
  <xs:element name="UnvestedRestrictedStockAwardsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_UnvestedRestrictedStockAwardsShares"/>
  <xs:element name="ChardanUnitPurchaseOptionWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ChardanUnitPurchaseOptionWarrants"/>
  <xs:element name="CleneNanomedicineContingentEarnoutShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_CleneNanomedicineContingentEarnoutShares"/>
  <xs:element name="InitialShareholdersContingentEarnoutShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_InitialShareholdersContingentEarnoutShares"/>
  <xs:element name="TotalDilutiveSecurities" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_TotalDilutiveSecurities"/>
  <xs:element name="GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationTable"/>
  <xs:element name="GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationLineItems"/>
  <xs:element name="GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentTable"/>
  <xs:element name="GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentLineItems"/>
  <xs:element name="TotalPropertyAndEquipmentNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_TotalPropertyAndEquipmentNet"/>
  <xs:element name="NatureoftheBusinessDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_NatureoftheBusinessDetailsTable"/>
  <xs:element name="NatureoftheBusinessDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_NatureoftheBusinessDetailsLineItems"/>
  <xs:element name="AggregateFutureProceedsWarrantsExercised" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_AggregateFutureProceedsWarrantsExercised"/>
  <xs:element name="OfferingCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_OfferingCost"/>
  <xs:element name="AggregateProceedsReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_AggregateProceedsReceived"/>
  <xs:element name="OfferingPricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_OfferingPricePerShare"/>
  <xs:element name="CommonStockUnderlyingWarrantOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_CommonStockUnderlyingWarrantOutstanding"/>
  <xs:element name="ShareIssuanceOfCommonStockPrivateOffering" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ShareIssuanceOfCommonStockPrivateOffering"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_SummaryofSignificantAccountingPoliciesDetailsTable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
  <xs:element name="GrantFundingRecognizedOnConditionalGrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_GrantFundingRecognizedOnConditionalGrants"/>
  <xs:element name="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable"/>
  <xs:element name="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems"/>
  <xs:element name="CommonStockParOrStatedValuesPerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="clnn_CommonStockParOrStatedValuesPerShare"/>
  <xs:element name="SharesCancelledUponReverseRecapitalization" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_SharesCancelledUponReverseRecapitalization"/>
  <xs:element name="InitialShareholdersContingentsEarnout" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_InitialShareholdersContingentsEarnout"/>
  <xs:element name="ExchangeOfSharesReceived" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ExchangeOfSharesReceived"/>
  <xs:element name="ReverseRecapitalizationExchangeRatio" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ReverseRecapitalizationExchangeRatio"/>
  <xs:element name="SharesHeldInEscrowPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_SharesHeldInEscrowPercentage"/>
  <xs:element name="SharesHeldInEscrow" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_SharesHeldInEscrow"/>
  <xs:element name="ExchangeRatioPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ExchangeRatioPercentage"/>
  <xs:element name="ProceedsFromReverseRecapitalization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_ProceedsFromReverseRecapitalization"/>
  <xs:element name="SaleOfUnitsNumberOfUnitsIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_SaleOfUnitsNumberOfUnitsIssued"/>
  <xs:element name="UnitsIssuedPricePerUnit" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="clnn_UnitsIssuedPricePerUnit"/>
  <xs:element name="ExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="clnn_ExercisePrice"/>
  <xs:element name="ServicesLetterAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ServicesLetterAgreementDescription"/>
  <xs:element name="WarrantsToPurchaseCommonStockIssuedAndOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="clnn_WarrantsToPurchaseCommonStockIssuedAndOutstanding"/>
  <xs:element name="AggregateGrossProceedWarrantsExercised" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_AggregateGrossProceedWarrantsExercised"/>
  <xs:element name="ChardanUnitPurchaseOption" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ChardanUnitPurchaseOption"/>
  <xs:element name="NetIssuanceSharesOfCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_NetIssuanceSharesOfCommonStock"/>
  <xs:element name="WarrantsToPurchaseSharesOfCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_WarrantsToPurchaseSharesOfCommonStock"/>
  <xs:element name="CleneNanomedicineContingentEarnOutMilestone1Shares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_CleneNanomedicineContingentEarnOutMilestone1Shares"/>
  <xs:element name="CleneNanomedicineContingentEarnoutMilestone1Price" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_CleneNanomedicineContingentEarnoutMilestone1Price"/>
  <xs:element name="CleneNanomedicineContingentEarnoutMilestone2Shares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_CleneNanomedicineContingentEarnoutMilestone2Shares"/>
  <xs:element name="CleneNanomedicineContingentEarnoutMilestone2Price" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_CleneNanomedicineContingentEarnoutMilestone2Price"/>
  <xs:element name="CleneNanomedicineContingentEarnoutMilestone3Shares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_CleneNanomedicineContingentEarnoutMilestone3Shares"/>
  <xs:element name="IncreaseInCleneNanomedicineContingentEarnoutSharesUponReverseRecapitalization" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_IncreaseInCleneNanomedicineContingentEarnoutSharesUponReverseRecapitalization"/>
  <xs:element name="TotalCleneNanomedicineContingentEarnoutShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_TotalCleneNanomedicineContingentEarnoutShares"/>
  <xs:element name="InitialShareholdersContingentEarnoutMilestone1Shares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_InitialShareholdersContingentEarnoutMilestone1Shares"/>
  <xs:element name="InitialShareholdersContingentEarnoutMilestone2Shares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_InitialShareholdersContingentEarnoutMilestone2Shares"/>
  <xs:element name="PropertyandEquipmentNetDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_PropertyandEquipmentNetDetailsTable"/>
  <xs:element name="PropertyandEquipmentNetDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_PropertyandEquipmentNetDetailsLineItems"/>
  <xs:element name="RemainingRightofuseAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_RemainingRightofuseAsset"/>
  <xs:element name="RecognizedGainOnOperatingLease" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_RecognizedGainOnOperatingLease"/>
  <xs:element name="RightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_RightOfUseAssets"/>
  <xs:element name="LeaseholdImprovements" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_LeaseholdImprovements"/>
  <xs:element name="IncreaseInRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_IncreaseInRightOfUseAssets"/>
  <xs:element name="IncreaseInLeaseholdImprovements" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_IncreaseInLeaseholdImprovements"/>
  <xs:element name="IncreaseInLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_IncreaseInLeaseLiability"/>
  <xs:element name="OperatingLeaseRightofUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_OperatingLeaseRightofUseAssets"/>
  <xs:element name="LeaseIncentiveRecordedConstructionInProgress" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_LeaseIncentiveRecordedConstructionInProgress"/>
  <xs:element name="FinanceLeaseObligationsWeightedaverageInterestRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="clnn_FinanceLeaseObligationsWeightedaverageInterestRate"/>
  <xs:element name="OperatingLeaseObligationsWeightedAverageInterestRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="clnn_OperatingLeaseObligationsWeightedAverageInterestRate"/>
  <xs:element name="NotesPayableDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_NotesPayableDetailsTable"/>
  <xs:element name="NotesPayableDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_NotesPayableDetailsLineItems"/>
  <xs:element name="SimpleInterestExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_SimpleInterestExpense"/>
  <xs:element name="FairValueOfLongTermNotesPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_FairValueOfLongTermNotesPayable"/>
  <xs:element name="PercentageOfLoanAmountUsedToPayrollExpenses" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_PercentageOfLoanAmountUsedToPayrollExpenses"/>
  <xs:element name="FundedAmountAtClosing" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_FundedAmountAtClosing"/>
  <xs:element name="AccruedDebtIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_AccruedDebtIssuanceCosts"/>
  <xs:element name="DebtInstrumentUnfundedBalance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_DebtInstrumentUnfundedBalance"/>
  <xs:element name="SecondLoanAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_SecondLoanAmount"/>
  <xs:element name="ConditionsForFutureFundingDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ConditionsForFutureFundingDescription"/>
  <xs:element name="RateOfInterestDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_RateOfInterestDescription"/>
  <xs:element name="AdditionalPaymentUponMaturityDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_AdditionalPaymentUponMaturityDescription"/>
  <xs:element name="WarrantToPurchaseShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_WarrantToPurchaseShares"/>
  <xs:element name="CommonStockAtAnExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_CommonStockAtAnExercisePrice"/>
  <xs:element name="Tranche2WarrantAdjustmentDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_Tranche2WarrantAdjustmentDescription"/>
  <xs:element name="ConversionPercentageOfCommonStockPriceForConvertibleNotePayable" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ConversionPercentageOfCommonStockPriceForConvertibleNotePayable"/>
  <xs:element name="TradingVolumeLimitForConversionOfConvertibleNotePayable" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_TradingVolumeLimitForConversionOfConvertibleNotePayable"/>
  <xs:element name="ThresholdForRemovalOfFinancialCovenantsDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ThresholdForRemovalOfFinancialCovenantsDescription"/>
  <xs:element name="MinimumCashBalanceForLoanCovenant" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_MinimumCashBalanceForLoanCovenant"/>
  <xs:element name="FairValueOfWarrant" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_FairValueOfWarrant"/>
  <xs:element name="DebtInstrumentFinancingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_DebtInstrumentFinancingCosts"/>
  <xs:element name="PreferredStockWarrantLiabilityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_PreferredStockWarrantLiabilityDetailsTable"/>
  <xs:element name="PreferredStockWarrantLiabilityDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_PreferredStockWarrantLiabilityDetailsLineItems"/>
  <xs:element name="SharesOfWarrantsExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_SharesOfWarrantsExercisable"/>
  <xs:element name="PercentOfFullydilutedEquityPurchasableUponExercise" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="clnn_PercentOfFullydilutedEquityPurchasableUponExercise"/>
  <xs:element name="LossInFairValueOfWarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_LossInFairValueOfWarrantLiability"/>
  <xs:element name="FairValueAdjustmentOfWarrantsOutstanding" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_FairValueAdjustmentOfWarrantsOutstanding"/>
  <xs:element name="CommonStockWarrantsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_CommonStockWarrantsDetailsTable"/>
  <xs:element name="CommonStockWarrantsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_CommonStockWarrantsDetailsLineItems"/>
  <xs:element name="PIPEWarrantsOwnershipLimit" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_PIPEWarrantsOwnershipLimit"/>
  <xs:element name="CompanyWarrantRedemptionRight" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_CompanyWarrantRedemptionRight"/>
  <xs:element name="ExercisePriceOfWarrantsDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ExercisePriceOfWarrantsDescription"/>
  <xs:element name="ConvertibleNotesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_ConvertibleNotesDetailsTable"/>
  <xs:element name="ConvertibleNotesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ConvertibleNotesDetailsLineItems"/>
  <xs:element name="DescriptionOfConvertibleNotes" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_DescriptionOfConvertibleNotes"/>
  <xs:element name="PercentageOfStockPrice" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_PercentageOfStockPrice"/>
  <xs:element name="DescriptionOfLossOnExtinguishment" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_DescriptionOfLossOnExtinguishment"/>
  <xs:element name="ConvertibleNotesPayableDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ConvertibleNotesPayableDescription"/>
  <xs:element name="LoanOutstanding" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_LoanOutstanding"/>
  <xs:element name="CouponInterestExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_CouponInterestExpense"/>
  <xs:element name="LossOnDerivativeInstruments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_LossOnDerivativeInstruments"/>
  <xs:element name="GainlossOnCleneNanomedicineContingentEarnout" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_GainlossOnCleneNanomedicineContingentEarnout"/>
  <xs:element name="GainlossOnInitialShareholdersContingentEarnout" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_GainlossOnInitialShareholdersContingentEarnout"/>
  <xs:element name="WarrantLiabilityFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_WarrantLiabilityFairValue"/>
  <xs:element name="Changeinfairvaluewarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_Changeinfairvaluewarrants"/>
  <xs:element name="StockBasedCompensationDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_StockBasedCompensationDetailsTable"/>
  <xs:element name="StockBasedCompensationDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_StockBasedCompensationDetailsLineItems"/>
  <xs:element name="MinimumFairMarketValueOfOptionGrantDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_MinimumFairMarketValueOfOptionGrantDescription"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants"/>
  <xs:element name="UnrecognizedStockbasedCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_UnrecognizedStockbasedCompensation"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm"/>
  <xs:element name="weightedAverageFairValuesOfOptionsGranted" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_weightedAverageFairValuesOfOptionsGranted"/>
  <xs:element name="RestrictedStockUnitsDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_RestrictedStockUnitsDescription"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm"/>
  <xs:element name="FairValueDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_FairValueDetailsTable"/>
  <xs:element name="FairValueDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_FairValueDetailsLineItems"/>
  <xs:element name="NotesPayableBasedOnClosingPrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_NotesPayableBasedOnClosingPrice"/>
  <xs:element name="FairValueAmortizedCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="clnn_FairValueAmortizedCost"/>
  <xs:element name="FairValueOfConvertibleNotesPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_FairValueOfConvertibleNotesPayable"/>
  <xs:element name="AdditionalWarrantToPurchaseShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_AdditionalWarrantToPurchaseShares"/>
  <xs:element name="RedeemableConvertiblePreferredStockDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_RedeemableConvertiblePreferredStockDetailsTable"/>
  <xs:element name="RedeemableConvertiblePreferredStockDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_RedeemableConvertiblePreferredStockDetailsLineItems"/>
  <xs:element name="CommonStockDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_CommonStockDetailsTable"/>
  <xs:element name="CommonStockDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_CommonStockDetailsLineItems"/>
  <xs:element name="PreferredStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_PreferredStockShares"/>
  <xs:element name="IssuanceOfCommonStockUponReverseRecapitalization" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_IssuanceOfCommonStockUponReverseRecapitalization"/>
  <xs:element name="RecapitalizationShare" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_RecapitalizationShare"/>
  <xs:element name="InvestorsPurchasedShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_InvestorsPurchasedShares"/>
  <xs:element name="NetProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_NetProceeds"/>
  <xs:element name="PrivatePlacementWarrantsDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_PrivatePlacementWarrantsDescription"/>
  <xs:element name="CommonStockSharesPurchased" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_CommonStockSharesPurchased"/>
  <xs:element name="CommonStockPricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_CommonStockPricePerShare"/>
  <xs:element name="WarrantsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_WarrantsShares"/>
  <xs:element name="ExercisePricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ExercisePricePerShare"/>
  <xs:element name="CashProceedsReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="clnn_CashProceedsReceived"/>
  <xs:element name="PurchaseOptionUnits" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="clnn_PurchaseOptionUnits"/>
  <xs:element name="NetIssuanceShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_NetIssuanceShares"/>
  <xs:element name="NetIssuanceWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_NetIssuanceWarrants"/>
  <xs:element name="NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsTable"/>
  <xs:element name="NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsLineItems"/>
  <xs:element name="ExclusiveRightsIntellectualPropertyTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ExclusiveRightsIntellectualPropertyTerm"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="clnn_SubsequentEventsDetailsTable"/>
  <xs:element name="SubsequentEventsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_SubsequentEventsDetailsLineItems"/>
  <xs:element name="TermLoansAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="clnn_TermLoansAxis"/>
  <xs:element name="AdvanceCecilIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_AdvanceCecilIncMember"/>
  <xs:element name="AvenueLoanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_AvenueLoanMember"/>
  <xs:element name="AvenueVentureOpportunitiesFundsLPMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_AvenueVentureOpportunitiesFundsLPMember"/>
  <xs:element name="BlackScholesValuationModelMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_BlackScholesValuationModelMember"/>
  <xs:element name="ChardanCapitalMarketsLLCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ChardanCapitalMarketsLLCMember"/>
  <xs:element name="ChardanUnitPurchaseOptionMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ChardanUnitPurchaseOptionMember"/>
  <xs:element name="CleneIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_CleneIncMember"/>
  <xs:element name="CleneNanomedicineContingentEarnoutMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_CleneNanomedicineContingentEarnoutMember"/>
  <xs:element name="CleneNanomedicineMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_CleneNanomedicineMember"/>
  <xs:element name="CommonStockWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_CommonStockWarrantsMember"/>
  <xs:element name="ContingentEarnOutMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ContingentEarnOutMember"/>
  <xs:element name="December20201Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_December20201Member"/>
  <xs:element name="DerivativeInstrumentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_DerivativeInstrumentMember"/>
  <xs:element name="DrugsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_DrugsMember"/>
  <xs:element name="FinanceLeasesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_FinanceLeasesMember"/>
  <xs:element name="InitialShareholdersContingentEarnoutMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_InitialShareholdersContingentEarnoutMember"/>
  <xs:element name="InvestorsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_InvestorsMember"/>
  <xs:element name="LifeSciCapitalLLCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_LifeSciCapitalLLCMember"/>
  <xs:element name="MarylandDepartmentOfHousingCommunityDevelopmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_MarylandDepartmentOfHousingCommunityDevelopmentMember"/>
  <xs:element name="May2021Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_May2021Member"/>
  <xs:element name="MonteCarloSimulationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_MonteCarloSimulationMember"/>
  <xs:element name="NetIncomeLossPerShareAttributableToCommonShareholdersMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_NetIncomeLossPerShareAttributableToCommonShareholdersMember"/>
  <xs:element name="OperatingLeasesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_OperatingLeasesMember"/>
  <xs:element name="OtherTermLoanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_OtherTermLoanMember"/>
  <xs:element name="PIPEMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_PIPEMember"/>
  <xs:element name="PIPEWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_PIPEWarrantsMember"/>
  <xs:element name="PaycheckProtectionProgramMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_PaycheckProtectionProgramMember"/>
  <xs:element name="PaycheckProtectionProgramNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_PaycheckProtectionProgramNoteMember"/>
  <xs:element name="PreferredStockWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_PreferredStockWarrantsMember"/>
  <xs:element name="ReverseRecapitalizationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_ReverseRecapitalizationMember"/>
  <xs:element name="StockPlan2014Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_StockPlan2014Member"/>
  <xs:element name="StockPlan2020Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_StockPlan2020Member"/>
  <xs:element name="SupplementsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_SupplementsMember"/>
  <xs:element name="TottenhamMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_TottenhamMember"/>
  <xs:element name="TwoThousandNineteenCecilLoanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_TwoThousandNineteenCecilLoanMember"/>
  <xs:element name="TwoThousandNineteenMDLoanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_TwoThousandNineteenMDLoanMember"/>
  <xs:element name="TwoThousandtwentyoneAvenueLoanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_TwoThousandtwentyoneAvenueLoanMember"/>
  <xs:element name="WarrantLiabilityMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_WarrantLiabilityMember"/>
  <xs:element name="WarrantsDate1Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_WarrantsDate1Member"/>
  <xs:element name="WarrantsDate2Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_WarrantsDate2Member"/>
  <xs:element name="WarrantsDateMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_WarrantsDateMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="clnn_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>clnn-20210930_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Nov 08 18:21:45 UTC 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ConsolidatedBalanceSheet" roleURI="http://www.cleaninccom/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ConsolidatedIncomeStatement" roleURI="http://www.cleaninccom/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ConsolidatedCashFlow" roleURI="http://www.cleaninccom/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleofprepaidexpensesandothercurrentassetsTable" roleURI="http://www.cleaninccom/role/ScheduleofprepaidexpensesandothercurrentassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleofpropertyandequipmentnetTable" roleURI="http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleofaccruedliabilitiesTable" roleURI="http://www.cleaninccom/role/ScheduleofaccruedliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable" roleURI="http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleoffinanceleaseobligationsincludedinpropertyandequipmentTable" roleURI="http://www.cleaninccom/role/ScheduleoffinanceleaseobligationsincludedinpropertyandequipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleoffinanceandoperatingleasecostsTable" roleURI="http://www.cleaninccom/role/ScheduleoffinanceandoperatingleasecostsTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleoffuturepaymentsnetofunamortizeddebtdiscountsTable" roleURI="http://www.cleaninccom/role/ScheduleoffuturepaymentsnetofunamortizeddebtdiscountsTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleofcomponentsofincomelossbeforeincometaxesTable" roleURI="http://www.cleaninccom/role/ScheduleofcomponentsofincomelossbeforeincometaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleofbasicanddilutednetlosspershareTable" roleURI="http://www.cleaninccom/role/ScheduleofbasicanddilutednetlosspershareTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleofsecuritiesexcludedfromcomputationofdilutednetincomelosspershareTable" roleURI="http://www.cleaninccom/role/ScheduleofsecuritiesexcludedfromcomputationofdilutednetincomelosspershareTable"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_Cash" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_TaxesPayableCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermNotesPayable" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_WarrantLiabilityNoncurrent" xlink:href="clnn-20210930.xsd#clnn_WarrantLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="clnn_WarrantLiabilityNoncurrent" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_InitialShareholdersContingentEarnout" xlink:href="clnn-20210930.xsd#clnn_InitialShareholdersContingentEarnout"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="clnn_InitialShareholdersContingentEarnout" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnContractTermination" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnContractTermination"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_GainLossOnContractTermination" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_ChangeInFairValueOfPreferredStockWarrantLiability" xlink:href="clnn-20210930.xsd#clnn_ChangeInFairValueOfPreferredStockWarrantLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="clnn_ChangeInFairValueOfPreferredStockWarrantLiability" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_ChangeInFairValueOfDerivativeLiability" xlink:href="clnn-20210930.xsd#clnn_ChangeInFairValueOfDerivativeLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="clnn_ChangeInFairValueOfDerivativeLiability" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_ChangeInFairValueOfContingentEarnout" xlink:href="clnn-20210930.xsd#clnn_ChangeInFairValueOfContingentEarnout"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="clnn_ChangeInFairValueOfContingentEarnout" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout" xlink:href="clnn-20210930.xsd#clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_ChangeInFairValueOfCommonStockWarrantLiability" xlink:href="clnn-20210930.xsd#clnn_ChangeInFairValueOfCommonStockWarrantLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="clnn_ChangeInFairValueOfCommonStockWarrantLiability" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_InterestIncomeexpense" xlink:href="clnn-20210930.xsd#clnn_InterestIncomeexpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="clnn_InterestIncomeexpense" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="clnn_GainOnExtinguishmentOfNotesPayable" xlink:href="clnn-20210930.xsd#clnn_GainOnExtinguishmentOfNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="clnn_GainOnExtinguishmentOfNotesPayable" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="clnn_LossOnExtinguishmentOfConvertibleNotesPayable" xlink:href="clnn-20210930.xsd#clnn_LossOnExtinguishmentOfConvertibleNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="clnn_LossOnExtinguishmentOfConvertibleNotesPayable" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="clnn_AustraliaResearchAndDevelopmentCredit" xlink:href="clnn-20210930.xsd#clnn_AustraliaResearchAndDevelopmentCredit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="clnn_AustraliaResearchAndDevelopmentCredit" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSoldDepreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_CostOfGoodsAndServicesSoldDepreciation" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_IncreaseInInterestAccruedOnNotesPayable" xlink:href="clnn-20210930.xsd#clnn_IncreaseInInterestAccruedOnNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="clnn_IncreaseInInterestAccruedOnNotesPayable" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties" order="10" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="11" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="12" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_ChangeInFairValueOfCleneNanomedicineContingentEarnouts" xlink:href="clnn-20210930.xsd#clnn_ChangeInFairValueOfCleneNanomedicineContingentEarnouts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="clnn_ChangeInFairValueOfCleneNanomedicineContingentEarnouts" order="13" weight="-1"/>
    <loc xlink:type="locator" xlink:label="clnn_ChangesInFairValueOfInitialShareholdersContingentEarnout" xlink:href="clnn-20210930.xsd#clnn_ChangesInFairValueOfInitialShareholdersContingentEarnout"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="clnn_ChangesInFairValueOfInitialShareholdersContingentEarnout" order="14" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" order="15" weight="-1"/>
    <loc xlink:type="locator" xlink:label="clnn_ChangeInFairValueOfCommonStockWarrantLiabilitys" xlink:href="clnn-20210930.xsd#clnn_ChangeInFairValueOfCommonStockWarrantLiabilitys"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="clnn_ChangeInFairValueOfCommonStockWarrantLiabilitys" order="16" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnTerminationOfLease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnTerminationOfLease" order="17" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="18" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnDispositionOfIntangibleAssets" order="19" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="20" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="21" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="22" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" order="23" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromOtherDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromOtherDebt" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="7" weight="-1"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSraqWjSnTNF4jeT3oaMW8W5R0MkiIXXy8k2PQbBklJ1lYSX00RI6mU1NUjmu2Z8DGiLsvWC/Nx+2e5I3XA4/waZZD17aBEHbiQmUEtZYNMriew3bFfu2eViLA2wfQ1rEEEBO8y7g2agPYYHRPjjYinU2w/zG3znhFzcUmf8sfjIqSy9wePOvcc8R] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_Cash" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCash" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofprepaidexpensesandothercurrentassetsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <loc xlink:type="locator" xlink:label="clnn_CROPrepayments" xlink:href="clnn-20210930.xsd#clnn_CROPrepayments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="clnn_CROPrepayments" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_MetalsToBeUsedInResearchAndDevelopment" xlink:href="clnn-20210930.xsd#clnn_MetalsToBeUsedInResearchAndDevelopment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="clnn_MetalsToBeUsedInResearchAndDevelopment" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_DirectorsOfficersInsurance" xlink:href="clnn-20210930.xsd#clnn_DirectorsOfficersInsurance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="clnn_DirectorsOfficersInsurance" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_AustraliaResearchAndDevelopmentCreditReceivable" xlink:href="clnn-20210930.xsd#clnn_AustraliaResearchAndDevelopmentCreditReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="clnn_AustraliaResearchAndDevelopmentCreditReceivable" order="5" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_MachineryAndEquipmentGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_FurnitureAndFixturesGross" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_LeaseholdImprovementsGross" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_ConstructionInProgressGross" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofaccruedliabilitiesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_AccruedCROFees" xlink:href="clnn-20210930.xsd#clnn_AccruedCROFees"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="clnn_AccruedCROFees" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_DeferredGrantFunds" xlink:href="clnn-20210930.xsd#clnn_DeferredGrantFunds"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="clnn_DeferredGrantFunds" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_AccruedExpenseReimbursements" xlink:href="clnn-20210930.xsd#clnn_AccruedExpenseReimbursements"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="clnn_AccruedExpenseReimbursements" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_AccruedTransactionCosts" xlink:href="clnn-20210930.xsd#clnn_AccruedTransactionCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="clnn_AccruedTransactionCosts" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="7" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_CapitalLeasesAmountRepresentingInterestdiscounting" xlink:href="clnn-20210930.xsd#clnn_CapitalLeasesAmountRepresentingInterestdiscounting"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:to="clnn_CapitalLeasesAmountRepresentingInterestdiscounting" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_OperatingLeasesAmountRepresentingInterestdiscounting" xlink:href="clnn-20210930.xsd#clnn_OperatingLeasesAmountRepresentingInterestdiscounting"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="clnn_OperatingLeasesAmountRepresentingInterestdiscounting" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleoffinanceleaseobligationsincludedinpropertyandequipmentTable">
    <loc xlink:type="locator" xlink:label="clnn_FinanceLeaseLiabilityGross" xlink:href="clnn-20210930.xsd#clnn_FinanceLeaseLiabilityGross"/>
    <loc xlink:type="locator" xlink:label="clnn_FinanceLeaseLaboratoryEquipmentGross" xlink:href="clnn-20210930.xsd#clnn_FinanceLeaseLaboratoryEquipmentGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="clnn_FinanceLeaseLiabilityGross" xlink:to="clnn_FinanceLeaseLaboratoryEquipmentGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_FinanceLeaseFurnitureAndFixturesGross" xlink:href="clnn-20210930.xsd#clnn_FinanceLeaseFurnitureAndFixturesGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="clnn_FinanceLeaseLiabilityGross" xlink:to="clnn_FinanceLeaseFurnitureAndFixturesGross" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_FinanceLeaseWorkInProcessGross" xlink:href="clnn-20210930.xsd#clnn_FinanceLeaseWorkInProcessGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="clnn_FinanceLeaseLiabilityGross" xlink:to="clnn_FinanceLeaseWorkInProcessGross" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_FinanceLeaseLiabilityNet" xlink:href="clnn-20210930.xsd#clnn_FinanceLeaseLiabilityNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="clnn_FinanceLeaseLiabilityNet" xlink:to="clnn_FinanceLeaseLiabilityGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_AccumulatedDepreciationDepletionAndAmortizationLeases" xlink:href="clnn-20210930.xsd#clnn_AccumulatedDepreciationDepletionAndAmortizationLeases"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="clnn_FinanceLeaseLiabilityNet" xlink:to="clnn_AccumulatedDepreciationDepletionAndAmortizationLeases" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleoffinanceandoperatingleasecostsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_ShortTermLeaseCost" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="5" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleoffuturepaymentsnetofunamortizeddebtdiscountsTable">
    <loc xlink:type="locator" xlink:label="clnn_FuturePrincipalPayments" xlink:href="clnn-20210930.xsd#clnn_FuturePrincipalPayments"/>
    <loc xlink:type="locator" xlink:label="clnn_DebtInstrumentUnamortizedDiscountRemainderOfFiscalYear" xlink:href="clnn-20210930.xsd#clnn_DebtInstrumentUnamortizedDiscountRemainderOfFiscalYear"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="clnn_FuturePrincipalPayments" xlink:to="clnn_DebtInstrumentUnamortizedDiscountRemainderOfFiscalYear" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_DebtInstrumentUnamortizedDiscountYearOne" xlink:href="clnn-20210930.xsd#clnn_DebtInstrumentUnamortizedDiscountYearOne"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="clnn_FuturePrincipalPayments" xlink:to="clnn_DebtInstrumentUnamortizedDiscountYearOne" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_DebtInstrumentUnamortizedDiscountYearTwo" xlink:href="clnn-20210930.xsd#clnn_DebtInstrumentUnamortizedDiscountYearTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="clnn_FuturePrincipalPayments" xlink:to="clnn_DebtInstrumentUnamortizedDiscountYearTwo" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_DebtInstrumentUnamortizedDiscountYearThree" xlink:href="clnn-20210930.xsd#clnn_DebtInstrumentUnamortizedDiscountYearThree"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="clnn_FuturePrincipalPayments" xlink:to="clnn_DebtInstrumentUnamortizedDiscountYearThree" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_DebtInstrumentUnamortizedDiscountYearFour" xlink:href="clnn-20210930.xsd#clnn_DebtInstrumentUnamortizedDiscountYearFour"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="clnn_FuturePrincipalPayments" xlink:to="clnn_DebtInstrumentUnamortizedDiscountYearFour" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_DebtInstrumentUnamortizedDiscountYearFive" xlink:href="clnn-20210930.xsd#clnn_DebtInstrumentUnamortizedDiscountYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="clnn_FuturePrincipalPayments" xlink:to="clnn_DebtInstrumentUnamortizedDiscountYearFive" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_DebtInstrumentThereafter" xlink:href="clnn-20210930.xsd#clnn_DebtInstrumentThereafter"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="clnn_FuturePrincipalPayments" xlink:to="clnn_DebtInstrumentThereafter" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecurities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecurities" xlink:to="clnn_FuturePrincipalPayments" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecurities" xlink:to="us-gaap_DebtInstrumentUnamortizedPremium" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofcomponentsofincomelossbeforeincometaxesTable">
    <loc xlink:type="locator" xlink:label="clnn_TotalLossBeforeIncomeTaxes" xlink:href="clnn-20210930.xsd#clnn_TotalLossBeforeIncomeTaxes"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="clnn_TotalLossBeforeIncomeTaxes" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="clnn_TotalLossBeforeIncomeTaxes" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofbasicanddilutednetlosspershareTable">
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:label="clnn_WeightedAverageSharesOutstanding" xlink:href="clnn-20210930.xsd#clnn_WeightedAverageSharesOutstanding"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="clnn_WeightedAverageSharesOutstanding" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_EffectOfPotentiallyDilutiveStockOptionsinDollars" xlink:href="clnn-20210930.xsd#clnn_EffectOfPotentiallyDilutiveStockOptionsinDollars"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="clnn_EffectOfPotentiallyDilutiveStockOptionsinDollars" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_EffectOfPotentiallyDilutiveRestrictedStockAwards" xlink:href="clnn-20210930.xsd#clnn_EffectOfPotentiallyDilutiveRestrictedStockAwards"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="clnn_EffectOfPotentiallyDilutiveRestrictedStockAwards" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_EffectOfPotentiallyDilutiveConvertibleNotesPayable" xlink:href="clnn-20210930.xsd#clnn_EffectOfPotentiallyDilutiveConvertibleNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="clnn_EffectOfPotentiallyDilutiveConvertibleNotesPayable" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_EffectOfPotentiallyDilutiveUnvestedRestrictedStockAwardsShares" xlink:href="clnn-20210930.xsd#clnn_EffectOfPotentiallyDilutiveUnvestedRestrictedStockAwardsShares"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="clnn_EffectOfPotentiallyDilutiveUnvestedRestrictedStockAwardsShares" order="5" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofsecuritiesexcludedfromcomputationofdilutednetincomelosspershareTable">
    <loc xlink:type="locator" xlink:label="clnn_TotalDilutiveSecurities" xlink:href="clnn-20210930.xsd#clnn_TotalDilutiveSecurities"/>
    <loc xlink:type="locator" xlink:label="clnn_SeriesDRedeemableConvertiblePreferredStock" xlink:href="clnn-20210930.xsd#clnn_SeriesDRedeemableConvertiblePreferredStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="clnn_TotalDilutiveSecurities" xlink:to="clnn_SeriesDRedeemableConvertiblePreferredStock" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_SeriesCRedeemableConvertiblePreferredStock" xlink:href="clnn-20210930.xsd#clnn_SeriesCRedeemableConvertiblePreferredStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="clnn_TotalDilutiveSecurities" xlink:to="clnn_SeriesCRedeemableConvertiblePreferredStock" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_SeriesBRedeemableConvertiblePreferredStock" xlink:href="clnn-20210930.xsd#clnn_SeriesBRedeemableConvertiblePreferredStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="clnn_TotalDilutiveSecurities" xlink:to="clnn_SeriesBRedeemableConvertiblePreferredStock" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_SeriesARedeemableConvertiblePreferredStock" xlink:href="clnn-20210930.xsd#clnn_SeriesARedeemableConvertiblePreferredStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="clnn_TotalDilutiveSecurities" xlink:to="clnn_SeriesARedeemableConvertiblePreferredStock" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_SeriesDRedeemableConvertiblePreferredStockWarrants" xlink:href="clnn-20210930.xsd#clnn_SeriesDRedeemableConvertiblePreferredStockWarrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="clnn_TotalDilutiveSecurities" xlink:to="clnn_SeriesDRedeemableConvertiblePreferredStockWarrants" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_SeriesARedeemableConvertiblePreferredStockWarrantsinShares" xlink:href="clnn-20210930.xsd#clnn_SeriesARedeemableConvertiblePreferredStockWarrantsinShares"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="clnn_TotalDilutiveSecurities" xlink:to="clnn_SeriesARedeemableConvertiblePreferredStockWarrantsinShares" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_ConvertibleNotesPayables" xlink:href="clnn-20210930.xsd#clnn_ConvertibleNotesPayables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="clnn_TotalDilutiveSecurities" xlink:to="clnn_ConvertibleNotesPayables" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrants" xlink:href="clnn-20210930.xsd#clnn_CommonStockWarrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="clnn_TotalDilutiveSecurities" xlink:to="clnn_CommonStockWarrants" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_OptionsToPurchaseCommonStockinShares" xlink:href="clnn-20210930.xsd#clnn_OptionsToPurchaseCommonStockinShares"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="clnn_TotalDilutiveSecurities" xlink:to="clnn_OptionsToPurchaseCommonStockinShares" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_UnvestedRestrictedStockAwardsShares" xlink:href="clnn-20210930.xsd#clnn_UnvestedRestrictedStockAwardsShares"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="clnn_TotalDilutiveSecurities" xlink:to="clnn_UnvestedRestrictedStockAwardsShares" order="10" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_ChardanUnitPurchaseOptionWarrants" xlink:href="clnn-20210930.xsd#clnn_ChardanUnitPurchaseOptionWarrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="clnn_TotalDilutiveSecurities" xlink:to="clnn_ChardanUnitPurchaseOptionWarrants" order="11" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_CleneNanomedicineContingentEarnoutShares" xlink:href="clnn-20210930.xsd#clnn_CleneNanomedicineContingentEarnoutShares"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="clnn_TotalDilutiveSecurities" xlink:to="clnn_CleneNanomedicineContingentEarnoutShares" order="12" weight="1"/>
    <loc xlink:type="locator" xlink:label="clnn_InitialShareholdersContingentEarnoutShares" xlink:href="clnn-20210930.xsd#clnn_InitialShareholdersContingentEarnoutShares"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="clnn_TotalDilutiveSecurities" xlink:to="clnn_InitialShareholdersContingentEarnoutShares" order="13" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>clnn-20210930_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Nov 08 18:21:45 UTC 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ConsolidatedBalanceSheet" roleURI="http://www.cleaninccom/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.cleaninccom/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ConsolidatedIncomeStatement" roleURI="http://www.cleaninccom/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ShareholdersEquityType2or3" roleURI="http://www.cleaninccom/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ShareholdersEquityType2or3_Parentheticals" roleURI="http://www.cleaninccom/role/ShareholdersEquityType2or3_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ConsolidatedCashFlow" roleURI="http://www.cleaninccom/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_NatureoftheBusiness" roleURI="http://www.cleaninccom/role/NatureoftheBusiness"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_SummaryofSignificantAccountingPolicies" roleURI="http://www.cleaninccom/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ReverseRecapitalizationwithTottenhamandCleneNanomedicine" roleURI="http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicine"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_PrepaidExpensesandOtherCurrentAssets" roleURI="http://www.cleaninccom/role/PrepaidExpensesandOtherCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_PropertyandEquipmentNet" roleURI="http://www.cleaninccom/role/PropertyandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_AccruedLiabilities" roleURI="http://www.cleaninccom/role/AccruedLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_Leases" roleURI="http://www.cleaninccom/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_NotesPayable" roleURI="http://www.cleaninccom/role/NotesPayable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_PreferredStockWarrantLiability" roleURI="http://www.cleaninccom/role/PreferredStockWarrantLiability"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_CommonStockWarrants" roleURI="http://www.cleaninccom/role/CommonStockWarrants"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ConvertibleNotes" roleURI="http://www.cleaninccom/role/ConvertibleNotes"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_DerivativeInstruments" roleURI="http://www.cleaninccom/role/DerivativeInstruments"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_CommitmentsandContingencies" roleURI="http://www.cleaninccom/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_IncomeTaxes" roleURI="http://www.cleaninccom/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_StockBasedCompensation" roleURI="http://www.cleaninccom/role/StockBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_FairValue" roleURI="http://www.cleaninccom/role/FairValue"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_RedeemableConvertiblePreferredStock" roleURI="http://www.cleaninccom/role/RedeemableConvertiblePreferredStock"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_CommonStock" roleURI="http://www.cleaninccom/role/CommonStock"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_NetIncomeLossPerShareAttributabletoCommonShareholders" roleURI="http://www.cleaninccom/role/NetIncomeLossPerShareAttributabletoCommonShareholders"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_RelatedPartyTransactions" roleURI="http://www.cleaninccom/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_GeographicandSegmentInformation" roleURI="http://www.cleaninccom/role/GeographicandSegmentInformation"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_SubsequentEvents" roleURI="http://www.cleaninccom/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_AccountingPoliciesByPolicy" roleURI="http://www.cleaninccom/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_PrepaidExpensesandOtherCurrentAssetsTables" roleURI="http://www.cleaninccom/role/PrepaidExpensesandOtherCurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_PropertyandEquipmentNetTables" roleURI="http://www.cleaninccom/role/PropertyandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_AccruedLiabilitiesTables" roleURI="http://www.cleaninccom/role/AccruedLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_LeasesTables" roleURI="http://www.cleaninccom/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_NotesPayableTables" roleURI="http://www.cleaninccom/role/NotesPayableTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_CommonStockWarrantsTables" roleURI="http://www.cleaninccom/role/CommonStockWarrantsTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_IncomeTaxesTables" roleURI="http://www.cleaninccom/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_StockBasedCompensationTables" roleURI="http://www.cleaninccom/role/StockBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_FairValueTables" roleURI="http://www.cleaninccom/role/FairValueTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_NetIncomeLossPerShareAttributabletoCommonShareholdersTables" roleURI="http://www.cleaninccom/role/NetIncomeLossPerShareAttributabletoCommonShareholdersTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_GeographicandSegmentInformationTables" roleURI="http://www.cleaninccom/role/GeographicandSegmentInformationTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleofprepaidexpensesandothercurrentassetsTable" roleURI="http://www.cleaninccom/role/ScheduleofprepaidexpensesandothercurrentassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleofpropertyandequipmentnetTable" roleURI="http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleofaccruedliabilitiesTable" roleURI="http://www.cleaninccom/role/ScheduleofaccruedliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable" roleURI="http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleoffinanceleaseobligationsincludedinpropertyandequipmentTable" roleURI="http://www.cleaninccom/role/ScheduleoffinanceleaseobligationsincludedinpropertyandequipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleoffinanceandoperatingleasecostsTable" roleURI="http://www.cleaninccom/role/ScheduleoffinanceandoperatingleasecostsTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleofsupplementalcashflowinformationTable" roleURI="http://www.cleaninccom/role/ScheduleofsupplementalcashflowinformationTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleoflongtermdebtnetoforiginalissuediscountandunamortizeddebtissuancecostsTable" roleURI="http://www.cleaninccom/role/ScheduleoflongtermdebtnetoforiginalissuediscountandunamortizeddebtissuancecostsTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleoffuturepaymentsnetofunamortizeddebtdiscountsTable" roleURI="http://www.cleaninccom/role/ScheduleoffuturepaymentsnetofunamortizeddebtdiscountsTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleofoutstandingwarrantstopurchasesharesofcommonstockTable" roleURI="http://www.cleaninccom/role/ScheduleofoutstandingwarrantstopurchasesharesofcommonstockTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleofcomponentsofincomelossbeforeincometaxesTable" roleURI="http://www.cleaninccom/role/ScheduleofcomponentsofincomelossbeforeincometaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleofstockbasedcompensationexpenseTable" roleURI="http://www.cleaninccom/role/ScheduleofstockbasedcompensationexpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleofoutstandingcommonstockoptionsandrelatedactivityTable" roleURI="http://www.cleaninccom/role/ScheduleofoutstandingcommonstockoptionsandrelatedactivityTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsTable" roleURI="http://www.cleaninccom/role/ScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleofrestrictedcommonstockactivityTable" roleURI="http://www.cleaninccom/role/ScheduleofrestrictedcommonstockactivityTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable" roleURI="http://www.cleaninccom/role/ScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleofunobservableinputstotheconversionfeaturewarrantliabilityandcontingentearnoutvaluationmodelsTable" roleURI="http://www.cleaninccom/role/ScheduleofunobservableinputstotheconversionfeaturewarrantliabilityandcontingentearnoutvaluationmodelsTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsTable" roleURI="http://www.cleaninccom/role/ScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleofbasicanddilutednetlosspershareTable" roleURI="http://www.cleaninccom/role/ScheduleofbasicanddilutednetlosspershareTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleofsecuritiesexcludedfromcomputationofdilutednetincomelosspershareTable" roleURI="http://www.cleaninccom/role/ScheduleofsecuritiesexcludedfromcomputationofdilutednetincomelosspershareTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleofpropertyandequipmentnetbylocationTable" roleURI="http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetbylocationTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleofdrugsandsupplementssegmentsTable" roleURI="http://www.cleaninccom/role/ScheduleofdrugsandsupplementssegmentsTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleofpropertyandequipmentnetbysegmentTable" roleURI="http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetbysegmentTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_NatureoftheBusinessDetails" roleURI="http://www.cleaninccom/role/NatureoftheBusinessDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.cleaninccom/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails" roleURI="http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_PropertyandEquipmentNetDetails" roleURI="http://www.cleaninccom/role/PropertyandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_LeasesDetails" roleURI="http://www.cleaninccom/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_NotesPayableDetails" roleURI="http://www.cleaninccom/role/NotesPayableDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_PreferredStockWarrantLiabilityDetails" roleURI="http://www.cleaninccom/role/PreferredStockWarrantLiabilityDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_CommonStockWarrantsDetails" roleURI="http://www.cleaninccom/role/CommonStockWarrantsDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ConvertibleNotesDetails" roleURI="http://www.cleaninccom/role/ConvertibleNotesDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_DerivativeInstrumentsDetails" roleURI="http://www.cleaninccom/role/DerivativeInstrumentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_IncomeTaxesDetails" roleURI="http://www.cleaninccom/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_StockBasedCompensationDetails" roleURI="http://www.cleaninccom/role/StockBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_FairValueDetails" roleURI="http://www.cleaninccom/role/FairValueDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_RedeemableConvertiblePreferredStockDetails" roleURI="http://www.cleaninccom/role/RedeemableConvertiblePreferredStockDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_CommonStockDetails" roleURI="http://www.cleaninccom/role/CommonStockDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_NetIncomeLossPerShareAttributabletoCommonShareholdersDetails" roleURI="http://www.cleaninccom/role/NetIncomeLossPerShareAttributabletoCommonShareholdersDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_RelatedPartyTransactionsDetails" roleURI="http://www.cleaninccom/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_SubsequentEventsDetails" roleURI="http://www.cleaninccom/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#DocumentAndEntityInformation" roleURI="http://www.cleaninccom/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Cash" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_TaxesPayableCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermNotesPayable" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_WarrantLiabilityNoncurrent" xlink:href="clnn-20210930.xsd#clnn_WarrantLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="clnn_WarrantLiabilityNoncurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_InitialShareholdersContingentEarnout" xlink:href="clnn-20210930.xsd#clnn_InitialShareholdersContingentEarnout"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="clnn_InitialShareholdersContingentEarnout" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_CommitmentsAndContingencies" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_InterestIncomeexpense" xlink:href="clnn-20210930.xsd#clnn_InterestIncomeexpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="clnn_InterestIncomeexpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_GainOnExtinguishmentOfNotesPayable" xlink:href="clnn-20210930.xsd#clnn_GainOnExtinguishmentOfNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="clnn_GainOnExtinguishmentOfNotesPayable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_LossOnExtinguishmentOfConvertibleNotesPayable" xlink:href="clnn-20210930.xsd#clnn_LossOnExtinguishmentOfConvertibleNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="clnn_LossOnExtinguishmentOfConvertibleNotesPayable" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnContractTermination" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnContractTermination"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainLossOnContractTermination" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ChangeInFairValueOfPreferredStockWarrantLiability" xlink:href="clnn-20210930.xsd#clnn_ChangeInFairValueOfPreferredStockWarrantLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="clnn_ChangeInFairValueOfPreferredStockWarrantLiability" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ChangeInFairValueOfDerivativeLiability" xlink:href="clnn-20210930.xsd#clnn_ChangeInFairValueOfDerivativeLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="clnn_ChangeInFairValueOfDerivativeLiability" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ChangeInFairValueOfContingentEarnout" xlink:href="clnn-20210930.xsd#clnn_ChangeInFairValueOfContingentEarnout"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="clnn_ChangeInFairValueOfContingentEarnout" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout" xlink:href="clnn-20210930.xsd#clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ChangeInFairValueOfCommonStockWarrantLiability" xlink:href="clnn-20210930.xsd#clnn_ChangeInFairValueOfCommonStockWarrantLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="clnn_ChangeInFairValueOfCommonStockWarrantLiability" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_AustraliaResearchAndDevelopmentCredit" xlink:href="clnn-20210930.xsd#clnn_AustraliaResearchAndDevelopmentCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="clnn_AustraliaResearchAndDevelopmentCredit" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NetIncomeLoss" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTax" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_NetIncomeLossPerCommonShareAttributableToCommonShareholdersNote191Abstract" xlink:href="clnn-20210930.xsd#clnn_NetIncomeLossPerCommonShareAttributableToCommonShareholdersNote191Abstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="clnn_NetIncomeLossPerCommonShareAttributableToCommonShareholdersNote191Abstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NetIncomeLossPerCommonShareAttributableToCommonShareholdersNote191Abstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NetIncomeLossPerCommonShareAttributableToCommonShareholdersNote191Abstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_WeightedAverageNumberOfCommonSharesOutstanding1Abstract" xlink:href="clnn-20210930.xsd#clnn_WeightedAverageNumberOfCommonSharesOutstanding1Abstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="clnn_WeightedAverageNumberOfCommonSharesOutstanding1Abstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_WeightedAverageNumberOfCommonSharesOutstanding1Abstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_WeightedAverageNumberOfCommonSharesOutstanding1Abstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_StockIssuedDuringPeriodOfSeriesDPreferredStock" xlink:href="clnn-20210930.xsd#clnn_StockIssuedDuringPeriodOfSeriesDPreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="clnn_StockIssuedDuringPeriodOfSeriesDPreferredStock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_StockIssuedDuringPeriodSharesSeriesDPreferredStock" xlink:href="clnn-20210930.xsd#clnn_StockIssuedDuringPeriodSharesSeriesDPreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="clnn_StockIssuedDuringPeriodSharesSeriesDPreferredStock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:href="clnn-20210930.xsd#clnn_StockIssuedDuringPeriodValueExerciseOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="clnn_StockIssuedDuringPeriodValueExerciseOfWarrants" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_StockIssueDuringPeriodSharesExerciseOfWarrants" xlink:href="clnn-20210930.xsd#clnn_StockIssueDuringPeriodSharesExerciseOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="clnn_StockIssueDuringPeriodSharesExerciseOfWarrants" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_StockIssuedDuringPeriodExerciseOfUnderwritersOption" xlink:href="clnn-20210930.xsd#clnn_StockIssuedDuringPeriodExerciseOfUnderwritersOption"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="clnn_StockIssuedDuringPeriodExerciseOfUnderwritersOption" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_StockIssuedDuringPeriodExerciseOfUnderwritersOptioninShares" xlink:href="clnn-20210930.xsd#clnn_StockIssuedDuringPeriodExerciseOfUnderwritersOptioninShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="clnn_StockIssuedDuringPeriodExerciseOfUnderwritersOptioninShares" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ForeignCurrencyTranslationAdjustment" xlink:href="clnn-20210930.xsd#clnn_ForeignCurrencyTranslationAdjustment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="clnn_ForeignCurrencyTranslationAdjustment" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="19" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ShareholdersEquityType2or3_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="clnn_NetOfIssuanceCosts" xlink:href="clnn-20210930.xsd#clnn_NetOfIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="clnn_NetOfIssuanceCosts" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSoldDepreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSoldDepreciation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ChangeInFairValueOfCleneNanomedicineContingentEarnouts" xlink:href="clnn-20210930.xsd#clnn_ChangeInFairValueOfCleneNanomedicineContingentEarnouts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="clnn_ChangeInFairValueOfCleneNanomedicineContingentEarnouts" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ChangesInFairValueOfInitialShareholdersContingentEarnout" xlink:href="clnn-20210930.xsd#clnn_ChangesInFairValueOfInitialShareholdersContingentEarnout"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="clnn_ChangesInFairValueOfInitialShareholdersContingentEarnout" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ChangeInFairValueOfCommonStockWarrantLiabilitys" xlink:href="clnn-20210930.xsd#clnn_ChangeInFairValueOfCommonStockWarrantLiabilitys"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="clnn_ChangeInFairValueOfCommonStockWarrantLiabilitys" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnTerminationOfLease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnTerminationOfLease" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfIntangibleAssets" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_IncreaseInInterestAccruedOnNotesPayable" xlink:href="clnn-20210930.xsd#clnn_IncreaseInInterestAccruedOnNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="clnn_IncreaseInInterestAccruedOnNotesPayable" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromOtherDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromOtherDebt" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAbstract" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:to="us-gaap_Cash" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCash" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_WarrantLiabilityRecordedAtIssuanceOfNotesPayable" xlink:href="clnn-20210930.xsd#clnn_WarrantLiabilityRecordedAtIssuanceOfNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="clnn_WarrantLiabilityRecordedAtIssuanceOfNotesPayable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_LeaseLiabilitySettledThroughTerminationOfLease" xlink:href="clnn-20210930.xsd#clnn_LeaseLiabilitySettledThroughTerminationOfLease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="clnn_LeaseLiabilitySettledThroughTerminationOfLease" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes" xlink:href="clnn-20210930.xsd#clnn_IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="clnn_IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN" xlink:href="clnn-20210930.xsd#clnn_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="clnn_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_DeferredOfferingCostsInAccruedLiabilities" xlink:href="clnn-20210930.xsd#clnn_DeferredOfferingCostsInAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="clnn_DeferredOfferingCostsInAccruedLiabilities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_CashPaidForInterestExpense" xlink:href="clnn-20210930.xsd#clnn_CashPaidForInterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="clnn_CashPaidForInterestExpense" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/NatureoftheBusiness">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicine">
    <loc xlink:type="locator" xlink:label="clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineAbstract" xlink:href="clnn-20210930.xsd#clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineAbstract"/>
    <loc xlink:type="locator" xlink:label="clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock" xlink:href="clnn-20210930.xsd#clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineAbstract" xlink:to="clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/PrepaidExpensesandOtherCurrentAssets">
    <loc xlink:type="locator" xlink:label="clnn_PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:href="clnn-20210930.xsd#clnn_PrepaidExpensesAndOtherCurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="clnn_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:href="clnn-20210930.xsd#clnn_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="clnn_PrepaidExpensesAndOtherCurrentAssetsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/PropertyandEquipmentNet">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/AccruedLiabilities">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/Leases">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/NotesPayable">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/PreferredStockWarrantLiability">
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrantsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrantsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrantsAbstract" xlink:to="us-gaap_PreferredStockTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/CommonStockWarrants">
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrantsDisclosureAbstract" xlink:href="clnn-20210930.xsd#clnn_CommonStockWarrantsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrantsDisclosureTextBlock" xlink:href="clnn-20210930.xsd#clnn_CommonStockWarrantsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CommonStockWarrantsDisclosureAbstract" xlink:to="clnn_CommonStockWarrantsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ConvertibleNotes">
    <loc xlink:type="locator" xlink:label="clnn_ConvertibleNotesDisclosureAbstract" xlink:href="clnn-20210930.xsd#clnn_ConvertibleNotesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="clnn_ConvertibleNotesDisclosureTextBlock" xlink:href="clnn-20210930.xsd#clnn_ConvertibleNotesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ConvertibleNotesDisclosureAbstract" xlink:to="clnn_ConvertibleNotesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/DerivativeInstruments">
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/StockBasedCompensation">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/FairValue">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/RedeemableConvertiblePreferredStock">
    <loc xlink:type="locator" xlink:label="clnn_RedeemableConvertiblePreferredStockDisclosureAbstract" xlink:href="clnn-20210930.xsd#clnn_RedeemableConvertiblePreferredStockDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="clnn_RedeemableConvertiblePreferredStockDisclosureTextBlock" xlink:href="clnn-20210930.xsd#clnn_RedeemableConvertiblePreferredStockDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_RedeemableConvertiblePreferredStockDisclosureAbstract" xlink:to="clnn_RedeemableConvertiblePreferredStockDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/CommonStock">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/NetIncomeLossPerShareAttributabletoCommonShareholders">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/GeographicandSegmentInformation">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_RiskAndUncertaintiesPolicyTextBlock" xlink:href="clnn-20210930.xsd#clnn_RiskAndUncertaintiesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="clnn_RiskAndUncertaintiesPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_DebtDiscountAndIssuanceCostsPolicyTextBlock" xlink:href="clnn-20210930.xsd#clnn_DebtDiscountAndIssuanceCostsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="clnn_DebtDiscountAndIssuanceCostsPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ConvertibleNotespolicytextblock" xlink:href="clnn-20210930.xsd#clnn_ConvertibleNotespolicytextblock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="clnn_ConvertibleNotespolicytextblock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_DebtWithWarrantsPolicyTextBlock" xlink:href="clnn-20210930.xsd#clnn_DebtWithWarrantsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="clnn_DebtWithWarrantsPolicyTextBlock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ContingentEarnoutPolicyTextBlock" xlink:href="clnn-20210930.xsd#clnn_ContingentEarnoutPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="clnn_ContingentEarnoutPolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrantsPolicyTextBlock" xlink:href="clnn-20210930.xsd#clnn_CommonStockWarrantsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="clnn_CommonStockWarrantsPolicyTextBlock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_GrantFundingPolicyTextBlock" xlink:href="clnn-20210930.xsd#clnn_GrantFundingPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="clnn_GrantFundingPolicyTextBlock" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ClinicalTrialAccrualPolicyTextBlock" xlink:href="clnn-20210930.xsd#clnn_ClinicalTrialAccrualPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="clnn_ClinicalTrialAccrualPolicyTextBlock" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:href="clnn-20210930.xsd#clnn_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="clnn_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" order="28" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/PrepaidExpensesandOtherCurrentAssetsTables">
    <loc xlink:type="locator" xlink:label="clnn_PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:href="clnn-20210930.xsd#clnn_PrepaidExpensesAndOtherCurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="clnn_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:href="clnn-20210930.xsd#clnn_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="clnn_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/PropertyandEquipmentNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/AccruedLiabilitiesTables">
    <loc xlink:type="locator" xlink:label="clnn_AccruedLiabilitiesTablesLineItems" xlink:href="clnn-20210930.xsd#clnn_AccruedLiabilitiesTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_AccruedLiabilitiesTablesTable" xlink:href="clnn-20210930.xsd#clnn_AccruedLiabilitiesTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_AccruedLiabilitiesTablesLineItems" xlink:to="clnn_AccruedLiabilitiesTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_AccruedLiabilitiesTablesLineItems" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/LeasesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="clnn_FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="clnn-20210930.xsd#clnn_FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="clnn_FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_FinanceLeaseByMajorClassPropertyAndEquipmentTableTextBlock" xlink:href="clnn-20210930.xsd#clnn_FinanceLeaseByMajorClassPropertyAndEquipmentTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="clnn_FinanceLeaseByMajorClassPropertyAndEquipmentTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/NotesPayableTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscounts" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="clnn_ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscounts" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/CommonStockWarrantsTables">
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrantsDisclosureAbstract" xlink:href="clnn-20210930.xsd#clnn_CommonStockWarrantsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CommonStockWarrantsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/StockBasedCompensationTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/FairValueTables">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/NetIncomeLossPerShareAttributabletoCommonShareholdersTables">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/GeographicandSegmentInformationTables">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="clnn_ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofprepaidexpensesandothercurrentassetsTable">
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="clnn_AustraliaResearchAndDevelopmentCreditReceivable" xlink:href="clnn-20210930.xsd#clnn_AustraliaResearchAndDevelopmentCreditReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="clnn_AustraliaResearchAndDevelopmentCreditReceivable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_CROPrepayments" xlink:href="clnn-20210930.xsd#clnn_CROPrepayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="clnn_CROPrepayments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_MetalsToBeUsedInResearchAndDevelopment" xlink:href="clnn-20210930.xsd#clnn_MetalsToBeUsedInResearchAndDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="clnn_MetalsToBeUsedInResearchAndDevelopment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_DirectorsOfficersInsurance" xlink:href="clnn-20210930.xsd#clnn_DirectorsOfficersInsurance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="clnn_DirectorsOfficersInsurance" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetTable">
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfPropertyAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="us-gaap_MachineryAndEquipmentGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="us-gaap_FurnitureAndFixturesGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="us-gaap_LeaseholdImprovementsGross" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="us-gaap_ConstructionInProgressGross" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofaccruedliabilitiesTable">
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfAccruedLiabilitiesAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfAccruedLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfAccruedLiabilitiesAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfAccruedLiabilitiesAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_AccruedCROFees" xlink:href="clnn-20210930.xsd#clnn_AccruedCROFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfAccruedLiabilitiesAbstract" xlink:to="clnn_AccruedCROFees" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_DeferredGrantFunds" xlink:href="clnn-20210930.xsd#clnn_DeferredGrantFunds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfAccruedLiabilitiesAbstract" xlink:to="clnn_DeferredGrantFunds" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_AccruedExpenseReimbursements" xlink:href="clnn-20210930.xsd#clnn_AccruedExpenseReimbursements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfAccruedLiabilitiesAbstract" xlink:to="clnn_AccruedExpenseReimbursements" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_AccruedTransactionCosts" xlink:href="clnn-20210930.xsd#clnn_AccruedTransactionCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfAccruedLiabilitiesAbstract" xlink:to="clnn_AccruedTransactionCosts" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfAccruedLiabilitiesAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfAccruedLiabilitiesAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable">
    <loc xlink:type="locator" xlink:label="clnn_LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems" xlink:href="clnn-20210930.xsd#clnn_LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable" xlink:href="clnn-20210930.xsd#clnn_LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems" xlink:to="clnn_LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_FinanceLeasesMember" xlink:href="clnn-20210930.xsd#clnn_FinanceLeasesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="clnn_FinanceLeasesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_OperatingLeasesMember" xlink:href="clnn-20210930.xsd#clnn_OperatingLeasesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="clnn_OperatingLeasesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_CapitalLeasesAmountRepresentingInterestdiscounting" xlink:href="clnn-20210930.xsd#clnn_CapitalLeasesAmountRepresentingInterestdiscounting"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="clnn_CapitalLeasesAmountRepresentingInterestdiscounting" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_OperatingLeasesAmountRepresentingInterestdiscounting" xlink:href="clnn-20210930.xsd#clnn_OperatingLeasesAmountRepresentingInterestdiscounting"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="clnn_OperatingLeasesAmountRepresentingInterestdiscounting" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_CapitalLeasesFutureLeaseIncentives" xlink:href="clnn-20210930.xsd#clnn_CapitalLeasesFutureLeaseIncentives"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="clnn_CapitalLeasesFutureLeaseIncentives" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_OperatingLeasesLessFutureLeaseIncentives" xlink:href="clnn-20210930.xsd#clnn_OperatingLeasesLessFutureLeaseIncentives"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="clnn_OperatingLeasesLessFutureLeaseIncentives" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_CapitalLeaseObligationsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="16" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleoffinanceleaseobligationsincludedinpropertyandequipmentTable">
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfFinanceLeaseObligationsIncludedInPropertyAndEquipmentAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfFinanceLeaseObligationsIncludedInPropertyAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="clnn_FinanceLeaseLaboratoryEquipmentGross" xlink:href="clnn-20210930.xsd#clnn_FinanceLeaseLaboratoryEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfFinanceLeaseObligationsIncludedInPropertyAndEquipmentAbstract" xlink:to="clnn_FinanceLeaseLaboratoryEquipmentGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_FinanceLeaseFurnitureAndFixturesGross" xlink:href="clnn-20210930.xsd#clnn_FinanceLeaseFurnitureAndFixturesGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfFinanceLeaseObligationsIncludedInPropertyAndEquipmentAbstract" xlink:to="clnn_FinanceLeaseFurnitureAndFixturesGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_FinanceLeaseWorkInProcessGross" xlink:href="clnn-20210930.xsd#clnn_FinanceLeaseWorkInProcessGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfFinanceLeaseObligationsIncludedInPropertyAndEquipmentAbstract" xlink:to="clnn_FinanceLeaseWorkInProcessGross" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_FinanceLeaseLiabilityGross" xlink:href="clnn-20210930.xsd#clnn_FinanceLeaseLiabilityGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfFinanceLeaseObligationsIncludedInPropertyAndEquipmentAbstract" xlink:to="clnn_FinanceLeaseLiabilityGross" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_AccumulatedDepreciationDepletionAndAmortizationLeases" xlink:href="clnn-20210930.xsd#clnn_AccumulatedDepreciationDepletionAndAmortizationLeases"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfFinanceLeaseObligationsIncludedInPropertyAndEquipmentAbstract" xlink:to="clnn_AccumulatedDepreciationDepletionAndAmortizationLeases" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_FinanceLeaseLiabilityNet" xlink:href="clnn-20210930.xsd#clnn_FinanceLeaseLiabilityNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfFinanceLeaseObligationsIncludedInPropertyAndEquipmentAbstract" xlink:to="clnn_FinanceLeaseLiabilityNet" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleoffinanceandoperatingleasecostsTable">
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfFinanceAndOperatingLeaseCostsAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfFinanceAndOperatingLeaseCostsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfFinanceAndOperatingLeaseCostsAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_VariableLeaseCost" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_LeaseCost" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofsupplementalcashflowinformationTable">
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfSupplementalCashFlowInformationAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfSupplementalCashFlowInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="clnn_OperatingCashFlowsFromOperatingLeases" xlink:href="clnn-20210930.xsd#clnn_OperatingCashFlowsFromOperatingLeases"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfSupplementalCashFlowInformationAbstract" xlink:to="clnn_OperatingCashFlowsFromOperatingLeases" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_OperatingCashFlowsFromFinanceLeases" xlink:href="clnn-20210930.xsd#clnn_OperatingCashFlowsFromFinanceLeases"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfSupplementalCashFlowInformationAbstract" xlink:to="clnn_OperatingCashFlowsFromFinanceLeases" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_FinanceCashFlowsFromFinanceLeases" xlink:href="clnn-20210930.xsd#clnn_FinanceCashFlowsFromFinanceLeases"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfSupplementalCashFlowInformationAbstract" xlink:to="clnn_FinanceCashFlowsFromFinanceLeases" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleoflongtermdebtnetoforiginalissuediscountandunamortizeddebtissuancecostsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_TermLoansAxis" xlink:href="clnn-20210930.xsd#clnn_TermLoansAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="clnn_TermLoansAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_TermLoansDomain" xlink:href="clnn-20210930.xsd#clnn_TermLoansDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="clnn_TermLoansAxis" xlink:to="clnn_TermLoansDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_TermLoansDomain_0" xlink:href="clnn-20210930.xsd#clnn_TermLoansDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="clnn_TermLoansAxis" xlink:to="clnn_TermLoansDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_MarylandDepartmentOfHousingCommunityDevelopmentMember" xlink:href="clnn-20210930.xsd#clnn_MarylandDepartmentOfHousingCommunityDevelopmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_TermLoansDomain" xlink:to="clnn_MarylandDepartmentOfHousingCommunityDevelopmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_AdvanceCecilIncMember" xlink:href="clnn-20210930.xsd#clnn_AdvanceCecilIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_TermLoansDomain" xlink:to="clnn_AdvanceCecilIncMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_PaycheckProtectionProgramMember" xlink:href="clnn-20210930.xsd#clnn_PaycheckProtectionProgramMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_TermLoansDomain" xlink:to="clnn_PaycheckProtectionProgramMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_AvenueVentureOpportunitiesFundsLPMember" xlink:href="clnn-20210930.xsd#clnn_AvenueVentureOpportunitiesFundsLPMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_TermLoansDomain" xlink:to="clnn_AvenueVentureOpportunitiesFundsLPMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_OtherTermLoanMember" xlink:href="clnn-20210930.xsd#clnn_OtherTermLoanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_TermLoansDomain" xlink:to="clnn_OtherTermLoanMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_TermLoansAbstract" xlink:href="clnn-20210930.xsd#clnn_TermLoansAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="clnn_TermLoansAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_InterestRate" xlink:href="clnn-20210930.xsd#clnn_InterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_TermLoansAbstract" xlink:to="clnn_InterestRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_TotalTermLoans" xlink:href="clnn-20210930.xsd#clnn_TotalTermLoans"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_TermLoansAbstract" xlink:to="clnn_TotalTermLoans" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_TermLoansAbstract" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_TermLoansAbstract" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_TotalNotesPayableAndConvertibleNotesPayable" xlink:href="clnn-20210930.xsd#clnn_TotalNotesPayableAndConvertibleNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_TermLoansAbstract" xlink:to="clnn_TotalNotesPayableAndConvertibleNotesPayable" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleoffuturepaymentsnetofunamortizeddebtdiscountsTable">
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscountsAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscountsAbstract"/>
    <loc xlink:type="locator" xlink:label="clnn_DebtInstrumentUnamortizedDiscountRemainderOfFiscalYear" xlink:href="clnn-20210930.xsd#clnn_DebtInstrumentUnamortizedDiscountRemainderOfFiscalYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscountsAbstract" xlink:to="clnn_DebtInstrumentUnamortizedDiscountRemainderOfFiscalYear" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_DebtInstrumentUnamortizedDiscountYearOne" xlink:href="clnn-20210930.xsd#clnn_DebtInstrumentUnamortizedDiscountYearOne"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscountsAbstract" xlink:to="clnn_DebtInstrumentUnamortizedDiscountYearOne" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_DebtInstrumentUnamortizedDiscountYearTwo" xlink:href="clnn-20210930.xsd#clnn_DebtInstrumentUnamortizedDiscountYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscountsAbstract" xlink:to="clnn_DebtInstrumentUnamortizedDiscountYearTwo" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_DebtInstrumentUnamortizedDiscountYearThree" xlink:href="clnn-20210930.xsd#clnn_DebtInstrumentUnamortizedDiscountYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscountsAbstract" xlink:to="clnn_DebtInstrumentUnamortizedDiscountYearThree" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_DebtInstrumentUnamortizedDiscountYearFour" xlink:href="clnn-20210930.xsd#clnn_DebtInstrumentUnamortizedDiscountYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscountsAbstract" xlink:to="clnn_DebtInstrumentUnamortizedDiscountYearFour" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_DebtInstrumentUnamortizedDiscountYearFive" xlink:href="clnn-20210930.xsd#clnn_DebtInstrumentUnamortizedDiscountYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscountsAbstract" xlink:to="clnn_DebtInstrumentUnamortizedDiscountYearFive" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_DebtInstrumentThereafter" xlink:href="clnn-20210930.xsd#clnn_DebtInstrumentThereafter"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_DebtInstrumentUnamortizedDiscountYearFive" xlink:to="clnn_DebtInstrumentThereafter" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_FuturePrincipalPayments" xlink:href="clnn-20210930.xsd#clnn_FuturePrincipalPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_DebtInstrumentThereafter" xlink:to="clnn_FuturePrincipalPayments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_DebtInstrumentUnamortizedDiscountYearFive" xlink:to="us-gaap_DebtInstrumentUnamortizedPremium" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentUnamortizedPremium" xlink:to="us-gaap_DebtSecurities" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofoutstandingwarrantstopurchasesharesofcommonstockTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_WarrantsDateMember" xlink:href="clnn-20210930.xsd#clnn_WarrantsDateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="clnn_WarrantsDateMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_WarrantsDate1Member" xlink:href="clnn-20210930.xsd#clnn_WarrantsDate1Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="clnn_WarrantsDate1Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_December20201Member" xlink:href="clnn-20210930.xsd#clnn_December20201Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="clnn_December20201Member" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_WarrantsDate2Member" xlink:href="clnn-20210930.xsd#clnn_WarrantsDate2Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="clnn_WarrantsDate2Member" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_May2021Member" xlink:href="clnn-20210930.xsd#clnn_May2021Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="clnn_May2021Member" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_NumberOfSharesIssuable" xlink:href="clnn-20210930.xsd#clnn_NumberOfSharesIssuable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="clnn_NumberOfSharesIssuable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrantsExercisePrice" xlink:href="clnn-20210930.xsd#clnn_CommonStockWarrantsExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="clnn_CommonStockWarrantsExercisePrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrantsExercisable" xlink:href="clnn-20210930.xsd#clnn_CommonStockWarrantsExercisable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="clnn_CommonStockWarrantsExercisable" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrantsClassification" xlink:href="clnn-20210930.xsd#clnn_CommonStockWarrantsClassification"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="clnn_CommonStockWarrantsClassification" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrantsExpiration" xlink:href="clnn-20210930.xsd#clnn_CommonStockWarrantsExpiration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="clnn_CommonStockWarrantsExpiration" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofcomponentsofincomelossbeforeincometaxesTable">
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_TotalLossBeforeIncomeTaxes" xlink:href="clnn-20210930.xsd#clnn_TotalLossBeforeIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesAbstract" xlink:to="clnn_TotalLossBeforeIncomeTaxes" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofstockbasedcompensationexpenseTable">
    <loc xlink:type="locator" xlink:label="clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems" xlink:href="clnn-20210930.xsd#clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable" xlink:href="clnn-20210930.xsd#clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems" xlink:to="clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofoutstandingcommonstockoptionsandrelatedactivityTable">
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValue" xlink:href="clnn-20210930.xsd#clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted" xlink:href="clnn-20210930.xsd#clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueGranted" xlink:href="clnn-20210930.xsd#clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueGranted" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ShareBasedCompensationArrangementNumberOfOptionsExercised" xlink:href="clnn-20210930.xsd#clnn_ShareBasedCompensationArrangementNumberOfOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="clnn_ShareBasedCompensationArrangementNumberOfOptionsExercised" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_WeightedAverageRemainingTermYearsExercised" xlink:href="clnn-20210930.xsd#clnn_WeightedAverageRemainingTermYearsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="clnn_WeightedAverageRemainingTermYearsExercised" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue" xlink:href="clnn-20210930.xsd#clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_WeightedAverageRemainingTermYearsForfeited" xlink:href="clnn-20210930.xsd#clnn_WeightedAverageRemainingTermYearsForfeited"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="clnn_WeightedAverageRemainingTermYearsForfeited" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue" xlink:href="clnn-20210930.xsd#clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber" xlink:href="clnn-20210930.xsd#clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_WeightedAverageExercisePricePerShareOptionVestedAndExercisable" xlink:href="clnn-20210930.xsd#clnn_WeightedAverageExercisePricePerShareOptionVestedAndExercisable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="clnn_WeightedAverageExercisePricePerShareOptionVestedAndExercisable" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_WeightedAverageExercisePriceWeightedAverageRemainingTermYearsOptionsVestedAndEexercisableEnding" xlink:href="clnn-20210930.xsd#clnn_WeightedAverageExercisePriceWeightedAverageRemainingTermYearsOptionsVestedAndEexercisableEnding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="clnn_WeightedAverageExercisePriceWeightedAverageRemainingTermYearsOptionsVestedAndEexercisableEnding" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueIntrinsicValueOptionsVestedAndExercisableEnding" xlink:href="clnn-20210930.xsd#clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueIntrinsicValueOptionsVestedAndExercisableEnding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueIntrinsicValueOptionsVestedAndExercisableEnding" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm1" xlink:href="clnn-20210930.xsd#clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm1" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_IntrinsicValueStockOptionsVestedAndExpectedToVestIntrinsicValueOptionsV" xlink:href="clnn-20210930.xsd#clnn_IntrinsicValueStockOptionsVestedAndExpectedToVestIntrinsicValueOptionsV"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="clnn_IntrinsicValueStockOptionsVestedAndExpectedToVestIntrinsicValueOptionsV" order="24" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsTable">
    <loc xlink:type="locator" xlink:label="clnn_StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsLineItems" xlink:href="clnn-20210930.xsd#clnn_StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsTable" xlink:href="clnn-20210930.xsd#clnn_StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsLineItems" xlink:to="clnn_StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofrestrictedcommonstockactivityTable">
    <loc xlink:type="locator" xlink:label="clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems" xlink:href="clnn-20210930.xsd#clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityTable" xlink:href="clnn-20210930.xsd#clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems" xlink:to="clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityTable" xlink:to="us-gaap_AwardTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable">
    <loc xlink:type="locator" xlink:label="clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems" xlink:href="clnn-20210930.xsd#clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable" xlink:href="clnn-20210930.xsd#clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems" xlink:to="clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems" xlink:to="us-gaap_NotesPayableFairValueDisclosure" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NotesPayableFairValueDisclosure" xlink:to="us-gaap_DerivativeLiabilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_CleneNanomedicineContingentEarnoutFairValueDisclosure" xlink:href="clnn-20210930.xsd#clnn_CleneNanomedicineContingentEarnoutFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NotesPayableFairValueDisclosure" xlink:to="clnn_CleneNanomedicineContingentEarnoutFairValueDisclosure" order="1" xbrldt:closed="true"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSraqWjSnTNF4jeT3oaMW8W5R0MkiIXXy8k2PQbBklJ1lYSX00RI6mU1NUjmu2Z8DGiLsvWC/Nx+2e5I3XA4/waZZD17aBEHbiQmUEtZYNMriew3bFfu2eViLA2wfQ1rEEEBO8y7g2agPYYHRPjjYinU2sOdZKJOmWibriB+2p9l9lEIdVA+FX4HG] CSR-->
    <loc xlink:type="locator" xlink:label="clnn_InitialShareholdersContingentEarnoutFairValueDisclosure" xlink:href="clnn-20210930.xsd#clnn_InitialShareholdersContingentEarnoutFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NotesPayableFairValueDisclosure" xlink:to="clnn_InitialShareholdersContingentEarnoutFairValueDisclosure" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofunobservableinputstotheconversionfeaturewarrantliabilityandcontingentearnoutvaluationmodelsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_ValuationTechniqueAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="srt_RangeAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_WarrantLiabilityMember" xlink:href="clnn-20210930.xsd#clnn_WarrantLiabilityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="clnn_WarrantLiabilityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_BlackScholesValuationModelMember" xlink:href="clnn-20210930.xsd#clnn_BlackScholesValuationModelMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="clnn_BlackScholesValuationModelMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_MonteCarloSimulationMember" xlink:href="clnn-20210930.xsd#clnn_MonteCarloSimulationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="clnn_MonteCarloSimulationMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ContingentEarnOutMember" xlink:href="clnn-20210930.xsd#clnn_ContingentEarnOutMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="clnn_ContingentEarnOutMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsTable">
    <loc xlink:type="locator" xlink:label="clnn_FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsLineItems" xlink:href="clnn-20210930.xsd#clnn_FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsTable" xlink:href="clnn-20210930.xsd#clnn_FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsLineItems" xlink:to="clnn_FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableOtherPayablesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_NotesPayableOtherPayablesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_CleneNanomedicineContingentEarnoutMember" xlink:href="clnn-20210930.xsd#clnn_CleneNanomedicineContingentEarnoutMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="clnn_CleneNanomedicineContingentEarnoutMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_InitialShareholdersContingentEarnoutMember" xlink:href="clnn-20210930.xsd#clnn_InitialShareholdersContingentEarnoutMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="clnn_InitialShareholdersContingentEarnoutMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_WarrantLiabilityMember" xlink:href="clnn-20210930.xsd#clnn_WarrantLiabilityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="clnn_WarrantLiabilityMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_DerivativeInstrumentMember" xlink:href="clnn-20210930.xsd#clnn_DerivativeInstrumentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="clnn_DerivativeInstrumentMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_PreferredStockWarrantsMember" xlink:href="clnn-20210930.xsd#clnn_PreferredStockWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="clnn_PreferredStockWarrantsMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_InitialFairValueOfInstrument" xlink:href="clnn-20210930.xsd#clnn_InitialFairValueOfInstrument"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsLineItems" xlink:to="clnn_InitialFairValueOfInstrument" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_FairValueIssuanceOfConvertiblePromissoryNotes" xlink:href="clnn-20210930.xsd#clnn_FairValueIssuanceOfConvertiblePromissoryNotes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsLineItems" xlink:to="clnn_FairValueIssuanceOfConvertiblePromissoryNotes" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_IncreseDecreaseInFairValue" xlink:href="clnn-20210930.xsd#clnn_IncreseDecreaseInFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsLineItems" xlink:to="clnn_IncreseDecreaseInFairValue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_FairValueMeasurementExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN" xlink:href="clnn-20210930.xsd#clnn_FairValueMeasurementExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsLineItems" xlink:to="clnn_FairValueMeasurementExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofbasicanddilutednetlosspershareTable">
    <loc xlink:type="locator" xlink:label="clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareLineItems" xlink:href="clnn-20210930.xsd#clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareTable" xlink:href="clnn-20210930.xsd#clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareLineItems" xlink:to="clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_NetIncomeLossPerShareAttributableToCommonShareholdersMember" xlink:href="clnn-20210930.xsd#clnn_NetIncomeLossPerShareAttributableToCommonShareholdersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="clnn_NetIncomeLossPerShareAttributableToCommonShareholdersMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareLineItems" xlink:to="us-gaap_InterestOnConvertibleDebtNetOfTax" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_WeightedAverageSharesOutstanding" xlink:href="clnn-20210930.xsd#clnn_WeightedAverageSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareLineItems" xlink:to="clnn_WeightedAverageSharesOutstanding" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_WeightedAverageEffectOfPotentiallyDilutiveSecuritiesAbstract" xlink:href="clnn-20210930.xsd#clnn_WeightedAverageEffectOfPotentiallyDilutiveSecuritiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareLineItems" xlink:to="clnn_WeightedAverageEffectOfPotentiallyDilutiveSecuritiesAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_EffectOfPotentiallyDilutiveStockOptionsinDollars" xlink:href="clnn-20210930.xsd#clnn_EffectOfPotentiallyDilutiveStockOptionsinDollars"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_WeightedAverageEffectOfPotentiallyDilutiveSecuritiesAbstract" xlink:to="clnn_EffectOfPotentiallyDilutiveStockOptionsinDollars" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_EffectOfPotentiallyDilutiveRestrictedStockAwards" xlink:href="clnn-20210930.xsd#clnn_EffectOfPotentiallyDilutiveRestrictedStockAwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_WeightedAverageEffectOfPotentiallyDilutiveSecuritiesAbstract" xlink:to="clnn_EffectOfPotentiallyDilutiveRestrictedStockAwards" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_EffectOfPotentiallyDilutiveConvertibleNotesPayable" xlink:href="clnn-20210930.xsd#clnn_EffectOfPotentiallyDilutiveConvertibleNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_WeightedAverageEffectOfPotentiallyDilutiveSecuritiesAbstract" xlink:to="clnn_EffectOfPotentiallyDilutiveConvertibleNotesPayable" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_EffectOfPotentiallyDilutiveUnvestedRestrictedStockAwardsShares" xlink:href="clnn-20210930.xsd#clnn_EffectOfPotentiallyDilutiveUnvestedRestrictedStockAwardsShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_WeightedAverageEffectOfPotentiallyDilutiveSecuritiesAbstract" xlink:to="clnn_EffectOfPotentiallyDilutiveUnvestedRestrictedStockAwardsShares" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofsecuritiesexcludedfromcomputationofdilutednetincomelosspershareTable">
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfSecuritiesExcludedFromComputationOfDilutedNetIncomeLossPerShareAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfSecuritiesExcludedFromComputationOfDilutedNetIncomeLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="clnn_SeriesDRedeemableConvertiblePreferredStock" xlink:href="clnn-20210930.xsd#clnn_SeriesDRedeemableConvertiblePreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfSecuritiesExcludedFromComputationOfDilutedNetIncomeLossPerShareAbstract" xlink:to="clnn_SeriesDRedeemableConvertiblePreferredStock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_SeriesCRedeemableConvertiblePreferredStock" xlink:href="clnn-20210930.xsd#clnn_SeriesCRedeemableConvertiblePreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfSecuritiesExcludedFromComputationOfDilutedNetIncomeLossPerShareAbstract" xlink:to="clnn_SeriesCRedeemableConvertiblePreferredStock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_SeriesBRedeemableConvertiblePreferredStock" xlink:href="clnn-20210930.xsd#clnn_SeriesBRedeemableConvertiblePreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfSecuritiesExcludedFromComputationOfDilutedNetIncomeLossPerShareAbstract" xlink:to="clnn_SeriesBRedeemableConvertiblePreferredStock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_SeriesARedeemableConvertiblePreferredStock" xlink:href="clnn-20210930.xsd#clnn_SeriesARedeemableConvertiblePreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfSecuritiesExcludedFromComputationOfDilutedNetIncomeLossPerShareAbstract" xlink:to="clnn_SeriesARedeemableConvertiblePreferredStock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_SeriesDRedeemableConvertiblePreferredStockWarrants" xlink:href="clnn-20210930.xsd#clnn_SeriesDRedeemableConvertiblePreferredStockWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfSecuritiesExcludedFromComputationOfDilutedNetIncomeLossPerShareAbstract" xlink:to="clnn_SeriesDRedeemableConvertiblePreferredStockWarrants" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_SeriesARedeemableConvertiblePreferredStockWarrantsinShares" xlink:href="clnn-20210930.xsd#clnn_SeriesARedeemableConvertiblePreferredStockWarrantsinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfSecuritiesExcludedFromComputationOfDilutedNetIncomeLossPerShareAbstract" xlink:to="clnn_SeriesARedeemableConvertiblePreferredStockWarrantsinShares" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ConvertibleNotesPayables" xlink:href="clnn-20210930.xsd#clnn_ConvertibleNotesPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfSecuritiesExcludedFromComputationOfDilutedNetIncomeLossPerShareAbstract" xlink:to="clnn_ConvertibleNotesPayables" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrants" xlink:href="clnn-20210930.xsd#clnn_CommonStockWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfSecuritiesExcludedFromComputationOfDilutedNetIncomeLossPerShareAbstract" xlink:to="clnn_CommonStockWarrants" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_OptionsToPurchaseCommonStockinShares" xlink:href="clnn-20210930.xsd#clnn_OptionsToPurchaseCommonStockinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfSecuritiesExcludedFromComputationOfDilutedNetIncomeLossPerShareAbstract" xlink:to="clnn_OptionsToPurchaseCommonStockinShares" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_UnvestedRestrictedStockAwardsShares" xlink:href="clnn-20210930.xsd#clnn_UnvestedRestrictedStockAwardsShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfSecuritiesExcludedFromComputationOfDilutedNetIncomeLossPerShareAbstract" xlink:to="clnn_UnvestedRestrictedStockAwardsShares" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ChardanUnitPurchaseOptionWarrants" xlink:href="clnn-20210930.xsd#clnn_ChardanUnitPurchaseOptionWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfSecuritiesExcludedFromComputationOfDilutedNetIncomeLossPerShareAbstract" xlink:to="clnn_ChardanUnitPurchaseOptionWarrants" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_CleneNanomedicineContingentEarnoutShares" xlink:href="clnn-20210930.xsd#clnn_CleneNanomedicineContingentEarnoutShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfSecuritiesExcludedFromComputationOfDilutedNetIncomeLossPerShareAbstract" xlink:to="clnn_CleneNanomedicineContingentEarnoutShares" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_InitialShareholdersContingentEarnoutShares" xlink:href="clnn-20210930.xsd#clnn_InitialShareholdersContingentEarnoutShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfSecuritiesExcludedFromComputationOfDilutedNetIncomeLossPerShareAbstract" xlink:to="clnn_InitialShareholdersContingentEarnoutShares" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_TotalDilutiveSecurities" xlink:href="clnn-20210930.xsd#clnn_TotalDilutiveSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ScheduleOfSecuritiesExcludedFromComputationOfDilutedNetIncomeLossPerShareAbstract" xlink:to="clnn_TotalDilutiveSecurities" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetbylocationTable">
    <loc xlink:type="locator" xlink:label="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationLineItems" xlink:href="clnn-20210930.xsd#clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationTable" xlink:href="clnn-20210930.xsd#clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationLineItems" xlink:to="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationTable" xlink:to="srt_StatementGeographicalAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_AU" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_AU"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_AU" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofdrugsandsupplementssegmentsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_DrugsMember" xlink:href="clnn-20210930.xsd#clnn_DrugsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="clnn_DrugsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_SupplementsMember" xlink:href="clnn-20210930.xsd#clnn_SupplementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="clnn_SupplementsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Revenues" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetbysegmentTable">
    <loc xlink:type="locator" xlink:label="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentLineItems" xlink:href="clnn-20210930.xsd#clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentTable" xlink:href="clnn-20210930.xsd#clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentLineItems" xlink:to="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_DrugsMember" xlink:href="clnn-20210930.xsd#clnn_DrugsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="clnn_DrugsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_SupplementsMember" xlink:href="clnn-20210930.xsd#clnn_SupplementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="clnn_SupplementsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_TotalPropertyAndEquipmentNet" xlink:href="clnn-20210930.xsd#clnn_TotalPropertyAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentLineItems" xlink:to="clnn_TotalPropertyAndEquipmentNet" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/NatureoftheBusinessDetails">
    <loc xlink:type="locator" xlink:label="clnn_NatureoftheBusinessDetailsLineItems" xlink:href="clnn-20210930.xsd#clnn_NatureoftheBusinessDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_NatureoftheBusinessDetailsTable" xlink:href="clnn-20210930.xsd#clnn_NatureoftheBusinessDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_NatureoftheBusinessDetailsLineItems" xlink:to="clnn_NatureoftheBusinessDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_NatureoftheBusinessDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_NatureoftheBusinessDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_NatureoftheBusinessDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_CleneIncMember" xlink:href="clnn-20210930.xsd#clnn_CleneIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="clnn_CleneIncMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_TottenhamMember" xlink:href="clnn-20210930.xsd#clnn_TottenhamMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="clnn_TottenhamMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_CleneNanomedicineMember" xlink:href="clnn-20210930.xsd#clnn_CleneNanomedicineMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="clnn_CleneNanomedicineMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_PIPEMember" xlink:href="clnn-20210930.xsd#clnn_PIPEMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="clnn_PIPEMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NatureoftheBusinessDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_AggregateFutureProceedsWarrantsExercised" xlink:href="clnn-20210930.xsd#clnn_AggregateFutureProceedsWarrantsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NatureoftheBusinessDetailsLineItems" xlink:to="clnn_AggregateFutureProceedsWarrantsExercised" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_OfferingCost" xlink:href="clnn-20210930.xsd#clnn_OfferingCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NatureoftheBusinessDetailsLineItems" xlink:to="clnn_OfferingCost" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_AggregateProceedsReceived" xlink:href="clnn-20210930.xsd#clnn_AggregateProceedsReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NatureoftheBusinessDetailsLineItems" xlink:to="clnn_AggregateProceedsReceived" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_OfferingPricePerShare" xlink:href="clnn-20210930.xsd#clnn_OfferingPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NatureoftheBusinessDetailsLineItems" xlink:to="clnn_OfferingPricePerShare" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NatureoftheBusinessDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockUnderlyingWarrantOutstanding" xlink:href="clnn-20210930.xsd#clnn_CommonStockUnderlyingWarrantOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NatureoftheBusinessDetailsLineItems" xlink:to="clnn_CommonStockUnderlyingWarrantOutstanding" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ShareIssuanceOfCommonStockPrivateOffering" xlink:href="clnn-20210930.xsd#clnn_ShareIssuanceOfCommonStockPrivateOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NatureoftheBusinessDetailsLineItems" xlink:to="clnn_ShareIssuanceOfCommonStockPrivateOffering" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NatureoftheBusinessDetailsLineItems" xlink:to="us-gaap_NetIncomeLoss" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NatureoftheBusinessDetailsLineItems" xlink:to="us-gaap_Cash" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NatureoftheBusinessDetailsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NatureoftheBusinessDetailsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="clnn-20210930.xsd#clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="clnn-20210930.xsd#clnn_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="clnn_SummaryofSignificantAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollateralAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollateralAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_CollateralAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollateralDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollateralDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CollateralAxis" xlink:to="us-gaap_CollateralDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollateralDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollateralDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CollateralAxis" xlink:to="us-gaap_CollateralDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_RangeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollateralDomain" xlink:to="us-gaap_EquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollateralDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_RestrictedInvestments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_InventoryRawMaterials" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_InventoryFinishedGoods" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DeferredRevenue" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_GrantFundingRecognizedOnConditionalGrants" xlink:href="clnn-20210930.xsd#clnn_GrantFundingRecognizedOnConditionalGrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="clnn_GrantFundingRecognizedOnConditionalGrants" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails">
    <loc xlink:type="locator" xlink:label="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:href="clnn-20210930.xsd#clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable" xlink:href="clnn-20210930.xsd#clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable" xlink:to="us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfFreshStartAdjustmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfFreshStartAdjustmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" xlink:to="us-gaap_TypeOfFreshStartAdjustmentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfFreshStartAdjustmentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfFreshStartAdjustmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" xlink:to="us-gaap_TypeOfFreshStartAdjustmentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExchangeClearedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExchangeClearedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfFreshStartAdjustmentDomain" xlink:to="us-gaap_ExchangeClearedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfFreshStartAdjustmentDomain" xlink:to="us-gaap_CommonStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_CleneIncMember" xlink:href="clnn-20210930.xsd#clnn_CleneIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="clnn_CleneIncMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_CleneNanomedicineMember" xlink:href="clnn-20210930.xsd#clnn_CleneNanomedicineMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="clnn_CleneNanomedicineMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ChardanCapitalMarketsLLCMember" xlink:href="clnn-20210930.xsd#clnn_ChardanCapitalMarketsLLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="clnn_ChardanCapitalMarketsLLCMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_LifeSciCapitalLLCMember" xlink:href="clnn-20210930.xsd#clnn_LifeSciCapitalLLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="clnn_LifeSciCapitalLLCMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_TottenhamMember" xlink:href="clnn-20210930.xsd#clnn_TottenhamMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="clnn_TottenhamMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_PIPEMember" xlink:href="clnn-20210930.xsd#clnn_PIPEMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="clnn_PIPEMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ReverseRecapitalizationMember" xlink:href="clnn-20210930.xsd#clnn_ReverseRecapitalizationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="clnn_ReverseRecapitalizationMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockParOrStatedValuesPerShare" xlink:href="clnn-20210930.xsd#clnn_CommonStockParOrStatedValuesPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="clnn_CommonStockParOrStatedValuesPerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_SharesCancelledUponReverseRecapitalization" xlink:href="clnn-20210930.xsd#clnn_SharesCancelledUponReverseRecapitalization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="clnn_SharesCancelledUponReverseRecapitalization" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_InitialShareholdersContingentsEarnout" xlink:href="clnn-20210930.xsd#clnn_InitialShareholdersContingentsEarnout"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="clnn_InitialShareholdersContingentsEarnout" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ExchangeOfSharesReceived" xlink:href="clnn-20210930.xsd#clnn_ExchangeOfSharesReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="clnn_ExchangeOfSharesReceived" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ReverseRecapitalizationExchangeRatio" xlink:href="clnn-20210930.xsd#clnn_ReverseRecapitalizationExchangeRatio"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="clnn_ReverseRecapitalizationExchangeRatio" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_SharesHeldInEscrowPercentage" xlink:href="clnn-20210930.xsd#clnn_SharesHeldInEscrowPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="clnn_SharesHeldInEscrowPercentage" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_SharesHeldInEscrow" xlink:href="clnn-20210930.xsd#clnn_SharesHeldInEscrow"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="clnn_SharesHeldInEscrow" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ExchangeRatioPercentage" xlink:href="clnn-20210930.xsd#clnn_ExchangeRatioPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="clnn_ExchangeRatioPercentage" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ProceedsFromReverseRecapitalization" xlink:href="clnn-20210930.xsd#clnn_ProceedsFromReverseRecapitalization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="clnn_ProceedsFromReverseRecapitalization" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_SaleOfUnitsNumberOfUnitsIssued" xlink:href="clnn-20210930.xsd#clnn_SaleOfUnitsNumberOfUnitsIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="clnn_SaleOfUnitsNumberOfUnitsIssued" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_UnitsIssuedPricePerUnit" xlink:href="clnn-20210930.xsd#clnn_UnitsIssuedPricePerUnit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="clnn_UnitsIssuedPricePerUnit" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ExercisePrice" xlink:href="clnn-20210930.xsd#clnn_ExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="clnn_ExercisePrice" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ServicesLetterAgreementDescription" xlink:href="clnn-20210930.xsd#clnn_ServicesLetterAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="clnn_ServicesLetterAgreementDescription" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockOtherSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="us-gaap_CommonStockOtherSharesOutstanding" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_WarrantsToPurchaseCommonStockIssuedAndOutstanding" xlink:href="clnn-20210930.xsd#clnn_WarrantsToPurchaseCommonStockIssuedAndOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="clnn_WarrantsToPurchaseCommonStockIssuedAndOutstanding" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherUnderwritingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherUnderwritingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="us-gaap_OtherUnderwritingExpense" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantExercisePriceIncrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="us-gaap_WarrantExercisePriceIncrease" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_AggregateGrossProceedWarrantsExercised" xlink:href="clnn-20210930.xsd#clnn_AggregateGrossProceedWarrantsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="clnn_AggregateGrossProceedWarrantsExercised" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ChardanUnitPurchaseOption" xlink:href="clnn-20210930.xsd#clnn_ChardanUnitPurchaseOption"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="clnn_ChardanUnitPurchaseOption" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_NetIssuanceSharesOfCommonStock" xlink:href="clnn-20210930.xsd#clnn_NetIssuanceSharesOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="clnn_NetIssuanceSharesOfCommonStock" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_WarrantsToPurchaseSharesOfCommonStock" xlink:href="clnn-20210930.xsd#clnn_WarrantsToPurchaseSharesOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="clnn_WarrantsToPurchaseSharesOfCommonStock" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_CleneNanomedicineContingentEarnOutMilestone1Shares" xlink:href="clnn-20210930.xsd#clnn_CleneNanomedicineContingentEarnOutMilestone1Shares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="clnn_CleneNanomedicineContingentEarnOutMilestone1Shares" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_CleneNanomedicineContingentEarnoutMilestone1Price" xlink:href="clnn-20210930.xsd#clnn_CleneNanomedicineContingentEarnoutMilestone1Price"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="clnn_CleneNanomedicineContingentEarnoutMilestone1Price" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_CleneNanomedicineContingentEarnoutMilestone2Shares" xlink:href="clnn-20210930.xsd#clnn_CleneNanomedicineContingentEarnoutMilestone2Shares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="clnn_CleneNanomedicineContingentEarnoutMilestone2Shares" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_CleneNanomedicineContingentEarnoutMilestone2Price" xlink:href="clnn-20210930.xsd#clnn_CleneNanomedicineContingentEarnoutMilestone2Price"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="clnn_CleneNanomedicineContingentEarnoutMilestone2Price" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_CleneNanomedicineContingentEarnoutMilestone3Shares" xlink:href="clnn-20210930.xsd#clnn_CleneNanomedicineContingentEarnoutMilestone3Shares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="clnn_CleneNanomedicineContingentEarnoutMilestone3Shares" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_IncreaseInCleneNanomedicineContingentEarnoutSharesUponReverseRecapitalization" xlink:href="clnn-20210930.xsd#clnn_IncreaseInCleneNanomedicineContingentEarnoutSharesUponReverseRecapitalization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="clnn_IncreaseInCleneNanomedicineContingentEarnoutSharesUponReverseRecapitalization" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_TotalCleneNanomedicineContingentEarnoutShares" xlink:href="clnn-20210930.xsd#clnn_TotalCleneNanomedicineContingentEarnoutShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="clnn_TotalCleneNanomedicineContingentEarnoutShares" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_InitialShareholdersContingentEarnoutMilestone1Shares" xlink:href="clnn-20210930.xsd#clnn_InitialShareholdersContingentEarnoutMilestone1Shares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="clnn_InitialShareholdersContingentEarnoutMilestone1Shares" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_InitialShareholdersContingentEarnoutMilestone2Shares" xlink:href="clnn-20210930.xsd#clnn_InitialShareholdersContingentEarnoutMilestone2Shares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="clnn_InitialShareholdersContingentEarnoutMilestone2Shares" order="37" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/PropertyandEquipmentNetDetails">
    <loc xlink:type="locator" xlink:label="clnn_PropertyandEquipmentNetDetailsLineItems" xlink:href="clnn-20210930.xsd#clnn_PropertyandEquipmentNetDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_PropertyandEquipmentNetDetailsTable" xlink:href="clnn-20210930.xsd#clnn_PropertyandEquipmentNetDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_PropertyandEquipmentNetDetailsLineItems" xlink:to="clnn_PropertyandEquipmentNetDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_PropertyandEquipmentNetDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_PropertyandEquipmentNetDetailsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_PropertyandEquipmentNetDetailsLineItems" xlink:to="us-gaap_Depreciation" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="clnn_RemainingRightofuseAsset" xlink:href="clnn-20210930.xsd#clnn_RemainingRightofuseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="clnn_RemainingRightofuseAsset" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_RecognizedGainOnOperatingLease" xlink:href="clnn-20210930.xsd#clnn_RecognizedGainOnOperatingLease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="clnn_RecognizedGainOnOperatingLease" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_RightOfUseAssets" xlink:href="clnn-20210930.xsd#clnn_RightOfUseAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="clnn_RightOfUseAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_LeaseholdImprovements" xlink:href="clnn-20210930.xsd#clnn_LeaseholdImprovements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="clnn_LeaseholdImprovements" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_IncreaseInRightOfUseAssets" xlink:href="clnn-20210930.xsd#clnn_IncreaseInRightOfUseAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="clnn_IncreaseInRightOfUseAssets" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_IncreaseInLeaseholdImprovements" xlink:href="clnn-20210930.xsd#clnn_IncreaseInLeaseholdImprovements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="clnn_IncreaseInLeaseholdImprovements" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_IncreaseInLeaseLiability" xlink:href="clnn-20210930.xsd#clnn_IncreaseInLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="clnn_IncreaseInLeaseLiability" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnTerminationOfLease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_GainLossOnTerminationOfLease" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_OperatingLeaseRightofUseAssets" xlink:href="clnn-20210930.xsd#clnn_OperatingLeaseRightofUseAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="clnn_OperatingLeaseRightofUseAssets" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncentiveToLessee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncentiveToLessee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_IncentiveToLessee" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_LeaseIncentiveRecordedConstructionInProgress" xlink:href="clnn-20210930.xsd#clnn_LeaseIncentiveRecordedConstructionInProgress"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="clnn_LeaseIncentiveRecordedConstructionInProgress" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LessorOperatingLeaseDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeaseDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LessorOperatingLeaseDescription" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_FinanceLeaseObligationsWeightedaverageInterestRate" xlink:href="clnn-20210930.xsd#clnn_FinanceLeaseObligationsWeightedaverageInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="clnn_FinanceLeaseObligationsWeightedaverageInterestRate" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_OperatingLeaseObligationsWeightedAverageInterestRate" xlink:href="clnn-20210930.xsd#clnn_OperatingLeaseObligationsWeightedAverageInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="clnn_OperatingLeaseObligationsWeightedAverageInterestRate" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="17" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/NotesPayableDetails">
    <loc xlink:type="locator" xlink:label="clnn_NotesPayableDetailsLineItems" xlink:href="clnn-20210930.xsd#clnn_NotesPayableDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_NotesPayableDetailsTable" xlink:href="clnn-20210930.xsd#clnn_NotesPayableDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="clnn_NotesPayableDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_NotesPayableDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_NotesPayableDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_NotesPayableDetailsTable" xlink:to="us-gaap_VestingAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VestingDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableOtherPayablesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_NotesPayableOtherPayablesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_TwoThousandNineteenMDLoanMember" xlink:href="clnn-20210930.xsd#clnn_TwoThousandNineteenMDLoanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="clnn_TwoThousandNineteenMDLoanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_TwoThousandNineteenCecilLoanMember" xlink:href="clnn-20210930.xsd#clnn_TwoThousandNineteenCecilLoanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="clnn_TwoThousandNineteenCecilLoanMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_PaycheckProtectionProgramNoteMember" xlink:href="clnn-20210930.xsd#clnn_PaycheckProtectionProgramNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="clnn_PaycheckProtectionProgramNoteMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_TwoThousandtwentyoneAvenueLoanMember" xlink:href="clnn-20210930.xsd#clnn_TwoThousandtwentyoneAvenueLoanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="clnn_TwoThousandtwentyoneAvenueLoanMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="us-gaap_LongTermDebt" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentDescription" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="us-gaap_InterestIncomeOther" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_SimpleInterestExpense" xlink:href="clnn-20210930.xsd#clnn_SimpleInterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="clnn_SimpleInterestExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_FairValueOfLongTermNotesPayable" xlink:href="clnn-20210930.xsd#clnn_FairValueOfLongTermNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="clnn_FairValueOfLongTermNotesPayable" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="us-gaap_OtherIncome" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesAndLoansPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="us-gaap_NotesAndLoansPayable" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_PercentageOfLoanAmountUsedToPayrollExpenses" xlink:href="clnn-20210930.xsd#clnn_PercentageOfLoanAmountUsedToPayrollExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="clnn_PercentageOfLoanAmountUsedToPayrollExpenses" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExtinguishmentOfDebtAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="us-gaap_ExtinguishmentOfDebtAmount" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_FundedAmountAtClosing" xlink:href="clnn-20210930.xsd#clnn_FundedAmountAtClosing"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="clnn_FundedAmountAtClosing" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_AccruedDebtIssuanceCosts" xlink:href="clnn-20210930.xsd#clnn_AccruedDebtIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="clnn_AccruedDebtIssuanceCosts" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_DebtInstrumentUnfundedBalance" xlink:href="clnn-20210930.xsd#clnn_DebtInstrumentUnfundedBalance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="clnn_DebtInstrumentUnfundedBalance" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_SecondLoanAmount" xlink:href="clnn-20210930.xsd#clnn_SecondLoanAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="clnn_SecondLoanAmount" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ConditionsForFutureFundingDescription" xlink:href="clnn-20210930.xsd#clnn_ConditionsForFutureFundingDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="clnn_ConditionsForFutureFundingDescription" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_RateOfInterestDescription" xlink:href="clnn-20210930.xsd#clnn_RateOfInterestDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="clnn_RateOfInterestDescription" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_AdditionalPaymentUponMaturityDescription" xlink:href="clnn-20210930.xsd#clnn_AdditionalPaymentUponMaturityDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="clnn_AdditionalPaymentUponMaturityDescription" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_WarrantToPurchaseShares" xlink:href="clnn-20210930.xsd#clnn_WarrantToPurchaseShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="clnn_WarrantToPurchaseShares" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockAtAnExercisePrice" xlink:href="clnn-20210930.xsd#clnn_CommonStockAtAnExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="clnn_CommonStockAtAnExercisePrice" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_Tranche2WarrantAdjustmentDescription" xlink:href="clnn-20210930.xsd#clnn_Tranche2WarrantAdjustmentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="clnn_Tranche2WarrantAdjustmentDescription" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ConversionPercentageOfCommonStockPriceForConvertibleNotePayable" xlink:href="clnn-20210930.xsd#clnn_ConversionPercentageOfCommonStockPriceForConvertibleNotePayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="clnn_ConversionPercentageOfCommonStockPriceForConvertibleNotePayable" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_TradingVolumeLimitForConversionOfConvertibleNotePayable" xlink:href="clnn-20210930.xsd#clnn_TradingVolumeLimitForConversionOfConvertibleNotePayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="clnn_TradingVolumeLimitForConversionOfConvertibleNotePayable" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ThresholdForRemovalOfFinancialCovenantsDescription" xlink:href="clnn-20210930.xsd#clnn_ThresholdForRemovalOfFinancialCovenantsDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="clnn_ThresholdForRemovalOfFinancialCovenantsDescription" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_MinimumCashBalanceForLoanCovenant" xlink:href="clnn-20210930.xsd#clnn_MinimumCashBalanceForLoanCovenant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="clnn_MinimumCashBalanceForLoanCovenant" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_FairValueOfWarrant" xlink:href="clnn-20210930.xsd#clnn_FairValueOfWarrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="clnn_FairValueOfWarrant" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_DebtInstrumentFinancingCosts" xlink:href="clnn-20210930.xsd#clnn_DebtInstrumentFinancingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="clnn_DebtInstrumentFinancingCosts" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="us-gaap_ConvertibleDebt" order="32" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/PreferredStockWarrantLiabilityDetails">
    <loc xlink:type="locator" xlink:label="clnn_PreferredStockWarrantLiabilityDetailsLineItems" xlink:href="clnn-20210930.xsd#clnn_PreferredStockWarrantLiabilityDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_PreferredStockWarrantLiabilityDetailsTable" xlink:href="clnn-20210930.xsd#clnn_PreferredStockWarrantLiabilityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_PreferredStockWarrantLiabilityDetailsLineItems" xlink:to="clnn_PreferredStockWarrantLiabilityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_PreferredStockWarrantLiabilityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesDPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_PreferredStockWarrantLiabilityDetailsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_PreferredStockWarrantLiabilityDetailsLineItems" xlink:to="us-gaap_WarrantExercisePriceDecrease" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_SharesOfWarrantsExercisable" xlink:href="clnn-20210930.xsd#clnn_SharesOfWarrantsExercisable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_PreferredStockWarrantLiabilityDetailsLineItems" xlink:to="clnn_SharesOfWarrantsExercisable" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_PercentOfFullydilutedEquityPurchasableUponExercise" xlink:href="clnn-20210930.xsd#clnn_PercentOfFullydilutedEquityPurchasableUponExercise"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_PreferredStockWarrantLiabilityDetailsLineItems" xlink:to="clnn_PercentOfFullydilutedEquityPurchasableUponExercise" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_LossInFairValueOfWarrantLiability" xlink:href="clnn-20210930.xsd#clnn_LossInFairValueOfWarrantLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_PreferredStockWarrantLiabilityDetailsLineItems" xlink:to="clnn_LossInFairValueOfWarrantLiability" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_FairValueAdjustmentOfWarrantsOutstanding" xlink:href="clnn-20210930.xsd#clnn_FairValueAdjustmentOfWarrantsOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_PreferredStockWarrantLiabilityDetailsLineItems" xlink:to="clnn_FairValueAdjustmentOfWarrantsOutstanding" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/CommonStockWarrantsDetails">
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrantsDetailsLineItems" xlink:href="clnn-20210930.xsd#clnn_CommonStockWarrantsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrantsDetailsTable" xlink:href="clnn-20210930.xsd#clnn_CommonStockWarrantsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_CommonStockWarrantsDetailsLineItems" xlink:to="clnn_CommonStockWarrantsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_CommonStockWarrantsDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_CommonStockWarrantsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_CommonStockWarrantsDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_PIPEWarrantsMember" xlink:href="clnn-20210930.xsd#clnn_PIPEWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="clnn_PIPEWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrantsMember" xlink:href="clnn-20210930.xsd#clnn_CommonStockWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="clnn_CommonStockWarrantsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_AvenueLoanMember" xlink:href="clnn-20210930.xsd#clnn_AvenueLoanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="clnn_AvenueLoanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_TwoThousandtwentyoneAvenueLoanMember" xlink:href="clnn-20210930.xsd#clnn_TwoThousandtwentyoneAvenueLoanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="clnn_TwoThousandtwentyoneAvenueLoanMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ChardanUnitPurchaseOptionMember" xlink:href="clnn-20210930.xsd#clnn_ChardanUnitPurchaseOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="clnn_ChardanUnitPurchaseOptionMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CommonStockWarrantsDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CommonStockWarrantsDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_PIPEWarrantsOwnershipLimit" xlink:href="clnn-20210930.xsd#clnn_PIPEWarrantsOwnershipLimit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CommonStockWarrantsDetailsLineItems" xlink:to="clnn_PIPEWarrantsOwnershipLimit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CommonStockWarrantsDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_CompanyWarrantRedemptionRight" xlink:href="clnn-20210930.xsd#clnn_CompanyWarrantRedemptionRight"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CommonStockWarrantsDetailsLineItems" xlink:to="clnn_CompanyWarrantRedemptionRight" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ExercisePriceOfWarrantsDescription" xlink:href="clnn-20210930.xsd#clnn_ExercisePriceOfWarrantsDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CommonStockWarrantsDetailsLineItems" xlink:to="clnn_ExercisePriceOfWarrantsDescription" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ConvertibleNotesDetails">
    <loc xlink:type="locator" xlink:label="clnn_ConvertibleNotesDetailsLineItems" xlink:href="clnn-20210930.xsd#clnn_ConvertibleNotesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_ConvertibleNotesDetailsTable" xlink:href="clnn-20210930.xsd#clnn_ConvertibleNotesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_ConvertibleNotesDetailsLineItems" xlink:to="clnn_ConvertibleNotesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_ConvertibleNotesDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_ConvertibleNotesDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_TwoThousandtwentyoneAvenueLoanMember" xlink:href="clnn-20210930.xsd#clnn_TwoThousandtwentyoneAvenueLoanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="clnn_TwoThousandtwentyoneAvenueLoanMember" order="1" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ConvertibleNotesDetailsLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ConvertibleNotesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_DescriptionOfConvertibleNotes" xlink:href="clnn-20210930.xsd#clnn_DescriptionOfConvertibleNotes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ConvertibleNotesDetailsLineItems" xlink:to="clnn_DescriptionOfConvertibleNotes" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ConvertibleNotesDetailsLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ConvertibleNotesDetailsLineItems" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExtinguishmentOfDebtAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ConvertibleNotesDetailsLineItems" xlink:to="us-gaap_ExtinguishmentOfDebtAmount" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ConvertibleNotesDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_PercentageOfStockPrice" xlink:href="clnn-20210930.xsd#clnn_PercentageOfStockPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ConvertibleNotesDetailsLineItems" xlink:to="clnn_PercentageOfStockPrice" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ConvertibleNotesDetailsLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ConvertibleNotesDetailsLineItems" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ConvertibleNotesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_DescriptionOfLossOnExtinguishment" xlink:href="clnn-20210930.xsd#clnn_DescriptionOfLossOnExtinguishment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ConvertibleNotesDetailsLineItems" xlink:to="clnn_DescriptionOfLossOnExtinguishment" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ConvertibleNotesPayableDescription" xlink:href="clnn-20210930.xsd#clnn_ConvertibleNotesPayableDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ConvertibleNotesDetailsLineItems" xlink:to="clnn_ConvertibleNotesPayableDescription" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_LoanOutstanding" xlink:href="clnn-20210930.xsd#clnn_LoanOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ConvertibleNotesDetailsLineItems" xlink:to="clnn_LoanOutstanding" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ConversionPercentageOfCommonStockPriceForConvertibleNotePayable" xlink:href="clnn-20210930.xsd#clnn_ConversionPercentageOfCommonStockPriceForConvertibleNotePayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ConvertibleNotesDetailsLineItems" xlink:to="clnn_ConversionPercentageOfCommonStockPriceForConvertibleNotePayable" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ConvertibleNotesDetailsLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ConvertibleNotesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_CouponInterestExpense" xlink:href="clnn-20210930.xsd#clnn_CouponInterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ConvertibleNotesDetailsLineItems" xlink:to="clnn_CouponInterestExpense" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_ConvertibleNotesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" order="19" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/DerivativeInstrumentsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFairValueOfDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeFairValueOfDerivativeNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_LossOnDerivativeInstruments" xlink:href="clnn-20210930.xsd#clnn_LossOnDerivativeInstruments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="clnn_LossOnDerivativeInstruments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityFairValueAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityFairValueAdjustment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_EquityFairValueAdjustment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_GainlossOnCleneNanomedicineContingentEarnout" xlink:href="clnn-20210930.xsd#clnn_GainlossOnCleneNanomedicineContingentEarnout"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="clnn_GainlossOnCleneNanomedicineContingentEarnout" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_GainlossOnInitialShareholdersContingentEarnout" xlink:href="clnn-20210930.xsd#clnn_GainlossOnInitialShareholdersContingentEarnout"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="clnn_GainlossOnInitialShareholdersContingentEarnout" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_WarrantLiabilityFairValue" xlink:href="clnn-20210930.xsd#clnn_WarrantLiabilityFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="clnn_WarrantLiabilityFairValue" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_Changeinfairvaluewarrants" xlink:href="clnn-20210930.xsd#clnn_Changeinfairvaluewarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="clnn_Changeinfairvaluewarrants" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/StockBasedCompensationDetails">
    <loc xlink:type="locator" xlink:label="clnn_StockBasedCompensationDetailsLineItems" xlink:href="clnn-20210930.xsd#clnn_StockBasedCompensationDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_StockBasedCompensationDetailsTable" xlink:href="clnn-20210930.xsd#clnn_StockBasedCompensationDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_StockBasedCompensationDetailsLineItems" xlink:to="clnn_StockBasedCompensationDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_StockBasedCompensationDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_StockBasedCompensationDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_StockBasedCompensationDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_StockPlan2020Member" xlink:href="clnn-20210930.xsd#clnn_StockPlan2020Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="clnn_StockPlan2020Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_StockPlan2014Member" xlink:href="clnn-20210930.xsd#clnn_StockPlan2014Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="clnn_StockPlan2014Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="clnn_StockPlan2020Member" order="1" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="clnn_StockPlan2020Member" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="clnn_StockPlan2014Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_MinimumFairMarketValueOfOptionGrantDescription" xlink:href="clnn-20210930.xsd#clnn_MinimumFairMarketValueOfOptionGrantDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsLineItems" xlink:to="clnn_MinimumFairMarketValueOfOptionGrantDescription" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants" xlink:href="clnn-20210930.xsd#clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsLineItems" xlink:to="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockOtherSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_CommonStockOtherSharesOutstanding" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionPlanExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionPlanExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_StockOptionPlanExpense" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_UnrecognizedStockbasedCompensation" xlink:href="clnn-20210930.xsd#clnn_UnrecognizedStockbasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsLineItems" xlink:to="clnn_UnrecognizedStockbasedCompensation" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm" xlink:href="clnn-20210930.xsd#clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsLineItems" xlink:to="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_weightedAverageFairValuesOfOptionsGranted" xlink:href="clnn-20210930.xsd#clnn_weightedAverageFairValuesOfOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsLineItems" xlink:to="clnn_weightedAverageFairValuesOfOptionsGranted" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_RestrictedStockUnitsDescription" xlink:href="clnn-20210930.xsd#clnn_RestrictedStockUnitsDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsLineItems" xlink:to="clnn_RestrictedStockUnitsDescription" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_RestrictedStockExpense" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm" xlink:href="clnn-20210930.xsd#clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_StockBasedCompensationDetailsLineItems" xlink:to="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm" order="19" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/FairValueDetails">
    <loc xlink:type="locator" xlink:label="clnn_FairValueDetailsLineItems" xlink:href="clnn-20210930.xsd#clnn_FairValueDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_FairValueDetailsTable" xlink:href="clnn-20210930.xsd#clnn_FairValueDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_FairValueDetailsLineItems" xlink:to="clnn_FairValueDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_FairValueDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_FairValueDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_AvenueLoanMember" xlink:href="clnn-20210930.xsd#clnn_AvenueLoanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="clnn_AvenueLoanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_NotesPayableBasedOnClosingPrice" xlink:href="clnn-20210930.xsd#clnn_NotesPayableBasedOnClosingPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_FairValueDetailsLineItems" xlink:to="clnn_NotesPayableBasedOnClosingPrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_FairValueAmortizedCost" xlink:href="clnn-20210930.xsd#clnn_FairValueAmortizedCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_FairValueDetailsLineItems" xlink:to="clnn_FairValueAmortizedCost" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_FairValueDetailsLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_FairValueDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_FairValueOfConvertibleNotesPayable" xlink:href="clnn-20210930.xsd#clnn_FairValueOfConvertibleNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_FairValueDetailsLineItems" xlink:to="clnn_FairValueOfConvertibleNotesPayable" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_FairValueDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_AdditionalWarrantToPurchaseShares" xlink:href="clnn-20210930.xsd#clnn_AdditionalWarrantToPurchaseShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_FairValueDetailsLineItems" xlink:to="clnn_AdditionalWarrantToPurchaseShares" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_FairValueDetailsLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/RedeemableConvertiblePreferredStockDetails">
    <loc xlink:type="locator" xlink:label="clnn_RedeemableConvertiblePreferredStockDetailsLineItems" xlink:href="clnn-20210930.xsd#clnn_RedeemableConvertiblePreferredStockDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_RedeemableConvertiblePreferredStockDetailsTable" xlink:href="clnn-20210930.xsd#clnn_RedeemableConvertiblePreferredStockDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_RedeemableConvertiblePreferredStockDetailsLineItems" xlink:to="clnn_RedeemableConvertiblePreferredStockDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_RedeemableConvertiblePreferredStockDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleCommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleCommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertibleCommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_RedeemableConvertiblePreferredStockDetailsLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/CommonStockDetails">
    <loc xlink:type="locator" xlink:label="clnn_CommonStockDetailsLineItems" xlink:href="clnn-20210930.xsd#clnn_CommonStockDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockDetailsTable" xlink:href="clnn-20210930.xsd#clnn_CommonStockDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_CommonStockDetailsLineItems" xlink:to="clnn_CommonStockDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_CommonStockDetailsTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_CommonStockDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_InvestorsMember" xlink:href="clnn-20210930.xsd#clnn_InvestorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="clnn_InvestorsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CommonStockDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CommonStockDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_PreferredStockShares" xlink:href="clnn-20210930.xsd#clnn_PreferredStockShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CommonStockDetailsLineItems" xlink:to="clnn_PreferredStockShares" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CommonStockDetailsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_IssuanceOfCommonStockUponReverseRecapitalization" xlink:href="clnn-20210930.xsd#clnn_IssuanceOfCommonStockUponReverseRecapitalization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CommonStockDetailsLineItems" xlink:to="clnn_IssuanceOfCommonStockUponReverseRecapitalization" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_RecapitalizationShare" xlink:href="clnn-20210930.xsd#clnn_RecapitalizationShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CommonStockDetailsLineItems" xlink:to="clnn_RecapitalizationShare" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_InvestorsPurchasedShares" xlink:href="clnn-20210930.xsd#clnn_InvestorsPurchasedShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CommonStockDetailsLineItems" xlink:to="clnn_InvestorsPurchasedShares" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CommonStockDetailsLineItems" xlink:to="us-gaap_SharePrice" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_NetProceeds" xlink:href="clnn-20210930.xsd#clnn_NetProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CommonStockDetailsLineItems" xlink:to="clnn_NetProceeds" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_PrivatePlacementWarrantsDescription" xlink:href="clnn-20210930.xsd#clnn_PrivatePlacementWarrantsDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CommonStockDetailsLineItems" xlink:to="clnn_PrivatePlacementWarrantsDescription" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockSharesPurchased" xlink:href="clnn-20210930.xsd#clnn_CommonStockSharesPurchased"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CommonStockDetailsLineItems" xlink:to="clnn_CommonStockSharesPurchased" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockPricePerShare" xlink:href="clnn-20210930.xsd#clnn_CommonStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CommonStockDetailsLineItems" xlink:to="clnn_CommonStockPricePerShare" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_WarrantsShares" xlink:href="clnn-20210930.xsd#clnn_WarrantsShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CommonStockDetailsLineItems" xlink:to="clnn_WarrantsShares" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ExercisePricePerShare" xlink:href="clnn-20210930.xsd#clnn_ExercisePricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CommonStockDetailsLineItems" xlink:to="clnn_ExercisePricePerShare" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_CashProceedsReceived" xlink:href="clnn-20210930.xsd#clnn_CashProceedsReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CommonStockDetailsLineItems" xlink:to="clnn_CashProceedsReceived" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_PurchaseOptionUnits" xlink:href="clnn-20210930.xsd#clnn_PurchaseOptionUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CommonStockDetailsLineItems" xlink:to="clnn_PurchaseOptionUnits" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_NetIssuanceShares" xlink:href="clnn-20210930.xsd#clnn_NetIssuanceShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CommonStockDetailsLineItems" xlink:to="clnn_NetIssuanceShares" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_NetIssuanceWarrants" xlink:href="clnn-20210930.xsd#clnn_NetIssuanceWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CommonStockDetailsLineItems" xlink:to="clnn_NetIssuanceWarrants" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CommonStockDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_CommonStockDetailsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="20" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/NetIncomeLossPerShareAttributabletoCommonShareholdersDetails">
    <loc xlink:type="locator" xlink:label="clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsLineItems" xlink:href="clnn-20210930.xsd#clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsTable" xlink:href="clnn-20210930.xsd#clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsLineItems" xlink:to="clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_PIPEWarrantsMember" xlink:href="clnn-20210930.xsd#clnn_PIPEWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="clnn_PIPEWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/RelatedPartyTransactionsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_ExclusiveRightsIntellectualPropertyTerm" xlink:href="clnn-20210930.xsd#clnn_ExclusiveRightsIntellectualPropertyTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="clnn_ExclusiveRightsIntellectualPropertyTerm" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsSoldSalesTypeLease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsSoldSalesTypeLease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_CostOfGoodsSoldSalesTypeLease" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRoyaltiesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRoyaltiesReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ProceedsFromRoyaltiesReceived" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvancesToAffiliate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvancesToAffiliate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_AdvancesToAffiliate" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsSoldDirectFinancingLease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsSoldDirectFinancingLease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_CostOfGoodsSoldDirectFinancingLease" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="clnn_SubsequentEventsDetailsLineItems" xlink:href="clnn-20210930.xsd#clnn_SubsequentEventsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="clnn_SubsequentEventsDetailsTable" xlink:href="clnn-20210930.xsd#clnn_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="clnn_SubsequentEventsDetailsLineItems" xlink:to="clnn_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="clnn_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_PIPEWarrantsMember" xlink:href="clnn-20210930.xsd#clnn_PIPEWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="clnn_PIPEWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SubsequentEventDescription" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="clnn_AggregateGrossProceedWarrantsExercised" xlink:href="clnn-20210930.xsd#clnn_AggregateGrossProceedWarrantsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="clnn_SubsequentEventsDetailsLineItems" xlink:to="clnn_AggregateGrossProceedWarrantsExercised" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentQuarterlyReport" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="31" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>clnn-20210930_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Nov 08 18:21:45 UTC 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">TOTAL STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Income (loss) from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expense), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Net income (loss) before income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net income loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossTax_lbl" xml:lang="en-US">Total other comprehensive income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balances (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net cash (used in) operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase in cash and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and restricted cash &#8211; beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and restricted cash &#8211; end of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineAbstract" xlink:href="clnn-20210930.xsd#clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineAbstract_lbl" xml:lang="en-US">Reverse Recapitalization With Tottenham And Clene Nanomedicine [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineAbstract" xlink:to="clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:href="clnn-20210930.xsd#clnn_PrepaidExpensesAndOtherCurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_PrepaidExpensesAndOtherCurrentAssetsAbstract_lbl" xml:lang="en-US">Prepaid Expenses And Other Current Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="clnn_PrepaidExpensesAndOtherCurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract_lbl" xml:lang="en-US">Schedule of prepaid expenses and other current assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="clnn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfPropertyAndEquipmentNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfPropertyAndEquipmentNetAbstract_lbl" xml:lang="en-US">Schedule of property and equipment, net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="clnn_ScheduleOfPropertyAndEquipmentNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Total property and equipment, gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Total property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US">Total property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract_lbl" xml:lang="en-US">Disclosure Text Block Supplement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_DisclosureTextBlockSupplementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfAccruedLiabilitiesAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfAccruedLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfAccruedLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule of accrued liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfAccruedLiabilitiesAbstract" xlink:to="clnn_ScheduleOfAccruedLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureTextBlockAbstract_lbl" xml:lang="en-US">Disclosure Text Block [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfNoncancelableFinanceAndOperatingLeaseLiabilitiesAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfNoncancelableFinanceAndOperatingLeaseLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfNoncancelableFinanceAndOperatingLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule of noncancelable finance and operating lease liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfNoncancelableFinanceAndOperatingLeaseLiabilitiesAbstract" xlink:to="clnn_ScheduleOfNoncancelableFinanceAndOperatingLeaseLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US">Total undiscounted cash flows</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US">Total undiscounted cash flows</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl" xml:lang="en-US">Present value of future lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of future lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Terminated operating lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xml:lang="en-US">Lease Contractual Term [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfFinanceLeaseObligationsIncludedInPropertyAndEquipmentAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfFinanceLeaseObligationsIncludedInPropertyAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfFinanceLeaseObligationsIncludedInPropertyAndEquipmentAbstract_lbl" xml:lang="en-US">Schedule of finance lease obligations included in property and equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfFinanceLeaseObligationsIncludedInPropertyAndEquipmentAbstract" xlink:to="clnn_ScheduleOfFinanceLeaseObligationsIncludedInPropertyAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_FinanceLeaseLiabilityGross" xlink:href="clnn-20210930.xsd#clnn_FinanceLeaseLiabilityGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="clnn_FinanceLeaseLiabilityGross_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FinanceLeaseLiabilityGross" xlink:to="clnn_FinanceLeaseLiabilityGross_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_FinanceLeaseLiabilityNet" xlink:href="clnn-20210930.xsd#clnn_FinanceLeaseLiabilityNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="clnn_FinanceLeaseLiabilityNet_lbl" xml:lang="en-US">Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FinanceLeaseLiabilityNet" xlink:to="clnn_FinanceLeaseLiabilityNet_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfFinanceAndOperatingLeaseCostsAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfFinanceAndOperatingLeaseCostsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfFinanceAndOperatingLeaseCostsAbstract_lbl" xml:lang="en-US">Schedule of finance and operating lease costs [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfFinanceAndOperatingLeaseCostsAbstract" xlink:to="clnn_ScheduleOfFinanceAndOperatingLeaseCostsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total lease costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfSupplementalCashFlowInformationAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfSupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfSupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Schedule of supplemental cash flow information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfSupplementalCashFlowInformationAbstract" xlink:to="clnn_ScheduleOfSupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfLongTermDebtNetOfOriginalIssueDiscountAndUnamortizedDebtIssuanceCostsAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfLongTermDebtNetOfOriginalIssueDiscountAndUnamortizedDebtIssuanceCostsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfLongTermDebtNetOfOriginalIssueDiscountAndUnamortizedDebtIssuanceCostsAbstract_lbl" xml:lang="en-US">Schedule of long-term debt, net of original issue discount and unamortized debt issuance costs [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfLongTermDebtNetOfOriginalIssueDiscountAndUnamortizedDebtIssuanceCostsAbstract" xlink:to="clnn_ScheduleOfLongTermDebtNetOfOriginalIssueDiscountAndUnamortizedDebtIssuanceCostsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_TermLoansAxis" xlink:href="clnn-20210930.xsd#clnn_TermLoansAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_TermLoansAxis_lbl" xml:lang="en-US">Term Loans [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TermLoansAxis" xlink:to="clnn_TermLoansAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscountsAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscountsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscountsAbstract_lbl" xml:lang="en-US">Schedule of future payments, net of unamortized debt discounts [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscountsAbstract" xlink:to="clnn_ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscountsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_FuturePrincipalPayments" xlink:href="clnn-20210930.xsd#clnn_FuturePrincipalPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="clnn_FuturePrincipalPayments_lbl" xml:lang="en-US">Subtotal of future principal payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FuturePrincipalPayments" xlink:to="clnn_FuturePrincipalPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DebtSecurities_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecurities" xlink:to="us-gaap_DebtSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrantsDisclosureAbstract" xlink:href="clnn-20210930.xsd#clnn_CommonStockWarrantsDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CommonStockWarrantsDisclosureAbstract_lbl" xml:lang="en-US">Common Stock Warrants Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockWarrantsDisclosureAbstract" xlink:to="clnn_CommonStockWarrantsDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockAbstract_lbl" xml:lang="en-US">Schedule of outstanding warrants to purchase shares of common stock [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockAbstract" xlink:to="clnn_ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ConvertibleNotesDisclosureAbstract" xlink:href="clnn-20210930.xsd#clnn_ConvertibleNotesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ConvertibleNotesDisclosureAbstract_lbl" xml:lang="en-US">Convertible Notes Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ConvertibleNotesDisclosureAbstract" xlink:to="clnn_ConvertibleNotesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesAbstract_lbl" xml:lang="en-US">Schedule of components of income (loss) before income taxes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesAbstract" xlink:to="clnn_ScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_TotalLossBeforeIncomeTaxes" xlink:href="clnn-20210930.xsd#clnn_TotalLossBeforeIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="clnn_TotalLossBeforeIncomeTaxes_lbl" xml:lang="en-US">Total loss before income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TotalLossBeforeIncomeTaxes" xlink:to="clnn_TotalLossBeforeIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfStockBasedCompensationExpenseAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfStockBasedCompensationExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfStockBasedCompensationExpenseAbstract_lbl" xml:lang="en-US">Schedule of stock-based compensation expense [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfStockBasedCompensationExpenseAbstract" xlink:to="clnn_ScheduleOfStockBasedCompensationExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract_lbl" xml:lang="en-US">Schedule of outstanding common stock options and related activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Options, Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Number of Options, Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted Average Exercise Price Per Share, Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValue" xlink:href="clnn-20210930.xsd#clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValue_lbl" xml:lang="en-US">Intrinsic Value, Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValue" xlink:to="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValue_lbl0" xml:lang="en-US">Intrinsic Value, Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValue" xlink:to="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfAssumptionsUsedToCalculateTheFairValueOfStockOptionsAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfAssumptionsUsedToCalculateTheFairValueOfStockOptionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfAssumptionsUsedToCalculateTheFairValueOfStockOptionsAbstract_lbl" xml:lang="en-US">Schedule of assumptions used to calculate the fair value of stock options [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfAssumptionsUsedToCalculateTheFairValueOfStockOptionsAbstract" xlink:to="clnn_ScheduleOfAssumptionsUsedToCalculateTheFairValueOfStockOptionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfRestrictedCommonStockActivityAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfRestrictedCommonStockActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfRestrictedCommonStockActivityAbstract_lbl" xml:lang="en-US">Schedule of restricted common stock activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfRestrictedCommonStockActivityAbstract" xlink:to="clnn_ScheduleOfRestrictedCommonStockActivityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Beginning balance, Number of Restricted Stock Awards, Unvested balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl0" xml:lang="en-US">Ending balance, Number of Restricted Stock Awards, Unvested balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Beginning balance, Weighted- Average Grant Date Fair Value, Unvested balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Ending balance, Weighted- Average Grant Date Fair Value, Unvested balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfFairValueHierarchyOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfFairValueHierarchyOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfFairValueHierarchyOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract_lbl" xml:lang="en-US">Schedule of fair value hierarchy of liabilities measured at fair value on recurring basis [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfFairValueHierarchyOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract" xlink:to="clnn_ScheduleOfFairValueHierarchyOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfUnobservableInputsToTheConversionFeatureWarrantLiabilityAndContingentEarnOutValuationModelsAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfUnobservableInputsToTheConversionFeatureWarrantLiabilityAndContingentEarnOutValuationModelsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfUnobservableInputsToTheConversionFeatureWarrantLiabilityAndContingentEarnOutValuationModelsAbstract_lbl" xml:lang="en-US">Schedule of unobservable inputs to the conversion feature, warrant liability, and contingent earn-out valuation models [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfUnobservableInputsToTheConversionFeatureWarrantLiabilityAndContingentEarnOutValuationModelsAbstract" xlink:to="clnn_ScheduleOfUnobservableInputsToTheConversionFeatureWarrantLiabilityAndContingentEarnOutValuationModelsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-term Debt, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationTechniqueAxis_lbl" xml:lang="en-US">Valuation Approach and Technique [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfChangesInFairValueOfFinancialLiabilitiesRelatedToTheNotesPayableTheDerivativeInstrumentThePreferredStockWarrantsAndTheContingentEarnOutsAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfChangesInFairValueOfFinancialLiabilitiesRelatedToTheNotesPayableTheDerivativeInstrumentThePreferredStockWarrantsAndTheContingentEarnOutsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfChangesInFairValueOfFinancialLiabilitiesRelatedToTheNotesPayableTheDerivativeInstrumentThePreferredStockWarrantsAndTheContingentEarnOutsAbstract_lbl" xml:lang="en-US">Schedule of changes in fair value of financial liabilities related to the notes payable, the derivative instrument, the preferred stock warrants, and the contingent earn-outs [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfChangesInFairValueOfFinancialLiabilitiesRelatedToTheNotesPayableTheDerivativeInstrumentThePreferredStockWarrantsAndTheContingentEarnOutsAbstract" xlink:to="clnn_ScheduleOfChangesInFairValueOfFinancialLiabilitiesRelatedToTheNotesPayableTheDerivativeInstrumentThePreferredStockWarrantsAndTheContingentEarnOutsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US">Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl0" xml:lang="en-US">Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="clnn_RedeemableConvertiblePreferredStockDisclosureAbstract" xlink:href="clnn-20210930.xsd#clnn_RedeemableConvertiblePreferredStockDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_RedeemableConvertiblePreferredStockDisclosureAbstract_lbl" xml:lang="en-US">Redeemable Convertible Preferred Stock Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RedeemableConvertiblePreferredStockDisclosureAbstract" xlink:to="clnn_RedeemableConvertiblePreferredStockDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders&apos; Equity Note [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfBasicAndDilutedNetLossPerShareAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfBasicAndDilutedNetLossPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfBasicAndDilutedNetLossPerShareAbstract_lbl" xml:lang="en-US">Schedule of basic and diluted net loss per share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfBasicAndDilutedNetLossPerShareAbstract" xlink:to="clnn_ScheduleOfBasicAndDilutedNetLossPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average common shares outstanding &#8211;Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl0" xml:lang="en-US">Weighted average common shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl0"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfSecuritiesExcludedFromComputationOfDilutedNetIncomeLossPerShareAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfSecuritiesExcludedFromComputationOfDilutedNetIncomeLossPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfSecuritiesExcludedFromComputationOfDilutedNetIncomeLossPerShareAbstract_lbl" xml:lang="en-US">Schedule of securities excluded from computation of diluted net income (loss) per share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfSecuritiesExcludedFromComputationOfDilutedNetIncomeLossPerShareAbstract" xlink:to="clnn_ScheduleOfSecuritiesExcludedFromComputationOfDilutedNetIncomeLossPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_TotalDilutiveSecurities" xlink:href="clnn-20210930.xsd#clnn_TotalDilutiveSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="clnn_TotalDilutiveSecurities_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TotalDilutiveSecurities" xlink:to="clnn_TotalDilutiveSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfPropertyAndEquipmentNetByLocationAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfPropertyAndEquipmentNetByLocationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfPropertyAndEquipmentNetByLocationAbstract_lbl" xml:lang="en-US">Schedule of property and equipment, net by location [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfPropertyAndEquipmentNetByLocationAbstract" xlink:to="clnn_ScheduleOfPropertyAndEquipmentNetByLocationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfDrugsAndSupplementsSegmentsAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfDrugsAndSupplementsSegmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfDrugsAndSupplementsSegmentsAbstract_lbl" xml:lang="en-US">Schedule of drugs and supplements segments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfDrugsAndSupplementsSegmentsAbstract" xlink:to="clnn_ScheduleOfDrugsAndSupplementsSegmentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfPropertyAndEquipmentNetBySegmentAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfPropertyAndEquipmentNetBySegmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfPropertyAndEquipmentNetBySegmentAbstract_lbl" xml:lang="en-US">Schedule of property and equipment, net by segment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfPropertyAndEquipmentNetBySegmentAbstract" xlink:to="clnn_ScheduleOfPropertyAndEquipmentNetBySegmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US">Income tax payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred revenue from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease obligations, current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Less lease obligations, current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Finance lease obligations, current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xml:lang="en-US">Clene Nanomedicine contingent earn-out, current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease obligations, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Lease obligations &#8211; long term portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Finance lease obligations, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl" xml:lang="en-US">Convertible notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US">Notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xml:lang="en-US">Deferred income tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_WarrantLiabilityNoncurrent" xlink:href="clnn-20210930.xsd#clnn_WarrantLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_WarrantLiabilityNoncurrent_lbl" xml:lang="en-US">Warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantLiabilityNoncurrent" xlink:to="clnn_WarrantLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US">Clene Nanomedicine contingent earn-out, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_InitialShareholdersContingentEarnout" xlink:href="clnn-20210930.xsd#clnn_InitialShareholdersContingentEarnout"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_InitialShareholdersContingentEarnout_lbl" xml:lang="en-US">Initial Shareholders contingent earn-out</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InitialShareholdersContingentEarnout" xlink:to="clnn_InitialShareholdersContingentEarnout_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Note 13)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.0001 par value: 150,000,000 and 100,000,000 shares authorized at September 30, 2021 and December 31, 2020, respectively; 62,177,020 and 59,526,171 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common share, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenue:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Total revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Revenue from external customers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Cost of revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense), net:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnContractTermination" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnContractTermination"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossOnContractTermination_lbl" xml:lang="en-US">Gain on termination of lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnContractTermination" xlink:to="us-gaap_GainLossOnContractTermination_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ChangeInFairValueOfPreferredStockWarrantLiability" xlink:href="clnn-20210930.xsd#clnn_ChangeInFairValueOfPreferredStockWarrantLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ChangeInFairValueOfPreferredStockWarrantLiability_lbl" xml:lang="en-US">Change in fair value of preferred stock warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChangeInFairValueOfPreferredStockWarrantLiability" xlink:to="clnn_ChangeInFairValueOfPreferredStockWarrantLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ChangeInFairValueOfDerivativeLiability" xlink:href="clnn-20210930.xsd#clnn_ChangeInFairValueOfDerivativeLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ChangeInFairValueOfDerivativeLiability_lbl" xml:lang="en-US">Change in fair value of derivative liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChangeInFairValueOfDerivativeLiability" xlink:to="clnn_ChangeInFairValueOfDerivativeLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ChangeInFairValueOfContingentEarnout" xlink:href="clnn-20210930.xsd#clnn_ChangeInFairValueOfContingentEarnout"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ChangeInFairValueOfContingentEarnout_lbl" xml:lang="en-US">Change in fair value of Clene Nanomedicine contingent earn-out</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChangeInFairValueOfContingentEarnout" xlink:to="clnn_ChangeInFairValueOfContingentEarnout_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout" xlink:href="clnn-20210930.xsd#clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout_lbl" xml:lang="en-US">Change in fair value of Initial Shareholders contingent earn-out</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout" xlink:to="clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ChangeInFairValueOfCommonStockWarrantLiability" xlink:href="clnn-20210930.xsd#clnn_ChangeInFairValueOfCommonStockWarrantLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ChangeInFairValueOfCommonStockWarrantLiability_lbl" xml:lang="en-US">Change in fair value of common stock warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChangeInFairValueOfCommonStockWarrantLiability" xlink:to="clnn_ChangeInFairValueOfCommonStockWarrantLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income (expense), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xml:lang="en-US">Other comprehensive income (loss):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Foreign currency translation adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_NetIncomeLossPerCommonShareAttributableToCommonShareholdersNote191Abstract" xlink:href="clnn-20210930.xsd#clnn_NetIncomeLossPerCommonShareAttributableToCommonShareholdersNote191Abstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_NetIncomeLossPerCommonShareAttributableToCommonShareholdersNote191Abstract_lbl" xml:lang="en-US">Net income (loss) per common share attributable to common shareholders (Note 19)(1):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NetIncomeLossPerCommonShareAttributableToCommonShareholdersNote191Abstract" xlink:to="clnn_NetIncomeLossPerCommonShareAttributableToCommonShareholdersNote191Abstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_WeightedAverageNumberOfCommonSharesOutstanding1Abstract" xlink:href="clnn-20210930.xsd#clnn_WeightedAverageNumberOfCommonSharesOutstanding1Abstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_WeightedAverageNumberOfCommonSharesOutstanding1Abstract_lbl" xml:lang="en-US">Weighted average number of common shares outstanding(1):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WeightedAverageNumberOfCommonSharesOutstanding1Abstract" xlink:to="clnn_WeightedAverageNumberOfCommonSharesOutstanding1Abstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Basic (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ForeignCurrencyTranslationAdjustment" xlink:href="clnn-20210930.xsd#clnn_ForeignCurrencyTranslationAdjustment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ForeignCurrencyTranslationAdjustment_lbl" xml:lang="en-US">Foreign currency translation adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ForeignCurrencyTranslationAdjustment" xlink:to="clnn_ForeignCurrencyTranslationAdjustment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock upon the private offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock upon the private offering (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Issuance of common stock upon vesting of restricted stock awards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Issuance of common stock upon vesting of restricted stock awards (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:href="clnn-20210930.xsd#clnn_StockIssuedDuringPeriodValueExerciseOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xml:lang="en-US">Exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:to="clnn_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_StockIssueDuringPeriodSharesExerciseOfWarrants" xlink:href="clnn-20210930.xsd#clnn_StockIssueDuringPeriodSharesExerciseOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_StockIssueDuringPeriodSharesExerciseOfWarrants_lbl" xml:lang="en-US">Exercise of warrants (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockIssueDuringPeriodSharesExerciseOfWarrants" xlink:to="clnn_StockIssueDuringPeriodSharesExerciseOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_StockIssuedDuringPeriodExerciseOfUnderwritersOption" xlink:href="clnn-20210930.xsd#clnn_StockIssuedDuringPeriodExerciseOfUnderwritersOption"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_StockIssuedDuringPeriodExerciseOfUnderwritersOption_lbl" xml:lang="en-US">Exercise of underwriter&#8217;s option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockIssuedDuringPeriodExerciseOfUnderwritersOption" xlink:to="clnn_StockIssuedDuringPeriodExerciseOfUnderwritersOption_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_StockIssuedDuringPeriodExerciseOfUnderwritersOptioninShares" xlink:href="clnn-20210930.xsd#clnn_StockIssuedDuringPeriodExerciseOfUnderwritersOptioninShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_StockIssuedDuringPeriodExerciseOfUnderwritersOptioninShares_lbl" xml:lang="en-US">Exercise of underwriter&#8217;s option (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockIssuedDuringPeriodExerciseOfUnderwritersOptioninShares" xlink:to="clnn_StockIssuedDuringPeriodExerciseOfUnderwritersOptioninShares_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_StockIssuedDuringPeriodOfSeriesDPreferredStock" xlink:href="clnn-20210930.xsd#clnn_StockIssuedDuringPeriodOfSeriesDPreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_StockIssuedDuringPeriodOfSeriesDPreferredStock_lbl" xml:lang="en-US">Issuance of Series D Preferred Stock, net of issuance costs of $1.3 million</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockIssuedDuringPeriodOfSeriesDPreferredStock" xlink:to="clnn_StockIssuedDuringPeriodOfSeriesDPreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_StockIssuedDuringPeriodSharesSeriesDPreferredStock" xlink:href="clnn-20210930.xsd#clnn_StockIssuedDuringPeriodSharesSeriesDPreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_StockIssuedDuringPeriodSharesSeriesDPreferredStock_lbl" xml:lang="en-US">Issuance of Series D Preferred Stock, net of issuance costs of $1.3 million (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockIssuedDuringPeriodSharesSeriesDPreferredStock" xlink:to="clnn_StockIssuedDuringPeriodSharesSeriesDPreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_NetOfIssuanceCosts" xlink:href="clnn-20210930.xsd#clnn_NetOfIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_NetOfIssuanceCosts_lbl" xml:lang="en-US">Net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NetOfIssuanceCosts" xlink:to="clnn_NetOfIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xml:lang="en-US">Issuance of Series D Preferred Stock in connection with the extinguishment of convertible promissory notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xml:lang="en-US">Issuance of Series D Preferred Stock in connection with the extinguishment of convertible promissory notes (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSoldDepreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSoldDepreciation_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSoldDepreciation" xlink:to="us-gaap_CostOfGoodsAndServicesSoldDepreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNoncashExpense_lbl" xml:lang="en-US">Non-cash lease expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Change in fair value of preferred stock warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Accretion of debt discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_IncreaseInInterestAccruedOnNotesPayable" xlink:href="clnn-20210930.xsd#clnn_IncreaseInInterestAccruedOnNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_IncreaseInInterestAccruedOnNotesPayable_lbl" xml:lang="en-US">Increase (decrease) in interest accrued on notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IncreaseInInterestAccruedOnNotesPayable" xlink:to="clnn_IncreaseInInterestAccruedOnNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" xml:lang="en-US">Payable to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US">Deferred revenue from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from issuance of convertible notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from warrants exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from the private placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromOtherDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromOtherDebt_lbl" xml:lang="en-US">Proceeds from the issuance of notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherDebt" xlink:to="us-gaap_ProceedsFromOtherDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US">Proceeds from issuance of Series D Preferred Stock, net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">Effect of foreign exchange rate changes on cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">Reconciliation of cash and restricted cash to the condensed consolidated balance sheets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_WarrantLiabilityRecordedAtIssuanceOfNotesPayable" xlink:href="clnn-20210930.xsd#clnn_WarrantLiabilityRecordedAtIssuanceOfNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_WarrantLiabilityRecordedAtIssuanceOfNotesPayable_lbl" xml:lang="en-US">Warrant liability recorded at issuance of notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantLiabilityRecordedAtIssuanceOfNotesPayable" xlink:to="clnn_WarrantLiabilityRecordedAtIssuanceOfNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Lease liability arising from obtaining right-of-use assets, leasehold improvements, and lease incentives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_LeaseLiabilitySettledThroughTerminationOfLease" xlink:href="clnn-20210930.xsd#clnn_LeaseLiabilitySettledThroughTerminationOfLease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_LeaseLiabilitySettledThroughTerminationOfLease_lbl" xml:lang="en-US">Lease liability settled through termination of lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_LeaseLiabilitySettledThroughTerminationOfLease" xlink:to="clnn_LeaseLiabilitySettledThroughTerminationOfLease_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes" xlink:href="clnn-20210930.xsd#clnn_IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes_lbl" xml:lang="en-US">Issuance of Series D Preferred Stock upon extinguishment of convertible promissory notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes" xlink:to="clnn_IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN" xlink:href="clnn-20210930.xsd#clnn_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN_lbl" xml:lang="en-US">Extinguishment of derivative liability in connection with extinguishment of convertible promissory notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN" xlink:to="clnn_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_DeferredOfferingCostsInAccruedLiabilities" xlink:href="clnn-20210930.xsd#clnn_DeferredOfferingCostsInAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_DeferredOfferingCostsInAccruedLiabilities_lbl" xml:lang="en-US">Deferred offering costs in accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DeferredOfferingCostsInAccruedLiabilities" xlink:to="clnn_DeferredOfferingCostsInAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Supplemental disclosure:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CashPaidForInterestExpense" xlink:href="clnn-20210930.xsd#clnn_CashPaidForInterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_CashPaidForInterestExpense_lbl" xml:lang="en-US">Cash paid for interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CashPaidForInterestExpense" xlink:to="clnn_CashPaidForInterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_InterestIncomeexpense" xlink:href="clnn-20210930.xsd#clnn_InterestIncomeexpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="clnn_InterestIncomeexpense_lbl" xml:lang="en-US">Interest income (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InterestIncomeexpense" xlink:to="clnn_InterestIncomeexpense_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_GainOnExtinguishmentOfNotesPayable" xlink:href="clnn-20210930.xsd#clnn_GainOnExtinguishmentOfNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="clnn_GainOnExtinguishmentOfNotesPayable_lbl" xml:lang="en-US">Gain on extinguishment of notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_GainOnExtinguishmentOfNotesPayable" xlink:to="clnn_GainOnExtinguishmentOfNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_LossOnExtinguishmentOfConvertibleNotesPayable" xlink:href="clnn-20210930.xsd#clnn_LossOnExtinguishmentOfConvertibleNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="clnn_LossOnExtinguishmentOfConvertibleNotesPayable_lbl" xml:lang="en-US">Loss on extinguishment of convertible notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_LossOnExtinguishmentOfConvertibleNotesPayable" xlink:to="clnn_LossOnExtinguishmentOfConvertibleNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_AustraliaResearchAndDevelopmentCredit" xlink:href="clnn-20210930.xsd#clnn_AustraliaResearchAndDevelopmentCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="clnn_AustraliaResearchAndDevelopmentCredit_lbl" xml:lang="en-US">Australia research and development credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AustraliaResearchAndDevelopmentCredit" xlink:to="clnn_AustraliaResearchAndDevelopmentCredit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ChangeInFairValueOfCleneNanomedicineContingentEarnouts" xlink:href="clnn-20210930.xsd#clnn_ChangeInFairValueOfCleneNanomedicineContingentEarnouts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="clnn_ChangeInFairValueOfCleneNanomedicineContingentEarnouts_lbl" xml:lang="en-US">Change in fair value of Clene Nanomedicine contingent earn-out</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChangeInFairValueOfCleneNanomedicineContingentEarnouts" xlink:to="clnn_ChangeInFairValueOfCleneNanomedicineContingentEarnouts_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ChangesInFairValueOfInitialShareholdersContingentEarnout" xlink:href="clnn-20210930.xsd#clnn_ChangesInFairValueOfInitialShareholdersContingentEarnout"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="clnn_ChangesInFairValueOfInitialShareholdersContingentEarnout_lbl" xml:lang="en-US">Change in fair value of Initial Shareholders contingent earn-out</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChangesInFairValueOfInitialShareholdersContingentEarnout" xlink:to="clnn_ChangesInFairValueOfInitialShareholdersContingentEarnout_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl" xml:lang="en-US">Change in fair value of derivative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ChangeInFairValueOfCommonStockWarrantLiabilitys" xlink:href="clnn-20210930.xsd#clnn_ChangeInFairValueOfCommonStockWarrantLiabilitys"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="clnn_ChangeInFairValueOfCommonStockWarrantLiabilitys_lbl" xml:lang="en-US">Change in fair value of common stock warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChangeInFairValueOfCommonStockWarrantLiabilitys" xlink:to="clnn_ChangeInFairValueOfCommonStockWarrantLiabilitys_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnTerminationOfLease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnTerminationOfLease_lbl" xml:lang="en-US">Gain on termination of lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnTerminationOfLease" xlink:to="us-gaap_GainLossOnTerminationOfLease_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossOnTerminationOfLease_lbl0" xml:lang="en-US">Gain on termination of lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnTerminationOfLease" xlink:to="us-gaap_GainLossOnTerminationOfLease_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Gain on extinguishment of notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnDispositionOfIntangibleAssets_lbl" xml:lang="en-US">Loss on extinguishment of convertible notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:to="us-gaap_GainLossOnDispositionOfIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl" xml:lang="en-US">Deferred income tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US">Payments of finance lease obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Payments of debt issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl0" xml:lang="en-US">Debt issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Payments of notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US">Payments of deferred transaction costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xml:lang="en-US">Issuance of derivative instrument related to convertible notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Product revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyMember_lbl" xml:lang="en-US">Royalty revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyMember" xlink:to="us-gaap_RoyaltyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Redeemable Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-In Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">Nature of the Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock" xlink:href="clnn-20210930.xsd#clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock_lbl" xml:lang="en-US">Reverse Recapitalization with Tottenham and Clene Nanomedicine</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock" xlink:to="clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:href="clnn-20210930.xsd#clnn_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="clnn_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:href="clnn-20210930.xsd#clnn_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="clnn_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CROPrepayments" xlink:href="clnn-20210930.xsd#clnn_CROPrepayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_CROPrepayments_lbl" xml:lang="en-US">CRO prepayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CROPrepayments" xlink:to="clnn_CROPrepayments_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_MetalsToBeUsedInResearchAndDevelopment" xlink:href="clnn-20210930.xsd#clnn_MetalsToBeUsedInResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_MetalsToBeUsedInResearchAndDevelopment_lbl" xml:lang="en-US">Metals to be used in research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_MetalsToBeUsedInResearchAndDevelopment" xlink:to="clnn_MetalsToBeUsedInResearchAndDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_DirectorsOfficersInsurance" xlink:href="clnn-20210930.xsd#clnn_DirectorsOfficersInsurance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_DirectorsOfficersInsurance_lbl" xml:lang="en-US">Directors &amp; Officers Insurance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DirectorsOfficersInsurance" xlink:to="clnn_DirectorsOfficersInsurance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MachineryAndEquipmentGross_lbl" xml:lang="en-US">Laboratory equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentGross" xlink:to="us-gaap_MachineryAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesGross_lbl" xml:lang="en-US">Furniture and fixtures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesGross" xlink:to="us-gaap_FurnitureAndFixturesGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xml:lang="en-US">Leasehold improvements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsGross" xlink:to="us-gaap_LeaseholdImprovementsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConstructionInProgressGross_lbl" xml:lang="en-US">Construction in progress</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressGross" xlink:to="us-gaap_ConstructionInProgressGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued professional fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xml:lang="en-US">Accrued compensation and benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_AccruedCROFees" xlink:href="clnn-20210930.xsd#clnn_AccruedCROFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_AccruedCROFees_lbl" xml:lang="en-US">Accrued CRO fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AccruedCROFees" xlink:to="clnn_AccruedCROFees_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_DeferredGrantFunds" xlink:href="clnn-20210930.xsd#clnn_DeferredGrantFunds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_DeferredGrantFunds_lbl" xml:lang="en-US">Deferred grant funds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DeferredGrantFunds" xlink:to="clnn_DeferredGrantFunds_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_AccruedExpenseReimbursements" xlink:href="clnn-20210930.xsd#clnn_AccruedExpenseReimbursements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_AccruedExpenseReimbursements_lbl" xml:lang="en-US">Accrued expense reimbursements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AccruedExpenseReimbursements" xlink:to="clnn_AccruedExpenseReimbursements_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_AccruedTransactionCosts" xlink:href="clnn-20210930.xsd#clnn_AccruedTransactionCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_AccruedTransactionCosts_lbl" xml:lang="en-US">Accrued transaction costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AccruedTransactionCosts" xlink:to="clnn_AccruedTransactionCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="clnn-20210930.xsd#clnn_FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of noncancelable operating lease arrangements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="clnn_FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US">2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US">2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter_lbl" xml:lang="en-US">Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xml:lang="en-US">Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CapitalLeasesFutureLeaseIncentives" xlink:href="clnn-20210930.xsd#clnn_CapitalLeasesFutureLeaseIncentives"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_CapitalLeasesFutureLeaseIncentives_lbl" xml:lang="en-US">Less future lease incentives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CapitalLeasesFutureLeaseIncentives" xlink:to="clnn_CapitalLeasesFutureLeaseIncentives_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_OperatingLeasesLessFutureLeaseIncentives" xlink:href="clnn-20210930.xsd#clnn_OperatingLeasesLessFutureLeaseIncentives"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_OperatingLeasesLessFutureLeaseIncentives_lbl" xml:lang="en-US">Less future lease incentives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_OperatingLeasesLessFutureLeaseIncentives" xlink:to="clnn_OperatingLeasesLessFutureLeaseIncentives_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent_lbl" xml:lang="en-US">Lease obligations &#8211; long term portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsNoncurrent" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_FinanceLeaseByMajorClassPropertyAndEquipmentTableTextBlock" xlink:href="clnn-20210930.xsd#clnn_FinanceLeaseByMajorClassPropertyAndEquipmentTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_FinanceLeaseByMajorClassPropertyAndEquipmentTableTextBlock_lbl" xml:lang="en-US">Schedule of finance lease obligations included in property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FinanceLeaseByMajorClassPropertyAndEquipmentTableTextBlock" xlink:to="clnn_FinanceLeaseByMajorClassPropertyAndEquipmentTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_FinanceLeaseLaboratoryEquipmentGross" xlink:href="clnn-20210930.xsd#clnn_FinanceLeaseLaboratoryEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_FinanceLeaseLaboratoryEquipmentGross_lbl" xml:lang="en-US">Laboratory equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FinanceLeaseLaboratoryEquipmentGross" xlink:to="clnn_FinanceLeaseLaboratoryEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_FinanceLeaseFurnitureAndFixturesGross" xlink:href="clnn-20210930.xsd#clnn_FinanceLeaseFurnitureAndFixturesGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_FinanceLeaseFurnitureAndFixturesGross_lbl" xml:lang="en-US">Furniture and fixtures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FinanceLeaseFurnitureAndFixturesGross" xlink:to="clnn_FinanceLeaseFurnitureAndFixturesGross_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_FinanceLeaseWorkInProcessGross" xlink:href="clnn-20210930.xsd#clnn_FinanceLeaseWorkInProcessGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_FinanceLeaseWorkInProcessGross_lbl" xml:lang="en-US">Work in process</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FinanceLeaseWorkInProcessGross" xlink:to="clnn_FinanceLeaseWorkInProcessGross_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_AccumulatedDepreciationDepletionAndAmortizationLeases" xlink:href="clnn-20210930.xsd#clnn_AccumulatedDepreciationDepletionAndAmortizationLeases"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_AccumulatedDepreciationDepletionAndAmortizationLeases_lbl" xml:lang="en-US">Less accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AccumulatedDepreciationDepletionAndAmortizationLeases" xlink:to="clnn_AccumulatedDepreciationDepletionAndAmortizationLeases_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of finance and operating lease costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityAbstract_lbl" xml:lang="en-US">Finance lease costs:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US">Interest on lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US">Short-term lease costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US">Variable lease costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xml:lang="en-US">Schedule of supplemental cash flow information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_OperatingCashFlowsFromOperatingLeases" xlink:href="clnn-20210930.xsd#clnn_OperatingCashFlowsFromOperatingLeases"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_OperatingCashFlowsFromOperatingLeases_lbl" xml:lang="en-US">Operating cash flows from operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_OperatingCashFlowsFromOperatingLeases" xlink:to="clnn_OperatingCashFlowsFromOperatingLeases_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_OperatingCashFlowsFromFinanceLeases" xlink:href="clnn-20210930.xsd#clnn_OperatingCashFlowsFromFinanceLeases"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_OperatingCashFlowsFromFinanceLeases_lbl" xml:lang="en-US">Operating cash flows from finance leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_OperatingCashFlowsFromFinanceLeases" xlink:to="clnn_OperatingCashFlowsFromFinanceLeases_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_FinanceCashFlowsFromFinanceLeases" xlink:href="clnn-20210930.xsd#clnn_FinanceCashFlowsFromFinanceLeases"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_FinanceCashFlowsFromFinanceLeases_lbl" xml:lang="en-US">Financing cash flows from finance leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FinanceCashFlowsFromFinanceLeases" xlink:to="clnn_FinanceCashFlowsFromFinanceLeases_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xml:lang="en-US">Schedule of long-term debt, net of original issue discount and unamortized debt issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_TermLoansAbstract" xlink:href="clnn-20210930.xsd#clnn_TermLoansAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_TermLoansAbstract_lbl" xml:lang="en-US">Term Loans:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TermLoansAbstract" xlink:to="clnn_TermLoansAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_InterestRate" xlink:href="clnn-20210930.xsd#clnn_InterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_InterestRate_lbl" xml:lang="en-US">Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InterestRate" xlink:to="clnn_InterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_TotalTermLoans" xlink:href="clnn-20210930.xsd#clnn_TotalTermLoans"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_TotalTermLoans_lbl" xml:lang="en-US">Total term loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TotalTermLoans" xlink:to="clnn_TotalTermLoans_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US">Less convertible notes payable, net of unamortized debt discount and issuance costs (see Note 11)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_TotalNotesPayableAndConvertibleNotesPayable" xlink:href="clnn-20210930.xsd#clnn_TotalNotesPayableAndConvertibleNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_TotalNotesPayableAndConvertibleNotesPayable_lbl" xml:lang="en-US">Total notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TotalNotesPayableAndConvertibleNotesPayable" xlink:to="clnn_TotalNotesPayableAndConvertibleNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscounts" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscounts_lbl" xml:lang="en-US">Schedule of future payments, net of unamortized debt discounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscounts" xlink:to="clnn_ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscounts_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_DebtInstrumentUnamortizedDiscountRemainderOfFiscalYear" xlink:href="clnn-20210930.xsd#clnn_DebtInstrumentUnamortizedDiscountRemainderOfFiscalYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_DebtInstrumentUnamortizedDiscountRemainderOfFiscalYear_lbl" xml:lang="en-US">2021 (remainder)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DebtInstrumentUnamortizedDiscountRemainderOfFiscalYear" xlink:to="clnn_DebtInstrumentUnamortizedDiscountRemainderOfFiscalYear_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_DebtInstrumentUnamortizedDiscountYearOne" xlink:href="clnn-20210930.xsd#clnn_DebtInstrumentUnamortizedDiscountYearOne"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_DebtInstrumentUnamortizedDiscountYearOne_lbl" xml:lang="en-US">2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DebtInstrumentUnamortizedDiscountYearOne" xlink:to="clnn_DebtInstrumentUnamortizedDiscountYearOne_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_DebtInstrumentUnamortizedDiscountYearTwo" xlink:href="clnn-20210930.xsd#clnn_DebtInstrumentUnamortizedDiscountYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_DebtInstrumentUnamortizedDiscountYearTwo_lbl" xml:lang="en-US">2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DebtInstrumentUnamortizedDiscountYearTwo" xlink:to="clnn_DebtInstrumentUnamortizedDiscountYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_DebtInstrumentUnamortizedDiscountYearThree" xlink:href="clnn-20210930.xsd#clnn_DebtInstrumentUnamortizedDiscountYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_DebtInstrumentUnamortizedDiscountYearThree_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DebtInstrumentUnamortizedDiscountYearThree" xlink:to="clnn_DebtInstrumentUnamortizedDiscountYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_DebtInstrumentUnamortizedDiscountYearFour" xlink:href="clnn-20210930.xsd#clnn_DebtInstrumentUnamortizedDiscountYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_DebtInstrumentUnamortizedDiscountYearFour_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DebtInstrumentUnamortizedDiscountYearFour" xlink:to="clnn_DebtInstrumentUnamortizedDiscountYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_DebtInstrumentUnamortizedDiscountYearFive" xlink:href="clnn-20210930.xsd#clnn_DebtInstrumentUnamortizedDiscountYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_DebtInstrumentUnamortizedDiscountYearFive_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DebtInstrumentUnamortizedDiscountYearFive" xlink:to="clnn_DebtInstrumentUnamortizedDiscountYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_DebtInstrumentThereafter" xlink:href="clnn-20210930.xsd#clnn_DebtInstrumentThereafter"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_DebtInstrumentThereafter_lbl" xml:lang="en-US">Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DebtInstrumentThereafter" xlink:to="clnn_DebtInstrumentThereafter_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xml:lang="en-US">Preferred Stock Warrant Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrantsDisclosureTextBlock" xlink:href="clnn-20210930.xsd#clnn_CommonStockWarrantsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_CommonStockWarrantsDisclosureTextBlock_lbl" xml:lang="en-US">Common Stock Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockWarrantsDisclosureTextBlock" xlink:to="clnn_CommonStockWarrantsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of outstanding warrants to purchase shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_NumberOfSharesIssuable" xlink:href="clnn-20210930.xsd#clnn_NumberOfSharesIssuable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_NumberOfSharesIssuable_lbl" xml:lang="en-US">Number of Shares Issuable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NumberOfSharesIssuable" xlink:to="clnn_NumberOfSharesIssuable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrantsExercisePrice" xlink:href="clnn-20210930.xsd#clnn_CommonStockWarrantsExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_CommonStockWarrantsExercisePrice_lbl" xml:lang="en-US">Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockWarrantsExercisePrice" xlink:to="clnn_CommonStockWarrantsExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrantsExercisable" xlink:href="clnn-20210930.xsd#clnn_CommonStockWarrantsExercisable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_CommonStockWarrantsExercisable_lbl" xml:lang="en-US">Exercisable for</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockWarrantsExercisable" xlink:to="clnn_CommonStockWarrantsExercisable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrantsClassification" xlink:href="clnn-20210930.xsd#clnn_CommonStockWarrantsClassification"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_CommonStockWarrantsClassification_lbl" xml:lang="en-US">Classification</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockWarrantsClassification" xlink:to="clnn_CommonStockWarrantsClassification_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrantsExpiration" xlink:href="clnn-20210930.xsd#clnn_CommonStockWarrantsExpiration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_CommonStockWarrantsExpiration_lbl" xml:lang="en-US">Expiration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockWarrantsExpiration" xlink:to="clnn_CommonStockWarrantsExpiration_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ConvertibleNotesDisclosureTextBlock" xlink:href="clnn-20210930.xsd#clnn_ConvertibleNotesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ConvertibleNotesDisclosureTextBlock_lbl" xml:lang="en-US">Convertible Notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ConvertibleNotesDisclosureTextBlock" xlink:to="clnn_ConvertibleNotesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xml:lang="en-US">Derivative Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US">Schedule of components of income (loss) before income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US">United States</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US">Foreign</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of outstanding common stock options and related activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Term (Years), Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Options, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted" xlink:href="clnn-20210930.xsd#clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted_lbl" xml:lang="en-US">Weighted Average Remaining Term, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted" xlink:to="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueGranted" xlink:href="clnn-20210930.xsd#clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueGranted_lbl" xml:lang="en-US">Intrinsic Value, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueGranted" xlink:to="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_WeightedAverageRemainingTermYearsExercised" xlink:href="clnn-20210930.xsd#clnn_WeightedAverageRemainingTermYearsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_WeightedAverageRemainingTermYearsExercised_lbl" xml:lang="en-US">Weighted Average Remaining Term (Years), Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WeightedAverageRemainingTermYearsExercised" xlink:to="clnn_WeightedAverageRemainingTermYearsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue" xlink:href="clnn-20210930.xsd#clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue_lbl" xml:lang="en-US">Intrinsic Value, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue" xlink:to="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_WeightedAverageRemainingTermYearsForfeited" xlink:href="clnn-20210930.xsd#clnn_WeightedAverageRemainingTermYearsForfeited"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_WeightedAverageRemainingTermYearsForfeited_lbl" xml:lang="en-US">Weighted Average Remaining Term (Years), Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WeightedAverageRemainingTermYearsForfeited" xlink:to="clnn_WeightedAverageRemainingTermYearsForfeited_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue" xlink:href="clnn-20210930.xsd#clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue_lbl" xml:lang="en-US">Intrinsic Value, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue" xlink:to="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Term (Years), Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber" xlink:href="clnn-20210930.xsd#clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber_lbl" xml:lang="en-US">Number of Options, Options vested and exercisable ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber" xlink:to="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_WeightedAverageExercisePricePerShareOptionVestedAndExercisable" xlink:href="clnn-20210930.xsd#clnn_WeightedAverageExercisePricePerShareOptionVestedAndExercisable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_WeightedAverageExercisePricePerShareOptionVestedAndExercisable_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Options vested and exercisable ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WeightedAverageExercisePricePerShareOptionVestedAndExercisable" xlink:to="clnn_WeightedAverageExercisePricePerShareOptionVestedAndExercisable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_WeightedAverageExercisePriceWeightedAverageRemainingTermYearsOptionsVestedAndEexercisableEnding" xlink:href="clnn-20210930.xsd#clnn_WeightedAverageExercisePriceWeightedAverageRemainingTermYearsOptionsVestedAndEexercisableEnding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_WeightedAverageExercisePriceWeightedAverageRemainingTermYearsOptionsVestedAndEexercisableEnding_lbl" xml:lang="en-US">Weighted Average Exercise Price Weighted Average Remaining Term (Years), Options vested and exercisable ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WeightedAverageExercisePriceWeightedAverageRemainingTermYearsOptionsVestedAndEexercisableEnding" xlink:to="clnn_WeightedAverageExercisePriceWeightedAverageRemainingTermYearsOptionsVestedAndEexercisableEnding_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueIntrinsicValueOptionsVestedAndExercisableEnding" xlink:href="clnn-20210930.xsd#clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueIntrinsicValueOptionsVestedAndExercisableEnding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueIntrinsicValueOptionsVestedAndExercisableEnding_lbl" xml:lang="en-US">Intrinsic Value, Options vested and exercisable ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueIntrinsicValueOptionsVestedAndExercisableEnding" xlink:to="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueIntrinsicValueOptionsVestedAndExercisableEnding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number of Options, Stock options vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Stock options vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm1" xlink:href="clnn-20210930.xsd#clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Exercise Price Weighted Average Remaining Term (Years), Stock options vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm1" xlink:to="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_IntrinsicValueStockOptionsVestedAndExpectedToVestIntrinsicValueOptionsV" xlink:href="clnn-20210930.xsd#clnn_IntrinsicValueStockOptionsVestedAndExpectedToVestIntrinsicValueOptionsV"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_IntrinsicValueStockOptionsVestedAndExpectedToVestIntrinsicValueOptionsV_lbl" xml:lang="en-US">Intrinsic Value, Stock options vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IntrinsicValueStockOptionsVestedAndExpectedToVestIntrinsicValueOptionsV" xlink:to="clnn_IntrinsicValueStockOptionsVestedAndExpectedToVestIntrinsicValueOptionsV_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of assumptions used to calculate the fair value of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected stock price volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of restricted common stock activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted- Average Grant Date Fair Value, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted- Average Grant Date Fair Value, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of fair value hierarchy of liabilities measured at fair value on recurring basis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableFairValueDisclosure_lbl" xml:lang="en-US">Notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableFairValueDisclosure" xlink:to="us-gaap_NotesPayableFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilities_lbl" xml:lang="en-US">Warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CleneNanomedicineContingentEarnoutFairValueDisclosure" xlink:href="clnn-20210930.xsd#clnn_CleneNanomedicineContingentEarnoutFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_CleneNanomedicineContingentEarnoutFairValueDisclosure_lbl" xml:lang="en-US">Clene Nanomedicine contingent earn-out</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CleneNanomedicineContingentEarnoutFairValueDisclosure" xlink:to="clnn_CleneNanomedicineContingentEarnoutFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_InitialShareholdersContingentEarnoutFairValueDisclosure" xlink:href="clnn-20210930.xsd#clnn_InitialShareholdersContingentEarnoutFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_InitialShareholdersContingentEarnoutFairValueDisclosure_lbl" xml:lang="en-US">Initial Shareholders contingent earn-out</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InitialShareholdersContingentEarnoutFairValueDisclosure" xlink:to="clnn_InitialShareholdersContingentEarnoutFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US">Schedule of unobservable inputs to the conversion feature, warrant liability, and contingent earn-out valuation models</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xml:lang="en-US">Schedule of changes in fair value of financial liabilities related to the notes payable, the derivative instrument, the preferred stock warrants, and the contingent earn-outs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_InitialFairValueOfInstrument" xlink:href="clnn-20210930.xsd#clnn_InitialFairValueOfInstrument"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_InitialFairValueOfInstrument_lbl" xml:lang="en-US">Initial fair value of instrument</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InitialFairValueOfInstrument" xlink:to="clnn_InitialFairValueOfInstrument_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_IncreseDecreaseInFairValue" xlink:href="clnn-20210930.xsd#clnn_IncreseDecreaseInFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_IncreseDecreaseInFairValue_lbl" xml:lang="en-US">Change in fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IncreseDecreaseInFairValue" xlink:to="clnn_IncreseDecreaseInFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_FairValueIssuanceOfConvertiblePromissoryNotes" xlink:href="clnn-20210930.xsd#clnn_FairValueIssuanceOfConvertiblePromissoryNotes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_FairValueIssuanceOfConvertiblePromissoryNotes_lbl" xml:lang="en-US">Issuance of convertible promissory notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FairValueIssuanceOfConvertiblePromissoryNotes" xlink:to="clnn_FairValueIssuanceOfConvertiblePromissoryNotes_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_FairValueMeasurementExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN" xlink:href="clnn-20210930.xsd#clnn_FairValueMeasurementExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_FairValueMeasurementExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN_lbl" xml:lang="en-US">Extinguishment of derivative liability in connection with extinguishment of convertible promissory notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FairValueMeasurementExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN" xlink:to="clnn_FairValueMeasurementExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_RedeemableConvertiblePreferredStockDisclosureTextBlock" xlink:href="clnn-20210930.xsd#clnn_RedeemableConvertiblePreferredStockDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_RedeemableConvertiblePreferredStockDisclosureTextBlock_lbl" xml:lang="en-US">Redeemable Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RedeemableConvertiblePreferredStockDisclosureTextBlock" xlink:to="clnn_RedeemableConvertiblePreferredStockDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Net Income (Loss) Per Share Attributable to Common Shareholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of basic and diluted net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_NumeratorAbstract" xlink:href="clnn-20210930.xsd#clnn_NumeratorAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_NumeratorAbstract_lbl" xml:lang="en-US">Numerator :</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NumeratorAbstract" xlink:to="clnn_NumeratorAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net income (loss) attributable to common shareholders &#8211; Basic (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestOnConvertibleDebtNetOfTax_lbl" xml:lang="en-US">Less interest expense on potentially dilutive convertible notes payable (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:to="us-gaap_InterestOnConvertibleDebtNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US">Net income (loss) attributable to common shareholders - Diluted (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_DenominatorAbstract" xlink:href="clnn-20210930.xsd#clnn_DenominatorAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_DenominatorAbstract_lbl" xml:lang="en-US">Denominator:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DenominatorAbstract" xlink:to="clnn_DenominatorAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_WeightedAverageSharesOutstanding" xlink:href="clnn-20210930.xsd#clnn_WeightedAverageSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_WeightedAverageSharesOutstanding_lbl" xml:lang="en-US">Weighted average common shares outstanding &#8211;Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WeightedAverageSharesOutstanding" xlink:to="clnn_WeightedAverageSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_WeightedAverageEffectOfPotentiallyDilutiveSecuritiesAbstract" xlink:href="clnn-20210930.xsd#clnn_WeightedAverageEffectOfPotentiallyDilutiveSecuritiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_WeightedAverageEffectOfPotentiallyDilutiveSecuritiesAbstract_lbl" xml:lang="en-US">Weighted average effect of potentially dilutive securities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WeightedAverageEffectOfPotentiallyDilutiveSecuritiesAbstract" xlink:to="clnn_WeightedAverageEffectOfPotentiallyDilutiveSecuritiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_EffectOfPotentiallyDilutiveStockOptionsinDollars" xlink:href="clnn-20210930.xsd#clnn_EffectOfPotentiallyDilutiveStockOptionsinDollars"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_EffectOfPotentiallyDilutiveStockOptionsinDollars_lbl" xml:lang="en-US">Effect of potentially dilutive stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_EffectOfPotentiallyDilutiveStockOptionsinDollars" xlink:to="clnn_EffectOfPotentiallyDilutiveStockOptionsinDollars_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_EffectOfPotentiallyDilutiveRestrictedStockAwards" xlink:href="clnn-20210930.xsd#clnn_EffectOfPotentiallyDilutiveRestrictedStockAwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_EffectOfPotentiallyDilutiveRestrictedStockAwards_lbl" xml:lang="en-US">Effect of potentially dilutive common stock warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_EffectOfPotentiallyDilutiveRestrictedStockAwards" xlink:to="clnn_EffectOfPotentiallyDilutiveRestrictedStockAwards_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_EffectOfPotentiallyDilutiveConvertibleNotesPayable" xlink:href="clnn-20210930.xsd#clnn_EffectOfPotentiallyDilutiveConvertibleNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_EffectOfPotentiallyDilutiveConvertibleNotesPayable_lbl" xml:lang="en-US">Effect of potentially dilutive convertible notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_EffectOfPotentiallyDilutiveConvertibleNotesPayable" xlink:to="clnn_EffectOfPotentiallyDilutiveConvertibleNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_EffectOfPotentiallyDilutiveUnvestedRestrictedStockAwardsShares" xlink:href="clnn-20210930.xsd#clnn_EffectOfPotentiallyDilutiveUnvestedRestrictedStockAwardsShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_EffectOfPotentiallyDilutiveUnvestedRestrictedStockAwardsShares_lbl" xml:lang="en-US">Effect of potentially dilutive restricted stock awards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_EffectOfPotentiallyDilutiveUnvestedRestrictedStockAwardsShares" xlink:to="clnn_EffectOfPotentiallyDilutiveUnvestedRestrictedStockAwardsShares_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_NetIncomeLossPerShareAttributableToCommonShareholdersAbstract" xlink:href="clnn-20210930.xsd#clnn_NetIncomeLossPerShareAttributableToCommonShareholdersAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_NetIncomeLossPerShareAttributableToCommonShareholdersAbstract_lbl" xml:lang="en-US">Net income (loss) per share attributable to common shareholders:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NetIncomeLossPerShareAttributableToCommonShareholdersAbstract" xlink:to="clnn_NetIncomeLossPerShareAttributableToCommonShareholdersAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of securities excluded from computation of diluted net income (loss) per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_SeriesDRedeemableConvertiblePreferredStock" xlink:href="clnn-20210930.xsd#clnn_SeriesDRedeemableConvertiblePreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_SeriesDRedeemableConvertiblePreferredStock_lbl" xml:lang="en-US">Series D redeemable convertible preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SeriesDRedeemableConvertiblePreferredStock" xlink:to="clnn_SeriesDRedeemableConvertiblePreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_SeriesCRedeemableConvertiblePreferredStock" xlink:href="clnn-20210930.xsd#clnn_SeriesCRedeemableConvertiblePreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_SeriesCRedeemableConvertiblePreferredStock_lbl" xml:lang="en-US">Series C redeemable convertible preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SeriesCRedeemableConvertiblePreferredStock" xlink:to="clnn_SeriesCRedeemableConvertiblePreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_SeriesBRedeemableConvertiblePreferredStock" xlink:href="clnn-20210930.xsd#clnn_SeriesBRedeemableConvertiblePreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_SeriesBRedeemableConvertiblePreferredStock_lbl" xml:lang="en-US">Series B redeemable convertible preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SeriesBRedeemableConvertiblePreferredStock" xlink:to="clnn_SeriesBRedeemableConvertiblePreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_SeriesARedeemableConvertiblePreferredStock" xlink:href="clnn-20210930.xsd#clnn_SeriesARedeemableConvertiblePreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_SeriesARedeemableConvertiblePreferredStock_lbl" xml:lang="en-US">Series A redeemable convertible preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SeriesARedeemableConvertiblePreferredStock" xlink:to="clnn_SeriesARedeemableConvertiblePreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_SeriesDRedeemableConvertiblePreferredStockWarrants" xlink:href="clnn-20210930.xsd#clnn_SeriesDRedeemableConvertiblePreferredStockWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_SeriesDRedeemableConvertiblePreferredStockWarrants_lbl" xml:lang="en-US">Series D redeemable convertible preferred stock warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SeriesDRedeemableConvertiblePreferredStockWarrants" xlink:to="clnn_SeriesDRedeemableConvertiblePreferredStockWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_SeriesARedeemableConvertiblePreferredStockWarrantsinShares" xlink:href="clnn-20210930.xsd#clnn_SeriesARedeemableConvertiblePreferredStockWarrantsinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_SeriesARedeemableConvertiblePreferredStockWarrantsinShares_lbl" xml:lang="en-US">Series A redeemable convertible preferred stock warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SeriesARedeemableConvertiblePreferredStockWarrantsinShares" xlink:to="clnn_SeriesARedeemableConvertiblePreferredStockWarrantsinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ConvertibleNotesPayables" xlink:href="clnn-20210930.xsd#clnn_ConvertibleNotesPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ConvertibleNotesPayables_lbl" xml:lang="en-US">Convertible notes payable (see Note 11)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ConvertibleNotesPayables" xlink:to="clnn_ConvertibleNotesPayables_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrants" xlink:href="clnn-20210930.xsd#clnn_CommonStockWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_CommonStockWarrants_lbl" xml:lang="en-US">Common stock warrants (see Note 10)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockWarrants" xlink:to="clnn_CommonStockWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_OptionsToPurchaseCommonStockinShares" xlink:href="clnn-20210930.xsd#clnn_OptionsToPurchaseCommonStockinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_OptionsToPurchaseCommonStockinShares_lbl" xml:lang="en-US">Options to purchase common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_OptionsToPurchaseCommonStockinShares" xlink:to="clnn_OptionsToPurchaseCommonStockinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_UnvestedRestrictedStockAwardsShares" xlink:href="clnn-20210930.xsd#clnn_UnvestedRestrictedStockAwardsShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_UnvestedRestrictedStockAwardsShares_lbl" xml:lang="en-US">Restricted stock awards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_UnvestedRestrictedStockAwardsShares" xlink:to="clnn_UnvestedRestrictedStockAwardsShares_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ChardanUnitPurchaseOptionWarrants" xlink:href="clnn-20210930.xsd#clnn_ChardanUnitPurchaseOptionWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ChardanUnitPurchaseOptionWarrants_lbl" xml:lang="en-US">Chardan Unit Purchase Option Warrants (see Notes 3 and 10)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChardanUnitPurchaseOptionWarrants" xlink:to="clnn_ChardanUnitPurchaseOptionWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CleneNanomedicineContingentEarnoutShares" xlink:href="clnn-20210930.xsd#clnn_CleneNanomedicineContingentEarnoutShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_CleneNanomedicineContingentEarnoutShares_lbl" xml:lang="en-US">Clene Nanomedicine contingent earn-out shares (see Note 3 and 12)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CleneNanomedicineContingentEarnoutShares" xlink:to="clnn_CleneNanomedicineContingentEarnoutShares_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_InitialShareholdersContingentEarnoutShares" xlink:href="clnn-20210930.xsd#clnn_InitialShareholdersContingentEarnoutShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_InitialShareholdersContingentEarnoutShares_lbl" xml:lang="en-US">Initial Shareholders contingent earn-out shares (see Note 3 and 12)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InitialShareholdersContingentEarnoutShares" xlink:to="clnn_InitialShareholdersContingentEarnoutShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">Geographic and Segment Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment, net by location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:to="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">Schedule of drugs and supplements segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment, net by segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock" xlink:to="clnn_ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_TotalPropertyAndEquipmentNet" xlink:href="clnn-20210930.xsd#clnn_TotalPropertyAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_TotalPropertyAndEquipmentNet_lbl" xml:lang="en-US">Total property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TotalPropertyAndEquipmentNet" xlink:to="clnn_TotalPropertyAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_AustraliaResearchAndDevelopmentCreditReceivable" xlink:href="clnn-20210930.xsd#clnn_AustraliaResearchAndDevelopmentCreditReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="clnn_AustraliaResearchAndDevelopmentCreditReceivable_lbl" xml:lang="en-US">Australia research and development credit receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AustraliaResearchAndDevelopmentCreditReceivable" xlink:to="clnn_AustraliaResearchAndDevelopmentCreditReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CapitalLeasesAmountRepresentingInterestdiscounting" xlink:href="clnn-20210930.xsd#clnn_CapitalLeasesAmountRepresentingInterestdiscounting"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="clnn_CapitalLeasesAmountRepresentingInterestdiscounting_lbl" xml:lang="en-US">Less amount representing interest/discounting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CapitalLeasesAmountRepresentingInterestdiscounting" xlink:to="clnn_CapitalLeasesAmountRepresentingInterestdiscounting_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_OperatingLeasesAmountRepresentingInterestdiscounting" xlink:href="clnn-20210930.xsd#clnn_OperatingLeasesAmountRepresentingInterestdiscounting"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="clnn_OperatingLeasesAmountRepresentingInterestdiscounting_lbl" xml:lang="en-US">Less amount representing interest/discounting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_OperatingLeasesAmountRepresentingInterestdiscounting" xlink:to="clnn_OperatingLeasesAmountRepresentingInterestdiscounting_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_lbl" xml:lang="en-US">Less lease obligations, current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsCurrent" xlink:to="us-gaap_CapitalLeaseObligationsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xml:lang="en-US">Unamortized debt issuance costs and original issue discounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedPremium_lbl" xml:lang="en-US">Unamortized debt discount associated with issuance date warrant fair value and financing costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedPremium" xlink:to="us-gaap_DebtInstrumentUnamortizedPremium_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ShareBasedCompensationArrangementNumberOfOptionsExercised" xlink:href="clnn-20210930.xsd#clnn_ShareBasedCompensationArrangementNumberOfOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="clnn_ShareBasedCompensationArrangementNumberOfOptionsExercised_lbl" xml:lang="en-US">Number of Options, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ShareBasedCompensationArrangementNumberOfOptionsExercised" xlink:to="clnn_ShareBasedCompensationArrangementNumberOfOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of Options, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0" xml:lang="en-US">Number of Restricted Stock Awards, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Number of Restricted Stock Awards, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_FinanceLeasesMember" xlink:href="clnn-20210930.xsd#clnn_FinanceLeasesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_FinanceLeasesMember_lbl" xml:lang="en-US">Finance Leases [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FinanceLeasesMember" xlink:to="clnn_FinanceLeasesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_OperatingLeasesMember" xlink:href="clnn-20210930.xsd#clnn_OperatingLeasesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_OperatingLeasesMember_lbl" xml:lang="en-US">Operating Leases [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_OperatingLeasesMember" xlink:to="clnn_OperatingLeasesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_MarylandDepartmentOfHousingCommunityDevelopmentMember" xlink:href="clnn-20210930.xsd#clnn_MarylandDepartmentOfHousingCommunityDevelopmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_MarylandDepartmentOfHousingCommunityDevelopmentMember_lbl" xml:lang="en-US">Maryland Department of Housing &amp; Community Development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_MarylandDepartmentOfHousingCommunityDevelopmentMember" xlink:to="clnn_MarylandDepartmentOfHousingCommunityDevelopmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_AdvanceCecilIncMember" xlink:href="clnn-20210930.xsd#clnn_AdvanceCecilIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_AdvanceCecilIncMember_lbl" xml:lang="en-US">Advance Cecil, Inc. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AdvanceCecilIncMember" xlink:to="clnn_AdvanceCecilIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_PaycheckProtectionProgramMember" xlink:href="clnn-20210930.xsd#clnn_PaycheckProtectionProgramMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_PaycheckProtectionProgramMember_lbl" xml:lang="en-US">Paycheck Protection Program [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PaycheckProtectionProgramMember" xlink:to="clnn_PaycheckProtectionProgramMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_AvenueVentureOpportunitiesFundsLPMember" xlink:href="clnn-20210930.xsd#clnn_AvenueVentureOpportunitiesFundsLPMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_AvenueVentureOpportunitiesFundsLPMember_lbl" xml:lang="en-US">Avenue Venture Opportunities Fund, L.P. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AvenueVentureOpportunitiesFundsLPMember" xlink:to="clnn_AvenueVentureOpportunitiesFundsLPMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_OtherTermLoanMember" xlink:href="clnn-20210930.xsd#clnn_OtherTermLoanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_OtherTermLoanMember_lbl" xml:lang="en-US">Other [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_OtherTermLoanMember" xlink:to="clnn_OtherTermLoanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_WarrantsDateMember" xlink:href="clnn-20210930.xsd#clnn_WarrantsDateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_WarrantsDateMember_lbl" xml:lang="en-US">June 2021 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantsDateMember" xlink:to="clnn_WarrantsDateMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_WarrantsDate1Member" xlink:href="clnn-20210930.xsd#clnn_WarrantsDate1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_WarrantsDate1Member_lbl" xml:lang="en-US">December 2020 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantsDate1Member" xlink:to="clnn_WarrantsDate1Member_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_December20201Member" xlink:href="clnn-20210930.xsd#clnn_December20201Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_December20201Member_lbl" xml:lang="en-US">December 2020 One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_December20201Member" xlink:to="clnn_December20201Member_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_WarrantsDate2Member" xlink:href="clnn-20210930.xsd#clnn_WarrantsDate2Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_WarrantsDate2Member_lbl" xml:lang="en-US">December 2020 Two [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantsDate2Member" xlink:to="clnn_WarrantsDate2Member_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_May2021Member" xlink:href="clnn-20210930.xsd#clnn_May2021Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_May2021Member_lbl" xml:lang="en-US">May 2021 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_May2021Member" xlink:to="clnn_May2021Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and administrative [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xml:lang="en-US">Convertible Notes Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl0" xml:lang="en-US">2020 Convertible Notes [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="clnn_BlackScholesValuationModelMember" xlink:href="clnn-20210930.xsd#clnn_BlackScholesValuationModelMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_BlackScholesValuationModelMember_lbl" xml:lang="en-US">Black-Scholes Valuation Model [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_BlackScholesValuationModelMember" xlink:to="clnn_BlackScholesValuationModelMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_MonteCarloSimulationMember" xlink:href="clnn-20210930.xsd#clnn_MonteCarloSimulationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_MonteCarloSimulationMember_lbl" xml:lang="en-US">Monte Carlo Simulation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_MonteCarloSimulationMember" xlink:to="clnn_MonteCarloSimulationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_WarrantLiabilityMember" xlink:href="clnn-20210930.xsd#clnn_WarrantLiabilityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_WarrantLiabilityMember_lbl" xml:lang="en-US">Warrant Liability [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantLiabilityMember" xlink:to="clnn_WarrantLiabilityMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ContingentEarnOutMember" xlink:href="clnn-20210930.xsd#clnn_ContingentEarnOutMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ContingentEarnOutMember_lbl" xml:lang="en-US">Contingent Earn-Out [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ContingentEarnOutMember" xlink:to="clnn_ContingentEarnOutMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableOtherPayablesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableOtherPayablesMember_lbl" xml:lang="en-US">Notes Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableOtherPayablesMember" xlink:to="us-gaap_NotesPayableOtherPayablesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CleneNanomedicineContingentEarnoutMember" xlink:href="clnn-20210930.xsd#clnn_CleneNanomedicineContingentEarnoutMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_CleneNanomedicineContingentEarnoutMember_lbl" xml:lang="en-US">Clene Nanomedicine Contingent Earn-out [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CleneNanomedicineContingentEarnoutMember" xlink:to="clnn_CleneNanomedicineContingentEarnoutMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_InitialShareholdersContingentEarnoutMember" xlink:href="clnn-20210930.xsd#clnn_InitialShareholdersContingentEarnoutMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_InitialShareholdersContingentEarnoutMember_lbl" xml:lang="en-US">Initial Shareholders Contingent Earn-out [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InitialShareholdersContingentEarnoutMember" xlink:to="clnn_InitialShareholdersContingentEarnoutMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_DerivativeInstrumentMember" xlink:href="clnn-20210930.xsd#clnn_DerivativeInstrumentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_DerivativeInstrumentMember_lbl" xml:lang="en-US">Derivative Instrument [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DerivativeInstrumentMember" xlink:to="clnn_DerivativeInstrumentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_PreferredStockWarrantsMember" xlink:href="clnn-20210930.xsd#clnn_PreferredStockWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_PreferredStockWarrantsMember_lbl" xml:lang="en-US">Preferred Stock Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PreferredStockWarrantsMember" xlink:to="clnn_PreferredStockWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_NetIncomeLossPerShareAttributableToCommonShareholdersMember" xlink:href="clnn-20210930.xsd#clnn_NetIncomeLossPerShareAttributableToCommonShareholdersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_NetIncomeLossPerShareAttributableToCommonShareholdersMember_lbl" xml:lang="en-US">Net Income (Loss) Per Share Attributable to Common Shareholders [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NetIncomeLossPerShareAttributableToCommonShareholdersMember" xlink:to="clnn_NetIncomeLossPerShareAttributableToCommonShareholdersMember_lbl"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_US_lbl" xml:lang="en-US">United States [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
    <loc xlink:type="locator" xlink:label="country_AU" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_AU"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_AU_lbl" xml:lang="en-US">Australia [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_AU" xlink:to="country_AU_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_DrugsMember" xlink:href="clnn-20210930.xsd#clnn_DrugsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_DrugsMember_lbl" xml:lang="en-US">Drugs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DrugsMember" xlink:to="clnn_DrugsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_SupplementsMember" xlink:href="clnn-20210930.xsd#clnn_SupplementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_SupplementsMember_lbl" xml:lang="en-US">Supplements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SupplementsMember" xlink:to="clnn_SupplementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollateralAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollateralAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollateralAxis_lbl" xml:lang="en-US">Collateral Held [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollateralAxis" xlink:to="us-gaap_CollateralAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis_lbl" xml:lang="en-US">Reorganization, Chapter 11 [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" xlink:to="us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US">Asset Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0" xml:lang="en-US">Warrants issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0"/>
    <loc xlink:type="locator" xlink:label="clnn_AggregateFutureProceedsWarrantsExercised" xlink:href="clnn-20210930.xsd#clnn_AggregateFutureProceedsWarrantsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_AggregateFutureProceedsWarrantsExercised_lbl" xml:lang="en-US">Aggregate proceeds if warrants exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AggregateFutureProceedsWarrantsExercised" xlink:to="clnn_AggregateFutureProceedsWarrantsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_OfferingCost" xlink:href="clnn-20210930.xsd#clnn_OfferingCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_OfferingCost_lbl" xml:lang="en-US">Offering Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_OfferingCost" xlink:to="clnn_OfferingCost_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_AggregateProceedsReceived" xlink:href="clnn-20210930.xsd#clnn_AggregateProceedsReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_AggregateProceedsReceived_lbl" xml:lang="en-US">Aggregate proceeds received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AggregateProceedsReceived" xlink:to="clnn_AggregateProceedsReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_OfferingPricePerShare" xlink:href="clnn-20210930.xsd#clnn_OfferingPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_OfferingPricePerShare_lbl" xml:lang="en-US">Offering price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_OfferingPricePerShare" xlink:to="clnn_OfferingPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockUnderlyingWarrantOutstanding" xlink:href="clnn-20210930.xsd#clnn_CommonStockUnderlyingWarrantOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_CommonStockUnderlyingWarrantOutstanding_lbl" xml:lang="en-US">Common stock underlying warrant outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockUnderlyingWarrantOutstanding" xlink:to="clnn_CommonStockUnderlyingWarrantOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ShareIssuanceOfCommonStockPrivateOffering" xlink:href="clnn-20210930.xsd#clnn_ShareIssuanceOfCommonStockPrivateOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ShareIssuanceOfCommonStockPrivateOffering_lbl" xml:lang="en-US">Common Stock, issued in a private placement (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ShareIssuanceOfCommonStockPrivateOffering" xlink:to="clnn_ShareIssuanceOfCommonStockPrivateOffering_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedInvestments_lbl" xml:lang="en-US">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedInvestments" xlink:to="us-gaap_RestrictedInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US">Inventory in raw materials</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Inventory Finished Goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Incurred of deferred offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredOfferingCosts_lbl0" xml:lang="en-US">Offering costs (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Useful lives of asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US">Deferred Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl" xml:lang="en-US">Other income and expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_GrantFundingRecognizedOnConditionalGrants" xlink:href="clnn-20210930.xsd#clnn_GrantFundingRecognizedOnConditionalGrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_GrantFundingRecognizedOnConditionalGrants_lbl" xml:lang="en-US">Grant funding recognized on conditional grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_GrantFundingRecognizedOnConditionalGrants" xlink:to="clnn_GrantFundingRecognizedOnConditionalGrants_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockParOrStatedValuesPerShare" xlink:href="clnn-20210930.xsd#clnn_CommonStockParOrStatedValuesPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_CommonStockParOrStatedValuesPerShare_lbl" xml:lang="en-US">Common stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockParOrStatedValuesPerShare" xlink:to="clnn_CommonStockParOrStatedValuesPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_SharesCancelledUponReverseRecapitalization" xlink:href="clnn-20210930.xsd#clnn_SharesCancelledUponReverseRecapitalization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_SharesCancelledUponReverseRecapitalization_lbl" xml:lang="en-US">Shares cancelled upon reverse recapitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharesCancelledUponReverseRecapitalization" xlink:to="clnn_SharesCancelledUponReverseRecapitalization_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_InitialShareholdersContingentsEarnout" xlink:href="clnn-20210930.xsd#clnn_InitialShareholdersContingentsEarnout"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_InitialShareholdersContingentsEarnout_lbl" xml:lang="en-US">Initial shareholders earn-out shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InitialShareholdersContingentsEarnout" xlink:to="clnn_InitialShareholdersContingentsEarnout_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ExchangeOfSharesReceived" xlink:href="clnn-20210930.xsd#clnn_ExchangeOfSharesReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ExchangeOfSharesReceived_lbl" xml:lang="en-US">Common stock, share issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ExchangeOfSharesReceived" xlink:to="clnn_ExchangeOfSharesReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ReverseRecapitalizationExchangeRatio" xlink:href="clnn-20210930.xsd#clnn_ReverseRecapitalizationExchangeRatio"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ReverseRecapitalizationExchangeRatio_lbl" xml:lang="en-US">Reverse recapitalization exchange ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ReverseRecapitalizationExchangeRatio" xlink:to="clnn_ReverseRecapitalizationExchangeRatio_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_SharesHeldInEscrowPercentage" xlink:href="clnn-20210930.xsd#clnn_SharesHeldInEscrowPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_SharesHeldInEscrowPercentage_lbl" xml:lang="en-US">Shares held in escrow, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharesHeldInEscrowPercentage" xlink:to="clnn_SharesHeldInEscrowPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_SharesHeldInEscrow" xlink:href="clnn-20210930.xsd#clnn_SharesHeldInEscrow"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_SharesHeldInEscrow_lbl" xml:lang="en-US">Shares held in escrow (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharesHeldInEscrow" xlink:to="clnn_SharesHeldInEscrow_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_lbl" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, Forfeited (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xml:lang="en-US">Shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ExchangeRatioPercentage" xlink:href="clnn-20210930.xsd#clnn_ExchangeRatioPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ExchangeRatioPercentage_lbl" xml:lang="en-US">Exchange ratio percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ExchangeRatioPercentage" xlink:to="clnn_ExchangeRatioPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ProceedsFromReverseRecapitalization" xlink:href="clnn-20210930.xsd#clnn_ProceedsFromReverseRecapitalization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ProceedsFromReverseRecapitalization_lbl" xml:lang="en-US">Proceeds from reverse recapitalization (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ProceedsFromReverseRecapitalization" xlink:to="clnn_ProceedsFromReverseRecapitalization_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_SaleOfUnitsNumberOfUnitsIssued" xlink:href="clnn-20210930.xsd#clnn_SaleOfUnitsNumberOfUnitsIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_SaleOfUnitsNumberOfUnitsIssued_lbl" xml:lang="en-US">Sale of units, number of units issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SaleOfUnitsNumberOfUnitsIssued" xlink:to="clnn_SaleOfUnitsNumberOfUnitsIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_UnitsIssuedPricePerUnit" xlink:href="clnn-20210930.xsd#clnn_UnitsIssuedPricePerUnit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_UnitsIssuedPricePerUnit_lbl" xml:lang="en-US">Units issued, price per unit (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_UnitsIssuedPricePerUnit" xlink:to="clnn_UnitsIssuedPricePerUnit_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ExercisePrice" xlink:href="clnn-20210930.xsd#clnn_ExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ExercisePrice_lbl" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ExercisePrice" xlink:to="clnn_ExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ServicesLetterAgreementDescription" xlink:href="clnn-20210930.xsd#clnn_ServicesLetterAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ServicesLetterAgreementDescription_lbl" xml:lang="en-US">Services letter agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ServicesLetterAgreementDescription" xlink:to="clnn_ServicesLetterAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssued_lbl0" xml:lang="en-US">Shares, issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_SharesIssued_lbl1" xml:lang="en-US">Warrants to purchase common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl2" xml:lang="en-US">Shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockOtherSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockOtherSharesOutstanding_lbl" xml:lang="en-US">Common stock, share outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockOtherSharesOutstanding" xlink:to="us-gaap_CommonStockOtherSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockOtherSharesOutstanding_lbl0" xml:lang="en-US">Stock option outstanding (pre-conversion)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockOtherSharesOutstanding" xlink:to="us-gaap_CommonStockOtherSharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="clnn_WarrantsToPurchaseCommonStockIssuedAndOutstanding" xlink:href="clnn-20210930.xsd#clnn_WarrantsToPurchaseCommonStockIssuedAndOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_WarrantsToPurchaseCommonStockIssuedAndOutstanding_lbl" xml:lang="en-US">Warrant outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantsToPurchaseCommonStockIssuedAndOutstanding" xlink:to="clnn_WarrantsToPurchaseCommonStockIssuedAndOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Shareholder ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherUnderwritingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherUnderwritingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherUnderwritingExpense_lbl" xml:lang="en-US">Deferred underwriting fees (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherUnderwritingExpense" xlink:to="us-gaap_OtherUnderwritingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_lbl" xml:lang="en-US">Underwriting fees (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:to="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantExercisePriceIncrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantExercisePriceIncrease_lbl" xml:lang="en-US">Warrant, Exercise Price, Increase (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceIncrease" xlink:to="us-gaap_WarrantExercisePriceIncrease_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_AggregateGrossProceedWarrantsExercised" xlink:href="clnn-20210930.xsd#clnn_AggregateGrossProceedWarrantsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_AggregateGrossProceedWarrantsExercised_lbl" xml:lang="en-US">Aggregate gross proceed warrants exercised (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AggregateGrossProceedWarrantsExercised" xlink:to="clnn_AggregateGrossProceedWarrantsExercised_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="clnn_AggregateGrossProceedWarrantsExercised_lbl0" xml:lang="en-US">Aggregate gross proceed warrants exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AggregateGrossProceedWarrantsExercised" xlink:to="clnn_AggregateGrossProceedWarrantsExercised_lbl0"/>
    <loc xlink:type="locator" xlink:label="clnn_ChardanUnitPurchaseOption" xlink:href="clnn-20210930.xsd#clnn_ChardanUnitPurchaseOption"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ChardanUnitPurchaseOption_lbl" xml:lang="en-US">Chardan unit purchase option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChardanUnitPurchaseOption" xlink:to="clnn_ChardanUnitPurchaseOption_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-US">Exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <loc xlink:type="locator" xlink:label="clnn_NetIssuanceSharesOfCommonStock" xlink:href="clnn-20210930.xsd#clnn_NetIssuanceSharesOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_NetIssuanceSharesOfCommonStock_lbl" xml:lang="en-US">Net issuance shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NetIssuanceSharesOfCommonStock" xlink:to="clnn_NetIssuanceSharesOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_WarrantsToPurchaseSharesOfCommonStock" xlink:href="clnn-20210930.xsd#clnn_WarrantsToPurchaseSharesOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_WarrantsToPurchaseSharesOfCommonStock_lbl" xml:lang="en-US">Warrants to purchase one-half of one share of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantsToPurchaseSharesOfCommonStock" xlink:to="clnn_WarrantsToPurchaseSharesOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CleneNanomedicineContingentEarnOutMilestone1Shares" xlink:href="clnn-20210930.xsd#clnn_CleneNanomedicineContingentEarnOutMilestone1Shares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_CleneNanomedicineContingentEarnOutMilestone1Shares_lbl" xml:lang="en-US">Clene nanomedicine contingent earnout milestone1 shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CleneNanomedicineContingentEarnOutMilestone1Shares" xlink:to="clnn_CleneNanomedicineContingentEarnOutMilestone1Shares_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CleneNanomedicineContingentEarnoutMilestone1Price" xlink:href="clnn-20210930.xsd#clnn_CleneNanomedicineContingentEarnoutMilestone1Price"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_CleneNanomedicineContingentEarnoutMilestone1Price_lbl" xml:lang="en-US">Clene nanomedicine contingent earnout milestone 1 price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CleneNanomedicineContingentEarnoutMilestone1Price" xlink:to="clnn_CleneNanomedicineContingentEarnoutMilestone1Price_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CleneNanomedicineContingentEarnoutMilestone2Shares" xlink:href="clnn-20210930.xsd#clnn_CleneNanomedicineContingentEarnoutMilestone2Shares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_CleneNanomedicineContingentEarnoutMilestone2Shares_lbl" xml:lang="en-US">Clene nanomedicine contingent earnout milestone 2 shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CleneNanomedicineContingentEarnoutMilestone2Shares" xlink:to="clnn_CleneNanomedicineContingentEarnoutMilestone2Shares_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CleneNanomedicineContingentEarnoutMilestone2Price" xlink:href="clnn-20210930.xsd#clnn_CleneNanomedicineContingentEarnoutMilestone2Price"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_CleneNanomedicineContingentEarnoutMilestone2Price_lbl" xml:lang="en-US">Clene nanomedicine contingent earnout milestone 2 price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CleneNanomedicineContingentEarnoutMilestone2Price" xlink:to="clnn_CleneNanomedicineContingentEarnoutMilestone2Price_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CleneNanomedicineContingentEarnoutMilestone3Shares" xlink:href="clnn-20210930.xsd#clnn_CleneNanomedicineContingentEarnoutMilestone3Shares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_CleneNanomedicineContingentEarnoutMilestone3Shares_lbl" xml:lang="en-US">Clene nanomedicine contingent earnout milestone 3 shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CleneNanomedicineContingentEarnoutMilestone3Shares" xlink:to="clnn_CleneNanomedicineContingentEarnoutMilestone3Shares_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_IncreaseInCleneNanomedicineContingentEarnoutSharesUponReverseRecapitalization" xlink:href="clnn-20210930.xsd#clnn_IncreaseInCleneNanomedicineContingentEarnoutSharesUponReverseRecapitalization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_IncreaseInCleneNanomedicineContingentEarnoutSharesUponReverseRecapitalization_lbl" xml:lang="en-US">Increase in clene nanomedicine contingent earnout shares upon reverse recapitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IncreaseInCleneNanomedicineContingentEarnoutSharesUponReverseRecapitalization" xlink:to="clnn_IncreaseInCleneNanomedicineContingentEarnoutSharesUponReverseRecapitalization_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_TotalCleneNanomedicineContingentEarnoutShares" xlink:href="clnn-20210930.xsd#clnn_TotalCleneNanomedicineContingentEarnoutShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_TotalCleneNanomedicineContingentEarnoutShares_lbl" xml:lang="en-US">Total clene nanomedicine contingent earnout shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TotalCleneNanomedicineContingentEarnoutShares" xlink:to="clnn_TotalCleneNanomedicineContingentEarnoutShares_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_InitialShareholdersContingentEarnoutMilestone1Shares" xlink:href="clnn-20210930.xsd#clnn_InitialShareholdersContingentEarnoutMilestone1Shares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_InitialShareholdersContingentEarnoutMilestone1Shares_lbl" xml:lang="en-US">Initial shareholders contingent earnout milestone1 shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InitialShareholdersContingentEarnoutMilestone1Shares" xlink:to="clnn_InitialShareholdersContingentEarnoutMilestone1Shares_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_InitialShareholdersContingentEarnoutMilestone2Shares" xlink:href="clnn-20210930.xsd#clnn_InitialShareholdersContingentEarnoutMilestone2Shares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_InitialShareholdersContingentEarnoutMilestone2Shares_lbl" xml:lang="en-US">Initial shareholders contingent earnout milestone 2 shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InitialShareholdersContingentEarnoutMilestone2Shares" xlink:to="clnn_InitialShareholdersContingentEarnoutMilestone2Shares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_RemainingRightofuseAsset" xlink:href="clnn-20210930.xsd#clnn_RemainingRightofuseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_RemainingRightofuseAsset_lbl" xml:lang="en-US">Terminated right-of-use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RemainingRightofuseAsset" xlink:to="clnn_RemainingRightofuseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_RecognizedGainOnOperatingLease" xlink:href="clnn-20210930.xsd#clnn_RecognizedGainOnOperatingLease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_RecognizedGainOnOperatingLease_lbl" xml:lang="en-US">Recognized gain on operating lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RecognizedGainOnOperatingLease" xlink:to="clnn_RecognizedGainOnOperatingLease_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_RightOfUseAssets" xlink:href="clnn-20210930.xsd#clnn_RightOfUseAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_RightOfUseAssets_lbl" xml:lang="en-US">Right of use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RightOfUseAssets" xlink:to="clnn_RightOfUseAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_LeaseholdImprovements" xlink:href="clnn-20210930.xsd#clnn_LeaseholdImprovements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_LeaseholdImprovements_lbl" xml:lang="en-US">Leasehold improvements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_LeaseholdImprovements" xlink:to="clnn_LeaseholdImprovements_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_IncreaseInRightOfUseAssets" xlink:href="clnn-20210930.xsd#clnn_IncreaseInRightOfUseAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_IncreaseInRightOfUseAssets_lbl" xml:lang="en-US">Increase in right of use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IncreaseInRightOfUseAssets" xlink:to="clnn_IncreaseInRightOfUseAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_IncreaseInLeaseholdImprovements" xlink:href="clnn-20210930.xsd#clnn_IncreaseInLeaseholdImprovements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_IncreaseInLeaseholdImprovements_lbl" xml:lang="en-US">Increase in leasehold imrovements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IncreaseInLeaseholdImprovements" xlink:to="clnn_IncreaseInLeaseholdImprovements_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_IncreaseInLeaseLiability" xlink:href="clnn-20210930.xsd#clnn_IncreaseInLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_IncreaseInLeaseLiability_lbl" xml:lang="en-US">Increase in lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IncreaseInLeaseLiability" xlink:to="clnn_IncreaseInLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_OperatingLeaseRightofUseAssets" xlink:href="clnn-20210930.xsd#clnn_OperatingLeaseRightofUseAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_OperatingLeaseRightofUseAssets_lbl" xml:lang="en-US">Right-of-use assets value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_OperatingLeaseRightofUseAssets" xlink:to="clnn_OperatingLeaseRightofUseAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncentiveToLessee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncentiveToLessee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncentiveToLessee_lbl" xml:lang="en-US">Lease incentive</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncentiveToLessee" xlink:to="us-gaap_IncentiveToLessee_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_LeaseIncentiveRecordedConstructionInProgress" xlink:href="clnn-20210930.xsd#clnn_LeaseIncentiveRecordedConstructionInProgress"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_LeaseIncentiveRecordedConstructionInProgress_lbl" xml:lang="en-US">Lease incentive recorded construction in progress</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_LeaseIncentiveRecordedConstructionInProgress" xlink:to="clnn_LeaseIncentiveRecordedConstructionInProgress_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LessorOperatingLeaseDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeaseDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LessorOperatingLeaseDescription_lbl" xml:lang="en-US">Description of lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeaseDescription" xlink:to="us-gaap_LessorOperatingLeaseDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_FinanceLeaseObligationsWeightedaverageInterestRate" xlink:href="clnn-20210930.xsd#clnn_FinanceLeaseObligationsWeightedaverageInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_FinanceLeaseObligationsWeightedaverageInterestRate_lbl" xml:lang="en-US">Finance lease obligations weighted-average interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FinanceLeaseObligationsWeightedaverageInterestRate" xlink:to="clnn_FinanceLeaseObligationsWeightedaverageInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Finance lease weighted-average remaining term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_OperatingLeaseObligationsWeightedAverageInterestRate" xlink:href="clnn-20210930.xsd#clnn_OperatingLeaseObligationsWeightedAverageInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_OperatingLeaseObligationsWeightedAverageInterestRate_lbl" xml:lang="en-US">Operating lease obligations weighted average interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_OperatingLeaseObligationsWeightedAverageInterestRate" xlink:to="clnn_OperatingLeaseObligationsWeightedAverageInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating lease weighted-average remaining term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Term loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl0" xml:lang="en-US">Investor to pay royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Outstanding due date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xml:lang="en-US">Phantom shares, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescription" xlink:to="us-gaap_DebtInstrumentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeOther_lbl" xml:lang="en-US">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_SimpleInterestExpense" xlink:href="clnn-20210930.xsd#clnn_SimpleInterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_SimpleInterestExpense_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SimpleInterestExpense" xlink:to="clnn_SimpleInterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_FairValueOfLongTermNotesPayable" xlink:href="clnn-20210930.xsd#clnn_FairValueOfLongTermNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_FairValueOfLongTermNotesPayable_lbl" xml:lang="en-US">Fair value of long-term notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FairValueOfLongTermNotesPayable" xlink:to="clnn_FairValueOfLongTermNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">Amount of income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesAndLoansPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesAndLoansPayable_lbl" xml:lang="en-US">Note payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansPayable" xlink:to="us-gaap_NotesAndLoansPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_PercentageOfLoanAmountUsedToPayrollExpenses" xlink:href="clnn-20210930.xsd#clnn_PercentageOfLoanAmountUsedToPayrollExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_PercentageOfLoanAmountUsedToPayrollExpenses_lbl" xml:lang="en-US">Percentage of loan amount used for payroll expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PercentageOfLoanAmountUsedToPayrollExpenses" xlink:to="clnn_PercentageOfLoanAmountUsedToPayrollExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExtinguishmentOfDebtAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ExtinguishmentOfDebtAmount_lbl" xml:lang="en-US">Debt extinguishment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtAmount" xlink:to="us-gaap_ExtinguishmentOfDebtAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">First loan amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_FundedAmountAtClosing" xlink:href="clnn-20210930.xsd#clnn_FundedAmountAtClosing"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_FundedAmountAtClosing_lbl" xml:lang="en-US">Funded amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FundedAmountAtClosing" xlink:to="clnn_FundedAmountAtClosing_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_AccruedDebtIssuanceCosts" xlink:href="clnn-20210930.xsd#clnn_AccruedDebtIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_AccruedDebtIssuanceCosts_lbl" xml:lang="en-US">Accrued debt issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AccruedDebtIssuanceCosts" xlink:to="clnn_AccruedDebtIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of Debt Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_DebtInstrumentUnfundedBalance" xlink:href="clnn-20210930.xsd#clnn_DebtInstrumentUnfundedBalance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_DebtInstrumentUnfundedBalance_lbl" xml:lang="en-US">Unfunded amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DebtInstrumentUnfundedBalance" xlink:to="clnn_DebtInstrumentUnfundedBalance_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_SecondLoanAmount" xlink:href="clnn-20210930.xsd#clnn_SecondLoanAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_SecondLoanAmount_lbl" xml:lang="en-US">Second loan amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SecondLoanAmount" xlink:to="clnn_SecondLoanAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ConditionsForFutureFundingDescription" xlink:href="clnn-20210930.xsd#clnn_ConditionsForFutureFundingDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ConditionsForFutureFundingDescription_lbl" xml:lang="en-US">Conditions for future funding, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ConditionsForFutureFundingDescription" xlink:to="clnn_ConditionsForFutureFundingDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_RateOfInterestDescription" xlink:href="clnn-20210930.xsd#clnn_RateOfInterestDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_RateOfInterestDescription_lbl" xml:lang="en-US">Rate of interest, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RateOfInterestDescription" xlink:to="clnn_RateOfInterestDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_AdditionalPaymentUponMaturityDescription" xlink:href="clnn-20210930.xsd#clnn_AdditionalPaymentUponMaturityDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_AdditionalPaymentUponMaturityDescription_lbl" xml:lang="en-US">Additional payment upon maturity, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AdditionalPaymentUponMaturityDescription" xlink:to="clnn_AdditionalPaymentUponMaturityDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_WarrantToPurchaseShares" xlink:href="clnn-20210930.xsd#clnn_WarrantToPurchaseShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_WarrantToPurchaseShares_lbl" xml:lang="en-US">Warrant to purchase shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantToPurchaseShares" xlink:to="clnn_WarrantToPurchaseShares_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockAtAnExercisePrice" xlink:href="clnn-20210930.xsd#clnn_CommonStockAtAnExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_CommonStockAtAnExercisePrice_lbl" xml:lang="en-US">Common stock at an exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockAtAnExercisePrice" xlink:to="clnn_CommonStockAtAnExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_Tranche2WarrantAdjustmentDescription" xlink:href="clnn-20210930.xsd#clnn_Tranche2WarrantAdjustmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_Tranche2WarrantAdjustmentDescription_lbl" xml:lang="en-US">Tranche warrant adjustment description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_Tranche2WarrantAdjustmentDescription" xlink:to="clnn_Tranche2WarrantAdjustmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US">Convertible note payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleNotesPayable_lbl0" xml:lang="en-US">Convertible notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl0"/>
    <loc xlink:type="locator" xlink:label="clnn_ConversionPercentageOfCommonStockPriceForConvertibleNotePayable" xlink:href="clnn-20210930.xsd#clnn_ConversionPercentageOfCommonStockPriceForConvertibleNotePayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ConversionPercentageOfCommonStockPriceForConvertibleNotePayable_lbl" xml:lang="en-US">Conversion percentage of common stock price for convertible note payable, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ConversionPercentageOfCommonStockPriceForConvertibleNotePayable" xlink:to="clnn_ConversionPercentageOfCommonStockPriceForConvertibleNotePayable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="clnn_ConversionPercentageOfCommonStockPriceForConvertibleNotePayable_lbl0" xml:lang="en-US">Conversion percentage of common stock price for convertible note payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ConversionPercentageOfCommonStockPriceForConvertibleNotePayable" xlink:to="clnn_ConversionPercentageOfCommonStockPriceForConvertibleNotePayable_lbl0"/>
    <loc xlink:type="locator" xlink:label="clnn_TradingVolumeLimitForConversionOfConvertibleNotePayable" xlink:href="clnn-20210930.xsd#clnn_TradingVolumeLimitForConversionOfConvertibleNotePayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_TradingVolumeLimitForConversionOfConvertibleNotePayable_lbl" xml:lang="en-US">Trading volume limit for conversion of convertible note payable, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TradingVolumeLimitForConversionOfConvertibleNotePayable" xlink:to="clnn_TradingVolumeLimitForConversionOfConvertibleNotePayable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ThresholdForRemovalOfFinancialCovenantsDescription" xlink:href="clnn-20210930.xsd#clnn_ThresholdForRemovalOfFinancialCovenantsDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ThresholdForRemovalOfFinancialCovenantsDescription_lbl" xml:lang="en-US">Threshold for removal of financial covenants, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ThresholdForRemovalOfFinancialCovenantsDescription" xlink:to="clnn_ThresholdForRemovalOfFinancialCovenantsDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_MinimumCashBalanceForLoanCovenant" xlink:href="clnn-20210930.xsd#clnn_MinimumCashBalanceForLoanCovenant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_MinimumCashBalanceForLoanCovenant_lbl" xml:lang="en-US">Minimum cash balance for loan covenant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_MinimumCashBalanceForLoanCovenant" xlink:to="clnn_MinimumCashBalanceForLoanCovenant_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_FairValueOfWarrant" xlink:href="clnn-20210930.xsd#clnn_FairValueOfWarrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_FairValueOfWarrant_lbl" xml:lang="en-US">Fair value of warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FairValueOfWarrant" xlink:to="clnn_FairValueOfWarrant_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_DebtInstrumentFinancingCosts" xlink:href="clnn-20210930.xsd#clnn_DebtInstrumentFinancingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_DebtInstrumentFinancingCosts_lbl" xml:lang="en-US">Financing costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DebtInstrumentFinancingCosts" xlink:to="clnn_DebtInstrumentFinancingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebt_lbl" xml:lang="en-US">Convertible debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrants expire</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantExercisePriceDecrease_lbl" xml:lang="en-US">Exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceDecrease" xlink:to="us-gaap_WarrantExercisePriceDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_SharesOfWarrantsExercisable" xlink:href="clnn-20210930.xsd#clnn_SharesOfWarrantsExercisable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_SharesOfWarrantsExercisable_lbl" xml:lang="en-US">Shares of warrants exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharesOfWarrantsExercisable" xlink:to="clnn_SharesOfWarrantsExercisable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_PercentOfFullydilutedEquityPurchasableUponExercise" xlink:href="clnn-20210930.xsd#clnn_PercentOfFullydilutedEquityPurchasableUponExercise"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_PercentOfFullydilutedEquityPurchasableUponExercise_lbl" xml:lang="en-US">Percent of fully-diluted equity purchasable upon exercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PercentOfFullydilutedEquityPurchasableUponExercise" xlink:to="clnn_PercentOfFullydilutedEquityPurchasableUponExercise_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_LossInFairValueOfWarrantLiability" xlink:href="clnn-20210930.xsd#clnn_LossInFairValueOfWarrantLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_LossInFairValueOfWarrantLiability_lbl" xml:lang="en-US">Loss in fair value of warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_LossInFairValueOfWarrantLiability" xlink:to="clnn_LossInFairValueOfWarrantLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_FairValueAdjustmentOfWarrantsOutstanding" xlink:href="clnn-20210930.xsd#clnn_FairValueAdjustmentOfWarrantsOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_FairValueAdjustmentOfWarrantsOutstanding_lbl" xml:lang="en-US">Fair value of the outstanding warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FairValueAdjustmentOfWarrantsOutstanding" xlink:to="clnn_FairValueAdjustmentOfWarrantsOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_PIPEWarrantsOwnershipLimit" xlink:href="clnn-20210930.xsd#clnn_PIPEWarrantsOwnershipLimit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_PIPEWarrantsOwnershipLimit_lbl" xml:lang="en-US">PIPE warrants ownership limit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PIPEWarrantsOwnershipLimit" xlink:to="clnn_PIPEWarrantsOwnershipLimit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Warrants exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CompanyWarrantRedemptionRight" xlink:href="clnn-20210930.xsd#clnn_CompanyWarrantRedemptionRight"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_CompanyWarrantRedemptionRight_lbl" xml:lang="en-US">Company warrant redemption right</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CompanyWarrantRedemptionRight" xlink:to="clnn_CompanyWarrantRedemptionRight_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ExercisePriceOfWarrantsDescription" xlink:href="clnn-20210930.xsd#clnn_ExercisePriceOfWarrantsDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ExercisePriceOfWarrantsDescription_lbl" xml:lang="en-US">Exercise price of warrants, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ExercisePriceOfWarrantsDescription" xlink:to="clnn_ExercisePriceOfWarrantsDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US">Annual debt interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_DescriptionOfConvertibleNotes" xlink:href="clnn-20210930.xsd#clnn_DescriptionOfConvertibleNotes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_DescriptionOfConvertibleNotes_lbl" xml:lang="en-US">Description of convertible notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DescriptionOfConvertibleNotes" xlink:to="clnn_DescriptionOfConvertibleNotes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of debt discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Convertible shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock option outstanding (post-conversion)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0"/>
    <loc xlink:type="locator" xlink:label="clnn_PercentageOfStockPrice" xlink:href="clnn-20210930.xsd#clnn_PercentageOfStockPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_PercentageOfStockPrice_lbl" xml:lang="en-US">Percentage of stock price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PercentageOfStockPrice" xlink:to="clnn_PercentageOfStockPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xml:lang="en-US">Convertible per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl" xml:lang="en-US">Loss on extinguishment of debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Unamortized discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_DescriptionOfLossOnExtinguishment" xlink:href="clnn-20210930.xsd#clnn_DescriptionOfLossOnExtinguishment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_DescriptionOfLossOnExtinguishment_lbl" xml:lang="en-US">Description of loss on extinguishment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DescriptionOfLossOnExtinguishment" xlink:to="clnn_DescriptionOfLossOnExtinguishment_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ConvertibleNotesPayableDescription" xlink:href="clnn-20210930.xsd#clnn_ConvertibleNotesPayableDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ConvertibleNotesPayableDescription_lbl" xml:lang="en-US">Convertible notes payable, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ConvertibleNotesPayableDescription" xlink:to="clnn_ConvertibleNotesPayableDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_LoanOutstanding" xlink:href="clnn-20210930.xsd#clnn_LoanOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_LoanOutstanding_lbl" xml:lang="en-US">Loan outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_LoanOutstanding" xlink:to="clnn_LoanOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Common stock potentially issuable upon conversion (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl0" xml:lang="en-US">Aggregate of converted shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountCurrent_lbl" xml:lang="en-US">Unamortized debt discount and issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CouponInterestExpense" xlink:href="clnn-20210930.xsd#clnn_CouponInterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_CouponInterestExpense_lbl" xml:lang="en-US">Coupon interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CouponInterestExpense" xlink:to="clnn_CouponInterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_lbl" xml:lang="en-US">Effective interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:to="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFairValueOfDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeFairValueOfDerivativeNet_lbl" xml:lang="en-US">Issuance of derivative instrument</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeNet" xlink:to="us-gaap_DerivativeFairValueOfDerivativeNet_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_LossOnDerivativeInstruments" xlink:href="clnn-20210930.xsd#clnn_LossOnDerivativeInstruments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_LossOnDerivativeInstruments_lbl" xml:lang="en-US">Loss on derivative instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_LossOnDerivativeInstruments" xlink:to="clnn_LossOnDerivativeInstruments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityFairValueAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityFairValueAdjustment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityFairValueAdjustment_lbl" xml:lang="en-US">Clene Nanomedicine contingent earn-out</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityFairValueAdjustment" xlink:to="us-gaap_EquityFairValueAdjustment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_lbl" xml:lang="en-US">Initial shareholders contingent earn-out</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:to="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_GainlossOnCleneNanomedicineContingentEarnout" xlink:href="clnn-20210930.xsd#clnn_GainlossOnCleneNanomedicineContingentEarnout"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_GainlossOnCleneNanomedicineContingentEarnout_lbl" xml:lang="en-US">Gain (loss) on Clene Nanomedicine contingent earn-out</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_GainlossOnCleneNanomedicineContingentEarnout" xlink:to="clnn_GainlossOnCleneNanomedicineContingentEarnout_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_GainlossOnInitialShareholdersContingentEarnout" xlink:href="clnn-20210930.xsd#clnn_GainlossOnInitialShareholdersContingentEarnout"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_GainlossOnInitialShareholdersContingentEarnout_lbl" xml:lang="en-US">Gain (loss) on Initial Shareholders contingent earn-out</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_GainlossOnInitialShareholdersContingentEarnout" xlink:to="clnn_GainlossOnInitialShareholdersContingentEarnout_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_WarrantLiabilityFairValue" xlink:href="clnn-20210930.xsd#clnn_WarrantLiabilityFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_WarrantLiabilityFairValue_lbl" xml:lang="en-US">Warrant fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantLiabilityFairValue" xlink:to="clnn_WarrantLiabilityFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_Changeinfairvaluewarrants" xlink:href="clnn-20210930.xsd#clnn_Changeinfairvaluewarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_Changeinfairvaluewarrants_lbl" xml:lang="en-US">Change in fair value warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_Changeinfairvaluewarrants" xlink:to="clnn_Changeinfairvaluewarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Shares available to be issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_MinimumFairMarketValueOfOptionGrantDescription" xlink:href="clnn-20210930.xsd#clnn_MinimumFairMarketValueOfOptionGrantDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_MinimumFairMarketValueOfOptionGrantDescription_lbl" xml:lang="en-US">Minimum fair market value of option grant, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_MinimumFairMarketValueOfOptionGrantDescription" xlink:to="clnn_MinimumFairMarketValueOfOptionGrantDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Shares granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants" xlink:href="clnn-20210930.xsd#clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants_lbl" xml:lang="en-US">Shares for future grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants" xlink:to="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionPlanExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionPlanExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionPlanExpense_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionPlanExpense" xlink:to="us-gaap_StockOptionPlanExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_UnrecognizedStockbasedCompensation" xlink:href="clnn-20210930.xsd#clnn_UnrecognizedStockbasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_UnrecognizedStockbasedCompensation_lbl" xml:lang="en-US">Unrecognized stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_UnrecognizedStockbasedCompensation" xlink:to="clnn_UnrecognizedStockbasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm" xlink:href="clnn-20210930.xsd#clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm_lbl" xml:lang="en-US">Weighted average period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm" xlink:to="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_weightedAverageFairValuesOfOptionsGranted" xlink:href="clnn-20210930.xsd#clnn_weightedAverageFairValuesOfOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_weightedAverageFairValuesOfOptionsGranted_lbl" xml:lang="en-US">Weighted average grant-date fair value of stock options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_weightedAverageFairValuesOfOptionsGranted" xlink:to="clnn_weightedAverageFairValuesOfOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_RestrictedStockUnitsDescription" xlink:href="clnn-20210930.xsd#clnn_RestrictedStockUnitsDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_RestrictedStockUnitsDescription_lbl" xml:lang="en-US">Restricted stock units shares, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RestrictedStockUnitsDescription" xlink:to="clnn_RestrictedStockUnitsDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_lbl" xml:lang="en-US">Expected stock price volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant-date fair value of RSUs granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockExpense_lbl" xml:lang="en-US">Stock-based compensation expense associated with restricted stock awards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockExpense" xlink:to="us-gaap_RestrictedStockExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized compensation cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm" xlink:href="clnn-20210930.xsd#clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm_lbl" xml:lang="en-US">Weighted average period for recognition of unrecognized compensation cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm" xlink:to="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_NotesPayableBasedOnClosingPrice" xlink:href="clnn-20210930.xsd#clnn_NotesPayableBasedOnClosingPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_NotesPayableBasedOnClosingPrice_lbl" xml:lang="en-US">Notes payable based on closing price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NotesPayableBasedOnClosingPrice" xlink:to="clnn_NotesPayableBasedOnClosingPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_FairValueAmortizedCost" xlink:href="clnn-20210930.xsd#clnn_FairValueAmortizedCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_FairValueAmortizedCost_lbl" xml:lang="en-US">Fair value amortized cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FairValueAmortizedCost" xlink:to="clnn_FairValueAmortizedCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl" xml:lang="en-US">Embedded conversion feature</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_FairValueOfConvertibleNotesPayable" xlink:href="clnn-20210930.xsd#clnn_FairValueOfConvertibleNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_FairValueOfConvertibleNotesPayable_lbl" xml:lang="en-US">Fair value of the convertible notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FairValueOfConvertibleNotesPayable" xlink:to="clnn_FairValueOfConvertibleNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_AdditionalWarrantToPurchaseShares" xlink:href="clnn-20210930.xsd#clnn_AdditionalWarrantToPurchaseShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_AdditionalWarrantToPurchaseShares_lbl" xml:lang="en-US">Additional warrant to purchase estimated shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AdditionalWarrantToPurchaseShares" xlink:to="clnn_AdditionalWarrantToPurchaseShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription_lbl" xml:lang="en-US">Contingent earn-out, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_PreferredStockShares" xlink:href="clnn-20210930.xsd#clnn_PreferredStockShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_PreferredStockShares_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PreferredStockShares" xlink:to="clnn_PreferredStockShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_IssuanceOfCommonStockUponReverseRecapitalization" xlink:href="clnn-20210930.xsd#clnn_IssuanceOfCommonStockUponReverseRecapitalization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_IssuanceOfCommonStockUponReverseRecapitalization_lbl" xml:lang="en-US">Issuance of common stock upon the reverse recapitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IssuanceOfCommonStockUponReverseRecapitalization" xlink:to="clnn_IssuanceOfCommonStockUponReverseRecapitalization_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_RecapitalizationShare" xlink:href="clnn-20210930.xsd#clnn_RecapitalizationShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_RecapitalizationShare_lbl" xml:lang="en-US">Issuance of common stock for advisory fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RecapitalizationShare" xlink:to="clnn_RecapitalizationShare_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_InvestorsPurchasedShares" xlink:href="clnn-20210930.xsd#clnn_InvestorsPurchasedShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_InvestorsPurchasedShares_lbl" xml:lang="en-US">Investors purchased shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InvestorsPurchasedShares" xlink:to="clnn_InvestorsPurchasedShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Shares price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_NetProceeds" xlink:href="clnn-20210930.xsd#clnn_NetProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_NetProceeds_lbl" xml:lang="en-US">Net proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NetProceeds" xlink:to="clnn_NetProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_PrivatePlacementWarrantsDescription" xlink:href="clnn-20210930.xsd#clnn_PrivatePlacementWarrantsDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_PrivatePlacementWarrantsDescription_lbl" xml:lang="en-US">Private placement warrants description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PrivatePlacementWarrantsDescription" xlink:to="clnn_PrivatePlacementWarrantsDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockSharesPurchased" xlink:href="clnn-20210930.xsd#clnn_CommonStockSharesPurchased"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_CommonStockSharesPurchased_lbl" xml:lang="en-US">Common Stock Shares Purchased</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockSharesPurchased" xlink:to="clnn_CommonStockSharesPurchased_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockPricePerShare" xlink:href="clnn-20210930.xsd#clnn_CommonStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_CommonStockPricePerShare_lbl" xml:lang="en-US">Common Stock Price Per Share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockPricePerShare" xlink:to="clnn_CommonStockPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_WarrantsShares" xlink:href="clnn-20210930.xsd#clnn_WarrantsShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_WarrantsShares_lbl" xml:lang="en-US">Warrants shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantsShares" xlink:to="clnn_WarrantsShares_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ExercisePricePerShare" xlink:href="clnn-20210930.xsd#clnn_ExercisePricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ExercisePricePerShare_lbl" xml:lang="en-US">Exercise price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ExercisePricePerShare" xlink:to="clnn_ExercisePricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CashProceedsReceived" xlink:href="clnn-20210930.xsd#clnn_CashProceedsReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_CashProceedsReceived_lbl" xml:lang="en-US">Cash proceeds received (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CashProceedsReceived" xlink:to="clnn_CashProceedsReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_PurchaseOptionUnits" xlink:href="clnn-20210930.xsd#clnn_PurchaseOptionUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_PurchaseOptionUnits_lbl" xml:lang="en-US">Purchase option units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PurchaseOptionUnits" xlink:to="clnn_PurchaseOptionUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_NetIssuanceShares" xlink:href="clnn-20210930.xsd#clnn_NetIssuanceShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_NetIssuanceShares_lbl" xml:lang="en-US">Net issuance shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NetIssuanceShares" xlink:to="clnn_NetIssuanceShares_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_NetIssuanceWarrants" xlink:href="clnn-20210930.xsd#clnn_NetIssuanceWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_NetIssuanceWarrants_lbl" xml:lang="en-US">Net issuance warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NetIssuanceWarrants" xlink:to="clnn_NetIssuanceWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US">Consulting services expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ExclusiveRightsIntellectualPropertyTerm" xlink:href="clnn-20210930.xsd#clnn_ExclusiveRightsIntellectualPropertyTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ExclusiveRightsIntellectualPropertyTerm_lbl" xml:lang="en-US">Exclusive rights intellectual property term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ExclusiveRightsIntellectualPropertyTerm" xlink:to="clnn_ExclusiveRightsIntellectualPropertyTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsSoldSalesTypeLease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsSoldSalesTypeLease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsSoldSalesTypeLease_lbl" xml:lang="en-US">Sale of product</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsSoldSalesTypeLease" xlink:to="us-gaap_CostOfGoodsSoldSalesTypeLease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRoyaltiesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRoyaltiesReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRoyaltiesReceived_lbl" xml:lang="en-US">Royalty revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRoyaltiesReceived" xlink:to="us-gaap_ProceedsFromRoyaltiesReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvancesToAffiliate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvancesToAffiliate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdvancesToAffiliate_lbl" xml:lang="en-US">Advances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvancesToAffiliate" xlink:to="us-gaap_AdvancesToAffiliate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsSoldDirectFinancingLease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsSoldDirectFinancingLease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsSoldDirectFinancingLease_lbl" xml:lang="en-US">Cost of goods sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsSoldDirectFinancingLease" xlink:to="us-gaap_CostOfGoodsSoldDirectFinancingLease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventDescription_lbl" xml:lang="en-US">Subsequent events, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventDescription" xlink:to="us-gaap_SubsequentEventDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_RiskAndUncertaintiesPolicyTextBlock" xlink:href="clnn-20210930.xsd#clnn_RiskAndUncertaintiesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_RiskAndUncertaintiesPolicyTextBlock_lbl" xml:lang="en-US">Risks and Uncertainties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RiskAndUncertaintiesPolicyTextBlock" xlink:to="clnn_RiskAndUncertaintiesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentrations of Credit Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_DebtDiscountAndIssuanceCostsPolicyTextBlock" xlink:href="clnn-20210930.xsd#clnn_DebtDiscountAndIssuanceCostsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_DebtDiscountAndIssuanceCostsPolicyTextBlock_lbl" xml:lang="en-US">Debt Discounts, Debt Premiums, and Debt Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DebtDiscountAndIssuanceCostsPolicyTextBlock" xlink:to="clnn_DebtDiscountAndIssuanceCostsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US">Deferred Offering Costs</label>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSraqWjSnTNF4jeT3oaMW8W5R0MkiIXXy8k2PQbBklJ1lYSX00RI6mU1NUjmu2Z8DGiLsvWC/Nx+2e5I3XA4/waZZD17aBEHbiQmUEtZYNMriew3bFfu2eViLA2wfQ1rEEEBO8y7g2agPYYHRPjjYinU2xGoDUwxQK30waaEGgMNzBqUdOwRa7uFs] CSR-->
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ConvertibleNotespolicytextblock" xlink:href="clnn-20210930.xsd#clnn_ConvertibleNotespolicytextblock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ConvertibleNotespolicytextblock_lbl" xml:lang="en-US">Convertible Notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ConvertibleNotespolicytextblock" xlink:to="clnn_ConvertibleNotespolicytextblock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_DebtWithWarrantsPolicyTextBlock" xlink:href="clnn-20210930.xsd#clnn_DebtWithWarrantsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_DebtWithWarrantsPolicyTextBlock_lbl" xml:lang="en-US">Debt With Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DebtWithWarrantsPolicyTextBlock" xlink:to="clnn_DebtWithWarrantsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ContingentEarnoutPolicyTextBlock" xlink:href="clnn-20210930.xsd#clnn_ContingentEarnoutPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ContingentEarnoutPolicyTextBlock_lbl" xml:lang="en-US">Contingent Earn-out</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ContingentEarnoutPolicyTextBlock" xlink:to="clnn_ContingentEarnoutPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrantsPolicyTextBlock" xlink:href="clnn-20210930.xsd#clnn_CommonStockWarrantsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_CommonStockWarrantsPolicyTextBlock_lbl" xml:lang="en-US">Common Stock Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockWarrantsPolicyTextBlock" xlink:to="clnn_CommonStockWarrantsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_GrantFundingPolicyTextBlock" xlink:href="clnn-20210930.xsd#clnn_GrantFundingPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_GrantFundingPolicyTextBlock_lbl" xml:lang="en-US">Grant Funding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_GrantFundingPolicyTextBlock" xlink:to="clnn_GrantFundingPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value of Financial Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign Currency Translation and Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Income (Loss) Per Share Attributable to Common Shareholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ClinicalTrialAccrualPolicyTextBlock" xlink:href="clnn-20210930.xsd#clnn_ClinicalTrialAccrualPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ClinicalTrialAccrualPolicyTextBlock_lbl" xml:lang="en-US">Clinical Trial Accrual</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ClinicalTrialAccrualPolicyTextBlock" xlink:to="clnn_ClinicalTrialAccrualPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:href="clnn-20210930.xsd#clnn_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements Not Yet Adopted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:to="clnn_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CleneIncMember" xlink:href="clnn-20210930.xsd#clnn_CleneIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_CleneIncMember_lbl" xml:lang="en-US">Clene Inc [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CleneIncMember" xlink:to="clnn_CleneIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_TottenhamMember" xlink:href="clnn-20210930.xsd#clnn_TottenhamMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_TottenhamMember_lbl" xml:lang="en-US">Tottenham [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TottenhamMember" xlink:to="clnn_TottenhamMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CleneNanomedicineMember" xlink:href="clnn-20210930.xsd#clnn_CleneNanomedicineMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_CleneNanomedicineMember_lbl" xml:lang="en-US">Clene Nanomedicine [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CleneNanomedicineMember" xlink:to="clnn_CleneNanomedicineMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_PIPEMember" xlink:href="clnn-20210930.xsd#clnn_PIPEMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_PIPEMember_lbl" xml:lang="en-US">PIPE [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PIPEMember" xlink:to="clnn_PIPEMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExchangeClearedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExchangeClearedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ExchangeClearedMember_lbl" xml:lang="en-US">Exchange Ratio [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExchangeClearedMember" xlink:to="us-gaap_ExchangeClearedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ReverseRecapitalizationMember" xlink:href="clnn-20210930.xsd#clnn_ReverseRecapitalizationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ReverseRecapitalizationMember_lbl" xml:lang="en-US">Reverse recapitalization [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ReverseRecapitalizationMember" xlink:to="clnn_ReverseRecapitalizationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ChardanCapitalMarketsLLCMember" xlink:href="clnn-20210930.xsd#clnn_ChardanCapitalMarketsLLCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ChardanCapitalMarketsLLCMember_lbl" xml:lang="en-US">Chardan Capital Markets, LLC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChardanCapitalMarketsLLCMember" xlink:to="clnn_ChardanCapitalMarketsLLCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_LifeSciCapitalLLCMember" xlink:href="clnn-20210930.xsd#clnn_LifeSciCapitalLLCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_LifeSciCapitalLLCMember_lbl" xml:lang="en-US">LifeSci Capital LLC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_LifeSciCapitalLLCMember" xlink:to="clnn_LifeSciCapitalLLCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_lbl" xml:lang="en-US">Property, Plant and Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentMember" xlink:to="us-gaap_PropertyPlantAndEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_TwoThousandNineteenMDLoanMember" xlink:href="clnn-20210930.xsd#clnn_TwoThousandNineteenMDLoanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_TwoThousandNineteenMDLoanMember_lbl" xml:lang="en-US">2019 MD Loan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TwoThousandNineteenMDLoanMember" xlink:to="clnn_TwoThousandNineteenMDLoanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_TwoThousandNineteenCecilLoanMember" xlink:href="clnn-20210930.xsd#clnn_TwoThousandNineteenCecilLoanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_TwoThousandNineteenCecilLoanMember_lbl" xml:lang="en-US">2019 Cecil Loan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TwoThousandNineteenCecilLoanMember" xlink:to="clnn_TwoThousandNineteenCecilLoanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_PaycheckProtectionProgramNoteMember" xlink:href="clnn-20210930.xsd#clnn_PaycheckProtectionProgramNoteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_PaycheckProtectionProgramNoteMember_lbl" xml:lang="en-US">PPP Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PaycheckProtectionProgramNoteMember" xlink:to="clnn_PaycheckProtectionProgramNoteMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_TwoThousandtwentyoneAvenueLoanMember" xlink:href="clnn-20210930.xsd#clnn_TwoThousandtwentyoneAvenueLoanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_TwoThousandtwentyoneAvenueLoanMember_lbl" xml:lang="en-US">2021 Avenue Loan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TwoThousandtwentyoneAvenueLoanMember" xlink:to="clnn_TwoThousandtwentyoneAvenueLoanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US">Tranche one [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US">Tranche Two [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xml:lang="en-US">Series C Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesDPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xml:lang="en-US">Series D Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesDPreferredStockMember" xlink:to="us-gaap_SeriesDPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_PIPEWarrantsMember" xlink:href="clnn-20210930.xsd#clnn_PIPEWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_PIPEWarrantsMember_lbl" xml:lang="en-US">PIPE Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PIPEWarrantsMember" xlink:to="clnn_PIPEWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ChardanUnitPurchaseOptionMember" xlink:href="clnn-20210930.xsd#clnn_ChardanUnitPurchaseOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_ChardanUnitPurchaseOptionMember_lbl" xml:lang="en-US">Chardan Unit Purchase Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChardanUnitPurchaseOptionMember" xlink:to="clnn_ChardanUnitPurchaseOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrantsMember" xlink:href="clnn-20210930.xsd#clnn_CommonStockWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_CommonStockWarrantsMember_lbl" xml:lang="en-US">Common Stock Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockWarrantsMember" xlink:to="clnn_CommonStockWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_AvenueLoanMember" xlink:href="clnn-20210930.xsd#clnn_AvenueLoanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_AvenueLoanMember_lbl" xml:lang="en-US">Avenue Loan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AvenueLoanMember" xlink:to="clnn_AvenueLoanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_StockPlan2020Member" xlink:href="clnn-20210930.xsd#clnn_StockPlan2020Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_StockPlan2020Member_lbl" xml:lang="en-US">2020 Stock Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockPlan2020Member" xlink:to="clnn_StockPlan2020Member_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_StockPlan2014Member" xlink:href="clnn-20210930.xsd#clnn_StockPlan2014Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_StockPlan2014Member_lbl" xml:lang="en-US">2014 Stock Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockPlan2014Member" xlink:to="clnn_StockPlan2014Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl" xml:lang="en-US">Series of Individually Immaterial Business Acquisitions [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleCommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleCommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleCommonStockMember_lbl" xml:lang="en-US">Convertible Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleCommonStockMember" xlink:to="us-gaap_ConvertibleCommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_InvestorsMember" xlink:href="clnn-20210930.xsd#clnn_InvestorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="clnn_InvestorsMember_lbl" xml:lang="en-US">PIPE investors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InvestorsMember" xlink:to="clnn_InvestorsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="clnn_InvestorsMember_lbl0" xml:lang="en-US">Investors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InvestorsMember" xlink:to="clnn_InvestorsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrantsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrantsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrantsAbstract_lbl" xml:lang="en-US">Preferred Stock Warrant Liability [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrantsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrantsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_AccruedLiabilitiesTablesTable" xlink:href="clnn-20210930.xsd#clnn_AccruedLiabilitiesTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_AccruedLiabilitiesTablesTable_lbl" xml:lang="en-US">Accrued Liabilities (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AccruedLiabilitiesTablesTable" xlink:to="clnn_AccruedLiabilitiesTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_AccruedLiabilitiesTablesLineItems" xlink:href="clnn-20210930.xsd#clnn_AccruedLiabilitiesTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_AccruedLiabilitiesTablesLineItems_lbl" xml:lang="en-US">Accrued Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AccruedLiabilitiesTablesLineItems" xlink:to="clnn_AccruedLiabilitiesTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xml:lang="en-US">Lease Contractual Term [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable" xlink:href="clnn-20210930.xsd#clnn_LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable_lbl" xml:lang="en-US">Leases (Details) - Schedule of noncancelable finance and operating lease liabilities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable" xlink:to="clnn_LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems" xlink:href="clnn-20210930.xsd#clnn_LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems_lbl" xml:lang="en-US">Leases (Details)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems" xlink:to="clnn_LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_TermLoansDomain" xlink:href="clnn-20210930.xsd#clnn_TermLoansDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_TermLoansDomain_lbl" xml:lang="en-US">TermLoans [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TermLoansDomain" xlink:to="clnn_TermLoansDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable" xlink:href="clnn-20210930.xsd#clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable_lbl" xml:lang="en-US">Stock-Based Compensation (Details) - Schedule of stock-based compensation expense [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable" xlink:to="clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems" xlink:href="clnn-20210930.xsd#clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems_lbl" xml:lang="en-US">Stock-Based Compensation (Details) - Schedule of stock-based compensation expense [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems" xlink:to="clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xml:lang="en-US">Derivative Contract [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsTable" xlink:href="clnn-20210930.xsd#clnn_StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsTable_lbl" xml:lang="en-US">Stock-Based Compensation (Details) - Schedule of assumptions used to calculate the fair value of stock options [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsTable" xlink:to="clnn_StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsLineItems" xlink:href="clnn-20210930.xsd#clnn_StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsLineItems_lbl" xml:lang="en-US">Schedule of assumptions used to calculate the fair value of stock option awards granted [Line Item]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsLineItems" xlink:to="clnn_StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityTable" xlink:href="clnn-20210930.xsd#clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityTable_lbl" xml:lang="en-US">Stock-Based Compensation (Details) - Schedule of restricted common stock activity [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityTable" xlink:to="clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems" xlink:href="clnn-20210930.xsd#clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems_lbl" xml:lang="en-US">Stock-Based Compensation (Details) - Schedule of restricted common stock activity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems" xlink:to="clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable" xlink:href="clnn-20210930.xsd#clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable_lbl" xml:lang="en-US">Fair Value (Details) - Schedule of fair value hierarchy of liabilities measured at fair value on recurring basis [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable" xlink:to="clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems" xlink:href="clnn-20210930.xsd#clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems_lbl" xml:lang="en-US">Fair Value (Details) - Schedule of fair value hierarchy of liabilities measured at fair value on recurring basis [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems" xlink:to="clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationTechniqueDomain_lbl" xml:lang="en-US">Valuation Approach and Technique [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xml:lang="en-US">Short-term Debt, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsTable" xlink:href="clnn-20210930.xsd#clnn_FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsTable_lbl" xml:lang="en-US">Fair Value (Details) - Schedule of changes in fair value of financial liabilities related to the notes payable, the derivative instrument, the preferred stock warrants, and the contingent earn-outs [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsTable" xlink:to="clnn_FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsLineItems" xlink:href="clnn-20210930.xsd#clnn_FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsLineItems_lbl" xml:lang="en-US">Fair Value (Details) - Schedule of changes in fair value of financial liabilities related to the notes payable, the derivative instrument, the preferred stock warrants, and the contingent earn-outs [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsLineItems" xlink:to="clnn_FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareTable" xlink:href="clnn-20210930.xsd#clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareTable_lbl" xml:lang="en-US">Net Income (Loss) Per Share Attributable to Common Shareholders (Details) - Schedule of basic and diluted net loss per share [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareTable" xlink:to="clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareLineItems" xlink:href="clnn-20210930.xsd#clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareLineItems_lbl" xml:lang="en-US">Net Income (Loss) Per Share Attributable to Common Shareholders (Details) - Schedule of basic and diluted net loss per share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareLineItems" xlink:to="clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationTable" xlink:href="clnn-20210930.xsd#clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationTable_lbl" xml:lang="en-US">Geographic and Segment Information (Details) - Schedule of property and equipment, net by location [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationTable" xlink:to="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationLineItems" xlink:href="clnn-20210930.xsd#clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationLineItems_lbl" xml:lang="en-US">Geographic and Segment Information (Details) - Schedule of property and equipment, net by location [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationLineItems" xlink:to="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US">Segment Reporting Information [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentTable" xlink:href="clnn-20210930.xsd#clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentTable_lbl" xml:lang="en-US">Geographic and Segment Information (Details) - Schedule of property and equipment, net by segment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentTable" xlink:to="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentLineItems" xlink:href="clnn-20210930.xsd#clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentLineItems_lbl" xml:lang="en-US">Geographic and Segment Information (Details) - Schedule of property and equipment, net by segment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentLineItems" xlink:to="clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_NatureoftheBusinessDetailsTable" xlink:href="clnn-20210930.xsd#clnn_NatureoftheBusinessDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_NatureoftheBusinessDetailsTable_lbl" xml:lang="en-US">Nature of the Business (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NatureoftheBusinessDetailsTable" xlink:to="clnn_NatureoftheBusinessDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_NatureoftheBusinessDetailsLineItems" xlink:href="clnn-20210930.xsd#clnn_NatureoftheBusinessDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_NatureoftheBusinessDetailsLineItems_lbl" xml:lang="en-US">Nature of the Business [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NatureoftheBusinessDetailsLineItems" xlink:to="clnn_NatureoftheBusinessDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollateralDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollateralDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollateralDomain_lbl" xml:lang="en-US">Collateral Held [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollateralDomain" xlink:to="us-gaap_CollateralDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="clnn-20210930.xsd#clnn_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_SummaryofSignificantAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="clnn_SummaryofSignificantAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="clnn-20210930.xsd#clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfFreshStartAdjustmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfFreshStartAdjustmentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfFreshStartAdjustmentDomain_lbl" xml:lang="en-US">Reorganization, Chapter 11 [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfFreshStartAdjustmentDomain" xlink:to="us-gaap_TypeOfFreshStartAdjustmentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable" xlink:href="clnn-20210930.xsd#clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable_lbl" xml:lang="en-US">Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable" xlink:to="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:href="clnn-20210930.xsd#clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems_lbl" xml:lang="en-US">Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US">Asset Class [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_PropertyandEquipmentNetDetailsTable" xlink:href="clnn-20210930.xsd#clnn_PropertyandEquipmentNetDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_PropertyandEquipmentNetDetailsTable_lbl" xml:lang="en-US">Property and Equipment, Net (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PropertyandEquipmentNetDetailsTable" xlink:to="clnn_PropertyandEquipmentNetDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_PropertyandEquipmentNetDetailsLineItems" xlink:href="clnn-20210930.xsd#clnn_PropertyandEquipmentNetDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_PropertyandEquipmentNetDetailsLineItems_lbl" xml:lang="en-US">Property and Equipment, Net (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PropertyandEquipmentNetDetailsLineItems" xlink:to="clnn_PropertyandEquipmentNetDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US">Vesting [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_NotesPayableDetailsTable" xlink:href="clnn-20210930.xsd#clnn_NotesPayableDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_NotesPayableDetailsTable_lbl" xml:lang="en-US">Notes Payable (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NotesPayableDetailsTable" xlink:to="clnn_NotesPayableDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_NotesPayableDetailsLineItems" xlink:href="clnn-20210930.xsd#clnn_NotesPayableDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_NotesPayableDetailsLineItems_lbl" xml:lang="en-US">Notes Payable (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NotesPayableDetailsLineItems" xlink:to="clnn_NotesPayableDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_PreferredStockWarrantLiabilityDetailsTable" xlink:href="clnn-20210930.xsd#clnn_PreferredStockWarrantLiabilityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_PreferredStockWarrantLiabilityDetailsTable_lbl" xml:lang="en-US">Preferred Stock Warrant Liability (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PreferredStockWarrantLiabilityDetailsTable" xlink:to="clnn_PreferredStockWarrantLiabilityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_PreferredStockWarrantLiabilityDetailsLineItems" xlink:href="clnn-20210930.xsd#clnn_PreferredStockWarrantLiabilityDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_PreferredStockWarrantLiabilityDetailsLineItems_lbl" xml:lang="en-US">Preferred Stock Warrant Liability (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PreferredStockWarrantLiabilityDetailsLineItems" xlink:to="clnn_PreferredStockWarrantLiabilityDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrantsDetailsTable" xlink:href="clnn-20210930.xsd#clnn_CommonStockWarrantsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CommonStockWarrantsDetailsTable_lbl" xml:lang="en-US">Common Stock Warrants (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockWarrantsDetailsTable" xlink:to="clnn_CommonStockWarrantsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockWarrantsDetailsLineItems" xlink:href="clnn-20210930.xsd#clnn_CommonStockWarrantsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CommonStockWarrantsDetailsLineItems_lbl" xml:lang="en-US">Common Stock Warrants (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockWarrantsDetailsLineItems" xlink:to="clnn_CommonStockWarrantsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ConvertibleNotesDetailsTable" xlink:href="clnn-20210930.xsd#clnn_ConvertibleNotesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ConvertibleNotesDetailsTable_lbl" xml:lang="en-US">Convertible Notes (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ConvertibleNotesDetailsTable" xlink:to="clnn_ConvertibleNotesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_ConvertibleNotesDetailsLineItems" xlink:href="clnn-20210930.xsd#clnn_ConvertibleNotesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ConvertibleNotesDetailsLineItems_lbl" xml:lang="en-US">Convertible Notes (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ConvertibleNotesDetailsLineItems" xlink:to="clnn_ConvertibleNotesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_StockBasedCompensationDetailsTable" xlink:href="clnn-20210930.xsd#clnn_StockBasedCompensationDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_StockBasedCompensationDetailsTable_lbl" xml:lang="en-US">Stock-Based Compensation (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockBasedCompensationDetailsTable" xlink:to="clnn_StockBasedCompensationDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_StockBasedCompensationDetailsLineItems" xlink:href="clnn-20210930.xsd#clnn_StockBasedCompensationDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_StockBasedCompensationDetailsLineItems_lbl" xml:lang="en-US">Stock-Based Compensation (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockBasedCompensationDetailsLineItems" xlink:to="clnn_StockBasedCompensationDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_FairValueDetailsTable" xlink:href="clnn-20210930.xsd#clnn_FairValueDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_FairValueDetailsTable_lbl" xml:lang="en-US">Fair Value (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FairValueDetailsTable" xlink:to="clnn_FairValueDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_FairValueDetailsLineItems" xlink:href="clnn-20210930.xsd#clnn_FairValueDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_FairValueDetailsLineItems_lbl" xml:lang="en-US">Fair Value (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FairValueDetailsLineItems" xlink:to="clnn_FairValueDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_RedeemableConvertiblePreferredStockDetailsTable" xlink:href="clnn-20210930.xsd#clnn_RedeemableConvertiblePreferredStockDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_RedeemableConvertiblePreferredStockDetailsTable_lbl" xml:lang="en-US">Redeemable Convertible Preferred Stock (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RedeemableConvertiblePreferredStockDetailsTable" xlink:to="clnn_RedeemableConvertiblePreferredStockDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_RedeemableConvertiblePreferredStockDetailsLineItems" xlink:href="clnn-20210930.xsd#clnn_RedeemableConvertiblePreferredStockDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_RedeemableConvertiblePreferredStockDetailsLineItems_lbl" xml:lang="en-US">Redeemable Convertible Preferred Stock (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RedeemableConvertiblePreferredStockDetailsLineItems" xlink:to="clnn_RedeemableConvertiblePreferredStockDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockDetailsTable" xlink:href="clnn-20210930.xsd#clnn_CommonStockDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CommonStockDetailsTable_lbl" xml:lang="en-US">Common Stock (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockDetailsTable" xlink:to="clnn_CommonStockDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_CommonStockDetailsLineItems" xlink:href="clnn-20210930.xsd#clnn_CommonStockDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CommonStockDetailsLineItems_lbl" xml:lang="en-US">Common Stock (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockDetailsLineItems" xlink:to="clnn_CommonStockDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsTable" xlink:href="clnn-20210930.xsd#clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsTable_lbl" xml:lang="en-US">Net Income (Loss) Per Share Attributable to Common Shareholders (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsTable" xlink:to="clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsLineItems" xlink:href="clnn-20210930.xsd#clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsLineItems_lbl" xml:lang="en-US">Net Income (Loss) Per Share Attributable to Common Shareholders (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsLineItems" xlink:to="clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_SubsequentEventsDetailsTable" xlink:href="clnn-20210930.xsd#clnn_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SubsequentEventsDetailsTable" xlink:to="clnn_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="clnn_SubsequentEventsDetailsLineItems" xlink:href="clnn-20210930.xsd#clnn_SubsequentEventsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_SubsequentEventsDetailsLineItems_lbl" xml:lang="en-US">Subsequent Events (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SubsequentEventsDetailsLineItems" xlink:to="clnn_SubsequentEventsDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_AccruedCROFees_lbl0" xml:lang="en-US">Accrued CRO fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AccruedCROFees" xlink:to="clnn_AccruedCROFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_AccruedDebtIssuanceCosts_lbl0" xml:lang="en-US">Accrued debt issuance costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AccruedDebtIssuanceCosts" xlink:to="clnn_AccruedDebtIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_AccruedExpenseReimbursements_lbl0" xml:lang="en-US">Accrued expense reimbursements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AccruedExpenseReimbursements" xlink:to="clnn_AccruedExpenseReimbursements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_AccruedTransactionCosts_lbl0" xml:lang="en-US">Accrued transaction costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AccruedTransactionCosts" xlink:to="clnn_AccruedTransactionCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_AccumulatedDepreciationDepletionAndAmortizationLeases_lbl0" xml:lang="en-US">Accumulated depreciation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AccumulatedDepreciationDepletionAndAmortizationLeases" xlink:to="clnn_AccumulatedDepreciationDepletionAndAmortizationLeases_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_AdditionalPaymentUponMaturityDescription_lbl0" xml:lang="en-US">Additional payment upon maturity description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AdditionalPaymentUponMaturityDescription" xlink:to="clnn_AdditionalPaymentUponMaturityDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_AdditionalWarrantToPurchaseShares_lbl0" xml:lang="en-US">Additional Warrant To Purchase Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AdditionalWarrantToPurchaseShares" xlink:to="clnn_AdditionalWarrantToPurchaseShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_AggregateFutureProceedsWarrantsExercised_lbl0" xml:lang="en-US">Aggregate future proceeds warrants exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AggregateFutureProceedsWarrantsExercised" xlink:to="clnn_AggregateFutureProceedsWarrantsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_AggregateGrossProceedWarrantsExercised_lbl1" xml:lang="en-US">Aggregate gross proceed warrants exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AggregateGrossProceedWarrantsExercised" xlink:to="clnn_AggregateGrossProceedWarrantsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_AggregateProceedsReceived_lbl0" xml:lang="en-US">Aggregate proceeds received.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AggregateProceedsReceived" xlink:to="clnn_AggregateProceedsReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_AustraliaResearchAndDevelopmentCreditReceivable_lbl0" xml:lang="en-US">Australia research and development credit receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AustraliaResearchAndDevelopmentCreditReceivable" xlink:to="clnn_AustraliaResearchAndDevelopmentCreditReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_CapitalLeasesAmountRepresentingInterestdiscounting_lbl0" xml:lang="en-US">The amount of capital lease representing discounting and interest.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CapitalLeasesAmountRepresentingInterestdiscounting" xlink:to="clnn_CapitalLeasesAmountRepresentingInterestdiscounting_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_CapitalLeasesFutureLeaseIncentives_lbl0" xml:lang="en-US">The amount of less future lease incentives.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CapitalLeasesFutureLeaseIncentives" xlink:to="clnn_CapitalLeasesFutureLeaseIncentives_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_CashPaidForInterestExpense_lbl0" xml:lang="en-US">Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CashPaidForInterestExpense" xlink:to="clnn_CashPaidForInterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_CashProceedsReceived_lbl0" xml:lang="en-US">Cash Proceeds Received.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CashProceedsReceived" xlink:to="clnn_CashProceedsReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ChangeInFairValueOfCleneNanomedicineContingentEarnouts_lbl0" xml:lang="en-US">For the period ended Change in fair value of contingent earn-out.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChangeInFairValueOfCleneNanomedicineContingentEarnouts" xlink:to="clnn_ChangeInFairValueOfCleneNanomedicineContingentEarnouts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ChangeInFairValueOfCommonStockWarrantLiability_lbl0" xml:lang="en-US">Change in fair value of common stock warrant liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChangeInFairValueOfCommonStockWarrantLiability" xlink:to="clnn_ChangeInFairValueOfCommonStockWarrantLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ChangeInFairValueOfCommonStockWarrantLiabilitys_lbl0" xml:lang="en-US">Change in fair value of common stock warrant liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChangeInFairValueOfCommonStockWarrantLiabilitys" xlink:to="clnn_ChangeInFairValueOfCommonStockWarrantLiabilitys_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ChangeInFairValueOfContingentEarnout_lbl0" xml:lang="en-US">For the period ended Change in fair value of contingent earn-out.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChangeInFairValueOfContingentEarnout" xlink:to="clnn_ChangeInFairValueOfContingentEarnout_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ChangeInFairValueOfDerivativeLiability_lbl0" xml:lang="en-US">Change in fair value of derivative liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChangeInFairValueOfDerivativeLiability" xlink:to="clnn_ChangeInFairValueOfDerivativeLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout_lbl0" xml:lang="en-US">Change in fair value of Initial Shareholders contingent earn-out&#xd;
..</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout" xlink:to="clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_Changeinfairvaluewarrants_lbl0" xml:lang="en-US">Changeinfairvaluewarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_Changeinfairvaluewarrants" xlink:to="clnn_Changeinfairvaluewarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ChangesInFairValueOfInitialShareholdersContingentEarnout_lbl0" xml:lang="en-US">Change in fair value of Initial Shareholders contingent earn-out.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChangesInFairValueOfInitialShareholdersContingentEarnout" xlink:to="clnn_ChangesInFairValueOfInitialShareholdersContingentEarnout_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ChardanUnitPurchaseOption_lbl0" xml:lang="en-US">Chardan unit purchase option.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChardanUnitPurchaseOption" xlink:to="clnn_ChardanUnitPurchaseOption_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_CleneNanomedicineContingentEarnOutMilestone1Shares_lbl0" xml:lang="en-US">Clene nanomedicine contingent earn out milestone1 shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CleneNanomedicineContingentEarnOutMilestone1Shares" xlink:to="clnn_CleneNanomedicineContingentEarnOutMilestone1Shares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_CleneNanomedicineContingentEarnoutFairValueDisclosure_lbl0" xml:lang="en-US">Clene nanomedicine contingent earnout fair value disclosure.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CleneNanomedicineContingentEarnoutFairValueDisclosure" xlink:to="clnn_CleneNanomedicineContingentEarnoutFairValueDisclosure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_CleneNanomedicineContingentEarnoutMilestone1Price_lbl0" xml:lang="en-US">Clene nanomedicine contingent earn out milestone 1 price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CleneNanomedicineContingentEarnoutMilestone1Price" xlink:to="clnn_CleneNanomedicineContingentEarnoutMilestone1Price_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_CleneNanomedicineContingentEarnoutMilestone2Price_lbl0" xml:lang="en-US">Clene nanomedicine contingent earnout milestone2 price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CleneNanomedicineContingentEarnoutMilestone2Price" xlink:to="clnn_CleneNanomedicineContingentEarnoutMilestone2Price_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_CleneNanomedicineContingentEarnoutMilestone2Shares_lbl0" xml:lang="en-US">Clene nanomedicine contingent earnout milestone 2 shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CleneNanomedicineContingentEarnoutMilestone2Shares" xlink:to="clnn_CleneNanomedicineContingentEarnoutMilestone2Shares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_CleneNanomedicineContingentEarnoutMilestone3Shares_lbl0" xml:lang="en-US">Clene nanomedicine contingent earnout milestone 3 shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CleneNanomedicineContingentEarnoutMilestone3Shares" xlink:to="clnn_CleneNanomedicineContingentEarnoutMilestone3Shares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_CleneNanomedicineContingentEarnoutShares_lbl0" xml:lang="en-US">Clene nanomedicine contingent earnout shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CleneNanomedicineContingentEarnoutShares" xlink:to="clnn_CleneNanomedicineContingentEarnoutShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ClinicalTrialAccrualPolicyTextBlock_lbl0" xml:lang="en-US">Clinical Trial Accrual Policy.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ClinicalTrialAccrualPolicyTextBlock" xlink:to="clnn_ClinicalTrialAccrualPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_CommonStockAtAnExercisePrice_lbl0" xml:lang="en-US">Common stock at an exercise price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockAtAnExercisePrice" xlink:to="clnn_CommonStockAtAnExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_CommonStockParOrStatedValuesPerShare_lbl0" xml:lang="en-US">Face amount or stated value per share of common stocks</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockParOrStatedValuesPerShare" xlink:to="clnn_CommonStockParOrStatedValuesPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_CommonStockPricePerShare_lbl0" xml:lang="en-US">Common Stock Price Per Share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockPricePerShare" xlink:to="clnn_CommonStockPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_CommonStockSharesPurchased_lbl0" xml:lang="en-US">Common Stock Shares Purchased.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockSharesPurchased" xlink:to="clnn_CommonStockSharesPurchased_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_CommonStockUnderlyingWarrantOutstanding_lbl0" xml:lang="en-US">CommonStockUnderlyingWarrantOutstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockUnderlyingWarrantOutstanding" xlink:to="clnn_CommonStockUnderlyingWarrantOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_CommonStockWarrantsDisclosureTextBlock_lbl0" xml:lang="en-US">he entire disclosure for shareholders&apos; equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockWarrantsDisclosureTextBlock" xlink:to="clnn_CommonStockWarrantsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_CommonStockWarrantsExercisePrice_lbl0" xml:lang="en-US">Exercise Price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockWarrantsExercisePrice" xlink:to="clnn_CommonStockWarrantsExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_CommonStockWarrantsExpiration_lbl0" xml:lang="en-US">Expiration.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockWarrantsExpiration" xlink:to="clnn_CommonStockWarrantsExpiration_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_CommonStockWarrantsPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for Common stock warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockWarrantsPolicyTextBlock" xlink:to="clnn_CommonStockWarrantsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_CompanyWarrantRedemptionRight_lbl0" xml:lang="en-US">Company warrant redemption right.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CompanyWarrantRedemptionRight" xlink:to="clnn_CompanyWarrantRedemptionRight_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ConditionsForFutureFundingDescription_lbl0" xml:lang="en-US">Conditions for future funding, description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ConditionsForFutureFundingDescription" xlink:to="clnn_ConditionsForFutureFundingDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ContingentEarnoutPolicyTextBlock_lbl0" xml:lang="en-US">Contingent Earn-out Policy.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ContingentEarnoutPolicyTextBlock" xlink:to="clnn_ContingentEarnoutPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ConversionPercentageOfCommonStockPriceForConvertibleNotePayable_lbl1" xml:lang="en-US">Conversion percentage of common stock price for convertible note payable percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ConversionPercentageOfCommonStockPriceForConvertibleNotePayable" xlink:to="clnn_ConversionPercentageOfCommonStockPriceForConvertibleNotePayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ConvertibleNotesPayableDescription_lbl0" xml:lang="en-US">Description of convertible notes payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ConvertibleNotesPayableDescription" xlink:to="clnn_ConvertibleNotesPayableDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ConvertibleNotesPayables_lbl0" xml:lang="en-US">Convertible notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ConvertibleNotesPayables" xlink:to="clnn_ConvertibleNotesPayables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ConvertibleNotespolicytextblock_lbl0" xml:lang="en-US">Convertible Notes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ConvertibleNotespolicytextblock" xlink:to="clnn_ConvertibleNotespolicytextblock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_CouponInterestExpense_lbl0" xml:lang="en-US">Coupon interest expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CouponInterestExpense" xlink:to="clnn_CouponInterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_DebtDiscountAndIssuanceCostsPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DebtDiscountAndIssuanceCostsPolicyTextBlock" xlink:to="clnn_DebtDiscountAndIssuanceCostsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_DebtInstrumentThereafter_lbl0" xml:lang="en-US">Amount of loans to be paid after fifth fiscal year following current fiscal year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DebtInstrumentThereafter" xlink:to="clnn_DebtInstrumentThereafter_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_DebtInstrumentUnamortizedDiscountRemainderOfFiscalYear_lbl0" xml:lang="en-US">Amount of loans to be paid in remainder of current fiscal year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DebtInstrumentUnamortizedDiscountRemainderOfFiscalYear" xlink:to="clnn_DebtInstrumentUnamortizedDiscountRemainderOfFiscalYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_DebtInstrumentUnamortizedDiscountYearFive_lbl0" xml:lang="en-US">Amount of loans to be paid in fifth fiscal year following current fiscal year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DebtInstrumentUnamortizedDiscountYearFive" xlink:to="clnn_DebtInstrumentUnamortizedDiscountYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_DebtInstrumentUnamortizedDiscountYearFour_lbl0" xml:lang="en-US">Amount of loan to be paid in fourth fiscal year following current fiscal year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DebtInstrumentUnamortizedDiscountYearFour" xlink:to="clnn_DebtInstrumentUnamortizedDiscountYearFour_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_DebtInstrumentUnamortizedDiscountYearOne_lbl0" xml:lang="en-US">Amount of loans to be paid in next fiscal year following current fiscal year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DebtInstrumentUnamortizedDiscountYearOne" xlink:to="clnn_DebtInstrumentUnamortizedDiscountYearOne_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_DebtInstrumentUnamortizedDiscountYearThree_lbl0" xml:lang="en-US">Amount of loan to be paid in third fiscal year following current fiscal year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DebtInstrumentUnamortizedDiscountYearThree" xlink:to="clnn_DebtInstrumentUnamortizedDiscountYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_DebtInstrumentUnamortizedDiscountYearTwo_lbl0" xml:lang="en-US">Amount of loan to be paid in second fiscal year following current fiscal year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DebtInstrumentUnamortizedDiscountYearTwo" xlink:to="clnn_DebtInstrumentUnamortizedDiscountYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_DebtInstrumentUnfundedBalance_lbl0" xml:lang="en-US">Debt instrument unfunded amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DebtInstrumentUnfundedBalance" xlink:to="clnn_DebtInstrumentUnfundedBalance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_DebtWithWarrantsPolicyTextBlock_lbl0" xml:lang="en-US">Debt with warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DebtWithWarrantsPolicyTextBlock" xlink:to="clnn_DebtWithWarrantsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_DeferredGrantFunds_lbl0" xml:lang="en-US">Deferred grant funds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DeferredGrantFunds" xlink:to="clnn_DeferredGrantFunds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_DeferredOfferingCostsInAccruedLiabilities_lbl0" xml:lang="en-US">Deferred offering costs in accrued liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DeferredOfferingCostsInAccruedLiabilities" xlink:to="clnn_DeferredOfferingCostsInAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_DescriptionOfLossOnExtinguishment_lbl0" xml:lang="en-US">Description of loss on extinguishment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DescriptionOfLossOnExtinguishment" xlink:to="clnn_DescriptionOfLossOnExtinguishment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_DirectorsOfficersInsurance_lbl0" xml:lang="en-US">Directors &amp; Officers Insurance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DirectorsOfficersInsurance" xlink:to="clnn_DirectorsOfficersInsurance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_EffectOfPotentiallyDilutiveConvertibleNotesPayable_lbl0" xml:lang="en-US">Effect of potentially dilutive convertible notes payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_EffectOfPotentiallyDilutiveConvertibleNotesPayable" xlink:to="clnn_EffectOfPotentiallyDilutiveConvertibleNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_EffectOfPotentiallyDilutiveRestrictedStockAwards_lbl0" xml:lang="en-US">Effect of potentially dilutive restricted stock awards.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_EffectOfPotentiallyDilutiveRestrictedStockAwards" xlink:to="clnn_EffectOfPotentiallyDilutiveRestrictedStockAwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_EffectOfPotentiallyDilutiveStockOptionsinDollars_lbl0" xml:lang="en-US">Effect of potentially dilutive stock options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_EffectOfPotentiallyDilutiveStockOptionsinDollars" xlink:to="clnn_EffectOfPotentiallyDilutiveStockOptionsinDollars_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_EffectOfPotentiallyDilutiveUnvestedRestrictedStockAwardsShares_lbl0" xml:lang="en-US">Effect of potentially dilutive unvested restricted stock awards.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_EffectOfPotentiallyDilutiveUnvestedRestrictedStockAwardsShares" xlink:to="clnn_EffectOfPotentiallyDilutiveUnvestedRestrictedStockAwardsShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ExchangeOfSharesReceived_lbl0" xml:lang="en-US">Exchange of shares received.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ExchangeOfSharesReceived" xlink:to="clnn_ExchangeOfSharesReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ExchangeRatioPercentage_lbl0" xml:lang="en-US">Exchange Ratio Percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ExchangeRatioPercentage" xlink:to="clnn_ExchangeRatioPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ExclusiveRightsIntellectualPropertyTerm_lbl0" xml:lang="en-US">Exclusive rights intellectual property term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ExclusiveRightsIntellectualPropertyTerm" xlink:to="clnn_ExclusiveRightsIntellectualPropertyTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ExercisePriceOfWarrantsDescription_lbl0" xml:lang="en-US">Description of warrants exercise price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ExercisePriceOfWarrantsDescription" xlink:to="clnn_ExercisePriceOfWarrantsDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ExercisePricePerShare_lbl0" xml:lang="en-US">Exercise price per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ExercisePricePerShare" xlink:to="clnn_ExercisePricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN_lbl0" xml:lang="en-US">Extinguishment of derivative liability in connection with extinguishment of convertible promissory notes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN" xlink:to="clnn_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_FairValueAdjustmentOfWarrantsOutstanding_lbl0" xml:lang="en-US">Amount of expense (income) related to adjustment to fair value of warrant outstanding liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FairValueAdjustmentOfWarrantsOutstanding" xlink:to="clnn_FairValueAdjustmentOfWarrantsOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_FairValueAmortizedCost_lbl0" xml:lang="en-US">Fair value amortized cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FairValueAmortizedCost" xlink:to="clnn_FairValueAmortizedCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_FairValueIssuanceOfConvertiblePromissoryNotes_lbl0" xml:lang="en-US">This value for issuance of convertible promissory notes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FairValueIssuanceOfConvertiblePromissoryNotes" xlink:to="clnn_FairValueIssuanceOfConvertiblePromissoryNotes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_FairValueMeasurementExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN_lbl0" xml:lang="en-US">This value for extinguishment of derivative liability in connection with extinguishment of convertible promissory note.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FairValueMeasurementExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN" xlink:to="clnn_FairValueMeasurementExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_FairValueOfConvertibleNotesPayable_lbl0" xml:lang="en-US">Fair value portion of notes payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FairValueOfConvertibleNotesPayable" xlink:to="clnn_FairValueOfConvertibleNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_FairValueOfLongTermNotesPayable_lbl0" xml:lang="en-US">Fair value of principal and accrued interest is included in long-term notes payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FairValueOfLongTermNotesPayable" xlink:to="clnn_FairValueOfLongTermNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_FairValueOfWarrant_lbl0" xml:lang="en-US">Fair value of warrant.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FairValueOfWarrant" xlink:to="clnn_FairValueOfWarrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Schedule of finance and operating lease liability maturity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="clnn_FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_FinanceLeaseByMajorClassPropertyAndEquipmentTableTextBlock_lbl0" xml:lang="en-US">Schedule of Finance lease by major class property and equipment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FinanceLeaseByMajorClassPropertyAndEquipmentTableTextBlock" xlink:to="clnn_FinanceLeaseByMajorClassPropertyAndEquipmentTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_FinanceLeaseFurnitureAndFixturesGross_lbl0" xml:lang="en-US">Finance lease furniture and fixtures.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FinanceLeaseFurnitureAndFixturesGross" xlink:to="clnn_FinanceLeaseFurnitureAndFixturesGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_FinanceLeaseLaboratoryEquipmentGross_lbl0" xml:lang="en-US">Finance lease laboratory equipment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FinanceLeaseLaboratoryEquipmentGross" xlink:to="clnn_FinanceLeaseLaboratoryEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_FinanceLeaseLiabilityGross_lbl0" xml:lang="en-US">Finance lease liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FinanceLeaseLiabilityGross" xlink:to="clnn_FinanceLeaseLiabilityGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_FinanceLeaseLiabilityNet_lbl0" xml:lang="en-US">Finance lease liability, net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FinanceLeaseLiabilityNet" xlink:to="clnn_FinanceLeaseLiabilityNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_FinanceLeaseObligationsWeightedaverageInterestRate_lbl0" xml:lang="en-US">Finance lease obligations weighted-average interest rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FinanceLeaseObligationsWeightedaverageInterestRate" xlink:to="clnn_FinanceLeaseObligationsWeightedaverageInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_FinanceLeaseWorkInProcessGross_lbl0" xml:lang="en-US">Finance lease work in process.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FinanceLeaseWorkInProcessGross" xlink:to="clnn_FinanceLeaseWorkInProcessGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_FundedAmountAtClosing_lbl0" xml:lang="en-US">FundedAmountAtClosing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FundedAmountAtClosing" xlink:to="clnn_FundedAmountAtClosing_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_FuturePrincipalPayments_lbl0" xml:lang="en-US">Amount of future principal payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FuturePrincipalPayments" xlink:to="clnn_FuturePrincipalPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_GainOnExtinguishmentOfNotesPayable_lbl0" xml:lang="en-US">Gain on extinguishment of notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_GainOnExtinguishmentOfNotesPayable" xlink:to="clnn_GainOnExtinguishmentOfNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_GainlossOnCleneNanomedicineContingentEarnout_lbl0" xml:lang="en-US">It represents the gain (loss) on Clene Nanomedicine contingent earn-out.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_GainlossOnCleneNanomedicineContingentEarnout" xlink:to="clnn_GainlossOnCleneNanomedicineContingentEarnout_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_GainlossOnInitialShareholdersContingentEarnout_lbl0" xml:lang="en-US">It represents amount of gain (loss) on Initial Shareholders contingent earn-out.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_GainlossOnInitialShareholdersContingentEarnout" xlink:to="clnn_GainlossOnInitialShareholdersContingentEarnout_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_GrantFundingPolicyTextBlock_lbl0" xml:lang="en-US">Grant Funding Policy.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_GrantFundingPolicyTextBlock" xlink:to="clnn_GrantFundingPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_GrantFundingRecognizedOnConditionalGrants_lbl0" xml:lang="en-US">Grant funding recognized on conditional grants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_GrantFundingRecognizedOnConditionalGrants" xlink:to="clnn_GrantFundingRecognizedOnConditionalGrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_IncreaseInCleneNanomedicineContingentEarnoutSharesUponReverseRecapitalization_lbl0" xml:lang="en-US">Increase in clene nanomedicine contingent earnout shares upon reverse recapitalization.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IncreaseInCleneNanomedicineContingentEarnoutSharesUponReverseRecapitalization" xlink:to="clnn_IncreaseInCleneNanomedicineContingentEarnoutSharesUponReverseRecapitalization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_IncreaseInInterestAccruedOnNotesPayable_lbl0" xml:lang="en-US">Increase in interest accrued on notes payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IncreaseInInterestAccruedOnNotesPayable" xlink:to="clnn_IncreaseInInterestAccruedOnNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_IncreaseInLeaseLiability_lbl0" xml:lang="en-US">The amount of increase in lease liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IncreaseInLeaseLiability" xlink:to="clnn_IncreaseInLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_IncreaseInLeaseholdImprovements_lbl0" xml:lang="en-US">The amount of Increase in leasehold improvements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IncreaseInLeaseholdImprovements" xlink:to="clnn_IncreaseInLeaseholdImprovements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_IncreaseInRightOfUseAssets_lbl0" xml:lang="en-US">The amount of Increase in right of use assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IncreaseInRightOfUseAssets" xlink:to="clnn_IncreaseInRightOfUseAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_IncreseDecreaseInFairValue_lbl0" xml:lang="en-US">This value for change in fair value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IncreseDecreaseInFairValue" xlink:to="clnn_IncreseDecreaseInFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_InitialFairValueOfInstrument_lbl0" xml:lang="en-US">This value for initial fair value of instrument.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InitialFairValueOfInstrument" xlink:to="clnn_InitialFairValueOfInstrument_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_InitialShareholdersContingentEarnout_lbl0" xml:lang="en-US">Initial Shareholders contingent earn-out.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InitialShareholdersContingentEarnout" xlink:to="clnn_InitialShareholdersContingentEarnout_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_InitialShareholdersContingentEarnoutFairValueDisclosure_lbl0" xml:lang="en-US">Initial shareholders contingent earnout fair value disclosure.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InitialShareholdersContingentEarnoutFairValueDisclosure" xlink:to="clnn_InitialShareholdersContingentEarnoutFairValueDisclosure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_InitialShareholdersContingentEarnoutMilestone1Shares_lbl0" xml:lang="en-US">Initial shareholders contingent earnout milestone1 shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InitialShareholdersContingentEarnoutMilestone1Shares" xlink:to="clnn_InitialShareholdersContingentEarnoutMilestone1Shares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_InitialShareholdersContingentEarnoutMilestone2Shares_lbl0" xml:lang="en-US">Initial shareholders contingent earnout milestone 2 shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InitialShareholdersContingentEarnoutMilestone2Shares" xlink:to="clnn_InitialShareholdersContingentEarnoutMilestone2Shares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_InitialShareholdersContingentEarnoutShares_lbl0" xml:lang="en-US">Initial shareholders contingent earnout shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InitialShareholdersContingentEarnoutShares" xlink:to="clnn_InitialShareholdersContingentEarnoutShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_InitialShareholdersContingentsEarnout_lbl0" xml:lang="en-US">It represents of initial shareholders contingents earnout.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InitialShareholdersContingentsEarnout" xlink:to="clnn_InitialShareholdersContingentsEarnout_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_InterestIncomeexpense_lbl0" xml:lang="en-US">Amount of interest income (expense).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InterestIncomeexpense" xlink:to="clnn_InterestIncomeexpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_InterestRate_lbl0" xml:lang="en-US">Interest Rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InterestRate" xlink:to="clnn_InterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_InvestorsPurchasedShares_lbl0" xml:lang="en-US">The amount of share investors purchased shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InvestorsPurchasedShares" xlink:to="clnn_InvestorsPurchasedShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes_lbl0" xml:lang="en-US">Issuance of Series D Preferred Stock upon extinguishment of convertible promissory notes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes" xlink:to="clnn_IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_LeaseIncentiveRecordedConstructionInProgress_lbl0" xml:lang="en-US">Lease incentive recorded construction in progress.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_LeaseIncentiveRecordedConstructionInProgress" xlink:to="clnn_LeaseIncentiveRecordedConstructionInProgress_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_LeaseLiabilitySettledThroughTerminationOfLease_lbl0" xml:lang="en-US">Lease liability settled through termination of lease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_LeaseLiabilitySettledThroughTerminationOfLease" xlink:to="clnn_LeaseLiabilitySettledThroughTerminationOfLease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_LeaseholdImprovements_lbl0" xml:lang="en-US">Amount held additions or improvements to assets held under a lease arrangement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_LeaseholdImprovements" xlink:to="clnn_LeaseholdImprovements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_LoanOutstanding_lbl0" xml:lang="en-US">Loan Outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_LoanOutstanding" xlink:to="clnn_LoanOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_LossInFairValueOfWarrantLiability_lbl0" xml:lang="en-US">It represents the amount of loss in fair value of warrant liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_LossInFairValueOfWarrantLiability" xlink:to="clnn_LossInFairValueOfWarrantLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_LossOnDerivativeInstruments_lbl0" xml:lang="en-US">It represents the amount of loss on derivative instruments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_LossOnDerivativeInstruments" xlink:to="clnn_LossOnDerivativeInstruments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_LossOnExtinguishmentOfConvertibleNotesPayable_lbl0" xml:lang="en-US">Loss on extinguishment of convertible notes payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_LossOnExtinguishmentOfConvertibleNotesPayable" xlink:to="clnn_LossOnExtinguishmentOfConvertibleNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_MetalsToBeUsedInResearchAndDevelopment_lbl0" xml:lang="en-US">Metals to be used in research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_MetalsToBeUsedInResearchAndDevelopment" xlink:to="clnn_MetalsToBeUsedInResearchAndDevelopment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_MinimumCashBalanceForLoanCovenant_lbl0" xml:lang="en-US">Amount of minimum cash balance for loan covenant.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_MinimumCashBalanceForLoanCovenant" xlink:to="clnn_MinimumCashBalanceForLoanCovenant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_MinimumFairMarketValueOfOptionGrantDescription_lbl0" xml:lang="en-US">Description of minimum fair market value of option grant.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_MinimumFairMarketValueOfOptionGrantDescription" xlink:to="clnn_MinimumFairMarketValueOfOptionGrantDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_NetIssuanceShares_lbl0" xml:lang="en-US">Net issuance shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NetIssuanceShares" xlink:to="clnn_NetIssuanceShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_NetIssuanceSharesOfCommonStock_lbl0" xml:lang="en-US">Net issuance shares of common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NetIssuanceSharesOfCommonStock" xlink:to="clnn_NetIssuanceSharesOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_NetIssuanceWarrants_lbl0" xml:lang="en-US">Net issuance warrants in shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NetIssuanceWarrants" xlink:to="clnn_NetIssuanceWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_NetOfIssuanceCosts_lbl0" xml:lang="en-US">Net of issuance costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NetOfIssuanceCosts" xlink:to="clnn_NetOfIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_NetProceeds_lbl0" xml:lang="en-US">The amount of net proceeds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NetProceeds" xlink:to="clnn_NetProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements Not Yet Adopted Policy.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:to="clnn_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_NotesPayableBasedOnClosingPrice_lbl0" xml:lang="en-US">Notes payable based on closing price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NotesPayableBasedOnClosingPrice" xlink:to="clnn_NotesPayableBasedOnClosingPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_NumberOfSharesIssuable_lbl0" xml:lang="en-US">Number of Shares Issuable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NumberOfSharesIssuable" xlink:to="clnn_NumberOfSharesIssuable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_OfferingCost_lbl0" xml:lang="en-US">OfferingCost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_OfferingCost" xlink:to="clnn_OfferingCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_OfferingPricePerShare_lbl0" xml:lang="en-US">Offering price per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_OfferingPricePerShare" xlink:to="clnn_OfferingPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_OperatingLeaseObligationsWeightedAverageInterestRate_lbl0" xml:lang="en-US">Operating lease obligations weighted average interest rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_OperatingLeaseObligationsWeightedAverageInterestRate" xlink:to="clnn_OperatingLeaseObligationsWeightedAverageInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_OperatingLeaseRightofUseAssets_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_OperatingLeaseRightofUseAssets" xlink:to="clnn_OperatingLeaseRightofUseAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_OperatingLeasesAmountRepresentingInterestdiscounting_lbl0" xml:lang="en-US">Amount representing interest/discounting.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_OperatingLeasesAmountRepresentingInterestdiscounting" xlink:to="clnn_OperatingLeasesAmountRepresentingInterestdiscounting_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_OperatingLeasesLessFutureLeaseIncentives_lbl0" xml:lang="en-US">The amount of less future lease incentives.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_OperatingLeasesLessFutureLeaseIncentives" xlink:to="clnn_OperatingLeasesLessFutureLeaseIncentives_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_PIPEWarrantsOwnershipLimit_lbl0" xml:lang="en-US">Description of PIPE warrants ownership limit.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PIPEWarrantsOwnershipLimit" xlink:to="clnn_PIPEWarrantsOwnershipLimit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_PercentOfFullydilutedEquityPurchasableUponExercise_lbl0" xml:lang="en-US">Percent of fully-diluted equity purchasable upon exercise.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PercentOfFullydilutedEquityPurchasableUponExercise" xlink:to="clnn_PercentOfFullydilutedEquityPurchasableUponExercise_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_PercentageOfLoanAmountUsedToPayrollExpenses_lbl0" xml:lang="en-US">Percentage of loan amount used to payroll expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PercentageOfLoanAmountUsedToPayrollExpenses" xlink:to="clnn_PercentageOfLoanAmountUsedToPayrollExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_PercentageOfStockPrice_lbl0" xml:lang="en-US">Percentage of stock price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PercentageOfStockPrice" xlink:to="clnn_PercentageOfStockPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_PreferredStockShares_lbl0" xml:lang="en-US">Preferred Stock Shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PreferredStockShares" xlink:to="clnn_PreferredStockShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl0" xml:lang="en-US">Prepaid Expenses And Other Current Assets [TableTextBlock]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="clnn_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl0" xml:lang="en-US">The entire disclosure for Prepaid expenses and other current assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="clnn_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_PrivatePlacementWarrantsDescription_lbl0" xml:lang="en-US">Private placement warrants description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PrivatePlacementWarrantsDescription" xlink:to="clnn_PrivatePlacementWarrantsDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ProceedsFromReverseRecapitalization_lbl0" xml:lang="en-US">It represents of proceeds from reverse recapitalization.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ProceedsFromReverseRecapitalization" xlink:to="clnn_ProceedsFromReverseRecapitalization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_PurchaseOptionUnits_lbl0" xml:lang="en-US">Unit purchase option shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PurchaseOptionUnits" xlink:to="clnn_PurchaseOptionUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_RateOfInterestDescription_lbl0" xml:lang="en-US">Rate of interest, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RateOfInterestDescription" xlink:to="clnn_RateOfInterestDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_RecognizedGainOnOperatingLease_lbl0" xml:lang="en-US">Recognized gain on operating lease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RecognizedGainOnOperatingLease" xlink:to="clnn_RecognizedGainOnOperatingLease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_RedeemableConvertiblePreferredStockDisclosureTextBlock_lbl0" xml:lang="en-US">Redeemable Convertible Preferred Stock [Text Block].</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RedeemableConvertiblePreferredStockDisclosureTextBlock" xlink:to="clnn_RedeemableConvertiblePreferredStockDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_RestrictedStockUnitsDescription_lbl0" xml:lang="en-US">Description of Restricted Stock Units.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RestrictedStockUnitsDescription" xlink:to="clnn_RestrictedStockUnitsDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ReverseRecapitalizationExchangeRatio_lbl0" xml:lang="en-US">Reverse recapitalization exchange ratio.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ReverseRecapitalizationExchangeRatio" xlink:to="clnn_ReverseRecapitalizationExchangeRatio_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_RightOfUseAssets_lbl0" xml:lang="en-US">Amount of lessee&apos;s right to use underlying asset under operating lease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RightOfUseAssets" xlink:to="clnn_RightOfUseAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_RiskAndUncertaintiesPolicyTextBlock_lbl0" xml:lang="en-US">Risk and Uncertainties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RiskAndUncertaintiesPolicyTextBlock" xlink:to="clnn_RiskAndUncertaintiesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_SaleOfUnitsNumberOfUnitsIssued_lbl0" xml:lang="en-US">The number of units issued or sold by the subsidiary or equity method investee per stock transaction.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SaleOfUnitsNumberOfUnitsIssued" xlink:to="clnn_SaleOfUnitsNumberOfUnitsIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscounts_lbl0" xml:lang="en-US">Schedule of future payments, net of unamortized debt discounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscounts" xlink:to="clnn_ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscounts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_SecondLoanAmount_lbl0" xml:lang="en-US">Second loan amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SecondLoanAmount" xlink:to="clnn_SecondLoanAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_SeriesDRedeemableConvertiblePreferredStock_lbl0" xml:lang="en-US">Series D redeemable convertible preferred stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SeriesDRedeemableConvertiblePreferredStock" xlink:to="clnn_SeriesDRedeemableConvertiblePreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_SeriesDRedeemableConvertiblePreferredStockWarrants_lbl0" xml:lang="en-US">Series D redeemable convertible preferred stock warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SeriesDRedeemableConvertiblePreferredStockWarrants" xlink:to="clnn_SeriesDRedeemableConvertiblePreferredStockWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueGranted_lbl0" xml:lang="en-US">Intrinsic Value, Granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueGranted" xlink:to="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber_lbl0" xml:lang="en-US">Number of fully vested and exercisable options that may be converted into shares under option plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber" xlink:to="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ShareBasedCompensationArrangementNumberOfOptionsExercised_lbl0" xml:lang="en-US">Number of options shares exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ShareBasedCompensationArrangementNumberOfOptionsExercised" xlink:to="clnn_ShareBasedCompensationArrangementNumberOfOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ShareIssuanceOfCommonStockPrivateOffering_lbl0" xml:lang="en-US">Share issuance of common stock private offering.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ShareIssuanceOfCommonStockPrivateOffering" xlink:to="clnn_ShareIssuanceOfCommonStockPrivateOffering_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm_lbl0" xml:lang="en-US">Expected term of award under share-based payment arrangement, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm" xlink:to="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm_lbl0" xml:lang="en-US">Expected term of award under share-based payment arrangement, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos;.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm" xlink:to="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants_lbl0" xml:lang="en-US">Gross number of share options (or share units) for future granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants" xlink:to="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Weighted average remaining contractual term for fully vested and expected to vest or convertible options, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm1" xlink:to="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_SharesCancelledUponReverseRecapitalization_lbl0" xml:lang="en-US">Shares cancelled upon reverse recapitalization.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharesCancelledUponReverseRecapitalization" xlink:to="clnn_SharesCancelledUponReverseRecapitalization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_SharesHeldInEscrow_lbl0" xml:lang="en-US">Number of shares held in Escrow.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharesHeldInEscrow" xlink:to="clnn_SharesHeldInEscrow_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_SharesHeldInEscrowPercentage_lbl0" xml:lang="en-US">Percentage shares held in escrow.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharesHeldInEscrowPercentage" xlink:to="clnn_SharesHeldInEscrowPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_SharesOfWarrantsExercisable_lbl0" xml:lang="en-US">Shares of warrants exercisable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharesOfWarrantsExercisable" xlink:to="clnn_SharesOfWarrantsExercisable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_SimpleInterestExpense_lbl0" xml:lang="en-US">Simple interest expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SimpleInterestExpense" xlink:to="clnn_SimpleInterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_StockIssueDuringPeriodSharesExerciseOfWarrants_lbl0" xml:lang="en-US">Exercise of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockIssueDuringPeriodSharesExerciseOfWarrants" xlink:to="clnn_StockIssueDuringPeriodSharesExerciseOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_StockIssuedDuringPeriodExerciseOfUnderwritersOption_lbl0" xml:lang="en-US">Exercise of underwriter&#8217;s option.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockIssuedDuringPeriodExerciseOfUnderwritersOption" xlink:to="clnn_StockIssuedDuringPeriodExerciseOfUnderwritersOption_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_StockIssuedDuringPeriodExerciseOfUnderwritersOptioninShares_lbl0" xml:lang="en-US">Exercise of underwriter&#8217;s option in shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockIssuedDuringPeriodExerciseOfUnderwritersOptioninShares" xlink:to="clnn_StockIssuedDuringPeriodExerciseOfUnderwritersOptioninShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_StockIssuedDuringPeriodOfSeriesDPreferredStock_lbl0" xml:lang="en-US">Issuance of Series D Preferred Stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockIssuedDuringPeriodOfSeriesDPreferredStock" xlink:to="clnn_StockIssuedDuringPeriodOfSeriesDPreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_StockIssuedDuringPeriodSharesSeriesDPreferredStock_lbl0" xml:lang="en-US">Issuance of Series D Preferred Stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockIssuedDuringPeriodSharesSeriesDPreferredStock" xlink:to="clnn_StockIssuedDuringPeriodSharesSeriesDPreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl0" xml:lang="en-US">Exercise of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:to="clnn_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ThresholdForRemovalOfFinancialCovenantsDescription_lbl0" xml:lang="en-US">Threshold for removal of financial covenants, description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ThresholdForRemovalOfFinancialCovenantsDescription" xlink:to="clnn_ThresholdForRemovalOfFinancialCovenantsDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_TotalCleneNanomedicineContingentEarnoutShares_lbl0" xml:lang="en-US">Total clene nanomedicine contingent earnout shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TotalCleneNanomedicineContingentEarnoutShares" xlink:to="clnn_TotalCleneNanomedicineContingentEarnoutShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_TotalDilutiveSecurities_lbl0" xml:lang="en-US">Total number potentially dilutive securities shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TotalDilutiveSecurities" xlink:to="clnn_TotalDilutiveSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_TotalLossBeforeIncomeTaxes_lbl0" xml:lang="en-US">Total loss before income taxes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TotalLossBeforeIncomeTaxes" xlink:to="clnn_TotalLossBeforeIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_TotalNotesPayableAndConvertibleNotesPayable_lbl0" xml:lang="en-US">Total notes payable and convertible notes payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TotalNotesPayableAndConvertibleNotesPayable" xlink:to="clnn_TotalNotesPayableAndConvertibleNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_TotalPropertyAndEquipmentNet_lbl0" xml:lang="en-US">Total property and equipment, net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TotalPropertyAndEquipmentNet" xlink:to="clnn_TotalPropertyAndEquipmentNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_TotalTermLoans_lbl0" xml:lang="en-US">Total Term Loans.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TotalTermLoans" xlink:to="clnn_TotalTermLoans_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_TradingVolumeLimitForConversionOfConvertibleNotePayable_lbl0" xml:lang="en-US">Trading volume limit for conversion of convertible note payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TradingVolumeLimitForConversionOfConvertibleNotePayable" xlink:to="clnn_TradingVolumeLimitForConversionOfConvertibleNotePayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_Tranche2WarrantAdjustmentDescription_lbl0" xml:lang="en-US">Description of tranche 2 warrant adjustment description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_Tranche2WarrantAdjustmentDescription" xlink:to="clnn_Tranche2WarrantAdjustmentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_UnitsIssuedPricePerUnit_lbl0" xml:lang="en-US">Per unit amount of equity securities issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_UnitsIssuedPricePerUnit" xlink:to="clnn_UnitsIssuedPricePerUnit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_UnvestedRestrictedStockAwardsShares_lbl0" xml:lang="en-US">Unvested restricted stock awards shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_UnvestedRestrictedStockAwardsShares" xlink:to="clnn_UnvestedRestrictedStockAwardsShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_WarrantLiabilityFairValue_lbl0" xml:lang="en-US">It represents amount of warrant liability fair value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantLiabilityFairValue" xlink:to="clnn_WarrantLiabilityFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_WarrantLiabilityNoncurrent_lbl0" xml:lang="en-US">WarrantLiabilityNoncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantLiabilityNoncurrent" xlink:to="clnn_WarrantLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_WarrantLiabilityRecordedAtIssuanceOfNotesPayable_lbl0" xml:lang="en-US">Warrant liability recorded at issuance of notes payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantLiabilityRecordedAtIssuanceOfNotesPayable" xlink:to="clnn_WarrantLiabilityRecordedAtIssuanceOfNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_WarrantToPurchaseShares_lbl0" xml:lang="en-US">Warrant to purchase shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantToPurchaseShares" xlink:to="clnn_WarrantToPurchaseShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_WarrantsShares_lbl0" xml:lang="en-US">Warrants Shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantsShares" xlink:to="clnn_WarrantsShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_WarrantsToPurchaseCommonStockIssuedAndOutstanding_lbl0" xml:lang="en-US">Warrants to purchase common stock issued and outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantsToPurchaseCommonStockIssuedAndOutstanding" xlink:to="clnn_WarrantsToPurchaseCommonStockIssuedAndOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_WarrantsToPurchaseSharesOfCommonStock_lbl0" xml:lang="en-US">Warrants to purchase shares of common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantsToPurchaseSharesOfCommonStock" xlink:to="clnn_WarrantsToPurchaseSharesOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_WeightedAverageExercisePricePerShareOptionVestedAndExercisable_lbl0" xml:lang="en-US">Weighted Average Exercise Price Per Share, Options vested and exercisable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WeightedAverageExercisePricePerShareOptionVestedAndExercisable" xlink:to="clnn_WeightedAverageExercisePricePerShareOptionVestedAndExercisable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_WeightedAverageSharesOutstanding_lbl0" xml:lang="en-US">WeightedAverageSharesOutstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WeightedAverageSharesOutstanding" xlink:to="clnn_WeightedAverageSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_weightedAverageFairValuesOfOptionsGranted_lbl0" xml:lang="en-US">Fair value of options granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_weightedAverageFairValuesOfOptionsGranted" xlink:to="clnn_weightedAverageFairValuesOfOptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_ChardanCapitalMarketsLLCMember_lbl0" xml:lang="en-US">Chardan Capital Markets, LLC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChardanCapitalMarketsLLCMember" xlink:to="clnn_ChardanCapitalMarketsLLCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_CommonStockWarrantsMember_lbl0" xml:lang="en-US">Common Stock Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockWarrantsMember" xlink:to="clnn_CommonStockWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_InitialShareholdersContingentEarnoutMember_lbl0" xml:lang="en-US">Initial Shareholders Contingent Earn-out [Member].</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InitialShareholdersContingentEarnoutMember" xlink:to="clnn_InitialShareholdersContingentEarnoutMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="clnn_WarrantLiabilityMember_lbl0" xml:lang="en-US">Warrant Liability [Member].</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantLiabilityMember" xlink:to="clnn_WarrantLiabilityMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ChangeInFairValueOfPreferredStockWarrantLiability_lbl0" xml:lang="en-US">ChangeInFairValueOfPreferredStockWarrantLiability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChangeInFairValueOfPreferredStockWarrantLiability" xlink:to="clnn_ChangeInFairValueOfPreferredStockWarrantLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_StockIssuedDuringPeriodSharesSeriesDPreferredStock_lbl1" xml:lang="en-US">StockIssuedDuringPeriodSharesSeriesDPreferredStock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockIssuedDuringPeriodSharesSeriesDPreferredStock" xlink:to="clnn_StockIssuedDuringPeriodSharesSeriesDPreferredStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_MarylandDepartmentOfHousingCommunityDevelopmentMember_lbl0" xml:lang="en-US">MarylandDepartmentOfHousingCommunityDevelopmentMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_MarylandDepartmentOfHousingCommunityDevelopmentMember" xlink:to="clnn_MarylandDepartmentOfHousingCommunityDevelopmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_WarrantsShares_lbl1" xml:lang="en-US">WarrantsShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantsShares" xlink:to="clnn_WarrantsShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_WarrantLiabilityMember_lbl1" xml:lang="en-US">WarrantLiabilityMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantLiabilityMember" xlink:to="clnn_WarrantLiabilityMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_OperatingLeasesLessFutureLeaseIncentives_lbl1" xml:lang="en-US">OperatingLeasesLessFutureLeaseIncentives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_OperatingLeasesLessFutureLeaseIncentives" xlink:to="clnn_OperatingLeasesLessFutureLeaseIncentives_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes_lbl1" xml:lang="en-US">IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes" xlink:to="clnn_IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_NetIncomeLossPerShareAttributableToCommonShareholdersMember_lbl0" xml:lang="en-US">NetIncomeLossPerShareAttributableToCommonShareholdersMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NetIncomeLossPerShareAttributableToCommonShareholdersMember" xlink:to="clnn_NetIncomeLossPerShareAttributableToCommonShareholdersMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ConvertibleNotesPayables_lbl1" xml:lang="en-US">ConvertibleNotesPayables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ConvertibleNotesPayables" xlink:to="clnn_ConvertibleNotesPayables_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue_lbl0" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue" xlink:to="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueGranted_lbl1" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueGranted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueGranted" xlink:to="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ConditionsForFutureFundingDescription_lbl1" xml:lang="en-US">ConditionsForFutureFundingDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ConditionsForFutureFundingDescription" xlink:to="clnn_ConditionsForFutureFundingDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_TotalPropertyAndEquipmentNet_lbl1" xml:lang="en-US">TotalPropertyAndEquipmentNet</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TotalPropertyAndEquipmentNet" xlink:to="clnn_TotalPropertyAndEquipmentNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_WeightedAverageEffectOfPotentiallyDilutiveSecuritiesAbstract_lbl0" xml:lang="en-US">WeightedAverageEffectOfPotentiallyDilutiveSecuritiesAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WeightedAverageEffectOfPotentiallyDilutiveSecuritiesAbstract" xlink:to="clnn_WeightedAverageEffectOfPotentiallyDilutiveSecuritiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_DebtInstrumentFinancingCosts_lbl0" xml:lang="en-US">DebtInstrumentFinancingCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DebtInstrumentFinancingCosts" xlink:to="clnn_DebtInstrumentFinancingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_InitialShareholdersContingentsEarnout_lbl1" xml:lang="en-US">InitialShareholdersContingentsEarnout</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InitialShareholdersContingentsEarnout" xlink:to="clnn_InitialShareholdersContingentsEarnout_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscounts_lbl1" xml:lang="en-US">ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscounts" xlink:to="clnn_ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscounts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_FairValueIssuanceOfConvertiblePromissoryNotes_lbl1" xml:lang="en-US">FairValueIssuanceOfConvertiblePromissoryNotes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FairValueIssuanceOfConvertiblePromissoryNotes" xlink:to="clnn_FairValueIssuanceOfConvertiblePromissoryNotes_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_MinimumFairMarketValueOfOptionGrantDescription_lbl1" xml:lang="en-US">MinimumFairMarketValueOfOptionGrantDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_MinimumFairMarketValueOfOptionGrantDescription" xlink:to="clnn_MinimumFairMarketValueOfOptionGrantDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_PercentOfFullydilutedEquityPurchasableUponExercise_lbl1" xml:lang="en-US">PercentOfFullydilutedEquityPurchasableUponExercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PercentOfFullydilutedEquityPurchasableUponExercise" xlink:to="clnn_PercentOfFullydilutedEquityPurchasableUponExercise_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ExclusiveRightsIntellectualPropertyTerm_lbl1" xml:lang="en-US">ExclusiveRightsIntellectualPropertyTerm</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ExclusiveRightsIntellectualPropertyTerm" xlink:to="clnn_ExclusiveRightsIntellectualPropertyTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm1_lbl1" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm1" xlink:to="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_December20201Member_lbl0" xml:lang="en-US">December20201Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_December20201Member" xlink:to="clnn_December20201Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_RecapitalizationShare_lbl0" xml:lang="en-US">RecapitalizationShare</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RecapitalizationShare" xlink:to="clnn_RecapitalizationShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_AccruedExpenseReimbursements_lbl1" xml:lang="en-US">AccruedExpenseReimbursements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AccruedExpenseReimbursements" xlink:to="clnn_AccruedExpenseReimbursements_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_FinanceLeaseByMajorClassPropertyAndEquipmentTableTextBlock_lbl1" xml:lang="en-US">FinanceLeaseByMajorClassPropertyAndEquipmentTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FinanceLeaseByMajorClassPropertyAndEquipmentTableTextBlock" xlink:to="clnn_FinanceLeaseByMajorClassPropertyAndEquipmentTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock_lbl0" xml:lang="en-US">ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock" xlink:to="clnn_ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_LifeSciCapitalLLCMember_lbl0" xml:lang="en-US">LifeSciCapitalLLCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_LifeSciCapitalLLCMember" xlink:to="clnn_LifeSciCapitalLLCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_IntrinsicValueStockOptionsVestedAndExpectedToVestIntrinsicValueOptionsV_lbl0" xml:lang="en-US">IntrinsicValueStockOptionsVestedAndExpectedToVestIntrinsicValueOptionsV</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IntrinsicValueStockOptionsVestedAndExpectedToVestIntrinsicValueOptionsV" xlink:to="clnn_IntrinsicValueStockOptionsVestedAndExpectedToVestIntrinsicValueOptionsV_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ForeignCurrencyTranslationAdjustment_lbl0" xml:lang="en-US">ForeignCurrencyTranslationAdjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ForeignCurrencyTranslationAdjustment" xlink:to="clnn_ForeignCurrencyTranslationAdjustment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_IssuanceOfCommonStockUponReverseRecapitalization_lbl0" xml:lang="en-US">IssuanceOfCommonStockUponReverseRecapitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IssuanceOfCommonStockUponReverseRecapitalization" xlink:to="clnn_IssuanceOfCommonStockUponReverseRecapitalization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_PaycheckProtectionProgramMember_lbl0" xml:lang="en-US">PaycheckProtectionProgramMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PaycheckProtectionProgramMember" xlink:to="clnn_PaycheckProtectionProgramMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CleneNanomedicineContingentEarnOutMilestone1Shares_lbl1" xml:lang="en-US">CleneNanomedicineContingentEarnOutMilestone1Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CleneNanomedicineContingentEarnOutMilestone1Shares" xlink:to="clnn_CleneNanomedicineContingentEarnOutMilestone1Shares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_NetIssuanceShares_lbl1" xml:lang="en-US">NetIssuanceShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NetIssuanceShares" xlink:to="clnn_NetIssuanceShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_TotalCleneNanomedicineContingentEarnoutShares_lbl1" xml:lang="en-US">TotalCleneNanomedicineContingentEarnoutShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TotalCleneNanomedicineContingentEarnoutShares" xlink:to="clnn_TotalCleneNanomedicineContingentEarnoutShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValue_lbl1" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValue" xlink:to="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_FinanceLeaseLiabilityNet_lbl1" xml:lang="en-US">FinanceLeaseLiabilityNet</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FinanceLeaseLiabilityNet" xlink:to="clnn_FinanceLeaseLiabilityNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_NetIncomeLossPerShareAttributableToCommonShareholdersAbstract_lbl0" xml:lang="en-US">NetIncomeLossPerShareAttributableToCommonShareholdersAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NetIncomeLossPerShareAttributableToCommonShareholdersAbstract" xlink:to="clnn_NetIncomeLossPerShareAttributableToCommonShareholdersAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_FinanceLeaseObligationsWeightedaverageInterestRate_lbl1" xml:lang="en-US">FinanceLeaseObligationsWeightedaverageInterestRate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FinanceLeaseObligationsWeightedaverageInterestRate" xlink:to="clnn_FinanceLeaseObligationsWeightedaverageInterestRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_DebtInstrumentThereafter_lbl1" xml:lang="en-US">DebtInstrumentThereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DebtInstrumentThereafter" xlink:to="clnn_DebtInstrumentThereafter_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_DescriptionOfLossOnExtinguishment_lbl1" xml:lang="en-US">DescriptionOfLossOnExtinguishment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DescriptionOfLossOnExtinguishment" xlink:to="clnn_DescriptionOfLossOnExtinguishment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ChangeInFairValueOfCommonStockWarrantLiability_lbl1" xml:lang="en-US">ChangeInFairValueOfCommonStockWarrantLiability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChangeInFairValueOfCommonStockWarrantLiability" xlink:to="clnn_ChangeInFairValueOfCommonStockWarrantLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CommonStockWarrantsDisclosureTextBlock_lbl1" xml:lang="en-US">CommonStockWarrantsDisclosureTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockWarrantsDisclosureTextBlock" xlink:to="clnn_CommonStockWarrantsDisclosureTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_InvestorsPurchasedShares_lbl1" xml:lang="en-US">InvestorsPurchasedShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InvestorsPurchasedShares" xlink:to="clnn_InvestorsPurchasedShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_TwoThousandNineteenMDLoanMember_lbl0" xml:lang="en-US">TwoThousandNineteenMDLoanMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TwoThousandNineteenMDLoanMember" xlink:to="clnn_TwoThousandNineteenMDLoanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_FinanceLeasesMember_lbl0" xml:lang="en-US">FinanceLeasesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FinanceLeasesMember" xlink:to="clnn_FinanceLeasesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_InterestIncomeexpense_lbl1" xml:lang="en-US">InterestIncomeexpense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InterestIncomeexpense" xlink:to="clnn_InterestIncomeexpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ChardanUnitPurchaseOption_lbl1" xml:lang="en-US">ChardanUnitPurchaseOption</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChardanUnitPurchaseOption" xlink:to="clnn_ChardanUnitPurchaseOption_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_TotalNotesPayableAndConvertibleNotesPayable_lbl1" xml:lang="en-US">TotalNotesPayableAndConvertibleNotesPayable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TotalNotesPayableAndConvertibleNotesPayable" xlink:to="clnn_TotalNotesPayableAndConvertibleNotesPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_FairValueAmortizedCost_lbl1" xml:lang="en-US">FairValueAmortizedCost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FairValueAmortizedCost" xlink:to="clnn_FairValueAmortizedCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_OfferingCost_lbl1" xml:lang="en-US">OfferingCost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_OfferingCost" xlink:to="clnn_OfferingCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CommonStockAtAnExercisePrice_lbl1" xml:lang="en-US">CommonStockAtAnExercisePrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockAtAnExercisePrice" xlink:to="clnn_CommonStockAtAnExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_AggregateFutureProceedsWarrantsExercised_lbl1" xml:lang="en-US">AggregateFutureProceedsWarrantsExercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AggregateFutureProceedsWarrantsExercised" xlink:to="clnn_AggregateFutureProceedsWarrantsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_TwoThousandNineteenCecilLoanMember_lbl0" xml:lang="en-US">TwoThousandNineteenCecilLoanMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TwoThousandNineteenCecilLoanMember" xlink:to="clnn_TwoThousandNineteenCecilLoanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_InitialShareholdersContingentEarnoutShares_lbl1" xml:lang="en-US">InitialShareholdersContingentEarnoutShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InitialShareholdersContingentEarnoutShares" xlink:to="clnn_InitialShareholdersContingentEarnoutShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ContingentEarnOutMember_lbl0" xml:lang="en-US">ContingentEarnOutMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ContingentEarnOutMember" xlink:to="clnn_ContingentEarnOutMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ConvertibleNotesPayableDescription_lbl1" xml:lang="en-US">ConvertibleNotesPayableDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ConvertibleNotesPayableDescription" xlink:to="clnn_ConvertibleNotesPayableDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_WeightedAverageSharesOutstanding_lbl1" xml:lang="en-US">WeightedAverageSharesOutstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WeightedAverageSharesOutstanding" xlink:to="clnn_WeightedAverageSharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl1" xml:lang="en-US">StockIssuedDuringPeriodValueExerciseOfWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:to="clnn_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_IncreseDecreaseInFairValue_lbl1" xml:lang="en-US">IncreseDecreaseInFairValue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IncreseDecreaseInFairValue" xlink:to="clnn_IncreseDecreaseInFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_FinanceLeaseWorkInProcessGross_lbl1" xml:lang="en-US">FinanceLeaseWorkInProcessGross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FinanceLeaseWorkInProcessGross" xlink:to="clnn_FinanceLeaseWorkInProcessGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_EffectOfPotentiallyDilutiveConvertibleNotesPayable_lbl1" xml:lang="en-US">EffectOfPotentiallyDilutiveConvertibleNotesPayable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_EffectOfPotentiallyDilutiveConvertibleNotesPayable" xlink:to="clnn_EffectOfPotentiallyDilutiveConvertibleNotesPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_DirectorsOfficersInsurance_lbl1" xml:lang="en-US">DirectorsOfficersInsurance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DirectorsOfficersInsurance" xlink:to="clnn_DirectorsOfficersInsurance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm_lbl1" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm" xlink:to="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_AustraliaResearchAndDevelopmentCredit_lbl0" xml:lang="en-US">AustraliaResearchAndDevelopmentCredit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AustraliaResearchAndDevelopmentCredit" xlink:to="clnn_AustraliaResearchAndDevelopmentCredit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CleneNanomedicineMember_lbl0" xml:lang="en-US">CleneNanomedicineMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CleneNanomedicineMember" xlink:to="clnn_CleneNanomedicineMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_InitialFairValueOfInstrument_lbl1" xml:lang="en-US">InitialFairValueOfInstrument</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InitialFairValueOfInstrument" xlink:to="clnn_InitialFairValueOfInstrument_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_TottenhamMember_lbl0" xml:lang="en-US">TottenhamMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TottenhamMember" xlink:to="clnn_TottenhamMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_UnvestedRestrictedStockAwardsShares_lbl1" xml:lang="en-US">UnvestedRestrictedStockAwardsShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_UnvestedRestrictedStockAwardsShares" xlink:to="clnn_UnvestedRestrictedStockAwardsShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_GainOnExtinguishmentOfNotesPayable_lbl1" xml:lang="en-US">GainOnExtinguishmentOfNotesPayable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_GainOnExtinguishmentOfNotesPayable" xlink:to="clnn_GainOnExtinguishmentOfNotesPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_RightOfUseAssets_lbl1" xml:lang="en-US">RightOfUseAssets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RightOfUseAssets" xlink:to="clnn_RightOfUseAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_NetIncomeLossPerCommonShareAttributableToCommonShareholdersNote191Abstract_lbl0" xml:lang="en-US">NetIncomeLossPerCommonShareAttributableToCommonShareholdersNote191Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NetIncomeLossPerCommonShareAttributableToCommonShareholdersNote191Abstract" xlink:to="clnn_NetIncomeLossPerCommonShareAttributableToCommonShareholdersNote191Abstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CROPrepayments_lbl0" xml:lang="en-US">CROPrepayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CROPrepayments" xlink:to="clnn_CROPrepayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_EffectOfPotentiallyDilutiveUnvestedRestrictedStockAwardsShares_lbl1" xml:lang="en-US">EffectOfPotentiallyDilutiveUnvestedRestrictedStockAwardsShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_EffectOfPotentiallyDilutiveUnvestedRestrictedStockAwardsShares" xlink:to="clnn_EffectOfPotentiallyDilutiveUnvestedRestrictedStockAwardsShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_AccruedCROFees_lbl1" xml:lang="en-US">AccruedCROFees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AccruedCROFees" xlink:to="clnn_AccruedCROFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ChangesInFairValueOfInitialShareholdersContingentEarnout_lbl1" xml:lang="en-US">ChangesInFairValueOfInitialShareholdersContingentEarnout</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChangesInFairValueOfInitialShareholdersContingentEarnout" xlink:to="clnn_ChangesInFairValueOfInitialShareholdersContingentEarnout_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ExercisePricePerShare_lbl1" xml:lang="en-US">ExercisePricePerShare</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ExercisePricePerShare" xlink:to="clnn_ExercisePricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_PurchaseOptionUnits_lbl1" xml:lang="en-US">PurchaseOptionUnits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PurchaseOptionUnits" xlink:to="clnn_PurchaseOptionUnits_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_TotalDilutiveSecurities_lbl1" xml:lang="en-US">TotalDilutiveSecurities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TotalDilutiveSecurities" xlink:to="clnn_TotalDilutiveSecurities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_PercentageOfStockPrice_lbl1" xml:lang="en-US">PercentageOfStockPrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PercentageOfStockPrice" xlink:to="clnn_PercentageOfStockPrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CleneNanomedicineContingentEarnoutMember_lbl0" xml:lang="en-US">CleneNanomedicineContingentEarnoutMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CleneNanomedicineContingentEarnoutMember" xlink:to="clnn_CleneNanomedicineContingentEarnoutMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CapitalLeasesAmountRepresentingInterestdiscounting_lbl1" xml:lang="en-US">CapitalLeasesAmountRepresentingInterestdiscounting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CapitalLeasesAmountRepresentingInterestdiscounting" xlink:to="clnn_CapitalLeasesAmountRepresentingInterestdiscounting_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl1" xml:lang="en-US">NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:to="clnn_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_PreferredStockShares_lbl1" xml:lang="en-US">PreferredStockShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PreferredStockShares" xlink:to="clnn_PreferredStockShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_Changeinfairvaluewarrants_lbl1" xml:lang="en-US">Changeinfairvaluewarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_Changeinfairvaluewarrants" xlink:to="clnn_Changeinfairvaluewarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CleneNanomedicineContingentEarnoutMilestone1Price_lbl1" xml:lang="en-US">CleneNanomedicineContingentEarnoutMilestone1Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CleneNanomedicineContingentEarnoutMilestone1Price" xlink:to="clnn_CleneNanomedicineContingentEarnoutMilestone1Price_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_BlackScholesValuationModelMember_lbl0" xml:lang="en-US">BlackScholesValuationModelMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_BlackScholesValuationModelMember" xlink:to="clnn_BlackScholesValuationModelMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_WarrantToPurchaseShares_lbl1" xml:lang="en-US">WarrantToPurchaseShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantToPurchaseShares" xlink:to="clnn_WarrantToPurchaseShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CleneIncMember_lbl0" xml:lang="en-US">CleneIncMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CleneIncMember" xlink:to="clnn_CleneIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_OptionsToPurchaseCommonStockinShares_lbl0" xml:lang="en-US">OptionsToPurchaseCommonStockinShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_OptionsToPurchaseCommonStockinShares" xlink:to="clnn_OptionsToPurchaseCommonStockinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl1" xml:lang="en-US">PrepaidExpensesAndOtherCurrentAssetsTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="clnn_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_MinimumCashBalanceForLoanCovenant_lbl1" xml:lang="en-US">MinimumCashBalanceForLoanCovenant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_MinimumCashBalanceForLoanCovenant" xlink:to="clnn_MinimumCashBalanceForLoanCovenant_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber_lbl1" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber" xlink:to="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_DenominatorAbstract_lbl0" xml:lang="en-US">DenominatorAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DenominatorAbstract" xlink:to="clnn_DenominatorAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_DebtInstrumentUnamortizedDiscountYearFour_lbl1" xml:lang="en-US">DebtInstrumentUnamortizedDiscountYearFour</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DebtInstrumentUnamortizedDiscountYearFour" xlink:to="clnn_DebtInstrumentUnamortizedDiscountYearFour_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_InitialShareholdersContingentEarnoutMilestone2Shares_lbl1" xml:lang="en-US">InitialShareholdersContingentEarnoutMilestone2Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InitialShareholdersContingentEarnoutMilestone2Shares" xlink:to="clnn_InitialShareholdersContingentEarnoutMilestone2Shares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_Tranche2WarrantAdjustmentDescription_lbl1" xml:lang="en-US">Tranche2WarrantAdjustmentDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_Tranche2WarrantAdjustmentDescription" xlink:to="clnn_Tranche2WarrantAdjustmentDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_NetIssuanceWarrants_lbl1" xml:lang="en-US">NetIssuanceWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NetIssuanceWarrants" xlink:to="clnn_NetIssuanceWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_WeightedAverageExercisePriceWeightedAverageRemainingTermYearsOptionsVestedAndEexercisableEnding_lbl0" xml:lang="en-US">WeightedAverageExercisePriceWeightedAverageRemainingTermYearsOptionsVestedAndEexercisableEnding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WeightedAverageExercisePriceWeightedAverageRemainingTermYearsOptionsVestedAndEexercisableEnding" xlink:to="clnn_WeightedAverageExercisePriceWeightedAverageRemainingTermYearsOptionsVestedAndEexercisableEnding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ThresholdForRemovalOfFinancialCovenantsDescription_lbl1" xml:lang="en-US">ThresholdForRemovalOfFinancialCovenantsDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ThresholdForRemovalOfFinancialCovenantsDescription" xlink:to="clnn_ThresholdForRemovalOfFinancialCovenantsDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ChardanUnitPurchaseOptionMember_lbl0" xml:lang="en-US">ChardanUnitPurchaseOptionMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChardanUnitPurchaseOptionMember" xlink:to="clnn_ChardanUnitPurchaseOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_StockIssuedDuringPeriodExerciseOfUnderwritersOption_lbl1" xml:lang="en-US">StockIssuedDuringPeriodExerciseOfUnderwritersOption</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockIssuedDuringPeriodExerciseOfUnderwritersOption" xlink:to="clnn_StockIssuedDuringPeriodExerciseOfUnderwritersOption_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CleneNanomedicineContingentEarnoutMilestone3Shares_lbl1" xml:lang="en-US">CleneNanomedicineContingentEarnoutMilestone3Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CleneNanomedicineContingentEarnoutMilestone3Shares" xlink:to="clnn_CleneNanomedicineContingentEarnoutMilestone3Shares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_DebtInstrumentUnamortizedDiscountRemainderOfFiscalYear_lbl1" xml:lang="en-US">DebtInstrumentUnamortizedDiscountRemainderOfFiscalYear</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DebtInstrumentUnamortizedDiscountRemainderOfFiscalYear" xlink:to="clnn_DebtInstrumentUnamortizedDiscountRemainderOfFiscalYear_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_SeriesDRedeemableConvertiblePreferredStock_lbl1" xml:lang="en-US">SeriesDRedeemableConvertiblePreferredStock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SeriesDRedeemableConvertiblePreferredStock" xlink:to="clnn_SeriesDRedeemableConvertiblePreferredStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_SharesHeldInEscrowPercentage_lbl1" xml:lang="en-US">SharesHeldInEscrowPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharesHeldInEscrowPercentage" xlink:to="clnn_SharesHeldInEscrowPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ChangeInFairValueOfContingentEarnout_lbl1" xml:lang="en-US">ChangeInFairValueOfContingentEarnout</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChangeInFairValueOfContingentEarnout" xlink:to="clnn_ChangeInFairValueOfContingentEarnout_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants_lbl1" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants" xlink:to="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_May2021Member_lbl0" xml:lang="en-US">May2021Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_May2021Member" xlink:to="clnn_May2021Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_InitialShareholdersContingentEarnout_lbl1" xml:lang="en-US">InitialShareholdersContingentEarnout</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InitialShareholdersContingentEarnout" xlink:to="clnn_InitialShareholdersContingentEarnout_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_WarrantsDate1Member_lbl0" xml:lang="en-US">WarrantsDate1Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantsDate1Member" xlink:to="clnn_WarrantsDate1Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_LeaseLiabilitySettledThroughTerminationOfLease_lbl1" xml:lang="en-US">LeaseLiabilitySettledThroughTerminationOfLease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_LeaseLiabilitySettledThroughTerminationOfLease" xlink:to="clnn_LeaseLiabilitySettledThroughTerminationOfLease_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_SharesOfWarrantsExercisable_lbl1" xml:lang="en-US">SharesOfWarrantsExercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharesOfWarrantsExercisable" xlink:to="clnn_SharesOfWarrantsExercisable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_RiskAndUncertaintiesPolicyTextBlock_lbl1" xml:lang="en-US">RiskAndUncertaintiesPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RiskAndUncertaintiesPolicyTextBlock" xlink:to="clnn_RiskAndUncertaintiesPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_AccruedTransactionCosts_lbl1" xml:lang="en-US">AccruedTransactionCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AccruedTransactionCosts" xlink:to="clnn_AccruedTransactionCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CleneNanomedicineContingentEarnoutMilestone2Shares_lbl1" xml:lang="en-US">CleneNanomedicineContingentEarnoutMilestone2Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CleneNanomedicineContingentEarnoutMilestone2Shares" xlink:to="clnn_CleneNanomedicineContingentEarnoutMilestone2Shares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CouponInterestExpense_lbl1" xml:lang="en-US">CouponInterestExpense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CouponInterestExpense" xlink:to="clnn_CouponInterestExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_LossOnDerivativeInstruments_lbl1" xml:lang="en-US">LossOnDerivativeInstruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_LossOnDerivativeInstruments" xlink:to="clnn_LossOnDerivativeInstruments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CompanyWarrantRedemptionRight_lbl1" xml:lang="en-US">CompanyWarrantRedemptionRight</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CompanyWarrantRedemptionRight" xlink:to="clnn_CompanyWarrantRedemptionRight_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CommonStockWarrantsClassification_lbl0" xml:lang="en-US">CommonStockWarrantsClassification</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockWarrantsClassification" xlink:to="clnn_CommonStockWarrantsClassification_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CleneNanomedicineContingentEarnoutFairValueDisclosure_lbl1" xml:lang="en-US">CleneNanomedicineContingentEarnoutFairValueDisclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CleneNanomedicineContingentEarnoutFairValueDisclosure" xlink:to="clnn_CleneNanomedicineContingentEarnoutFairValueDisclosure_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CommonStockSharesPurchased_lbl1" xml:lang="en-US">CommonStockSharesPurchased</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockSharesPurchased" xlink:to="clnn_CommonStockSharesPurchased_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_DeferredGrantFunds_lbl1" xml:lang="en-US">DeferredGrantFunds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DeferredGrantFunds" xlink:to="clnn_DeferredGrantFunds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_WarrantsDate2Member_lbl0" xml:lang="en-US">WarrantsDate2Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantsDate2Member" xlink:to="clnn_WarrantsDate2Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_WeightedAverageNumberOfCommonSharesOutstanding1Abstract_lbl0" xml:lang="en-US">WeightedAverageNumberOfCommonSharesOutstanding1Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WeightedAverageNumberOfCommonSharesOutstanding1Abstract" xlink:to="clnn_WeightedAverageNumberOfCommonSharesOutstanding1Abstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CommonStockWarrantsExercisable_lbl0" xml:lang="en-US">CommonStockWarrantsExercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockWarrantsExercisable" xlink:to="clnn_CommonStockWarrantsExercisable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_NetIssuanceSharesOfCommonStock_lbl1" xml:lang="en-US">NetIssuanceSharesOfCommonStock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NetIssuanceSharesOfCommonStock" xlink:to="clnn_NetIssuanceSharesOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock_lbl0" xml:lang="en-US">ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock" xlink:to="clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_SeriesARedeemableConvertiblePreferredStock_lbl0" xml:lang="en-US">SeriesARedeemableConvertiblePreferredStock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SeriesARedeemableConvertiblePreferredStock" xlink:to="clnn_SeriesARedeemableConvertiblePreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_PIPEWarrantsMember_lbl0" xml:lang="en-US">PIPEWarrantsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PIPEWarrantsMember" xlink:to="clnn_PIPEWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ConvertibleNotesDisclosureTextBlock_lbl0" xml:lang="en-US">ConvertibleNotesDisclosureTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ConvertibleNotesDisclosureTextBlock" xlink:to="clnn_ConvertibleNotesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_TermLoansAxis_lbl0" xml:lang="en-US">TermLoansAxis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TermLoansAxis" xlink:to="clnn_TermLoansAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_IncreaseInLeaseholdImprovements_lbl1" xml:lang="en-US">IncreaseInLeaseholdImprovements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IncreaseInLeaseholdImprovements" xlink:to="clnn_IncreaseInLeaseholdImprovements_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CommonStockWarrantsPolicyTextBlock_lbl1" xml:lang="en-US">CommonStockWarrantsPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockWarrantsPolicyTextBlock" xlink:to="clnn_CommonStockWarrantsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CleneNanomedicineContingentEarnoutShares_lbl1" xml:lang="en-US">CleneNanomedicineContingentEarnoutShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CleneNanomedicineContingentEarnoutShares" xlink:to="clnn_CleneNanomedicineContingentEarnoutShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_AggregateGrossProceedWarrantsExercised_lbl2" xml:lang="en-US">AggregateGrossProceedWarrantsExercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AggregateGrossProceedWarrantsExercised" xlink:to="clnn_AggregateGrossProceedWarrantsExercised_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_InitialShareholdersContingentEarnoutFairValueDisclosure_lbl1" xml:lang="en-US">InitialShareholdersContingentEarnoutFairValueDisclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InitialShareholdersContingentEarnoutFairValueDisclosure" xlink:to="clnn_InitialShareholdersContingentEarnoutFairValueDisclosure_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ContingentEarnoutPolicyTextBlock_lbl1" xml:lang="en-US">ContingentEarnoutPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ContingentEarnoutPolicyTextBlock" xlink:to="clnn_ContingentEarnoutPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_SeriesARedeemableConvertiblePreferredStockWarrantsinShares_lbl0" xml:lang="en-US">SeriesARedeemableConvertiblePreferredStockWarrantsinShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SeriesARedeemableConvertiblePreferredStockWarrantsinShares" xlink:to="clnn_SeriesARedeemableConvertiblePreferredStockWarrantsinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CashProceedsReceived_lbl1" xml:lang="en-US">CashProceedsReceived</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CashProceedsReceived" xlink:to="clnn_CashProceedsReceived_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ServicesLetterAgreementDescription_lbl0" xml:lang="en-US">ServicesLetterAgreementDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ServicesLetterAgreementDescription" xlink:to="clnn_ServicesLetterAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_GainlossOnCleneNanomedicineContingentEarnout_lbl1" xml:lang="en-US">GainlossOnCleneNanomedicineContingentEarnout</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_GainlossOnCleneNanomedicineContingentEarnout" xlink:to="clnn_GainlossOnCleneNanomedicineContingentEarnout_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted_lbl0" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted" xlink:to="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_InitialShareholdersContingentEarnoutMilestone1Shares_lbl1" xml:lang="en-US">InitialShareholdersContingentEarnoutMilestone1Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InitialShareholdersContingentEarnoutMilestone1Shares" xlink:to="clnn_InitialShareholdersContingentEarnoutMilestone1Shares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_FairValueMeasurementExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN_lbl1" xml:lang="en-US">FairValueMeasurementExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FairValueMeasurementExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN" xlink:to="clnn_FairValueMeasurementExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm_lbl1" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm" xlink:to="clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_IncreaseInRightOfUseAssets_lbl1" xml:lang="en-US">IncreaseInRightOfUseAssets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IncreaseInRightOfUseAssets" xlink:to="clnn_IncreaseInRightOfUseAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_RateOfInterestDescription_lbl1" xml:lang="en-US">RateOfInterestDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RateOfInterestDescription" xlink:to="clnn_RateOfInterestDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CommonStockPricePerShare_lbl1" xml:lang="en-US">CommonStockPricePerShare</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockPricePerShare" xlink:to="clnn_CommonStockPricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_WarrantLiabilityFairValue_lbl1" xml:lang="en-US">WarrantLiabilityFairValue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantLiabilityFairValue" xlink:to="clnn_WarrantLiabilityFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_MetalsToBeUsedInResearchAndDevelopment_lbl1" xml:lang="en-US">MetalsToBeUsedInResearchAndDevelopment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_MetalsToBeUsedInResearchAndDevelopment" xlink:to="clnn_MetalsToBeUsedInResearchAndDevelopment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_InitialShareholdersContingentEarnoutMember_lbl1" xml:lang="en-US">InitialShareholdersContingentEarnoutMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InitialShareholdersContingentEarnoutMember" xlink:to="clnn_InitialShareholdersContingentEarnoutMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_SharesCancelledUponReverseRecapitalization_lbl1" xml:lang="en-US">SharesCancelledUponReverseRecapitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharesCancelledUponReverseRecapitalization" xlink:to="clnn_SharesCancelledUponReverseRecapitalization_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl1" xml:lang="en-US">PrepaidExpensesAndOtherCurrentAssetsTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="clnn_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_IncreaseInCleneNanomedicineContingentEarnoutSharesUponReverseRecapitalization_lbl1" xml:lang="en-US">IncreaseInCleneNanomedicineContingentEarnoutSharesUponReverseRecapitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IncreaseInCleneNanomedicineContingentEarnoutSharesUponReverseRecapitalization" xlink:to="clnn_IncreaseInCleneNanomedicineContingentEarnoutSharesUponReverseRecapitalization_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_DebtInstrumentUnamortizedDiscountYearFive_lbl1" xml:lang="en-US">DebtInstrumentUnamortizedDiscountYearFive</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DebtInstrumentUnamortizedDiscountYearFive" xlink:to="clnn_DebtInstrumentUnamortizedDiscountYearFive_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_OperatingLeasesAmountRepresentingInterestdiscounting_lbl1" xml:lang="en-US">OperatingLeasesAmountRepresentingInterestdiscounting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_OperatingLeasesAmountRepresentingInterestdiscounting" xlink:to="clnn_OperatingLeasesAmountRepresentingInterestdiscounting_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_SimpleInterestExpense_lbl1" xml:lang="en-US">SimpleInterestExpense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SimpleInterestExpense" xlink:to="clnn_SimpleInterestExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_AccumulatedDepreciationDepletionAndAmortizationLeases_lbl1" xml:lang="en-US">AccumulatedDepreciationDepletionAndAmortizationLeases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AccumulatedDepreciationDepletionAndAmortizationLeases" xlink:to="clnn_AccumulatedDepreciationDepletionAndAmortizationLeases_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ShareIssuanceOfCommonStockPrivateOffering_lbl1" xml:lang="en-US">ShareIssuanceOfCommonStockPrivateOffering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ShareIssuanceOfCommonStockPrivateOffering" xlink:to="clnn_ShareIssuanceOfCommonStockPrivateOffering_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_WarrantsDateMember_lbl0" xml:lang="en-US">WarrantsDateMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantsDateMember" xlink:to="clnn_WarrantsDateMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_AccruedDebtIssuanceCosts_lbl1" xml:lang="en-US">AccruedDebtIssuanceCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AccruedDebtIssuanceCosts" xlink:to="clnn_AccruedDebtIssuanceCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN_lbl1" xml:lang="en-US">ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN" xlink:to="clnn_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_SharesHeldInEscrow_lbl1" xml:lang="en-US">SharesHeldInEscrow</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SharesHeldInEscrow" xlink:to="clnn_SharesHeldInEscrow_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_StockPlan2014Member_lbl0" xml:lang="en-US">StockPlan2014Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockPlan2014Member" xlink:to="clnn_StockPlan2014Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_WarrantLiabilityRecordedAtIssuanceOfNotesPayable_lbl1" xml:lang="en-US">WarrantLiabilityRecordedAtIssuanceOfNotesPayable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantLiabilityRecordedAtIssuanceOfNotesPayable" xlink:to="clnn_WarrantLiabilityRecordedAtIssuanceOfNotesPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_NotesPayableBasedOnClosingPrice_lbl1" xml:lang="en-US">NotesPayableBasedOnClosingPrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NotesPayableBasedOnClosingPrice" xlink:to="clnn_NotesPayableBasedOnClosingPrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_EffectOfPotentiallyDilutiveStockOptionsinDollars_lbl1" xml:lang="en-US">EffectOfPotentiallyDilutiveStockOptionsinDollars</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_EffectOfPotentiallyDilutiveStockOptionsinDollars" xlink:to="clnn_EffectOfPotentiallyDilutiveStockOptionsinDollars_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_AdditionalPaymentUponMaturityDescription_lbl1" xml:lang="en-US">AdditionalPaymentUponMaturityDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AdditionalPaymentUponMaturityDescription" xlink:to="clnn_AdditionalPaymentUponMaturityDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ConversionPercentageOfCommonStockPriceForConvertibleNotePayable_lbl2" xml:lang="en-US">ConversionPercentageOfCommonStockPriceForConvertibleNotePayable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ConversionPercentageOfCommonStockPriceForConvertibleNotePayable" xlink:to="clnn_ConversionPercentageOfCommonStockPriceForConvertibleNotePayable_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_FundedAmountAtClosing_lbl1" xml:lang="en-US">FundedAmountAtClosing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FundedAmountAtClosing" xlink:to="clnn_FundedAmountAtClosing_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ChangeInFairValueOfCleneNanomedicineContingentEarnouts_lbl1" xml:lang="en-US">ChangeInFairValueOfCleneNanomedicineContingentEarnouts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChangeInFairValueOfCleneNanomedicineContingentEarnouts" xlink:to="clnn_ChangeInFairValueOfCleneNanomedicineContingentEarnouts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_GrantFundingRecognizedOnConditionalGrants_lbl1" xml:lang="en-US">GrantFundingRecognizedOnConditionalGrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_GrantFundingRecognizedOnConditionalGrants" xlink:to="clnn_GrantFundingRecognizedOnConditionalGrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ExchangeOfSharesReceived_lbl1" xml:lang="en-US">ExchangeOfSharesReceived</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ExchangeOfSharesReceived" xlink:to="clnn_ExchangeOfSharesReceived_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_DebtDiscountAndIssuanceCostsPolicyTextBlock_lbl1" xml:lang="en-US">DebtDiscountAndIssuanceCostsPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DebtDiscountAndIssuanceCostsPolicyTextBlock" xlink:to="clnn_DebtDiscountAndIssuanceCostsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_StockIssueDuringPeriodSharesExerciseOfWarrants_lbl1" xml:lang="en-US">StockIssueDuringPeriodSharesExerciseOfWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockIssueDuringPeriodSharesExerciseOfWarrants" xlink:to="clnn_StockIssueDuringPeriodSharesExerciseOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_LossOnExtinguishmentOfConvertibleNotesPayable_lbl1" xml:lang="en-US">LossOnExtinguishmentOfConvertibleNotesPayable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_LossOnExtinguishmentOfConvertibleNotesPayable" xlink:to="clnn_LossOnExtinguishmentOfConvertibleNotesPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_FinanceLeaseLaboratoryEquipmentGross_lbl1" xml:lang="en-US">FinanceLeaseLaboratoryEquipmentGross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FinanceLeaseLaboratoryEquipmentGross" xlink:to="clnn_FinanceLeaseLaboratoryEquipmentGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_LeaseIncentiveRecordedConstructionInProgress_lbl1" xml:lang="en-US">LeaseIncentiveRecordedConstructionInProgress</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_LeaseIncentiveRecordedConstructionInProgress" xlink:to="clnn_LeaseIncentiveRecordedConstructionInProgress_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_InterestRate_lbl1" xml:lang="en-US">InterestRate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InterestRate" xlink:to="clnn_InterestRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_TradingVolumeLimitForConversionOfConvertibleNotePayable_lbl1" xml:lang="en-US">TradingVolumeLimitForConversionOfConvertibleNotePayable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TradingVolumeLimitForConversionOfConvertibleNotePayable" xlink:to="clnn_TradingVolumeLimitForConversionOfConvertibleNotePayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CapitalLeasesFutureLeaseIncentives_lbl1" xml:lang="en-US">CapitalLeasesFutureLeaseIncentives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CapitalLeasesFutureLeaseIncentives" xlink:to="clnn_CapitalLeasesFutureLeaseIncentives_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_AvenueLoanMember_lbl0" xml:lang="en-US">AvenueLoanMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AvenueLoanMember" xlink:to="clnn_AvenueLoanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_TotalTermLoans_lbl1" xml:lang="en-US">TotalTermLoans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TotalTermLoans" xlink:to="clnn_TotalTermLoans_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout_lbl1" xml:lang="en-US">ChangeInFairValueOfInitialShareholdersContingentEarnout</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout" xlink:to="clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_WarrantsToPurchaseCommonStockIssuedAndOutstanding_lbl1" xml:lang="en-US">WarrantsToPurchaseCommonStockIssuedAndOutstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantsToPurchaseCommonStockIssuedAndOutstanding" xlink:to="clnn_WarrantsToPurchaseCommonStockIssuedAndOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_FairValueOfWarrant_lbl1" xml:lang="en-US">FairValueOfWarrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FairValueOfWarrant" xlink:to="clnn_FairValueOfWarrant_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CommonStockUnderlyingWarrantOutstanding_lbl1" xml:lang="en-US">CommonStockUnderlyingWarrantOutstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockUnderlyingWarrantOutstanding" xlink:to="clnn_CommonStockUnderlyingWarrantOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueIntrinsicValueOptionsVestedAndExercisableEnding_lbl0" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueIntrinsicValueOptionsVestedAndExercisableEnding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueIntrinsicValueOptionsVestedAndExercisableEnding" xlink:to="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueIntrinsicValueOptionsVestedAndExercisableEnding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_OperatingCashFlowsFromFinanceLeases_lbl0" xml:lang="en-US">OperatingCashFlowsFromFinanceLeases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_OperatingCashFlowsFromFinanceLeases" xlink:to="clnn_OperatingCashFlowsFromFinanceLeases_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_AggregateProceedsReceived_lbl1" xml:lang="en-US">AggregateProceedsReceived</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AggregateProceedsReceived" xlink:to="clnn_AggregateProceedsReceived_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_LossInFairValueOfWarrantLiability_lbl1" xml:lang="en-US">LossInFairValueOfWarrantLiability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_LossInFairValueOfWarrantLiability" xlink:to="clnn_LossInFairValueOfWarrantLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_SaleOfUnitsNumberOfUnitsIssued_lbl1" xml:lang="en-US">SaleOfUnitsNumberOfUnitsIssued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SaleOfUnitsNumberOfUnitsIssued" xlink:to="clnn_SaleOfUnitsNumberOfUnitsIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_FairValueOfConvertibleNotesPayable_lbl1" xml:lang="en-US">FairValueOfConvertibleNotesPayable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FairValueOfConvertibleNotesPayable" xlink:to="clnn_FairValueOfConvertibleNotesPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_AustraliaResearchAndDevelopmentCreditReceivable_lbl1" xml:lang="en-US">AustraliaResearchAndDevelopmentCreditReceivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AustraliaResearchAndDevelopmentCreditReceivable" xlink:to="clnn_AustraliaResearchAndDevelopmentCreditReceivable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_OfferingPricePerShare_lbl1" xml:lang="en-US">OfferingPricePerShare</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_OfferingPricePerShare" xlink:to="clnn_OfferingPricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CommonStockWarrants_lbl0" xml:lang="en-US">CommonStockWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockWarrants" xlink:to="clnn_CommonStockWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_IncreaseInInterestAccruedOnNotesPayable_lbl1" xml:lang="en-US">IncreaseInInterestAccruedOnNotesPayable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IncreaseInInterestAccruedOnNotesPayable" xlink:to="clnn_IncreaseInInterestAccruedOnNotesPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_WeightedAverageExercisePricePerShareOptionVestedAndExercisable_lbl1" xml:lang="en-US">WeightedAverageExercisePricePerShareOptionVestedAndExercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WeightedAverageExercisePricePerShareOptionVestedAndExercisable" xlink:to="clnn_WeightedAverageExercisePricePerShareOptionVestedAndExercisable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_MonteCarloSimulationMember_lbl0" xml:lang="en-US">MonteCarloSimulationMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_MonteCarloSimulationMember" xlink:to="clnn_MonteCarloSimulationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_OperatingLeaseRightofUseAssets_lbl1" xml:lang="en-US">OperatingLeaseRightofUseAssets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_OperatingLeaseRightofUseAssets" xlink:to="clnn_OperatingLeaseRightofUseAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_PaycheckProtectionProgramNoteMember_lbl0" xml:lang="en-US">PaycheckProtectionProgramNoteMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PaycheckProtectionProgramNoteMember" xlink:to="clnn_PaycheckProtectionProgramNoteMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_FinanceLeaseLiabilityGross_lbl1" xml:lang="en-US">FinanceLeaseLiabilityGross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FinanceLeaseLiabilityGross" xlink:to="clnn_FinanceLeaseLiabilityGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_WeightedAverageRemainingTermYearsForfeited_lbl0" xml:lang="en-US">WeightedAverageRemainingTermYearsForfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WeightedAverageRemainingTermYearsForfeited" xlink:to="clnn_WeightedAverageRemainingTermYearsForfeited_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ReverseRecapitalizationExchangeRatio_lbl1" xml:lang="en-US">ReverseRecapitalizationExchangeRatio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ReverseRecapitalizationExchangeRatio" xlink:to="clnn_ReverseRecapitalizationExchangeRatio_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_OperatingLeaseObligationsWeightedAverageInterestRate_lbl1" xml:lang="en-US">OperatingLeaseObligationsWeightedAverageInterestRate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_OperatingLeaseObligationsWeightedAverageInterestRate" xlink:to="clnn_OperatingLeaseObligationsWeightedAverageInterestRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_GrantFundingPolicyTextBlock_lbl1" xml:lang="en-US">GrantFundingPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_GrantFundingPolicyTextBlock" xlink:to="clnn_GrantFundingPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CommonStockWarrantsExpiration_lbl1" xml:lang="en-US">CommonStockWarrantsExpiration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockWarrantsExpiration" xlink:to="clnn_CommonStockWarrantsExpiration_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ReverseRecapitalizationMember_lbl0" xml:lang="en-US">ReverseRecapitalizationMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ReverseRecapitalizationMember" xlink:to="clnn_ReverseRecapitalizationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock_lbl1" xml:lang="en-US">FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="clnn_FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_DebtInstrumentUnamortizedDiscountYearTwo_lbl1" xml:lang="en-US">DebtInstrumentUnamortizedDiscountYearTwo</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DebtInstrumentUnamortizedDiscountYearTwo" xlink:to="clnn_DebtInstrumentUnamortizedDiscountYearTwo_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_PercentageOfLoanAmountUsedToPayrollExpenses_lbl1" xml:lang="en-US">PercentageOfLoanAmountUsedToPayrollExpenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PercentageOfLoanAmountUsedToPayrollExpenses" xlink:to="clnn_PercentageOfLoanAmountUsedToPayrollExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_RedeemableConvertiblePreferredStockDisclosureTextBlock_lbl1" xml:lang="en-US">RedeemableConvertiblePreferredStockDisclosureTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RedeemableConvertiblePreferredStockDisclosureTextBlock" xlink:to="clnn_RedeemableConvertiblePreferredStockDisclosureTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CommonStockWarrantsExercisePrice_lbl1" xml:lang="en-US">CommonStockWarrantsExercisePrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockWarrantsExercisePrice" xlink:to="clnn_CommonStockWarrantsExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_SeriesDRedeemableConvertiblePreferredStockWarrants_lbl1" xml:lang="en-US">SeriesDRedeemableConvertiblePreferredStockWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SeriesDRedeemableConvertiblePreferredStockWarrants" xlink:to="clnn_SeriesDRedeemableConvertiblePreferredStockWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ChardanUnitPurchaseOptionWarrants_lbl0" xml:lang="en-US">ChardanUnitPurchaseOptionWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChardanUnitPurchaseOptionWarrants" xlink:to="clnn_ChardanUnitPurchaseOptionWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ChangeInFairValueOfCommonStockWarrantLiabilitys_lbl1" xml:lang="en-US">ChangeInFairValueOfCommonStockWarrantLiabilitys</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChangeInFairValueOfCommonStockWarrantLiabilitys" xlink:to="clnn_ChangeInFairValueOfCommonStockWarrantLiabilitys_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_WarrantLiabilityNoncurrent_lbl1" xml:lang="en-US">WarrantLiabilityNoncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantLiabilityNoncurrent" xlink:to="clnn_WarrantLiabilityNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ExercisePriceOfWarrantsDescription_lbl1" xml:lang="en-US">ExercisePriceOfWarrantsDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ExercisePriceOfWarrantsDescription" xlink:to="clnn_ExercisePriceOfWarrantsDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_FuturePrincipalPayments_lbl1" xml:lang="en-US">FuturePrincipalPayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FuturePrincipalPayments" xlink:to="clnn_FuturePrincipalPayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ChangeInFairValueOfDerivativeLiability_lbl1" xml:lang="en-US">ChangeInFairValueOfDerivativeLiability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChangeInFairValueOfDerivativeLiability" xlink:to="clnn_ChangeInFairValueOfDerivativeLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_FairValueAdjustmentOfWarrantsOutstanding_lbl1" xml:lang="en-US">FairValueAdjustmentOfWarrantsOutstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FairValueAdjustmentOfWarrantsOutstanding" xlink:to="clnn_FairValueAdjustmentOfWarrantsOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_TwoThousandtwentyoneAvenueLoanMember_lbl0" xml:lang="en-US">TwoThousandtwentyoneAvenueLoanMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TwoThousandtwentyoneAvenueLoanMember" xlink:to="clnn_TwoThousandtwentyoneAvenueLoanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_OtherTermLoanMember_lbl0" xml:lang="en-US">OtherTermLoanMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_OtherTermLoanMember" xlink:to="clnn_OtherTermLoanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_RecognizedGainOnOperatingLease_lbl1" xml:lang="en-US">RecognizedGainOnOperatingLease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RecognizedGainOnOperatingLease" xlink:to="clnn_RecognizedGainOnOperatingLease_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_DebtInstrumentUnamortizedDiscountYearOne_lbl1" xml:lang="en-US">DebtInstrumentUnamortizedDiscountYearOne</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DebtInstrumentUnamortizedDiscountYearOne" xlink:to="clnn_DebtInstrumentUnamortizedDiscountYearOne_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CleneNanomedicineContingentEarnoutMilestone2Price_lbl1" xml:lang="en-US">CleneNanomedicineContingentEarnoutMilestone2Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CleneNanomedicineContingentEarnoutMilestone2Price" xlink:to="clnn_CleneNanomedicineContingentEarnoutMilestone2Price_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_LeaseholdImprovements_lbl1" xml:lang="en-US">LeaseholdImprovements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_LeaseholdImprovements" xlink:to="clnn_LeaseholdImprovements_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_OperatingLeasesMember_lbl0" xml:lang="en-US">OperatingLeasesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_OperatingLeasesMember" xlink:to="clnn_OperatingLeasesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_SeriesBRedeemableConvertiblePreferredStock_lbl0" xml:lang="en-US">SeriesBRedeemableConvertiblePreferredStock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SeriesBRedeemableConvertiblePreferredStock" xlink:to="clnn_SeriesBRedeemableConvertiblePreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_SupplementsMember_lbl0" xml:lang="en-US">SupplementsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SupplementsMember" xlink:to="clnn_SupplementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ExercisePrice_lbl0" xml:lang="en-US">ExercisePrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ExercisePrice" xlink:to="clnn_ExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_RemainingRightofuseAsset_lbl0" xml:lang="en-US">RemainingRightofuseAsset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RemainingRightofuseAsset" xlink:to="clnn_RemainingRightofuseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_AvenueVentureOpportunitiesFundsLPMember_lbl0" xml:lang="en-US">AvenueVentureOpportunitiesFundsLPMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AvenueVentureOpportunitiesFundsLPMember" xlink:to="clnn_AvenueVentureOpportunitiesFundsLPMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_NumeratorAbstract_lbl0" xml:lang="en-US">NumeratorAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NumeratorAbstract" xlink:to="clnn_NumeratorAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue_lbl0" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue" xlink:to="clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_NetProceeds_lbl1" xml:lang="en-US">NetProceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NetProceeds" xlink:to="clnn_NetProceeds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ProceedsFromReverseRecapitalization_lbl1" xml:lang="en-US">ProceedsFromReverseRecapitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ProceedsFromReverseRecapitalization" xlink:to="clnn_ProceedsFromReverseRecapitalization_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_OperatingCashFlowsFromOperatingLeases_lbl0" xml:lang="en-US">OperatingCashFlowsFromOperatingLeases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_OperatingCashFlowsFromOperatingLeases" xlink:to="clnn_OperatingCashFlowsFromOperatingLeases_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_WarrantsToPurchaseSharesOfCommonStock_lbl1" xml:lang="en-US">WarrantsToPurchaseSharesOfCommonStock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WarrantsToPurchaseSharesOfCommonStock" xlink:to="clnn_WarrantsToPurchaseSharesOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_PrivatePlacementWarrantsDescription_lbl1" xml:lang="en-US">PrivatePlacementWarrantsDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PrivatePlacementWarrantsDescription" xlink:to="clnn_PrivatePlacementWarrantsDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CashPaidForInterestExpense_lbl1" xml:lang="en-US">CashPaidForInterestExpense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CashPaidForInterestExpense" xlink:to="clnn_CashPaidForInterestExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ChardanCapitalMarketsLLCMember_lbl1" xml:lang="en-US">ChardanCapitalMarketsLLCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ChardanCapitalMarketsLLCMember" xlink:to="clnn_ChardanCapitalMarketsLLCMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_SeriesCRedeemableConvertiblePreferredStock_lbl0" xml:lang="en-US">SeriesCRedeemableConvertiblePreferredStock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SeriesCRedeemableConvertiblePreferredStock" xlink:to="clnn_SeriesCRedeemableConvertiblePreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ConvertibleNotespolicytextblock_lbl1" xml:lang="en-US">ConvertibleNotespolicytextblock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ConvertibleNotespolicytextblock" xlink:to="clnn_ConvertibleNotespolicytextblock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_NumberOfSharesIssuable_lbl1" xml:lang="en-US">NumberOfSharesIssuable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NumberOfSharesIssuable" xlink:to="clnn_NumberOfSharesIssuable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CommonStockParOrStatedValuesPerShare_lbl1" xml:lang="en-US">CommonStockParOrStatedValuesPerShare</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockParOrStatedValuesPerShare" xlink:to="clnn_CommonStockParOrStatedValuesPerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_StockIssuedDuringPeriodExerciseOfUnderwritersOptioninShares_lbl1" xml:lang="en-US">StockIssuedDuringPeriodExerciseOfUnderwritersOptioninShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockIssuedDuringPeriodExerciseOfUnderwritersOptioninShares" xlink:to="clnn_StockIssuedDuringPeriodExerciseOfUnderwritersOptioninShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_AdvanceCecilIncMember_lbl0" xml:lang="en-US">AdvanceCecilIncMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AdvanceCecilIncMember" xlink:to="clnn_AdvanceCecilIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_EffectOfPotentiallyDilutiveRestrictedStockAwards_lbl1" xml:lang="en-US">EffectOfPotentiallyDilutiveRestrictedStockAwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_EffectOfPotentiallyDilutiveRestrictedStockAwards" xlink:to="clnn_EffectOfPotentiallyDilutiveRestrictedStockAwards_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_InvestorsMember_lbl1" xml:lang="en-US">InvestorsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_InvestorsMember" xlink:to="clnn_InvestorsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_FinanceCashFlowsFromFinanceLeases_lbl0" xml:lang="en-US">FinanceCashFlowsFromFinanceLeases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FinanceCashFlowsFromFinanceLeases" xlink:to="clnn_FinanceCashFlowsFromFinanceLeases_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_DebtInstrumentUnamortizedDiscountYearThree_lbl1" xml:lang="en-US">DebtInstrumentUnamortizedDiscountYearThree</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DebtInstrumentUnamortizedDiscountYearThree" xlink:to="clnn_DebtInstrumentUnamortizedDiscountYearThree_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_DeferredOfferingCostsInAccruedLiabilities_lbl1" xml:lang="en-US">DeferredOfferingCostsInAccruedLiabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DeferredOfferingCostsInAccruedLiabilities" xlink:to="clnn_DeferredOfferingCostsInAccruedLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_GainlossOnInitialShareholdersContingentEarnout_lbl1" xml:lang="en-US">GainlossOnInitialShareholdersContingentEarnout</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_GainlossOnInitialShareholdersContingentEarnout" xlink:to="clnn_GainlossOnInitialShareholdersContingentEarnout_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_FairValueOfLongTermNotesPayable_lbl1" xml:lang="en-US">FairValueOfLongTermNotesPayable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FairValueOfLongTermNotesPayable" xlink:to="clnn_FairValueOfLongTermNotesPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_WeightedAverageRemainingTermYearsExercised_lbl0" xml:lang="en-US">WeightedAverageRemainingTermYearsExercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_WeightedAverageRemainingTermYearsExercised" xlink:to="clnn_WeightedAverageRemainingTermYearsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_UnitsIssuedPricePerUnit_lbl1" xml:lang="en-US">UnitsIssuedPricePerUnit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_UnitsIssuedPricePerUnit" xlink:to="clnn_UnitsIssuedPricePerUnit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_LoanOutstanding_lbl1" xml:lang="en-US">LoanOutstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_LoanOutstanding" xlink:to="clnn_LoanOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_IncreaseInLeaseLiability_lbl1" xml:lang="en-US">IncreaseInLeaseLiability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_IncreaseInLeaseLiability" xlink:to="clnn_IncreaseInLeaseLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ShareBasedCompensationArrangementNumberOfOptionsExercised_lbl1" xml:lang="en-US">ShareBasedCompensationArrangementNumberOfOptionsExercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ShareBasedCompensationArrangementNumberOfOptionsExercised" xlink:to="clnn_ShareBasedCompensationArrangementNumberOfOptionsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_NetOfIssuanceCosts_lbl1" xml:lang="en-US">NetOfIssuanceCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_NetOfIssuanceCosts" xlink:to="clnn_NetOfIssuanceCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ClinicalTrialAccrualPolicyTextBlock_lbl1" xml:lang="en-US">ClinicalTrialAccrualPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ClinicalTrialAccrualPolicyTextBlock" xlink:to="clnn_ClinicalTrialAccrualPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_DrugsMember_lbl0" xml:lang="en-US">DrugsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DrugsMember" xlink:to="clnn_DrugsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_StockIssuedDuringPeriodOfSeriesDPreferredStock_lbl1" xml:lang="en-US">StockIssuedDuringPeriodOfSeriesDPreferredStock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockIssuedDuringPeriodOfSeriesDPreferredStock" xlink:to="clnn_StockIssuedDuringPeriodOfSeriesDPreferredStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_weightedAverageFairValuesOfOptionsGranted_lbl1" xml:lang="en-US">weightedAverageFairValuesOfOptionsGranted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_weightedAverageFairValuesOfOptionsGranted" xlink:to="clnn_weightedAverageFairValuesOfOptionsGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_DerivativeInstrumentMember_lbl0" xml:lang="en-US">DerivativeInstrumentMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DerivativeInstrumentMember" xlink:to="clnn_DerivativeInstrumentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_DescriptionOfConvertibleNotes_lbl0" xml:lang="en-US">DescriptionOfConvertibleNotes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DescriptionOfConvertibleNotes" xlink:to="clnn_DescriptionOfConvertibleNotes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_DebtWithWarrantsPolicyTextBlock_lbl1" xml:lang="en-US">DebtWithWarrantsPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DebtWithWarrantsPolicyTextBlock" xlink:to="clnn_DebtWithWarrantsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_CommonStockWarrantsMember_lbl1" xml:lang="en-US">CommonStockWarrantsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_CommonStockWarrantsMember" xlink:to="clnn_CommonStockWarrantsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_TotalLossBeforeIncomeTaxes_lbl1" xml:lang="en-US">TotalLossBeforeIncomeTaxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TotalLossBeforeIncomeTaxes" xlink:to="clnn_TotalLossBeforeIncomeTaxes_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_StockPlan2020Member_lbl0" xml:lang="en-US">StockPlan2020Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_StockPlan2020Member" xlink:to="clnn_StockPlan2020Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_DebtInstrumentUnfundedBalance_lbl1" xml:lang="en-US">DebtInstrumentUnfundedBalance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_DebtInstrumentUnfundedBalance" xlink:to="clnn_DebtInstrumentUnfundedBalance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_UnrecognizedStockbasedCompensation_lbl0" xml:lang="en-US">UnrecognizedStockbasedCompensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_UnrecognizedStockbasedCompensation" xlink:to="clnn_UnrecognizedStockbasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_FinanceLeaseFurnitureAndFixturesGross_lbl1" xml:lang="en-US">FinanceLeaseFurnitureAndFixturesGross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_FinanceLeaseFurnitureAndFixturesGross" xlink:to="clnn_FinanceLeaseFurnitureAndFixturesGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_RestrictedStockUnitsDescription_lbl1" xml:lang="en-US">RestrictedStockUnitsDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_RestrictedStockUnitsDescription" xlink:to="clnn_RestrictedStockUnitsDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_PreferredStockWarrantsMember_lbl0" xml:lang="en-US">PreferredStockWarrantsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PreferredStockWarrantsMember" xlink:to="clnn_PreferredStockWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_PIPEMember_lbl0" xml:lang="en-US">PIPEMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PIPEMember" xlink:to="clnn_PIPEMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_PIPEWarrantsOwnershipLimit_lbl1" xml:lang="en-US">PIPEWarrantsOwnershipLimit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_PIPEWarrantsOwnershipLimit" xlink:to="clnn_PIPEWarrantsOwnershipLimit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_AdditionalWarrantToPurchaseShares_lbl1" xml:lang="en-US">AdditionalWarrantToPurchaseShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_AdditionalWarrantToPurchaseShares" xlink:to="clnn_AdditionalWarrantToPurchaseShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_TermLoansAbstract_lbl0" xml:lang="en-US">TermLoansAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_TermLoansAbstract" xlink:to="clnn_TermLoansAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_ExchangeRatioPercentage_lbl1" xml:lang="en-US">ExchangeRatioPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_ExchangeRatioPercentage" xlink:to="clnn_ExchangeRatioPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="clnn_SecondLoanAmount_lbl1" xml:lang="en-US">SecondLoanAmount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clnn_SecondLoanAmount" xlink:to="clnn_SecondLoanAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionPlanExpense_lbl0" xml:lang="en-US">Stock or Unit Option Plan Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionPlanExpense" xlink:to="us-gaap_StockOptionPlanExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl0" xml:lang="en-US">Inventory, Finished Goods, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl0" xml:lang="en-US">Other Operating Income (Expense), Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_lbl0" xml:lang="en-US">Contingent Consideration Classified as Equity, Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:to="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent_lbl0" xml:lang="en-US">Capital Lease Obligations, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsNoncurrent" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0" xml:lang="en-US">Schedule of Stockholders&apos; Equity Note, Warrants or Rights [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl0" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl1" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl0" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl0" xml:lang="en-US">Debt Instrument, Convertible, Beneficial Conversion Feature</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl0" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCash_lbl0" xml:lang="en-US">Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentGross_lbl0" xml:lang="en-US">Machinery and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentGross" xlink:to="us-gaap_MachineryAndEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedPremium_lbl0" xml:lang="en-US">Debt Instrument, Unamortized Premium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedPremium" xlink:to="us-gaap_DebtInstrumentUnamortizedPremium_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl0" xml:lang="en-US">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvancesToAffiliate_lbl0" xml:lang="en-US">Advances to Affiliate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvancesToAffiliate" xlink:to="us-gaap_AdvancesToAffiliate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_lbl0" xml:lang="en-US">Capital Leases, Future Minimum Payments Due in Three Years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockExpense_lbl0" xml:lang="en-US">Restricted Stock or Unit Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockExpense" xlink:to="us-gaap_RestrictedStockExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_lbl0" xml:lang="en-US">Other Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl0" xml:lang="en-US">Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl0" xml:lang="en-US">Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl0" xml:lang="en-US">Accounts Receivable [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl0" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl0" xml:lang="en-US">UNITED STATES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl0" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl0" xml:lang="en-US">Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl0" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl2" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Finance Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl0" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRoyaltiesReceived_lbl0" xml:lang="en-US">Proceeds from Royalties Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRoyaltiesReceived" xlink:to="us-gaap_ProceedsFromRoyaltiesReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl0" xml:lang="en-US">Schedule of Derivative Liabilities at Fair Value [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl0" xml:lang="en-US">Leasehold Improvements, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsGross" xlink:to="us-gaap_LeaseholdImprovementsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl0" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl0" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl0" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Tax [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAbstract_lbl0" xml:lang="en-US">Restricted Cash and Cash Equivalents [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl0" xml:lang="en-US">Series C Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl0" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl0" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl0" xml:lang="en-US">Finance Lease, Principal Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl0" xml:lang="en-US">Accrued Professional Fees, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashExpense_lbl0" xml:lang="en-US">Other Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl0" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl0" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl0" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl0" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl0" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl0" xml:lang="en-US">Debt Instrument, Unamortized Discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnContractTermination_lbl0" xml:lang="en-US">Gain (Loss) on Contract Termination</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnContractTermination" xlink:to="us-gaap_GainLossOnContractTermination_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl0" xml:lang="en-US">Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl0" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityAbstract_lbl0" xml:lang="en-US">Finance Lease Liability [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription_lbl0" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestOnConvertibleDebtNetOfTax_lbl0" xml:lang="en-US">Interest on Convertible Debt, Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:to="us-gaap_InterestOnConvertibleDebtNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl1" xml:lang="en-US">Convertible Notes Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl0" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl0" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl0" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl0" xml:lang="en-US">Inventory, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl0" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl0" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_lbl0" xml:lang="en-US">Capital Lease Obligations, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsCurrent" xlink:to="us-gaap_CapitalLeaseObligationsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_lbl0" xml:lang="en-US">Property, Plant and Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentMember" xlink:to="us-gaap_PropertyPlantAndEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate During Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_lbl0" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl0" xml:lang="en-US">Amortization of Debt Discount (Premium)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl0" xml:lang="en-US">Finance Lease, Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl0" xml:lang="en-US">Repayments of Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl0" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSoldDepreciation_lbl0" xml:lang="en-US">Cost, Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSoldDepreciation" xlink:to="us-gaap_CostOfGoodsAndServicesSoldDepreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_lbl0" xml:lang="en-US">Deferred Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl0" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityFairValueAdjustment_lbl0" xml:lang="en-US">Equity, Fair Value Adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityFairValueAdjustment" xlink:to="us-gaap_EquityFairValueAdjustment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl0" xml:lang="en-US">Payments of Financing Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense_lbl0" xml:lang="en-US">Unamortized Debt Issuance Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyMember_lbl0" xml:lang="en-US">Royalty [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyMember" xlink:to="us-gaap_RoyaltyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl0" xml:lang="en-US">Deferred Income Tax Liabilities, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebt_lbl0" xml:lang="en-US">Convertible Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl1" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantExercisePriceIncrease_lbl0" xml:lang="en-US">Warrant, Exercise Price, Increase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceIncrease" xlink:to="us-gaap_WarrantExercisePriceIncrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl0" xml:lang="en-US">Long-term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl0" xml:lang="en-US">Entity Tax Identification Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl0" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl0" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear_lbl0" xml:lang="en-US">Capital Leases, Future Minimum Payments, Remainder of Fiscal Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedInvestments_lbl0" xml:lang="en-US">Restricted Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedInvestments" xlink:to="us-gaap_RestrictedInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl0" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsSoldDirectFinancingLease_lbl0" xml:lang="en-US">Cost of Goods Sold, Direct Financing Lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsSoldDirectFinancingLease" xlink:to="us-gaap_CostOfGoodsSoldDirectFinancingLease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl0" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LessorOperatingLeaseDescription_lbl0" xml:lang="en-US">Lessor, Operating Lease, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeaseDescription" xlink:to="us-gaap_LessorOperatingLeaseDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl0" xml:lang="en-US">Preferred Stock, Convertible, Conversion Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_lbl0" xml:lang="en-US">Capital Leases, Future Minimum Payments Due in Two Years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockTextBlock_lbl0" xml:lang="en-US">Preferred Stock [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl0" xml:lang="en-US">Fair Value Adjustment of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl0" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockOtherSharesOutstanding_lbl1" xml:lang="en-US">Common Stock, Other Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockOtherSharesOutstanding" xlink:to="us-gaap_CommonStockOtherSharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl1" xml:lang="en-US">Conversion of Stock, Shares Converted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl0" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl1" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_lbl0" xml:lang="en-US">Capital Leases, Future Minimum Payments Due in Four Years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl0" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl1" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl0" xml:lang="en-US">Accounts Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecurities_lbl0" xml:lang="en-US">Debt Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecurities" xlink:to="us-gaap_DebtSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl0" xml:lang="en-US">Warrants and Rights Outstanding, Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnTerminationOfLease_lbl1" xml:lang="en-US">Gain (Loss) on Termination of Lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnTerminationOfLease" xlink:to="us-gaap_GainLossOnTerminationOfLease_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_lbl0" xml:lang="en-US">Capital Leases, Future Minimum Payments Due</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableFairValueDisclosure_lbl0" xml:lang="en-US">Notes Payable, Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableFairValueDisclosure" xlink:to="us-gaap_NotesPayableFairValueDisclosure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl0" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossTax_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl1" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl1" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl0" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountCurrent_lbl0" xml:lang="en-US">Debt Instrument, Unamortized Discount, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl0" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl0" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesGross_lbl0" xml:lang="en-US">Furniture and Fixtures, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesGross" xlink:to="us-gaap_FurnitureAndFixturesGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl0" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeaseCost_lbl0" xml:lang="en-US">Short-term Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl0" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxesPayableCurrent_lbl0" xml:lang="en-US">Taxes Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressGross_lbl0" xml:lang="en-US">Construction in Progress, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressGross" xlink:to="us-gaap_ConstructionInProgressGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromOtherDebt_lbl0" xml:lang="en-US">Proceeds from Other Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherDebt" xlink:to="us-gaap_ProceedsFromOtherDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl0" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl0" xml:lang="en-US">Inventory, Raw Materials, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter_lbl0" xml:lang="en-US">Capital Leases, Future Minimum Payments Due Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantExercisePriceDecrease_lbl0" xml:lang="en-US">Warrant, Exercise Price, Decrease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceDecrease" xlink:to="us-gaap_WarrantExercisePriceDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl0" xml:lang="en-US">Amortization of Debt Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Finance Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncentiveToLessee_lbl0" xml:lang="en-US">Incentive to Lessee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncentiveToLessee" xlink:to="us-gaap_IncentiveToLessee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl0" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleCommonStockMember_lbl0" xml:lang="en-US">Convertible Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleCommonStockMember" xlink:to="us-gaap_ConvertibleCommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermNotesPayable_lbl0" xml:lang="en-US">Notes Payable, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl0" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl0" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl0" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl0" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl0" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl1" xml:lang="en-US">Convertible Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl0" xml:lang="en-US">Restricted Cash, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl0" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableOtherPayablesMember_lbl0" xml:lang="en-US">Notes Payable, Other Payables [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableOtherPayablesMember" xlink:to="us-gaap_NotesPayableOtherPayablesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl0" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl0" xml:lang="en-US">Product [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl0" xml:lang="en-US">Derivative Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl0" xml:lang="en-US">Payment for Debt Extinguishment or Debt Prepayment Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl0" xml:lang="en-US">Series D Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesDPreferredStockMember" xlink:to="us-gaap_SeriesDPreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl0" xml:lang="en-US">Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl0" xml:lang="en-US">Deferred Revenue, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl0" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl0" xml:lang="en-US">Cost of Goods and Services Sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfIntangibleAssets_lbl0" xml:lang="en-US">Gain (Loss) on Disposition of Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:to="us-gaap_GainLossOnDispositionOfIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_lbl0" xml:lang="en-US">Expense Related to Distribution or Servicing and Underwriting Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:to="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl0" xml:lang="en-US">Proceeds from Warrant Exercises</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_AU_lbl0" xml:lang="en-US">AUSTRALIA</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_AU" xlink:to="country_AU_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate, Basis for Effective Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:to="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl0" xml:lang="en-US">Revenues [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl0" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventDescription_lbl0" xml:lang="en-US">Subsequent Event, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventDescription" xlink:to="us-gaap_SubsequentEventDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl0" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl0" xml:lang="en-US">Series of Individually Immaterial Business Acquisitions [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl0" xml:lang="en-US">Proceeds from Convertible Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl0" xml:lang="en-US">Leases of Lessee Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExchangeClearedMember_lbl0" xml:lang="en-US">Exchange Cleared [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExchangeClearedMember" xlink:to="us-gaap_ExchangeClearedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl0" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl0" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl0" xml:lang="en-US">Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExtinguishmentOfDebtAmount_lbl0" xml:lang="en-US">Extinguishment of Debt, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtAmount" xlink:to="us-gaap_ExtinguishmentOfDebtAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl0" xml:lang="en-US">Proceeds from Issuance of Private Placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsSoldSalesTypeLease_lbl0" xml:lang="en-US">Cost of Goods Sold, Sales-type Lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsSoldSalesTypeLease" xlink:to="us-gaap_CostOfGoodsSoldSalesTypeLease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFairValueOfDerivativeNet_lbl0" xml:lang="en-US">Derivative, Fair Value, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeNet" xlink:to="us-gaap_DerivativeFairValueOfDerivativeNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilities_lbl0" xml:lang="en-US">Derivative Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_lbl0" xml:lang="en-US">Operating Leases, Future Minimum Payments, Remainder of Fiscal Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesAndLoansPayable_lbl0" xml:lang="en-US">Notes and Loans Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansPayable" xlink:to="us-gaap_NotesAndLoansPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_lbl0" xml:lang="en-US">Long-lived Assets by Geographic Areas [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:to="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeOther_lbl0" xml:lang="en-US">Interest Income, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl0" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl0" xml:lang="en-US">Increase (Decrease) in Due to Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl0" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableLeaseCost_lbl0" xml:lang="en-US">Variable Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl0" xml:lang="en-US">Interest Expense, Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl0" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherUnderwritingExpense_lbl0" xml:lang="en-US">Other Underwriting Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherUnderwritingExpense" xlink:to="us-gaap_OtherUnderwritingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl0" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl0" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl0" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl1" xml:lang="en-US">Deferred Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl2" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Current Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl0" xml:lang="en-US">Debt Instrument, Maturity Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl0" xml:lang="en-US">Convertible Notes Payable, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl0" xml:lang="en-US">Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl1" xml:lang="en-US">Payments of Debt Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl0" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl0" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl1" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl0" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl0" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl0" xml:lang="en-US">Prepaid Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl1" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl0" xml:lang="en-US">Document Quarterly Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl0" xml:lang="en-US">Other Nonoperating Income (Expense) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl0" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl0" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl0" xml:lang="en-US">Other Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl0" xml:lang="en-US">Derivative Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_lbl0" xml:lang="en-US">Capital Leases, Future Minimum Payments Due, Next Twelve Months</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Outstanding Award, Activity, Excluding Option [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl0" xml:lang="en-US">Accrued Employee Benefits, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl0" xml:lang="en-US">Operating Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDescription_lbl0" xml:lang="en-US">Debt Instrument, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescription" xlink:to="us-gaap_DebtInstrumentDescription_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>clnn-20210930_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Nov 08 18:21:45 UTC 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ConsolidatedBalanceSheet" roleURI="http://www.cleaninccom/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.cleaninccom/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ConsolidatedIncomeStatement" roleURI="http://www.cleaninccom/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ShareholdersEquityType2or3" roleURI="http://www.cleaninccom/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ShareholdersEquityType2or3_Parentheticals" roleURI="http://www.cleaninccom/role/ShareholdersEquityType2or3_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ConsolidatedCashFlow" roleURI="http://www.cleaninccom/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_NatureoftheBusiness" roleURI="http://www.cleaninccom/role/NatureoftheBusiness"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_SummaryofSignificantAccountingPolicies" roleURI="http://www.cleaninccom/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ReverseRecapitalizationwithTottenhamandCleneNanomedicine" roleURI="http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicine"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_PrepaidExpensesandOtherCurrentAssets" roleURI="http://www.cleaninccom/role/PrepaidExpensesandOtherCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_PropertyandEquipmentNet" roleURI="http://www.cleaninccom/role/PropertyandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_AccruedLiabilities" roleURI="http://www.cleaninccom/role/AccruedLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_Leases" roleURI="http://www.cleaninccom/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_NotesPayable" roleURI="http://www.cleaninccom/role/NotesPayable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_PreferredStockWarrantLiability" roleURI="http://www.cleaninccom/role/PreferredStockWarrantLiability"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_CommonStockWarrants" roleURI="http://www.cleaninccom/role/CommonStockWarrants"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ConvertibleNotes" roleURI="http://www.cleaninccom/role/ConvertibleNotes"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_DerivativeInstruments" roleURI="http://www.cleaninccom/role/DerivativeInstruments"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_CommitmentsandContingencies" roleURI="http://www.cleaninccom/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_IncomeTaxes" roleURI="http://www.cleaninccom/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_StockBasedCompensation" roleURI="http://www.cleaninccom/role/StockBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_FairValue" roleURI="http://www.cleaninccom/role/FairValue"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_RedeemableConvertiblePreferredStock" roleURI="http://www.cleaninccom/role/RedeemableConvertiblePreferredStock"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_CommonStock" roleURI="http://www.cleaninccom/role/CommonStock"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_NetIncomeLossPerShareAttributabletoCommonShareholders" roleURI="http://www.cleaninccom/role/NetIncomeLossPerShareAttributabletoCommonShareholders"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_RelatedPartyTransactions" roleURI="http://www.cleaninccom/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_GeographicandSegmentInformation" roleURI="http://www.cleaninccom/role/GeographicandSegmentInformation"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_SubsequentEvents" roleURI="http://www.cleaninccom/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_AccountingPoliciesByPolicy" roleURI="http://www.cleaninccom/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_PrepaidExpensesandOtherCurrentAssetsTables" roleURI="http://www.cleaninccom/role/PrepaidExpensesandOtherCurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_PropertyandEquipmentNetTables" roleURI="http://www.cleaninccom/role/PropertyandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_AccruedLiabilitiesTables" roleURI="http://www.cleaninccom/role/AccruedLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_LeasesTables" roleURI="http://www.cleaninccom/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_NotesPayableTables" roleURI="http://www.cleaninccom/role/NotesPayableTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_CommonStockWarrantsTables" roleURI="http://www.cleaninccom/role/CommonStockWarrantsTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_IncomeTaxesTables" roleURI="http://www.cleaninccom/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_StockBasedCompensationTables" roleURI="http://www.cleaninccom/role/StockBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_FairValueTables" roleURI="http://www.cleaninccom/role/FairValueTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_NetIncomeLossPerShareAttributabletoCommonShareholdersTables" roleURI="http://www.cleaninccom/role/NetIncomeLossPerShareAttributabletoCommonShareholdersTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_GeographicandSegmentInformationTables" roleURI="http://www.cleaninccom/role/GeographicandSegmentInformationTables"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleofprepaidexpensesandothercurrentassetsTable" roleURI="http://www.cleaninccom/role/ScheduleofprepaidexpensesandothercurrentassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleofpropertyandequipmentnetTable" roleURI="http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleofaccruedliabilitiesTable" roleURI="http://www.cleaninccom/role/ScheduleofaccruedliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable" roleURI="http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleoffinanceleaseobligationsincludedinpropertyandequipmentTable" roleURI="http://www.cleaninccom/role/ScheduleoffinanceleaseobligationsincludedinpropertyandequipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleoffinanceandoperatingleasecostsTable" roleURI="http://www.cleaninccom/role/ScheduleoffinanceandoperatingleasecostsTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleofsupplementalcashflowinformationTable" roleURI="http://www.cleaninccom/role/ScheduleofsupplementalcashflowinformationTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleoflongtermdebtnetoforiginalissuediscountandunamortizeddebtissuancecostsTable" roleURI="http://www.cleaninccom/role/ScheduleoflongtermdebtnetoforiginalissuediscountandunamortizeddebtissuancecostsTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleoffuturepaymentsnetofunamortizeddebtdiscountsTable" roleURI="http://www.cleaninccom/role/ScheduleoffuturepaymentsnetofunamortizeddebtdiscountsTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleofoutstandingwarrantstopurchasesharesofcommonstockTable" roleURI="http://www.cleaninccom/role/ScheduleofoutstandingwarrantstopurchasesharesofcommonstockTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleofcomponentsofincomelossbeforeincometaxesTable" roleURI="http://www.cleaninccom/role/ScheduleofcomponentsofincomelossbeforeincometaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleofstockbasedcompensationexpenseTable" roleURI="http://www.cleaninccom/role/ScheduleofstockbasedcompensationexpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleofoutstandingcommonstockoptionsandrelatedactivityTable" roleURI="http://www.cleaninccom/role/ScheduleofoutstandingcommonstockoptionsandrelatedactivityTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsTable" roleURI="http://www.cleaninccom/role/ScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleofrestrictedcommonstockactivityTable" roleURI="http://www.cleaninccom/role/ScheduleofrestrictedcommonstockactivityTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable" roleURI="http://www.cleaninccom/role/ScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleofunobservableinputstotheconversionfeaturewarrantliabilityandcontingentearnoutvaluationmodelsTable" roleURI="http://www.cleaninccom/role/ScheduleofunobservableinputstotheconversionfeaturewarrantliabilityandcontingentearnoutvaluationmodelsTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsTable" roleURI="http://www.cleaninccom/role/ScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleofbasicanddilutednetlosspershareTable" roleURI="http://www.cleaninccom/role/ScheduleofbasicanddilutednetlosspershareTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleofsecuritiesexcludedfromcomputationofdilutednetincomelosspershareTable" roleURI="http://www.cleaninccom/role/ScheduleofsecuritiesexcludedfromcomputationofdilutednetincomelosspershareTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleofpropertyandequipmentnetbylocationTable" roleURI="http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetbylocationTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleofdrugsandsupplementssegmentsTable" roleURI="http://www.cleaninccom/role/ScheduleofdrugsandsupplementssegmentsTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ScheduleofpropertyandequipmentnetbysegmentTable" roleURI="http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetbysegmentTable"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_NatureoftheBusinessDetails" roleURI="http://www.cleaninccom/role/NatureoftheBusinessDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.cleaninccom/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails" roleURI="http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_PropertyandEquipmentNetDetails" roleURI="http://www.cleaninccom/role/PropertyandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_LeasesDetails" roleURI="http://www.cleaninccom/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_NotesPayableDetails" roleURI="http://www.cleaninccom/role/NotesPayableDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_PreferredStockWarrantLiabilityDetails" roleURI="http://www.cleaninccom/role/PreferredStockWarrantLiabilityDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_CommonStockWarrantsDetails" roleURI="http://www.cleaninccom/role/CommonStockWarrantsDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_ConvertibleNotesDetails" roleURI="http://www.cleaninccom/role/ConvertibleNotesDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_DerivativeInstrumentsDetails" roleURI="http://www.cleaninccom/role/DerivativeInstrumentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_IncomeTaxesDetails" roleURI="http://www.cleaninccom/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_StockBasedCompensationDetails" roleURI="http://www.cleaninccom/role/StockBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_FairValueDetails" roleURI="http://www.cleaninccom/role/FairValueDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_RedeemableConvertiblePreferredStockDetails" roleURI="http://www.cleaninccom/role/RedeemableConvertiblePreferredStockDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_CommonStockDetails" roleURI="http://www.cleaninccom/role/CommonStockDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_NetIncomeLossPerShareAttributabletoCommonShareholdersDetails" roleURI="http://www.cleaninccom/role/NetIncomeLossPerShareAttributabletoCommonShareholdersDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_RelatedPartyTransactionsDetails" roleURI="http://www.cleaninccom/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#clnn_r_SubsequentEventsDetails" roleURI="http://www.cleaninccom/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="clnn-20210930.xsd#DocumentAndEntityInformation" roleURI="http://www.cleaninccom/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Cash" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_TaxesPayableCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermNotesPayable" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantLiabilityNoncurrent" xlink:href="clnn-20210930.xsd#clnn_WarrantLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="WarrantLiabilityNoncurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InitialShareholdersContingentEarnout" xlink:href="clnn-20210930.xsd#clnn_InitialShareholdersContingentEarnout"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="InitialShareholdersContingentEarnout" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_CommitmentsAndContingencies" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_ProductMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_RoyaltyMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestIncomeexpense" xlink:href="clnn-20210930.xsd#clnn_InterestIncomeexpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="InterestIncomeexpense" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="GainOnExtinguishmentOfNotesPayable" xlink:href="clnn-20210930.xsd#clnn_GainOnExtinguishmentOfNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="GainOnExtinguishmentOfNotesPayable" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="LossOnExtinguishmentOfConvertibleNotesPayable" xlink:href="clnn-20210930.xsd#clnn_LossOnExtinguishmentOfConvertibleNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="LossOnExtinguishmentOfConvertibleNotesPayable" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnContractTermination" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnContractTermination"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainLossOnContractTermination" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChangeInFairValueOfPreferredStockWarrantLiability" xlink:href="clnn-20210930.xsd#clnn_ChangeInFairValueOfPreferredStockWarrantLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="ChangeInFairValueOfPreferredStockWarrantLiability" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChangeInFairValueOfDerivativeLiability" xlink:href="clnn-20210930.xsd#clnn_ChangeInFairValueOfDerivativeLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="ChangeInFairValueOfDerivativeLiability" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChangeInFairValueOfContingentEarnout" xlink:href="clnn-20210930.xsd#clnn_ChangeInFairValueOfContingentEarnout"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="ChangeInFairValueOfContingentEarnout" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChangeInFairValueOfInitialShareholdersContingentEarnout" xlink:href="clnn-20210930.xsd#clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="ChangeInFairValueOfInitialShareholdersContingentEarnout" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChangeInFairValueOfCommonStockWarrantLiability" xlink:href="clnn-20210930.xsd#clnn_ChangeInFairValueOfCommonStockWarrantLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="ChangeInFairValueOfCommonStockWarrantLiability" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AustraliaResearchAndDevelopmentCredit" xlink:href="clnn-20210930.xsd#clnn_AustraliaResearchAndDevelopmentCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="AustraliaResearchAndDevelopmentCredit" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="13.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NetIncomeLoss" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTax" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="NetIncomeLossPerCommonShareAttributableToCommonShareholdersNote191Abstract" xlink:href="clnn-20210930.xsd#clnn_NetIncomeLossPerCommonShareAttributableToCommonShareholdersNote191Abstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="NetIncomeLossPerCommonShareAttributableToCommonShareholdersNote191Abstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetIncomeLossPerCommonShareAttributableToCommonShareholdersNote191Abstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetIncomeLossPerCommonShareAttributableToCommonShareholdersNote191Abstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageNumberOfCommonSharesOutstanding1Abstract" xlink:href="clnn-20210930.xsd#clnn_WeightedAverageNumberOfCommonSharesOutstanding1Abstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="WeightedAverageNumberOfCommonSharesOutstanding1Abstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageNumberOfCommonSharesOutstanding1Abstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageNumberOfCommonSharesOutstanding1Abstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_PreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="5.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodOfSeriesDPreferredStock" xlink:href="clnn-20210930.xsd#clnn_StockIssuedDuringPeriodOfSeriesDPreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodOfSeriesDPreferredStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesSeriesDPreferredStock" xlink:href="clnn-20210930.xsd#clnn_StockIssuedDuringPeriodSharesSeriesDPreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesSeriesDPreferredStock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:href="clnn-20210930.xsd#clnn_StockIssuedDuringPeriodValueExerciseOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueExerciseOfWarrants" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssueDuringPeriodSharesExerciseOfWarrants" xlink:href="clnn-20210930.xsd#clnn_StockIssueDuringPeriodSharesExerciseOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssueDuringPeriodSharesExerciseOfWarrants" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodExerciseOfUnderwritersOption" xlink:href="clnn-20210930.xsd#clnn_StockIssuedDuringPeriodExerciseOfUnderwritersOption"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodExerciseOfUnderwritersOption" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodExerciseOfUnderwritersOptioninShares" xlink:href="clnn-20210930.xsd#clnn_StockIssuedDuringPeriodExerciseOfUnderwritersOptioninShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodExerciseOfUnderwritersOptioninShares" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ForeignCurrencyTranslationAdjustment" xlink:href="clnn-20210930.xsd#clnn_ForeignCurrencyTranslationAdjustment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ForeignCurrencyTranslationAdjustment" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ShareholdersEquityType2or3_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="NetOfIssuanceCosts" xlink:href="clnn-20210930.xsd#clnn_NetOfIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="NetOfIssuanceCosts" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSoldDepreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSoldDepreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChangeInFairValueOfCleneNanomedicineContingentEarnouts" xlink:href="clnn-20210930.xsd#clnn_ChangeInFairValueOfCleneNanomedicineContingentEarnouts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ChangeInFairValueOfCleneNanomedicineContingentEarnouts" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ChangesInFairValueOfInitialShareholdersContingentEarnout" xlink:href="clnn-20210930.xsd#clnn_ChangesInFairValueOfInitialShareholdersContingentEarnout"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ChangesInFairValueOfInitialShareholdersContingentEarnout" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ChangeInFairValueOfCommonStockWarrantLiabilitys" xlink:href="clnn-20210930.xsd#clnn_ChangeInFairValueOfCommonStockWarrantLiabilitys"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ChangeInFairValueOfCommonStockWarrantLiabilitys" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnTerminationOfLease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnTerminationOfLease" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfIntangibleAssets" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseInInterestAccruedOnNotesPayable" xlink:href="clnn-20210930.xsd#clnn_IncreaseInInterestAccruedOnNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IncreaseInInterestAccruedOnNotesPayable" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromOtherDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromOtherDebt" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_0" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAbstract" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:to="us-gaap_Cash" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCash" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantLiabilityRecordedAtIssuanceOfNotesPayable" xlink:href="clnn-20210930.xsd#clnn_WarrantLiabilityRecordedAtIssuanceOfNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="WarrantLiabilityRecordedAtIssuanceOfNotesPayable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LeaseLiabilitySettledThroughTerminationOfLease" xlink:href="clnn-20210930.xsd#clnn_LeaseLiabilitySettledThroughTerminationOfLease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="LeaseLiabilitySettledThroughTerminationOfLease" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes" xlink:href="clnn-20210930.xsd#clnn_IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN" xlink:href="clnn-20210930.xsd#clnn_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredOfferingCostsInAccruedLiabilities" xlink:href="clnn-20210930.xsd#clnn_DeferredOfferingCostsInAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="DeferredOfferingCostsInAccruedLiabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashPaidForInterestExpense" xlink:href="clnn-20210930.xsd#clnn_CashPaidForInterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="CashPaidForInterestExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/NatureoftheBusiness">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicine">
    <loc xlink:type="locator" xlink:label="ReverseRecapitalizationWithTottenhamAndCleneNanomedicineAbstract" xlink:href="clnn-20210930.xsd#clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineAbstract"/>
    <loc xlink:type="locator" xlink:label="ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock" xlink:href="clnn-20210930.xsd#clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationWithTottenhamAndCleneNanomedicineAbstract" xlink:to="ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/PrepaidExpensesandOtherCurrentAssets">
    <loc xlink:type="locator" xlink:label="PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:href="clnn-20210930.xsd#clnn_PrepaidExpensesAndOtherCurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:href="clnn-20210930.xsd#clnn_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="PrepaidExpensesAndOtherCurrentAssetsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/PropertyandEquipmentNet">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/AccruedLiabilities">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/Leases">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/NotesPayable">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/PreferredStockWarrantLiability">
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrantsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrantsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrantsAbstract" xlink:to="us-gaap_PreferredStockTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/CommonStockWarrants">
    <loc xlink:type="locator" xlink:label="CommonStockWarrantsDisclosureAbstract" xlink:href="clnn-20210930.xsd#clnn_CommonStockWarrantsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="CommonStockWarrantsDisclosureTextBlock" xlink:href="clnn-20210930.xsd#clnn_CommonStockWarrantsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockWarrantsDisclosureAbstract" xlink:to="CommonStockWarrantsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ConvertibleNotes">
    <loc xlink:type="locator" xlink:label="ConvertibleNotesDisclosureAbstract" xlink:href="clnn-20210930.xsd#clnn_ConvertibleNotesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotesDisclosureTextBlock" xlink:href="clnn-20210930.xsd#clnn_ConvertibleNotesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesDisclosureAbstract" xlink:to="ConvertibleNotesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/DerivativeInstruments">
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/StockBasedCompensation">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/FairValue">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/RedeemableConvertiblePreferredStock">
    <loc xlink:type="locator" xlink:label="RedeemableConvertiblePreferredStockDisclosureAbstract" xlink:href="clnn-20210930.xsd#clnn_RedeemableConvertiblePreferredStockDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="RedeemableConvertiblePreferredStockDisclosureTextBlock" xlink:href="clnn-20210930.xsd#clnn_RedeemableConvertiblePreferredStockDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RedeemableConvertiblePreferredStockDisclosureAbstract" xlink:to="RedeemableConvertiblePreferredStockDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/CommonStock">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/NetIncomeLossPerShareAttributabletoCommonShareholders">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/GeographicandSegmentInformation">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RiskAndUncertaintiesPolicyTextBlock" xlink:href="clnn-20210930.xsd#clnn_RiskAndUncertaintiesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="RiskAndUncertaintiesPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtDiscountAndIssuanceCostsPolicyTextBlock" xlink:href="clnn-20210930.xsd#clnn_DebtDiscountAndIssuanceCostsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DebtDiscountAndIssuanceCostsPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotespolicytextblock" xlink:href="clnn-20210930.xsd#clnn_ConvertibleNotespolicytextblock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ConvertibleNotespolicytextblock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtWithWarrantsPolicyTextBlock" xlink:href="clnn-20210930.xsd#clnn_DebtWithWarrantsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DebtWithWarrantsPolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ContingentEarnoutPolicyTextBlock" xlink:href="clnn-20210930.xsd#clnn_ContingentEarnoutPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ContingentEarnoutPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockWarrantsPolicyTextBlock" xlink:href="clnn-20210930.xsd#clnn_CommonStockWarrantsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="CommonStockWarrantsPolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrantFundingPolicyTextBlock" xlink:href="clnn-20210930.xsd#clnn_GrantFundingPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="GrantFundingPolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClinicalTrialAccrualPolicyTextBlock" xlink:href="clnn-20210930.xsd#clnn_ClinicalTrialAccrualPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ClinicalTrialAccrualPolicyTextBlock" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:href="clnn-20210930.xsd#clnn_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/PrepaidExpensesandOtherCurrentAssetsTables">
    <loc xlink:type="locator" xlink:label="PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:href="clnn-20210930.xsd#clnn_PrepaidExpensesAndOtherCurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:href="clnn-20210930.xsd#clnn_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/PropertyandEquipmentNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/AccruedLiabilitiesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="AccruedLiabilitiesTablesTable" xlink:href="clnn-20210930.xsd#clnn_AccruedLiabilitiesTablesTable"/>
    <loc xlink:type="locator" xlink:label="AccruedLiabilitiesTablesLineItems" xlink:href="clnn-20210930.xsd#clnn_AccruedLiabilitiesTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="AccruedLiabilitiesTablesTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesTablesTable" xlink:to="AccruedLiabilitiesTablesLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesTablesLineItems" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/LeasesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="clnn-20210930.xsd#clnn_FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceLeaseByMajorClassPropertyAndEquipmentTableTextBlock" xlink:href="clnn-20210930.xsd#clnn_FinanceLeaseByMajorClassPropertyAndEquipmentTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="FinanceLeaseByMajorClassPropertyAndEquipmentTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/NotesPayableTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscounts" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscounts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/CommonStockWarrantsTables">
    <loc xlink:type="locator" xlink:label="CommonStockWarrantsDisclosureAbstract" xlink:href="clnn-20210930.xsd#clnn_CommonStockWarrantsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockWarrantsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/StockBasedCompensationTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/FairValueTables">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/NetIncomeLossPerShareAttributabletoCommonShareholdersTables">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/GeographicandSegmentInformationTables">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofprepaidexpensesandothercurrentassetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="AustraliaResearchAndDevelopmentCreditReceivable" xlink:href="clnn-20210930.xsd#clnn_AustraliaResearchAndDevelopmentCreditReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="AustraliaResearchAndDevelopmentCreditReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="CROPrepayments" xlink:href="clnn-20210930.xsd#clnn_CROPrepayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="CROPrepayments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MetalsToBeUsedInResearchAndDevelopment" xlink:href="clnn-20210930.xsd#clnn_MetalsToBeUsedInResearchAndDevelopment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="MetalsToBeUsedInResearchAndDevelopment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DirectorsOfficersInsurance" xlink:href="clnn-20210930.xsd#clnn_DirectorsOfficersInsurance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="DirectorsOfficersInsurance" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentNetAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfPropertyAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="us-gaap_MachineryAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="us-gaap_FurnitureAndFixturesGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="us-gaap_LeaseholdImprovementsGross" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="us-gaap_ConstructionInProgressGross" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofaccruedliabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAccruedLiabilitiesAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfAccruedLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedLiabilitiesAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedLiabilitiesAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedCROFees" xlink:href="clnn-20210930.xsd#clnn_AccruedCROFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedLiabilitiesAbstract" xlink:to="AccruedCROFees" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredGrantFunds" xlink:href="clnn-20210930.xsd#clnn_DeferredGrantFunds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedLiabilitiesAbstract" xlink:to="DeferredGrantFunds" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedExpenseReimbursements" xlink:href="clnn-20210930.xsd#clnn_AccruedExpenseReimbursements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedLiabilitiesAbstract" xlink:to="AccruedExpenseReimbursements" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedTransactionCosts" xlink:href="clnn-20210930.xsd#clnn_AccruedTransactionCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedLiabilitiesAbstract" xlink:to="AccruedTransactionCosts" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedLiabilitiesAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedLiabilitiesAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfNoncancelableFinanceAndOperatingLeaseLiabilitiesAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfNoncancelableFinanceAndOperatingLeaseLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable" xlink:href="clnn-20210930.xsd#clnn_LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems" xlink:href="clnn-20210930.xsd#clnn_LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNoncancelableFinanceAndOperatingLeaseLiabilitiesAbstract" xlink:to="LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="FinanceLeasesMember" xlink:href="clnn-20210930.xsd#clnn_FinanceLeasesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="FinanceLeasesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeasesMember" xlink:href="clnn-20210930.xsd#clnn_OperatingLeasesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="OperatingLeasesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable" xlink:to="LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="CapitalLeasesAmountRepresentingInterestdiscounting" xlink:href="clnn-20210930.xsd#clnn_CapitalLeasesAmountRepresentingInterestdiscounting"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="CapitalLeasesAmountRepresentingInterestdiscounting" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeasesAmountRepresentingInterestdiscounting" xlink:href="clnn-20210930.xsd#clnn_OperatingLeasesAmountRepresentingInterestdiscounting"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="OperatingLeasesAmountRepresentingInterestdiscounting" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="CapitalLeasesFutureLeaseIncentives" xlink:href="clnn-20210930.xsd#clnn_CapitalLeasesFutureLeaseIncentives"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="CapitalLeasesFutureLeaseIncentives" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeasesLessFutureLeaseIncentives" xlink:href="clnn-20210930.xsd#clnn_OperatingLeasesLessFutureLeaseIncentives"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="OperatingLeasesLessFutureLeaseIncentives" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_CapitalLeaseObligationsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleoffinanceleaseobligationsincludedinpropertyandequipmentTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinanceLeaseObligationsIncludedInPropertyAndEquipmentAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfFinanceLeaseObligationsIncludedInPropertyAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="FinanceLeaseLaboratoryEquipmentGross" xlink:href="clnn-20210930.xsd#clnn_FinanceLeaseLaboratoryEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinanceLeaseObligationsIncludedInPropertyAndEquipmentAbstract" xlink:to="FinanceLeaseLaboratoryEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceLeaseFurnitureAndFixturesGross" xlink:href="clnn-20210930.xsd#clnn_FinanceLeaseFurnitureAndFixturesGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinanceLeaseObligationsIncludedInPropertyAndEquipmentAbstract" xlink:to="FinanceLeaseFurnitureAndFixturesGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceLeaseWorkInProcessGross" xlink:href="clnn-20210930.xsd#clnn_FinanceLeaseWorkInProcessGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinanceLeaseObligationsIncludedInPropertyAndEquipmentAbstract" xlink:to="FinanceLeaseWorkInProcessGross" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceLeaseLiabilityGross" xlink:href="clnn-20210930.xsd#clnn_FinanceLeaseLiabilityGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinanceLeaseObligationsIncludedInPropertyAndEquipmentAbstract" xlink:to="FinanceLeaseLiabilityGross" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="AccumulatedDepreciationDepletionAndAmortizationLeases" xlink:href="clnn-20210930.xsd#clnn_AccumulatedDepreciationDepletionAndAmortizationLeases"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinanceLeaseObligationsIncludedInPropertyAndEquipmentAbstract" xlink:to="AccumulatedDepreciationDepletionAndAmortizationLeases" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceLeaseLiabilityNet" xlink:href="clnn-20210930.xsd#clnn_FinanceLeaseLiabilityNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinanceLeaseObligationsIncludedInPropertyAndEquipmentAbstract" xlink:to="FinanceLeaseLiabilityNet" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleoffinanceandoperatingleasecostsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinanceAndOperatingLeaseCostsAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfFinanceAndOperatingLeaseCostsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinanceAndOperatingLeaseCostsAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_VariableLeaseCost" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_LeaseCost" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofsupplementalcashflowinformationTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfSupplementalCashFlowInformationAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfSupplementalCashFlowInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="OperatingCashFlowsFromOperatingLeases" xlink:href="clnn-20210930.xsd#clnn_OperatingCashFlowsFromOperatingLeases"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalCashFlowInformationAbstract" xlink:to="OperatingCashFlowsFromOperatingLeases" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingCashFlowsFromFinanceLeases" xlink:href="clnn-20210930.xsd#clnn_OperatingCashFlowsFromFinanceLeases"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalCashFlowInformationAbstract" xlink:to="OperatingCashFlowsFromFinanceLeases" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceCashFlowsFromFinanceLeases" xlink:href="clnn-20210930.xsd#clnn_FinanceCashFlowsFromFinanceLeases"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalCashFlowInformationAbstract" xlink:to="FinanceCashFlowsFromFinanceLeases" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleoflongtermdebtnetoforiginalissuediscountandunamortizeddebtissuancecostsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfLongTermDebtNetOfOriginalIssueDiscountAndUnamortizedDebtIssuanceCostsAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfLongTermDebtNetOfOriginalIssueDiscountAndUnamortizedDebtIssuanceCostsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLongTermDebtNetOfOriginalIssueDiscountAndUnamortizedDebtIssuanceCostsAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="TermLoansAxis" xlink:href="clnn-20210930.xsd#clnn_TermLoansAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="TermLoansAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TermLoansDomain" xlink:href="clnn-20210930.xsd#clnn_TermLoansDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TermLoansAxis" xlink:to="TermLoansDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MarylandDepartmentOfHousingCommunityDevelopmentMember" xlink:href="clnn-20210930.xsd#clnn_MarylandDepartmentOfHousingCommunityDevelopmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TermLoansAxis" xlink:to="MarylandDepartmentOfHousingCommunityDevelopmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdvanceCecilIncMember" xlink:href="clnn-20210930.xsd#clnn_AdvanceCecilIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TermLoansAxis" xlink:to="AdvanceCecilIncMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaycheckProtectionProgramMember" xlink:href="clnn-20210930.xsd#clnn_PaycheckProtectionProgramMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TermLoansAxis" xlink:to="PaycheckProtectionProgramMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AvenueVentureOpportunitiesFundsLPMember" xlink:href="clnn-20210930.xsd#clnn_AvenueVentureOpportunitiesFundsLPMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TermLoansAxis" xlink:to="AvenueVentureOpportunitiesFundsLPMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherTermLoanMember" xlink:href="clnn-20210930.xsd#clnn_OtherTermLoanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TermLoansAxis" xlink:to="OtherTermLoanMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="TermLoansAbstract" xlink:href="clnn-20210930.xsd#clnn_TermLoansAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="TermLoansAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestRate" xlink:href="clnn-20210930.xsd#clnn_InterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TermLoansAbstract" xlink:to="InterestRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalTermLoans" xlink:href="clnn-20210930.xsd#clnn_TotalTermLoans"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TermLoansAbstract" xlink:to="TotalTermLoans" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TermLoansAbstract" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TermLoansAbstract" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalNotesPayableAndConvertibleNotesPayable" xlink:href="clnn-20210930.xsd#clnn_TotalNotesPayableAndConvertibleNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TermLoansAbstract" xlink:to="TotalNotesPayableAndConvertibleNotesPayable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleoffuturepaymentsnetofunamortizeddebtdiscountsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscountsAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscountsAbstract"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentUnamortizedDiscountRemainderOfFiscalYear" xlink:href="clnn-20210930.xsd#clnn_DebtInstrumentUnamortizedDiscountRemainderOfFiscalYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscountsAbstract" xlink:to="DebtInstrumentUnamortizedDiscountRemainderOfFiscalYear" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentUnamortizedDiscountYearOne" xlink:href="clnn-20210930.xsd#clnn_DebtInstrumentUnamortizedDiscountYearOne"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscountsAbstract" xlink:to="DebtInstrumentUnamortizedDiscountYearOne" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentUnamortizedDiscountYearTwo" xlink:href="clnn-20210930.xsd#clnn_DebtInstrumentUnamortizedDiscountYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscountsAbstract" xlink:to="DebtInstrumentUnamortizedDiscountYearTwo" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentUnamortizedDiscountYearThree" xlink:href="clnn-20210930.xsd#clnn_DebtInstrumentUnamortizedDiscountYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscountsAbstract" xlink:to="DebtInstrumentUnamortizedDiscountYearThree" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentUnamortizedDiscountYearFour" xlink:href="clnn-20210930.xsd#clnn_DebtInstrumentUnamortizedDiscountYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscountsAbstract" xlink:to="DebtInstrumentUnamortizedDiscountYearFour" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentUnamortizedDiscountYearFive" xlink:href="clnn-20210930.xsd#clnn_DebtInstrumentUnamortizedDiscountYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscountsAbstract" xlink:to="DebtInstrumentUnamortizedDiscountYearFive" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentThereafter" xlink:href="clnn-20210930.xsd#clnn_DebtInstrumentThereafter"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentUnamortizedDiscountYearFive" xlink:to="DebtInstrumentThereafter" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FuturePrincipalPayments" xlink:href="clnn-20210930.xsd#clnn_FuturePrincipalPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentThereafter" xlink:to="FuturePrincipalPayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentUnamortizedDiscountYearFive" xlink:to="us-gaap_DebtInstrumentUnamortizedPremium" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentUnamortizedPremium" xlink:to="us-gaap_DebtSecurities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofoutstandingwarrantstopurchasesharesofcommonstockTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="WarrantsDateMember" xlink:href="clnn-20210930.xsd#clnn_WarrantsDateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="WarrantsDateMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsDate1Member" xlink:href="clnn-20210930.xsd#clnn_WarrantsDate1Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="WarrantsDate1Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="December20201Member" xlink:href="clnn-20210930.xsd#clnn_December20201Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="December20201Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsDate2Member" xlink:href="clnn-20210930.xsd#clnn_WarrantsDate2Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="WarrantsDate2Member" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="May2021Member" xlink:href="clnn-20210930.xsd#clnn_May2021Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="May2021Member" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesIssuable" xlink:href="clnn-20210930.xsd#clnn_NumberOfSharesIssuable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="NumberOfSharesIssuable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockWarrantsExercisePrice" xlink:href="clnn-20210930.xsd#clnn_CommonStockWarrantsExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="CommonStockWarrantsExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockWarrantsExercisable" xlink:href="clnn-20210930.xsd#clnn_CommonStockWarrantsExercisable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="CommonStockWarrantsExercisable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockWarrantsClassification" xlink:href="clnn-20210930.xsd#clnn_CommonStockWarrantsClassification"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="CommonStockWarrantsClassification" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockWarrantsExpiration" xlink:href="clnn-20210930.xsd#clnn_CommonStockWarrantsExpiration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="CommonStockWarrantsExpiration" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofcomponentsofincomelossbeforeincometaxesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalLossBeforeIncomeTaxes" xlink:href="clnn-20210930.xsd#clnn_TotalLossBeforeIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesAbstract" xlink:to="TotalLossBeforeIncomeTaxes" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofstockbasedcompensationexpenseTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfStockBasedCompensationExpenseAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfStockBasedCompensationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable" xlink:href="clnn-20210930.xsd#clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems" xlink:href="clnn-20210930.xsd#clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockBasedCompensationExpenseAbstract" xlink:to="StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable" xlink:to="StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofoutstandingcommonstockoptionsandrelatedactivityTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValue" xlink:href="clnn-20210930.xsd#clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted" xlink:href="clnn-20210930.xsd#clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueGranted" xlink:href="clnn-20210930.xsd#clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueGranted" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementNumberOfOptionsExercised" xlink:href="clnn-20210930.xsd#clnn_ShareBasedCompensationArrangementNumberOfOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="ShareBasedCompensationArrangementNumberOfOptionsExercised" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageRemainingTermYearsExercised" xlink:href="clnn-20210930.xsd#clnn_WeightedAverageRemainingTermYearsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="WeightedAverageRemainingTermYearsExercised" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue" xlink:href="clnn-20210930.xsd#clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="12.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageRemainingTermYearsForfeited" xlink:href="clnn-20210930.xsd#clnn_WeightedAverageRemainingTermYearsForfeited"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="WeightedAverageRemainingTermYearsForfeited" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue" xlink:href="clnn-20210930.xsd#clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValue_0" xlink:href="clnn-20210930.xsd#clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValue_0" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber" xlink:href="clnn-20210930.xsd#clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageExercisePricePerShareOptionVestedAndExercisable" xlink:href="clnn-20210930.xsd#clnn_WeightedAverageExercisePricePerShareOptionVestedAndExercisable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="WeightedAverageExercisePricePerShareOptionVestedAndExercisable" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageExercisePriceWeightedAverageRemainingTermYearsOptionsVestedAndEexercisableEnding" xlink:href="clnn-20210930.xsd#clnn_WeightedAverageExercisePriceWeightedAverageRemainingTermYearsOptionsVestedAndEexercisableEnding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="WeightedAverageExercisePriceWeightedAverageRemainingTermYearsOptionsVestedAndEexercisableEnding" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueIntrinsicValueOptionsVestedAndExercisableEnding" xlink:href="clnn-20210930.xsd#clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueIntrinsicValueOptionsVestedAndExercisableEnding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueIntrinsicValueOptionsVestedAndExercisableEnding" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm1" xlink:href="clnn-20210930.xsd#clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm1" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IntrinsicValueStockOptionsVestedAndExpectedToVestIntrinsicValueOptionsV" xlink:href="clnn-20210930.xsd#clnn_IntrinsicValueStockOptionsVestedAndExpectedToVestIntrinsicValueOptionsV"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract" xlink:to="IntrinsicValueStockOptionsVestedAndExpectedToVestIntrinsicValueOptionsV" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAssumptionsUsedToCalculateTheFairValueOfStockOptionsAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfAssumptionsUsedToCalculateTheFairValueOfStockOptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsTable" xlink:href="clnn-20210930.xsd#clnn_StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsTable"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsLineItems" xlink:href="clnn-20210930.xsd#clnn_StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAssumptionsUsedToCalculateTheFairValueOfStockOptionsAbstract" xlink:to="StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_StockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsTable" xlink:to="StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofrestrictedcommonstockactivityTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfRestrictedCommonStockActivityAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfRestrictedCommonStockActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityTable" xlink:href="clnn-20210930.xsd#clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityTable"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems" xlink:href="clnn-20210930.xsd#clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRestrictedCommonStockActivityAbstract" xlink:to="StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityTable" xlink:to="StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSraqWjSnTNF4jeT3oaMW8W5R0MkiIXXy8k2PQbBklJ1lYSX00RI6mU1NUjmu2Z8DGiLsvWC/Nx+2e5I3XA4/waZZD17aBEHbiQmUEtZYNMriew3bFfu2eViLA2wfQ1rEEEBO8y7g2agPYYHRPjjYinU2N7wn7wmM2L15NQDoNITe4D20JOUkoCAA] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueHierarchyOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfFairValueHierarchyOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract"/>
    <loc xlink:type="locator" xlink:label="FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable" xlink:href="clnn-20210930.xsd#clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable"/>
    <loc xlink:type="locator" xlink:label="FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems" xlink:href="clnn-20210930.xsd#clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueHierarchyOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract" xlink:to="FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable" xlink:to="FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems" xlink:to="us-gaap_NotesPayableFairValueDisclosure" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableFairValueDisclosure" xlink:to="us-gaap_DerivativeLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CleneNanomedicineContingentEarnoutFairValueDisclosure" xlink:href="clnn-20210930.xsd#clnn_CleneNanomedicineContingentEarnoutFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableFairValueDisclosure" xlink:to="CleneNanomedicineContingentEarnoutFairValueDisclosure" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InitialShareholdersContingentEarnoutFairValueDisclosure" xlink:href="clnn-20210930.xsd#clnn_InitialShareholdersContingentEarnoutFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableFairValueDisclosure" xlink:to="InitialShareholdersContingentEarnoutFairValueDisclosure" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofunobservableinputstotheconversionfeaturewarrantliabilityandcontingentearnoutvaluationmodelsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfUnobservableInputsToTheConversionFeatureWarrantLiabilityAndContingentEarnOutValuationModelsAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfUnobservableInputsToTheConversionFeatureWarrantLiabilityAndContingentEarnOutValuationModelsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfUnobservableInputsToTheConversionFeatureWarrantLiabilityAndContingentEarnOutValuationModelsAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_ValuationTechniqueAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="BlackScholesValuationModelMember" xlink:href="clnn-20210930.xsd#clnn_BlackScholesValuationModelMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="BlackScholesValuationModelMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MonteCarloSimulationMember" xlink:href="clnn-20210930.xsd#clnn_MonteCarloSimulationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="MonteCarloSimulationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ContingentEarnOutMember" xlink:href="clnn-20210930.xsd#clnn_ContingentEarnOutMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="ContingentEarnOutMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="WarrantLiabilityMember" xlink:href="clnn-20210930.xsd#clnn_WarrantLiabilityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="WarrantLiabilityMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="srt_RangeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="5.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfChangesInFairValueOfFinancialLiabilitiesRelatedToTheNotesPayableTheDerivativeInstrumentThePreferredStockWarrantsAndTheContingentEarnOutsAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfChangesInFairValueOfFinancialLiabilitiesRelatedToTheNotesPayableTheDerivativeInstrumentThePreferredStockWarrantsAndTheContingentEarnOutsAbstract"/>
    <loc xlink:type="locator" xlink:label="FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsTable" xlink:href="clnn-20210930.xsd#clnn_FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsTable"/>
    <loc xlink:type="locator" xlink:label="FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsLineItems" xlink:href="clnn-20210930.xsd#clnn_FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfChangesInFairValueOfFinancialLiabilitiesRelatedToTheNotesPayableTheDerivativeInstrumentThePreferredStockWarrantsAndTheContingentEarnOutsAbstract" xlink:to="FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableOtherPayablesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_NotesPayableOtherPayablesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CleneNanomedicineContingentEarnoutMember" xlink:href="clnn-20210930.xsd#clnn_CleneNanomedicineContingentEarnoutMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="CleneNanomedicineContingentEarnoutMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InitialShareholdersContingentEarnoutMember" xlink:href="clnn-20210930.xsd#clnn_InitialShareholdersContingentEarnoutMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="InitialShareholdersContingentEarnoutMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantLiabilityMember" xlink:href="clnn-20210930.xsd#clnn_WarrantLiabilityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="WarrantLiabilityMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DerivativeInstrumentMember" xlink:href="clnn-20210930.xsd#clnn_DerivativeInstrumentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="DerivativeInstrumentMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PreferredStockWarrantsMember" xlink:href="clnn-20210930.xsd#clnn_PreferredStockWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="PreferredStockWarrantsMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsTable" xlink:to="FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="InitialFairValueOfInstrument" xlink:href="clnn-20210930.xsd#clnn_InitialFairValueOfInstrument"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsLineItems" xlink:to="InitialFairValueOfInstrument" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueIssuanceOfConvertiblePromissoryNotes" xlink:href="clnn-20210930.xsd#clnn_FairValueIssuanceOfConvertiblePromissoryNotes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsLineItems" xlink:to="FairValueIssuanceOfConvertiblePromissoryNotes" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreseDecreaseInFairValue" xlink:href="clnn-20210930.xsd#clnn_IncreseDecreaseInFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsLineItems" xlink:to="IncreseDecreaseInFairValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueMeasurementExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN" xlink:href="clnn-20210930.xsd#clnn_FairValueMeasurementExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsLineItems" xlink:to="FairValueMeasurementExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofbasicanddilutednetlosspershareTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfBasicAndDilutedNetLossPerShareAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfBasicAndDilutedNetLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareTable" xlink:href="clnn-20210930.xsd#clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareTable"/>
    <loc xlink:type="locator" xlink:label="NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareLineItems" xlink:href="clnn-20210930.xsd#clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicAndDilutedNetLossPerShareAbstract" xlink:to="NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NetIncomeLossPerShareAttributableToCommonShareholdersMember" xlink:href="clnn-20210930.xsd#clnn_NetIncomeLossPerShareAttributableToCommonShareholdersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="NetIncomeLossPerShareAttributableToCommonShareholdersMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareTable" xlink:to="NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareLineItems" xlink:to="us-gaap_InterestOnConvertibleDebtNetOfTax" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageSharesOutstanding" xlink:href="clnn-20210930.xsd#clnn_WeightedAverageSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareLineItems" xlink:to="WeightedAverageSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageEffectOfPotentiallyDilutiveSecuritiesAbstract" xlink:href="clnn-20210930.xsd#clnn_WeightedAverageEffectOfPotentiallyDilutiveSecuritiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareLineItems" xlink:to="WeightedAverageEffectOfPotentiallyDilutiveSecuritiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EffectOfPotentiallyDilutiveStockOptionsinDollars" xlink:href="clnn-20210930.xsd#clnn_EffectOfPotentiallyDilutiveStockOptionsinDollars"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageEffectOfPotentiallyDilutiveSecuritiesAbstract" xlink:to="EffectOfPotentiallyDilutiveStockOptionsinDollars" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EffectOfPotentiallyDilutiveRestrictedStockAwards" xlink:href="clnn-20210930.xsd#clnn_EffectOfPotentiallyDilutiveRestrictedStockAwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageEffectOfPotentiallyDilutiveSecuritiesAbstract" xlink:to="EffectOfPotentiallyDilutiveRestrictedStockAwards" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EffectOfPotentiallyDilutiveConvertibleNotesPayable" xlink:href="clnn-20210930.xsd#clnn_EffectOfPotentiallyDilutiveConvertibleNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageEffectOfPotentiallyDilutiveSecuritiesAbstract" xlink:to="EffectOfPotentiallyDilutiveConvertibleNotesPayable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EffectOfPotentiallyDilutiveUnvestedRestrictedStockAwardsShares" xlink:href="clnn-20210930.xsd#clnn_EffectOfPotentiallyDilutiveUnvestedRestrictedStockAwardsShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageEffectOfPotentiallyDilutiveSecuritiesAbstract" xlink:to="EffectOfPotentiallyDilutiveUnvestedRestrictedStockAwardsShares" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofsecuritiesexcludedfromcomputationofdilutednetincomelosspershareTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfSecuritiesExcludedFromComputationOfDilutedNetIncomeLossPerShareAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfSecuritiesExcludedFromComputationOfDilutedNetIncomeLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="SeriesDRedeemableConvertiblePreferredStock" xlink:href="clnn-20210930.xsd#clnn_SeriesDRedeemableConvertiblePreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSecuritiesExcludedFromComputationOfDilutedNetIncomeLossPerShareAbstract" xlink:to="SeriesDRedeemableConvertiblePreferredStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesCRedeemableConvertiblePreferredStock" xlink:href="clnn-20210930.xsd#clnn_SeriesCRedeemableConvertiblePreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSecuritiesExcludedFromComputationOfDilutedNetIncomeLossPerShareAbstract" xlink:to="SeriesCRedeemableConvertiblePreferredStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesBRedeemableConvertiblePreferredStock" xlink:href="clnn-20210930.xsd#clnn_SeriesBRedeemableConvertiblePreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSecuritiesExcludedFromComputationOfDilutedNetIncomeLossPerShareAbstract" xlink:to="SeriesBRedeemableConvertiblePreferredStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesARedeemableConvertiblePreferredStock" xlink:href="clnn-20210930.xsd#clnn_SeriesARedeemableConvertiblePreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSecuritiesExcludedFromComputationOfDilutedNetIncomeLossPerShareAbstract" xlink:to="SeriesARedeemableConvertiblePreferredStock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesDRedeemableConvertiblePreferredStockWarrants" xlink:href="clnn-20210930.xsd#clnn_SeriesDRedeemableConvertiblePreferredStockWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSecuritiesExcludedFromComputationOfDilutedNetIncomeLossPerShareAbstract" xlink:to="SeriesDRedeemableConvertiblePreferredStockWarrants" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesARedeemableConvertiblePreferredStockWarrantsinShares" xlink:href="clnn-20210930.xsd#clnn_SeriesARedeemableConvertiblePreferredStockWarrantsinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSecuritiesExcludedFromComputationOfDilutedNetIncomeLossPerShareAbstract" xlink:to="SeriesARedeemableConvertiblePreferredStockWarrantsinShares" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotesPayables" xlink:href="clnn-20210930.xsd#clnn_ConvertibleNotesPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSecuritiesExcludedFromComputationOfDilutedNetIncomeLossPerShareAbstract" xlink:to="ConvertibleNotesPayables" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockWarrants" xlink:href="clnn-20210930.xsd#clnn_CommonStockWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSecuritiesExcludedFromComputationOfDilutedNetIncomeLossPerShareAbstract" xlink:to="CommonStockWarrants" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OptionsToPurchaseCommonStockinShares" xlink:href="clnn-20210930.xsd#clnn_OptionsToPurchaseCommonStockinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSecuritiesExcludedFromComputationOfDilutedNetIncomeLossPerShareAbstract" xlink:to="OptionsToPurchaseCommonStockinShares" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnvestedRestrictedStockAwardsShares" xlink:href="clnn-20210930.xsd#clnn_UnvestedRestrictedStockAwardsShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSecuritiesExcludedFromComputationOfDilutedNetIncomeLossPerShareAbstract" xlink:to="UnvestedRestrictedStockAwardsShares" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChardanUnitPurchaseOptionWarrants" xlink:href="clnn-20210930.xsd#clnn_ChardanUnitPurchaseOptionWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSecuritiesExcludedFromComputationOfDilutedNetIncomeLossPerShareAbstract" xlink:to="ChardanUnitPurchaseOptionWarrants" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CleneNanomedicineContingentEarnoutShares" xlink:href="clnn-20210930.xsd#clnn_CleneNanomedicineContingentEarnoutShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSecuritiesExcludedFromComputationOfDilutedNetIncomeLossPerShareAbstract" xlink:to="CleneNanomedicineContingentEarnoutShares" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InitialShareholdersContingentEarnoutShares" xlink:href="clnn-20210930.xsd#clnn_InitialShareholdersContingentEarnoutShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSecuritiesExcludedFromComputationOfDilutedNetIncomeLossPerShareAbstract" xlink:to="InitialShareholdersContingentEarnoutShares" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalDilutiveSecurities" xlink:href="clnn-20210930.xsd#clnn_TotalDilutiveSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSecuritiesExcludedFromComputationOfDilutedNetIncomeLossPerShareAbstract" xlink:to="TotalDilutiveSecurities" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetbylocationTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentNetByLocationAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfPropertyAndEquipmentNetByLocationAbstract"/>
    <loc xlink:type="locator" xlink:label="GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationTable" xlink:href="clnn-20210930.xsd#clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationTable"/>
    <loc xlink:type="locator" xlink:label="GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationLineItems" xlink:href="clnn-20210930.xsd#clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentNetByLocationAbstract" xlink:to="GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_US" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_AU" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_AU"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_AU" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationTable" xlink:to="GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofdrugsandsupplementssegmentsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDrugsAndSupplementsSegmentsAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfDrugsAndSupplementsSegmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDrugsAndSupplementsSegmentsAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="DrugsMember" xlink:href="clnn-20210930.xsd#clnn_DrugsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="DrugsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SupplementsMember" xlink:href="clnn-20210930.xsd#clnn_SupplementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="SupplementsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetbysegmentTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentNetBySegmentAbstract" xlink:href="clnn-20210930.xsd#clnn_ScheduleOfPropertyAndEquipmentNetBySegmentAbstract"/>
    <loc xlink:type="locator" xlink:label="GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentTable" xlink:href="clnn-20210930.xsd#clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentTable"/>
    <loc xlink:type="locator" xlink:label="GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentLineItems" xlink:href="clnn-20210930.xsd#clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentNetBySegmentAbstract" xlink:to="GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="DrugsMember" xlink:href="clnn-20210930.xsd#clnn_DrugsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="DrugsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SupplementsMember" xlink:href="clnn-20210930.xsd#clnn_SupplementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="SupplementsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentTable" xlink:to="GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="TotalPropertyAndEquipmentNet" xlink:href="clnn-20210930.xsd#clnn_TotalPropertyAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentLineItems" xlink:to="TotalPropertyAndEquipmentNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/NatureoftheBusinessDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="NatureoftheBusinessDetailsTable" xlink:href="clnn-20210930.xsd#clnn_NatureoftheBusinessDetailsTable"/>
    <loc xlink:type="locator" xlink:label="NatureoftheBusinessDetailsLineItems" xlink:href="clnn-20210930.xsd#clnn_NatureoftheBusinessDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="NatureoftheBusinessDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CleneIncMember" xlink:href="clnn-20210930.xsd#clnn_CleneIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="CleneIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TottenhamMember" xlink:href="clnn-20210930.xsd#clnn_TottenhamMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="TottenhamMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CleneNanomedicineMember" xlink:href="clnn-20210930.xsd#clnn_CleneNanomedicineMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="CleneNanomedicineMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PIPEMember" xlink:href="clnn-20210930.xsd#clnn_PIPEMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="PIPEMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessDetailsTable" xlink:to="NatureoftheBusinessDetailsLineItems" order="4.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateFutureProceedsWarrantsExercised" xlink:href="clnn-20210930.xsd#clnn_AggregateFutureProceedsWarrantsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessDetailsLineItems" xlink:to="AggregateFutureProceedsWarrantsExercised" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OfferingCost" xlink:href="clnn-20210930.xsd#clnn_OfferingCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessDetailsLineItems" xlink:to="OfferingCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateProceedsReceived" xlink:href="clnn-20210930.xsd#clnn_AggregateProceedsReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessDetailsLineItems" xlink:to="AggregateProceedsReceived" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OfferingPricePerShare" xlink:href="clnn-20210930.xsd#clnn_OfferingPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessDetailsLineItems" xlink:to="OfferingPricePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockUnderlyingWarrantOutstanding" xlink:href="clnn-20210930.xsd#clnn_CommonStockUnderlyingWarrantOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessDetailsLineItems" xlink:to="CommonStockUnderlyingWarrantOutstanding" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareIssuanceOfCommonStockPrivateOffering" xlink:href="clnn-20210930.xsd#clnn_ShareIssuanceOfCommonStockPrivateOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessDetailsLineItems" xlink:to="ShareIssuanceOfCommonStockPrivateOffering" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessDetailsLineItems" xlink:to="us-gaap_NetIncomeLoss" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessDetailsLineItems" xlink:to="us-gaap_Cash" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessDetailsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessDetailsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="clnn-20210930.xsd#clnn_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="clnn-20210930.xsd#clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollateralAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollateralAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_CollateralAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollateralDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollateralDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollateralAxis" xlink:to="us-gaap_CollateralDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollateralAxis" xlink:to="us-gaap_EquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollateralAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="SummaryofSignificantAccountingPoliciesDetailsLineItems" order="4.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_RestrictedInvestments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_InventoryRawMaterials" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_InventoryFinishedGoods" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DeferredRevenue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrantFundingRecognizedOnConditionalGrants" xlink:href="clnn-20210930.xsd#clnn_GrantFundingRecognizedOnConditionalGrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="GrantFundingRecognizedOnConditionalGrants" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails">
    <loc xlink:type="locator" xlink:label="ReverseRecapitalizationWithTottenhamAndCleneNanomedicineAbstract" xlink:href="clnn-20210930.xsd#clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineAbstract"/>
    <loc xlink:type="locator" xlink:label="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable" xlink:href="clnn-20210930.xsd#clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:href="clnn-20210930.xsd#clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationWithTottenhamAndCleneNanomedicineAbstract" xlink:to="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable" xlink:to="us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfFreshStartAdjustmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfFreshStartAdjustmentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" xlink:to="us-gaap_TypeOfFreshStartAdjustmentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExchangeClearedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExchangeClearedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" xlink:to="us-gaap_ExchangeClearedMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" xlink:to="us-gaap_CommonStockMember_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CleneIncMember" xlink:href="clnn-20210930.xsd#clnn_CleneIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="CleneIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CleneNanomedicineMember" xlink:href="clnn-20210930.xsd#clnn_CleneNanomedicineMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="CleneNanomedicineMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChardanCapitalMarketsLLCMember" xlink:href="clnn-20210930.xsd#clnn_ChardanCapitalMarketsLLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="ChardanCapitalMarketsLLCMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LifeSciCapitalLLCMember" xlink:href="clnn-20210930.xsd#clnn_LifeSciCapitalLLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="LifeSciCapitalLLCMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TottenhamMember" xlink:href="clnn-20210930.xsd#clnn_TottenhamMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="TottenhamMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PIPEMember" xlink:href="clnn-20210930.xsd#clnn_PIPEMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="PIPEMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ReverseRecapitalizationMember" xlink:href="clnn-20210930.xsd#clnn_ReverseRecapitalizationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="ReverseRecapitalizationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable" xlink:to="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" order="6.0"/>
    <loc xlink:type="locator" xlink:label="CommonStockParOrStatedValuesPerShare" xlink:href="clnn-20210930.xsd#clnn_CommonStockParOrStatedValuesPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="CommonStockParOrStatedValuesPerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesCancelledUponReverseRecapitalization" xlink:href="clnn-20210930.xsd#clnn_SharesCancelledUponReverseRecapitalization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="SharesCancelledUponReverseRecapitalization" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InitialShareholdersContingentsEarnout" xlink:href="clnn-20210930.xsd#clnn_InitialShareholdersContingentsEarnout"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="InitialShareholdersContingentsEarnout" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExchangeOfSharesReceived" xlink:href="clnn-20210930.xsd#clnn_ExchangeOfSharesReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="ExchangeOfSharesReceived" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReverseRecapitalizationExchangeRatio" xlink:href="clnn-20210930.xsd#clnn_ReverseRecapitalizationExchangeRatio"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="ReverseRecapitalizationExchangeRatio" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesHeldInEscrowPercentage" xlink:href="clnn-20210930.xsd#clnn_SharesHeldInEscrowPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="SharesHeldInEscrowPercentage" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesHeldInEscrow" xlink:href="clnn-20210930.xsd#clnn_SharesHeldInEscrow"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="SharesHeldInEscrow" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExchangeRatioPercentage" xlink:href="clnn-20210930.xsd#clnn_ExchangeRatioPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="ExchangeRatioPercentage" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromReverseRecapitalization" xlink:href="clnn-20210930.xsd#clnn_ProceedsFromReverseRecapitalization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="ProceedsFromReverseRecapitalization" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="SaleOfUnitsNumberOfUnitsIssued" xlink:href="clnn-20210930.xsd#clnn_SaleOfUnitsNumberOfUnitsIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="SaleOfUnitsNumberOfUnitsIssued" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnitsIssuedPricePerUnit" xlink:href="clnn-20210930.xsd#clnn_UnitsIssuedPricePerUnit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="UnitsIssuedPricePerUnit" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePrice" xlink:href="clnn-20210930.xsd#clnn_ExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="ExercisePrice" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ServicesLetterAgreementDescription" xlink:href="clnn-20210930.xsd#clnn_ServicesLetterAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="ServicesLetterAgreementDescription" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockOtherSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="us-gaap_CommonStockOtherSharesOutstanding" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsToPurchaseCommonStockIssuedAndOutstanding" xlink:href="clnn-20210930.xsd#clnn_WarrantsToPurchaseCommonStockIssuedAndOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="WarrantsToPurchaseCommonStockIssuedAndOutstanding" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherUnderwritingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherUnderwritingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="us-gaap_OtherUnderwritingExpense" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantExercisePriceIncrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="us-gaap_WarrantExercisePriceIncrease" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateGrossProceedWarrantsExercised" xlink:href="clnn-20210930.xsd#clnn_AggregateGrossProceedWarrantsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="AggregateGrossProceedWarrantsExercised" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChardanUnitPurchaseOption" xlink:href="clnn-20210930.xsd#clnn_ChardanUnitPurchaseOption"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="ChardanUnitPurchaseOption" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetIssuanceSharesOfCommonStock" xlink:href="clnn-20210930.xsd#clnn_NetIssuanceSharesOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="NetIssuanceSharesOfCommonStock" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsToPurchaseSharesOfCommonStock" xlink:href="clnn-20210930.xsd#clnn_WarrantsToPurchaseSharesOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="WarrantsToPurchaseSharesOfCommonStock" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CleneNanomedicineContingentEarnOutMilestone1Shares" xlink:href="clnn-20210930.xsd#clnn_CleneNanomedicineContingentEarnOutMilestone1Shares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="CleneNanomedicineContingentEarnOutMilestone1Shares" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CleneNanomedicineContingentEarnoutMilestone1Price" xlink:href="clnn-20210930.xsd#clnn_CleneNanomedicineContingentEarnoutMilestone1Price"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="CleneNanomedicineContingentEarnoutMilestone1Price" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CleneNanomedicineContingentEarnoutMilestone2Shares" xlink:href="clnn-20210930.xsd#clnn_CleneNanomedicineContingentEarnoutMilestone2Shares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="CleneNanomedicineContingentEarnoutMilestone2Shares" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CleneNanomedicineContingentEarnoutMilestone2Price" xlink:href="clnn-20210930.xsd#clnn_CleneNanomedicineContingentEarnoutMilestone2Price"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="CleneNanomedicineContingentEarnoutMilestone2Price" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CleneNanomedicineContingentEarnoutMilestone3Shares" xlink:href="clnn-20210930.xsd#clnn_CleneNanomedicineContingentEarnoutMilestone3Shares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="CleneNanomedicineContingentEarnoutMilestone3Shares" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseInCleneNanomedicineContingentEarnoutSharesUponReverseRecapitalization" xlink:href="clnn-20210930.xsd#clnn_IncreaseInCleneNanomedicineContingentEarnoutSharesUponReverseRecapitalization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="IncreaseInCleneNanomedicineContingentEarnoutSharesUponReverseRecapitalization" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalCleneNanomedicineContingentEarnoutShares" xlink:href="clnn-20210930.xsd#clnn_TotalCleneNanomedicineContingentEarnoutShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="TotalCleneNanomedicineContingentEarnoutShares" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InitialShareholdersContingentEarnoutMilestone1Shares" xlink:href="clnn-20210930.xsd#clnn_InitialShareholdersContingentEarnoutMilestone1Shares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="InitialShareholdersContingentEarnoutMilestone1Shares" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InitialShareholdersContingentEarnoutMilestone2Shares" xlink:href="clnn-20210930.xsd#clnn_InitialShareholdersContingentEarnoutMilestone2Shares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems" xlink:to="InitialShareholdersContingentEarnoutMilestone2Shares" order="36.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/PropertyandEquipmentNetDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="PropertyandEquipmentNetDetailsTable" xlink:href="clnn-20210930.xsd#clnn_PropertyandEquipmentNetDetailsTable"/>
    <loc xlink:type="locator" xlink:label="PropertyandEquipmentNetDetailsLineItems" xlink:href="clnn-20210930.xsd#clnn_PropertyandEquipmentNetDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="PropertyandEquipmentNetDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetDetailsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetDetailsTable" xlink:to="PropertyandEquipmentNetDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetDetailsLineItems" xlink:to="us-gaap_Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="RemainingRightofuseAsset" xlink:href="clnn-20210930.xsd#clnn_RemainingRightofuseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="RemainingRightofuseAsset" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RecognizedGainOnOperatingLease" xlink:href="clnn-20210930.xsd#clnn_RecognizedGainOnOperatingLease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="RecognizedGainOnOperatingLease" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RightOfUseAssets" xlink:href="clnn-20210930.xsd#clnn_RightOfUseAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="RightOfUseAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LeaseholdImprovements" xlink:href="clnn-20210930.xsd#clnn_LeaseholdImprovements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="LeaseholdImprovements" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseInRightOfUseAssets" xlink:href="clnn-20210930.xsd#clnn_IncreaseInRightOfUseAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="IncreaseInRightOfUseAssets" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseInLeaseholdImprovements" xlink:href="clnn-20210930.xsd#clnn_IncreaseInLeaseholdImprovements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="IncreaseInLeaseholdImprovements" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseInLeaseLiability" xlink:href="clnn-20210930.xsd#clnn_IncreaseInLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="IncreaseInLeaseLiability" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnTerminationOfLease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_GainLossOnTerminationOfLease" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeaseRightofUseAssets" xlink:href="clnn-20210930.xsd#clnn_OperatingLeaseRightofUseAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="OperatingLeaseRightofUseAssets" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncentiveToLessee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncentiveToLessee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_IncentiveToLessee" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LeaseIncentiveRecordedConstructionInProgress" xlink:href="clnn-20210930.xsd#clnn_LeaseIncentiveRecordedConstructionInProgress"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="LeaseIncentiveRecordedConstructionInProgress" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LessorOperatingLeaseDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeaseDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LessorOperatingLeaseDescription" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceLeaseObligationsWeightedaverageInterestRate" xlink:href="clnn-20210930.xsd#clnn_FinanceLeaseObligationsWeightedaverageInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="FinanceLeaseObligationsWeightedaverageInterestRate" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeaseObligationsWeightedAverageInterestRate" xlink:href="clnn-20210930.xsd#clnn_OperatingLeaseObligationsWeightedAverageInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="OperatingLeaseObligationsWeightedAverageInterestRate" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/NotesPayableDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="NotesPayableDetailsTable" xlink:href="clnn-20210930.xsd#clnn_NotesPayableDetailsTable"/>
    <loc xlink:type="locator" xlink:label="NotesPayableDetailsLineItems" xlink:href="clnn-20210930.xsd#clnn_NotesPayableDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="NotesPayableDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="TwoThousandNineteenMDLoanMember" xlink:href="clnn-20210930.xsd#clnn_TwoThousandNineteenMDLoanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="TwoThousandNineteenMDLoanMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoThousandNineteenCecilLoanMember" xlink:href="clnn-20210930.xsd#clnn_TwoThousandNineteenCecilLoanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="TwoThousandNineteenCecilLoanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaycheckProtectionProgramNoteMember" xlink:href="clnn-20210930.xsd#clnn_PaycheckProtectionProgramNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PaycheckProtectionProgramNoteMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoThousandtwentyoneAvenueLoanMember" xlink:href="clnn-20210930.xsd#clnn_TwoThousandtwentyoneAvenueLoanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="TwoThousandtwentyoneAvenueLoanMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableOtherPayablesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_NotesPayableOtherPayablesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsTable" xlink:to="us-gaap_VestingAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsTable" xlink:to="NotesPayableDetailsLineItems" order="4.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="us-gaap_LongTermDebt" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentDescription" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="us-gaap_InterestIncomeOther" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SimpleInterestExpense" xlink:href="clnn-20210930.xsd#clnn_SimpleInterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="SimpleInterestExpense" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueOfLongTermNotesPayable" xlink:href="clnn-20210930.xsd#clnn_FairValueOfLongTermNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="FairValueOfLongTermNotesPayable" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="us-gaap_OtherIncome" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesAndLoansPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="us-gaap_NotesAndLoansPayable" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfLoanAmountUsedToPayrollExpenses" xlink:href="clnn-20210930.xsd#clnn_PercentageOfLoanAmountUsedToPayrollExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="PercentageOfLoanAmountUsedToPayrollExpenses" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExtinguishmentOfDebtAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="us-gaap_ExtinguishmentOfDebtAmount" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FundedAmountAtClosing" xlink:href="clnn-20210930.xsd#clnn_FundedAmountAtClosing"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="FundedAmountAtClosing" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedDebtIssuanceCosts" xlink:href="clnn-20210930.xsd#clnn_AccruedDebtIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="AccruedDebtIssuanceCosts" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentUnfundedBalance" xlink:href="clnn-20210930.xsd#clnn_DebtInstrumentUnfundedBalance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="DebtInstrumentUnfundedBalance" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SecondLoanAmount" xlink:href="clnn-20210930.xsd#clnn_SecondLoanAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="SecondLoanAmount" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConditionsForFutureFundingDescription" xlink:href="clnn-20210930.xsd#clnn_ConditionsForFutureFundingDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="ConditionsForFutureFundingDescription" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RateOfInterestDescription" xlink:href="clnn-20210930.xsd#clnn_RateOfInterestDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="RateOfInterestDescription" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalPaymentUponMaturityDescription" xlink:href="clnn-20210930.xsd#clnn_AdditionalPaymentUponMaturityDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="AdditionalPaymentUponMaturityDescription" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantToPurchaseShares" xlink:href="clnn-20210930.xsd#clnn_WarrantToPurchaseShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="WarrantToPurchaseShares" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockAtAnExercisePrice" xlink:href="clnn-20210930.xsd#clnn_CommonStockAtAnExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="CommonStockAtAnExercisePrice" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Tranche2WarrantAdjustmentDescription" xlink:href="clnn-20210930.xsd#clnn_Tranche2WarrantAdjustmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="Tranche2WarrantAdjustmentDescription" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionPercentageOfCommonStockPriceForConvertibleNotePayable" xlink:href="clnn-20210930.xsd#clnn_ConversionPercentageOfCommonStockPriceForConvertibleNotePayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="ConversionPercentageOfCommonStockPriceForConvertibleNotePayable" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TradingVolumeLimitForConversionOfConvertibleNotePayable" xlink:href="clnn-20210930.xsd#clnn_TradingVolumeLimitForConversionOfConvertibleNotePayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="TradingVolumeLimitForConversionOfConvertibleNotePayable" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ThresholdForRemovalOfFinancialCovenantsDescription" xlink:href="clnn-20210930.xsd#clnn_ThresholdForRemovalOfFinancialCovenantsDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="ThresholdForRemovalOfFinancialCovenantsDescription" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MinimumCashBalanceForLoanCovenant" xlink:href="clnn-20210930.xsd#clnn_MinimumCashBalanceForLoanCovenant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="MinimumCashBalanceForLoanCovenant" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueOfWarrant" xlink:href="clnn-20210930.xsd#clnn_FairValueOfWarrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="FairValueOfWarrant" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentFinancingCosts" xlink:href="clnn-20210930.xsd#clnn_DebtInstrumentFinancingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="DebtInstrumentFinancingCosts" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="us-gaap_ConvertibleDebt" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/PreferredStockWarrantLiabilityDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="PreferredStockWarrantLiabilityDetailsTable" xlink:href="clnn-20210930.xsd#clnn_PreferredStockWarrantLiabilityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="PreferredStockWarrantLiabilityDetailsLineItems" xlink:href="clnn-20210930.xsd#clnn_PreferredStockWarrantLiabilityDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="PreferredStockWarrantLiabilityDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockWarrantLiabilityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesCPreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesDPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesDPreferredStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockWarrantLiabilityDetailsTable" xlink:to="PreferredStockWarrantLiabilityDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockWarrantLiabilityDetailsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockWarrantLiabilityDetailsLineItems" xlink:to="us-gaap_WarrantExercisePriceDecrease" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesOfWarrantsExercisable" xlink:href="clnn-20210930.xsd#clnn_SharesOfWarrantsExercisable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockWarrantLiabilityDetailsLineItems" xlink:to="SharesOfWarrantsExercisable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentOfFullydilutedEquityPurchasableUponExercise" xlink:href="clnn-20210930.xsd#clnn_PercentOfFullydilutedEquityPurchasableUponExercise"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockWarrantLiabilityDetailsLineItems" xlink:to="PercentOfFullydilutedEquityPurchasableUponExercise" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LossInFairValueOfWarrantLiability" xlink:href="clnn-20210930.xsd#clnn_LossInFairValueOfWarrantLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockWarrantLiabilityDetailsLineItems" xlink:to="LossInFairValueOfWarrantLiability" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueAdjustmentOfWarrantsOutstanding" xlink:href="clnn-20210930.xsd#clnn_FairValueAdjustmentOfWarrantsOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockWarrantLiabilityDetailsLineItems" xlink:to="FairValueAdjustmentOfWarrantsOutstanding" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/CommonStockWarrantsDetails">
    <loc xlink:type="locator" xlink:label="CommonStockWarrantsDisclosureAbstract" xlink:href="clnn-20210930.xsd#clnn_CommonStockWarrantsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="CommonStockWarrantsDetailsTable" xlink:href="clnn-20210930.xsd#clnn_CommonStockWarrantsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="CommonStockWarrantsDetailsLineItems" xlink:href="clnn-20210930.xsd#clnn_CommonStockWarrantsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockWarrantsDisclosureAbstract" xlink:to="CommonStockWarrantsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockWarrantsDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChardanUnitPurchaseOptionMember" xlink:href="clnn-20210930.xsd#clnn_ChardanUnitPurchaseOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="ChardanUnitPurchaseOptionMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockWarrantsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PIPEWarrantsMember" xlink:href="clnn-20210930.xsd#clnn_PIPEWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="PIPEWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_WarrantMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockWarrantsMember" xlink:href="clnn-20210930.xsd#clnn_CommonStockWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="CommonStockWarrantsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockWarrantsDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AvenueLoanMember" xlink:href="clnn-20210930.xsd#clnn_AvenueLoanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="AvenueLoanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoThousandtwentyoneAvenueLoanMember" xlink:href="clnn-20210930.xsd#clnn_TwoThousandtwentyoneAvenueLoanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="TwoThousandtwentyoneAvenueLoanMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockWarrantsDetailsTable" xlink:to="CommonStockWarrantsDetailsLineItems" order="4.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockWarrantsDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockWarrantsDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PIPEWarrantsOwnershipLimit" xlink:href="clnn-20210930.xsd#clnn_PIPEWarrantsOwnershipLimit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockWarrantsDetailsLineItems" xlink:to="PIPEWarrantsOwnershipLimit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockWarrantsDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CompanyWarrantRedemptionRight" xlink:href="clnn-20210930.xsd#clnn_CompanyWarrantRedemptionRight"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockWarrantsDetailsLineItems" xlink:to="CompanyWarrantRedemptionRight" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceOfWarrantsDescription" xlink:href="clnn-20210930.xsd#clnn_ExercisePriceOfWarrantsDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockWarrantsDetailsLineItems" xlink:to="ExercisePriceOfWarrantsDescription" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/ConvertibleNotesDetails">
    <loc xlink:type="locator" xlink:label="ConvertibleNotesDisclosureAbstract" xlink:href="clnn-20210930.xsd#clnn_ConvertibleNotesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotesDetailsTable" xlink:href="clnn-20210930.xsd#clnn_ConvertibleNotesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotesDetailsLineItems" xlink:href="clnn-20210930.xsd#clnn_ConvertibleNotesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesDisclosureAbstract" xlink:to="ConvertibleNotesDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoThousandtwentyoneAvenueLoanMember" xlink:href="clnn-20210930.xsd#clnn_TwoThousandtwentyoneAvenueLoanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="TwoThousandtwentyoneAvenueLoanMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ConvertibleNotesPayableMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesDetailsTable" xlink:to="ConvertibleNotesDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesDetailsLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfConvertibleNotes" xlink:href="clnn-20210930.xsd#clnn_DescriptionOfConvertibleNotes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesDetailsLineItems" xlink:to="DescriptionOfConvertibleNotes" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesDetailsLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesDetailsLineItems" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExtinguishmentOfDebtAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesDetailsLineItems" xlink:to="us-gaap_ExtinguishmentOfDebtAmount" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfStockPrice" xlink:href="clnn-20210930.xsd#clnn_PercentageOfStockPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesDetailsLineItems" xlink:to="PercentageOfStockPrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesDetailsLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesDetailsLineItems" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfLossOnExtinguishment" xlink:href="clnn-20210930.xsd#clnn_DescriptionOfLossOnExtinguishment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesDetailsLineItems" xlink:to="DescriptionOfLossOnExtinguishment" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotesPayableDescription" xlink:href="clnn-20210930.xsd#clnn_ConvertibleNotesPayableDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesDetailsLineItems" xlink:to="ConvertibleNotesPayableDescription" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LoanOutstanding" xlink:href="clnn-20210930.xsd#clnn_LoanOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesDetailsLineItems" xlink:to="LoanOutstanding" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionPercentageOfCommonStockPriceForConvertibleNotePayable" xlink:href="clnn-20210930.xsd#clnn_ConversionPercentageOfCommonStockPriceForConvertibleNotePayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesDetailsLineItems" xlink:to="ConversionPercentageOfCommonStockPriceForConvertibleNotePayable" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesDetailsLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CouponInterestExpense" xlink:href="clnn-20210930.xsd#clnn_CouponInterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesDetailsLineItems" xlink:to="CouponInterestExpense" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/DerivativeInstrumentsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFairValueOfDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeFairValueOfDerivativeNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LossOnDerivativeInstruments" xlink:href="clnn-20210930.xsd#clnn_LossOnDerivativeInstruments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="LossOnDerivativeInstruments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityFairValueAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityFairValueAdjustment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_EquityFairValueAdjustment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GainlossOnCleneNanomedicineContingentEarnout" xlink:href="clnn-20210930.xsd#clnn_GainlossOnCleneNanomedicineContingentEarnout"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="GainlossOnCleneNanomedicineContingentEarnout" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GainlossOnInitialShareholdersContingentEarnout" xlink:href="clnn-20210930.xsd#clnn_GainlossOnInitialShareholdersContingentEarnout"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="GainlossOnInitialShareholdersContingentEarnout" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantLiabilityFairValue" xlink:href="clnn-20210930.xsd#clnn_WarrantLiabilityFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="WarrantLiabilityFairValue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Changeinfairvaluewarrants" xlink:href="clnn-20210930.xsd#clnn_Changeinfairvaluewarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="Changeinfairvaluewarrants" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/StockBasedCompensationDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsTable" xlink:href="clnn-20210930.xsd#clnn_StockBasedCompensationDetailsTable"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsLineItems" xlink:href="clnn-20210930.xsd#clnn_StockBasedCompensationDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="StockBasedCompensationDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="StockPlan2020Member" xlink:href="clnn-20210930.xsd#clnn_StockPlan2020Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="StockPlan2020Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockPlan2014Member" xlink:href="clnn-20210930.xsd#clnn_StockPlan2014Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="StockPlan2014Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="StockPlan2020Member_0" xlink:href="clnn-20210930.xsd#clnn_StockPlan2020Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="StockPlan2020Member_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockPlan2014Member_0" xlink:href="clnn-20210930.xsd#clnn_StockPlan2014Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="StockPlan2014Member_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockPlan2020Member_1" xlink:href="clnn-20210930.xsd#clnn_StockPlan2020Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="StockPlan2020Member_1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsTable" xlink:to="StockBasedCompensationDetailsLineItems" order="4.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MinimumFairMarketValueOfOptionGrantDescription" xlink:href="clnn-20210930.xsd#clnn_MinimumFairMarketValueOfOptionGrantDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="MinimumFairMarketValueOfOptionGrantDescription" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants" xlink:href="clnn-20210930.xsd#clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockOtherSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_CommonStockOtherSharesOutstanding" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionPlanExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionPlanExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_StockOptionPlanExpense" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnrecognizedStockbasedCompensation" xlink:href="clnn-20210930.xsd#clnn_UnrecognizedStockbasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="UnrecognizedStockbasedCompensation" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm" xlink:href="clnn-20210930.xsd#clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="weightedAverageFairValuesOfOptionsGranted" xlink:href="clnn-20210930.xsd#clnn_weightedAverageFairValuesOfOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="weightedAverageFairValuesOfOptionsGranted" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RestrictedStockUnitsDescription" xlink:href="clnn-20210930.xsd#clnn_RestrictedStockUnitsDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="RestrictedStockUnitsDescription" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_RestrictedStockExpense" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm" xlink:href="clnn-20210930.xsd#clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/FairValueDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="FairValueDetailsTable" xlink:href="clnn-20210930.xsd#clnn_FairValueDetailsTable"/>
    <loc xlink:type="locator" xlink:label="FairValueDetailsLineItems" xlink:href="clnn-20210930.xsd#clnn_FairValueDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="FairValueDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AvenueLoanMember" xlink:href="clnn-20210930.xsd#clnn_AvenueLoanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="AvenueLoanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDetailsTable" xlink:to="FairValueDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="NotesPayableBasedOnClosingPrice" xlink:href="clnn-20210930.xsd#clnn_NotesPayableBasedOnClosingPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDetailsLineItems" xlink:to="NotesPayableBasedOnClosingPrice" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueAmortizedCost" xlink:href="clnn-20210930.xsd#clnn_FairValueAmortizedCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDetailsLineItems" xlink:to="FairValueAmortizedCost" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDetailsLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueOfConvertibleNotesPayable" xlink:href="clnn-20210930.xsd#clnn_FairValueOfConvertibleNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDetailsLineItems" xlink:to="FairValueOfConvertibleNotesPayable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalWarrantToPurchaseShares" xlink:href="clnn-20210930.xsd#clnn_AdditionalWarrantToPurchaseShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDetailsLineItems" xlink:to="AdditionalWarrantToPurchaseShares" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDetailsLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/RedeemableConvertiblePreferredStockDetails">
    <loc xlink:type="locator" xlink:label="RedeemableConvertiblePreferredStockDisclosureAbstract" xlink:href="clnn-20210930.xsd#clnn_RedeemableConvertiblePreferredStockDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="RedeemableConvertiblePreferredStockDetailsTable" xlink:href="clnn-20210930.xsd#clnn_RedeemableConvertiblePreferredStockDetailsTable"/>
    <loc xlink:type="locator" xlink:label="RedeemableConvertiblePreferredStockDetailsLineItems" xlink:href="clnn-20210930.xsd#clnn_RedeemableConvertiblePreferredStockDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RedeemableConvertiblePreferredStockDisclosureAbstract" xlink:to="RedeemableConvertiblePreferredStockDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RedeemableConvertiblePreferredStockDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleCommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleCommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ConvertibleCommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RedeemableConvertiblePreferredStockDetailsTable" xlink:to="RedeemableConvertiblePreferredStockDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RedeemableConvertiblePreferredStockDetailsLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/CommonStockDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="CommonStockDetailsTable" xlink:href="clnn-20210930.xsd#clnn_CommonStockDetailsTable"/>
    <loc xlink:type="locator" xlink:label="CommonStockDetailsLineItems" xlink:href="clnn-20210930.xsd#clnn_CommonStockDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="CommonStockDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="InvestorsMember" xlink:href="clnn-20210930.xsd#clnn_InvestorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="InvestorsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockDetailsTable" xlink:to="CommonStockDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PreferredStockShares" xlink:href="clnn-20210930.xsd#clnn_PreferredStockShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockDetailsLineItems" xlink:to="PreferredStockShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockDetailsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockUponReverseRecapitalization" xlink:href="clnn-20210930.xsd#clnn_IssuanceOfCommonStockUponReverseRecapitalization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockDetailsLineItems" xlink:to="IssuanceOfCommonStockUponReverseRecapitalization" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RecapitalizationShare" xlink:href="clnn-20210930.xsd#clnn_RecapitalizationShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockDetailsLineItems" xlink:to="RecapitalizationShare" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestorsPurchasedShares" xlink:href="clnn-20210930.xsd#clnn_InvestorsPurchasedShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockDetailsLineItems" xlink:to="InvestorsPurchasedShares" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockDetailsLineItems" xlink:to="us-gaap_SharePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetProceeds" xlink:href="clnn-20210930.xsd#clnn_NetProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockDetailsLineItems" xlink:to="NetProceeds" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrivatePlacementWarrantsDescription" xlink:href="clnn-20210930.xsd#clnn_PrivatePlacementWarrantsDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockDetailsLineItems" xlink:to="PrivatePlacementWarrantsDescription" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockSharesPurchased" xlink:href="clnn-20210930.xsd#clnn_CommonStockSharesPurchased"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockDetailsLineItems" xlink:to="CommonStockSharesPurchased" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockPricePerShare" xlink:href="clnn-20210930.xsd#clnn_CommonStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockDetailsLineItems" xlink:to="CommonStockPricePerShare" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsShares" xlink:href="clnn-20210930.xsd#clnn_WarrantsShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockDetailsLineItems" xlink:to="WarrantsShares" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePricePerShare" xlink:href="clnn-20210930.xsd#clnn_ExercisePricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockDetailsLineItems" xlink:to="ExercisePricePerShare" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashProceedsReceived" xlink:href="clnn-20210930.xsd#clnn_CashProceedsReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockDetailsLineItems" xlink:to="CashProceedsReceived" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseOptionUnits" xlink:href="clnn-20210930.xsd#clnn_PurchaseOptionUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockDetailsLineItems" xlink:to="PurchaseOptionUnits" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetIssuanceShares" xlink:href="clnn-20210930.xsd#clnn_NetIssuanceShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockDetailsLineItems" xlink:to="NetIssuanceShares" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetIssuanceWarrants" xlink:href="clnn-20210930.xsd#clnn_NetIssuanceWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockDetailsLineItems" xlink:to="NetIssuanceWarrants" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockDetailsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/NetIncomeLossPerShareAttributabletoCommonShareholdersDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsTable" xlink:href="clnn-20210930.xsd#clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsTable"/>
    <loc xlink:type="locator" xlink:label="NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsLineItems" xlink:href="clnn-20210930.xsd#clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PIPEWarrantsMember" xlink:href="clnn-20210930.xsd#clnn_PIPEWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="PIPEWarrantsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsTable" xlink:to="NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/RelatedPartyTransactionsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExclusiveRightsIntellectualPropertyTerm" xlink:href="clnn-20210930.xsd#clnn_ExclusiveRightsIntellectualPropertyTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="ExclusiveRightsIntellectualPropertyTerm" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsSoldSalesTypeLease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsSoldSalesTypeLease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_CostOfGoodsSoldSalesTypeLease" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRoyaltiesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRoyaltiesReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ProceedsFromRoyaltiesReceived" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvancesToAffiliate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvancesToAffiliate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_AdvancesToAffiliate" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsSoldDirectFinancingLease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsSoldDirectFinancingLease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_CostOfGoodsSoldDirectFinancingLease" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="clnn-20210930.xsd#clnn_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsLineItems" xlink:href="clnn-20210930.xsd#clnn_SubsequentEventsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PIPEWarrantsMember" xlink:href="clnn-20210930.xsd#clnn_PIPEWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="PIPEWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="SubsequentEventsDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SubsequentEventDescription" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateGrossProceedWarrantsExercised" xlink:href="clnn-20210930.xsd#clnn_AggregateGrossProceedWarrantsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="AggregateGrossProceedWarrantsExercised" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.cleaninccom/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="clnn-20210930.xsd#clnn_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentQuarterlyReport" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>f10q0921_cleneinc_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:clnn="http://www.cleaninccom/20210930"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="clnn-20210930.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
        </entity>
        <period>
            <instant>2021-11-04</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:CleneIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:TottenhamMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:CleneNanomedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:PIPEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
        </entity>
        <period>
            <startDate>2021-02-16</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:PIPEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
        </entity>
        <period>
            <instant>2021-07-22</instant>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-22</endDate>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
        </entity>
        <period>
            <startDate>2021-05-18</startDate>
            <endDate>2021-05-21</endDate>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-18</startDate>
            <endDate>2021-05-21</endDate>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:CleneIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-30</instant>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:CleneIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-30</endDate>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:CleneNanomedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-30</endDate>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:CleneIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-30</endDate>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis">us-gaap:ExchangeClearedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:CleneIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-30</endDate>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:CleneIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-30</endDate>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis">us-gaap:ExchangeClearedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:CleneIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-30</endDate>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:CleneIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-30</endDate>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-30</endDate>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">clnn:ReverseRecapitalizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-30</instant>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:ChardanCapitalMarketsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-15</startDate>
            <endDate>2018-08-01</endDate>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:ChardanCapitalMarketsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-01</instant>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:LifeSciCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-15</startDate>
            <endDate>2020-07-02</endDate>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:LifeSciCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-30</instant>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:CleneIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-30</instant>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:CleneNanomedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-30</instant>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:TottenhamMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-30</instant>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:PIPEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-30</instant>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:PIPEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-15</instant>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clnn:PIPEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-15</endDate>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-15</endDate>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
        </entity>
        <period>
            <startDate>2021-07-10</startDate>
            <endDate>2021-07-15</endDate>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
        </entity>
        <period>
            <instant>2021-07-15</instant>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">clnn:FinanceLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">clnn:OperatingLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandNineteenMDLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandNineteenMDLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandNineteenMDLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandNineteenMDLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandNineteenMDLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandNineteenMDLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandNineteenMDLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandNineteenMDLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandNineteenCecilLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandNineteenCecilLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandNineteenCecilLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandNineteenCecilLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandNineteenCecilLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandNineteenCecilLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandNineteenCecilLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandNineteenCecilLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:PaycheckProtectionProgramNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="c170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:PaycheckProtectionProgramNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="c171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:PaycheckProtectionProgramNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-15</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="c172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandtwentyoneAvenueLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandtwentyoneAvenueLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandtwentyoneAvenueLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandtwentyoneAvenueLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandtwentyoneAvenueLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandtwentyoneAvenueLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandtwentyoneAvenueLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandtwentyoneAvenueLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="clnn:TermLoansAxis">clnn:MarylandDepartmentOfHousingCommunityDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="clnn:TermLoansAxis">clnn:MarylandDepartmentOfHousingCommunityDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="clnn:TermLoansAxis">clnn:MarylandDepartmentOfHousingCommunityDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="clnn:TermLoansAxis">clnn:AdvanceCecilIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="clnn:TermLoansAxis">clnn:AdvanceCecilIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="clnn:TermLoansAxis">clnn:AdvanceCecilIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="clnn:TermLoansAxis">clnn:PaycheckProtectionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="clnn:TermLoansAxis">clnn:PaycheckProtectionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="clnn:TermLoansAxis">clnn:PaycheckProtectionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="clnn:TermLoansAxis">clnn:AvenueVentureOpportunitiesFundsLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="clnn:TermLoansAxis">clnn:AvenueVentureOpportunitiesFundsLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="clnn:TermLoansAxis">clnn:AvenueVentureOpportunitiesFundsLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="clnn:TermLoansAxis">clnn:OtherTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="clnn:TermLoansAxis">clnn:OtherTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="clnn:TermLoansAxis">clnn:OtherTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-04-08</instant>
        </period>
    </context>
    <context id="c196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-04-08</instant>
        </period>
    </context>
    <context id="c198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-04</startDate>
            <endDate>2020-08-11</endDate>
        </period>
    </context>
    <context id="c200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:PIPEWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-30</instant>
        </period>
    </context>
    <context id="c201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:PIPEWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-30</endDate>
        </period>
    </context>
    <context id="c202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:PIPEWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:PIPEWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clnn:ChardanUnitPurchaseOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clnn:ChardanUnitPurchaseOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-15</instant>
        </period>
    </context>
    <context id="c206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clnn:ChardanUnitPurchaseOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-15</instant>
        </period>
    </context>
    <context id="c207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clnn:ChardanUnitPurchaseOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-15</instant>
        </period>
    </context>
    <context id="c208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:AvenueLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:AvenueLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandtwentyoneAvenueLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantsDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantsDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantsDate1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantsDate1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:December20201Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:December20201Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantsDate2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantsDate2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:May2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:May2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantsDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantsDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantsDate1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantsDate1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:December20201Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:December20201Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantsDate2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantsDate2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="c231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="c232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-11</endDate>
        </period>
    </context>
    <context id="c235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-11</instant>
        </period>
    </context>
    <context id="c236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandtwentyoneAvenueLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandtwentyoneAvenueLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandtwentyoneAvenueLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">clnn:TwoThousandtwentyoneAvenueLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="c243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
        </entity>
        <period>
            <instant>2020-12-30</instant>
        </period>
    </context>
    <context id="c244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:StockPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:StockPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clnn:StockPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clnn:StockPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:StockPlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:StockPlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clnn:StockPlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">clnn:StockPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">clnn:BlackScholesValuationModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">clnn:BlackScholesValuationModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">clnn:MonteCarloSimulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">clnn:MonteCarloSimulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">clnn:BlackScholesValuationModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">clnn:BlackScholesValuationModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">clnn:BlackScholesValuationModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">clnn:BlackScholesValuationModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">clnn:MonteCarloSimulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">clnn:MonteCarloSimulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">clnn:MonteCarloSimulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">clnn:MonteCarloSimulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">clnn:ContingentEarnOutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">clnn:ContingentEarnOutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:CleneNanomedicineContingentEarnoutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:InitialShareholdersContingentEarnoutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:CleneNanomedicineContingentEarnoutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:InitialShareholdersContingentEarnoutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:CleneNanomedicineContingentEarnoutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:InitialShareholdersContingentEarnoutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:DerivativeInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:PreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:DerivativeInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:PreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:DerivativeInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">clnn:PreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertibleCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-18</instant>
        </period>
    </context>
    <context id="c304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-18</instant>
        </period>
    </context>
    <context id="c305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-28</endDate>
        </period>
    </context>
    <context id="c306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
        </entity>
        <period>
            <instant>2020-12-28</instant>
        </period>
    </context>
    <context id="c307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">clnn:InvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-21</endDate>
        </period>
    </context>
    <context id="c308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-15</endDate>
        </period>
    </context>
    <context id="c309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
        </entity>
        <period>
            <startDate>2021-07-02</startDate>
            <endDate>2021-07-15</endDate>
        </period>
    </context>
    <context id="c310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:PIPEWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:PIPEWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">clnn:NetIncomeLossPerShareAttributableToCommonShareholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">clnn:NetIncomeLossPerShareAttributableToCommonShareholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">clnn:NetIncomeLossPerShareAttributableToCommonShareholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">clnn:NetIncomeLossPerShareAttributableToCommonShareholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
        </entity>
        <period>
            <startDate>2018-08-02</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="c317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="c318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">clnn:DrugsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">clnn:SupplementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">clnn:DrugsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">clnn:SupplementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">clnn:DrugsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">clnn:SupplementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">clnn:DrugsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">clnn:SupplementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">clnn:DrugsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">clnn:DrugsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">clnn:SupplementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">clnn:SupplementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clnn:PIPEWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="c335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822791</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-25</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <dei:DocumentType contextRef="c0">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c0">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c0">2021-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c0">01-39834</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0">Clene Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c0">85-2828339</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c0">6550 South Millrock Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c0">Suite G50</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c0">Salt Lake City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c0">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c0">84121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c0">(801)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c0">676-9695</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c0">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0">CLNN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c0">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c0">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany contextRef="c0">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c1" decimals="INF" unitRef="shares">62203532</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Cash contextRef="c2" decimals="-3" unitRef="usd">60552000</us-gaap:Cash>
    <us-gaap:Cash contextRef="c3" decimals="-3" unitRef="usd">59275000</us-gaap:Cash>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c2" decimals="-3" unitRef="usd">68000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c3" decimals="-3" unitRef="usd">21000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c2" decimals="-3" unitRef="usd">41000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c3" decimals="-3" unitRef="usd">191000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c2" decimals="-3" unitRef="usd">4732000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="-3" unitRef="usd">3502000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c2" decimals="-3" unitRef="usd">65393000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="-3" unitRef="usd">62989000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c2" decimals="-3" unitRef="usd">58000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c2" decimals="-3" unitRef="usd">3340000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="-3" unitRef="usd">1029000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="-3" unitRef="usd">4246000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="-3" unitRef="usd">4225000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Assets contextRef="c2" decimals="-3" unitRef="usd">73037000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c3" decimals="-3" unitRef="usd">68243000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c2" decimals="-3" unitRef="usd">1023000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c3" decimals="-3" unitRef="usd">1124000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c2" decimals="-3" unitRef="usd">3117000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c3" decimals="-3" unitRef="usd">3960000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c2" decimals="-3" unitRef="usd">164000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c3" decimals="-3" unitRef="usd">164000</us-gaap:TaxesPayableCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="c2" decimals="-3" unitRef="usd">112000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="c3" decimals="-3" unitRef="usd">112000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c2" decimals="-3" unitRef="usd">262000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="-3" unitRef="usd">194000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c2" decimals="-3" unitRef="usd">153000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c3" decimals="-3" unitRef="usd">190000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c3" decimals="-3" unitRef="usd">5924000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c2" decimals="-3" unitRef="usd">4831000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="-3" unitRef="usd">11668000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c2" decimals="-3" unitRef="usd">4068000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="-3" unitRef="usd">1785000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c2" decimals="-3" unitRef="usd">125000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c3" decimals="-3" unitRef="usd">205000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="c2" decimals="-3" unitRef="usd">4559000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:LongTermNotesPayable contextRef="c2" decimals="-3" unitRef="usd">14613000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable contextRef="c3" decimals="-3" unitRef="usd">1949000</us-gaap:LongTermNotesPayable>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c2" decimals="-3" unitRef="usd">68000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c3" decimals="-3" unitRef="usd">260000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <clnn:WarrantLiabilityNoncurrent contextRef="c2" decimals="-3" unitRef="usd">910000</clnn:WarrantLiabilityNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="c2" decimals="-3" unitRef="usd">33981000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="c3" decimals="-3" unitRef="usd">46129000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <clnn:InitialShareholdersContingentEarnout contextRef="c2" decimals="-3" unitRef="usd">4196000</clnn:InitialShareholdersContingentEarnout>
    <clnn:InitialShareholdersContingentEarnout contextRef="c3" decimals="-3" unitRef="usd">5906000</clnn:InitialShareholdersContingentEarnout>
    <us-gaap:Liabilities contextRef="c2" decimals="-3" unitRef="usd">67351000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c3" decimals="-3" unitRef="usd">67902000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c2" decimals="4" unitRef="usdPershares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c3" decimals="4" unitRef="usdPershares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c2" decimals="0" unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c3" decimals="0" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c2" decimals="0" unitRef="shares">62177020</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c2" decimals="0" unitRef="shares">62177020</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c3" decimals="0" unitRef="shares">59526171</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c3" decimals="0" unitRef="shares">59526171</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c2" decimals="-3" unitRef="usd">6000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c3" decimals="-3" unitRef="usd">6000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c2" decimals="-3" unitRef="usd">173203000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c3" decimals="-3" unitRef="usd">153571000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="-3" unitRef="usd">-167724000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="-3" unitRef="usd">-153561000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c2" decimals="-3" unitRef="usd">201000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c3" decimals="-3" unitRef="usd">325000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" unitRef="usd">5686000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" unitRef="usd">341000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c2" decimals="-3" unitRef="usd">73037000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="-3" unitRef="usd">68243000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c4" decimals="-3" unitRef="usd">63000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c5" decimals="-3" unitRef="usd">81000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c6" decimals="-3" unitRef="usd">400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c7" decimals="-3" unitRef="usd">160000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c8" decimals="-3" unitRef="usd">47000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c9" decimals="-3" unitRef="usd">17000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c10" decimals="-3" unitRef="usd">124000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c11" decimals="-3" unitRef="usd">17000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c12" decimals="-3" unitRef="usd">110000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c13" decimals="-3" unitRef="usd">98000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c0" decimals="-3" unitRef="usd">524000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c14" decimals="-3" unitRef="usd">177000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c12" decimals="-3" unitRef="usd">14000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c0" decimals="-3" unitRef="usd">812000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c14" decimals="-3" unitRef="usd">58000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c12" decimals="-3" unitRef="usd">6146000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c13" decimals="-3" unitRef="usd">3994000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" unitRef="usd">18893000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c14" decimals="-3" unitRef="usd">10750000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c12" decimals="-3" unitRef="usd">4400000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c13" decimals="-3" unitRef="usd">1795000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="-3" unitRef="usd">16739000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c14" decimals="-3" unitRef="usd">3623000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c12" decimals="-3" unitRef="usd">10560000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c13" decimals="-3" unitRef="usd">5789000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="-3" unitRef="usd">36444000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c14" decimals="-3" unitRef="usd">14431000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c12" decimals="-3" unitRef="usd">-10450000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c13" decimals="-3" unitRef="usd">-5691000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-35920000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c14" decimals="-3" unitRef="usd">-14254000</us-gaap:OperatingIncomeLoss>
    <clnn:InterestIncomeexpense contextRef="c12" decimals="-3" unitRef="usd">-80000</clnn:InterestIncomeexpense>
    <clnn:InterestIncomeexpense contextRef="c13" decimals="-3" unitRef="usd">367000</clnn:InterestIncomeexpense>
    <clnn:InterestIncomeexpense contextRef="c0" decimals="-3" unitRef="usd">497000</clnn:InterestIncomeexpense>
    <clnn:InterestIncomeexpense contextRef="c14" decimals="-3" unitRef="usd">608000</clnn:InterestIncomeexpense>
    <clnn:GainOnExtinguishmentOfNotesPayable contextRef="c0" decimals="-3" unitRef="usd">-647000</clnn:GainOnExtinguishmentOfNotesPayable>
    <clnn:LossOnExtinguishmentOfConvertibleNotesPayable contextRef="c13" decimals="-3" unitRef="usd">540000</clnn:LossOnExtinguishmentOfConvertibleNotesPayable>
    <clnn:LossOnExtinguishmentOfConvertibleNotesPayable contextRef="c14" decimals="-3" unitRef="usd">540000</clnn:LossOnExtinguishmentOfConvertibleNotesPayable>
    <us-gaap:GainLossOnContractTermination contextRef="c14" decimals="-3" unitRef="usd">51000</us-gaap:GainLossOnContractTermination>
    <clnn:ChangeInFairValueOfPreferredStockWarrantLiability contextRef="c13" decimals="-3" unitRef="usd">-5071000</clnn:ChangeInFairValueOfPreferredStockWarrantLiability>
    <clnn:ChangeInFairValueOfPreferredStockWarrantLiability contextRef="c14" decimals="-3" unitRef="usd">-7378000</clnn:ChangeInFairValueOfPreferredStockWarrantLiability>
    <clnn:ChangeInFairValueOfDerivativeLiability contextRef="c13" decimals="-3" unitRef="usd">15000</clnn:ChangeInFairValueOfDerivativeLiability>
    <clnn:ChangeInFairValueOfDerivativeLiability contextRef="c14" decimals="-3" unitRef="usd">29000</clnn:ChangeInFairValueOfDerivativeLiability>
    <clnn:ChangeInFairValueOfContingentEarnout contextRef="c12" decimals="-3" unitRef="usd">35042000</clnn:ChangeInFairValueOfContingentEarnout>
    <clnn:ChangeInFairValueOfContingentEarnout contextRef="c0" decimals="-3" unitRef="usd">18072000</clnn:ChangeInFairValueOfContingentEarnout>
    <clnn:ChangeInFairValueOfInitialShareholdersContingentEarnout contextRef="c12" decimals="-3" unitRef="usd">3439000</clnn:ChangeInFairValueOfInitialShareholdersContingentEarnout>
    <clnn:ChangeInFairValueOfInitialShareholdersContingentEarnout contextRef="c0" decimals="-3" unitRef="usd">1710000</clnn:ChangeInFairValueOfInitialShareholdersContingentEarnout>
    <clnn:ChangeInFairValueOfCommonStockWarrantLiability contextRef="c12" decimals="-3" unitRef="usd">414000</clnn:ChangeInFairValueOfCommonStockWarrantLiability>
    <clnn:ChangeInFairValueOfCommonStockWarrantLiability contextRef="c0" decimals="-3" unitRef="usd">547000</clnn:ChangeInFairValueOfCommonStockWarrantLiability>
    <clnn:AustraliaResearchAndDevelopmentCredit contextRef="c12" decimals="-3" unitRef="usd">-364000</clnn:AustraliaResearchAndDevelopmentCredit>
    <clnn:AustraliaResearchAndDevelopmentCredit contextRef="c13" decimals="-3" unitRef="usd">-1343000</clnn:AustraliaResearchAndDevelopmentCredit>
    <clnn:AustraliaResearchAndDevelopmentCredit contextRef="c0" decimals="-3" unitRef="usd">-1078000</clnn:AustraliaResearchAndDevelopmentCredit>
    <clnn:AustraliaResearchAndDevelopmentCredit contextRef="c14" decimals="-3" unitRef="usd">-2611000</clnn:AustraliaResearchAndDevelopmentCredit>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c12" decimals="-3" unitRef="usd">-14000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c13" decimals="-3" unitRef="usd">16000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c0" decimals="-3" unitRef="usd">-13000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c14" decimals="-3" unitRef="usd">34000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c12" decimals="-3" unitRef="usd">39325000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c13" decimals="-3" unitRef="usd">-4604000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="-3" unitRef="usd">21544000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c14" decimals="-3" unitRef="usd">-5801000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c12" decimals="-3" unitRef="usd">28875000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c13" decimals="-3" unitRef="usd">-10295000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c0" decimals="-3" unitRef="usd">-14376000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c14" decimals="-3" unitRef="usd">-20055000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c12" decimals="-3" unitRef="usd">-69000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c0" decimals="-3" unitRef="usd">-213000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c12" decimals="-3" unitRef="usd">28944000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c13" decimals="-3" unitRef="usd">-10295000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-14163000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c14" decimals="-3" unitRef="usd">-20055000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c12" decimals="-3" unitRef="usd">-87000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c13" decimals="-3" unitRef="usd">2000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c0" decimals="-3" unitRef="usd">-124000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c14" decimals="-3" unitRef="usd">18000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossTax contextRef="c12" decimals="-3" unitRef="usd">87000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax contextRef="c13" decimals="-3" unitRef="usd">-2000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax contextRef="c0" decimals="-3" unitRef="usd">124000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax contextRef="c14" decimals="-3" unitRef="usd">-18000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c12" decimals="-3" unitRef="usd">28857000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c13" decimals="-3" unitRef="usd">-10293000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c0" decimals="-3" unitRef="usd">-14287000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c14" decimals="-3" unitRef="usd">-20037000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="c12"
      decimals="2"
      id="ix_0_fact"
      unitRef="usdPershares">0.47</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c13"
      decimals="2"
      id="ix_1_fact"
      unitRef="usdPershares">-0.59</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ix_2_fact"
      unitRef="usdPershares">-0.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c14"
      decimals="2"
      id="ix_3_fact"
      unitRef="usdPershares">-1.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c12"
      decimals="2"
      id="ix_4_fact"
      unitRef="usdPershares">0.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c13"
      decimals="2"
      id="ix_5_fact"
      unitRef="usdPershares">-0.59</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="ix_6_fact"
      unitRef="usdPershares">-0.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c14"
      decimals="2"
      id="ix_7_fact"
      unitRef="usdPershares">-1.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c12"
      decimals="INF"
      id="ix_8_fact"
      unitRef="shares">62071754</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c13"
      decimals="INF"
      id="ix_9_fact"
      unitRef="shares">17358159</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="INF"
      id="ix_10_fact"
      unitRef="shares">61307699</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c14"
      decimals="INF"
      id="ix_11_fact"
      unitRef="shares">17358159</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c12"
      decimals="INF"
      id="ix_12_fact"
      unitRef="shares">70038634</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c13"
      decimals="INF"
      id="ix_13_fact"
      unitRef="shares">17358159</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="INF"
      id="ix_14_fact"
      unitRef="shares">61307699</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c14"
      decimals="INF"
      id="ix_15_fact"
      unitRef="shares">17358159</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="c16" decimals="INF" unitRef="shares">59526171</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c16" decimals="-3" unitRef="usd">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c17" decimals="-3" unitRef="usd">153571000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c18" decimals="-3" unitRef="usd">-153561000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c19" decimals="-3" unitRef="usd">325000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" unitRef="usd">341000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c21" decimals="INF" unitRef="shares">48211</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c22" decimals="-3" unitRef="usd">50000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c25" decimals="-3" unitRef="usd">50000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c22" decimals="-3" unitRef="usd">3265000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c25" decimals="-3" unitRef="usd">3265000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <clnn:ForeignCurrencyTranslationAdjustment contextRef="c24" decimals="-3" unitRef="usd">24000</clnn:ForeignCurrencyTranslationAdjustment>
    <clnn:ForeignCurrencyTranslationAdjustment contextRef="c25" decimals="-3" unitRef="usd">24000</clnn:ForeignCurrencyTranslationAdjustment>
    <us-gaap:ProfitLoss contextRef="c23" decimals="-3" unitRef="usd">-39756000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c25" decimals="-3" unitRef="usd">-39756000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding contextRef="c27" decimals="INF" unitRef="shares">59574382</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c27" decimals="-3" unitRef="usd">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c28" decimals="-3" unitRef="usd">156886000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c29" decimals="-3" unitRef="usd">-193317000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c30" decimals="-3" unitRef="usd">349000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c31" decimals="-3" unitRef="usd">-36076000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c33" decimals="INF" unitRef="shares">960540</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c34" decimals="-3" unitRef="usd">9250000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c37" decimals="-3" unitRef="usd">9250000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c33" decimals="INF" unitRef="shares">124680</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c34" decimals="-3" unitRef="usd">58000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c37" decimals="-3" unitRef="usd">58000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c33" decimals="INF" unitRef="shares">21989</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c34" decimals="-3" unitRef="usd">4255000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c37" decimals="-3" unitRef="usd">4255000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <clnn:ForeignCurrencyTranslationAdjustment contextRef="c36" decimals="-3" unitRef="usd">-61000</clnn:ForeignCurrencyTranslationAdjustment>
    <clnn:ForeignCurrencyTranslationAdjustment contextRef="c37" decimals="-3" unitRef="usd">-61000</clnn:ForeignCurrencyTranslationAdjustment>
    <us-gaap:ProfitLoss contextRef="c35" decimals="-3" unitRef="usd">-3351000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c37" decimals="-3" unitRef="usd">-3351000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding contextRef="c39" decimals="INF" unitRef="shares">60681591</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c39" decimals="-3" unitRef="usd">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c40" decimals="-3" unitRef="usd">170449000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c41" decimals="-3" unitRef="usd">-196668000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c42" decimals="-3" unitRef="usd">288000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c43" decimals="-3" unitRef="usd">-25925000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c45" decimals="INF" unitRef="shares">236976</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c46" decimals="-3" unitRef="usd">319000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c12" decimals="-3" unitRef="usd">319000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <clnn:StockIssueDuringPeriodSharesExerciseOfWarrants contextRef="c45" decimals="INF" unitRef="shares">1002250</clnn:StockIssueDuringPeriodSharesExerciseOfWarrants>
    <clnn:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="c46" decimals="-3" unitRef="usd">10000</clnn:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <clnn:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="c12" decimals="-3" unitRef="usd">10000</clnn:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <clnn:StockIssuedDuringPeriodExerciseOfUnderwritersOptioninShares contextRef="c45" decimals="INF" unitRef="shares">54083</clnn:StockIssuedDuringPeriodExerciseOfUnderwritersOptioninShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c46" decimals="-3" unitRef="usd">2425000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c12" decimals="-3" unitRef="usd">2425000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c45" decimals="INF" unitRef="shares">202120</us-gaap:StockIssuedDuringPeriodSharesOther>
    <clnn:ForeignCurrencyTranslationAdjustment contextRef="c48" decimals="-3" unitRef="usd">-87000</clnn:ForeignCurrencyTranslationAdjustment>
    <clnn:ForeignCurrencyTranslationAdjustment contextRef="c12" decimals="-3" unitRef="usd">-87000</clnn:ForeignCurrencyTranslationAdjustment>
    <us-gaap:ProfitLoss contextRef="c47" decimals="-3" unitRef="usd">28944000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c12" decimals="-3" unitRef="usd">28944000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding contextRef="c50" decimals="INF" unitRef="shares">62177020</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c50" decimals="-3" unitRef="usd">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c51" decimals="-3" unitRef="usd">173203000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c52" decimals="-3" unitRef="usd">-167724000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c53" decimals="-3" unitRef="usd">201000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" unitRef="usd">5686000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c54"
      decimals="INF"
      id="ix_16_fact"
      unitRef="shares">27499837</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c54"
      decimals="-3"
      id="ix_17_fact"
      unitRef="usd">72661000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c55"
      decimals="INF"
      id="ix_18_fact"
      unitRef="shares">17357505</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c55"
      decimals="-3"
      id="ix_19_fact"
      unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c56"
      decimals="-3"
      id="ix_20_fact"
      unitRef="usd">1754000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c57"
      decimals="-3"
      id="ix_21_fact"
      unitRef="usd">-69571000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c58"
      decimals="-3"
      id="ix_22_fact"
      unitRef="usd">41000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c59"
      decimals="-3"
      id="ix_23_fact"
      unitRef="usd">-67774000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c62" decimals="-3" unitRef="usd">171000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c65" decimals="-3" unitRef="usd">171000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <clnn:ForeignCurrencyTranslationAdjustment contextRef="c64" decimals="-3" unitRef="usd">6000</clnn:ForeignCurrencyTranslationAdjustment>
    <clnn:ForeignCurrencyTranslationAdjustment contextRef="c65" decimals="-3" unitRef="usd">6000</clnn:ForeignCurrencyTranslationAdjustment>
    <us-gaap:ProfitLoss contextRef="c63" decimals="-3" unitRef="usd">-3941000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c65" decimals="-3" unitRef="usd">-3941000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="c66"
      decimals="INF"
      id="ix_24_fact"
      unitRef="shares">27499837</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c66"
      decimals="-3"
      id="ix_25_fact"
      unitRef="usd">72661000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c67"
      decimals="INF"
      id="ix_26_fact"
      unitRef="shares">17357505</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c67"
      decimals="-3"
      id="ix_27_fact"
      unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c68"
      decimals="-3"
      id="ix_28_fact"
      unitRef="usd">1925000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c69"
      decimals="-3"
      id="ix_29_fact"
      unitRef="usd">-73512000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c70"
      decimals="-3"
      id="ix_30_fact"
      unitRef="usd">47000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c71"
      decimals="-3"
      id="ix_31_fact"
      unitRef="usd">-71538000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c74" decimals="-3" unitRef="usd">174000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c77" decimals="-3" unitRef="usd">174000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <clnn:ForeignCurrencyTranslationAdjustment contextRef="c76" decimals="-3" unitRef="usd">10000</clnn:ForeignCurrencyTranslationAdjustment>
    <clnn:ForeignCurrencyTranslationAdjustment contextRef="c77" decimals="-3" unitRef="usd">10000</clnn:ForeignCurrencyTranslationAdjustment>
    <us-gaap:ProfitLoss contextRef="c75" decimals="-3" unitRef="usd">-5819000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c77" decimals="-3" unitRef="usd">-5819000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="c78"
      decimals="INF"
      id="ix_32_fact"
      unitRef="shares">27499837</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c78"
      decimals="-3"
      id="ix_33_fact"
      unitRef="usd">72661000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c79"
      decimals="INF"
      id="ix_34_fact"
      unitRef="shares">17357505</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c79"
      decimals="-3"
      id="ix_35_fact"
      unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c80"
      decimals="-3"
      id="ix_36_fact"
      unitRef="usd">2099000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c81"
      decimals="-3"
      id="ix_37_fact"
      unitRef="usd">-79331000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c82"
      decimals="-3"
      id="ix_38_fact"
      unitRef="usd">57000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c83"
      decimals="-3"
      id="ix_39_fact"
      unitRef="usd">-77173000</us-gaap:StockholdersEquity>
    <clnn:NetOfIssuanceCosts contextRef="c13" decimals="-2" unitRef="usd">1300</clnn:NetOfIssuanceCosts>
    <clnn:StockIssuedDuringPeriodSharesSeriesDPreferredStock
      contextRef="c84"
      decimals="INF"
      id="ix_40_fact"
      unitRef="shares">7896922</clnn:StockIssuedDuringPeriodSharesSeriesDPreferredStock>
    <clnn:StockIssuedDuringPeriodOfSeriesDPreferredStock
      contextRef="c84"
      decimals="-3"
      id="ix_41_fact"
      unitRef="usd">35051000</clnn:StockIssuedDuringPeriodOfSeriesDPreferredStock>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="c84"
      decimals="INF"
      id="ix_42_fact"
      unitRef="shares">1497135</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="c84"
      decimals="-3"
      id="ix_43_fact"
      unitRef="usd">6891000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c85"
      decimals="INF"
      id="ix_44_fact"
      unitRef="shares">2663</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c86"
      decimals="-3"
      id="ix_45_fact"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c13"
      decimals="-3"
      id="ix_46_fact"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c86" decimals="-3" unitRef="usd">209000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c13" decimals="-3" unitRef="usd">209000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <clnn:ForeignCurrencyTranslationAdjustment contextRef="c88" decimals="-3" unitRef="usd">2000</clnn:ForeignCurrencyTranslationAdjustment>
    <clnn:ForeignCurrencyTranslationAdjustment contextRef="c13" decimals="-3" unitRef="usd">2000</clnn:ForeignCurrencyTranslationAdjustment>
    <us-gaap:ProfitLoss contextRef="c87" decimals="-3" unitRef="usd">-10295000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c13" decimals="-3" unitRef="usd">-10295000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="c89"
      decimals="INF"
      id="ix_47_fact"
      unitRef="shares">36893894</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c89"
      decimals="-3"
      id="ix_48_fact"
      unitRef="usd">114603000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c90"
      decimals="INF"
      id="ix_49_fact"
      unitRef="shares">17360168</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c90"
      decimals="-3"
      id="ix_50_fact"
      unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c91"
      decimals="-3"
      id="ix_51_fact"
      unitRef="usd">2310000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c92"
      decimals="-3"
      id="ix_52_fact"
      unitRef="usd">-89626000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c93"
      decimals="-3"
      id="ix_53_fact"
      unitRef="usd">59000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c94"
      decimals="-3"
      id="ix_54_fact"
      unitRef="usd">-87255000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-14163000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c14" decimals="-3" unitRef="usd">-20055000</us-gaap:NetIncomeLoss>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciation contextRef="c0" decimals="-3" unitRef="usd">734000</us-gaap:CostOfGoodsAndServicesSoldDepreciation>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciation contextRef="c14" decimals="-3" unitRef="usd">696000</us-gaap:CostOfGoodsAndServicesSoldDepreciation>
    <us-gaap:OtherNoncashExpense contextRef="c0" decimals="-3" unitRef="usd">81000</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense contextRef="c14" decimals="-3" unitRef="usd">87000</us-gaap:OtherNoncashExpense>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c14" decimals="-3" unitRef="usd">7378000</us-gaap:FairValueAdjustmentOfWarrants>
    <clnn:ChangeInFairValueOfCleneNanomedicineContingentEarnouts contextRef="c0" decimals="-3" unitRef="usd">18072000</clnn:ChangeInFairValueOfCleneNanomedicineContingentEarnouts>
    <clnn:ChangesInFairValueOfInitialShareholdersContingentEarnout contextRef="c0" decimals="-3" unitRef="usd">1710000</clnn:ChangesInFairValueOfInitialShareholdersContingentEarnout>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="c14" decimals="-3" unitRef="usd">29000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <clnn:ChangeInFairValueOfCommonStockWarrantLiabilitys contextRef="c0" decimals="-3" unitRef="usd">547000</clnn:ChangeInFairValueOfCommonStockWarrantLiabilitys>
    <us-gaap:GainLossOnTerminationOfLease contextRef="c14" decimals="-3" unitRef="usd">51000</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="-3" unitRef="usd">9945000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c14" decimals="-3" unitRef="usd">554000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c0" decimals="-3" unitRef="usd">647000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="c14" decimals="-3" unitRef="usd">-540000</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c14" decimals="-3" unitRef="usd">179000</us-gaap:AmortizationOfDebtDiscountPremium>
    <clnn:IncreaseInInterestAccruedOnNotesPayable contextRef="c0" decimals="-3" unitRef="usd">-134000</clnn:IncreaseInInterestAccruedOnNotesPayable>
    <clnn:IncreaseInInterestAccruedOnNotesPayable contextRef="c14" decimals="-3" unitRef="usd">399000</clnn:IncreaseInInterestAccruedOnNotesPayable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c0" decimals="-3" unitRef="usd">-150000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c14" decimals="-3" unitRef="usd">32000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c0" decimals="-3" unitRef="usd">48000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c14" decimals="-3" unitRef="usd">21000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c0" decimals="-3" unitRef="usd">1230000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c14" decimals="-3" unitRef="usd">2112000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c0" decimals="-3" unitRef="usd">446000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c14" decimals="-3" unitRef="usd">-242000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c0" decimals="-3" unitRef="usd">511000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c14" decimals="-3" unitRef="usd">-335000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties contextRef="c14" decimals="-3" unitRef="usd">-131000</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c14" decimals="-3" unitRef="usd">112000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes contextRef="c0" decimals="-3" unitRef="usd">192000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c0" decimals="-3" unitRef="usd">-142000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c14" decimals="-3" unitRef="usd">-58000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="-3" unitRef="usd">-25018000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c14" decimals="-3" unitRef="usd">-13121000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="-3" unitRef="usd">661000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c14" decimals="-3" unitRef="usd">269000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="-3" unitRef="usd">-661000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c14" decimals="-3" unitRef="usd">-269000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c0" decimals="-3" unitRef="usd">427000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c14" decimals="-3" unitRef="usd">2000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c14" decimals="-3" unitRef="usd">6125000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c0" decimals="-3" unitRef="usd">10000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c0" decimals="-3" unitRef="usd">117000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c14" decimals="-3" unitRef="usd">156000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c0" decimals="-3" unitRef="usd">9250000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromOtherDebt contextRef="c0" decimals="-3" unitRef="usd">20000000</us-gaap:ProceedsFromOtherDebt>
    <us-gaap:ProceedsFromOtherDebt contextRef="c14" decimals="-3" unitRef="usd">652000</us-gaap:ProceedsFromOtherDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c0" decimals="-3" unitRef="usd">534000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c0" decimals="-3" unitRef="usd">5000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:PaymentsOfFinancingCosts contextRef="c0" decimals="-3" unitRef="usd">1901000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts contextRef="c14" decimals="-3" unitRef="usd">310000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="c14" decimals="-3" unitRef="usd">35051000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="-3" unitRef="usd">27130000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c14" decimals="-3" unitRef="usd">41364000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="c0" decimals="-3" unitRef="usd">-116000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="c14" decimals="-3" unitRef="usd">19000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c0" decimals="-3" unitRef="usd">1335000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c14" decimals="-3" unitRef="usd">27993000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="-3" unitRef="usd">59275000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c59" decimals="-3" unitRef="usd">8788000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="-3" unitRef="usd">60610000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c94" decimals="-3" unitRef="usd">36781000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:Cash contextRef="c2" decimals="-3" unitRef="usd">60552000</us-gaap:Cash>
    <us-gaap:Cash contextRef="c94" decimals="-3" unitRef="usd">36781000</us-gaap:Cash>
    <us-gaap:RestrictedCash contextRef="c2" decimals="-3" unitRef="usd">58000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="-3" unitRef="usd">60610000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c94" decimals="-3" unitRef="usd">36781000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <clnn:WarrantLiabilityRecordedAtIssuanceOfNotesPayable contextRef="c0" decimals="-3" unitRef="usd">1457000</clnn:WarrantLiabilityRecordedAtIssuanceOfNotesPayable>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c0" decimals="-3" unitRef="usd">2492000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c14" decimals="-3" unitRef="usd">820000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <clnn:LeaseLiabilitySettledThroughTerminationOfLease contextRef="c14" decimals="-3" unitRef="usd">349000</clnn:LeaseLiabilitySettledThroughTerminationOfLease>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction contextRef="c14" decimals="-3" unitRef="usd">705000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <clnn:IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes contextRef="c14" decimals="-3" unitRef="usd">5675000</clnn:IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes>
    <clnn:ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN contextRef="c14" decimals="-3" unitRef="usd">676000</clnn:ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN>
    <clnn:DeferredOfferingCostsInAccruedLiabilities contextRef="c14" decimals="-3" unitRef="usd">2011000</clnn:DeferredOfferingCostsInAccruedLiabilities>
    <clnn:CashPaidForInterestExpense contextRef="c0" decimals="-3" unitRef="usd">631000</clnn:CashPaidForInterestExpense>
    <clnn:CashPaidForInterestExpense contextRef="c14" decimals="-3" unitRef="usd">30000</clnn:CashPaidForInterestExpense>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;1. Nature of the Business&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Clene Inc. (formerly Chelsea
Worldwide Inc.) (the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; or similar such references) is a clinical-stage pharmaceutical
company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. We have developed
an electro-crystal-chemistry drug development platform which enables production of concentrated, stable, highly active, clean-surfaced
nanocrystal suspensions. We have multiple drug assets currently in development for applications in neurology, infectious disease, and
oncology. Our efforts are currently focused on addressing the high unmet medical needs in two areas: first, those related to central nervous
system disorders including Multiple Sclerosis (&#x201c;MS&#x201d;), Parkinson&#x2019;s Disease (&#x201c;PD&#x201d;) and Amyotrophic Lateral
Sclerosis (&#x201c;ALS&#x201d;); and second, those related to COVID-19, a highly infectious viral respiratory disease with serious and sometimes
fatal co-morbidities. Our patented electro-crystal-chemistry manufacturing platform further enables us to develop very low concentration
dietary supplements to advance the health and well-being of broad populations. These dietary supplements can vary greatly and include
nanocrystals of varying composition, shapes and sizes as well as ionic solutions with diverse metallic constituents. Dietary supplements
are marketed and distributed through our wholly owned subsidiary, dOrbital, Inc. (&#x201c;dOrbital&#x201d;), or through an exclusive license
with 4Life Research LLC (&#x201c;4Life&#x201d;), a related party (see Note 20).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The accompanying condensed
consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Clene Nanomedicine, Inc. (&#x201c;Clene
Nanomedicine&#x201d;), a subsidiary incorporated in Delaware, Clene Australia Pty Ltd (&#x201c;Clene Australia&#x201d;), a subsidiary incorporated
in Australia, and dOrbital, Inc., a subsidiary incorporated in Delaware, after elimination of all intercompany accounts and transactions.
The wholly-owned subsidiary, Clene Netherlands B.V. (&#x201c;Clene Netherlands&#x201d;) was established on April 21, 2021 and has no financial
positions or operations to date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Registration Statements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On February 16, 2021, we filed
a registration statement on Form S-1 (file number 333-253173) to register 4,541,481 shares of Clene Inc. common stock (&#x201c;Common Stock&#x201d;)
underlying outstanding warrants that we have previously issued, among which 2,517,500 warrants (the &#x201c;Public Warrants&#x201d;) and
904,231 warrants (the &#x201c;Kensington Warrants&#x201d;) were originally issued by Tottenham Acquisition I Limited (&#x201c;Tottenham&#x201d;)
and Clene Nanomedicine, respectively, prior to the closing of the Reverse Recapitalization, and 2,239,500 warrants (the &#x201c;December
2020 PIPE Warrants&#x201d;) were issued as part of a private placement (the &#x201c;December 2020 PIPE&#x201d;) in connection with the closing
of the Reverse Recapitalization. We will receive aggregate proceeds of $30.7 million if all of these warrants are exercised. On April
19, 2021, the registration statement was declared effective by the Securities and Exchange Commission (the &#x201c;SEC&#x201d;). In connection
with the registration statement on Form S-1, we incurred $0 and $27 thousand of certain offering costs during the three and nine months
ended September 30, 2021, respectively, recognized as an expense within general and administrative expenses in the condensed consolidated
statement of operations and comprehensive income (loss) during the three and nine months ended September 30, 2021. As of September 30,
2021, the Company received aggregate proceeds of $10.0 thousand from the exercise of certain warrants, representing 2,004,500 December
2020 PIPE Warrants at an offering price per share of $0.01.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;On July 22, 2021, we
filed a registration statement on Form S-1 (file number 333-258098) to register 1,140,731 shares of Common Stock underlying
outstanding warrants that we have previously issued, among which 1,024,880 warrants (the &#x201c;AK Warrants&#x201d;, and collectively
with the Kensington Warrants, the &#x201c;Founder Warrants&#x201d;) were originally issued by Clene Nanomedicine prior to the Reverse
Recapitalization in April 2013 and 115,851 warrants (the &#x201c;Avenue Warrants&#x201d;) were issued pursuant to a loan agreement
(the &#x201c;2021 Avenue Loan&#x201d;) with Avenue Venture Opportunities Fund, L.P. (&#x201c;Avenue&#x201d;) (see Note 8). We will
receive aggregate proceeds of $3.0 million if all of these warrants are exercised. In addition, the registration statement on Form
S-1 registered 960,540 shares of Common Stock, issued in a private placement in May 2021 (the &#x201c;May 2021 PIPE&#x201d;). We will
not receive any proceeds from the possible sale of these shares by the selling shareholders. On August 2, 2021, the registration
statement was declared effective by the SEC. In connection with the registration statement on Form S-1, we incurred an immaterial
amount of certain offering costs, which were recognized as an expense within general and administrative expenses in the condensed
consolidated statements of operations and comprehensive income (loss) during the three and nine months ended September 30, 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Liquidity&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We have incurred significant losses and negative cash flows from operations
since our inception. We incurred a net loss of $14.2 million for the nine months ended September 30, 2021. We incurred net losses of $10.3
million and $20.1 million for the three and nine months ended September 30, 2020, respectively. As of September 30, 2021, our cash totaled
$60.6 million, and our accumulated deficit was $167.7 million. As of December 31, 2020, our cash totaled $59.3 million, and our accumulated
deficit was $153.6 million. We had net cash used in operating activities of $25.0 million and $13.1 million for the nine months ended
September 30, 2021 and 2020, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Prior to the Reverse Recapitalization,
Clene Nanomedicine&#x2019;s operations were financed through the issuance of equity instruments and the issuance of convertible promissory
notes. Subsequent to the Reverse Recapitalization, we have obtained additional liquidity through a term loan and private placements of
equity instruments. We have not generated significant revenues to date and do not anticipate generating any significant revenues unless
we successfully complete development and obtain regulatory approval for our drugs or for our COVID-19 study. We expect to incur additional
losses in the future to fund our operations and conduct product research and development and we recognize the need to raise additional
capital to fully implement our business plan. Additionally, we may attempt to negotiate a collaboration agreement with a third party for
development and commercialization of a drug candidate, which may provide upfront and milestone payments to reduce our spending going forward.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We expect to continue investing
in product development, sales and marketing and customer support for our products. The long-term continuation of our business plan is
dependent upon the generation of sufficient revenues from our products to offset expenses and capital expenditures. In the event that
we do not generate sufficient revenues and are unable to obtain funding, we will be forced to delay, reduce, or eliminate some or all
of our research and development programs, product portfolio expansion, commercialization efforts, or capital expenditures, which could
adversely affect our business prospects, ability to meet long-term liquidity needs, or we may be unable to continue operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We expect that the cash on
hand as of September 30, 2021 will be sufficient to fund our operations for a period extending beyond twelve months from the date these
condensed consolidated financial statements for the three and nine months ended September 30, 2021 were issued.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Impact of the COVID-19 Pandemic&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The COVID-19 pandemic, which
began in December&#160;2019 and has spread worldwide, has caused many governments to implement measures to slow the spread of the outbreak.
The outbreak and government measures taken in response have had a significant impact, both direct and indirect, on businesses and commerce,
as worker shortages have occurred, supply chains have been disrupted, and facilities and production have been suspended. The future progression
of the pandemic and its effects on our business and operations remains uncertain. The COVID-19 pandemic may affect our ability to initiate
and complete preclinical studies, delay the initiation of future clinical trials, disrupt regulatory activities, or have other adverse
effects on our business and operations. In particular, the Company and our clinical research organizations (&#x201c;CROs&#x201d;) may face
disruptions that may affect our ability to initiate and complete preclinical studies, manufacturing disruptions, and delays at clinical
trial sites. The pandemic has already caused significant disruptions in the financial markets, and may continue to cause such disruptions,
which could impact our ability to raise additional funds to support our operations. Moreover, the pandemic has significantly impacted
economies worldwide and could result in adverse effects on our business and operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We are monitoring the potential
impact of the COVID-19 pandemic on our business and financial statements. While the COVID-19 pandemic has led to various research restrictions
and paused certain of our clinical trials, these impacts have been temporary and to date we have not experienced material business disruptions
or incurred impairment losses in the carrying values of our assets as a result of the pandemic and we are not aware of any specific related
event or circumstance that would require us to revise the estimates reflected in these condensed consolidated financial statements. The
extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations, cash flows, and financial
condition, including planned and future clinical trials and research and development costs, will depend on future developments that are
highly uncertain, including as a result of new information that may emerge concerning COVID-19, the actions taken to contain or treat
it, and the duration and intensity of the related effects.&#160;&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c95" decimals="0" unitRef="shares">4541481</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c96" decimals="0" unitRef="shares">2517500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c97" decimals="0" unitRef="shares">904231</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c98" decimals="0" unitRef="shares">2239500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <clnn:AggregateFutureProceedsWarrantsExercised contextRef="c99" decimals="-5" unitRef="usd">30700000</clnn:AggregateFutureProceedsWarrantsExercised>
    <clnn:OfferingCost contextRef="c12" decimals="0" unitRef="usd">0</clnn:OfferingCost>
    <clnn:OfferingCost contextRef="c0" decimals="-3" unitRef="usd">27000</clnn:OfferingCost>
    <clnn:AggregateProceedsReceived contextRef="c2" decimals="-2" unitRef="usd">10000</clnn:AggregateProceedsReceived>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c100" decimals="0" unitRef="shares">2004500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <clnn:OfferingPricePerShare contextRef="c0" decimals="2" unitRef="usdPershares">0.01</clnn:OfferingPricePerShare>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c101" decimals="0" unitRef="shares">1140731</us-gaap:ClassOfWarrantOrRightOutstanding>
    <clnn:CommonStockUnderlyingWarrantOutstanding contextRef="c102" decimals="0" unitRef="shares">1024880</clnn:CommonStockUnderlyingWarrantOutstanding>
    <clnn:CommonStockUnderlyingWarrantOutstanding contextRef="c103" decimals="0" unitRef="shares">115851</clnn:CommonStockUnderlyingWarrantOutstanding>
    <clnn:AggregateFutureProceedsWarrantsExercised contextRef="c102" decimals="-5" unitRef="usd">3000000</clnn:AggregateFutureProceedsWarrantsExercised>
    <clnn:ShareIssuanceOfCommonStockPrivateOffering contextRef="c104" decimals="0" unitRef="shares">960540</clnn:ShareIssuanceOfCommonStockPrivateOffering>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-5" unitRef="usd">-14200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c13" decimals="-5" unitRef="usd">-10300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c14" decimals="-5" unitRef="usd">-20100000</us-gaap:NetIncomeLoss>
    <us-gaap:Cash contextRef="c2" decimals="-5" unitRef="usd">60600000</us-gaap:Cash>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="-5" unitRef="usd">-167700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:Cash contextRef="c3" decimals="-5" unitRef="usd">59300000</us-gaap:Cash>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="-5" unitRef="usd">-153600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="-5" unitRef="usd">-25000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c14" decimals="-5" unitRef="usd">-13100000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;2. Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We have prepared the accompanying
condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States of America
(&#x201c;GAAP&#x201d;) for interim financial reporting and as required by Regulation S-X, Rule 10-01. The condensed consolidated financial
statements have been prepared on the same basis as our audited annual consolidated financial statements and, in the opinion of management,
reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of our financial condition as
of September 30, 2021, the results of our operations for the three and nine months ended September 30, 2021, our cash flows for the nine
months ended September 30, 2021 and 2020, and the condensed consolidated statement of stockholders&#x2019; equity (deficit) for the three
and nine months ended September 30, 2021 and 2020. The financial data and other information disclosed in these notes related to the three
and nine months ended September 30, 2021 and 2020 are unaudited. The results of operations for the three and nine months ended September
30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021, any other interim periods,
or any future year or period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Prior period balances for
accounts receivable have been reclassified to conform to the current year presentation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The preparation of condensed
consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets, liabilities, and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial
statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying
condensed consolidated financial statements include, but are not limited to, the valuation of common stock, stock options, contingent
earn-out liabilities, Preferred Stock warrants, and Common Stock warrants.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We base our estimates on historical
experience and on various other assumptions that are believed to be reasonable. Actual results may differ from those estimates or assumptions.
Estimates are periodically reviewed in light of changes in circumstances, facts, and experience. Changes in estimates will be recorded
in future periods as they develop.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Risks and Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The product candidates we
develop require approvals from the U.S. Food and Drug Administration or foreign regulatory agencies prior to commercial sales. There can
be no assurance that our current and future product candidates will receive the necessary approvals or be commercially successful. If
we are denied approval or approval is delayed, it will have a material adverse impact on our business and our condensed consolidated financial
statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We are subject to risks common
to companies in the development stage including, but not limited to, dependency on the need for substantial additional financing to achieve
our goals, uncertainty of broad adoption of our approved products, if any, by physicians and patients, significant competition, and untested
manufacturing capabilities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We are subject to certain
risks and uncertainties and believe that changes in any of the following areas could have a material adverse effect on future financial
condition or results of operations: ability to obtain additional financing; regulatory approval and market acceptance of, and reimbursement
for, product candidates; performance of third-party CROs and manufacturers upon which we rely; protection of our intellectual property;
litigation or claims against us based on intellectual property, patent, product, regulatory, or other factors; and our ability to attract
and retain employees necessary to support our growth.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Concentrations of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Financial instruments which
potentially subject us to significant concentrations of credit risk consist primarily of cash. Our cash is mainly held in financial institutions.
Amounts on deposit may at times exceed federally insured limits. We have not experienced any losses on our deposits of cash and do not
believe that we are subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We consider all short-term
investments with an original maturity of three months or less when purchased to be cash equivalents. As of September 30, 2021 and December
31, 2020, we had no cash equivalents.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Restricted Cash&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We classify cash as restricted when it is unavailable for withdrawal
or use in our general operating activities. Restricted cash and investments are classified as current and noncurrent on the consolidated
balance sheets based on the nature of the restriction. Our restricted cash balance includes contractually restricted deposits related
to our corporate credit card. As of September 30, 2021 and December 31, 2020, we had restricted cash of $0.1 million and $0, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Accounts Receivable&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Accounts receivable are stated
at invoice value less estimated allowances for sales returns and doubtful accounts. We estimate the allowance for sales returns based
on historical percentage of returns over a 12-month trailing average of sales. We continually monitor customer payments and maintain a
reserve for estimated losses resulting from our customers&#x2019; inability to make required payments. We consider factors when estimating
the allowance for doubtful accounts such as historical experience, age of the accounts receivable balances, geographic related risks,
and economic conditions that may affect a customer&#x2019;s ability to pay. In cases where there are circumstances that may impair a specific
customer&#x2019;s ability to meet its financial obligations, a specific allowance is recorded against amounts due, thereby reducing the
net recognized receivable to the amount reasonably believed to be collectible. Accounts receivable are written off when deemed uncollectible.
Recoveries of accounts receivable previously written off are recorded when received. Historically, there have been no sales returns, no
written-off accounts receivable, and no allowance for doubtful accounts reducing the balance of the accounts receivable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Inventory&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Inventory is stated at historic
cost on a first-in first-out basis. Our inventory consisted of $26 thousand in raw materials and $14 thousand in finished goods as of
September 30, 2021. Our inventory consisted of $0.1 million in raw material and $0.1 million in finished goods as of December 31, 2020.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Debt Discounts, Debt Premiums, and Debt
Issuance Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;When debt is issued and a
derivative is required to be bifurcated (e.g., bifurcated conversion option) or another separate freestanding financial instrument (e.g.,
warrant) is issued, costs and fees incurred are allocated to the instruments issued (or bifurcated) in proportion to the allocation of
proceeds. When some portions of the costs and fees relate to a bifurcated derivative or freestanding financial instrument that is being
subsequently measured at fair value, those allocated costs are expensed immediately. Debt discounts, debt premiums, and debt issuance
costs related to convertible loans are recorded as deductions that net against the principal value of the debt and are amortized to interest
expense over the contractual term of the debt using the effective interest method.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Deferred Offering Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We capitalize certain legal,
professional accounting. and other third-party fees that are directly associated with in-process equity financings, including the Reverse
Recapitalization and the December 2020 PIPE, as deferred offering costs until such financings are consummated. After consummation of the
equity financing, these costs are recorded in stockholders&#x2019; equity (deficit) as a reduction of proceeds generated as a result of
the offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge
to operating expenses in the condensed consolidated statements of operations and comprehensive income (loss).&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the three and nine
months ended September 30, 2021, we did not incur any offering costs.&#160;During the three and nine months ended September 30, 2020,
we incurred $2.3 million of deferred offering costs related to the Reverse Recapitalization that were comprised of legal and professional
accounting fees and other costs.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;At inception of a contract,
we determine if a contract meets the definition of a lease. A lease is a contract, or part of a contract, that conveys the right to control
the use of identified property, plant, or equipment for a period of time in exchange for consideration. We determine if the contract conveys
the right to control the use of an identified asset for a period of time. We assess throughout the period of use whether we have both
of the following: (i)&#160;the right to obtain substantially all of the economic benefits from use of the identified asset, and (ii)&#160;the
right to direct the use of the identified asset. This determination is reassessed if the terms of the contract are changed. Leases are
classified as operating or finance leases based on the terms of the lease agreement and certain characteristics of the identified asset.
Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of the future lease
payments less any lease incentives received. At the lease commencement date, the discount rate implicit in the lease is used to discount
the lease liability if readily determinable. If not readily determinable or leases do not contain an implicit rate, our incremental borrowing
rate is used as the discount rate.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We lease laboratory and office
space and certain equipment under non-cancellable operating and finance leases. The carrying value of our right-of-use lease assets is
substantially concentrated in our real estate leases, while the volume of lease agreements is primarily concentrated in equipment leases.
Our policy is to not record leases with an original term of twelve months or less within the condensed consolidated balance sheets. We
recognize lease expense for these short-term leases on a straight-line basis over the lease term in the condensed consolidated statements
of operations and comprehensive income (loss).&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Certain lease agreements may
require us to pay additional amounts for taxes, insurance, maintenance, and other expenses, which are generally referred to as non-lease
components. Such variable non-lease components are treated as variable lease payments and recognized in the period in which the obligation
for these payments is incurred. Variable lease components and variable non-lease components are not measured as part of the right-of-use
asset and liability. Only when lease components and their associated non-lease components are fixed are they accounted for as a single
lease component and are recognized as part of a right-of-use asset and liability. Total contract consideration is allocated to the combined
fixed lease and non-lease component. This policy election applies consistently to all asset classes under lease agreements.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Leases may contain clauses
for renewal at our option. Payments to be made in option periods are recognized as part of the right-of-use lease assets and lease liabilities
when it is reasonably certain that the option to extend the lease will be exercised, or is not at our option. We determine whether the
reasonably certain threshold is met by considering contract-, asset-, market-, and entity-based factors. In the condensed consolidated
statements of operations and comprehensive income (loss), operating lease expense, which is recognized on a straight-line basis over the
lease term, and the amortization of finance lease right-of-use assets, which are included in property and equipment and depreciated, are
included in research and development or general and administrative expenses consistent with the leased assets&#x2019; primary use. Accretion
on the liabilities for finance leases is included in interest expense.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Property and equipment are
stated at cost less accumulated depreciation. Property and equipment consist of laboratory and office equipment and leasehold improvements.
Depreciation is calculated using the straight-line method over the estimated economic useful lives of the assets, which are 3-5&#160;years
for laboratory equipment and 3-7&#160;years for furniture and fixtures. Leasehold improvements are amortized over the lesser of the estimated
lease term or the estimated useful life of the assets. Costs for capital assets not yet placed into service are capitalized as construction
in progress and depreciated or amortized in accordance with the above useful lives once placed into service. Upon retirement or sale,
the related cost and accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included
in the condensed consolidated statements of operations and comprehensive income (loss). Maintenance and repairs that do not improve or
extend the lives of the respective assets are expensed to operations as incurred.&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Convertible Notes&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In accordance with ASU 2020-06,
&lt;i&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own
Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/i&gt;, when we issue notes
with conversion features, we evaluate if the conversion features are freestanding or embedded. If the conversion feature is embedded,
we do not separate the conversion feature from the host contract for convertible notes that are not required to be accounted for as derivatives,
or that do not result in substantial premiums accounted for as paid-in-capital. Consequently, we account for a convertible note as a single
liability measured at its amortized cost, and we account for a convertible preferred stock as a single equity instrument measured at its
historical cost, as long as no other features require bifurcation and recognition as derivatives.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;If the conversion feature
is freestanding, or is embedded and meets the requirements to be bifurcated, we account for the conversion feature as a derivative under
ASC 815, &lt;i&gt;Derivatives and Hedging&lt;/i&gt; (&#x201c;ASC 815&#x201d;). We record the derivative instrument at fair value at inception, and subsequently
re-measure to fair value at each reporting period and immediately prior to the extinguishment of the derivative instrument, with any changes
recorded in the condensed consolidated statements of operations and comprehensive income (loss).&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Debt With Warrants&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In accordance with ASC 470-20, &lt;i&gt;Debt with Conversion and Other Options&lt;/i&gt;,
when we issue debt with warrants, we treat the warrants as a debt discount, recorded as a contra-liability against the debt, and amortize
the balance over the life of the underlying debt as amortization of debt discount expense in the condensed consolidated statements of
operations and comprehensive income (loss). The offset to the contra-liability is recorded as additional paid-in capital in the condensed
consolidated balance sheets if the warrants are not treated as a derivative or liability under ASC 480, &lt;i&gt;Distinguishing Liabilities
from Equity&lt;/i&gt; (&#x201c;ASC 480&#x201d;). Otherwise, the offset to the contra-liability is recorded as a warrant liability in the condensed
consolidated balance sheets and is subject to re-measurement to fair value at each balance sheet date, with any changes in fair value
recognized in the condensed consolidated statements of operations and comprehensive income (loss). If the debt is retired early, the associated
debt discount is then recognized immediately as amortization of debt discount expense in the condensed consolidated statements of operations
and comprehensive income (loss).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Contingent Earn-Out Liabilities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In connection with the Reverse
Recapitalization, certain shareholders are entitled to receive additional shares of Common Stock (the &#x201c;Contingent Earn-outs&#x201d;)
upon us achieving certain milestones (see Notes 3 and 12). In accordance with ASC 815, the Contingent Earn-outs are not indexed to our
own stock and therefore are accounted for as a liability at the Reverse Recapitalization date and subsequently remeasured at each reporting
date with changes in fair value recorded as a component of other income (expense), net in the condensed consolidated statements of operations
and comprehensive income (loss).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Common Stock Warrants&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We account for common stock
warrants as either equity-classified instruments or liability-classified instruments based on an assessment of the warrant terms and applicable
authoritative guidance in accordance with ASC 480 and ASC 815. The assessment considers whether the warrants are freestanding financial
instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements
for equity classification under ASC 815, including whether the warrants are indexed to our Common Stock, among other conditions for equity
classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and, for
liability-classified warrants, as of each subsequent quarterly period end date while the warrants are outstanding.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Under ASC 606, &lt;i&gt;Revenue
from Contracts with Customers&lt;/i&gt; (&#x201c;ASC 606&#x201d;), an entity recognizes revenue when its customer obtains control of promised
goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services.
To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following
five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine
the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations
in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the five-step
model to contracts when it is probable that we will collect the consideration to which we are entitled in exchange for the goods or services
we transfer to the customer.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Once a contract is determined
to be within the scope of ASC 606 at contract inception, we review the contract to determine which performance obligations we must deliver,
and which performance obligations are distinct. We recognize as revenue the amount of the transaction price that is allocated to each
performance obligation when that performance obligation is satisfied or as it is satisfied. We typically satisfy our performance obligations
via delivery of dietary supplements to the customer. Payments are due upon receipt for commercial transactions, or a prepayment is collected
for online retail sales. Our revenue for the three and nine months ended September 30, 2021 and 2020 was comprised of sales of dietary
supplements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We recorded deferred revenue of $0.1 and $0.1 million as of September
30, 2021 and December 31, 2020 from the dietary supply agreement with the related party (see Note 20).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Grant Funding&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We may submit applications
to receive grant funding from governmental and non-governmental entities. Grant funding received that involves no conditions or continuing
performance obligations of the Company is recognized upon receipt. Grant funding with conditions or obligations of the Company is recognized
as the conditions or obligations are fulfilled. We have made an accounting policy election to record such unconditional grants, such as
the Australian Research and Development Credit, as other income in the condensed consolidated statements of operations and comprehensive
income (loss). Income from grants is recognized in the period during which the related qualifying expenses are incurred, provided that
the conditions under which the grants were provided have been met. We recognize the Australian Research and Development Credit in an amount
equal to the qualifying expenses incurred in each period multiplied by the applicable reimbursement percentage. During the three and nine
months ended September 30, 2021, we recognized $0.4 million and $1.1 million, respectively, of Australian Research and Development Credit
within other income (expense), net in the condensed consolidated statements of operations and comprehensive income (loss). During the
three and nine months ended September 30, 2020, we recognized $1.3 million and $2.6 million, respectively, of Australian Research and
Development Credit within other income (expense), net in the condensed consolidated statements of operations and comprehensive income
(loss). As of September 30, 2021, and December 31, 2020, we recorded $1.2 million and $2.1 million, respectively, of Australian Research
and Development Credit receivable in prepaid expenses and other current assets on the condensed consolidated balance sheets.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Any amount received in advance
of fulfilling such conditions or obligations is recorded in accrued liabilities on the condensed consolidated balance sheets if the conditions
or obligations are expected to be met within the next twelve months. As of September 30, 2021 and December 31, 2020, we recorded $0.6
million and $0.3 million, respectively, of deferred grant funds received in advance in accrued liabilities.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Grant funding recognized on
conditional grants is included as a reduction in research and development expenses in the condensed consolidated statements of operations
and comprehensive income (loss) as the conditions are tied to our research and development efforts, and as the arrangement between us
and the organizations are not part of our ongoing, major, or central operations. During the three and nine months ended September 30,
2021, we recorded a grant of $0 and $0.2 million, respectively, as a reduction of research and development expenses in the condensed consolidated
statements of operations and comprehensive income (loss). During the three and nine months ended September 30, 2020, we recorded a grant
of $0.2 million and $0.7 million, respectively, as a reduction of research and development expenses in the condensed consolidated statements
of operations and comprehensive income (loss).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Certain assets and liabilities
are carried at fair value under GAAP. Fair value is defined as the price that would be received for an asset or paid to transfer a liability
(an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants
on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use
of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following
three levels of the fair value hierarchy:&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;i&gt;&#x2014;&lt;/i&gt;Inputs
based upon quoted market prices for identical assets or liabilities in active markets at the measurement date.&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;i&gt;&#x2014;&lt;/i&gt;Observable
inputs other than quoted market prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets;
quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can
be corroborated by observable market data.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;i&gt;&#x2014;&lt;/i&gt;Inputs
that are management&#x2019;s best estimate of what market participants would use in pricing the asset or liability at the measurement date.
The inputs are unobservable in the market and significant to the instrument&#x2019;s valuation.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We review the fair value hierarchy
classification of our applicable assets and liabilities on a quarterly basis. Changes in the observability of valuation inputs may result
in a reclassification for certain financial assets or liabilities. Reclassifications impacting all levels of the fair value hierarchy
are reported as transfers in or out of the Level 1, 2, or 3 categories as of the beginning of the quarter during which the reclassifications
occur.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Foreign Currency Translation and Transactions&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Our functional currency is
the U.S. dollar. Our Australian subsidiary determined its functional currency to be the Australian dollar and our Netherlands subsidiary
determined its functional currency to be the Euro. We use the U.S. dollar as our reporting currency for the condensed consolidated financial
statements. The results of our non-U.S. dollar based functional currency operations are translated to U.S. dollars at the average exchange
rates during the period. Our assets and liabilities are translated using the current exchange rate as of the balance sheet date and shareholders&#x2019;
equity is translated using historical rates.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Adjustments resulting from
the translation of the condensed consolidated financial statements of our foreign functional currency subsidiaries into U.S. dollars are
excluded from the determination of net loss and are accumulated in a separate component of shareholders&#x2019; equity. These foreign currency
translation gains and losses are currently the only component of other comprehensive income (loss).&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We also incur foreign exchange
transaction gains and losses for purchases denominated in foreign currencies. Foreign exchange transaction gains and losses are included
in other income (expense) in the condensed consolidated statements of operations and comprehensive income (loss) as incurred.&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Comprehensive Income (Loss&lt;/i&gt;&lt;/b&gt;)&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Comprehensive income (loss)
includes net income (loss) as well as other changes in stockholders&#x2019; equity (deficit) that result from transactions and economic
events other than those with stockholders. The only element of other comprehensive income (loss) in any period presented was translation
of Australian dollar denominated balances of our Australian subsidiary to U.S. dollars for consolidation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Net Income (Loss) Per Share Attributable
to Common Shareholders&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Basic net income (loss) per share attributable to common shareholders
is calculated using our weighted-average outstanding common shares. Diluted net income (loss) per share attributable to common shareholders
is calculated using our weighted-average outstanding common shares including the dilutive effect of securities as determined under the
treasury stock method, except for the dilutive effect of convertible notes payable, which is calculated under the if-converted method,
even if the embedded conversion option is out-of-the-money. In periods in which we report a net loss attributable to common shareholders,
diluted net loss per share attributable to common shareholders is the same as basic net loss per share attributable to common shareholders,
since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Segment Information&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We have determined that our
chief executive officer is the chief operating decision maker (&#x201c;CODM&#x201d;). Operating segments are identified as components of
an enterprise about which separate discrete financial information is available for evaluation by the CODM in making decisions regarding
resource allocation and assessing performance. We view our operations and manage our business in two operating segments: (1) the development
and commercialization of proprietary nanotechnology drug suspensions (&#x201c;Drugs&#x201d;), and (2) the development and commercialization
of dietary supplements (&#x201c;Supplements&#x201d;). Our operating segment profit measure is segment loss from operations, which is calculated
as revenue less cost of revenue, research and development, and general and administrative expenses (see Note 21).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We account for income taxes
using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax
consequences of events that have been recognized in the condensed consolidated financial statements or in our tax returns. Deferred tax
assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities
using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities
are recorded in the provision for income taxes. We assess the likelihood that our deferred tax assets will be recovered from future taxable
income and, to the extent we believe, based upon the weight of available evidence, that it is more likely than not that all or a portion
of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential
for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible
tax planning strategies.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We account for uncertainty
in income taxes recognized in the condensed consolidated financial statements by applying a two-step process to determine the amount of
tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external
examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed
to determine the amount of benefit to recognize in the condensed consolidated financial statements. The amount of the benefit that may
be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for
income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well
as the related net interest and penalties.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We account for stock-based
compensation arrangements with employees using a fair value-based method for costs related to all share-based payments including stock
options and stock awards. Stock-based compensation expense is recorded in research and development and general and administrative expenses
based on the classification of the work performed by the grantees.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The fair value is recognized
over the period during which a grantee was required to provide services in exchange for the option award and service-based stock awards,
known as the requisite service period (usually the vesting period), on a straight-line basis. For stock awards with market conditions,
the fair value is recognized over the period based on the expected milestone achievement dates as the derived service period (usually
the vesting period), on a straight-line basis. For stock awards with performance conditions, the grant-date fair value of these awards
is the market price on the applicable grant date, and compensation expense will be recognized when the conditions become probable of
being satisfied. We will recognize a cumulative true-up adjustment once the conditions become probable of being satisfied as the related
service period had been completed in a prior period.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Stock-based compensation expense
is recognized at fair value. We elect to account for forfeitures as they occur, rather than estimating expected forfeitures.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;After the closing of the Reverse
Recapitalization, we determine the fair value of each share of Common Stock underlying stock-based awards based on the closing price of
our Common Stock as reported by the Nasdaq Stock Market LLC (&#x201c;Nasdaq&#x201d;) on the date of grant. The fair value of stock awards
with market conditions are determined using a Monte Carlo valuation model.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Research and Development&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Research and development costs
are charged to expense as incurred. We account for nonrefundable advance payments for goods and services that will be used in future research
and development activities as expenses when the goods have been received or when the service has been performed. Research and development
expenses consist of costs incurred for the discovery and development of our product candidates. Research and development costs include,
but are not limited to, payroll and personnel expenses including stock-based compensation, clinical trial supplies, fees for clinical
trial services, consulting costs, and allocated overhead, including rent, equipment, and utilities.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Clinical Trial Accrual&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Our clinical trial accrual
process accounts for expenses resulting from obligations under contracts with CROs, consultants, and under clinical site agreements in
connection with conducting clinical trials. Clinical trial costs are charged to research and development expense as incurred. The financial
terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not
match the periods over which materials or services are provided to us under such contracts. We reflect the appropriate clinical trial
expense in the condensed consolidated financial statements by matching the appropriate expenses with the period in which services and
efforts are expended. In the event advance payments are made to a CRO, the payments will be recorded as a prepaid asset which will be
amortized to research and development expense over the period the contracted services are performed. In addition to pass-through costs,
we generally incur costs in clinical trials in four distinct groups as follows:&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;CRO Start-up&#x2014;These costs
include the initial set-up of the clinical trial and usually occur within a few months after the contract has been executed and includes
costs which are expensed ratably over the start-up period when such period is identifiable and expensed as incurred when no such period
exists. Start-up phase activities include study initiation, site recruitment, regulatory applications, investigator meetings, screening,
preparation, pre-study visits, and training.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;CRO Site and Study Management&#x2014;These
costs include medical and safety monitoring, patient administration and data management. These costs are usually calculated on a per-patient
basis and expensed ratably over the treatment period beginning on the date that the patient enrolls.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;CRO Close-Down and Reporting&#x2014;These
costs include analyzing the data obtained and reporting results, which occurs after patients have ceased treatment and the database of
information collected is locked. These costs are expensed as incurred over the course of any close-down and reporting period.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Third-Party Contracts&#x2014;These
costs include fees charged by third parties for various support services which are not provided by CROs and include such items as laboratory
fees, data quality review costs, and fees incurred for investigational product monitoring and inventory control. These items are expensed
ratably over any identifiable service period with the engaged third-party vendors.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The CRO contracts generally
include pass-through fees including, but not limited to, regulatory expenses, investigator fees, travel costs, and other miscellaneous
costs, including shipping and printing fees. We determine accrual estimates through reports from and discussion with applicable personnel
and outside service providers as to the progress or state of completion of trials or the services completed. We estimate accrued expenses
as of each balance sheet date in the condensed consolidated financial statements based on the facts and circumstances known to us at that
time.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Recently Adopted Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In August 2020, the FASB issued
ASU 2020-06, &lt;i&gt;Debt&lt;/i&gt;&#x2014;&lt;i&gt;Debt with Conversion and Other Options (Subtopic 470-20) &lt;/i&gt;and &lt;i&gt;Derivatives and Hedging&lt;/i&gt;&#x2014;&lt;i&gt;Contracts
in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/i&gt;
to simplify accounting for certain financial instruments by removing certain separation models for convertible instruments. Under the
amendments in ASU 2020-06, the embedded conversion features no longer are separated from the host contract for convertible instruments
with conversion features that are not required to be accounted for as derivatives, or that do not result in substantial premiums accounted
for as paid-in-capital. Consequently, a convertible debt instrument will be accounted as a single liability measured at its amortized
cost, and a convertible preferred stock will be accounted for as a single equity instrument measured at its historical cost, as long as
no other features require bifurcation and recognition as derivatives. The new standard also introduces additional disclosures for convertible
debt and freestanding instruments that are indexed to and settled in an entity&#x2019;s own equity. ASU 2020-06 amends the diluted earnings
per share guidance, including the requirements to use the if-converted method for all convertible instruments. For smaller reporting companies,
the new guidance is effective for fiscal years beginning after December 15, 2023, and should be applied on a full or modified retrospective
basis, with early adoption permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods with
those fiscal years. We early adopted ASU 2020-06 on January 1, 2021. The adoption of this guidance did not have a material impact on our
condensed consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In March 2020, the FASB issued
ASU 2020-04, &lt;i&gt;Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting&lt;/i&gt;, which
provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions in which the
reference LIBOR or another reference rate is expected to be discontinued as a result of the Reference Rate Reform. This ASU is intended
to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The new guidance
was effective immediately and through December 31, 2022. We adopted this guidance on March 1, 2020. The adoption of this guidance did
not have a material impact on our condensed consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In December 2019, the FASB
issued ASU 2019-12, &lt;i&gt;Income Taxes (Topic 740)&lt;/i&gt;, which amends the existing guidance relating to the accounting for income taxes. This
ASU is intended to simplify the accounting for income taxes by removing certain exceptions to the general principles of accounting for
income taxes and to improve the consistent application of GAAP for other areas of accounting for income taxes by clarifying and amending
existing guidance. The new guidance was effective for our fiscal year, and interim periods within our fiscal year, beginning after December
15, 2020. The adoption of this guidance did not have a material impact on our condensed consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In August 2018, the FASB issued
ASU 2018-15, &lt;i&gt;Intangibles&lt;/i&gt;&#x2014;&lt;i&gt;Goodwill and Other&lt;/i&gt;&#x2014;&lt;i&gt;Internal-Use Software (Subtopic 350-40): Customer&#x2019;s Accounting
for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract&lt;/i&gt;. The new guidance provides for the deferral
of implementation costs for cloud computing arrangements and expensing those costs over the term of the cloud services arrangement. The
new guidance was effective for our fiscal year beginning after December 15, 2020. The adoption of this guidance did not have a material
impact on our condensed consolidated financial statements.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;In&#160;August
2018,&#160;the FASB issued ASU&#160;2018-13,&#160;&lt;i&gt;Fair Value Measurement (Topic&#160;&lt;/i&gt;&lt;/span&gt;&lt;i&gt;820&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/i&gt;&lt;span style="font-size: 10pt"&gt;.
The new guidance improves the effectiveness of disclosures about fair value measurements required under ASC&#160;820.&#160;The new guidance&#160;amends
the disclosure requirements for recurring and nonrecurring fair value measurements by removing, modifying, and adding certain disclosures.
The new guidance was effective for our fiscal year, and interim periods with our fiscal year, beginning after December 15, 2019. The adoption
of this guidance&#160;did&#160;not&#160;have a material impact on our condensed consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements Not Yet
Adopted&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In June 2016, the FASB issued
ASU 2016-13, &lt;i&gt;Financial Instruments&lt;/i&gt;&#x2014;&lt;i&gt;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/i&gt;.
The amendments in this ASU, among other things, require the measurement of all expected credit losses for financial assets held at the
reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions and
other organizations will now use forward-looking information to better inform their credit loss estimates. As a smaller reporting company,
the guidance is effective for our fiscal years beginning after December 15, 2022. We are currently evaluating the expected impact of the
new guidance as a result of this extended deadline of implementation for smaller reporting companies.&#160;&#160;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We have prepared the accompanying
condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States of America
(&#x201c;GAAP&#x201d;) for interim financial reporting and as required by Regulation S-X, Rule 10-01. The condensed consolidated financial
statements have been prepared on the same basis as our audited annual consolidated financial statements and, in the opinion of management,
reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of our financial condition as
of September 30, 2021, the results of our operations for the three and nine months ended September 30, 2021, our cash flows for the nine
months ended September 30, 2021 and 2020, and the condensed consolidated statement of stockholders&#x2019; equity (deficit) for the three
and nine months ended September 30, 2021 and 2020. The financial data and other information disclosed in these notes related to the three
and nine months ended September 30, 2021 and 2020 are unaudited. The results of operations for the three and nine months ended September
30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021, any other interim periods,
or any future year or period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Prior period balances for
accounts receivable have been reclassified to conform to the current year presentation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The preparation of condensed
consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets, liabilities, and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial
statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying
condensed consolidated financial statements include, but are not limited to, the valuation of common stock, stock options, contingent
earn-out liabilities, Preferred Stock warrants, and Common Stock warrants.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We base our estimates on historical
experience and on various other assumptions that are believed to be reasonable. Actual results may differ from those estimates or assumptions.
Estimates are periodically reviewed in light of changes in circumstances, facts, and experience. Changes in estimates will be recorded
in future periods as they develop.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <clnn:RiskAndUncertaintiesPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Risks and Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The product candidates we
develop require approvals from the U.S. Food and Drug Administration or foreign regulatory agencies prior to commercial sales. There can
be no assurance that our current and future product candidates will receive the necessary approvals or be commercially successful. If
we are denied approval or approval is delayed, it will have a material adverse impact on our business and our condensed consolidated financial
statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We are subject to risks common
to companies in the development stage including, but not limited to, dependency on the need for substantial additional financing to achieve
our goals, uncertainty of broad adoption of our approved products, if any, by physicians and patients, significant competition, and untested
manufacturing capabilities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We are subject to certain
risks and uncertainties and believe that changes in any of the following areas could have a material adverse effect on future financial
condition or results of operations: ability to obtain additional financing; regulatory approval and market acceptance of, and reimbursement
for, product candidates; performance of third-party CROs and manufacturers upon which we rely; protection of our intellectual property;
litigation or claims against us based on intellectual property, patent, product, regulatory, or other factors; and our ability to attract
and retain employees necessary to support our growth.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</clnn:RiskAndUncertaintiesPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Concentrations of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Financial instruments which
potentially subject us to significant concentrations of credit risk consist primarily of cash. Our cash is mainly held in financial institutions.
Amounts on deposit may at times exceed federally insured limits. We have not experienced any losses on our deposits of cash and do not
believe that we are subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We consider all short-term
investments with an original maturity of three months or less when purchased to be cash equivalents. As of September 30, 2021 and December
31, 2020, we had no cash equivalents.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Restricted Cash&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We classify cash as restricted when it is unavailable for withdrawal
or use in our general operating activities. Restricted cash and investments are classified as current and noncurrent on the consolidated
balance sheets based on the nature of the restriction. Our restricted cash balance includes contractually restricted deposits related
to our corporate credit card. As of September 30, 2021 and December 31, 2020, we had restricted cash of $0.1 million and $0, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedInvestments contextRef="c2" decimals="-5" unitRef="usd">100000</us-gaap:RestrictedInvestments>
    <us-gaap:RestrictedInvestments contextRef="c3" decimals="0" unitRef="usd">0</us-gaap:RestrictedInvestments>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Accounts Receivable&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Accounts receivable are stated
at invoice value less estimated allowances for sales returns and doubtful accounts. We estimate the allowance for sales returns based
on historical percentage of returns over a 12-month trailing average of sales. We continually monitor customer payments and maintain a
reserve for estimated losses resulting from our customers&#x2019; inability to make required payments. We consider factors when estimating
the allowance for doubtful accounts such as historical experience, age of the accounts receivable balances, geographic related risks,
and economic conditions that may affect a customer&#x2019;s ability to pay. In cases where there are circumstances that may impair a specific
customer&#x2019;s ability to meet its financial obligations, a specific allowance is recorded against amounts due, thereby reducing the
net recognized receivable to the amount reasonably believed to be collectible. Accounts receivable are written off when deemed uncollectible.
Recoveries of accounts receivable previously written off are recorded when received. Historically, there have been no sales returns, no
written-off accounts receivable, and no allowance for doubtful accounts reducing the balance of the accounts receivable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:InventoryPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Inventory&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Inventory is stated at historic
cost on a first-in first-out basis. Our inventory consisted of $26 thousand in raw materials and $14 thousand in finished goods as of
September 30, 2021. Our inventory consisted of $0.1 million in raw material and $0.1 million in finished goods as of December 31, 2020.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:InventoryRawMaterials contextRef="c2" decimals="-6" unitRef="usd">26000000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryFinishedGoods contextRef="c2" decimals="-6" unitRef="usd">14000000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryRawMaterials contextRef="c3" decimals="-5" unitRef="usd">100000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryFinishedGoods contextRef="c3" decimals="-5" unitRef="usd">100000</us-gaap:InventoryFinishedGoods>
    <clnn:DebtDiscountAndIssuanceCostsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Debt Discounts, Debt Premiums, and Debt
Issuance Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;When debt is issued and a
derivative is required to be bifurcated (e.g., bifurcated conversion option) or another separate freestanding financial instrument (e.g.,
warrant) is issued, costs and fees incurred are allocated to the instruments issued (or bifurcated) in proportion to the allocation of
proceeds. When some portions of the costs and fees relate to a bifurcated derivative or freestanding financial instrument that is being
subsequently measured at fair value, those allocated costs are expensed immediately. Debt discounts, debt premiums, and debt issuance
costs related to convertible loans are recorded as deductions that net against the principal value of the debt and are amortized to interest
expense over the contractual term of the debt using the effective interest method.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</clnn:DebtDiscountAndIssuanceCostsPolicyTextBlock>
    <us-gaap:DeferredChargesPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Deferred Offering Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We capitalize certain legal,
professional accounting. and other third-party fees that are directly associated with in-process equity financings, including the Reverse
Recapitalization and the December 2020 PIPE, as deferred offering costs until such financings are consummated. After consummation of the
equity financing, these costs are recorded in stockholders&#x2019; equity (deficit) as a reduction of proceeds generated as a result of
the offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge
to operating expenses in the condensed consolidated statements of operations and comprehensive income (loss).&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the three and nine
months ended September 30, 2021, we did not incur any offering costs.&#160;During the three and nine months ended September 30, 2020,
we incurred $2.3 million of deferred offering costs related to the Reverse Recapitalization that were comprised of legal and professional
accounting fees and other costs.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:DeferredOfferingCosts contextRef="c2" decimals="-5" unitRef="usd">2300000</us-gaap:DeferredOfferingCosts>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;At inception of a contract,
we determine if a contract meets the definition of a lease. A lease is a contract, or part of a contract, that conveys the right to control
the use of identified property, plant, or equipment for a period of time in exchange for consideration. We determine if the contract conveys
the right to control the use of an identified asset for a period of time. We assess throughout the period of use whether we have both
of the following: (i)&#160;the right to obtain substantially all of the economic benefits from use of the identified asset, and (ii)&#160;the
right to direct the use of the identified asset. This determination is reassessed if the terms of the contract are changed. Leases are
classified as operating or finance leases based on the terms of the lease agreement and certain characteristics of the identified asset.
Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of the future lease
payments less any lease incentives received. At the lease commencement date, the discount rate implicit in the lease is used to discount
the lease liability if readily determinable. If not readily determinable or leases do not contain an implicit rate, our incremental borrowing
rate is used as the discount rate.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We lease laboratory and office
space and certain equipment under non-cancellable operating and finance leases. The carrying value of our right-of-use lease assets is
substantially concentrated in our real estate leases, while the volume of lease agreements is primarily concentrated in equipment leases.
Our policy is to not record leases with an original term of twelve months or less within the condensed consolidated balance sheets. We
recognize lease expense for these short-term leases on a straight-line basis over the lease term in the condensed consolidated statements
of operations and comprehensive income (loss).&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Certain lease agreements may
require us to pay additional amounts for taxes, insurance, maintenance, and other expenses, which are generally referred to as non-lease
components. Such variable non-lease components are treated as variable lease payments and recognized in the period in which the obligation
for these payments is incurred. Variable lease components and variable non-lease components are not measured as part of the right-of-use
asset and liability. Only when lease components and their associated non-lease components are fixed are they accounted for as a single
lease component and are recognized as part of a right-of-use asset and liability. Total contract consideration is allocated to the combined
fixed lease and non-lease component. This policy election applies consistently to all asset classes under lease agreements.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Leases may contain clauses
for renewal at our option. Payments to be made in option periods are recognized as part of the right-of-use lease assets and lease liabilities
when it is reasonably certain that the option to extend the lease will be exercised, or is not at our option. We determine whether the
reasonably certain threshold is met by considering contract-, asset-, market-, and entity-based factors. In the condensed consolidated
statements of operations and comprehensive income (loss), operating lease expense, which is recognized on a straight-line basis over the
lease term, and the amortization of finance lease right-of-use assets, which are included in property and equipment and depreciated, are
included in research and development or general and administrative expenses consistent with the leased assets&#x2019; primary use. Accretion
on the liabilities for finance leases is included in interest expense.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Property and equipment are
stated at cost less accumulated depreciation. Property and equipment consist of laboratory and office equipment and leasehold improvements.
Depreciation is calculated using the straight-line method over the estimated economic useful lives of the assets, which are 3-5&#160;years
for laboratory equipment and 3-7&#160;years for furniture and fixtures. Leasehold improvements are amortized over the lesser of the estimated
lease term or the estimated useful life of the assets. Costs for capital assets not yet placed into service are capitalized as construction
in progress and depreciated or amortized in accordance with the above useful lives once placed into service. Upon retirement or sale,
the related cost and accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included
in the condensed consolidated statements of operations and comprehensive income (loss). Maintenance and repairs that do not improve or
extend the lives of the respective assets are expensed to operations as incurred.&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c105">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c106">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c107">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c108">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <clnn:ConvertibleNotespolicytextblock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Convertible Notes&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In accordance with ASU 2020-06,
&lt;i&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own
Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/i&gt;, when we issue notes
with conversion features, we evaluate if the conversion features are freestanding or embedded. If the conversion feature is embedded,
we do not separate the conversion feature from the host contract for convertible notes that are not required to be accounted for as derivatives,
or that do not result in substantial premiums accounted for as paid-in-capital. Consequently, we account for a convertible note as a single
liability measured at its amortized cost, and we account for a convertible preferred stock as a single equity instrument measured at its
historical cost, as long as no other features require bifurcation and recognition as derivatives.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;If the conversion feature
is freestanding, or is embedded and meets the requirements to be bifurcated, we account for the conversion feature as a derivative under
ASC 815, &lt;i&gt;Derivatives and Hedging&lt;/i&gt; (&#x201c;ASC 815&#x201d;). We record the derivative instrument at fair value at inception, and subsequently
re-measure to fair value at each reporting period and immediately prior to the extinguishment of the derivative instrument, with any changes
recorded in the condensed consolidated statements of operations and comprehensive income (loss).&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</clnn:ConvertibleNotespolicytextblock>
    <clnn:DebtWithWarrantsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Debt With Warrants&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In accordance with ASC 470-20, &lt;i&gt;Debt with Conversion and Other Options&lt;/i&gt;,
when we issue debt with warrants, we treat the warrants as a debt discount, recorded as a contra-liability against the debt, and amortize
the balance over the life of the underlying debt as amortization of debt discount expense in the condensed consolidated statements of
operations and comprehensive income (loss). The offset to the contra-liability is recorded as additional paid-in capital in the condensed
consolidated balance sheets if the warrants are not treated as a derivative or liability under ASC 480, &lt;i&gt;Distinguishing Liabilities
from Equity&lt;/i&gt; (&#x201c;ASC 480&#x201d;). Otherwise, the offset to the contra-liability is recorded as a warrant liability in the condensed
consolidated balance sheets and is subject to re-measurement to fair value at each balance sheet date, with any changes in fair value
recognized in the condensed consolidated statements of operations and comprehensive income (loss). If the debt is retired early, the associated
debt discount is then recognized immediately as amortization of debt discount expense in the condensed consolidated statements of operations
and comprehensive income (loss).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</clnn:DebtWithWarrantsPolicyTextBlock>
    <clnn:ContingentEarnoutPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Contingent Earn-Out Liabilities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In connection with the Reverse
Recapitalization, certain shareholders are entitled to receive additional shares of Common Stock (the &#x201c;Contingent Earn-outs&#x201d;)
upon us achieving certain milestones (see Notes 3 and 12). In accordance with ASC 815, the Contingent Earn-outs are not indexed to our
own stock and therefore are accounted for as a liability at the Reverse Recapitalization date and subsequently remeasured at each reporting
date with changes in fair value recorded as a component of other income (expense), net in the condensed consolidated statements of operations
and comprehensive income (loss).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</clnn:ContingentEarnoutPolicyTextBlock>
    <clnn:CommonStockWarrantsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Common Stock Warrants&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We account for common stock
warrants as either equity-classified instruments or liability-classified instruments based on an assessment of the warrant terms and applicable
authoritative guidance in accordance with ASC 480 and ASC 815. The assessment considers whether the warrants are freestanding financial
instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements
for equity classification under ASC 815, including whether the warrants are indexed to our Common Stock, among other conditions for equity
classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and, for
liability-classified warrants, as of each subsequent quarterly period end date while the warrants are outstanding.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</clnn:CommonStockWarrantsPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Under ASC 606, &lt;i&gt;Revenue
from Contracts with Customers&lt;/i&gt; (&#x201c;ASC 606&#x201d;), an entity recognizes revenue when its customer obtains control of promised
goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services.
To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following
five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine
the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations
in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the five-step
model to contracts when it is probable that we will collect the consideration to which we are entitled in exchange for the goods or services
we transfer to the customer.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Once a contract is determined
to be within the scope of ASC 606 at contract inception, we review the contract to determine which performance obligations we must deliver,
and which performance obligations are distinct. We recognize as revenue the amount of the transaction price that is allocated to each
performance obligation when that performance obligation is satisfied or as it is satisfied. We typically satisfy our performance obligations
via delivery of dietary supplements to the customer. Payments are due upon receipt for commercial transactions, or a prepayment is collected
for online retail sales. Our revenue for the three and nine months ended September 30, 2021 and 2020 was comprised of sales of dietary
supplements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We recorded deferred revenue of $0.1 and $0.1 million as of September
30, 2021 and December 31, 2020 from the dietary supply agreement with the related party (see Note 20).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:DeferredRevenue contextRef="c2" decimals="-5" unitRef="usd">100000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue contextRef="c3" decimals="-5" unitRef="usd">100000</us-gaap:DeferredRevenue>
    <clnn:GrantFundingPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Grant Funding&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We may submit applications
to receive grant funding from governmental and non-governmental entities. Grant funding received that involves no conditions or continuing
performance obligations of the Company is recognized upon receipt. Grant funding with conditions or obligations of the Company is recognized
as the conditions or obligations are fulfilled. We have made an accounting policy election to record such unconditional grants, such as
the Australian Research and Development Credit, as other income in the condensed consolidated statements of operations and comprehensive
income (loss). Income from grants is recognized in the period during which the related qualifying expenses are incurred, provided that
the conditions under which the grants were provided have been met. We recognize the Australian Research and Development Credit in an amount
equal to the qualifying expenses incurred in each period multiplied by the applicable reimbursement percentage. During the three and nine
months ended September 30, 2021, we recognized $0.4 million and $1.1 million, respectively, of Australian Research and Development Credit
within other income (expense), net in the condensed consolidated statements of operations and comprehensive income (loss). During the
three and nine months ended September 30, 2020, we recognized $1.3 million and $2.6 million, respectively, of Australian Research and
Development Credit within other income (expense), net in the condensed consolidated statements of operations and comprehensive income
(loss). As of September 30, 2021, and December 31, 2020, we recorded $1.2 million and $2.1 million, respectively, of Australian Research
and Development Credit receivable in prepaid expenses and other current assets on the condensed consolidated balance sheets.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Any amount received in advance
of fulfilling such conditions or obligations is recorded in accrued liabilities on the condensed consolidated balance sheets if the conditions
or obligations are expected to be met within the next twelve months. As of September 30, 2021 and December 31, 2020, we recorded $0.6
million and $0.3 million, respectively, of deferred grant funds received in advance in accrued liabilities.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Grant funding recognized on
conditional grants is included as a reduction in research and development expenses in the condensed consolidated statements of operations
and comprehensive income (loss) as the conditions are tied to our research and development efforts, and as the arrangement between us
and the organizations are not part of our ongoing, major, or central operations. During the three and nine months ended September 30,
2021, we recorded a grant of $0 and $0.2 million, respectively, as a reduction of research and development expenses in the condensed consolidated
statements of operations and comprehensive income (loss). During the three and nine months ended September 30, 2020, we recorded a grant
of $0.2 million and $0.7 million, respectively, as a reduction of research and development expenses in the condensed consolidated statements
of operations and comprehensive income (loss).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</clnn:GrantFundingPolicyTextBlock>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c109" decimals="-5" unitRef="usd">400000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c110" decimals="-5" unitRef="usd">1100000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c111" decimals="-5" unitRef="usd">1300000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c112" decimals="-5" unitRef="usd">2600000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent contextRef="c113" decimals="-5" unitRef="usd">1200000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent contextRef="c114" decimals="-5" unitRef="usd">2100000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="c115" decimals="-5" unitRef="usd">600000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="c114" decimals="-5" unitRef="usd">300000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <clnn:GrantFundingRecognizedOnConditionalGrants contextRef="c12" decimals="-6" unitRef="usd">0</clnn:GrantFundingRecognizedOnConditionalGrants>
    <clnn:GrantFundingRecognizedOnConditionalGrants contextRef="c0" decimals="-5" unitRef="usd">200000</clnn:GrantFundingRecognizedOnConditionalGrants>
    <clnn:GrantFundingRecognizedOnConditionalGrants contextRef="c13" decimals="-5" unitRef="usd">200000</clnn:GrantFundingRecognizedOnConditionalGrants>
    <clnn:GrantFundingRecognizedOnConditionalGrants contextRef="c14" decimals="-5" unitRef="usd">700000</clnn:GrantFundingRecognizedOnConditionalGrants>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Certain assets and liabilities
are carried at fair value under GAAP. Fair value is defined as the price that would be received for an asset or paid to transfer a liability
(an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants
on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use
of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following
three levels of the fair value hierarchy:&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;i&gt;&#x2014;&lt;/i&gt;Inputs
based upon quoted market prices for identical assets or liabilities in active markets at the measurement date.&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;i&gt;&#x2014;&lt;/i&gt;Observable
inputs other than quoted market prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets;
quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can
be corroborated by observable market data.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;i&gt;&#x2014;&lt;/i&gt;Inputs
that are management&#x2019;s best estimate of what market participants would use in pricing the asset or liability at the measurement date.
The inputs are unobservable in the market and significant to the instrument&#x2019;s valuation.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We review the fair value hierarchy
classification of our applicable assets and liabilities on a quarterly basis. Changes in the observability of valuation inputs may result
in a reclassification for certain financial assets or liabilities. Reclassifications impacting all levels of the fair value hierarchy
are reported as transfers in or out of the Level 1, 2, or 3 categories as of the beginning of the quarter during which the reclassifications
occur.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Foreign Currency Translation and Transactions&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Our functional currency is
the U.S. dollar. Our Australian subsidiary determined its functional currency to be the Australian dollar and our Netherlands subsidiary
determined its functional currency to be the Euro. We use the U.S. dollar as our reporting currency for the condensed consolidated financial
statements. The results of our non-U.S. dollar based functional currency operations are translated to U.S. dollars at the average exchange
rates during the period. Our assets and liabilities are translated using the current exchange rate as of the balance sheet date and shareholders&#x2019;
equity is translated using historical rates.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Adjustments resulting from
the translation of the condensed consolidated financial statements of our foreign functional currency subsidiaries into U.S. dollars are
excluded from the determination of net loss and are accumulated in a separate component of shareholders&#x2019; equity. These foreign currency
translation gains and losses are currently the only component of other comprehensive income (loss).&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We also incur foreign exchange
transaction gains and losses for purchases denominated in foreign currencies. Foreign exchange transaction gains and losses are included
in other income (expense) in the condensed consolidated statements of operations and comprehensive income (loss) as incurred.&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Comprehensive Income (Loss&lt;/i&gt;&lt;/b&gt;)&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Comprehensive income (loss)
includes net income (loss) as well as other changes in stockholders&#x2019; equity (deficit) that result from transactions and economic
events other than those with stockholders. The only element of other comprehensive income (loss) in any period presented was translation
of Australian dollar denominated balances of our Australian subsidiary to U.S. dollars for consolidation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Net Income (Loss) Per Share Attributable
to Common Shareholders&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Basic net income (loss) per share attributable to common shareholders
is calculated using our weighted-average outstanding common shares. Diluted net income (loss) per share attributable to common shareholders
is calculated using our weighted-average outstanding common shares including the dilutive effect of securities as determined under the
treasury stock method, except for the dilutive effect of convertible notes payable, which is calculated under the if-converted method,
even if the embedded conversion option is out-of-the-money. In periods in which we report a net loss attributable to common shareholders,
diluted net loss per share attributable to common shareholders is the same as basic net loss per share attributable to common shareholders,
since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Segment Information&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We have determined that our
chief executive officer is the chief operating decision maker (&#x201c;CODM&#x201d;). Operating segments are identified as components of
an enterprise about which separate discrete financial information is available for evaluation by the CODM in making decisions regarding
resource allocation and assessing performance. We view our operations and manage our business in two operating segments: (1) the development
and commercialization of proprietary nanotechnology drug suspensions (&#x201c;Drugs&#x201d;), and (2) the development and commercialization
of dietary supplements (&#x201c;Supplements&#x201d;). Our operating segment profit measure is segment loss from operations, which is calculated
as revenue less cost of revenue, research and development, and general and administrative expenses (see Note 21).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We account for income taxes
using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax
consequences of events that have been recognized in the condensed consolidated financial statements or in our tax returns. Deferred tax
assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities
using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities
are recorded in the provision for income taxes. We assess the likelihood that our deferred tax assets will be recovered from future taxable
income and, to the extent we believe, based upon the weight of available evidence, that it is more likely than not that all or a portion
of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential
for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible
tax planning strategies.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We account for uncertainty
in income taxes recognized in the condensed consolidated financial statements by applying a two-step process to determine the amount of
tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external
examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed
to determine the amount of benefit to recognize in the condensed consolidated financial statements. The amount of the benefit that may
be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for
income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well
as the related net interest and penalties.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We account for stock-based
compensation arrangements with employees using a fair value-based method for costs related to all share-based payments including stock
options and stock awards. Stock-based compensation expense is recorded in research and development and general and administrative expenses
based on the classification of the work performed by the grantees.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The fair value is recognized
over the period during which a grantee was required to provide services in exchange for the option award and service-based stock awards,
known as the requisite service period (usually the vesting period), on a straight-line basis. For stock awards with market conditions,
the fair value is recognized over the period based on the expected milestone achievement dates as the derived service period (usually
the vesting period), on a straight-line basis. For stock awards with performance conditions, the grant-date fair value of these awards
is the market price on the applicable grant date, and compensation expense will be recognized when the conditions become probable of
being satisfied. We will recognize a cumulative true-up adjustment once the conditions become probable of being satisfied as the related
service period had been completed in a prior period.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Stock-based compensation expense
is recognized at fair value. We elect to account for forfeitures as they occur, rather than estimating expected forfeitures.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;After the closing of the Reverse
Recapitalization, we determine the fair value of each share of Common Stock underlying stock-based awards based on the closing price of
our Common Stock as reported by the Nasdaq Stock Market LLC (&#x201c;Nasdaq&#x201d;) on the date of grant. The fair value of stock awards
with market conditions are determined using a Monte Carlo valuation model.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Research and Development&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Research and development costs
are charged to expense as incurred. We account for nonrefundable advance payments for goods and services that will be used in future research
and development activities as expenses when the goods have been received or when the service has been performed. Research and development
expenses consist of costs incurred for the discovery and development of our product candidates. Research and development costs include,
but are not limited to, payroll and personnel expenses including stock-based compensation, clinical trial supplies, fees for clinical
trial services, consulting costs, and allocated overhead, including rent, equipment, and utilities.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <clnn:ClinicalTrialAccrualPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Clinical Trial Accrual&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Our clinical trial accrual
process accounts for expenses resulting from obligations under contracts with CROs, consultants, and under clinical site agreements in
connection with conducting clinical trials. Clinical trial costs are charged to research and development expense as incurred. The financial
terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not
match the periods over which materials or services are provided to us under such contracts. We reflect the appropriate clinical trial
expense in the condensed consolidated financial statements by matching the appropriate expenses with the period in which services and
efforts are expended. In the event advance payments are made to a CRO, the payments will be recorded as a prepaid asset which will be
amortized to research and development expense over the period the contracted services are performed. In addition to pass-through costs,
we generally incur costs in clinical trials in four distinct groups as follows:&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;CRO Start-up&#x2014;These costs
include the initial set-up of the clinical trial and usually occur within a few months after the contract has been executed and includes
costs which are expensed ratably over the start-up period when such period is identifiable and expensed as incurred when no such period
exists. Start-up phase activities include study initiation, site recruitment, regulatory applications, investigator meetings, screening,
preparation, pre-study visits, and training.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;CRO Site and Study Management&#x2014;These
costs include medical and safety monitoring, patient administration and data management. These costs are usually calculated on a per-patient
basis and expensed ratably over the treatment period beginning on the date that the patient enrolls.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;CRO Close-Down and Reporting&#x2014;These
costs include analyzing the data obtained and reporting results, which occurs after patients have ceased treatment and the database of
information collected is locked. These costs are expensed as incurred over the course of any close-down and reporting period.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Third-Party Contracts&#x2014;These
costs include fees charged by third parties for various support services which are not provided by CROs and include such items as laboratory
fees, data quality review costs, and fees incurred for investigational product monitoring and inventory control. These items are expensed
ratably over any identifiable service period with the engaged third-party vendors.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The CRO contracts generally
include pass-through fees including, but not limited to, regulatory expenses, investigator fees, travel costs, and other miscellaneous
costs, including shipping and printing fees. We determine accrual estimates through reports from and discussion with applicable personnel
and outside service providers as to the progress or state of completion of trials or the services completed. We estimate accrued expenses
as of each balance sheet date in the condensed consolidated financial statements based on the facts and circumstances known to us at that
time.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</clnn:ClinicalTrialAccrualPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Recently Adopted Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In August 2020, the FASB issued
ASU 2020-06, &lt;i&gt;Debt&lt;/i&gt;&#x2014;&lt;i&gt;Debt with Conversion and Other Options (Subtopic 470-20) &lt;/i&gt;and &lt;i&gt;Derivatives and Hedging&lt;/i&gt;&#x2014;&lt;i&gt;Contracts
in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/i&gt;
to simplify accounting for certain financial instruments by removing certain separation models for convertible instruments. Under the
amendments in ASU 2020-06, the embedded conversion features no longer are separated from the host contract for convertible instruments
with conversion features that are not required to be accounted for as derivatives, or that do not result in substantial premiums accounted
for as paid-in-capital. Consequently, a convertible debt instrument will be accounted as a single liability measured at its amortized
cost, and a convertible preferred stock will be accounted for as a single equity instrument measured at its historical cost, as long as
no other features require bifurcation and recognition as derivatives. The new standard also introduces additional disclosures for convertible
debt and freestanding instruments that are indexed to and settled in an entity&#x2019;s own equity. ASU 2020-06 amends the diluted earnings
per share guidance, including the requirements to use the if-converted method for all convertible instruments. For smaller reporting companies,
the new guidance is effective for fiscal years beginning after December 15, 2023, and should be applied on a full or modified retrospective
basis, with early adoption permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods with
those fiscal years. We early adopted ASU 2020-06 on January 1, 2021. The adoption of this guidance did not have a material impact on our
condensed consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In March 2020, the FASB issued
ASU 2020-04, &lt;i&gt;Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting&lt;/i&gt;, which
provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions in which the
reference LIBOR or another reference rate is expected to be discontinued as a result of the Reference Rate Reform. This ASU is intended
to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The new guidance
was effective immediately and through December 31, 2022. We adopted this guidance on March 1, 2020. The adoption of this guidance did
not have a material impact on our condensed consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In December 2019, the FASB
issued ASU 2019-12, &lt;i&gt;Income Taxes (Topic 740)&lt;/i&gt;, which amends the existing guidance relating to the accounting for income taxes. This
ASU is intended to simplify the accounting for income taxes by removing certain exceptions to the general principles of accounting for
income taxes and to improve the consistent application of GAAP for other areas of accounting for income taxes by clarifying and amending
existing guidance. The new guidance was effective for our fiscal year, and interim periods within our fiscal year, beginning after December
15, 2020. The adoption of this guidance did not have a material impact on our condensed consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In August 2018, the FASB issued
ASU 2018-15, &lt;i&gt;Intangibles&lt;/i&gt;&#x2014;&lt;i&gt;Goodwill and Other&lt;/i&gt;&#x2014;&lt;i&gt;Internal-Use Software (Subtopic 350-40): Customer&#x2019;s Accounting
for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract&lt;/i&gt;. The new guidance provides for the deferral
of implementation costs for cloud computing arrangements and expensing those costs over the term of the cloud services arrangement. The
new guidance was effective for our fiscal year beginning after December 15, 2020. The adoption of this guidance did not have a material
impact on our condensed consolidated financial statements.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;In&#160;August
2018,&#160;the FASB issued ASU&#160;2018-13,&#160;&lt;i&gt;Fair Value Measurement (Topic&#160;&lt;/i&gt;&lt;/span&gt;&lt;i&gt;820&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/i&gt;&lt;span style="font-size: 10pt"&gt;.
The new guidance improves the effectiveness of disclosures about fair value measurements required under ASC&#160;820.&#160;The new guidance&#160;amends
the disclosure requirements for recurring and nonrecurring fair value measurements by removing, modifying, and adding certain disclosures.
The new guidance was effective for our fiscal year, and interim periods with our fiscal year, beginning after December 15, 2019. The adoption
of this guidance&#160;did&#160;not&#160;have a material impact on our condensed consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <clnn:NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements Not Yet
Adopted&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In June 2016, the FASB issued
ASU 2016-13, &lt;i&gt;Financial Instruments&lt;/i&gt;&#x2014;&lt;i&gt;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/i&gt;.
The amendments in this ASU, among other things, require the measurement of all expected credit losses for financial assets held at the
reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions and
other organizations will now use forward-looking information to better inform their credit loss estimates. As a smaller reporting company,
the guidance is effective for our fiscal years beginning after December 15, 2022. We are currently evaluating the expected impact of the
new guidance as a result of this extended deadline of implementation for smaller reporting companies.&#160;&#160;&lt;/p&gt;</clnn:NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock>
    <clnn:ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;3. Reverse Recapitalization with Tottenham
and Clene Nanomedicine&lt;/b&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On December 30, 2020 (the
&#x201c;Closing Date&#x201d;), Chelsea Worldwide Inc., our predecessor company, consummated the previously announced business combination
(referred to as the &#x201c;Reverse Recapitalization&#x201d;) pursuant to a merger agreement, dated as of September 1, 2020 (the &#x201c;Merger
Agreement&#x201d;), by and among Clene Nanomedicine, Tottenham, Chelsea Worldwide Inc. (&#x201c;PubCo&#x201d;), a Delaware corporation and
wholly-owned subsidiary of Tottenham, Creative Worldwide Inc. (&#x201c;Merger Sub&#x201d;), a Delaware corporation and wholly-owned subsidiary
of PubCo, and Fortis Advisors LLC, a Delaware limited liability company as the representative of our shareholders. Prior to the Reincorporation
Merger discussed below, Tottenham was incorporated in the British Virgin Islands as a blank check company for the purpose of entering
into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination
with one or more businesses or entities. Prior to the Reverse Recapitalization, there was not a public market for the shares of Clene
Nanomedicine common stock.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Reverse Recapitalization
was effected in two steps: (i) Tottenham was reincorporated to the state of Delaware by merging with and into PubCo (the &#x201c;Reincorporation
Merger&#x201d;); and (ii) promptly following the Reincorporation Merger, Merger Sub was merged with and into Clene Nanomedicine, resulting
in Clene Nanomedicine becoming a wholly-owned subsidiary of PubCo (the &#x201c;Acquisition Merger&#x201d;). On the Closing Date, PubCo
changed its name from Chelsea Worldwide Inc. to Clene Inc. and listed its shares of Common Stock, par value $0.0001 per share on Nasdaq
under the symbol &#x201c;CLNN.&#x201d;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Upon the consummation of the
Reverse Recapitalization, each Tottenham ordinary share issued and outstanding immediately prior to the effective time of the Reincorporation
Merger, which totaled 2,303,495 shares held by the Initial Shareholders and Tottenham public shareholders (excluding certain shares that
were canceled pursuant to the Merger Agreement, any redeemed shares, and any dissenting shares), was automatically cancelled and ceased
to exist and (i) for each Tottenham ordinary share, we issued to each shareholder one validly-issued share of our Common Stock; (ii) each
warrant to purchase one-half (1/2) of one Tottenham Ordinary Share converted into a warrant to purchase one-half (1/2) of one share of
our Common Stock; (iii) each right exchangeable into one-tenth (1/10) of one Tottenham ordinary share converted into a right exchangeable
for one-tenth (1/10) of one share of our Common Stock; provided, however, that no fractional shares were issued and all fractional shares
were rounded down to the nearest whole share. In addition, pursuant to the Merger Agreement, the Initial Shareholders are entitled to
receive up to 750,000 shares of Common Stock as earn-out shares upon the achievement of certain milestones described below. &#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On the Closing Date, each
share of Clene Nanomedicine common stock then issued and outstanding was cancelled and the holders thereof in exchange received 54,339,012
shares of Clene Inc. Common Stock, which is equal to 0.1389 newly-issued shares of Clene Inc. Common Stock for each single share of Clene
Nanomedicine common stock (the &#x201c;Exchange Ratio&#x201d;). Pursuant to the Merger Agreement, 5% of the aggregate amount of the closing
payment shares, or 2,716,958 shares were held in escrow to satisfy any indemnification obligation incurred and were released six months
after the closing of the Reverse Recapitalization. In addition, each share of Clene Nanomedicine&#x2019;s preferred stock outstanding immediately
prior to the closing of the Reverse Recapitalization was converted into the right to receive our Common Stock based on the same Exchange
Ratio. All outstanding warrants exercisable for common stock in Clene Nanomedicine (other than warrants that expired, were exercised or
were deemed automatically net exercised immediately prior to the Acquisition Merger) were exchanged for warrants exercisable for our Common
Stock with the same terms and conditions except adjusted by the Exchange Ratio.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;All outstanding stock options
of Clene Nanomedicine common stock, totaling 53,286,115 stock options, was cancelled and the holders thereof in exchange received 0.1320
newly issued stock options of our Common Stock for a total of 7,032,591 stock options, which is 95% of the Exchange Ratio. Pursuant to
the Merger Agreement, we agreed to issue rights to 370,101 restricted stock awards to the option holders which complements the 5% closing
payment shares held in escrow for Clene Nanomedicine common shareholders. The modification of the stock options did not result in a material
incremental compensation expense upon closing of the Reverse Recapitalization.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In addition, we issued rights
to 1,136,961 restricted stock awards to option holders to complement the earn-out payments that would contingently be issued to certain
current Clene Nanomedicine shareholders upon the achievement of milestones described below.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The proceeds received from
the Reverse Recapitalization were $3.7 million, net of offering costs of $5.9 million which excludes the fair value of common shares issued
as a payment of related offering costs.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In connection with Tottenham&#x2019;s
initial public offering in August 2018, Tottenham issued to Chardan Capital Markets, LLC (&#x201c;Chardan&#x201d;), options to purchase
220,000 units at $11.50 per unit. Each of the units consists of one and one-tenth shares of Tottenham&#x2019;s ordinary shares and one
warrant to purchase one-half of one of Tottenham&#x2019;s ordinary shares at an exercise price of $11.50 per share (the &#x201c;Chardan
Unit Purchase Option&#x201d;). In connection with the Reverse Recapitalization, the Chardan Unit Purchase Option was converted into one
Company unit purchase option. The warrants included in the Chardan Unit Purchase Option (the &#x201c;Chardan Unit Purchase Option Warrants&#x201d;)
are exercisable upon the completion of the Reverse Recapitalization and will expire on December 30, 2025, five years after the consummation
of the Reverse Recapitalization (see Note 10).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Also, in connection with the
Reverse Recapitalization, Clene Nanomedicine entered into a letter agreement with LifeSci Capital LLC (&#x201c;LifeSci&#x201d;) on July
2, 2020, according to which LifeSci was engaged to act as Clene Nanomedicine&#x2019;s financial advisor with respect to identifying and
soliciting special purpose acquisition companies for the purpose of entering into a merger or similar transaction with Clene Nanomedicine
and its shareholders. Under this agreement, Clene Nanomedicine agreed that if it consummated a merger with Tottenham, LifeSci would receive
consideration of (i) 3% of the amount by which the total transaction consideration exceeded $350 million, plus (ii) 7% of cash and cash-equivalents
received by Clene Nanomedicine from the Tottenham&#x2019;s trust account. Clene Nanomedicine could elect to pay LifeSci either in cash,
equity interests of the surviving company, or a combination of the two. Upon the consummation of the Reverse Recapitalization, 644,164
shares of Common Stock were issued to LifeSci as consideration for its services as pursuant to the letter agreement (see Note 18).&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Immediately after giving effect
to the Reverse Recapitalization, there were 59,526,171 shares of Common Stock issued and outstanding and warrants to purchase 5,566,363
shares of Common Stock issued and outstanding (see Note 10).&#160;Based on the number of shares of Common Stock outstanding on December
30, 2020 (in each case, not giving effect to any shares issuable upon exercise of warrants, options, or earn-out shares), Clene Nanomedicine&#x2019;s
shareholders owned approximately 91% of the Common Stock of the Company, Tottenham shareholders owned approximately 4% of the Common Stock
of the Company, and investors from the December 2020 PIPE owned approximately 4% of the Common Stock of the Company.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During Tottenham&#x2019;s IPO,
Tottenham incurred deferred underwriters&#x2019; fees which were payable to Chardan from the amounts held in the trust account upon completion
of the Reverse Recapitalization. Upon the closing of the Reverse Recapitalization, we paid $2.1 million to Chardan as settlement of the
deferred underwriting fees, which amount was included in the total offering costs of the Reverse Recapitalization.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the year ended December
31, 2020, we recorded $5.9 million of offering costs related to third-party legal, accounting, and other professional services to consummate
the Reverse Recapitalization, excluding the fair value of common shares issued as a payment of related offering costs and Chardan underwriting
fees discussed above. These offering costs are recorded as a reduction of additional paid-in capital upon the close of the Reverse Recapitalization
in our condensed consolidated balance sheets.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The transaction was accounted for as a &#x201c;reverse recapitalization&#x201d;
in accordance with GAAP. Under this method of accounting, Tottenham was treated as the &#x201c;acquired&#x201d; company for financial reporting
purposes. This determination was primarily based on the fact that subsequent to the Reverse Recapitalization, Clene Nanomedicine&#x2019;s
shareholders have a majority of the voting power of the combined company, Clene Nanomedicine comprises all of the ongoing operations of
the combined entity, Clene Nanomedicine comprises a majority of the governing body of the combined company, and Clene Nanomedicine&#x2019;s
senior management comprises all of the senior management of the combined company. Accordingly, for accounting purposes, this transaction
was treated as the equivalent of Clene Nanomedicine issuing shares for the net assets of Tottenham, accompanied by a recapitalization.
The shares and net loss per common share in historical periods prior to the Reverse Recapitalization have been retroactively restated
using the Exchange Ratio established in the Reverse Recapitalization. The net assets of Tottenham were recorded at historical costs, with
no goodwill or other intangible assets recorded. Operations prior to the Reverse Recapitalization are those of Clene Nanomedicine.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Between July 1, 2021 and September
15, 2021, various investors exercised December 2020 PIPE Warrants for 1,002,250 shares of Common Stock at an exercise price of $0.01 per
share. The December 2020 PIPE Warrants were issued prior to the completion of the Reverse Recapitalization on December 30, 2020, and were
subject to a 180-day holding period which expired on June 28, 2021. We received cash proceeds of $10.0 thousand.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On July 15, 2021, Chardan
exercised the Chardan Unit Purchase Option for 220,000 units, each unit consisting of one and one-tenth shares of Common Stock and one
warrant to purchase one-half of one share of Common Stock at an exercise price of $11.50 per share. Chardan elected to perform a cashless
or net exercise, which resulted in a net issuance of 54,083 shares of Common Stock and 49,166 warrants to purchase one-half of one share
of Common Stock. The Chardan Unit Purchase Option was originally issued in connection with Tottenham&#x2019;s initial public offering in
August 2018. We received no cash proceeds.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Earn-Out Shares&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Certain of Clene Nanomedicine&#x2019;s
current shareholders are entitled to receive earn-out shares as follows (the &#x201c;Clene Nanomedicine Contingent Earn-out&#x201d;): (i)
3,333,333 shares of Common Stock if (A) the volume-weighted average price (&#x201c;VWAP&#x201d;) of the shares of our Common Stock equals
or exceeds $15.00 (or any foreign currency equivalent) (the &#x201c;Milestone 1 Price&#x201d;) in any twenty trading days within a thirty
trading day period within the three years following the closing of the Reverse Recapitalization on any securities exchange or securities
market on which the shares of our Common Stock are then traded or (B) the change of control price equals or exceeds the Milestone 1 Price
if a change of control transaction occurs within the three years following the closing of the Reverse Recapitalization (the requirements
set forth in clause (A) and (B), &#x201c;Milestone 1&#x201d;); (ii) 2,500,000 shares of Common Stock if (A) the VWAP of the shares of our
Common Stock equals or exceeds $20.00 (or any foreign currency equivalent) (the &#x201c;Milestone 2 Price&#x201d;) in any twenty trading
days within a thirty trading day period within the five years following the closing of the Reverse Recapitalization on any securities
exchange or securities market on which the shares of our Common Stock are then traded or (B) the change of control price equals or exceeds
the Milestone 2 Price if a change of control transaction occurs within the five years following the closing of the Reverse Recapitalization
(the requirements set forth in clause (A) or (B), &#x201c;Milestone 2&#x201d;); and (iii) 2,500,000 shares of Common Stock if Clene Nanomedicine
completes a randomized placebo-controlled study for treatment of COVID-19 which results in a statistically significant finding of clinical
efficacy within twelve months after the closing of the Reverse Recapitalization (&#x201c;Milestone 3&#x201d;). If Milestone 1 is not achieved
but Milestone 2 is achieved, the Clene Nanomedicine shareholders will receive a catch-up issuance equal to the shares issued upon satisfaction
of Milestone 1. Upon the consummation of the Reverse Recapitalization, the Clene Nanomedicine Contingent Earn-out shares increased by
12,852 as a result of the exercise of stock options during November 2020. Therefore, the total Clene Nanomedicine Contingent Earn-out
shares has increased to 8,346,185 shares of Common Stock.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Initial Shareholders of
Tottenham may be entitled to receive earn-out shares as follows (the &#x201c;Initial Shareholders Contingent Earn-out&#x201d;): (i) 375,000
shares of Common Stock upon satisfaction of the requirements of Milestone 1; and (ii) another 375,000 shares of the Company&#x2019;s Common
Stock upon satisfaction of the requirements of Milestone 2. If Milestone 1 is not achieved but Milestone 2 is achieved, the Initial Shareholders
shall receive a catch-up issuance equal to the shares granted upon satisfaction of the requirements of Milestone 1.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Clene Nanomedicine Contingent
Earn-out and Initial Shareholders Contingent Earn-out (collectively, the &#x201c;Contingent Earn-out&lt;b&gt;s&lt;/b&gt;&#x201d;) have been classified
as liabilities in the condensed consolidated balance sheets and were initially measured at fair value on the date of the Reverse Recapitalization
and are subsequently remeasured to fair value at each reporting date (see Note 16).&#160;&lt;/p&gt;</clnn:ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock>
    <clnn:CommonStockParOrStatedValuesPerShare contextRef="c116" decimals="4" unitRef="usdPershares">0.0001</clnn:CommonStockParOrStatedValuesPerShare>
    <clnn:SharesCancelledUponReverseRecapitalization contextRef="c117" decimals="0" unitRef="shares">2303495</clnn:SharesCancelledUponReverseRecapitalization>
    <clnn:InitialShareholdersContingentsEarnout contextRef="c118" decimals="0" unitRef="shares">750000</clnn:InitialShareholdersContingentsEarnout>
    <clnn:ExchangeOfSharesReceived contextRef="c118" decimals="0" unitRef="shares">54339012</clnn:ExchangeOfSharesReceived>
    <clnn:ReverseRecapitalizationExchangeRatio contextRef="c117" decimals="4" unitRef="pure">0.1389</clnn:ReverseRecapitalizationExchangeRatio>
    <clnn:SharesHeldInEscrowPercentage contextRef="c117" decimals="2" unitRef="pure">0.05</clnn:SharesHeldInEscrowPercentage>
    <clnn:SharesHeldInEscrow contextRef="c117" decimals="0" unitRef="shares">2716958</clnn:SharesHeldInEscrow>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited contextRef="c119" decimals="0" unitRef="usd">53286115</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <clnn:ReverseRecapitalizationExchangeRatio contextRef="c119" decimals="4" unitRef="pure">0.132</clnn:ReverseRecapitalizationExchangeRatio>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward contextRef="c120" decimals="0" unitRef="shares">7032591</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <clnn:ExchangeRatioPercentage contextRef="c120" decimals="2" unitRef="pure">0.95</clnn:ExchangeRatioPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward contextRef="c121" decimals="0" unitRef="shares">370101</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <clnn:SharesHeldInEscrowPercentage contextRef="c122" decimals="2" unitRef="pure">0.05</clnn:SharesHeldInEscrowPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward contextRef="c123" decimals="0" unitRef="shares">1136961</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <clnn:ProceedsFromReverseRecapitalization contextRef="c124" decimals="-5" unitRef="usd">3700000</clnn:ProceedsFromReverseRecapitalization>
    <us-gaap:DeferredOfferingCosts contextRef="c125" decimals="-5" unitRef="usd">5900000</us-gaap:DeferredOfferingCosts>
    <clnn:SaleOfUnitsNumberOfUnitsIssued contextRef="c126" decimals="0" unitRef="shares">220000</clnn:SaleOfUnitsNumberOfUnitsIssued>
    <clnn:UnitsIssuedPricePerUnit contextRef="c127" decimals="2" unitRef="usdPershares">11.5</clnn:UnitsIssuedPricePerUnit>
    <clnn:ExercisePrice contextRef="c127" decimals="2" unitRef="usdPershares">11.5</clnn:ExercisePrice>
    <clnn:ServicesLetterAgreementDescription contextRef="c128">(i) 3% of the amount by which the total transaction consideration exceeded $350 million, plus (ii) 7% of cash and cash-equivalents
received by Clene Nanomedicine from the Tottenham&#x2019;s trust account. Clene Nanomedicine could elect to pay LifeSci either in cash,
equity interests of the surviving company, or a combination of the two. Upon the consummation of the Reverse Recapitalization, 644,164
shares of Common Stock were issued to LifeSci as consideration for its services as pursuant to the letter agreement (see Note 18).</clnn:ServicesLetterAgreementDescription>
    <us-gaap:SharesIssued contextRef="c129" decimals="0" unitRef="shares">644164</us-gaap:SharesIssued>
    <us-gaap:CommonStockOtherSharesOutstanding contextRef="c116" decimals="0" unitRef="shares">59526171</us-gaap:CommonStockOtherSharesOutstanding>
    <clnn:WarrantsToPurchaseCommonStockIssuedAndOutstanding contextRef="c130" decimals="0" unitRef="shares">5566363</clnn:WarrantsToPurchaseCommonStockIssuedAndOutstanding>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c131" decimals="2" unitRef="pure">0.91</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c132" decimals="2" unitRef="pure">0.04</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c133" decimals="2" unitRef="pure">0.04</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:OtherUnderwritingExpense contextRef="c124" decimals="-5" unitRef="usd">2100000</us-gaap:OtherUnderwritingExpense>
    <us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees contextRef="c134" decimals="-5" unitRef="usd">5900000</us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees>
    <us-gaap:SharesIssued contextRef="c135" decimals="0" unitRef="shares">1002250</us-gaap:SharesIssued>
    <us-gaap:WarrantExercisePriceIncrease contextRef="c136" decimals="2" unitRef="usdPershares">0.01</us-gaap:WarrantExercisePriceIncrease>
    <clnn:AggregateGrossProceedWarrantsExercised contextRef="c137" decimals="-2" unitRef="usdPershares">10000</clnn:AggregateGrossProceedWarrantsExercised>
    <clnn:ChardanUnitPurchaseOption contextRef="c138" decimals="0" unitRef="shares">220000</clnn:ChardanUnitPurchaseOption>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c139" decimals="2" unitRef="usdPershares">11.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <clnn:NetIssuanceSharesOfCommonStock contextRef="c138" decimals="0" unitRef="shares">54083</clnn:NetIssuanceSharesOfCommonStock>
    <clnn:WarrantsToPurchaseSharesOfCommonStock contextRef="c138" decimals="0" unitRef="shares">49166</clnn:WarrantsToPurchaseSharesOfCommonStock>
    <clnn:CleneNanomedicineContingentEarnOutMilestone1Shares contextRef="c134" decimals="0" unitRef="shares">3333333</clnn:CleneNanomedicineContingentEarnOutMilestone1Shares>
    <clnn:CleneNanomedicineContingentEarnoutMilestone1Price contextRef="c134" decimals="2" unitRef="usdPershares">15</clnn:CleneNanomedicineContingentEarnoutMilestone1Price>
    <clnn:CleneNanomedicineContingentEarnoutMilestone2Shares contextRef="c134" decimals="0" unitRef="shares">2500000</clnn:CleneNanomedicineContingentEarnoutMilestone2Shares>
    <clnn:CleneNanomedicineContingentEarnoutMilestone2Price contextRef="c134" decimals="2" unitRef="usdPershares">20</clnn:CleneNanomedicineContingentEarnoutMilestone2Price>
    <clnn:CleneNanomedicineContingentEarnoutMilestone3Shares contextRef="c134" decimals="0" unitRef="shares">2500000</clnn:CleneNanomedicineContingentEarnoutMilestone3Shares>
    <clnn:IncreaseInCleneNanomedicineContingentEarnoutSharesUponReverseRecapitalization contextRef="c134" decimals="0" unitRef="shares">12852</clnn:IncreaseInCleneNanomedicineContingentEarnoutSharesUponReverseRecapitalization>
    <clnn:TotalCleneNanomedicineContingentEarnoutShares contextRef="c134" decimals="0" unitRef="shares">8346185</clnn:TotalCleneNanomedicineContingentEarnoutShares>
    <clnn:InitialShareholdersContingentEarnoutMilestone1Shares contextRef="c134" decimals="0" unitRef="shares">375000</clnn:InitialShareholdersContingentEarnoutMilestone1Shares>
    <clnn:InitialShareholdersContingentEarnoutMilestone2Shares contextRef="c134" decimals="0" unitRef="shares">375000</clnn:InitialShareholdersContingentEarnoutMilestone2Shares>
    <clnn:PrepaidExpensesAndOtherCurrentAssetsTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;4. Prepaid Expenses and Other Current Assets&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Prepaid expenses and other
current assets consisted of the following as of September 30, 2021 and December 31, 2020:&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;September&#160;30,&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Australia research and development credit receivable&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,212&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,148&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;CRO prepayments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;693&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,211&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Metals to be used in research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,691&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;31&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Directors &amp;amp; Officers Insurance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;934&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-194"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;202&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;112&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,732&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,502&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</clnn:PrepaidExpensesAndOtherCurrentAssetsTextBlock>
    <clnn:PrepaidExpensesAndOtherCurrentAssetsTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;September&#160;30,&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Australia research and development credit receivable&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,212&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,148&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;CRO prepayments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;693&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,211&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Metals to be used in research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,691&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;31&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Directors &amp;amp; Officers Insurance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;934&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-194"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;202&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;112&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,732&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,502&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</clnn:PrepaidExpensesAndOtherCurrentAssetsTableTextBlock>
    <clnn:AustraliaResearchAndDevelopmentCreditReceivable contextRef="c2" decimals="-3" unitRef="usd">-1212000</clnn:AustraliaResearchAndDevelopmentCreditReceivable>
    <clnn:AustraliaResearchAndDevelopmentCreditReceivable contextRef="c3" decimals="-3" unitRef="usd">-2148000</clnn:AustraliaResearchAndDevelopmentCreditReceivable>
    <clnn:CROPrepayments contextRef="c2" decimals="-3" unitRef="usd">693000</clnn:CROPrepayments>
    <clnn:CROPrepayments contextRef="c3" decimals="-3" unitRef="usd">1211000</clnn:CROPrepayments>
    <clnn:MetalsToBeUsedInResearchAndDevelopment contextRef="c2" decimals="-3" unitRef="usd">1691000</clnn:MetalsToBeUsedInResearchAndDevelopment>
    <clnn:MetalsToBeUsedInResearchAndDevelopment contextRef="c3" decimals="-3" unitRef="usd">31000</clnn:MetalsToBeUsedInResearchAndDevelopment>
    <clnn:DirectorsOfficersInsurance contextRef="c2" decimals="-3" unitRef="usd">934000</clnn:DirectorsOfficersInsurance>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c2" decimals="-3" unitRef="usd">202000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c3" decimals="-3" unitRef="usd">112000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c2" decimals="-3" unitRef="usd">4732000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c3" decimals="-3" unitRef="usd">3502000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;5. Property and Equipment, Net&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Property and equipment, net
consisted of the following as of September 30, 2021 and December 31, 2020:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;September&#160;30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Laboratory equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,183&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,077&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;147&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;147&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,927&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,889&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Construction in progress&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,061&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;490&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,318&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,603&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,072&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,378&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,246&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,225&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Depreciation expense related
to property and equipment, net for the three and nine months ended September 30, 2021 was approximately $0.2 million and $0.7 million,
respectively. Depreciation expense is reported in research and development expense and in general and administrative expense for $0.6
million and $0.1 million, respectively, for the nine months ended September 30, 2021; and in research and development expense and in general
and administrative expense for $0.2 million and $29 thousand, respectively, for the three months ended September 30, 2021, in the condensed
consolidated statements of operations and comprehensive income (loss).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Depreciation expense related
to property and equipment, net for the three and nine months ended September 30, 2020 was approximately $0.2 million and $0.7 million,
respectively. Depreciation expense is reported in research and development expense and in general and administrative expense for $0.6
million and $47 thousand, respectively, for the nine months ended September 30, 2020; and in research and development expense and in general
and administrative expense for $0.2 million and $34 thousand, respectively, for the three months ended September 30, 2020, in the condensed
consolidated statements of operations and comprehensive income (loss).&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;September&#160;30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Laboratory equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,183&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,077&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;147&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;147&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,927&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,889&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Construction in progress&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,061&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;490&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,318&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,603&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,072&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,378&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,246&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,225&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:MachineryAndEquipmentGross contextRef="c2" decimals="-3" unitRef="usd">3183000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:MachineryAndEquipmentGross contextRef="c3" decimals="-3" unitRef="usd">3077000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:FurnitureAndFixturesGross contextRef="c2" decimals="-3" unitRef="usd">147000</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:FurnitureAndFixturesGross contextRef="c3" decimals="-3" unitRef="usd">147000</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:LeaseholdImprovementsGross contextRef="c2" decimals="-3" unitRef="usd">3927000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:LeaseholdImprovementsGross contextRef="c3" decimals="-3" unitRef="usd">3889000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:ConstructionInProgressGross contextRef="c2" decimals="-3" unitRef="usd">1061000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross contextRef="c3" decimals="-3" unitRef="usd">490000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c2" decimals="-3" unitRef="usd">8318000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c3" decimals="-3" unitRef="usd">7603000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c2" decimals="-3" unitRef="usd">4072000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c3" decimals="-3" unitRef="usd">3378000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="-3" unitRef="usd">4246000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="-3" unitRef="usd">4225000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c140" decimals="-5" unitRef="usd">200000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c141" decimals="-5" unitRef="usd">700000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c110" decimals="-5" unitRef="usd">600000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c142" decimals="-5" unitRef="usd">100000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c109" decimals="-5" unitRef="usd">200000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c143" decimals="-3" unitRef="usd">29000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c144" decimals="-5" unitRef="usd">200000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c145" decimals="-5" unitRef="usd">700000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c112" decimals="-5" unitRef="usd">600000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c146" decimals="-3" unitRef="usd">47000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c111" decimals="-5" unitRef="usd">200000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c147" decimals="-3" unitRef="usd">34000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;6. Accrued Liabilities&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Accrued liabilities consisted
of the following as of September 30, 2021 and December 31, 2020:&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;September&#160;30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Accrued professional fees&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-195"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;189&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accrued compensation and benefits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,744&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,225&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued CRO fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;675&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;788&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Deferred grant funds&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;601&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;301&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued expense reimbursements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accrued transaction costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-196"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,354&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;64&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;70&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,117&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,960&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;September&#160;30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Accrued professional fees&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-195"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;189&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accrued compensation and benefits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,744&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,225&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued CRO fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;675&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;788&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Deferred grant funds&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;601&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;301&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued expense reimbursements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accrued transaction costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-196"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,354&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;64&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;70&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,117&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,960&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c3" decimals="-3" unitRef="usd">189000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent contextRef="c2" decimals="-3" unitRef="usd">1744000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent contextRef="c3" decimals="-3" unitRef="usd">1225000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <clnn:AccruedCROFees contextRef="c2" decimals="-3" unitRef="usd">675000</clnn:AccruedCROFees>
    <clnn:AccruedCROFees contextRef="c3" decimals="-3" unitRef="usd">788000</clnn:AccruedCROFees>
    <clnn:DeferredGrantFunds contextRef="c2" decimals="-3" unitRef="usd">601000</clnn:DeferredGrantFunds>
    <clnn:DeferredGrantFunds contextRef="c3" decimals="-3" unitRef="usd">301000</clnn:DeferredGrantFunds>
    <clnn:AccruedExpenseReimbursements contextRef="c2" decimals="-3" unitRef="usd">33000</clnn:AccruedExpenseReimbursements>
    <clnn:AccruedExpenseReimbursements contextRef="c3" decimals="-3" unitRef="usd">33000</clnn:AccruedExpenseReimbursements>
    <clnn:AccruedTransactionCosts contextRef="c3" decimals="-3" unitRef="usd">1354000</clnn:AccruedTransactionCosts>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c2" decimals="-3" unitRef="usd">64000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c3" decimals="-3" unitRef="usd">70000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c2" decimals="-3" unitRef="usd">3117000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c3" decimals="-3" unitRef="usd">3960000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:LeasesOfLesseeDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;7. Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We adopted ASC 842, &lt;i&gt;Leases&lt;/i&gt;
(&#x201c;ASC 842&#x201d;) on January 1, 2019 using the modified retrospective approach. &#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In April&#160;2020, we terminated
an existing operating lease for office space. At the time of termination, we removed the remaining right-of-use asset of $0.3 million,
lease liability of $0.3 million, and recognized a gain of $0.1 million. Further, in April&#160;2020, we commenced a new operating lease.
At the time of commencement, we recorded the right-of-use asset value of $0.4 million, leasehold improvements of $0.4 million, and a lease
liability of $0.8 million. The net effect of the change in leases being an increase in right-of-use assets of $0.1 million, an increase
in leasehold improvements of $0.5 million, an increase in lease liability of $0.4 million, and a gain on termination of $0.1 million.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In August 2021, we entered into an operating lease for laboratory space.
At the time of commencement, we recorded a right-of-use asset value of $2.4 million and a lease liability of $2.4 million, net of a lease
incentive of $1.0 million. The lease incentive represents an allowance from the lessor for facility alterations. As the lease incentive
is payable based on events within our control and are deemed reasonably certain to occur, we recorded the lease incentive as a reduction
of the right-of-use asset and lease liability at the lease commencement. As of September 30, 2021, we incurred $0.1 million of costs related
to the lease incentive which we recorded as construction in progress, with a corresponding increase to the lease liability, and the construction
in progress will be capitalized as leasehold improvements when the facility is placed into service. The lease has an initial ten-year
term and provides us the right and option to extend or renew for two periods of five years each. In accordance with ASC 842, the payments
to be made in option periods have not been recognized as part of the right-of-use asset or lease liability because we do not assess the
exercise of the option to be reasonably certain.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Additionally, in August 2021, we entered into an operating lease for
laboratory space that will replace a previous operating lease for the same facility. The commencement of the new lease and the termination
of the previous lease will be effective as of December 1, 2021, and had no impact on the condensed consolidated financial statements for
the three and nine months ended September 30, 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We have noncancelable operating
lease arrangements primarily for office and laboratory space. We also have noncancelable finance leases for certain laboratory equipment.
The maturity analysis of finance and operating lease liabilities as of September 30, 2021 are as follows:&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Finance&lt;br/&gt; Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Operating&lt;br/&gt; Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 9pt"&gt;2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;43&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;870&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;136&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;960&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;82&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;982&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,007&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-197"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,031&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-198"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,887&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25in"&gt;Total undiscounted cash flows&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;281&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,737&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Less amount representing interest/discounting&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,507&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25in"&gt;Present value of future lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;278&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,230&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Less future lease incentives&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-199"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(900&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Less lease obligations, current portion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(153&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(262&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Lease obligations&#160;&#x2013; long term portion&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;125&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,068&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We expect that, in the normal
course of business, the existing leases will be renewed or replaced by similar leases.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Finance Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Assets recorded under finance
lease obligations and included with property and equipment as of September 30, 2021 and December 31, 2020 are summarized as follows:&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;September&#160;30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Laboratory equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,148&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;920&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Work in process&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-200"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;228&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,194&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,194&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(629&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(593&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;565&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;601&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As of September 30, 2021, our finance lease obligations had a weighted-average
interest rate of 8.6% and had a weighted-average remaining term of 2.2 years. As of December 31, 2020, our finance lease obligations had
a weighted-average interest rate of 8.1% and had a weighted-average remaining term of 2.7 years.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Operating Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Our balance of right-of-use assets on the face of the balance sheet
pertain to operating leases. As of September 30, 2021, our operating lease obligations had a weighted-average discount rate of 9.6% and
had a weighted-average remaining term of 8.3 years. As of December 31, 2020, our operating lease obligations had a weighted-average discount
rate of 9.6% and a weighted-average remaining term of 6.3 years.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Components of Lease Cost&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The components of finance
and operating lease costs for the three and nine months ended September 30, 2021 and 2020 were as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three Months Ended&lt;br/&gt; September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Nine Months Ended&lt;br/&gt; September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Finance lease costs:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 52%"&gt;Amortization&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;37&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;41&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;110&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;137&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Interest on lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Operating lease costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;107&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;95&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;247&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;308&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Short-term lease costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;98&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;66&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;214&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Variable lease costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;32&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;71&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;70&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total lease costs&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;280&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;233&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;663&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;748&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Supplemental Cash Flow Information&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Operating cash flows from operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(533&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(497&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Operating cash flows from finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(21&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(30&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Financing cash flows from finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(117&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(156&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LeasesOfLesseeDisclosureTextBlock>
    <clnn:RemainingRightofuseAsset contextRef="c148" decimals="-5" unitRef="usd">300000</clnn:RemainingRightofuseAsset>
    <us-gaap:OperatingLeaseLiability contextRef="c148" decimals="-5" unitRef="usd">300000</us-gaap:OperatingLeaseLiability>
    <clnn:RecognizedGainOnOperatingLease contextRef="c149" decimals="-5" unitRef="usd">100000</clnn:RecognizedGainOnOperatingLease>
    <clnn:RightOfUseAssets contextRef="c148" decimals="-5" unitRef="usd">400000</clnn:RightOfUseAssets>
    <clnn:LeaseholdImprovements contextRef="c148" decimals="-5" unitRef="usd">400000</clnn:LeaseholdImprovements>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c148" decimals="-5" unitRef="usd">800000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <clnn:IncreaseInRightOfUseAssets contextRef="c149" decimals="-5" unitRef="usd">100000</clnn:IncreaseInRightOfUseAssets>
    <clnn:IncreaseInLeaseholdImprovements contextRef="c149" decimals="-5" unitRef="usd">500000</clnn:IncreaseInLeaseholdImprovements>
    <clnn:IncreaseInLeaseLiability contextRef="c149" decimals="-5" unitRef="usd">400000</clnn:IncreaseInLeaseLiability>
    <us-gaap:GainLossOnTerminationOfLease contextRef="c149" decimals="-5" unitRef="usd">100000</us-gaap:GainLossOnTerminationOfLease>
    <clnn:OperatingLeaseRightofUseAssets contextRef="c150" decimals="-5" unitRef="usd">2400000</clnn:OperatingLeaseRightofUseAssets>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c150" decimals="-5" unitRef="usd">2400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:IncentiveToLessee contextRef="c150" decimals="-5" unitRef="usd">1000000</us-gaap:IncentiveToLessee>
    <clnn:LeaseIncentiveRecordedConstructionInProgress contextRef="c2" decimals="-5" unitRef="usd">100000</clnn:LeaseIncentiveRecordedConstructionInProgress>
    <us-gaap:LessorOperatingLeaseDescription contextRef="c0">The lease has an initial ten-year
term and provides us the right and option to extend or renew for two periods of five years each. In accordance with ASC 842, the payments
to be made in option periods have not been recognized as part of the right-of-use asset or lease liability because we do not assess the
exercise of the option to be reasonably certain.</us-gaap:LessorOperatingLeaseDescription>
    <clnn:FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Finance&lt;br/&gt; Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Operating&lt;br/&gt; Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 9pt"&gt;2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;43&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;870&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;136&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;960&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;82&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;982&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,007&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-197"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,031&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-198"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,887&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25in"&gt;Total undiscounted cash flows&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;281&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,737&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Less amount representing interest/discounting&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,507&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25in"&gt;Present value of future lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;278&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,230&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Less future lease incentives&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-199"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(900&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Less lease obligations, current portion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(153&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(262&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Lease obligations&#160;&#x2013; long term portion&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;125&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,068&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/&gt;</clnn:FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear contextRef="c151" decimals="-3" unitRef="usd">43000</us-gaap:CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear contextRef="c152" decimals="-3" unitRef="usd">870000</us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent contextRef="c151" decimals="-3" unitRef="usd">136000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="c152" decimals="-3" unitRef="usd">960000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears contextRef="c151" decimals="-3" unitRef="usd">82000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="c152" decimals="-3" unitRef="usd">982000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears contextRef="c151" decimals="-3" unitRef="usd">20000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="c152" decimals="-3" unitRef="usd">1007000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="c152" decimals="-3" unitRef="usd">1031000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="c152" decimals="-3" unitRef="usd">2887000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDue contextRef="c151" decimals="-3" unitRef="usd">281000</us-gaap:CapitalLeasesFutureMinimumPaymentsDue>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="c152" decimals="-3" unitRef="usd">7737000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <clnn:CapitalLeasesAmountRepresentingInterestdiscounting contextRef="c151" decimals="-3" unitRef="usd">3000</clnn:CapitalLeasesAmountRepresentingInterestdiscounting>
    <clnn:OperatingLeasesAmountRepresentingInterestdiscounting contextRef="c152" decimals="-3" unitRef="usd">2507000</clnn:OperatingLeasesAmountRepresentingInterestdiscounting>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments contextRef="c151" decimals="-3" unitRef="usd">278000</us-gaap:CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments>
    <us-gaap:OperatingLeaseLiability contextRef="c152" decimals="-3" unitRef="usd">5230000</us-gaap:OperatingLeaseLiability>
    <clnn:OperatingLeasesLessFutureLeaseIncentives contextRef="c152" decimals="-3" unitRef="usd">-900000</clnn:OperatingLeasesLessFutureLeaseIncentives>
    <us-gaap:CapitalLeaseObligationsCurrent contextRef="c151" decimals="-3" unitRef="usd">153000</us-gaap:CapitalLeaseObligationsCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c152" decimals="-3" unitRef="usd">262000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:CapitalLeaseObligationsNoncurrent contextRef="c151" decimals="-3" unitRef="usd">125000</us-gaap:CapitalLeaseObligationsNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c152" decimals="-3" unitRef="usd">4068000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <clnn:FinanceLeaseByMajorClassPropertyAndEquipmentTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;September&#160;30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Laboratory equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,148&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;920&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Work in process&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-200"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;228&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,194&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,194&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(629&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(593&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;565&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;601&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</clnn:FinanceLeaseByMajorClassPropertyAndEquipmentTableTextBlock>
    <clnn:FinanceLeaseLaboratoryEquipmentGross contextRef="c2" decimals="-3" unitRef="usd">1148000</clnn:FinanceLeaseLaboratoryEquipmentGross>
    <clnn:FinanceLeaseLaboratoryEquipmentGross contextRef="c3" decimals="-3" unitRef="usd">920000</clnn:FinanceLeaseLaboratoryEquipmentGross>
    <clnn:FinanceLeaseFurnitureAndFixturesGross contextRef="c2" decimals="-3" unitRef="usd">46000</clnn:FinanceLeaseFurnitureAndFixturesGross>
    <clnn:FinanceLeaseFurnitureAndFixturesGross contextRef="c3" decimals="-3" unitRef="usd">46000</clnn:FinanceLeaseFurnitureAndFixturesGross>
    <clnn:FinanceLeaseWorkInProcessGross contextRef="c3" decimals="-3" unitRef="usd">228000</clnn:FinanceLeaseWorkInProcessGross>
    <clnn:FinanceLeaseLiabilityGross contextRef="c2" decimals="-3" unitRef="usd">1194000</clnn:FinanceLeaseLiabilityGross>
    <clnn:FinanceLeaseLiabilityGross contextRef="c3" decimals="-3" unitRef="usd">1194000</clnn:FinanceLeaseLiabilityGross>
    <clnn:AccumulatedDepreciationDepletionAndAmortizationLeases contextRef="c2" decimals="-3" unitRef="usd">-629000</clnn:AccumulatedDepreciationDepletionAndAmortizationLeases>
    <clnn:AccumulatedDepreciationDepletionAndAmortizationLeases contextRef="c3" decimals="-3" unitRef="usd">-593000</clnn:AccumulatedDepreciationDepletionAndAmortizationLeases>
    <clnn:FinanceLeaseLiabilityNet contextRef="c2" decimals="-3" unitRef="usd">565000</clnn:FinanceLeaseLiabilityNet>
    <clnn:FinanceLeaseLiabilityNet contextRef="c3" decimals="-3" unitRef="usd">601000</clnn:FinanceLeaseLiabilityNet>
    <clnn:FinanceLeaseObligationsWeightedaverageInterestRate contextRef="c2" decimals="3" unitRef="pure">0.086</clnn:FinanceLeaseObligationsWeightedaverageInterestRate>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c2">P2Y2M12D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <clnn:FinanceLeaseObligationsWeightedaverageInterestRate contextRef="c3" decimals="3" unitRef="pure">0.081</clnn:FinanceLeaseObligationsWeightedaverageInterestRate>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c3">P2Y8M12D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <clnn:OperatingLeaseObligationsWeightedAverageInterestRate contextRef="c2" decimals="3" unitRef="pure">0.096</clnn:OperatingLeaseObligationsWeightedAverageInterestRate>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c2">P8Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <clnn:OperatingLeaseObligationsWeightedAverageInterestRate contextRef="c3" decimals="3" unitRef="pure">0.096</clnn:OperatingLeaseObligationsWeightedAverageInterestRate>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c3">P6Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LeaseCostTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three Months Ended&lt;br/&gt; September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Nine Months Ended&lt;br/&gt; September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Finance lease costs:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 52%"&gt;Amortization&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;37&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;41&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;110&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;137&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Interest on lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Operating lease costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;107&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;95&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;247&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;308&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Short-term lease costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;98&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;66&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;214&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Variable lease costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;32&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;71&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;70&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total lease costs&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;280&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;233&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;663&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;748&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c12" decimals="-3" unitRef="usd">37000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c13" decimals="-3" unitRef="usd">41000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c0" decimals="-3" unitRef="usd">110000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c14" decimals="-3" unitRef="usd">137000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c12" decimals="-3" unitRef="usd">6000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c13" decimals="-3" unitRef="usd">9000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c0" decimals="-3" unitRef="usd">21000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c14" decimals="-3" unitRef="usd">30000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:OperatingLeaseCost contextRef="c12" decimals="-3" unitRef="usd">107000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c13" decimals="-3" unitRef="usd">95000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c0" decimals="-3" unitRef="usd">247000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c14" decimals="-3" unitRef="usd">308000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c12" decimals="-3" unitRef="usd">98000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c13" decimals="-3" unitRef="usd">66000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c0" decimals="-3" unitRef="usd">214000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c14" decimals="-3" unitRef="usd">203000</us-gaap:ShortTermLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c12" decimals="-3" unitRef="usd">32000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c13" decimals="-3" unitRef="usd">22000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c0" decimals="-3" unitRef="usd">71000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c14" decimals="-3" unitRef="usd">70000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost contextRef="c12" decimals="-3" unitRef="usd">280000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c13" decimals="-3" unitRef="usd">233000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c0" decimals="-3" unitRef="usd">663000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c14" decimals="-3" unitRef="usd">748000</us-gaap:LeaseCost>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Operating cash flows from operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(533&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(497&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Operating cash flows from finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(21&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(30&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Financing cash flows from finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(117&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(156&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <clnn:OperatingCashFlowsFromOperatingLeases contextRef="c2" decimals="-3" unitRef="usd">-533000</clnn:OperatingCashFlowsFromOperatingLeases>
    <clnn:OperatingCashFlowsFromOperatingLeases contextRef="c94" decimals="-3" unitRef="usd">-497000</clnn:OperatingCashFlowsFromOperatingLeases>
    <clnn:OperatingCashFlowsFromFinanceLeases contextRef="c2" decimals="-3" unitRef="usd">-21000</clnn:OperatingCashFlowsFromFinanceLeases>
    <clnn:OperatingCashFlowsFromFinanceLeases contextRef="c94" decimals="-3" unitRef="usd">-30000</clnn:OperatingCashFlowsFromFinanceLeases>
    <clnn:FinanceCashFlowsFromFinanceLeases contextRef="c2" decimals="-3" unitRef="usd">-117000</clnn:FinanceCashFlowsFromFinanceLeases>
    <clnn:FinanceCashFlowsFromFinanceLeases contextRef="c94" decimals="-3" unitRef="usd">-156000</clnn:FinanceCashFlowsFromFinanceLeases>
    <us-gaap:DebtDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;8. Notes Payable&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Our long-term debt, net of
original issue discount and unamortized debt issuance costs, consisted of the following:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Interest&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;September&#160;30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Rate&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Term Loans:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-left: 9pt"&gt;Maryland Department of Housing &amp;amp; Community Development&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;819&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,080&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Advance Cecil, Inc.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;164&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;216&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Paycheck Protection Program&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-201"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;647&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Avenue Venture Opportunities Fund, L.P.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9.85&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-202"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-203"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,983&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,949&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Unamortized debt issuance costs and original issue discounts&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,811&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-204"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Less convertible notes payable, net of unamortized debt discount and issuance costs (see Note 11)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,559&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-205"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt"&gt;Total notes payable&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;14,613&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,949&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Maryland Loan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In February&#160;2019, we
entered into a loan agreement (the &#x201c;2019 MD Loan&#x201d;) with the Department of Housing and Community Development, a principal department
of the State of Maryland (&#x201c;Maryland&#x201d;). Pursuant to the 2019 MD Loan, Maryland agreed to provide a $0.5 million term loan.
Amounts outstanding under the 2019 MD Loan bear simple interest at an annual rate of 8.00%. Under the 2019 MD Loan, we agreed to affirmative
and negative covenants to which we will remain subject until maturity. These covenants include providing information about the Company
and our operations; limitations on our ability to retire, repurchase, or redeem our common or preferred stock, options, and warrants other
than per the terms of the securities; and limitations on our ability to pay dividends of cash or property. There are no financial covenants
associated with the 2019 MD Loan. Events of default under the 2019 MD Loan include failure to make payments when due, insolvency events,
and failure to comply with covenants. We are not in violation of any affirmative covenants. Repayment of the full balance outstanding
is due on February 22, 2034. The 2019 MD Loan establishes &#x201c;Phantom Shares,&#x201d; based on 119,906 shares of Common Stock (based
on 863,110 Series C Preferred Shares prior to the Reverse Recapitalization), determined at issuance. The 2019 MD Loan states the repayment
amount is to be the greater of the balance of principal and accrued interest or the Phantom Shares value. We determined that the note
should be accounted for at fair value. We record the fair value of the debt at the end of each reporting period. In order to value the
note, we consider the amount of the simple interest expense that would be due and the value of Phantom Shares. Upon the closing of the
Reverse Recapitalization and as of December 31, 2020, the fair value of the 2019 MD Loan is determined based on the closing price of CLNN
shares listed on Nasdaq.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Income of $0.5 million and
$0.3 million were recognized during the three and nine months ended September 30, 2021, respectively. Expense of $0.2 million and $0.3
million was recognized during the three and nine months ended September 30, 2020, respectively. The fair value of $0.8 million and $1.1
million of principal and accrued interest is included in long-term notes payable as of September 30, 2021 and December 31, 2020, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Cecil County Loan&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In April&#160;2019, we entered
into a loan agreement (the &#x201c;2019 Cecil Loan&#x201d;) with Advance Cecil Inc., a non-stock corporation formed under the laws of the
state of Maryland with application for 501(c)(3) non-profit status pending before the United States Internal Revenue Service at the time
of execution of the 2019 Cecil Loan. Pursuant to the 2019 Cecil Loan, Cecil agreed to provide a $0.1 million term loan. Amounts outstanding
under the 2019 Cecil Loan bear simple interest at an annual rate of 8.00%. Under the 2019 Cecil Loan, we agreed to affirmative covenants
to which we will remain subject until maturity. These covenants include providing information about the Company and our operations. There
are no financial covenants associated with the 2019 Cecil Loan. Events of default under the 2019 Cecil Loan include failure to make payments
when due, insolvency events, failure to comply with covenants, and material adverse effects with respect to the Company. We are not in
violation of any affirmative covenants. Repayment of the full balance outstanding is due on April 30, 2034. The 2019 Cecil Loan establishes
&#x201c;Phantom Shares,&#x201d; based on 23,981 shares of Common Stock (based on 172,622 Series C Preferred Shares prior to the Reverse
Recapitalization), determined at issuance. The 2019 Cecil Loan states the repayment amount is to be the greater of the balance of principal
and accrued interest or the Phantom Share value. We determined that the note should be accounted for at fair value. We record the fair
value of the debt at the end of each reporting period. In order to value the note, we consider the amount of the simple interest expense
that would be due and the value of Phantom Shares. Upon the closing of the Reverse Recapitalization and as of December 31, 2020, the fair
value of the 2019 Cecil Loan is determined based on the closing price of CLNN shares listed on Nasdaq.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Income of $0.1 million and
expense of $52 thousand were recognized during the three and nine months ended September 30, 2021, respectively. Expense of $42 thousand
and $55 thousand was recognized during the three and nine months ended September 30, 2020, respectively. The fair value of $0.2 million
and $0.2 million of principal and accrued interest is included in long-term notes payable as of September 30, 2021 and December 31, 2020,
respectively.&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;PPP Loan&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In May&#160;2020, we entered
into a note payable in the amount of $0.6 million (the &#x201c;PPP Note&#x201d;) under the Paycheck Protection Program of the CARES Act
(the &#x201c;PPP&#x201d;). As amended, the PPP permits forgiveness of amounts loaned for payments of payroll and other qualifying expenses
within 24 weeks of receipt of loaned funds, given that at least 60% of the total loan is used for payroll. Amounts not forgiven have a
repayment period of five years. In January 2021, the full $0.6 million balance of the PPP Note was forgiven and has been recorded as a
gain on extinguishment of debt during the nine months ended September 30, 2021. There was no gain on extinguishment of debt recorded during
the three months ended September 30, 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Avenue Loan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In May 2021, we entered into the 2021 Avenue Loan with Avenue. The
agreement provides for a 42-month term loan of up to $30.0 million. The first tranche is $20.0 million (&#x201c;Tranche 1&#x201d;), of which
$15.0 million was funded at close. We incurred issuance costs for a total of $0.5 million of which $35 thousand has been expensed immediately.
The remaining balance from Tranche 1 of $5.0 million was funded on September 28, 2021 and an additional tranche of $10.0 million (&#x201c;Tranche
2&#x201d;) is available at the Company&#x2019;s request until June 30, 2022. Pursuant to the 2021 Avenue Loan, funding of Tranche 2 is subject
to evidence reasonably satisfactory to Avenue of receipt of an additional $5.0 million financing through Maryland&#x2019;s State Incentive
Programs and/or other Maryland State programs and mutual agreement of the Company and Avenue. On September 27, 2021, we obtained a waiver
from this additional financing requirement for the funding of the remaining $5.0 million of Tranche 1 and exercised the option to postpone
principal repayment by one year. We incurred additional issuance costs of $75 thousand upon funding the remaining $5.0 million of Tranche
1, of which $12 thousand has been expensed immediately. Funding of Tranche 2 is also subject to (a) our achievement of a statistically
significant result on the primary endpoint as defined within the statistical analysis plan for each respective study, or the totality
of the results for any study warrant advancement into a subsequent clinical efficacy study, as reasonably determined by the Company and
Avenue with respect to at least two of the following studies: (i) RESCUE-ALS or the Healey ALS Platform Trial; (ii) REPAIR-PD; or (iii)
REPAIR-MS (&#x201c;Performance Milestone 1&#x201d;); and (b) our receipt of net proceeds of at least $30 million from the sale and issuance
of our equity securities (including any private placement or follow-on offering) between May 2, 2021 and June 30, 2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The loans bear interest at
a variable rate per annum equal to the sum of (i) the greater of (A) the prime rate, as published by the Wall Street Journal from time
to time or (B) 3.25%, plus (ii) 6.60%. Payments for the loan are interest only for the initial 12 months and can be extended to (i) 12
months (the &#x201c;First Interest-only Period Extension&#x201d;) if we achieve Performance Milestone 1 and (ii) up to 36 months if (a)
we achieve the First Interest-only Period Extension and (b) have drawn from Tranche 2. On August 16, 2021, we mutually confirmed with
Avenue that Performance Milestone 1 and the First Interest-only Period Extension had been achieved. The loan will amortize in equal payments
of principal from the end of the interest period to the expiration of the 42-month term on December 1, 2024. On the maturity date, an
additional payment equal to 4.25% of the funded loans, or $0.6 million, is due in addition to the remaining unpaid principal and accrued
interest. The final payment is recorded as a debt premium and is being amortized over the contractual term using the effective interest
method. The final payment provision is related to the loan host and is not bifurcated pursuant to ASC 815.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Pursuant to the agreement, we granted to Avenue the Avenue Warrants
for the purchase of 115,851 shares of Common Stock at an exercise price equal to the lower of (i) $8.63 (which is equal to the five-day
volume weighted average price (&#x201c;VWAP&#x201d;) per share, determined as of the end of trading on the last trading day prior to execution
of the loan agreement), or (ii) the lowest price per share paid by cash investors for our Common Stock issued in the next bona fide round
of equity financing prior to March 31, 2022 (the &#x201c;Next Round Price&#x201d;) (see Note 10). Upon the funding of Tranche 2, the Avenue
Warrant shall be automatically adjusted to include an additional estimated 86,679 shares of Common Stock, which is equal to 5% of the
principal amount of Tranche 2, divided by the lower of (i) the five (5)-day VWAP per share; determined as of the end of trading on the
last trading day before the date of issuance of Tranche 2; or (ii) the Next Round Price. We accounted for the Tranche 2 warrants at inception
of the 2021 Avenue Loan in accordance with ASC 815 and the fair value and issuable shares will be remeasured at each reporting period
(see Note 10). Avenue also has the right, in its discretion, but not the obligation, at any time from time to time from the first through
the third-year anniversary of the agreement, while the loan is outstanding, to convert an amount of up to $5.0 million of the principal
amount of the outstanding loan into Common Stock (the &#x201c;Conversion Feature&#x201d;) at a price per share equal to 120% of the stock
purchase price set forth in the warrant. The Conversion Feature is subject to (i) the closing price of our Common Stock for each of the
seven consecutive trading days immediately preceding the conversion being greater than or equal to the conversion price and (ii) the Common
Stock issued in connection with any such conversion not exceeding 20% of the total trading volume of our Common Stock for the twenty-two
consecutive trading days immediately prior to and including the effective date of such conversion.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Under the 2021 Avenue Loan, we agreed to affirmative and negative covenants
to which we will remain subject upon maturity in the absence of prepayments. These covenants include providing information about the Company
and our operations; limitation on our ability to retire, repurchase, or redeem our Common Stock, options, and warrants other than per
the terms of the securities; and limitations on our ability to pay dividends of cash or property. The financial covenant associated with
the loan agreement includes maintaining minimum unrestricted cash and cash equivalents of at least $5.0 million; provided that upon our
(i) achievement of Performance Milestone 1, and (ii) receiving of net proceeds of at least $30.0 million from the sale and issuance of
our equity securities (including any PIPE or follow-on offering) between May 1, 2021 and June 30, 2022, we shall no longer be subject
to financial covenants. We are not in violation of the covenants. The agreement provides for events of default customary for loans of
this type, including but not limited to non-payment, breaches, the occurrence of a material adverse change, or defaults in the performance
of covenants, insolvency, and bankruptcy. The 2021 Avenue Loan is collateralized by substantially all of our assets other than intellectual
property, including capital stock of the Company and its subsidiaries, in which Avenue is granted a continuing security interest. The
net proceeds from the issuance of the loan were initially allocated to the warrant at an amount equal to their fair value of $1.0 million
and the remainder to the loan. The allocation of incurred financing costs of $0.5 million and the fair value of the warrant, together
with the final payment, are recorded as a debt discount and debt premium, respectively, and are being amortized over the contractual term
using the effective interest method. During the three and nine months ended September 30, 2021, we recorded interest expense of $0.6 million
and $0.8 million, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Following is a schedule of
future payments, net of unamortized debt discounts, if Avenue does not convert up to $5.0 million of the loan into Common Stock between
May 21, 2022 through May 21, 2024:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;2021 (remainder)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-206"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-207"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,667&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,333&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-208"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-209"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-210"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Subtotal of future principal payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Unamortized debt discount associated with issuance date warrant fair value and financing costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,811&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;18,189&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Interest&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;September&#160;30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Rate&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Term Loans:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-left: 9pt"&gt;Maryland Department of Housing &amp;amp; Community Development&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;819&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,080&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Advance Cecil, Inc.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;164&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;216&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Paycheck Protection Program&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-201"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;647&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Avenue Venture Opportunities Fund, L.P.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9.85&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-202"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-203"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,983&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,949&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Unamortized debt issuance costs and original issue discounts&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,811&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-204"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Less convertible notes payable, net of unamortized debt discount and issuance costs (see Note 11)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,559&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-205"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt"&gt;Total notes payable&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;14,613&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,949&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <clnn:InterestRate contextRef="c180" decimals="4" unitRef="pure">0.08</clnn:InterestRate>
    <clnn:TotalTermLoans contextRef="c181" decimals="-3" unitRef="usd">819000</clnn:TotalTermLoans>
    <clnn:TotalTermLoans contextRef="c182" decimals="-3" unitRef="usd">1080000</clnn:TotalTermLoans>
    <clnn:InterestRate contextRef="c183" decimals="4" unitRef="pure">0.08</clnn:InterestRate>
    <clnn:TotalTermLoans contextRef="c184" decimals="-3" unitRef="usd">164000</clnn:TotalTermLoans>
    <clnn:TotalTermLoans contextRef="c185" decimals="-3" unitRef="usd">216000</clnn:TotalTermLoans>
    <clnn:InterestRate contextRef="c186" decimals="4" unitRef="pure">0.01</clnn:InterestRate>
    <clnn:TotalTermLoans contextRef="c188" decimals="-3" unitRef="usd">647000</clnn:TotalTermLoans>
    <clnn:InterestRate contextRef="c189" decimals="4" unitRef="pure">0.0985</clnn:InterestRate>
    <clnn:TotalTermLoans contextRef="c190" decimals="-3" unitRef="usd">20000000</clnn:TotalTermLoans>
    <clnn:InterestRate contextRef="c192" decimals="4" unitRef="pure">0</clnn:InterestRate>
    <clnn:TotalTermLoans contextRef="c194" decimals="-3" unitRef="usd">6000</clnn:TotalTermLoans>
    <clnn:TotalTermLoans contextRef="c2" decimals="-3" unitRef="usd">20983000</clnn:TotalTermLoans>
    <clnn:TotalTermLoans contextRef="c3" decimals="-3" unitRef="usd">1949000</clnn:TotalTermLoans>
    <us-gaap:UnamortizedDebtIssuanceExpense contextRef="c2" decimals="-3" unitRef="usd">1811000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="c2" decimals="-3" unitRef="usd">-4559000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <clnn:TotalNotesPayableAndConvertibleNotesPayable contextRef="c0" decimals="-3" unitRef="usd">14613000</clnn:TotalNotesPayableAndConvertibleNotesPayable>
    <clnn:TotalNotesPayableAndConvertibleNotesPayable contextRef="c134" decimals="-3" unitRef="usd">1949000</clnn:TotalNotesPayableAndConvertibleNotesPayable>
    <us-gaap:LongTermDebt contextRef="c153" decimals="-5" unitRef="usd">500000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c153" decimals="4" unitRef="pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c154">2034-02-22</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentDescription contextRef="c154">The 2019 MD Loan establishes &#x201c;Phantom Shares,&#x201d; based on 119,906 shares of Common Stock (based
on 863,110 Series C Preferred Shares prior to the Reverse Recapitalization), determined at issuance.</us-gaap:DebtInstrumentDescription>
    <us-gaap:InterestIncomeOther contextRef="c155" decimals="-5" unitRef="usd">500000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther contextRef="c156" decimals="-5" unitRef="usd">300000</us-gaap:InterestIncomeOther>
    <clnn:SimpleInterestExpense contextRef="c157" decimals="-5" unitRef="usd">200000</clnn:SimpleInterestExpense>
    <clnn:SimpleInterestExpense contextRef="c158" decimals="-5" unitRef="usd">300000</clnn:SimpleInterestExpense>
    <clnn:FairValueOfLongTermNotesPayable contextRef="c159" decimals="-5" unitRef="usd">800000</clnn:FairValueOfLongTermNotesPayable>
    <clnn:FairValueOfLongTermNotesPayable contextRef="c160" decimals="-5" unitRef="usd">1100000</clnn:FairValueOfLongTermNotesPayable>
    <us-gaap:LongTermDebt contextRef="c161" decimals="-5" unitRef="usd">100000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c161" decimals="4" unitRef="pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c162">2034-04-30</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentDescription contextRef="c162">The 2019 Cecil Loan establishes
&#x201c;Phantom Shares,&#x201d; based on 23,981 shares of Common Stock (based on 172,622 Series C Preferred Shares prior to the Reverse
Recapitalization), determined at issuance.</us-gaap:DebtInstrumentDescription>
    <us-gaap:OtherIncome contextRef="c163" decimals="-5" unitRef="usd">100000</us-gaap:OtherIncome>
    <clnn:SimpleInterestExpense contextRef="c164" decimals="-3" unitRef="usd">52000</clnn:SimpleInterestExpense>
    <clnn:SimpleInterestExpense contextRef="c163" decimals="-3" unitRef="usd">9000</clnn:SimpleInterestExpense>
    <clnn:SimpleInterestExpense contextRef="c165" decimals="-3" unitRef="usd">42000</clnn:SimpleInterestExpense>
    <clnn:SimpleInterestExpense contextRef="c166" decimals="-3" unitRef="usd">55000</clnn:SimpleInterestExpense>
    <clnn:FairValueOfLongTermNotesPayable contextRef="c167" decimals="-5" unitRef="usd">200000</clnn:FairValueOfLongTermNotesPayable>
    <clnn:FairValueOfLongTermNotesPayable contextRef="c168" decimals="-5" unitRef="usd">200000</clnn:FairValueOfLongTermNotesPayable>
    <us-gaap:NotesAndLoansPayable contextRef="c169" decimals="-5" unitRef="usd">600000</us-gaap:NotesAndLoansPayable>
    <clnn:PercentageOfLoanAmountUsedToPayrollExpenses contextRef="c170" decimals="2" unitRef="pure">0.60</clnn:PercentageOfLoanAmountUsedToPayrollExpenses>
    <us-gaap:ExtinguishmentOfDebtAmount contextRef="c171" decimals="-5" unitRef="usd">600000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:LongTermDebt contextRef="c172" decimals="-5" unitRef="usd">30000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c173" decimals="-5" unitRef="usd">20000000</us-gaap:DebtInstrumentFaceAmount>
    <clnn:FundedAmountAtClosing contextRef="c173" decimals="-5" unitRef="usd">15000000</clnn:FundedAmountAtClosing>
    <clnn:AccruedDebtIssuanceCosts contextRef="c174" decimals="-5" unitRef="usd">500000</clnn:AccruedDebtIssuanceCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c174" decimals="-3" unitRef="usd">35000</us-gaap:AmortizationOfFinancingCosts>
    <clnn:DebtInstrumentUnfundedBalance contextRef="c173" decimals="-5" unitRef="usd">5000000</clnn:DebtInstrumentUnfundedBalance>
    <clnn:SecondLoanAmount contextRef="c175" decimals="-5" unitRef="usd">10000000</clnn:SecondLoanAmount>
    <clnn:ConditionsForFutureFundingDescription contextRef="c174">funding of Tranche 2 is subject
to evidence reasonably satisfactory to Avenue of receipt of an additional $5.0 million financing through Maryland&#x2019;s State Incentive
Programs and/or other Maryland State programs and mutual agreement of the Company and Avenue. On September 27, 2021, we obtained a waiver
from this additional financing requirement for the funding of the remaining $5.0 million of Tranche 1 and exercised the option to postpone
principal repayment by one year. We incurred additional issuance costs of $75 thousand upon funding the remaining $5.0 million of Tranche
1, of which $12 thousand has been expensed immediately. Funding of Tranche 2 is also subject to (a) our achievement of a statistically
significant result on the primary endpoint as defined within the statistical analysis plan for each respective study, or the totality
of the results for any study warrant advancement into a subsequent clinical efficacy study, as reasonably determined by the Company and
Avenue with respect to at least two of the following studies: (i) RESCUE-ALS or the Healey ALS Platform Trial; (ii) REPAIR-PD; or (iii)
REPAIR-MS (&#x201c;Performance Milestone 1&#x201d;); and (b) our receipt of net proceeds of at least $30 million from the sale and issuance
of our equity securities (including any private placement or follow-on offering) between May 2, 2021 and June 30, 2022.</clnn:ConditionsForFutureFundingDescription>
    <clnn:AccruedDebtIssuanceCosts contextRef="c176" decimals="-3" unitRef="usd">75000</clnn:AccruedDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c176" decimals="-3" unitRef="usd">12000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <clnn:RateOfInterestDescription contextRef="c176">The loans bear interest at
a variable rate per annum equal to the sum of (i) the greater of (A) the prime rate, as published by the Wall Street Journal from time
to time or (B) 3.25%, plus (ii) 6.60%. Payments for the loan are interest only for the initial 12 months and can be extended to (i) 12
months (the &#x201c;First Interest-only Period Extension&#x201d;) if we achieve Performance Milestone 1 and (ii) up to 36 months if (a)
we achieve the First Interest-only Period Extension and (b) have drawn from Tranche 2. On August 16, 2021, we mutually confirmed with
Avenue that Performance Milestone 1 and the First Interest-only Period Extension had been achieved.</clnn:RateOfInterestDescription>
    <clnn:AdditionalPaymentUponMaturityDescription contextRef="c177">On the maturity date, an
additional payment equal to 4.25% of the funded loans, or $0.6 million, is due in addition to the remaining unpaid principal and accrued
interest.</clnn:AdditionalPaymentUponMaturityDescription>
    <clnn:WarrantToPurchaseShares contextRef="c174" decimals="0" unitRef="shares">115851</clnn:WarrantToPurchaseShares>
    <clnn:CommonStockAtAnExercisePrice contextRef="c174" decimals="2" unitRef="usdPershares">8.63</clnn:CommonStockAtAnExercisePrice>
    <clnn:Tranche2WarrantAdjustmentDescription contextRef="c174">Upon the funding of Tranche 2, the Avenue
Warrant shall be automatically adjusted to include an additional estimated 86,679 shares of Common Stock, which is equal to 5% of the
principal amount of Tranche 2, divided by the lower of (i) the five (5)-day VWAP per share; determined as of the end of trading on the
last trading day before the date of issuance of Tranche 2; or (ii) the Next Round Price.</clnn:Tranche2WarrantAdjustmentDescription>
    <us-gaap:ConvertibleNotesPayable contextRef="c172" decimals="-5" unitRef="usd">5000000</us-gaap:ConvertibleNotesPayable>
    <clnn:ConversionPercentageOfCommonStockPriceForConvertibleNotePayable contextRef="c174" decimals="2" unitRef="pure">1.20</clnn:ConversionPercentageOfCommonStockPriceForConvertibleNotePayable>
    <clnn:TradingVolumeLimitForConversionOfConvertibleNotePayable contextRef="c174" decimals="2" unitRef="pure">0.20</clnn:TradingVolumeLimitForConversionOfConvertibleNotePayable>
    <clnn:ThresholdForRemovalOfFinancialCovenantsDescription contextRef="c176">The financial covenant associated with
the loan agreement includes maintaining minimum unrestricted cash and cash equivalents of at least $5.0 million; provided that upon our
(i) achievement of Performance Milestone 1, and (ii) receiving of net proceeds of at least $30.0 million from the sale and issuance of
our equity securities (including any PIPE or follow-on offering) between May 1, 2021 and June 30, 2022, we shall no longer be subject
to financial covenants.</clnn:ThresholdForRemovalOfFinancialCovenantsDescription>
    <clnn:MinimumCashBalanceForLoanCovenant contextRef="c176" decimals="-5" unitRef="usd">5000000</clnn:MinimumCashBalanceForLoanCovenant>
    <clnn:FairValueOfWarrant contextRef="c174" decimals="-5" unitRef="usd">1000000</clnn:FairValueOfWarrant>
    <clnn:DebtInstrumentFinancingCosts contextRef="c174" decimals="-5" unitRef="usd">500000</clnn:DebtInstrumentFinancingCosts>
    <clnn:SimpleInterestExpense contextRef="c178" decimals="-5" unitRef="usd">600000</clnn:SimpleInterestExpense>
    <clnn:SimpleInterestExpense contextRef="c176" decimals="-5" unitRef="usd">800000</clnn:SimpleInterestExpense>
    <us-gaap:ConvertibleDebt contextRef="c179" decimals="-5" unitRef="usd">5000000</us-gaap:ConvertibleDebt>
    <clnn:ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscounts contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;2021 (remainder)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-206"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-207"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,667&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,333&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-208"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-209"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-210"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Subtotal of future principal payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Unamortized debt discount associated with issuance date warrant fair value and financing costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,811&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;18,189&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</clnn:ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscounts>
    <clnn:DebtInstrumentUnamortizedDiscountYearTwo contextRef="c2" decimals="-3" unitRef="usd">6667000</clnn:DebtInstrumentUnamortizedDiscountYearTwo>
    <clnn:DebtInstrumentUnamortizedDiscountYearThree contextRef="c2" decimals="-3" unitRef="usd">13333000</clnn:DebtInstrumentUnamortizedDiscountYearThree>
    <clnn:FuturePrincipalPayments contextRef="c2" decimals="-3" unitRef="usd">20000000</clnn:FuturePrincipalPayments>
    <us-gaap:DebtInstrumentUnamortizedPremium contextRef="c2" decimals="-3" unitRef="usd">1811000</us-gaap:DebtInstrumentUnamortizedPremium>
    <us-gaap:DebtSecurities contextRef="c2" decimals="-3" unitRef="usd">18189000</us-gaap:DebtSecurities>
    <us-gaap:PreferredStockTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;9. Preferred Stock Warrant Liability&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Prior to the Reverse Recapitalization,
we issued Series A Preferred Stock Warrants in 2013 pursuant to certain note purchase agreements. The warrants expire &lt;span style="-sec-ix-hidden: hidden-fact-211"&gt;ten&#160;years&lt;/span&gt; from
issuance. These warrants are exercisable at a fixed exercise price of $1.97, which is equal to the price per share of the Series A Preferred
Stock. As of December 31, 2019, these warrants were exercisable into 1,608,670 shares of the Series A Preferred Stock.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Prior to the Reverse Recapitalization,
on April 8, 2013, we issued ten-year warrants to purchase units of our most senior equity equal to 0.25% of our fully diluted equity at
the time of exercise pursuant to certain note purchase agreements. As of December 31, 2019, these warrants were exercisable into 271,439
shares of our most senior equity, Series C Preferred Stock, at a fixed exercise price of $1.97 per share. On August 11, 2020, in connection
with our issuance of Series D Preferred Stock, these warrants became exercisable into 320,441 shares of our most senior equity, Series
D Preferred Stock, at a fixed exercise price of $1.97 per share.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Prior to the Reverse Recapitalization,
we classified Preferred Stock warrants as a liability on the condensed consolidated balance sheets because the warrants are freestanding
financial instruments that may have required us to transfer assets upon exercise. The liability associated with each of these warrants
was initially recorded at fair value upon the issuance date of each warrant and is subsequently remeasured to fair value as a component
of other income (expense), net in the condensed consolidated statements of operations and comprehensive income (loss). Upon the closing
of the Reverse Recapitalization (see Note 3), and pursuant to the Merger Agreement, all of the outstanding Clene Nanomedicine Preferred
Stock was converted into Common Stock and the Clene Nanomedicine Preferred Stock warrants to purchase Clene Nanomedicine Preferred Stock
were converted to warrants to purchase Common Stock (see Note 10). Upon conversion, we assessed the features of the warrants and determined
that they qualify for classification as permanent equity upon the closing of the Reverse Recapitalization. Accordingly, we remeasured
the warrants to fair value one final time upon the close of the Reverse Recapitalization, and recognized a loss of $14.6 million for the
year ended December 31, 2020, within other income, (expense), net on the condensed consolidated statements of operations and comprehensive
income (loss). Upon the closing of the Reverse Recapitalization, the warrant liability was reclassified to additional paid-in capital
(see Note 17).&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As of September 30, 2021 and
December 31, 2020, we do not have any Preferred Stock warrants outstanding.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We recognized a change in
fair value of the outstanding warrants of $5.1 million during the three months ended September 30, 2020 and $7.4 million during the nine
months ended September 30, 2020 in the condensed consolidated statements of operations and comprehensive&#160;income (loss).&#160;&lt;/p&gt;</us-gaap:PreferredStockTextBlock>
    <us-gaap:WarrantExercisePriceDecrease contextRef="c196" decimals="2" unitRef="usdPershares">1.97</us-gaap:WarrantExercisePriceDecrease>
    <clnn:SharesOfWarrantsExercisable contextRef="c196" decimals="0" unitRef="shares">1608670</clnn:SharesOfWarrantsExercisable>
    <clnn:PercentOfFullydilutedEquityPurchasableUponExercise contextRef="c197" decimals="4" unitRef="pure">0.0025</clnn:PercentOfFullydilutedEquityPurchasableUponExercise>
    <clnn:SharesOfWarrantsExercisable contextRef="c198" decimals="0" unitRef="shares">271439</clnn:SharesOfWarrantsExercisable>
    <us-gaap:WarrantExercisePriceDecrease contextRef="c198" decimals="2" unitRef="usdPershares">1.97</us-gaap:WarrantExercisePriceDecrease>
    <clnn:SharesOfWarrantsExercisable contextRef="c199" decimals="0" unitRef="shares">320441</clnn:SharesOfWarrantsExercisable>
    <us-gaap:WarrantExercisePriceDecrease contextRef="c199" decimals="2" unitRef="usdPershares">1.97</us-gaap:WarrantExercisePriceDecrease>
    <clnn:LossInFairValueOfWarrantLiability contextRef="c134" decimals="-5" unitRef="usd">14600000</clnn:LossInFairValueOfWarrantLiability>
    <clnn:FairValueAdjustmentOfWarrantsOutstanding contextRef="c13" decimals="-5" unitRef="usd">5100000</clnn:FairValueAdjustmentOfWarrantsOutstanding>
    <clnn:FairValueAdjustmentOfWarrantsOutstanding contextRef="c14" decimals="-5" unitRef="usd">7400000</clnn:FairValueAdjustmentOfWarrantsOutstanding>
    <clnn:CommonStockWarrantsDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;10. Common Stock Warrants&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As of September 30, 2021,
outstanding warrants to purchase shares of Common Stock consisted of the following:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Date Exercisable&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of&lt;br/&gt; Shares&lt;br/&gt;
 Issuable&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Exercise Price&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Exercisable for&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Classification&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Expiration&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%"&gt;June 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;117,500&lt;/td&gt;&lt;td style="white-space: nowrap; width: 2%; text-align: left"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;0.01&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: center"&gt;Common Stock&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;December 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,407,500&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;11.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Common Stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;December 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,583&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&lt;sup&gt;(3)&lt;/sup&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;11.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Common Stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;December 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,929,111&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&lt;sup&gt;(4)&lt;/sup&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1.97&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Common Stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;April 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;May 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;115,851&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&lt;sup&gt;(5)(6)&lt;/sup&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;8.63&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;Common Stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;May 2026&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,594,545&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As of December 31, 2020, outstanding
warrants to purchase shares of Common Stock consisted of the following:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Date Exercisable&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of&lt;br/&gt; Shares Issuable&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Exercise Price&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Exercisable for&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Classification&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Expiration&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%"&gt;June 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;1,119,750&lt;/td&gt;&lt;td style="width: 2%; text-align: left"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;0.01&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: center"&gt;Common Stock&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;December 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,407,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;11.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Common Stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;December 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;110,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;sup&gt;(3)&lt;/sup&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;11.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Common Stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;December 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,929,111&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;sup&gt;(4)&lt;/sup&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;1.97&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;Common Stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;April 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,566,361&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Consisted of 1,119,750 shares of Common Stock underlying 2,239,500 December 2020 PIPE Warrants issued on December 30, 2020, in connection with the December 2020 PIPE (see Note 18). A holder of the December 2020 PIPE Warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of the Company&#x2019;s Common Stock outstanding immediately after giving effect to such exercise. As of September 30, 2021, 2,004,500 December 2020 PIPE Warrants were exercised into 1,002,250 shares of Common Stock. The outstanding balance as of September 30, 2021 consists of 117,500 shares of Common Stock underlying 235,000 December 2020 PIPE Warrants. As of December 31, 2020, none of the warrants had been exercised.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Consists of 2,407,500 shares of Common Stock underlying 4,815,000 warrants issued in connection with Tottenham&#x2019;s initial public offering. The Company may redeem the outstanding warrants, in whole and not in part, at a price of $0.01 per warrant if, and only if, the last sales price of the Company&#x2019;s Common Stock equals or exceeds $16.50 per share for any 20 trading days within a 30-trading day period ending three business days before the Company sends the notice of redemption. As of September 30, 2021, and December 31, 2020, none of the warrants had been exercised.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Consisted of 110,000 shares of Common Stock underlying 220,000 warrants issued as part of the Chardan Unit Purchase Option (see Note 3). On July 15, 2021 the Chardan Unit Purchase Option was net exercised, resulting in the issuance of 54,083 shares of Common Stock and 49,166 warrants to purchase one-half of one share of Common Stock, or 24,583 shares of Common Stock. As of September 30, 2021, none of the warrants had been exercised. As of December 31, 2020, the Chardan Unit Purchase Option had not been exercised.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Consists of 1,929,111 shares of Common Stock underlying 1,929,111 warrants originally issued by Clene Nanomedicine as Series A and Series D Preferred Stock Warrants (see Note 9). As of September 30, 2021, and December 31, 2020, none of the warrants had been exercised.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(5)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Consists of 115,851 shares of Common Stock underlying 115,851 Avenue Warrants issued pursuant to Tranche 1 of the 2021 Avenue Loan at an exercise price equal to the lower of (i) $8.63 (which is equal to the five-day VWAP per share, determined as of the end of trading on the last trading day prior to execution of the loan agreement), or (ii) the Next Round Price. (see Note 8). As of September 30, 2021, the Avenue Warrant had not been exercised.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(6)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant to the 2021 Avenue Loan, an additional estimated 86,679 shares
of Common Stock underlying warrants are issuable pursuant to our draw of Tranche 2 between January 1, 2022 and June 30, 2022 (see Note
8). In accordance with ASC 815, we recognized these warrants at the inception of the 2021 Avenue Loan and classified them as a warrant
liability and the fair value and issuable shares will be remeasured at each reporting period (see Note 16). As of September 30, 2021,
the warrants are not issued or outstanding.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</clnn:CommonStockWarrantsDisclosureTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Date Exercisable&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of&lt;br/&gt; Shares&lt;br/&gt;
 Issuable&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Exercise Price&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Exercisable for&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Classification&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Expiration&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%"&gt;June 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;117,500&lt;/td&gt;&lt;td style="white-space: nowrap; width: 2%; text-align: left"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;0.01&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: center"&gt;Common Stock&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;December 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,407,500&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;11.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Common Stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;December 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,583&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&lt;sup&gt;(3)&lt;/sup&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;11.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Common Stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;December 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,929,111&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&lt;sup&gt;(4)&lt;/sup&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1.97&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Common Stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;April 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;May 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;115,851&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&lt;sup&gt;(5)(6)&lt;/sup&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;8.63&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;Common Stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;May 2026&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,594,545&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Date Exercisable&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of&lt;br/&gt; Shares Issuable&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Exercise Price&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Exercisable for&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Classification&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Expiration&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%"&gt;June 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;1,119,750&lt;/td&gt;&lt;td style="width: 2%; text-align: left"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;0.01&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: center"&gt;Common Stock&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;December 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,407,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;11.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Common Stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;December 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;110,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;sup&gt;(3)&lt;/sup&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;11.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Common Stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;December 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,929,111&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;sup&gt;(4)&lt;/sup&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;1.97&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;Common Stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;April 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,566,361&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Consisted of 1,119,750 shares of Common Stock underlying 2,239,500 December 2020 PIPE Warrants issued on December 30, 2020, in connection with the December 2020 PIPE (see Note 18). A holder of the December 2020 PIPE Warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of the Company&#x2019;s Common Stock outstanding immediately after giving effect to such exercise. As of September 30, 2021, 2,004,500 December 2020 PIPE Warrants were exercised into 1,002,250 shares of Common Stock. The outstanding balance as of September 30, 2021 consists of 117,500 shares of Common Stock underlying 235,000 December 2020 PIPE Warrants. As of December 31, 2020, none of the warrants had been exercised.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Consists of 2,407,500 shares of Common Stock underlying 4,815,000 warrants issued in connection with Tottenham&#x2019;s initial public offering. The Company may redeem the outstanding warrants, in whole and not in part, at a price of $0.01 per warrant if, and only if, the last sales price of the Company&#x2019;s Common Stock equals or exceeds $16.50 per share for any 20 trading days within a 30-trading day period ending three business days before the Company sends the notice of redemption. As of September 30, 2021, and December 31, 2020, none of the warrants had been exercised.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Consisted of 110,000 shares of Common Stock underlying 220,000 warrants issued as part of the Chardan Unit Purchase Option (see Note 3). On July 15, 2021 the Chardan Unit Purchase Option was net exercised, resulting in the issuance of 54,083 shares of Common Stock and 49,166 warrants to purchase one-half of one share of Common Stock, or 24,583 shares of Common Stock. As of September 30, 2021, none of the warrants had been exercised. As of December 31, 2020, the Chardan Unit Purchase Option had not been exercised.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Consists of 1,929,111 shares of Common Stock underlying 1,929,111 warrants originally issued by Clene Nanomedicine as Series A and Series D Preferred Stock Warrants (see Note 9). As of September 30, 2021, and December 31, 2020, none of the warrants had been exercised.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(5)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Consists of 115,851 shares of Common Stock underlying 115,851 Avenue Warrants issued pursuant to Tranche 1 of the 2021 Avenue Loan at an exercise price equal to the lower of (i) $8.63 (which is equal to the five-day VWAP per share, determined as of the end of trading on the last trading day prior to execution of the loan agreement), or (ii) the Next Round Price. (see Note 8). As of September 30, 2021, the Avenue Warrant had not been exercised.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(6)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant to the 2021 Avenue Loan, an additional estimated 86,679 shares
of Common Stock underlying warrants are issuable pursuant to our draw of Tranche 2 between January 1, 2022 and June 30, 2022 (see Note
8). In accordance with ASC 815, we recognized these warrants at the inception of the 2021 Avenue Loan and classified them as a warrant
liability and the fair value and issuable shares will be remeasured at each reporting period (see Note 16). As of September 30, 2021,
the warrants are not issued or outstanding.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <clnn:NumberOfSharesIssuable contextRef="c212" decimals="0" unitRef="shares">117500</clnn:NumberOfSharesIssuable>
    <clnn:CommonStockWarrantsExercisePrice contextRef="c212" decimals="2" unitRef="usdPershares">0.01</clnn:CommonStockWarrantsExercisePrice>
    <clnn:CommonStockWarrantsExercisable contextRef="c213">Common Stock</clnn:CommonStockWarrantsExercisable>
    <clnn:CommonStockWarrantsClassification contextRef="c213">Equity</clnn:CommonStockWarrantsClassification>
    <clnn:CommonStockWarrantsExpiration contextRef="c213">December 2021</clnn:CommonStockWarrantsExpiration>
    <clnn:NumberOfSharesIssuable contextRef="c214" decimals="0" unitRef="shares">2407500</clnn:NumberOfSharesIssuable>
    <clnn:CommonStockWarrantsExercisePrice contextRef="c214" decimals="2" unitRef="usdPershares">11.5</clnn:CommonStockWarrantsExercisePrice>
    <clnn:CommonStockWarrantsExercisable contextRef="c215">Common Stock</clnn:CommonStockWarrantsExercisable>
    <clnn:CommonStockWarrantsClassification contextRef="c215">Equity</clnn:CommonStockWarrantsClassification>
    <clnn:CommonStockWarrantsExpiration contextRef="c215">December 2025</clnn:CommonStockWarrantsExpiration>
    <clnn:NumberOfSharesIssuable contextRef="c216" decimals="0" unitRef="shares">24583</clnn:NumberOfSharesIssuable>
    <clnn:CommonStockWarrantsExercisePrice contextRef="c216" decimals="2" unitRef="usdPershares">11.5</clnn:CommonStockWarrantsExercisePrice>
    <clnn:CommonStockWarrantsExercisable contextRef="c217">Common Stock</clnn:CommonStockWarrantsExercisable>
    <clnn:CommonStockWarrantsClassification contextRef="c217">Equity</clnn:CommonStockWarrantsClassification>
    <clnn:CommonStockWarrantsExpiration contextRef="c217">December 2025</clnn:CommonStockWarrantsExpiration>
    <clnn:NumberOfSharesIssuable contextRef="c218" decimals="0" unitRef="shares">1929111</clnn:NumberOfSharesIssuable>
    <clnn:CommonStockWarrantsExercisePrice contextRef="c218" decimals="2" unitRef="usdPershares">1.97</clnn:CommonStockWarrantsExercisePrice>
    <clnn:CommonStockWarrantsExercisable contextRef="c219">Common Stock</clnn:CommonStockWarrantsExercisable>
    <clnn:CommonStockWarrantsClassification contextRef="c219">Equity</clnn:CommonStockWarrantsClassification>
    <clnn:CommonStockWarrantsExpiration contextRef="c219">April 2023</clnn:CommonStockWarrantsExpiration>
    <clnn:NumberOfSharesIssuable contextRef="c220" decimals="0" unitRef="shares">115851</clnn:NumberOfSharesIssuable>
    <clnn:CommonStockWarrantsExercisePrice contextRef="c220" decimals="2" unitRef="usdPershares">8.63</clnn:CommonStockWarrantsExercisePrice>
    <clnn:CommonStockWarrantsExercisable contextRef="c221">Common Stock</clnn:CommonStockWarrantsExercisable>
    <clnn:CommonStockWarrantsClassification contextRef="c221">Liability</clnn:CommonStockWarrantsClassification>
    <clnn:CommonStockWarrantsExpiration contextRef="c221">May 2026</clnn:CommonStockWarrantsExpiration>
    <clnn:NumberOfSharesIssuable contextRef="c2" decimals="0" unitRef="shares">4594545</clnn:NumberOfSharesIssuable>
    <clnn:NumberOfSharesIssuable contextRef="c222" decimals="0" unitRef="shares">1119750</clnn:NumberOfSharesIssuable>
    <clnn:CommonStockWarrantsExercisePrice contextRef="c222" decimals="2" unitRef="usdPershares">0.01</clnn:CommonStockWarrantsExercisePrice>
    <clnn:CommonStockWarrantsExercisable contextRef="c223">Common Stock</clnn:CommonStockWarrantsExercisable>
    <clnn:CommonStockWarrantsClassification contextRef="c223">Equity</clnn:CommonStockWarrantsClassification>
    <clnn:CommonStockWarrantsExpiration contextRef="c223">December 2021</clnn:CommonStockWarrantsExpiration>
    <clnn:NumberOfSharesIssuable contextRef="c224" decimals="0" unitRef="shares">2407500</clnn:NumberOfSharesIssuable>
    <clnn:CommonStockWarrantsExercisePrice contextRef="c224" decimals="2" unitRef="usdPershares">11.5</clnn:CommonStockWarrantsExercisePrice>
    <clnn:CommonStockWarrantsExercisable contextRef="c225">Common Stock</clnn:CommonStockWarrantsExercisable>
    <clnn:CommonStockWarrantsClassification contextRef="c225">Equity</clnn:CommonStockWarrantsClassification>
    <clnn:CommonStockWarrantsExpiration contextRef="c225">December 2025</clnn:CommonStockWarrantsExpiration>
    <clnn:NumberOfSharesIssuable contextRef="c226" decimals="0" unitRef="shares">110000</clnn:NumberOfSharesIssuable>
    <clnn:CommonStockWarrantsExercisePrice contextRef="c226" decimals="2" unitRef="usdPershares">11.5</clnn:CommonStockWarrantsExercisePrice>
    <clnn:CommonStockWarrantsExercisable contextRef="c227">Common Stock</clnn:CommonStockWarrantsExercisable>
    <clnn:CommonStockWarrantsClassification contextRef="c227">Equity</clnn:CommonStockWarrantsClassification>
    <clnn:CommonStockWarrantsExpiration contextRef="c227">December 2025</clnn:CommonStockWarrantsExpiration>
    <clnn:NumberOfSharesIssuable contextRef="c228" decimals="0" unitRef="shares">1929111</clnn:NumberOfSharesIssuable>
    <clnn:CommonStockWarrantsExercisePrice contextRef="c228" decimals="2" unitRef="usdPershares">1.97</clnn:CommonStockWarrantsExercisePrice>
    <clnn:CommonStockWarrantsExercisable contextRef="c229">Common Stock</clnn:CommonStockWarrantsExercisable>
    <clnn:CommonStockWarrantsClassification contextRef="c229">Equity</clnn:CommonStockWarrantsClassification>
    <clnn:CommonStockWarrantsExpiration contextRef="c229">April 2023</clnn:CommonStockWarrantsExpiration>
    <clnn:NumberOfSharesIssuable contextRef="c3" decimals="0" unitRef="shares">5566361</clnn:NumberOfSharesIssuable>
    <us-gaap:SharesIssued contextRef="c200" decimals="0" unitRef="shares">1119750</us-gaap:SharesIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c200" decimals="0" unitRef="shares">2239500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <clnn:PIPEWarrantsOwnershipLimit contextRef="c201">9.99%</clnn:PIPEWarrantsOwnershipLimit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="c202" decimals="0" unitRef="shares">2004500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:SharesIssued contextRef="c203" decimals="0" unitRef="shares">1002250</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="c202" decimals="0" unitRef="shares">117500</us-gaap:SharesIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c202" decimals="0" unitRef="shares">235000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssued contextRef="c2" decimals="0" unitRef="shares">2407500</us-gaap:SharesIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c2" decimals="0" unitRef="shares">4815000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <clnn:CompanyWarrantRedemptionRight contextRef="c0">The Company may redeem the outstanding warrants, in whole and not in part, at a price of $0.01 per warrant if, and only if, the last sales price of the Company&#x2019;s Common Stock equals or exceeds $16.50 per share for any 20 trading days within a 30-trading day period ending three business days before the Company sends the notice of redemption.</clnn:CompanyWarrantRedemptionRight>
    <us-gaap:SharesIssued contextRef="c204" decimals="0" unitRef="shares">110000</us-gaap:SharesIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c204" decimals="0" unitRef="shares">220000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssued contextRef="c205" decimals="0" unitRef="shares">54083</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="c206" decimals="0" unitRef="shares">49166</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="c207" decimals="0" unitRef="shares">24583</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="c208" decimals="0" unitRef="shares">1929111</us-gaap:SharesIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c208" decimals="0" unitRef="shares">1929111</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <clnn:ExercisePriceOfWarrantsDescription contextRef="c209">(5)Consists of 115,851 shares of Common Stock underlying 115,851 Avenue Warrants issued pursuant to Tranche 1 of the 2021 Avenue Loan at an exercise price equal to the lower of (i) $8.63 (which is equal to the five-day VWAP per share, determined as of the end of trading on the last trading day prior to execution of the loan agreement), or (ii) the Next Round Price.</clnn:ExercisePriceOfWarrantsDescription>
    <us-gaap:SharesIssued contextRef="c210" decimals="0" unitRef="shares">115851</us-gaap:SharesIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c210" decimals="0" unitRef="shares">115851</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssued contextRef="c211" decimals="0" unitRef="shares">86679</us-gaap:SharesIssued>
    <clnn:ConvertibleNotesDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;11. Convertible Notes&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2020 Convertible Notes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In February through July 2020,
we issued convertible promissory notes (the &#x201c;2020 Convertible Notes&#x201d;) in an aggregate principal amount of $6.1 million, bearing
interest at an annual rate of 5%. The 2020 Convertible Notes were convertible at the earlier of (i)&#160;one year, at which point the
notes would be convertible into Series C Preferred Shares at the Series C Preferred Share issuance price, and (ii)&#160;next equity financing
of no less than $10.0 million, at which point the notes would be convertible into shares issued in the next equity financing at 90% of
the per share issuance price of the next equity financing. The 2020 Convertible Notes contained embedded features that provide the lenders
with multiple settlement alternatives. Certain of these settlement features provided the lenders with a right to a fixed number of our
shares upon conversion of the notes. Other settlement features provided the lenders with the right or the obligation to receive cash or
a variable number of shares upon the completion of a capital raising transaction, change of control, or default of the Company (the &#x201c;Redemption
Features&#x201d;). The Redemption Features of the 2020 Convertible Notes met the requirements for separate accounting and were accounted
for as a single derivative instrument (the &#x201c;2020 Derivative Instrument&#x201d;). Accordingly, the 2020 Derivative Instrument of $0.7
million was recorded at fair value at inception as redeemable convertible preferred stock derivative liability in the condensed consolidated
balance sheets (see Note 12).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We recognized interest expense
of $34 thousand, including amortization of debt discount of $0.1 million during the three months ended September 30, 2020, in connection
with the 2020 Convertible Notes. We recognized interest expense of $0.1 million, including amortization of debt discount of $0.2 million
during the nine months ended September 30, 2020, in connection with the 2020 Convertible Notes.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On August 11, 2020, in connection
with our issuance and sale of Series D Preferred Stock, all of the outstanding principal and accrued interest under the 2020 Convertible
Notes, totaling $6.9 million, was automatically converted into 1,497,135 shares of Series D Preferred Stock at a price equal to 90% of
$4.60 per share, the per share price paid in cash by investors in the Series D Preferred Stock financing.&#160;Upon the closing of the
Reverse Recapitalization (see Note 3), and pursuant to the Merger Agreement, all outstanding Clene Nanomedicine Series D Preferred Stock
was converted to Clene Inc. Common Stock.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We accounted for the conversion
of the 2020 Convertible Notes as a debt extinguishment and recognized a loss on extinguishment of debt of $0.5 million within other income
(expense), net in the consolidated statements of operations and comprehensive income (loss) for the year ended December 31, 2020. As of
the date of conversion, the unamortized discount on the 2020 Convertible Notes was $0.5 million. The loss on extinguishment was calculated
as the difference between (i) the fair value of the 1,497,135 shares of Series D Preferred Stock issued to settle the 2020 Convertible
Notes of $6.9 million and (ii) the carrying value of the 2020 Convertible Notes of $5.7 million, which includes the principal balance
of the 2020 Convertible Notes of $6.1 million and accrued but unpaid interest of $0.1 million, net of the unamortized debt discount of
$0.5 million, plus the then-current fair value of derivative liability associated with the 2020 Convertible Notes at the time of the extinguishment
of $0.7 million.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Convertible Notes Payable&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In May 2021, we entered into
the 2021 Avenue Loan from which we granted to Avenue the right, in its discretion, but not the obligation, at any time from time to time
from May 21, 2022 through May 21, 2024, while the loan is outstanding, to convert an amount of up to $5.0 million of the principal amount
of the outstanding loan into shares of Common Stock at a price per share equal to 120% of the stock purchase price set forth in the Avenue
Warrant (see Note 8). The Conversion Feature is subject to (i) the closing price of our Common Stock for each of the seven consecutive
trading days immediately preceding the conversion being greater than or equal to the conversion price and (ii) the Common Stock issued
in connection with any such conversion not exceeding 20% of the total trading volume of our Common Stock for the twenty-two consecutive
trading days immediately prior to and including the effective date of such conversion. The Conversion Feature did not meet the requirements
for separate accounting and is not accounted for as a derivative instrument. As of September 30, 2021, the number of shares of Common
Stock potentially issuable upon conversion was 482,703.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We classified $5.0 million of the 2021 Avenue Loan as convertible notes
payable in the condensed consolidated balance sheets as of September 30, 2021, with unamortized debt discount and issuance costs of $0.4
million.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the three and nine months ended September 30, 2021, we recognized
(i) total interest expense of $0.2 million and $0.3 million, respectively; (ii) coupon interest expense of $0.1 million and $0.2 million,
respectively; and (iii) amortization of debt discount and issuance costs of $41 thousand and $64 thousand, respectively, in connection
with the convertible notes payable. During the three and nine months ended September 30, 2020, we did not recognize any interest expense
or amortization in connection with the convertible notes payable. The effective interest rate was 15.46% for the three and nine months
ended September 30, 2021.&lt;/p&gt;</clnn:ConvertibleNotesDisclosureTextBlock>
    <us-gaap:ConvertibleNotesPayable contextRef="c230" decimals="-5" unitRef="usd">6100000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="c231" decimals="2" unitRef="pure">0.05</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <clnn:DescriptionOfConvertibleNotes contextRef="c231">The 2020 Convertible Notes were convertible at the earlier of (i)&#160;one year, at which point the
notes would be convertible into Series C Preferred Shares at the Series C Preferred Share issuance price, and (ii)&#160;next equity financing
of no less than $10.0 million, at which point the notes would be convertible into shares issued in the next equity financing at 90% of
the per share issuance price of the next equity financing. The 2020 Convertible Notes contained embedded features that provide the lenders
with multiple settlement alternatives. Certain of these settlement features provided the lenders with a right to a fixed number of our
shares upon conversion of the notes. Other settlement features provided the lenders with the right or the obligation to receive cash or
a variable number of shares upon the completion of a capital raising transaction, change of control, or default of the Company (the &#x201c;Redemption
Features&#x201d;). The Redemption Features of the 2020 Convertible Notes met the requirements for separate accounting and were accounted
for as a single derivative instrument (the &#x201c;2020 Derivative Instrument&#x201d;). Accordingly, the 2020 Derivative Instrument of $0.7
million was recorded at fair value at inception as redeemable convertible preferred stock derivative liability in the condensed consolidated
balance sheets (see Note 12).</clnn:DescriptionOfConvertibleNotes>
    <us-gaap:InterestExpenseDebt contextRef="c232" decimals="-3" unitRef="usd">34000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c232" decimals="-5" unitRef="usd">100000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c233" decimals="-5" unitRef="usd">100000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:InterestExpenseDebt contextRef="c233" decimals="-5" unitRef="usd">200000</us-gaap:InterestExpenseDebt>
    <us-gaap:ExtinguishmentOfDebtAmount contextRef="c234" decimals="-5" unitRef="usd">6900000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c234" decimals="0" unitRef="shares">1497135</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <clnn:PercentageOfStockPrice contextRef="c234" decimals="2" unitRef="pure">0.90</clnn:PercentageOfStockPrice>
    <us-gaap:PreferredStockConvertibleConversionPrice contextRef="c235" decimals="2" unitRef="usdPershares">4.6</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts contextRef="c236" decimals="-5" unitRef="usd">500000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c237" decimals="-5" unitRef="usd">500000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <clnn:DescriptionOfLossOnExtinguishment contextRef="c236">The loss on extinguishment was calculated
as the difference between (i) the fair value of the 1,497,135 shares of Series D Preferred Stock issued to settle the 2020 Convertible
Notes of $6.9 million and (ii) the carrying value of the 2020 Convertible Notes of $5.7 million, which includes the principal balance
of the 2020 Convertible Notes of $6.1 million and accrued but unpaid interest of $0.1 million, net of the unamortized debt discount of
$0.5 million, plus the then-current fair value of derivative liability associated with the 2020 Convertible Notes at the time of the extinguishment
of $0.7 million.</clnn:DescriptionOfLossOnExtinguishment>
    <clnn:ConvertibleNotesPayableDescription contextRef="c238">In May 2021, we entered into
the 2021 Avenue Loan from which we granted to Avenue the right, in its discretion, but not the obligation, at any time from time to time
from May 21, 2022 through May 21, 2024, while the loan is outstanding, to convert an amount of up to $5.0 million of the principal amount
of the outstanding loan into shares of Common Stock at a price per share equal to 120% of the stock purchase price set forth in the Avenue
Warrant (see Note 8).</clnn:ConvertibleNotesPayableDescription>
    <clnn:LoanOutstanding contextRef="c238" decimals="-5" unitRef="usd">5000000</clnn:LoanOutstanding>
    <clnn:ConversionPercentageOfCommonStockPriceForConvertibleNotePayable contextRef="c238" decimals="2" unitRef="pure">1.20</clnn:ConversionPercentageOfCommonStockPriceForConvertibleNotePayable>
    <us-gaap:ConversionOfStockSharesConverted1 contextRef="c0" decimals="0" unitRef="shares">482703</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConvertibleNotesPayable contextRef="c239" decimals="-5" unitRef="usd">5000000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:DebtInstrumentUnamortizedDiscountCurrent contextRef="c239" decimals="-5" unitRef="usd">400000</us-gaap:DebtInstrumentUnamortizedDiscountCurrent>
    <us-gaap:InterestExpenseDebt contextRef="c240" decimals="-5" unitRef="usd">200000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c241" decimals="-5" unitRef="usd">300000</us-gaap:InterestExpenseDebt>
    <clnn:CouponInterestExpense contextRef="c240" decimals="-5" unitRef="usd">100000</clnn:CouponInterestExpense>
    <clnn:CouponInterestExpense contextRef="c241" decimals="-5" unitRef="usd">200000</clnn:CouponInterestExpense>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c240" decimals="-3" unitRef="usd">41000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c241" decimals="-3" unitRef="usd">64000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate contextRef="c0">The effective interest rate was 15.46% for the three and nine months
ended September 30, 2021.</us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate>
    <us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate contextRef="c240">15.46%</us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;12. Derivative Instruments&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Derivative Instrument in Connection with
the 2020 Convertible Notes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;One of the redemption features
of the 2020 Convertible Notes met the requirements for separate accounting and was accounted for as a derivative instrument. The 2020
Derivative Instrument was recorded at fair value, which was $0.7 million at issuance. In August 2020, in connection with our issuance
and sale of Series D Preferred Stock, all of the outstanding principal and accrued interest under the 2020 Convertible Notes was automatically
converted into shares of Series D Preferred Stock and the derivative liability was extinguished. Prior to the extinguishment of derivative
liability, the 2020 Derivative Instrument was marked to fair value and we recorded the change in the 2020 Derivative Instrument of ($29)
thousand in the consolidated statements of operations and comprehensive income (loss) for the year ended December 31, 2020 (see Note 11).
For the three and nine months ended September 30, 2020, we recorded the change in the 2020 Derivative Instrument of $15 thousand and $29
thousand, respectively, in the condensed consolidated statements of operations and comprehensive income (loss). Upon the closing of the
Reverse Recapitalization (see Note 3), and pursuant to the Merger Agreement, all outstanding Clene Nanomedicine Preferred Stock was converted
to Clene Inc. Common Stock.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Derivative Instruments in Connection with
the Contingent Earn-Outs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The earn-out shares issued
in connection with the Reverse Recapitalization met the requirements for separate accounting and are therefore accounted for as derivative
instruments. Accordingly, upon the consummation of the Reverse Recapitalization, we recorded a liability in the condensed consolidated
balance sheets and a debit to additional paid-in capital for the earn-out provision associated with the Initial Shareholders Contingent
Earn-out and a debit to accumulated deficit for the earn-out provisions associated with the Clene Nanomedicine Contingent Earn-out. The
contingent shares to be issued to the Clene Nanomedicine shareholders immediately prior to the Reverse Capitalization were treated as
a deemed distribution. The Contingent Earn-outs were subsequently remeasured to fair value at each reporting date as a component of other
income (expense), net in the condensed consolidated statements of operations and comprehensive income (loss).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Upon the closing of the Reverse
Recapitalization, we recognized the Clene Nanomedicine Contingent Earn-out and Initial Shareholders Contingent Earn-out liabilities at
their fair value of $64.7 million and $7.4 million, respectively, in the condensed consolidated balance sheets. As of December 31, 2020,
the carrying values of the Clene Nanomedicine Contingent Earn-out and Initial Shareholders Contingent Earn-out were $52.1 million and
$5.9 million, respectively. As of September 30, 2021, the carrying values of the Clene Nanomedicine Contingent Earn-out and Initial Shareholders
Contingent Earn-out were $34.0 million and $4.2 million, respectively. For the three months ended September 30, 2021, we recognized gains
of $35.0 million in change in fair value of the Clene Nanomedicine Contingent Earn-out and $3.4 million in change in fair value of the
Initial Shareholders Contingent Earn-out as components of other income (expense), net in the condensed consolidated statements of operations
and comprehensive income (loss). For the nine months ended September 30, 2021, we recognized gains of $18.1 million in change in fair
value of the Clene Nanomedicine Contingent Earn-out and $1.7 million in change in fair value of the Initial Shareholders Contingent Earn-out
as components of other income (expense), net in the condensed consolidated statements of operations and comprehensive income (loss). To
date, none of the milestones have been achieved.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Derivative Instrument in Connection with
the 2021 Avenue Loan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Avenue Warrants issued
pursuant to Tranche 1 of the 2021 Avenue Loan and the warrants issuable pursuant to the draw of Tranche 2 (see Note 8) met the requirements
for separate accounting and are therefore accounted for as derivative instruments. The 2021 Avenue Loan has the following features: (i)
prepayment provision, (ii) final payment provision, (iii) event of default redemption provision, and (iv) event of default interest provision.
The provisions (i) to (iii) are related to the loan host and are not bifurcated pursuant to ASC 815. For the provision (iv), we have not
experienced an event of default in the past and believe the probability of triggering one in the future is remote. Therefore, we determined
the value of this feature to be de minimis on the remote probability of occurrence of a triggering event.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Upon the closing of the 2021
Avenue Loan, we recognized the warrant liability as a debt discount based on its fair value of $1.5 million. The debt discount is being
amortized over the contractual term using the effective interest method. Our determination of the fair value of the warrant utilized the
Black-Scholes option-pricing valuation model. Additionally, a Monte Carlo simulation was used to simulate the exercise price as an input
in the Black-Scholes valuation model (see Note 10). For the three and nine months ended September 30, 2021, we recognized income of $0.4
million and $0.5 million, respectively, in change in fair value of the warrant as a component of other income (expense), net in the condensed
consolidated statements of operations and comprehensive income (loss). To date, the warrants have not been exercised.&lt;/p&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeNet contextRef="c242" decimals="-5" unitRef="usd">700000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <clnn:LossOnDerivativeInstruments contextRef="c134" decimals="-3" unitRef="usd">-29000</clnn:LossOnDerivativeInstruments>
    <clnn:LossOnDerivativeInstruments contextRef="c13" decimals="-3" unitRef="usd">15000</clnn:LossOnDerivativeInstruments>
    <clnn:LossOnDerivativeInstruments contextRef="c14" decimals="-3" unitRef="usd">29000</clnn:LossOnDerivativeInstruments>
    <us-gaap:EquityFairValueAdjustment contextRef="c124" decimals="-5" unitRef="usd">64700000</us-gaap:EquityFairValueAdjustment>
    <us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="c243" decimals="-5" unitRef="usd">7400000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
    <us-gaap:EquityFairValueAdjustment contextRef="c134" decimals="-5" unitRef="usd">52100000</us-gaap:EquityFairValueAdjustment>
    <us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="c3" decimals="-5" unitRef="usd">5900000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
    <us-gaap:EquityFairValueAdjustment contextRef="c0" decimals="-5" unitRef="usd">34000000</us-gaap:EquityFairValueAdjustment>
    <us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="c2" decimals="-5" unitRef="usd">4200000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
    <clnn:GainlossOnCleneNanomedicineContingentEarnout contextRef="c12" decimals="-5" unitRef="usd">35000000</clnn:GainlossOnCleneNanomedicineContingentEarnout>
    <clnn:GainlossOnInitialShareholdersContingentEarnout contextRef="c12" decimals="-5" unitRef="usd">3400000</clnn:GainlossOnInitialShareholdersContingentEarnout>
    <clnn:GainlossOnCleneNanomedicineContingentEarnout contextRef="c0" decimals="-5" unitRef="usd">-18100000</clnn:GainlossOnCleneNanomedicineContingentEarnout>
    <clnn:GainlossOnInitialShareholdersContingentEarnout contextRef="c0" decimals="-5" unitRef="usd">-1700000</clnn:GainlossOnInitialShareholdersContingentEarnout>
    <clnn:WarrantLiabilityFairValue contextRef="c0" decimals="-5" unitRef="usd">1500000</clnn:WarrantLiabilityFairValue>
    <clnn:Changeinfairvaluewarrants contextRef="c12" decimals="-5" unitRef="usd">400000</clnn:Changeinfairvaluewarrants>
    <clnn:Changeinfairvaluewarrants contextRef="c0" decimals="-5" unitRef="usd">500000</clnn:Changeinfairvaluewarrants>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;13. Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Litigation&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;From time to time, we may
have certain contingent liabilities that arise in the ordinary course of business activities. We accrue a liability for such matters when
it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. We are not aware of any current
pending legal matters or claims.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;14. Income Taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We recorded income tax benefits
of $0.1 million and $0.2 million for the net operating losses incurred for the three and nine months ended September 30, 2021. We have
not recorded income tax benefits for the net operating losses incurred during the three and nine months ended September 30, 2020. We have
not recorded income tax benefits for research and development tax credits and other deferred tax assets generated, due to its uncertainty
of realizing a benefit from those items.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The components of income (loss)
before income taxes for the three and nine months ended September 30, 2021 and 2020 were as follows:&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three Months Ended&lt;br/&gt; September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Nine Months Ended&lt;br/&gt; September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;United States&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;29,860&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(11,370&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(11,435&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(20,724&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(985&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,075&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,941&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;669&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total loss before income taxes&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;28,875&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(10,295&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(14,376&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(20,055&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company is subject to
taxation in the United States, Australia, and various state jurisdictions. The Company computes its quarterly income tax provision by
using a forecasted annual effective tax rate and adjusts for any discrete items arising during the quarter. The primary difference between
the effective tax rate and the federal statutory tax rate relates to the full valuation allowance on the Company&#x2019;s U.S. net operating
losses and other deferred tax assets.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c12" decimals="-5" unitRef="usd">100000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c0" decimals="-5" unitRef="usd">200000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three Months Ended&lt;br/&gt; September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Nine Months Ended&lt;br/&gt; September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;United States&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;29,860&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(11,370&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(11,435&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(20,724&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(985&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,075&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,941&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;669&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total loss before income taxes&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;28,875&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(10,295&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(14,376&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(20,055&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c12" decimals="-3" unitRef="usd">29860000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c13" decimals="-3" unitRef="usd">-11370000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c0" decimals="-3" unitRef="usd">-11435000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c14" decimals="-3" unitRef="usd">-20724000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c12" decimals="-3" unitRef="usd">-985000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c13" decimals="-3" unitRef="usd">1075000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c0" decimals="-3" unitRef="usd">-2941000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c14" decimals="-3" unitRef="usd">669000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <clnn:TotalLossBeforeIncomeTaxes contextRef="c12" decimals="-3" unitRef="usd">28875000</clnn:TotalLossBeforeIncomeTaxes>
    <clnn:TotalLossBeforeIncomeTaxes contextRef="c13" decimals="-3" unitRef="usd">-10295000</clnn:TotalLossBeforeIncomeTaxes>
    <clnn:TotalLossBeforeIncomeTaxes contextRef="c0" decimals="-3" unitRef="usd">-14376000</clnn:TotalLossBeforeIncomeTaxes>
    <clnn:TotalLossBeforeIncomeTaxes contextRef="c14" decimals="-3" unitRef="usd">-20055000</clnn:TotalLossBeforeIncomeTaxes>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;15. Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2020 Stock Plan&lt;/i&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In December 2020, in connection
with the Reverse Recapitalization, the Company&#x2019;s Board of Directors approved the 2020 Stock Plan (the &#x201c;2020 Stock Plan&#x201d;)
and reserved 12,000,000 shares of Common Stock for issuance thereunder, all of which may be issued pursuant to incentive stock options
or any other type of award under the 2020 Stock Plan. The 2020 Stock Plan became effective immediately upon the closing of the Reverse
Recapitalization. The maximum number of shares of Common Stock that may be issued pursuant to the exercise of incentive stock options
under the 2020 Stock Plan is 12,000,000. Selected employees, officers, directors, and consultants are eligible to participate in the traditional
stock option grants, stock appreciation rights, restricted stock awards, restricted stock units, other stock awards, and performance awards
under the 2020 Stock Plan. The purpose of this 2020 Stock Plan is to enable us to offer competitive equity compensation packages in order
to attract and retain the talent necessary for the combined company.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The 2020 Stock Plan is administered
by the Company&#x2019;s Board of Directors. The exercise prices, vesting periods, and other restrictions are determined at the discretion
of the Company&#x2019;s Board of Directors, except that the exercise price per share of options may not be less than 100% of the fair market
value of the Common Stock on the date of grant. Stock options awarded under the 2020 Stock Plan expire ten years after the grant date,
unless the Company&#x2019;s Board of Directors sets a shorter term. Stock options and restricted stock granted to employees, officers,
members of the Company&#x2019;s Board of Directors, and consultants generally vest over a four-year period. If an option or other award
granted under the 2020 Stock Plan expires, terminates, or is cancelled, the unissued shares subject to that option or award shall again
be available under the 2020 Stock Plan. If shares awarded pursuant to the 2020 Stock Plan are forfeited to or repurchased at original
cost by the Company, the number of shares forfeited or repurchased at original cost shall again be available under the 2020 Stock Plan.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As of September 30, 2021, the Company&#x2019;s Board of Directors granted
rights to 3,819,930 restricted stock awards and stock options under the 2020 Stock Plan. As of September 30, 2021, 8,180,070 shares remained
available for future grant.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As of December 31, 2020, the
Company&#x2019;s Board of Directors granted rights to 1,507,062 restricted stock awards under the 2020 Stock Plan. As of December 31, 2020,
10,492,938 shares remained available for future grant.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2014 Stock Plan&lt;/i&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Following the closing of the
Reverse Recapitalization, the 2014 Stock Plan is administered by the Company&#x2019;s Board of Directors. Stock options awarded under the
2014 Stock Plan expire ten years after the grant date. Stock options and restricted stock granted to employees, officers, members of the
Company&#x2019;s Board of Directors, and consultants typically vest over a four-year period.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As a result of the Reverse
Recapitalization (see Note 3), stock options outstanding under the 2014 Stock Plan of 53,286,115 were converted into 7,032,591 of stock
options of the Company based on the Exchange Ratio determined in accordance with the terms of the Merger Agreement. The exchange of Clene
Nanomedicine&#x2019;s stock options for Clene Inc. stock options was treated as a modification of the awards. The modification of the stock
options did not result in a material incremental compensation expense to be recognized at the closing of the Reverse Recapitalization.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the year ended December
31, 2020, the Company&#x2019;s Board of Directors granted stock options for 270,555 shares under the 2014 Stock Plan. Effective as of the
closing of the Reverse Recapitalization on December 30, 2020, no additional awards may be made under the 2014 Stock Plan and as a result,
(i) any shares in respect of stock options that are expired or terminated under the 2014 Stock Plan without having been fully exercised
will not be available for future awards; (ii) any shares in respect of restricted stock that are forfeited to, or otherwise repurchased
by the Company, will not be available for future awards; and (iii) any shares of Common Stock that are tendered to the Company by a participant
to exercise an award will not be available for future awards.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Stock-based compensation expense for the three months ended September
30, 2021 and 2020 was approximately $2.4 million and $0.2 million, respectively, and approximately $9.9 million and $0.6 million for the
nine months ended September 30, 2021 and 2020, respectively. Stock-based compensation is recorded in research and development and general
and administrative expenses in the condensed consolidated statements of operations and comprehensive income (loss) as follows:&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three Months Ended&lt;br/&gt; September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Nine Months Ended&lt;br/&gt; September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;858&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;134&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,861&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;364&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,567&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;75&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,084&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;190&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total stock-based compensation&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,425&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;209&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,945&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;554&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Stock Options&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following sets forth the
outstanding stock options and related activity for the nine months ended September 30, 2021 (in thousands, except share and per share
data):&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;Equity&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Options&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise &lt;br/&gt; Price &lt;br/&gt; Per Share&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Term &lt;br/&gt; (Years)&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Intrinsic &lt;br/&gt; Value&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-indent: -10pt; padding-left: 10pt"&gt;Outstanding - December&#160;31, 2020&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,032,591&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.97&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5.34&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;62,462&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,574,441&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.85&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9.61&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-212"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(409,867&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.04&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-213"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,373&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 0.125in"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(133,742&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8.66&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-214"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-215"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Outstanding - September 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,063,423&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3.09&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5.90&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;38,863&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Options vested and exercisable - September 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,000,723&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.82&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4.33&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;36,247&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Stock options vested and expected to vest - September 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,063,423&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3.09&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5.90&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;38,863&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As of September 30, 2021 and December 31, 2020, we had approximately
$15.2 million and $2.4 million of unrecognized stock-based compensation costs related to non-vested stock options which is expected to
be recognized over a weighted-average period of 2.33 years and 2.04 years, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Prior to the consummation
of the Reverse Recapitalization, the exercise price of the stock options granted was based on the fair market value of the common shares
of the Company as of the grant date as determined by the Board of Directors, with input from management. The Board of Directors determined
the fair value of the common stock at the time of grant of the options by considering a number of objective and subjective factors, including
third-party valuation reports, valuations of comparable companies, sales of redeemable convertible Preferred Stock, sales of common stock
to unrelated third parties, operating and financial performance, the lack of liquidity of the Company&#x2019;s capital stock, and general
and industry-specific economic outlook.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Stock options are valued using
the Black-Scholes valuation model. Since we have limited trading history of our Common Stock, the expected volatility is derived from
the average historical stock volatilities of several unrelated public companies within our industry that we consider to be comparable
to its own business over a period equivalent to the expected term of the stock option grants. The risk-free interest rate for periods
within the contractual life of the stock options is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected
dividend is assumed to be zero as we have never paid dividends and have no current plans to do so. The expected term represents the period
that stock-based awards are expected to be outstanding. For option grants that are considered to be &#x201c;plain vanilla,&#x201d; we determine
the expected term using the simplified method. The simplified method deems the term to be the average of the time-to-vesting and the contractual
life of the options. For other option grants, we estimate the expected term using historical data on employee exercises and post-vesting
employment termination behavior taking into account the contractual life of the award.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the nine months ended
September 30, 2021, we granted stock options for 2,574,441 shares under the 2020 Stock Plan. The assumptions used to calculate the value
of the stock option awards granted for the nine months ended September 30, 2021 are presented as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; white-space: nowrap; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold"&gt;Nine months ended&lt;br/&gt; September 30,&lt;br/&gt;
 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; white-space: nowrap; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected stock price volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;84.8
&#x2013; 87.4% &lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"/&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.59 &#x2013; 0.94%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"/&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;0.00%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"/&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Expected term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.00 years &#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The weighted-average grant-date
fair value of options granted during the nine months ended September 30, 2021 was $8.85.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Restricted Stock Awards&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On December 30, 2020, we granted
rights to awards of the following shares of restricted stock under the 2020 Stock Plan:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;370,101 shares to various employees and non-employee directors, which
vest on various dates between June 30, 2021 and January 15, 2022, subject to the employee&#x2019;s continuous employment through such vesting
date. The restricted stock awards convert to shares of Common Stock on a one-for-one basis upon vesting. The award represents 5% of the
converted stock options under 2014 Stock Plan as a result of the Reverse Recapitalization and complements the 5% closing payment shares
held in escrow for Clene Nanomedicine common shareholders (see Note 3). The grant-date fair value of these awards was $4.0 million based
on the closing price of CLNN shares listed on Nasdaq of $10.82 per share on December 30, 2020, the date of the Reverse Recapitalization.
As of September 30, 2021, there were 224,109 shares of Common Stock issued upon the vesting of restricted stock awards. As of December
31, 2020 no shares were vested.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;454,781 shares to various employees and non-employee directors, which were eligible to vest based on certain market conditions, subject to the employee&#x2019;s continuous employment through such vesting date. The award complements the Milestone 1 earn-out share entitlement of Clene Nanomedicine shareholders and vests based on the same market condition (see Note 3). The grant-date fair value of these awards, using a Monte Carlo simulation, was $4.3 million. Based on the outcome of the market condition as of the September 30, 2021 and December 31, 2020 measurement dates, no shares were vested.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;341,090 shares to various employees and non-employee directors, which were eligible to vest based on certain market conditions, subject to the employee&#x2019;s continuous employment through such vesting date. The award complements the Milestone 2 earn-out share entitlement of Clene Nanomedicine. shareholders and vests based on the same market condition (see Note 3). The grant-date fair value of these awards, using a Monte Carlo simulation, was $3.5 million. Based on the outcome of the market condition as of the September 30, 2021 and December 31, 2020 measurement dates, no shares were vested.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;341,090 shares to various employees and non-employee directors, which were eligible to vest based on certain performance conditions tied to the completion of the COVID-19 coronavirus treatment study, subject to the employee&#x2019;s continuous employment through such vesting date. The award complements the Milestone 3 earn-out share entitlement of Clene Nanomedicine shareholders and vests based on the same performance condition (see Note 3). The grant-date fair value of these awards was $3.7 million, based on the closing price of CLNN shares listed on Nasdaq of $10.82 per share on December 30, 2020, the date of the Reverse Recapitalization. We did not recognize compensation expense because the occurrence of achieving this milestone was not probable. As of the September 30, 2021 and December 31, 2020 measurement dates, no shares were vested.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following table summarizes
the restricted stock award activity during the nine months ended September 30, 2021:&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of&lt;br/&gt; Restricted Stock Awards&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Grant &lt;br/&gt; Date Fair &lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Outstanding and unvested balance as of December 31, 2020&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,507,062&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10.30&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Converted to shares of Common Stock upon vesting&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(224,109&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-216"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(37,464&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10.82&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding and unvested balance as of September 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,245,489&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10.14&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The assumptions used to calculate
the value of the rights to restricted stock awards granted in 2020 in the Monte Carlo valuation model include projected stock price, volatility,
and risk-free rate based on the achievement of certain stock price milestones. Our significant unobservable inputs as of December 31,
2020 were as follows: (i) 85% of expected stock price volatility, (ii) risk-free interest rate of 0.4%, and (iii) expected term of five
years. The weighted average grant-date fair value of rights to restricted stock awards granted as of December 31, 2020 was $10.3034.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The stock-based compensation expense associated with the rights to
restricted stock awards was $0.8 million and $6.8 million for the three and nine months ended September 30, 2021. As of September 30,
2021 and December 31, 2020, total unrecognized compensation cost related to the unvested stock-based awards was $0.9 million and $15.5
million, respectively, which is expected to be recognized over a weighted average period of less than 1 month and 6 months, respectively.
We did not issue any restricted stock awards during the nine months ended September 30, 2020.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c244" decimals="0" unitRef="shares">12000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="c244" decimals="0" unitRef="shares">12000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <clnn:MinimumFairMarketValueOfOptionGrantDescription contextRef="c245">The exercise prices, vesting periods, and other restrictions are determined at the discretion
of the Company&#x2019;s Board of Directors, except that the exercise price per share of options may not be less than 100% of the fair market
value of the Common Stock on the date of grant.</clnn:MinimumFairMarketValueOfOptionGrantDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="c246" decimals="0" unitRef="shares">3819930</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <clnn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants contextRef="c246" decimals="0" unitRef="shares">8180070</clnn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="c247" decimals="0" unitRef="shares">1507062</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <clnn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants contextRef="c247" decimals="0" unitRef="shares">10492938</clnn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants>
    <us-gaap:CommonStockOtherSharesOutstanding contextRef="c248" decimals="0" unitRef="shares">53286115</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c249" decimals="0" unitRef="shares">7032591</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="c250" decimals="0" unitRef="shares">270555</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockOptionPlanExpense contextRef="c12" decimals="-5" unitRef="usd">2400000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense contextRef="c13" decimals="-5" unitRef="usd">200000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense contextRef="c0" decimals="-5" unitRef="usd">9900000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense contextRef="c14" decimals="-5" unitRef="usd">600000</us-gaap:StockOptionPlanExpense>
    <us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three Months Ended&lt;br/&gt; September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Nine Months Ended&lt;br/&gt; September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;858&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;134&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,861&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;364&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,567&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;75&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,084&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;190&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total stock-based compensation&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,425&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;209&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,945&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;554&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c109" decimals="-3" unitRef="usd">858000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c111" decimals="-3" unitRef="usd">134000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c110" decimals="-3" unitRef="usd">3861000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c112" decimals="-3" unitRef="usd">364000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c143" decimals="-3" unitRef="usd">1567000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c147" decimals="-3" unitRef="usd">75000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c142" decimals="-3" unitRef="usd">6084000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c146" decimals="-3" unitRef="usd">190000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c12" decimals="-3" unitRef="usd">2425000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c13" decimals="-3" unitRef="usd">209000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c0" decimals="-3" unitRef="usd">9945000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c14" decimals="-3" unitRef="usd">554000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;Equity&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Options&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise &lt;br/&gt; Price &lt;br/&gt; Per Share&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Term &lt;br/&gt; (Years)&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Intrinsic &lt;br/&gt; Value&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-indent: -10pt; padding-left: 10pt"&gt;Outstanding - December&#160;31, 2020&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,032,591&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.97&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5.34&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;62,462&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,574,441&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.85&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9.61&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-212"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(409,867&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.04&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-213"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,373&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 0.125in"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(133,742&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8.66&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-214"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-215"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Outstanding - September 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,063,423&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3.09&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5.90&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;38,863&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Options vested and exercisable - September 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,000,723&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.82&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4.33&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;36,247&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Stock options vested and expected to vest - September 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,063,423&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3.09&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5.90&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;38,863&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c3" decimals="0" unitRef="shares">7032591</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c3" decimals="2" unitRef="usdPershares">0.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c0">P5Y4M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <clnn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValue contextRef="c3" decimals="-3" unitRef="usd">62462000</clnn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c0" decimals="0" unitRef="shares">2574441</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c0" decimals="2" unitRef="usdPershares">8.85</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <clnn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted contextRef="c0">P9Y7M9D</clnn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted>
    <clnn:ShareBasedCompensationArrangementNumberOfOptionsExercised contextRef="c0" decimals="0" unitRef="shares">409867</clnn:ShareBasedCompensationArrangementNumberOfOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="c0" decimals="2" unitRef="usdPershares">1.04</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <clnn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue contextRef="c0" decimals="-3" unitRef="usd">2373000</clnn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c0" decimals="0" unitRef="shares">133742</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="c0" decimals="2" unitRef="usdPershares">8.66</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c2" decimals="0" unitRef="shares">9063423</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c2" decimals="2" unitRef="usdPershares">3.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c0">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <clnn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValue contextRef="c2" decimals="-3" unitRef="usd">38863000</clnn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValue>
    <clnn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber contextRef="c2" decimals="0" unitRef="shares">6000723</clnn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber>
    <clnn:WeightedAverageExercisePricePerShareOptionVestedAndExercisable contextRef="c2" decimals="2" unitRef="usdPershares">0.82</clnn:WeightedAverageExercisePricePerShareOptionVestedAndExercisable>
    <clnn:WeightedAverageExercisePriceWeightedAverageRemainingTermYearsOptionsVestedAndEexercisableEnding contextRef="c0">P4Y3M29D</clnn:WeightedAverageExercisePriceWeightedAverageRemainingTermYearsOptionsVestedAndEexercisableEnding>
    <clnn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueIntrinsicValueOptionsVestedAndExercisableEnding contextRef="c2" decimals="-3" unitRef="usd">36247000</clnn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueIntrinsicValueOptionsVestedAndExercisableEnding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="c2" decimals="0" unitRef="shares">9063423</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice contextRef="c2" decimals="2" unitRef="usdPershares">3.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <clnn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm1 contextRef="c0">P5Y10M24D</clnn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm1>
    <clnn:IntrinsicValueStockOptionsVestedAndExpectedToVestIntrinsicValueOptionsV contextRef="c2" decimals="-3" unitRef="usd">38863000</clnn:IntrinsicValueStockOptionsVestedAndExpectedToVestIntrinsicValueOptionsV>
    <clnn:UnrecognizedStockbasedCompensation contextRef="c0" decimals="-5" unitRef="usd">15200000</clnn:UnrecognizedStockbasedCompensation>
    <clnn:UnrecognizedStockbasedCompensation contextRef="c134" decimals="-5" unitRef="usd">2400000</clnn:UnrecognizedStockbasedCompensation>
    <clnn:SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm contextRef="c0">P2Y3M29D</clnn:SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm>
    <clnn:SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm contextRef="c134">P2Y14D</clnn:SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="c251" decimals="0" unitRef="shares">2574441</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; white-space: nowrap; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold"&gt;Nine months ended&lt;br/&gt; September 30,&lt;br/&gt;
 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; white-space: nowrap; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected stock price volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;84.8
&#x2013; 87.4% &lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"/&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.59 &#x2013; 0.94%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"/&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;0.00%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"/&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Expected term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.00 years &#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c257" decimals="3" unitRef="pure">0.848</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c258" decimals="3" unitRef="pure">0.874</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c257" decimals="4" unitRef="pure">0.0059</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c258" decimals="4" unitRef="pure">0.0094</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c259" decimals="4" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c259">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <clnn:weightedAverageFairValuesOfOptionsGranted contextRef="c0" decimals="2" unitRef="usdPershares">8.85</clnn:weightedAverageFairValuesOfOptionsGranted>
    <clnn:RestrictedStockUnitsDescription contextRef="c252">On December 30, 2020, we granted
rights to awards of the following shares of restricted stock under the 2020 Stock Plan:&#160;

    &#160;
    &#x25cf;
    370,101 shares to various employees and non-employee directors, which
vest on various dates between June 30, 2021 and January 15, 2022, subject to the employee&#x2019;s continuous employment through such vesting
date. The restricted stock awards convert to shares of Common Stock on a one-for-one basis upon vesting. The award represents 5% of the
converted stock options under 2014 Stock Plan as a result of the Reverse Recapitalization and complements the 5% closing payment shares
held in escrow for Clene Nanomedicine common shareholders (see Note 3). The grant-date fair value of these awards was $4.0 million based
on the closing price of CLNN shares listed on Nasdaq of $10.82 per share on December 30, 2020, the date of the Reverse Recapitalization.
As of September 30, 2021, there were 224,109 shares of Common Stock issued upon the vesting of restricted stock awards. As of December
31, 2020 no shares were vested.
  &#160;

    &#160;
    &#x25cf;
    454,781 shares to various employees and non-employee directors, which were eligible to vest based on certain market conditions, subject to the employee&#x2019;s continuous employment through such vesting date. The award complements the Milestone 1 earn-out share entitlement of Clene Nanomedicine shareholders and vests based on the same market condition (see Note 3). The grant-date fair value of these awards, using a Monte Carlo simulation, was $4.3 million. Based on the outcome of the market condition as of the September 30, 2021 and December 31, 2020 measurement dates, no shares were vested.
  &#160;

    &#160;
    &#x25cf;
    341,090 shares to various employees and non-employee directors, which were eligible to vest based on certain market conditions, subject to the employee&#x2019;s continuous employment through such vesting date. The award complements the Milestone 2 earn-out share entitlement of Clene Nanomedicine. shareholders and vests based on the same market condition (see Note 3). The grant-date fair value of these awards, using a Monte Carlo simulation, was $3.5 million. Based on the outcome of the market condition as of the September 30, 2021 and December 31, 2020 measurement dates, no shares were vested.
  &#160;&#160;&#x25cf;341,090 shares to various employees and non-employee directors, which were eligible to vest based on certain performance conditions tied to the completion of the COVID-19 coronavirus treatment study, subject to the employee&#x2019;s continuous employment through such vesting date. The award complements the Milestone 3 earn-out share entitlement of Clene Nanomedicine shareholders and vests based on the same performance condition (see Note 3). The grant-date fair value of these awards was $3.7 million, based on the closing price of CLNN shares listed on Nasdaq of $10.82 per share on December 30, 2020, the date of the Reverse Recapitalization. We did not recognize compensation expense because the occurrence of achieving this milestone was not probable. As of the September 30, 2021 and December 31, 2020 measurement dates, no shares were vested.</clnn:RestrictedStockUnitsDescription>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of&lt;br/&gt; Restricted Stock Awards&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Grant &lt;br/&gt; Date Fair &lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Outstanding and unvested balance as of December 31, 2020&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,507,062&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10.30&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Converted to shares of Common Stock upon vesting&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(224,109&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-216"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(37,464&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10.82&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding and unvested balance as of September 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,245,489&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10.14&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="c256" decimals="0" unitRef="shares">1507062</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="c256" decimals="2" unitRef="usdPershares">10.3</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="c252" decimals="0" unitRef="shares">224109</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c252" decimals="0" unitRef="shares">37464</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue contextRef="c252" decimals="2" unitRef="usdPershares">10.82</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="c255" decimals="0" unitRef="shares">1245489</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="c255" decimals="2" unitRef="usdPershares">10.14</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate contextRef="c253" decimals="2" unitRef="pure">0.85</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c253" decimals="3" unitRef="pure">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c253">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="c253" decimals="4" unitRef="usdPershares">10.3034</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:RestrictedStockExpense contextRef="c254" decimals="-5" unitRef="usd">800000</us-gaap:RestrictedStockExpense>
    <us-gaap:RestrictedStockExpense contextRef="c252" decimals="-5" unitRef="usd">6800000</us-gaap:RestrictedStockExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c255" decimals="-5" unitRef="usd">900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c256" decimals="-5" unitRef="usd">15500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <clnn:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm contextRef="c252">P1M</clnn:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm>
    <clnn:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm contextRef="c253">P6M</clnn:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;16. Fair Value&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Cash is carried at fair
value. Financial instruments, including accounts receivable, accounts payable, and accrued expenses are carried at cost, which
approximates fair value given their short-term nature. The 2019 MD Loan, the 2019 Cecil Loan, the derivative instruments associated
with the 2021 Avenue Loan, and the derivative instruments associated with the Contingent Earn-outs are carried at fair value. The
2021 Avenue Loan, related convertible notes payable, and Conversion Feature are carried at amortized cost, which approximate fair value due to our credit
risk and market interest rates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Liabilities with Fair Value Measurements on a Recurring Basis&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following tables present
our fair value hierarchy for liabilities measured at fair value on a recurring basis as of September 30, 2021 and December 31, 2020:&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Fair Value Measurements on a Recurring Basis &lt;br/&gt; September 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Notes payable&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;983&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-217"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-218"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;983&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Warrant liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-219"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-220"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;910&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;910&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Clene Nanomedicine contingent earn-out&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-221"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-222"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33,981&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33,981&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Initial Shareholders contingent earn-out&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-223"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-224"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,196&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,196&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Fair Value Measurements on a Recurring Basis &lt;br/&gt; December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Notes payable&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,296&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-225"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-226"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,296&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Clene Nanomedicine contingent earn-out&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-227"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-228"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52,053&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52,053&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Initial Shareholders contingent earn-out&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-229"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-230"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,906&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,906&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;There were no transfers between
levels in the fair value hierarchy as of September 30, 2021 and December 31, 2020.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Valuation of Notes Payable and Convertible
Notes Payable&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The carrying value of notes payable and convertible notes payable includes
certain notes carried at amortized cost, and certain notes remeasured at fair value on a recurring basis in the condensed consolidated
balance sheets as of September 30, 2021 and December 31, 2020. In order to value the notes, we considered the amount of simple interest
expense that would be due and the value of our Common Stock.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As of September 30, 2021 and
December 31, 2020, the fair value of the 2019 MD Loan and the 2019 Cecil Loan was determined based on the closing prices of $6.83 and
$9.01 per share, respectively, as reported by Nasdaq.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As of September 30, 2021,
the amortized cost of the 2021 Avenue Loan was $18.2 million, which includes the notes payable, carried at $13.6 million;
and the convertible notes payable and embedded Conversion Feature, carried at $4.6 million. The valuation of the Conversion Feature is
discussed below. The 2021 Avenue Loan was not outstanding as of December 31, 2020.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Valuation of Conversion Feature&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Conversion Feature of the convertible notes payable from the 2021
Avenue Loan is carried at amortized cost and did not meet the requirements for separate accounting and is not accounted for as a derivative
instrument. The estimated fair value of the Conversion Feature was $2.0 million and was determined using a Black-Scholes valuation model,
with a Monte Carlo analysis performed in order to simulate the Next Round Price as an input in the Black-Scholes valuation model. The
unobservable inputs to the model were as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Black-Scholes Valuation Model&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, &lt;br/&gt; 2020&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Expected stock price volatility&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;85.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-231"&gt;N/A&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.50&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-232"&gt;N/A&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-233"&gt;N/A&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Expected term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.56 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-234"&gt;N/A&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Monte Carlo Simulation&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;September&#160;30,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, &lt;br/&gt; 2020&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Expected stock price volatility&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;35.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-235"&gt;N/A&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.07&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-236"&gt;N/A&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-237"&gt;N/A&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Expected term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.09 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-238"&gt;N/A&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Valuation of Warrants to Purchase Preferred
Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;Our Preferred Stock
warrant liabilities contain unobservable inputs that reflect our own assumptions. Accordingly, the Preferred Stock warrant liabilities
were measured at fair value on a recurring basis using unobservable inputs. Prior to the extinguishment of the Preferred Stock warrant
liabilities on December 30, 2020, the Preferred Stock warrant liability was valued using a Black-Scholes valuation model.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Board of Directors determined
the fair value of the Preferred Stock by considering a number of objective and subjective factors, including third-party valuations, valuations
of comparable companies, sales of redeemable convertible Preferred Stock, sales of common stock to unrelated third parties, operating
and financial performance, the lack of liquidity of our capital stock, and general and industry-specific economic outlook. We estimated
the volatility of our Preferred Stock based on comparable peer companies&#x2019; historical volatility. The risk-free interest rate for
periods within the contractual life of the warrants was based on the U.S. Treasury yield curve in effect at the valuation date. We have
no plans to declare any future dividends. The determination of the fair value of the Preferred Stock warrant liability could change in
future periods based upon changes in the value of our Preferred Stock and other assumptions as presented above. We record any such change
in fair value to the change in fair value of Preferred Stock warrant liability expense line in the condensed consolidated statements of
operations and comprehensive income (loss).&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Upon the closing of the Reverse
Recapitalization (see Note 3), all of the outstanding Clene Nanomedicine Preferred Stock was converted to Clene Inc. Common Stock and
the Clene Nanomedicine Preferred Stock warrants were converted to warrants for the purchase of Clene Inc. Common Stock. Accordingly, the
Preferred Stock warrant liabilities were extinguished in connection with the conversion of Clene Nanomedicine Preferred Stock on December
30, 2020 (see Note 9).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Valuation of the Warrant Liability&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Pursuant to the 2021 Avenue Loan, we issued the Avenue Warrants to
purchase 115,851 shares of Common Stock pursuant to Tranche 1 of the 2021 Avenue Loan. In accordance with ASC 815, we recognized an additional
warrant to purchase an estimated 86,679 shares of Common Stock that will be issued pursuant to the draw of Tranche 2 of the 2021 Avenue
Loan (see Note 10). The warrants were recorded at fair value at the closing of the 2021 Avenue Loan on May 21, 2021, and the fair value
and issuable shares will be remeasured at each reporting period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The estimated fair value of
the warrant liability was determined using a Black-Scholes valuation model, with a Monte Carlo analysis performed in order to simulate
the Next Round Price as an input in the Black-Scholes valuation model. The carrying amount of the liability may fluctuate significantly
and actual amounts may be materially different from the liabilities&#x2019; estimated value. As of September 30, 2021, the warrant was
revalued using a similar Black-Scholes valuation model. The unobservable inputs to the model were as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Black-Scholes Valuation Model&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September 30,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, &lt;br/&gt; 2020&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Expected stock price volatility&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;95.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-239"&gt;N/A&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.90&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-240"&gt;N/A&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-241"&gt;N/A&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Expected term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.89 years &#x2013; 4.56 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-242"&gt;N/A&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Monte Carlo Simulation&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September 30,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, &lt;br/&gt; 2020&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected stock price volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;40.00 &#x2013; 70.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-243"&gt;N/A&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;0.07&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-244"&gt;N/A&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-245"&gt;N/A&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Expected term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.09 years &#x2013; 0.66 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-246"&gt;N/A&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Valuation of the Contingent Earn-Outs&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Pursuant to the Merger Agreement,
Clene Nanomedicine&#x2019;s common shareholders immediately prior to the Reverse Recapitalization and Initial Shareholders of Tottenham
were entitled to receive additional shares of up to 8,333,333 shares and 750,000 shares of Common Stock, respectively, upon us achieving
certain milestones (see Note 3). Upon the consummation of the Reverse Recapitalization, Clene Nanomedicine and the Initial Shareholders
are entitled to receive up to 8,346,185 additional shares as a result of the exercise of the stock options in November 2020, and 750,000
shares of Common Stock. The Contingent Earn-outs were recorded at fair value on the closing of the Reverse Recapitalization on December
30, 2020 and will be remeasured at each reporting period. As of September 30, 2021 and December 31, 2020, no milestone has been achieved.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The estimated fair value of
the initial Contingent Earn-outs was determined using a Monte Carlo analysis in order to simulate the future path of our stock price over
the earn-out periods. The carrying amount of the liabilities may fluctuate significantly and actual amounts paid may be materially different
from the liabilities&#x2019; estimated value. As of September 30, 2021 and December 31, 2020, the Contingent Earn-outs were revalued using
a similar Monte Carlo analysis. The unobservable inputs to the models were as follows:&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September 30,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, &lt;br/&gt; 2020&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Expected stock price volatility&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;95.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;85.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.80&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.40&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Expected term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.2 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.00 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following is a summary
of changes in the fair value of our financial liabilities related to the notes payable, the derivative instrument, the Preferred Stock
warrants, the warrant liability, and the Contingent Earn-outs measured at fair value for the nine months ended September 30, 2021 and
2020:&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Notes &lt;br/&gt; Payable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Clene Nanomedicine&lt;br/&gt; Contingent &lt;br/&gt; Earn-out&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Initial Shareholders&lt;br/&gt; Contingent &lt;br/&gt; Earn-out&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Warrant&lt;br/&gt; Liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Balance - December 31, 2020&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,296&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;52,053&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,906&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-247"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 10pt"&gt;Initial fair value of instrument&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-248"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-249"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-250"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,457&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(313&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(18,072&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,710&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(547&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance - September 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;983&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;33,981&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,196&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;910&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Notes &lt;br/&gt; Payable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Derivative&lt;br/&gt; Instrument&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Preferred&lt;br/&gt; Stock&lt;br/&gt; Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Balance - December 31, 2019&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;640&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-251"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,213&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Issuance of convertible promissory notes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-252"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;705&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-253"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Change in fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;323&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(29&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,378&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in"&gt;Extinguishment of derivative liability in connection with extinguishment of convertible promissory notes&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-254"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(676&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-255"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance - September 30, 2020&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;963&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-256"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,591&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Fair Value Measurements on a Recurring Basis &lt;br/&gt; September 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Notes payable&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;983&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-217"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-218"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;983&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Warrant liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-219"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-220"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;910&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;910&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Clene Nanomedicine contingent earn-out&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-221"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-222"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33,981&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33,981&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Initial Shareholders contingent earn-out&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-223"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-224"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,196&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,196&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Fair Value Measurements on a Recurring Basis &lt;br/&gt; December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Notes payable&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,296&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-225"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-226"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,296&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Clene Nanomedicine contingent earn-out&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-227"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-228"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52,053&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52,053&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Initial Shareholders contingent earn-out&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-229"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-230"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,906&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,906&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c261" decimals="-3" unitRef="usd">983000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c2" decimals="-3" unitRef="usd">983000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:DerivativeLiabilities contextRef="c263" decimals="-3" unitRef="usd">910000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c2" decimals="-3" unitRef="usd">910000</us-gaap:DerivativeLiabilities>
    <clnn:CleneNanomedicineContingentEarnoutFairValueDisclosure contextRef="c263" decimals="-3" unitRef="usd">33981000</clnn:CleneNanomedicineContingentEarnoutFairValueDisclosure>
    <clnn:CleneNanomedicineContingentEarnoutFairValueDisclosure contextRef="c2" decimals="-3" unitRef="usd">33981000</clnn:CleneNanomedicineContingentEarnoutFairValueDisclosure>
    <clnn:InitialShareholdersContingentEarnoutFairValueDisclosure contextRef="c263" decimals="-3" unitRef="usd">4196000</clnn:InitialShareholdersContingentEarnoutFairValueDisclosure>
    <clnn:InitialShareholdersContingentEarnoutFairValueDisclosure contextRef="c2" decimals="-3" unitRef="usd">4196000</clnn:InitialShareholdersContingentEarnoutFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c264" decimals="-3" unitRef="usd">1296000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c3" decimals="-3" unitRef="usd">1296000</us-gaap:NotesPayableFairValueDisclosure>
    <clnn:CleneNanomedicineContingentEarnoutFairValueDisclosure contextRef="c266" decimals="-3" unitRef="usd">52053000</clnn:CleneNanomedicineContingentEarnoutFairValueDisclosure>
    <clnn:CleneNanomedicineContingentEarnoutFairValueDisclosure contextRef="c3" decimals="-3" unitRef="usd">52053000</clnn:CleneNanomedicineContingentEarnoutFairValueDisclosure>
    <clnn:InitialShareholdersContingentEarnoutFairValueDisclosure contextRef="c266" decimals="-3" unitRef="usd">5906000</clnn:InitialShareholdersContingentEarnoutFairValueDisclosure>
    <clnn:InitialShareholdersContingentEarnoutFairValueDisclosure contextRef="c3" decimals="-3" unitRef="usd">5906000</clnn:InitialShareholdersContingentEarnoutFairValueDisclosure>
    <clnn:NotesPayableBasedOnClosingPrice contextRef="c0" decimals="2" unitRef="usdPershares">6.83</clnn:NotesPayableBasedOnClosingPrice>
    <clnn:NotesPayableBasedOnClosingPrice contextRef="c134" decimals="2" unitRef="usdPershares">9.01</clnn:NotesPayableBasedOnClosingPrice>
    <clnn:FairValueAmortizedCost contextRef="c0" decimals="-5" unitRef="usd">18200000</clnn:FairValueAmortizedCost>
    <us-gaap:ConvertibleNotesPayable contextRef="c2" decimals="-5" unitRef="usd">13600000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="c0" decimals="-5" unitRef="usd">4600000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <clnn:FairValueOfConvertibleNotesPayable contextRef="c2" decimals="-5" unitRef="usd">2000000</clnn:FairValueOfConvertibleNotesPayable>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, &lt;br/&gt; 2020&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Expected stock price volatility&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;85.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-231"&gt;N/A&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.50&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-232"&gt;N/A&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-233"&gt;N/A&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Expected term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.56 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-234"&gt;N/A&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;September&#160;30,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, &lt;br/&gt; 2020&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Expected stock price volatility&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;35.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-235"&gt;N/A&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.07&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-236"&gt;N/A&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-237"&gt;N/A&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Expected term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.09 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-238"&gt;N/A&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September 30,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, &lt;br/&gt; 2020&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Expected stock price volatility&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;95.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-239"&gt;N/A&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.90&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-240"&gt;N/A&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-241"&gt;N/A&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Expected term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.89 years &#x2013; 4.56 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-242"&gt;N/A&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September 30,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, &lt;br/&gt; 2020&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected stock price volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;40.00 &#x2013; 70.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-243"&gt;N/A&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;0.07&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-244"&gt;N/A&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-245"&gt;N/A&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Expected term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.09 years &#x2013; 0.66 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-246"&gt;N/A&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September 30,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, &lt;br/&gt; 2020&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Expected stock price volatility&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;95.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;85.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.80&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.40&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Expected term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.2 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.00 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c267" decimals="4" unitRef="pure">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c267" decimals="4" unitRef="pure">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c267" decimals="4" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c267">P2Y6M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c269" decimals="4" unitRef="pure">0.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c269" decimals="4" unitRef="pure">0.0007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c269" decimals="4" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c269">P0Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharesIssued contextRef="c210" decimals="0" unitRef="shares">115851</us-gaap:SharesIssued>
    <clnn:AdditionalWarrantToPurchaseShares contextRef="c0" decimals="0" unitRef="shares">86679</clnn:AdditionalWarrantToPurchaseShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c271" decimals="4" unitRef="pure">0.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c271" decimals="4" unitRef="pure">0.009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c271" decimals="4" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c273">P3Y10M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c274">P4Y6M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c275" decimals="4" unitRef="pure">0.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c276" decimals="4" unitRef="pure">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c278" decimals="4" unitRef="pure">0.0007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c278" decimals="4" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c275">P0Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c276">P0Y7M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsDescription contextRef="c260">Pursuant to the Merger Agreement,
Clene Nanomedicine&#x2019;s common shareholders immediately prior to the Reverse Recapitalization and Initial Shareholders of Tottenham
were entitled to receive additional shares of up to 8,333,333 shares and 750,000 shares of Common Stock, respectively, upon us achieving
certain milestones (see Note 3). Upon the consummation of the Reverse Recapitalization, Clene Nanomedicine and the Initial Shareholders
are entitled to receive up to 8,346,185 additional shares as a result of the exercise of the stock options in November 2020, and 750,000
shares of Common Stock</us-gaap:BusinessCombinationContingentConsiderationArrangementsDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c279" decimals="4" unitRef="pure">0.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c280" decimals="4" unitRef="pure">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c279" decimals="4" unitRef="pure">0.008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c280" decimals="4" unitRef="pure">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c279" decimals="4" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c280" decimals="4" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c279">P4Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c280">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Notes &lt;br/&gt; Payable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Clene Nanomedicine&lt;br/&gt; Contingent &lt;br/&gt; Earn-out&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Initial Shareholders&lt;br/&gt; Contingent &lt;br/&gt; Earn-out&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Warrant&lt;br/&gt; Liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Balance - December 31, 2020&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,296&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;52,053&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,906&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-247"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 10pt"&gt;Initial fair value of instrument&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-248"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-249"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-250"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,457&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(313&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(18,072&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,710&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(547&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance - September 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;983&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;33,981&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,196&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;910&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Notes &lt;br/&gt; Payable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Derivative&lt;br/&gt; Instrument&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Preferred&lt;br/&gt; Stock&lt;br/&gt; Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Balance - December 31, 2019&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;640&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-251"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,213&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Issuance of convertible promissory notes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-252"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;705&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-253"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Change in fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;323&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(29&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,378&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in"&gt;Extinguishment of derivative liability in connection with extinguishment of convertible promissory notes&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-254"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(676&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-255"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance - September 30, 2020&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;963&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-256"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,591&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c281" decimals="-3" unitRef="usd">1296000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c282" decimals="-3" unitRef="usd">52053000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c283" decimals="-3" unitRef="usd">5906000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <clnn:InitialFairValueOfInstrument contextRef="c288" decimals="-3" unitRef="usd">1457000</clnn:InitialFairValueOfInstrument>
    <clnn:IncreseDecreaseInFairValue contextRef="c285" decimals="-3" unitRef="usd">-313000</clnn:IncreseDecreaseInFairValue>
    <clnn:IncreseDecreaseInFairValue contextRef="c286" decimals="-3" unitRef="usd">-18072000</clnn:IncreseDecreaseInFairValue>
    <clnn:IncreseDecreaseInFairValue contextRef="c287" decimals="-3" unitRef="usd">-1710000</clnn:IncreseDecreaseInFairValue>
    <clnn:IncreseDecreaseInFairValue contextRef="c288" decimals="-3" unitRef="usd">-547000</clnn:IncreseDecreaseInFairValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c289" decimals="-3" unitRef="usd">983000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c290" decimals="-3" unitRef="usd">33981000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c291" decimals="-3" unitRef="usd">4196000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c292" decimals="-3" unitRef="usd">910000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c293" decimals="-3" unitRef="usd">640000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c295" decimals="-3" unitRef="usd">3213000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <clnn:FairValueIssuanceOfConvertiblePromissoryNotes contextRef="c297" decimals="-3" unitRef="usd">705000</clnn:FairValueIssuanceOfConvertiblePromissoryNotes>
    <clnn:IncreseDecreaseInFairValue contextRef="c296" decimals="-3" unitRef="usd">323000</clnn:IncreseDecreaseInFairValue>
    <clnn:IncreseDecreaseInFairValue contextRef="c297" decimals="-3" unitRef="usd">-29000</clnn:IncreseDecreaseInFairValue>
    <clnn:IncreseDecreaseInFairValue contextRef="c298" decimals="-3" unitRef="usd">7378000</clnn:IncreseDecreaseInFairValue>
    <clnn:FairValueMeasurementExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN contextRef="c297" decimals="-3" unitRef="usd">-676000</clnn:FairValueMeasurementExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c299" decimals="-3" unitRef="usd">963000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c301" decimals="-3" unitRef="usd">10591000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <clnn:RedeemableConvertiblePreferredStockDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;17. Redeemable Convertible Preferred Stock&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In connection with the closing
of the Reverse Recapitalization, the Preferred Stock converted into 36,893,894 shares of Common Stock on a 1:0.1389 basis (see Note 3).
As of September 30, 2021 and December 31, 2020, there were no Preferred Stock outstanding.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The redeemable convertible
preferred stock is described in Note 17, Redeemable Convertible Preferred Stock in Part II, Item 8 of our 2020 Annual Report on Form 10-K
for the year ended December 31, 2020 (&#x201c;2020 Annual Report&#x201d;) which was filed with the SEC on March 29, 2021. There have been
no changes since our 2020 Annual Report.&lt;/p&gt;</clnn:RedeemableConvertiblePreferredStockDisclosureTextBlock>
    <us-gaap:ConversionOfStockSharesConverted1 contextRef="c302" decimals="0" unitRef="shares">36893894</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;18. Common Stock&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As of September 30, 2021 and
December 31, 2020, our certificate of incorporation, as amended and restated, authorized us to issue 150,000,000 and 100,000,000 shares
of Common Stock, respectively, par value $0.0001 per share and 1,000,000 shares of Preferred Stock, par value $0.0001 per share. At our
2021 Annual Meeting of Stockholders on May 18, 2021, our stockholders approved an amendment to the Amended and Restated Certificate of
Incorporation to increase the number of authorized shares of Common Stock from 100,000,000 to 150,000,000.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Our common shareholders are
entitled to one vote per share and to notice of any shareholders&#x2019; meeting. Voting, dividend, and liquidation rights of the holders
of Common Stock are subject to the prior rights of holders of all classes of stock and are qualified by the rights, powers, preferences,
and privileges of the holders of Preferred Stock. No distributions shall be made with respect to Common Stock until all declared dividends
to Preferred Shares have been paid or set aside for payment to the holders of Preferred Stock. Common Stock is not redeemable at the option
of the holder.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On the closing of the Reverse
Recapitalization, the total outstanding 2,303,495 Tottenham ordinary shares held by the Initial Shareholders and public shareholders were
converted into the same number of Common Stock (see Note 3).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On the closing of the Reverse
Recapitalization, 644,164 shares of Common Stock were issued to LifeSci as financial advisor to the Reverse Recapitalization (see Note
3).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Prior to the completion of
the Reverse Recapitalization on December 30, 2020, the Company entered into a subscription agreement on December 28, 2020, with various
investors. Pursuant to the subscription agreements, the Company issued 2,239,500 shares of Common Stock (the &#x201c;December 2020 PIPE
Shares&#x201d;) at a price of $10.00 per share with net proceeds of $22.2 million. The purpose of the December 2020 PIPE was to fund general
corporate expenses. In addition, investors in the December 2020 PIPE offering also received warrants to purchase a number of shares equal
to one-half (1/2) of the number of December 2020 PIPE Shares, totaling 1,119,750 shares of Common Stock, at an exercise price of $0.01
per share, subject to a 180-day holding period (see Note 10).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On May 21, 2021, the Company
entered into the May 2021 PIPE subscription agreements with various investors. Pursuant to the subscription agreements, the Company issued
960,540 shares of Common Stock at a price of $9.63 per share with net proceeds of $9.3 million. The closing of the May 2021 PIPE occurred
substantially concurrently with, and was conditioned upon, the closing of the 2021 Avenue Loan (see Note 8). The purpose of the May 2021
PIPE was to fund the expansion of manufacturing capabilities in the state of Maryland and to fund general corporate expenses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Between July 1, 2021 and September
15, 2021, various investors exercised December 2020 PIPE Warrants for 1,002,250 shares of Common Stock at an exercise price of $0.01 per
share. The December 2020 PIPE Warrants were issued prior to the completion of the Reverse Recapitalization on December 30, 2020, and were
subject to a 180-day holding period which expired on June 28, 2021. We received cash proceeds of $10.0 thousand.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On July 15, 2021, Chardan
exercised the Chardan Unit Purchase Option for 220,000 units, each unit consisting of one and one-tenth shares of Common Stock and one
warrant to purchase one-half of one share of Common Stock at an exercise price of $11.50 per share. Chardan elected to perform a cashless
or net exercise, which resulted in a net issuance of 54,083 shares of Common Stock and 49,166 warrants to purchase one-half of one share
of Common Stock. The Chardan Unit Purchase Option was originally issued in connection with Tottenham&#x2019;s initial public offering in
August 2018. We received no cash proceeds.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As of September 30, 2021 and
December 31, 2020, our common shares issued and outstanding were 62,177,020 and 59,526,171, respectively. As of September 30, 2021 and
December 31, 2020, there were no preferred shares issued and outstanding (see Note 17).&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized contextRef="c2" decimals="0" unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c3" decimals="0" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c2" decimals="4" unitRef="usdPershares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <clnn:PreferredStockShares contextRef="c0" decimals="0" unitRef="shares">1000000</clnn:PreferredStockShares>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c2" decimals="4" unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c303" decimals="0" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c304" decimals="0" unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <clnn:IssuanceOfCommonStockUponReverseRecapitalization contextRef="c124" decimals="0" unitRef="shares">2303495</clnn:IssuanceOfCommonStockUponReverseRecapitalization>
    <clnn:RecapitalizationShare contextRef="c124" decimals="0" unitRef="shares">644164</clnn:RecapitalizationShare>
    <clnn:InvestorsPurchasedShares contextRef="c305" decimals="0" unitRef="shares">2239500</clnn:InvestorsPurchasedShares>
    <us-gaap:SharePrice contextRef="c306" decimals="2" unitRef="usdPershares">10</us-gaap:SharePrice>
    <clnn:NetProceeds contextRef="c305" decimals="-5" unitRef="usd">22200000</clnn:NetProceeds>
    <clnn:PrivatePlacementWarrantsDescription contextRef="c134">In addition, investors in the December 2020 PIPE offering also received warrants to purchase a number of shares equal
to one-half (1/2) of the number of December 2020 PIPE Shares, totaling 1,119,750 shares of Common Stock, at an exercise price of $0.01
per share, subject to a 180-day holding period (see Note 10).</clnn:PrivatePlacementWarrantsDescription>
    <clnn:CommonStockSharesPurchased contextRef="c307" decimals="0" unitRef="shares">960540</clnn:CommonStockSharesPurchased>
    <clnn:CommonStockPricePerShare contextRef="c307" decimals="2" unitRef="usdPershares">9.63</clnn:CommonStockPricePerShare>
    <clnn:NetProceeds contextRef="c307" decimals="-5" unitRef="usd">9300000</clnn:NetProceeds>
    <clnn:WarrantsShares contextRef="c308" decimals="0" unitRef="shares">1002250</clnn:WarrantsShares>
    <clnn:ExercisePricePerShare contextRef="c308" decimals="2" unitRef="usdPershares">0.01</clnn:ExercisePricePerShare>
    <clnn:CashProceedsReceived contextRef="c308" decimals="-2" unitRef="usd">10000</clnn:CashProceedsReceived>
    <clnn:PurchaseOptionUnits contextRef="c139" decimals="0" unitRef="shares">220000</clnn:PurchaseOptionUnits>
    <clnn:ExercisePricePerShare contextRef="c309" decimals="2" unitRef="usdPershares">11.5</clnn:ExercisePricePerShare>
    <clnn:NetIssuanceShares contextRef="c309" decimals="0" unitRef="shares">54083</clnn:NetIssuanceShares>
    <clnn:NetIssuanceWarrants contextRef="c309" decimals="0" unitRef="shares">49166</clnn:NetIssuanceWarrants>
    <us-gaap:CommonStockSharesIssued contextRef="c2" decimals="0" unitRef="shares">62177020</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c3" decimals="0" unitRef="shares">59526171</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:EarningsPerShareTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;19. Net Income (Loss) Per Share Attributable
to Common Shareholders&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following table sets forth
the computation of basic and diluted net income (loss) per share attributable to common shareholders (in thousands, except share and per
share data):&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three Months Ended&lt;br/&gt; September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Nine Months Ended&lt;br/&gt; September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="text-decoration:underline"&gt;Numerator&#160;:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Net income (loss) attributable to common shareholders &#x2013; Basic&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;28,944&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(10,295&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(14,163&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(20,055&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"&gt;Less interest expense on potentially dilutive convertible notes payable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;196&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in"&gt;Net income (loss) attributable to common shareholders - Diluted&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;29,140&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(10,295&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(14,163&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(20,055&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="text-decoration:underline"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 0.25in"&gt;Weighted average common shares outstanding &#x2013;Basic&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;62,071,754&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,358,159&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;61,307,699&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,358,159&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 0.25in"&gt;Weighted average effect of potentially dilutive securities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 27pt"&gt;Effect of potentially dilutive stock options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,791,023&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-257"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-258"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-259"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 27pt"&gt;Effect of potentially dilutive common stock warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,485,049&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-260"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-261"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-262"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 27pt"&gt;Effect of potentially dilutive convertible notes payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;482,703&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-263"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-264"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-265"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt"&gt;Effect of potentially dilutive restricted stock awards&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;208,105&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-266"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-267"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-268"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in"&gt;Weighted average common shares outstanding &#x2013;Diluted&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;70,038,634&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;17,358,159&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;61,307,699&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;17,358,159&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Net income (loss) per share attributable to common shareholders:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 0.25in"&gt;Basic&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.47&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.59&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.23&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(1.16&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 0.25in"&gt;Diluted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.59&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.23&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(1.16&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Included within weighted average common shares outstanding are the
remaining 117,500 (originally 1,119,750) common shares issuable upon the exercise of the December 2020 PIPE Warrants, as these warrants
are exercisable at any time for nominal consideration, and as such, the shares are considered outstanding for the purpose of calculating
basic and diluted net loss per share attributable to common shareholders.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following shares of potentially dilutive securities were excluded
from the computation of diluted net income (loss) per share attributable to common shareholders for the periods presented because including
them would have been antidilutive, or issuance of such shares is contingent upon the satisfaction of certain conditions which were not
satisfied by the end of the period, or they were out-of-the money:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three Months Ended&lt;br/&gt; September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Nine Months Ended&lt;br/&gt; September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Series D redeemable convertible preferred stock&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-269"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9,394,057&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-270"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9,394,057&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Series C redeemable convertible preferred stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-271"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,264,519&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-272"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,264,519&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Series B redeemable convertible preferred stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-273"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,168,815&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-274"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,168,815&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Series A redeemable convertible preferred stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-275"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,066,503&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-276"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,066,503&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Series D redeemable convertible preferred stock warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-277"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;320,441&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-278"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;320,441&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Series A redeemable convertible preferred stock warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-279"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,608,670&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-280"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,608,670&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Convertible notes payable (see Note 11)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-281"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-282"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;482,703&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-283"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Common stock warrants (see Note 10)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,523,351&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-284"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,569,962&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-285"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Options to purchase common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,685,575&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,509,810&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,063,423&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,509,810&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Restricted stock awards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,100,050&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-286"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,245,489&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-287"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Chardan Unit Purchase Option Warrants (see Notes 3 and 10)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,583&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-288"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,583&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-289"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Clene Nanomedicine contingent earn-out shares (see Note 3 and 12)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,346,185&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-290"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,346,185&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-291"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Initial Shareholders contingent earn-out shares (see Note 3 and 12)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;750,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-292"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;750,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-293"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;15,429,744&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;46,332,815&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;24,482,345&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;46,332,815&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three Months Ended&lt;br/&gt; September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Nine Months Ended&lt;br/&gt; September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="text-decoration:underline"&gt;Numerator&#160;:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Net income (loss) attributable to common shareholders &#x2013; Basic&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;28,944&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(10,295&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(14,163&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(20,055&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"&gt;Less interest expense on potentially dilutive convertible notes payable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;196&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in"&gt;Net income (loss) attributable to common shareholders - Diluted&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;29,140&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(10,295&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(14,163&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(20,055&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="text-decoration:underline"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 0.25in"&gt;Weighted average common shares outstanding &#x2013;Basic&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;62,071,754&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,358,159&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;61,307,699&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,358,159&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 0.25in"&gt;Weighted average effect of potentially dilutive securities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 27pt"&gt;Effect of potentially dilutive stock options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,791,023&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-257"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-258"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-259"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 27pt"&gt;Effect of potentially dilutive common stock warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,485,049&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-260"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-261"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-262"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 27pt"&gt;Effect of potentially dilutive convertible notes payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;482,703&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-263"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-264"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-265"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt"&gt;Effect of potentially dilutive restricted stock awards&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;208,105&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-266"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-267"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-268"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in"&gt;Weighted average common shares outstanding &#x2013;Diluted&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;70,038,634&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;17,358,159&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;61,307,699&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;17,358,159&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Net income (loss) per share attributable to common shareholders:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 0.25in"&gt;Basic&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.47&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.59&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.23&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(1.16&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 0.25in"&gt;Diluted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.59&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.23&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(1.16&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c312" decimals="-3" unitRef="usd">28944000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c313" decimals="-3" unitRef="usd">-10295000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c314" decimals="-3" unitRef="usd">-14163000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c315" decimals="-3" unitRef="usd">-20055000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:InterestOnConvertibleDebtNetOfTax contextRef="c312" decimals="-3" unitRef="usd">196000</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c312" decimals="-3" unitRef="usd">29140000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c313" decimals="-3" unitRef="usd">-10295000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c314" decimals="-3" unitRef="usd">-14163000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c315" decimals="-3" unitRef="usd">-20055000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <clnn:WeightedAverageSharesOutstanding contextRef="c312" decimals="INF" unitRef="shares">62071754</clnn:WeightedAverageSharesOutstanding>
    <clnn:WeightedAverageSharesOutstanding contextRef="c313" decimals="INF" unitRef="shares">17358159</clnn:WeightedAverageSharesOutstanding>
    <clnn:WeightedAverageSharesOutstanding contextRef="c314" decimals="INF" unitRef="shares">61307699</clnn:WeightedAverageSharesOutstanding>
    <clnn:WeightedAverageSharesOutstanding contextRef="c315" decimals="INF" unitRef="shares">17358159</clnn:WeightedAverageSharesOutstanding>
    <clnn:EffectOfPotentiallyDilutiveStockOptionsinDollars contextRef="c312" decimals="INF" unitRef="shares">5791023</clnn:EffectOfPotentiallyDilutiveStockOptionsinDollars>
    <clnn:EffectOfPotentiallyDilutiveRestrictedStockAwards contextRef="c312" decimals="INF" unitRef="shares">1485049</clnn:EffectOfPotentiallyDilutiveRestrictedStockAwards>
    <clnn:EffectOfPotentiallyDilutiveConvertibleNotesPayable contextRef="c312" decimals="INF" unitRef="shares">482703</clnn:EffectOfPotentiallyDilutiveConvertibleNotesPayable>
    <clnn:EffectOfPotentiallyDilutiveUnvestedRestrictedStockAwardsShares contextRef="c312" decimals="INF" unitRef="shares">208105</clnn:EffectOfPotentiallyDilutiveUnvestedRestrictedStockAwardsShares>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="c312" decimals="INF" unitRef="shares">70038634</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="c313" decimals="INF" unitRef="shares">17358159</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="c314" decimals="INF" unitRef="shares">61307699</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="c315" decimals="INF" unitRef="shares">17358159</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasic contextRef="c312" decimals="2" unitRef="usdPershares">0.47</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="c313" decimals="2" unitRef="usdPershares">-0.59</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="c314" decimals="2" unitRef="usdPershares">-0.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="c315" decimals="2" unitRef="usdPershares">-1.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted contextRef="c312" decimals="2" unitRef="usdPershares">0.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted contextRef="c313" decimals="2" unitRef="usdPershares">-0.59</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted contextRef="c314" decimals="2" unitRef="usdPershares">-0.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted contextRef="c315" decimals="2" unitRef="usdPershares">-1.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="c310" decimals="0" unitRef="shares">117500</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="c311" decimals="0" unitRef="shares">1119750</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three Months Ended&lt;br/&gt; September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Nine Months Ended&lt;br/&gt; September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Series D redeemable convertible preferred stock&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-269"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9,394,057&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-270"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9,394,057&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Series C redeemable convertible preferred stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-271"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,264,519&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-272"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,264,519&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Series B redeemable convertible preferred stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-273"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,168,815&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-274"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,168,815&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Series A redeemable convertible preferred stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-275"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,066,503&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-276"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,066,503&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Series D redeemable convertible preferred stock warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-277"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;320,441&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-278"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;320,441&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Series A redeemable convertible preferred stock warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-279"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,608,670&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-280"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,608,670&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Convertible notes payable (see Note 11)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-281"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-282"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;482,703&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-283"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Common stock warrants (see Note 10)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,523,351&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-284"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,569,962&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-285"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Options to purchase common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,685,575&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,509,810&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,063,423&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,509,810&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Restricted stock awards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,100,050&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-286"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,245,489&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-287"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Chardan Unit Purchase Option Warrants (see Notes 3 and 10)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,583&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-288"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,583&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-289"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Clene Nanomedicine contingent earn-out shares (see Note 3 and 12)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,346,185&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-290"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,346,185&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-291"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Initial Shareholders contingent earn-out shares (see Note 3 and 12)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;750,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-292"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;750,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-293"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;15,429,744&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;46,332,815&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;24,482,345&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;46,332,815&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <clnn:SeriesDRedeemableConvertiblePreferredStock contextRef="c13" decimals="0" unitRef="shares">9394057</clnn:SeriesDRedeemableConvertiblePreferredStock>
    <clnn:SeriesDRedeemableConvertiblePreferredStock contextRef="c14" decimals="0" unitRef="shares">9394057</clnn:SeriesDRedeemableConvertiblePreferredStock>
    <clnn:SeriesCRedeemableConvertiblePreferredStock contextRef="c13" decimals="0" unitRef="shares">7264519</clnn:SeriesCRedeemableConvertiblePreferredStock>
    <clnn:SeriesCRedeemableConvertiblePreferredStock contextRef="c14" decimals="0" unitRef="shares">7264519</clnn:SeriesCRedeemableConvertiblePreferredStock>
    <clnn:SeriesBRedeemableConvertiblePreferredStock contextRef="c13" decimals="0" unitRef="shares">4168815</clnn:SeriesBRedeemableConvertiblePreferredStock>
    <clnn:SeriesBRedeemableConvertiblePreferredStock contextRef="c14" decimals="0" unitRef="shares">4168815</clnn:SeriesBRedeemableConvertiblePreferredStock>
    <clnn:SeriesARedeemableConvertiblePreferredStock contextRef="c13" decimals="0" unitRef="shares">16066503</clnn:SeriesARedeemableConvertiblePreferredStock>
    <clnn:SeriesARedeemableConvertiblePreferredStock contextRef="c14" decimals="0" unitRef="shares">16066503</clnn:SeriesARedeemableConvertiblePreferredStock>
    <clnn:SeriesDRedeemableConvertiblePreferredStockWarrants contextRef="c13" decimals="0" unitRef="shares">320441</clnn:SeriesDRedeemableConvertiblePreferredStockWarrants>
    <clnn:SeriesDRedeemableConvertiblePreferredStockWarrants contextRef="c14" decimals="0" unitRef="shares">320441</clnn:SeriesDRedeemableConvertiblePreferredStockWarrants>
    <clnn:SeriesARedeemableConvertiblePreferredStockWarrantsinShares contextRef="c13" decimals="0" unitRef="shares">1608670</clnn:SeriesARedeemableConvertiblePreferredStockWarrantsinShares>
    <clnn:SeriesARedeemableConvertiblePreferredStockWarrantsinShares contextRef="c14" decimals="0" unitRef="shares">1608670</clnn:SeriesARedeemableConvertiblePreferredStockWarrantsinShares>
    <clnn:ConvertibleNotesPayables contextRef="c0" decimals="0" unitRef="shares">482703</clnn:ConvertibleNotesPayables>
    <clnn:CommonStockWarrants contextRef="c12" decimals="0" unitRef="shares">2523351</clnn:CommonStockWarrants>
    <clnn:CommonStockWarrants contextRef="c0" decimals="0" unitRef="shares">4569962</clnn:CommonStockWarrants>
    <clnn:OptionsToPurchaseCommonStockinShares contextRef="c12" decimals="0" unitRef="shares">2685575</clnn:OptionsToPurchaseCommonStockinShares>
    <clnn:OptionsToPurchaseCommonStockinShares contextRef="c13" decimals="0" unitRef="shares">7509810</clnn:OptionsToPurchaseCommonStockinShares>
    <clnn:OptionsToPurchaseCommonStockinShares contextRef="c0" decimals="0" unitRef="shares">9063423</clnn:OptionsToPurchaseCommonStockinShares>
    <clnn:OptionsToPurchaseCommonStockinShares contextRef="c14" decimals="0" unitRef="shares">7509810</clnn:OptionsToPurchaseCommonStockinShares>
    <clnn:UnvestedRestrictedStockAwardsShares contextRef="c12" decimals="0" unitRef="shares">1100050</clnn:UnvestedRestrictedStockAwardsShares>
    <clnn:UnvestedRestrictedStockAwardsShares contextRef="c0" decimals="0" unitRef="shares">1245489</clnn:UnvestedRestrictedStockAwardsShares>
    <clnn:ChardanUnitPurchaseOptionWarrants contextRef="c12" decimals="0" unitRef="shares">24583</clnn:ChardanUnitPurchaseOptionWarrants>
    <clnn:ChardanUnitPurchaseOptionWarrants contextRef="c0" decimals="0" unitRef="shares">24583</clnn:ChardanUnitPurchaseOptionWarrants>
    <clnn:CleneNanomedicineContingentEarnoutShares contextRef="c12" decimals="0" unitRef="shares">8346185</clnn:CleneNanomedicineContingentEarnoutShares>
    <clnn:CleneNanomedicineContingentEarnoutShares contextRef="c0" decimals="0" unitRef="shares">8346185</clnn:CleneNanomedicineContingentEarnoutShares>
    <clnn:InitialShareholdersContingentEarnoutShares contextRef="c12" decimals="0" unitRef="shares">750000</clnn:InitialShareholdersContingentEarnoutShares>
    <clnn:InitialShareholdersContingentEarnoutShares contextRef="c0" decimals="0" unitRef="shares">750000</clnn:InitialShareholdersContingentEarnoutShares>
    <clnn:TotalDilutiveSecurities contextRef="c12" decimals="0" unitRef="shares">15429744</clnn:TotalDilutiveSecurities>
    <clnn:TotalDilutiveSecurities contextRef="c13" decimals="0" unitRef="shares">46332815</clnn:TotalDilutiveSecurities>
    <clnn:TotalDilutiveSecurities contextRef="c0" decimals="0" unitRef="shares">24482345</clnn:TotalDilutiveSecurities>
    <clnn:TotalDilutiveSecurities contextRef="c14" decimals="0" unitRef="shares">46332815</clnn:TotalDilutiveSecurities>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;20. Related Party Transactions&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;For the three and nine months
ended September 30, 2020, we incurred $0 and $0.1 million, respectively, of expenses for compensation for consulting services provided
by a member of the Board of Directors. These expenses were paid in their entirety and as of September 30, 2020 and December 30, 2020,
there was no outstanding balance due to this related party.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;License and Supply Agreements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In August&#160;2018, in conjunction
with an investment made in our Series C Preferred Stock and Series C Preferred Stock Warrants by 4Life Research, LLC, an investor, we
entered into a supply agreement with the investor. Under the terms of this agreement, we granted the investor an exclusive license to
pursue development of dietary supplements using certain of our intellectual property (&#x201c;IP&#x201d;). The exclusive rights to the IP
is for a term of &lt;span style="-sec-ix-hidden: hidden-fact-294"&gt;five&lt;/span&gt;&#160;years from the commencement of sales of licensed product by the investor, with a deemed commencement date of
January 1, 2023 if sales have not yet commenced, and is subject to annual minimum sales. The agreement may be renewed for additional five-year
terms. If the investor fails to meet the annual minimum sales requirements, the investor may pay an additional fee to maintain exclusivity
or have the investor&#x2019;s license converted to non-exclusive rights. As part of this agreement, we will provide non-pharmaceutical
product to the investor for development efforts and potential future production, and the investor is to pay royalties of 3% of incremental
sales, as defined in the agreement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;For the three and nine months
ended September 30, 2021, we sold $0.1 million and $0.4 million of product, respectively, under this agreement. We did not sell any products
outside of this agreement. For the three and nine months ended September 30, 2021, the investor has made commercial sales of their products
under the agreement which we recognized as royalty revenues of $47 thousand and $0.1 million, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;For the nine months ended September 30, 2020, we sold $0.1 million
of product under this agreement, as well as $0.1 million of product not under this agreement, and received $0.1 million in advance to
be applied against future sales of product under this agreement. We recorded this advanced amount as deferred revenue as of September
30, 2020. The investor did not make sales of their products under the agreement, and as such we did not recognize any royalty revenues
for the nine months ended September 30, 2020. For the three months ended September 30, 2020, we did not sell any product under this agreement,
we sold $2 thousand of product not under this agreement, and there were no balances outstanding due to or from the investor.&#160;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="c13" decimals="-6" unitRef="usd">0</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="c14" decimals="-5" unitRef="usd">100000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c317" decimals="2" unitRef="pure">0.03</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:CostOfGoodsSoldSalesTypeLease contextRef="c12" decimals="-5" unitRef="usd">100000</us-gaap:CostOfGoodsSoldSalesTypeLease>
    <us-gaap:CostOfGoodsSoldSalesTypeLease contextRef="c0" decimals="-5" unitRef="usd">400000</us-gaap:CostOfGoodsSoldSalesTypeLease>
    <us-gaap:ProceedsFromRoyaltiesReceived contextRef="c12" decimals="-3" unitRef="usd">47000</us-gaap:ProceedsFromRoyaltiesReceived>
    <us-gaap:ProceedsFromRoyaltiesReceived contextRef="c0" decimals="-5" unitRef="usd">100000</us-gaap:ProceedsFromRoyaltiesReceived>
    <us-gaap:CostOfGoodsSoldSalesTypeLease contextRef="c13" decimals="-5" unitRef="usd">100000</us-gaap:CostOfGoodsSoldSalesTypeLease>
    <us-gaap:CostOfGoodsSoldSalesTypeLease contextRef="c14" decimals="-5" unitRef="usd">100000</us-gaap:CostOfGoodsSoldSalesTypeLease>
    <us-gaap:AdvancesToAffiliate contextRef="c2" decimals="-5" unitRef="usd">100000</us-gaap:AdvancesToAffiliate>
    <us-gaap:CostOfGoodsSoldDirectFinancingLease contextRef="c0" decimals="-3" unitRef="usd">2000</us-gaap:CostOfGoodsSoldDirectFinancingLease>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;21. Geographic and Segment Information&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Geographic Information&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Our long-lived assets, which
were composed of property and equipment, net by location were as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;As of&lt;br/&gt; September&#160;30,&lt;br/&gt;
&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;As of&lt;br/&gt; December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;United States&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,193&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,997&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Australia&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;53&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;228&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,246&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,225&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Segment Information&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The operating results of the
Drugs and Supplements segments were as follows:&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the Three Months ended &lt;br/&gt; September 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the Nine Months ended &lt;br/&gt; September 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Drugs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Supplements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Drugs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Supplements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Revenue from external customers&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-295"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;110&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;110&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-296"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;524&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;524&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Income (loss) from operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(10,546&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;96&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(10,450&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(35,632&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(288&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(35,920&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the Three Months ended &lt;br/&gt; September 30, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the Nine Months ended &lt;br/&gt; September 30, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Drugs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Supplements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Drugs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Supplements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Revenue from external customers&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-297"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;98&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;98&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-298"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;177&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;177&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Income (loss) from operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,789&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;98&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,691&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(14,373&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;119&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(14,254&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Our long-lived assets, which
were composed of property and equipment, net by segment were as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;As of &lt;br/&gt; September 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;As of &lt;br/&gt; December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Drugs&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-299"&gt;4, 038&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,990&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Supplements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;208&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;235&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,246&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,225&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;As of&lt;br/&gt; September&#160;30,&lt;br/&gt;
&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;As of&lt;br/&gt; December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;United States&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,193&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,997&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Australia&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;53&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;228&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,246&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,225&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c318" decimals="-3" unitRef="usd">4193000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c319" decimals="-3" unitRef="usd">3997000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c320" decimals="-3" unitRef="usd">53000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c321" decimals="-3" unitRef="usd">228000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="-3" unitRef="usd">4246000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="-3" unitRef="usd">4225000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the Three Months ended &lt;br/&gt; September 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the Nine Months ended &lt;br/&gt; September 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Drugs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Supplements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Drugs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Supplements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Revenue from external customers&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-295"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;110&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;110&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-296"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;524&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;524&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Income (loss) from operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(10,546&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;96&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(10,450&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(35,632&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(288&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(35,920&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the Three Months ended &lt;br/&gt; September 30, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the Nine Months ended &lt;br/&gt; September 30, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Drugs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Supplements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Drugs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Supplements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Revenue from external customers&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-297"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;98&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;98&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-298"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;177&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;177&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Income (loss) from operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,789&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;98&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,691&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(14,373&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;119&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(14,254&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Revenues contextRef="c323" decimals="-3" unitRef="usd">110000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c12" decimals="-3" unitRef="usd">110000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c325" decimals="-3" unitRef="usd">524000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c0" decimals="-3" unitRef="usd">524000</us-gaap:Revenues>
    <us-gaap:OperatingIncomeLoss contextRef="c322" decimals="-3" unitRef="usd">-10546000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c323" decimals="-3" unitRef="usd">96000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c12" decimals="-3" unitRef="usd">-10450000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c324" decimals="-3" unitRef="usd">-35632000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c325" decimals="-3" unitRef="usd">-288000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-35920000</us-gaap:OperatingIncomeLoss>
    <us-gaap:Revenues contextRef="c327" decimals="-3" unitRef="usd">98000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c13" decimals="-3" unitRef="usd">98000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c329" decimals="-3" unitRef="usd">177000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c14" decimals="-3" unitRef="usd">177000</us-gaap:Revenues>
    <us-gaap:OperatingIncomeLoss contextRef="c326" decimals="-3" unitRef="usd">-5789000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c327" decimals="-3" unitRef="usd">98000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c13" decimals="-3" unitRef="usd">-5691000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c328" decimals="-3" unitRef="usd">-14373000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c329" decimals="-3" unitRef="usd">119000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c14" decimals="-3" unitRef="usd">-14254000</us-gaap:OperatingIncomeLoss>
    <clnn:ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;As of &lt;br/&gt; September 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;As of &lt;br/&gt; December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Drugs&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-299"&gt;4, 038&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,990&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Supplements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;208&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;235&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,246&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,225&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</clnn:ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock>
    <clnn:TotalPropertyAndEquipmentNet contextRef="c331" decimals="-3" unitRef="usd">3990000</clnn:TotalPropertyAndEquipmentNet>
    <clnn:TotalPropertyAndEquipmentNet contextRef="c332" decimals="-3" unitRef="usd">208000</clnn:TotalPropertyAndEquipmentNet>
    <clnn:TotalPropertyAndEquipmentNet contextRef="c333" decimals="-3" unitRef="usd">235000</clnn:TotalPropertyAndEquipmentNet>
    <clnn:TotalPropertyAndEquipmentNet contextRef="c2" decimals="-3" unitRef="usd">4246000</clnn:TotalPropertyAndEquipmentNet>
    <clnn:TotalPropertyAndEquipmentNet contextRef="c3" decimals="-3" unitRef="usd">4225000</clnn:TotalPropertyAndEquipmentNet>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;22. Subsequent Events&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On October 1, 2021, various
investors exercised December 2020 PIPE Warrants for 25,000 shares of Common Stock at an exercise price of $0.01 per share. The December
2020 PIPE Warrants were issued prior to the completion of the Reverse Recapitalization on December 30, 2020, and were subject to a 180-day
holding period which expired on June 28, 2021. We received cash proceeds of $250.&#160;&#160;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SharesIssued contextRef="c334" decimals="0" unitRef="shares">25000</us-gaap:SharesIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c334" decimals="2" unitRef="usdPershares">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SubsequentEventDescription contextRef="c335">The December
2020 PIPE Warrants were issued prior to the completion of the Reverse Recapitalization on December 30, 2020, and were subject to a 180-day
holding period which expired on June 28, 2021.</us-gaap:SubsequentEventDescription>
    <clnn:AggregateGrossProceedWarrantsExercised contextRef="c335" decimals="0" unitRef="usdPershares">250</clnn:AggregateGrossProceedWarrantsExercised>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="c3"
      id="hidden-fact-0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="c2"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="c3"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:WarrantLiabilityNoncurrent
      contextRef="c3"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c2"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c3"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="c13"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:GainOnExtinguishmentOfNotesPayable
      contextRef="c12"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:GainOnExtinguishmentOfNotesPayable
      contextRef="c13"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:GainOnExtinguishmentOfNotesPayable
      contextRef="c14"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:LossOnExtinguishmentOfConvertibleNotesPayable
      contextRef="c12"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:LossOnExtinguishmentOfConvertibleNotesPayable
      contextRef="c0"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnContractTermination
      contextRef="c12"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnContractTermination
      contextRef="c13"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnContractTermination
      contextRef="c0"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:ChangeInFairValueOfPreferredStockWarrantLiability
      contextRef="c12"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:ChangeInFairValueOfPreferredStockWarrantLiability
      contextRef="c0"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:ChangeInFairValueOfDerivativeLiability
      contextRef="c12"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:ChangeInFairValueOfDerivativeLiability
      contextRef="c0"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:ChangeInFairValueOfContingentEarnout
      contextRef="c13"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:ChangeInFairValueOfContingentEarnout
      contextRef="c14"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:ChangeInFairValueOfInitialShareholdersContingentEarnout
      contextRef="c13"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:ChangeInFairValueOfInitialShareholdersContingentEarnout
      contextRef="c14"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:ChangeInFairValueOfCommonStockWarrantLiability
      contextRef="c13"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:ChangeInFairValueOfCommonStockWarrantLiability
      contextRef="c14"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c13"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c14"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c15"
      id="hidden-fact-27"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c15"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20"
      id="hidden-fact-29"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c21"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c23"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c24"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c21"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c23"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c24"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:ForeignCurrencyTranslationAdjustment
      contextRef="c20"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:ForeignCurrencyTranslationAdjustment
      contextRef="c21"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:ForeignCurrencyTranslationAdjustment
      contextRef="c22"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:ForeignCurrencyTranslationAdjustment
      contextRef="c23"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c20"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c21"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c22"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c24"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c26"
      id="hidden-fact-46"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c26"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c32"
      id="hidden-fact-48"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c32"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c33"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c35"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c36"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c32"
      id="hidden-fact-53"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c32"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c33"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c35"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c36"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="c32"
      id="hidden-fact-58"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c32"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c33"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c34"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c35"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c36"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c37"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c32"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c33"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c35"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c36"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:ForeignCurrencyTranslationAdjustment
      contextRef="c32"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:ForeignCurrencyTranslationAdjustment
      contextRef="c33"
      id="hidden-fact-70"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:ForeignCurrencyTranslationAdjustment
      contextRef="c34"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:ForeignCurrencyTranslationAdjustment
      contextRef="c35"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c32"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c33"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c34"
      id="hidden-fact-75"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c36"
      id="hidden-fact-76"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c38"
      id="hidden-fact-77"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c38"
      id="hidden-fact-78"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c44"
      id="hidden-fact-79"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c44"
      id="hidden-fact-80"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c45"
      id="hidden-fact-81"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c47"
      id="hidden-fact-82"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c48"
      id="hidden-fact-83"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:StockIssueDuringPeriodSharesExerciseOfWarrants
      contextRef="c44"
      id="hidden-fact-84"
      unitRef="shares"
      xsi:nil="true"/>
    <clnn:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="c44"
      id="hidden-fact-85"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="c45"
      id="hidden-fact-86"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="c47"
      id="hidden-fact-87"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="c48"
      id="hidden-fact-88"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:StockIssuedDuringPeriodExerciseOfUnderwritersOptioninShares
      contextRef="c44"
      id="hidden-fact-89"
      unitRef="shares"
      xsi:nil="true"/>
    <clnn:StockIssuedDuringPeriodExerciseOfUnderwritersOption
      contextRef="c44"
      id="hidden-fact-90"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:StockIssuedDuringPeriodExerciseOfUnderwritersOption
      contextRef="c45"
      id="hidden-fact-91"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:StockIssuedDuringPeriodExerciseOfUnderwritersOption
      contextRef="c46"
      id="hidden-fact-92"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:StockIssuedDuringPeriodExerciseOfUnderwritersOption
      contextRef="c47"
      id="hidden-fact-93"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:StockIssuedDuringPeriodExerciseOfUnderwritersOption
      contextRef="c48"
      id="hidden-fact-94"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:StockIssuedDuringPeriodExerciseOfUnderwritersOption
      contextRef="c12"
      id="hidden-fact-95"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c44"
      id="hidden-fact-96"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c45"
      id="hidden-fact-97"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c47"
      id="hidden-fact-98"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c48"
      id="hidden-fact-99"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="c44"
      id="hidden-fact-100"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c44"
      id="hidden-fact-101"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c45"
      id="hidden-fact-102"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c46"
      id="hidden-fact-103"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c47"
      id="hidden-fact-104"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c48"
      id="hidden-fact-105"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c12"
      id="hidden-fact-106"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:ForeignCurrencyTranslationAdjustment
      contextRef="c44"
      id="hidden-fact-107"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:ForeignCurrencyTranslationAdjustment
      contextRef="c45"
      id="hidden-fact-108"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:ForeignCurrencyTranslationAdjustment
      contextRef="c46"
      id="hidden-fact-109"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:ForeignCurrencyTranslationAdjustment
      contextRef="c47"
      id="hidden-fact-110"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c44"
      id="hidden-fact-111"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c45"
      id="hidden-fact-112"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c46"
      id="hidden-fact-113"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c48"
      id="hidden-fact-114"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c49"
      id="hidden-fact-115"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c60"
      id="hidden-fact-116"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c61"
      id="hidden-fact-117"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c63"
      id="hidden-fact-118"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c64"
      id="hidden-fact-119"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:ForeignCurrencyTranslationAdjustment
      contextRef="c60"
      id="hidden-fact-120"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:ForeignCurrencyTranslationAdjustment
      contextRef="c61"
      id="hidden-fact-121"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:ForeignCurrencyTranslationAdjustment
      contextRef="c62"
      id="hidden-fact-122"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:ForeignCurrencyTranslationAdjustment
      contextRef="c63"
      id="hidden-fact-123"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c60"
      id="hidden-fact-124"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c61"
      id="hidden-fact-125"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c62"
      id="hidden-fact-126"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c64"
      id="hidden-fact-127"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c72"
      id="hidden-fact-128"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c73"
      id="hidden-fact-129"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c75"
      id="hidden-fact-130"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c76"
      id="hidden-fact-131"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:ForeignCurrencyTranslationAdjustment
      contextRef="c72"
      id="hidden-fact-132"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:ForeignCurrencyTranslationAdjustment
      contextRef="c73"
      id="hidden-fact-133"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:ForeignCurrencyTranslationAdjustment
      contextRef="c74"
      id="hidden-fact-134"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:ForeignCurrencyTranslationAdjustment
      contextRef="c75"
      id="hidden-fact-135"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c72"
      id="hidden-fact-136"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c73"
      id="hidden-fact-137"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c74"
      id="hidden-fact-138"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c76"
      id="hidden-fact-139"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:StockIssuedDuringPeriodSharesSeriesDPreferredStock
      contextRef="c85"
      id="hidden-fact-140"
      unitRef="shares"
      xsi:nil="true"/>
    <clnn:StockIssuedDuringPeriodOfSeriesDPreferredStock
      contextRef="c85"
      id="hidden-fact-141"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:StockIssuedDuringPeriodOfSeriesDPreferredStock
      contextRef="c86"
      id="hidden-fact-142"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:StockIssuedDuringPeriodOfSeriesDPreferredStock
      contextRef="c87"
      id="hidden-fact-143"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:StockIssuedDuringPeriodOfSeriesDPreferredStock
      contextRef="c88"
      id="hidden-fact-144"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:StockIssuedDuringPeriodOfSeriesDPreferredStock
      contextRef="c13"
      id="hidden-fact-145"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="c85"
      id="hidden-fact-146"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="c85"
      id="hidden-fact-147"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="c86"
      id="hidden-fact-148"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="c87"
      id="hidden-fact-149"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="c88"
      id="hidden-fact-150"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="c13"
      id="hidden-fact-151"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c84"
      id="hidden-fact-152"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c84"
      id="hidden-fact-153"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c85"
      id="hidden-fact-154"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c87"
      id="hidden-fact-155"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c88"
      id="hidden-fact-156"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c84"
      id="hidden-fact-157"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c85"
      id="hidden-fact-158"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c87"
      id="hidden-fact-159"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c88"
      id="hidden-fact-160"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:ForeignCurrencyTranslationAdjustment
      contextRef="c84"
      id="hidden-fact-161"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:ForeignCurrencyTranslationAdjustment
      contextRef="c85"
      id="hidden-fact-162"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:ForeignCurrencyTranslationAdjustment
      contextRef="c86"
      id="hidden-fact-163"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:ForeignCurrencyTranslationAdjustment
      contextRef="c87"
      id="hidden-fact-164"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c84"
      id="hidden-fact-165"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c85"
      id="hidden-fact-166"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c86"
      id="hidden-fact-167"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c88"
      id="hidden-fact-168"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="c0"
      id="hidden-fact-169"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:ChangeInFairValueOfCleneNanomedicineContingentEarnouts
      contextRef="c14"
      id="hidden-fact-170"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:ChangesInFairValueOfInitialShareholdersContingentEarnout
      contextRef="c14"
      id="hidden-fact-171"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="c0"
      id="hidden-fact-172"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:ChangeInFairValueOfCommonStockWarrantLiabilitys
      contextRef="c14"
      id="hidden-fact-173"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="c0"
      id="hidden-fact-174"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c14"
      id="hidden-fact-175"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="c0"
      id="hidden-fact-176"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="c0"
      id="hidden-fact-177"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties
      contextRef="c0"
      id="hidden-fact-178"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="c0"
      id="hidden-fact-179"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="c14"
      id="hidden-fact-180"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="c0"
      id="hidden-fact-181"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="c14"
      id="hidden-fact-182"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="c14"
      id="hidden-fact-183"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="c14"
      id="hidden-fact-184"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="c14"
      id="hidden-fact-185"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="c0"
      id="hidden-fact-186"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RestrictedCash
      contextRef="c94"
      id="hidden-fact-187"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:WarrantLiabilityRecordedAtIssuanceOfNotesPayable
      contextRef="c14"
      id="hidden-fact-188"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:LeaseLiabilitySettledThroughTerminationOfLease
      contextRef="c0"
      id="hidden-fact-189"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="c0"
      id="hidden-fact-190"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes
      contextRef="c0"
      id="hidden-fact-191"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN
      contextRef="c0"
      id="hidden-fact-192"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:DeferredOfferingCostsInAccruedLiabilities
      contextRef="c0"
      id="hidden-fact-193"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:DirectorsOfficersInsurance
      contextRef="c3"
      id="hidden-fact-194"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="c2"
      id="hidden-fact-195"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:AccruedTransactionCosts
      contextRef="c2"
      id="hidden-fact-196"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="c151"
      id="hidden-fact-197"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueThereafter
      contextRef="c151"
      id="hidden-fact-198"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:CapitalLeasesFutureLeaseIncentives
      contextRef="c151"
      id="hidden-fact-199"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:FinanceLeaseWorkInProcessGross
      contextRef="c2"
      id="hidden-fact-200"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:TotalTermLoans
      contextRef="c187"
      id="hidden-fact-201"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:TotalTermLoans
      contextRef="c191"
      id="hidden-fact-202"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:TotalTermLoans
      contextRef="c193"
      id="hidden-fact-203"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="c3"
      id="hidden-fact-204"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="c3"
      id="hidden-fact-205"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:DebtInstrumentUnamortizedDiscountRemainderOfFiscalYear
      contextRef="c2"
      id="hidden-fact-206"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:DebtInstrumentUnamortizedDiscountYearOne
      contextRef="c2"
      id="hidden-fact-207"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:DebtInstrumentUnamortizedDiscountYearFour
      contextRef="c2"
      id="hidden-fact-208"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:DebtInstrumentUnamortizedDiscountYearFive
      contextRef="c2"
      id="hidden-fact-209"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:DebtInstrumentThereafter
      contextRef="c2"
      id="hidden-fact-210"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c195" id="hidden-fact-211">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <clnn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueGranted
      contextRef="c0"
      id="hidden-fact-212"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:WeightedAverageRemainingTermYearsExercised contextRef="c0" id="hidden-fact-213" xsi:nil="true"/>
    <clnn:WeightedAverageRemainingTermYearsForfeited contextRef="c0" id="hidden-fact-214" xsi:nil="true"/>
    <clnn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue
      contextRef="c0"
      id="hidden-fact-215"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="c252"
      id="hidden-fact-216"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="c262"
      id="hidden-fact-217"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="c263"
      id="hidden-fact-218"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="c261"
      id="hidden-fact-219"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="c262"
      id="hidden-fact-220"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:CleneNanomedicineContingentEarnoutFairValueDisclosure
      contextRef="c261"
      id="hidden-fact-221"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:CleneNanomedicineContingentEarnoutFairValueDisclosure
      contextRef="c262"
      id="hidden-fact-222"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:InitialShareholdersContingentEarnoutFairValueDisclosure
      contextRef="c261"
      id="hidden-fact-223"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:InitialShareholdersContingentEarnoutFairValueDisclosure
      contextRef="c262"
      id="hidden-fact-224"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="c265"
      id="hidden-fact-225"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="c266"
      id="hidden-fact-226"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:CleneNanomedicineContingentEarnoutFairValueDisclosure
      contextRef="c264"
      id="hidden-fact-227"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:CleneNanomedicineContingentEarnoutFairValueDisclosure
      contextRef="c265"
      id="hidden-fact-228"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:InitialShareholdersContingentEarnoutFairValueDisclosure
      contextRef="c264"
      id="hidden-fact-229"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:InitialShareholdersContingentEarnoutFairValueDisclosure
      contextRef="c265"
      id="hidden-fact-230"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c268"
      id="hidden-fact-231"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c268"
      id="hidden-fact-232"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c268"
      id="hidden-fact-233"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c268" id="hidden-fact-234" xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c270"
      id="hidden-fact-235"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c270"
      id="hidden-fact-236"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c270"
      id="hidden-fact-237"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c270" id="hidden-fact-238" xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c272"
      id="hidden-fact-239"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c272"
      id="hidden-fact-240"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c272"
      id="hidden-fact-241"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c272" id="hidden-fact-242" xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c277"
      id="hidden-fact-243"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c277"
      id="hidden-fact-244"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c277"
      id="hidden-fact-245"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c277" id="hidden-fact-246" xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="c284"
      id="hidden-fact-247"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:InitialFairValueOfInstrument
      contextRef="c285"
      id="hidden-fact-248"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:InitialFairValueOfInstrument
      contextRef="c286"
      id="hidden-fact-249"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:InitialFairValueOfInstrument
      contextRef="c287"
      id="hidden-fact-250"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="c294"
      id="hidden-fact-251"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:FairValueIssuanceOfConvertiblePromissoryNotes
      contextRef="c296"
      id="hidden-fact-252"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:FairValueIssuanceOfConvertiblePromissoryNotes
      contextRef="c298"
      id="hidden-fact-253"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:FairValueMeasurementExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN
      contextRef="c296"
      id="hidden-fact-254"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:FairValueMeasurementExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN
      contextRef="c298"
      id="hidden-fact-255"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="c300"
      id="hidden-fact-256"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:EffectOfPotentiallyDilutiveStockOptionsinDollars
      contextRef="c313"
      id="hidden-fact-257"
      unitRef="shares"
      xsi:nil="true"/>
    <clnn:EffectOfPotentiallyDilutiveStockOptionsinDollars
      contextRef="c314"
      id="hidden-fact-258"
      unitRef="shares"
      xsi:nil="true"/>
    <clnn:EffectOfPotentiallyDilutiveStockOptionsinDollars
      contextRef="c315"
      id="hidden-fact-259"
      unitRef="shares"
      xsi:nil="true"/>
    <clnn:EffectOfPotentiallyDilutiveRestrictedStockAwards
      contextRef="c313"
      id="hidden-fact-260"
      unitRef="shares"
      xsi:nil="true"/>
    <clnn:EffectOfPotentiallyDilutiveRestrictedStockAwards
      contextRef="c314"
      id="hidden-fact-261"
      unitRef="shares"
      xsi:nil="true"/>
    <clnn:EffectOfPotentiallyDilutiveRestrictedStockAwards
      contextRef="c315"
      id="hidden-fact-262"
      unitRef="shares"
      xsi:nil="true"/>
    <clnn:EffectOfPotentiallyDilutiveConvertibleNotesPayable
      contextRef="c313"
      id="hidden-fact-263"
      unitRef="shares"
      xsi:nil="true"/>
    <clnn:EffectOfPotentiallyDilutiveConvertibleNotesPayable
      contextRef="c314"
      id="hidden-fact-264"
      unitRef="shares"
      xsi:nil="true"/>
    <clnn:EffectOfPotentiallyDilutiveConvertibleNotesPayable
      contextRef="c315"
      id="hidden-fact-265"
      unitRef="shares"
      xsi:nil="true"/>
    <clnn:EffectOfPotentiallyDilutiveUnvestedRestrictedStockAwardsShares
      contextRef="c313"
      id="hidden-fact-266"
      unitRef="shares"
      xsi:nil="true"/>
    <clnn:EffectOfPotentiallyDilutiveUnvestedRestrictedStockAwardsShares
      contextRef="c314"
      id="hidden-fact-267"
      unitRef="shares"
      xsi:nil="true"/>
    <clnn:EffectOfPotentiallyDilutiveUnvestedRestrictedStockAwardsShares
      contextRef="c315"
      id="hidden-fact-268"
      unitRef="shares"
      xsi:nil="true"/>
    <clnn:SeriesDRedeemableConvertiblePreferredStock
      contextRef="c12"
      id="hidden-fact-269"
      unitRef="shares"
      xsi:nil="true"/>
    <clnn:SeriesDRedeemableConvertiblePreferredStock
      contextRef="c0"
      id="hidden-fact-270"
      unitRef="shares"
      xsi:nil="true"/>
    <clnn:SeriesCRedeemableConvertiblePreferredStock
      contextRef="c12"
      id="hidden-fact-271"
      unitRef="shares"
      xsi:nil="true"/>
    <clnn:SeriesCRedeemableConvertiblePreferredStock
      contextRef="c0"
      id="hidden-fact-272"
      unitRef="shares"
      xsi:nil="true"/>
    <clnn:SeriesBRedeemableConvertiblePreferredStock
      contextRef="c12"
      id="hidden-fact-273"
      unitRef="shares"
      xsi:nil="true"/>
    <clnn:SeriesBRedeemableConvertiblePreferredStock
      contextRef="c0"
      id="hidden-fact-274"
      unitRef="shares"
      xsi:nil="true"/>
    <clnn:SeriesARedeemableConvertiblePreferredStock
      contextRef="c12"
      id="hidden-fact-275"
      unitRef="shares"
      xsi:nil="true"/>
    <clnn:SeriesARedeemableConvertiblePreferredStock
      contextRef="c0"
      id="hidden-fact-276"
      unitRef="shares"
      xsi:nil="true"/>
    <clnn:SeriesDRedeemableConvertiblePreferredStockWarrants
      contextRef="c12"
      id="hidden-fact-277"
      unitRef="shares"
      xsi:nil="true"/>
    <clnn:SeriesDRedeemableConvertiblePreferredStockWarrants
      contextRef="c0"
      id="hidden-fact-278"
      unitRef="shares"
      xsi:nil="true"/>
    <clnn:SeriesARedeemableConvertiblePreferredStockWarrantsinShares
      contextRef="c12"
      id="hidden-fact-279"
      unitRef="shares"
      xsi:nil="true"/>
    <clnn:SeriesARedeemableConvertiblePreferredStockWarrantsinShares
      contextRef="c0"
      id="hidden-fact-280"
      unitRef="shares"
      xsi:nil="true"/>
    <clnn:ConvertibleNotesPayables
      contextRef="c12"
      id="hidden-fact-281"
      unitRef="shares"
      xsi:nil="true"/>
    <clnn:ConvertibleNotesPayables
      contextRef="c13"
      id="hidden-fact-282"
      unitRef="shares"
      xsi:nil="true"/>
    <clnn:ConvertibleNotesPayables
      contextRef="c14"
      id="hidden-fact-283"
      unitRef="shares"
      xsi:nil="true"/>
    <clnn:CommonStockWarrants
      contextRef="c13"
      id="hidden-fact-284"
      unitRef="shares"
      xsi:nil="true"/>
    <clnn:CommonStockWarrants
      contextRef="c14"
      id="hidden-fact-285"
      unitRef="shares"
      xsi:nil="true"/>
    <clnn:UnvestedRestrictedStockAwardsShares
      contextRef="c13"
      id="hidden-fact-286"
      unitRef="shares"
      xsi:nil="true"/>
    <clnn:UnvestedRestrictedStockAwardsShares
      contextRef="c14"
      id="hidden-fact-287"
      unitRef="shares"
      xsi:nil="true"/>
    <clnn:ChardanUnitPurchaseOptionWarrants
      contextRef="c13"
      id="hidden-fact-288"
      unitRef="shares"
      xsi:nil="true"/>
    <clnn:ChardanUnitPurchaseOptionWarrants
      contextRef="c14"
      id="hidden-fact-289"
      unitRef="shares"
      xsi:nil="true"/>
    <clnn:CleneNanomedicineContingentEarnoutShares
      contextRef="c13"
      id="hidden-fact-290"
      unitRef="shares"
      xsi:nil="true"/>
    <clnn:CleneNanomedicineContingentEarnoutShares
      contextRef="c14"
      id="hidden-fact-291"
      unitRef="shares"
      xsi:nil="true"/>
    <clnn:InitialShareholdersContingentEarnoutShares
      contextRef="c13"
      id="hidden-fact-292"
      unitRef="shares"
      xsi:nil="true"/>
    <clnn:InitialShareholdersContingentEarnoutShares
      contextRef="c14"
      id="hidden-fact-293"
      unitRef="shares"
      xsi:nil="true"/>
    <clnn:ExclusiveRightsIntellectualPropertyTerm contextRef="c316" id="hidden-fact-294">P5Y</clnn:ExclusiveRightsIntellectualPropertyTerm>
    <us-gaap:Revenues
      contextRef="c322"
      id="hidden-fact-295"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c324"
      id="hidden-fact-296"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c326"
      id="hidden-fact-297"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c328"
      id="hidden-fact-298"
      unitRef="usd"
      xsi:nil="true"/>
    <clnn:TotalPropertyAndEquipmentNet
      contextRef="c330"
      decimals="-3"
      id="hidden-fact-299"
      unitRef="usd">4038000</clnn:TotalPropertyAndEquipmentNet>
    <dei:AmendmentFlag contextRef="c0">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="c0">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="c0">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c0">0001822791</dei:EntityCentralIndexKey>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#ix_9_fact"
          xlink:label="ix_9_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_7_fact"
          xlink:label="ix_7_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_11_fact"
          xlink:label="ix_11_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_4_fact"
          xlink:label="ix_4_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_8_fact"
          xlink:label="ix_8_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_10_fact"
          xlink:label="ix_10_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_2_fact"
          xlink:label="ix_2_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_0_fact"
          xlink:label="ix_0_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_6_fact"
          xlink:label="ix_6_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_1_fact"
          xlink:label="ix_1_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_5_fact"
          xlink:label="ix_5_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_15_fact"
          xlink:label="ix_15_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_13_fact"
          xlink:label="ix_13_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_14_fact"
          xlink:label="ix_14_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_3_fact"
          xlink:label="ix_3_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_12_fact"
          xlink:label="ix_12_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retroactively restated for the three and nine months ended September 30, 2020 for the Reverse Recapitalization as described in Note 3</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_9_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_7_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_11_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_4_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_8_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_10_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_2_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_6_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_1_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_5_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_15_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_13_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_14_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_3_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_12_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_25_fact"
          xlink:label="ix_25_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_24_fact"
          xlink:label="ix_24_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_34_fact"
          xlink:label="ix_34_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_29_fact"
          xlink:label="ix_29_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-151"
          xlink:label="hidden-fact-151"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-148"
          xlink:label="hidden-fact-148"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-154"
          xlink:label="hidden-fact-154"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_48_fact"
          xlink:label="ix_48_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_41_fact"
          xlink:label="ix_41_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-140"
          xlink:label="hidden-fact-140"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-146"
          xlink:label="hidden-fact-146"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_33_fact"
          xlink:label="ix_33_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_54_fact"
          xlink:label="ix_54_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_37_fact"
          xlink:label="ix_37_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-142"
          xlink:label="hidden-fact-142"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_44_fact"
          xlink:label="ix_44_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_39_fact"
          xlink:label="ix_39_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_27_fact"
          xlink:label="ix_27_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_17_fact"
          xlink:label="ix_17_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-149"
          xlink:label="hidden-fact-149"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_26_fact"
          xlink:label="ix_26_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-147"
          xlink:label="hidden-fact-147"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_23_fact"
          xlink:label="ix_23_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_32_fact"
          xlink:label="ix_32_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_49_fact"
          xlink:label="ix_49_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-144"
          xlink:label="hidden-fact-144"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_52_fact"
          xlink:label="ix_52_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_16_fact"
          xlink:label="ix_16_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_40_fact"
          xlink:label="ix_40_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_43_fact"
          xlink:label="ix_43_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_53_fact"
          xlink:label="ix_53_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_35_fact"
          xlink:label="ix_35_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_46_fact"
          xlink:label="ix_46_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_30_fact"
          xlink:label="ix_30_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-150"
          xlink:label="hidden-fact-150"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_42_fact"
          xlink:label="ix_42_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-152"
          xlink:label="hidden-fact-152"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_20_fact"
          xlink:label="ix_20_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_36_fact"
          xlink:label="ix_36_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-143"
          xlink:label="hidden-fact-143"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-153"
          xlink:label="hidden-fact-153"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_47_fact"
          xlink:label="ix_47_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-145"
          xlink:label="hidden-fact-145"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_50_fact"
          xlink:label="ix_50_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_18_fact"
          xlink:label="ix_18_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_38_fact"
          xlink:label="ix_38_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-155"
          xlink:label="hidden-fact-155"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-141"
          xlink:label="hidden-fact-141"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_31_fact"
          xlink:label="ix_31_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_51_fact"
          xlink:label="ix_51_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_22_fact"
          xlink:label="ix_22_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_45_fact"
          xlink:label="ix_45_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_21_fact"
          xlink:label="ix_21_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_19_fact"
          xlink:label="ix_19_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_28_fact"
          xlink:label="ix_28_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-156"
          xlink:label="hidden-fact-156"
          xlink:type="locator"/>
        <link:footnote id="ix_1_footnote" xlink:label="ix_1_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retroactively restated for the Reverse Recapitalization as described in Note 3</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_25_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_24_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_34_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_29_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-151"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-148"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-154"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_48_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_41_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-140"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-146"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_33_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_54_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_37_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-142"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_44_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_39_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_27_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_17_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-149"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_26_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-147"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_23_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_32_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_49_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-144"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_52_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_16_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_40_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_43_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_53_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_35_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_46_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_30_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-150"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_42_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-152"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_20_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_36_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-143"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-153"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_47_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-145"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_50_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_18_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_38_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-155"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-141"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_31_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_51_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_22_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_45_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_21_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_19_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_28_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-156"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724067870024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Nov. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Clene Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CLNN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,203,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001822791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">01-39834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">85-2828339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">6550 South Millrock Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite G50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Salt Lake City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(801)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">676-9695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724066945240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 60,552<span></span>
</td>
<td class="nump">$ 59,275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,732<span></span>
</td>
<td class="nump">3,502<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">65,393<span></span>
</td>
<td class="nump">62,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">58<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">3,340<span></span>
</td>
<td class="nump">1,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,246<span></span>
</td>
<td class="nump">4,225<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">73,037<span></span>
</td>
<td class="nump">68,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,023<span></span>
</td>
<td class="nump">1,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">3,117<span></span>
</td>
<td class="nump">3,960<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income tax payable</a></td>
<td class="nump">164<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue from related parties</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease obligations, current portion</a></td>
<td class="nump">262<span></span>
</td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease obligations, current portion</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Clene Nanomedicine contingent earn-out, current portion</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,924<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">4,831<span></span>
</td>
<td class="nump">11,668<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease obligations, net of current portion</a></td>
<td class="nump">4,068<span></span>
</td>
<td class="nump">1,785<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease obligations, net of current portion</a></td>
<td class="nump">125<span></span>
</td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible notes payable</a></td>
<td class="nump">4,559<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable</a></td>
<td class="nump">14,613<span></span>
</td>
<td class="nump">1,949<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income tax</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_WarrantLiabilityNoncurrent', window );">Warrant liability</a></td>
<td class="nump">910<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Clene Nanomedicine contingent earn-out, net of current portion</a></td>
<td class="nump">33,981<span></span>
</td>
<td class="nump">46,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_InitialShareholdersContingentEarnout', window );">Initial Shareholders contingent earn-out</a></td>
<td class="nump">4,196<span></span>
</td>
<td class="nump">5,906<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">67,351<span></span>
</td>
<td class="nump">67,902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 13)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value: 150,000,000 and 100,000,000 shares authorized at September 30, 2021 and December 31, 2020, respectively; 62,177,020 and 59,526,171 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">173,203<span></span>
</td>
<td class="nump">153,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(167,724)<span></span>
</td>
<td class="num">(153,561)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">201<span></span>
</td>
<td class="nump">325<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">5,686<span></span>
</td>
<td class="nump">341<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">$ 73,037<span></span>
</td>
<td class="nump">$ 68,243<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_InitialShareholdersContingentEarnout">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial Shareholders contingent earn-out.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_InitialShareholdersContingentEarnout</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_WarrantLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>WarrantLiabilityNoncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_WarrantLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724060421288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">62,177,020<span></span>
</td>
<td class="nump">59,526,171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">62,177,020<span></span>
</td>
<td class="nump">59,526,171<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724061757320">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 110<span></span>
</td>
<td class="nump">$ 98<span></span>
</td>
<td class="nump">$ 524<span></span>
</td>
<td class="nump">$ 177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">812<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,146<span></span>
</td>
<td class="nump">3,994<span></span>
</td>
<td class="nump">18,893<span></span>
</td>
<td class="nump">10,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,400<span></span>
</td>
<td class="nump">1,795<span></span>
</td>
<td class="nump">16,739<span></span>
</td>
<td class="nump">3,623<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,560<span></span>
</td>
<td class="nump">5,789<span></span>
</td>
<td class="nump">36,444<span></span>
</td>
<td class="nump">14,431<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(10,450)<span></span>
</td>
<td class="num">(5,691)<span></span>
</td>
<td class="num">(35,920)<span></span>
</td>
<td class="num">(14,254)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense), net:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_InterestIncomeexpense', window );">Interest income (expense)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">80<span></span>
</td>
<td class="num">(367)<span></span>
</td>
<td class="num">(497)<span></span>
</td>
<td class="num">(608)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_GainOnExtinguishmentOfNotesPayable', window );">Gain on extinguishment of notes payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">647<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_LossOnExtinguishmentOfConvertibleNotesPayable', window );">Loss on extinguishment of convertible notes payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="num">(540)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(540)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnContractTermination', window );">Gain on termination of lease</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ChangeInFairValueOfPreferredStockWarrantLiability', window );">Change in fair value of preferred stock warrant liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="num">(5,071)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,378)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ChangeInFairValueOfDerivativeLiability', window );">Change in fair value of derivative liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ChangeInFairValueOfContingentEarnout', window );">Change in fair value of Clene Nanomedicine contingent earn-out</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">35,042<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">18,072<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout', window );">Change in fair value of Initial Shareholders contingent earn-out</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,439<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,710<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ChangeInFairValueOfCommonStockWarrantLiability', window );">Change in fair value of common stock warrant liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">414<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">547<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_AustraliaResearchAndDevelopmentCredit', window );">Australia research and development credit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">364<span></span>
</td>
<td class="nump">1,343<span></span>
</td>
<td class="nump">1,078<span></span>
</td>
<td class="nump">2,611<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(14)<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">39,325<span></span>
</td>
<td class="num">(4,604)<span></span>
</td>
<td class="nump">21,544<span></span>
</td>
<td class="num">(5,801)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net income (loss) before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">28,875<span></span>
</td>
<td class="num">(10,295)<span></span>
</td>
<td class="num">(14,376)<span></span>
</td>
<td class="num">(20,055)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">69<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">213<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">28,944<span></span>
</td>
<td class="num">(10,295)<span></span>
</td>
<td class="num">(14,163)<span></span>
</td>
<td class="num">(20,055)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(87)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="num">(124)<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Total other comprehensive income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(87)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="num">(124)<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 28,857<span></span>
</td>
<td class="num">$ (10,293)<span></span>
</td>
<td class="num">$ (14,287)<span></span>
</td>
<td class="num">$ (20,037)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NetIncomeLossPerCommonShareAttributableToCommonShareholdersNote191Abstract', window );"><strong>Net income (loss) per common share attributable to common shareholders (Note 19)(1):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 0.47<span></span>
</td>
<td class="num">$ (0.59)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (1.16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 0.42<span></span>
</td>
<td class="num">$ (0.59)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (1.16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_WeightedAverageNumberOfCommonSharesOutstanding1Abstract', window );"><strong>Weighted average number of common shares outstanding(1):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">62,071,754<span></span>
</td>
<td class="nump">17,358,159<span></span>
</td>
<td class="nump">61,307,699<span></span>
</td>
<td class="nump">17,358,159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">70,038,634<span></span>
</td>
<td class="nump">17,358,159<span></span>
</td>
<td class="nump">61,307,699<span></span>
</td>
<td class="nump">17,358,159<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 47<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 124<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retroactively restated for the three and nine months ended September 30, 2020 for the Reverse Recapitalization as described in Note 3</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_AustraliaResearchAndDevelopmentCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_AustraliaResearchAndDevelopmentCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ChangeInFairValueOfCommonStockWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of common stock warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ChangeInFairValueOfCommonStockWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ChangeInFairValueOfContingentEarnout">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the period ended Change in fair value of contingent earn-out.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ChangeInFairValueOfContingentEarnout</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ChangeInFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ChangeInFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of Initial Shareholders contingent earn-out

..</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ChangeInFairValueOfPreferredStockWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ChangeInFairValueOfPreferredStockWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_GainOnExtinguishmentOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain on extinguishment of notes payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_GainOnExtinguishmentOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_InterestIncomeexpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_InterestIncomeexpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_LossOnExtinguishmentOfConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss on extinguishment of convertible notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_LossOnExtinguishmentOfConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_NetIncomeLossPerCommonShareAttributableToCommonShareholdersNote191Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_NetIncomeLossPerCommonShareAttributableToCommonShareholdersNote191Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_WeightedAverageNumberOfCommonSharesOutstanding1Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_WeightedAverageNumberOfCommonSharesOutstanding1Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e39076-109324<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724060648680">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements Of Stockholders' Equity (Deficit) (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Redeemable Convertible Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 72,661<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 1,754<span></span>
</td>
<td class="num">$ (69,571)<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="num">$ (67,774)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in Shares) at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">27,499,837<span></span>
</td>
<td class="nump">17,357,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">171<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ForeignCurrencyTranslationAdjustment', window );">Foreign currency translation adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,941)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,941)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 72,661<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">1,925<span></span>
</td>
<td class="num">(73,512)<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="num">(71,538)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">27,499,837<span></span>
</td>
<td class="nump">17,357,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">174<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ForeignCurrencyTranslationAdjustment', window );">Foreign currency translation adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,819)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,819)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 72,661<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">2,099<span></span>
</td>
<td class="num">(79,331)<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="num">(77,173)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">27,499,837<span></span>
</td>
<td class="nump">17,357,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_StockIssuedDuringPeriodOfSeriesDPreferredStock', window );">Issuance of Series D Preferred Stock, net of issuance costs of $1.3 million</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 35,051<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_StockIssuedDuringPeriodSharesSeriesDPreferredStock', window );">Issuance of Series D Preferred Stock, net of issuance costs of $1.3 million (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">7,896,922<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Issuance of Series D Preferred Stock in connection with the extinguishment of convertible promissory notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 6,891<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Issuance of Series D Preferred Stock in connection with the extinguishment of convertible promissory notes (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,497,135<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">209<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ForeignCurrencyTranslationAdjustment', window );">Foreign currency translation adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,295)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,295)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 114,603<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">2,310<span></span>
</td>
<td class="num">(89,626)<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="num">(87,255)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">36,893,894<span></span>
</td>
<td class="nump">17,360,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">153,571<span></span>
</td>
<td class="num">(153,561)<span></span>
</td>
<td class="nump">325<span></span>
</td>
<td class="nump">341<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in Shares) at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">59,526,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">48,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,265<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ForeignCurrencyTranslationAdjustment', window );">Foreign currency translation adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(39,756)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(39,756)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">156,886<span></span>
</td>
<td class="num">(193,317)<span></span>
</td>
<td class="nump">349<span></span>
</td>
<td class="num">(36,076)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">59,574,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock upon the private offering</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">9,250<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">9,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon the private offering (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">960,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">124,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock upon vesting of restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock upon vesting of restricted stock awards (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">21,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,255<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ForeignCurrencyTranslationAdjustment', window );">Foreign currency translation adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(61)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,351)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,351)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">170,449<span></span>
</td>
<td class="num">(196,668)<span></span>
</td>
<td class="nump">288<span></span>
</td>
<td class="num">(25,925)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">60,681,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">319<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">236,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_StockIssuedDuringPeriodValueExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_StockIssueDuringPeriodSharesExerciseOfWarrants', window );">Exercise of warrants (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,002,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_StockIssuedDuringPeriodExerciseOfUnderwritersOption', window );">Exercise of underwriter&#8217;s option</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_StockIssuedDuringPeriodExerciseOfUnderwritersOptioninShares', window );">Exercise of underwriter&#8217;s option (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">54,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock upon vesting of restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock upon vesting of restricted stock awards (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">202,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,425<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ForeignCurrencyTranslationAdjustment', window );">Foreign currency translation adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(87)<span></span>
</td>
<td class="num">(87)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">28,944<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">28,944<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 173,203<span></span>
</td>
<td class="num">$ (167,724)<span></span>
</td>
<td class="nump">$ 201<span></span>
</td>
<td class="nump">$ 5,686<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,177,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retroactively restated for the Reverse Recapitalization as described in Note 3</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ForeignCurrencyTranslationAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ForeignCurrencyTranslationAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_StockIssueDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_StockIssueDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_StockIssuedDuringPeriodExerciseOfUnderwritersOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise of underwriter&#8217;s option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_StockIssuedDuringPeriodExerciseOfUnderwritersOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_StockIssuedDuringPeriodExerciseOfUnderwritersOptioninShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise of underwriter&#8217;s option in shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_StockIssuedDuringPeriodExerciseOfUnderwritersOptioninShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_StockIssuedDuringPeriodOfSeriesDPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of Series D Preferred Stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_StockIssuedDuringPeriodOfSeriesDPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_StockIssuedDuringPeriodSharesSeriesDPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of Series D Preferred Stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_StockIssuedDuringPeriodSharesSeriesDPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_StockIssuedDuringPeriodValueExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_StockIssuedDuringPeriodValueExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724148287864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements Of Stockholders' Equity (Deficit) (Unaudited) (Parentheticals)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NetOfIssuanceCosts', window );">Net of issuance costs</a></td>
<td class="nump">$ 1,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_NetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_NetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724067218024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (14,163)<span></span>
</td>
<td class="num">$ (20,055)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldDepreciation', window );">Depreciation</a></td>
<td class="nump">734<span></span>
</td>
<td class="nump">696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Non-cash lease expense</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of preferred stock warrant liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">7,378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ChangeInFairValueOfCleneNanomedicineContingentEarnouts', window );">Change in fair value of Clene Nanomedicine contingent earn-out</a></td>
<td class="num">(18,072)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ChangesInFairValueOfInitialShareholdersContingentEarnout', window );">Change in fair value of Initial Shareholders contingent earn-out</a></td>
<td class="num">(1,710)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Change in fair value of derivative</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ChangeInFairValueOfCommonStockWarrantLiabilitys', window );">Change in fair value of common stock warrant liability</a></td>
<td class="num">(547)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Gain on termination of lease</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">9,945<span></span>
</td>
<td class="nump">554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of notes payable</a></td>
<td class="num">(647)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfIntangibleAssets', window );">Loss on extinguishment of convertible notes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Accretion of debt discount</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_IncreaseInInterestAccruedOnNotesPayable', window );">Increase (decrease) in interest accrued on notes payable</a></td>
<td class="num">(134)<span></span>
</td>
<td class="nump">399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">150<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(48)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,230)<span></span>
</td>
<td class="num">(2,112)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">446<span></span>
</td>
<td class="num">(242)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">511<span></span>
</td>
<td class="num">(335)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedParties', window );">Payable to related parties</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(131)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Deferred revenue from related parties</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred income tax</a></td>
<td class="num">(192)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease obligations</a></td>
<td class="num">(142)<span></span>
</td>
<td class="num">(58)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(25,018)<span></span>
</td>
<td class="num">(13,121)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(661)<span></span>
</td>
<td class="num">(269)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(661)<span></span>
</td>
<td class="num">(269)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">427<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">6,125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrants exercised</a></td>
<td class="nump">10<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments of finance lease obligations</a></td>
<td class="num">(117)<span></span>
</td>
<td class="num">(156)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from the private placement</a></td>
<td class="nump">9,250<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherDebt', window );">Proceeds from the issuance of notes payable</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="num">(534)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payments of notes payable</a></td>
<td class="num">(5)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payments of deferred transaction costs</a></td>
<td class="num">(1,901)<span></span>
</td>
<td class="num">(310)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of Series D Preferred Stock, net of issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">35,051<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">27,130<span></span>
</td>
<td class="nump">41,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of foreign exchange rate changes on cash</a></td>
<td class="num">(116)<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and restricted cash</a></td>
<td class="nump">1,335<span></span>
</td>
<td class="nump">27,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and restricted cash &#8211; beginning of period</a></td>
<td class="nump">59,275<span></span>
</td>
<td class="nump">8,788<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and restricted cash &#8211; end of period</a></td>
<td class="nump">60,610<span></span>
</td>
<td class="nump">36,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract', window );"><strong>Reconciliation of cash and restricted cash to the condensed consolidated balance sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">60,552<span></span>
</td>
<td class="nump">36,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">58<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and restricted cash</a></td>
<td class="nump">60,610<span></span>
</td>
<td class="nump">36,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_WarrantLiabilityRecordedAtIssuanceOfNotesPayable', window );">Warrant liability recorded at issuance of notes payable</a></td>
<td class="nump">1,457<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Lease liability arising from obtaining right-of-use assets, leasehold improvements, and lease incentives</a></td>
<td class="nump">2,492<span></span>
</td>
<td class="nump">820<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_LeaseLiabilitySettledThroughTerminationOfLease', window );">Lease liability settled through termination of lease</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Issuance of derivative instrument related to convertible notes</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(705)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes', window );">Issuance of Series D Preferred Stock upon extinguishment of convertible promissory notes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN', window );">Extinguishment of derivative liability in connection with extinguishment of convertible promissory notes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_DeferredOfferingCostsInAccruedLiabilities', window );">Deferred offering costs in accrued liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CashPaidForInterestExpense', window );">Cash paid for interest expense</a></td>
<td class="nump">$ 631<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CashPaidForInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CashPaidForInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ChangeInFairValueOfCleneNanomedicineContingentEarnouts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the period ended Change in fair value of contingent earn-out.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ChangeInFairValueOfCleneNanomedicineContingentEarnouts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ChangeInFairValueOfCommonStockWarrantLiabilitys">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of common stock warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ChangeInFairValueOfCommonStockWarrantLiabilitys</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ChangesInFairValueOfInitialShareholdersContingentEarnout">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of Initial Shareholders contingent earn-out.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ChangesInFairValueOfInitialShareholdersContingentEarnout</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_DeferredOfferingCostsInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred offering costs in accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_DeferredOfferingCostsInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Extinguishment of derivative liability in connection with extinguishment of convertible promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_IncreaseInInterestAccruedOnNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase in interest accrued on notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_IncreaseInInterestAccruedOnNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of Series D Preferred Stock upon extinguishment of convertible promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_LeaseLiabilitySettledThroughTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease liability settled through termination of lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_LeaseLiabilitySettledThroughTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_WarrantLiabilityRecordedAtIssuanceOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant liability recorded at issuance of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_WarrantLiabilityRecordedAtIssuanceOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of tangible asset over its useful life directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of lease before expiration of lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 40<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123386189&amp;loc=SL77918607-209975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724060313272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Nature of the Business</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. Nature of the Business</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clene Inc. (formerly Chelsea
Worldwide Inc.) (the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or similar such references) is a clinical-stage pharmaceutical
company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. We have developed
an electro-crystal-chemistry drug development platform which enables production of concentrated, stable, highly active, clean-surfaced
nanocrystal suspensions. We have multiple drug assets currently in development for applications in neurology, infectious disease, and
oncology. Our efforts are currently focused on addressing the high unmet medical needs in two areas: first, those related to central nervous
system disorders including Multiple Sclerosis (&#8220;MS&#8221;), Parkinson&#8217;s Disease (&#8220;PD&#8221;) and Amyotrophic Lateral
Sclerosis (&#8220;ALS&#8221;); and second, those related to COVID-19, a highly infectious viral respiratory disease with serious and sometimes
fatal co-morbidities. Our patented electro-crystal-chemistry manufacturing platform further enables us to develop very low concentration
dietary supplements to advance the health and well-being of broad populations. These dietary supplements can vary greatly and include
nanocrystals of varying composition, shapes and sizes as well as ionic solutions with diverse metallic constituents. Dietary supplements
are marketed and distributed through our wholly owned subsidiary, dOrbital, Inc. (&#8220;dOrbital&#8221;), or through an exclusive license
with 4Life Research LLC (&#8220;4Life&#8221;), a related party (see Note 20).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying condensed
consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Clene Nanomedicine, Inc. (&#8220;Clene
Nanomedicine&#8221;), a subsidiary incorporated in Delaware, Clene Australia Pty Ltd (&#8220;Clene Australia&#8221;), a subsidiary incorporated
in Australia, and dOrbital, Inc., a subsidiary incorporated in Delaware, after elimination of all intercompany accounts and transactions.
The wholly-owned subsidiary, Clene Netherlands B.V. (&#8220;Clene Netherlands&#8221;) was established on April 21, 2021 and has no financial
positions or operations to date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Registration Statements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 16, 2021, we filed
a registration statement on Form S-1 (file number 333-253173) to register 4,541,481 shares of Clene Inc. common stock (&#8220;Common Stock&#8221;)
underlying outstanding warrants that we have previously issued, among which 2,517,500 warrants (the &#8220;Public Warrants&#8221;) and
904,231 warrants (the &#8220;Kensington Warrants&#8221;) were originally issued by Tottenham Acquisition I Limited (&#8220;Tottenham&#8221;)
and Clene Nanomedicine, respectively, prior to the closing of the Reverse Recapitalization, and 2,239,500 warrants (the &#8220;December
2020 PIPE Warrants&#8221;) were issued as part of a private placement (the &#8220;December 2020 PIPE&#8221;) in connection with the closing
of the Reverse Recapitalization. We will receive aggregate proceeds of $30.7 million if all of these warrants are exercised. On April
19, 2021, the registration statement was declared effective by the Securities and Exchange Commission (the &#8220;SEC&#8221;). In connection
with the registration statement on Form S-1, we incurred $0 and $27 thousand of certain offering costs during the three and nine months
ended September 30, 2021, respectively, recognized as an expense within general and administrative expenses in the condensed consolidated
statement of operations and comprehensive income (loss) during the three and nine months ended September 30, 2021. As of September 30,
2021, the Company received aggregate proceeds of $10.0 thousand from the exercise of certain warrants, representing 2,004,500 December
2020 PIPE Warrants at an offering price per share of $0.01.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On July 22, 2021, we
filed a registration statement on Form S-1 (file number 333-258098) to register 1,140,731 shares of Common Stock underlying
outstanding warrants that we have previously issued, among which 1,024,880 warrants (the &#8220;AK Warrants&#8221;, and collectively
with the Kensington Warrants, the &#8220;Founder Warrants&#8221;) were originally issued by Clene Nanomedicine prior to the Reverse
Recapitalization in April 2013 and 115,851 warrants (the &#8220;Avenue Warrants&#8221;) were issued pursuant to a loan agreement
(the &#8220;2021 Avenue Loan&#8221;) with Avenue Venture Opportunities Fund, L.P. (&#8220;Avenue&#8221;) (see Note 8). We will
receive aggregate proceeds of $3.0 million if all of these warrants are exercised. In addition, the registration statement on Form
S-1 registered 960,540 shares of Common Stock, issued in a private placement in May 2021 (the &#8220;May 2021 PIPE&#8221;). We will
not receive any proceeds from the possible sale of these shares by the selling shareholders. On August 2, 2021, the registration
statement was declared effective by the SEC. In connection with the registration statement on Form S-1, we incurred an immaterial
amount of certain offering costs, which were recognized as an expense within general and administrative expenses in the condensed
consolidated statements of operations and comprehensive income (loss) during the three and nine months ended September 30, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Liquidity</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have incurred significant losses and negative cash flows from operations
since our inception. We incurred a net loss of $14.2 million for the nine months ended September 30, 2021. We incurred net losses of $10.3
million and $20.1 million for the three and nine months ended September 30, 2020, respectively. As of September 30, 2021, our cash totaled
$60.6 million, and our accumulated deficit was $167.7 million. As of December 31, 2020, our cash totaled $59.3 million, and our accumulated
deficit was $153.6 million. We had net cash used in operating activities of $25.0 million and $13.1 million for the nine months ended
September 30, 2021 and 2020, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the Reverse Recapitalization,
Clene Nanomedicine&#8217;s operations were financed through the issuance of equity instruments and the issuance of convertible promissory
notes. Subsequent to the Reverse Recapitalization, we have obtained additional liquidity through a term loan and private placements of
equity instruments. We have not generated significant revenues to date and do not anticipate generating any significant revenues unless
we successfully complete development and obtain regulatory approval for our drugs or for our COVID-19 study. We expect to incur additional
losses in the future to fund our operations and conduct product research and development and we recognize the need to raise additional
capital to fully implement our business plan. Additionally, we may attempt to negotiate a collaboration agreement with a third party for
development and commercialization of a drug candidate, which may provide upfront and milestone payments to reduce our spending going forward.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to continue investing
in product development, sales and marketing and customer support for our products. The long-term continuation of our business plan is
dependent upon the generation of sufficient revenues from our products to offset expenses and capital expenditures. In the event that
we do not generate sufficient revenues and are unable to obtain funding, we will be forced to delay, reduce, or eliminate some or all
of our research and development programs, product portfolio expansion, commercialization efforts, or capital expenditures, which could
adversely affect our business prospects, ability to meet long-term liquidity needs, or we may be unable to continue operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that the cash on
hand as of September 30, 2021 will be sufficient to fund our operations for a period extending beyond twelve months from the date these
condensed consolidated financial statements for the three and nine months ended September 30, 2021 were issued.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Impact of the COVID-19 Pandemic</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The COVID-19 pandemic, which
began in December&#160;2019 and has spread worldwide, has caused many governments to implement measures to slow the spread of the outbreak.
The outbreak and government measures taken in response have had a significant impact, both direct and indirect, on businesses and commerce,
as worker shortages have occurred, supply chains have been disrupted, and facilities and production have been suspended. The future progression
of the pandemic and its effects on our business and operations remains uncertain. The COVID-19 pandemic may affect our ability to initiate
and complete preclinical studies, delay the initiation of future clinical trials, disrupt regulatory activities, or have other adverse
effects on our business and operations. In particular, the Company and our clinical research organizations (&#8220;CROs&#8221;) may face
disruptions that may affect our ability to initiate and complete preclinical studies, manufacturing disruptions, and delays at clinical
trial sites. The pandemic has already caused significant disruptions in the financial markets, and may continue to cause such disruptions,
which could impact our ability to raise additional funds to support our operations. Moreover, the pandemic has significantly impacted
economies worldwide and could result in adverse effects on our business and operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are monitoring the potential
impact of the COVID-19 pandemic on our business and financial statements. While the COVID-19 pandemic has led to various research restrictions
and paused certain of our clinical trials, these impacts have been temporary and to date we have not experienced material business disruptions
or incurred impairment losses in the carrying values of our assets as a result of the pandemic and we are not aware of any specific related
event or circumstance that would require us to revise the estimates reflected in these condensed consolidated financial statements. The
extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations, cash flows, and financial
condition, including planned and future clinical trials and research and development costs, will depend on future developments that are
highly uncertain, including as a result of new information that may emerge concerning COVID-19, the actions taken to contain or treat
it, and the duration and intensity of the related effects.&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724150514136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>2. Summary of Significant Accounting Policies</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Basis of Presentation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have prepared the accompanying
condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States of America
(&#8220;GAAP&#8221;) for interim financial reporting and as required by Regulation S-X, Rule 10-01. The condensed consolidated financial
statements have been prepared on the same basis as our audited annual consolidated financial statements and, in the opinion of management,
reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of our financial condition as
of September 30, 2021, the results of our operations for the three and nine months ended September 30, 2021, our cash flows for the nine
months ended September 30, 2021 and 2020, and the condensed consolidated statement of stockholders&#8217; equity (deficit) for the three
and nine months ended September 30, 2021 and 2020. The financial data and other information disclosed in these notes related to the three
and nine months ended September 30, 2021 and 2020 are unaudited. The results of operations for the three and nine months ended September
30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021, any other interim periods,
or any future year or period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior period balances for
accounts receivable have been reclassified to conform to the current year presentation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of condensed
consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets, liabilities, and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial
statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying
condensed consolidated financial statements include, but are not limited to, the valuation of common stock, stock options, contingent
earn-out liabilities, Preferred Stock warrants, and Common Stock warrants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We base our estimates on historical
experience and on various other assumptions that are believed to be reasonable. Actual results may differ from those estimates or assumptions.
Estimates are periodically reviewed in light of changes in circumstances, facts, and experience. Changes in estimates will be recorded
in future periods as they develop.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Risks and Uncertainties</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The product candidates we
develop require approvals from the U.S. Food and Drug Administration or foreign regulatory agencies prior to commercial sales. There can
be no assurance that our current and future product candidates will receive the necessary approvals or be commercially successful. If
we are denied approval or approval is delayed, it will have a material adverse impact on our business and our condensed consolidated financial
statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to risks common
to companies in the development stage including, but not limited to, dependency on the need for substantial additional financing to achieve
our goals, uncertainty of broad adoption of our approved products, if any, by physicians and patients, significant competition, and untested
manufacturing capabilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to certain
risks and uncertainties and believe that changes in any of the following areas could have a material adverse effect on future financial
condition or results of operations: ability to obtain additional financing; regulatory approval and market acceptance of, and reimbursement
for, product candidates; performance of third-party CROs and manufacturers upon which we rely; protection of our intellectual property;
litigation or claims against us based on intellectual property, patent, product, regulatory, or other factors; and our ability to attract
and retain employees necessary to support our growth.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Concentrations of Credit Risk</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial instruments which
potentially subject us to significant concentrations of credit risk consist primarily of cash. Our cash is mainly held in financial institutions.
Amounts on deposit may at times exceed federally insured limits. We have not experienced any losses on our deposits of cash and do not
believe that we are subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cash and Cash Equivalents</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We consider all short-term
investments with an original maturity of three months or less when purchased to be cash equivalents. As of September 30, 2021 and December
31, 2020, we had no cash equivalents.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Restricted Cash</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We classify cash as restricted when it is unavailable for withdrawal
or use in our general operating activities. Restricted cash and investments are classified as current and noncurrent on the consolidated
balance sheets based on the nature of the restriction. Our restricted cash balance includes contractually restricted deposits related
to our corporate credit card. As of September 30, 2021 and December 31, 2020, we had restricted cash of $0.1 million and $0, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Accounts Receivable</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Accounts receivable are stated
at invoice value less estimated allowances for sales returns and doubtful accounts. We estimate the allowance for sales returns based
on historical percentage of returns over a 12-month trailing average of sales. We continually monitor customer payments and maintain a
reserve for estimated losses resulting from our customers&#8217; inability to make required payments. We consider factors when estimating
the allowance for doubtful accounts such as historical experience, age of the accounts receivable balances, geographic related risks,
and economic conditions that may affect a customer&#8217;s ability to pay. In cases where there are circumstances that may impair a specific
customer&#8217;s ability to meet its financial obligations, a specific allowance is recorded against amounts due, thereby reducing the
net recognized receivable to the amount reasonably believed to be collectible. Accounts receivable are written off when deemed uncollectible.
Recoveries of accounts receivable previously written off are recorded when received. Historically, there have been no sales returns, no
written-off accounts receivable, and no allowance for doubtful accounts reducing the balance of the accounts receivable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Inventory</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Inventory is stated at historic
cost on a first-in first-out basis. Our inventory consisted of $26 thousand in raw materials and $14 thousand in finished goods as of
September 30, 2021. Our inventory consisted of $0.1 million in raw material and $0.1 million in finished goods as of December 31, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Debt Discounts, Debt Premiums, and Debt
Issuance Costs</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">When debt is issued and a
derivative is required to be bifurcated (e.g., bifurcated conversion option) or another separate freestanding financial instrument (e.g.,
warrant) is issued, costs and fees incurred are allocated to the instruments issued (or bifurcated) in proportion to the allocation of
proceeds. When some portions of the costs and fees relate to a bifurcated derivative or freestanding financial instrument that is being
subsequently measured at fair value, those allocated costs are expensed immediately. Debt discounts, debt premiums, and debt issuance
costs related to convertible loans are recorded as deductions that net against the principal value of the debt and are amortized to interest
expense over the contractual term of the debt using the effective interest method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Deferred Offering Costs</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We capitalize certain legal,
professional accounting. and other third-party fees that are directly associated with in-process equity financings, including the Reverse
Recapitalization and the December 2020 PIPE, as deferred offering costs until such financings are consummated. After consummation of the
equity financing, these costs are recorded in stockholders&#8217; equity (deficit) as a reduction of proceeds generated as a result of
the offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge
to operating expenses in the condensed consolidated statements of operations and comprehensive income (loss).&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the three and nine
months ended September 30, 2021, we did not incur any offering costs.&#160;During the three and nine months ended September 30, 2020,
we incurred $2.3 million of deferred offering costs related to the Reverse Recapitalization that were comprised of legal and professional
accounting fees and other costs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Leases</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At inception of a contract,
we determine if a contract meets the definition of a lease. A lease is a contract, or part of a contract, that conveys the right to control
the use of identified property, plant, or equipment for a period of time in exchange for consideration. We determine if the contract conveys
the right to control the use of an identified asset for a period of time. We assess throughout the period of use whether we have both
of the following: (i)&#160;the right to obtain substantially all of the economic benefits from use of the identified asset, and (ii)&#160;the
right to direct the use of the identified asset. This determination is reassessed if the terms of the contract are changed. Leases are
classified as operating or finance leases based on the terms of the lease agreement and certain characteristics of the identified asset.
Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of the future lease
payments less any lease incentives received. At the lease commencement date, the discount rate implicit in the lease is used to discount
the lease liability if readily determinable. If not readily determinable or leases do not contain an implicit rate, our incremental borrowing
rate is used as the discount rate.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We lease laboratory and office
space and certain equipment under non-cancellable operating and finance leases. The carrying value of our right-of-use lease assets is
substantially concentrated in our real estate leases, while the volume of lease agreements is primarily concentrated in equipment leases.
Our policy is to not record leases with an original term of twelve months or less within the condensed consolidated balance sheets. We
recognize lease expense for these short-term leases on a straight-line basis over the lease term in the condensed consolidated statements
of operations and comprehensive income (loss).&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain lease agreements may
require us to pay additional amounts for taxes, insurance, maintenance, and other expenses, which are generally referred to as non-lease
components. Such variable non-lease components are treated as variable lease payments and recognized in the period in which the obligation
for these payments is incurred. Variable lease components and variable non-lease components are not measured as part of the right-of-use
asset and liability. Only when lease components and their associated non-lease components are fixed are they accounted for as a single
lease component and are recognized as part of a right-of-use asset and liability. Total contract consideration is allocated to the combined
fixed lease and non-lease component. This policy election applies consistently to all asset classes under lease agreements.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Leases may contain clauses
for renewal at our option. Payments to be made in option periods are recognized as part of the right-of-use lease assets and lease liabilities
when it is reasonably certain that the option to extend the lease will be exercised, or is not at our option. We determine whether the
reasonably certain threshold is met by considering contract-, asset-, market-, and entity-based factors. In the condensed consolidated
statements of operations and comprehensive income (loss), operating lease expense, which is recognized on a straight-line basis over the
lease term, and the amortization of finance lease right-of-use assets, which are included in property and equipment and depreciated, are
included in research and development or general and administrative expenses consistent with the leased assets&#8217; primary use. Accretion
on the liabilities for finance leases is included in interest expense.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Property and Equipment</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Property and equipment are
stated at cost less accumulated depreciation. Property and equipment consist of laboratory and office equipment and leasehold improvements.
Depreciation is calculated using the straight-line method over the estimated economic useful lives of the assets, which are 3-5&#160;years
for laboratory equipment and 3-7&#160;years for furniture and fixtures. Leasehold improvements are amortized over the lesser of the estimated
lease term or the estimated useful life of the assets. Costs for capital assets not yet placed into service are capitalized as construction
in progress and depreciated or amortized in accordance with the above useful lives once placed into service. Upon retirement or sale,
the related cost and accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included
in the condensed consolidated statements of operations and comprehensive income (loss). Maintenance and repairs that do not improve or
extend the lives of the respective assets are expensed to operations as incurred.&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Convertible Notes</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with ASU 2020-06,
<i>Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own
Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</i>, when we issue notes
with conversion features, we evaluate if the conversion features are freestanding or embedded. If the conversion feature is embedded,
we do not separate the conversion feature from the host contract for convertible notes that are not required to be accounted for as derivatives,
or that do not result in substantial premiums accounted for as paid-in-capital. Consequently, we account for a convertible note as a single
liability measured at its amortized cost, and we account for a convertible preferred stock as a single equity instrument measured at its
historical cost, as long as no other features require bifurcation and recognition as derivatives.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the conversion feature
is freestanding, or is embedded and meets the requirements to be bifurcated, we account for the conversion feature as a derivative under
ASC 815, <i>Derivatives and Hedging</i> (&#8220;ASC 815&#8221;). We record the derivative instrument at fair value at inception, and subsequently
re-measure to fair value at each reporting period and immediately prior to the extinguishment of the derivative instrument, with any changes
recorded in the condensed consolidated statements of operations and comprehensive income (loss).&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Debt With Warrants</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with ASC 470-20, <i>Debt with Conversion and Other Options</i>,
when we issue debt with warrants, we treat the warrants as a debt discount, recorded as a contra-liability against the debt, and amortize
the balance over the life of the underlying debt as amortization of debt discount expense in the condensed consolidated statements of
operations and comprehensive income (loss). The offset to the contra-liability is recorded as additional paid-in capital in the condensed
consolidated balance sheets if the warrants are not treated as a derivative or liability under ASC 480, <i>Distinguishing Liabilities
from Equity</i> (&#8220;ASC 480&#8221;). Otherwise, the offset to the contra-liability is recorded as a warrant liability in the condensed
consolidated balance sheets and is subject to re-measurement to fair value at each balance sheet date, with any changes in fair value
recognized in the condensed consolidated statements of operations and comprehensive income (loss). If the debt is retired early, the associated
debt discount is then recognized immediately as amortization of debt discount expense in the condensed consolidated statements of operations
and comprehensive income (loss).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Contingent Earn-Out Liabilities</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the Reverse
Recapitalization, certain shareholders are entitled to receive additional shares of Common Stock (the &#8220;Contingent Earn-outs&#8221;)
upon us achieving certain milestones (see Notes 3 and 12). In accordance with ASC 815, the Contingent Earn-outs are not indexed to our
own stock and therefore are accounted for as a liability at the Reverse Recapitalization date and subsequently remeasured at each reporting
date with changes in fair value recorded as a component of other income (expense), net in the condensed consolidated statements of operations
and comprehensive income (loss).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Common Stock Warrants</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We account for common stock
warrants as either equity-classified instruments or liability-classified instruments based on an assessment of the warrant terms and applicable
authoritative guidance in accordance with ASC 480 and ASC 815. The assessment considers whether the warrants are freestanding financial
instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements
for equity classification under ASC 815, including whether the warrants are indexed to our Common Stock, among other conditions for equity
classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and, for
liability-classified warrants, as of each subsequent quarterly period end date while the warrants are outstanding.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue Recognition</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under ASC 606, <i>Revenue
from Contracts with Customers</i> (&#8220;ASC 606&#8221;), an entity recognizes revenue when its customer obtains control of promised
goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services.
To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following
five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine
the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations
in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the five-step
model to contracts when it is probable that we will collect the consideration to which we are entitled in exchange for the goods or services
we transfer to the customer.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Once a contract is determined
to be within the scope of ASC 606 at contract inception, we review the contract to determine which performance obligations we must deliver,
and which performance obligations are distinct. We recognize as revenue the amount of the transaction price that is allocated to each
performance obligation when that performance obligation is satisfied or as it is satisfied. We typically satisfy our performance obligations
via delivery of dietary supplements to the customer. Payments are due upon receipt for commercial transactions, or a prepayment is collected
for online retail sales. Our revenue for the three and nine months ended September 30, 2021 and 2020 was comprised of sales of dietary
supplements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recorded deferred revenue of $0.1 and $0.1 million as of September
30, 2021 and December 31, 2020 from the dietary supply agreement with the related party (see Note 20).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Grant Funding</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may submit applications
to receive grant funding from governmental and non-governmental entities. Grant funding received that involves no conditions or continuing
performance obligations of the Company is recognized upon receipt. Grant funding with conditions or obligations of the Company is recognized
as the conditions or obligations are fulfilled. We have made an accounting policy election to record such unconditional grants, such as
the Australian Research and Development Credit, as other income in the condensed consolidated statements of operations and comprehensive
income (loss). Income from grants is recognized in the period during which the related qualifying expenses are incurred, provided that
the conditions under which the grants were provided have been met. We recognize the Australian Research and Development Credit in an amount
equal to the qualifying expenses incurred in each period multiplied by the applicable reimbursement percentage. During the three and nine
months ended September 30, 2021, we recognized $0.4 million and $1.1 million, respectively, of Australian Research and Development Credit
within other income (expense), net in the condensed consolidated statements of operations and comprehensive income (loss). During the
three and nine months ended September 30, 2020, we recognized $1.3 million and $2.6 million, respectively, of Australian Research and
Development Credit within other income (expense), net in the condensed consolidated statements of operations and comprehensive income
(loss). As of September 30, 2021, and December 31, 2020, we recorded $1.2 million and $2.1 million, respectively, of Australian Research
and Development Credit receivable in prepaid expenses and other current assets on the condensed consolidated balance sheets.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any amount received in advance
of fulfilling such conditions or obligations is recorded in accrued liabilities on the condensed consolidated balance sheets if the conditions
or obligations are expected to be met within the next twelve months. As of September 30, 2021 and December 31, 2020, we recorded $0.6
million and $0.3 million, respectively, of deferred grant funds received in advance in accrued liabilities.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Grant funding recognized on
conditional grants is included as a reduction in research and development expenses in the condensed consolidated statements of operations
and comprehensive income (loss) as the conditions are tied to our research and development efforts, and as the arrangement between us
and the organizations are not part of our ongoing, major, or central operations. During the three and nine months ended September 30,
2021, we recorded a grant of $0 and $0.2 million, respectively, as a reduction of research and development expenses in the condensed consolidated
statements of operations and comprehensive income (loss). During the three and nine months ended September 30, 2020, we recorded a grant
of $0.2 million and $0.7 million, respectively, as a reduction of research and development expenses in the condensed consolidated statements
of operations and comprehensive income (loss).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Fair Value of Financial Instruments</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain assets and liabilities
are carried at fair value under GAAP. Fair value is defined as the price that would be received for an asset or paid to transfer a liability
(an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants
on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use
of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following
three levels of the fair value hierarchy:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Level 1</b><i>&#8212;</i>Inputs
based upon quoted market prices for identical assets or liabilities in active markets at the measurement date.&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Level 2</b><i>&#8212;</i>Observable
inputs other than quoted market prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets;
quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can
be corroborated by observable market data.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Level 3</b><i>&#8212;</i>Inputs
that are management&#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date.
The inputs are unobservable in the market and significant to the instrument&#8217;s valuation.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We review the fair value hierarchy
classification of our applicable assets and liabilities on a quarterly basis. Changes in the observability of valuation inputs may result
in a reclassification for certain financial assets or liabilities. Reclassifications impacting all levels of the fair value hierarchy
are reported as transfers in or out of the Level 1, 2, or 3 categories as of the beginning of the quarter during which the reclassifications
occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Foreign Currency Translation and Transactions</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our functional currency is
the U.S. dollar. Our Australian subsidiary determined its functional currency to be the Australian dollar and our Netherlands subsidiary
determined its functional currency to be the Euro. We use the U.S. dollar as our reporting currency for the condensed consolidated financial
statements. The results of our non-U.S. dollar based functional currency operations are translated to U.S. dollars at the average exchange
rates during the period. Our assets and liabilities are translated using the current exchange rate as of the balance sheet date and shareholders&#8217;
equity is translated using historical rates.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Adjustments resulting from
the translation of the condensed consolidated financial statements of our foreign functional currency subsidiaries into U.S. dollars are
excluded from the determination of net loss and are accumulated in a separate component of shareholders&#8217; equity. These foreign currency
translation gains and losses are currently the only component of other comprehensive income (loss).&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also incur foreign exchange
transaction gains and losses for purchases denominated in foreign currencies. Foreign exchange transaction gains and losses are included
in other income (expense) in the condensed consolidated statements of operations and comprehensive income (loss) as incurred.&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Comprehensive Income (Loss</i></b>)</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Comprehensive income (loss)
includes net income (loss) as well as other changes in stockholders&#8217; equity (deficit) that result from transactions and economic
events other than those with stockholders. The only element of other comprehensive income (loss) in any period presented was translation
of Australian dollar denominated balances of our Australian subsidiary to U.S. dollars for consolidation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Net Income (Loss) Per Share Attributable
to Common Shareholders</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Basic net income (loss) per share attributable to common shareholders
is calculated using our weighted-average outstanding common shares. Diluted net income (loss) per share attributable to common shareholders
is calculated using our weighted-average outstanding common shares including the dilutive effect of securities as determined under the
treasury stock method, except for the dilutive effect of convertible notes payable, which is calculated under the if-converted method,
even if the embedded conversion option is out-of-the-money. In periods in which we report a net loss attributable to common shareholders,
diluted net loss per share attributable to common shareholders is the same as basic net loss per share attributable to common shareholders,
since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Segment Information</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have determined that our
chief executive officer is the chief operating decision maker (&#8220;CODM&#8221;). Operating segments are identified as components of
an enterprise about which separate discrete financial information is available for evaluation by the CODM in making decisions regarding
resource allocation and assessing performance. We view our operations and manage our business in two operating segments: (1) the development
and commercialization of proprietary nanotechnology drug suspensions (&#8220;Drugs&#8221;), and (2) the development and commercialization
of dietary supplements (&#8220;Supplements&#8221;). Our operating segment profit measure is segment loss from operations, which is calculated
as revenue less cost of revenue, research and development, and general and administrative expenses (see Note 21).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Income Taxes</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We account for income taxes
using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax
consequences of events that have been recognized in the condensed consolidated financial statements or in our tax returns. Deferred tax
assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities
using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities
are recorded in the provision for income taxes. We assess the likelihood that our deferred tax assets will be recovered from future taxable
income and, to the extent we believe, based upon the weight of available evidence, that it is more likely than not that all or a portion
of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential
for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible
tax planning strategies.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We account for uncertainty
in income taxes recognized in the condensed consolidated financial statements by applying a two-step process to determine the amount of
tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external
examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed
to determine the amount of benefit to recognize in the condensed consolidated financial statements. The amount of the benefit that may
be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for
income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well
as the related net interest and penalties.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock-Based Compensation</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We account for stock-based
compensation arrangements with employees using a fair value-based method for costs related to all share-based payments including stock
options and stock awards. Stock-based compensation expense is recorded in research and development and general and administrative expenses
based on the classification of the work performed by the grantees.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair value is recognized
over the period during which a grantee was required to provide services in exchange for the option award and service-based stock awards,
known as the requisite service period (usually the vesting period), on a straight-line basis. For stock awards with market conditions,
the fair value is recognized over the period based on the expected milestone achievement dates as the derived service period (usually
the vesting period), on a straight-line basis. For stock awards with performance conditions, the grant-date fair value of these awards
is the market price on the applicable grant date, and compensation expense will be recognized when the conditions become probable of
being satisfied. We will recognize a cumulative true-up adjustment once the conditions become probable of being satisfied as the related
service period had been completed in a prior period.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stock-based compensation expense
is recognized at fair value. We elect to account for forfeitures as they occur, rather than estimating expected forfeitures.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After the closing of the Reverse
Recapitalization, we determine the fair value of each share of Common Stock underlying stock-based awards based on the closing price of
our Common Stock as reported by the Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) on the date of grant. The fair value of stock awards
with market conditions are determined using a Monte Carlo valuation model.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development costs
are charged to expense as incurred. We account for nonrefundable advance payments for goods and services that will be used in future research
and development activities as expenses when the goods have been received or when the service has been performed. Research and development
expenses consist of costs incurred for the discovery and development of our product candidates. Research and development costs include,
but are not limited to, payroll and personnel expenses including stock-based compensation, clinical trial supplies, fees for clinical
trial services, consulting costs, and allocated overhead, including rent, equipment, and utilities.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Clinical Trial Accrual</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our clinical trial accrual
process accounts for expenses resulting from obligations under contracts with CROs, consultants, and under clinical site agreements in
connection with conducting clinical trials. Clinical trial costs are charged to research and development expense as incurred. The financial
terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not
match the periods over which materials or services are provided to us under such contracts. We reflect the appropriate clinical trial
expense in the condensed consolidated financial statements by matching the appropriate expenses with the period in which services and
efforts are expended. In the event advance payments are made to a CRO, the payments will be recorded as a prepaid asset which will be
amortized to research and development expense over the period the contracted services are performed. In addition to pass-through costs,
we generally incur costs in clinical trials in four distinct groups as follows:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">CRO Start-up&#8212;These costs
include the initial set-up of the clinical trial and usually occur within a few months after the contract has been executed and includes
costs which are expensed ratably over the start-up period when such period is identifiable and expensed as incurred when no such period
exists. Start-up phase activities include study initiation, site recruitment, regulatory applications, investigator meetings, screening,
preparation, pre-study visits, and training.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">CRO Site and Study Management&#8212;These
costs include medical and safety monitoring, patient administration and data management. These costs are usually calculated on a per-patient
basis and expensed ratably over the treatment period beginning on the date that the patient enrolls.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">CRO Close-Down and Reporting&#8212;These
costs include analyzing the data obtained and reporting results, which occurs after patients have ceased treatment and the database of
information collected is locked. These costs are expensed as incurred over the course of any close-down and reporting period.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Third-Party Contracts&#8212;These
costs include fees charged by third parties for various support services which are not provided by CROs and include such items as laboratory
fees, data quality review costs, and fees incurred for investigational product monitoring and inventory control. These items are expensed
ratably over any identifiable service period with the engaged third-party vendors.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The CRO contracts generally
include pass-through fees including, but not limited to, regulatory expenses, investigator fees, travel costs, and other miscellaneous
costs, including shipping and printing fees. We determine accrual estimates through reports from and discussion with applicable personnel
and outside service providers as to the progress or state of completion of trials or the services completed. We estimate accrued expenses
as of each balance sheet date in the condensed consolidated financial statements based on the facts and circumstances known to us at that
time.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Recently Adopted Accounting Pronouncements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2020, the FASB issued
ASU 2020-06, <i>Debt</i>&#8212;<i>Debt with Conversion and Other Options (Subtopic 470-20) </i>and <i>Derivatives and Hedging</i>&#8212;<i>Contracts
in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</i>
to simplify accounting for certain financial instruments by removing certain separation models for convertible instruments. Under the
amendments in ASU 2020-06, the embedded conversion features no longer are separated from the host contract for convertible instruments
with conversion features that are not required to be accounted for as derivatives, or that do not result in substantial premiums accounted
for as paid-in-capital. Consequently, a convertible debt instrument will be accounted as a single liability measured at its amortized
cost, and a convertible preferred stock will be accounted for as a single equity instrument measured at its historical cost, as long as
no other features require bifurcation and recognition as derivatives. The new standard also introduces additional disclosures for convertible
debt and freestanding instruments that are indexed to and settled in an entity&#8217;s own equity. ASU 2020-06 amends the diluted earnings
per share guidance, including the requirements to use the if-converted method for all convertible instruments. For smaller reporting companies,
the new guidance is effective for fiscal years beginning after December 15, 2023, and should be applied on a full or modified retrospective
basis, with early adoption permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods with
those fiscal years. We early adopted ASU 2020-06 on January 1, 2021. The adoption of this guidance did not have a material impact on our
condensed consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2020, the FASB issued
ASU 2020-04, <i>Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</i>, which
provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions in which the
reference LIBOR or another reference rate is expected to be discontinued as a result of the Reference Rate Reform. This ASU is intended
to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The new guidance
was effective immediately and through December 31, 2022. We adopted this guidance on March 1, 2020. The adoption of this guidance did
not have a material impact on our condensed consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2019, the FASB
issued ASU 2019-12, <i>Income Taxes (Topic 740)</i>, which amends the existing guidance relating to the accounting for income taxes. This
ASU is intended to simplify the accounting for income taxes by removing certain exceptions to the general principles of accounting for
income taxes and to improve the consistent application of GAAP for other areas of accounting for income taxes by clarifying and amending
existing guidance. The new guidance was effective for our fiscal year, and interim periods within our fiscal year, beginning after December
15, 2020. The adoption of this guidance did not have a material impact on our condensed consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2018, the FASB issued
ASU 2018-15, <i>Intangibles</i>&#8212;<i>Goodwill and Other</i>&#8212;<i>Internal-Use Software (Subtopic 350-40): Customer&#8217;s Accounting
for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract</i>. The new guidance provides for the deferral
of implementation costs for cloud computing arrangements and expensing those costs over the term of the cloud services arrangement. The
new guidance was effective for our fiscal year beginning after December 15, 2020. The adoption of this guidance did not have a material
impact on our condensed consolidated financial statements.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">In&#160;August
2018,&#160;the FASB issued ASU&#160;2018-13,&#160;<i>Fair Value Measurement (Topic&#160;</i></span><i>820<span style="font-size: 10pt">)</span></i><span style="font-size: 10pt">.
The new guidance improves the effectiveness of disclosures about fair value measurements required under ASC&#160;820.&#160;The new guidance&#160;amends
the disclosure requirements for recurring and nonrecurring fair value measurements by removing, modifying, and adding certain disclosures.
The new guidance was effective for our fiscal year, and interim periods with our fiscal year, beginning after December 15, 2019. The adoption
of this guidance&#160;did&#160;not&#160;have a material impact on our condensed consolidated financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Recent Accounting Pronouncements Not Yet
Adopted</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2016, the FASB issued
ASU 2016-13, <i>Financial Instruments</i>&#8212;<i>Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>.
The amendments in this ASU, among other things, require the measurement of all expected credit losses for financial assets held at the
reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions and
other organizations will now use forward-looking information to better inform their credit loss estimates. As a smaller reporting company,
the guidance is effective for our fiscal years beginning after December 15, 2022. We are currently evaluating the expected impact of the
new guidance as a result of this extended deadline of implementation for smaller reporting companies.&#160;&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724058383208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reverse Recapitalization with Tottenham and Clene Nanomedicine<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineAbstract', window );"><strong>Reverse Recapitalization With Tottenham And Clene Nanomedicine [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock', window );">Reverse Recapitalization with Tottenham and Clene Nanomedicine</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>3. Reverse Recapitalization with Tottenham
and Clene Nanomedicine</b>&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 30, 2020 (the
&#8220;Closing Date&#8221;), Chelsea Worldwide Inc., our predecessor company, consummated the previously announced business combination
(referred to as the &#8220;Reverse Recapitalization&#8221;) pursuant to a merger agreement, dated as of September 1, 2020 (the &#8220;Merger
Agreement&#8221;), by and among Clene Nanomedicine, Tottenham, Chelsea Worldwide Inc. (&#8220;PubCo&#8221;), a Delaware corporation and
wholly-owned subsidiary of Tottenham, Creative Worldwide Inc. (&#8220;Merger Sub&#8221;), a Delaware corporation and wholly-owned subsidiary
of PubCo, and Fortis Advisors LLC, a Delaware limited liability company as the representative of our shareholders. Prior to the Reincorporation
Merger discussed below, Tottenham was incorporated in the British Virgin Islands as a blank check company for the purpose of entering
into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination
with one or more businesses or entities. Prior to the Reverse Recapitalization, there was not a public market for the shares of Clene
Nanomedicine common stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Reverse Recapitalization
was effected in two steps: (i) Tottenham was reincorporated to the state of Delaware by merging with and into PubCo (the &#8220;Reincorporation
Merger&#8221;); and (ii) promptly following the Reincorporation Merger, Merger Sub was merged with and into Clene Nanomedicine, resulting
in Clene Nanomedicine becoming a wholly-owned subsidiary of PubCo (the &#8220;Acquisition Merger&#8221;). On the Closing Date, PubCo
changed its name from Chelsea Worldwide Inc. to Clene Inc. and listed its shares of Common Stock, par value $0.0001 per share on Nasdaq
under the symbol &#8220;CLNN.&#8221;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the consummation of the
Reverse Recapitalization, each Tottenham ordinary share issued and outstanding immediately prior to the effective time of the Reincorporation
Merger, which totaled 2,303,495 shares held by the Initial Shareholders and Tottenham public shareholders (excluding certain shares that
were canceled pursuant to the Merger Agreement, any redeemed shares, and any dissenting shares), was automatically cancelled and ceased
to exist and (i) for each Tottenham ordinary share, we issued to each shareholder one validly-issued share of our Common Stock; (ii) each
warrant to purchase one-half (1/2) of one Tottenham Ordinary Share converted into a warrant to purchase one-half (1/2) of one share of
our Common Stock; (iii) each right exchangeable into one-tenth (1/10) of one Tottenham ordinary share converted into a right exchangeable
for one-tenth (1/10) of one share of our Common Stock; provided, however, that no fractional shares were issued and all fractional shares
were rounded down to the nearest whole share. In addition, pursuant to the Merger Agreement, the Initial Shareholders are entitled to
receive up to 750,000 shares of Common Stock as earn-out shares upon the achievement of certain milestones described below. &#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On the Closing Date, each
share of Clene Nanomedicine common stock then issued and outstanding was cancelled and the holders thereof in exchange received 54,339,012
shares of Clene Inc. Common Stock, which is equal to 0.1389 newly-issued shares of Clene Inc. Common Stock for each single share of Clene
Nanomedicine common stock (the &#8220;Exchange Ratio&#8221;). Pursuant to the Merger Agreement, 5% of the aggregate amount of the closing
payment shares, or 2,716,958 shares were held in escrow to satisfy any indemnification obligation incurred and were released six months
after the closing of the Reverse Recapitalization. In addition, each share of Clene Nanomedicine&#8217;s preferred stock outstanding immediately
prior to the closing of the Reverse Recapitalization was converted into the right to receive our Common Stock based on the same Exchange
Ratio. All outstanding warrants exercisable for common stock in Clene Nanomedicine (other than warrants that expired, were exercised or
were deemed automatically net exercised immediately prior to the Acquisition Merger) were exchanged for warrants exercisable for our Common
Stock with the same terms and conditions except adjusted by the Exchange Ratio.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All outstanding stock options
of Clene Nanomedicine common stock, totaling 53,286,115 stock options, was cancelled and the holders thereof in exchange received 0.1320
newly issued stock options of our Common Stock for a total of 7,032,591 stock options, which is 95% of the Exchange Ratio. Pursuant to
the Merger Agreement, we agreed to issue rights to 370,101 restricted stock awards to the option holders which complements the 5% closing
payment shares held in escrow for Clene Nanomedicine common shareholders. The modification of the stock options did not result in a material
incremental compensation expense upon closing of the Reverse Recapitalization.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we issued rights
to 1,136,961 restricted stock awards to option holders to complement the earn-out payments that would contingently be issued to certain
current Clene Nanomedicine shareholders upon the achievement of milestones described below.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The proceeds received from
the Reverse Recapitalization were $3.7 million, net of offering costs of $5.9 million which excludes the fair value of common shares issued
as a payment of related offering costs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with Tottenham&#8217;s
initial public offering in August 2018, Tottenham issued to Chardan Capital Markets, LLC (&#8220;Chardan&#8221;), options to purchase
220,000 units at $11.50 per unit. Each of the units consists of one and one-tenth shares of Tottenham&#8217;s ordinary shares and one
warrant to purchase one-half of one of Tottenham&#8217;s ordinary shares at an exercise price of $11.50 per share (the &#8220;Chardan
Unit Purchase Option&#8221;). In connection with the Reverse Recapitalization, the Chardan Unit Purchase Option was converted into one
Company unit purchase option. The warrants included in the Chardan Unit Purchase Option (the &#8220;Chardan Unit Purchase Option Warrants&#8221;)
are exercisable upon the completion of the Reverse Recapitalization and will expire on December 30, 2025, five years after the consummation
of the Reverse Recapitalization (see Note 10).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Also, in connection with the
Reverse Recapitalization, Clene Nanomedicine entered into a letter agreement with LifeSci Capital LLC (&#8220;LifeSci&#8221;) on July
2, 2020, according to which LifeSci was engaged to act as Clene Nanomedicine&#8217;s financial advisor with respect to identifying and
soliciting special purpose acquisition companies for the purpose of entering into a merger or similar transaction with Clene Nanomedicine
and its shareholders. Under this agreement, Clene Nanomedicine agreed that if it consummated a merger with Tottenham, LifeSci would receive
consideration of (i) 3% of the amount by which the total transaction consideration exceeded $350 million, plus (ii) 7% of cash and cash-equivalents
received by Clene Nanomedicine from the Tottenham&#8217;s trust account. Clene Nanomedicine could elect to pay LifeSci either in cash,
equity interests of the surviving company, or a combination of the two. Upon the consummation of the Reverse Recapitalization, 644,164
shares of Common Stock were issued to LifeSci as consideration for its services as pursuant to the letter agreement (see Note 18).&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Immediately after giving effect
to the Reverse Recapitalization, there were 59,526,171 shares of Common Stock issued and outstanding and warrants to purchase 5,566,363
shares of Common Stock issued and outstanding (see Note 10).&#160;Based on the number of shares of Common Stock outstanding on December
30, 2020 (in each case, not giving effect to any shares issuable upon exercise of warrants, options, or earn-out shares), Clene Nanomedicine&#8217;s
shareholders owned approximately 91% of the Common Stock of the Company, Tottenham shareholders owned approximately 4% of the Common Stock
of the Company, and investors from the December 2020 PIPE owned approximately 4% of the Common Stock of the Company.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During Tottenham&#8217;s IPO,
Tottenham incurred deferred underwriters&#8217; fees which were payable to Chardan from the amounts held in the trust account upon completion
of the Reverse Recapitalization. Upon the closing of the Reverse Recapitalization, we paid $2.1 million to Chardan as settlement of the
deferred underwriting fees, which amount was included in the total offering costs of the Reverse Recapitalization.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2020, we recorded $5.9 million of offering costs related to third-party legal, accounting, and other professional services to consummate
the Reverse Recapitalization, excluding the fair value of common shares issued as a payment of related offering costs and Chardan underwriting
fees discussed above. These offering costs are recorded as a reduction of additional paid-in capital upon the close of the Reverse Recapitalization
in our condensed consolidated balance sheets.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The transaction was accounted for as a &#8220;reverse recapitalization&#8221;
in accordance with GAAP. Under this method of accounting, Tottenham was treated as the &#8220;acquired&#8221; company for financial reporting
purposes. This determination was primarily based on the fact that subsequent to the Reverse Recapitalization, Clene Nanomedicine&#8217;s
shareholders have a majority of the voting power of the combined company, Clene Nanomedicine comprises all of the ongoing operations of
the combined entity, Clene Nanomedicine comprises a majority of the governing body of the combined company, and Clene Nanomedicine&#8217;s
senior management comprises all of the senior management of the combined company. Accordingly, for accounting purposes, this transaction
was treated as the equivalent of Clene Nanomedicine issuing shares for the net assets of Tottenham, accompanied by a recapitalization.
The shares and net loss per common share in historical periods prior to the Reverse Recapitalization have been retroactively restated
using the Exchange Ratio established in the Reverse Recapitalization. The net assets of Tottenham were recorded at historical costs, with
no goodwill or other intangible assets recorded. Operations prior to the Reverse Recapitalization are those of Clene Nanomedicine.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Between July 1, 2021 and September
15, 2021, various investors exercised December 2020 PIPE Warrants for 1,002,250 shares of Common Stock at an exercise price of $0.01 per
share. The December 2020 PIPE Warrants were issued prior to the completion of the Reverse Recapitalization on December 30, 2020, and were
subject to a 180-day holding period which expired on June 28, 2021. We received cash proceeds of $10.0 thousand.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 15, 2021, Chardan
exercised the Chardan Unit Purchase Option for 220,000 units, each unit consisting of one and one-tenth shares of Common Stock and one
warrant to purchase one-half of one share of Common Stock at an exercise price of $11.50 per share. Chardan elected to perform a cashless
or net exercise, which resulted in a net issuance of 54,083 shares of Common Stock and 49,166 warrants to purchase one-half of one share
of Common Stock. The Chardan Unit Purchase Option was originally issued in connection with Tottenham&#8217;s initial public offering in
August 2018. We received no cash proceeds.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Earn-Out Shares</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain of Clene Nanomedicine&#8217;s
current shareholders are entitled to receive earn-out shares as follows (the &#8220;Clene Nanomedicine Contingent Earn-out&#8221;): (i)
3,333,333 shares of Common Stock if (A) the volume-weighted average price (&#8220;VWAP&#8221;) of the shares of our Common Stock equals
or exceeds $15.00 (or any foreign currency equivalent) (the &#8220;Milestone 1 Price&#8221;) in any twenty trading days within a thirty
trading day period within the three years following the closing of the Reverse Recapitalization on any securities exchange or securities
market on which the shares of our Common Stock are then traded or (B) the change of control price equals or exceeds the Milestone 1 Price
if a change of control transaction occurs within the three years following the closing of the Reverse Recapitalization (the requirements
set forth in clause (A) and (B), &#8220;Milestone 1&#8221;); (ii) 2,500,000 shares of Common Stock if (A) the VWAP of the shares of our
Common Stock equals or exceeds $20.00 (or any foreign currency equivalent) (the &#8220;Milestone 2 Price&#8221;) in any twenty trading
days within a thirty trading day period within the five years following the closing of the Reverse Recapitalization on any securities
exchange or securities market on which the shares of our Common Stock are then traded or (B) the change of control price equals or exceeds
the Milestone 2 Price if a change of control transaction occurs within the five years following the closing of the Reverse Recapitalization
(the requirements set forth in clause (A) or (B), &#8220;Milestone 2&#8221;); and (iii) 2,500,000 shares of Common Stock if Clene Nanomedicine
completes a randomized placebo-controlled study for treatment of COVID-19 which results in a statistically significant finding of clinical
efficacy within twelve months after the closing of the Reverse Recapitalization (&#8220;Milestone 3&#8221;). If Milestone 1 is not achieved
but Milestone 2 is achieved, the Clene Nanomedicine shareholders will receive a catch-up issuance equal to the shares issued upon satisfaction
of Milestone 1. Upon the consummation of the Reverse Recapitalization, the Clene Nanomedicine Contingent Earn-out shares increased by
12,852 as a result of the exercise of stock options during November 2020. Therefore, the total Clene Nanomedicine Contingent Earn-out
shares has increased to 8,346,185 shares of Common Stock.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Initial Shareholders of
Tottenham may be entitled to receive earn-out shares as follows (the &#8220;Initial Shareholders Contingent Earn-out&#8221;): (i) 375,000
shares of Common Stock upon satisfaction of the requirements of Milestone 1; and (ii) another 375,000 shares of the Company&#8217;s Common
Stock upon satisfaction of the requirements of Milestone 2. If Milestone 1 is not achieved but Milestone 2 is achieved, the Initial Shareholders
shall receive a catch-up issuance equal to the shares granted upon satisfaction of the requirements of Milestone 1.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Clene Nanomedicine Contingent
Earn-out and Initial Shareholders Contingent Earn-out (collectively, the &#8220;Contingent Earn-out<b>s</b>&#8221;) have been classified
as liabilities in the condensed consolidated balance sheets and were initially measured at fair value on the date of the Reverse Recapitalization
and are subsequently remeasured to fair value at each reporting date (see Note 16).&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724155128184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_PrepaidExpensesAndOtherCurrentAssetsAbstract', window );"><strong>Prepaid Expenses And Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_PrepaidExpensesAndOtherCurrentAssetsTextBlock', window );">Prepaid expenses and other current assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>4. Prepaid Expenses and Other Current Assets</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prepaid expenses and other
current assets consisted of the following as of September 30, 2021 and December 31, 2020:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">September&#160;30,</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">December&#160;31,</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Australia research and development credit receivable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,212</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,148</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">CRO prepayments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">693</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,211</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Metals to be used in research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,691</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Directors &amp; Officers Insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">934</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-194">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">202</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">112</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,732</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,502</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_PrepaidExpensesAndOtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_PrepaidExpensesAndOtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_PrepaidExpensesAndOtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for Prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_PrepaidExpensesAndOtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724155904520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>5. Property and Equipment, Net</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Property and equipment, net
consisted of the following as of September 30, 2021 and December 31, 2020:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">September&#160;30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Laboratory equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,183</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,077</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">147</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">147</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,927</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,889</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Construction in progress</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,061</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">490</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,318</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,603</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,072</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,378</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,246</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,225</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Depreciation expense related
to property and equipment, net for the three and nine months ended September 30, 2021 was approximately $0.2 million and $0.7 million,
respectively. Depreciation expense is reported in research and development expense and in general and administrative expense for $0.6
million and $0.1 million, respectively, for the nine months ended September 30, 2021; and in research and development expense and in general
and administrative expense for $0.2 million and $29 thousand, respectively, for the three months ended September 30, 2021, in the condensed
consolidated statements of operations and comprehensive income (loss).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Depreciation expense related
to property and equipment, net for the three and nine months ended September 30, 2020 was approximately $0.2 million and $0.7 million,
respectively. Depreciation expense is reported in research and development expense and in general and administrative expense for $0.6
million and $47 thousand, respectively, for the nine months ended September 30, 2020; and in research and development expense and in general
and administrative expense for $0.2 million and $34 thousand, respectively, for the three months ended September 30, 2020, in the condensed
consolidated statements of operations and comprehensive income (loss).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724067279752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accounts Payable and Accrued Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>6. Accrued Liabilities</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Accrued liabilities consisted
of the following as of September 30, 2021 and December 31, 2020:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">September&#160;30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accrued professional fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-195">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">189</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued compensation and benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,744</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,225</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued CRO fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">675</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">788</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Deferred grant funds</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">601</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">301</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued expense reimbursements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued transaction costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-196">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,354</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">64</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">70</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,117</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,960</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724060932568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>7. Leases</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We adopted ASC 842, <i>Leases</i>
(&#8220;ASC 842&#8221;) on January 1, 2019 using the modified retrospective approach. &#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April&#160;2020, we terminated
an existing operating lease for office space. At the time of termination, we removed the remaining right-of-use asset of $0.3 million,
lease liability of $0.3 million, and recognized a gain of $0.1 million. Further, in April&#160;2020, we commenced a new operating lease.
At the time of commencement, we recorded the right-of-use asset value of $0.4 million, leasehold improvements of $0.4 million, and a lease
liability of $0.8 million. The net effect of the change in leases being an increase in right-of-use assets of $0.1 million, an increase
in leasehold improvements of $0.5 million, an increase in lease liability of $0.4 million, and a gain on termination of $0.1 million.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2021, we entered into an operating lease for laboratory space.
At the time of commencement, we recorded a right-of-use asset value of $2.4 million and a lease liability of $2.4 million, net of a lease
incentive of $1.0 million. The lease incentive represents an allowance from the lessor for facility alterations. As the lease incentive
is payable based on events within our control and are deemed reasonably certain to occur, we recorded the lease incentive as a reduction
of the right-of-use asset and lease liability at the lease commencement. As of September 30, 2021, we incurred $0.1 million of costs related
to the lease incentive which we recorded as construction in progress, with a corresponding increase to the lease liability, and the construction
in progress will be capitalized as leasehold improvements when the facility is placed into service. The lease has an initial ten-year
term and provides us the right and option to extend or renew for two periods of five years each. In accordance with ASC 842, the payments
to be made in option periods have not been recognized as part of the right-of-use asset or lease liability because we do not assess the
exercise of the option to be reasonably certain.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, in August 2021, we entered into an operating lease for
laboratory space that will replace a previous operating lease for the same facility. The commencement of the new lease and the termination
of the previous lease will be effective as of December 1, 2021, and had no impact on the condensed consolidated financial statements for
the three and nine months ended September 30, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have noncancelable operating
lease arrangements primarily for office and laboratory space. We also have noncancelable finance leases for certain laboratory equipment.
The maturity analysis of finance and operating lease liabilities as of September 30, 2021 are as follows:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Finance<br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Operating<br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">43</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">870</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">136</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">960</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">82</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">982</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,007</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-197">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,031</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-198">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,887</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Total undiscounted cash flows</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">281</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,737</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Less amount representing interest/discounting</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,507</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Present value of future lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">278</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,230</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Less future lease incentives</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-199">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(900</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Less lease obligations, current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(153</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(262</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Lease obligations&#160;&#8211; long term portion</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">125</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,068</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that, in the normal
course of business, the existing leases will be renewed or replaced by similar leases.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Finance Leases</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Assets recorded under finance
lease obligations and included with property and equipment as of September 30, 2021 and December 31, 2020 are summarized as follows:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">September&#160;30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Laboratory equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,148</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">920</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Work in process</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-200">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">228</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,194</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,194</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(629</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(593</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">565</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">601</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of September 30, 2021, our finance lease obligations had a weighted-average
interest rate of 8.6% and had a weighted-average remaining term of 2.2 years. As of December 31, 2020, our finance lease obligations had
a weighted-average interest rate of 8.1% and had a weighted-average remaining term of 2.7 years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Operating Leases</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our balance of right-of-use assets on the face of the balance sheet
pertain to operating leases. As of September 30, 2021, our operating lease obligations had a weighted-average discount rate of 9.6% and
had a weighted-average remaining term of 8.3 years. As of December 31, 2020, our operating lease obligations had a weighted-average discount
rate of 9.6% and a weighted-average remaining term of 6.3 years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Components of Lease Cost</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The components of finance
and operating lease costs for the three and nine months ended September 30, 2021 and 2020 were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Finance lease costs:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 52%">Amortization</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">37</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">41</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">110</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">137</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Interest on lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">107</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">247</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">308</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Short-term lease costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">98</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">214</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">203</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Variable lease costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">32</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">71</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">70</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total lease costs</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">280</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">233</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">663</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">748</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Supplemental Cash Flow Information</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating cash flows from operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(533</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(497</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating cash flows from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(21</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(30</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financing cash flows from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(117</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(156</td><td style="text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -URI http://asc.fasb.org/topic&amp;trid=2208923<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724058428920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Notes Payable</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>8. Notes Payable</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our long-term debt, net of
original issue discount and unamortized debt issuance costs, consisted of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">September&#160;30,</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Rate</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Term Loans:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 9pt">Maryland Department of Housing &amp; Community Development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">819</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,080</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Advance Cecil, Inc.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">164</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">216</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Paycheck Protection Program</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-201">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">647</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Avenue Venture Opportunities Fund, L.P.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.85</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-202">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">0.00</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-203">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,983</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,949</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Unamortized debt issuance costs and original issue discounts</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,811</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-204">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Less convertible notes payable, net of unamortized debt discount and issuance costs (see Note 11)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,559</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-205">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Total notes payable</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">14,613</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,949</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Maryland Loan</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February&#160;2019, we
entered into a loan agreement (the &#8220;2019 MD Loan&#8221;) with the Department of Housing and Community Development, a principal department
of the State of Maryland (&#8220;Maryland&#8221;). Pursuant to the 2019 MD Loan, Maryland agreed to provide a $0.5 million term loan.
Amounts outstanding under the 2019 MD Loan bear simple interest at an annual rate of 8.00%. Under the 2019 MD Loan, we agreed to affirmative
and negative covenants to which we will remain subject until maturity. These covenants include providing information about the Company
and our operations; limitations on our ability to retire, repurchase, or redeem our common or preferred stock, options, and warrants other
than per the terms of the securities; and limitations on our ability to pay dividends of cash or property. There are no financial covenants
associated with the 2019 MD Loan. Events of default under the 2019 MD Loan include failure to make payments when due, insolvency events,
and failure to comply with covenants. We are not in violation of any affirmative covenants. Repayment of the full balance outstanding
is due on February 22, 2034. The 2019 MD Loan establishes &#8220;Phantom Shares,&#8221; based on 119,906 shares of Common Stock (based
on 863,110 Series C Preferred Shares prior to the Reverse Recapitalization), determined at issuance. The 2019 MD Loan states the repayment
amount is to be the greater of the balance of principal and accrued interest or the Phantom Shares value. We determined that the note
should be accounted for at fair value. We record the fair value of the debt at the end of each reporting period. In order to value the
note, we consider the amount of the simple interest expense that would be due and the value of Phantom Shares. Upon the closing of the
Reverse Recapitalization and as of December 31, 2020, the fair value of the 2019 MD Loan is determined based on the closing price of CLNN
shares listed on Nasdaq.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Income of $0.5 million and
$0.3 million were recognized during the three and nine months ended September 30, 2021, respectively. Expense of $0.2 million and $0.3
million was recognized during the three and nine months ended September 30, 2020, respectively. The fair value of $0.8 million and $1.1
million of principal and accrued interest is included in long-term notes payable as of September 30, 2021 and December 31, 2020, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cecil County Loan</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April&#160;2019, we entered
into a loan agreement (the &#8220;2019 Cecil Loan&#8221;) with Advance Cecil Inc., a non-stock corporation formed under the laws of the
state of Maryland with application for 501(c)(3) non-profit status pending before the United States Internal Revenue Service at the time
of execution of the 2019 Cecil Loan. Pursuant to the 2019 Cecil Loan, Cecil agreed to provide a $0.1 million term loan. Amounts outstanding
under the 2019 Cecil Loan bear simple interest at an annual rate of 8.00%. Under the 2019 Cecil Loan, we agreed to affirmative covenants
to which we will remain subject until maturity. These covenants include providing information about the Company and our operations. There
are no financial covenants associated with the 2019 Cecil Loan. Events of default under the 2019 Cecil Loan include failure to make payments
when due, insolvency events, failure to comply with covenants, and material adverse effects with respect to the Company. We are not in
violation of any affirmative covenants. Repayment of the full balance outstanding is due on April 30, 2034. The 2019 Cecil Loan establishes
&#8220;Phantom Shares,&#8221; based on 23,981 shares of Common Stock (based on 172,622 Series C Preferred Shares prior to the Reverse
Recapitalization), determined at issuance. The 2019 Cecil Loan states the repayment amount is to be the greater of the balance of principal
and accrued interest or the Phantom Share value. We determined that the note should be accounted for at fair value. We record the fair
value of the debt at the end of each reporting period. In order to value the note, we consider the amount of the simple interest expense
that would be due and the value of Phantom Shares. Upon the closing of the Reverse Recapitalization and as of December 31, 2020, the fair
value of the 2019 Cecil Loan is determined based on the closing price of CLNN shares listed on Nasdaq.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Income of $0.1 million and
expense of $52 thousand were recognized during the three and nine months ended September 30, 2021, respectively. Expense of $42 thousand
and $55 thousand was recognized during the three and nine months ended September 30, 2020, respectively. The fair value of $0.2 million
and $0.2 million of principal and accrued interest is included in long-term notes payable as of September 30, 2021 and December 31, 2020,
respectively.&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>PPP Loan</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May&#160;2020, we entered
into a note payable in the amount of $0.6 million (the &#8220;PPP Note&#8221;) under the Paycheck Protection Program of the CARES Act
(the &#8220;PPP&#8221;). As amended, the PPP permits forgiveness of amounts loaned for payments of payroll and other qualifying expenses
within 24 weeks of receipt of loaned funds, given that at least 60% of the total loan is used for payroll. Amounts not forgiven have a
repayment period of five years. In January 2021, the full $0.6 million balance of the PPP Note was forgiven and has been recorded as a
gain on extinguishment of debt during the nine months ended September 30, 2021. There was no gain on extinguishment of debt recorded during
the three months ended September 30, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Avenue Loan</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2021, we entered into the 2021 Avenue Loan with Avenue. The
agreement provides for a 42-month term loan of up to $30.0 million. The first tranche is $20.0 million (&#8220;Tranche 1&#8221;), of which
$15.0 million was funded at close. We incurred issuance costs for a total of $0.5 million of which $35 thousand has been expensed immediately.
The remaining balance from Tranche 1 of $5.0 million was funded on September 28, 2021 and an additional tranche of $10.0 million (&#8220;Tranche
2&#8221;) is available at the Company&#8217;s request until June 30, 2022. Pursuant to the 2021 Avenue Loan, funding of Tranche 2 is subject
to evidence reasonably satisfactory to Avenue of receipt of an additional $5.0 million financing through Maryland&#8217;s State Incentive
Programs and/or other Maryland State programs and mutual agreement of the Company and Avenue. On September 27, 2021, we obtained a waiver
from this additional financing requirement for the funding of the remaining $5.0 million of Tranche 1 and exercised the option to postpone
principal repayment by one year. We incurred additional issuance costs of $75 thousand upon funding the remaining $5.0 million of Tranche
1, of which $12 thousand has been expensed immediately. Funding of Tranche 2 is also subject to (a) our achievement of a statistically
significant result on the primary endpoint as defined within the statistical analysis plan for each respective study, or the totality
of the results for any study warrant advancement into a subsequent clinical efficacy study, as reasonably determined by the Company and
Avenue with respect to at least two of the following studies: (i) RESCUE-ALS or the Healey ALS Platform Trial; (ii) REPAIR-PD; or (iii)
REPAIR-MS (&#8220;Performance Milestone 1&#8221;); and (b) our receipt of net proceeds of at least $30 million from the sale and issuance
of our equity securities (including any private placement or follow-on offering) between May 2, 2021 and June 30, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The loans bear interest at
a variable rate per annum equal to the sum of (i) the greater of (A) the prime rate, as published by the Wall Street Journal from time
to time or (B) 3.25%, plus (ii) 6.60%. Payments for the loan are interest only for the initial 12 months and can be extended to (i) 12
months (the &#8220;First Interest-only Period Extension&#8221;) if we achieve Performance Milestone 1 and (ii) up to 36 months if (a)
we achieve the First Interest-only Period Extension and (b) have drawn from Tranche 2. On August 16, 2021, we mutually confirmed with
Avenue that Performance Milestone 1 and the First Interest-only Period Extension had been achieved. The loan will amortize in equal payments
of principal from the end of the interest period to the expiration of the 42-month term on December 1, 2024. On the maturity date, an
additional payment equal to 4.25% of the funded loans, or $0.6 million, is due in addition to the remaining unpaid principal and accrued
interest. The final payment is recorded as a debt premium and is being amortized over the contractual term using the effective interest
method. The final payment provision is related to the loan host and is not bifurcated pursuant to ASC 815.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the agreement, we granted to Avenue the Avenue Warrants
for the purchase of 115,851 shares of Common Stock at an exercise price equal to the lower of (i) $8.63 (which is equal to the five-day
volume weighted average price (&#8220;VWAP&#8221;) per share, determined as of the end of trading on the last trading day prior to execution
of the loan agreement), or (ii) the lowest price per share paid by cash investors for our Common Stock issued in the next bona fide round
of equity financing prior to March 31, 2022 (the &#8220;Next Round Price&#8221;) (see Note 10). Upon the funding of Tranche 2, the Avenue
Warrant shall be automatically adjusted to include an additional estimated 86,679 shares of Common Stock, which is equal to 5% of the
principal amount of Tranche 2, divided by the lower of (i) the five (5)-day VWAP per share; determined as of the end of trading on the
last trading day before the date of issuance of Tranche 2; or (ii) the Next Round Price. We accounted for the Tranche 2 warrants at inception
of the 2021 Avenue Loan in accordance with ASC 815 and the fair value and issuable shares will be remeasured at each reporting period
(see Note 10). Avenue also has the right, in its discretion, but not the obligation, at any time from time to time from the first through
the third-year anniversary of the agreement, while the loan is outstanding, to convert an amount of up to $5.0 million of the principal
amount of the outstanding loan into Common Stock (the &#8220;Conversion Feature&#8221;) at a price per share equal to 120% of the stock
purchase price set forth in the warrant. The Conversion Feature is subject to (i) the closing price of our Common Stock for each of the
seven consecutive trading days immediately preceding the conversion being greater than or equal to the conversion price and (ii) the Common
Stock issued in connection with any such conversion not exceeding 20% of the total trading volume of our Common Stock for the twenty-two
consecutive trading days immediately prior to and including the effective date of such conversion.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the 2021 Avenue Loan, we agreed to affirmative and negative covenants
to which we will remain subject upon maturity in the absence of prepayments. These covenants include providing information about the Company
and our operations; limitation on our ability to retire, repurchase, or redeem our Common Stock, options, and warrants other than per
the terms of the securities; and limitations on our ability to pay dividends of cash or property. The financial covenant associated with
the loan agreement includes maintaining minimum unrestricted cash and cash equivalents of at least $5.0 million; provided that upon our
(i) achievement of Performance Milestone 1, and (ii) receiving of net proceeds of at least $30.0 million from the sale and issuance of
our equity securities (including any PIPE or follow-on offering) between May 1, 2021 and June 30, 2022, we shall no longer be subject
to financial covenants. We are not in violation of the covenants. The agreement provides for events of default customary for loans of
this type, including but not limited to non-payment, breaches, the occurrence of a material adverse change, or defaults in the performance
of covenants, insolvency, and bankruptcy. The 2021 Avenue Loan is collateralized by substantially all of our assets other than intellectual
property, including capital stock of the Company and its subsidiaries, in which Avenue is granted a continuing security interest. The
net proceeds from the issuance of the loan were initially allocated to the warrant at an amount equal to their fair value of $1.0 million
and the remainder to the loan. The allocation of incurred financing costs of $0.5 million and the fair value of the warrant, together
with the final payment, are recorded as a debt discount and debt premium, respectively, and are being amortized over the contractual term
using the effective interest method. During the three and nine months ended September 30, 2021, we recorded interest expense of $0.6 million
and $0.8 million, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following is a schedule of
future payments, net of unamortized debt discounts, if Avenue does not convert up to $5.0 million of the loan into Common Stock between
May 21, 2022 through May 21, 2024:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>2021 (remainder)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-206">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-207">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6,667</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,333</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-208">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-209">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-210">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Subtotal of future principal payments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">20,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Unamortized debt discount associated with issuance date warrant fair value and financing costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,811</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">18,189</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724060920328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred Stock Warrant Liability<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrantsAbstract', window );"><strong>Preferred Stock Warrant Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Preferred Stock Warrant Liability</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>9. Preferred Stock Warrant Liability</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the Reverse Recapitalization,
we issued Series A Preferred Stock Warrants in 2013 pursuant to certain note purchase agreements. The warrants expire <span style="-sec-ix-hidden: hidden-fact-211">ten&#160;years</span> from
issuance. These warrants are exercisable at a fixed exercise price of $1.97, which is equal to the price per share of the Series A Preferred
Stock. As of December 31, 2019, these warrants were exercisable into 1,608,670 shares of the Series A Preferred Stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the Reverse Recapitalization,
on April 8, 2013, we issued ten-year warrants to purchase units of our most senior equity equal to 0.25% of our fully diluted equity at
the time of exercise pursuant to certain note purchase agreements. As of December 31, 2019, these warrants were exercisable into 271,439
shares of our most senior equity, Series C Preferred Stock, at a fixed exercise price of $1.97 per share. On August 11, 2020, in connection
with our issuance of Series D Preferred Stock, these warrants became exercisable into 320,441 shares of our most senior equity, Series
D Preferred Stock, at a fixed exercise price of $1.97 per share.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the Reverse Recapitalization,
we classified Preferred Stock warrants as a liability on the condensed consolidated balance sheets because the warrants are freestanding
financial instruments that may have required us to transfer assets upon exercise. The liability associated with each of these warrants
was initially recorded at fair value upon the issuance date of each warrant and is subsequently remeasured to fair value as a component
of other income (expense), net in the condensed consolidated statements of operations and comprehensive income (loss). Upon the closing
of the Reverse Recapitalization (see Note 3), and pursuant to the Merger Agreement, all of the outstanding Clene Nanomedicine Preferred
Stock was converted into Common Stock and the Clene Nanomedicine Preferred Stock warrants to purchase Clene Nanomedicine Preferred Stock
were converted to warrants to purchase Common Stock (see Note 10). Upon conversion, we assessed the features of the warrants and determined
that they qualify for classification as permanent equity upon the closing of the Reverse Recapitalization. Accordingly, we remeasured
the warrants to fair value one final time upon the close of the Reverse Recapitalization, and recognized a loss of $14.6 million for the
year ended December 31, 2020, within other income, (expense), net on the condensed consolidated statements of operations and comprehensive
income (loss). Upon the closing of the Reverse Recapitalization, the warrant liability was reclassified to additional paid-in capital
(see Note 17).&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of September 30, 2021 and
December 31, 2020, we do not have any Preferred Stock warrants outstanding.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recognized a change in
fair value of the outstanding warrants of $5.1 million during the three months ended September 30, 2020 and $7.4 million during the nine
months ended September 30, 2020 in the condensed consolidated statements of operations and comprehensive&#160;income (loss).&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724058428920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsDisclosureAbstract', window );"><strong>Common Stock Warrants Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsDisclosureTextBlock', window );">Common Stock Warrants</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>10. Common Stock Warrants</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of September 30, 2021,
outstanding warrants to purchase shares of Common Stock consisted of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1.5pt solid">Date Exercisable</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Shares<br/>
 Issuable</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercise Price</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercisable for</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Classification</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Expiration</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%">June 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">117,500</td><td style="white-space: nowrap; width: 2%; text-align: left"><sup>(1)</sup></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">0.01</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: center">Common Stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 2021</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>December 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,407,500</td><td style="white-space: nowrap; text-align: left"><sup>(2)</sup></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">11.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">Common Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 2025</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>December 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,583</td><td style="white-space: nowrap; text-align: left"><sup>(3)</sup></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">11.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">Common Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 2025</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>December 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,929,111</td><td style="white-space: nowrap; text-align: left"><sup>(4)</sup></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.97</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">Common Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2023</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">May 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">115,851</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><sup>(5)(6)</sup></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">8.63</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">Common Stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liability</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2026</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,594,545</td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2020, outstanding
warrants to purchase shares of Common Stock consisted of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1.5pt solid">Date Exercisable</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Shares Issuable</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercise Price</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercisable for</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Classification</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Expiration</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%">June 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">1,119,750</td><td style="width: 2%; text-align: left"><sup>(1)</sup></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">0.01</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: center">Common Stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 2021</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>December 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,407,500</td><td style="text-align: left"><sup>(2)</sup></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">11.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">Common Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 2025</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>December 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">110,000</td><td style="text-align: left"><sup>(3)</sup></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">11.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">Common Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 2025</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">December 2020</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,929,111</td><td style="padding-bottom: 1.5pt; text-align: left"><sup>(4)</sup></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">1.97</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">Common Stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2023</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,566,361</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consisted of 1,119,750 shares of Common Stock underlying 2,239,500 December 2020 PIPE Warrants issued on December 30, 2020, in connection with the December 2020 PIPE (see Note 18). A holder of the December 2020 PIPE Warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of the Company&#8217;s Common Stock outstanding immediately after giving effect to such exercise. As of September 30, 2021, 2,004,500 December 2020 PIPE Warrants were exercised into 1,002,250 shares of Common Stock. The outstanding balance as of September 30, 2021 consists of 117,500 shares of Common Stock underlying 235,000 December 2020 PIPE Warrants. As of December 31, 2020, none of the warrants had been exercised.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of 2,407,500 shares of Common Stock underlying 4,815,000 warrants issued in connection with Tottenham&#8217;s initial public offering. The Company may redeem the outstanding warrants, in whole and not in part, at a price of $0.01 per warrant if, and only if, the last sales price of the Company&#8217;s Common Stock equals or exceeds $16.50 per share for any 20 trading days within a 30-trading day period ending three business days before the Company sends the notice of redemption. As of September 30, 2021, and December 31, 2020, none of the warrants had been exercised.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consisted of 110,000 shares of Common Stock underlying 220,000 warrants issued as part of the Chardan Unit Purchase Option (see Note 3). On July 15, 2021 the Chardan Unit Purchase Option was net exercised, resulting in the issuance of 54,083 shares of Common Stock and 49,166 warrants to purchase one-half of one share of Common Stock, or 24,583 shares of Common Stock. As of September 30, 2021, none of the warrants had been exercised. As of December 31, 2020, the Chardan Unit Purchase Option had not been exercised.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of 1,929,111 shares of Common Stock underlying 1,929,111 warrants originally issued by Clene Nanomedicine as Series A and Series D Preferred Stock Warrants (see Note 9). As of September 30, 2021, and December 31, 2020, none of the warrants had been exercised.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of 115,851 shares of Common Stock underlying 115,851 Avenue Warrants issued pursuant to Tranche 1 of the 2021 Avenue Loan at an exercise price equal to the lower of (i) $8.63 (which is equal to the five-day VWAP per share, determined as of the end of trading on the last trading day prior to execution of the loan agreement), or (ii) the Next Round Price. (see Note 8). As of September 30, 2021, the Avenue Warrant had not been exercised.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the 2021 Avenue Loan, an additional estimated 86,679 shares
of Common Stock underlying warrants are issuable pursuant to our draw of Tranche 2 between January 1, 2022 and June 30, 2022 (see Note
8). In accordance with ASC 815, we recognized these warrants at the inception of the 2021 Avenue Loan and classified them as a warrant
liability and the fair value and issuable shares will be remeasured at each reporting period (see Note 16). As of September 30, 2021,
the warrants are not issued or outstanding.</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CommonStockWarrantsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CommonStockWarrantsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CommonStockWarrantsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>he entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CommonStockWarrantsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724058389576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ConvertibleNotesDisclosureAbstract', window );"><strong>Convertible Notes Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ConvertibleNotesDisclosureTextBlock', window );">Convertible Notes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>11. Convertible Notes</b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>2020 Convertible Notes</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February through July 2020,
we issued convertible promissory notes (the &#8220;2020 Convertible Notes&#8221;) in an aggregate principal amount of $6.1 million, bearing
interest at an annual rate of 5%. The 2020 Convertible Notes were convertible at the earlier of (i)&#160;one year, at which point the
notes would be convertible into Series C Preferred Shares at the Series C Preferred Share issuance price, and (ii)&#160;next equity financing
of no less than $10.0 million, at which point the notes would be convertible into shares issued in the next equity financing at 90% of
the per share issuance price of the next equity financing. The 2020 Convertible Notes contained embedded features that provide the lenders
with multiple settlement alternatives. Certain of these settlement features provided the lenders with a right to a fixed number of our
shares upon conversion of the notes. Other settlement features provided the lenders with the right or the obligation to receive cash or
a variable number of shares upon the completion of a capital raising transaction, change of control, or default of the Company (the &#8220;Redemption
Features&#8221;). The Redemption Features of the 2020 Convertible Notes met the requirements for separate accounting and were accounted
for as a single derivative instrument (the &#8220;2020 Derivative Instrument&#8221;). Accordingly, the 2020 Derivative Instrument of $0.7
million was recorded at fair value at inception as redeemable convertible preferred stock derivative liability in the condensed consolidated
balance sheets (see Note 12).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recognized interest expense
of $34 thousand, including amortization of debt discount of $0.1 million during the three months ended September 30, 2020, in connection
with the 2020 Convertible Notes. We recognized interest expense of $0.1 million, including amortization of debt discount of $0.2 million
during the nine months ended September 30, 2020, in connection with the 2020 Convertible Notes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 11, 2020, in connection
with our issuance and sale of Series D Preferred Stock, all of the outstanding principal and accrued interest under the 2020 Convertible
Notes, totaling $6.9 million, was automatically converted into 1,497,135 shares of Series D Preferred Stock at a price equal to 90% of
$4.60 per share, the per share price paid in cash by investors in the Series D Preferred Stock financing.&#160;Upon the closing of the
Reverse Recapitalization (see Note 3), and pursuant to the Merger Agreement, all outstanding Clene Nanomedicine Series D Preferred Stock
was converted to Clene Inc. Common Stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We accounted for the conversion
of the 2020 Convertible Notes as a debt extinguishment and recognized a loss on extinguishment of debt of $0.5 million within other income
(expense), net in the consolidated statements of operations and comprehensive income (loss) for the year ended December 31, 2020. As of
the date of conversion, the unamortized discount on the 2020 Convertible Notes was $0.5 million. The loss on extinguishment was calculated
as the difference between (i) the fair value of the 1,497,135 shares of Series D Preferred Stock issued to settle the 2020 Convertible
Notes of $6.9 million and (ii) the carrying value of the 2020 Convertible Notes of $5.7 million, which includes the principal balance
of the 2020 Convertible Notes of $6.1 million and accrued but unpaid interest of $0.1 million, net of the unamortized debt discount of
$0.5 million, plus the then-current fair value of derivative liability associated with the 2020 Convertible Notes at the time of the extinguishment
of $0.7 million.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Convertible Notes Payable</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2021, we entered into
the 2021 Avenue Loan from which we granted to Avenue the right, in its discretion, but not the obligation, at any time from time to time
from May 21, 2022 through May 21, 2024, while the loan is outstanding, to convert an amount of up to $5.0 million of the principal amount
of the outstanding loan into shares of Common Stock at a price per share equal to 120% of the stock purchase price set forth in the Avenue
Warrant (see Note 8). The Conversion Feature is subject to (i) the closing price of our Common Stock for each of the seven consecutive
trading days immediately preceding the conversion being greater than or equal to the conversion price and (ii) the Common Stock issued
in connection with any such conversion not exceeding 20% of the total trading volume of our Common Stock for the twenty-two consecutive
trading days immediately prior to and including the effective date of such conversion. The Conversion Feature did not meet the requirements
for separate accounting and is not accounted for as a derivative instrument. As of September 30, 2021, the number of shares of Common
Stock potentially issuable upon conversion was 482,703.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We classified $5.0 million of the 2021 Avenue Loan as convertible notes
payable in the condensed consolidated balance sheets as of September 30, 2021, with unamortized debt discount and issuance costs of $0.4
million.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the three and nine months ended September 30, 2021, we recognized
(i) total interest expense of $0.2 million and $0.3 million, respectively; (ii) coupon interest expense of $0.1 million and $0.2 million,
respectively; and (iii) amortization of debt discount and issuance costs of $41 thousand and $64 thousand, respectively, in connection
with the convertible notes payable. During the three and nine months ended September 30, 2020, we did not recognize any interest expense
or amortization in connection with the convertible notes payable. The effective interest rate was 15.46% for the three and nine months
ended September 30, 2021.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ConvertibleNotesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ConvertibleNotesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ConvertibleNotesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ConvertibleNotesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724058428920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Instruments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>12. Derivative Instruments</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Derivative Instrument in Connection with
the 2020 Convertible Notes</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">One of the redemption features
of the 2020 Convertible Notes met the requirements for separate accounting and was accounted for as a derivative instrument. The 2020
Derivative Instrument was recorded at fair value, which was $0.7 million at issuance. In August 2020, in connection with our issuance
and sale of Series D Preferred Stock, all of the outstanding principal and accrued interest under the 2020 Convertible Notes was automatically
converted into shares of Series D Preferred Stock and the derivative liability was extinguished. Prior to the extinguishment of derivative
liability, the 2020 Derivative Instrument was marked to fair value and we recorded the change in the 2020 Derivative Instrument of ($29)
thousand in the consolidated statements of operations and comprehensive income (loss) for the year ended December 31, 2020 (see Note 11).
For the three and nine months ended September 30, 2020, we recorded the change in the 2020 Derivative Instrument of $15 thousand and $29
thousand, respectively, in the condensed consolidated statements of operations and comprehensive income (loss). Upon the closing of the
Reverse Recapitalization (see Note 3), and pursuant to the Merger Agreement, all outstanding Clene Nanomedicine Preferred Stock was converted
to Clene Inc. Common Stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Derivative Instruments in Connection with
the Contingent Earn-Outs</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The earn-out shares issued
in connection with the Reverse Recapitalization met the requirements for separate accounting and are therefore accounted for as derivative
instruments. Accordingly, upon the consummation of the Reverse Recapitalization, we recorded a liability in the condensed consolidated
balance sheets and a debit to additional paid-in capital for the earn-out provision associated with the Initial Shareholders Contingent
Earn-out and a debit to accumulated deficit for the earn-out provisions associated with the Clene Nanomedicine Contingent Earn-out. The
contingent shares to be issued to the Clene Nanomedicine shareholders immediately prior to the Reverse Capitalization were treated as
a deemed distribution. The Contingent Earn-outs were subsequently remeasured to fair value at each reporting date as a component of other
income (expense), net in the condensed consolidated statements of operations and comprehensive income (loss).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the closing of the Reverse
Recapitalization, we recognized the Clene Nanomedicine Contingent Earn-out and Initial Shareholders Contingent Earn-out liabilities at
their fair value of $64.7 million and $7.4 million, respectively, in the condensed consolidated balance sheets. As of December 31, 2020,
the carrying values of the Clene Nanomedicine Contingent Earn-out and Initial Shareholders Contingent Earn-out were $52.1 million and
$5.9 million, respectively. As of September 30, 2021, the carrying values of the Clene Nanomedicine Contingent Earn-out and Initial Shareholders
Contingent Earn-out were $34.0 million and $4.2 million, respectively. For the three months ended September 30, 2021, we recognized gains
of $35.0 million in change in fair value of the Clene Nanomedicine Contingent Earn-out and $3.4 million in change in fair value of the
Initial Shareholders Contingent Earn-out as components of other income (expense), net in the condensed consolidated statements of operations
and comprehensive income (loss). For the nine months ended September 30, 2021, we recognized gains of $18.1 million in change in fair
value of the Clene Nanomedicine Contingent Earn-out and $1.7 million in change in fair value of the Initial Shareholders Contingent Earn-out
as components of other income (expense), net in the condensed consolidated statements of operations and comprehensive income (loss). To
date, none of the milestones have been achieved.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Derivative Instrument in Connection with
the 2021 Avenue Loan</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Avenue Warrants issued
pursuant to Tranche 1 of the 2021 Avenue Loan and the warrants issuable pursuant to the draw of Tranche 2 (see Note 8) met the requirements
for separate accounting and are therefore accounted for as derivative instruments. The 2021 Avenue Loan has the following features: (i)
prepayment provision, (ii) final payment provision, (iii) event of default redemption provision, and (iv) event of default interest provision.
The provisions (i) to (iii) are related to the loan host and are not bifurcated pursuant to ASC 815. For the provision (iv), we have not
experienced an event of default in the past and believe the probability of triggering one in the future is remote. Therefore, we determined
the value of this feature to be de minimis on the remote probability of occurrence of a triggering event.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the closing of the 2021
Avenue Loan, we recognized the warrant liability as a debt discount based on its fair value of $1.5 million. The debt discount is being
amortized over the contractual term using the effective interest method. Our determination of the fair value of the warrant utilized the
Black-Scholes option-pricing valuation model. Additionally, a Monte Carlo simulation was used to simulate the exercise price as an input
in the Black-Scholes valuation model (see Note 10). For the three and nine months ended September 30, 2021, we recognized income of $0.4
million and $0.5 million, respectively, in change in fair value of the warrant as a component of other income (expense), net in the condensed
consolidated statements of operations and comprehensive income (loss). To date, the warrants have not been exercised.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123477628&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724061022328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>13. Commitments and Contingencies</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Litigation</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may
have certain contingent liabilities that arise in the ordinary course of business activities. We accrue a liability for such matters when
it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. We are not aware of any current
pending legal matters or claims.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724171729256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>14. Income Taxes</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recorded income tax benefits
of $0.1 million and $0.2 million for the net operating losses incurred for the three and nine months ended September 30, 2021. We have
not recorded income tax benefits for the net operating losses incurred during the three and nine months ended September 30, 2020. We have
not recorded income tax benefits for research and development tax credits and other deferred tax assets generated, due to its uncertainty
of realizing a benefit from those items.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The components of income (loss)
before income taxes for the three and nine months ended September 30, 2021 and 2020 were as follows:&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">United States</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">29,860</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(11,370</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(11,435</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(20,724</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(985</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,075</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,941</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">669</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total loss before income taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">28,875</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(10,295</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(14,376</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(20,055</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is subject to
taxation in the United States, Australia, and various state jurisdictions. The Company computes its quarterly income tax provision by
using a forecasted annual effective tax rate and adjusts for any discrete items arising during the quarter. The primary difference between
the effective tax rate and the federal statutory tax rate relates to the full valuation allowance on the Company&#8217;s U.S. net operating
losses and other deferred tax assets.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724147638344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>15. Stock-Based Compensation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>2020 Stock Plan</i>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2020, in connection
with the Reverse Recapitalization, the Company&#8217;s Board of Directors approved the 2020 Stock Plan (the &#8220;2020 Stock Plan&#8221;)
and reserved 12,000,000 shares of Common Stock for issuance thereunder, all of which may be issued pursuant to incentive stock options
or any other type of award under the 2020 Stock Plan. The 2020 Stock Plan became effective immediately upon the closing of the Reverse
Recapitalization. The maximum number of shares of Common Stock that may be issued pursuant to the exercise of incentive stock options
under the 2020 Stock Plan is 12,000,000. Selected employees, officers, directors, and consultants are eligible to participate in the traditional
stock option grants, stock appreciation rights, restricted stock awards, restricted stock units, other stock awards, and performance awards
under the 2020 Stock Plan. The purpose of this 2020 Stock Plan is to enable us to offer competitive equity compensation packages in order
to attract and retain the talent necessary for the combined company.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The 2020 Stock Plan is administered
by the Company&#8217;s Board of Directors. The exercise prices, vesting periods, and other restrictions are determined at the discretion
of the Company&#8217;s Board of Directors, except that the exercise price per share of options may not be less than 100% of the fair market
value of the Common Stock on the date of grant. Stock options awarded under the 2020 Stock Plan expire ten years after the grant date,
unless the Company&#8217;s Board of Directors sets a shorter term. Stock options and restricted stock granted to employees, officers,
members of the Company&#8217;s Board of Directors, and consultants generally vest over a four-year period. If an option or other award
granted under the 2020 Stock Plan expires, terminates, or is cancelled, the unissued shares subject to that option or award shall again
be available under the 2020 Stock Plan. If shares awarded pursuant to the 2020 Stock Plan are forfeited to or repurchased at original
cost by the Company, the number of shares forfeited or repurchased at original cost shall again be available under the 2020 Stock Plan.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of September 30, 2021, the Company&#8217;s Board of Directors granted
rights to 3,819,930 restricted stock awards and stock options under the 2020 Stock Plan. As of September 30, 2021, 8,180,070 shares remained
available for future grant.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2020, the
Company&#8217;s Board of Directors granted rights to 1,507,062 restricted stock awards under the 2020 Stock Plan. As of December 31, 2020,
10,492,938 shares remained available for future grant.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>2014 Stock Plan</i>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the closing of the
Reverse Recapitalization, the 2014 Stock Plan is administered by the Company&#8217;s Board of Directors. Stock options awarded under the
2014 Stock Plan expire ten years after the grant date. Stock options and restricted stock granted to employees, officers, members of the
Company&#8217;s Board of Directors, and consultants typically vest over a four-year period.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the Reverse
Recapitalization (see Note 3), stock options outstanding under the 2014 Stock Plan of 53,286,115 were converted into 7,032,591 of stock
options of the Company based on the Exchange Ratio determined in accordance with the terms of the Merger Agreement. The exchange of Clene
Nanomedicine&#8217;s stock options for Clene Inc. stock options was treated as a modification of the awards. The modification of the stock
options did not result in a material incremental compensation expense to be recognized at the closing of the Reverse Recapitalization.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2020, the Company&#8217;s Board of Directors granted stock options for 270,555 shares under the 2014 Stock Plan. Effective as of the
closing of the Reverse Recapitalization on December 30, 2020, no additional awards may be made under the 2014 Stock Plan and as a result,
(i) any shares in respect of stock options that are expired or terminated under the 2014 Stock Plan without having been fully exercised
will not be available for future awards; (ii) any shares in respect of restricted stock that are forfeited to, or otherwise repurchased
by the Company, will not be available for future awards; and (iii) any shares of Common Stock that are tendered to the Company by a participant
to exercise an award will not be available for future awards.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stock-based compensation expense for the three months ended September
30, 2021 and 2020 was approximately $2.4 million and $0.2 million, respectively, and approximately $9.9 million and $0.6 million for the
nine months ended September 30, 2021 and 2020, respectively. Stock-based compensation is recorded in research and development and general
and administrative expenses in the condensed consolidated statements of operations and comprehensive income (loss) as follows:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">858</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">134</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,861</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">364</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,567</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">75</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,084</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">190</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total stock-based compensation</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,425</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">209</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,945</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">554</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock Options</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following sets forth the
outstanding stock options and related activity for the nine months ended September 30, 2021 (in thousands, except share and per share
data):&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Equity</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/> Average <br/> Exercise <br/> Price <br/> Per Share</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/> Average <br/> Remaining <br/> Term <br/> (Years)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Intrinsic <br/> Value</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -10pt; padding-left: 10pt">Outstanding - December&#160;31, 2020</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7,032,591</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.97</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5.34</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">62,462</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,574,441</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.85</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.61</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-212">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(409,867</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.04</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-213">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,373</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 0.125in">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(133,742</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8.66</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-214">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-215">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Outstanding - September 30, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">9,063,423</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3.09</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5.90</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">38,863</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Options vested and exercisable - September 30, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6,000,723</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.82</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4.33</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">36,247</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Stock options vested and expected to vest - September 30, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">9,063,423</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3.09</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5.90</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">38,863</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of September 30, 2021 and December 31, 2020, we had approximately
$15.2 million and $2.4 million of unrecognized stock-based compensation costs related to non-vested stock options which is expected to
be recognized over a weighted-average period of 2.33 years and 2.04 years, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the consummation
of the Reverse Recapitalization, the exercise price of the stock options granted was based on the fair market value of the common shares
of the Company as of the grant date as determined by the Board of Directors, with input from management. The Board of Directors determined
the fair value of the common stock at the time of grant of the options by considering a number of objective and subjective factors, including
third-party valuation reports, valuations of comparable companies, sales of redeemable convertible Preferred Stock, sales of common stock
to unrelated third parties, operating and financial performance, the lack of liquidity of the Company&#8217;s capital stock, and general
and industry-specific economic outlook.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stock options are valued using
the Black-Scholes valuation model. Since we have limited trading history of our Common Stock, the expected volatility is derived from
the average historical stock volatilities of several unrelated public companies within our industry that we consider to be comparable
to its own business over a period equivalent to the expected term of the stock option grants. The risk-free interest rate for periods
within the contractual life of the stock options is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected
dividend is assumed to be zero as we have never paid dividends and have no current plans to do so. The expected term represents the period
that stock-based awards are expected to be outstanding. For option grants that are considered to be &#8220;plain vanilla,&#8221; we determine
the expected term using the simplified method. The simplified method deems the term to be the average of the time-to-vesting and the contractual
life of the options. For other option grants, we estimate the expected term using historical data on employee exercises and post-vesting
employment termination behavior taking into account the contractual life of the award.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the nine months ended
September 30, 2021, we granted stock options for 2,574,441 shares under the 2020 Stock Plan. The assumptions used to calculate the value
of the stock option awards granted for the nine months ended September 30, 2021 are presented as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; white-space: nowrap; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; white-space: nowrap; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">Nine months ended<br/> September 30,<br/>
 2021</td><td style="padding-bottom: 1.5pt; white-space: nowrap; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected stock price volatility</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">84.8
&#8211; 87.4% </span></td><td style="text-align: left"/></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.59 &#8211; 0.94%</span></td><td style="text-align: left"/></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Expected dividend yield</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center">0.00%</td><td style="width: 1%; text-align: left"/></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected term</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.00 years &#160;</span></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The weighted-average grant-date
fair value of options granted during the nine months ended September 30, 2021 was $8.85.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Restricted Stock Awards</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 30, 2020, we granted
rights to awards of the following shares of restricted stock under the 2020 Stock Plan:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in">&#9679;</td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">370,101 shares to various employees and non-employee directors, which
vest on various dates between June 30, 2021 and January 15, 2022, subject to the employee&#8217;s continuous employment through such vesting
date. The restricted stock awards convert to shares of Common Stock on a one-for-one basis upon vesting. The award represents 5% of the
converted stock options under 2014 Stock Plan as a result of the Reverse Recapitalization and complements the 5% closing payment shares
held in escrow for Clene Nanomedicine common shareholders (see Note 3). The grant-date fair value of these awards was $4.0 million based
on the closing price of CLNN shares listed on Nasdaq of $10.82 per share on December 30, 2020, the date of the Reverse Recapitalization.
As of September 30, 2021, there were 224,109 shares of Common Stock issued upon the vesting of restricted stock awards. As of December
31, 2020 no shares were vested.</p></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">454,781 shares to various employees and non-employee directors, which were eligible to vest based on certain market conditions, subject to the employee&#8217;s continuous employment through such vesting date. The award complements the Milestone 1 earn-out share entitlement of Clene Nanomedicine shareholders and vests based on the same market condition (see Note 3). The grant-date fair value of these awards, using a Monte Carlo simulation, was $4.3 million. Based on the outcome of the market condition as of the September 30, 2021 and December 31, 2020 measurement dates, no shares were vested.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">341,090 shares to various employees and non-employee directors, which were eligible to vest based on certain market conditions, subject to the employee&#8217;s continuous employment through such vesting date. The award complements the Milestone 2 earn-out share entitlement of Clene Nanomedicine. shareholders and vests based on the same market condition (see Note 3). The grant-date fair value of these awards, using a Monte Carlo simulation, was $3.5 million. Based on the outcome of the market condition as of the September 30, 2021 and December 31, 2020 measurement dates, no shares were vested.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.5in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">341,090 shares to various employees and non-employee directors, which were eligible to vest based on certain performance conditions tied to the completion of the COVID-19 coronavirus treatment study, subject to the employee&#8217;s continuous employment through such vesting date. The award complements the Milestone 3 earn-out share entitlement of Clene Nanomedicine shareholders and vests based on the same performance condition (see Note 3). The grant-date fair value of these awards was $3.7 million, based on the closing price of CLNN shares listed on Nasdaq of $10.82 per share on December 30, 2020, the date of the Reverse Recapitalization. We did not recognize compensation expense because the occurrence of achieving this milestone was not probable. As of the September 30, 2021 and December 31, 2020 measurement dates, no shares were vested.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes
the restricted stock award activity during the nine months ended September 30, 2021:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Restricted Stock Awards</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-<br/> Average<br/> Grant <br/> Date Fair <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Outstanding and unvested balance as of December 31, 2020</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,507,062</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10.30</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Converted to shares of Common Stock upon vesting</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(224,109</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-216">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(37,464</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10.82</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Outstanding and unvested balance as of September 30, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,245,489</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10.14</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The assumptions used to calculate
the value of the rights to restricted stock awards granted in 2020 in the Monte Carlo valuation model include projected stock price, volatility,
and risk-free rate based on the achievement of certain stock price milestones. Our significant unobservable inputs as of December 31,
2020 were as follows: (i) 85% of expected stock price volatility, (ii) risk-free interest rate of 0.4%, and (iii) expected term of five
years. The weighted average grant-date fair value of rights to restricted stock awards granted as of December 31, 2020 was $10.3034.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The stock-based compensation expense associated with the rights to
restricted stock awards was $0.8 million and $6.8 million for the three and nine months ended September 30, 2021. As of September 30,
2021 and December 31, 2020, total unrecognized compensation cost related to the unvested stock-based awards was $0.9 million and $15.5
million, respectively, which is expected to be recognized over a weighted average period of less than 1 month and 6 months, respectively.
We did not issue any restricted stock awards during the nine months ended September 30, 2020.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724061050888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>16. Fair Value</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cash is carried at fair
value. Financial instruments, including accounts receivable, accounts payable, and accrued expenses are carried at cost, which
approximates fair value given their short-term nature. The 2019 MD Loan, the 2019 Cecil Loan, the derivative instruments associated
with the 2021 Avenue Loan, and the derivative instruments associated with the Contingent Earn-outs are carried at fair value. The
2021 Avenue Loan, related convertible notes payable, and Conversion Feature are carried at amortized cost, which approximate fair value due to our credit
risk and market interest rates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Liabilities with Fair Value Measurements on a Recurring Basis</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following tables present
our fair value hierarchy for liabilities measured at fair value on a recurring basis as of September 30, 2021 and December 31, 2020:&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair Value Measurements on a Recurring Basis <br/> September 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Notes payable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">983</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-217">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-218">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">983</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-219">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-220">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">910</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">910</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Clene Nanomedicine contingent earn-out</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-221">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-222">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,981</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,981</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Initial Shareholders contingent earn-out</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-223">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-224">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,196</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,196</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair Value Measurements on a Recurring Basis <br/> December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Notes payable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,296</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-225">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-226">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,296</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Clene Nanomedicine contingent earn-out</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-227">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-228">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52,053</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52,053</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Initial Shareholders contingent earn-out</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-229">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-230">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,906</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,906</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There were no transfers between
levels in the fair value hierarchy as of September 30, 2021 and December 31, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Valuation of Notes Payable and Convertible
Notes Payable</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The carrying value of notes payable and convertible notes payable includes
certain notes carried at amortized cost, and certain notes remeasured at fair value on a recurring basis in the condensed consolidated
balance sheets as of September 30, 2021 and December 31, 2020. In order to value the notes, we considered the amount of simple interest
expense that would be due and the value of our Common Stock.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of September 30, 2021 and
December 31, 2020, the fair value of the 2019 MD Loan and the 2019 Cecil Loan was determined based on the closing prices of $6.83 and
$9.01 per share, respectively, as reported by Nasdaq.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of September 30, 2021,
the amortized cost of the 2021 Avenue Loan was $18.2 million, which includes the notes payable, carried at $13.6 million;
and the convertible notes payable and embedded Conversion Feature, carried at $4.6 million. The valuation of the Conversion Feature is
discussed below. The 2021 Avenue Loan was not outstanding as of December 31, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Valuation of Conversion Feature</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Conversion Feature of the convertible notes payable from the 2021
Avenue Loan is carried at amortized cost and did not meet the requirements for separate accounting and is not accounted for as a derivative
instrument. The estimated fair value of the Conversion Feature was $2.0 million and was determined using a Black-Scholes valuation model,
with a Monte Carlo analysis performed in order to simulate the Next Round Price as an input in the Black-Scholes valuation model. The
unobservable inputs to the model were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Black-Scholes Valuation Model</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2020</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Expected stock price volatility</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">85.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-231">N/A</div></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.50</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-232">N/A</div></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-233">N/A</div></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.56 years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-234">N/A</div></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Monte Carlo Simulation</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September&#160;30,<br/> 2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, <br/> 2020</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Expected stock price volatility</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">35.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-235">N/A</div></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.07</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-236">N/A</div></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-237">N/A</div></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.09 years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-238">N/A</div></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Valuation of Warrants to Purchase Preferred
Stock</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;Our Preferred Stock
warrant liabilities contain unobservable inputs that reflect our own assumptions. Accordingly, the Preferred Stock warrant liabilities
were measured at fair value on a recurring basis using unobservable inputs. Prior to the extinguishment of the Preferred Stock warrant
liabilities on December 30, 2020, the Preferred Stock warrant liability was valued using a Black-Scholes valuation model.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board of Directors determined
the fair value of the Preferred Stock by considering a number of objective and subjective factors, including third-party valuations, valuations
of comparable companies, sales of redeemable convertible Preferred Stock, sales of common stock to unrelated third parties, operating
and financial performance, the lack of liquidity of our capital stock, and general and industry-specific economic outlook. We estimated
the volatility of our Preferred Stock based on comparable peer companies&#8217; historical volatility. The risk-free interest rate for
periods within the contractual life of the warrants was based on the U.S. Treasury yield curve in effect at the valuation date. We have
no plans to declare any future dividends. The determination of the fair value of the Preferred Stock warrant liability could change in
future periods based upon changes in the value of our Preferred Stock and other assumptions as presented above. We record any such change
in fair value to the change in fair value of Preferred Stock warrant liability expense line in the condensed consolidated statements of
operations and comprehensive income (loss).&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the closing of the Reverse
Recapitalization (see Note 3), all of the outstanding Clene Nanomedicine Preferred Stock was converted to Clene Inc. Common Stock and
the Clene Nanomedicine Preferred Stock warrants were converted to warrants for the purchase of Clene Inc. Common Stock. Accordingly, the
Preferred Stock warrant liabilities were extinguished in connection with the conversion of Clene Nanomedicine Preferred Stock on December
30, 2020 (see Note 9).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Valuation of the Warrant Liability</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the 2021 Avenue Loan, we issued the Avenue Warrants to
purchase 115,851 shares of Common Stock pursuant to Tranche 1 of the 2021 Avenue Loan. In accordance with ASC 815, we recognized an additional
warrant to purchase an estimated 86,679 shares of Common Stock that will be issued pursuant to the draw of Tranche 2 of the 2021 Avenue
Loan (see Note 10). The warrants were recorded at fair value at the closing of the 2021 Avenue Loan on May 21, 2021, and the fair value
and issuable shares will be remeasured at each reporting period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The estimated fair value of
the warrant liability was determined using a Black-Scholes valuation model, with a Monte Carlo analysis performed in order to simulate
the Next Round Price as an input in the Black-Scholes valuation model. The carrying amount of the liability may fluctuate significantly
and actual amounts may be materially different from the liabilities&#8217; estimated value. As of September 30, 2021, the warrant was
revalued using a similar Black-Scholes valuation model. The unobservable inputs to the model were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Black-Scholes Valuation Model</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,<br/> 2021</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2020</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Expected stock price volatility</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">95.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-239">N/A</div></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.90</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-240">N/A</div></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-241">N/A</div></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.89 years &#8211; 4.56 years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-242">N/A</div></td>
    <td>&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Monte Carlo Simulation</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,<br/> 2021</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2020</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected stock price volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40.00 &#8211; 70.00</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-243">N/A</div></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 78%; text-align: left">Risk-free interest rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">0.07</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-244">N/A</div></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-245">N/A</div></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.09 years &#8211; 0.66 years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-246">N/A</div></td>
    <td>&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Valuation of the Contingent Earn-Outs</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Merger Agreement,
Clene Nanomedicine&#8217;s common shareholders immediately prior to the Reverse Recapitalization and Initial Shareholders of Tottenham
were entitled to receive additional shares of up to 8,333,333 shares and 750,000 shares of Common Stock, respectively, upon us achieving
certain milestones (see Note 3). Upon the consummation of the Reverse Recapitalization, Clene Nanomedicine and the Initial Shareholders
are entitled to receive up to 8,346,185 additional shares as a result of the exercise of the stock options in November 2020, and 750,000
shares of Common Stock. The Contingent Earn-outs were recorded at fair value on the closing of the Reverse Recapitalization on December
30, 2020 and will be remeasured at each reporting period. As of September 30, 2021 and December 31, 2020, no milestone has been achieved.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The estimated fair value of
the initial Contingent Earn-outs was determined using a Monte Carlo analysis in order to simulate the future path of our stock price over
the earn-out periods. The carrying amount of the liabilities may fluctuate significantly and actual amounts paid may be materially different
from the liabilities&#8217; estimated value. As of September 30, 2021 and December 31, 2020, the Contingent Earn-outs were revalued using
a similar Monte Carlo analysis. The unobservable inputs to the models were as follows:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,<br/> 2021</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2020</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Expected stock price volatility</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">95.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">85.00</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.80</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.40</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2 years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.00 years</span></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of changes in the fair value of our financial liabilities related to the notes payable, the derivative instrument, the Preferred Stock
warrants, the warrant liability, and the Contingent Earn-outs measured at fair value for the nine months ended September 30, 2021 and
2020:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Notes <br/> Payable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Clene Nanomedicine<br/> Contingent <br/> Earn-out</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Initial Shareholders<br/> Contingent <br/> Earn-out</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Warrant<br/> Liability</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Balance - December 31, 2020</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,296</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">52,053</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,906</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-247">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10pt">Initial fair value of instrument</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-248">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-249">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-250">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,457</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(313</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(18,072</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,710</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(547</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Balance - September 30, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">983</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">33,981</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,196</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">910</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Notes <br/> Payable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Derivative<br/> Instrument</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Preferred<br/> Stock<br/> Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Balance - December 31, 2019</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">640</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-251">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,213</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 10pt">Issuance of convertible promissory notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-252">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">705</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-253">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">323</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(29</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,378</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Extinguishment of derivative liability in connection with extinguishment of convertible promissory notes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-254">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(676</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-255">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance - September 30, 2020</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">963</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-256">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,591</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724060997848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_RedeemableConvertiblePreferredStockDisclosureAbstract', window );"><strong>Redeemable Convertible Preferred Stock Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_RedeemableConvertiblePreferredStockDisclosureTextBlock', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>17. Redeemable Convertible Preferred Stock</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the closing
of the Reverse Recapitalization, the Preferred Stock converted into 36,893,894 shares of Common Stock on a 1:0.1389 basis (see Note 3).
As of September 30, 2021 and December 31, 2020, there were no Preferred Stock outstanding.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The redeemable convertible
preferred stock is described in Note 17, Redeemable Convertible Preferred Stock in Part II, Item 8 of our 2020 Annual Report on Form 10-K
for the year ended December 31, 2020 (&#8220;2020 Annual Report&#8221;) which was filed with the SEC on March 29, 2021. There have been
no changes since our 2020 Annual Report.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_RedeemableConvertiblePreferredStockDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_RedeemableConvertiblePreferredStockDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_RedeemableConvertiblePreferredStockDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redeemable Convertible Preferred Stock [Text Block].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_RedeemableConvertiblePreferredStockDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724058627880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>18. Common Stock</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of September 30, 2021 and
December 31, 2020, our certificate of incorporation, as amended and restated, authorized us to issue 150,000,000 and 100,000,000 shares
of Common Stock, respectively, par value $0.0001 per share and 1,000,000 shares of Preferred Stock, par value $0.0001 per share. At our
2021 Annual Meeting of Stockholders on May 18, 2021, our stockholders approved an amendment to the Amended and Restated Certificate of
Incorporation to increase the number of authorized shares of Common Stock from 100,000,000 to 150,000,000.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common shareholders are
entitled to one vote per share and to notice of any shareholders&#8217; meeting. Voting, dividend, and liquidation rights of the holders
of Common Stock are subject to the prior rights of holders of all classes of stock and are qualified by the rights, powers, preferences,
and privileges of the holders of Preferred Stock. No distributions shall be made with respect to Common Stock until all declared dividends
to Preferred Shares have been paid or set aside for payment to the holders of Preferred Stock. Common Stock is not redeemable at the option
of the holder.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On the closing of the Reverse
Recapitalization, the total outstanding 2,303,495 Tottenham ordinary shares held by the Initial Shareholders and public shareholders were
converted into the same number of Common Stock (see Note 3).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On the closing of the Reverse
Recapitalization, 644,164 shares of Common Stock were issued to LifeSci as financial advisor to the Reverse Recapitalization (see Note
3).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the completion of
the Reverse Recapitalization on December 30, 2020, the Company entered into a subscription agreement on December 28, 2020, with various
investors. Pursuant to the subscription agreements, the Company issued 2,239,500 shares of Common Stock (the &#8220;December 2020 PIPE
Shares&#8221;) at a price of $10.00 per share with net proceeds of $22.2 million. The purpose of the December 2020 PIPE was to fund general
corporate expenses. In addition, investors in the December 2020 PIPE offering also received warrants to purchase a number of shares equal
to one-half (1/2) of the number of December 2020 PIPE Shares, totaling 1,119,750 shares of Common Stock, at an exercise price of $0.01
per share, subject to a 180-day holding period (see Note 10).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 21, 2021, the Company
entered into the May 2021 PIPE subscription agreements with various investors. Pursuant to the subscription agreements, the Company issued
960,540 shares of Common Stock at a price of $9.63 per share with net proceeds of $9.3 million. The closing of the May 2021 PIPE occurred
substantially concurrently with, and was conditioned upon, the closing of the 2021 Avenue Loan (see Note 8). The purpose of the May 2021
PIPE was to fund the expansion of manufacturing capabilities in the state of Maryland and to fund general corporate expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Between July 1, 2021 and September
15, 2021, various investors exercised December 2020 PIPE Warrants for 1,002,250 shares of Common Stock at an exercise price of $0.01 per
share. The December 2020 PIPE Warrants were issued prior to the completion of the Reverse Recapitalization on December 30, 2020, and were
subject to a 180-day holding period which expired on June 28, 2021. We received cash proceeds of $10.0 thousand.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 15, 2021, Chardan
exercised the Chardan Unit Purchase Option for 220,000 units, each unit consisting of one and one-tenth shares of Common Stock and one
warrant to purchase one-half of one share of Common Stock at an exercise price of $11.50 per share. Chardan elected to perform a cashless
or net exercise, which resulted in a net issuance of 54,083 shares of Common Stock and 49,166 warrants to purchase one-half of one share
of Common Stock. The Chardan Unit Purchase Option was originally issued in connection with Tottenham&#8217;s initial public offering in
August 2018. We received no cash proceeds.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of September 30, 2021 and
December 31, 2020, our common shares issued and outstanding were 62,177,020 and 59,526,171, respectively. As of September 30, 2021 and
December 31, 2020, there were no preferred shares issued and outstanding (see Note 17).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724153879720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share Attributable to Common Shareholders<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income (Loss) Per Share Attributable to Common Shareholders</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>19. Net Income (Loss) Per Share Attributable
to Common Shareholders</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
the computation of basic and diluted net income (loss) per share attributable to common shareholders (in thousands, except share and per
share data):&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="text-decoration:underline">Numerator&#160;:</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -9pt; padding-left: 0.25in">Net income (loss) attributable to common shareholders &#8211; Basic</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">28,944</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(10,295</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(14,163</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(20,055</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Less interest expense on potentially dilutive convertible notes payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">196</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Net income (loss) attributable to common shareholders - Diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">29,140</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(10,295</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(14,163</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(20,055</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="text-decoration:underline">Denominator:</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 0.25in">Weighted average common shares outstanding &#8211;Basic</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62,071,754</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,358,159</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">61,307,699</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,358,159</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 0.25in">Weighted average effect of potentially dilutive securities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Effect of potentially dilutive stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,791,023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-257">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-258">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-259">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Effect of potentially dilutive common stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,485,049</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-260">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-261">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-262">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Effect of potentially dilutive convertible notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">482,703</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-263">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-264">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-265">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Effect of potentially dilutive restricted stock awards</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">208,105</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-266">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-267">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-268">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Weighted average common shares outstanding &#8211;Diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">70,038,634</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">17,358,159</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">61,307,699</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">17,358,159</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Net income (loss) per share attributable to common shareholders:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 0.25in">Basic</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.47</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.59</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.23</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1.16</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 0.25in">Diluted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.42</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.59</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.23</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1.16</td><td style="text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Included within weighted average common shares outstanding are the
remaining 117,500 (originally 1,119,750) common shares issuable upon the exercise of the December 2020 PIPE Warrants, as these warrants
are exercisable at any time for nominal consideration, and as such, the shares are considered outstanding for the purpose of calculating
basic and diluted net loss per share attributable to common shareholders.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following shares of potentially dilutive securities were excluded
from the computation of diluted net income (loss) per share attributable to common shareholders for the periods presented because including
them would have been antidilutive, or issuance of such shares is contingent upon the satisfaction of certain conditions which were not
satisfied by the end of the period, or they were out-of-the money:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Series D redeemable convertible preferred stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-269">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">9,394,057</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-270">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">9,394,057</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Series C redeemable convertible preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-271">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,264,519</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-272">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,264,519</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Series B redeemable convertible preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-273">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,168,815</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-274">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,168,815</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Series A redeemable convertible preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-275">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,066,503</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-276">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,066,503</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Series D redeemable convertible preferred stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-277">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">320,441</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-278">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">320,441</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Series A redeemable convertible preferred stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-279">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,608,670</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-280">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,608,670</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Convertible notes payable (see Note 11)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-281">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-282">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">482,703</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-283">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Common stock warrants (see Note 10)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,523,351</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-284">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,569,962</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-285">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Options to purchase common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,685,575</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,509,810</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,063,423</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,509,810</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Restricted stock awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,100,050</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-286">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,245,489</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-287">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Chardan Unit Purchase Option Warrants (see Notes 3 and 10)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,583</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-288">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,583</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-289">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Clene Nanomedicine contingent earn-out shares (see Note 3 and 12)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,346,185</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-290">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,346,185</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-291">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Initial Shareholders contingent earn-out shares (see Note 3 and 12)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">750,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-292">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">750,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-293">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif">15,429,744</p></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">46,332,815</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">24,482,345</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">46,332,815</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724061057688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>20. Related Party Transactions</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the three and nine months
ended September 30, 2020, we incurred $0 and $0.1 million, respectively, of expenses for compensation for consulting services provided
by a member of the Board of Directors. These expenses were paid in their entirety and as of September 30, 2020 and December 30, 2020,
there was no outstanding balance due to this related party.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>License and Supply Agreements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August&#160;2018, in conjunction
with an investment made in our Series C Preferred Stock and Series C Preferred Stock Warrants by 4Life Research, LLC, an investor, we
entered into a supply agreement with the investor. Under the terms of this agreement, we granted the investor an exclusive license to
pursue development of dietary supplements using certain of our intellectual property (&#8220;IP&#8221;). The exclusive rights to the IP
is for a term of <span style="-sec-ix-hidden: hidden-fact-294">five</span>&#160;years from the commencement of sales of licensed product by the investor, with a deemed commencement date of
January 1, 2023 if sales have not yet commenced, and is subject to annual minimum sales. The agreement may be renewed for additional five-year
terms. If the investor fails to meet the annual minimum sales requirements, the investor may pay an additional fee to maintain exclusivity
or have the investor&#8217;s license converted to non-exclusive rights. As part of this agreement, we will provide non-pharmaceutical
product to the investor for development efforts and potential future production, and the investor is to pay royalties of 3% of incremental
sales, as defined in the agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the three and nine months
ended September 30, 2021, we sold $0.1 million and $0.4 million of product, respectively, under this agreement. We did not sell any products
outside of this agreement. For the three and nine months ended September 30, 2021, the investor has made commercial sales of their products
under the agreement which we recognized as royalty revenues of $47 thousand and $0.1 million, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the nine months ended September 30, 2020, we sold $0.1 million
of product under this agreement, as well as $0.1 million of product not under this agreement, and received $0.1 million in advance to
be applied against future sales of product under this agreement. We recorded this advanced amount as deferred revenue as of September
30, 2020. The investor did not make sales of their products under the agreement, and as such we did not recognize any royalty revenues
for the nine months ended September 30, 2020. For the three months ended September 30, 2020, we did not sell any product under this agreement,
we sold $2 thousand of product not under this agreement, and there were no balances outstanding due to or from the investor.&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724245945608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geographic and Segment Information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Geographic and Segment Information</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>21. Geographic and Segment Information</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Geographic Information</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our long-lived assets, which
were composed of property and equipment, net by location were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">As of<br/> September&#160;30,<br/>
</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">As of<br/> December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">United States</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,193</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,997</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Australia</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">53</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">228</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,246</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,225</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Segment Information</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The operating results of the
Drugs and Supplements segments were as follows:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Three Months ended <br/> September 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Nine Months ended <br/> September 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Drugs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Supplements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Drugs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Supplements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; text-indent: -9pt; padding-left: 9pt">Revenue from external customers</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-295">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">110</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">110</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-296">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">524</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">524</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Income (loss) from operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(10,546</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">96</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(10,450</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(35,632</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(288</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(35,920</td><td style="text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Three Months ended <br/> September 30, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Nine Months ended <br/> September 30, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Drugs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Supplements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Drugs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Supplements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; text-indent: -9pt; padding-left: 9pt">Revenue from external customers</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-297">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">98</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">98</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-298">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">177</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">177</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Income (loss) from operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(5,789</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">98</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(5,691</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(14,373</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">119</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(14,254</td><td style="text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our long-lived assets, which
were composed of property and equipment, net by segment were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">As of <br/> September 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">As of <br/> December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Drugs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-299">4, 038</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,990</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Supplements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">208</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">235</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,246</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,225</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724155904520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>22. Subsequent Events</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 1, 2021, various
investors exercised December 2020 PIPE Warrants for 25,000 shares of Common Stock at an exercise price of $0.01 per share. The December
2020 PIPE Warrants were issued prior to the completion of the Reverse Recapitalization on December 30, 2020, and were subject to a 180-day
holding period which expired on June 28, 2021. We received cash proceeds of $250.&#160;&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724150380680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Basis of Presentation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have prepared the accompanying
condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States of America
(&#8220;GAAP&#8221;) for interim financial reporting and as required by Regulation S-X, Rule 10-01. The condensed consolidated financial
statements have been prepared on the same basis as our audited annual consolidated financial statements and, in the opinion of management,
reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of our financial condition as
of September 30, 2021, the results of our operations for the three and nine months ended September 30, 2021, our cash flows for the nine
months ended September 30, 2021 and 2020, and the condensed consolidated statement of stockholders&#8217; equity (deficit) for the three
and nine months ended September 30, 2021 and 2020. The financial data and other information disclosed in these notes related to the three
and nine months ended September 30, 2021 and 2020 are unaudited. The results of operations for the three and nine months ended September
30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021, any other interim periods,
or any future year or period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior period balances for
accounts receivable have been reclassified to conform to the current year presentation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of condensed
consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets, liabilities, and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial
statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying
condensed consolidated financial statements include, but are not limited to, the valuation of common stock, stock options, contingent
earn-out liabilities, Preferred Stock warrants, and Common Stock warrants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We base our estimates on historical
experience and on various other assumptions that are believed to be reasonable. Actual results may differ from those estimates or assumptions.
Estimates are periodically reviewed in light of changes in circumstances, facts, and experience. Changes in estimates will be recorded
in future periods as they develop.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_RiskAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Risks and Uncertainties</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The product candidates we
develop require approvals from the U.S. Food and Drug Administration or foreign regulatory agencies prior to commercial sales. There can
be no assurance that our current and future product candidates will receive the necessary approvals or be commercially successful. If
we are denied approval or approval is delayed, it will have a material adverse impact on our business and our condensed consolidated financial
statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to risks common
to companies in the development stage including, but not limited to, dependency on the need for substantial additional financing to achieve
our goals, uncertainty of broad adoption of our approved products, if any, by physicians and patients, significant competition, and untested
manufacturing capabilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to certain
risks and uncertainties and believe that changes in any of the following areas could have a material adverse effect on future financial
condition or results of operations: ability to obtain additional financing; regulatory approval and market acceptance of, and reimbursement
for, product candidates; performance of third-party CROs and manufacturers upon which we rely; protection of our intellectual property;
litigation or claims against us based on intellectual property, patent, product, regulatory, or other factors; and our ability to attract
and retain employees necessary to support our growth.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Concentrations of Credit Risk</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial instruments which
potentially subject us to significant concentrations of credit risk consist primarily of cash. Our cash is mainly held in financial institutions.
Amounts on deposit may at times exceed federally insured limits. We have not experienced any losses on our deposits of cash and do not
believe that we are subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cash and Cash Equivalents</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We consider all short-term
investments with an original maturity of three months or less when purchased to be cash equivalents. As of September 30, 2021 and December
31, 2020, we had no cash equivalents.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Restricted Cash</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We classify cash as restricted when it is unavailable for withdrawal
or use in our general operating activities. Restricted cash and investments are classified as current and noncurrent on the consolidated
balance sheets based on the nature of the restriction. Our restricted cash balance includes contractually restricted deposits related
to our corporate credit card. As of September 30, 2021 and December 31, 2020, we had restricted cash of $0.1 million and $0, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Accounts Receivable</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Accounts receivable are stated
at invoice value less estimated allowances for sales returns and doubtful accounts. We estimate the allowance for sales returns based
on historical percentage of returns over a 12-month trailing average of sales. We continually monitor customer payments and maintain a
reserve for estimated losses resulting from our customers&#8217; inability to make required payments. We consider factors when estimating
the allowance for doubtful accounts such as historical experience, age of the accounts receivable balances, geographic related risks,
and economic conditions that may affect a customer&#8217;s ability to pay. In cases where there are circumstances that may impair a specific
customer&#8217;s ability to meet its financial obligations, a specific allowance is recorded against amounts due, thereby reducing the
net recognized receivable to the amount reasonably believed to be collectible. Accounts receivable are written off when deemed uncollectible.
Recoveries of accounts receivable previously written off are recorded when received. Historically, there have been no sales returns, no
written-off accounts receivable, and no allowance for doubtful accounts reducing the balance of the accounts receivable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Inventory</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Inventory is stated at historic
cost on a first-in first-out basis. Our inventory consisted of $26 thousand in raw materials and $14 thousand in finished goods as of
September 30, 2021. Our inventory consisted of $0.1 million in raw material and $0.1 million in finished goods as of December 31, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_DebtDiscountAndIssuanceCostsPolicyTextBlock', window );">Debt Discounts, Debt Premiums, and Debt Issuance Costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Debt Discounts, Debt Premiums, and Debt
Issuance Costs</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">When debt is issued and a
derivative is required to be bifurcated (e.g., bifurcated conversion option) or another separate freestanding financial instrument (e.g.,
warrant) is issued, costs and fees incurred are allocated to the instruments issued (or bifurcated) in proportion to the allocation of
proceeds. When some portions of the costs and fees relate to a bifurcated derivative or freestanding financial instrument that is being
subsequently measured at fair value, those allocated costs are expensed immediately. Debt discounts, debt premiums, and debt issuance
costs related to convertible loans are recorded as deductions that net against the principal value of the debt and are amortized to interest
expense over the contractual term of the debt using the effective interest method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Deferred Offering Costs</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We capitalize certain legal,
professional accounting. and other third-party fees that are directly associated with in-process equity financings, including the Reverse
Recapitalization and the December 2020 PIPE, as deferred offering costs until such financings are consummated. After consummation of the
equity financing, these costs are recorded in stockholders&#8217; equity (deficit) as a reduction of proceeds generated as a result of
the offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge
to operating expenses in the condensed consolidated statements of operations and comprehensive income (loss).&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the three and nine
months ended September 30, 2021, we did not incur any offering costs.&#160;During the three and nine months ended September 30, 2020,
we incurred $2.3 million of deferred offering costs related to the Reverse Recapitalization that were comprised of legal and professional
accounting fees and other costs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Leases</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At inception of a contract,
we determine if a contract meets the definition of a lease. A lease is a contract, or part of a contract, that conveys the right to control
the use of identified property, plant, or equipment for a period of time in exchange for consideration. We determine if the contract conveys
the right to control the use of an identified asset for a period of time. We assess throughout the period of use whether we have both
of the following: (i)&#160;the right to obtain substantially all of the economic benefits from use of the identified asset, and (ii)&#160;the
right to direct the use of the identified asset. This determination is reassessed if the terms of the contract are changed. Leases are
classified as operating or finance leases based on the terms of the lease agreement and certain characteristics of the identified asset.
Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of the future lease
payments less any lease incentives received. At the lease commencement date, the discount rate implicit in the lease is used to discount
the lease liability if readily determinable. If not readily determinable or leases do not contain an implicit rate, our incremental borrowing
rate is used as the discount rate.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We lease laboratory and office
space and certain equipment under non-cancellable operating and finance leases. The carrying value of our right-of-use lease assets is
substantially concentrated in our real estate leases, while the volume of lease agreements is primarily concentrated in equipment leases.
Our policy is to not record leases with an original term of twelve months or less within the condensed consolidated balance sheets. We
recognize lease expense for these short-term leases on a straight-line basis over the lease term in the condensed consolidated statements
of operations and comprehensive income (loss).&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain lease agreements may
require us to pay additional amounts for taxes, insurance, maintenance, and other expenses, which are generally referred to as non-lease
components. Such variable non-lease components are treated as variable lease payments and recognized in the period in which the obligation
for these payments is incurred. Variable lease components and variable non-lease components are not measured as part of the right-of-use
asset and liability. Only when lease components and their associated non-lease components are fixed are they accounted for as a single
lease component and are recognized as part of a right-of-use asset and liability. Total contract consideration is allocated to the combined
fixed lease and non-lease component. This policy election applies consistently to all asset classes under lease agreements.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Leases may contain clauses
for renewal at our option. Payments to be made in option periods are recognized as part of the right-of-use lease assets and lease liabilities
when it is reasonably certain that the option to extend the lease will be exercised, or is not at our option. We determine whether the
reasonably certain threshold is met by considering contract-, asset-, market-, and entity-based factors. In the condensed consolidated
statements of operations and comprehensive income (loss), operating lease expense, which is recognized on a straight-line basis over the
lease term, and the amortization of finance lease right-of-use assets, which are included in property and equipment and depreciated, are
included in research and development or general and administrative expenses consistent with the leased assets&#8217; primary use. Accretion
on the liabilities for finance leases is included in interest expense.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Property and Equipment</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Property and equipment are
stated at cost less accumulated depreciation. Property and equipment consist of laboratory and office equipment and leasehold improvements.
Depreciation is calculated using the straight-line method over the estimated economic useful lives of the assets, which are 3-5&#160;years
for laboratory equipment and 3-7&#160;years for furniture and fixtures. Leasehold improvements are amortized over the lesser of the estimated
lease term or the estimated useful life of the assets. Costs for capital assets not yet placed into service are capitalized as construction
in progress and depreciated or amortized in accordance with the above useful lives once placed into service. Upon retirement or sale,
the related cost and accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included
in the condensed consolidated statements of operations and comprehensive income (loss). Maintenance and repairs that do not improve or
extend the lives of the respective assets are expensed to operations as incurred.&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ConvertibleNotespolicytextblock', window );">Convertible Notes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Convertible Notes</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with ASU 2020-06,
<i>Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own
Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</i>, when we issue notes
with conversion features, we evaluate if the conversion features are freestanding or embedded. If the conversion feature is embedded,
we do not separate the conversion feature from the host contract for convertible notes that are not required to be accounted for as derivatives,
or that do not result in substantial premiums accounted for as paid-in-capital. Consequently, we account for a convertible note as a single
liability measured at its amortized cost, and we account for a convertible preferred stock as a single equity instrument measured at its
historical cost, as long as no other features require bifurcation and recognition as derivatives.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the conversion feature
is freestanding, or is embedded and meets the requirements to be bifurcated, we account for the conversion feature as a derivative under
ASC 815, <i>Derivatives and Hedging</i> (&#8220;ASC 815&#8221;). We record the derivative instrument at fair value at inception, and subsequently
re-measure to fair value at each reporting period and immediately prior to the extinguishment of the derivative instrument, with any changes
recorded in the condensed consolidated statements of operations and comprehensive income (loss).&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_DebtWithWarrantsPolicyTextBlock', window );">Debt With Warrants</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Debt With Warrants</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with ASC 470-20, <i>Debt with Conversion and Other Options</i>,
when we issue debt with warrants, we treat the warrants as a debt discount, recorded as a contra-liability against the debt, and amortize
the balance over the life of the underlying debt as amortization of debt discount expense in the condensed consolidated statements of
operations and comprehensive income (loss). The offset to the contra-liability is recorded as additional paid-in capital in the condensed
consolidated balance sheets if the warrants are not treated as a derivative or liability under ASC 480, <i>Distinguishing Liabilities
from Equity</i> (&#8220;ASC 480&#8221;). Otherwise, the offset to the contra-liability is recorded as a warrant liability in the condensed
consolidated balance sheets and is subject to re-measurement to fair value at each balance sheet date, with any changes in fair value
recognized in the condensed consolidated statements of operations and comprehensive income (loss). If the debt is retired early, the associated
debt discount is then recognized immediately as amortization of debt discount expense in the condensed consolidated statements of operations
and comprehensive income (loss).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ContingentEarnoutPolicyTextBlock', window );">Contingent Earn-out</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Contingent Earn-Out Liabilities</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the Reverse
Recapitalization, certain shareholders are entitled to receive additional shares of Common Stock (the &#8220;Contingent Earn-outs&#8221;)
upon us achieving certain milestones (see Notes 3 and 12). In accordance with ASC 815, the Contingent Earn-outs are not indexed to our
own stock and therefore are accounted for as a liability at the Reverse Recapitalization date and subsequently remeasured at each reporting
date with changes in fair value recorded as a component of other income (expense), net in the condensed consolidated statements of operations
and comprehensive income (loss).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsPolicyTextBlock', window );">Common Stock Warrants</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Common Stock Warrants</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We account for common stock
warrants as either equity-classified instruments or liability-classified instruments based on an assessment of the warrant terms and applicable
authoritative guidance in accordance with ASC 480 and ASC 815. The assessment considers whether the warrants are freestanding financial
instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements
for equity classification under ASC 815, including whether the warrants are indexed to our Common Stock, among other conditions for equity
classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and, for
liability-classified warrants, as of each subsequent quarterly period end date while the warrants are outstanding.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue Recognition</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under ASC 606, <i>Revenue
from Contracts with Customers</i> (&#8220;ASC 606&#8221;), an entity recognizes revenue when its customer obtains control of promised
goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services.
To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following
five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine
the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations
in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the five-step
model to contracts when it is probable that we will collect the consideration to which we are entitled in exchange for the goods or services
we transfer to the customer.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Once a contract is determined
to be within the scope of ASC 606 at contract inception, we review the contract to determine which performance obligations we must deliver,
and which performance obligations are distinct. We recognize as revenue the amount of the transaction price that is allocated to each
performance obligation when that performance obligation is satisfied or as it is satisfied. We typically satisfy our performance obligations
via delivery of dietary supplements to the customer. Payments are due upon receipt for commercial transactions, or a prepayment is collected
for online retail sales. Our revenue for the three and nine months ended September 30, 2021 and 2020 was comprised of sales of dietary
supplements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recorded deferred revenue of $0.1 and $0.1 million as of September
30, 2021 and December 31, 2020 from the dietary supply agreement with the related party (see Note 20).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_GrantFundingPolicyTextBlock', window );">Grant Funding</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Grant Funding</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may submit applications
to receive grant funding from governmental and non-governmental entities. Grant funding received that involves no conditions or continuing
performance obligations of the Company is recognized upon receipt. Grant funding with conditions or obligations of the Company is recognized
as the conditions or obligations are fulfilled. We have made an accounting policy election to record such unconditional grants, such as
the Australian Research and Development Credit, as other income in the condensed consolidated statements of operations and comprehensive
income (loss). Income from grants is recognized in the period during which the related qualifying expenses are incurred, provided that
the conditions under which the grants were provided have been met. We recognize the Australian Research and Development Credit in an amount
equal to the qualifying expenses incurred in each period multiplied by the applicable reimbursement percentage. During the three and nine
months ended September 30, 2021, we recognized $0.4 million and $1.1 million, respectively, of Australian Research and Development Credit
within other income (expense), net in the condensed consolidated statements of operations and comprehensive income (loss). During the
three and nine months ended September 30, 2020, we recognized $1.3 million and $2.6 million, respectively, of Australian Research and
Development Credit within other income (expense), net in the condensed consolidated statements of operations and comprehensive income
(loss). As of September 30, 2021, and December 31, 2020, we recorded $1.2 million and $2.1 million, respectively, of Australian Research
and Development Credit receivable in prepaid expenses and other current assets on the condensed consolidated balance sheets.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any amount received in advance
of fulfilling such conditions or obligations is recorded in accrued liabilities on the condensed consolidated balance sheets if the conditions
or obligations are expected to be met within the next twelve months. As of September 30, 2021 and December 31, 2020, we recorded $0.6
million and $0.3 million, respectively, of deferred grant funds received in advance in accrued liabilities.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Grant funding recognized on
conditional grants is included as a reduction in research and development expenses in the condensed consolidated statements of operations
and comprehensive income (loss) as the conditions are tied to our research and development efforts, and as the arrangement between us
and the organizations are not part of our ongoing, major, or central operations. During the three and nine months ended September 30,
2021, we recorded a grant of $0 and $0.2 million, respectively, as a reduction of research and development expenses in the condensed consolidated
statements of operations and comprehensive income (loss). During the three and nine months ended September 30, 2020, we recorded a grant
of $0.2 million and $0.7 million, respectively, as a reduction of research and development expenses in the condensed consolidated statements
of operations and comprehensive income (loss).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Fair Value of Financial Instruments</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain assets and liabilities
are carried at fair value under GAAP. Fair value is defined as the price that would be received for an asset or paid to transfer a liability
(an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants
on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use
of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following
three levels of the fair value hierarchy:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Level 1</b><i>&#8212;</i>Inputs
based upon quoted market prices for identical assets or liabilities in active markets at the measurement date.&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Level 2</b><i>&#8212;</i>Observable
inputs other than quoted market prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets;
quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can
be corroborated by observable market data.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Level 3</b><i>&#8212;</i>Inputs
that are management&#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date.
The inputs are unobservable in the market and significant to the instrument&#8217;s valuation.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We review the fair value hierarchy
classification of our applicable assets and liabilities on a quarterly basis. Changes in the observability of valuation inputs may result
in a reclassification for certain financial assets or liabilities. Reclassifications impacting all levels of the fair value hierarchy
are reported as transfers in or out of the Level 1, 2, or 3 categories as of the beginning of the quarter during which the reclassifications
occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation and Transactions</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Foreign Currency Translation and Transactions</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our functional currency is
the U.S. dollar. Our Australian subsidiary determined its functional currency to be the Australian dollar and our Netherlands subsidiary
determined its functional currency to be the Euro. We use the U.S. dollar as our reporting currency for the condensed consolidated financial
statements. The results of our non-U.S. dollar based functional currency operations are translated to U.S. dollars at the average exchange
rates during the period. Our assets and liabilities are translated using the current exchange rate as of the balance sheet date and shareholders&#8217;
equity is translated using historical rates.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Adjustments resulting from
the translation of the condensed consolidated financial statements of our foreign functional currency subsidiaries into U.S. dollars are
excluded from the determination of net loss and are accumulated in a separate component of shareholders&#8217; equity. These foreign currency
translation gains and losses are currently the only component of other comprehensive income (loss).&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also incur foreign exchange
transaction gains and losses for purchases denominated in foreign currencies. Foreign exchange transaction gains and losses are included
in other income (expense) in the condensed consolidated statements of operations and comprehensive income (loss) as incurred.&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Comprehensive Income (Loss</i></b>)</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Comprehensive income (loss)
includes net income (loss) as well as other changes in stockholders&#8217; equity (deficit) that result from transactions and economic
events other than those with stockholders. The only element of other comprehensive income (loss) in any period presented was translation
of Australian dollar denominated balances of our Australian subsidiary to U.S. dollars for consolidation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Income (Loss) Per Share Attributable to Common Shareholders</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Net Income (Loss) Per Share Attributable
to Common Shareholders</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Basic net income (loss) per share attributable to common shareholders
is calculated using our weighted-average outstanding common shares. Diluted net income (loss) per share attributable to common shareholders
is calculated using our weighted-average outstanding common shares including the dilutive effect of securities as determined under the
treasury stock method, except for the dilutive effect of convertible notes payable, which is calculated under the if-converted method,
even if the embedded conversion option is out-of-the-money. In periods in which we report a net loss attributable to common shareholders,
diluted net loss per share attributable to common shareholders is the same as basic net loss per share attributable to common shareholders,
since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Segment Information</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have determined that our
chief executive officer is the chief operating decision maker (&#8220;CODM&#8221;). Operating segments are identified as components of
an enterprise about which separate discrete financial information is available for evaluation by the CODM in making decisions regarding
resource allocation and assessing performance. We view our operations and manage our business in two operating segments: (1) the development
and commercialization of proprietary nanotechnology drug suspensions (&#8220;Drugs&#8221;), and (2) the development and commercialization
of dietary supplements (&#8220;Supplements&#8221;). Our operating segment profit measure is segment loss from operations, which is calculated
as revenue less cost of revenue, research and development, and general and administrative expenses (see Note 21).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Income Taxes</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We account for income taxes
using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax
consequences of events that have been recognized in the condensed consolidated financial statements or in our tax returns. Deferred tax
assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities
using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities
are recorded in the provision for income taxes. We assess the likelihood that our deferred tax assets will be recovered from future taxable
income and, to the extent we believe, based upon the weight of available evidence, that it is more likely than not that all or a portion
of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential
for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible
tax planning strategies.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We account for uncertainty
in income taxes recognized in the condensed consolidated financial statements by applying a two-step process to determine the amount of
tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external
examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed
to determine the amount of benefit to recognize in the condensed consolidated financial statements. The amount of the benefit that may
be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for
income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well
as the related net interest and penalties.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock-Based Compensation</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We account for stock-based
compensation arrangements with employees using a fair value-based method for costs related to all share-based payments including stock
options and stock awards. Stock-based compensation expense is recorded in research and development and general and administrative expenses
based on the classification of the work performed by the grantees.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair value is recognized
over the period during which a grantee was required to provide services in exchange for the option award and service-based stock awards,
known as the requisite service period (usually the vesting period), on a straight-line basis. For stock awards with market conditions,
the fair value is recognized over the period based on the expected milestone achievement dates as the derived service period (usually
the vesting period), on a straight-line basis. For stock awards with performance conditions, the grant-date fair value of these awards
is the market price on the applicable grant date, and compensation expense will be recognized when the conditions become probable of
being satisfied. We will recognize a cumulative true-up adjustment once the conditions become probable of being satisfied as the related
service period had been completed in a prior period.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stock-based compensation expense
is recognized at fair value. We elect to account for forfeitures as they occur, rather than estimating expected forfeitures.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After the closing of the Reverse
Recapitalization, we determine the fair value of each share of Common Stock underlying stock-based awards based on the closing price of
our Common Stock as reported by the Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) on the date of grant. The fair value of stock awards
with market conditions are determined using a Monte Carlo valuation model.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development costs
are charged to expense as incurred. We account for nonrefundable advance payments for goods and services that will be used in future research
and development activities as expenses when the goods have been received or when the service has been performed. Research and development
expenses consist of costs incurred for the discovery and development of our product candidates. Research and development costs include,
but are not limited to, payroll and personnel expenses including stock-based compensation, clinical trial supplies, fees for clinical
trial services, consulting costs, and allocated overhead, including rent, equipment, and utilities.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ClinicalTrialAccrualPolicyTextBlock', window );">Clinical Trial Accrual</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Clinical Trial Accrual</i></b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our clinical trial accrual
process accounts for expenses resulting from obligations under contracts with CROs, consultants, and under clinical site agreements in
connection with conducting clinical trials. Clinical trial costs are charged to research and development expense as incurred. The financial
terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not
match the periods over which materials or services are provided to us under such contracts. We reflect the appropriate clinical trial
expense in the condensed consolidated financial statements by matching the appropriate expenses with the period in which services and
efforts are expended. In the event advance payments are made to a CRO, the payments will be recorded as a prepaid asset which will be
amortized to research and development expense over the period the contracted services are performed. In addition to pass-through costs,
we generally incur costs in clinical trials in four distinct groups as follows:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">CRO Start-up&#8212;These costs
include the initial set-up of the clinical trial and usually occur within a few months after the contract has been executed and includes
costs which are expensed ratably over the start-up period when such period is identifiable and expensed as incurred when no such period
exists. Start-up phase activities include study initiation, site recruitment, regulatory applications, investigator meetings, screening,
preparation, pre-study visits, and training.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">CRO Site and Study Management&#8212;These
costs include medical and safety monitoring, patient administration and data management. These costs are usually calculated on a per-patient
basis and expensed ratably over the treatment period beginning on the date that the patient enrolls.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">CRO Close-Down and Reporting&#8212;These
costs include analyzing the data obtained and reporting results, which occurs after patients have ceased treatment and the database of
information collected is locked. These costs are expensed as incurred over the course of any close-down and reporting period.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Third-Party Contracts&#8212;These
costs include fees charged by third parties for various support services which are not provided by CROs and include such items as laboratory
fees, data quality review costs, and fees incurred for investigational product monitoring and inventory control. These items are expensed
ratably over any identifiable service period with the engaged third-party vendors.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The CRO contracts generally
include pass-through fees including, but not limited to, regulatory expenses, investigator fees, travel costs, and other miscellaneous
costs, including shipping and printing fees. We determine accrual estimates through reports from and discussion with applicable personnel
and outside service providers as to the progress or state of completion of trials or the services completed. We estimate accrued expenses
as of each balance sheet date in the condensed consolidated financial statements based on the facts and circumstances known to us at that
time.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Recently Adopted Accounting Pronouncements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2020, the FASB issued
ASU 2020-06, <i>Debt</i>&#8212;<i>Debt with Conversion and Other Options (Subtopic 470-20) </i>and <i>Derivatives and Hedging</i>&#8212;<i>Contracts
in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</i>
to simplify accounting for certain financial instruments by removing certain separation models for convertible instruments. Under the
amendments in ASU 2020-06, the embedded conversion features no longer are separated from the host contract for convertible instruments
with conversion features that are not required to be accounted for as derivatives, or that do not result in substantial premiums accounted
for as paid-in-capital. Consequently, a convertible debt instrument will be accounted as a single liability measured at its amortized
cost, and a convertible preferred stock will be accounted for as a single equity instrument measured at its historical cost, as long as
no other features require bifurcation and recognition as derivatives. The new standard also introduces additional disclosures for convertible
debt and freestanding instruments that are indexed to and settled in an entity&#8217;s own equity. ASU 2020-06 amends the diluted earnings
per share guidance, including the requirements to use the if-converted method for all convertible instruments. For smaller reporting companies,
the new guidance is effective for fiscal years beginning after December 15, 2023, and should be applied on a full or modified retrospective
basis, with early adoption permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods with
those fiscal years. We early adopted ASU 2020-06 on January 1, 2021. The adoption of this guidance did not have a material impact on our
condensed consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2020, the FASB issued
ASU 2020-04, <i>Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</i>, which
provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions in which the
reference LIBOR or another reference rate is expected to be discontinued as a result of the Reference Rate Reform. This ASU is intended
to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The new guidance
was effective immediately and through December 31, 2022. We adopted this guidance on March 1, 2020. The adoption of this guidance did
not have a material impact on our condensed consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2019, the FASB
issued ASU 2019-12, <i>Income Taxes (Topic 740)</i>, which amends the existing guidance relating to the accounting for income taxes. This
ASU is intended to simplify the accounting for income taxes by removing certain exceptions to the general principles of accounting for
income taxes and to improve the consistent application of GAAP for other areas of accounting for income taxes by clarifying and amending
existing guidance. The new guidance was effective for our fiscal year, and interim periods within our fiscal year, beginning after December
15, 2020. The adoption of this guidance did not have a material impact on our condensed consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2018, the FASB issued
ASU 2018-15, <i>Intangibles</i>&#8212;<i>Goodwill and Other</i>&#8212;<i>Internal-Use Software (Subtopic 350-40): Customer&#8217;s Accounting
for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract</i>. The new guidance provides for the deferral
of implementation costs for cloud computing arrangements and expensing those costs over the term of the cloud services arrangement. The
new guidance was effective for our fiscal year beginning after December 15, 2020. The adoption of this guidance did not have a material
impact on our condensed consolidated financial statements.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">In&#160;August
2018,&#160;the FASB issued ASU&#160;2018-13,&#160;<i>Fair Value Measurement (Topic&#160;</i></span><i>820<span style="font-size: 10pt">)</span></i><span style="font-size: 10pt">.
The new guidance improves the effectiveness of disclosures about fair value measurements required under ASC&#160;820.&#160;The new guidance&#160;amends
the disclosure requirements for recurring and nonrecurring fair value measurements by removing, modifying, and adding certain disclosures.
The new guidance was effective for our fiscal year, and interim periods with our fiscal year, beginning after December 15, 2019. The adoption
of this guidance&#160;did&#160;not&#160;have a material impact on our condensed consolidated financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Recent Accounting Pronouncements Not Yet
Adopted</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2016, the FASB issued
ASU 2016-13, <i>Financial Instruments</i>&#8212;<i>Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>.
The amendments in this ASU, among other things, require the measurement of all expected credit losses for financial assets held at the
reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions and
other organizations will now use forward-looking information to better inform their credit loss estimates. As a smaller reporting company,
the guidance is effective for our fiscal years beginning after December 15, 2022. We are currently evaluating the expected impact of the
new guidance as a result of this extended deadline of implementation for smaller reporting companies.&#160;&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ClinicalTrialAccrualPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical Trial Accrual Policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ClinicalTrialAccrualPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CommonStockWarrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for Common stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CommonStockWarrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ContingentEarnoutPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Earn-out Policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ContingentEarnoutPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ConvertibleNotespolicytextblock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ConvertibleNotespolicytextblock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_DebtDiscountAndIssuanceCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_DebtDiscountAndIssuanceCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_DebtWithWarrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt with warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_DebtWithWarrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_GrantFundingPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant Funding Policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_GrantFundingPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>New Accounting Pronouncements Not Yet Adopted Policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_RiskAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk and Uncertainties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_RiskAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724060993768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_PrepaidExpensesAndOtherCurrentAssetsAbstract', window );"><strong>Prepaid Expenses And Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock', window );">Schedule of prepaid expenses and other current assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">September&#160;30,</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">December&#160;31,</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Australia research and development credit receivable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,212</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,148</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">CRO prepayments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">693</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,211</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Metals to be used in research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,691</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Directors &amp; Officers Insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">934</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-194">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">202</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">112</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,732</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,502</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_PrepaidExpensesAndOtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_PrepaidExpensesAndOtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expenses And Other Current Assets [TableTextBlock]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724060752840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment, net</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">September&#160;30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Laboratory equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,183</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,077</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">147</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">147</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,927</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,889</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Construction in progress</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,061</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">490</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,318</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,603</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,072</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,378</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,246</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,225</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724156365288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_AccruedLiabilitiesTablesLineItems', window );"><strong>Accrued Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">September&#160;30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accrued professional fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-195">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">189</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued compensation and benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,744</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,225</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued CRO fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">675</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">788</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Deferred grant funds</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">601</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">301</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued expense reimbursements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued transaction costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-196">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,354</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">64</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">70</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,117</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,960</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_AccruedLiabilitiesTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_AccruedLiabilitiesTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724067355336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of noncancelable operating lease arrangements</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Finance<br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Operating<br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">43</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">870</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">136</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">960</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">82</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">982</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,007</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-197">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,031</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-198">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,887</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Total undiscounted cash flows</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">281</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,737</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Less amount representing interest/discounting</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,507</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Present value of future lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">278</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,230</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Less future lease incentives</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-199">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(900</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Less lease obligations, current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(153</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(262</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Lease obligations&#160;&#8211; long term portion</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">125</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,068</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FinanceLeaseByMajorClassPropertyAndEquipmentTableTextBlock', window );">Schedule of finance lease obligations included in property and equipment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">September&#160;30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Laboratory equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,148</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">920</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Work in process</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-200">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">228</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,194</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,194</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(629</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(593</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">565</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">601</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of finance and operating lease costs</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Finance lease costs:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 52%">Amortization</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">37</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">41</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">110</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">137</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Interest on lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">107</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">247</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">308</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Short-term lease costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">98</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">214</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">203</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Variable lease costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">32</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">71</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">70</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total lease costs</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">280</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">233</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">663</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">748</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of supplemental cash flow information</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating cash flows from operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(533</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(497</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating cash flows from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(21</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(30</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financing cash flows from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(117</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(156</td><td style="text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of finance and operating lease liability maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_FinanceLeaseByMajorClassPropertyAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Finance lease by major class property and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_FinanceLeaseByMajorClassPropertyAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724246810264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of long-term debt, net of original issue discount and unamortized debt issuance costs</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">September&#160;30,</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Rate</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Term Loans:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 9pt">Maryland Department of Housing &amp; Community Development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">819</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,080</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Advance Cecil, Inc.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">164</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">216</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Paycheck Protection Program</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-201">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">647</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Avenue Venture Opportunities Fund, L.P.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.85</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-202">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">0.00</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-203">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,983</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,949</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Unamortized debt issuance costs and original issue discounts</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,811</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-204">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Less convertible notes payable, net of unamortized debt discount and issuance costs (see Note 11)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,559</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-205">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Total notes payable</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">14,613</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,949</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscounts', window );">Schedule of future payments, net of unamortized debt discounts</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>2021 (remainder)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-206">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-207">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6,667</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,333</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-208">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-209">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-210">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Subtotal of future principal payments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">20,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Unamortized debt discount associated with issuance date warrant fair value and financing costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,811</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">18,189</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of future payments, net of unamortized debt discounts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724060318616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsDisclosureAbstract', window );"><strong>Common Stock Warrants Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of outstanding warrants to purchase shares of common stock</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1.5pt solid">Date Exercisable</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Shares<br/>
 Issuable</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercise Price</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercisable for</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Classification</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Expiration</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%">June 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">117,500</td><td style="white-space: nowrap; width: 2%; text-align: left"><sup>(1)</sup></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">0.01</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: center">Common Stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 2021</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>December 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,407,500</td><td style="white-space: nowrap; text-align: left"><sup>(2)</sup></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">11.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">Common Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 2025</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>December 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,583</td><td style="white-space: nowrap; text-align: left"><sup>(3)</sup></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">11.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">Common Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 2025</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>December 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,929,111</td><td style="white-space: nowrap; text-align: left"><sup>(4)</sup></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.97</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">Common Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2023</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">May 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">115,851</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><sup>(5)(6)</sup></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">8.63</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">Common Stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liability</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2026</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,594,545</td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1.5pt solid">Date Exercisable</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Shares Issuable</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercise Price</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercisable for</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Classification</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Expiration</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%">June 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">1,119,750</td><td style="width: 2%; text-align: left"><sup>(1)</sup></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">0.01</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: center">Common Stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 2021</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>December 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,407,500</td><td style="text-align: left"><sup>(2)</sup></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">11.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">Common Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 2025</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>December 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">110,000</td><td style="text-align: left"><sup>(3)</sup></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">11.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">Common Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 2025</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">December 2020</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,929,111</td><td style="padding-bottom: 1.5pt; text-align: left"><sup>(4)</sup></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">1.97</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">Common Stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2023</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,566,361</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consisted of 1,119,750 shares of Common Stock underlying 2,239,500 December 2020 PIPE Warrants issued on December 30, 2020, in connection with the December 2020 PIPE (see Note 18). A holder of the December 2020 PIPE Warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of the Company&#8217;s Common Stock outstanding immediately after giving effect to such exercise. As of September 30, 2021, 2,004,500 December 2020 PIPE Warrants were exercised into 1,002,250 shares of Common Stock. The outstanding balance as of September 30, 2021 consists of 117,500 shares of Common Stock underlying 235,000 December 2020 PIPE Warrants. As of December 31, 2020, none of the warrants had been exercised.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of 2,407,500 shares of Common Stock underlying 4,815,000 warrants issued in connection with Tottenham&#8217;s initial public offering. The Company may redeem the outstanding warrants, in whole and not in part, at a price of $0.01 per warrant if, and only if, the last sales price of the Company&#8217;s Common Stock equals or exceeds $16.50 per share for any 20 trading days within a 30-trading day period ending three business days before the Company sends the notice of redemption. As of September 30, 2021, and December 31, 2020, none of the warrants had been exercised.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consisted of 110,000 shares of Common Stock underlying 220,000 warrants issued as part of the Chardan Unit Purchase Option (see Note 3). On July 15, 2021 the Chardan Unit Purchase Option was net exercised, resulting in the issuance of 54,083 shares of Common Stock and 49,166 warrants to purchase one-half of one share of Common Stock, or 24,583 shares of Common Stock. As of September 30, 2021, none of the warrants had been exercised. As of December 31, 2020, the Chardan Unit Purchase Option had not been exercised.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of 1,929,111 shares of Common Stock underlying 1,929,111 warrants originally issued by Clene Nanomedicine as Series A and Series D Preferred Stock Warrants (see Note 9). As of September 30, 2021, and December 31, 2020, none of the warrants had been exercised.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of 115,851 shares of Common Stock underlying 115,851 Avenue Warrants issued pursuant to Tranche 1 of the 2021 Avenue Loan at an exercise price equal to the lower of (i) $8.63 (which is equal to the five-day VWAP per share, determined as of the end of trading on the last trading day prior to execution of the loan agreement), or (ii) the Next Round Price. (see Note 8). As of September 30, 2021, the Avenue Warrant had not been exercised.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the 2021 Avenue Loan, an additional estimated 86,679 shares
of Common Stock underlying warrants are issuable pursuant to our draw of Tranche 2 between January 1, 2022 and June 30, 2022 (see Note
8). In accordance with ASC 815, we recognized these warrants at the inception of the 2021 Avenue Loan and classified them as a warrant
liability and the fair value and issuable shares will be remeasured at each reporting period (see Note 16). As of September 30, 2021,
the warrants are not issued or outstanding.</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CommonStockWarrantsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CommonStockWarrantsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724057393368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of components of income (loss) before income taxes</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">United States</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">29,860</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(11,370</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(11,435</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(20,724</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(985</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,075</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,941</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">669</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total loss before income taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">28,875</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(10,295</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(14,376</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(20,055</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724060878168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock', window );">Schedule of stock-based compensation expense</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">858</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">134</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,861</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">364</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,567</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">75</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,084</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">190</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total stock-based compensation</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,425</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">209</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,945</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">554</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of outstanding common stock options and related activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Equity</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/> Average <br/> Exercise <br/> Price <br/> Per Share</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/> Average <br/> Remaining <br/> Term <br/> (Years)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Intrinsic <br/> Value</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -10pt; padding-left: 10pt">Outstanding - December&#160;31, 2020</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7,032,591</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.97</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5.34</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">62,462</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,574,441</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.85</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.61</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-212">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(409,867</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.04</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-213">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,373</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 0.125in">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(133,742</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8.66</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-214">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-215">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Outstanding - September 30, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">9,063,423</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3.09</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5.90</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">38,863</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Options vested and exercisable - September 30, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6,000,723</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.82</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4.33</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">36,247</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Stock options vested and expected to vest - September 30, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">9,063,423</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3.09</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5.90</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">38,863</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used to calculate the fair value of stock options</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; white-space: nowrap; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; white-space: nowrap; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">Nine months ended<br/> September 30,<br/>
 2021</td><td style="padding-bottom: 1.5pt; white-space: nowrap; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected stock price volatility</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">84.8
&#8211; 87.4% </span></td><td style="text-align: left"/></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.59 &#8211; 0.94%</span></td><td style="text-align: left"/></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Expected dividend yield</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center">0.00%</td><td style="width: 1%; text-align: left"/></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected term</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.00 years &#160;</span></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of restricted common stock activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Restricted Stock Awards</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-<br/> Average<br/> Grant <br/> Date Fair <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Outstanding and unvested balance as of December 31, 2020</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,507,062</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10.30</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Converted to shares of Common Stock upon vesting</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(224,109</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-216">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(37,464</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10.82</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Outstanding and unvested balance as of September 30, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,245,489</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10.14</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724066823192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of fair value hierarchy of liabilities measured at fair value on recurring basis</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair Value Measurements on a Recurring Basis <br/> September 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Notes payable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">983</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-217">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-218">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">983</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-219">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-220">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">910</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">910</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Clene Nanomedicine contingent earn-out</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-221">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-222">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,981</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,981</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Initial Shareholders contingent earn-out</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-223">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-224">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,196</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,196</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair Value Measurements on a Recurring Basis <br/> December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Notes payable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,296</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-225">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-226">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,296</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Clene Nanomedicine contingent earn-out</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-227">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-228">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52,053</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52,053</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Initial Shareholders contingent earn-out</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-229">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-230">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,906</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,906</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of unobservable inputs to the conversion feature, warrant liability, and contingent earn-out valuation models</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2020</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Expected stock price volatility</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">85.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-231">N/A</div></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.50</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-232">N/A</div></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-233">N/A</div></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.56 years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-234">N/A</div></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September&#160;30,<br/> 2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, <br/> 2020</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Expected stock price volatility</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">35.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-235">N/A</div></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.07</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-236">N/A</div></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-237">N/A</div></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.09 years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-238">N/A</div></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,<br/> 2021</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2020</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Expected stock price volatility</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">95.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-239">N/A</div></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.90</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-240">N/A</div></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-241">N/A</div></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.89 years &#8211; 4.56 years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-242">N/A</div></td>
    <td>&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,<br/> 2021</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2020</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected stock price volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40.00 &#8211; 70.00</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-243">N/A</div></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 78%; text-align: left">Risk-free interest rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">0.07</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-244">N/A</div></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-245">N/A</div></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.09 years &#8211; 0.66 years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-246">N/A</div></td>
    <td>&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,<br/> 2021</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2020</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Expected stock price volatility</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">95.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">85.00</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.80</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.40</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2 years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.00 years</span></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule of changes in fair value of financial liabilities related to the notes payable, the derivative instrument, the preferred stock warrants, and the contingent earn-outs</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Notes <br/> Payable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Clene Nanomedicine<br/> Contingent <br/> Earn-out</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Initial Shareholders<br/> Contingent <br/> Earn-out</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Warrant<br/> Liability</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Balance - December 31, 2020</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,296</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">52,053</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,906</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-247">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10pt">Initial fair value of instrument</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-248">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-249">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-250">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,457</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(313</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(18,072</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,710</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(547</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Balance - September 30, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">983</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">33,981</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,196</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">910</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Notes <br/> Payable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Derivative<br/> Instrument</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Preferred<br/> Stock<br/> Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Balance - December 31, 2019</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">640</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-251">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,213</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 10pt">Issuance of convertible promissory notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-252">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">705</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-253">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">323</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(29</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,378</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Extinguishment of derivative liability in connection with extinguishment of convertible promissory notes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-254">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(676</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-255">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance - September 30, 2020</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">963</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-256">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,591</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724068733560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share Attributable to Common Shareholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of basic and diluted net loss per share</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="text-decoration:underline">Numerator&#160;:</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -9pt; padding-left: 0.25in">Net income (loss) attributable to common shareholders &#8211; Basic</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">28,944</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(10,295</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(14,163</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(20,055</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Less interest expense on potentially dilutive convertible notes payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">196</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Net income (loss) attributable to common shareholders - Diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">29,140</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(10,295</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(14,163</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(20,055</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="text-decoration:underline">Denominator:</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 0.25in">Weighted average common shares outstanding &#8211;Basic</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62,071,754</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,358,159</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">61,307,699</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,358,159</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 0.25in">Weighted average effect of potentially dilutive securities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Effect of potentially dilutive stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,791,023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-257">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-258">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-259">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Effect of potentially dilutive common stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,485,049</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-260">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-261">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-262">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Effect of potentially dilutive convertible notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">482,703</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-263">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-264">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-265">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Effect of potentially dilutive restricted stock awards</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">208,105</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-266">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-267">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-268">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Weighted average common shares outstanding &#8211;Diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">70,038,634</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">17,358,159</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">61,307,699</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">17,358,159</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Net income (loss) per share attributable to common shareholders:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 0.25in">Basic</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.47</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.59</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.23</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1.16</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 0.25in">Diluted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.42</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.59</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.23</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1.16</td><td style="text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of securities excluded from computation of diluted net income (loss) per share</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Series D redeemable convertible preferred stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-269">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">9,394,057</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-270">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">9,394,057</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Series C redeemable convertible preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-271">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,264,519</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-272">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,264,519</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Series B redeemable convertible preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-273">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,168,815</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-274">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,168,815</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Series A redeemable convertible preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-275">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,066,503</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-276">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,066,503</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Series D redeemable convertible preferred stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-277">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">320,441</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-278">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">320,441</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Series A redeemable convertible preferred stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-279">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,608,670</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-280">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,608,670</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Convertible notes payable (see Note 11)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-281">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-282">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">482,703</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-283">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Common stock warrants (see Note 10)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,523,351</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-284">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,569,962</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-285">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Options to purchase common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,685,575</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,509,810</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,063,423</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,509,810</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Restricted stock awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,100,050</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-286">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,245,489</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-287">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Chardan Unit Purchase Option Warrants (see Notes 3 and 10)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,583</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-288">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,583</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-289">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Clene Nanomedicine contingent earn-out shares (see Note 3 and 12)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,346,185</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-290">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,346,185</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-291">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Initial Shareholders contingent earn-out shares (see Note 3 and 12)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">750,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-292">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">750,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-293">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif">15,429,744</p></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">46,332,815</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">24,482,345</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">46,332,815</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724147513784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geographic and Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock', window );">Schedule of property and equipment, net by location</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">As of<br/> September&#160;30,<br/>
</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">As of<br/> December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">United States</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,193</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,997</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Australia</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">53</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">228</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,246</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,225</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of drugs and supplements segments</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Three Months ended <br/> September 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Nine Months ended <br/> September 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Drugs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Supplements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Drugs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Supplements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; text-indent: -9pt; padding-left: 9pt">Revenue from external customers</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-295">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">110</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">110</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-296">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">524</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">524</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Income (loss) from operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(10,546</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">96</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(10,450</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(35,632</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(288</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(35,920</td><td style="text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Three Months ended <br/> September 30, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Nine Months ended <br/> September 30, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Drugs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Supplements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Drugs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Supplements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; text-indent: -9pt; padding-left: 9pt">Revenue from external customers</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-297">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">98</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">98</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-298">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">177</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">177</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Income (loss) from operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(5,789</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">98</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(5,691</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(14,373</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">119</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(14,254</td><td style="text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock', window );">Schedule of property and equipment, net by segment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">As of <br/> September 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">As of <br/> December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Drugs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-299">4, 038</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,990</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Supplements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">208</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">235</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,246</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,225</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724060476184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 21, 2021</div></th>
<th class="th"><div>Feb. 16, 2021</div></th>
<th class="th"><div>Jul. 22, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NatureoftheBusinessDetailsLineItems', window );"><strong>Nature of the Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants outstanding (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,815,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,815,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_AggregateFutureProceedsWarrantsExercised', window );">Aggregate proceeds if warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,700,000<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_OfferingCost', window );">Offering Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_AggregateProceedsReceived', window );">Aggregate proceeds received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_OfferingPricePerShare', window );">Offering price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,140,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockUnderlyingWarrantOutstanding', window );">Common stock underlying warrant outstanding (in Shares)</a></td>
<td class="nump">115,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,024,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,944,000<span></span>
</td>
<td class="num">$ (10,295,000)<span></span>
</td>
<td class="num">$ (14,163,000)<span></span>
</td>
<td class="num">$ (20,055,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,552,000<span></span>
</td>
<td class="nump">$ 36,781,000<span></span>
</td>
<td class="nump">60,552,000<span></span>
</td>
<td class="nump">36,781,000<span></span>
</td>
<td class="nump">$ 59,275,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (167,724,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(167,724,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (153,561,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (25,018,000)<span></span>
</td>
<td class="num">$ (13,121,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=clnn_TottenhamMember', window );">Tottenham [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NatureoftheBusinessDetailsLineItems', window );"><strong>Nature of the Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants outstanding (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,517,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=clnn_CleneNanomedicineMember', window );">Clene Nanomedicine [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NatureoftheBusinessDetailsLineItems', window );"><strong>Nature of the Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants outstanding (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">904,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=clnn_PIPEMember', window );">PIPE [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NatureoftheBusinessDetailsLineItems', window );"><strong>Nature of the Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants outstanding (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,239,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Clene Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NatureoftheBusinessDetailsLineItems', window );"><strong>Nature of the Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants outstanding (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,541,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | PIPE [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NatureoftheBusinessDetailsLineItems', window );"><strong>Nature of the Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants outstanding (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,004,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NatureoftheBusinessDetailsLineItems', window );"><strong>Nature of the Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ShareIssuanceOfCommonStockPrivateOffering', window );">Common Stock, issued in a private placement (in Shares)</a></td>
<td class="nump">960,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_AggregateFutureProceedsWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate future proceeds warrants exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_AggregateFutureProceedsWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_AggregateProceedsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate proceeds received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_AggregateProceedsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CommonStockUnderlyingWarrantOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>CommonStockUnderlyingWarrantOutstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CommonStockUnderlyingWarrantOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_NatureoftheBusinessDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_NatureoftheBusinessDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_OfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>OfferingCost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_OfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_OfferingPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Offering price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_OfferingPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ShareIssuanceOfCommonStockPrivateOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share issuance of common stock private offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ShareIssuanceOfCommonStockPrivateOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=clnn_TottenhamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=clnn_TottenhamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=clnn_CleneNanomedicineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=clnn_CleneNanomedicineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=clnn_PIPEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=clnn_PIPEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=clnn_CleneIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=clnn_CleneIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724061667640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedInvestments', window );">Restricted cash</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Inventory in raw materials</a></td>
<td class="nump">26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Inventory Finished Goods</a></td>
<td class="nump">14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Incurred of deferred offering costs</a></td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred Revenue</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_GrantFundingRecognizedOnConditionalGrants', window );">Grant funding recognized on conditional grants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income and expenses</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent', window );">Prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued liabilities</a></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollateralAxis=us-gaap_EquipmentMember', window );">Equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives of asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollateralAxis=us-gaap_EquipmentMember', window );">Equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives of asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollateralAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives of asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollateralAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives of asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_GrantFundingRecognizedOnConditionalGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant funding recognized on conditional grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_GrantFundingRecognizedOnConditionalGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040515&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments which are not defined as or included in marketable (debt, equity, or other) securities whose use is restricted in whole or in part, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724054013032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 15, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 15, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Jul. 02, 2020</div></th>
<th class="th">
<div>Aug. 01, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems', window );"><strong>Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ProceedsFromReverseRecapitalization', window );">Proceeds from reverse recapitalization (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Offering costs (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,407,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherUnderwritingExpense', window );">Deferred underwriting fees (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees', window );">Underwriting fees (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_AggregateGrossProceedWarrantsExercised', window );">Aggregate gross proceed warrants exercised (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ChardanUnitPurchaseOption', window );">Chardan unit purchase option</a></td>
<td class="nump">220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NetIssuanceSharesOfCommonStock', window );">Net issuance shares of common stock</a></td>
<td class="nump">54,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_WarrantsToPurchaseSharesOfCommonStock', window );">Warrants to purchase one-half of one share of common stock</a></td>
<td class="nump">49,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CleneNanomedicineContingentEarnOutMilestone1Shares', window );">Clene nanomedicine contingent earnout milestone1 shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CleneNanomedicineContingentEarnoutMilestone1Price', window );">Clene nanomedicine contingent earnout milestone 1 price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CleneNanomedicineContingentEarnoutMilestone2Shares', window );">Clene nanomedicine contingent earnout milestone 2 shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CleneNanomedicineContingentEarnoutMilestone2Price', window );">Clene nanomedicine contingent earnout milestone 2 price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CleneNanomedicineContingentEarnoutMilestone3Shares', window );">Clene nanomedicine contingent earnout milestone 3 shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_IncreaseInCleneNanomedicineContingentEarnoutSharesUponReverseRecapitalization', window );">Increase in clene nanomedicine contingent earnout shares upon reverse recapitalization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_TotalCleneNanomedicineContingentEarnoutShares', window );">Total clene nanomedicine contingent earnout shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,346,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_InitialShareholdersContingentEarnoutMilestone1Shares', window );">Initial shareholders contingent earnout milestone1 shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_InitialShareholdersContingentEarnoutMilestone2Shares', window );">Initial shareholders contingent earnout milestone 2 shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=clnn_ReverseRecapitalizationMember', window );">Reverse recapitalization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems', window );"><strong>Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Offering costs (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=clnn_CleneIncMember', window );">Clene Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems', window );"><strong>Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockParOrStatedValuesPerShare', window );">Common stock, par value (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SharesCancelledUponReverseRecapitalization', window );">Shares cancelled upon reverse recapitalization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,303,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ReverseRecapitalizationExchangeRatio', window );">Reverse recapitalization exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SharesHeldInEscrowPercentage', window );">Shares held in escrow, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SharesHeldInEscrow', window );">Shares held in escrow (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,716,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Common stock, share outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,526,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=clnn_CleneIncMember', window );">Clene Inc [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems', window );"><strong>Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,136,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=clnn_CleneNanomedicineMember', window );">Clene Nanomedicine [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems', window );"><strong>Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_InitialShareholdersContingentsEarnout', window );">Initial shareholders earn-out shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ExchangeOfSharesReceived', window );">Common stock, share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,339,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Shareholder ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=clnn_ChardanCapitalMarketsLLCMember', window );">Chardan Capital Markets, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems', window );"><strong>Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SaleOfUnitsNumberOfUnitsIssued', window );">Sale of units, number of units issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_UnitsIssuedPricePerUnit', window );">Units issued, price per unit (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ExercisePrice', window );">Exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=clnn_LifeSciCapitalLLCMember', window );">LifeSci Capital LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems', window );"><strong>Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ServicesLetterAgreementDescription', window );">Services letter agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) 3% of the amount by which the total transaction consideration exceeded $350 million, plus (ii) 7% of cash and cash-equivalents
received by Clene Nanomedicine from the Tottenham&#8217;s trust account. Clene Nanomedicine could elect to pay LifeSci either in cash,
equity interests of the surviving company, or a combination of the two. Upon the consummation of the Reverse Recapitalization, 644,164
shares of Common Stock were issued to LifeSci as consideration for its services as pursuant to the letter agreement (see Note 18).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">644,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=clnn_TottenhamMember', window );">Tottenham [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems', window );"><strong>Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Shareholder ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=clnn_PIPEMember', window );">PIPE [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems', window );"><strong>Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Shareholder ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis=us-gaap_ExchangeClearedMember', window );">Exchange Ratio [Member] | Clene Inc [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems', window );"><strong>Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SharesHeldInEscrowPercentage', window );">Shares held in escrow, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Clene Inc [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems', window );"><strong>Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Clene Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems', window );"><strong>Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ReverseRecapitalizationExchangeRatio', window );">Reverse recapitalization exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited', window );">Shares Issued, Value, Share-based Payment Arrangement, Forfeited (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,286,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_WarrantsToPurchaseCommonStockIssuedAndOutstanding', window );">Warrant outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,566,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | PIPE [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems', window );"><strong>Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,002,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Warrant, Exercise Price, Increase (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Exchange Ratio [Member] | Clene Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems', window );"><strong>Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,032,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ExchangeRatioPercentage', window );">Exchange ratio percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_AggregateGrossProceedWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate gross proceed warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_AggregateGrossProceedWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ChardanUnitPurchaseOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Chardan unit purchase option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ChardanUnitPurchaseOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CleneNanomedicineContingentEarnOutMilestone1Shares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clene nanomedicine contingent earn out milestone1 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CleneNanomedicineContingentEarnOutMilestone1Shares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CleneNanomedicineContingentEarnoutMilestone1Price">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clene nanomedicine contingent earn out milestone 1 price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CleneNanomedicineContingentEarnoutMilestone1Price</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CleneNanomedicineContingentEarnoutMilestone2Price">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clene nanomedicine contingent earnout milestone2 price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CleneNanomedicineContingentEarnoutMilestone2Price</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CleneNanomedicineContingentEarnoutMilestone2Shares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clene nanomedicine contingent earnout milestone 2 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CleneNanomedicineContingentEarnoutMilestone2Shares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CleneNanomedicineContingentEarnoutMilestone3Shares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clene nanomedicine contingent earnout milestone 3 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CleneNanomedicineContingentEarnoutMilestone3Shares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CommonStockParOrStatedValuesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stocks</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CommonStockParOrStatedValuesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ExchangeOfSharesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exchange of shares received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ExchangeOfSharesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ExchangeRatioPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exchange Ratio Percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ExchangeRatioPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_IncreaseInCleneNanomedicineContingentEarnoutSharesUponReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase in clene nanomedicine contingent earnout shares upon reverse recapitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_IncreaseInCleneNanomedicineContingentEarnoutSharesUponReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_InitialShareholdersContingentEarnoutMilestone1Shares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial shareholders contingent earnout milestone1 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_InitialShareholdersContingentEarnoutMilestone1Shares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_InitialShareholdersContingentEarnoutMilestone2Shares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial shareholders contingent earnout milestone 2 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_InitialShareholdersContingentEarnoutMilestone2Shares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_InitialShareholdersContingentsEarnout">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents of initial shareholders contingents earnout.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_InitialShareholdersContingentsEarnout</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_NetIssuanceSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net issuance shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_NetIssuanceSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ProceedsFromReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents of proceeds from reverse recapitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ProceedsFromReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ReverseRecapitalizationExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reverse recapitalization exchange ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ReverseRecapitalizationExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_SaleOfUnitsNumberOfUnitsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of units issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_SaleOfUnitsNumberOfUnitsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ServicesLetterAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ServicesLetterAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_SharesCancelledUponReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares cancelled upon reverse recapitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_SharesCancelledUponReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_SharesHeldInEscrow">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares held in Escrow.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_SharesHeldInEscrow</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_SharesHeldInEscrowPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage shares held in escrow.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_SharesHeldInEscrowPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_TotalCleneNanomedicineContingentEarnoutShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total clene nanomedicine contingent earnout shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_TotalCleneNanomedicineContingentEarnoutShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_UnitsIssuedPricePerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_UnitsIssuedPricePerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_WarrantsToPurchaseCommonStockIssuedAndOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants to purchase common stock issued and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_WarrantsToPurchaseCommonStockIssuedAndOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_WarrantsToPurchaseSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants to purchase shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_WarrantsToPurchaseSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockOtherSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockOtherSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040515&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense related to distribution, servicing and underwriting fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherUnderwritingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs incurred during the period, such as those relating to general administration and policy maintenance that do not vary with and are not primarily related to the acquisition or renewal of insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 720<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=35755714&amp;loc=d3e28434-158551<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherUnderwritingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph c(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=clnn_ReverseRecapitalizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=clnn_ReverseRecapitalizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=clnn_CleneIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=clnn_CleneIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=clnn_CleneNanomedicineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=clnn_CleneNanomedicineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=clnn_ChardanCapitalMarketsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=clnn_ChardanCapitalMarketsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=clnn_LifeSciCapitalLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=clnn_LifeSciCapitalLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=clnn_TottenhamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=clnn_TottenhamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=clnn_PIPEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=clnn_PIPEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis=us-gaap_ExchangeClearedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis=us-gaap_ExchangeClearedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724147233512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract', window );"><strong>Schedule of prepaid expenses and other current assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_AustraliaResearchAndDevelopmentCreditReceivable', window );">Australia research and development credit receivable</a></td>
<td class="nump">$ 1,212<span></span>
</td>
<td class="nump">$ 2,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CROPrepayments', window );">CRO prepayments</a></td>
<td class="nump">693<span></span>
</td>
<td class="nump">1,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_MetalsToBeUsedInResearchAndDevelopment', window );">Metals to be used in research and development</a></td>
<td class="nump">1,691<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_DirectorsOfficersInsurance', window );">Directors &amp; Officers Insurance</a></td>
<td class="nump">934<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other</a></td>
<td class="nump">202<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Total</a></td>
<td class="nump">$ 4,732<span></span>
</td>
<td class="nump">$ 3,502<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_AustraliaResearchAndDevelopmentCreditReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Australia research and development credit receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_AustraliaResearchAndDevelopmentCreditReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CROPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CROPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_DirectorsOfficersInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Directors &amp; Officers Insurance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_DirectorsOfficersInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_MetalsToBeUsedInResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Metals to be used in research and development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_MetalsToBeUsedInResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724147647288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Property, Plant and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_PropertyandEquipmentNetDetailsLineItems', window );"><strong>Property and Equipment, Net (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_PropertyandEquipmentNetDetailsLineItems', window );"><strong>Property and Equipment, Net (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_PropertyandEquipmentNetDetailsLineItems', window );"><strong>Property and Equipment, Net (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_PropertyandEquipmentNetDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_PropertyandEquipmentNetDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724061711192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - Schedule of property and equipment, net - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ScheduleOfPropertyAndEquipmentNetAbstract', window );"><strong>Schedule of property and equipment, net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Laboratory equipment</a></td>
<td class="nump">$ 3,183<span></span>
</td>
<td class="nump">$ 3,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FurnitureAndFixturesGross', window );">Furniture and fixtures</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="nump">3,927<span></span>
</td>
<td class="nump">3,889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">1,061<span></span>
</td>
<td class="nump">490<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">8,318<span></span>
</td>
<td class="nump">7,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(4,072)<span></span>
</td>
<td class="num">(3,378)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">$ 4,246<span></span>
</td>
<td class="nump">$ 4,225<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ScheduleOfPropertyAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ScheduleOfPropertyAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FurnitureAndFixturesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FurnitureAndFixturesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724058354568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities (Details) - Schedule of accrued liabilities - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ScheduleOfAccruedLiabilitiesAbstract', window );"><strong>Schedule of accrued liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">1,744<span></span>
</td>
<td class="nump">1,225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_AccruedCROFees', window );">Accrued CRO fees</a></td>
<td class="nump">675<span></span>
</td>
<td class="nump">788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_DeferredGrantFunds', window );">Deferred grant funds</a></td>
<td class="nump">601<span></span>
</td>
<td class="nump">301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_AccruedExpenseReimbursements', window );">Accrued expense reimbursements</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_AccruedTransactionCosts', window );">Accrued transaction costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">$ 3,117<span></span>
</td>
<td class="nump">$ 3,960<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_AccruedCROFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued CRO fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_AccruedCROFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_AccruedExpenseReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expense reimbursements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_AccruedExpenseReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_AccruedTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued transaction costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_AccruedTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_DeferredGrantFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred grant funds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_DeferredGrantFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ScheduleOfAccruedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ScheduleOfAccruedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724061108584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_RemainingRightofuseAsset', window );">Terminated right-of-use asset</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Terminated operating lease liability</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_RecognizedGainOnOperatingLease', window );">Recognized gain on operating lease</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_RightOfUseAssets', window );">Right of use asset</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_LeaseholdImprovements', window );">Leasehold improvements</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Lease liability</a></td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_IncreaseInRightOfUseAssets', window );">Increase in right of use assets</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_IncreaseInLeaseholdImprovements', window );">Increase in leasehold imrovements</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_IncreaseInLeaseLiability', window );">Increase in lease liability</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Gain on termination of lease</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_OperatingLeaseRightofUseAssets', window );">Right-of-use assets value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncentiveToLessee', window );">Lease incentive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_LeaseIncentiveRecordedConstructionInProgress', window );">Lease incentive recorded construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseDescription', window );">Description of lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The lease has an initial ten-year
term and provides us the right and option to extend or renew for two periods of five years each. In accordance with ASC 842, the payments
to be made in option periods have not been recognized as part of the right-of-use asset or lease liability because we do not assess the
exercise of the option to be reasonably certain.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FinanceLeaseObligationsWeightedaverageInterestRate', window );">Finance lease obligations weighted-average interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance lease weighted-average remaining term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_OperatingLeaseObligationsWeightedAverageInterestRate', window );">Operating lease obligations weighted average interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease weighted-average remaining term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_FinanceLeaseObligationsWeightedaverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance lease obligations weighted-average interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_FinanceLeaseObligationsWeightedaverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_IncreaseInLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of increase in lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_IncreaseInLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_IncreaseInLeaseholdImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of Increase in leasehold improvements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_IncreaseInLeaseholdImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_IncreaseInRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of Increase in right of use assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_IncreaseInRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_LeaseIncentiveRecordedConstructionInProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease incentive recorded construction in progress.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_LeaseIncentiveRecordedConstructionInProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_LeaseholdImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount held additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_LeaseholdImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_OperatingLeaseObligationsWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease obligations weighted average interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_OperatingLeaseObligationsWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_OperatingLeaseRightofUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Right-of-Use Assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_OperatingLeaseRightofUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_RecognizedGainOnOperatingLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recognized gain on operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_RecognizedGainOnOperatingLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_RemainingRightofuseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_RemainingRightofuseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_RightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_RightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of lease before expiration of lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 40<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123386189&amp;loc=SL77918607-209975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncentiveToLessee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of incentive granted by lessor to lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e40010-112707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e40019-112707<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 30<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123388062&amp;loc=SL77916639-209961<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncentiveToLessee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of lessor's operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919359-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724060188136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - Schedule of noncancelable finance and operating lease liabilities<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=clnn_FinanceLeasesMember', window );">Finance Leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems', window );"><strong>Leases (Details)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear', window );">2022</a></td>
<td class="nump">$ 43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent', window );">2023</a></td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears', window );">2024</a></td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears', window );">2025</a></td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears', window );">2026</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue', window );">Total undiscounted cash flows</a></td>
<td class="nump">281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CapitalLeasesAmountRepresentingInterestdiscounting', window );">Less amount representing interest/discounting</a></td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments', window );">Present value of future lease payments</a></td>
<td class="nump">278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CapitalLeasesFutureLeaseIncentives', window );">Less future lease incentives</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Less lease obligations, current portion</a></td>
<td class="num">(153)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsNoncurrent', window );">Lease obligations &#8211; long term portion</a></td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=clnn_OperatingLeasesMember', window );">Operating Leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems', window );"><strong>Leases (Details)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear', window );">2022</a></td>
<td class="nump">870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2023</a></td>
<td class="nump">960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2024</a></td>
<td class="nump">982<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2025</a></td>
<td class="nump">1,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2026</a></td>
<td class="nump">1,031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="nump">2,887<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total undiscounted cash flows</a></td>
<td class="nump">7,737<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_OperatingLeasesAmountRepresentingInterestdiscounting', window );">Less amount representing interest/discounting</a></td>
<td class="num">(2,507)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of future lease payments</a></td>
<td class="nump">5,230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_OperatingLeasesLessFutureLeaseIncentives', window );">Less future lease incentives</a></td>
<td class="num">(900)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less lease obligations, current portion</a></td>
<td class="num">(262)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease obligations &#8211; long term portion</a></td>
<td class="nump">$ 4,068<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CapitalLeasesAmountRepresentingInterestdiscounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of capital lease representing discounting and interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CapitalLeasesAmountRepresentingInterestdiscounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CapitalLeasesFutureLeaseIncentives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of less future lease incentives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CapitalLeasesFutureLeaseIncentives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_OperatingLeasesAmountRepresentingInterestdiscounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount representing interest/discounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_OperatingLeasesAmountRepresentingInterestdiscounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_OperatingLeasesLessFutureLeaseIncentives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of less future lease incentives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_OperatingLeasesLessFutureLeaseIncentives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of capital lease obligation due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123406127&amp;loc=d3e45023-112735<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123386454&amp;loc=d3e45280-112737<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123386454&amp;loc=d3e45280-112737<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123406127&amp;loc=d3e45023-112735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123386454&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123386454&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123386454&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123386454&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123386454&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123386454&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of minimum lease payments for capital leases net of executory costs, including amounts paid by the lessee to the lessor for insurance, maintenance and taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123386454&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=clnn_FinanceLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=clnn_FinanceLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=clnn_OperatingLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=clnn_OperatingLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724058522152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - Schedule of finance lease obligations included in property and equipment - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ScheduleOfFinanceLeaseObligationsIncludedInPropertyAndEquipmentAbstract', window );"><strong>Schedule of finance lease obligations included in property and equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FinanceLeaseLaboratoryEquipmentGross', window );">Laboratory equipment</a></td>
<td class="nump">$ 1,148<span></span>
</td>
<td class="nump">$ 920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FinanceLeaseFurnitureAndFixturesGross', window );">Furniture and fixtures</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FinanceLeaseWorkInProcessGross', window );">Work in process</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FinanceLeaseLiabilityGross', window );">Total</a></td>
<td class="nump">1,194<span></span>
</td>
<td class="nump">1,194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_AccumulatedDepreciationDepletionAndAmortizationLeases', window );">Less accumulated depreciation</a></td>
<td class="num">(629)<span></span>
</td>
<td class="num">(593)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FinanceLeaseLiabilityNet', window );">Net</a></td>
<td class="nump">$ 565<span></span>
</td>
<td class="nump">$ 601<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_AccumulatedDepreciationDepletionAndAmortizationLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_AccumulatedDepreciationDepletionAndAmortizationLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_FinanceLeaseFurnitureAndFixturesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance lease furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_FinanceLeaseFurnitureAndFixturesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_FinanceLeaseLaboratoryEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance lease laboratory equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_FinanceLeaseLaboratoryEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_FinanceLeaseLiabilityGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_FinanceLeaseLiabilityGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_FinanceLeaseLiabilityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance lease liability, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_FinanceLeaseLiabilityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_FinanceLeaseWorkInProcessGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance lease work in process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_FinanceLeaseWorkInProcessGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ScheduleOfFinanceLeaseObligationsIncludedInPropertyAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ScheduleOfFinanceLeaseObligationsIncludedInPropertyAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724066782456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - Schedule of finance and operating lease costs - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityAbstract', window );"><strong>Finance lease costs:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">$ 110<span></span>
</td>
<td class="nump">$ 137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="nump">247<span></span>
</td>
<td class="nump">308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease costs</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="nump">214<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">$ 280<span></span>
</td>
<td class="nump">$ 233<span></span>
</td>
<td class="nump">$ 663<span></span>
</td>
<td class="nump">$ 748<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724059706904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - Schedule of supplemental cash flow information - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ScheduleOfSupplementalCashFlowInformationAbstract', window );"><strong>Schedule of supplemental cash flow information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_OperatingCashFlowsFromOperatingLeases', window );">Operating cash flows from operating leases</a></td>
<td class="num">$ (533)<span></span>
</td>
<td class="num">$ (497)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_OperatingCashFlowsFromFinanceLeases', window );">Operating cash flows from finance leases</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FinanceCashFlowsFromFinanceLeases', window );">Financing cash flows from finance leases</a></td>
<td class="num">$ (117)<span></span>
</td>
<td class="num">$ (156)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_FinanceCashFlowsFromFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_FinanceCashFlowsFromFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_OperatingCashFlowsFromFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_OperatingCashFlowsFromFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_OperatingCashFlowsFromOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_OperatingCashFlowsFromOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ScheduleOfSupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ScheduleOfSupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724053510120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Feb. 28, 2019</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=clnn_TwoThousandNineteenMDLoanMember', window );">2019 MD Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NotesPayableDetailsLineItems', window );"><strong>Notes Payable (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Outstanding due date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 22,  2034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Phantom shares, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The 2019 MD Loan establishes &#8220;Phantom Shares,&#8221; based on 119,906 shares of Common Stock (based
on 863,110 Series C Preferred Shares prior to the Reverse Recapitalization), determined at issuance.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SimpleInterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueOfLongTermNotesPayable', window );">Fair value of long-term notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=clnn_TwoThousandNineteenCecilLoanMember', window );">2019 Cecil Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NotesPayableDetailsLineItems', window );"><strong>Notes Payable (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Outstanding due date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 30,  2034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Phantom shares, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The 2019 Cecil Loan establishes
&#8220;Phantom Shares,&#8221; based on 23,981 shares of Common Stock (based on 172,622 Series C Preferred Shares prior to the Reverse
Recapitalization), determined at issuance.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SimpleInterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueOfLongTermNotesPayable', window );">Fair value of long-term notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Amount of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=clnn_PaycheckProtectionProgramNoteMember', window );">PPP Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NotesPayableDetailsLineItems', window );"><strong>Notes Payable (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansPayable', window );">Note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_PercentageOfLoanAmountUsedToPayrollExpenses', window );">Percentage of loan amount used for payroll expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=clnn_TwoThousandtwentyoneAvenueLoanMember', window );">2021 Avenue Loan [Member] | Tranche one [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NotesPayableDetailsLineItems', window );"><strong>Notes Payable (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">First loan amount</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FundedAmountAtClosing', window );">Funded amount</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_DebtInstrumentUnfundedBalance', window );">Unfunded amount</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=clnn_TwoThousandtwentyoneAvenueLoanMember', window );">2021 Avenue Loan [Member] | Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NotesPayableDetailsLineItems', window );"><strong>Notes Payable (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SecondLoanAmount', window );">Second loan amount</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=clnn_TwoThousandtwentyoneAvenueLoanMember', window );">2021 Avenue Loan [Member] | Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NotesPayableDetailsLineItems', window );"><strong>Notes Payable (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Term loan</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SimpleInterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_AccruedDebtIssuanceCosts', window );">Accrued debt issuance costs</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of Debt Issuance Costs</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ConditionsForFutureFundingDescription', window );">Conditions for future funding, description</a></td>
<td class="text">funding of Tranche 2 is subject
to evidence reasonably satisfactory to Avenue of receipt of an additional $5.0 million financing through Maryland&#8217;s State Incentive
Programs and/or other Maryland State programs and mutual agreement of the Company and Avenue. On September 27, 2021, we obtained a waiver
from this additional financing requirement for the funding of the remaining $5.0 million of Tranche 1 and exercised the option to postpone
principal repayment by one year. We incurred additional issuance costs of $75 thousand upon funding the remaining $5.0 million of Tranche
1, of which $12 thousand has been expensed immediately. Funding of Tranche 2 is also subject to (a) our achievement of a statistically
significant result on the primary endpoint as defined within the statistical analysis plan for each respective study, or the totality
of the results for any study warrant advancement into a subsequent clinical efficacy study, as reasonably determined by the Company and
Avenue with respect to at least two of the following studies: (i) RESCUE-ALS or the Healey ALS Platform Trial; (ii) REPAIR-PD; or (iii)
REPAIR-MS (&#8220;Performance Milestone 1&#8221;); and (b) our receipt of net proceeds of at least $30 million from the sale and issuance
of our equity securities (including any private placement or follow-on offering) between May 2, 2021 and June 30, 2022.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_RateOfInterestDescription', window );">Rate of interest, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The loans bear interest at
a variable rate per annum equal to the sum of (i) the greater of (A) the prime rate, as published by the Wall Street Journal from time
to time or (B) 3.25%, plus (ii) 6.60%. Payments for the loan are interest only for the initial 12 months and can be extended to (i) 12
months (the &#8220;First Interest-only Period Extension&#8221;) if we achieve Performance Milestone 1 and (ii) up to 36 months if (a)
we achieve the First Interest-only Period Extension and (b) have drawn from Tranche 2. On August 16, 2021, we mutually confirmed with
Avenue that Performance Milestone 1 and the First Interest-only Period Extension had been achieved.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_AdditionalPaymentUponMaturityDescription', window );">Additional payment upon maturity, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On the maturity date, an
additional payment equal to 4.25% of the funded loans, or $0.6 million, is due in addition to the remaining unpaid principal and accrued
interest.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_WarrantToPurchaseShares', window );">Warrant to purchase shares (in Shares)</a></td>
<td class="nump">115,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockAtAnExercisePrice', window );">Common stock at an exercise price (in Dollars per share)</a></td>
<td class="nump">$ 8.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_Tranche2WarrantAdjustmentDescription', window );">Tranche warrant adjustment description</a></td>
<td class="text">Upon the funding of Tranche 2, the Avenue
Warrant shall be automatically adjusted to include an additional estimated 86,679 shares of Common Stock, which is equal to 5% of the
principal amount of Tranche 2, divided by the lower of (i) the five (5)-day VWAP per share; determined as of the end of trading on the
last trading day before the date of issuance of Tranche 2; or (ii) the Next Round Price.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible note payable</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ConversionPercentageOfCommonStockPriceForConvertibleNotePayable', window );">Conversion percentage of common stock price for convertible note payable, percentage</a></td>
<td class="nump">120.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_TradingVolumeLimitForConversionOfConvertibleNotePayable', window );">Trading volume limit for conversion of convertible note payable, percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ThresholdForRemovalOfFinancialCovenantsDescription', window );">Threshold for removal of financial covenants, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The financial covenant associated with
the loan agreement includes maintaining minimum unrestricted cash and cash equivalents of at least $5.0 million; provided that upon our
(i) achievement of Performance Milestone 1, and (ii) receiving of net proceeds of at least $30.0 million from the sale and issuance of
our equity securities (including any PIPE or follow-on offering) between May 1, 2021 and June 30, 2022, we shall no longer be subject
to financial covenants.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_MinimumCashBalanceForLoanCovenant', window );">Minimum cash balance for loan covenant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueOfWarrant', window );">Fair value of warrant</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_DebtInstrumentFinancingCosts', window );">Financing costs</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_AccruedDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_AccruedDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_AdditionalPaymentUponMaturityDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional payment upon maturity description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_AdditionalPaymentUponMaturityDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CommonStockAtAnExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock at an exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CommonStockAtAnExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ConditionsForFutureFundingDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conditions for future funding, description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ConditionsForFutureFundingDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ConversionPercentageOfCommonStockPriceForConvertibleNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion percentage of common stock price for convertible note payable percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ConversionPercentageOfCommonStockPriceForConvertibleNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_DebtInstrumentFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_DebtInstrumentFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_DebtInstrumentUnfundedBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument unfunded amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_DebtInstrumentUnfundedBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_FairValueOfLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of principal and accrued interest is included in long-term notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_FairValueOfLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_FairValueOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_FairValueOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_FundedAmountAtClosing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>FundedAmountAtClosing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_FundedAmountAtClosing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_MinimumCashBalanceForLoanCovenant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum cash balance for loan covenant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_MinimumCashBalanceForLoanCovenant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_NotesPayableDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_NotesPayableDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_PercentageOfLoanAmountUsedToPayrollExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of loan amount used to payroll expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_PercentageOfLoanAmountUsedToPayrollExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_RateOfInterestDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of interest, Description</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_RateOfInterestDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_SecondLoanAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Second loan amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_SecondLoanAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_SimpleInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Simple interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_SimpleInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ThresholdForRemovalOfFinancialCovenantsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold for removal of financial covenants, description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ThresholdForRemovalOfFinancialCovenantsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_TradingVolumeLimitForConversionOfConvertibleNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading volume limit for conversion of convertible note payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_TradingVolumeLimitForConversionOfConvertibleNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_Tranche2WarrantAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of tranche 2 warrant adjustment description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_Tranche2WarrantAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_WarrantToPurchaseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant to purchase shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_WarrantToPurchaseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of all notes and loans payable (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=clnn_TwoThousandNineteenMDLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=clnn_TwoThousandNineteenMDLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=clnn_TwoThousandNineteenCecilLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=clnn_TwoThousandNineteenCecilLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=clnn_PaycheckProtectionProgramNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=clnn_PaycheckProtectionProgramNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=clnn_TwoThousandtwentyoneAvenueLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=clnn_TwoThousandtwentyoneAvenueLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724060191352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable (Details) - Schedule of long-term debt, net of original issue discount and unamortized debt issuance costs - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_TermLoansAbstract', window );"><strong>Term Loans:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_TotalTermLoans', window );">Total term loans</a></td>
<td class="nump">$ 20,983<span></span>
</td>
<td class="nump">$ 1,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Unamortized debt issuance costs and original issue discounts</a></td>
<td class="num">(1,811)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less convertible notes payable, net of unamortized debt discount and issuance costs (see Note 11)</a></td>
<td class="num">(4,559)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_TotalNotesPayableAndConvertibleNotesPayable', window );">Total notes payable</a></td>
<td class="nump">$ 14,613<span></span>
</td>
<td class="nump">1,949<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_TermLoansAxis=clnn_MarylandDepartmentOfHousingCommunityDevelopmentMember', window );">Maryland Department of Housing &amp; Community Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_TermLoansAbstract', window );"><strong>Term Loans:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_InterestRate', window );">Interest Rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_TotalTermLoans', window );">Total term loans</a></td>
<td class="nump">$ 819<span></span>
</td>
<td class="nump">1,080<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_TermLoansAxis=clnn_AdvanceCecilIncMember', window );">Advance Cecil, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_TermLoansAbstract', window );"><strong>Term Loans:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_InterestRate', window );">Interest Rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_TotalTermLoans', window );">Total term loans</a></td>
<td class="nump">$ 164<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_TermLoansAxis=clnn_PaycheckProtectionProgramMember', window );">Paycheck Protection Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_TermLoansAbstract', window );"><strong>Term Loans:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_InterestRate', window );">Interest Rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_TotalTermLoans', window );">Total term loans</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">647<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_TermLoansAxis=clnn_AvenueVentureOpportunitiesFundsLPMember', window );">Avenue Venture Opportunities Fund, L.P. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_TermLoansAbstract', window );"><strong>Term Loans:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_InterestRate', window );">Interest Rate</a></td>
<td class="nump">9.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_TotalTermLoans', window );">Total term loans</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_TermLoansAxis=clnn_OtherTermLoanMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_TermLoansAbstract', window );"><strong>Term Loans:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_InterestRate', window );">Interest Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_TotalTermLoans', window );">Total term loans</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_InterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest Rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_InterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_TermLoansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_TermLoansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_TotalNotesPayableAndConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total notes payable and convertible notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_TotalNotesPayableAndConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_TotalTermLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total Term Loans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_TotalTermLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_TermLoansAxis=clnn_MarylandDepartmentOfHousingCommunityDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_TermLoansAxis=clnn_MarylandDepartmentOfHousingCommunityDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_TermLoansAxis=clnn_AdvanceCecilIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_TermLoansAxis=clnn_AdvanceCecilIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_TermLoansAxis=clnn_PaycheckProtectionProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_TermLoansAxis=clnn_PaycheckProtectionProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_TermLoansAxis=clnn_AvenueVentureOpportunitiesFundsLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_TermLoansAxis=clnn_AvenueVentureOpportunitiesFundsLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_TermLoansAxis=clnn_OtherTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_TermLoansAxis=clnn_OtherTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724147743432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes Payable (Details) - Schedule of future payments, net of unamortized debt discounts<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscountsAbstract', window );"><strong>Schedule of future payments, net of unamortized debt discounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_DebtInstrumentUnamortizedDiscountRemainderOfFiscalYear', window );">2021 (remainder)</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_DebtInstrumentUnamortizedDiscountYearOne', window );">2022</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_DebtInstrumentUnamortizedDiscountYearTwo', window );">2023</a></td>
<td class="nump">6,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_DebtInstrumentUnamortizedDiscountYearThree', window );">2024</a></td>
<td class="nump">13,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_DebtInstrumentUnamortizedDiscountYearFour', window );">2025</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_DebtInstrumentUnamortizedDiscountYearFive', window );">2026</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_DebtInstrumentThereafter', window );">Thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FuturePrincipalPayments', window );">Subtotal of future principal payments</a></td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremium', window );">Unamortized debt discount associated with issuance date warrant fair value and financing costs</a></td>
<td class="num">(1,811)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecurities', window );">Total</a></td>
<td class="nump">$ 18,189<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_DebtInstrumentThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loans to be paid after fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_DebtInstrumentThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_DebtInstrumentUnamortizedDiscountRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loans to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_DebtInstrumentUnamortizedDiscountRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_DebtInstrumentUnamortizedDiscountYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loans to be paid in fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_DebtInstrumentUnamortizedDiscountYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_DebtInstrumentUnamortizedDiscountYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loan to be paid in fourth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_DebtInstrumentUnamortizedDiscountYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_DebtInstrumentUnamortizedDiscountYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loans to be paid in next fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_DebtInstrumentUnamortizedDiscountYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_DebtInstrumentUnamortizedDiscountYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loan to be paid in third fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_DebtInstrumentUnamortizedDiscountYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_DebtInstrumentUnamortizedDiscountYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loan to be paid in second fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_DebtInstrumentUnamortizedDiscountYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_FuturePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of future principal payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_FuturePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724067218360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred Stock Warrant Liability (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 11, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Apr. 08, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_PreferredStockWarrantLiabilityDetailsLineItems', window );"><strong>Preferred Stock Warrant Liability (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_LossInFairValueOfWarrantLiability', window );">Loss in fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueAdjustmentOfWarrantsOutstanding', window );">Fair value of the outstanding warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.1<span></span>
</td>
<td class="nump">$ 7.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_PreferredStockWarrantLiabilityDetailsLineItems', window );"><strong>Preferred Stock Warrant Liability (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants expire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SharesOfWarrantsExercisable', window );">Shares of warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,608,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_PreferredStockWarrantLiabilityDetailsLineItems', window );"><strong>Preferred Stock Warrant Liability (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SharesOfWarrantsExercisable', window );">Shares of warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_PercentOfFullydilutedEquityPurchasableUponExercise', window );">Percent of fully-diluted equity purchasable upon exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_PreferredStockWarrantLiabilityDetailsLineItems', window );"><strong>Preferred Stock Warrant Liability (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Exercise price</a></td>
<td class="nump">$ 1.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SharesOfWarrantsExercisable', window );">Shares of warrants exercisable</a></td>
<td class="nump">320,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_FairValueAdjustmentOfWarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant outstanding liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_FairValueAdjustmentOfWarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_LossInFairValueOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents the amount of loss in fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_LossInFairValueOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_PercentOfFullydilutedEquityPurchasableUponExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percent of fully-diluted equity purchasable upon exercise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_PercentOfFullydilutedEquityPurchasableUponExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_PreferredStockWarrantLiabilityDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_PreferredStockWarrantLiabilityDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_SharesOfWarrantsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares of warrants exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_SharesOfWarrantsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724062261944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jul. 15, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsDetailsLineItems', window );"><strong>Common Stock Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,407,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,815,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CompanyWarrantRedemptionRight', window );">Company warrant redemption right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company may redeem the outstanding warrants, in whole and not in part, at a price of $0.01 per warrant if, and only if, the last sales price of the Company&#8217;s Common Stock equals or exceeds $16.50 per share for any 20 trading days within a 30-trading day period ending three business days before the Company sends the notice of redemption.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=clnn_AvenueLoanMember', window );">Avenue Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsDetailsLineItems', window );"><strong>Common Stock Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ExercisePriceOfWarrantsDescription', window );">Exercise price of warrants, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(5)Consists of 115,851 shares of Common Stock underlying 115,851 Avenue Warrants issued pursuant to Tranche 1 of the 2021 Avenue Loan at an exercise price equal to the lower of (i) $8.63 (which is equal to the five-day VWAP per share, determined as of the end of trading on the last trading day prior to execution of the loan agreement), or (ii) the Next Round Price.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=clnn_TwoThousandtwentyoneAvenueLoanMember', window );">2021 Avenue Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsDetailsLineItems', window );"><strong>Common Stock Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=clnn_PIPEWarrantsMember', window );">PIPE Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsDetailsLineItems', window );"><strong>Common Stock Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">235,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,004,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=clnn_CommonStockWarrantsMember', window );">Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsDetailsLineItems', window );"><strong>Common Stock Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,929,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,929,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | PIPE Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsDetailsLineItems', window );"><strong>Common Stock Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares, issued</a></td>
<td class="nump">1,119,750<span></span>
</td>
<td class="nump">1,002,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="nump">2,239,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_PIPEWarrantsOwnershipLimit', window );">PIPE warrants ownership limit</a></td>
<td class="text">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=clnn_ChardanUnitPurchaseOptionMember', window );">Chardan Unit Purchase Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsDetailsLineItems', window );"><strong>Common Stock Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
<td class="nump">54,083<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=clnn_ChardanUnitPurchaseOptionMember', window );">Chardan Unit Purchase Option [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsDetailsLineItems', window );"><strong>Common Stock Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,166<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=clnn_ChardanUnitPurchaseOptionMember', window );">Chardan Unit Purchase Option [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsDetailsLineItems', window );"><strong>Common Stock Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,583<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CommonStockWarrantsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CommonStockWarrantsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CompanyWarrantRedemptionRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Company warrant redemption right.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CompanyWarrantRedemptionRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ExercisePriceOfWarrantsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of warrants exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ExercisePriceOfWarrantsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_PIPEWarrantsOwnershipLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of PIPE warrants ownership limit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_PIPEWarrantsOwnershipLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=clnn_AvenueLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=clnn_AvenueLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=clnn_TwoThousandtwentyoneAvenueLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=clnn_TwoThousandtwentyoneAvenueLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=clnn_PIPEWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=clnn_PIPEWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=clnn_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=clnn_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=clnn_ChardanUnitPurchaseOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=clnn_ChardanUnitPurchaseOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724061124920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants (Details) - Schedule of outstanding warrants to purchase shares of common stock - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NumberOfSharesIssuable', window );">Number of Shares Issuable</a></td>
<td class="nump">4,594,545<span></span>
</td>
<td class="nump">5,566,361<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=clnn_WarrantsDateMember', window );">June 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NumberOfSharesIssuable', window );">Number of Shares Issuable</a></td>
<td class="nump">117,500<span></span>
</td>
<td class="nump">1,119,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsExercisable', window );">Exercisable for</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsClassification', window );">Classification</a></td>
<td class="text">Equity<span></span>
</td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsExpiration', window );">Expiration</a></td>
<td class="text">December 2021<span></span>
</td>
<td class="text">December 2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=clnn_WarrantsDate1Member', window );">December 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NumberOfSharesIssuable', window );">Number of Shares Issuable</a></td>
<td class="nump">2,407,500<span></span>
</td>
<td class="nump">2,407,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsExercisable', window );">Exercisable for</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsClassification', window );">Classification</a></td>
<td class="text">Equity<span></span>
</td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsExpiration', window );">Expiration</a></td>
<td class="text">December 2025<span></span>
</td>
<td class="text">December 2025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=clnn_December20201Member', window );">December 2020 One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NumberOfSharesIssuable', window );">Number of Shares Issuable</a></td>
<td class="nump">24,583<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsExercisable', window );">Exercisable for</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsClassification', window );">Classification</a></td>
<td class="text">Equity<span></span>
</td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsExpiration', window );">Expiration</a></td>
<td class="text">December 2025<span></span>
</td>
<td class="text">December 2025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=clnn_WarrantsDate2Member', window );">December 2020 Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NumberOfSharesIssuable', window );">Number of Shares Issuable</a></td>
<td class="nump">1,929,111<span></span>
</td>
<td class="nump">1,929,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 1.97<span></span>
</td>
<td class="nump">$ 1.97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsExercisable', window );">Exercisable for</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsClassification', window );">Classification</a></td>
<td class="text">Equity<span></span>
</td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsExpiration', window );">Expiration</a></td>
<td class="text">April 2023<span></span>
</td>
<td class="text">April 2023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=clnn_May2021Member', window );">May 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NumberOfSharesIssuable', window );">Number of Shares Issuable</a></td>
<td class="nump">115,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 8.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsExercisable', window );">Exercisable for</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsClassification', window );">Classification</a></td>
<td class="text">Liability<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrantsExpiration', window );">Expiration</a></td>
<td class="text">May 2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CommonStockWarrantsClassification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CommonStockWarrantsClassification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CommonStockWarrantsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CommonStockWarrantsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CommonStockWarrantsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise Price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CommonStockWarrantsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CommonStockWarrantsExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CommonStockWarrantsExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_NumberOfSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Shares Issuable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_NumberOfSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=clnn_WarrantsDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=clnn_WarrantsDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=clnn_WarrantsDate1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=clnn_WarrantsDate1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=clnn_December20201Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=clnn_December20201Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=clnn_WarrantsDate2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=clnn_WarrantsDate2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=clnn_May2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=clnn_May2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724060663192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 11, 2020</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ConvertibleNotesDetailsLineItems', window );"><strong>Convertible Notes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Common stock potentially issuable upon conversion (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">482,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The effective interest rate was 15.46% for the three and nine months
ended September 30, 2021.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ConvertibleNotesDetailsLineItems', window );"><strong>Convertible Notes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Annual debt interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_DescriptionOfConvertibleNotes', window );">Description of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The 2020 Convertible Notes were convertible at the earlier of (i)&#160;one year, at which point the
notes would be convertible into Series C Preferred Shares at the Series C Preferred Share issuance price, and (ii)&#160;next equity financing
of no less than $10.0 million, at which point the notes would be convertible into shares issued in the next equity financing at 90% of
the per share issuance price of the next equity financing. The 2020 Convertible Notes contained embedded features that provide the lenders
with multiple settlement alternatives. Certain of these settlement features provided the lenders with a right to a fixed number of our
shares upon conversion of the notes. Other settlement features provided the lenders with the right or the obligation to receive cash or
a variable number of shares upon the completion of a capital raising transaction, change of control, or default of the Company (the &#8220;Redemption
Features&#8221;). The Redemption Features of the 2020 Convertible Notes met the requirements for separate accounting and were accounted
for as a single derivative instrument (the &#8220;2020 Derivative Instrument&#8221;). Accordingly, the 2020 Derivative Instrument of $0.7
million was recorded at fair value at inception as redeemable convertible preferred stock derivative liability in the condensed consolidated
balance sheets (see Note 12).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Debt extinguishment</a></td>
<td class="nump">$ 6,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Convertible shares (in Shares)</a></td>
<td class="nump">1,497,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_PercentageOfStockPrice', window );">Percentage of stock price</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Convertible per share (in Dollars per share)</a></td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_DescriptionOfLossOnExtinguishment', window );">Description of loss on extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The loss on extinguishment was calculated
as the difference between (i) the fair value of the 1,497,135 shares of Series D Preferred Stock issued to settle the 2020 Convertible
Notes of $6.9 million and (ii) the carrying value of the 2020 Convertible Notes of $5.7 million, which includes the principal balance
of the 2020 Convertible Notes of $6.1 million and accrued but unpaid interest of $0.1 million, net of the unamortized debt discount of
$0.5 million, plus the then-current fair value of derivative liability associated with the 2020 Convertible Notes at the time of the extinguishment
of $0.7 million.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=clnn_TwoThousandtwentyoneAvenueLoanMember', window );">2021 Avenue Loan [Member] | Convertible Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ConvertibleNotesDetailsLineItems', window );"><strong>Convertible Notes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ConvertibleNotesPayableDescription', window );">Convertible notes payable, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In May 2021, we entered into
the 2021 Avenue Loan from which we granted to Avenue the right, in its discretion, but not the obligation, at any time from time to time
from May 21, 2022 through May 21, 2024, while the loan is outstanding, to convert an amount of up to $5.0 million of the principal amount
of the outstanding loan into shares of Common Stock at a price per share equal to 120% of the stock purchase price set forth in the Avenue
Warrant (see Note 8).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_LoanOutstanding', window );">Loan outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ConversionPercentageOfCommonStockPriceForConvertibleNotePayable', window );">Conversion percentage of common stock price for convertible note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent', window );">Unamortized debt discount and issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CouponInterestExpense', window );">Coupon interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15.46%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ConversionPercentageOfCommonStockPriceForConvertibleNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion percentage of common stock price for convertible note payable percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ConversionPercentageOfCommonStockPriceForConvertibleNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ConvertibleNotesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ConvertibleNotesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ConvertibleNotesPayableDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of convertible notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ConvertibleNotesPayableDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CouponInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Coupon interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CouponInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_DescriptionOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_DescriptionOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_DescriptionOfLossOnExtinguishment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of loss on extinguishment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_DescriptionOfLossOnExtinguishment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_LoanOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loan Outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_LoanOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_PercentageOfStockPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_PercentageOfStockPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of any adjustments made to the stated rate to determine the effective rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=clnn_TwoThousandtwentyoneAvenueLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=clnn_TwoThousandtwentyoneAvenueLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724061759288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Issuance of derivative instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_LossOnDerivativeInstruments', window );">Loss on derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="num">$ (29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueAdjustment', window );">Clene Nanomedicine contingent earn-out</a></td>
<td class="nump">$ 64,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Initial shareholders contingent earn-out</a></td>
<td class="nump">$ 7,400<span></span>
</td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_GainlossOnCleneNanomedicineContingentEarnout', window );">Gain (loss) on Clene Nanomedicine contingent earn-out</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_GainlossOnInitialShareholdersContingentEarnout', window );">Gain (loss) on Initial Shareholders contingent earn-out</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_WarrantLiabilityFairValue', window );">Warrant fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_Changeinfairvaluewarrants', window );">Change in fair value warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_Changeinfairvaluewarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changeinfairvaluewarrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_Changeinfairvaluewarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_GainlossOnCleneNanomedicineContingentEarnout">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents the gain (loss) on Clene Nanomedicine contingent earn-out.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_GainlossOnCleneNanomedicineContingentEarnout</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_GainlossOnInitialShareholdersContingentEarnout">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents amount of gain (loss) on Initial Shareholders contingent earn-out.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_GainlossOnInitialShareholdersContingentEarnout</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_LossOnDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents the amount of loss on derivative instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_LossOnDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_WarrantLiabilityFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents amount of warrant liability fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_WarrantLiabilityFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of contingent consideration in a business combination that is classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of the assets less the liabilities of a derivative or group of derivatives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724059931800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724060413816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of components of income (loss) before income taxes - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesAbstract', window );"><strong>Schedule of components of income (loss) before income taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="nump">$ 29,860<span></span>
</td>
<td class="num">$ (11,370)<span></span>
</td>
<td class="num">$ (11,435)<span></span>
</td>
<td class="num">$ (20,724)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(985)<span></span>
</td>
<td class="nump">1,075<span></span>
</td>
<td class="num">(2,941)<span></span>
</td>
<td class="nump">669<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_TotalLossBeforeIncomeTaxes', window );">Total loss before income taxes</a></td>
<td class="nump">$ 28,875<span></span>
</td>
<td class="num">$ (10,295)<span></span>
</td>
<td class="num">$ (14,376)<span></span>
</td>
<td class="num">$ (20,055)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_TotalLossBeforeIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total loss before income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_TotalLossBeforeIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724060268744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_StockBasedCompensationDetailsLineItems', window );"><strong>Stock-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 9.9<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_UnrecognizedStockbasedCompensation', window );">Unrecognized stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm', window );">Weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 14 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_weightedAverageFairValuesOfOptionsGranted', window );">Weighted average grant-date fair value of stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_StockBasedCompensationDetailsLineItems', window );"><strong>Stock-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_RestrictedStockUnitsDescription', window );">Restricted stock units shares, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On December 30, 2020, we granted
rights to awards of the following shares of restricted stock under the 2020 Stock Plan:&#160;

    &#160;
    &#9679;
    370,101 shares to various employees and non-employee directors, which
vest on various dates between June 30, 2021 and January 15, 2022, subject to the employee&#8217;s continuous employment through such vesting
date. The restricted stock awards convert to shares of Common Stock on a one-for-one basis upon vesting. The award represents 5% of the
converted stock options under 2014 Stock Plan as a result of the Reverse Recapitalization and complements the 5% closing payment shares
held in escrow for Clene Nanomedicine common shareholders (see Note 3). The grant-date fair value of these awards was $4.0 million based
on the closing price of CLNN shares listed on Nasdaq of $10.82 per share on December 30, 2020, the date of the Reverse Recapitalization.
As of September 30, 2021, there were 224,109 shares of Common Stock issued upon the vesting of restricted stock awards. As of December
31, 2020 no shares were vested.
  &#160;

    &#160;
    &#9679;
    454,781 shares to various employees and non-employee directors, which were eligible to vest based on certain market conditions, subject to the employee&#8217;s continuous employment through such vesting date. The award complements the Milestone 1 earn-out share entitlement of Clene Nanomedicine shareholders and vests based on the same market condition (see Note 3). The grant-date fair value of these awards, using a Monte Carlo simulation, was $4.3 million. Based on the outcome of the market condition as of the September 30, 2021 and December 31, 2020 measurement dates, no shares were vested.
  &#160;

    &#160;
    &#9679;
    341,090 shares to various employees and non-employee directors, which were eligible to vest based on certain market conditions, subject to the employee&#8217;s continuous employment through such vesting date. The award complements the Milestone 2 earn-out share entitlement of Clene Nanomedicine. shareholders and vests based on the same market condition (see Note 3). The grant-date fair value of these awards, using a Monte Carlo simulation, was $3.5 million. Based on the outcome of the market condition as of the September 30, 2021 and December 31, 2020 measurement dates, no shares were vested.
  &#160;&#160;&#9679;341,090 shares to various employees and non-employee directors, which were eligible to vest based on certain performance conditions tied to the completion of the COVID-19 coronavirus treatment study, subject to the employee&#8217;s continuous employment through such vesting date. The award complements the Milestone 3 earn-out share entitlement of Clene Nanomedicine shareholders and vests based on the same performance condition (see Note 3). The grant-date fair value of these awards was $3.7 million, based on the closing price of CLNN shares listed on Nasdaq of $10.82 per share on December 30, 2020, the date of the Reverse Recapitalization. We did not recognize compensation expense because the occurrence of achieving this milestone was not probable. As of the September 30, 2021 and December 31, 2020 measurement dates, no shares were vested.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value of RSUs granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.3034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockExpense', window );">Stock-based compensation expense associated with restricted stock awards</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm', window );">Weighted average period for recognition of unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=clnn_StockPlan2020Member', window );">2020 Stock Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_StockBasedCompensationDetailsLineItems', window );"><strong>Stock-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,574,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=clnn_StockPlan2020Member', window );">2020 Stock Plan [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_StockBasedCompensationDetailsLineItems', window );"><strong>Stock-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,819,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,507,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants', window );">Shares for future grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,180,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,492,938<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=clnn_StockPlan2014Member', window );">2014 Stock Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_StockBasedCompensationDetailsLineItems', window );"><strong>Stock-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,555<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=clnn_StockPlan2020Member', window );">2020 Stock Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_StockBasedCompensationDetailsLineItems', window );"><strong>Stock-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available to be issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_MinimumFairMarketValueOfOptionGrantDescription', window );">Minimum fair market value of option grant, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The exercise prices, vesting periods, and other restrictions are determined at the discretion
of the Company&#8217;s Board of Directors, except that the exercise price per share of options may not be less than 100% of the fair market
value of the Common Stock on the date of grant.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=clnn_StockPlan2014Member', window );">2014 Stock Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_StockBasedCompensationDetailsLineItems', window );"><strong>Stock-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Stock option outstanding (pre-conversion)</a></td>
<td class="nump">53,286,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,286,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock option outstanding (post-conversion)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,032,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_MinimumFairMarketValueOfOptionGrantDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of minimum fair market value of option grant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_MinimumFairMarketValueOfOptionGrantDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_RestrictedStockUnitsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of Restricted Stock Units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_RestrictedStockUnitsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) for future granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_StockBasedCompensationDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_StockBasedCompensationDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_UnrecognizedStockbasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_UnrecognizedStockbasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_weightedAverageFairValuesOfOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_weightedAverageFairValuesOfOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockOtherSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockOtherSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage amount by which a share price is expected to fluctuate during the expected term of a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=clnn_StockPlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=clnn_StockPlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=clnn_StockPlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=clnn_StockPlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=clnn_StockPlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=clnn_StockPlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=clnn_StockPlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=clnn_StockPlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=clnn_StockPlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=clnn_StockPlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724067432248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - Schedule of stock-based compensation expense - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems', window );"><strong>Stock-Based Compensation (Details) - Schedule of stock-based compensation expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 2,425<span></span>
</td>
<td class="nump">$ 209<span></span>
</td>
<td class="nump">$ 9,945<span></span>
</td>
<td class="nump">$ 554<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems', window );"><strong>Stock-Based Compensation (Details) - Schedule of stock-based compensation expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">858<span></span>
</td>
<td class="nump">134<span></span>
</td>
<td class="nump">3,861<span></span>
</td>
<td class="nump">364<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems', window );"><strong>Stock-Based Compensation (Details) - Schedule of stock-based compensation expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 1,567<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">$ 6,084<span></span>
</td>
<td class="nump">$ 190<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724061776792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - Schedule of outstanding common stock options and related activity<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract', window );"><strong>Schedule of outstanding common stock options and related activity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Beginning Balance | shares</a></td>
<td class="nump">7,032,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Beginning Balance | $ / shares</a></td>
<td class="nump">$ 0.97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Term (Years), Beginning Balance</a></td>
<td class="text">5 years 4 months 2 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValue', window );">Intrinsic Value, Beginning Balance | $</a></td>
<td class="nump">$ 62,462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted | shares</a></td>
<td class="nump">2,574,441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Granted | $ / shares</a></td>
<td class="nump">$ 8.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted', window );">Weighted Average Remaining Term, Granted</a></td>
<td class="text">9 years 7 months 9 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueGranted', window );">Intrinsic Value, Granted | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ShareBasedCompensationArrangementNumberOfOptionsExercised', window );">Number of Options, Exercised | shares</a></td>
<td class="num">(409,867)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Exercised | $ / shares</a></td>
<td class="nump">$ 1.04<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_WeightedAverageRemainingTermYearsExercised', window );">Weighted Average Remaining Term (Years), Exercised</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue', window );">Intrinsic Value, Exercised | $</a></td>
<td class="nump">$ 2,373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Forfeited | shares</a></td>
<td class="num">(133,742)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Forfeited | $ / shares</a></td>
<td class="nump">$ 8.66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_WeightedAverageRemainingTermYearsForfeited', window );">Weighted Average Remaining Term (Years), Forfeited</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue', window );">Intrinsic Value, Forfeited | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Ending Balance | shares</a></td>
<td class="nump">9,063,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Ending Balance | $ / shares</a></td>
<td class="nump">$ 3.09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Term (Years), Ending Balance</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValue', window );">Intrinsic Value, Ending Balance | $</a></td>
<td class="nump">$ 38,863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber', window );">Number of Options, Options vested and exercisable ending | shares</a></td>
<td class="nump">6,000,723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_WeightedAverageExercisePricePerShareOptionVestedAndExercisable', window );">Weighted Average Exercise Price Per Share, Options vested and exercisable ending | $ / shares</a></td>
<td class="nump">$ 0.82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_WeightedAverageExercisePriceWeightedAverageRemainingTermYearsOptionsVestedAndEexercisableEnding', window );">Weighted Average Exercise Price Weighted Average Remaining Term (Years), Options vested and exercisable ending</a></td>
<td class="text">4 years 3 months 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueIntrinsicValueOptionsVestedAndExercisableEnding', window );">Intrinsic Value, Options vested and exercisable ending | $</a></td>
<td class="nump">$ 36,247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options, Stock options vested and expected to vest | shares</a></td>
<td class="nump">9,063,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Stock options vested and expected to vest | $ / shares</a></td>
<td class="nump">$ 3.09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm1', window );">Weighted Average Exercise Price Weighted Average Remaining Term (Years), Stock options vested and expected to vest</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_IntrinsicValueStockOptionsVestedAndExpectedToVestIntrinsicValueOptionsV', window );">Intrinsic Value, Stock options vested and expected to vest | $</a></td>
<td class="nump">$ 38,863<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_IntrinsicValueStockOptionsVestedAndExpectedToVestIntrinsicValueOptionsV">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_IntrinsicValueStockOptionsVestedAndExpectedToVestIntrinsicValueOptionsV</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic Value, Granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueIntrinsicValueOptionsVestedAndExercisableEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueIntrinsicValueOptionsVestedAndExercisableEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and exercisable options that may be converted into shares under option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ShareBasedCompensationArrangementNumberOfOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options shares exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ShareBasedCompensationArrangementNumberOfOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_WeightedAverageExercisePricePerShareOptionVestedAndExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price Per Share, Options vested and exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_WeightedAverageExercisePricePerShareOptionVestedAndExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_WeightedAverageExercisePriceWeightedAverageRemainingTermYearsOptionsVestedAndEexercisableEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_WeightedAverageExercisePriceWeightedAverageRemainingTermYearsOptionsVestedAndEexercisableEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_WeightedAverageRemainingTermYearsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_WeightedAverageRemainingTermYearsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_WeightedAverageRemainingTermYearsForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_WeightedAverageRemainingTermYearsForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724147512616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - Schedule of assumptions used to calculate the fair value of stock options - Equity Option [Member]<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsLineItems', window );"><strong>Schedule of assumptions used to calculate the fair value of stock option awards granted [Line Item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsLineItems', window );"><strong>Schedule of assumptions used to calculate the fair value of stock option awards granted [Line Item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">84.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.59%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsLineItems', window );"><strong>Schedule of assumptions used to calculate the fair value of stock option awards granted [Line Item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">87.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.94%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724058544520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - Schedule of restricted common stock activity - Restricted Stock Units (RSUs) [Member]<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems', window );"><strong>Stock-Based Compensation (Details) - Schedule of restricted common stock activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Beginning balance, Number of Restricted Stock Awards, Unvested balance | shares</a></td>
<td class="nump">1,507,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance, Weighted- Average Grant Date Fair Value, Unvested balance | $ / shares</a></td>
<td class="nump">$ 10.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of Restricted Stock Awards, Vested | shares</a></td>
<td class="num">(224,109)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted- Average Grant Date Fair Value, Vested | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Restricted Stock Awards, Forfeited | shares</a></td>
<td class="num">(37,464)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted- Average Grant Date Fair Value, Forfeited | $ / shares</a></td>
<td class="nump">$ 10.82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Ending balance, Number of Restricted Stock Awards, Unvested balance | shares</a></td>
<td class="nump">1,245,489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance, Weighted- Average Grant Date Fair Value, Unvested balance | $ / shares</a></td>
<td class="nump">$ 10.14<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724147653960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueDetailsLineItems', window );"><strong>Fair Value (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NotesPayableBasedOnClosingPrice', window );">Notes payable based on closing price (in Dollars per share)</a></td>
<td class="nump">$ 6.83<span></span>
</td>
<td class="nump">$ 9.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueAmortizedCost', window );">Fair value amortized cost</a></td>
<td class="nump">$ 18.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes payable</a></td>
<td class="nump">13.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Embedded conversion feature</a></td>
<td class="nump">4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueOfConvertibleNotesPayable', window );">Fair value of the convertible notes payable</a></td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Warrants to purchase common stock (in Shares)</a></td>
<td class="nump">2,407,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_AdditionalWarrantToPurchaseShares', window );">Additional warrant to purchase estimated shares (in Shares)</a></td>
<td class="nump">86,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Series of Individually Immaterial Business Acquisitions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueDetailsLineItems', window );"><strong>Fair Value (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription', window );">Contingent earn-out, description</a></td>
<td class="text">Pursuant to the Merger Agreement,
Clene Nanomedicine&#8217;s common shareholders immediately prior to the Reverse Recapitalization and Initial Shareholders of Tottenham
were entitled to receive additional shares of up to 8,333,333 shares and 750,000 shares of Common Stock, respectively, upon us achieving
certain milestones (see Note 3). Upon the consummation of the Reverse Recapitalization, Clene Nanomedicine and the Initial Shareholders
are entitled to receive up to 8,346,185 additional shares as a result of the exercise of the stock options in November 2020, and 750,000
shares of Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=clnn_AvenueLoanMember', window );">Avenue Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueDetailsLineItems', window );"><strong>Fair Value (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Warrants to purchase common stock (in Shares)</a></td>
<td class="nump">115,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_AdditionalWarrantToPurchaseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Warrant To Purchase Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_AdditionalWarrantToPurchaseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_FairValueAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value amortized cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_FairValueAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_FairValueDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_FairValueDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_FairValueOfConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_FairValueOfConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_NotesPayableBasedOnClosingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Notes payable based on closing price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_NotesPayableBasedOnClosingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents a description of such arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=clnn_AvenueLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=clnn_AvenueLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724061402296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value (Details) - Schedule of fair value hierarchy of liabilities measured at fair value on recurring basis - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems', window );"><strong>Fair Value (Details) - Schedule of fair value hierarchy of liabilities measured at fair value on recurring basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable</a></td>
<td class="nump">$ 983<span></span>
</td>
<td class="nump">$ 1,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liability</a></td>
<td class="nump">910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CleneNanomedicineContingentEarnoutFairValueDisclosure', window );">Clene Nanomedicine contingent earn-out</a></td>
<td class="nump">33,981<span></span>
</td>
<td class="nump">52,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_InitialShareholdersContingentEarnoutFairValueDisclosure', window );">Initial Shareholders contingent earn-out</a></td>
<td class="nump">4,196<span></span>
</td>
<td class="nump">5,906<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems', window );"><strong>Fair Value (Details) - Schedule of fair value hierarchy of liabilities measured at fair value on recurring basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable</a></td>
<td class="nump">983<span></span>
</td>
<td class="nump">1,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CleneNanomedicineContingentEarnoutFairValueDisclosure', window );">Clene Nanomedicine contingent earn-out</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_InitialShareholdersContingentEarnoutFairValueDisclosure', window );">Initial Shareholders contingent earn-out</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems', window );"><strong>Fair Value (Details) - Schedule of fair value hierarchy of liabilities measured at fair value on recurring basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CleneNanomedicineContingentEarnoutFairValueDisclosure', window );">Clene Nanomedicine contingent earn-out</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_InitialShareholdersContingentEarnoutFairValueDisclosure', window );">Initial Shareholders contingent earn-out</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems', window );"><strong>Fair Value (Details) - Schedule of fair value hierarchy of liabilities measured at fair value on recurring basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liability</a></td>
<td class="nump">910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CleneNanomedicineContingentEarnoutFairValueDisclosure', window );">Clene Nanomedicine contingent earn-out</a></td>
<td class="nump">33,981<span></span>
</td>
<td class="nump">52,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_InitialShareholdersContingentEarnoutFairValueDisclosure', window );">Initial Shareholders contingent earn-out</a></td>
<td class="nump">$ 4,196<span></span>
</td>
<td class="nump">$ 5,906<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CleneNanomedicineContingentEarnoutFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clene nanomedicine contingent earnout fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CleneNanomedicineContingentEarnoutFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_InitialShareholdersContingentEarnoutFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial shareholders contingent earnout fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_InitialShareholdersContingentEarnoutFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724066676904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value (Details) - Schedule of unobservable inputs to the conversion feature, warrant liability, and contingent earn-out valuation models<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=clnn_BlackScholesValuationModelMember', window );">Black-Scholes Valuation Model [Member] | Convertible Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">2 years 6 months 21 days<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=clnn_BlackScholesValuationModelMember', window );">Black-Scholes Valuation Model [Member] | Warrant Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">95.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=clnn_BlackScholesValuationModelMember', window );">Black-Scholes Valuation Model [Member] | Warrant Liability [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">3 years 10 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=clnn_BlackScholesValuationModelMember', window );">Black-Scholes Valuation Model [Member] | Warrant Liability [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">4 years 6 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=clnn_MonteCarloSimulationMember', window );">Monte Carlo Simulation [Member] | Convertible Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.07%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">1 month 2 days<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=clnn_MonteCarloSimulationMember', window );">Monte Carlo Simulation [Member] | Warrant Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.07%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=clnn_MonteCarloSimulationMember', window );">Monte Carlo Simulation [Member] | Warrant Liability [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">1 month 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=clnn_MonteCarloSimulationMember', window );">Monte Carlo Simulation [Member] | Warrant Liability [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">7 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=clnn_ContingentEarnOutMember', window );">Contingent Earn-Out [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">95.00%<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=clnn_BlackScholesValuationModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=clnn_BlackScholesValuationModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=clnn_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=clnn_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=clnn_MonteCarloSimulationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=clnn_MonteCarloSimulationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=clnn_ContingentEarnOutMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=clnn_ContingentEarnOutMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724061355080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value (Details) - Schedule of changes in fair value of financial liabilities related to the notes payable, the derivative instrument, the preferred stock warrants, and the contingent earn-outs - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsLineItems', window );"><strong>Fair Value (Details) - Schedule of changes in fair value of financial liabilities related to the notes payable, the derivative instrument, the preferred stock warrants, and the contingent earn-outs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 1,296<span></span>
</td>
<td class="nump">$ 640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">983<span></span>
</td>
<td class="nump">963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_InitialFairValueOfInstrument', window );">Initial fair value of instrument</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueIssuanceOfConvertiblePromissoryNotes', window );">Issuance of convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_IncreseDecreaseInFairValue', window );">Change in fair value</a></td>
<td class="num">(313)<span></span>
</td>
<td class="nump">323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueMeasurementExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN', window );">Extinguishment of derivative liability in connection with extinguishment of convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=clnn_CleneNanomedicineContingentEarnoutMember', window );">Clene Nanomedicine Contingent Earn-out [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsLineItems', window );"><strong>Fair Value (Details) - Schedule of changes in fair value of financial liabilities related to the notes payable, the derivative instrument, the preferred stock warrants, and the contingent earn-outs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">52,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">33,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_InitialFairValueOfInstrument', window );">Initial fair value of instrument</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_IncreseDecreaseInFairValue', window );">Change in fair value</a></td>
<td class="num">(18,072)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=clnn_InitialShareholdersContingentEarnoutMember', window );">Initial Shareholders Contingent Earn-out [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsLineItems', window );"><strong>Fair Value (Details) - Schedule of changes in fair value of financial liabilities related to the notes payable, the derivative instrument, the preferred stock warrants, and the contingent earn-outs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">5,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">4,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_InitialFairValueOfInstrument', window );">Initial fair value of instrument</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_IncreseDecreaseInFairValue', window );">Change in fair value</a></td>
<td class="num">(1,710)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=clnn_WarrantLiabilityMember', window );">Warrant Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsLineItems', window );"><strong>Fair Value (Details) - Schedule of changes in fair value of financial liabilities related to the notes payable, the derivative instrument, the preferred stock warrants, and the contingent earn-outs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_InitialFairValueOfInstrument', window );">Initial fair value of instrument</a></td>
<td class="nump">1,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_IncreseDecreaseInFairValue', window );">Change in fair value</a></td>
<td class="num">$ (547)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=clnn_DerivativeInstrumentMember', window );">Derivative Instrument [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsLineItems', window );"><strong>Fair Value (Details) - Schedule of changes in fair value of financial liabilities related to the notes payable, the derivative instrument, the preferred stock warrants, and the contingent earn-outs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueIssuanceOfConvertiblePromissoryNotes', window );">Issuance of convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_IncreseDecreaseInFairValue', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueMeasurementExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN', window );">Extinguishment of derivative liability in connection with extinguishment of convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(676)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=clnn_PreferredStockWarrantsMember', window );">Preferred Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsLineItems', window );"><strong>Fair Value (Details) - Schedule of changes in fair value of financial liabilities related to the notes payable, the derivative instrument, the preferred stock warrants, and the contingent earn-outs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueIssuanceOfConvertiblePromissoryNotes', window );">Issuance of convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_IncreseDecreaseInFairValue', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_FairValueMeasurementExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN', window );">Extinguishment of derivative liability in connection with extinguishment of convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_FairValueIssuanceOfConvertiblePromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This value for issuance of convertible promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_FairValueIssuanceOfConvertiblePromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_FairValueMeasurementExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This value for extinguishment of derivative liability in connection with extinguishment of convertible promissory note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_FairValueMeasurementExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_IncreseDecreaseInFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This value for change in fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_IncreseDecreaseInFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_InitialFairValueOfInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This value for initial fair value of instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_InitialFairValueOfInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=clnn_CleneNanomedicineContingentEarnoutMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=clnn_CleneNanomedicineContingentEarnoutMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=clnn_InitialShareholdersContingentEarnoutMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=clnn_InitialShareholdersContingentEarnoutMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=clnn_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=clnn_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=clnn_DerivativeInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=clnn_DerivativeInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=clnn_PreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=clnn_PreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724059858312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertibleCommonStockMember', window );">Convertible Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_RedeemableConvertiblePreferredStockDetailsLineItems', window );"><strong>Redeemable Convertible Preferred Stock (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Aggregate of converted shares</a></td>
<td class="nump">36,893,894<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_RedeemableConvertiblePreferredStockDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_RedeemableConvertiblePreferredStockDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertibleCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertibleCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724053458680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 15, 2021</div></th>
<th class="th"><div>May 21, 2021</div></th>
<th class="th"><div>Dec. 30, 2020</div></th>
<th class="th"><div>Dec. 28, 2020</div></th>
<th class="th"><div>Sep. 15, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>May 18, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockDetailsLineItems', window );"><strong>Common Stock (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common share, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_PreferredStockShares', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_IssuanceOfCommonStockUponReverseRecapitalization', window );">Issuance of common stock upon the reverse recapitalization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,303,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_RecapitalizationShare', window );">Issuance of common stock for advisory fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">644,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_InvestorsPurchasedShares', window );">Investors purchased shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,239,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Shares price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NetProceeds', window );">Net proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_PrivatePlacementWarrantsDescription', window );">Private placement warrants description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In addition, investors in the December 2020 PIPE offering also received warrants to purchase a number of shares equal
to one-half (1/2) of the number of December 2020 PIPE Shares, totaling 1,119,750 shares of Common Stock, at an exercise price of $0.01
per share, subject to a 180-day holding period (see Note 10).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_WarrantsShares', window );">Warrants shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,002,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ExercisePricePerShare', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CashProceedsReceived', window );">Cash proceeds received (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_PurchaseOptionUnits', window );">Purchase option units</a></td>
<td class="nump">220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NetIssuanceShares', window );">Net issuance shares</a></td>
<td class="nump">54,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NetIssuanceWarrants', window );">Net issuance warrants</a></td>
<td class="nump">49,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,177,020<span></span>
</td>
<td class="nump">59,526,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,177,020<span></span>
</td>
<td class="nump">59,526,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=clnn_InvestorsMember', window );">Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockDetailsLineItems', window );"><strong>Common Stock (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NetProceeds', window );">Net proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockSharesPurchased', window );">Common Stock Shares Purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">960,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockPricePerShare', window );">Common Stock Price Per Share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockDetailsLineItems', window );"><strong>Common Stock (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockDetailsLineItems', window );"><strong>Common Stock (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CashProceedsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Proceeds Received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CashProceedsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CommonStockDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CommonStockDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CommonStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Price Per Share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CommonStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CommonStockSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Shares Purchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CommonStockSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ExercisePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ExercisePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_InvestorsPurchasedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of share investors purchased shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_InvestorsPurchasedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_IssuanceOfCommonStockUponReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_IssuanceOfCommonStockUponReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_NetIssuanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net issuance shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_NetIssuanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_NetIssuanceWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net issuance warrants in shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_NetIssuanceWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_NetProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_NetProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_PreferredStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock Shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_PreferredStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_PrivatePlacementWarrantsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Private placement warrants description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_PrivatePlacementWarrantsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_PurchaseOptionUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unit purchase option shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_PurchaseOptionUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_RecapitalizationShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_RecapitalizationShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_WarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_WarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=clnn_InvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=clnn_InvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724175206264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share Attributable to Common Shareholders (Details) - PIPE Warrants [Member]<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsLineItems', window );"><strong>Net Income (Loss) Per Share Attributable to Common Shareholders (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding</a></td>
<td class="nump">117,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsLineItems', window );"><strong>Net Income (Loss) Per Share Attributable to Common Shareholders (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding</a></td>
<td class="nump">1,119,750<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=clnn_PIPEWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=clnn_PIPEWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724067632696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share Attributable to Common Shareholders (Details) - Schedule of basic and diluted net loss per share - Net Income (Loss) Per Share Attributable to Common Shareholders [Member] - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareLineItems', window );"><strong>Net Income (Loss) Per Share Attributable to Common Shareholders (Details) - Schedule of basic and diluted net loss per share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss) attributable to common shareholders &#8211; Basic (in Dollars)</a></td>
<td class="nump">$ 28,944<span></span>
</td>
<td class="num">$ (10,295)<span></span>
</td>
<td class="num">$ (14,163)<span></span>
</td>
<td class="num">$ (20,055)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestOnConvertibleDebtNetOfTax', window );">Less interest expense on potentially dilutive convertible notes payable (in Dollars)</a></td>
<td class="nump">196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income (loss) attributable to common shareholders - Diluted (in Dollars)</a></td>
<td class="nump">$ 29,140<span></span>
</td>
<td class="num">$ (10,295)<span></span>
</td>
<td class="num">$ (14,163)<span></span>
</td>
<td class="num">$ (20,055)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_WeightedAverageSharesOutstanding', window );">Weighted average common shares outstanding &#8211;Basic</a></td>
<td class="nump">62,071,754<span></span>
</td>
<td class="nump">17,358,159<span></span>
</td>
<td class="nump">61,307,699<span></span>
</td>
<td class="nump">17,358,159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_WeightedAverageEffectOfPotentiallyDilutiveSecuritiesAbstract', window );"><strong>Weighted average effect of potentially dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_EffectOfPotentiallyDilutiveStockOptionsinDollars', window );">Effect of potentially dilutive stock options</a></td>
<td class="nump">5,791,023<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_EffectOfPotentiallyDilutiveRestrictedStockAwards', window );">Effect of potentially dilutive common stock warrants</a></td>
<td class="nump">1,485,049<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_EffectOfPotentiallyDilutiveConvertibleNotesPayable', window );">Effect of potentially dilutive convertible notes payable</a></td>
<td class="nump">482,703<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_EffectOfPotentiallyDilutiveUnvestedRestrictedStockAwardsShares', window );">Effect of potentially dilutive restricted stock awards</a></td>
<td class="nump">208,105<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding &#8211;Diluted</a></td>
<td class="nump">70,038,634<span></span>
</td>
<td class="nump">17,358,159<span></span>
</td>
<td class="nump">61,307,699<span></span>
</td>
<td class="nump">17,358,159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in Dollars per share)</a></td>
<td class="nump">$ 0.47<span></span>
</td>
<td class="num">$ (0.59)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (1.16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in Dollars per share)</a></td>
<td class="nump">$ 0.42<span></span>
</td>
<td class="num">$ (0.59)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (1.16)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_EffectOfPotentiallyDilutiveConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effect of potentially dilutive convertible notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_EffectOfPotentiallyDilutiveConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_EffectOfPotentiallyDilutiveRestrictedStockAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effect of potentially dilutive restricted stock awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_EffectOfPotentiallyDilutiveRestrictedStockAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_EffectOfPotentiallyDilutiveStockOptionsinDollars">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effect of potentially dilutive stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_EffectOfPotentiallyDilutiveStockOptionsinDollars</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_EffectOfPotentiallyDilutiveUnvestedRestrictedStockAwardsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effect of potentially dilutive unvested restricted stock awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_EffectOfPotentiallyDilutiveUnvestedRestrictedStockAwardsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_WeightedAverageEffectOfPotentiallyDilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_WeightedAverageEffectOfPotentiallyDilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_WeightedAverageSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>WeightedAverageSharesOutstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_WeightedAverageSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestOnConvertibleDebtNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of interest recognized on convertible debt instrument excluding interest on principal required to be paid in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestOnConvertibleDebtNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=clnn_NetIncomeLossPerShareAttributableToCommonShareholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=clnn_NetIncomeLossPerShareAttributableToCommonShareholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724062300136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share Attributable to Common Shareholders (Details) - Schedule of securities excluded from computation of diluted net income (loss) per share - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ScheduleOfSecuritiesExcludedFromComputationOfDilutedNetIncomeLossPerShareAbstract', window );"><strong>Schedule of securities excluded from computation of diluted net income (loss) per share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SeriesDRedeemableConvertiblePreferredStock', window );">Series D redeemable convertible preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">9,394,057<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">9,394,057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SeriesCRedeemableConvertiblePreferredStock', window );">Series C redeemable convertible preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">7,264,519<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,264,519<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SeriesBRedeemableConvertiblePreferredStock', window );">Series B redeemable convertible preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,168,815<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,168,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SeriesARedeemableConvertiblePreferredStock', window );">Series A redeemable convertible preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">16,066,503<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">16,066,503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SeriesDRedeemableConvertiblePreferredStockWarrants', window );">Series D redeemable convertible preferred stock warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">320,441<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">320,441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SeriesARedeemableConvertiblePreferredStockWarrantsinShares', window );">Series A redeemable convertible preferred stock warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,608,670<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,608,670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ConvertibleNotesPayables', window );">Convertible notes payable (see Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">482,703<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CommonStockWarrants', window );">Common stock warrants (see Note 10)</a></td>
<td class="nump">2,523,351<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,569,962<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_OptionsToPurchaseCommonStockinShares', window );">Options to purchase common stock</a></td>
<td class="nump">2,685,575<span></span>
</td>
<td class="nump">7,509,810<span></span>
</td>
<td class="nump">9,063,423<span></span>
</td>
<td class="nump">7,509,810<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_UnvestedRestrictedStockAwardsShares', window );">Restricted stock awards</a></td>
<td class="nump">1,100,050<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,245,489<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ChardanUnitPurchaseOptionWarrants', window );">Chardan Unit Purchase Option Warrants (see Notes 3 and 10)</a></td>
<td class="nump">24,583<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">24,583<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_CleneNanomedicineContingentEarnoutShares', window );">Clene Nanomedicine contingent earn-out shares (see Note 3 and 12)</a></td>
<td class="nump">8,346,185<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,346,185<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_InitialShareholdersContingentEarnoutShares', window );">Initial Shareholders contingent earn-out shares (see Note 3 and 12)</a></td>
<td class="nump">750,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_TotalDilutiveSecurities', window );">Total</a></td>
<td class="nump">15,429,744<span></span>
</td>
<td class="nump">46,332,815<span></span>
</td>
<td class="nump">24,482,345<span></span>
</td>
<td class="nump">46,332,815<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ChardanUnitPurchaseOptionWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ChardanUnitPurchaseOptionWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CleneNanomedicineContingentEarnoutShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clene nanomedicine contingent earnout shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CleneNanomedicineContingentEarnoutShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_CommonStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_CommonStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ConvertibleNotesPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible notes payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ConvertibleNotesPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_InitialShareholdersContingentEarnoutShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial shareholders contingent earnout shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_InitialShareholdersContingentEarnoutShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_OptionsToPurchaseCommonStockinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_OptionsToPurchaseCommonStockinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ScheduleOfSecuritiesExcludedFromComputationOfDilutedNetIncomeLossPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ScheduleOfSecuritiesExcludedFromComputationOfDilutedNetIncomeLossPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_SeriesARedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_SeriesARedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_SeriesARedeemableConvertiblePreferredStockWarrantsinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_SeriesARedeemableConvertiblePreferredStockWarrantsinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_SeriesBRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_SeriesBRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_SeriesCRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_SeriesCRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_SeriesDRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Series D redeemable convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_SeriesDRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_SeriesDRedeemableConvertiblePreferredStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Series D redeemable convertible preferred stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_SeriesDRedeemableConvertiblePreferredStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_TotalDilutiveSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number potentially dilutive securities shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_TotalDilutiveSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_UnvestedRestrictedStockAwardsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unvested restricted stock awards shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_UnvestedRestrictedStockAwardsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724060743656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Consulting services expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_ExclusiveRightsIntellectualPropertyTerm', window );">Exclusive rights intellectual property term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Investor to pay royalties</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSoldSalesTypeLease', window );">Sale of product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRoyaltiesReceived', window );">Royalty revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvancesToAffiliate', window );">Advances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSoldDirectFinancingLease', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_ExclusiveRightsIntellectualPropertyTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exclusive rights intellectual property term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_ExclusiveRightsIntellectualPropertyTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvancesToAffiliate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-Term advances receivable from a party that is affiliated with the reporting entity by means of direct or indirect ownership. This does not include advances to clients.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvancesToAffiliate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSoldDirectFinancingLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of goods sold for direct financing lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919372-209981<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -URI http://asc.fasb.org/extlink&amp;oid=124502072&amp;loc=SL77927221-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSoldDirectFinancingLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSoldSalesTypeLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of goods sold for sales-type financing lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919372-209981<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -URI http://asc.fasb.org/extlink&amp;oid=124502072&amp;loc=SL77927221-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSoldSalesTypeLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRoyaltiesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRoyaltiesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724059672376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Geographic and Segment Information (Details) - Schedule of property and equipment, net by location - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationLineItems', window );"><strong>Geographic and Segment Information (Details) - Schedule of property and equipment, net by location [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">$ 4,246<span></span>
</td>
<td class="nump">$ 4,225<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationLineItems', window );"><strong>Geographic and Segment Information (Details) - Schedule of property and equipment, net by location [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">4,193<span></span>
</td>
<td class="nump">3,997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_AU', window );">Australia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationLineItems', window );"><strong>Geographic and Segment Information (Details) - Schedule of property and equipment, net by location [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">$ 53<span></span>
</td>
<td class="nump">$ 228<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_AU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_AU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724147244120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geographic and Segment Information (Details) - Schedule of drugs and supplements segments - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue from external customers</a></td>
<td class="nump">$ 110<span></span>
</td>
<td class="nump">$ 98<span></span>
</td>
<td class="nump">$ 524<span></span>
</td>
<td class="nump">$ 177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(10,450)<span></span>
</td>
<td class="num">(5,691)<span></span>
</td>
<td class="num">(35,920)<span></span>
</td>
<td class="num">(14,254)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=clnn_DrugsMember', window );">Drugs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue from external customers</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(10,546)<span></span>
</td>
<td class="num">(5,789)<span></span>
</td>
<td class="num">(35,632)<span></span>
</td>
<td class="num">(14,373)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=clnn_SupplementsMember', window );">Supplements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue from external customers</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="nump">524<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">$ 96<span></span>
</td>
<td class="nump">$ 98<span></span>
</td>
<td class="num">$ (288)<span></span>
</td>
<td class="nump">$ 119<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=clnn_DrugsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=clnn_DrugsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=clnn_SupplementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=clnn_SupplementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724066864504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Geographic and Segment Information (Details) - Schedule of property and equipment, net by segment - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentLineItems', window );"><strong>Geographic and Segment Information (Details) - Schedule of property and equipment, net by segment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_TotalPropertyAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">$ 4,246<span></span>
</td>
<td class="nump">$ 4,225<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=clnn_DrugsMember', window );">Drugs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentLineItems', window );"><strong>Geographic and Segment Information (Details) - Schedule of property and equipment, net by segment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_TotalPropertyAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">4,038<span></span>
</td>
<td class="nump">3,990<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=clnn_SupplementsMember', window );">Supplements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentLineItems', window );"><strong>Geographic and Segment Information (Details) - Schedule of property and equipment, net by segment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_TotalPropertyAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">$ 208<span></span>
</td>
<td class="nump">$ 235<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_TotalPropertyAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total property and equipment, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_TotalPropertyAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=clnn_DrugsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=clnn_DrugsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=clnn_SupplementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=clnn_SupplementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139724058515416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Event [Member]<br></strong></div></th>
<th class="th">
<div>Oct. 01, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventDescription', window );">Subsequent events, description</a></td>
<td class="text">The December
2020 PIPE Warrants were issued prior to the completion of the Reverse Recapitalization on December 30, 2020, and were subject to a 180-day
holding period which expired on June 28, 2021.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_AggregateGrossProceedWarrantsExercised', window );">Aggregate gross proceed warrants exercised</a></td>
<td class="nump">$ 250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=clnn_PIPEWarrantsMember', window );">PIPE Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clnn_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued (in Shares) | shares</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_AggregateGrossProceedWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate gross proceed warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_AggregateGrossProceedWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clnn_SubsequentEventsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clnn_SubsequentEventsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clnn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the event or transaction that occurred between the balance sheet date and the date the financial statements are issued or available to be issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=clnn_PIPEWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=clnn_PIPEWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>94
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$
MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)I#-ZG7TZSFN4
M?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R.AQG0GS/]O:1
MI24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG LR+7E$8D19_(
M+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(R-^-B/>K;YH]
M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M
MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1CVFS(Z=T)LWH
M,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.FJW"$2M"/F(9
M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+
MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T
M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M?;FB1 5=;:#>+[G"3'.C/SNUGQGG_P%02P,$%     @ NX9H4X$J=M6/ @
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M.\!F%[662''_R>:W4LW64XW?0.C:;%D33[U;YX!;);SE(/P0#N*Y(-'H[Q=
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M 2 "ZBT>ZJUC/^]D/V],'&E"QR])^2UT8%L7.LQ(/:'#&Q6U52DY:GOJDRC
M5'I\JD)S'GZ0A!6I8HX4R&(=$J+$UVO;/VG;'Z5M*6@/:MZ,VJ-Y?VS05@7-
M03LXS38 #]I&Q F/"B"<9:#1C;Q6!.HK L*)S6/NF!+9@C_:/RILFY$G&!4*
M: D%%$(!14>@CM%LZ9EDENG:]2PO@+X_@)LQIE@0"&@)!10>@3I/>NHWW*D3
M,J#ZBP?[Z]I1T&\TBG\WX>0?^YR'$[L_G Q ]<03-(Z :\3D6'X4Z80F.Y!4
M'FJDYEY B+R^TLA1.9QKL3P>YGK4+F@X&L7#Y8@^;(*+>#@:3<0UDN:@C@05
M1V8N_JZJ]NV<BP?KGI4IJZP[.5WWDY7SYPH72+\)KXJJKIIO7J#7Q-JF6<8#
MAU8SYM[[-.,H7D?X7!7GA"+S4$ A%% $!10# '4]2V0&D#DU .A9YS>DULO,
M(^GS,I4_>W[@!AC+?O;]E+ZK0\''D9F0C]%AD[%?%7E^K"L]I_7&JC>,K\OK
M-'_<I]6F6<HU"*NSC/RN++9<Z47YU<J+FNE2_6\'!M>G5E>Y>5T_4.Y=*/H/
M!11" 4500#$ 4-?O1!X!F>G__\_O!F_MB_(42)-@< (/$2J[H1'^ A6+Y $R
M\_SE%U:NTJI5<=7JL]@UBM3?B1?E#,RMIBST@8"62)/&D!>*0'U%4$"Q<=!=
MZXMD"C)G4WJM/W@_F''[/ $J$X/4= 1G#3T+;RSR$=B<C[@DN62&G# G** E
M5BD]9T)R+1(JR0 %% \,NVM2D8K YE3$=Z28S,A3+ N5H( ""J& (JQF'J0G
M:6P4Z5KU;%^ .9LP*L%DQIAB/R"@)110B#6I!V3C0%I71% =QL,==BTI<AUX
M7*XCJ?D*;V?.;PQ ]6WQ( H10,AQ;2*MP31RRBX/3:J$R"G54",UYX0.N[)Q
M5#D:R#>/#LO#M$_O(N&"S2F/GAS3L TNRJ1@M>9/.!LC?N#(5M#M#B"NC=R>
M,AD6F0!LYM\]NXFT\[PU8TUY>%"5A\INI68 $"7*QJ!0(S=O!.5T::01)')=
M,]8)]55^L4@58#,;'[&'J$?A4 5]K-:T:4"QV[O)! L^BLTT;PI9NC5C39D0
M$- 2JW24*@\OH,XB**#8/.JN)07MQ1?2W@'B<VO&G6)5E<XY/D9]/BHH'88O
MD)LAITP*JD2.58)'L"MOS8#J+H("BH?&W=V7*8@I^6&%<C/R!-M" 2VA@$(H
MH(AHJ*>T,(G-,EV["G9*  KE9HPI%H3BH5! (=$4KDG@47FI#-5A/-QAUY*"
MD9+1I?+SG5=(:U H8DK4LKB\MB0J<4/4]7U)+M3(S5%3&/=D4ZB"Q)%IBPZ-
M+^*]/C6?[5"_J#0^K'(C[!25ZT@;]1SB]R0UB*!D9'P-?'5XT>2P--GO^&53
MT]B5Z5-2-P(/K$SS1^U,@4JV=U! 2Z)2N@ K"T^H[B(HH'AHW%TS"QI*QA>D
MQYEY:$UJ[G"*R55*&+@V=?KF+%@A,;/"2<3)C#5E.E#%7:*AE+[LOU!U6RB@
MV#SJKB4%!2874N!!)X6BPT135,6.Z_<YJ>"$Q,P)S3?F$ZN:@G+S(Q]?7::K
MYJVY@T#RG)3ZUQ3-74Z9-53M$PHHA **H(!B *"NZPC23<RD^WM=9_#F@2+H
M1%,X18'?4V9S!$%UX"NG9L@I+]-!,5-'Y7C.>:[]X/A0W4500/'0N+M&%>S4
M^6&U4S/R%-M"<58HH! **'(T7%1.Y<<#0EW+"K;J -1/S1A3; A5/X4""AT=
M/R7RSMX(JK]XL+^N'04==D973\]WAVLIL!EJBCG50JF<=7!T.\5M1\X3A!JY
M.0I<U_5E2V@JK[XOWRL:-$S/W^CKJOGL1?&+BJ7#*H?BXHY*15W;]1$-^EQ(
MT%''3$<G43,SUI0)0;TN[6BJF/*+-B%4;Q$44#PP[*XM!<UV+J390^M+,^X4
MNZJ<$Q,WZ$O\.8)W.N-Y)U\R\X5(K?=0*)H)!;1T-'Q53GY!=19! <7F47>-
M*!BV,[[J^LV(@ZX)Q: =S2O)MHU[,WJ.8'_.^%VT^WS-RN<RK5GYU[_X&'E_
MKXXWH79R4+P."F@)!11" 4500#$ 4/=P$L&.J9D=CW.0H3O!W,F4HTI4ND@=
MV^_9/DT%7Z1FOO@C$FCF+J=,&HI(0@&%4$ 1%% , -1U'4%(J9F0_N@$FKG[
M*6ZD>\T8(]P31*B@<M1,Y2[)H)DAI\P*"&A)-3S-48Y4@>HN@@**A\;=-:H@
MCM1,'+_G7"HH[@@%M(0""J& (JK2XKDOOZ8_(-2U[-F!8V;:/"J#9L:88D.P
MT\7 CA=3"2SV T?:-15!]1</]M>UHZ#,=-1^97GONS:=8X::8D[-N\E2!DTC
M@CR"Y;<60HW<'+F>)^]?BS2"V):SS1HAZOH]Y)T*\D[''0AF>-E I_ [JI)0
MEZ^8/;LWW#94M/N-8''TDG<6WPZT^L#JLC@<HIQ];5<G[6FJ#T79;N7XP)Y8
M637_5X>37M,_CP__REJS:E6FG[@T5\NO1<TLHEM++<X.Z-VR\K$]K+GB:X1]
M7A_.]CQ]>SH0^FU[;K+\/?7?1-37_,(GR7]ISY!>B"X.)U#_DI2/:5Y9&7O@
MW=FO/6Z-\G"H\^%#7>S:(X(_%75=;-O+#4LXR6D$^.\/!9_:\4/3P>EH[9O_
M 5!+ P04    " "[AFA3 IOM.C "  "<!   &    'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;'U4WX_:, S^5Z)JTD"::"G<;3J52ORX:7NX#1UB>YCV$%J7
M1J1)+W'A[K^?DY:.28,78B?^/G\V=I.3-@=; B![K:2RLZ!$K!_"T&8E5-R.
M= V*7@IM*H[DFGUH:P,\]Z!*AG$4W8<5%RI($W^W-FFB&Y1"P=HPVU05-V\+
MD/HT"\;!^>)9[$MT%V&:U'P/&\!MO3;DA3U++BI05FC%#!2S8#Y^6$Q=O _X
M(>!D+VSF*MEI?7#.UWP61$X02,C0,7 ZCK $*1T1R7CI.(,^I0->VF?VS[YV
MJF7'+2RU_"ER+&?!IX#E4/!&XK,^?8&NGCO'EVEI_2\[=;%1P++&HJXZ,"FH
MA&I/_MKUX0(0CZ\ X@X0>]UM(J]RQ9&GB=$G9EPTL3G#E^K1)$XH]Z=LT-"K
M(!RF2ZUR:C'DC"RKI<@YDK-!.JCW:-GW@CR='4HM<S#V/7M\:02^L<$*"I$)
M'++!5O$F%X0C>\T-P4I D7%IATF(I-+E"K-.T:)5%%]1-&%/F@@L>R1E^;_X
MD*KK2XS/)2[BFX0;J$=L$GU@<11'V\V*#=X-;]!.^LY-/.WD&NVY14Q?Z="O
M^<ZBH;G[?2/=M$\W]>FF5])] Y](6-MPE0'+M$7[O^ZV-/>>QJWD,1U/HB@)
MCY?)PXN)J<#L_5Y8(FT4ML/3W_:K-V\G[F]XN[=/W.R%LDQ"0=!H]/$N8*;=
MA=9!7?OYVVFD:?9F29\/,"Z W@NM\>RX!/T'*?T#4$L#!!0    ( +N&:%-R
MNGFI!PH  ,4P   8    >&PO=V]R:W-H965T<R]S:&5E=#<N>&ULK5MM<]NX
M$?XK'/6FD\Q$$0D0E)3:GDF<7.N9N]03-[W/$ E9:"A"!U)^^?==@#0A$R\2
M=;D/L2SC99_=Q3Z["]S%HY _Z@UC3?2T+:OZ<K)IFMV'V:S.-VQ+Z_=BQRKX
MRUK(+6W@5WD_JW>2T4)/VI8S%,?9;$MY-;FZT-_=RJL+L6]*7K%;&=7[[9;*
MYT^L%(^7DV3R\L4W?K]IU!>SJXL=O6=WK/F^NY7PVZQ?I>!;5M5<5)%DZ\O)
MQ^3#=8;4!#WBOYP]U@>?(P5E)<0/]<M-<3F)E42L9'FCEJ#PXX%=L[)4*X$<
M?W:+3OH]U<3#SR^K_ZK! Y@5K=FU*/_@1;.YG"PF4<'6=%\VW\3COU@'B*CU
M<E'6^M_HL1L;3Z)\7S=BVTT&";:\:G_2ITX1!Q-@'?<$U$U PPFI9P+N)F -
MM)5,P_I,&WIU(<5C)-5H6$U]T+K1LP$-KY09[QH)?^4PK[FZ%E4!1F%%!)]J
M4?*"-O#+70,_P%I-'8EU=$WK3?0K6+R.WGROZ+[@,.9M-(V^WWV.WOSR-OHE
MXE7TGXW8U[0JZHM9 Y*I]6=Y)\6G5@KDD6(9_2ZJ9E-'7T":XO7\&2#J8:$7
M6)]0<,$[MGL?X?A=A&*4..2Y/GUZ'! ']UK&>CWLT[)2X%HK<"W%-H)3*&G#
MJ_O6C7G#6?TAL$_:[Y/J?5+//E_AW)>B=EJ@G9GIF>IP/UQ-DS3)\,7LX5 Q
MCF$0$@CIA[T2C/2"D: "/A;_ U]N':H1</YS4>6\9%'52:R^59]SI:F]\D?P
MJ+%JRGIILJ":/C,(>3FG*I"X5-7.)@<ZF.-TH"=[3+;,W$J:]V+-P]83U53C
M+QD$IH@][=3)= DXMS9?) /Y'$/F;O$6O7B+H'C7&UK=,V67->4R>J#EGJGH
M +I<,RG!9!"M\A_1(Y625F!63E>\Y,VS"T%P*\5='^H=S=GE!%:OF7Q@DZO(
M=8X7#E/-%VZ@RQ[H\BR@UR6K6/255F++"I[#K C<6/DG^'7$J*RF0)0NM$M+
MRFFRB.=H8+.@6"<IY17>)#8D$)^%^*:",T?+Z&Y#)=N(LF"R/A5SM^5KT/,D
M'F .2W8&Z /F2\X"#2#Y U79A1-6<-$1GMLM]$H_:.GVW 094.@L4+G8;B%K
M&G%"NXU>R4?2^=!\07'.,)^AU 0'D?Z3*H:HHH9)R(MT+%= =>QTX@DN-\9P
MV*&8Q&,XP]Q)F+KOE&6F*B,ME+%4Z&\Q!6B@6_)0DN4R)4,3V:,(23WR&D)/
MR$GJ9T\J&.QYO5'LKBQ0B8;5T8X^TU7I%IO8"LQLSPKN?X9GF>P@":<'OZE\
MQ D-0M\#DPU?J<SE*,S@+F,<SLXU2!I[#&B2C22<;7S,<\E>3DW!5DU4\#H7
M^\H=S8.+C0%C)R;)W!?V3&J2A'.3FPK J*3I3<':3V]5#.051 =6-Y _YG(/
M)PO0'K>;G5-,$RO_<XS"2Q\.DWDDRW"AH,-W/4A^ZYI!W@RE51^QCR3"R# _
M"C/_#3ATU0CII !D4WA"A@3N&#3%R*T(9,@9A<D9O%.Y8JU*!09T[+$5<I!H
MNAA*Z&):3\!&AFE1F&EO)=M17KS$Y]8^HMDP"74[I,,0,5K#.>5VD&N"L*5;
MQS"4)#[M&NY$8>[LM1LX!LBFN33-A@(ZN!"E/OD,&:(P&7[LCNN!NSM%=#!;
M,BR$'(.F&'OJ663X#X7Y[[;57%O-EKIILJ/2*^E?)[,.C8,[$^QS9D-YZ%A%
MW)5PDD$\@)11MRE. ?:S2 [9).=W=$-R*$QR/2Y>05(%UJ)/3A0V*4V3Y; \
M"^\U/B-!AMY0F-[^W7-!VQH0JY+?Z_30;107@Z46',<HXBF=D6$P%"Z>OY[2
MQ'$*[2B2$8D3*YJ[BFF<^ (Z-E2(XU%-.@[46(_H/F%#;CA,;K=[F6^HX@S=
M/E$::IXU?[ _]WRGLDV7AK"#Q[)L&.]<HU#FR4RPH3L<ICO+KB[U.*5V<)A#
M:A?3>:4^Z+N.:[RNH5*L\A$V-92%PY1U*T7.6-'MPYZ8S'FM2^^VYA8[[W'%
M-D.E:%@..09YHB,V'(:/<-@KF7E=[T$Y;'2A$]YE! =@F]RR!'FH&AMRPV%R
M>PVS:W[4O8T*)R8''0VSL_"VX_D &UK#85J#Y*._G&E=FIW&#-A%=(GE:ZY1
MQ-/=QH;%<)C%7ML!,F6(?:K3!C]+4),W[-D\M416&1+>^PQC&,;#8<:S81V>
MI..GQ^8S%,-_0WSVL(QX(D!J."\-EW^'CJ1[ +WHN:C=I4OJJ/>(51Z']QUO
MCM20:WJ$7 \@'55^ZB#+8?\LO-\94 SGID=*S%?6Z3+9!J)73=M+<+^17/7E
M,AZRKFL83CRMI=2P;AHN+_V\<L<D,&[T.;KM+XUTX_.=OOR# 2?XW\_JXZ9V
M[8I)[.ODI@=WL,<O876F!)G= R\ XNK9F7@XT3EH?IY8C0''L#3!F:>KFYJ,
M( UG!%_6:Y9K0ZR%9/Q>-4'S]DI!JD"==_TIY7L T8G 5:$FP\:!8U3BR?92
M0_1IF.B5YOE+)Y"W(NJT6O4 )<]5+>L5VT'XAVV"3FQ[%)HOE]@CN2'T-$SH
MUQY)H[__;8&2Y!_1BMWSJE+^HTH&.$7"F;:D-G.3)9I;,%RWPPM/[9<:@D^/
MW! ?0\%4BRPHO\WU69Q9F9=C&,[F"]_1-52>AMNOW[IW";R_3O*YD.K[**K/
M^_<S^>'[F14M=133#W/J !D00]7DR!VMQW&)S<=93,BPVG<,"ZB,&+HE8;K]
M=OQH$9MDR;"J#^\RGF2)(5ERY,9T1) @-E^ZW-,Q+*1KPZLD7,W>[7>[4N?)
MM-2W-:6H][)+,[NW(P=E.6 :6^\2PW(DS')_#.^0]:,>J>B.-N,R8&*369*2
M85$2EN<,#SEXNQ0FQ=\TGQB@5/):J;1]RK5J*->!6:H7@U.QGNYA=-OZ?]=6
M9>KE1,2W*A]H']6]:R]S.I[*X2O^X,X'B,V3*+4ZDXY1"^1)XXBA4W+D'G2
M&Q UI<I -U+L[S<GW[R'MQF1L1&;?7'JR1J(X5X2YMZ; U\U;S_ +A .]OKF
M]Z4/#C'?:HPX ?^LRU+B*,3GL>\MGN%I<N2V](2,/-KOCEZ!@T-OX:0+^1S0
MQ<]ZZ45LSB?9W*<+0_DD7+U_L1 >^(#Q?95-BJKJ'A\_\F;S,W3SUQ]\=;IQ
M- ?FGGY-9C*.+)QQ])<G JH"J4*<+LJ4+NAI%W3A#48 S.SL!<6)AU SD[QD
MR3F$&GQC:A*+[(3$0E\10RUEGB($WO-T"QX^OLWPL&9W#,+#4#\[>!"^9?)>
MOY-7+_?V5=,^HNZ_[=_B?]0OT ???TH^7+<OZLTR[0/_WZF$BJ2&J+^&)>/W
M<["-;-_,M[\T8J>?G:]$TXBM_KAA% Z7&@!_7PLX%MTO:H/^_URX^C]02P,$
M%     @ NX9H4_"0,(J7$   .RT  !@   !X;"]W;W)K<VAE971S+W-H965T
M."YX;6R]6FUOVS@2_JY?0>2*0PLHCE^2)MUM"Z1IB^MMN@V:WNZ'PWV@)=H6
M*HE:4K+K_?7WS/!%LF.WW5W<?6EC21P.9YYY9CCD\XTVG^U*J59\J<K:OCA9
MM6WSP]F9S5:JDG:D&U7CS4*;2K;X:99GMC%*YCRH*L^FX_'3LTH6]<G+Y_SL
MSKQ\KKNV+&IU9X3MJDJ:[2M5ZLV+D\E)>/"Q6*Y:>G#V\GDCE^I>M?]J[@Q^
MG44I>5&IVA:Z%D8M7IQ<3WYX=4[?\P>_%&IC!W\+6LE<Z\_TXUW^XF1,"JE2
M92U)D/AOK6Y469(@J/&;EWD2IZ2!P[^#]+>\=JQE+JVZT>6O1=ZN7IQ<G8A<
M+617MA_UYA_*K^>"Y&6ZM/ROV+AO9Y@QZVRK*S\8OZNB=O_++]X.@P%7XR,#
MIG[ E/5V$[&6KV4K7SXW>B,,?0UI] <OE4=#N:(FI]RW!F\+C&M?_BS;SBBA
M%Z)=*?&JLWAO[?.S%K+IB[/,RWGEY$R/R'DFWNNZ75GQILY5OCO^##I%Q:9!
ML5?3KPJ\5\U(S,:IF(ZGDZ_(F\6%SEC>[(B\ZRS37=T6]5+<Z;+("F7%OZ_G
MMC4 QG^^,L%YG."<)SC_RY;\JAR*PA]L(S/UX@1A9I59JY.7DY$X+%_<E*I6
MXEV=C<1CBE%ERJVX6:G2*IG\JDV9 U#N@R?B,0W]^]^NIM/QCS>Z:F2]3?GG
MY,?P>*/VGW0V/M$(YZ(J2DEAG:TH*I51=:;L$U%8(46&U129+$]MBY 6S4HB
M<C+5M?0PR=R4HD$\*F7(%Z107MA,KY79IHBG-7BB0=2WJ9!U+C $2\H*61:_
M2XYC&*#&UR7F4K(^M9U98(9<U++6K<I6M2[U<DN"C6QX9CL2ORJQDFL5Y*L\
MD;5@:C#Z-#-;J%N>$N$5 ,16Y*9;#G4132E;LJ[8K JL6]5R7@) C=%YEP6U
M,@U+U !4J_)40"2^2<4*O "7./I)][1.2&L_/TQJ&T=W XTKT$O1E,KI)*U5
MK04Q&)B]A=BBWM$3.@K9-, W&\O2^UIUAFV2XM>"V;"S9'0%-F,K)U"<OQB)
M#YT1:@$QF$4";OU,"PTZ@IV)2O,<R+3!?[1"T=454DBE<O(TYE0Y3]YN-,F1
M]@>Q*(R%5]N5M@K(*<E,HM7"V8S&F#4T2RRLH2I24)M<&1*3E5U.L[T/QKB'
M&8VVP-QCC]+W]QZD3U)Q)\WGHK:ZID>3RQ^M>.U6&[^^>QV^9I1=5UL-)#1P
MKKB%7E G>3C%]6V<XT<>9A5<GA]8TLV'7]Z]/IT\@W6#_P>F7Q>T7%BPP1^M
M)KQY]39%NX)4PY_Q#!I611*TR4(21#)]6FDS+_*B!8$Y=S68M::)C^.YDG4'
MO(% R(H1S(O.4)A$.&-2*._Q)"@B!9+V -> 5)(7JD7Z!EJ!,T6HXU$R7TM\
MY@"A9(F%T (VR+>G<T73(D+F1LM<-+KI2H?/D?BT L>)0T(SA.B:'BZ!'T(@
MR7-84,.XL229/J1)B&+@-!*.$%R! ;PAB]_I+\L*T?_X ,ZVNNQ<H+#I<X2H
M@3HPNBP11+1TVQ9M1PJ-@*('6B84)"AG/BOR ,V4D\F+><=06!G=(3@TW+19
MZ1*+T)L:+VPWMW"B9,[[ (=BOM2SN$=;>-S#&K$=!!)[?8$E+!064!2TH1)>
MPOEML5#B(XPJ#9CJ]O8F2N17O3@9$=M(TV[%8ZN4^!D<BI3[A!T#TO*4[4R+
MU(YY\H2L@AR:\^!% 5\001/CM=YWWDV,!NDRKPVIRR<>-E9OF-,]PP#>J4]N
M/\/73"S(>'M&X@^2X0?#]?56)H6T:31S,_'2:RQ] ]^%.:X[J@3*0HH[F.*V
MS7>GZ-]_A_P$\N/W+HWM^OB[=9.+EL*S1,ZM8_8#,O$57H1T&@U,,V'6VLK,
M15="3CQLWVVTKB(.*#'6BE>C7_9L.WP=*7.#^%&<WPI4GIP2KAM3E&(Z<?4:
M:[+"5[7N\9&$P+2$9"1AXW,4<0[6/@)JEQ0\;J7W/9H^U.*MFIN.C#5YZJ9(
M$<F075(J!Y ' R,,22\JW<7]Z03%$;X5=5?-8='9;'8ZO9A-+F=/:'8W',_/
MTXOS27I^-2'J $&3N0<%%A4C/('./O=F<@_OZ6&P4-(A5%"(,>UU+32J.7_!
MJW /$>9*MK0 3O$H\];$^)0EK.VH>) 0N?3%QC2]F%RF%^-Q/WQ8Q]UU<V*J
M7_V[85Y+GHW/T^EL<GC@3U1KU,L6RC\8O%%4:IIB">>542\QWXI/ND6Z6<E*
M7&>_=87SJ'@G;H%1PF\P2_PNVH0P<2B@*1$JKHY*@!(X(I[33!59J:U/'?3S
MHW+T_%%ELJ%P\C6AB[$IEOKLN)U>JTR1\Q.@9RSNWMV].;)LOU:@EWB1(XZT
M6@-5E#HSAZU#HD44'24BG,&6M=^#,D,/%I9\8V%<!FZ*DJJ%3!'7RR6RX9)5
M,3KC*@LR'LW&HTML#Y&S,$OA.,+)IJHBF(-RE?I"Y318?$1AQ6&;4*'B8HJ4
M.1),%/2YRE#[4ZFQ6#B7$21HT+U"I<A%"?OBS9=L)>LEDSUJ$-["#RUV_^8F
MF&B$V!K8*(DV^G90,P> /:E&S<6C,4_]:'I)!5EG.;^@*E>FE04QY\)M.3)M
M88N\B_L/)%5D/OJ\!B!%Q1O91-%&%NMJ6N?;L!?=!RP\HY<UR@N&#"=FJN)=
M,8=YET \U7LD7^8@<K^HM0I?ND*94!$RK!AFV&2P]L60-_W^"/2QHE!>LRT0
M6.(QT(4=V;>6*(XM<22N&58[;Y(>(2&#>U#FQU Y&8_&O2\61E<\/$!PZ)V
M4;(G;WO=5GV:CD%A%--?"5\!+I4#!P/3*$1A)\?BK HTF3#B_]F!SJ;3/HDD
MG$3$GTTB5^-G5[M)9)).SL?IY6PGB0R2A.B30_*7D\,D'4_/TZNK(Z1W_=,^
MR85M=5D&"/<1=R C.(=[:6\UJ_Y'TL5#PM]E>,]\R3[S44CXFF(\F;'.D\E%
M>G5Q))E=KU7=J:\S>M,9V^$M;U>PLP%F)'#+;DZ&PKB$\1)O\5DOC2SE7_R"
M4=20^="@=&N[VI'?VXXVA+>CN[Z.<M]'&7V9??4D\GOR+7Y'(/U1>G_'&W6_
M%?HVH28$\ !B6.O9TS&JH?$1$*?!J/#3H?2(Q^_EUA6#0]/&A\,LV9NAUFV?
MZJA3%(P0R0-%I"VP6Q56EJHW@M?29R.+31Z%%#]%^4MM!)?ONB4*<S$]EN^2
M[\YW;V[V$I?XTXD+."RJBMH.5"4CNCM']8<S5^HCGY']OT@^N]N[P:;N_Y9]
M;@M4ED#N-G;!HJUL@>4NBHS"F.;Q]49-,4,Z9-*NQ*+4&P^97N$$U(:T0#M.
M^J.)]57O!XAQ4EWV.A]-8] M>/.MOG,!0ZE!IHHY<98$J:Y>&8\F#^;Y0R8;
M[]8D!].W!SPMGVW4:I MG/WHZ7CT-$R?QDTY]I1=U;GV0*Y@\,)%Q*/)T\N^
MU PSQ0)X-@D*[4\D'ET\&\V^.E&R.]'%K%?,]T.=-5DL]R(I.)R#@33NL#H6
M)D-/+P:<R8:>S X8^H%YDX=F<]N+ W:^.Y#*'NY.DH=),#8F!P'% >UVRX/6
M$4DFJN7F&M:E$!HM]0P0R)V+2][V[WV&&(8V+3,E2)1J<&VVQ*_4-KSOYA:"
ME,N%7]]:A4)$SXF,*$Q\4@&ME#%08V-*@,8JGURAUX/,0,Y)'BZB;WA3"G"T
MU>[%.RHARJ2Q8> Z*YI'X#T,2ZW0,)@A@11R4$)7E\K:!&NS79;AST5'=0OQ
M6:E:M=-39Z3RXHG9":K4LI4-S+J&#0A(!&3JSW-G(SP(36!0:)=O>8'$N1G;
MG.EA8,K$4X0GXT7'M04^7'0^4!Y0;TU'#^$(@H#I.GYLE#WU-X-,X5"O7*/:
M2*K#!VIX[[N9N92K?*N3E9B'8R?XDZ(_#J2=T(8ZH; ,-OY5PZL$+>NV8%=Q
MR2GGVJ?%6'BYM G8K H3.I&P8+*_A(,'0=*=BF1401,B0FXD-<@]=/+5-4@$
M7@B"7UF4M\"CW,;6-5BZ\YF!#F"X&%]J^A>*H+K*]WP'TP-='7'\&N*HCH?;
M@B-VCK"H2''^<CUB!\K<G^S2#J7C\C&"QDMQC7&$4;T\Y8#R<\:5/W &HA\V
M(_7)8EVC'9!",+A1MEL0PZIA*+@T.9B:EHB2PX)I8XW .GMH\$/X'0"U7 /Q
MGF[-9(*="P65#\H0Q@?GY9($&._X\($G=4%&B(>=&$_<^Y@K,D_F$)NK4O*N
MFWS&/?'0'E5\6D)/ ,?$V^AH6&"U2R,KFT;'D1\6J'LTK5#R.5QZ ';^=(RG
M/F22@,%,=V6>R)QYE4XON(3<<YS1G$XP2,Z+DHE4BTIQR1!<WY,LGZKQQ#[4
MYD/S15CV3+$#7-I5<J%'Z1.E[HH]<*12B)8?N.X(&_&9(VVW"XU"^4OK(VBN
MMIH2TT:5ZYAA8QG/_,VE>W*XZW'X7.%/E4>3X2X0B*T:F;7Q-"*P]!VDJ:K(
M./#BT\8_]5Y-YB@T:]>DCST_?!;ZW>YF#-U$<>?N*3_-)%<K%:6C)9UTUY%[
M>GJME+2$'WIJZ=B--S).GM=5=^T<OS^[OG[XQ9/W8@>"Y&?%NE+1HFE7P F6
MRBBYDQ8+MD@JYIK/P S!Q1VVN1\I[5T":)4=\K%*$SI4TR W:K<@,N027[B*
M(7,E<.H.S)!>5XAO_W*NH%M>6-,U?%S.'2*941"$)N+@=+T?X@[)<W+DISY1
M<C0K[C.&GFKPG%L)K.WV<);6LA.$G-][.!M5L99=[?=?H\.(<+FN#^I! !?4
M# !FD[!'XIH"K@S7([@DX!,NIC-7O;E!GJG]NN* EO:&]+VSV$XE$NM>I@9G
M>C[7]>23?-_*F<LI 1<91)O=5E\HUZ-"D5BU041X<NS/RF\^?NB;,&0INNZ0
M>.W=J0_QT;=M*+YMP]W3[<$<_NR-3,Q-PC T86LB!+@8_C0$"X6K+"GHMB%L
MAY$R7$ HU2)/N13O9Z65148F=B9A[M;,4,-DD"Q\'.Y;8K]&8Q)V-.&+AUU"
M'HGWVBCB@W0W$)B@^L6XX@X38L]#%QFP25"VIRYO>-(+ONY*[NEX1'UG+''Z
MX0-R#6_JV ]H--U8H&9'<9B+H\J'Y!]*#)AI1:W9PU)HX:4K'];27:Z(\,4?
M0(,[+^5X;9S7^^;++NY#(+JVD]-_2&E4^Z+(-2YDPDYE,]C<4#XVA>)=7NCZ
M]"L<@"/1IF\CT$R%88+?W2IDTKBK#]B,=&[ORP!R-X4(SL%_AXAQXQS$6ZB-
M;Y;SK@DU ^$DW!%(7(%'-4]AL&.GKC7?]J!6M0<)RA2JYWQ-O2;4<FF($IG6
M249?4-?9;=R= ?] \N=(3;C X%K$1<YACW/UXI(7W;DP,95%T._@*O4FVNMQ
MI8-V4KJ+/:Y:?&^UOY]$A7CM[X$<9G!^=;0H#0T^UIZ+>8H +VGPH6=/^"OQ
MUXMBMAJJL^?\6FWH&A)?9BUX?^ 9&/8U2^7N^9B:1O87F-P-#D_97%#X4I.#
M ]487<Y)"G]=CTN[+NSQN(1HJ3L()O/H"W=./(.,Q*&KEV>#"ZVL&UW;M8*O
M.;B[K?%IO!E\[2[$]I^[:\7OI5E2.B_5 D/'H\N+$V'<55WWH]4-7X]%\8,M
M&?^Y OTK0Q_@_4*#K?P/FB#>EW[Y7U!+ P04    " "[AFA3D4QVL:0I  !$
MA0  &    'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;,5]ZX_;1K+O]_XK")^]
M%S8@R3-CY[&.8V R=G8-)&O#XZPO<'$^4&)+XIHB%38Y8^U??^I75?T@1<W8
MSNZ>#W%&$OM1U?6NZN+SVZ;]Z+;6=MFG756['Q]LNV[_[/%CM]K:7>X6S=[6
M],NZ:7=Y1Q_;S6.W;VU>\*!=]?CB[.S;Q[N\K!^\>,[?O6U?/&_ZKBIK^[;-
M7+_;Y>WA)ULUMS\^.'_@OWA7;K8=OGC\XOD^W]AKV_VV?]O2I\=AEJ+<V=J5
M39VU=OWC@\OS9S\]Q?/\P-]+>^N2OS- LFR:C_CPNOCQP1DV9"N[ZC!#3O^[
ML5>VJC 1;>-WG?-!6!(#T[_][#\S[ 3+,G?VJJD^E$6W_?'!]P^RPJ[SONK>
M-;=_M0K/-YAOU52._\UNY=FG3QYDJ]YUS4X'TPYV92W_SS\I'I(!WY^=&'"A
M RYXW[(0[_)EWN4OGK?-;=;B:9H-?S"H/)HV5]8XE.NNI5]+&M>]N);#R)IU
M=EUNZG)=KO*ZRRY7JZ:ON[+>9&^;JER5UCU_W-%Z&/5XI7/_)'-?G)C[S]FO
M3=UM7?:J+FPQ'/^8]ADV>^$W^]/%G1->V_TB>W(VRR[.+L[OF.]) /X)S_?D
MQ'P34&;__W+INI:(Y;_O6.!I6. I+_#TWX+=N^>^6&2?/WWV4^Y*AP??MM;9
MNLN9)S[8;)O?V(SX>9^WMLBZK25&636[?5X?: *S:NCL:D<_T5^.9BORCCZL
MRSJO5V5>98ZFLL2EG<O*FL>V!?UDB8Z[+7_6K>S;DD;L*]K,QM:VS:OJ@-_M
M'A/26*S]6UWBTS4FY>U>[FQ+4)F'__>_OK^X./OA+Y>7;_G/\Q\>9223:&!'
M3^R2'1$L3<M+YG61Y8Z^^+TO =WRD+VSF[X2X*_G_V^6O>LKFYV?S<_.%]E[
MVL!]\)H$7D;=TMHZXJ\1,%R^LQ 6A'):O^G;+.\+ABROZY[V>#\R:>\SCY5F
M7];8,>%CE]<D*_'(S)#\@G#+")-97OR#A 4/G66WVW*UI<&KJB]H=$V(KB'"
M@)M5W[:,FW1 ;5?6.9 24)IGZ[QLXV:P+F"(^P262I&JSH#Z<(B[I6T#=\YX
MXT1K)!V=GX!42<NX=[P.GNBVK;5\4#71=[83@6$A,"9GQ32KW&VS-:F3. T&
MFWL&\RKT!WW$7]WITQY 3B)X]7';5(5M'2CO_+L?,A!4=\@>DO@G]NH>#<$Q
MGPM.V)'07L0O;2/G'QN:%#0NVA<(+TJWJAH76,81\ V8I;45;[YK_LA.,B+C
MK*^57&5?Z2E^Y0F:N%#+&PXD5Q)QED1-JQSJ&6NDA$/ +&UF/^V)SL$INN;!
MYBV6 "&_I(D$EG-/)"2[ N9$.M"VRZ9P,P/RIE_7?=>W.@]])3\O2#B6X1/Q
M;P5!QI :%61 \\J6-_FRL@G_TY=5[AP)8#D HB:<F#\+\!RHB9?;)P)XD?WF
M&.97KBMW+/. <!$G<M[T8Z!2\UDR6!<'@;(,ALCT,M E @2[V^4?";UA<1&8
M9*#MY8R[;4[B9;V&E)%C@6BEC>0[P0;MCIZWD"%5F2_+BJ2"=<)@2JG LP !
MF8QU900_DPS*<ED#P'DR^ )I')G:;S)+-@D*HGE<5O0L_>)SK)KT^%,E>AHI
MNYR$JDKF/Z K63C/LF7?!9ZHRETI+"SB\R:O^H0*=L1;(HYF\C]B1][2+,&N
M(1JKYV1^#P^$U/[:MBWK5HR\S=LV#VB[DKF'/RU@'L#B9:$;\4$/;DM:'WJY
M,L!L6UIH?!98->V:L-D[Y<!C<FK!-%5I;X17ECB)W#4U>&I!QDO7LZ(2 ;#+
M#T1(1(&D?MJ&.&I+LB_=S&"%A8F,A'7D8+%/DC*MO2&;7@1G!6.=L;K-"6W"
M-V6[ZG=T1F#Z&>G E4=/A'&17<4!<1>W):E@!@3F#_$'_:HB1B4/[ #"!P%#
M<%<-V;'O2O=1B.LWFKCMR(%B-A !T!0]\1Q18L%41$M8HT,]+V?YGIXC&G$>
M-60_+:X7V<]-4_#$+]M^DUT6Y#:4L&F%DEK(,W)6(+78%FI([9-(J-E.W+,$
M9!&V(]-+R#8GHXU5 2U*6S)+D"OCO653C\^5-;,*.BSNX9\ !=@2.6I%>P?S
M(X)$NUC:9!=T@*Y?X;EU7RVRUVMS:_F,B>4@=?U(I@C_-]E?!:G%@X4MU<G"
M++7S# ?7 KJ\N"'-3AQ-?$S[!(H(DF7O2)LY.2 &[?-%$3,.MN;ZY3]8=#99
MRZ<M/&P$O20V2B$D%GMRN"R8::J-51%!7"U"8BP@"KN'DJU7!V]UUE95)*T+
M,NX$/+'4Z$_=*\0?G=YJ"Q8T@&W3$,9GI/8]';)+L6R;G/!:B)#Q-IS@EA;2
M@Z5QY1HZ=0;S>K\].+*(\EH0MR>:$^'L$M$*V&W'NQ+^(BE-O$1L0\JI!]^)
MD%[E^R#!IG"JNS5MX*1^P$GX1B6-D&C"[&PBB))9-Q79DFP30Q#1]OJJ.$DF
M5K1A$Q@\4D"TBND,)HVF9YD =,#VFR5V.GE /PQXTU,SX"%_[Z/MU&]BYFO6
M@D3BZ=VRIRV"A R1P6R"]WZ /&)C4H82 LJVF).U07NZ>O?&Z2+^& CDK-\3
M1.)2W$+$58<?,'.G<16E"UA:%=P12&_ZF=;I#C\8G-XF2!ZRDLH=K;$AP%V7
MD9* ?F&M,3E^!@J"K^-!F26(F6%&43+8;-,2=)Y;$S3G';OS1G#$*+>[?=4<
M+%%"E#STI.OWL AX@@UY^MV6Q'U#B*H[;_02L%>D1$F60'QG/P?5#GC:7G0[
MX\KL&^S<2RXAVIXMVB$OC.=?R?P@:A8U)+HAE7=B*N,!<G\6V1OO")50DB5\
MO*VM6+FM![LJNUYUXZ6WAVH(C\;1*E"OL+O*'2'#?EJQ!+&%>N<TO(?)P&)'
M6)#9 J(HZL2"F8DL/2?& ="G\SN_7S$(&XPT Y:\/>+JONX=N\@)'I;VT*AU
MIXYL^BLIHH; A6!D@S=17<N\_@C.9N<(6-B6>P+DRF^)_WA%ZI3XB\_N@Q6D
M%S!=2%NX+5'$G&3 CG3ZC56/68,;H.ER4X)U24Z0T.I4J, C4D>(:+2"'KG=
M(D[0MR2#7#!\&#4V+D_F#Z/LA(/F71VCK@[]=HLC*:".C^=Z1]LE(PUX83@!
MF[@I!ST4N#/A&=XAX90(BAS F[RLV,N!0@&X19O?DI"C3[UC^Y?91"(Y7L1!
MAB+,JB([V4 @@A2+./G$<8+L30R(FEA#/ZJ"2S6O4?<LX]AG(DB82/).W0YU
M)GD;['"!;]K1OOQ4:I0[-J<A-'HU',/C@:[5VX8J%^N@)=$!ST4)<Y6WQ6>>
M9G9TFN/]T1Q_.EN<9SNR7SCH0J/_= 99Z. 8DQE5'18^[.<([<%%O9QP6YG?
M.MX],2"=1U.NQ->P0JK>KBW  <UM<(+%$(00[5M5\$73+SLRR'R@3X2$GT!<
M)#_'Q!1\:&;@4$!!02+" B*X_9-D<B P=7XQ9[[*Z'A(PH/>Z =]5NU486$B
M1CD]>K[LH'LXF$ZS[/-#"+&QZ!0U;."7MS>RS8@"E6NBSK$@V]IB[,J$(2I$
M@B"J'?:L0^31K[D8"!A56\)YNB0<R6.T'>$9QC S<(*Y*))GF:+$^ZAC&O"Q
MC1EQ<+-I\SVIK!!!8GMJQ@J3_)FZV=%OP;91+XX5AYA"><"$(L*EZI<@)VN]
M!B%;AK1ELFB%#@<^5YP9MGB)\P9]0U6:NY;8(7D%IHR*KUE6:G; A0O3)%@M
M7?#6@CWB P9%;V>RR26XGPP/C1F8FE;",%+@_P2F(D8UU"-31(_V,/9U5PU;
M.:4ZN]/L>4NJA*P'.L&U$$=AR:QC^S89;HC1P1>EA,JGSGD/IY><<=I'.B?6
M"-#S NJ.D<SZ:R"HZJ!82")=I&@&+#RC;XQ./>>ICW<Q4W%^+TVGJ Y"^305
M@ZYNB*M@),>_Z&!%NL&P\=Q!MKEC-9(3D;2NF[.9A#\0*>%(O:B&,LRCMA>4
M"HG?BV\1>NB=J+",=&%P#420_.G\Z>")-9SN+8W>-.K^-VMSK GN7C45^J-5
M50D,'YA:]%C/+.BK99>]+)V@=":?W[9V5Q(SSE0[+3OSFEQ\/H0K0A\91T**
M2[812OK-2IPA-R3-Z$PX@ELF"1<A^66Y)KN'C^2A76P6L_0; AB.%3L([&@^
M8@^^%L/>22"4"(9,*H@)#OFN)\QNG=IH].I1W"*B8T[%_=JR^\=V1<%L )I<
MI8'SU))7&!\B&!&V_ B8AH>"Z"$,CB;HN96/UAGZ'<8T!#Z0YDAV93K Q>CF
M8%LB?MEE21&4H!:QFWOQP$*4@%]:J!*$ N@TZ >H0I)*;-#3$YSB8:4_TZ!:
MQ(1NK+4^;DH4329U 1L;E@:32Q')ATEB/R ?I1(A'R,3)AD*.7468Z1A.5R0
MBJ0<<1OX>U'A0/)Z.=UQB(S3B02[6"Z*4UZ7:;)E84QK_%.6Y%0 X<XH3&)2
MJ%GIK;T,EOY@+L2!1"")Y\\DKE,10@EU!1"BP=4WB%1B@#(,3/Q]V>45[<+'
M*\C(VN35#"2R)G-+7/^8*%TDB9_4.V<:"1'4@OAKA3,=.S]E/6?:@QTG6:H0
M54"HQL>4&*)WEF,:T"-^ET+ /I0>1 >GAMZ^?OMJ)F>CX#8>7#E@ %")91(7
M%3U/YXAD->>4+M>$OOB5!A&@7L<[GFF&*Q)D()&R_KS,'&TW%\7B%_*LJ<Y+
M)_26JXD'YN6<JX*VR*ZW'!#*Z[MP"SF7D[=9-#4DCI#/-)9\L'B*MV0GY".V
M&\N^1?"K0@:C#+[0G:G+<;H.1XK 6VNW**EA*EY!*CV$A?N(:#AF1H8IO?OR
MJNRV%&7!80&6K1I=2Z&^8_Y[<I-G,T1Z@\S^T\7B25!Y!.(I+(_2H4KJV1&I
M:Q2":92P4SI1O<RC$L-,V-0D]0S,CY%5%<I?+-NYEXP)&R*G>1 R#$UA(6<
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M0HO/4)RFMT@OCM;,)M<T)_+R?N[K^%U"!1$G$5(N6BG##1\N'M!?F*&D9U+
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M] D]2WZ?D;<+>;]:QQ;NO  =6YL7Z5VNED-!X0*_OEJD"_4,5WX[[WDQ=&-
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M#9V>S@D3;%WB>8%T&DZOKL+)U:3/5#T"=YCTM5^X9A43-R3UR/0%>50?-&?
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M$L#SM5(V7- !W??ZF_\"4$L#!!0    ( +N&:%,SR^W;:!,  !T[   9
M>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;,5;6V_;2+)^YZ]H^&06-D#+HF0[
M<IP$\#@))H,D(\3)Y.'@/+3(EL0-17)XL:+]]?M5]85-71Q/=G8.$,02U9>Z
MUU?5S>?KHOI:+Y5JQ+=5EM<OCI9-4SX[.ZOCI5K)>E"4*L<O\Z):R09?J\59
M759*)CQIE9V-AL/+LY5,\Z.7S_G9M'KYO&B;+,W5M!)UNUK):O.SRHKUBZ/H
MR#[XF"Z6#3TX>_F\E MUIYK/Y;3"MS.W2I*N5%ZG12XJ-7]Q=!,]^_F<QO.
MWU.UKKW/@CB9%<57^O(V>7$T)()4IN*&5I#X<Z]N59;10B#C#[/FD=N2)OJ?
M[>IOF'?P,I.UNBVR+VG2+%\<38Y$HN:RS9J/Q?H79?BYH/7B(JOY?['68T=/
MCT3<UDVQ,I-!P2K-]5_YS<C!FS 9'I@P,A-&3+?>B*E\)1OY\GE5K$5%H[$:
M?6!6>3:(2W-2REU3X=<4\YJ7'XI&U6(J-W*6J>=G#9:D'\YB,_UG/7UT8/J5
M>%_DS;(6K_-$)?WY9R#%T3.R]/P\>G#!.U4.Q'@8BM%P%#VPWMCQ-^;UQ@?6
M>Z5FC7B5UG%6U&VEQ/_>S.JF@BW\WP.+G[O%SWGQ\Q\5WH/3R=^>U:6,U8LC
M.%2MJGMU]'(R$+UEQ6]M);(B7YPVJEK!X&9-*')X:S$/BBI=I+G,1%K7K1()
MV"S:O!$R3T2;RU51->F_5,*3>(S,8R7BHF[J$'_@676#GXNY:)9*S(L,+IKF
MBV?!VQR;J;H14$>C5C-5L4Y>J=A\B<+@.,TQK6AK[%:?B(^R4:PT^F\8?")B
MWQ4RKY\%[^'M&='T2I6R:N#21+WX!7.QF_B'7)77XK98K=H\;388=8]84?*P
MR6 X%#^))V(27>'_*!Q.AL%-<L^,W*HXS4+Q-H\'=F!T>2Y&T64 X2%\Q5_%
MM((P=0# QT4E5R+20T_%Y?G3X.9>Y1#=[]B,S..WLH30B(X4*GC3YDDHW@VF
M W$UF%Q@TF@8#C'[-/@-$JO$T"T5X)>KR1@47IU?!9\?%CXKZ(#R:G$<A9,H
M$B?8Y9VJ:U+4O<)B9 PYFT:I3</:P:ZN>Y:PM?=QK12;F(BB$W%\'EY<7/%F
MGXH&U/1V()&?AY>1X4LX39)F(7CQ1LVJ%@\AF.@J%&L5*#8=[)HWA9"P7 R4
MBTHIUN<Q&=H__F<R&@VO:8IX_XK7XD?1]0FB7[-D:]QO*[3W7DL)L5=9I7F<
MEF B<9,#8]QW#=DGOC@6C@T9]H$E82"F;442:P0XH+D^H6&W '.5T*"R*N[3
M1(&$)\/!!<)TEI'!L<.2  ;!S4KK%FFQ;C"9>(%QP82V-Q S)9$TTU4)\:?6
M#R6I$O_R%MQ5AA6R^9\&XO/>=4@9'HER/D\IB2$%!D1\KA;\!48!#Y!$&T:M
MEVF\I(EKL("<2UD=^7KV3[@0Z&W2#+D'C@+A#\2G)6*6-Q_"SUI(04N#.$QS
MC1HX_<[ .U,)_94RWS 9!8(; $;%8^IKD:6KM-%?!";1SW*69J1LD%>I)JU@
M]I4JVRI>(AF'<"-\36!>/#B&;="\"E2HN:K($I%#XZ\86/*R(=O06E85$UV0
M'P?-$M(MC11);;4-BK6*B5U$@VN>^#"!<!OX'MD"8B(M$<MZJ:DA+HW4$&=D
M1;XLY@@ ,%GHU(DQD'5=X!$%9N<,OF('XC6&-KR\@1^'3,EJ9"[3C*(;*%S)
MKXK(7/$2ZZ7*1=)"C&E>%QG6C3="\?(AZ\>;"=&6V4;3Y*@=B"^6&02Y7-RG
M1:;U#>J@9-_N_%D?E:'!)9\6!C>3&0<JSTN"M"8"2=9=K!D1/!B?LS#[',-7
M$+=2X*':AIDI= L4)>Z6H+,.C9LSE$MHV0B!ZVIX*6K^G>BYU49T1W8CCGE@
M@.^3RW$814/DQ(J2PRT2BC4QO38%(.C:1(V/D&-5T]]8EK"9+/T72^8DA-K(
MQH &$G)L&Y_WL%-3U*IYN<I*+) <2S"-=IHI_A5^CI&5E:83Y-P+BARSXKAJ
M=736@:709M,7DKB76:M8MQZI<!+MP)0B@AJI/TMH?ZQ)!&$$O)T8@M%4WA*5
MBHLJT5IVOUA*.5V9=57.6$1)Q""P2QD-001^DQ;)@+(-EE$L7[T$Y@1$"X<Z
MAC/6"XR(K ]O!5/U#25-K31#:\L&61F)B&8X$OMR0:PM*:YC!.%)HDYO$1Q2
MMA8Z6Y4/GA@CA0=$TG?AVE>!,UJ?!&A8J_KVW8</@3'CS$"[7'R0=2+_(/G!
M@WE<+TF!P  /QN[!FN(3Z6R1:T"!^(==.#(ND4Z8I1SDB)6&_HJ@_Q92)"!(
M<;HN%9==&2+?:R-V3<'(IX >C -' 03V%Q PW";@TXZXL>VD3T<TB!P=W_>>
MU&4]>NC!]#Z*T@:P*R&A0?&.7?3)9IB+H 2+WCC@=0/*,H>ZA$%=P2-1EUYR
M%WCUD#4#:\)5>9&?<A*%DU5P2VW9E-I5XJ6>3*YMV@SJ';C%Z\NRS-+8S1<7
MP^@X/CD>G_ >2)+SM.&@UT)X2L.DF<)('>4^ _61IG54Y"*% #0Y'X%X!.9[
M<@433IITI0C^J6_(X38G.0?K1'  \'4#0O/Y ."+]@ ^L0?P!5M9NMO@/\9\
M/JV'8)\',?YFI"=VD9[!0<%A'"0.XB!?<]^%0IZ0OX>&@H?0T'>1D,:5*\K"
MQ(=,=$)0\SDD6NO!QJ^MF1GQ;&&HX"_'4*+#4#ILZ/C3 U">G#P,%3P20XW&
M*'ZCAR$48ZVGH_!R-/J3$"KX$0CE,;0/18D?1%'!HU'4(T"4^&$0%?R5($K\
M!R J^.M U$'$_#@0%>R"*-_Y_R2.$H_#45$/1RD/X5R,7'?L[X%4Y]V&;*1/
M+BX\"OY.2.6@76"@78?U_K\@5= G>SJ=.B3U7FX,:[LXBIW4;IGF6VX!SBX=
M9S[&HN6IP^; 59>4'FI,&M.]O?GX^D[<Q$VPM6;7H;I!>ERQCK3]TX8E&3<R
M#>+' FSFU#JD!&* ",$2$UU<^4_:D)NJR+0NN!<B_@#<2.<;L@]CS\B,R%Y@
M?W0.&:FO/!'6I-*2Y6"7!I=(@[RYCG/XERD)I5X.?[+<-=QES(Q/MG5'$]'1
M 2=*AI85L91(?3+HHK>.9[3FG++B!OBIYNCVJ\Q-/Y*\Q67%GJJ\N&Z%Q_U0
M<A*W)0EDB0<SI7(3?15'(1DL""MA'?6-8FN+3&FSL&Z^=L[U&)^V+2':'5#H
M.XL[2O0N0>?"W]W&M+JW[#[R[5YW;77\A"_Y,W1]P ^8XJ K+PP:KG7J$N>C
M4Z:E@\/<HRXIYSP9#P=#JP@3/M(*%M)44 F^P2:>C+PQKDW[R0R(K!>$M"K#
MV.!)=.'-8#6V+ 88($5WG4(15EJ&&EL-<4VUMLOMZMAN <*]:.KLPC@(EERA
M%B*PBN@2?&*@08B:ZQ=C;?,**=!QH7/$?JH).#G]C29>8*-Z($E2BAH@ULJ,
MEHH>D%DP<H$(XI7W0+(ZAO90.HV)GEY3GOBCI4BLJX!?6YBP,:+1OE*I;R<A
M,V&2NN5V1/N:XH**#\4=TIBD)&NP,@.:KI'JZ[F,FZ+B5JI9LQ]I^OSWY&=*
M"':\JF@72^$W]IDQ?0: _ VCI3ZXB;M\'',&(]#QSU6L>GCI#1*KMJ%BK#-]
M&[*]0L?ZR&\]+3X-.V<K9HW4R!5:!R%5P+:!$%O[['4<D4;22N\X-UC3$W/3
ML[>>5#PE: M",5S%::TT1-,]<:YHX0J 92KHTG,7;6<;V*2.LGU/\JC=<BJR
MR:>>R[2$^2S-CR(XB$+/_:+18]V/3^WV&:#,ZL*5N&#Y6)[H_GV\3($\K3XE
MUPN ?6DLLVP3U"E TQQ?<HJ^-=68!CA"5'21@4)N6:144Q#(G+-J3<9DY-PM
M!Q7(;%.#F!(FQKHT0-VB$XQNDTUH*PJ.2JC! Z=F(L#$+!@<C[:G&51TD@J8
M$X-@P&]-_IQ3)(2\B0C4I/@;;^Q>C V=(_HP>;-MW?:\=+N<=9F^61<[Y\F\
M#^J]9^(X/1$ -[>?7Y_>O+NS3/ZB9*8V@IY,4?E2)P&:0Q5]C0D\8WKS]N/I
M]-4US<"C]"0PS][?N6 W517W(,@&WZ<9(AC9K$L7^OCF>*9U[L44.D.%D\=*
MZ2,;QPIR51==M(-"/3)3O5-5T@RM2"[:;+SS(A#*.%8?6V[(6NXYH&32J C,
M:!F=LN&C$,;8$YAVLR;KY@3M!?^M2$Q9AI)KK;M'7MLHD(#CD!_%>.X;T<D6
M]9%61"4E#AV[ZY8Q)REEJ_H]OCEQ%J[78"LI6]T7<);Q!1Z".%G1[:%?(04.
M6RPJZKW1-C2?E/;SB1@/1A<_A>"_K;5>+P>7U,N:6CAJ0YON7E9>L5GD,$S[
M<TJG\]@((<%@'I).S&TT@DT: 9&#8X]H%)A!/IA^PYC#WG(XY>6G&E*^I@7H
MRE&7,^?<4]-10APP,VU=Q)4&.N-+2QRF(]($WA)$R&,H<!;+\#>IY#KOHX@1
M9YF;=M%BK>C22S$Z46%-5/34/#(1R;HOH_.'.'DTB4N9Z%ALF$LZP]2M17LS
M@<HG;7VNW]8K!IV'F0:&UK31OX'[QFX1]M-*^AW=/N3$<U<!Z@+PG 5%(VU3
M4R3:J%&C=CG,YCOG)>=DLEU[C0V+?8X#M%]4A+;)EG80Q=+;I;HV+V6:["^!
M \NMA<4^16G=KT%T,5!BY11.K.,1],"QQET%*>Y-T0DCX#M/S!5)2%^F8%ER
M?Y(2C]T^6"EDVF0?%0ST6>U,3\;-6<,D:WQ9U/;."1=PLW3>5C$/*SW@>'-W
M*R; [#MHT@$K-N(%)36]@[-;93]^,2?X@0T+]DH J2N*+L+)Q<&&I.ZL6RAD
M&C^]T(B@;"(A//K)9' Y%L<:B8"SWDBJ/T\3N0GNBZQ%L%OS/4!2$Z0O%W9U
MFZ5^_W+CZGB.RTQBOY_I+A]85ZBD!C2Y.6?1]1(_P\Y=S]2==%BXT#\'.@E-
M_CQQ/))O,7V.%,$6BOC.5Q?2_)[B0J6#,^6YGB#YZE)B.R,Y@J^8P9,@E 1F
MCT(^X0,8G1H[/.L(!M:&2$V79M0+T1]HL8^TA)@2A4YHWOVEX8G73-Q7=X2>
MQ03&8HA-ZI/#VMJFH+8ZXSQX[3_;VIB;/2KHUQN01+IB8YY<AI=/KPZ85RAV
M+<5%$0]?=XTDCUY]>\0EV)X=6G,3QQ<G9'*"C*G3W/6?,*)@QXB\8[;$G#4Y
M2.^3>-VSH6TMZ;.,7B^;AG4XW%V\H:X]UBY]<]UI.E PC2GL,1FZ!:%CA\M2
M7O?1P3("/D8WG(-F'(,!ZMI*-P7V=L>#+<LRA'#90"4'AW)R;CH?$M1JHVMV
M=">)PO^L;3CD<5D%F+20^CG'FHT&0@X:"0N-7-8S71!=NIJN3EHEIU1S$7:C
M,K&F8L.(RH^42R3OSMW3WJ%CJ ^L^ 8AF[,S.M.0V2J^#.JSAQV](P#_2$EO
M135&_ZC'\^!;WI73Q1M%:;?S81+*3N!QSA*-NG8AGSL'+K;K.;7B.KA9VLAC
MK$KGK-U]O?:#Q85[&_\[\<T5:/98FTX#^92$ RUAN<Z%:K\,I=P<*U?MQAU-
M.DM;L,TWSXJJGU.\T9HV!RY-.08*@^T(C$FY:2CKLW8J#]MXZ:]&!JJ^4:E#
M-(RVN[*6&9/*#DF$)ZQA>YM3E'O!(\5A0CX[J2N,^A#$!IXMLOO'W=O]IH/G
MW?NO.7[_\)L2BH.)MNF/*MH=!=J^2/W?O@/Y0U<@^ZGH@5N/PMYZU.'FOWWK
M<<\A__89?["+6:Q$:T%*:@R.1HY+5P"^;4Z(%2Y"*_"NNA3$!P(=2 OVG*.K
MZKV =VU;U^9<EE4/Y@**$%MMH0/54MCY)O<4[@T$>:BK,'A,7X'O]S^FKS!]
M.WW]F%9"=*B5P"ZD05%>\($;;&.F_(;MGOL9#][\U$',C?SD)ZS^<8':N<"A
M7WJA5$>_ZPX'9,'=T693\NT,R[]-NFR?.@+P12+MGTC*%45O56L<6,3<MC1^
M+'<O:\"?P#P[E*&FM@&@[-1/:,6[]M'=%=&V,)/YUZHMFWAC;R-L@QJZTI]1
M\531$;<&>]2G0VZEQ@9AT2RST1<NHOH>2X5:1F\U(6,$UL5\J9C3<YT[][6H
M";O0AHA0DBYB,*#10=$0"AIM]26Y?$SSECMYV@PWHE>L!CUK=S;MXT?GV7P6
M;EHXFM,B]NM(U\OTX8J?'0'WMDZ<H\ZA @L+=5 W-QWLYL82]9;&5%TONRM/
MN@[VUD7);<!I^#(D$]1:*-)3X"XL]>KGD/UE3QW?>UW#K^S[Q^W:OFB-1U?Z
MP4.5OK"5_JL?OX^P]AC:N6"[=49NKP-,NJ9)_UC^C>L84[M>T!N(29MQ*)RW
M#.1LYOW^JR]DU'-KSDFA=$/"(N'#X/< L#61-."FK*U7NY,F]_#\V?:+43VI
M!1P-CIUUGH@GXC3@Q?C/6*"RO'Q*'\]%- ['XS%]OM"_7M);.G18+.>$'4^#
MNW;FSBVMA%Q]Z8[YGYC7EG9?2^H,;^NRG7-=AF36)[=JK6V/L2\NF3>)GHAH
M$D:3*['O3;LS[Y7%E:H6_&(F!490H]]>=$_=NY\W^I7';KA^<?2]K!8(PLBO
M<TP=#IY>'.DZS7YIBI)?@)P5#3(+?UPJ">G3 /P^+U#SF2^T@7LC]N6_ 5!+
M P04    " "[AFA3'*5Z'JH%  !S#P  &0   'AL+W=O<FMS:&5E=',O<VAE
M970Q-BYX;6RU5VMOVS84_:Y?<6%T0 NX?J=IBB1 FF[8@'4+FG7],.P#+5W;
M1"G2):DX[J_?N90L*VE>'38@B"6*//><^R)YO''^<U@Q1[HNC0TGO56,ZS?#
M8<A77*HP<&NV^+)POE01KWXY#&O/JDB+2C.<C$:OAJ72MG=ZG,8N_.FQJZ+1
MEB\\A:HLE=^^9>,V)[UQ;S?P02]740:&I\=KM>1+CA_7%QYOPQ:ET"7;H)TE
MSXN3WMGXS=N9S$\3_M2\"9UG$B5SYS[+RR_%26\DA-AP'@5!X>>*S]D8 0*-
M+PUFKS4I"[O/._2?DG9HF:O Y\Y\TD5<G?1>]ZC@A:I,_. V/W.CYT#P<F="
M^D^;>N[LH$=Y%:(KF\5@4&I;_ZKKQ@^=!:]']RR8- LFB7=M*+%\IZ(Z/?9N
M0UYF TT>DM2T&N2TE:!<1H^O&NOBZ06<P-YS09?1Y9_ID_)>V4B_:C771L?M
M\3#"C$P>Y@WDVQIR<@_D$;UW-JX"_6@++FZN'X)>RW&RX_AV\B#@):\'-!WU
M:3*:C!_ F[::IPEO^F\UTU]G\Q ],N;O!\S-6G.S9&[V7[KX04BIU#=AK7(^
MZ:$4 _LK[IT>#>AQ91=>.T_145PQ?> K]D%^<[7641G]54FM]+,-DPZA$B#V
MF@.=W8<=2%L$9CRE=>5#)=: GK./Z AD763YD*]0.:26GAD5C39"?\#^9@?!
MUVOMF2);VK+RX:DT4=9G:Z\-O>XG#GW:$P?82P';6P%<2Z6R&B-N0:[R5+H0
M*; 5F_RE$C_A1QE9,1I,#G[835Q4QFRIT*:*L-!,53$3EA&]2N;Q-?M<!_Y.
M?YPE-N\XYW+.GJ;CI.BH+QX('5=M&(YJ;*BY@5P+_,GAN#^;'F5AI9 /]^OJ
M[^)Y?CN>?>@@10M]+<I:#5[G2=6S\>#HD-9@EDP,Z'>XOEJB0=$X49V@/B$P
M=];6#3?;Z+A*-"0@RM8XC?EWWYJ_I7..8)=W*)W"T&PVIJ<JS>XP]7U*GUXR
MN5$AZ(4&[NUJ:74I_)%IZQ$9++!P6X&=#M/Q%)S1A9(,FRN3')?Z>^V3"L9C
MMW; D1;(HQ"5+;1=9@MML4@C?;5%%ZM2@F$-5)=J2RMUQ=A.X21A5Z6R0*^S
M 7S!+HBA:@U>.]?4M;JGC#D.\,(OA9A5OA+'W0Q@ME'2&G0$$=2,Y]QY; ?B
M^X72GJZ4J;@V)'+:'!'AJ8P$M0$C*,,,G!SF <2A)R&6K$(E(J"@@YD\G+L2
MT)B928;  M+08I#I.9J-N/I%GRP./?K! ,"IL:[0E&G(BA3MD!B)#<\K.:%<
M<0MO7 @O!O1QIRS'@(2E]M"]"43/ S/])OUA"FJ"WVT@LO0]^R5TG.VZ!F89
MTW@>51!W&4#GABVPE 6A0N?8//;YF.WR,8A2<!&9J;+.75F"1_U=[ OL0U"W
M4[O;7Q]?EZ5.MN> U7<C=6GMG30>[9Q<0\@I,;5_2>$@@13Z"U:Q:OK$S:J!
MOH(C>YRIX)14'9BP)>G[>K$EG'?;>L[K",%E2(!225KMFG]U*\ST2)C1Z'.I
M!$PUV\1WG\?9#88WDQJY3%+8IMYG;ICEQXS6Z20EN+3ZJQ0A29;6W6XV>(6#
MI3&B4$0#*$O[)LOQ[?:.)&U>JAYETZVJ_NVR>KBO/;VLLD?*ZG'I':=VFICD
M/QRR;]APMRH*+6O@Y+72Q4O9SFJPK)-WAR]VFS7.I;'Q37,X%?[971Y#7W.R
M^=?=5]GM_574*>0!?>*;84-)V*7TFJR;&]]V@#T:0GPP&+<1+BHOW].!984^
M@ITSG=7K8'^C:)0B\NQP,+L+P:)VLL< _J\&>]?)?-BY")72+>6Z)XVNLK&^
M$[6C[8WRK+Y([:?7U]'WRB^Q?Y+A!9:.!H>XP/GZBE>_1+=.UZJYB[BDI<<5
M;L7L90*^+QS2I7D1 ^T]^_0?4$L#!!0    ( +N&:%-7RQU<% <  +,4   9
M    >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;-58;6_;-A#^[E]!>-V0 *HM
MR2^QNR2 FV98B[X83;M^&/:!EDX648E422I*]NMW1\FRG-I.MV'#]J&-)?&.
MS]T]]_"D\TKISR8%L.PNSZ2YZ*?6%L^&0Q.ED',S4 5(?)(HG7.+EWH]-(4&
M'CNC/!N&OC\=YES(_N6YN[?4E^>JM)F0L-3,E'G.]?USR%1UT0_ZFQOOQ3JU
M=&-X>5[P-=R _5@L-5X-6R^QR$$:H233D%ST%\&SYV-:[Q;\(J RG=^,(EDI
M]9DN7L87?9\ 00:1)0\<_]S"%609.4(87QJ?_79+,NS^WGC_R<6.L:RX@2N5
M?1*Q32_ZLSZ+(>%E9M^KZF=HXIF0OTAEQOW/JGKM>-QG46FLRAMC1) +6?_E
M=TT>.@8S_X!!V!B$#G>]D4/Y@EM^>:Y5Q32M1F_TPX7JK!&<D%24&ZOQJ4 [
M>WFE\AR3<V-5])E]XEIS:<WYT*)K6C",&C?/:S?A 3=S]D9)FQIV+6.(=^V'
M"*G%%6YP/0^/.KR!8L!&OL="/PR.^!NU<8Z<O]&?B9.]$";*E"DUL%\7*V,U
MDN2W([N-V]W&;K?QW\WJ<3>!/V#[@2\,4PG#)%G(5Z#;3'D];#QCN8R%7+-J
ML]PJ5I0Z2I&^S*1<@S/?<1TI;#1C(:8G-@66J P[%MT\ZR&S@%W?@8Z$X:L,
MV-O2[8HKF[O EEI$NXM0,=A5QHT1B8BXZ\'KNT)H][/WJI3@(+,@./,FOL].
M@E/VA/D#/]A%=OVE%/:>O8"HCI6,>MTKGX7>V&^<A.0D" 83_U$ODX=>QMYD
M-F(GH[_N(O#FX=P+@H"=C)V7P?QLKY-%H45&-J/>&WZ_2<3$FTW0=')Z,B7K
MV6 ZVK5^+?A*9.2@L9KV/BC+,X;0Y_AO/&FHT<(:!8X9R(\.,WK_$V9@)N?>
MV>0_P(T@\#V??/S+Y*BK._$FTZDWF@8N$5?=@FQS=*!\)2JRSNY)#T(O',U=
M*G:!+5\NK[?:(HPIR;?LD,C?D$A(XH-LSM1*V-118H^_$P-(!X7\"&:G [9@
MJ<KBFAH'+%H$.7);*LM@0R$R:"C+1&U?>_.0P&O :UUC$6C-DP1;!(EI/!P)
MRBQF*Y" 3!,\R^Z9JB3+E2:G7++Y8#[_?H-)MN3=YI+N8SX++N]_^&X6!F<_
MFMW\=@57Y#G$M#7NPQ.+OM;BEAY DF#*J-M,&:5M8(/#0H[%\OWQH\6J "/9
MN(NQ/+A%@)98ZH.4&+ /&%07]XIG7&*3\@-H-AK@'F_T^AOX-IJXICD2P."P
M7DF%.M!4H-6KE%,Y06YC'KB^ONH W';\XQ#'WBRH058/^+^'Z=B,%F3*\Y8)
M0@J+M$(-764BPHT2T.BVSG!#&T=G#3% [F+9=T*[QJJ0TU@#&3ORXXV":^LQ
M;AEGA1-1#.2)$\&""-\VA.>,E$36T05M@NIJF>$91M^:/DIE^%+R#-.E,;L1
M0&S8DV!*2D?;N5PZZ::8L(XX+;D88GYO7'X0,4?*/.T\($NA8@9UN#;5* JK
MTN"@8TQMN8*D[L9MP@PN-W5'*MN IP3F!=7B6--0'OX6E48/Y;71_6\@>^CO
MY1'V%-6Q+0 ZBE%X/B)SV')S]+YSD74T<X22^4ZR5R76% E:=^&C]A5N)F$K
MG+&'>3/X@N+$23H'!,LU.P*:C#T?)YX#P5$RQWA@3:?[)TE,ZM.49PD94H)K
MACSPXA&=FLGJD!P=KN<W%^Z@BCR:,_)&_?85%<:[JK(]O1_GPG9M"UIIL1;2
MG4 -,5;W. 3AR<3><JGHW(BP*X@N-]@SZ'_A"M!<O, Q"E!<L T>O@ML23,_
M_4=[8_(@(<VX^@WI:%8N;D&6\-6D@80B2KKC\0,^B1!)L('DB-\8OE981)+#
M+:Y&W9QRD;W3/E75I_B)P#'+#=$G52KPW!5F=V4B;N$IR=0OGQ;+K<IY^%Z/
MAS>^;M?]VT !68_ C;PIN57:'<E#Q=.T V*,2L>QQD'F\*]1 W.0]M2UQHE
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M10$<U144.>5]K@#\*)0<15-* FZ'ML!5T!V-<SN2[251?]:_0/ %4EB":(&
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M2!_,BIH;[@2V8J:;RA'FA/^*VW9(Y'XF#6!O=8[(SI&4?8DK)]L=)65&9-J
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M0LL*)"^-\;L-.Q@^MU;_ %!+ P04    " "[AFA36=KUNB@1  !?.   &0
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MDSD-<E(-^N+?^JECYIO /'FI#08S\_(=U?L3);QU-C2[&YC2RKF+2;0(N++
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M9'PQ'X57L?;&Z<I_>5H@M7KC+]<"KU"&-F!]J6%I<T,'=)\B;W\'4$L#!!0
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M%)!& ?</0NC3PCB8_WLV?P-02P,$%     @ NX9H4V2Q>/G& @  ZP4  !D
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M=6,TWH#.5UJ[W<('Z/K[]#=02P,$%     @ NX9H4[]<0N_$+   T)D  !D
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M:*1R2SZ&*"^%,Z_#WE6T=X\#I%GXQ!BW%I>W>Y*?J],2&C5=0A.\ @GXCU%
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MW3;F/RIUB0F#C_';=]D7MC,L+/L<QA4%,W(6=W327X;T]>5T^CI(TQ2=LO<
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MT::Z-:PCC&SLZK.4!A<I>USCYLH5,>![(:79$F1@V(47_P)02P,$%     @
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M+W=O<FMS:&5E=',O<VAE970S-RYX;6R%5$UOVS ,O>=7$$8/"6#4CN-\%4F
MIMVP'CH43;H=AAT4FXF%RI(GR4WW[T?)B9L";7:Q2(KO/5(R-=LK_6P*1 NO
MI9!F'A365E=19+("2V8N5862=K9*E\R2JW>1J32RW(-*$25Q/(I*QF6PF/G8
M@U[,5&T%E_B@P=1ER?3?)0JUGP?]X!AXY+O"ND"TF%5LARNT3]6#)B]J67)>
MHC1<2="XG0?7_:MEZO)]P@^.>W-B@^MDH]2S<^[R>1"[@E!@9AT#H^4%;U (
M1T1E_#EP!JVD Y[:1_:OOG?J9<,,WBCQD^>VF >3 '+<LEK81[7_AH=^AHXO
M4\+X+^R;W%$<0%8;J\H#F"HHN6Q6]GHXAQ/ Y#- <@ DONY&R%=YRRQ;S+3:
M@W;9Q.8,WZI'4W%<NDM964V[G'!V<2<S52*LV2L:Z*[91J#IS2)+U"XAR@XT
MRX8F^81F"O=*VL+ %YEC_AX?44EM7<FQKF5REG"%U24,XA"2..F?X1NT?0X\
MW^"_?<(M-YE0IM8(OZXWQFKZ,WZ?D4A;B=1+I)^53 .3UP)!;8'$*B516N,\
MWHAW2=7T8(,T2W@,6G?R'QWX63$WJU>F8AG. QI&@_H%@\6ZT(CO;@*^$^Y=
MI-/E$FRA:L-D3M6X\W6?^,WJ/$EN";NRS-)?<0')-)R,8NCV^^%@'$//6^E@
MZ*PD#L=)"KT.#0F-@(3N=.(V^F$\'M)V.$W[Y(Y&T\Y:62; '<)'9^!T)N&$
M0!?$'X?)U-$X.R7546.36CQT\8_N*SH9@Q+US@^[H;NHI6TFHHVV[\EU,T9O
MZ<UC=,_TCDL# K<$C2_'PP!T,^"-8U7EAVJC+(VH-PMZ$U&[!-K?*F6/CA-H
M7]G%/U!+ P04    " "[AFA3WZ[%,I<$   R"P  &0   'AL+W=O<FMS:&5E
M=',O<VAE970S."YX;6R=5DMOXS80ONM7$.ZV2 !9IMY2:AM(LNEV#[L;)&GW
M4/1 2V-;B"1J2<I._GV'E*S8K6T$O4@D-?/--T]QNN7B6:X!%'FIREK.1FNE
MFJO)1&9KJ)AT> ,U?EER43&%6[&:R$8 RXU254X\2J-)Q8IZ-)^:LWLQG_)6
ME44-]X+(MJJ8>+V!DF]G(W>T.W@H5FNE#R;S:<-6\ CJC^9>X&XRH.1%!;4L
M>$T$+&>C:_?J)M;R1N#/ K9R;TVT)PO.G_7F<SX;44T(2LB41F#XVL ME*4&
M0AH_>LS18%(K[J]WZ+\9W]&7!9-PR\OO1:[6LU$R(CDL65NJ![[]'7I_0HV7
M\5*:)]EVLG$P(EDK%:]Z9610%77W9B]]'/84$GI"P>L5/,.[,V18?F2*S:>"
M;XG0THBF%\95HXWDBEHGY5$)_%J@GIH_*IX]CV_0KYS<\@IS+9D)U\436Y0@
M+Z<3A6:T\"3K(6\Z2.\$9$J^\%JM);FK<\@/]2=(;^#H[3C>>&<!'Z%QB$]M
MXE'//8/G#S[[!L\_A;=F L8+X_,]>\424^1:"%:OP*S_NEY();!>_CYC+!B,
M!<98<,H8ME'>ED#XDD@3[,YPMA]L>-%K.!;KL^BZ9:]DPS*8C; G)8@-C.9/
M:P%PD 3R%?4.3JR+HB9JS5O)ZEQ>FM#J!WU;60\(R$2V)BB"E;[!#FY,@#Z0
M)$SPZ?H!/GT[B5S]C@+K$]0@6&DT6([U6NA(ZL8CKAU&,8E#$MDT"8B;4NN)
M*Y0]&94/Q+,#+]1OFN(SM=- [\(P(&<R$PZ9"=^=&1Q74B'IHEYI#A5:-[0(
M;S05:1P24#*%),TD*=3KL72=-7D\77<_6@0C7]MJ 4*3^=;;_&Y&"AH<%I]K
M)0H<B)GU;8_PF'R$#(RV[]I=%F.;^IX=ICHQU$EC$CHF61&&-/*L3UCM&A!%
MXL . I<D3A*2U,%,CJV[%Q!9H?-Q$= 4TQN32^(Z-$!3GNW'OH43<0F%1KAP
M?=^. P\E$B>*4&+\+W+8OJIGU_<P9I)&/N;6UV7C8')#)Z5ZG: QW]H%8 /2
MQ!MC#QTE/9..0V)546K'!I(ZB4<"QS?PD>T%L?5XD,T#X 9_$+A1W!S_'\+G
MJC$:JC%Z=S4RB?_(GFHK.VX9*[-6UQ]V+9 E*P39L+)]FRL[YXY5Y5G3QZO2
M3(RJFQA@)L;=+E*=N484&9 -1TY%J0LX"9S$^N6GQ'/=7TD2.\'/UD,AG\=+
M/8T*+#>APRNT"]0)4[(3Q?)$T0$]Q][*T2)Y+:#,\2NE>U\1I2(1GI%7G$WR
M7.3C(?+QNR.O*:)?JAM%;V/@7,N?13\1W*'7=ZU]V#2Z,-NZK](%*UF-H692
M*_RWU7&P4FSWR-,3F3H^M6XYZHJ^J*7^VQG5V\ZCKA7:!I?:@K9WX7F![6)9
M7V+W[O6V'^.T"'3SZY9Z+\4C_>-B$X9VD*0=1_?X )_LW6,J$"MS6Y.8B;96
MW95F.!TNA-?=/>A-O+M-?F%BA9.2E+!$5>K$.)A%=T/K-HHWYE:TX KO6&:Y
MQDLM""V WY><J]U&&QBNR?-_ %!+ P04    " "[AFA3 :C*@_ $  #<#@
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MX 9Z81J>BXL)3*P1^HN8+#]LM!!/:H]N0._)2N!*Z.I(T" %-]M::&Z51HO
MP:;L8%-YV/!_@25OP6+&8/GYISFC]!=TY;-]A=@<9U$$P@DEF&4QFGHYPC0)
M6YD13&)8#]X**$4IK8 \+!)?@90,5$ZB1EDA;<FKZEM;.QAR<"Z_"&U+%XN$
M#5!%_LU']@K1+('/T_[_/Z9RBJZ[1D$:&:81.2J-:R$53+&KXB+XY"D#3' (
M%ACPB2.#@$*-!4@ !OO*M85+&"8IQ6D<(9KB,)YC&F<HH3@D*4ZR;+3ZO0^Q
M7@,A.LP]6SDC\JTN;2G,(GC]@ZU6Y9^1:AR[&A3C-*.8L!!* W\_4NY3]39V
M7&LNK4$41_,8DR@[ULB^-D=SAE-R9"P.4KK,797:>#@$5!A /=20Q)V1EW>K
M1T@*W0_G. F/Z-?W:!SF_QA<+H)^MLA9E#KHD3/P-6TEUL&1GM'$@7% ,&QF
MAS>C X07#X07'TUXCSB#8<ZKK:.AM5:U2ZJ!%/U/-NP;T^&>NCS'BP<#^9]Y
M\4YHE\8UX*@0<&1RW1DC$URLA=8#NDY1AL,L D9(QW)O9W6\G12S),(QS<9R
M;^?J>#N.J>9X3N.QW-NY/-X.33!)$AS[P7M\>'&%!CXX12%09Q311^G%88V,
M49S 2"<I&<O!:B^+G!A Q TL(4JGG@8&7@E6SQ+82(-,$<,Q"V&TJ:]KG&0X
M2QCH_MYQ)LQPL]7Y!DZ53PF1X01X,$YC:&M,,F@' :"0),01C.6P%KS?PUP4
M>,O]Y+2)LB@&7LU<T# O!9?HHRPMNNU=M^&@3]\E85#HSR0^%TA@[OK:"\&J
M$C >-QQ^T411YFY6H \6"! H%@DX/9T"*?;\^%B9SB:;HCD.HP33N</=2 [>
M0'C T4]/FB^TG<90 .(*,$C!!V7!*H5JP$]V"B</\!B&S",?TG+-#:-XO/H<
MZ\U&IVTX$3WX.X6+;RMM>_ >5H=KRV5[6G_<WMYYWG']4 (0*K$&57*6 F_I
M]A[1/EC5^+/[O;)P$_#B!JY>0KL-\'ZM(.ONP3D8+G/+?P!02P,$%     @
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MPN-%2U1,),O-FS]E4G409IBH-A*X-E#[,\;D>J()JL9T\ =02P,$%     @
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MM);OC_H';OXEZ /1H"$:=&]'-!&[=%+E%:<:CT$*:$O"[.EH(QT<05Q&P>B
MM"4H'/7:28<-Z;"3]#NTGI/AT1$(H_  YS@F\OP#&G>O.YN;\1N52X;]@4.&
M*N]J@-7(W6VSFVA1VH:]$!K;OQVN\((&:0+P?2:$?I^8.Z"Y\N/?4$L#!!0
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ME7N*(PC4_&N(:@G!0@ BP^S1/GH+X!4<!';-3'4Z"'@@P[)[>M$1TNK8R;K
MO-0[4>PAGGCLDQMD@&\NY8%$^ *3F$9-TA!V6;3AKM(URG8FN7) #LC;J[!
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MT8D8)^">Y7(CP&V^I,L6_;5;#Y'#0: *5E<-':IVA9P>YW3;!SC\%: 0P;:
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MI? ^M,NQ?><,<O'>9NAY4SSE[J8UE)-%,/?&S3"G)<QI)\Q?-AMFFQ54 L/
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MX_/BQP:AUMEV7/7\<7?//_T7A-412_E/!$VG/JK].HH_X'^AZH$GF@BV 4M
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M4>^1?#0M>K3CXD6F (J\%3F38RM5JKRQ;;E*H:#RFI? \&3-14$5;L7&EJ4
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M 7HA17ZW .QH@8P08*R>8>ZA?P*5'6,5]@5BD&N666U9B#4H#H4!32\,+VP
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MFI2EIF-9@9G1)#>&?7UVRX=]MI9IDL,M)V*=993_'D'*M@/#-G8'=\DRENK
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M;=O=4> X3MA)6R5!\-WZHW/#.,%F7=,TZI +J!0,]FR;?HKC;+:?%:4V,#-
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M[)EC3A8=13'1(G.W^%QHTQ.XX<IT82BM@?F^$$(?)G:#JJ\;_P=02P,$%
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M!;XQ1/^"-2K8,^[@W"KEB-BKE2D[L/F:"+!AB<^E5(Y(?KM70\Z*.X*<\>;
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MYD*RQ( 5@X2FY2=^,1/1 ,!1!P 9 'H-<#L K@&XYU88&<#H7(!G -ZY -\
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M>'FH6]Y(EA4G?D],2I84EQN"(\)U@/I]S=3FT=SH0\3J:'WV/U!+ P04
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M$)0 /%\P>#^6-\I =? X^@=02P,$%     @ NX9H4[Z$3OD*!0  @A@  !D
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MK(<>R;)K*@=:Y/:6?Q0:>P;[N,).$Z0)P/<+(?3SP"2H>]?1'U!+ P04
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M3<]QP\)\%:"T 69_*81^F=C&TWUGI/\ 4$L#!!0    ( +N&:%/.F%I-C@,
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M%E4'-@HJRMLG>>SJL $8#-\!A!T@_"@@Z@"12[15YM):$$V26(HU2!MMV.S
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MFU;CAJ7Y&$!I \S^2@C]/+']IO^\2/X!4$L#!!0    ( +N&:%-IZ]12TP(
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MG2')ENXU=A,M*OL"SH2F]]0.,_K 4!H#VI\+H=<3\ZBV7^+D#U!+ P04
M" "[AFA398@A(CL#   P%   #0   'AL+W-T>6QE<RYX;6S=6-%NVC 4_97(
MG:96FAH@:R K(&U(E29M4Z7V86^5(0Y8<IS,,1WTZ^=KAQ"H+V)]6,N"VMCW
M^)Q[;-\0M\-*KP6[6S"F@U4N9#4B"ZW+3V%8S18LI]5E43)ID*Q0.=6FJ^9A
M52I&TPI(N0A[G4X<YI1+,A[*97Z3ZRJ8%4NI1Z3?A )W^YJ.2#?^2 (G-RE2
M-B(/Y^]_+0M]_2YP][,/9V>=AXOK_?BY!2Y(Z!6].D+TLF,N5-FBF'Q\G/PA
M<4RZ?Y3T 65,>+ KO+,$1TPY0>@[;(3<[WC)+:HEAG7!C(=9(;=U$Q$7,,HT
M9\$C%2,RH8)/%0=61G,NUB[<@\"L$(4*M"E8DZH+D>K)P5W7@UJN=7(N"V5S
MNPSN][0>O@=L>F"0"]$8[!$7& ]+JC53\L9T[& ;? 8%=?M^71J'<T77W=X5
MV1+LS229%BIEJDG3)9O0>"A8!G84GR_@KHLR!%#K(C>-E--Y(:GUL&'4#2,[
M8T+<P8/^,]O17F6M/;,[)INF,50WG8SK@'Y;S6FW9:,7Z08E?RSTEZ69CK1]
M*'!VJUC&5[:_RAH#F'H75Z=E*=:?!9_+G+G)'YUP/*0;7K H%'\RV:!49B;
M% D>F=)\UH[\5K2\9RN]*:=5AGONG:#G?[O.<R:9HJ)MVM3^6U[E%SN.^J]E
MV7ZK[!OV>JS?WF_=Y-4IF(Q/P>1)U.3@%$PF)V"R_VK?F@=-AO4IHW64V3G(
M--$ #HPC\@..GF*;-)@NN=!<UKT%3U,FGYUGC+RF4_/GT(Z^&9^RC"Z%OF_
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MW&,EC'%BM/XU@LD/['X 4$L#!!0    ( +N&:%/Z3V.0V 4  -@U   /
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M4^]A_#R4X=;SM<;K?R?5X^7<<KO\=?FU<W)?KCC7]Q7#\U]02P,$%     @
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M2P$"% ,4    " "[AFA3!T%-8H$   "Q    $               @ $
M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( +N&:%,O'[4K[P   "L"   1
M              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (
M +N&:%.97)PC$ 8  )PG   3              "  <T!  !X;"]T:&5M92]T
M:&5M93$N>&UL4$L! A0#%     @ NX9H4S/?3']E!0  MQ8  !@
M     ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (
M +N&:%.""C=!R08  '(<   8              " @:D-  !X;"]W;W)K<VAE
M971S+W-H965T,BYX;6Q02P$"% ,4    " "[AFA3@2IVU8\"  ##!@  &
M            @(&H%   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#
M%     @ NX9H4^Q/JQGK"   _BL  !@              ("!;1<  'AL+W=O
M<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( +N&:%-"_7!@B0L  &9;
M   8              " @8X@  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q0
M2P$"% ,4    " "[AFA3 IOM.C "  "<!   &               @(%-+
M>&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ NX9H4W*Z>:D'
M"@  Q3   !@              ("!LRX  'AL+W=O<FMS:&5E=',O<VAE970W
M+GAM;%!+ 0(4 Q0    ( +N&:%/PD#"*EQ   #LM   8              "
M@? X  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " "[AFA3
MD4QVL:0I  !$A0  &               @(&]20  >&PO=V]R:W-H965T<R]S
M:&5E=#DN>&UL4$L! A0#%     @ NX9H4^K>3+/S$@  R#T  !D
M     ("!EW,  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +N&:%,SR^W;:!,  !T[   9              "
M@;&9  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ NX9H
M4QRE>AZJ!0  <P\  !D              ("!4*T  'AL+W=O<FMS:&5E=',O
M<VAE970Q-BYX;6Q02P$"% ,4    " "[AFA35\L=7!0'  "S%   &0
M        @($QLP  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0
M   ( +N&:%,(>5(>40D  *$:   9              " @7RZ  !X;"]W;W)K
M<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ NX9H4\?ZJ)!-"   3QH
M !D              ("!!,0  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q0
M2P$"% ,4    " "[AFA3+JPW):0"  #H!0  &0              @(&(S
M>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( +N&:%-5"J&"
M&@0  'H)   9              " @6//  !X;"]W;W)K<VAE971S+W-H965T
M,C$N>&UL4$L! A0#%     @ NX9H4UG:];HH$0  7S@  !D
M ("!M-,  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " "[
MAFA3;=G;3!@-   .*@  &0              @($3Y0  >&PO=V]R:W-H965T
M<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( +N&:%/UR47S#0,   L'   9
M          " @6+R  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#
M%     @ NX9H4QL)3J;$!P  EA0  !D              ("!IO4  'AL+W=O
M<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " "[AFA3O2<IL$T&   P
M$0  &0              @(&A_0  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM
M;%!+ 0(4 Q0    ( +N&:%.WBD-VU00  &$,   9              " @24$
M 0!X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ NX9H4TU2
M36AN P   PD  !D              ("!,0D! 'AL+W=O<FMS:&5E=',O<VAE
M970R."YX;6Q02P$"% ,4    " "[AFA39+%X^<8"  #K!0  &0
M    @('6# $ >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    (
M +N&:%._7$+OQ"P  -"9   9              " @=,/ 0!X;"]W;W)K<VAE
M971S+W-H965T,S N>&UL4$L! A0#%     @ NX9H4S#,IP^X @  P@4  !D
M             ("!SCP! 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"
M% ,4    " "[AFA3OPMZE;H"  "U!0  &0              @(&]/P$ >&PO
M=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( +N&:%,<PB0JI (
M (X%   9              " @:Y" 0!X;"]W;W)K<VAE971S+W-H965T,S,N
M>&UL4$L! A0#%     @ NX9H4_4G^*6!!   %PL  !D              ("!
MB44! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " "[AFA3
MX?3?--\#  "5"   &0              @(%!2@$ >&PO=V]R:W-H965T<R]S
M:&5E=#,U+GAM;%!+ 0(4 Q0    ( +N&:%.(/BB "@<  /43   9
M      " @5=. 0!X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%
M  @ NX9H4WY#8W20 @  <04  !D              ("!F%4! 'AL+W=O<FMS
M:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " "[AFA3WZ[%,I<$   R"P
M&0              @(%?6 $ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+
M 0(4 Q0    ( +N&:%,!J,J#\ 0  -P.   9              " @2U= 0!X
M;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ NX9H4SY1S%\1
M!0  V T  !D              ("!5&(! 'AL+W=O<FMS:&5E=',O<VAE970T
M,"YX;6Q02P$"% ,4    " "[AFA3CZT/45<#   A"0  &0
M@(&<9P$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( +N&
M:%-$O1<%$04  ,$6   9              " @2IK 0!X;"]W;W)K<VAE971S
M+W-H965T-#(N>&UL4$L! A0#%     @ NX9H4T"O)8*(!   [10  !D
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M=#0W+GAM;%!+ 0(4 Q0    ( +N&:%/Y[!%#^0(  $4)   9
M  " @4F( 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @
MNX9H4_Q_*98<!0  $!,  !D              ("!>8L! 'AL+W=O<FMS:&5E
M=',O<VAE970T.2YX;6Q02P$"% ,4    " "[AFA3VIW,%A8$  #1$   &0
M            @(',D $ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4
M Q0    ( +N&:%,T/6['U (  /X'   9              " @1F5 0!X;"]W
M;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ NX9H4SOZOV,T P
M%0L  !D              ("!))@! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX
M;6Q02P$"% ,4    " "[AFA3CI,9CU,"   B!@  &0              @(&/
MFP$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( +N&:%,H
MMAFA1@T  "@S   9              " @1F> 0!X;"]W;W)K<VAE971S+W-H
M965T-30N>&UL4$L! A0#%     @ NX9H4]<#[V. !   ^!$  !D
M     ("!EJL! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +N&:%,R1R=)# D  *4@   9              "
M@63" 0!X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ NX9H
M4^1+5T.T P  >@T  !D              ("!I\L! 'AL+W=O<FMS:&5E=',O
M<VAE970V,2YX;6Q02P$"% ,4    " "[AFA33)=]I24"   G!0  &0
M        @(&2SP$ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0
M   ( +N&:%.RV<P%WP(  ,0(   9              " @>[1 0!X;"]W;W)K
M<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ NX9H4W/83'M9"0  C2<
M !D              ("!!-4! 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q0
M2P$"% ,4    " "[AFA3(#&KJPT#  #^"@  &0              @(&4W@$
M>&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( +N&:%,"G=YQ
M#04  ,@7   9              " @=CA 0!X;"]W;W)K<VAE971S+W-H965T
M-C8N>&UL4$L! A0#%     @ NX9H4_/5,[3G @  XPD  !D
M ("!'.<! 'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q02P$"% ,4    " "[
MAFA35!)#X"8#   7"@  &0              @($ZZ@$ >&PO=V]R:W-H965T
M<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    ( +N&:%/>/1GXP 0  /(-   9
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M970W,RYX;6Q02P$"% ,4    " "[AFA3-HGW'9\%  !F%P  &0
M    @($T! ( >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4 Q0    (
M +N&:%/+':W*:P(  &D&   9              " @0H* @!X;"]W;W)K<VAE
M971S+W-H965T-S4N>&UL4$L! A0#%     @ NX9H4P('RT+/!   A!0  !D
M             ("!K P" 'AL+W=O<FMS:&5E=',O<VAE970W-BYX;6Q02P$"
M% ,4    " "[AFA3OH1.^0H%  ""&   &0              @(&R$0( >&PO
M=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+ 0(4 Q0    ( +N&:%,\?(F\.0,
M ,<*   9              " @?,6 @!X;"]W;W)K<VAE971S+W-H965T-S@N
M>&UL4$L! A0#%     @ NX9H4XV:$S6, @  <P@  !D              ("!
M8QH" 'AL+W=O<FMS:&5E=',O<VAE970W.2YX;6Q02P$"% ,4    " "[AFA3
MSIA:38X#  #$#0  &0              @($F'0( >&PO=V]R:W-H965T<R]S
M:&5E=#@P+GAM;%!+ 0(4 Q0    ( +N&:%,$.=2BA0(  &H(   9
M      " @>L@ @!X;"]W;W)K<VAE971S+W-H965T.#$N>&UL4$L! A0#%
M  @ NX9H4VGKU%+3 @  '@<  !D              ("!IR," 'AL+W=O<FMS
M:&5E=',O<VAE970X,BYX;6Q02P$"% ,4    " "[AFA398@A(CL#   P%
M#0              @ &Q)@( >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( +N&
M:%.7BKL<P    !,"   +              "  1<J @!?<F5L<R\N<F5L<U!+
M 0(4 Q0    ( +N&:%/Z3V.0V 4  -@U   /              "  0 K @!X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "[AFA39LT1.G0"  !M,   &@
M            @ $%,0( >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    " "[AFA3$@%B4"$"   @+P  $P              @ &Q,P( 6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     6@!: *T8   #-@(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>336</ContextCount>
  <ElementCount>632</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>81</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Condensed Consolidated Statements Of Stockholders' Equity (Deficit) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ShareholdersEquityType2or3</Role>
      <ShortName>Condensed Consolidated Statements Of Stockholders' Equity (Deficit) (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Condensed Consolidated Statements Of Stockholders' Equity (Deficit) (Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ShareholdersEquityType2or3_Parentheticals</Role>
      <ShortName>Condensed Consolidated Statements Of Stockholders' Equity (Deficit) (Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ConsolidatedCashFlow</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Nature of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/NatureoftheBusiness</Role>
      <ShortName>Nature of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Reverse Recapitalization with Tottenham and Clene Nanomedicine</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicine</Role>
      <ShortName>Reverse Recapitalization with Tottenham and Clene Nanomedicine</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/PrepaidExpensesandOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/AccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.cleaninccom/role/NotesPayable</Role>
      <ShortName>Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Preferred Stock Warrant Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/PreferredStockWarrantLiability</Role>
      <ShortName>Preferred Stock Warrant Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Common Stock Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/CommonStockWarrants</Role>
      <ShortName>Common Stock Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Convertible Notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.cleaninccom/role/ConvertibleNotes</Role>
      <ShortName>Convertible Notes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Derivative Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/DerivativeInstruments</Role>
      <ShortName>Derivative Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/FairValue</Role>
      <ShortName>Fair Value</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Redeemable Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/RedeemableConvertiblePreferredStock</Role>
      <ShortName>Redeemable Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/CommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Net Income (Loss) Per Share Attributable to Common Shareholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/NetIncomeLossPerShareAttributabletoCommonShareholders</Role>
      <ShortName>Net Income (Loss) Per Share Attributable to Common Shareholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Geographic and Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/GeographicandSegmentInformation</Role>
      <ShortName>Geographic and Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/PrepaidExpensesandOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/PrepaidExpensesandOtherCurrentAssets</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/PropertyandEquipmentNet</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/AccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/AccruedLiabilities</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/Leases</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Notes Payable (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.cleaninccom/role/NotesPayableTables</Role>
      <ShortName>Notes Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/NotesPayable</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Common Stock Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/CommonStockWarrantsTables</Role>
      <ShortName>Common Stock Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/CommonStockWarrants</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/IncomeTaxes</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/StockBasedCompensation</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Fair Value (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/FairValueTables</Role>
      <ShortName>Fair Value (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/FairValue</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Net Income (Loss) Per Share Attributable to Common Shareholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/NetIncomeLossPerShareAttributabletoCommonShareholdersTables</Role>
      <ShortName>Net Income (Loss) Per Share Attributable to Common Shareholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/NetIncomeLossPerShareAttributabletoCommonShareholders</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Geographic and Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/GeographicandSegmentInformationTables</Role>
      <ShortName>Geographic and Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/GeographicandSegmentInformation</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Nature of the Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/NatureoftheBusinessDetails</Role>
      <ShortName>Nature of the Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/NatureoftheBusiness</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails</Role>
      <ShortName>Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicine</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleofprepaidexpensesandothercurrentassetsTable</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/PrepaidExpensesandOtherCurrentAssetsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Disclosure - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/PropertyandEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/PropertyandEquipmentNetTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>046 - Disclosure - Property and Equipment, Net (Details) - Schedule of property and equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetTable</Role>
      <ShortName>Property and Equipment, Net (Details) - Schedule of property and equipment, net</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/PropertyandEquipmentNetTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>047 - Disclosure - Accrued Liabilities (Details) - Schedule of accrued liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleofaccruedliabilitiesTable</Role>
      <ShortName>Accrued Liabilities (Details) - Schedule of accrued liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/AccruedLiabilitiesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>048 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/LeasesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>049 - Disclosure - Leases (Details) - Schedule of noncancelable finance and operating lease liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable</Role>
      <ShortName>Leases (Details) - Schedule of noncancelable finance and operating lease liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/LeasesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>050 - Disclosure - Leases (Details) - Schedule of finance lease obligations included in property and equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleoffinanceleaseobligationsincludedinpropertyandequipmentTable</Role>
      <ShortName>Leases (Details) - Schedule of finance lease obligations included in property and equipment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/LeasesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>051 - Disclosure - Leases (Details) - Schedule of finance and operating lease costs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleoffinanceandoperatingleasecostsTable</Role>
      <ShortName>Leases (Details) - Schedule of finance and operating lease costs</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/LeasesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>052 - Disclosure - Leases (Details) - Schedule of supplemental cash flow information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleofsupplementalcashflowinformationTable</Role>
      <ShortName>Leases (Details) - Schedule of supplemental cash flow information</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/LeasesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>053 - Disclosure - Notes Payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.cleaninccom/role/NotesPayableDetails</Role>
      <ShortName>Notes Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/NotesPayableTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>054 - Disclosure - Notes Payable (Details) - Schedule of long-term debt, net of original issue discount and unamortized debt issuance costs</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleoflongtermdebtnetoforiginalissuediscountandunamortizeddebtissuancecostsTable</Role>
      <ShortName>Notes Payable (Details) - Schedule of long-term debt, net of original issue discount and unamortized debt issuance costs</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/NotesPayableTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>055 - Disclosure - Notes Payable (Details) - Schedule of future payments, net of unamortized debt discounts</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleoffuturepaymentsnetofunamortizeddebtdiscountsTable</Role>
      <ShortName>Notes Payable (Details) - Schedule of future payments, net of unamortized debt discounts</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/NotesPayableTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>056 - Disclosure - Preferred Stock Warrant Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/PreferredStockWarrantLiabilityDetails</Role>
      <ShortName>Preferred Stock Warrant Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/PreferredStockWarrantLiability</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>057 - Disclosure - Common Stock Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/CommonStockWarrantsDetails</Role>
      <ShortName>Common Stock Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/CommonStockWarrantsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>058 - Disclosure - Common Stock Warrants (Details) - Schedule of outstanding warrants to purchase shares of common stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleofoutstandingwarrantstopurchasesharesofcommonstockTable</Role>
      <ShortName>Common Stock Warrants (Details) - Schedule of outstanding warrants to purchase shares of common stock</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/CommonStockWarrantsTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>059 - Disclosure - Convertible Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.cleaninccom/role/ConvertibleNotesDetails</Role>
      <ShortName>Convertible Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/ConvertibleNotes</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>060 - Disclosure - Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/DerivativeInstrumentsDetails</Role>
      <ShortName>Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/DerivativeInstruments</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>061 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/IncomeTaxesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>062 - Disclosure - Income Taxes (Details) - Schedule of components of income (loss) before income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleofcomponentsofincomelossbeforeincometaxesTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of components of income (loss) before income taxes</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/IncomeTaxesTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>063 - Disclosure - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/StockBasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/StockBasedCompensationTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>064 - Disclosure - Stock-Based Compensation (Details) - Schedule of stock-based compensation expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleofstockbasedcompensationexpenseTable</Role>
      <ShortName>Stock-Based Compensation (Details) - Schedule of stock-based compensation expense</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/StockBasedCompensationTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>065 - Disclosure - Stock-Based Compensation (Details) - Schedule of outstanding common stock options and related activity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleofoutstandingcommonstockoptionsandrelatedactivityTable</Role>
      <ShortName>Stock-Based Compensation (Details) - Schedule of outstanding common stock options and related activity</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/StockBasedCompensationTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>066 - Disclosure - Stock-Based Compensation (Details) - Schedule of assumptions used to calculate the fair value of stock options</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsTable</Role>
      <ShortName>Stock-Based Compensation (Details) - Schedule of assumptions used to calculate the fair value of stock options</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/StockBasedCompensationTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>067 - Disclosure - Stock-Based Compensation (Details) - Schedule of restricted common stock activity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleofrestrictedcommonstockactivityTable</Role>
      <ShortName>Stock-Based Compensation (Details) - Schedule of restricted common stock activity</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/StockBasedCompensationTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>068 - Disclosure - Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/FairValueDetails</Role>
      <ShortName>Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/FairValueTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>069 - Disclosure - Fair Value (Details) - Schedule of fair value hierarchy of liabilities measured at fair value on recurring basis</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable</Role>
      <ShortName>Fair Value (Details) - Schedule of fair value hierarchy of liabilities measured at fair value on recurring basis</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/FairValueTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>070 - Disclosure - Fair Value (Details) - Schedule of unobservable inputs to the conversion feature, warrant liability, and contingent earn-out valuation models</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleofunobservableinputstotheconversionfeaturewarrantliabilityandcontingentearnoutvaluationmodelsTable</Role>
      <ShortName>Fair Value (Details) - Schedule of unobservable inputs to the conversion feature, warrant liability, and contingent earn-out valuation models</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/FairValueTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>071 - Disclosure - Fair Value (Details) - Schedule of changes in fair value of financial liabilities related to the notes payable, the derivative instrument, the preferred stock warrants, and the contingent earn-outs</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsTable</Role>
      <ShortName>Fair Value (Details) - Schedule of changes in fair value of financial liabilities related to the notes payable, the derivative instrument, the preferred stock warrants, and the contingent earn-outs</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/FairValueTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>072 - Disclosure - Redeemable Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/RedeemableConvertiblePreferredStockDetails</Role>
      <ShortName>Redeemable Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/RedeemableConvertiblePreferredStock</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>073 - Disclosure - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/CommonStockDetails</Role>
      <ShortName>Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/CommonStockWarrantsTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>074 - Disclosure - Net Income (Loss) Per Share Attributable to Common Shareholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/NetIncomeLossPerShareAttributabletoCommonShareholdersDetails</Role>
      <ShortName>Net Income (Loss) Per Share Attributable to Common Shareholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/NetIncomeLossPerShareAttributabletoCommonShareholdersTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>075 - Disclosure - Net Income (Loss) Per Share Attributable to Common Shareholders (Details) - Schedule of basic and diluted net loss per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleofbasicanddilutednetlosspershareTable</Role>
      <ShortName>Net Income (Loss) Per Share Attributable to Common Shareholders (Details) - Schedule of basic and diluted net loss per share</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/NetIncomeLossPerShareAttributabletoCommonShareholdersTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>076 - Disclosure - Net Income (Loss) Per Share Attributable to Common Shareholders (Details) - Schedule of securities excluded from computation of diluted net income (loss) per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleofsecuritiesexcludedfromcomputationofdilutednetincomelosspershareTable</Role>
      <ShortName>Net Income (Loss) Per Share Attributable to Common Shareholders (Details) - Schedule of securities excluded from computation of diluted net income (loss) per share</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/NetIncomeLossPerShareAttributabletoCommonShareholdersTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>077 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/RelatedPartyTransactions</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>078 - Disclosure - Geographic and Segment Information (Details) - Schedule of property and equipment, net by location</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetbylocationTable</Role>
      <ShortName>Geographic and Segment Information (Details) - Schedule of property and equipment, net by location</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/GeographicandSegmentInformationTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>079 - Disclosure - Geographic and Segment Information (Details) - Schedule of drugs and supplements segments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleofdrugsandsupplementssegmentsTable</Role>
      <ShortName>Geographic and Segment Information (Details) - Schedule of drugs and supplements segments</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/GeographicandSegmentInformationTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>080 - Disclosure - Geographic and Segment Information (Details) - Schedule of property and equipment, net by segment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetbysegmentTable</Role>
      <ShortName>Geographic and Segment Information (Details) - Schedule of property and equipment, net by segment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/GeographicandSegmentInformationTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="f10q0921_cleneinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>081 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cleaninccom/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cleaninccom/role/SubsequentEvents</ParentRole>
      <Position>82</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="f10q0921_cleneinc.htm">f10q0921_cleneinc.htm</File>
    <File>clnn-20210930.xsd</File>
    <File>clnn-20210930_cal.xml</File>
    <File>clnn-20210930_def.xml</File>
    <File>clnn-20210930_lab.xml</File>
    <File>clnn-20210930_pre.xml</File>
    <File>f10q0921ex31-1_cleneinc.htm</File>
    <File>f10q0921ex31-2_cleneinc.htm</File>
    <File>f10q0921ex32-1_cleneinc.htm</File>
    <File>f10q0921ex32-2_cleneinc.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>100
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "f10q0921_cleneinc.htm": {
   "axisCustom": 1,
   "axisStandard": 24,
   "contextCount": 336,
   "dts": {
    "calculationLink": {
     "local": [
      "clnn-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "clnn-20210930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "f10q0921_cleneinc.htm"
     ]
    },
    "labelLink": {
     "local": [
      "clnn-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "clnn-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "clnn-20210930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 820,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 164,
    "http://www.cleaninccom/20210930": 136,
    "http://xbrl.sec.gov/dei/2021": 4,
    "total": 304
   },
   "keyCustom": 234,
   "keyStandard": 398,
   "memberCustom": 41,
   "memberStandard": 34,
   "nsprefix": "clnn",
   "nsuri": "http://www.cleaninccom/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "role": "http://www.cleaninccom/role/DocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "clnn:ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "009 - Disclosure - Reverse Recapitalization with Tottenham and Clene Nanomedicine",
     "role": "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicine",
     "shortName": "Reverse Recapitalization with Tottenham and Clene Nanomedicine",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "clnn:ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "clnn:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "010 - Disclosure - Prepaid Expenses and Other Current Assets",
     "role": "http://www.cleaninccom/role/PrepaidExpensesandOtherCurrentAssets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "clnn:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "011 - Disclosure - Property and Equipment, Net",
     "role": "http://www.cleaninccom/role/PropertyandEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "012 - Disclosure - Accrued Liabilities",
     "role": "http://www.cleaninccom/role/AccruedLiabilities",
     "shortName": "Accrued Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - Leases",
     "role": "http://www.cleaninccom/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - Notes Payable",
     "role": "http://www.cleaninccom/role/NotesPayable",
     "shortName": "Notes Payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - Preferred Stock Warrant Liability",
     "role": "http://www.cleaninccom/role/PreferredStockWarrantLiability",
     "shortName": "Preferred Stock Warrant Liability",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "clnn:CommonStockWarrantsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - Common Stock Warrants",
     "role": "http://www.cleaninccom/role/CommonStockWarrants",
     "shortName": "Common Stock Warrants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "clnn:CommonStockWarrantsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "clnn:ConvertibleNotesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - Convertible Notes",
     "role": "http://www.cleaninccom/role/ConvertibleNotes",
     "shortName": "Convertible Notes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "clnn:ConvertibleNotesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - Derivative Instruments",
     "role": "http://www.cleaninccom/role/DerivativeInstruments",
     "shortName": "Derivative Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "role": "http://www.cleaninccom/role/ConsolidatedBalanceSheet",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - Commitments and Contingencies",
     "role": "http://www.cleaninccom/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - Income Taxes",
     "role": "http://www.cleaninccom/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - Stock-Based Compensation",
     "role": "http://www.cleaninccom/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - Fair Value",
     "role": "http://www.cleaninccom/role/FairValue",
     "shortName": "Fair Value",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "clnn:RedeemableConvertiblePreferredStockDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - Redeemable Convertible Preferred Stock",
     "role": "http://www.cleaninccom/role/RedeemableConvertiblePreferredStock",
     "shortName": "Redeemable Convertible Preferred Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "clnn:RedeemableConvertiblePreferredStockDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - Common Stock",
     "role": "http://www.cleaninccom/role/CommonStock",
     "shortName": "Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - Net Income (Loss) Per Share Attributable to Common Shareholders",
     "role": "http://www.cleaninccom/role/NetIncomeLossPerShareAttributabletoCommonShareholders",
     "shortName": "Net Income (Loss) Per Share Attributable to Common Shareholders",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - Related Party Transactions",
     "role": "http://www.cleaninccom/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "027 - Disclosure - Geographic and Segment Information",
     "role": "http://www.cleaninccom/role/GeographicandSegmentInformation",
     "shortName": "Geographic and Segment Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "028 - Disclosure - Subsequent Events",
     "role": "http://www.cleaninccom/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c2",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)",
     "role": "http://www.cleaninccom/role/ConsolidatedBalanceSheet_Parentheticals",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "029 - Disclosure - Accounting Policies, by Policy (Policies)",
     "role": "http://www.cleaninccom/role/AccountingPoliciesByPolicy",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "clnn:PrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "030 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "role": "http://www.cleaninccom/role/PrepaidExpensesandOtherCurrentAssetsTables",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "clnn:PrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "031 - Disclosure - Property and Equipment, Net (Tables)",
     "role": "http://www.cleaninccom/role/PropertyandEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "032 - Disclosure - Accrued Liabilities (Tables)",
     "role": "http://www.cleaninccom/role/AccruedLiabilitiesTables",
     "shortName": "Accrued Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "clnn:FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "033 - Disclosure - Leases (Tables)",
     "role": "http://www.cleaninccom/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "clnn:FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "034 - Disclosure - Notes Payable (Tables)",
     "role": "http://www.cleaninccom/role/NotesPayableTables",
     "shortName": "Notes Payable (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "035 - Disclosure - Common Stock Warrants (Tables)",
     "role": "http://www.cleaninccom/role/CommonStockWarrantsTables",
     "shortName": "Common Stock Warrants (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "036 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.cleaninccom/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "037 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.cleaninccom/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "038 - Disclosure - Fair Value (Tables)",
     "role": "http://www.cleaninccom/role/FairValueTables",
     "shortName": "Fair Value (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c12",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)",
     "role": "http://www.cleaninccom/role/ConsolidatedIncomeStatement",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c12",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "039 - Disclosure - Net Income (Loss) Per Share Attributable to Common Shareholders (Tables)",
     "role": "http://www.cleaninccom/role/NetIncomeLossPerShareAttributabletoCommonShareholdersTables",
     "shortName": "Net Income (Loss) Per Share Attributable to Common Shareholders (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "040 - Disclosure - Geographic and Segment Information (Tables)",
     "role": "http://www.cleaninccom/role/GeographicandSegmentInformationTables",
     "shortName": "Geographic and Segment Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "041 - Disclosure - Nature of the Business (Details)",
     "role": "http://www.cleaninccom/role/NatureoftheBusinessDetails",
     "shortName": "Nature of the Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c99",
      "decimals": "-5",
      "lang": null,
      "name": "clnn:AggregateFutureProceedsWarrantsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestrictedInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "042 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://www.cleaninccom/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c3",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:RestrictedInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c124",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "clnn:ProceedsFromReverseRecapitalization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "043 - Disclosure - Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details)",
     "role": "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails",
     "shortName": "Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c124",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "clnn:ProceedsFromReverseRecapitalization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "clnn:PrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "clnn:AustraliaResearchAndDevelopmentCreditReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "044 - Disclosure - Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets",
     "role": "http://www.cleaninccom/role/ScheduleofprepaidexpensesandothercurrentassetsTable",
     "shortName": "Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "clnn:PrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "clnn:AustraliaResearchAndDevelopmentCreditReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c140",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "045 - Disclosure - Property and Equipment, Net (Details)",
     "role": "http://www.cleaninccom/role/PropertyandEquipmentNetDetails",
     "shortName": "Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c140",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:MachineryAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "046 - Disclosure - Property and Equipment, Net (Details) - Schedule of property and equipment, net",
     "role": "http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetTable",
     "shortName": "Property and Equipment, Net (Details) - Schedule of property and equipment, net",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:MachineryAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "047 - Disclosure - Accrued Liabilities (Details) - Schedule of accrued liabilities",
     "role": "http://www.cleaninccom/role/ScheduleofaccruedliabilitiesTable",
     "shortName": "Accrued Liabilities (Details) - Schedule of accrued liabilities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c148",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "clnn:RemainingRightofuseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "048 - Disclosure - Leases (Details)",
     "role": "http://www.cleaninccom/role/LeasesDetails",
     "shortName": "Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c148",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "clnn:RemainingRightofuseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c54",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - Condensed Consolidated Statements Of Stockholders' Equity (Deficit) (Unaudited)",
     "role": "http://www.cleaninccom/role/ShareholdersEquityType2or3",
     "shortName": "Condensed Consolidated Statements Of Stockholders' Equity (Deficit) (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c54",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "clnn:FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c151",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "049 - Disclosure - Leases (Details) - Schedule of noncancelable finance and operating lease liabilities",
     "role": "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable",
     "shortName": "Leases (Details) - Schedule of noncancelable finance and operating lease liabilities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "clnn:FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c151",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "clnn:FinanceLeaseByMajorClassPropertyAndEquipmentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "clnn:FinanceLeaseLaboratoryEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "050 - Disclosure - Leases (Details) - Schedule of finance lease obligations included in property and equipment",
     "role": "http://www.cleaninccom/role/ScheduleoffinanceleaseobligationsincludedinpropertyandequipmentTable",
     "shortName": "Leases (Details) - Schedule of finance lease obligations included in property and equipment",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "clnn:FinanceLeaseByMajorClassPropertyAndEquipmentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "clnn:FinanceLeaseLaboratoryEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c12",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "051 - Disclosure - Leases (Details) - Schedule of finance and operating lease costs",
     "role": "http://www.cleaninccom/role/ScheduleoffinanceandoperatingleasecostsTable",
     "shortName": "Leases (Details) - Schedule of finance and operating lease costs",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c12",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "clnn:OperatingCashFlowsFromOperatingLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "052 - Disclosure - Leases (Details) - Schedule of supplemental cash flow information",
     "role": "http://www.cleaninccom/role/ScheduleofsupplementalcashflowinformationTable",
     "shortName": "Leases (Details) - Schedule of supplemental cash flow information",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "clnn:OperatingCashFlowsFromOperatingLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c153",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "053 - Disclosure - Notes Payable (Details)",
     "role": "http://www.cleaninccom/role/NotesPayableDetails",
     "shortName": "Notes Payable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c153",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "clnn:TotalTermLoans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "054 - Disclosure - Notes Payable (Details) - Schedule of long-term debt, net of original issue discount and unamortized debt issuance costs",
     "role": "http://www.cleaninccom/role/ScheduleoflongtermdebtnetoforiginalissuediscountandunamortizeddebtissuancecostsTable",
     "shortName": "Notes Payable (Details) - Schedule of long-term debt, net of original issue discount and unamortized debt issuance costs",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "clnn:TotalTermLoans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "clnn:ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscounts",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "clnn:DebtInstrumentUnamortizedDiscountYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "055 - Disclosure - Notes Payable (Details) - Schedule of future payments, net of unamortized debt discounts",
     "role": "http://www.cleaninccom/role/ScheduleoffuturepaymentsnetofunamortizeddebtdiscountsTable",
     "shortName": "Notes Payable (Details) - Schedule of future payments, net of unamortized debt discounts",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "clnn:ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscounts",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "clnn:DebtInstrumentUnamortizedDiscountYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c134",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "clnn:LossInFairValueOfWarrantLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "056 - Disclosure - Preferred Stock Warrant Liability (Details)",
     "role": "http://www.cleaninccom/role/PreferredStockWarrantLiabilityDetails",
     "shortName": "Preferred Stock Warrant Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c134",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "clnn:LossInFairValueOfWarrantLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "057 - Disclosure - Common Stock Warrants (Details)",
     "role": "http://www.cleaninccom/role/CommonStockWarrantsDetails",
     "shortName": "Common Stock Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "lang": "en-US",
      "name": "clnn:CompanyWarrantRedemptionRight",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "clnn:NumberOfSharesIssuable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "058 - Disclosure - Common Stock Warrants (Details) - Schedule of outstanding warrants to purchase shares of common stock",
     "role": "http://www.cleaninccom/role/ScheduleofoutstandingwarrantstopurchasesharesofcommonstockTable",
     "shortName": "Common Stock Warrants (Details) - Schedule of outstanding warrants to purchase shares of common stock",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "clnn:NumberOfSharesIssuable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c13",
      "decimals": "-2",
      "first": true,
      "lang": null,
      "name": "clnn:NetOfIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "005 - Statement - Condensed Consolidated Statements Of Stockholders' Equity (Deficit) (Unaudited) (Parentheticals)",
     "role": "http://www.cleaninccom/role/ShareholdersEquityType2or3_Parentheticals",
     "shortName": "Condensed Consolidated Statements Of Stockholders' Equity (Deficit) (Unaudited) (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c13",
      "decimals": "-2",
      "first": true,
      "lang": null,
      "name": "clnn:NetOfIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConvertibleNotesPayable",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "059 - Disclosure - Convertible Notes (Details)",
     "role": "http://www.cleaninccom/role/ConvertibleNotesDetails",
     "shortName": "Convertible Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ConversionOfStockSharesConverted1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c242",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeFairValueOfDerivativeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060 - Disclosure - Derivative Instruments (Details)",
     "role": "http://www.cleaninccom/role/DerivativeInstrumentsDetails",
     "shortName": "Derivative Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c242",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeFairValueOfDerivativeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c12",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061 - Disclosure - Income Taxes (Details)",
     "role": "http://www.cleaninccom/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c12",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c12",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "062 - Disclosure - Income Taxes (Details) - Schedule of components of income (loss) before income taxes",
     "role": "http://www.cleaninccom/role/ScheduleofcomponentsofincomelossbeforeincometaxesTable",
     "shortName": "Income Taxes (Details) - Schedule of components of income (loss) before income taxes",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c12",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c12",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockOptionPlanExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "063 - Disclosure - Stock-Based Compensation (Details)",
     "role": "http://www.cleaninccom/role/StockBasedCompensationDetails",
     "shortName": "Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c12",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockOptionPlanExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c12",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "064 - Disclosure - Stock-Based Compensation (Details) - Schedule of stock-based compensation expense",
     "role": "http://www.cleaninccom/role/ScheduleofstockbasedcompensationexpenseTable",
     "shortName": "Stock-Based Compensation (Details) - Schedule of stock-based compensation expense",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c12",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "065 - Disclosure - Stock-Based Compensation (Details) - Schedule of outstanding common stock options and related activity",
     "role": "http://www.cleaninccom/role/ScheduleofoutstandingcommonstockoptionsandrelatedactivityTable",
     "shortName": "Stock-Based Compensation (Details) - Schedule of outstanding common stock options and related activity",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c259",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "066 - Disclosure - Stock-Based Compensation (Details) - Schedule of assumptions used to calculate the fair value of stock options",
     "role": "http://www.cleaninccom/role/ScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsTable",
     "shortName": "Stock-Based Compensation (Details) - Schedule of assumptions used to calculate the fair value of stock options",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c259",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c256",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "067 - Disclosure - Stock-Based Compensation (Details) - Schedule of restricted common stock activity",
     "role": "http://www.cleaninccom/role/ScheduleofrestrictedcommonstockactivityTable",
     "shortName": "Stock-Based Compensation (Details) - Schedule of restricted common stock activity",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c256",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "clnn:NotesPayableBasedOnClosingPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "068 - Disclosure - Fair Value (Details)",
     "role": "http://www.cleaninccom/role/FairValueDetails",
     "shortName": "Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "clnn:NotesPayableBasedOnClosingPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://www.cleaninccom/role/ConsolidatedCashFlow",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSoldDepreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesPayableFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "069 - Disclosure - Fair Value (Details) - Schedule of fair value hierarchy of liabilities measured at fair value on recurring basis",
     "role": "http://www.cleaninccom/role/ScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable",
     "shortName": "Fair Value (Details) - Schedule of fair value hierarchy of liabilities measured at fair value on recurring basis",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesPayableFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c267",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "070 - Disclosure - Fair Value (Details) - Schedule of unobservable inputs to the conversion feature, warrant liability, and contingent earn-out valuation models",
     "role": "http://www.cleaninccom/role/ScheduleofunobservableinputstotheconversionfeaturewarrantliabilityandcontingentearnoutvaluationmodelsTable",
     "shortName": "Fair Value (Details) - Schedule of unobservable inputs to the conversion feature, warrant liability, and contingent earn-out valuation models",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c267",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c281",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "071 - Disclosure - Fair Value (Details) - Schedule of changes in fair value of financial liabilities related to the notes payable, the derivative instrument, the preferred stock warrants, and the contingent earn-outs",
     "role": "http://www.cleaninccom/role/ScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsTable",
     "shortName": "Fair Value (Details) - Schedule of changes in fair value of financial liabilities related to the notes payable, the derivative instrument, the preferred stock warrants, and the contingent earn-outs",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c281",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c302",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConversionOfStockSharesConverted1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "072 - Disclosure - Redeemable Convertible Preferred Stock (Details)",
     "role": "http://www.cleaninccom/role/RedeemableConvertiblePreferredStockDetails",
     "shortName": "Redeemable Convertible Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c302",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConversionOfStockSharesConverted1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "073 - Disclosure - Common Stock (Details)",
     "role": "http://www.cleaninccom/role/CommonStockDetails",
     "shortName": "Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": "0",
      "lang": null,
      "name": "clnn:PreferredStockShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c310",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "074 - Disclosure - Net Income (Loss) Per Share Attributable to Common Shareholders (Details)",
     "role": "http://www.cleaninccom/role/NetIncomeLossPerShareAttributabletoCommonShareholdersDetails",
     "shortName": "Net Income (Loss) Per Share Attributable to Common Shareholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c310",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c312",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "075 - Disclosure - Net Income (Loss) Per Share Attributable to Common Shareholders (Details) - Schedule of basic and diluted net loss per share",
     "role": "http://www.cleaninccom/role/ScheduleofbasicanddilutednetlosspershareTable",
     "shortName": "Net Income (Loss) Per Share Attributable to Common Shareholders (Details) - Schedule of basic and diluted net loss per share",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c312",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c13",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "clnn:SeriesDRedeemableConvertiblePreferredStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "076 - Disclosure - Net Income (Loss) Per Share Attributable to Common Shareholders (Details) - Schedule of securities excluded from computation of diluted net income (loss) per share",
     "role": "http://www.cleaninccom/role/ScheduleofsecuritiesexcludedfromcomputationofdilutednetincomelosspershareTable",
     "shortName": "Net Income (Loss) Per Share Attributable to Common Shareholders (Details) - Schedule of securities excluded from computation of diluted net income (loss) per share",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c13",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "clnn:SeriesDRedeemableConvertiblePreferredStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c13",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "077 - Disclosure - Related Party Transactions (Details)",
     "role": "http://www.cleaninccom/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c13",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "078 - Disclosure - Geographic and Segment Information (Details) - Schedule of property and equipment, net by location",
     "role": "http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetbylocationTable",
     "shortName": "Geographic and Segment Information (Details) - Schedule of property and equipment, net by location",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c318",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "007 - Disclosure - Nature of the Business",
     "role": "http://www.cleaninccom/role/NatureoftheBusiness",
     "shortName": "Nature of the Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c12",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "079 - Disclosure - Geographic and Segment Information (Details) - Schedule of drugs and supplements segments",
     "role": "http://www.cleaninccom/role/ScheduleofdrugsandsupplementssegmentsTable",
     "shortName": "Geographic and Segment Information (Details) - Schedule of drugs and supplements segments",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c322",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OperatingIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "clnn:ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "clnn:TotalPropertyAndEquipmentNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080 - Disclosure - Geographic and Segment Information (Details) - Schedule of property and equipment, net by segment",
     "role": "http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetbysegmentTable",
     "shortName": "Geographic and Segment Information (Details) - Schedule of property and equipment, net by segment",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "clnn:ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "clnn:TotalPropertyAndEquipmentNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c335",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "081 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.cleaninccom/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c335",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "008 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.cleaninccom/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0921_cleneinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 81,
   "tag": {
    "clnn_AccruedCROFees": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofaccruedliabilitiesTable": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued CRO fees.",
        "label": "AccruedCROFees",
        "terseLabel": "Accrued CRO fees"
       }
      }
     },
     "localname": "AccruedCROFees",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofaccruedliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_AccruedDebtIssuanceCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued debt issuance costs.",
        "label": "AccruedDebtIssuanceCosts",
        "terseLabel": "Accrued debt issuance costs"
       }
      }
     },
     "localname": "AccruedDebtIssuanceCosts",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/NotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_AccruedExpenseReimbursements": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofaccruedliabilitiesTable": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expense reimbursements.",
        "label": "AccruedExpenseReimbursements",
        "terseLabel": "Accrued expense reimbursements"
       }
      }
     },
     "localname": "AccruedExpenseReimbursements",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofaccruedliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_AccruedLiabilitiesTablesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesTablesLineItems",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/AccruedLiabilitiesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_AccruedLiabilitiesTablesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities (Tables) [Table]"
       }
      }
     },
     "localname": "AccruedLiabilitiesTablesTable",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/AccruedLiabilitiesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_AccruedTransactionCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofaccruedliabilitiesTable": {
       "order": 6.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued transaction costs",
        "label": "AccruedTransactionCosts",
        "terseLabel": "Accrued transaction costs"
       }
      }
     },
     "localname": "AccruedTransactionCosts",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofaccruedliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_AccumulatedDepreciationDepletionAndAmortizationLeases": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleoffinanceleaseobligationsincludedinpropertyandequipmentTable": {
       "order": 2.0,
       "parentTag": "clnn_FinanceLeaseLiabilityNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated depreciation.",
        "label": "AccumulatedDepreciationDepletionAndAmortizationLeases",
        "terseLabel": "Less accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationLeases",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoffinanceleaseobligationsincludedinpropertyandequipmentTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_AdditionalPaymentUponMaturityDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional payment upon maturity description.",
        "label": "AdditionalPaymentUponMaturityDescription",
        "terseLabel": "Additional payment upon maturity, description"
       }
      }
     },
     "localname": "AdditionalPaymentUponMaturityDescription",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/NotesPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_AdditionalWarrantToPurchaseShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Warrant To Purchase Shares",
        "label": "AdditionalWarrantToPurchaseShares",
        "terseLabel": "Additional warrant to purchase estimated shares (in Shares)"
       }
      }
     },
     "localname": "AdditionalWarrantToPurchaseShares",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/FairValueDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_AdvanceCecilIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AdvanceCecilIncMember",
        "terseLabel": "Advance Cecil, Inc. [Member]"
       }
      }
     },
     "localname": "AdvanceCecilIncMember",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoflongtermdebtnetoforiginalissuediscountandunamortizeddebtissuancecostsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "clnn_AggregateFutureProceedsWarrantsExercised": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate future proceeds warrants exercised",
        "label": "AggregateFutureProceedsWarrantsExercised",
        "terseLabel": "Aggregate proceeds if warrants exercised"
       }
      }
     },
     "localname": "AggregateFutureProceedsWarrantsExercised",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/NatureoftheBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_AggregateGrossProceedWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate gross proceed warrants exercised.",
        "label": "AggregateGrossProceedWarrantsExercised",
        "terseLabel": "Aggregate gross proceed warrants exercised (in Dollars per share)",
        "verboseLabel": "Aggregate gross proceed warrants exercised"
       }
      }
     },
     "localname": "AggregateGrossProceedWarrantsExercised",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails",
      "http://www.cleaninccom/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clnn_AggregateProceedsReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate proceeds received.",
        "label": "AggregateProceedsReceived",
        "terseLabel": "Aggregate proceeds received"
       }
      }
     },
     "localname": "AggregateProceedsReceived",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/NatureoftheBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_AustraliaResearchAndDevelopmentCredit": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement": {
       "order": 11.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "AustraliaResearchAndDevelopmentCredit",
        "negatedLabel": "Australia research and development credit"
       }
      }
     },
     "localname": "AustraliaResearchAndDevelopmentCredit",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_AustraliaResearchAndDevelopmentCreditReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofprepaidexpensesandothercurrentassetsTable": {
       "order": 5.0,
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Australia research and development credit receivable",
        "label": "AustraliaResearchAndDevelopmentCreditReceivable",
        "negatedLabel": "Australia research and development credit receivable"
       }
      }
     },
     "localname": "AustraliaResearchAndDevelopmentCreditReceivable",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofprepaidexpensesandothercurrentassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_AvenueLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AvenueLoanMember",
        "terseLabel": "Avenue Loan [Member]"
       }
      }
     },
     "localname": "AvenueLoanMember",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockWarrantsDetails",
      "http://www.cleaninccom/role/FairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clnn_AvenueVentureOpportunitiesFundsLPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AvenueVentureOpportunitiesFundsLPMember",
        "terseLabel": "Avenue Venture Opportunities Fund, L.P. [Member]"
       }
      }
     },
     "localname": "AvenueVentureOpportunitiesFundsLPMember",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoflongtermdebtnetoforiginalissuediscountandunamortizeddebtissuancecostsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "clnn_BlackScholesValuationModelMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BlackScholesValuationModelMember",
        "terseLabel": "Black-Scholes Valuation Model [Member]"
       }
      }
     },
     "localname": "BlackScholesValuationModelMember",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofunobservableinputstotheconversionfeaturewarrantliabilityandcontingentearnoutvaluationmodelsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "clnn_CROPrepayments": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofprepaidexpensesandothercurrentassetsTable": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "CROPrepayments",
        "terseLabel": "CRO prepayments"
       }
      }
     },
     "localname": "CROPrepayments",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofprepaidexpensesandothercurrentassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_CapitalLeasesAmountRepresentingInterestdiscounting": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable": {
       "order": 2.0,
       "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of capital lease representing discounting and interest.",
        "label": "CapitalLeasesAmountRepresentingInterestdiscounting",
        "negatedLabel": "Less amount representing interest/discounting"
       }
      }
     },
     "localname": "CapitalLeasesAmountRepresentingInterestdiscounting",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_CapitalLeasesFutureLeaseIncentives": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of less future lease incentives.",
        "label": "CapitalLeasesFutureLeaseIncentives",
        "terseLabel": "Less future lease incentives"
       }
      }
     },
     "localname": "CapitalLeasesFutureLeaseIncentives",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_CashPaidForInterestExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.",
        "label": "CashPaidForInterestExpense",
        "terseLabel": "Cash paid for interest expense"
       }
      }
     },
     "localname": "CashPaidForInterestExpense",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_CashProceedsReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Proceeds Received.",
        "label": "CashProceedsReceived",
        "terseLabel": "Cash proceeds received (in Dollars)"
       }
      }
     },
     "localname": "CashProceedsReceived",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_ChangeInFairValueOfCleneNanomedicineContingentEarnouts": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedCashFlow": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the period ended Change in fair value of contingent earn-out.",
        "label": "ChangeInFairValueOfCleneNanomedicineContingentEarnouts",
        "negatedLabel": "Change in fair value of Clene Nanomedicine contingent earn-out"
       }
      }
     },
     "localname": "ChangeInFairValueOfCleneNanomedicineContingentEarnouts",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_ChangeInFairValueOfCommonStockWarrantLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement": {
       "order": 6.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value of common stock warrant liability.",
        "label": "ChangeInFairValueOfCommonStockWarrantLiability",
        "terseLabel": "Change in fair value of common stock warrant liability"
       }
      }
     },
     "localname": "ChangeInFairValueOfCommonStockWarrantLiability",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_ChangeInFairValueOfCommonStockWarrantLiabilitys": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedCashFlow": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value of common stock warrant liability.",
        "label": "ChangeInFairValueOfCommonStockWarrantLiabilitys",
        "negatedLabel": "Change in fair value of common stock warrant liability"
       }
      }
     },
     "localname": "ChangeInFairValueOfCommonStockWarrantLiabilitys",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_ChangeInFairValueOfContingentEarnout": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the period ended Change in fair value of contingent earn-out.",
        "label": "ChangeInFairValueOfContingentEarnout",
        "terseLabel": "Change in fair value of Clene Nanomedicine contingent earn-out"
       }
      }
     },
     "localname": "ChangeInFairValueOfContingentEarnout",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_ChangeInFairValueOfDerivativeLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value of derivative liability.",
        "label": "ChangeInFairValueOfDerivativeLiability",
        "terseLabel": "Change in fair value of derivative liability"
       }
      }
     },
     "localname": "ChangeInFairValueOfDerivativeLiability",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_ChangeInFairValueOfInitialShareholdersContingentEarnout": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value of Initial Shareholders contingent earn-out\r  \n.",
        "label": "ChangeInFairValueOfInitialShareholdersContingentEarnout",
        "terseLabel": "Change in fair value of Initial Shareholders contingent earn-out"
       }
      }
     },
     "localname": "ChangeInFairValueOfInitialShareholdersContingentEarnout",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_ChangeInFairValueOfPreferredStockWarrantLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "ChangeInFairValueOfPreferredStockWarrantLiability",
        "terseLabel": "Change in fair value of preferred stock warrant liability"
       }
      }
     },
     "localname": "ChangeInFairValueOfPreferredStockWarrantLiability",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_Changeinfairvaluewarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Changeinfairvaluewarrants",
        "label": "Changeinfairvaluewarrants",
        "terseLabel": "Change in fair value warrants"
       }
      }
     },
     "localname": "Changeinfairvaluewarrants",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_ChangesInFairValueOfInitialShareholdersContingentEarnout": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedCashFlow": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value of Initial Shareholders contingent earn-out.",
        "label": "ChangesInFairValueOfInitialShareholdersContingentEarnout",
        "negatedLabel": "Change in fair value of Initial Shareholders contingent earn-out"
       }
      }
     },
     "localname": "ChangesInFairValueOfInitialShareholdersContingentEarnout",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_ChardanCapitalMarketsLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chardan Capital Markets, LLC [Member]",
        "label": "ChardanCapitalMarketsLLCMember",
        "terseLabel": "Chardan Capital Markets, LLC [Member]"
       }
      }
     },
     "localname": "ChardanCapitalMarketsLLCMember",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clnn_ChardanUnitPurchaseOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chardan unit purchase option.",
        "label": "ChardanUnitPurchaseOption",
        "terseLabel": "Chardan unit purchase option"
       }
      }
     },
     "localname": "ChardanUnitPurchaseOption",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_ChardanUnitPurchaseOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ChardanUnitPurchaseOptionMember",
        "terseLabel": "Chardan Unit Purchase Option [Member]"
       }
      }
     },
     "localname": "ChardanUnitPurchaseOptionMember",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clnn_ChardanUnitPurchaseOptionWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofsecuritiesexcludedfromcomputationofdilutednetincomelosspershareTable": {
       "order": 11.0,
       "parentTag": "clnn_TotalDilutiveSecurities",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "ChardanUnitPurchaseOptionWarrants",
        "terseLabel": "Chardan Unit Purchase Option Warrants (see Notes 3 and 10)"
       }
      }
     },
     "localname": "ChardanUnitPurchaseOptionWarrants",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofsecuritiesexcludedfromcomputationofdilutednetincomelosspershareTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_CleneIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CleneIncMember",
        "terseLabel": "Clene Inc [Member]"
       }
      }
     },
     "localname": "CleneIncMember",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/NatureoftheBusinessDetails",
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clnn_CleneNanomedicineContingentEarnOutMilestone1Shares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clene nanomedicine contingent earn out milestone1 shares.",
        "label": "CleneNanomedicineContingentEarnOutMilestone1Shares",
        "terseLabel": "Clene nanomedicine contingent earnout milestone1 shares"
       }
      }
     },
     "localname": "CleneNanomedicineContingentEarnOutMilestone1Shares",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_CleneNanomedicineContingentEarnoutFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clene nanomedicine contingent earnout fair value disclosure.",
        "label": "CleneNanomedicineContingentEarnoutFairValueDisclosure",
        "terseLabel": "Clene Nanomedicine contingent earn-out"
       }
      }
     },
     "localname": "CleneNanomedicineContingentEarnoutFairValueDisclosure",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_CleneNanomedicineContingentEarnoutMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CleneNanomedicineContingentEarnoutMember",
        "terseLabel": "Clene Nanomedicine Contingent Earn-out [Member]"
       }
      }
     },
     "localname": "CleneNanomedicineContingentEarnoutMember",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "clnn_CleneNanomedicineContingentEarnoutMilestone1Price": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clene nanomedicine contingent earn out milestone 1 price.",
        "label": "CleneNanomedicineContingentEarnoutMilestone1Price",
        "terseLabel": "Clene nanomedicine contingent earnout milestone 1 price (in Dollars per share)"
       }
      }
     },
     "localname": "CleneNanomedicineContingentEarnoutMilestone1Price",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clnn_CleneNanomedicineContingentEarnoutMilestone2Price": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clene nanomedicine contingent earnout milestone2 price.",
        "label": "CleneNanomedicineContingentEarnoutMilestone2Price",
        "terseLabel": "Clene nanomedicine contingent earnout milestone 2 price (in Dollars per share)"
       }
      }
     },
     "localname": "CleneNanomedicineContingentEarnoutMilestone2Price",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clnn_CleneNanomedicineContingentEarnoutMilestone2Shares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clene nanomedicine contingent earnout milestone 2 shares.",
        "label": "CleneNanomedicineContingentEarnoutMilestone2Shares",
        "terseLabel": "Clene nanomedicine contingent earnout milestone 2 shares"
       }
      }
     },
     "localname": "CleneNanomedicineContingentEarnoutMilestone2Shares",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_CleneNanomedicineContingentEarnoutMilestone3Shares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clene nanomedicine contingent earnout milestone 3 shares.",
        "label": "CleneNanomedicineContingentEarnoutMilestone3Shares",
        "terseLabel": "Clene nanomedicine contingent earnout milestone 3 shares"
       }
      }
     },
     "localname": "CleneNanomedicineContingentEarnoutMilestone3Shares",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_CleneNanomedicineContingentEarnoutShares": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofsecuritiesexcludedfromcomputationofdilutednetincomelosspershareTable": {
       "order": 12.0,
       "parentTag": "clnn_TotalDilutiveSecurities",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clene nanomedicine contingent earnout shares.",
        "label": "CleneNanomedicineContingentEarnoutShares",
        "terseLabel": "Clene Nanomedicine contingent earn-out shares (see Note 3 and 12)"
       }
      }
     },
     "localname": "CleneNanomedicineContingentEarnoutShares",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofsecuritiesexcludedfromcomputationofdilutednetincomelosspershareTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_CleneNanomedicineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CleneNanomedicineMember",
        "terseLabel": "Clene Nanomedicine [Member]"
       }
      }
     },
     "localname": "CleneNanomedicineMember",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/NatureoftheBusinessDetails",
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clnn_ClinicalTrialAccrualPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Trial Accrual Policy.",
        "label": "ClinicalTrialAccrualPolicyTextBlock",
        "terseLabel": "Clinical Trial Accrual"
       }
      }
     },
     "localname": "ClinicalTrialAccrualPolicyTextBlock",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "clnn_CommonStockAtAnExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock at an exercise price.",
        "label": "CommonStockAtAnExercisePrice",
        "terseLabel": "Common stock at an exercise price (in Dollars per share)"
       }
      }
     },
     "localname": "CommonStockAtAnExercisePrice",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/NotesPayableDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clnn_CommonStockDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock (Details) [Line Items]"
       }
      }
     },
     "localname": "CommonStockDetailsLineItems",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_CommonStockDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock (Details) [Table]"
       }
      }
     },
     "localname": "CommonStockDetailsTable",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_CommonStockParOrStatedValuesPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stocks",
        "label": "CommonStockParOrStatedValuesPerShare",
        "terseLabel": "Common stock, par value (in Dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuesPerShare",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clnn_CommonStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Price Per Share.",
        "label": "CommonStockPricePerShare",
        "terseLabel": "Common Stock Price Per Share (in Dollars per share)"
       }
      }
     },
     "localname": "CommonStockPricePerShare",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clnn_CommonStockSharesPurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Shares Purchased.",
        "label": "CommonStockSharesPurchased",
        "terseLabel": "Common Stock Shares Purchased"
       }
      }
     },
     "localname": "CommonStockSharesPurchased",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_CommonStockUnderlyingWarrantOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CommonStockUnderlyingWarrantOutstanding",
        "label": "CommonStockUnderlyingWarrantOutstanding",
        "terseLabel": "Common stock underlying warrant outstanding (in Shares)"
       }
      }
     },
     "localname": "CommonStockUnderlyingWarrantOutstanding",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/NatureoftheBusinessDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_CommonStockWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofsecuritiesexcludedfromcomputationofdilutednetincomelosspershareTable": {
       "order": 8.0,
       "parentTag": "clnn_TotalDilutiveSecurities",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "CommonStockWarrants",
        "terseLabel": "Common stock warrants (see Note 10)"
       }
      }
     },
     "localname": "CommonStockWarrants",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofsecuritiesexcludedfromcomputationofdilutednetincomelosspershareTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_CommonStockWarrantsClassification": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CommonStockWarrantsClassification",
        "terseLabel": "Classification"
       }
      }
     },
     "localname": "CommonStockWarrantsClassification",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofoutstandingwarrantstopurchasesharesofcommonstockTable"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_CommonStockWarrantsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Warrants (Details) [Line Items]"
       }
      }
     },
     "localname": "CommonStockWarrantsDetailsLineItems",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_CommonStockWarrantsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Warrants (Details) [Table]"
       }
      }
     },
     "localname": "CommonStockWarrantsDetailsTable",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_CommonStockWarrantsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Warrants Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommonStockWarrantsDisclosureAbstract",
     "nsuri": "http://www.cleaninccom/20210930",
     "xbrltype": "stringItemType"
    },
    "clnn_CommonStockWarrantsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "he entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "CommonStockWarrantsDisclosureTextBlock",
        "terseLabel": "Common Stock Warrants"
       }
      }
     },
     "localname": "CommonStockWarrantsDisclosureTextBlock",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockWarrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "clnn_CommonStockWarrantsExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CommonStockWarrantsExercisable",
        "terseLabel": "Exercisable for"
       }
      }
     },
     "localname": "CommonStockWarrantsExercisable",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofoutstandingwarrantstopurchasesharesofcommonstockTable"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_CommonStockWarrantsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price.",
        "label": "CommonStockWarrantsExercisePrice",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "localname": "CommonStockWarrantsExercisePrice",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofoutstandingwarrantstopurchasesharesofcommonstockTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "clnn_CommonStockWarrantsExpiration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration.",
        "label": "CommonStockWarrantsExpiration",
        "terseLabel": "Expiration"
       }
      }
     },
     "localname": "CommonStockWarrantsExpiration",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofoutstandingwarrantstopurchasesharesofcommonstockTable"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_CommonStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Warrants [Member]",
        "label": "CommonStockWarrantsMember",
        "terseLabel": "Common Stock Warrants [Member]"
       }
      }
     },
     "localname": "CommonStockWarrantsMember",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clnn_CommonStockWarrantsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for Common stock warrants.",
        "label": "CommonStockWarrantsPolicyTextBlock",
        "terseLabel": "Common Stock Warrants"
       }
      }
     },
     "localname": "CommonStockWarrantsPolicyTextBlock",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "clnn_CompanyWarrantRedemptionRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Company warrant redemption right.",
        "label": "CompanyWarrantRedemptionRight",
        "terseLabel": "Company warrant redemption right"
       }
      }
     },
     "localname": "CompanyWarrantRedemptionRight",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_ConditionsForFutureFundingDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conditions for future funding, description.",
        "label": "ConditionsForFutureFundingDescription",
        "terseLabel": "Conditions for future funding, description"
       }
      }
     },
     "localname": "ConditionsForFutureFundingDescription",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/NotesPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_ContingentEarnOutMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ContingentEarnOutMember",
        "terseLabel": "Contingent Earn-Out [Member]"
       }
      }
     },
     "localname": "ContingentEarnOutMember",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofunobservableinputstotheconversionfeaturewarrantliabilityandcontingentearnoutvaluationmodelsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "clnn_ContingentEarnoutPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Earn-out Policy.",
        "label": "ContingentEarnoutPolicyTextBlock",
        "terseLabel": "Contingent Earn-out"
       }
      }
     },
     "localname": "ContingentEarnoutPolicyTextBlock",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "clnn_ConversionPercentageOfCommonStockPriceForConvertibleNotePayable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion percentage of common stock price for convertible note payable percentage.",
        "label": "ConversionPercentageOfCommonStockPriceForConvertibleNotePayable",
        "terseLabel": "Conversion percentage of common stock price for convertible note payable, percentage",
        "verboseLabel": "Conversion percentage of common stock price for convertible note payable"
       }
      }
     },
     "localname": "ConversionPercentageOfCommonStockPriceForConvertibleNotePayable",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ConvertibleNotesDetails",
      "http://www.cleaninccom/role/NotesPayableDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "clnn_ConvertibleNotesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes (Details) [Line Items]"
       }
      }
     },
     "localname": "ConvertibleNotesDetailsLineItems",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_ConvertibleNotesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes (Details) [Table]"
       }
      }
     },
     "localname": "ConvertibleNotesDetailsTable",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_ConvertibleNotesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes Disclosure [Abstract]"
       }
      }
     },
     "localname": "ConvertibleNotesDisclosureAbstract",
     "nsuri": "http://www.cleaninccom/20210930",
     "xbrltype": "stringItemType"
    },
    "clnn_ConvertibleNotesDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ConvertibleNotesDisclosureTextBlock",
        "terseLabel": "Convertible Notes"
       }
      }
     },
     "localname": "ConvertibleNotesDisclosureTextBlock",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ConvertibleNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "clnn_ConvertibleNotesPayableDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of convertible notes payable.",
        "label": "ConvertibleNotesPayableDescription",
        "terseLabel": "Convertible notes payable, description"
       }
      }
     },
     "localname": "ConvertibleNotesPayableDescription",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_ConvertibleNotesPayables": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofsecuritiesexcludedfromcomputationofdilutednetincomelosspershareTable": {
       "order": 7.0,
       "parentTag": "clnn_TotalDilutiveSecurities",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible notes payable",
        "label": "ConvertibleNotesPayables",
        "terseLabel": "Convertible notes payable (see Note 11)"
       }
      }
     },
     "localname": "ConvertibleNotesPayables",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofsecuritiesexcludedfromcomputationofdilutednetincomelosspershareTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_ConvertibleNotespolicytextblock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Notes.",
        "label": "ConvertibleNotespolicytextblock",
        "terseLabel": "Convertible Notes"
       }
      }
     },
     "localname": "ConvertibleNotespolicytextblock",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "clnn_CouponInterestExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coupon interest expense.",
        "label": "CouponInterestExpense",
        "terseLabel": "Coupon interest expense"
       }
      }
     },
     "localname": "CouponInterestExpense",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_DebtDiscountAndIssuanceCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.",
        "label": "DebtDiscountAndIssuanceCostsPolicyTextBlock",
        "terseLabel": "Debt Discounts, Debt Premiums, and Debt Issuance Costs"
       }
      }
     },
     "localname": "DebtDiscountAndIssuanceCostsPolicyTextBlock",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "clnn_DebtInstrumentFinancingCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "DebtInstrumentFinancingCosts",
        "terseLabel": "Financing costs"
       }
      }
     },
     "localname": "DebtInstrumentFinancingCosts",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/NotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_DebtInstrumentThereafter": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleoffuturepaymentsnetofunamortizeddebtdiscountsTable": {
       "order": 7.0,
       "parentTag": "clnn_FuturePrincipalPayments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loans to be paid after fifth fiscal year following current fiscal year.",
        "label": "DebtInstrumentThereafter",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "DebtInstrumentThereafter",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoffuturepaymentsnetofunamortizeddebtdiscountsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_DebtInstrumentUnamortizedDiscountRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleoffuturepaymentsnetofunamortizeddebtdiscountsTable": {
       "order": 1.0,
       "parentTag": "clnn_FuturePrincipalPayments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loans to be paid in remainder of current fiscal year.",
        "label": "DebtInstrumentUnamortizedDiscountRemainderOfFiscalYear",
        "terseLabel": "2021 (remainder)"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountRemainderOfFiscalYear",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoffuturepaymentsnetofunamortizeddebtdiscountsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_DebtInstrumentUnamortizedDiscountYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleoffuturepaymentsnetofunamortizeddebtdiscountsTable": {
       "order": 6.0,
       "parentTag": "clnn_FuturePrincipalPayments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loans to be paid in fifth fiscal year following current fiscal year.",
        "label": "DebtInstrumentUnamortizedDiscountYearFive",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountYearFive",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoffuturepaymentsnetofunamortizeddebtdiscountsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_DebtInstrumentUnamortizedDiscountYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleoffuturepaymentsnetofunamortizeddebtdiscountsTable": {
       "order": 5.0,
       "parentTag": "clnn_FuturePrincipalPayments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loan to be paid in fourth fiscal year following current fiscal year.",
        "label": "DebtInstrumentUnamortizedDiscountYearFour",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountYearFour",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoffuturepaymentsnetofunamortizeddebtdiscountsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_DebtInstrumentUnamortizedDiscountYearOne": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleoffuturepaymentsnetofunamortizeddebtdiscountsTable": {
       "order": 2.0,
       "parentTag": "clnn_FuturePrincipalPayments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loans to be paid in next fiscal year following current fiscal year.",
        "label": "DebtInstrumentUnamortizedDiscountYearOne",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountYearOne",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoffuturepaymentsnetofunamortizeddebtdiscountsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_DebtInstrumentUnamortizedDiscountYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleoffuturepaymentsnetofunamortizeddebtdiscountsTable": {
       "order": 4.0,
       "parentTag": "clnn_FuturePrincipalPayments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loan to be paid in third fiscal year following current fiscal year.",
        "label": "DebtInstrumentUnamortizedDiscountYearThree",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountYearThree",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoffuturepaymentsnetofunamortizeddebtdiscountsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_DebtInstrumentUnamortizedDiscountYearTwo": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleoffuturepaymentsnetofunamortizeddebtdiscountsTable": {
       "order": 3.0,
       "parentTag": "clnn_FuturePrincipalPayments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loan to be paid in second fiscal year following current fiscal year.",
        "label": "DebtInstrumentUnamortizedDiscountYearTwo",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountYearTwo",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoffuturepaymentsnetofunamortizeddebtdiscountsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_DebtInstrumentUnfundedBalance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument unfunded amount.",
        "label": "DebtInstrumentUnfundedBalance",
        "terseLabel": "Unfunded amount"
       }
      }
     },
     "localname": "DebtInstrumentUnfundedBalance",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/NotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_DebtWithWarrantsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt with warrants.",
        "label": "DebtWithWarrantsPolicyTextBlock",
        "terseLabel": "Debt With Warrants"
       }
      }
     },
     "localname": "DebtWithWarrantsPolicyTextBlock",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "clnn_December20201Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "December20201Member",
        "terseLabel": "December 2020 One [Member]"
       }
      }
     },
     "localname": "December20201Member",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofoutstandingwarrantstopurchasesharesofcommonstockTable"
     ],
     "xbrltype": "domainItemType"
    },
    "clnn_DeferredGrantFunds": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofaccruedliabilitiesTable": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred grant funds",
        "label": "DeferredGrantFunds",
        "terseLabel": "Deferred grant funds"
       }
      }
     },
     "localname": "DeferredGrantFunds",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofaccruedliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_DeferredOfferingCostsInAccruedLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred offering costs in accrued liabilities.",
        "label": "DeferredOfferingCostsInAccruedLiabilities",
        "terseLabel": "Deferred offering costs in accrued liabilities"
       }
      }
     },
     "localname": "DeferredOfferingCostsInAccruedLiabilities",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_DerivativeInstrumentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DerivativeInstrumentMember",
        "terseLabel": "Derivative Instrument [Member]"
       }
      }
     },
     "localname": "DerivativeInstrumentMember",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "clnn_DescriptionOfConvertibleNotes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DescriptionOfConvertibleNotes",
        "terseLabel": "Description of convertible notes"
       }
      }
     },
     "localname": "DescriptionOfConvertibleNotes",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_DescriptionOfLossOnExtinguishment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of loss on extinguishment.",
        "label": "DescriptionOfLossOnExtinguishment",
        "terseLabel": "Description of loss on extinguishment"
       }
      }
     },
     "localname": "DescriptionOfLossOnExtinguishment",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_DirectorsOfficersInsurance": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofprepaidexpensesandothercurrentassetsTable": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Directors &amp; Officers Insurance.",
        "label": "DirectorsOfficersInsurance",
        "terseLabel": "Directors &amp; Officers Insurance"
       }
      }
     },
     "localname": "DirectorsOfficersInsurance",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofprepaidexpensesandothercurrentassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.cleaninccom/20210930",
     "xbrltype": "stringItemType"
    },
    "clnn_DrugsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DrugsMember",
        "terseLabel": "Drugs [Member]"
       }
      }
     },
     "localname": "DrugsMember",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofdrugsandsupplementssegmentsTable",
      "http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetbysegmentTable"
     ],
     "xbrltype": "domainItemType"
    },
    "clnn_EffectOfPotentiallyDilutiveConvertibleNotesPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofbasicanddilutednetlosspershareTable": {
       "order": 4.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effect of potentially dilutive convertible notes payable.",
        "label": "EffectOfPotentiallyDilutiveConvertibleNotesPayable",
        "terseLabel": "Effect of potentially dilutive convertible notes payable"
       }
      }
     },
     "localname": "EffectOfPotentiallyDilutiveConvertibleNotesPayable",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofbasicanddilutednetlosspershareTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_EffectOfPotentiallyDilutiveRestrictedStockAwards": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofbasicanddilutednetlosspershareTable": {
       "order": 3.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effect of potentially dilutive restricted stock awards.",
        "label": "EffectOfPotentiallyDilutiveRestrictedStockAwards",
        "terseLabel": "Effect of potentially dilutive common stock warrants"
       }
      }
     },
     "localname": "EffectOfPotentiallyDilutiveRestrictedStockAwards",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofbasicanddilutednetlosspershareTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_EffectOfPotentiallyDilutiveStockOptionsinDollars": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofbasicanddilutednetlosspershareTable": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effect of potentially dilutive stock options.",
        "label": "EffectOfPotentiallyDilutiveStockOptionsinDollars",
        "terseLabel": "Effect of potentially dilutive stock options"
       }
      }
     },
     "localname": "EffectOfPotentiallyDilutiveStockOptionsinDollars",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofbasicanddilutednetlosspershareTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_EffectOfPotentiallyDilutiveUnvestedRestrictedStockAwardsShares": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofbasicanddilutednetlosspershareTable": {
       "order": 5.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effect of potentially dilutive unvested restricted stock awards.",
        "label": "EffectOfPotentiallyDilutiveUnvestedRestrictedStockAwardsShares",
        "terseLabel": "Effect of potentially dilutive restricted stock awards"
       }
      }
     },
     "localname": "EffectOfPotentiallyDilutiveUnvestedRestrictedStockAwardsShares",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofbasicanddilutednetlosspershareTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_ExchangeOfSharesReceived": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange of shares received.",
        "label": "ExchangeOfSharesReceived",
        "terseLabel": "Common stock, share issued"
       }
      }
     },
     "localname": "ExchangeOfSharesReceived",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_ExchangeRatioPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange Ratio Percentage.",
        "label": "ExchangeRatioPercentage",
        "terseLabel": "Exchange ratio percentage"
       }
      }
     },
     "localname": "ExchangeRatioPercentage",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "clnn_ExclusiveRightsIntellectualPropertyTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive rights intellectual property term.",
        "label": "ExclusiveRightsIntellectualPropertyTerm",
        "terseLabel": "Exclusive rights intellectual property term"
       }
      }
     },
     "localname": "ExclusiveRightsIntellectualPropertyTerm",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "clnn_ExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ExercisePrice",
        "terseLabel": "Exercise price (in Dollars per share)"
       }
      }
     },
     "localname": "ExercisePrice",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clnn_ExercisePriceOfWarrantsDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of warrants exercise price.",
        "label": "ExercisePriceOfWarrantsDescription",
        "terseLabel": "Exercise price of warrants, description"
       }
      }
     },
     "localname": "ExercisePriceOfWarrantsDescription",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_ExercisePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share.",
        "label": "ExercisePricePerShare",
        "terseLabel": "Exercise price per share (in Dollars per share)"
       }
      }
     },
     "localname": "ExercisePricePerShare",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clnn_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extinguishment of derivative liability in connection with extinguishment of convertible promissory notes.",
        "label": "ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN",
        "terseLabel": "Extinguishment of derivative liability in connection with extinguishment of convertible promissory notes"
       }
      }
     },
     "localname": "ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_FairValueAdjustmentOfWarrantsOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant outstanding liability.",
        "label": "FairValueAdjustmentOfWarrantsOutstanding",
        "terseLabel": "Fair value of the outstanding warrants"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrantsOutstanding",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/PreferredStockWarrantLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_FairValueAmortizedCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value amortized cost.",
        "label": "FairValueAmortizedCost",
        "terseLabel": "Fair value amortized cost"
       }
      }
     },
     "localname": "FairValueAmortizedCost",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/FairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_FairValueDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value (Details) [Line Items]"
       }
      }
     },
     "localname": "FairValueDetailsLineItems",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/FairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value (Details) - Schedule of changes in fair value of financial liabilities related to the notes payable, the derivative instrument, the preferred stock warrants, and the contingent earn-outs [Line Items]"
       }
      }
     },
     "localname": "FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsLineItems",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value (Details) - Schedule of changes in fair value of financial liabilities related to the notes payable, the derivative instrument, the preferred stock warrants, and the contingent earn-outs [Table]"
       }
      }
     },
     "localname": "FairValueDetailsScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsTable",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value (Details) - Schedule of fair value hierarchy of liabilities measured at fair value on recurring basis [Line Items]"
       }
      }
     },
     "localname": "FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisLineItems",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value (Details) - Schedule of fair value hierarchy of liabilities measured at fair value on recurring basis [Table]"
       }
      }
     },
     "localname": "FairValueDetailsScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_FairValueDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value (Details) [Table]"
       }
      }
     },
     "localname": "FairValueDetailsTable",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/FairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_FairValueIssuanceOfConvertiblePromissoryNotes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This value for issuance of convertible promissory notes.",
        "label": "FairValueIssuanceOfConvertiblePromissoryNotes",
        "terseLabel": "Issuance of convertible promissory notes"
       }
      }
     },
     "localname": "FairValueIssuanceOfConvertiblePromissoryNotes",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_FairValueMeasurementExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This value for extinguishment of derivative liability in connection with extinguishment of convertible promissory note.",
        "label": "FairValueMeasurementExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN",
        "terseLabel": "Extinguishment of derivative liability in connection with extinguishment of convertible promissory notes"
       }
      }
     },
     "localname": "FairValueMeasurementExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_FairValueOfConvertibleNotesPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of notes payable.",
        "label": "FairValueOfConvertibleNotesPayable",
        "terseLabel": "Fair value of the convertible notes payable"
       }
      }
     },
     "localname": "FairValueOfConvertibleNotesPayable",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/FairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_FairValueOfLongTermNotesPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of principal and accrued interest is included in long-term notes payable.",
        "label": "FairValueOfLongTermNotesPayable",
        "terseLabel": "Fair value of long-term notes payable"
       }
      }
     },
     "localname": "FairValueOfLongTermNotesPayable",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/NotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_FairValueOfWarrant": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of warrant.",
        "label": "FairValueOfWarrant",
        "terseLabel": "Fair value of warrant"
       }
      }
     },
     "localname": "FairValueOfWarrant",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/NotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of finance and operating lease liability maturity.",
        "label": "FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock",
        "terseLabel": "Schedule of noncancelable operating lease arrangements"
       }
      }
     },
     "localname": "FinanceAndOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "clnn_FinanceCashFlowsFromFinanceLeases": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "FinanceCashFlowsFromFinanceLeases",
        "terseLabel": "Financing cash flows from finance leases"
       }
      }
     },
     "localname": "FinanceCashFlowsFromFinanceLeases",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofsupplementalcashflowinformationTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_FinanceLeaseByMajorClassPropertyAndEquipmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Finance lease by major class property and equipment.",
        "label": "FinanceLeaseByMajorClassPropertyAndEquipmentTableTextBlock",
        "terseLabel": "Schedule of finance lease obligations included in property and equipment"
       }
      }
     },
     "localname": "FinanceLeaseByMajorClassPropertyAndEquipmentTableTextBlock",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "clnn_FinanceLeaseFurnitureAndFixturesGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleoffinanceleaseobligationsincludedinpropertyandequipmentTable": {
       "order": 2.0,
       "parentTag": "clnn_FinanceLeaseLiabilityGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance lease furniture and fixtures.",
        "label": "FinanceLeaseFurnitureAndFixturesGross",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FinanceLeaseFurnitureAndFixturesGross",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoffinanceleaseobligationsincludedinpropertyandequipmentTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_FinanceLeaseLaboratoryEquipmentGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleoffinanceleaseobligationsincludedinpropertyandequipmentTable": {
       "order": 1.0,
       "parentTag": "clnn_FinanceLeaseLiabilityGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance lease laboratory equipment.",
        "label": "FinanceLeaseLaboratoryEquipmentGross",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "FinanceLeaseLaboratoryEquipmentGross",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoffinanceleaseobligationsincludedinpropertyandequipmentTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_FinanceLeaseLiabilityGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleoffinanceleaseobligationsincludedinpropertyandequipmentTable": {
       "order": 1.0,
       "parentTag": "clnn_FinanceLeaseLiabilityNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance lease liability.",
        "label": "FinanceLeaseLiabilityGross",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityGross",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoffinanceleaseobligationsincludedinpropertyandequipmentTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_FinanceLeaseLiabilityNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleoffinanceleaseobligationsincludedinpropertyandequipmentTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance lease liability, net.",
        "label": "FinanceLeaseLiabilityNet",
        "totalLabel": "Net"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNet",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoffinanceleaseobligationsincludedinpropertyandequipmentTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_FinanceLeaseObligationsWeightedaverageInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance lease obligations weighted-average interest rate.",
        "label": "FinanceLeaseObligationsWeightedaverageInterestRate",
        "terseLabel": "Finance lease obligations weighted-average interest rate"
       }
      }
     },
     "localname": "FinanceLeaseObligationsWeightedaverageInterestRate",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/LeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "clnn_FinanceLeaseWorkInProcessGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleoffinanceleaseobligationsincludedinpropertyandequipmentTable": {
       "order": 3.0,
       "parentTag": "clnn_FinanceLeaseLiabilityGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance lease work in process.",
        "label": "FinanceLeaseWorkInProcessGross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "FinanceLeaseWorkInProcessGross",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoffinanceleaseobligationsincludedinpropertyandequipmentTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_FinanceLeasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FinanceLeasesMember",
        "terseLabel": "Finance Leases [Member]"
       }
      }
     },
     "localname": "FinanceLeasesMember",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "clnn_ForeignCurrencyTranslationAdjustment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "ForeignCurrencyTranslationAdjustment",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "ForeignCurrencyTranslationAdjustment",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_FundedAmountAtClosing": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FundedAmountAtClosing",
        "label": "FundedAmountAtClosing",
        "terseLabel": "Funded amount"
       }
      }
     },
     "localname": "FundedAmountAtClosing",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/NotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_FuturePrincipalPayments": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleoffuturepaymentsnetofunamortizeddebtdiscountsTable": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of future principal payments.",
        "label": "FuturePrincipalPayments",
        "totalLabel": "Subtotal of future principal payments"
       }
      }
     },
     "localname": "FuturePrincipalPayments",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoffuturepaymentsnetofunamortizeddebtdiscountsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_GainOnExtinguishmentOfNotesPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement": {
       "order": 9.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain on extinguishment of notes payable",
        "label": "GainOnExtinguishmentOfNotesPayable",
        "negatedLabel": "Gain on extinguishment of notes payable"
       }
      }
     },
     "localname": "GainOnExtinguishmentOfNotesPayable",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_GainlossOnCleneNanomedicineContingentEarnout": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents the gain (loss) on Clene Nanomedicine contingent earn-out.",
        "label": "GainlossOnCleneNanomedicineContingentEarnout",
        "terseLabel": "Gain (loss) on Clene Nanomedicine contingent earn-out"
       }
      }
     },
     "localname": "GainlossOnCleneNanomedicineContingentEarnout",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_GainlossOnInitialShareholdersContingentEarnout": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents amount of gain (loss) on Initial Shareholders contingent earn-out.",
        "label": "GainlossOnInitialShareholdersContingentEarnout",
        "terseLabel": "Gain (loss) on Initial Shareholders contingent earn-out"
       }
      }
     },
     "localname": "GainlossOnInitialShareholdersContingentEarnout",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographic and Segment Information (Details) - Schedule of property and equipment, net by location [Line Items]"
       }
      }
     },
     "localname": "GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationLineItems",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetbylocationTable"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographic and Segment Information (Details) - Schedule of property and equipment, net by location [Table]"
       }
      }
     },
     "localname": "GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbylocationTable",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetbylocationTable"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographic and Segment Information (Details) - Schedule of property and equipment, net by segment [Line Items]"
       }
      }
     },
     "localname": "GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentLineItems",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetbysegmentTable"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographic and Segment Information (Details) - Schedule of property and equipment, net by segment [Table]"
       }
      }
     },
     "localname": "GeographicandSegmentInformationDetailsScheduleofpropertyandequipmentnetbysegmentTable",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetbysegmentTable"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_GrantFundingPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant Funding Policy.",
        "label": "GrantFundingPolicyTextBlock",
        "terseLabel": "Grant Funding"
       }
      }
     },
     "localname": "GrantFundingPolicyTextBlock",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "clnn_GrantFundingRecognizedOnConditionalGrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant funding recognized on conditional grants.",
        "label": "GrantFundingRecognizedOnConditionalGrants",
        "terseLabel": "Grant funding recognized on conditional grants"
       }
      }
     },
     "localname": "GrantFundingRecognizedOnConditionalGrants",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_IncreaseInCleneNanomedicineContingentEarnoutSharesUponReverseRecapitalization": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in clene nanomedicine contingent earnout shares upon reverse recapitalization.",
        "label": "IncreaseInCleneNanomedicineContingentEarnoutSharesUponReverseRecapitalization",
        "terseLabel": "Increase in clene nanomedicine contingent earnout shares upon reverse recapitalization"
       }
      }
     },
     "localname": "IncreaseInCleneNanomedicineContingentEarnoutSharesUponReverseRecapitalization",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_IncreaseInInterestAccruedOnNotesPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedCashFlow": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in interest accrued on notes payable.",
        "label": "IncreaseInInterestAccruedOnNotesPayable",
        "terseLabel": "Increase (decrease) in interest accrued on notes payable"
       }
      }
     },
     "localname": "IncreaseInInterestAccruedOnNotesPayable",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_IncreaseInLeaseLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of increase in lease liability.",
        "label": "IncreaseInLeaseLiability",
        "terseLabel": "Increase in lease liability"
       }
      }
     },
     "localname": "IncreaseInLeaseLiability",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_IncreaseInLeaseholdImprovements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of Increase in leasehold improvements.",
        "label": "IncreaseInLeaseholdImprovements",
        "terseLabel": "Increase in leasehold imrovements"
       }
      }
     },
     "localname": "IncreaseInLeaseholdImprovements",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_IncreaseInRightOfUseAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of Increase in right of use assets.",
        "label": "IncreaseInRightOfUseAssets",
        "terseLabel": "Increase in right of use assets"
       }
      }
     },
     "localname": "IncreaseInRightOfUseAssets",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_IncreseDecreaseInFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This value for change in fair value.",
        "label": "IncreseDecreaseInFairValue",
        "terseLabel": "Change in fair value"
       }
      }
     },
     "localname": "IncreseDecreaseInFairValue",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_InitialFairValueOfInstrument": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This value for initial fair value of instrument.",
        "label": "InitialFairValueOfInstrument",
        "terseLabel": "Initial fair value of instrument"
       }
      }
     },
     "localname": "InitialFairValueOfInstrument",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_InitialShareholdersContingentEarnout": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet": {
       "order": 9.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial Shareholders contingent earn-out.",
        "label": "InitialShareholdersContingentEarnout",
        "terseLabel": "Initial Shareholders contingent earn-out"
       }
      }
     },
     "localname": "InitialShareholdersContingentEarnout",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_InitialShareholdersContingentEarnoutFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial shareholders contingent earnout fair value disclosure.",
        "label": "InitialShareholdersContingentEarnoutFairValueDisclosure",
        "terseLabel": "Initial Shareholders contingent earn-out"
       }
      }
     },
     "localname": "InitialShareholdersContingentEarnoutFairValueDisclosure",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_InitialShareholdersContingentEarnoutMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial Shareholders Contingent Earn-out [Member].",
        "label": "InitialShareholdersContingentEarnoutMember",
        "terseLabel": "Initial Shareholders Contingent Earn-out [Member]"
       }
      }
     },
     "localname": "InitialShareholdersContingentEarnoutMember",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "clnn_InitialShareholdersContingentEarnoutMilestone1Shares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial shareholders contingent earnout milestone1 shares.",
        "label": "InitialShareholdersContingentEarnoutMilestone1Shares",
        "terseLabel": "Initial shareholders contingent earnout milestone1 shares"
       }
      }
     },
     "localname": "InitialShareholdersContingentEarnoutMilestone1Shares",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_InitialShareholdersContingentEarnoutMilestone2Shares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial shareholders contingent earnout milestone 2 shares.",
        "label": "InitialShareholdersContingentEarnoutMilestone2Shares",
        "terseLabel": "Initial shareholders contingent earnout milestone 2 shares"
       }
      }
     },
     "localname": "InitialShareholdersContingentEarnoutMilestone2Shares",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_InitialShareholdersContingentEarnoutShares": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofsecuritiesexcludedfromcomputationofdilutednetincomelosspershareTable": {
       "order": 13.0,
       "parentTag": "clnn_TotalDilutiveSecurities",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial shareholders contingent earnout shares.",
        "label": "InitialShareholdersContingentEarnoutShares",
        "terseLabel": "Initial Shareholders contingent earn-out shares (see Note 3 and 12)"
       }
      }
     },
     "localname": "InitialShareholdersContingentEarnoutShares",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofsecuritiesexcludedfromcomputationofdilutednetincomelosspershareTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_InitialShareholdersContingentsEarnout": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents of initial shareholders contingents earnout.",
        "label": "InitialShareholdersContingentsEarnout",
        "terseLabel": "Initial shareholders earn-out shares"
       }
      }
     },
     "localname": "InitialShareholdersContingentsEarnout",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_InterestIncomeexpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement": {
       "order": 8.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income (expense).",
        "label": "InterestIncomeexpense",
        "negatedLabel": "Interest income (expense)"
       }
      }
     },
     "localname": "InterestIncomeexpense",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_InterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Rate.",
        "label": "InterestRate",
        "terseLabel": "Interest Rate"
       }
      }
     },
     "localname": "InterestRate",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoflongtermdebtnetoforiginalissuediscountandunamortizeddebtissuancecostsTable"
     ],
     "xbrltype": "percentItemType"
    },
    "clnn_IntrinsicValueStockOptionsVestedAndExpectedToVestIntrinsicValueOptionsV": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "IntrinsicValueStockOptionsVestedAndExpectedToVestIntrinsicValueOptionsV",
        "terseLabel": "Intrinsic Value, Stock options vested and expected to vest"
       }
      }
     },
     "localname": "IntrinsicValueStockOptionsVestedAndExpectedToVestIntrinsicValueOptionsV",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofoutstandingcommonstockoptionsandrelatedactivityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_InvestorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "InvestorsMember",
        "terseLabel": "PIPE investors [Member]",
        "verboseLabel": "Investors [Member]"
       }
      }
     },
     "localname": "InvestorsMember",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clnn_InvestorsPurchasedShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of share investors purchased shares.",
        "label": "InvestorsPurchasedShares",
        "terseLabel": "Investors purchased shares"
       }
      }
     },
     "localname": "InvestorsPurchasedShares",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_IssuanceOfCommonStockUponReverseRecapitalization": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IssuanceOfCommonStockUponReverseRecapitalization",
        "terseLabel": "Issuance of common stock upon the reverse recapitalization"
       }
      }
     },
     "localname": "IssuanceOfCommonStockUponReverseRecapitalization",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of Series D Preferred Stock upon extinguishment of convertible promissory notes.",
        "label": "IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes",
        "terseLabel": "Issuance of Series D Preferred Stock upon extinguishment of convertible promissory notes"
       }
      }
     },
     "localname": "IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_LeaseIncentiveRecordedConstructionInProgress": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease incentive recorded construction in progress.",
        "label": "LeaseIncentiveRecordedConstructionInProgress",
        "terseLabel": "Lease incentive recorded construction in progress"
       }
      }
     },
     "localname": "LeaseIncentiveRecordedConstructionInProgress",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_LeaseLiabilitySettledThroughTerminationOfLease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease liability settled through termination of lease.",
        "label": "LeaseLiabilitySettledThroughTerminationOfLease",
        "terseLabel": "Lease liability settled through termination of lease"
       }
      }
     },
     "localname": "LeaseLiabilitySettledThroughTerminationOfLease",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_LeaseholdImprovements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount held additions or improvements to assets held under a lease arrangement.",
        "label": "LeaseholdImprovements",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovements",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details)"
       }
      }
     },
     "localname": "LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesLineItems",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) - Schedule of noncancelable finance and operating lease liabilities [Table]"
       }
      }
     },
     "localname": "LeasesDetailsScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_LifeSciCapitalLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LifeSciCapitalLLCMember",
        "terseLabel": "LifeSci Capital LLC [Member]"
       }
      }
     },
     "localname": "LifeSciCapitalLLCMember",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clnn_LoanOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Outstanding.",
        "label": "LoanOutstanding",
        "terseLabel": "Loan outstanding"
       }
      }
     },
     "localname": "LoanOutstanding",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_LossInFairValueOfWarrantLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents the amount of loss in fair value of warrant liability.",
        "label": "LossInFairValueOfWarrantLiability",
        "terseLabel": "Loss in fair value of warrant liability"
       }
      }
     },
     "localname": "LossInFairValueOfWarrantLiability",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/PreferredStockWarrantLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_LossOnDerivativeInstruments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents the amount of loss on derivative instruments.",
        "label": "LossOnDerivativeInstruments",
        "terseLabel": "Loss on derivative instruments"
       }
      }
     },
     "localname": "LossOnDerivativeInstruments",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_LossOnExtinguishmentOfConvertibleNotesPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement": {
       "order": 10.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss on extinguishment of convertible notes payable.",
        "label": "LossOnExtinguishmentOfConvertibleNotesPayable",
        "negatedLabel": "Loss on extinguishment of convertible notes payable"
       }
      }
     },
     "localname": "LossOnExtinguishmentOfConvertibleNotesPayable",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_MarylandDepartmentOfHousingCommunityDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MarylandDepartmentOfHousingCommunityDevelopmentMember",
        "terseLabel": "Maryland Department of Housing &amp; Community Development [Member]"
       }
      }
     },
     "localname": "MarylandDepartmentOfHousingCommunityDevelopmentMember",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoflongtermdebtnetoforiginalissuediscountandunamortizeddebtissuancecostsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "clnn_May2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "May2021Member",
        "terseLabel": "May 2021 [Member]"
       }
      }
     },
     "localname": "May2021Member",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofoutstandingwarrantstopurchasesharesofcommonstockTable"
     ],
     "xbrltype": "domainItemType"
    },
    "clnn_MetalsToBeUsedInResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofprepaidexpensesandothercurrentassetsTable": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Metals to be used in research and development",
        "label": "MetalsToBeUsedInResearchAndDevelopment",
        "terseLabel": "Metals to be used in research and development"
       }
      }
     },
     "localname": "MetalsToBeUsedInResearchAndDevelopment",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofprepaidexpensesandothercurrentassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_MinimumCashBalanceForLoanCovenant": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of minimum cash balance for loan covenant.",
        "label": "MinimumCashBalanceForLoanCovenant",
        "terseLabel": "Minimum cash balance for loan covenant"
       }
      }
     },
     "localname": "MinimumCashBalanceForLoanCovenant",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/NotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_MinimumFairMarketValueOfOptionGrantDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of minimum fair market value of option grant.",
        "label": "MinimumFairMarketValueOfOptionGrantDescription",
        "terseLabel": "Minimum fair market value of option grant, description"
       }
      }
     },
     "localname": "MinimumFairMarketValueOfOptionGrantDescription",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_MonteCarloSimulationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MonteCarloSimulationMember",
        "terseLabel": "Monte Carlo Simulation [Member]"
       }
      }
     },
     "localname": "MonteCarloSimulationMember",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofunobservableinputstotheconversionfeaturewarrantliabilityandcontingentearnoutvaluationmodelsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "clnn_NatureoftheBusinessDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of the Business [Line Items]"
       }
      }
     },
     "localname": "NatureoftheBusinessDetailsLineItems",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/NatureoftheBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_NatureoftheBusinessDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of the Business (Details) [Table]"
       }
      }
     },
     "localname": "NatureoftheBusinessDetailsTable",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/NatureoftheBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_NetIncomeLossPerCommonShareAttributableToCommonShareholdersNote191Abstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NetIncomeLossPerCommonShareAttributableToCommonShareholdersNote191Abstract",
        "terseLabel": "Net income (loss) per common share attributable to common shareholders (Note 19)(1):"
       }
      }
     },
     "localname": "NetIncomeLossPerCommonShareAttributableToCommonShareholdersNote191Abstract",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_NetIncomeLossPerShareAttributableToCommonShareholdersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NetIncomeLossPerShareAttributableToCommonShareholdersMember",
        "terseLabel": "Net Income (Loss) Per Share Attributable to Common Shareholders [Member]"
       }
      }
     },
     "localname": "NetIncomeLossPerShareAttributableToCommonShareholdersMember",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofbasicanddilutednetlosspershareTable"
     ],
     "xbrltype": "domainItemType"
    },
    "clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Per Share Attributable to Common Shareholders (Details) [Line Items]"
       }
      }
     },
     "localname": "NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsLineItems",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/NetIncomeLossPerShareAttributabletoCommonShareholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Per Share Attributable to Common Shareholders (Details) - Schedule of basic and diluted net loss per share [Line Items]"
       }
      }
     },
     "localname": "NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareLineItems",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofbasicanddilutednetlosspershareTable"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Per Share Attributable to Common Shareholders (Details) - Schedule of basic and diluted net loss per share [Table]"
       }
      }
     },
     "localname": "NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsScheduleofbasicanddilutednetlosspershareTable",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofbasicanddilutednetlosspershareTable"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Per Share Attributable to Common Shareholders (Details) [Table]"
       }
      }
     },
     "localname": "NetIncomeLossPerShareAttributabletoCommonShareholdersDetailsTable",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/NetIncomeLossPerShareAttributabletoCommonShareholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_NetIssuanceShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net issuance shares.",
        "label": "NetIssuanceShares",
        "terseLabel": "Net issuance shares"
       }
      }
     },
     "localname": "NetIssuanceShares",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_NetIssuanceSharesOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net issuance shares of common stock.",
        "label": "NetIssuanceSharesOfCommonStock",
        "terseLabel": "Net issuance shares of common stock"
       }
      }
     },
     "localname": "NetIssuanceSharesOfCommonStock",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_NetIssuanceWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net issuance warrants in shares.",
        "label": "NetIssuanceWarrants",
        "terseLabel": "Net issuance warrants"
       }
      }
     },
     "localname": "NetIssuanceWarrants",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_NetOfIssuanceCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net of issuance costs.",
        "label": "NetOfIssuanceCosts",
        "terseLabel": "Net of issuance costs"
       }
      }
     },
     "localname": "NetOfIssuanceCosts",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ShareholdersEquityType2or3_Parentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_NetProceeds": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net proceeds.",
        "label": "NetProceeds",
        "terseLabel": "Net proceeds (in Dollars)"
       }
      }
     },
     "localname": "NetProceeds",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Accounting Pronouncements Not Yet Adopted Policy.",
        "label": "NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock",
        "terseLabel": "Recent Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "clnn_NotesPayableBasedOnClosingPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes payable based on closing price.",
        "label": "NotesPayableBasedOnClosingPrice",
        "terseLabel": "Notes payable based on closing price (in Dollars per share)"
       }
      }
     },
     "localname": "NotesPayableBasedOnClosingPrice",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/FairValueDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clnn_NotesPayableDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable (Details) [Line Items]"
       }
      }
     },
     "localname": "NotesPayableDetailsLineItems",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/NotesPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_NotesPayableDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable (Details) [Table]"
       }
      }
     },
     "localname": "NotesPayableDetailsTable",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/NotesPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_NumberOfSharesIssuable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Shares Issuable.",
        "label": "NumberOfSharesIssuable",
        "terseLabel": "Number of Shares Issuable"
       }
      }
     },
     "localname": "NumberOfSharesIssuable",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofoutstandingwarrantstopurchasesharesofcommonstockTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_OfferingCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OfferingCost",
        "label": "OfferingCost",
        "terseLabel": "Offering Cost"
       }
      }
     },
     "localname": "OfferingCost",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/NatureoftheBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_OfferingPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering price per share.",
        "label": "OfferingPricePerShare",
        "terseLabel": "Offering price per share (in Dollars per share)"
       }
      }
     },
     "localname": "OfferingPricePerShare",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/NatureoftheBusinessDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clnn_OperatingCashFlowsFromFinanceLeases": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "OperatingCashFlowsFromFinanceLeases",
        "terseLabel": "Operating cash flows from finance leases"
       }
      }
     },
     "localname": "OperatingCashFlowsFromFinanceLeases",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofsupplementalcashflowinformationTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_OperatingCashFlowsFromOperatingLeases": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "OperatingCashFlowsFromOperatingLeases",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingCashFlowsFromOperatingLeases",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofsupplementalcashflowinformationTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_OperatingLeaseObligationsWeightedAverageInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease obligations weighted average interest rate.",
        "label": "OperatingLeaseObligationsWeightedAverageInterestRate",
        "terseLabel": "Operating lease obligations weighted average interest rate"
       }
      }
     },
     "localname": "OperatingLeaseObligationsWeightedAverageInterestRate",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/LeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "clnn_OperatingLeaseRightofUseAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Right-of-Use Assets.",
        "label": "OperatingLeaseRightofUseAssets",
        "terseLabel": "Right-of-use assets value"
       }
      }
     },
     "localname": "OperatingLeaseRightofUseAssets",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_OperatingLeasesAmountRepresentingInterestdiscounting": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount representing interest/discounting.",
        "label": "OperatingLeasesAmountRepresentingInterestdiscounting",
        "negatedLabel": "Less amount representing interest/discounting"
       }
      }
     },
     "localname": "OperatingLeasesAmountRepresentingInterestdiscounting",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_OperatingLeasesLessFutureLeaseIncentives": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of less future lease incentives.",
        "label": "OperatingLeasesLessFutureLeaseIncentives",
        "terseLabel": "Less future lease incentives"
       }
      }
     },
     "localname": "OperatingLeasesLessFutureLeaseIncentives",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_OperatingLeasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OperatingLeasesMember",
        "terseLabel": "Operating Leases [Member]"
       }
      }
     },
     "localname": "OperatingLeasesMember",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "clnn_OptionsToPurchaseCommonStockinShares": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofsecuritiesexcludedfromcomputationofdilutednetincomelosspershareTable": {
       "order": 9.0,
       "parentTag": "clnn_TotalDilutiveSecurities",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "OptionsToPurchaseCommonStockinShares",
        "terseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "OptionsToPurchaseCommonStockinShares",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofsecuritiesexcludedfromcomputationofdilutednetincomelosspershareTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_OtherTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OtherTermLoanMember",
        "terseLabel": "Other [Member]"
       }
      }
     },
     "localname": "OtherTermLoanMember",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoflongtermdebtnetoforiginalissuediscountandunamortizeddebtissuancecostsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "clnn_PIPEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PIPEMember",
        "terseLabel": "PIPE [Member]"
       }
      }
     },
     "localname": "PIPEMember",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/NatureoftheBusinessDetails",
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clnn_PIPEWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PIPEWarrantsMember",
        "terseLabel": "PIPE Warrants [Member]"
       }
      }
     },
     "localname": "PIPEWarrantsMember",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockWarrantsDetails",
      "http://www.cleaninccom/role/NetIncomeLossPerShareAttributabletoCommonShareholdersDetails",
      "http://www.cleaninccom/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clnn_PIPEWarrantsOwnershipLimit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of PIPE warrants ownership limit.",
        "label": "PIPEWarrantsOwnershipLimit",
        "terseLabel": "PIPE warrants ownership limit"
       }
      }
     },
     "localname": "PIPEWarrantsOwnershipLimit",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_PaycheckProtectionProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PaycheckProtectionProgramMember",
        "terseLabel": "Paycheck Protection Program [Member]"
       }
      }
     },
     "localname": "PaycheckProtectionProgramMember",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoflongtermdebtnetoforiginalissuediscountandunamortizeddebtissuancecostsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "clnn_PaycheckProtectionProgramNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PaycheckProtectionProgramNoteMember",
        "terseLabel": "PPP Note [Member]"
       }
      }
     },
     "localname": "PaycheckProtectionProgramNoteMember",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/NotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clnn_PercentOfFullydilutedEquityPurchasableUponExercise": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percent of fully-diluted equity purchasable upon exercise.",
        "label": "PercentOfFullydilutedEquityPurchasableUponExercise",
        "terseLabel": "Percent of fully-diluted equity purchasable upon exercise"
       }
      }
     },
     "localname": "PercentOfFullydilutedEquityPurchasableUponExercise",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/PreferredStockWarrantLiabilityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "clnn_PercentageOfLoanAmountUsedToPayrollExpenses": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of loan amount used to payroll expenses.",
        "label": "PercentageOfLoanAmountUsedToPayrollExpenses",
        "terseLabel": "Percentage of loan amount used for payroll expenses"
       }
      }
     },
     "localname": "PercentageOfLoanAmountUsedToPayrollExpenses",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/NotesPayableDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "clnn_PercentageOfStockPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of stock price.",
        "label": "PercentageOfStockPrice",
        "terseLabel": "Percentage of stock price"
       }
      }
     },
     "localname": "PercentageOfStockPrice",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "clnn_PreferredStockShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Stock Shares.",
        "label": "PreferredStockShares",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockShares",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_PreferredStockWarrantLiabilityDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Warrant Liability (Details) [Line Items]"
       }
      }
     },
     "localname": "PreferredStockWarrantLiabilityDetailsLineItems",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/PreferredStockWarrantLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_PreferredStockWarrantLiabilityDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Warrant Liability (Details) [Table]"
       }
      }
     },
     "localname": "PreferredStockWarrantLiabilityDetailsTable",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/PreferredStockWarrantLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_PreferredStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PreferredStockWarrantsMember",
        "terseLabel": "Preferred Stock Warrants [Member]"
       }
      }
     },
     "localname": "PreferredStockWarrantsMember",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "clnn_PrepaidExpensesAndOtherCurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses And Other Current Assets [Abstract]"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsAbstract",
     "nsuri": "http://www.cleaninccom/20210930",
     "xbrltype": "stringItemType"
    },
    "clnn_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Expenses And Other Current Assets [TableTextBlock]",
        "label": "PrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
        "terseLabel": "Schedule of prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/PrepaidExpensesandOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "clnn_PrepaidExpensesAndOtherCurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for Prepaid expenses and other current assets.",
        "label": "PrepaidExpensesAndOtherCurrentAssetsTextBlock",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsTextBlock",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/PrepaidExpensesandOtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "clnn_PrivatePlacementWarrantsDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private placement warrants description.",
        "label": "PrivatePlacementWarrantsDescription",
        "terseLabel": "Private placement warrants description"
       }
      }
     },
     "localname": "PrivatePlacementWarrantsDescription",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_ProceedsFromReverseRecapitalization": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents of proceeds from reverse recapitalization.",
        "label": "ProceedsFromReverseRecapitalization",
        "terseLabel": "Proceeds from reverse recapitalization (in Dollars)"
       }
      }
     },
     "localname": "ProceedsFromReverseRecapitalization",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_PropertyandEquipmentNetDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, Net (Details) [Line Items]"
       }
      }
     },
     "localname": "PropertyandEquipmentNetDetailsLineItems",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_PropertyandEquipmentNetDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, Net (Details) [Table]"
       }
      }
     },
     "localname": "PropertyandEquipmentNetDetailsTable",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_PurchaseOptionUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unit purchase option shares.",
        "label": "PurchaseOptionUnits",
        "terseLabel": "Purchase option units"
       }
      }
     },
     "localname": "PurchaseOptionUnits",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_RateOfInterestDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of interest, Description",
        "label": "RateOfInterestDescription",
        "terseLabel": "Rate of interest, description"
       }
      }
     },
     "localname": "RateOfInterestDescription",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/NotesPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_RecapitalizationShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RecapitalizationShare",
        "terseLabel": "Issuance of common stock for advisory fees"
       }
      }
     },
     "localname": "RecapitalizationShare",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_RecognizedGainOnOperatingLease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recognized gain on operating lease.",
        "label": "RecognizedGainOnOperatingLease",
        "terseLabel": "Recognized gain on operating lease"
       }
      }
     },
     "localname": "RecognizedGainOnOperatingLease",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_RedeemableConvertiblePreferredStockDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable Convertible Preferred Stock (Details) [Line Items]"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockDetailsLineItems",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/RedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_RedeemableConvertiblePreferredStockDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable Convertible Preferred Stock (Details) [Table]"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockDetailsTable",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/RedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_RedeemableConvertiblePreferredStockDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable Convertible Preferred Stock Disclosure [Abstract]"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockDisclosureAbstract",
     "nsuri": "http://www.cleaninccom/20210930",
     "xbrltype": "stringItemType"
    },
    "clnn_RedeemableConvertiblePreferredStockDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Convertible Preferred Stock [Text Block].",
        "label": "RedeemableConvertiblePreferredStockDisclosureTextBlock",
        "terseLabel": "Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockDisclosureTextBlock",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/RedeemableConvertiblePreferredStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "clnn_RemainingRightofuseAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "RemainingRightofuseAsset",
        "terseLabel": "Terminated right-of-use asset"
       }
      }
     },
     "localname": "RemainingRightofuseAsset",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_RestrictedStockUnitsDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of Restricted Stock Units.",
        "label": "RestrictedStockUnitsDescription",
        "terseLabel": "Restricted stock units shares, description"
       }
      }
     },
     "localname": "RestrictedStockUnitsDescription",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_ReverseRecapitalizationExchangeRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reverse recapitalization exchange ratio.",
        "label": "ReverseRecapitalizationExchangeRatio",
        "terseLabel": "Reverse recapitalization exchange ratio"
       }
      }
     },
     "localname": "ReverseRecapitalizationExchangeRatio",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "clnn_ReverseRecapitalizationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ReverseRecapitalizationMember",
        "terseLabel": "Reverse recapitalization [Member]"
       }
      }
     },
     "localname": "ReverseRecapitalizationMember",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse Recapitalization With Tottenham And Clene Nanomedicine [Abstract]"
       }
      }
     },
     "localname": "ReverseRecapitalizationWithTottenhamAndCleneNanomedicineAbstract",
     "nsuri": "http://www.cleaninccom/20210930",
     "xbrltype": "stringItemType"
    },
    "clnn_ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock",
        "terseLabel": "Reverse Recapitalization with Tottenham and Clene Nanomedicine"
       }
      }
     },
     "localname": "ReverseRecapitalizationWithTottenhamAndCleneNanomedicineTextBlock",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicine"
     ],
     "xbrltype": "textBlockItemType"
    },
    "clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items]"
       }
      }
     },
     "localname": "ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Table]"
       }
      }
     },
     "localname": "ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsTable",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_RightOfUseAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "RightOfUseAssets",
        "terseLabel": "Right of use asset"
       }
      }
     },
     "localname": "RightOfUseAssets",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_RiskAndUncertaintiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk and Uncertainties.",
        "label": "RiskAndUncertaintiesPolicyTextBlock",
        "terseLabel": "Risks and Uncertainties"
       }
      }
     },
     "localname": "RiskAndUncertaintiesPolicyTextBlock",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "clnn_SaleOfUnitsNumberOfUnitsIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of units issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "SaleOfUnitsNumberOfUnitsIssued",
        "terseLabel": "Sale of units, number of units issued"
       }
      }
     },
     "localname": "SaleOfUnitsNumberOfUnitsIssued",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_ScheduleOfAccruedLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of accrued liabilities [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesAbstract",
     "nsuri": "http://www.cleaninccom/20210930",
     "xbrltype": "stringItemType"
    },
    "clnn_ScheduleOfAssumptionsUsedToCalculateTheFairValueOfStockOptionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of assumptions used to calculate the fair value of stock options [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfAssumptionsUsedToCalculateTheFairValueOfStockOptionsAbstract",
     "nsuri": "http://www.cleaninccom/20210930",
     "xbrltype": "stringItemType"
    },
    "clnn_ScheduleOfBasicAndDilutedNetLossPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of basic and diluted net loss per share [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfBasicAndDilutedNetLossPerShareAbstract",
     "nsuri": "http://www.cleaninccom/20210930",
     "xbrltype": "stringItemType"
    },
    "clnn_ScheduleOfChangesInFairValueOfFinancialLiabilitiesRelatedToTheNotesPayableTheDerivativeInstrumentThePreferredStockWarrantsAndTheContingentEarnOutsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of changes in fair value of financial liabilities related to the notes payable, the derivative instrument, the preferred stock warrants, and the contingent earn-outs [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfChangesInFairValueOfFinancialLiabilitiesRelatedToTheNotesPayableTheDerivativeInstrumentThePreferredStockWarrantsAndTheContingentEarnOutsAbstract",
     "nsuri": "http://www.cleaninccom/20210930",
     "xbrltype": "stringItemType"
    },
    "clnn_ScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of components of income (loss) before income taxes [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeLossBeforeIncomeTaxesAbstract",
     "nsuri": "http://www.cleaninccom/20210930",
     "xbrltype": "stringItemType"
    },
    "clnn_ScheduleOfDrugsAndSupplementsSegmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of drugs and supplements segments [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfDrugsAndSupplementsSegmentsAbstract",
     "nsuri": "http://www.cleaninccom/20210930",
     "xbrltype": "stringItemType"
    },
    "clnn_ScheduleOfFairValueHierarchyOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of fair value hierarchy of liabilities measured at fair value on recurring basis [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfFairValueHierarchyOfLiabilitiesMeasuredAtFairValueOnRecurringBasisAbstract",
     "nsuri": "http://www.cleaninccom/20210930",
     "xbrltype": "stringItemType"
    },
    "clnn_ScheduleOfFinanceAndOperatingLeaseCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of finance and operating lease costs [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfFinanceAndOperatingLeaseCostsAbstract",
     "nsuri": "http://www.cleaninccom/20210930",
     "xbrltype": "stringItemType"
    },
    "clnn_ScheduleOfFinanceLeaseObligationsIncludedInPropertyAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of finance lease obligations included in property and equipment [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfFinanceLeaseObligationsIncludedInPropertyAndEquipmentAbstract",
     "nsuri": "http://www.cleaninccom/20210930",
     "xbrltype": "stringItemType"
    },
    "clnn_ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscounts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of future payments, net of unamortized debt discounts",
        "label": "ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscounts",
        "terseLabel": "Schedule of future payments, net of unamortized debt discounts"
       }
      }
     },
     "localname": "ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscounts",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/NotesPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "clnn_ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscountsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of future payments, net of unamortized debt discounts [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscountsAbstract",
     "nsuri": "http://www.cleaninccom/20210930",
     "xbrltype": "stringItemType"
    },
    "clnn_ScheduleOfLongTermDebtNetOfOriginalIssueDiscountAndUnamortizedDebtIssuanceCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of long-term debt, net of original issue discount and unamortized debt issuance costs [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfLongTermDebtNetOfOriginalIssueDiscountAndUnamortizedDebtIssuanceCostsAbstract",
     "nsuri": "http://www.cleaninccom/20210930",
     "xbrltype": "stringItemType"
    },
    "clnn_ScheduleOfNoncancelableFinanceAndOperatingLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of noncancelable finance and operating lease liabilities [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfNoncancelableFinanceAndOperatingLeaseLiabilitiesAbstract",
     "nsuri": "http://www.cleaninccom/20210930",
     "xbrltype": "stringItemType"
    },
    "clnn_ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of outstanding common stock options and related activity [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfOutstandingCommonStockOptionsAndRelatedActivityAbstract",
     "nsuri": "http://www.cleaninccom/20210930",
     "xbrltype": "stringItemType"
    },
    "clnn_ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of outstanding warrants to purchase shares of common stock [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockAbstract",
     "nsuri": "http://www.cleaninccom/20210930",
     "xbrltype": "stringItemType"
    },
    "clnn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of prepaid expenses and other current assets [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract",
     "nsuri": "http://www.cleaninccom/20210930",
     "xbrltype": "stringItemType"
    },
    "clnn_ScheduleOfPropertyAndEquipmentNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of property and equipment, net [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfPropertyAndEquipmentNetAbstract",
     "nsuri": "http://www.cleaninccom/20210930",
     "xbrltype": "stringItemType"
    },
    "clnn_ScheduleOfPropertyAndEquipmentNetByLocationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of property and equipment, net by location [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfPropertyAndEquipmentNetByLocationAbstract",
     "nsuri": "http://www.cleaninccom/20210930",
     "xbrltype": "stringItemType"
    },
    "clnn_ScheduleOfPropertyAndEquipmentNetBySegmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of property and equipment, net by segment [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfPropertyAndEquipmentNetBySegmentAbstract",
     "nsuri": "http://www.cleaninccom/20210930",
     "xbrltype": "stringItemType"
    },
    "clnn_ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock",
        "terseLabel": "Schedule of property and equipment, net by segment"
       }
      }
     },
     "localname": "ScheduleOfPropertyAndEquipmentNetBySegmentTableTextBlock",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/GeographicandSegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "clnn_ScheduleOfRestrictedCommonStockActivityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of restricted common stock activity [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCommonStockActivityAbstract",
     "nsuri": "http://www.cleaninccom/20210930",
     "xbrltype": "stringItemType"
    },
    "clnn_ScheduleOfSecuritiesExcludedFromComputationOfDilutedNetIncomeLossPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of securities excluded from computation of diluted net income (loss) per share [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfSecuritiesExcludedFromComputationOfDilutedNetIncomeLossPerShareAbstract",
     "nsuri": "http://www.cleaninccom/20210930",
     "xbrltype": "stringItemType"
    },
    "clnn_ScheduleOfStockBasedCompensationExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of stock-based compensation expense [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfStockBasedCompensationExpenseAbstract",
     "nsuri": "http://www.cleaninccom/20210930",
     "xbrltype": "stringItemType"
    },
    "clnn_ScheduleOfSupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of supplemental cash flow information [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfSupplementalCashFlowInformationAbstract",
     "nsuri": "http://www.cleaninccom/20210930",
     "xbrltype": "stringItemType"
    },
    "clnn_ScheduleOfUnobservableInputsToTheConversionFeatureWarrantLiabilityAndContingentEarnOutValuationModelsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of unobservable inputs to the conversion feature, warrant liability, and contingent earn-out valuation models [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfUnobservableInputsToTheConversionFeatureWarrantLiabilityAndContingentEarnOutValuationModelsAbstract",
     "nsuri": "http://www.cleaninccom/20210930",
     "xbrltype": "stringItemType"
    },
    "clnn_SecondLoanAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second loan amount.",
        "label": "SecondLoanAmount",
        "terseLabel": "Second loan amount"
       }
      }
     },
     "localname": "SecondLoanAmount",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/NotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_SeriesARedeemableConvertiblePreferredStock": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofsecuritiesexcludedfromcomputationofdilutednetincomelosspershareTable": {
       "order": 4.0,
       "parentTag": "clnn_TotalDilutiveSecurities",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "SeriesARedeemableConvertiblePreferredStock",
        "terseLabel": "Series A redeemable convertible preferred stock"
       }
      }
     },
     "localname": "SeriesARedeemableConvertiblePreferredStock",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofsecuritiesexcludedfromcomputationofdilutednetincomelosspershareTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_SeriesARedeemableConvertiblePreferredStockWarrantsinShares": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofsecuritiesexcludedfromcomputationofdilutednetincomelosspershareTable": {
       "order": 6.0,
       "parentTag": "clnn_TotalDilutiveSecurities",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "SeriesARedeemableConvertiblePreferredStockWarrantsinShares",
        "terseLabel": "Series A redeemable convertible preferred stock warrants"
       }
      }
     },
     "localname": "SeriesARedeemableConvertiblePreferredStockWarrantsinShares",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofsecuritiesexcludedfromcomputationofdilutednetincomelosspershareTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_SeriesBRedeemableConvertiblePreferredStock": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofsecuritiesexcludedfromcomputationofdilutednetincomelosspershareTable": {
       "order": 3.0,
       "parentTag": "clnn_TotalDilutiveSecurities",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "SeriesBRedeemableConvertiblePreferredStock",
        "terseLabel": "Series B redeemable convertible preferred stock"
       }
      }
     },
     "localname": "SeriesBRedeemableConvertiblePreferredStock",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofsecuritiesexcludedfromcomputationofdilutednetincomelosspershareTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_SeriesCRedeemableConvertiblePreferredStock": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofsecuritiesexcludedfromcomputationofdilutednetincomelosspershareTable": {
       "order": 2.0,
       "parentTag": "clnn_TotalDilutiveSecurities",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "SeriesCRedeemableConvertiblePreferredStock",
        "terseLabel": "Series C redeemable convertible preferred stock"
       }
      }
     },
     "localname": "SeriesCRedeemableConvertiblePreferredStock",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofsecuritiesexcludedfromcomputationofdilutednetincomelosspershareTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_SeriesDRedeemableConvertiblePreferredStock": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofsecuritiesexcludedfromcomputationofdilutednetincomelosspershareTable": {
       "order": 1.0,
       "parentTag": "clnn_TotalDilutiveSecurities",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series D redeemable convertible preferred stock.",
        "label": "SeriesDRedeemableConvertiblePreferredStock",
        "terseLabel": "Series D redeemable convertible preferred stock"
       }
      }
     },
     "localname": "SeriesDRedeemableConvertiblePreferredStock",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofsecuritiesexcludedfromcomputationofdilutednetincomelosspershareTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_SeriesDRedeemableConvertiblePreferredStockWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofsecuritiesexcludedfromcomputationofdilutednetincomelosspershareTable": {
       "order": 5.0,
       "parentTag": "clnn_TotalDilutiveSecurities",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series D redeemable convertible preferred stock warrants.",
        "label": "SeriesDRedeemableConvertiblePreferredStockWarrants",
        "terseLabel": "Series D redeemable convertible preferred stock warrants"
       }
      }
     },
     "localname": "SeriesDRedeemableConvertiblePreferredStockWarrants",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofsecuritiesexcludedfromcomputationofdilutednetincomelosspershareTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_ServicesLetterAgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ServicesLetterAgreementDescription",
        "terseLabel": "Services letter agreement, description"
       }
      }
     },
     "localname": "ServicesLetterAgreementDescription",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValue",
        "periodEndLabel": "Intrinsic Value, Ending Balance",
        "periodStartLabel": "Intrinsic Value, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValue",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofoutstandingcommonstockoptionsandrelatedactivityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueGranted": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic Value, Granted.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueGranted",
        "terseLabel": "Intrinsic Value, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueGranted",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofoutstandingcommonstockoptionsandrelatedactivityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueIntrinsicValueOptionsVestedAndExercisableEnding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueIntrinsicValueOptionsVestedAndExercisableEnding",
        "terseLabel": "Intrinsic Value, Options vested and exercisable ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueIntrinsicValueOptionsVestedAndExercisableEnding",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofoutstandingcommonstockoptionsandrelatedactivityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue",
        "terseLabel": "Intrinsic Value, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofoutstandingcommonstockoptionsandrelatedactivityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue",
        "terseLabel": "Intrinsic Value, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofoutstandingcommonstockoptionsandrelatedactivityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and exercisable options that may be converted into shares under option plan.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber",
        "terseLabel": "Number of Options, Options vested and exercisable ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofoutstandingcommonstockoptionsandrelatedactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_ShareBasedCompensationArrangementNumberOfOptionsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options shares exercised.",
        "label": "ShareBasedCompensationArrangementNumberOfOptionsExercised",
        "negatedLabel": "Number of Options, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementNumberOfOptionsExercised",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofoutstandingcommonstockoptionsandrelatedactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_ShareIssuanceOfCommonStockPrivateOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share issuance of common stock private offering.",
        "label": "ShareIssuanceOfCommonStockPrivateOffering",
        "terseLabel": "Common Stock, issued in a private placement (in Shares)"
       }
      }
     },
     "localname": "ShareIssuanceOfCommonStockPrivateOffering",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/NatureoftheBusinessDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm",
        "terseLabel": "Weighted average period for recognition of unrecognized compensation cost"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D'.",
        "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm",
        "terseLabel": "Weighted average period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) for future granted.",
        "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants",
        "terseLabel": "Shares for future grants"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFutureGrants",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted",
        "terseLabel": "Weighted Average Remaining Term, Granted"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofoutstandingcommonstockoptionsandrelatedactivityTable"
     ],
     "xbrltype": "durationItemType"
    },
    "clnn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm1",
        "terseLabel": "Weighted Average Exercise Price Weighted Average Remaining Term (Years), Stock options vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofoutstandingcommonstockoptionsandrelatedactivityTable"
     ],
     "xbrltype": "durationItemType"
    },
    "clnn_SharesCancelledUponReverseRecapitalization": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares cancelled upon reverse recapitalization.",
        "label": "SharesCancelledUponReverseRecapitalization",
        "terseLabel": "Shares cancelled upon reverse recapitalization"
       }
      }
     },
     "localname": "SharesCancelledUponReverseRecapitalization",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_SharesHeldInEscrow": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares held in Escrow.",
        "label": "SharesHeldInEscrow",
        "terseLabel": "Shares held in escrow (in Shares)"
       }
      }
     },
     "localname": "SharesHeldInEscrow",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_SharesHeldInEscrowPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage shares held in escrow.",
        "label": "SharesHeldInEscrowPercentage",
        "terseLabel": "Shares held in escrow, percentage"
       }
      }
     },
     "localname": "SharesHeldInEscrowPercentage",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "clnn_SharesOfWarrantsExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of warrants exercisable.",
        "label": "SharesOfWarrantsExercisable",
        "terseLabel": "Shares of warrants exercisable"
       }
      }
     },
     "localname": "SharesOfWarrantsExercisable",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/PreferredStockWarrantLiabilityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_SimpleInterestExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Simple interest expense.",
        "label": "SimpleInterestExpense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "SimpleInterestExpense",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/NotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_StockBasedCompensationDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation (Details) [Line Items]"
       }
      }
     },
     "localname": "StockBasedCompensationDetailsLineItems",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of assumptions used to calculate the fair value of stock option awards granted [Line Item]"
       }
      }
     },
     "localname": "StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsLineItems",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation (Details) - Schedule of assumptions used to calculate the fair value of stock options [Table]"
       }
      }
     },
     "localname": "StockBasedCompensationDetailsScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsTable",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation (Details) - Schedule of restricted common stock activity [Line Items]"
       }
      }
     },
     "localname": "StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityLineItems",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofrestrictedcommonstockactivityTable"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation (Details) - Schedule of restricted common stock activity [Table]"
       }
      }
     },
     "localname": "StockBasedCompensationDetailsScheduleofrestrictedcommonstockactivityTable",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofrestrictedcommonstockactivityTable"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation (Details) - Schedule of stock-based compensation expense [Line Items]"
       }
      }
     },
     "localname": "StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofstockbasedcompensationexpenseTable"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation (Details) - Schedule of stock-based compensation expense [Table]"
       }
      }
     },
     "localname": "StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofstockbasedcompensationexpenseTable"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_StockBasedCompensationDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation (Details) [Table]"
       }
      }
     },
     "localname": "StockBasedCompensationDetailsTable",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_StockIssueDuringPeriodSharesExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise of warrants.",
        "label": "StockIssueDuringPeriodSharesExerciseOfWarrants",
        "terseLabel": "Exercise of warrants (in Shares)"
       }
      }
     },
     "localname": "StockIssueDuringPeriodSharesExerciseOfWarrants",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_StockIssuedDuringPeriodExerciseOfUnderwritersOption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise of underwriter\u2019s option.",
        "label": "StockIssuedDuringPeriodExerciseOfUnderwritersOption",
        "terseLabel": "Exercise of underwriter\u2019s option"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodExerciseOfUnderwritersOption",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_StockIssuedDuringPeriodExerciseOfUnderwritersOptioninShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise of underwriter\u2019s option in shares.",
        "label": "StockIssuedDuringPeriodExerciseOfUnderwritersOptioninShares",
        "terseLabel": "Exercise of underwriter\u2019s option (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodExerciseOfUnderwritersOptioninShares",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_StockIssuedDuringPeriodOfSeriesDPreferredStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of Series D Preferred Stock.",
        "label": "StockIssuedDuringPeriodOfSeriesDPreferredStock",
        "terseLabel": "Issuance of Series D Preferred Stock, net of issuance costs of $1.3 million"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodOfSeriesDPreferredStock",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_StockIssuedDuringPeriodSharesSeriesDPreferredStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of Series D Preferred Stock.",
        "label": "StockIssuedDuringPeriodSharesSeriesDPreferredStock",
        "terseLabel": "Issuance of Series D Preferred Stock, net of issuance costs of $1.3 million (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesSeriesDPreferredStock",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_StockIssuedDuringPeriodValueExerciseOfWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise of warrants.",
        "label": "StockIssuedDuringPeriodValueExerciseOfWarrants",
        "terseLabel": "Exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueExerciseOfWarrants",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_StockPlan2014Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "StockPlan2014Member",
        "terseLabel": "2014 Stock Plan [Member]"
       }
      }
     },
     "localname": "StockPlan2014Member",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clnn_StockPlan2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "StockPlan2020Member",
        "terseLabel": "2020 Stock Plan [Member]"
       }
      }
     },
     "localname": "StockPlan2020Member",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clnn_SubsequentEventsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventsDetailsLineItems",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_SubsequentEventsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Table]"
       }
      }
     },
     "localname": "SubsequentEventsDetailsTable",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_SummaryofSignificantAccountingPoliciesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) [Line Items]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsLineItems",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_SummaryofSignificantAccountingPoliciesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) [Table]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsTable",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_SupplementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SupplementsMember",
        "terseLabel": "Supplements [Member]"
       }
      }
     },
     "localname": "SupplementsMember",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofdrugsandsupplementssegmentsTable",
      "http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetbysegmentTable"
     ],
     "xbrltype": "domainItemType"
    },
    "clnn_TermLoansAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TermLoansAbstract",
        "terseLabel": "Term Loans:"
       }
      }
     },
     "localname": "TermLoansAbstract",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoflongtermdebtnetoforiginalissuediscountandunamortizeddebtissuancecostsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_TermLoansAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TermLoansAxis",
        "terseLabel": "Term Loans [Axis]"
       }
      }
     },
     "localname": "TermLoansAxis",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoflongtermdebtnetoforiginalissuediscountandunamortizeddebtissuancecostsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_TermLoansDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TermLoans [Domain]"
       }
      }
     },
     "localname": "TermLoansDomain",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoflongtermdebtnetoforiginalissuediscountandunamortizeddebtissuancecostsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "clnn_ThresholdForRemovalOfFinancialCovenantsDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold for removal of financial covenants, description.",
        "label": "ThresholdForRemovalOfFinancialCovenantsDescription",
        "terseLabel": "Threshold for removal of financial covenants, description"
       }
      }
     },
     "localname": "ThresholdForRemovalOfFinancialCovenantsDescription",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/NotesPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_TotalCleneNanomedicineContingentEarnoutShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total clene nanomedicine contingent earnout shares.",
        "label": "TotalCleneNanomedicineContingentEarnoutShares",
        "terseLabel": "Total clene nanomedicine contingent earnout shares"
       }
      }
     },
     "localname": "TotalCleneNanomedicineContingentEarnoutShares",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_TotalDilutiveSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofsecuritiesexcludedfromcomputationofdilutednetincomelosspershareTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number potentially dilutive securities shares.",
        "label": "TotalDilutiveSecurities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "TotalDilutiveSecurities",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofsecuritiesexcludedfromcomputationofdilutednetincomelosspershareTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_TotalLossBeforeIncomeTaxes": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofcomponentsofincomelossbeforeincometaxesTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total loss before income taxes.",
        "label": "TotalLossBeforeIncomeTaxes",
        "totalLabel": "Total loss before income taxes"
       }
      }
     },
     "localname": "TotalLossBeforeIncomeTaxes",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofcomponentsofincomelossbeforeincometaxesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_TotalNotesPayableAndConvertibleNotesPayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total notes payable and convertible notes payable.",
        "label": "TotalNotesPayableAndConvertibleNotesPayable",
        "terseLabel": "Total notes payable"
       }
      }
     },
     "localname": "TotalNotesPayableAndConvertibleNotesPayable",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoflongtermdebtnetoforiginalissuediscountandunamortizeddebtissuancecostsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_TotalPropertyAndEquipmentNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total property and equipment, net.",
        "label": "TotalPropertyAndEquipmentNet",
        "terseLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "TotalPropertyAndEquipmentNet",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetbysegmentTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_TotalTermLoans": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Term Loans.",
        "label": "TotalTermLoans",
        "terseLabel": "Total term loans"
       }
      }
     },
     "localname": "TotalTermLoans",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoflongtermdebtnetoforiginalissuediscountandunamortizeddebtissuancecostsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_TottenhamMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TottenhamMember",
        "terseLabel": "Tottenham [Member]"
       }
      }
     },
     "localname": "TottenhamMember",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/NatureoftheBusinessDetails",
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clnn_TradingVolumeLimitForConversionOfConvertibleNotePayable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading volume limit for conversion of convertible note payable.",
        "label": "TradingVolumeLimitForConversionOfConvertibleNotePayable",
        "terseLabel": "Trading volume limit for conversion of convertible note payable, percentage"
       }
      }
     },
     "localname": "TradingVolumeLimitForConversionOfConvertibleNotePayable",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/NotesPayableDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "clnn_Tranche2WarrantAdjustmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of tranche 2 warrant adjustment description.",
        "label": "Tranche2WarrantAdjustmentDescription",
        "terseLabel": "Tranche warrant adjustment description"
       }
      }
     },
     "localname": "Tranche2WarrantAdjustmentDescription",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/NotesPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_TwoThousandNineteenCecilLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TwoThousandNineteenCecilLoanMember",
        "terseLabel": "2019 Cecil Loan [Member]"
       }
      }
     },
     "localname": "TwoThousandNineteenCecilLoanMember",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/NotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clnn_TwoThousandNineteenMDLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TwoThousandNineteenMDLoanMember",
        "terseLabel": "2019 MD Loan [Member]"
       }
      }
     },
     "localname": "TwoThousandNineteenMDLoanMember",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/NotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clnn_TwoThousandtwentyoneAvenueLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TwoThousandtwentyoneAvenueLoanMember",
        "terseLabel": "2021 Avenue Loan [Member]"
       }
      }
     },
     "localname": "TwoThousandtwentyoneAvenueLoanMember",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockWarrantsDetails",
      "http://www.cleaninccom/role/ConvertibleNotesDetails",
      "http://www.cleaninccom/role/NotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clnn_UnitsIssuedPricePerUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per unit amount of equity securities issued.",
        "label": "UnitsIssuedPricePerUnit",
        "terseLabel": "Units issued, price per unit (in Dollars per share)"
       }
      }
     },
     "localname": "UnitsIssuedPricePerUnit",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clnn_UnrecognizedStockbasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "UnrecognizedStockbasedCompensation",
        "terseLabel": "Unrecognized stock-based compensation"
       }
      }
     },
     "localname": "UnrecognizedStockbasedCompensation",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_UnvestedRestrictedStockAwardsShares": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofsecuritiesexcludedfromcomputationofdilutednetincomelosspershareTable": {
       "order": 10.0,
       "parentTag": "clnn_TotalDilutiveSecurities",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested restricted stock awards shares",
        "label": "UnvestedRestrictedStockAwardsShares",
        "terseLabel": "Restricted stock awards"
       }
      }
     },
     "localname": "UnvestedRestrictedStockAwardsShares",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofsecuritiesexcludedfromcomputationofdilutednetincomelosspershareTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_WarrantLiabilityFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents amount of warrant liability fair value.",
        "label": "WarrantLiabilityFairValue",
        "terseLabel": "Warrant fair value"
       }
      }
     },
     "localname": "WarrantLiabilityFairValue",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_WarrantLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Liability [Member].",
        "label": "WarrantLiabilityMember",
        "terseLabel": "Warrant Liability [Member]"
       }
      }
     },
     "localname": "WarrantLiabilityMember",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsTable",
      "http://www.cleaninccom/role/ScheduleofunobservableinputstotheconversionfeaturewarrantliabilityandcontingentearnoutvaluationmodelsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "clnn_WarrantLiabilityNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet": {
       "order": 7.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "WarrantLiabilityNoncurrent",
        "label": "WarrantLiabilityNoncurrent",
        "terseLabel": "Warrant liability"
       }
      }
     },
     "localname": "WarrantLiabilityNoncurrent",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_WarrantLiabilityRecordedAtIssuanceOfNotesPayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant liability recorded at issuance of notes payable.",
        "label": "WarrantLiabilityRecordedAtIssuanceOfNotesPayable",
        "terseLabel": "Warrant liability recorded at issuance of notes payable"
       }
      }
     },
     "localname": "WarrantLiabilityRecordedAtIssuanceOfNotesPayable",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clnn_WarrantToPurchaseShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant to purchase shares.",
        "label": "WarrantToPurchaseShares",
        "terseLabel": "Warrant to purchase shares (in Shares)"
       }
      }
     },
     "localname": "WarrantToPurchaseShares",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/NotesPayableDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_WarrantsDate1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WarrantsDate1Member",
        "terseLabel": "December 2020 [Member]"
       }
      }
     },
     "localname": "WarrantsDate1Member",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofoutstandingwarrantstopurchasesharesofcommonstockTable"
     ],
     "xbrltype": "domainItemType"
    },
    "clnn_WarrantsDate2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WarrantsDate2Member",
        "terseLabel": "December 2020 Two [Member]"
       }
      }
     },
     "localname": "WarrantsDate2Member",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofoutstandingwarrantstopurchasesharesofcommonstockTable"
     ],
     "xbrltype": "domainItemType"
    },
    "clnn_WarrantsDateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WarrantsDateMember",
        "terseLabel": "June 2021 [Member]"
       }
      }
     },
     "localname": "WarrantsDateMember",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofoutstandingwarrantstopurchasesharesofcommonstockTable"
     ],
     "xbrltype": "domainItemType"
    },
    "clnn_WarrantsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Shares.",
        "label": "WarrantsShares",
        "terseLabel": "Warrants shares"
       }
      }
     },
     "localname": "WarrantsShares",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_WarrantsToPurchaseCommonStockIssuedAndOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants to purchase common stock issued and outstanding.",
        "label": "WarrantsToPurchaseCommonStockIssuedAndOutstanding",
        "terseLabel": "Warrant outstanding"
       }
      }
     },
     "localname": "WarrantsToPurchaseCommonStockIssuedAndOutstanding",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_WarrantsToPurchaseSharesOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants to purchase shares of common stock.",
        "label": "WarrantsToPurchaseSharesOfCommonStock",
        "terseLabel": "Warrants to purchase one-half of one share of common stock"
       }
      }
     },
     "localname": "WarrantsToPurchaseSharesOfCommonStock",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_WeightedAverageEffectOfPotentiallyDilutiveSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WeightedAverageEffectOfPotentiallyDilutiveSecuritiesAbstract",
        "terseLabel": "Weighted average effect of potentially dilutive securities:"
       }
      }
     },
     "localname": "WeightedAverageEffectOfPotentiallyDilutiveSecuritiesAbstract",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofbasicanddilutednetlosspershareTable"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_WeightedAverageExercisePricePerShareOptionVestedAndExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price Per Share, Options vested and exercisable.",
        "label": "WeightedAverageExercisePricePerShareOptionVestedAndExercisable",
        "terseLabel": "Weighted Average Exercise Price Per Share, Options vested and exercisable ending"
       }
      }
     },
     "localname": "WeightedAverageExercisePricePerShareOptionVestedAndExercisable",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofoutstandingcommonstockoptionsandrelatedactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "clnn_WeightedAverageExercisePriceWeightedAverageRemainingTermYearsOptionsVestedAndEexercisableEnding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WeightedAverageExercisePriceWeightedAverageRemainingTermYearsOptionsVestedAndEexercisableEnding",
        "terseLabel": "Weighted Average Exercise Price Weighted Average Remaining Term (Years), Options vested and exercisable ending"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceWeightedAverageRemainingTermYearsOptionsVestedAndEexercisableEnding",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofoutstandingcommonstockoptionsandrelatedactivityTable"
     ],
     "xbrltype": "durationItemType"
    },
    "clnn_WeightedAverageNumberOfCommonSharesOutstanding1Abstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WeightedAverageNumberOfCommonSharesOutstanding1Abstract",
        "terseLabel": "Weighted average number of common shares outstanding(1):"
       }
      }
     },
     "localname": "WeightedAverageNumberOfCommonSharesOutstanding1Abstract",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "clnn_WeightedAverageRemainingTermYearsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WeightedAverageRemainingTermYearsExercised",
        "terseLabel": "Weighted Average Remaining Term (Years), Exercised"
       }
      }
     },
     "localname": "WeightedAverageRemainingTermYearsExercised",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofoutstandingcommonstockoptionsandrelatedactivityTable"
     ],
     "xbrltype": "durationItemType"
    },
    "clnn_WeightedAverageRemainingTermYearsForfeited": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WeightedAverageRemainingTermYearsForfeited",
        "terseLabel": "Weighted Average Remaining Term (Years), Forfeited"
       }
      }
     },
     "localname": "WeightedAverageRemainingTermYearsForfeited",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofoutstandingcommonstockoptionsandrelatedactivityTable"
     ],
     "xbrltype": "durationItemType"
    },
    "clnn_WeightedAverageSharesOutstanding": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofbasicanddilutednetlosspershareTable": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "WeightedAverageSharesOutstanding",
        "label": "WeightedAverageSharesOutstanding",
        "terseLabel": "Weighted average common shares outstanding \u2013Basic"
       }
      }
     },
     "localname": "WeightedAverageSharesOutstanding",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofbasicanddilutednetlosspershareTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "clnn_weightedAverageFairValuesOfOptionsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options granted.",
        "label": "weightedAverageFairValuesOfOptionsGranted",
        "terseLabel": "Weighted average grant-date fair value of stock options granted"
       }
      }
     },
     "localname": "weightedAverageFairValuesOfOptionsGranted",
     "nsuri": "http://www.cleaninccom/20210930",
     "presentation": [
      "http://www.cleaninccom/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "country_AU": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AUSTRALIA",
        "terseLabel": "Australia [Member]"
       }
      }
     },
     "localname": "AU",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetbylocationTable"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States [Member]"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetbylocationTable"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cleaninccom/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cleaninccom/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cleaninccom/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cleaninccom/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cleaninccom/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cleaninccom/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cleaninccom/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cleaninccom/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cleaninccom/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cleaninccom/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cleaninccom/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cleaninccom/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cleaninccom/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cleaninccom/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cleaninccom/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cleaninccom/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cleaninccom/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cleaninccom/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cleaninccom/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cleaninccom/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cleaninccom/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cleaninccom/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cleaninccom/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cleaninccom/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cleaninccom/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cleaninccom/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cleaninccom/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cleaninccom/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cleaninccom/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cleaninccom/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cleaninccom/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cleaninccom/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cleaninccom/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r261",
      "r300",
      "r334",
      "r336",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r554",
      "r557",
      "r588",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockDetails",
      "http://www.cleaninccom/role/ScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsTable",
      "http://www.cleaninccom/role/ScheduleofunobservableinputstotheconversionfeaturewarrantliabilityandcontingentearnoutvaluationmodelsTable",
      "http://www.cleaninccom/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r261",
      "r300",
      "r334",
      "r336",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r554",
      "r557",
      "r588",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockDetails",
      "http://www.cleaninccom/role/ScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsTable",
      "http://www.cleaninccom/role/ScheduleofunobservableinputstotheconversionfeaturewarrantliabilityandcontingentearnoutvaluationmodelsTable",
      "http://www.cleaninccom/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r208",
      "r320",
      "r321",
      "r500",
      "r553",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r208",
      "r320",
      "r321",
      "r500",
      "r553",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r261",
      "r300",
      "r323",
      "r334",
      "r336",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r554",
      "r557",
      "r588",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockDetails",
      "http://www.cleaninccom/role/ScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsTable",
      "http://www.cleaninccom/role/ScheduleofunobservableinputstotheconversionfeaturewarrantliabilityandcontingentearnoutvaluationmodelsTable",
      "http://www.cleaninccom/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r261",
      "r300",
      "r323",
      "r334",
      "r336",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r554",
      "r557",
      "r588",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockDetails",
      "http://www.cleaninccom/role/ScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsTable",
      "http://www.cleaninccom/role/ScheduleofunobservableinputstotheconversionfeaturewarrantliabilityandcontingentearnoutvaluationmodelsTable",
      "http://www.cleaninccom/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r209",
      "r210",
      "r320",
      "r322",
      "r556",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetbylocationTable"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r209",
      "r210",
      "r320",
      "r322",
      "r556",
      "r570",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetbylocationTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/AccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofaccruedliabilitiesTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "totalLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofaccruedliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities [Abstract]"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r42",
      "r484"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r5",
      "r27",
      "r215",
      "r216"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r47"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofaccruedliabilitiesTable": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofaccruedliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r520",
      "r544"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.",
        "label": "Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r47"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofaccruedliabilitiesTable": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofaccruedliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r40",
      "r237"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetTable": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r30",
      "r67",
      "r69",
      "r70",
      "r538",
      "r562",
      "r563"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r66",
      "r70",
      "r77",
      "r78",
      "r79",
      "r129",
      "r130",
      "r131",
      "r409",
      "r558",
      "r559",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r28",
      "r368",
      "r484"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r365",
      "r366",
      "r367",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r337",
      "r339",
      "r371",
      "r372"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvancesToAffiliate": {
     "auth_ref": [
      "r11",
      "r569"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term advances receivable from a party that is affiliated with the reporting entity by means of direct or indirect ownership. This does not include advances to clients.",
        "label": "Advances to Affiliate",
        "terseLabel": "Advances"
       }
      }
     },
     "localname": "AdvancesToAffiliate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r339",
      "r360",
      "r370"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofstockbasedcompensationexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r92",
      "r106",
      "r281",
      "r443"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedCashFlow": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Accretion of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r87",
      "r106",
      "r281",
      "r445"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of Debt Issuance Costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/NotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r106",
      "r281",
      "r291",
      "r292",
      "r445"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r122",
      "r186",
      "r197",
      "r204",
      "r225",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r405",
      "r410",
      "r433",
      "r482",
      "r484",
      "r515",
      "r534"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r7",
      "r9",
      "r61",
      "r122",
      "r225",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r405",
      "r410",
      "r433",
      "r482",
      "r484"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r340",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails",
      "http://www.cleaninccom/role/ScheduleofrestrictedcommonstockactivityTable",
      "http://www.cleaninccom/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r333",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/FairValueDetails",
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r333",
      "r335",
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/FairValueDetails",
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents a description of such arrangements.",
        "label": "Business Combination, Contingent Consideration Arrangements, Description",
        "terseLabel": "Contingent earn-out, description"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/FairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r2",
      "r128",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Nature of the Business"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/NatureoftheBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalLeaseObligationsCurrent": {
     "auth_ref": [
      "r21",
      "r452",
      "r453"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of capital lease obligation due within one year or the normal operating cycle, if longer.",
        "label": "Capital Lease Obligations, Current",
        "negatedLabel": "Less lease obligations, current portion"
       }
      }
     },
     "localname": "CapitalLeaseObligationsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeaseObligationsNoncurrent": {
     "auth_ref": [
      "r51",
      "r452",
      "r453"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.",
        "label": "Capital Lease Obligations, Noncurrent",
        "terseLabel": "Lease obligations \u2013 long term portion"
       }
      }
     },
     "localname": "CapitalLeaseObligationsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r453"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable": {
       "order": 1.0,
       "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of minimum lease payments for capital leases.",
        "label": "Capital Leases, Future Minimum Payments Due",
        "totalLabel": "Total undiscounted cash flows"
       }
      }
     },
     "localname": "CapitalLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r453"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable": {
       "order": 2.0,
       "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of minimum lease payments for capital leases due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Capital Leases, Future Minimum Payments Due, Next Twelve Months",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "CapitalLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r453"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable": {
       "order": 5.0,
       "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of minimum lease payments for capital leases due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Capital Leases, Future Minimum Payments Due in Four Years",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "CapitalLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r453"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable": {
       "order": 4.0,
       "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of minimum lease payments for capital leases due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Capital Leases, Future Minimum Payments Due in Three Years",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "CapitalLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r453"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable": {
       "order": 3.0,
       "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of minimum lease payments for capital leases due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Capital Leases, Future Minimum Payments Due in Two Years",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "CapitalLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter": {
     "auth_ref": [
      "r453"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable": {
       "order": 6.0,
       "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of minimum lease payments for capital leases due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Capital Leases, Future Minimum Payments Due Thereafter",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "CapitalLeasesFutureMinimumPaymentsDueThereafter",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments": {
     "auth_ref": [
      "r453"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of minimum lease payments for capital leases net of executory costs, including amounts paid by the lessee to the lessor for insurance, maintenance and taxes.",
        "label": "Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments",
        "totalLabel": "Present value of future lease payments"
       }
      }
     },
     "localname": "CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable": {
       "order": 1.0,
       "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of minimum lease payments for capital leases due in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Capital Leases, Future Minimum Payments, Remainder of Fiscal Year",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r37",
      "r484",
      "r566",
      "r567"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.cleaninccom/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet",
      "http://www.cleaninccom/role/ConsolidatedCashFlow",
      "http://www.cleaninccom/role/NatureoftheBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r37",
      "r108"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and restricted cash \u2013 end of period",
        "periodStartLabel": "Cash and restricted cash \u2013 beginning of period"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r17",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r17",
      "r109",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r102",
      "r108",
      "r113"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedCashFlow": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "totalLabel": "Cash and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r102",
      "r434"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedCashFlow": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r119",
      "r122",
      "r145",
      "r146",
      "r151",
      "r154",
      "r156",
      "r166",
      "r167",
      "r168",
      "r225",
      "r247",
      "r251",
      "r252",
      "r253",
      "r256",
      "r257",
      "r297",
      "r298",
      "r302",
      "r306",
      "r433",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/PreferredStockWarrantLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price per share (in Dollars per share)",
        "verboseLabel": "Exercise price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails",
      "http://www.cleaninccom/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofoutstandingwarrantstopurchasesharesofcommonstockTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Warrants exercised"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants outstanding (in Shares)",
        "verboseLabel": "Warrants issued"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockWarrantsDetails",
      "http://www.cleaninccom/role/NatureoftheBusinessDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants outstanding (in Shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/NatureoftheBusinessDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r318",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofoutstandingwarrantstopurchasesharesofcommonstockTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollateralAxis": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of collateral or no collateral, from lender's perspective.",
        "label": "Collateral Held [Axis]"
       }
      }
     },
     "localname": "CollateralAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollateralDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Category of collateral or no collateral, from lender's perspective.",
        "label": "Collateral Held [Domain]"
       }
      }
     },
     "localname": "CollateralDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r52",
      "r245",
      "r521",
      "r542"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 13)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r242",
      "r243",
      "r244",
      "r246",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares authorized"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r129",
      "r130",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "verboseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockWarrantsDetails",
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails",
      "http://www.cleaninccom/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockOtherSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.",
        "label": "Common Stock, Other Shares, Outstanding",
        "terseLabel": "Common stock, share outstanding",
        "verboseLabel": "Stock option outstanding (pre-conversion)"
       }
      }
     },
     "localname": "CommonStockOtherSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails",
      "http://www.cleaninccom/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in Dollars per share)",
        "verboseLabel": "Common share, par value (in Dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockDetails",
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockDetails",
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockDetails",
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r26",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockDetails",
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r26",
      "r484"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value: 150,000,000 and 100,000,000 shares authorized at September 30, 2021 and December 31, 2020, respectively; 62,177,020 and 59,526,171 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r72",
      "r74",
      "r75",
      "r84",
      "r525",
      "r547"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r174",
      "r175",
      "r213",
      "r431",
      "r432",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofdrugsandsupplementssegmentsTable",
      "http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetbysegmentTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r174",
      "r175",
      "r213",
      "r431",
      "r432",
      "r565",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofdrugsandsupplementssegmentsTable",
      "http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetbysegmentTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r171",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r236"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetTable": {
       "order": 4.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure": {
     "auth_ref": [
      "r423"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of contingent consideration in a business combination that is classified in shareholders' equity.",
        "label": "Contingent Consideration Classified as Equity, Fair Value Disclosure",
        "terseLabel": "Initial shareholders contingent earn-out"
       }
      }
     },
     "localname": "ContingentConsiderationClassifiedAsEquityFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r110",
      "r111",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Common stock potentially issuable upon conversion (in Shares)",
        "verboseLabel": "Aggregate of converted shares"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConvertibleNotesDetails",
      "http://www.cleaninccom/role/RedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertibleCommonStockMember": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock securities that may be converted to another form of security.",
        "label": "Convertible Common Stock [Member]",
        "terseLabel": "Convertible Common Stock [Member]"
       }
      }
     },
     "localname": "ConvertibleCommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/RedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebt": {
     "auth_ref": [
      "r23",
      "r517",
      "r536"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.",
        "label": "Convertible Debt",
        "terseLabel": "Convertible debt"
       }
      }
     },
     "localname": "ConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/NotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.",
        "label": "Convertible Notes Payable, Noncurrent",
        "terseLabel": "Convertible notes payable"
       }
      }
     },
     "localname": "ConvertibleLongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayable": {
     "auth_ref": [
      "r23",
      "r517",
      "r535",
      "r568"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable",
        "terseLabel": "Convertible note payable",
        "verboseLabel": "Convertible notes payable"
       }
      }
     },
     "localname": "ConvertibleNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConvertibleNotesDetails",
      "http://www.cleaninccom/role/FairValueDetails",
      "http://www.cleaninccom/role/NotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "auth_ref": [
      "r21",
      "r516",
      "r533",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable [Member]",
        "terseLabel": "Convertible Notes Payable [Member]",
        "verboseLabel": "2020 Convertible Notes [Member]"
       }
      }
     },
     "localname": "ConvertibleNotesPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConvertibleNotesDetails",
      "http://www.cleaninccom/role/ScheduleofunobservableinputstotheconversionfeaturewarrantliabilityandcontingentearnoutvaluationmodelsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r89",
      "r500"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSoldDepreciation": {
     "auth_ref": [
      "r88",
      "r235"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for allocation of cost of tangible asset over its useful life directly used in production of good and rendering of service.",
        "label": "Cost, Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSoldDepreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsSoldDirectFinancingLease": {
     "auth_ref": [
      "r164",
      "r474"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of goods sold for direct financing lease.",
        "label": "Cost of Goods Sold, Direct Financing Lease",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsSoldDirectFinancingLease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsSoldSalesTypeLease": {
     "auth_ref": [
      "r164",
      "r474"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of goods sold for sales-type financing lease.",
        "label": "Cost of Goods Sold, Sales-type Lease",
        "terseLabel": "Sale of product"
       }
      }
     },
     "localname": "CostOfGoodsSoldSalesTypeLease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r123",
      "r385",
      "r391",
      "r392"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "terseLabel": "Income tax benefit"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r118",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r275",
      "r282",
      "r283",
      "r285",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Notes Payable"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/NotesPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r21",
      "r22",
      "r23",
      "r121",
      "r127",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r265",
      "r271",
      "r272",
      "r273",
      "r274",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r289",
      "r290",
      "r291",
      "r292",
      "r446",
      "r516",
      "r517",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockWarrantsDetails",
      "http://www.cleaninccom/role/ConvertibleNotesDetails",
      "http://www.cleaninccom/role/FairValueDetails",
      "http://www.cleaninccom/role/NotesPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature": {
     "auth_ref": [
      "r316"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.",
        "label": "Debt Instrument, Convertible, Beneficial Conversion Feature",
        "terseLabel": "Embedded conversion feature"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleBeneficialConversionFeature",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/FairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentDescription": {
     "auth_ref": [
      "r21",
      "r23",
      "r313",
      "r516",
      "r517",
      "r530",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.",
        "label": "Debt Instrument, Description",
        "terseLabel": "Phantom shares, description"
       }
      }
     },
     "localname": "DebtInstrumentDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/NotesPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r258",
      "r289",
      "r290",
      "r444",
      "r446",
      "r447"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "First loan amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/NotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate": {
     "auth_ref": [
      "r49",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of any adjustments made to the stated rate to determine the effective rate.",
        "label": "Debt Instrument, Interest Rate, Basis for Effective Rate",
        "terseLabel": "Effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateBasisForEffectiveRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r49",
      "r278",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Debt Instrument, Interest Rate During Period",
        "terseLabel": "Annual debt interest"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r49",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate",
        "verboseLabel": "Investor to pay royalties"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/NotesPayableDetails",
      "http://www.cleaninccom/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoflongtermdebtnetoforiginalissuediscountandunamortizeddebtissuancecostsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r50",
      "r261",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Outstanding due date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/NotesPayableDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r51",
      "r121",
      "r127",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r265",
      "r271",
      "r272",
      "r273",
      "r274",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r289",
      "r290",
      "r291",
      "r292",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockWarrantsDetails",
      "http://www.cleaninccom/role/ConvertibleNotesDetails",
      "http://www.cleaninccom/role/FairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r51",
      "r121",
      "r127",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r265",
      "r271",
      "r272",
      "r273",
      "r274",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r284",
      "r289",
      "r290",
      "r291",
      "r292",
      "r313",
      "r314",
      "r315",
      "r316",
      "r443",
      "r444",
      "r446",
      "r447",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoflongtermdebtnetoforiginalissuediscountandunamortizeddebtissuancecostsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r271",
      "r443",
      "r447"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "terseLabel": "Unamortized discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountCurrent": {
     "auth_ref": [
      "r443",
      "r447"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.",
        "label": "Debt Instrument, Unamortized Discount, Current",
        "terseLabel": "Unamortized debt discount and issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r271",
      "r286",
      "r289",
      "r290",
      "r445"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "terseLabel": "Less convertible notes payable, net of unamortized debt discount and issuance costs (see Note 11)"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoflongtermdebtnetoforiginalissuediscountandunamortizeddebtissuancecostsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedPremium": {
     "auth_ref": [
      "r271",
      "r443",
      "r447"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleoffuturepaymentsnetofunamortizeddebtdiscountsTable": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecurities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt premium.",
        "label": "Debt Instrument, Unamortized Premium",
        "negatedLabel": "Unamortized debt discount associated with issuance date warrant fair value and financing costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoffuturepaymentsnetofunamortizeddebtdiscountsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": {
     "auth_ref": [
      "r110",
      "r111",
      "r112"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.",
        "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction",
        "negatedLabel": "Issuance of derivative instrument related to convertible notes"
       }
      }
     },
     "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleoffuturepaymentsnetofunamortizeddebtdiscountsTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading).",
        "label": "Debt Securities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "DebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoffuturepaymentsnetofunamortizeddebtdiscountsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Deferred Offering Costs"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r377",
      "r378"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred income tax"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r60",
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred Offering Costs",
        "terseLabel": "Incurred of deferred offering costs",
        "verboseLabel": "Offering costs (in Dollars)"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails",
      "http://www.cleaninccom/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenue": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Deferred Revenue",
        "terseLabel": "Deferred Revenue"
       }
      }
     },
     "localname": "DeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Revenue, Current",
        "terseLabel": "Deferred revenue from related parties"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r106",
      "r235"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeNet": {
     "auth_ref": [
      "r430"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives.",
        "label": "Derivative, Fair Value, Net",
        "terseLabel": "Issuance of derivative instrument"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r64",
      "r414",
      "r415",
      "r416",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r418",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "Derivative Instruments"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/DerivativeInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r62",
      "r63",
      "r64",
      "r430"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Warrant liability"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Current",
        "terseLabel": "Clene Nanomedicine contingent earn-out, current portion"
       }
      }
     },
     "localname": "DerivativeLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet": {
       "order": 8.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Noncurrent",
        "terseLabel": "Clene Nanomedicine contingent earn-out, net of current portion"
       }
      }
     },
     "localname": "DerivativeLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureTextBlockSupplementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Text Block Supplement [Abstract]"
       }
      }
     },
     "localname": "DisclosureTextBlockSupplementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r85",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r142",
      "r145",
      "r154",
      "r155",
      "r156",
      "r160",
      "r161",
      "r420",
      "r421",
      "r526",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in Dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement",
      "http://www.cleaninccom/role/ScheduleofbasicanddilutednetlosspershareTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r85",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r145",
      "r154",
      "r155",
      "r156",
      "r160",
      "r161",
      "r420",
      "r421",
      "r526",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in Dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement",
      "http://www.cleaninccom/role/ScheduleofbasicanddilutednetlosspershareTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r157",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Income (Loss) Per Share Attributable to Common Shareholders"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Income (Loss) Per Share Attributable to Common Shareholders"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/NetIncomeLossPerShareAttributabletoCommonShareholders"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r434"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "terseLabel": "Effect of foreign exchange rate changes on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r361"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Equipment [Member]"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r77",
      "r78",
      "r79",
      "r129",
      "r130",
      "r131",
      "r133",
      "r139",
      "r141",
      "r165",
      "r226",
      "r312",
      "r317",
      "r365",
      "r366",
      "r367",
      "r387",
      "r388",
      "r419",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r558",
      "r559",
      "r560",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockWarrantsDetails",
      "http://www.cleaninccom/role/NatureoftheBusinessDetails",
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails",
      "http://www.cleaninccom/role/ScheduleofoutstandingwarrantstopurchasesharesofcommonstockTable",
      "http://www.cleaninccom/role/ScheduleofunobservableinputstotheconversionfeaturewarrantliabilityandcontingentearnoutvaluationmodelsTable",
      "http://www.cleaninccom/role/ShareholdersEquityType2or3",
      "http://www.cleaninccom/role/StockBasedCompensationDetails",
      "http://www.cleaninccom/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityFairValueAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties.",
        "label": "Equity, Fair Value Adjustment",
        "terseLabel": "Clene Nanomedicine contingent earn-out"
       }
      }
     },
     "localname": "EquityFairValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Shareholder ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ExchangeClearedMember": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction where an organization acts as an intermediary, reconciling orders between transacting parties.",
        "label": "Exchange Cleared [Member]",
        "terseLabel": "Exchange Ratio [Member]"
       }
      }
     },
     "localname": "ExchangeClearedMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees": {
     "auth_ref": [
      "r527"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expense related to distribution, servicing and underwriting fees.",
        "label": "Expense Related to Distribution or Servicing and Underwriting Fees",
        "terseLabel": "Underwriting fees (in Dollars)"
       }
      }
     },
     "localname": "ExpenseRelatedToDistributionOrServicingAndUnderwritingFees",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of debt extinguished.",
        "label": "Extinguishment of Debt, Amount",
        "terseLabel": "Debt extinguishment"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConvertibleNotesDetails",
      "http://www.cleaninccom/role/NotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r106",
      "r296"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Change in fair value of preferred stock warrant liability"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r423",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r273",
      "r289",
      "r290",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r424",
      "r488",
      "r489",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/FairValue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r273",
      "r324",
      "r325",
      "r330",
      "r332",
      "r424",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r273",
      "r289",
      "r290",
      "r324",
      "r325",
      "r330",
      "r332",
      "r424",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r273",
      "r289",
      "r290",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r424",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofunobservableinputstotheconversionfeaturewarrantliabilityandcontingentearnoutvaluationmodelsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r427",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofunobservableinputstotheconversionfeaturewarrantliabilityandcontingentearnoutvaluationmodelsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r427",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of unobservable inputs to the conversion feature, warrant liability, and contingent earn-out valuation models"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/FairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r427"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r273",
      "r289",
      "r290",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r488",
      "r489",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r459",
      "r463",
      "r472"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleoffinanceandoperatingleasecostsTable": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest on lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoffinanceandoperatingleasecostsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease Liability [Abstract]",
        "terseLabel": "Finance lease costs:"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoffinanceandoperatingleasecostsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r458"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Finance lease obligations, current portion"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r458"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Finance lease obligations, net of current portion"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r460",
      "r467"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedCashFlow": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Payments of finance lease obligations"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r459",
      "r463",
      "r472"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleoffinanceandoperatingleasecostsTable": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoffinanceandoperatingleasecostsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r469",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Finance lease weighted-average remaining term"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/LeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation and Transactions"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis": {
     "auth_ref": [
      "r482",
      "r483",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by adjustment for effect of reorganization under Chapter 11 of Bankruptcy Code. Includes, but is not limited to, adjustment for reorganization plan effect and adoption of fresh-start reporting.",
        "label": "Reorganization, Chapter 11 [Axis]"
       }
      }
     },
     "localname": "FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesGross": {
     "auth_ref": [
      "r236"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetTable": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures, Gross",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnContractTermination": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform.",
        "label": "Gain (Loss) on Contract Termination",
        "terseLabel": "Gain on termination of lease"
       }
      }
     },
     "localname": "GainLossOnContractTermination",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": {
     "auth_ref": [
      "r414"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedCashFlow": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.",
        "label": "Gain (Loss) on Derivative Instruments, Net, Pretax",
        "negatedLabel": "Change in fair value of derivative"
       }
      }
     },
     "localname": "GainLossOnDerivativeInstrumentsNetPretax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnDispositionOfIntangibleAssets": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedCashFlow": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of intangible assets.",
        "label": "Gain (Loss) on Disposition of Intangible Assets",
        "negatedLabel": "Loss on extinguishment of convertible notes payable"
       }
      }
     },
     "localname": "GainLossOnDispositionOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnTerminationOfLease": {
     "auth_ref": [
      "r456"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedCashFlow": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term.",
        "label": "Gain (Loss) on Termination of Lease",
        "negatedLabel": "Gain on termination of lease",
        "terseLabel": "Gain on termination of lease"
       }
      }
     },
     "localname": "GainLossOnTerminationOfLease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow",
      "http://www.cleaninccom/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r106",
      "r293",
      "r294"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedCashFlow": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Gain on extinguishment of notes payable"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative [Member]",
        "verboseLabel": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/PropertyandEquipmentNetDetails",
      "http://www.cleaninccom/role/ScheduleofstockbasedcompensationexpenseTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncentiveToLessee": {
     "auth_ref": [
      "r449",
      "r450",
      "r455"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of incentive granted by lessor to lessee.",
        "label": "Incentive to Lessee",
        "terseLabel": "Lease incentive"
       }
      }
     },
     "localname": "IncentiveToLessee",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r124",
      "r393"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofcomponentsofincomelossbeforeincometaxesTable": {
       "order": 1.0,
       "parentTag": "clnn_TotalLossBeforeIncomeTaxes",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofcomponentsofincomelossbeforeincometaxesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r81",
      "r186",
      "r196",
      "r200",
      "r203",
      "r206",
      "r513",
      "r522",
      "r528",
      "r549"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net income (loss) before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r124",
      "r393"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofcomponentsofincomelossbeforeincometaxesTable": {
       "order": 2.0,
       "parentTag": "clnn_TotalLossBeforeIncomeTaxes",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofcomponentsofincomelossbeforeincometaxesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r239",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/PropertyandEquipmentNetDetails",
      "http://www.cleaninccom/role/ScheduleofbasicanddilutednetlosspershareTable",
      "http://www.cleaninccom/role/ScheduleofstockbasedcompensationexpenseTable",
      "http://www.cleaninccom/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/PropertyandEquipmentNetDetails",
      "http://www.cleaninccom/role/ScheduleofstockbasedcompensationexpenseTable",
      "http://www.cleaninccom/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r125",
      "r380",
      "r381",
      "r384",
      "r389",
      "r394",
      "r398",
      "r399",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r126",
      "r140",
      "r141",
      "r185",
      "r379",
      "r390",
      "r396",
      "r550"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r76",
      "r375",
      "r376",
      "r381",
      "r382",
      "r383",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedCashFlow": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedCashFlow": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedCashFlow": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedCashFlow": {
       "order": 23.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedLabel": "Deferred income tax"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueToRelatedParties": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedCashFlow": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.",
        "label": "Increase (Decrease) in Due to Related Parties",
        "terseLabel": "Payable to related parties"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueToRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedCashFlow": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r105",
      "r467"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedCashFlow": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease obligations"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedCashFlow": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Deferred revenue from related parties"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedCashFlow": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r92",
      "r279",
      "r288",
      "r291",
      "r292"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income earned from interest bearing assets classified as other.",
        "label": "Interest Income, Other",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/NotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestOnConvertibleDebtNetOfTax": {
     "auth_ref": [
      "r144",
      "r148",
      "r156"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of interest recognized on convertible debt instrument excluding interest on principal required to be paid in cash.",
        "label": "Interest on Convertible Debt, Net of Tax",
        "terseLabel": "Less interest expense on potentially dilutive convertible notes payable (in Dollars)"
       }
      }
     },
     "localname": "InterestOnConvertibleDebtNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofbasicanddilutednetlosspershareTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Inventory Finished Goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r4",
      "r58",
      "r484"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r16",
      "r59",
      "r115",
      "r163",
      "r228",
      "r229",
      "r230",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r57"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Inventory in raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r470",
      "r472"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleoffinanceandoperatingleasecostsTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoffinanceandoperatingleasecostsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of finance and operating lease costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "auth_ref": [
      "r12",
      "r236"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetTable": {
       "order": 3.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements, Gross",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeasesOfLesseeDisclosureTextBlock": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.",
        "label": "Leases of Lessee Disclosure [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LeasesOfLesseeDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r471"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeaseDescription": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of lessor's operating lease.",
        "label": "Lessor, Operating Lease, Description",
        "terseLabel": "Description of lease term"
       }
      }
     },
     "localname": "LessorOperatingLeaseDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r46",
      "r122",
      "r198",
      "r225",
      "r247",
      "r248",
      "r249",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r406",
      "r410",
      "r411",
      "r433",
      "r482",
      "r483"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "TOTAL LIABILITIES"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r33",
      "r122",
      "r225",
      "r433",
      "r484",
      "r518",
      "r540"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r48",
      "r122",
      "r225",
      "r247",
      "r248",
      "r249",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r406",
      "r410",
      "r411",
      "r433",
      "r482",
      "r483",
      "r484"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.",
        "label": "Long-lived Assets by Geographic Areas [Table Text Block]",
        "terseLabel": "Schedule of property and equipment, net by location"
       }
      }
     },
     "localname": "LongLivedAssetsByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/GeographicandSegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r23",
      "r272",
      "r287",
      "r289",
      "r290",
      "r517",
      "r536"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Term loan"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/NotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermNotesPayable": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Notes Payable, Noncurrent",
        "terseLabel": "Notes payable"
       }
      }
     },
     "localname": "LongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MachineryAndEquipmentGross": {
     "auth_ref": [
      "r12",
      "r236"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetTable": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment, Gross",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r102",
      "r104",
      "r107"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "terseLabel": "Net cash (used in) operating activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow",
      "http://www.cleaninccom/role/NatureoftheBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r71",
      "r73",
      "r79",
      "r82",
      "r107",
      "r122",
      "r132",
      "r134",
      "r135",
      "r136",
      "r137",
      "r140",
      "r141",
      "r152",
      "r186",
      "r196",
      "r200",
      "r203",
      "r206",
      "r225",
      "r247",
      "r248",
      "r249",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r421",
      "r433",
      "r523",
      "r545"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net income (loss)",
        "verboseLabel": "Net income loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow",
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement",
      "http://www.cleaninccom/role/NatureoftheBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r134",
      "r135",
      "r136",
      "r137",
      "r142",
      "r143",
      "r153",
      "r156",
      "r186",
      "r196",
      "r200",
      "r203",
      "r206"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net income (loss) attributable to common shareholders \u2013 Basic (in Dollars)"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofbasicanddilutednetlosspershareTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r144",
      "r147",
      "r148",
      "r149",
      "r150",
      "r153",
      "r156"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "terseLabel": "Net income (loss) attributable to common shareholders - Diluted (in Dollars)"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofbasicanddilutednetlosspershareTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosure:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesAndLoansPayable": {
     "auth_ref": [
      "r23",
      "r517",
      "r536"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of all notes and loans payable (with maturities initially due after one year or beyond the operating cycle if longer).",
        "label": "Notes and Loans Payable",
        "terseLabel": "Note payable"
       }
      }
     },
     "localname": "NotesAndLoansPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/NotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "auth_ref": [
      "r45"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of notes payable.",
        "label": "Notes Payable, Fair Value Disclosure",
        "terseLabel": "Notes payable"
       }
      }
     },
     "localname": "NotesPayableFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoffairvaluehierarchyofliabilitiesmeasuredatfairvalueonrecurringbasisTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableOtherPayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A written promise to pay a note to a third party.",
        "label": "Notes Payable, Other Payables [Member]",
        "terseLabel": "Notes Payable [Member]"
       }
      }
     },
     "localname": "NotesPayableOtherPayablesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/NotesPayableDetails",
      "http://www.cleaninccom/role/ScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r186",
      "r196",
      "r200",
      "r203",
      "r206"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Income (loss) from operations",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement",
      "http://www.cleaninccom/role/ScheduleofdrugsandsupplementssegmentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r464",
      "r472"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleoffinanceandoperatingleasecostsTable": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoffinanceandoperatingleasecostsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r458"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Terminated operating lease liability",
        "totalLabel": "Present value of future lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/LeasesDetails",
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r458"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedLabel": "Less lease obligations, current portion",
        "terseLabel": "Operating lease obligations, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet",
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r458"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease obligations, net of current portion",
        "verboseLabel": "Lease obligations \u2013 long term portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet",
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r457"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r469",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating lease weighted-average remaining term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/LeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r448",
      "r451"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Operating Leases, Future Minimum Payments Due",
        "totalLabel": "Total undiscounted cash flows"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r448",
      "r451"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r448",
      "r451"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Four Years",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r448",
      "r451"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Three Years",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r448",
      "r451"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Two Years",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": {
     "auth_ref": [
      "r448",
      "r451"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due Thereafter",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Remainder of Fiscal Year",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofnoncancelablefinanceandoperatingleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r47"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofaccruedliabilitiesTable": {
       "order": 7.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofaccruedliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTax": {
     "auth_ref": [
      "r68",
      "r77",
      "r83",
      "r379",
      "r395",
      "r397",
      "r435",
      "r438",
      "r440",
      "r524",
      "r546"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Tax",
        "negatedTotalLabel": "Total other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncome": {
     "auth_ref": [
      "r551"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue and income classified as other.",
        "label": "Other Income",
        "terseLabel": "Amount of income"
       }
      }
     },
     "localname": "OtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/NotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashExpense": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other.",
        "label": "Other Noncash Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "OtherNoncashExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement": {
       "order": 7.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense), net:"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "terseLabel": "Other income and expenses"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r6",
      "r8",
      "r232"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofprepaidexpensesandothercurrentassetsTable": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofprepaidexpensesandothercurrentassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherUnderwritingExpense": {
     "auth_ref": [
      "r552",
      "r564"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs incurred during the period, such as those relating to general administration and policy maintenance that do not vary with and are not primarily related to the acquisition or renewal of insurance contracts.",
        "label": "Other Underwriting Expense",
        "terseLabel": "Deferred underwriting fees (in Dollars)"
       }
      }
     },
     "localname": "OtherUnderwritingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtExtinguishmentCosts": {
     "auth_ref": [
      "r99"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.",
        "label": "Payment for Debt Extinguishment or Debt Prepayment Cost",
        "terseLabel": "Loss on extinguishment of debt"
       }
      }
     },
     "localname": "PaymentsOfDebtExtinguishmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedCashFlow": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Payments of debt issuance costs",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow",
      "http://www.cleaninccom/role/NotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedCashFlow": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "negatedLabel": "Payments of deferred transaction costs"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r340",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockConvertibleConversionPrice": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share conversion price of preferred stock.",
        "label": "Preferred Stock, Convertible, Conversion Price",
        "terseLabel": "Convertible per share (in Dollars per share)"
       }
      }
     },
     "localname": "PreferredStockConvertibleConversionPrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r25",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock par value (in Dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockTextBlock": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.",
        "label": "Preferred Stock [Text Block]",
        "terseLabel": "Preferred Stock Warrant Liability"
       }
      }
     },
     "localname": "PreferredStockTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/PreferredStockWarrantLiability"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r7",
      "r35",
      "r36"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r6",
      "r8",
      "r231",
      "r232"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofprepaidexpensesandothercurrentassetsTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofprepaidexpensesandothercurrentassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrentAndNoncurrent": {
     "auth_ref": [
      "r519",
      "r543"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.",
        "label": "Prepaid Expense",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement [Member]"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockWarrantsDetails",
      "http://www.cleaninccom/role/NatureoftheBusinessDetails",
      "http://www.cleaninccom/role/NetIncomeLossPerShareAttributabletoCommonShareholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from issuance of convertible notes payable"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedCashFlow": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "terseLabel": "Proceeds from issuance of Series D Preferred Stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrantsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Warrant Liability [Abstract]"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrantsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Proceeds from the private placement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromOtherDebt": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from debt classified as other.",
        "label": "Proceeds from Other Debt",
        "terseLabel": "Proceeds from the issuance of notes payable"
       }
      }
     },
     "localname": "ProceedsFromOtherDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRoyaltiesReceived": {
     "auth_ref": [
      "r103"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received for royalties during the current period.",
        "label": "Proceeds from Royalties Received",
        "terseLabel": "Royalty revenues"
       }
      }
     },
     "localname": "ProceedsFromRoyaltiesReceived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r95",
      "r364"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from warrants exercised"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product revenue"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r71",
      "r73",
      "r79",
      "r101",
      "r122",
      "r132",
      "r140",
      "r141",
      "r186",
      "r196",
      "r200",
      "r203",
      "r206",
      "r225",
      "r247",
      "r248",
      "r249",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r404",
      "r407",
      "r408",
      "r412",
      "r413",
      "r421",
      "r433",
      "r528"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r240",
      "r576",
      "r577",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/PropertyandEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r39",
      "r236"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetTable": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "totalLabel": "Total property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment [Member]",
        "terseLabel": "Property, Plant and Equipment [Member]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r18",
      "r19",
      "r238",
      "r484",
      "r529",
      "r541"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net",
        "verboseLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet",
      "http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetTable",
      "http://www.cleaninccom/role/ScheduleofpropertyandequipmentnetbylocationTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r38",
      "r238",
      "r576",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r18",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/PropertyandEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful lives of asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r331",
      "r477",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r331",
      "r477",
      "r478",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/NatureoftheBusinessDetails",
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/NatureoftheBusinessDetails",
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r477"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Consulting services expenses"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r331",
      "r477",
      "r479",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r475",
      "r476",
      "r478",
      "r480",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedCashFlow": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedLabel": "Payments of notes payable"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r374",
      "r499",
      "r590"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development [Member]",
        "verboseLabel": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/PropertyandEquipmentNetDetails",
      "http://www.cleaninccom/role/ScheduleofstockbasedcompensationexpenseTable",
      "http://www.cleaninccom/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r113",
      "r514",
      "r537"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Reconciliation of cash and restricted cash to the condensed consolidated balance sheets"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r10",
      "r20",
      "r113",
      "r572"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedInvestments": {
     "auth_ref": [
      "r571",
      "r573"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not defined as or included in marketable (debt, equity, or other) securities whose use is restricted in whole or in part, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet.",
        "label": "Restricted Investments",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockExpense": {
     "auth_ref": [
      "r106"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement.",
        "label": "Restricted Stock or Unit Expense",
        "terseLabel": "Stock-based compensation expense associated with restricted stock awards"
       }
      }
     },
     "localname": "RestrictedStockExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails",
      "http://www.cleaninccom/role/ScheduleofrestrictedcommonstockactivityTable",
      "http://www.cleaninccom/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r29",
      "r317",
      "r368",
      "r484",
      "r539",
      "r561",
      "r563"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet",
      "http://www.cleaninccom/role/NatureoftheBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r129",
      "r130",
      "r131",
      "r133",
      "r139",
      "r141",
      "r226",
      "r365",
      "r366",
      "r367",
      "r387",
      "r388",
      "r419",
      "r558",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r116",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r80",
      "r122",
      "r183",
      "r184",
      "r195",
      "r201",
      "r202",
      "r208",
      "r209",
      "r213",
      "r225",
      "r247",
      "r248",
      "r249",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r433",
      "r528"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Total revenue",
        "verboseLabel": "Revenue from external customers"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement",
      "http://www.cleaninccom/role/ScheduleofdrugsandsupplementssegmentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r468",
      "r472"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Lease liability arising from obtaining right-of-use assets, leasehold improvements, and lease incentives"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty revenue"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockWarrantsDetails",
      "http://www.cleaninccom/role/NatureoftheBusinessDetails",
      "http://www.cleaninccom/role/NetIncomeLossPerShareAttributabletoCommonShareholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/AccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of securities excluded from computation of diluted net income (loss) per share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/NetIncomeLossPerShareAttributabletoCommonShareholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Schedule of supplemental cash flow information"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r51",
      "r127",
      "r289",
      "r291",
      "r313",
      "r314",
      "r315",
      "r316",
      "r443",
      "r444",
      "r447",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of long-term debt, net of original issue discount and unamortized debt issuance costs"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/NotesPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative liabilities at fair value.",
        "label": "Schedule of Derivative Liabilities at Fair Value [Table Text Block]",
        "terseLabel": "Schedule of changes in fair value of financial liabilities related to the notes payable, the derivative instrument, the preferred stock warrants, and the contingent earn-outs"
       }
      }
     },
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/FairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of basic and diluted net loss per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/NetIncomeLossPerShareAttributabletoCommonShareholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r423",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of fair value hierarchy of liabilities measured at fair value on recurring basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/FairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of components of income (loss) before income taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.",
        "label": "Share-based Payment Arrangement, Outstanding Award, Activity, Excluding Option [Table Text Block]",
        "terseLabel": "Schedule of stock-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r186",
      "r187",
      "r199",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofdrugsandsupplementssegmentsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r186",
      "r187",
      "r199",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of drugs and supplements segments"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/GeographicandSegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of restricted common stock activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r343",
      "r351",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of outstanding common stock options and related activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of assumptions used to calculate the fair value of stock options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r318",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of outstanding warrants to purchase shares of common stock"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockWarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r180",
      "r181",
      "r182",
      "r186",
      "r188",
      "r200",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r212",
      "r213",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Geographic and Segment Information"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/GeographicandSegmentInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofdrugsandsupplementssegmentsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/PreferredStockWarrantLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series C preferred stock or outstanding series C preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series C Preferred Stock [Member]",
        "terseLabel": "Series C Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesCPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/PreferredStockWarrantLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesDPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series D preferred stock or outstanding series D preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series D Preferred Stock [Member]",
        "terseLabel": "Series D Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesDPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/PreferredStockWarrantLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period.",
        "label": "Series of Individually Immaterial Business Acquisitions [Member]",
        "terseLabel": "Series of Individually Immaterial Business Acquisitions [Member]"
       }
      }
     },
     "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/FairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant-date fair value of RSUs granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsTable",
      "http://www.cleaninccom/role/ScheduleofunobservableinputstotheconversionfeaturewarrantliabilityandcontingentearnoutvaluationmodelsTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected stock price volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsTable",
      "http://www.cleaninccom/role/ScheduleofunobservableinputstotheconversionfeaturewarrantliabilityandcontingentearnoutvaluationmodelsTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "verboseLabel": "risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsTable",
      "http://www.cleaninccom/role/ScheduleofunobservableinputstotheconversionfeaturewarrantliabilityandcontingentearnoutvaluationmodelsTable",
      "http://www.cleaninccom/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available to be issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of Options, Forfeited",
        "negatedTerseLabel": "Number of Restricted Stock Awards, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofoutstandingcommonstockoptionsandrelatedactivityTable",
      "http://www.cleaninccom/role/ScheduleofrestrictedcommonstockactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Shares granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of Options, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofoutstandingcommonstockoptionsandrelatedactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r345",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Options, Ending Balance",
        "periodStartLabel": "Number of Options, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofoutstandingcommonstockoptionsandrelatedactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price Per Share, Ending Balance",
        "periodStartLabel": "Weighted Average Exercise Price Per Share, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofoutstandingcommonstockoptionsandrelatedactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per Share, Stock options vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofoutstandingcommonstockoptionsandrelatedactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of Options, Stock options vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofoutstandingcommonstockoptionsandrelatedactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": {
     "auth_ref": [
      "r338",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares purchased for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award",
        "terseLabel": "Shares issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r338",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails",
      "http://www.cleaninccom/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per Share, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofoutstandingcommonstockoptionsandrelatedactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per Share, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofoutstandingcommonstockoptionsandrelatedactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per Share, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofoutstandingcommonstockoptionsandrelatedactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Tranche one [Member]"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/NotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Tranche Two [Member]"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/NotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r340",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage amount by which a share price is expected to fluctuate during the expected term of a nonvested share or option award issued to other than an employee.",
        "label": "Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate",
        "terseLabel": "Expected stock price volatility"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Shares price (in Dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r356",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsTable",
      "http://www.cleaninccom/role/ScheduleofunobservableinputstotheconversionfeaturewarrantliabilityandcontingentearnoutvaluationmodelsTable",
      "http://www.cleaninccom/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Term (Years), Ending Balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofoutstandingcommonstockoptionsandrelatedactivityTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares",
        "periodEndLabel": "Ending balance, Number of Restricted Stock Awards, Unvested balance",
        "periodStartLabel": "Beginning balance, Number of Restricted Stock Awards, Unvested balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofrestrictedcommonstockactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted- Average Grant Date Fair Value, Forfeited"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofrestrictedcommonstockactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance, Weighted- Average Grant Date Fair Value, Unvested balance",
        "periodStartLabel": "Beginning balance, Weighted- Average Grant Date Fair Value, Unvested balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofrestrictedcommonstockactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Term (Years), Beginning Balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofoutstandingcommonstockoptionsandrelatedactivityTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares",
        "negatedLabel": "Number of Restricted Stock Awards, Vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofrestrictedcommonstockactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted- Average Grant Date Fair Value, Vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofrestrictedcommonstockactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares issued (in Shares)",
        "netLabel": "Warrants to purchase common stock (in Shares)",
        "terseLabel": "Shares issued",
        "verboseLabel": "Shares, issued"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockWarrantsDetails",
      "http://www.cleaninccom/role/FairValueDetails",
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails",
      "http://www.cleaninccom/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in Shares)",
        "periodStartLabel": "Balances (in Shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConvertibleNotesDetails",
      "http://www.cleaninccom/role/NotesPayableDetails",
      "http://www.cleaninccom/role/ScheduleofchangesinfairvalueoffinancialliabilitiesrelatedtothenotespayablethederivativeinstrumentthepreferredstockwarrantsandthecontingentearnoutsTable",
      "http://www.cleaninccom/role/ScheduleofunobservableinputstotheconversionfeaturewarrantliabilityandcontingentearnoutvaluationmodelsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConvertibleNotesDetails",
      "http://www.cleaninccom/role/NotesPayableDetails",
      "http://www.cleaninccom/role/ScheduleofunobservableinputstotheconversionfeaturewarrantliabilityandcontingentearnoutvaluationmodelsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r465",
      "r472"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleoffinanceandoperatingleasecostsTable": {
       "order": 4.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term Lease, Cost",
        "terseLabel": "Short-term lease costs"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoffinanceandoperatingleasecostsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r114",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r24",
      "r25",
      "r26",
      "r119",
      "r122",
      "r145",
      "r146",
      "r151",
      "r154",
      "r156",
      "r166",
      "r167",
      "r168",
      "r225",
      "r247",
      "r251",
      "r252",
      "r253",
      "r256",
      "r257",
      "r297",
      "r298",
      "r302",
      "r306",
      "r312",
      "r433",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/PreferredStockWarrantLiabilityDetails",
      "http://www.cleaninccom/role/RedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r55",
      "r77",
      "r78",
      "r79",
      "r129",
      "r130",
      "r131",
      "r133",
      "r139",
      "r141",
      "r165",
      "r226",
      "r312",
      "r317",
      "r365",
      "r366",
      "r367",
      "r387",
      "r388",
      "r419",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r558",
      "r559",
      "r560",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockWarrantsDetails",
      "http://www.cleaninccom/role/NatureoftheBusinessDetails",
      "http://www.cleaninccom/role/NetIncomeLossPerShareAttributabletoCommonShareholdersDetails",
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails",
      "http://www.cleaninccom/role/ScheduleofoutstandingwarrantstopurchasesharesofcommonstockTable",
      "http://www.cleaninccom/role/ScheduleofunobservableinputstotheconversionfeaturewarrantliabilityandcontingentearnoutvaluationmodelsTable",
      "http://www.cleaninccom/role/ShareholdersEquityType2or3",
      "http://www.cleaninccom/role/StockBasedCompensationDetails",
      "http://www.cleaninccom/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement",
      "http://www.cleaninccom/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r165",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement",
      "http://www.cleaninccom/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r54",
      "r276",
      "r312",
      "r313",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Convertible shares (in Shares)",
        "verboseLabel": "Stock option outstanding (post-conversion)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConvertibleNotesDetails",
      "http://www.cleaninccom/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "auth_ref": [
      "r25",
      "r26",
      "r312",
      "r313",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).",
        "label": "Stock Issued During Period, Shares, Conversion of Units",
        "terseLabel": "Issuance of Series D Preferred Stock in connection with the extinguishment of convertible promissory notes (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r25",
      "r26",
      "r312",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock upon the private offering (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Shares, Other",
        "terseLabel": "Issuance of common stock upon vesting of restricted stock awards (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r25",
      "r26",
      "r312",
      "r317",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "terseLabel": "Exercise of stock options (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": {
     "auth_ref": [
      "r55",
      "r312",
      "r317"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).",
        "label": "Stock Issued During Period, Value, Conversion of Units",
        "terseLabel": "Issuance of Series D Preferred Stock in connection with the extinguishment of convertible promissory notes"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfUnits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r25",
      "r26",
      "r312",
      "r317"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock upon the private offering"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Value, Other",
        "terseLabel": "Issuance of common stock upon vesting of restricted stock awards"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited": {
     "auth_ref": [
      "r362"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, Forfeited",
        "terseLabel": "Shares Issued, Value, Share-based Payment Arrangement, Forfeited (in Dollars)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationForfeited",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r55",
      "r312",
      "r317"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Equity Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofassumptionsusedtocalculatethefairvalueofstockoptionsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockOptionPlanExpense": {
     "auth_ref": [
      "r106"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for option under share-based payment arrangement.",
        "label": "Stock or Unit Option Plan Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "StockOptionPlanExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r26",
      "r31",
      "r32",
      "r122",
      "r222",
      "r225",
      "r433",
      "r484"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balances",
        "totalLabel": "TOTAL STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet",
      "http://www.cleaninccom/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r120",
      "r298",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r317",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/CommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventDescription": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the event or transaction that occurred between the balance sheet date and the date the financial statements are issued or available to be issued.",
        "label": "Subsequent Event, Description",
        "terseLabel": "Subsequent events, description"
       }
      }
     },
     "localname": "SubsequentEventDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r441",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r441",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r485",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockWarrantsDetails",
      "http://www.cleaninccom/role/NatureoftheBusinessDetails",
      "http://www.cleaninccom/role/NetIncomeLossPerShareAttributabletoCommonShareholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Income tax payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TypeOfFreshStartAdjustmentDomain": {
     "auth_ref": [
      "r482",
      "r483",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment for effect of reorganization under Chapter 11 of Bankruptcy Code. Includes, but is not limited to, adjustment for reorganization plan effect and adoption of fresh-start reporting.",
        "label": "Reorganization, Chapter 11 [Domain]"
       }
      }
     },
     "localname": "TypeOfFreshStartAdjustmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.",
        "label": "Unamortized Debt Issuance Expense",
        "negatedLabel": "Unamortized debt issuance costs and original issue discounts"
       }
      }
     },
     "localname": "UnamortizedDebtIssuanceExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoflongtermdebtnetoforiginalissuediscountandunamortizeddebtissuancecostsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r169",
      "r170",
      "r172",
      "r173",
      "r176",
      "r177",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Approach and Technique [Axis]"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleofunobservableinputstotheconversionfeaturewarrantliabilityandcontingentearnoutvaluationmodelsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r466",
      "r472"
     ],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleoffinanceandoperatingleasecostsTable": {
       "order": 5.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease costs"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ScheduleoffinanceandoperatingleasecostsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/NotesPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/NotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantExercisePriceDecrease": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.",
        "label": "Warrant, Exercise Price, Decrease",
        "terseLabel": "Exercise price"
       }
      }
     },
     "localname": "WarrantExercisePriceDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/PreferredStockWarrantLiabilityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_WarrantExercisePriceIncrease": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision.",
        "label": "Warrant, Exercise Price, Increase",
        "terseLabel": "Warrant, Exercise Price, Increase (in Dollars per share)"
       }
      }
     },
     "localname": "WarrantExercisePriceIncrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/CommonStockWarrantsDetails",
      "http://www.cleaninccom/role/NatureoftheBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrants expire"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/PreferredStockWarrantLiabilityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r144",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in Shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "calculation": {
      "http://www.cleaninccom/role/ScheduleofbasicanddilutednetlosspershareTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted average common shares outstanding",
        "totalLabel": "Weighted average common shares outstanding \u2013Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/NetIncomeLossPerShareAttributabletoCommonShareholdersDetails",
      "http://www.cleaninccom/role/ScheduleofbasicanddilutednetlosspershareTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r142",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in Shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cleaninccom/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124502072&loc=SL77927221-108306"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "b",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124267575&loc=SL82921835-210448"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "c(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e39076-109324"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123415192&loc=d3e40010-112707"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20,22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123415192&loc=d3e40019-112707"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406127&loc=d3e45023-112735"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123386454&loc=d3e45280-112737"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "840",
   "URI": "http://asc.fasb.org/topic&trid=2208923"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123388062&loc=SL77916639-209961"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123386189&loc=SL77918607-209975"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919359-209981"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919372-209981"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.14)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.10)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.4)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.7)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "720",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=35755714&loc=d3e28434-158551"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04.2)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413209&loc=SL6242269-115581"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r591": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r592": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r593": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r594": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r595": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r596": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r597": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r598": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>101
<FILENAME>0001213900-21-057373-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-21-057373-xbrl.zip
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M7((=&#%^7IH'DLN]2E)FP1[Y%_EJ8>[P6!>!:PCYV83$\Z2_F+Y+&]F^P_)
MHQF:V%[X %],8VE!\N*V!E&[TRJ]460S']Z^<.MJ5,H"(WK?AVPZ.O5'+-Q+
MASO[#IPK?,A*6VRASFH0M08K(/W*]FFB)CF2<PQ9C?=&U[D>SSPZNX7.;!E,
M2@<)Y\B&XHFN'14*CT.XTQ6812=2SSSKN7EB7X;1!NGM\Y IW/I67G11X,OK
M?QJ<:MR-'IF9U+GD8KMXU)4BV8D'H1([R;TA'B[-\LFI:[C;NM#F$+$#1E%
M'0+,JG8F*=+T3S<OQ^[EBS_Z>)%5IV4F_#%-C+"Q2W]S<GI0>EW+%IE6LUC6
MQ4";0L%6F'GSF*6X5;QR U#V.9,SBJ2XQ<0Z<*S_!&6WV>3-S295B%I\%#E[
MI;AE9#MO26E'B/1L>M;31>)DP4]_R:M1GI<1XKGF$D5)(B D!F:['\.(&O)Q
M'#$K&*19DB6OIF%JP2EVJ/US/3^FII0RFKHVA#*2[8H9YR(\']&RY/-G &'0
M//V\Y(KO0*L&RI,,^U(^EP%Y/4J(LFNF)A-J'*XFU]028YB;_>4)L(K:D'+(
MV\,G 047FG!Y;&O((L="TM%-'IQB7;(-%<-IYT/N0+O605_3J.]RKE?2W3WM
M#39YN$PUYAKE%0F01?,1N]Q.XS(: ]C0 JR2Y.-M(ED+K)+DHVTB60NLDN3A
M-I&L!78M8SD[TV0,Z:U 2[?8M#F9=9??-V\*+SJ!%Q^TXTZ7)E KA-;JP*<1
MA#11R>HT):D,P74<.C.;H%)S@W11"Z9P,;4=;I6^[R2\3SUT;7R/O2CC4L(V
MDY13B;'[1J4Q@M2&NNJVHS$4MP K\1C8P=]\30T;V9P+D%^$/A$RD;)^1,$T
MM!<S%@-*;P89X4D0SOE)*8OT5A'Z-LH*J&(4C9=^D!Q=-RXTN2$*GXVA!D4<
M-TB;["+!=7V5E"Z^^5-J:(7 9^3HGU%%&Z3):P$*;ELR-WM;BEJVR0*WK%'&
M13-T%--U%"+9GH)QXTH%57C_I;"=08JN U(BQN%T&J*I':&LR%/@(.22>B4A
MDP^Y:Y,@8</59()"=JJ#;#0O9-7;',HP)3>U91S)>)'<9;86*6ZJ8K<0LB02
MD'*C<KYPY5.0:UCZ<W%)[B?/ P/W4$O47T+UBT1[S=H_U46J.*A6SG7).[QF
M&1DHXYT!U.IC%1^MC.=S.L""R:TWQ:RJ%XY*-Q+#A<,>,G;>[(!>%EUOTYM!
M$VQ'W$*=*%\X3HU<0#O] [E7D'[D>@#&]C]R@E]F)5GI$R'DPPUZ0"'<"><D
M]_*D=S$\>M&,^J01PC-[3NU)(S1EZFA9"SVR^-J*'S!H2*V-$JV=CFL[O IO
M(\A$9GF!9&VNPCIK=XI12NN>D&-V,YR/W/M%@ 6,-64RU0,KF4.D45N2AFT-
MH%8/IRS;["G)L<\JU?(=^)?)I1%!$P]&@:2SGF[@KUH- >1X<]M_9M*T<"J<
M6_(3\MT1/B5.&#Q>)Y=QV-.ZK7F!*SJDZ*0I 8V&!F@A!Y0P@Z\L/I,D(@(F
M$T:V/(9+;K2LO5'Q"QWTLB6$#1?:PU8LR2KPL3]@D6:$;50 E FV]%X6-X!'
M+^^CB(!)$T;-*I'.J8<N3G]ZH.^0<T3=T' X#1'[]011$^,M.+[42Q37U@ I
M*:65AD6YB2F)F(?876?<:?6R8JTA"Q>=>9B178F8FB-AL/L%8XB:0(6Y)Z*L
M%0.,I!B;;&3"*9<T%I>>VRA'Y P@2P%01EM3P<TD40^G[-)Q>9X1'<(7GH](
M1'V6 V-2A3J EB:]*7.MBN[6,W\^1WY8';,D,J/?UV!;=( '>DTZ,-A"'1BL
M40<.MU$'#C5T@)U[9P?>=;,OS8[PK9<>5=+E%B77ML.[:H:M@1-H)]A=H\#F
MSB&=8$O8<%VDK)63MDS='].!VYE:@S:W=(%*-D;3$K,W<%H]F,0$#0DQ.8=0
MB%BT/"VVC#_2AE>X>DN[R1O?"N32_5M@SM7D/F6.P1<^-I#*R&*$@ST;S1=A
M\,!^,I@V/EP]1VT#$MQL624^:LF=\EF;30GU&<@5"UB'YKP>D,&[*$+(0B*K
M5BJUTEM@B!2XQ0O,\X0_L*/&*GXX0>A"F5U61(W5>!IA.E%/J8NU2?)7U>I6
M9(BKI;'2?(AU=C7VO2G32I)5P[&3:C@C'"$H-7QC1ROOC:X<\N\ 679BN*Q%
MG.Z&!G*@$VBA"I0/B)NZ0!!B;$.500L!*3KI)J0W7_BY8$^3&SX-GH_X>(77
MGQ<U+<^#Y H;<?4DHZRQ"KF(XB*U QK:>#B'Y&$ZC;EW 6T;!KZ?,HVL:G;6
ML'QM 59:CS+&=*I*6@^C8S\@F[WC9V7A<O&*1#IT'-J[>X+&^:8?G,DQVD46
M8A;/G.S=O/#L/9XP)ATEB P6IARW^+@&U!AV"ZTWF,(&5$D!FR0C'^[Z2T[(
MI7G[9B6UZ.&4! AOV(F<;!8RBS@Q-ID)';K968KTNBK8,+F \YYTL6<6@=I0
M-=(@ZMD%!H3N1<C$@RY/AQA&0[S>=+BUGN-KPA/1=$<YX,S0(.7%T/T2D\B\
MY#@MF)*SF%!3B]!WRGY0]>B?@ZB%JA7?JCFO+^>^K4J ;'Q2UH(]_CGPZ;1Z
M[LV]*.\'/EBID6T44[H"EVU"S^CXAR@C[>D&S8,'V[^:G&5W(!P'#PA#II1A
M8Z,]:)D^7'C8F\?S8YO,4M>*]@LN2=:3P6M6-7:M8OM7D]3.F.SX<]"*C'S5
M<4Y5(ZDW8/3:1HI;N"[GE83,H^FFALE:H!8O[+0Z,2B6UA*O_,AD/@P(Y_;L
M%_0R9>ADF1')G$HM>>S[R[1^?W+U<.JN0@_@D&>.WHL'MSM ENSU!(24;HW)
M^;<-6WEJ[%K34.'E%MHC/,)A% .T29!EE3?KQYIJO%50-1:4M78&&6D=D#([
M-KH^S27_B.'F$6_!O'4#7&<).%EAGX6-EVDSJ$J=7"C,]K$-H$F.3VQP*_&"
M8K2:M=;1 "FK'E$MK6VN.9'@E!Y X#<TRI@H$,IV+7(9-Y;VVI1M4#7E^"1.
M>RFB4\1R7CZ\(L"E*2!P@:YP];HUTX3$Q=CRR@"SS*,&2)G';>-G<B]7SJ"J
M094;Q7@!&57;DG?!QRM2RT2'BYL/BW#)1B,[:U@@B5"+%11RLWW64GWNQF3M
M;46'#CMTSJ!L!T.T*!%?5EA;9C_+3;DK#@4Q9MG:F%68*=W4G-VI;#"A8LRR
MVC#@>!S9!-)CYV )RW6^C7/<-="*LU1D;0WRX#5Q:NPP@:9?V.%7%*51LJ1>
M!*LP:99;U1*P6,9@UL9UW@UA&$S9>T?+XI4TY8)=NY->.Y0DT/#JB+Y<9'M=
MY$@N30KSTUE,^1I?--CH:8!?O[9<!NP&I\=J2ODU(Q?\2;C2"=)<:\7Y4A9L
MBQ)I4RERG6LM\XF79 .;,-4THG"0/E;) 512OLZ+%0 SR\RJ$*Y_I!3[%(3$
M29B4_'E&B)(ZK5TH4YTM/D#E^03S/"HQ--E%+:7P#O/&8#')LMM-24=4(10?
M;,O5=AZ$$<R<AM_?(0 L7KF7=H:U;ALW*D== [RX4%^>4&QN5K :H[C^@?*&
M6E.-:5OHLJK0NCT99(*[@-;8U#=5VB*(\C!ZO8U!\I.!TTV7,\8 <6%)2UGP
M;K,QO*Q86\B2FC.5%RM70+P@@7Q<DGH5L)8-0I)--:XQZBB$)AY8ERC*:H*;
MO.U0ABF43'HKU+5O.^RQF7DQ.B@UK7LBW5S8!FB@!)S.]6NF720GA*8N[VV,
M4:@!TLPJ,T@(?%QB=;+); /7+F[,M''Q2F^@J-3L9J&WER\1SP,E+AM2K]1M
MP#!I8I*%=(J7/W&W<U^:A$^5#5LA#=@)Y@@R/+)A-8SHE#B.(_A\%*3FK[3#
M;^HR:75B%-+NVKE!*Z_UD"$<U*=/CA\3J)(%^Q\$LJ)\'SE17-QN;4R<7A>K
MM$@0_1;Z/89DEP=D\(D'*<X.!!JDT4J$8NL'XH741#)\\IZ?$BHNUZ-H2*KZ
MY2/"%6#RZA0/K(0,<CR?#NP+!/<=E?TU-X"JL,\K$CXHB7$=4LG%""@VA( Z
M'B7VG^F#.*2>SR((HQBRXA"!RBGD_-HDDM0P9<IV1)>K7V\=.BL@ EL*#-)%
MX"+?#!J5^!07]1PG(: D9XB<GQ^;098"G7@1)+KBQRBRA/!4-]@88^YJ:%:\
M<L0<DG1PBI6OWH.AA)6%IGOHTQ!2A,!DA75J=R890@D?ENSLDL->&>P/]@_,
M((('268*>*<I3*%$B$QBDT_">&K(R"A#D2 NES<V!#D/TLIWT1A!60ND(B\M
MW]DRA:(J'*'5/?<FZ-;Q4O_-&+=2!$ML=:GKN?1M[)Z@A1VF52)^"F+":OS,
MY[">6)Z@!^0'"W.L63?0,B8LJ8DW9-*I@I& ID,-'=NA']QZ\]BWS5D%2)"M
M$HV]XX0QS2!X%>BRJ:!:JMX08OF@)(*]BF8HS,)?AM# @23=FAM=GYJ!O(1$
MG"]1*JEB#FK.@D8 WUXZ,P0[\T&$V%T<["8.>VX(+0IXLD(\HJ:0NFLX=26(
MDD0=3C$Y4U10ADV62\M-AC.#)CDXZ1X02WVA/A1=V+XR@Q@>)$T2!OO&D9!#
MDN_$+1;) T,&21.0L&AU$$4(STPQRG4X0A-U]QC<S>A2@:X>+CV,(H0PV],R
MQS?10"BM)=UL?G%B-'45>++*T$73Z)$^7@88F;;+J(510F.]%(495 E0B6Q#
MGOEJ1\B0134/DL:-">S]@7DD#%J28!X%ZNV P&%1ZB%V3S'M?3G"DR"<)P=O
M4[ OGZFBA1+&R0][E$)"7>NYS4C^?U!+ P04    " "[AFA3I>35^4<7  !4
M. $ %0   &-L;FXM,C R,3 Y,S!?8V%L+GAM;.U=6W/;.+)^WU^A];Z<4UL:
M^9),+I7LEBW;6<TZED>R)Y>MK2F*A&PD)* !2-G*KS\ 2$J41) @"(BBYSQL
MK:.1NAO?!S0:C0;P[I]/@=^9 T(A1N\/CGXZ/.@ Y&(/HOOW!W?C[NFX/Q@<
M_/,?G<Y?WOVUV^U\  @0)P1>9[+H]'$P&[NP<TL<1*>8!)W_"8/_[70[#V$X
M>]OK/3X^_N2R[U 7$D!Q1%Q ^0>=;I<)3$7V"> "WW8^8M2YQO/.X>O.T>NW
MQT=O7[SLW-WV.\>'QT?Q3_[RSH?H^\2AH,/L1O3]04;3TX3X/V%RWSL^/#SI
MI5\\B+_Y]HE_L/;]QQ/Q[:,W;][TQ']=?I7"O"\RL4>]SQ^OQNX#")PN1#1T
MD,L54/B6B@^OL.N$ LE2NSK2;_!_==.O=?E'W:/C[LG13T_4.XAQZW3>$>R#
M$9AVA.5OP\4,O#^@,)CYW"#QV0,!T_<'KH]0ER-X^.;DD(OX&__D=_)['R.*
M?>AQ[,\<GS=E_ ! >-#AHN]&@[5&N#YP$$0N8Z_'_WM/^O.>'1,'K%<&8!RR
MOP. =*S<E! ;:M[2OD,?+GW\J&'B\J?,-B-V\;[J13[ TQD!,P=ZX&D&$ 74
M01X.'P!Q(T(8& ZE(*2WSH1+5C);1[) W'B[\ R0<,'4@C\B../4(A#J-J5
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M!BPAYV<3V;-S0."<&3T'.YKJ"Q6V@)IBP!)J7IF@)B/?=MS><"8GIZ59R N
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M]'<_M^[?5*F]Y\SE6&M.J_MX7I>-T3*X$[6NW=*":4W%<Z-D$\&&G^(<NP_
MBWR I[.X+"BYF9TZR,,\[>N**\E"1Y0%W8HU7ITM,:$C*3F*;SNSE9#/TZ3W
MIL]H**3EY2AEAR?6?]+L/D AZ*M3$!NM+(FU*^#W$82.3V_Q&8@#J_R[M95P
M5135^+)*#7)58(R]3G4."8M@,*'#Z12Z@- !HA'A638E] M^WNB^I!K:18V7
M/W^I?Q'9[GQ=@;H]]SPJ@$D#:3O/'L@JS.L\@+!1/+[/C.@!M;TKO"HKW7D8
M$]<-LO@%I"6#"(3+R$5SFSJ_%O$#L75]9XG*&L[IH^,^0 3(8C<-*5#7M'-2
M(37KI8J0DX5+6GOD$4$PC BOR;^$3_PO:H\@N;8]"*.J4E0 G<&+1L6&.S^Z
M/PB8NYF+PB6+#!6H:]L0*D+.Y(6C_$;JD$3B!FU^X@7?LXY@D:(B?4WORE=G
MJ1 ](_%8J6W7P%JAGEQAPZN8<B@V*KD*:94_NZ)UQ:CK1D$D+@#+WM_,_O:!
M@ EYV2LS=WM*QIAQ>SM4)7W '"O2IV%V'\$[\?6!_NHNLEK!^\:MDAR2K?L)
M;:[.J^C7C$<2@8S>*?/3C _'OP366U6DLO'048/UC8%5B*AQY\JU700S'R]
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MB00.&5_(1Z'0AJ>K$'6UIM\*5/56\LMI2Y*2*UK&Y_Q6UPV. 6$_/Q\!#X"
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M]8!NO4;AJ<&0==48#A?7X4'"B$_IYPY9K(X81FQU/G$IV_91PX@CP8?.;+C
M@3?B3?Z]JXV\Y?D9<7;XG=. J-#Y,V)0.80S >]<0B/>^E\YBR+:>"QFBV4
MA?$<#Z,IP<9RJMWAAJS*F*3KIVH?)/M],&7[8%CM@\%^'X0JO<7(#MVK%O7=
M)DF:33*I-TF+J2@&<[:2]_2":N>,>SNG,=^R<1!83M(D9%=J,2.PCA+V9R;R
M)W:O3'W#F.VZ@R=D1P5ANC5M3B]]B*-'OE)SRG5<KL@J2D0J8S?G :3P)GX
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ML.-HQ7)/(K:T/E':':[(5WHH7)%5PQ?[V/(E?656*+DX#3LT>&PIS1H2<?!
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M?XZ*#8QAD(+@4?=YK+/4%411.'[BP-EMGK NU_3_S=6[OHR#1!/@H\W/43!
M"BU7J-YC]@]@DM7N?I7W'L1]A *F[G'=.C^G&V#N//^]JE?-;M6#:$7/$DVI
M/&%G%UG];_GG'I-E315Y7[U;@0;HG#U2]\&KH"@SDJZ+#3DI<WHJS'D+3:MR
MHU4U']:V.8VC$+WOEYR<;:BB0>",Y&$6\8<_5.(G01[E++F9Y,P:LY_>4:!/
M8JRT*PLV/#<]T$J^;:EL4 96\!NK&VVYW0;92[J^C1Z3:!V%[ GO 0;?63;>
MF_TR4J*"NW2 I#U6(#9:*E DI[2CW!!Z*LC)#0FK:B9U&>0O] 1QEQ9TM$VP
M#9+503<C\\[-?*.5D/NY36XA("=>5!+G9# 1JQB*+57)$G,\M_[F,_*"<BK\
MG=OF '+(\^"1EF)=/[-V//.@+IQYRL*#U*)4]3/MEEUOZ(5H:*,E9C2@U7*"
M4#!;.F8C^ELF-L+:+0E#V":E_E6)E:!57>6*%)9^F;1@"ZI[IJ=J_XA2/##K
M5$!%1D^%N*Z:$0,^P_%@P??>D1C "ZWX,]+"$00+!YUEFA0#BL/AT(TA258L
MVE+_9803CSU3ULE+?<H'9!OCVOK17E]JGG!7I6,6O1^T!JM>IZV+8_E-;-GS
MU $+A["!I_H>=>WV2%BOQ&H<EBU!_1<RUI:GI^IOO8B%U]9^ &834^A.>MNP
ME)?]=%'U6T+*_F%(=T!<]9;1\J?4:LGULVAL57K4 WTKH:.?X?F=K36457-I
M$ZO^1NB_\+_2G:YI.(]]_G'!VJ"B7FU:V&<B,2U_*\BM:G1/2!)<)Q1!.&RX
M;'P[6MT&'XZCVU!DU^2@D>R2;)1CFT7&@$/YN;8T%\G^6A\(T90N9%IY6E5F
MGUW$MS^,M0)KA[&*[LK'-=5<_3C^(KEP(;14%@#,A&SN/A/Q,J%3*JM*@0,<
M8,%P=(OZ*UD]=LI]C.;AV_-C?=RU((I]5!C D-]D%P<*U3UX#!'-M/:9[3:J
M^O&R^_V4)RM0KS!JMAR[)\#[41>]44=:L68<#"D; R&$NRX-6?"90&NC%YT'
MSH9H3RL%K=W+:4B'RVJ0D5:2BMZ@/IW]47$7B9*@UZYP.FGV.DDI8)M4V(N?
MMTX"2I\N6I:&P)-RAD1T=U-FSUCV0]9-#OF;B=M-D)$'1K0I_8CK%PYC:4"$
M&$KXI$T8V3T<R)/'B+,3S>HXB$/E,ZFE?!%$654,RS*Y>#? 'A?<A:DD:-MG
M0# F[HI24_297@,1:*>C@!J[B5U!WI 5(5MV 2FO(6L5K 4,;!FALQO9]MF8
M$373S&:KH3T<:H9+M)7!;(?GM(XWK3B[_?&&?[Y)8SJQG.7?%?QE.VZ)*#7)
M <$!\<AC'7G@U+V6.(/(N_.^!@[JM-;'%2FJ\]NG-&<59;D#N"B*+'HH"[;X
MB[1>0NP?ZAE:)G&>!QFE_;@G@[F I,3LJVWW1L1=*')J?J/6.B%VJFC+$9M2
MO+D^ +&Z-B^M<C;6[Y=EXR'7SM40'5(36#ST6'N&"7U_!W:HU+O%3PV0G=3Q
M^R-)'[/@:<.>E*YNR2.+%;2JB@SPM:JQ;LA3FO%*":A>EHR8?5G1WHBC^54
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MQ*DL%3=LSZX4C?_YDLXA8;7V@=5)]<-X3.W3J*QX!Y: X;86EFBW^$3R 9(
M#S8A'TDN$3@T@%2OH=OG\B&.'GE=$-377!J2?JO- P0'A4Z;8N5P=QHO@>:
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MALT@I%\%-6*BZP#7GK%+1JT3FAQR([@AF!YDXS]P&D-!A><39Q+U]>CII\9
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M",M3%6&A?UWM7K5$NTZ.],=/5+-)1@7$2]O46==YD*RJI.QNPC52_96IS.Y
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MIJA!,L+'2S1EFWJ6$\IS\!0501S]QJ.P7Z)BLZLT$B2K@WH8^]138PT;2/)
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M20H-#!BHNJ_Q,KJ@VQ15%DYN^1!'CWS3RG\FS):25?!,^7FD^E00JC#%35#
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M[ODA/;6O4,O]="EX+5UF9WYZ$#DNTKO;JEC4\8"W!0NI//(M+#]YV?]._4*
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M7?<IN77R>KPA)5??H.HC?XNR<,0;M8X[8NFE-?BX?*DJE$X^U! 2=!H+$$D
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M/Y-^+ @]D)E[EP42!:SGWWR.PKY'XP-+*J7U*_9+.CK!]=D>,+W"GCY>XZ#
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M:T8?2*\O[?H,%PY'7Z1H;Q<"> %$X;U;_M(S?B%*H5YI>"3[G#U1D-=PO^[
M3LG;;R\&U!7XEK6E,#>O=YJ'TBAO]S25&'W;6J7VA'= A-VUS7P]SPJRD/^<
M91$K2X7SYSC$Q5V6+!6( ]EY."V%9 %C* 5++UN!T5:KK1\LD?9TRLI=8"+U
M$Z%Z008ER0XT#:0&Z$++N8RCET*=L#QPM4[6AAU81UTKW]M<#5T.2G<JNCYA
M<_LS3HFY2PCM3;2/TYB:.GJ$OR2V5#R=6RB%0 "\ZE8,74&OG5=W2%.C/,)T
M^C_!=Z+;V\]9FC4+:[6[;6H9+^I(Z;%V?F]:2RS(O6)1D?H6R)O:Q7K+<K*]
MUE4T4W//X](?#NN0\<]!G-)XRC:EB9.4'KW8%*?L"NDR5D[*T?T**I4',G&D
M#<I2=J^[_I(Z9NP*KE\CIZ/.GHE3]MYB$66YW^=/9,3P5?HQB'.6"[+=W>3U
M-2=V;C:\Y])'&Y#V;T[5V:II)Q_DZS,ZQ)RA':%4)PT1B!T:8M51*OHJN>7D
M^HJ M<;;^P)VHV=Y%47 ;'SQQ1J5(E(NHQ0&<AE",&HIB._6K0!V$CW*L :-
MC6EP Z)O=]-)BY#3FTXZ$AF"2N^&G=<KG"8*E:%LIAM0$/G9;MC9TG9XQCI%
M3D. &E_16P$\K>[L31E.PX-8>(:TR55S.8DRDOYM)RB;(4A#+LM.YAJN )L:
M.I8;4?F8V=>PDVZZ/41C_)QM244RC\#X+?VJI5+]R,ND R]94LM]\+)\V$^#
MMX?'HO0DDP)/E!"%WB2$PEO/MU -=3Y"HN; 3'FN3,+F8Y;C^#&M*H2&K_?$
MV!:$99REFS1B/R4L6K2)_OM8L'O8BZ;\+22J\\.59?H!%0FL"-:52<)75'9$
M4-!2\?H$Y+(8U)U4$X?>,A9%:'0BW##AJ'M#'>Y-6>;QP[&D1<;N,^X/M2=.
M*S:<_G J7C@ !WE&=F[#J_,)#E6CPV5_Z6"W,QN_FI)# <<(E5GOC\W&L*ZC
M\</;-Z>]Q<>]ZST_LEJW?&9EV)^D-CGNS6W3LZ"(PT46'S$GYVN'4 P T>QO
MZ[QO+-4;;[#A_LX'FHLX.98+W?^$>+D^8 ?D@$HK5G]58V<%T!EH3P8>OM-V
M4==?,7W7%4>;9[(]?,2?C[3B1QN3&%X'-%N:;6F[CKI:R@D5:ZRIH: BAU)&
MCX]IC:Z,#I96YQ4=IX&@*_<X82 M+[X +$?,EEM'S23P$0$SDE"Y]%;-WGH-
M@UEIG3>DYD-B&R0#.-66V\V->U,9/%PM-!118YD?XG0],%7I7@.HTG&94B6P
MJBAQ<<P),>)EQ%E5_(;];7M@CS%<ON \C(N%_$MS*=R'>(UE!.#:_)WZ!M5!
M5U8U]+R9L4;"J *A\2!-"/P"#*LYXAW ,C%\. 7F8IJ">#7>@CTP-/"L&C!;
MOZ$+RA;W&5!B@_%^" @K&@'&:<'"N;>T7&D1E[B^G53)>8O#[#%E5):KV[FX
MT,[#4TOW2%:%]H319(>!#='FOJ7?B(4K;/:KS#A0A.61A^B@97BTHA4QT2+D
M-,='1Z)I!W7^4GE,U-;&.+0'Q#IMYR;/=G%)#R(6L=$<>1]^1\=>]]C*J^\P
M5@9OE :=L5WK9:[R9_R5_649,.AQ]A /T!(,>H*"_)&](SA,(SP>Z$6G)XP.
M+#F>?K##>:]DWWK<4['V=7=8_3&:-R)0N;Q>@#ED[?K424^LV7 IWD*M*B@
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M(_*&&=L%TKP]^EOZ[Y!.K2--9*:%IN7SRG\V\\P@!3.8YU3.A#LS\',F%_A
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MAL*6&L*$W FAY_%*PB1MMRG0]D-F53GK*B4H#Q*V&WO*DHBH<S:0VM)V77?
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ME=,Q\>C$!)SO+F32*)RS/L [='IWRJ2Z&7I><,\M]P(A41*^P.0_04&L/W#
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MA .]5WY,X_*52RPP@(0=9><I<%9B K!J:*&.&%W5:G+H#\'^\!-JJ2*.K "
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MG88LY4V7 7ZFT'=[OV:"I)!'CNECK90D>D.)OD6$;+72(9XP*C-4D>XO@RM
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M?PH.1)WH]'0=:]L$1/027RT'S+Y _1DM<8J+8A/^]1@7\:*^%<1KYNV3#)&
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MSZ^WP==/-&4V#I)E0"+FY!PD0C' *A#UM]02Y<%7M&\:>#TMD^J,!PS<UQD
M\Y&^;/*$HY^S+%H8,7U6'AQRL21*U#1?(_:Y3QLCUYH0,^.N6AZ<7M0% O@
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MF/M_G1L63F</Q)_*(6+KX1=H5KDY&F# :(_$CY*ELTL-K\WKS>*63C//A2*
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M?@:@>=::CQ;'H<)[!TZQ/X:UZH])T>EO".@N8M4[QA%M1.0QRY&HG\(J,Z)
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M GP>]26:B[Q=K'^EG\']W(S [ -VA+TR"'J<2,KIY8TMWSEM')77AZ-N8P^
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MAX%UC TX$TO^-!:';42-WAV\%659L-Y7PL/_7&O$VFP..(RQH:(B77]KS2J
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MW)<5A3E.+E QB92#67]$?:%L^)C884'^Z.^ +T-ZM?*]3D3=:Q7 SP/FQ6_
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M2A'[&EVOZ1(8-AK&OOE8E&7QPN^<8!#_0I900HA!PD8E%8'*EDGO_GJ6-?3
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MKDKKBZ:+DP[Z1#^>=]=WEVV+JI><EM4FW7U(MZE1[!NY 6"!SIQ6-$N0#-9
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M+PC#+I!KIR J2V:@#,*X!>=8ZM!]6OVVR%>?&6IES11KR#SU3'+RF(IH</*
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ME%T+KX<L#@1.$(;#;7F7E%"O5_[\P&Z%B@%L=<?!.R%7YC=%19JUB5B<R-7
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M:*>19AYR$P<+1@8%U46"F(&V4Z5B768DE&V_*BF]SFO* *V;6^5$6=:F1%<
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M5YW.WC(BNYL,%AK6K3(5[D0J=!2"OXZGDT@8\]FY+UZ3K'YU-!<6@V9CF!@
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M" Q"N4W&D(ZIJ6(1YU+N?UO$P8L@PROV.Z.CMR6GC/L74PB?@R5J6A$Q4=N
M<72#EZ*#N.SVGE;Z,X,FA^G^M6!K,+C8B1/WM>6!3 E4G*$729TX-#-YS_<F
M06I,@ME<VH6*_IJWH1TSV2]+JNIV_?]7=VU-<3O+_:NH*E4INVJ=A)/'/&%C
M7%1L0P#_S\-Y2(G=65"R2$3:Y?+M,ST7:23U7+2[=(LG&Y@93??<^OIK(]%>
MUM=@DVE-,6T-@F_Y9B-67]^^Y\N'?EOO>8*!X="8YEE59ZK#PC5XM1_(]!?
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M&^4T+)BG,/ ;+>AY)5FG/]QS_5I1:AA32\ ,Q/U I1*,2KV3F$5;:CI0_B@
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MH#43AWV3=UD<)I <15B_&]?B692[&*92BSUKFL]&^,2(P,5./[G$+^4  "
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M@6?Y=YGJ<!"-Q1,.G[+^.!_@?I[?FW?H94NR7M2Q;'W=[$PTR[I0  2I2BG
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MY>[X7[.3Y6_D#Z#D TG_#U!+ P04    " "[AFA3Q-DTD4YP  "'5P< %0
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M2SZC:'FA[Z7K51B_X);959Z,U* V#%X81T\92C8!>J2V*28D\1-!-L1I2FP
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M4H8<.3S%,6L/SC>:9J,UC%6O1D1+,RBW'^C>6@9.BX3V:MZ/0Y0 79(_VKF
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M*%6D+FO]F^][B!JA;?:L6I$^>E,(\^I)NA=%@P2AME>O).*&4W/#ID8CE#0
MO<BR!#_F&;VFOX]K_U!&INDU_H<?/_!]#4&$$)#<A%\.08+JYFZUFF=5P*^J
M3W/BI=BWLN;YE)P(&7Y-U,V  %*7E4O;+)WA,,\LE841T7)Q)AQ7T'M4W3RA
M^)EXFVM"?_%,#KY/Z#JG;V;W5U+MXB=J9EUW[*G40^!:<6W '/>J$?#=X=B>
M+5?CP-4M@N&"J"]U1<A=VGH!JZ5Q&J>,E"H/CLR$?041HPZZ1XQ5>JJ^018U
M0^_)2!_CY/MO#*LWD;4T=H\#&<KZ1OJM+M7$ZU(IJ9Y"E2HC"134:2 ACA#M
M0R)9L4I?&%R*$XGL#Y=(X>,%4=)*K[12/8W::H4E#B'7R1I22MRLO,2#RVVU
MCUH"GT7Y=:E,Y: D*SL.3G >C6;#!W[#$8MB[*<X$2,J*]$!^)PVTFZW&[%9
M'XU/:F[K4X28ZR;9$DU#;"Y8:>K3N'R07KORJ +VS=:*1#=G)%_S4ST.S:4T
M+[D*T*K%'R=Q@AJ]E.'7VLQ')N.IIZ^+AD^]10F.B8/N)9E15'*<N.-D(HN*
M(H,,#_(DIFJMF0X5+1#.\H0P=,,&7:[NR/]1>M8\N4G=("D..=UUIHJ-J\HP
M CX+70.78]^PDUZ#.C !.M':NU^79?8$L:C"D1)TEZN'"&>VHH<J'$PF,#6\
M;\JC"N9' VI H;1.54#$PC3\;AT%$((*EP4 ;02NT0O[E_$7_X'RI(V^(HB
M51C 5[L36;=)3]=;4\40L/0"^+)F_[;<L@>&YZ\H\7%J*8=/G8N)!+NU5[L
M6ZB2#>#+WKDN]+$Q:X>O%U^-&A#F7E^?WE:\+5=EO9'6/J!VBA,-.5W[KHH-
M6&$'/0%V%<U8@%)#SD& <MB85&\ $&!#RP[\/42$JY<$4Q*%U3!9AKWCSD&4
M"BB9E#L84YZX3 BU)=?]^!,^*1O!IE,$8:RH&;LT'=V3+JA.=STK(&=2*\&N
MHSRZ:.MD9WPJ:J!7B7?<\J&'S*3J@7QZ'PO2E!B[CQYQTNEM.8I2!O0M^BW'
M*3%'9?.B8FJWR(^?(C8*TV%+N6&6F9[P/C&>X"K%'#LTQZOMT*[F(.4I2 TT
MW2U"#H=*2L91-;VD['B%,VN%CVK#SR/L4<>C$@Q 25*8-)Y?WX^8R#-Y4?'Q
MJ82F$80J<D/.(\T&)\)\%5MBXZ7S3%UF/&RJ'!#M!*RZR";QWN_7&X;7&F78
M]\+T[?G?H=S*<D6]:2_R$6V@*1<PX'PVF=U$]GT<;^J #Z''TOG3.$KC$ <T
MF?K42]<78?SRC<F%WA[&:C2['81["6KZ4$2T="SB.CQC N;)[H'XZY?1ON?=
MPL_P,_'++3='UF!C0JM(*/Y6#4IEI,%>S+V5%NT7IOXR&"XSZD9ZC1,Z/5Y'
M/@Y1@\/[> I+WPJC$SD#2)H&.[*">K6I]]A6U&#\#!%>?&RO29LD:9?6QN;:
ME&OSWI2"RZ(V55%GGTQWC(87=3INK<186L!%&.Q)MX[,]VUU#A"(DB2 I-]/
M\>O0@P'4G3P#YS5:"E&$KKV(3#W /HY0IXV6W,%;<VBGER^V54$7;HUG,0"-
M7@MN4YN]ZC0&/V;'01]QC4<SH'TP#DUL#TTR+R,RPYRA12"Z25!FJ>BU-''7
M,8NQMAIY:6@\M0%J#J[6XT]_S^D;\[@=#V6$-5[CB)7!S(K46F O5U?(LW0J
MZ25XS#N-'.(:;W9 =Y6JRG<SA<7>C6B7E./'=F.I@0AH5XU5Z^J9TEDBHJ'G
MKW1".4[7Q=GI##W:"8D.4_U:3,, ]JX;M];\')QNXQ07UNN2""1ZPH\A6A#N
M+84T9&D?MX^A+ F=9T) 'N<>DTV<9/CW<JNCFDQX]N,\HE[Q!N<;._<L@U2_
M!J,B@3W8.R0EY2#S3*C3<QE5#4,7OI_D*%A&M&%%>N/MNN6F!<<0V;&..M8E
M#2C8.R5=>U!Q>H8JCO=3+%.IK5[ *I"?2ND'R7M5%6 !BSG!Z,!E]$QF&M,R
M12.)O4[1K=>@OB+ZQ=[ 4N.V4^0 P$B:V"6Z :7$""+\;*VI@!1AIUL"M-AY
MP!KW9(1?Z<3SV'HX."N9J?H91T7%5XM'"$U6CLLVR*&OL3V,8S2X?J%UBU'S
M((]&$3J(.BX&R.60.K!5R'P\SX!#^-@VB@ZP3LL =ED\RQ$])K%*X#=>,J+P
M>90='P2@Y<\%UVT50,X4Z7ZTG^?X1D!,_YAV@1Z4'1<+Y*AMR4,1,;GW7L>S
M"1S*QV83>.!"7DB"!XO8I>G^/GWL6%&+^E'Y!T*(P>XG[;[=LO5Z1Y;\S.*&
M*L :'!)BHH>FFX* 51KP2MV_W^MCPW4N')!2]"+M] Q!SK%5@1;_MQPGB+!.
M-#C;W81>E"VB@#[XW7;KF4"5SY G[]@\Z*^A1O4-!;@!0]"6K89C:^%:->P9
M":/SI<6=XP)'7N0[WSGZV#B2G:,7:;"SIF9A)1^A(+T@TQZO'/4PU0F^$)=8
M+JT234/(.GTU7N>O:(R1T>0I:YF.??2FZ148"+P#J,L7VG7&RE3\2@FME5,3
M$SRNE=W%TVF/W6(FB,4N;A),)K6EI1H+=]6*K/LINKT_AA'W *9P#R9UW;NZ
M/E:EFY:K&_8:"Y$CB8_LG?SD2!_7FN_#V&T8H,8DN]P893,_4'(:"(:7<PU"
MN M"LP!/D<?<4YH..*+#HW<<SEH?H)"/$W6D?8NV>_;$&>% HA82.X:]6XRD
M^^N]@PKN)S7&@FX1.P8IBY'4N+0;Q3FKG0]O>MKW6O72Q#P<AX57!1ZJ+9C=
M"*WCR*QKW; 7D#5J&PD1I3]?K9!/YG7^ZK-J"K=DILN(<K^(6!%;>JOT[(76
MCO)*#,RK[*(:MBX;1E)F6@S=(C(Q[)>EC G#S;^H_6;18:.;U.*'.:UB7I]]
M@8@5/1IY"G.[(QI;P@;[6M.LZ:IS=XDMB%%.DAUAV%[O'CG*,]O.).$T:)!9
MM"H@?"69L1T;Y-12RPEIT1^7W.M]130NFKA-*C1B%RU3UN;99H:!-/&Y[1GR
MJ (^<===]M;6M&.G4U6UVPL8\,(?8&F.L !G+*\V5F!%E,<_%$S/QY](V\,Q
M_'6SEKD0886[?+L-V7R]L)KO9;2*DTT!NM4V-I*TW=H)D-75*'$G"SG<?J"D
M&NUZG+0D#^$D6&2'0*ER)2+E09W[8&H+@PI8'3C'.SY^6A,S]Y 6-=&6CYF'
M(QK_K.($%W$RYILR$WX<!QS5E05$"$Z:-S29N$-9%J+@?IW$^=-ZJ%JNP#HH
M#NGT;*XN:E7 H'($=6Q")]_A,O)IY]^R<7C9/629L,?Q7EC^S)H"DUG;JHEK
MSM4,MQ- D;C+0CSL?'>(5MTZ:]ZK/FSC3D77QB5LO,%I&B<[MF]*V1)8BK/;
M5X !=Y*QV*WQ6_4.V%O1RXAP'2&FWS_C;"TW)RD%LD?=[<%679<LR@$P95)%
MLZI:#LL5^7^5"#1<3TF@*?*CS<QC48 )ZGV:5EY,L=4='E5&P3YU@W7OMOM@
M49JZTW4/'K]00-W%NR:6T./A@)R;JGJ_W':"HLXMXL^=OE-05776=Z4'"M#0
MPUB-NZ^]+$]0O,K6Z"1/R3DY3;_1#GV69?X(@#=QB'WK[6W%Y'33)RH,SE#J
M)Y@]("5Z<>*E.*6O3P[0WQ.H3T);":0:;+@^C@W+OF[Q=' &#-Z.N<+N\LW&
M2W;QZ@X_17B%?5JRH@/6-[HAQ_FON5Y<[*XS2=).NS<HK2M9+&>Y5]VB9TK\
M%OE%H;&RU\0+.23=QQD9;>UMO"CHM-W\1LW=$9#YN4YFP2'#7W<"I\B8B.IJ
MTR4H6(# TVKO8Z,O-RBAT\4( #5DI8JQEF=9[;OTAU.O+/-]2B.KQ!P5U;[5
MEF)KR 5O2*5EIS2@ZA*3&5QM.:F-Z&CIZ B)+A-%N.:Y)(HZ95ZM1-DURK2=
M/6'=,ZL^WS!5_4(I_(%IXZ@P3LG)U*[_I\2 VXL+:=&WWN0I  RUPD9<8)SX
MJ>%!JDHE(6AU!Z]L4Q30Z%'YPPC'+7VFM%-9VI0[9"M[7?NK@U:5/-E=O< L
M3N"49ZQ\C7Y\P!*<H7E@Z1^J3F>%7_&QU>7=(J&]6(MQ:+H+\9K06+OG,%67
M2XHOOOH"D4!MACK?R(?4#,E5S3L+/*PN 0$I_?SKYH!V5X"(EDN][Y==.PW*
MJM:/&QYLIN6T4X>_@:_W5B=7_(3(O[ ?R=9:,F!W P%BS:C>2IV6[>,:GY;+
MY0:K',W#FP#9.49"3N/-)H[J*U/CGIDSR- N)<I)D!I)V1_K'58M]"<YE*MK
M7R51L,P)26AF>3-5R\DKLCP5$VQ:GVLK]> PJB%M\9"JVCP\CJ/PM3SXA1I+
M #)' WW(1+V,R+3SHMJN[I,'SEADU_L["IX:-:!&.V/H\Z-])M<@:ONP8L"0
MZ_0B )5J'GU,A#/3/6JSP1F;*$V2B%EJ"/%)RYBYUC/YPY"+UI CK6PU#@R.
M.5*$[*Y?11;<IDCK:$:C"( BWC--#JQWP-3;:_<CC+3B^N@9-6!MCVIW,?42
M=-QT=TB>K8::/<#-,Y#'#HDG7HK(NM_0Y! VL'8L>P\,?3MU&*_L2<T>XMRM
MB5P>*<6JM+%=?]2,)8/8N"SADSIARVZI(4].8^T@NM5P3$TE-,\E?^'AI*@2
MJ*W;^R$.$-I=Q;T$-3.B>&/:77[]%-WF/,F(M-$YJ!^]&5[FWJ( H0V]RA47
M4E<_U$B,JAF"U!M9XURF1$@UAUUK:"?G+2-)%KGJ>CC.]+Q5NX70/&^Q;]=Q
M2*:?TG3*C-5UL%O5K9^D052#/_)89S!YZH[K%\I(O/$*2Q[6F:ZC:Y05)\^K
M.*4UTIE+NLBR!#_F&;4F65PN-?H/)13:J;GG7D*H/QT(V5QM0F+:-P'M$>VN
M*C$UUS'\(3$V&DB(,9ME]+T\O]&*4KM:(2F#Q_:B$2T7_!X@JA^;$ T]UFZD
M0M]ES$%6[LWJR@K8SC."\ G%3XFW7=.WS\$=>J)QD5I-'EUOKQCH%FWCA!4)
ML>KGB8AI[SSM$4?S["3HNMZ-AD3;<.AD<)SEOG27/Z;HMYR,>/YLD/'1'L9R
ME6L!,?UUTAK1\NH04G.^)@;$V"RZ+<1LEBNA6R_C9,?^M--<$_.OS,*IQ[,@
MFZN[>BU&#+E>7(H5DHRP!PXK*&O.0XJ6J_,TP\3[LM1#LT7"[4V%FFS;Z, U
M.U&+H>.4OD5XB'R4T!KI--^ML'B* 7.)<1SW?9.3CQ0@4+7$-=/0"&]1EA1W
MPH3=4T(<9_1/EG+.Q/1F(5(IX#2*>0.*E-LKJ7<=0@E7BO*\Q"P'II,:W/T\
M#C7/*EW1\?1 DJ%Y>55FV .6V-;2G/O$"U!5M:$J[W"+?$08I=>V]E1$CO*L
M3(4DF%#5N#738NG1.DYV8VP'0F)S<JW%B!ETFS>KCU\\LJ=S(-K6:#NBXVRK
MC#</VZR$$%2K>%T37-7Q/UU[R=/ <0GLW58OR7D(618_@^;I(/(M:L$4E6'&
M$&X?O5EMI[W &?1'AVC+)RR#-X:$I8G/:R'+8VK0(MV@9T7KG?:6<941KAZE
MM]JA,290,&Y 6(,H '8O5_:*:#WDJA2$KB?4-\;TQ3.(@DDO8Q/Q[-];9C0/
M*\[[#:5X^?0/,H=SQ3 2E8S,@TG*0NI45-$3T^ P3M-O9>4T#$8E*?/XC5Y^
M&SF9YK0J?/P480K@&-[',-7IFTD%!"L1FX=KU(3\B6K<11X%U504%V'?]W,P
MD[WSKX0"$7HQ>U7WF1Q/\@0=W-0QEJ \]1G860U(*_&;QVRT9!\G"#]%13EC
MOYDQ&P7LQY#!/,IQ7Y^;604##$"OM 4@ J19YX407:,H9;6!Z!.7\2R%-/%Y
MA0KD,:UR*R">Z!H_TQE#XD,T9[0C#,)7"=<\S0DB%7Z\52U'>5;V71+,2N(
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MU$9-*ML?24,O39>K4IF6R2U^6C=-Q_X?T_)?TP]VP@%:G!R;\=:41Z5#YN%
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M!F8OW2[BY"+/\@31W8[F6(C"WZ(.BE(C3=O=DD0#[LF79C7GLH)6X<SW. %
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M0"=[KNPRJ:#F0^$H"8DR=)]X-''Q;K=YC$,CH31'<K.*5<71FKV3?*(ZSS0
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M)O>!_\;MK]]1AAZ]%-&?_G]02P,$%     @ NX9H4T?M3&.YR0( OJ 9 !4
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MT)W:E"@#NO,Q,<!$FFL&"Y&BA-&I8I=&FC3+1EZQ5Y[V%.W#K[Q=NI7G5QH
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MB+X".3'A] D7B6<9<*+<DUJ=GM1IO.6I8L5P8B<5)_;WYL1FA;D],9=L%J#
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M)#9393N]I,+A(7"X7R:WPN&!!./V8IGN/GW?X5/.(HIB6E(_?G%3-M02=RS
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MOAN&9#<,5^=]!-XAFML1Q*SDV[VUQJ )+,!B,8]!8D%V571DNE>7;8.<$MR
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MC\^$-IY0@\6U;,0 F_E3XY.EA(I@%<Z&=UP->NEXK)APZ;$L4E1#@H>(D^=
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M"3Q*P)2ESWW1:)!T9;!#89#3Q^7H".HJK"&\?% (+Z^F9%M=>G&;Q!HE>;4
M$0&A#DE%!*#4GE%++D7;.@X<W$F=P1@TV>M#$-(JQO_"\Y/6 DDG+O?F:&A%
M\EHQDG0U*:C"'0(E;LS&QNI3S5F)4[I(IQ1B!AC;)H;<+#XYPT1H1$8DZ.J?
M]VZXF6*&F\BKX)#=K]1QY[@YZX"S#L_PK"-80\]$=P60D^7JC"^[HH2.2LR*
MO2JC:0:YHSG="7=0]4H,]3TK]0.-V ^,>\L(:)@"#20\^QS5F;"C@@I@*H&
M&/+B95(.-F/@8(JL_CL4#-&_5]B/WH^)$TC#:X3M3W:<O8_U)WOH2H9$Q$,!
M&?@ZL,*K-16_!3995Q&QT ,?LVQ0Q@D3DU7 -S&,'S#G,6@(-1_4A9K?"<&Z
MPTCJM3=]+V6K80*DZO-VG0VYTP^,&L2Q="PC, T1YH-"A'D#B6JYCV.^*@7-
M&1>643T9!T\GDV@>N0(D+50MV_[\!PF527&3O/!02GV3"F2;.2?>>O8_C7?:
MNU!!3BQW(H81@X63!HEQPG%D(BYU5\%^4,]8E^M2"%C6WV8LSSH-TNLFD_%G
MH3WY>1H%V+^RLC+XG8;QR9G9;]X.TH?A;/WKQ]M]_2C]>CZE^#SV_+1-3.[<
M^F%>O.PJ76[W]1=K5HDM>A1X#F4@.(+Y%_X[%$F:C'BG</-:+ UD,5 I*BF_
MFF]E^FG95B(]LY,2?<Y@9\[W,21#.M;HYZ[ /UVXUH1\#F1OM8,G/)Z48U(H
M6*:$\JGP@:Z6!GMC<%,4C5HT_XMJ2M2L<GJ?T^#N8;JI@X@?R!G+N?D[,MRC
M+Q78TFW#(OT.)R,% (64%7EQ!;J*_ZC[HGPCF5.;#-7(1Q7BT\>]E4:-@241
M%'P%UUEWUXP=P3O-SW&\2<1UD#="((I%"DA(%(S+T*\XNFZ+V9;4G4JO-XDA
MJS0H+>[S*F*N>XLR[1]1IAF4::][A)D>.,QTT+1/>FWFY;BP[8N_!!U'KC5^
MX;YR47#),UH@W%>U>?3^X]TL(Q8-RY4&Y>5*505(AB&J"US+M" 9%^OZV^\$
M-C[KCCN&*#BG(%7_%RHHI0_=Q.7 Z%P0P9MY*WK3GGR+[D%APB$<7G3/^MU3
M494N"V39>_E?>PI#?A"/OA&13:IW>4]A3,5G=?OL&>]%G8]Z]&5O=#;LGOYL
M7FMX7W"P]&/Q4:L1YK;+VDNLO/>8_!X\2AU.&R'B&LN+T6'"V#'SZ*O9SVRB
M*0T)_VUS VD= 9?^'.>2].I@Q-[-[^WI%)-E'XN^B#ZC_!A##-F%4Y77!5]3
MONDC^K@JAR0@?&JE:')QM1G#"Q+5X9F$5USP''8,NE3$CJ4HK4K"YU3I<?99
MX)I.033/Q+4!+QZ>JH>FI15?$7C ]-"3"3@%E-(+J1&@%U\MT./G*//:9R]4
M I;[?VNOD15A6DEWZG6&QC\GWA>"_X\8%;Q R?Y64C!D;EG6E,NS)6+H_'-B
MV8\%S:RM&]:F# IK4ZHK]W:5=9%R,)PPH5-D-DHJ#*9S5-AC(6EZWBTF,LB<
MM@+%0D=!(SV@-+!Q_>T&-7/'),.1J_!1MYHGJ'3[W5_$Y^FGWB^GE"T3N"9&
M2<=\%?$Y2] BT&&34&P^TCJ9@A'89^)<XE23W[.MR2->C%$KP+$40 =B6])*
M-%5W70J;_(4?C9SPD<,)L^)Q=B0F:R6[$QIZ->ONBCIW[0#NK2)H6.<RJ%OG
M@G[0'["W?S")26-*H37/:(5&"-]OR@$<KP\9N6A8_C+(*W]1Y$'5!.?E;P$W
MPGL7NKR*YT]NLY%TFZ?JFX+RAUUE0J.1#I2_EA9%XZSI)*AF9.7+6>S@Z4PS
M^,V.'JBUC017J@J1:W%N,EHNP8*9D2;,( X2 U*(UQKZVZ@3M?W.3 2(KU)8
MKM2<$^R\H0Y %%ZTBM6G!VFLP??**TN\&^(:H,$&K13)43PFQH"1S%P*@<%"
M#S:4N+J?-/@-74GB>U;"%X"OQ[X R=:S$XH2BIKK(J>B%T[461!R \)$@V_E
M2C"#4ZX[D7B** !)^P%$$JB^:F0AEUO/!GS4J))HH99TM;.M0# 9:QA((RGR
M#CF-7@(8FB*PV/:1T:9FE$WM> <BD].PU&1P63]PBD^$%7EO!9X?U86YR,CI
MVH>T$#H5[S=Q &>WT5+74,<28 U$VK!08)!7*" OUU4EJ&TG"%[K"?RSRC87
M<29U%&@S? 1;*6B).#N*8467(V>B2E WT_1Y[I#KS^?PKF\46SK!MPE3F!90
M6*50VD6#FK9'&$5[=.PG@H6*D<P=UPZ7O@=//PEMD18P!V0>>OU30H+F.7IT
M8\?7Y[U7>0*X7G^)G&\4&/ZS)Z-BG#@.*''&R(0L.EYSVI;KZ1ZH7C-]C\=D
MNQ9>2][<#?H*AV;S+&S&C938?#0UY,!*FR*,U6F'B R/)NM TN&#8SH\FP[O
M'=/A!YX.'S:L&QEV:WMU:(C(#FT2TRI_S.X].\VB'B-;A0+2$!T_[!5[=34D
MJ.U:<SV=,6$)(<_%T&-/ML,%F128.-,(,72F:3WJ4?09135A>8*E1$\5R*@$
M4V=0N I+[2:H# TK6C[Z 3A#%&)YB)RIZ&F9'Y^[[-(#A O'T2/MC1-1.13J
M94?)"$\^3[6A3V<1!4@/3?$.%>&AOE*Y/#;*S<O]'F5<\P9##]385?0<%:&(
M1;I5KKE(D,:!)_)A8[K3PADGO=B$"][!2 9FY 5;F&KK%;_?2+Y?%$_&:RY!
MX&+XH<[GDN!__7<T?> O. 2/1;[2F,6$*'?@*U)8)$,WKE\'AV/D2F$<8>6>
M$^0EQUZT^9_("I88\)2I+H1\LN^L2 L2BX7^OY".'["&:-BPM&/8KVE^\2H$
M/WR-,_T-BX=*'[3[7M4T %,;P='Z9N2C(<IQ."B%I567).D!U)&]5G?N=Z7:
MQ]TQY13$4#F!$&.Y."TE.TYF4@KP;1DZ0?LC:F3C<#9&PUEH15UP&/?#9 ZP
M4)&5L1:?8\6OP<U]L)Z :PV([H%L/O<Y)#P47'>PHCZ4<02M<%_5&8L!8>AA
MPH ,&31*DZYQ XC,B\^-[[Y68RRGHP.'* R#BOU!PCX(ZJ560WV;];[&#A-.
M_ 79(K43VIC!C&"13)AD5#-F./AP:2]"C5Q-<'VM$H1D)^&IR(ZH1?]%8TA+
M?$>\C+-Y<1-++4I#CZ3ORP>H>5$N$/[NA8(L=0$ZP-8]!L5$D=BF#C'X>2M\
MZI-XJ.1;,'.?*1-4!<,U,L,E4CCY[)AB)R&5)Q1&.]77/H3GA3-B0BMX%Z%I
M?"3 0!>3%Q&WY@RWQIC[4]M53'Q\DN+">!#S>V[>R>2K7/(N6FSF2;,O/)]G
M.QD#S<IPC@0;SV(A9[9"VDAY.#))Z":@(:)Y6(YHKFX(!K5-1\M N5MRE6.T
MJ\:8"(J;$6]K5!S7K\KOQMBR9SJ4#HPVP:FX]!,$#W@(BE05/&$. X?/8Y%5
MP(V$UW^%FS]@,GVR5/ XUA!6;+H$5T(4WS-S])+H.)2@B\$K@I'_;E8']*V"
M#V!Z7&@A+MT+A?90OZ41+U<+[IDK?K^BFU>1?GQR++D^*\HF._82B1'"")18
M#%I,J(B81H26"Q8DXKH_L*.+^-Z/9!W(C!8O34A020N!OH*]B.]CI.:00 ?^
M"AJ4S2KX J[LI'U+[&^\^%*MU2+S[M$'J<_&,U5(:LS6W$8XGKNAS?U'O(<U
M!/@."P&^=71=V\$JE:M2M.E2SFKV66W&^2Z6IF;WR]TVZ-QL;)*)GF,BZB :
MB8.8:<\95TXD%-!*([A5.6)91\R->U3J%9ZSRV3?WA[7AC#<85T8[C\P4/4A
MHO!4DW3%FN_O.DY"KS;%NX\1DHPH-$3>#LN)YZL(C8R-5!.PM@T$,JR%T?T<
M7"V1.F#'20L</)!XS2(1UT=-]H  6$\P.DLNP,0OZ<KFH'/SC\37)=&U<""]
M)]_%D@[/UT/D7$^&ZXP!@")G5OBF-^#L(!PRR1"FNVSI,<BR.^UU59]K6"KZ
M4O!M2H1$[@SLA/!8B2V>N.@L3VO5EF%)Y"7':A5J@A9YZB6PG@\B%D]_LIC^
M_CI"QAG7@<=^U9G%WFG,8C=@Z1RN%DN 4[:%#372V%#^D:6$8__)C4GR@$ZY
M>TW,!2JMWW\BF-ALE6A>)FC8B!*B@T&%)V<J),E(;0JG<N+'BJ%0WQ?U1:;Q
MM^%>,K?3UZ%ZZYL(UF$C.LN5UXJ\B:BN.QC/L/B^AJLQ1WX/I,J<(E<?7<-4
M.@_&YLSOHR!D=P&^@: /Z\$^-S?K,Z3MS7JGJ]>]VL#M(OSUK23Y8S%YSPOR
MQ5ZN\\)R&MDK+ZS44^SUNB\PZ-X:U[&CT: @7AI#!94%S1"1ANT#S<IAW[&8
M&34[3=43LU[O179L3=NI*F*VR76IZ:#[Y^,MB)F1H\_:%S-#BMEU\F:E*:O<
MJY42+KKFENW2)A?'.V(]FHJ-N4$-3A1=7WQ6Y]Y:\>IO)E[#%QIX?V--9A28
M3/8$R;01B1>-43/V<:<U'J.DC/+K-!K8BUO0*\3(#H\8V2Q&MG_$R!XZ1K9A
MY=.PO,E.E>O_H$:HH.4LV#7<A$5.2%WA\=(S?4)UBRU4Q*47742ZI!9?D?7B
M2D8C!I$]3=!2UU'R&D&.>*&1<R=G1(1BH$$^="UKY\&4D\UMBAV1;?@AHPW,
M^36OEU9C5L^D=W.\1J,M7V3SP1?[Z3G^B$I[Q$&L,$^ "^3PT/V'K2K'4</J
MO6%A]5XUG=CJTF>BE7'+ 2,;CTMPY5,Y&,@:,].NY?O7(D&[* HSLU%*ZC7C
MQ%#EXJ'-X#03ZM=37?DTL!?H3E"3-M8,&K*O@A\\6)XHN(LK_&13#6I?X3WX
M1"4TM_[M!Y0FYR9EKC:K-8&L-1$&(Q'(XKH\<=I+4YRI2_NXDB;+9'N^*B&Y
M]6YB$:&/K&ETW6V2^&P2S-K:@-?<8=.J-W46_-FF9Z%Q9Y%F4I5CTH54&>52
MU23(T,8F53'N36S[]L9^\7("UKPAX-$[(.^@87GAJ&YYX0?+"2CV\#FF3V'G
MH6&=0^4'[CJ/CP/AL K*\P=90*4SCQZS^QGY:5A].,JK/MQ4TN18FLCHBS2F
MU%N;::Q*W'4A"!RN(M/(#SBQ^H_KZ[MS\T/\:P+%SA 1*WU&#2;Z[$?N%"_=
MZN)%%03B[=R/WN%^@Q*VK=7^&2=86?"7L^1'GJH,,ECUB;- %S( 2XY-%_ N
MARE1/PI%*S,%IU2O2A X48M;8NU*0%RECRN>@9ZL@Z\BV\!OU[F;T'Z<T\$5
M\'5[\N@Y_XGLN 6W9(W45I*PNW/K+V<N\\VBM,^_1R2["(PO(K$]V!%,_R0:
MJ<C+?/9<TQOYFUNPL19S6L(NZ>W;T90ZX00,'5^7?2]N<:XJ--BK<M'D*O2$
M]N1'!TPI&.;5SR^CM7Z-U:6@X=DGL]FP+'"4U_%I4_4U:*R^6HY&PI9^0G$S
M>[2GSEM!_(WF\2.= X,+IPD&])_(1P=/GF;4(ER&RQ5!D_BH:/K!88?1XG8E
M_-U0EM1F3O]+-BC9;_EN6)XX*B]/K"^EP\;RW7(42LEW/RO?MTKE&\(\^*(X
MW2H0=;V;HS@V"D@FOZ&=BA#LC&L%1>8C<RA^,;+/B$]6I0?*XY7@C.>W_$+9
M X%#H.FJ#VG&CYI*>09:+S\(?.H1QB@J[4-B5># 6B\4V-WOH]JP'&Q47@Y6
M_\"-&A_5ECL5JZ,Z*#1%2F#AM1:'456;B'OJK"K:IQ%+ WXXQ_$47G04"K@$
M_%X$M7)<VR(S92"IAW0JL?5\TH'D+_&[B3,M%@0)9XS)/-04GJ3C>\R6Z +<
ML,YH5%AGU.00M5]OI$H:\VX *<83F1[04*X%-H(:/L>,(]3L^=R\B?GY* \A
M9)G/ #Q;2::4>42[<SL1K)S& &)J0%3<)^[&L_1%*ND=GB,O1>+;(?; 0ZN%
M73E<M\*-R.#.?\@\*&[.X@),<T+#%ZD:3&6Y^Y0_&9A8=OG@!U2TK=YR;\/6
M>=0*9B;QQ[AH>4CKU.@-?S*)@A^PQFC4L,9H5+?&Z(,?V/ *SGC#@=5*1Z^]
M*?WH\EXT#64V?<'.0YL\,%..S-3&0H=='^HQR)F1M(8E3*/R$J;-95(%/;<@
MW>U6]D?8*=>;B)3^1,JFP^4UOY]_.S>GO@M7%R[1UL"MR(/E3!VLY(S) (CN
M)>^!'%=+E93PDQGG"@__0A1CKH4 E?CI1JVGOX\"G^I8T$M,38%L!"7^98<:
M]0"M,4]>8BQF<HM39$P/QZ8TE&8<B\#T-W(()F_(>G8M$/0"KF01T!ZA B[6
M$WSAP5;L'P;>[T)IU.*"(MZH B<B]:JX<;=$&"MN$6J"IAG5# T_N\<:5[/P
MA@W9R"O,ODGKX$6C/[K+NJ9JB+P<E2,O-]=+@ZUIN+91FU/\,Z,FXO;16)P7
M4QBYRA6OH@/2F"14H<*VYQUTI<DXT),YW8%MP*'CZ%1<(R]TGAH8EIM0KVO"
M)#$EN&JM38Z\ZER8H./..:"">I'T5VBKL<L!&_J24#\8UB)^* L0A:X0#$A$
MB)1# 5[>5^MX[/$\C!MB"D>%F,)MG/;6*67=T.>B4"60RM#I><F,0*+E7D1P
MD[3P)WBL3\>&3T5*MNG*^B'U>'/MXT7!K>HMGU\.MJ."P[UI ']8=3RMU$F,
M&X)]Q@VXQ&/YX,+(C; ^59_7 K6X)O>B:/[D$\B]O/R>'N^]("\-P3WC==3B
M=06J76!.L4(TA"H.1?EM2E<^VZX;TSQHK4N(G3S7"S)/$+0S<9:GDF"4.BVS
M(Z893E+5-BP'F)>)@;Q)R:PC4XD2K8;^,M&!#ETDFPG'*CE(#,Q1M-(+!'92
M^Y=G*]1=5B-9;RHNG;H1%/<VY:GF7^#33JEH9RTL&.8U#B(DNBM]5:LN='2L
M"\W6A0Z.=:&[DL7='\H=&K>&T*]Q749X[+X%3PSO[. ;WH@;^DXEC]FUR_0%
MC)[N*)V:,!"31F)>+Y>!<Q\M"14#^EPV8M#N_R^;5-C8K7IU-XB&N+!Q'BZ,
M'E1=REM=S=^L$ YHUF,#[X;C4Z:E"2]3:'-3&4UX#>21M=Q)I,>3T:-YAMO\
M(_SJ3 ;(M28;B0=A=9WC1OCMEQ^+1I3.G)@P,'0#[=D,"<$Q<F?#Q5]$[76^
M98$_)PZB@& 0*]$W<&Z#%SKM8&3#7L2X[YQG3ZCI]-+!*7K4U'!AK7#"LM]*
M:H+RC:8S.Q/?18@=OX^\85F!CN5CTRD'0&1?:W_!(HK9E^69/SN##Y[!4M@K
MZJ#(3B[YZ8KRG%,TIJ7%/<NWI6-,M?VE;]7:5M&:UPQ!Y^.:WRNYK?^LCA$B
MTW6\^,G=5P"_, 152#F?F(J-&GU/Q8HZ@=PWI)J&$W\F']EZU=6^>NAE;"X[
M]L@$Y(TMAM;I=H>6HR%,<3RLZ39]LZFITE>9,-TH\%3I8;MVH<0@0.]P5:=S
M;*B3(R<-@7OC0N!>74%J._U RE>SL10+PJZ\V!-X!A85C#&I<7\&RX$9 $$O
M0'_V)6\=%0Z3S9M;?\*G9-^<F]MWGV73G'-3T=R!C7^(:?9%<Q:'87 JHX:A
M&X,[R]@!<=J;UCV"XMA8JK0?%BD%, ,M4>G$0D[6X\ER7+)9U( MA@8*IDT<
M)4/1_]3G@GG3!RM 7\4 VP6K@MT@N.F!Q"YQQS:B=(VI:@F'06!((D!(ICT8
M"$Q_N4<'"KY.691G7UM.N3X_FR>]4Y$8557-D@)"M"&0[8ZYIQ L%+.,PUKX
M5(WFN_[#RIP&$9+SA)BWH;'(+7H'?PCUQD93\Z2?>:>9^TZCH*V"?/:W^'>:
M%,1K$L^4FMHY2U4LA[T?Q%_(!Z&X9+R2N>Z:H?6Q<'%9)U@92.7A],M.89TX
M3_O!]NQ D!I;4RRZPY A>Y"RCESC9._]B)SLXX9XR7%=O"1?][];?S4TND7?
MW[6=%6$*>+%]!#-FQ: AF'%<#F8L%1B93ZH@62_95U9<SY<H0$:,4^-*#QW6
MME+WWIQ6H7K/-IT+"QY;!)&3UV;%EC:+EJB*X2M(?Q2*V#4W!.4\$'D+\?TM
M2_5="U(4$/ =K ,.$BQZ%! QD#9T8PVZ3W-B5.-<C@+ +3+@D<OB;FY@EAD#
M/1=?3C4&U(<VOT:>M\7V+&:5P^$2)A$YO?G.*A=S!?8FON"GQY,FIT-#%81V
MHKJAPM:)4H*85H]KY/TG=LG24D7N"3LN]$G7^=-VG4??C]V_W+=2YS8NY4>Z
M?PG;BL5$%";2FZC!K"@< J&G-B<H)JX#<^R86HDN?H+C1[3BRE>SD:G=P]YZ
MW"^  @%S/Q #7G'^$8,)7&3ENJ(%$WK:[)NP$U,P$_PFS0;=&625M[2B$73S
MGID=+L0:+1B1$SZ2@QSXT0/U&7R$ T]AD'AQI:-P;M[Y.&=$SN+RBR5;%9U%
M? F_G"L71568//S))1:^4AB+#CMGW$:/?-$@FDIYGH%'Y5!L'%ZW<"VN$"'/
MQGXX\MRE[$Q#*.HX#XI:S=JT# M-69O($R5/RQ6BO'0UL:$ZOQ?=(JDB"J\W
MU"T297="BD=O=I?H.D>">@^^.-X'&. >CP0Y+H)PR<U#2:+]D*T<<6K<V]HY
MRKPBK>B([)QU&MR,<!6D3D*-%7AP>.V_+(5&%;=%>"O-2;18)VS=QUEV0,2+
M8F.0$Y76&2NM,U1:9Z2T_,1[<V;$5VW9^YT;#A:LF;Y><2.+^KLF6K\G&@"J
M1W-UZLI(;(@,"+BH#)&(16M:^TA,70^@89<2+C+J_J1O XV<V199"_/R(UB9
MBF)!.2[Y LDC2Q@U(R&M"B%#%H>L,)MP;Z7AG]FUP%I!FUOV19XV%TWRPDY<
M;"Y5*VK:!=^Q19$  F]D7QC9OH1S+#!C6@[0P& 1+)?D9/?WQ?U4JQ<-H;[C
MJ[IQ6\PR_(:^!8*I0.AI\+>4A[GVIJ",T2@_V7=@!P4(N'(4M_ZC=Q[3Q>S7
M&8W)U =UO'=F!+ A:/6B6WKOW$3D%,1Q([%]2?^!$K!GY,T;$VWLR2;A! ^T
MYPO77]G$C,5.05P6S4\0%UJ!P@NI<$65AJ%_3TE$\=F%[-0:)Y1I, 9G7?F2
MQ/EAZ]D*IF#;OL6#-1.#%5Y[FIV\D%:R8K302%Q$L_7O=//Q@S]E[#CN_41T
MH_;1.4\>QH:(X(MRNK]-#N!@"X>XY4O ]R0G0;+-'5Y4"_NT65(T"9$K0DYT
M/D5K-=6*/;=ANT!$T('D \J?%H=2/ZX=XT_/?_9,Y5W!J\ Q5B^0PSN)PHAZ
M0N.GGO#BS,D8^-MIA\DC\&!B?.&,^B\+ HD/4GN)][&2$@PH$\6>W3&6:Q;+
M3"]6XL2K^_G<<6%@2*!G8>+L*:9E">7\\.:.](@%LS.V,CN]G:(VQ5CEG%&!
MJS9;UE*8>J/'&,+;UTFFY&PU)@_FX,9G=52I3T;9ZN$DL9JB47B"O?S>)B<?
MQ.M>8%4-OC(D>X/3T[26YJ:H$D1]C.[<6;0 -2U+(F',$[O\36;J36;2U3=2
MF_5H33D0BO-U;56A",OD![)*^5 U>A4(^/@( <]"P(='"'A-N6X)AWK1$(1]
M4<Z_N8DO,-R"/]%R'6N98VTDC6:"?9:T-S7")2]?NUO _V:V@Y%O:257)O$4
M=3#=HBJ0M%AYG+J*OWJP"G<G(M\0>GU1"+W>3-+;9428+86SAJ3&&D_65TZ[
M&5_MB;5PE@K>0DT@DA'7I&M$#7P9&DOZDRL/R.TBZ#!'O[4[LO3&4A=#'HWP
MIF8&)N 2#R-76S"%B1OB%RN<6O\1?__,[MBG3S<*>L-_EZ@;E0P53(/DH'%(
M-3DCW6<T\CWB=+95WN8_H_DP;ZS ];5$VMR?VN[Q#.IGJ2&(]:(NB%5VX81C
MJ/7@%*U ZP4_*SQJU\'.HN[(QV!G1E :HE@O"E&L]22IU0WX6A2CHP B=S.@
M1#T%*>3=4^>7,%,A3=A#\(Y!?S,II6@2I\*-^)$''^LVM/B%@,+(*VTD*/-%
MWC[0V^$FXHA(<ZQ*713(4%V#^3T)@ TW4?"#^$/R$HK9-OJ4BB:>FT6K8ZAW
M46XK%,4QX5)K4!^7T80"O) >OBBMA@LS]N)!%N8IY1;#XA?'+\%D7<>XCV+2
M9]>9.QSL[>!R![[KBOQ9$/J>9[MZ.Y]$S#?']>R 674\8MQ:!I3D1"RJ@Q(W
MLP7:27["$)\0>]FA11$)0QJOZ(C&T%\1]7FTK6E'&TA .%*,4FF0TFC95C?!
MO;5V#0&C%W4!HS=B,[_C7E*K2<NMB1VE9E85GK-SAA IN30&4PSB:.@R,M(0
M37I1CB:M(TTR+5%/ ENGNTSI0XL':$A CC"!K!F5HDTRQR4ZZW)Q),X&&[:)
M"//-U]M8?R)WN="#_%DY HKC6P^!;<L4'B),/9NYJ.A!>-^(F$\Y.7#D?D[.
MA$U*RM*7M81+N@#?=4"H@5>;, Y]QU/$=X31_;]%L,*S'_REDZQ(>,):"%HK
M^34NE!3_Y@H0B4@A.G=V+,R9ZS\+-V+JHSTTYM928$9EI2AE&_@]"(^AY: N
M"](+P0&*1 RM0B2W2;9EYHF0SP-.#D==.':O8"W)Y394;K01!(SFH##,VEMB
M9P=W6\N@*+!L/"EO:HC6I HQBVT;J8B6\BQ/Y$RE/36FW9\21--"R>1$A_J[
MGH (5!?7!=RTL245 ZY%82Y_TK#FB"W];T4)2^>&Q/+1%MC3U*;%/MM'[$S,
M=VW*J\% SB3JE+T1X]F6Z6=W)<CCI%^5/BW,!H>(7@>31[#?#_"H!3F<W,8I
M?*'>3'OJKS1$@%Z4DY'6L0^#!C:EY20R'"CSV](*EF?10C2^^"[T)=Z\A(LO
M.D<X2_:P\<.*;S1ED-!.B%PNA7EEDW8+//9GV;#5BH-X4J>JBP]7*PH\M,0#
M&GPR1/HZ4)IGBD%DN.*MXG,:BMG( TM7+-*<4C>%JEB1+X?(C24?IQD4_J;G
MZU\&10HGD% H\BU(W:C? >62A<MHNA*+QG<9,IB@IX+(6?+M(K ?,+WI!RN9
M>!5FR/$H3?R ?S/GMHUB"[_&&DD;H=\=@S1<()X,/YSQ^Q!8*>TUII3QP\?
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M[)']/RZ[QF\\.HM$B"[1L$QG6S0"-?Q/'W^[_4H,@1Y_*?X3T4@[88**\5X
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M5K'!V_/<V287L,^(K??L8*6;!6)W6^?R]W)XAXXYR<W7M7N1;1._)XG'#U$
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M$),JV:3A81:E;46D7V*Y]B)I^^;M'W[PIR"9FH#;?O!IOJHXA7ZW>T2$MW;
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MJ'1]UO[>SFC[94'#MVBQ<&UDY0.;?H,=93^X_K/YT6/A(A30P90VU%W=RXV
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M;#7'XV.YPSG<F&A*TZU#E8;-+;4MD._X!RX"R/!D%P#JAC\M51IT'.H*Q.,
M/UCH^M*5?U(GO7$_'*9-4T7Q3,!Y/$>C,RRUG2OFB&H@/ZXB7^ O#7N)8^38
M=#F<HG?ONX:ENR[[)2NCC&X.)Y8O7:;[V![?O!- N)=2E/+5%83+LV6&PW.P
MSO9(,MQ#-\C.-SE<-SA@]ZWJ!H.< R>Y(8YB!B82W'[X_1*(X$]XH?Q9%*#>
M;5.#M7ORG27_RP>& GR7Z8.EO\<QO#@N.+@^"EQ:US<]LD$2X\O+"6=\!,(9
MCY1^1L_?/+I!;E*RZSVRK&KO>C17U$G&Y.?,ZF+@=%=KS5S1'$Z+5QLG3Z8@
MSR\YV?08BDUV#^9<HR:?\5?E\/D*<RF]X]M04)^5S!AU7X'N[Y%?LH<%G9=8
M<KC0.&#_;0J-@B.'LYH=X\&PR-/%)<C]3KXQ=;A,GS3+1C_2 G0WE"N(: #3
M-7%%_L?;U"3NP),22I?YJZ*+VT&-K=#)-T].^HQET(03FM_J[L(QB'-<X<^"
MH9X1FZ+\IXWR@O&KHD#]$7E#=K2F)B!K<!CU*"&#G+Z?!_.70W;?*G_)._#U
MHPZW(Q4B !4%E4'R/W^#;Q9PM55QQTGEY#_\8 .=H14<7G1NU)+!BK\GD]=^
M8F[RE\8K^2?LWRF_?%H;BS4L&']R93SJ5VB=_ONOZ\^A<:L 6#W=V0"#6W*_
M*#ZM6ZP%"[=J;2LTL&.6+ABZ#JX >USXA#?^ I/V_P"F+TY$?T7*UDL#-HE?
M?@+$PC4![+/6!KUTN#3".V>%O!/?%P?V>2HIDU,I*9\C))E%A2B>9 SZ(EZ
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M@O3#4^A+!79-\A)_XUM<1GH[I&\0+*;Q#X4 Q 9X^]*UC5(23N'V.C'-N9E
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MG\&/U!YWC[Y7Z8X"5 ZD%[=J4P . (B\WLSAQ(U*,#IAI[#Z39 R>B"QQO$
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M2SMRAL#Z-M73IM@5-59&@[DR'65-/=I>)JXT'#S:!T6@'P^'@TJ%,A?T'"3
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MM0AO6 N-GQU[H>M+LG&_"+;]!2P[ 'PX!VF81&/&)&(XGNV[9#6V2GC5=GR
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M1GF_@Q<M&,CHAYK+QV"ZYSIW<7_,C_; _/"@\8T? (D?$(?7A,+?=^&]NW9
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M2QF!)\+&7JW &HG?/+%]^A .A0X(2A[!=2BL)@L;:&G'I$KFNG29'?(,H/#
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M^HIT<'\T/"X3PL-LCXI;@=H2'?=$53.2T_(](P_%E0!C),^#MUIL!7V&UDF
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M*!88$R(<$T<G9H?P.*CL<G@"!0ZL0EII85R7$8$-"APWWEJJI/20<F81=^^
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M7NGV\"1A(=FEQN-2JJBJHN'4]E/32@6+QMI$92'-:48-EY&XB$$ (3(6-43
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M@E?F0/>]FD:9^&)@:%A FK0.[KX:!@W."F(J0+:$9.R+DJ!,8,WC6.1!"H=
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MBRHOEOS7<3PBM  SD-//.X@JY%WX2[C0@_Y/-ZVGU]>7@<P*:8E1FY3W95C
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M$^-9C -.%(+($<HH07W)?0PHZW=,R54).DT9CW3P+'K^K'_V7'NSX/= Y!2
M@TT/\:U9/N+T*7'SZA,A\PHM&+*;"!839D_YA9B2H/%%J^B+H%IC&)$R$5E.
MP46+9P+J11;.950D^0+SI!""C &X_[U("L'R=(*4B'5.0M9#-4LT+'9$_MPJ
M:-^11*#D8&EICMAH#12^"[R'YNW WT\7(!R]?>Q[EY78T"_A%.)7J@IY(.7
M><LA+#51UQ@5L(J+C(SWK"KRE $^+:JIW17&4=4G>+A_^.S"GE]47$197.Z]
M_TI]3_ ,R<7G3;-4TI\2&'ZV-X^P<P/_>UQP>(L3Z.27$\Q00'S8(AI.%\!N
M+_/&\1AO(H521HMA3'VR, : D.0NN&X13Z("]T_!A(8+ C/T,."DBS6'J^%X
M>>D,_0:<\>O2@7A]1/SP-@*\A[L ;S/ .]@%>'_H*P(2DU1*8%41I]!TR,H
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MS\D=]TRM*84_HGW,\^"0IX@MZ'Q1D0GG5.%+_,!M+H^7BD(S140VDKEM+JZ
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M>OM */_N,.G[+29]T&+2JYH=9C_PS5:].]<NP]XQ(N_9E@^:MKQ8NJK;TFU
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M='"L)P>O@RZBG"%P(NO,P,@T\GZ,BN@J\^V, >FAYXL)-G/J'SM***NRC,V
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M\\;3O$I&U10?W?_I":H%?ZT*/0@U9AY&J9XV:"=/1'.H1OHA>;\V^6K4_>
MGGP1X SW2C!?>)H@BF$9F3O_O7$T2]+ES]>MH#'2?_V?L^.3,Y@%COA+ZV1:
M3^,.I^2D; D;)(1/S0?'G%[9$L8,'7-4[']MJSJWDSJ6Q(0@),Q!##CF&I;&
M[1="5Q@YW(<_Y!2\Z<^9[' WH839QF4"&V&Y(F6S9YB4Y22>_Z_@<<5X^>/2
M.QWX3T&T]Q<B<B'\AU&DOH-KUDKRNWMW@WO74#Z$S,MX4L03J^<M2!PZ$%.S
MB+2M&E'W@D_L8R%PF="D!X,>4*+&G+(OEXO>38DWV'A3G<O%#BC,$&G_ FDE
MF*Y#)2BC&!MIQ73CZ YBL6L^B[%Z6C]8^]B:W]E=S]WU?/CK>:U8Y#!!0RJ*
M<FWD$8Q3T[!98'[UDH3KM_>:R6WX18,/@9?0(LYXK<KU2HCDR @L<K3U$*6<
MF\R048)F\HAZ+L0$\XL:N"NRR6!BV<UJ@6<V(-)31*E8B]+Z@DV<BE$I=M?_
M'I3@A[_<6R!JM8QTPRE5/)QF>9I/E@:I[\UG@^\TB3-$=[#CH#?IS>>@7)95
M/'-R4T%>QY<.GF$S$[K53[49'_B9/ QPE3#1&#F2QQ@D8.1:W>VZA0FW1".$
M9" G@<9?D=$I- 56;QI/XI'^F <@XK3@9 Y)S02$$>&ME]",.QVCF[P@1X*\
M)/75KM.M95DT8=AY_9+YCL[3Y)1PIRX#)@G/N_.DERCTE5+JL</LV3?"^;#6
MU10">2!D7ZC]%R8"1KWO9NS1\MPML+3A<^*&"T(4MOGX78NB55Q$PR^+.7_?
M?HM//\^2*@?&+2Z8T7.:%>/&R-<OZS2JMVF$7J1\3KM:^VX&UZW,Q]451Q[M
M<]12@..0) -,_1U^#K;4=7_U'I9[;X%COQNB6OM^/.>22590T04P)8F^6^'8
MYF]E5"@61Y[$]B6Z!EW1R?/+T#26\PHA-%,CZADA!A.6>U-N@RZ'"(/S!?X2
MWL.(<QE3SC1#FEA"&<*WDTJ<?5)]06I%&I4E,37CMA>_F+<TFUV@H\II#;S3
M\1-T>/3;'?K],X%GZ]Q2XL^)K?]PT1NXM,T4D6B08F\/X=/9'MH\M1*3FQY4
M]YD$]DQDC]4&>\RP4UMX1(/]7G!N'+ H^UQ\PM57)^"K,Z0>HWR!*/VD>=(9
M)3W,$'A4J\M2<4?@">[DG;:ET@V%AVP-A&C4XGH@9(TD;.<[JV(C/4J'I^0"
MW)Q:5&H:>=U+:4QG_]2:^Y<!!ZM 3K5%7.X/CN&!<C4WRD[H[[(3FMD)9[OL
MA._Z!K0D) 0?8\8Z1:GPV+(-WCIA?TP\8RPSD%\3^/5(Z>RSI-+A1"YO9'C?
M&+3W+$9#*2H$XE-08[LE&O%MRX9'XD'-+ULXLH9V4Z9A*T$+>2%-F.I4-\KR
M\:K\N.@=1!WU >Z\*=^C-R4B'Y]&2+ Q!-%S\F(29;KW.ORNQ KD"?RE%NUV
M#.HJCF8A1P$()I0\,"7#CIO, 2>9M)8[X+SHA.EU^ ^=.7[N>>FAZG?FMY,:
M'/ ]IWP,K DUZ56[2,3N\MS@\HA\(%AY)%ADZ& _: \\&EIEI8U1=NN%UH$D
M%1MD6^?#A?D5PYKZ:23:X3@:%>20FSJ.QR(IOY0,2\I@LI2IS/GDH4XVIPM%
M)9V.6\YT+454; <>V6U%Y$QBY[3?W90[O2FVBB'VBNDB<EF^1G($RBUCQ!0@
MR ?LKID1K)9VX;_^:'OML*^>,K,*@1(&%0[1M^)6^@XFT5RC4%BX=%;5X#-L
ML\L5M(U4M-<(O@QWD!J6M'K?C7@354VFT!J0:$0?'!5NYWCMAKTH'!N&M'C)
M.Y3J&T'!EE[U# +QIMF[C/5P"=AR,_&ONBTL$[+;\8RT'_TI)T(:UL'-597?
M5]+?M8;ECEMN+;?D\V#7);&$.OA((<RO=)E)A[VW4VQW!+CI#)#,T/O >60V
MF?T::@R9-Y(SXJL5K*Z8UWIHN9A30:L(1$_Z$R"6)_WI)NA<&B^J"W_$(M.P
M.1"%+[56;0*FZ-TN=8%@&YR/7YFYTW=W%^@F,S 6'A$>ZZZ@'-94/TZ5&BZ#
M1C63I"3@A6)@$NJU!XKBT,2W6+6%:S!<I6S"1 I49=A5\[UIFENA5?YI-,?8
M/4 X(.!@U,U0>[?8.249@WM<Q..5?-NRF7I"ABW.<@MG2C3A]8'K,IIEZ%?0
M<(17"3-S<G"%=ER-V !J-$-^A$?(R 4\I;RF3<]3W=SXPI<)CKM;70>WH+>A
MU86X1@%=*>@=]C@$MU'0:?/B"]9L"]F'FXWO(D$P?J,.LQK?B];WI>$CFZ[B
MDFES\RL*08],M+UTNB/[.TLHASJ&\,,'8"]^>2FY6UTUL-:#JXR3]K$%I:0]
MEW:=Z#Y6S& T6(V3+.@[%O5M7YO^==9#EDDC$[\DDF)="*6E![8);LJ&H?"I
MCS$WX_H82Q\KB1]X+8K^S> FJYL2Z:L^<E=._GZ]5$^\JNT0KVI-\?K"0&K;
M91H'P^VZE-7U+F5F^*Y+>=>6@Q) !KL$D$8"R/'^+@'D;DF?_F-!^_JW"MK7
M1BTDEC^<?_P<O'E#@#V#%^\__^/UQ^#-N]_>?WQ[_OG-^W=W(X'7WH3!'2$7
M]GO![Z__?OX[0Q:^?O7FW=]_?,S"3IUC1BW;W5XF*<B_5#>(! %.7NY+S$27
M1B:ASBQ-9H1C1C: UPP:\?:T)#99Y8UNXAJ2.?(1F0,L0*0T@?I$ K<7,&70
M$X;@$O,I31D_MZ:0Y%]NMHFV%B,1TB*W$["I1OT'=T7]YSU"F0U^.W_Y^?W'
M[:!\=8O<Y6&AL))?WO!=80V;$JU-*V %]PA[SR*FQ#293$&CPZY(A+0,*E@O
M^/_R15!.*6=X"/0]7B 4!>J$B89Q(U5-ZENDS*GR<WX)&S%LZ7S*6>\>ZEH'
M]& =7&T37$/;TI4SR+G&,)K/XZB03?&_J?L.XHL2U;U#)/I0PL4!*R.$\8;K
M5%=3WBY*+\(3;!X?@];X78G=S',-*"HMD@N_FX)S1*S/EWR:NE$#<-441E.4
M9.ZA C%&#<VN8^R0V#@Y\%O:)'.9G.E$(_R8>Y)K&T*:9H1.QO]UT)%< +"@
M_"[@M P_Z;0FIKD*\F?QA?IK)T-C3[IMSR7#?T0MO,2[LX2K0+]65.J*?!Z7
M+9V6EVR$X3F1ZS+X(Z,&B;1+5Y@S@&@NA!T8<JL@.C!-?*4 31&D3EK&5^R1
MZT+BY 1+9229M/+E[44$'=I@_)3N7P^_!"LM&DJR_S0J9E1E!;,WR6M9\X (
M$"HRH\@8>@281^A-Q#_"34 _Y;AU!(3/K@;*9"ME.IB.LG"1.HA.A4,>)W)Z
MCE=L_3.>9?QU&B$GE;?T4\2H,M@^;&M"@);1,'8K2#HG@V\+9@^\+@U4<HP.
M48T*XT8Y[:QBS!69V;*/"-M;E^1LP!;1GNIBMTY0B1HD0J^BJ0W3H<YR5U$Q
MVDOSG#*'ZV4A(@>ZUM(+WC=[S,@=X2XS>MH:OLF0HM.& KN3$[HR@[9R G'G
MO"+&"J."&,[!,5A6AD%9J6!%41V4%_MX;*5^=8=M+9"+_R;M=C[1G5@^N&J_
M!1[-]^X52DK'QD"@M+C +D6=W(;NR=+J0YB+=<7MW[3LEJY#!%NB)8$!;=6=
M$7DT8;I46H=*#7ZH#)675+^#Z-H\\'MX.O]Z(VR2P6'KBP\=%[[3*?V)ZB8:
MMW@34'.KF(/GF5BG5'X/2C_[XPN4Y3H97^/2%XL)9B>.2 4W^9.LA>EN;BC*
MQE&2,J@0WR]L-TTHB4L70]#I#0I32Z/E0]=Y?\_W8%VR?W@JOV6B;O0(Y3 (
M8<0LC:JI&^,YQ!V4$2*$8YRE1M<2*D%RY41<ZBF.8)H)$\(5!I0Y3Q/U;E2;
M40E+=_2[H]]-Z9?L9M 0%ERZ[_#$#*Q6[&,/(X(:,]2QOV$\M^:CR15V,Q5H
MM*ZA=-$\*C%E'!-A, ?_KI*]=Q2]G11-MJ/-##)D218>=3.ESB]Q87I,V/81
M^04!)SD9/^.%]%;)3=F@GP[@:AVZ:,(TV:+$?+PN''J/J0V$9=;!.2DJE!F5
MZX^3#\96V$I6 7/\+(Y'Y(9$DX!B^-)8EK27D'/O"9]CP1V@=</TV*I/+K))
M7K3H6O%XC#TU=I=Q=QEO3;Q$NBQ$WQRX4MS[=^E>(.J/G%3DYDF&Z(MQTM[8
M%R_U1QY8TQP!>H:<QJ<]LK; ;T?(.T*^#4(FXS&CS-.XL"2:L!U*Z90Z8C0I
M\JMJJA4D:<_ERPW'WDW-'6#&7O>LU^(6ZSNZ:_[MW3W8W8-OG8&3RCK!W$I.
MV2[B";:N(D\-Q>_FV*0]&6J$9]&@**\10SG1,%Y(FVF@T(LD=Y((@4 0D\TO
M+PSF.28V(=%/XRBMID-&HT0>']KX&3;[X!1'U)3(TFAQ&X7L"F)10Z%+3]Z(
M'B9K0J!8C3U8=HUH.G9I38HF,=O=N-V-^^89O!F#9<)60[;D=%8,BAJT0@^T
M1!>&O_SXWA2&7VG1A:FVH7&-4HW94N"/;9YNE(9RQ;A^(1K'8$BET54I*";Z
MII>2M,S1"7)0.5E4V/*30H_S.(M82!)G&%(^15D94"!\?=/(?8L$+'<B<'<A
M[\_!X*27"P*N0"6''&[' /1"8!/PVL)]I O (3XP\8O1'N?NZ0N-P5,RQVT&
M?.WBFK@&];>D.+@DYRP#S# >3N.')O =,7]OQ$QV3;; ' <"JN+\HC85!WX'
M-LFE*0>A?!;=N$._/P/6#FK;F#O5IR!+""E5JU (L _#.H-Q#WM\T+6 ;D$@
M? _R8,MK00YVM2#-6I#^KA9D)RD>HZ1X10D2DIR+/5 TT$01#^/DDM$Q5IC,
M5DQ0\X)HJ%LB:NL=AF?!XP0HL%RX7!FFJ N.8N;)AIW&OR/]VW+^:LMY$E=M
MI&XH'7[$"J"2%76LR;&]*R27SPF-4S(NT'X\VM'JCE:_G4U',Y3BF"L_BAF$
M0R?0B=E:+.;Z5T*IE,Q1K>;2 N5O$_Q;8A-;I5SOR/E'(.?W-J0K 3-)(BVU
M%>CD>A0Q>>Z_Q)CE&0\7U,;-P&55Y&>1EM*A?IA;#U78](UP&E)&<\%?8XT:
M$'KY)4E3[&6MX:(?W&KTZ@@?)N$?$?1M8 =/Z5>O?1('<>ZS#H"F]M?$[ ?6
M8=S[Q]?.<58/FN-\KWM38\0#+T7^ 4L.SDO!4[E(<C\JZ5287;7D][)W*EN*
M+\NF>XT]0T72>S/L=I,;A$'['@5 Z'<7<9Q9#QF.@J\J@=QU54W;7IY K"1U
M\Y*ZM\%JW,,FH!M+5F(N<=6B@PZCT363[@982H9(XXABL3Z%AL'+=V_WSA>G
M?RT7<SS7DT,4&/#O$&8TC*HH75;<^&^/>TT$DQQ5B2C+A\6RQ.2V<E%B\R=R
MV^EN]-A["EZ!OT^P[\1BA%5NV!"HG&)MFPT(ZWS2JHBC2F/:S.%.46$7Q;=F
MF*<!-FM0#M,8]).D-)&RMY]TH RK8Y9Y50 Q),, RW<1RZ;YQOGOYA7JE?$A
M*KXD&8@&4ZT[2DH*1.LW/KS2+TAIFQ59)E?<+4ELYGM[3,!(0(_'J-Q[AHE/
M#T^!B*YSXN*CMCBY.0L8,G,%;ZU@PZ4<Y=KO>@<^_E<TF[]X9;>ZQ7X*6XQ\
M#D%:&*8Z<[05C]3O,, *6LHK<,EW#0+)XD6!Z0?\;E*2HY+O& $M8'FC#(DW
M +D&7^*+"*,\HHHX60SV<B/'6,:5(L\D53_#L4\7,U*0B*JY\!1)=$;=+$7/
MZ9(';B49IG]RQWK*:Y7&GZ!J 4?(,S^%0MI7*POWO2OYVEP5?]Q8GPQWN"0
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M< 33DILQJK9FC'G7Q'$Z_99)]D][9[7EK#.=8/5,]E?.Y+"WWS:3_=[IRIF
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M3(]V_V>1\,)B*M\B$))JP4I@3[.)'BX2W@,GN6!CAA#NW:TS&R3>]-4_;O!
MA ?7<(FQ%-]F?0O< [Z_>;<_\7MFS J_*>WQG<?&P'>"=0)WIL$]I!?VU5RF
MH20GJ]@:I0#%N''18)4^EK=QV"1].Q@XM:?NBL'@2)S&2WJ>K[ZDBO\N C:G
MO[D:?I.;I]JK<M<9CN4=SLRZ6-E$<8((WO@9T:D<.('FI'L#+/*-:IL8%.=D
M.Z/8#@\?_JA*B,YE7[0Y-EYF'*.9+>=<>6C!&^04[FD^+>$EA1!=(0I5?O#2
MR&>T9,-T[E#NB"RZ%E9-%)>%AUAA8<;2L[RS5J^H;NC4V9)D"^93+K!?S1FK
M<57=:[#=8;J&;0D,[W3J44C'W.Y.HJZ!Q;%VYBB>S&;3<(,C9:%I!N^A0'*$
ML5*5@;*FYHD*>;@,L1$[AQ"GD?%KC$, NZ%^4@0PA@^33/5#-<[/%;68):S=
M$<8^8KE.Z7644FT$X# N!@<K8,V9'/M^23+YK_5-<:WBK1,X9S7RIB$3^M:2
MGY.\0O9)\EB5DL< C'7C,.]X$6:TM)[LM16ZM6S,+?[.6LUE3;GPW13<C)'#
MG[H<#ZPCN&>Q)]4YLK=N63Y=T#[\)'3Q'^@2]5RG QUBUL!K!])WW I,*Q:S
M'B;4).0\B+6B$UH4Z3+],$%N:_@DIAMC5@5_K8KF[\K]WB=:%F\N:J7 >Y%I
MXM="B[L*+R'T6KVLD>*MU1[C37VV SNP%:Z;YU=EL5N]W1#GSNH5;EW<_V_J
M]>I+W#ZP#3K]*G_V2Q/?DD_3=9PZE]:U.'=@BLUA5M213U\R&9CIA:?,#],T
M_5*)PJ7%ZT"Q2@E_OS_UW0JTJI/Q/'&OC'<5C4RPWDU>!7Y!SXQ6CS7&<95'
M%KR8<W'/DV^OR[9NVLC09H=]8"6BK:%"5PDJ=.@HQ/J7>CI#U/,C#CBGM\>;
M8M/ W$9X@<*TS<J$^*HRP4:2%&84Q1P(89)WF0D%Z4C7,M7Y8G"9TJ!X^"SQ
M/_1"_?M-%1+*.Z*](<<MH8B.E,-$5*/+*B:"_*JKG#AH_"S:X!:K)Z)-@?VS
MO>@Q$O2^;)DT,$Y BGWSS'[3.'L1C3W=OKVF]U7<I<G.&G$N2W\<N;3"8(%E
MJ\)KNT_*%<P-NB:P@AU5;4&(! BR;$=Y_]R'"L8^G:8>;!8>ZP;\$<KRGSU9
M0&UC4-OG"ZCMM[%!7(OBNJB*7=EQRX]1&N4_I*3.V!F+]IQZ%"GS]<.Q;#PH
MQ?7;WJDGSQJ>8L8>@43 +=,<3#ZO3;B2\0W ,4-J=\)WK^KHD;)FAL!;)&'_
M40B&D>1<D1J!PE>\,+(J=E&('G555075_UT;$BMD\.%Y?-MQ=<*P8M'-9K5;
M6 W@[9_VB*/6-.G4!?#W>D^^WZIL6:,"GV^W:R'&WA781K.7XY?+1?D/A05[
MXPLCIU)32XK6#?(F3D8^G ZY&8S\TT_.__![[+G1D4FO-S7;P 7UR9+KX9/\
M)6_!TWGCW\@+]T:^LTG%NWSR>W5#]AC&4[=D <N($.^)&FTK33?X6;TWWJM8
M75 .)8L-48.9XY=15M3OQ'-FW:3"*N_4P0Q\Y420!6S(7PYP,Q1#1?27OBR^
MI6+"^+=R_4W>-"6+7-_D#8M=MYCJ<->/T+#X8O!M@"MVL,RF/31= 9\I&'%N
MDF#B1"M\/]U%?M[H>(0H$&;O7UA:O&*F./S3]Q!E4E<<;:^X QZMRS3%L3.2
MZ@HX4]Y^#8P6_R+'I<4-8$.= #U2QOIGNH[H4-EF!H+$?R?M>MS1!\LS=J-*
M+S*)!4PT(6\F5>*)%8+)5E)1T&VQ*5OETTG40]VW7;WY/+S@^\=VG%ONJ S%
MD>MA(#5+_4OX@_LFE;-;ZZ32[9.$>ZSS>823X Q?0G+B<N"1MU>K';P:F^SA
M48WV(6K%#4@[(I&K@3-DKA_/GO%)21>3(7=CA>>)*51P9CFX<XU#<G@SPF9"
M9EK>@X.KZV*@YO)<E6B6;"/[5-272\PT6,1S"GU!4OE<EL3_'*TI3S)Y>+SR
M'$M/L.Z0O6VD"DXI+Y*.!8GSU7>U^+^$^M3V2$^FPCJY'9E'NAZ/)J/6XB)R
MZQ )"QR4)SLF[U@@)M6.9,BP_U[ QL=,)K^-3YYF\':>/1'&\ZWK3A W*HQ7
M)5G3;U_]+>.1R$#HZO_QV;/S9_S] PS5L6"IO?#:]5+[G%[8G _4KO M.,+H
MMP5_2VTV7_<=99%IQ9M6?8E=@%);0B:=JNHI&V1:CYA#PS]^_N3WG#&E#Z3#
M&/!<YM-S&)(Y9#<*)FAB?O[PQ?GG#S(_603K_,<G7YQ_FEPTC"=N-35Q\/V]
M""87!\DL_L>S)X.KP;@NRTI80:C+=(=P_&=//GEVQZK"=G@A)M[.AQ[1=YJ8
ML*?GG_WX^?+*N4&X1^@!.FO:X7(;/2$]OGNV1VXL_TYEEI%!H !T#_/52F2)
MV<BZ(F#,KFBDO5O\:(QAGO>2\OV?>MVN+L" 6AO0\_]QW4KPE4.]Y=*9N$W/
MZP:\=M)"6%V4X,:]P=+OCJ[VI?3^AK=*(7:QZ3(-+9Y?O/GR+?]F_ 2P-=MX
M!G!,C6O(!1JC%3&UPI]^IJQJT;<=7H>IF;W!CGL2R^1HNQ@HP01AU@]$_48_
M:NSA/F-_]L2;3#!S')U5ZCU<U3>V1UJ.DL5Q-"XW>L'P"KD4IQ,^X"3C8MU;
M[I:3 7S^3#W5;U32\ WKY\ ;WY*;^/2+S_](2P*I&;>JN+&I&[F_L)Y<BYN-
M\T56=Y_?\(F'GT5L%2U1&L1E349 RW#U#:HY795'<;4SK<99=!RUZ^F%J6M[
M24PHQ&U6K?X 9X=\GUL!]ST>N6!Y.V8XP9=I=V)J/9+C*,[P704VQ$I';2.V
MIKV!BXA7/3;%F=!4CL^86,)S'Z.(JNN:$A:;L-NQQT"70W>?/QCDZ,4]1-&_
M&%E;)!>QZ[U&I ,1@6(B@A]4R/Q*)DZY+&@<3%7*6EE>.(&\(!99V:@W1JX7
MJ^6(^\7<YC#TR\NB,2KLX;M#IIH66_3QV>;6&BXMRA^8%*408^.+A>73;T]2
M7R(JG2L:?L" D&X[O&>;#MY 'U$$9N(K@]@(W4]*B'<,IS.)RK:K-^_B][,P
MYE=8%Z;18RR>Q*["'*(3D\12+%;&'2PM_-5X/951MWU_"K(0LL@B9/6E"<HW
M*5E.@:90L4XIY4D/R!3OZ@C6H#1;%"QX/.>QQHC/8PZ G)G\9IIQ."BYTZ1)
M?2O2>]0$BAJ<G'%#G34P9=)R0?&^L%:VQ$E4*6M47').-"TA -1E&Z86@1S(
M9!E-GI9<AM5;7.5+;"HL.W*:9J9. 3.4GMS/GF&D\?2SS+<5^]1+=!=DO?@<
MUEK8C?'?>+I/)]FE38.+">C=#04K^(P(Q =KYY5HX)[8!1^WNJOWHE_Q6>95
M(URVSY[^GOP0BABT6P3AM2Z3P0W,1AA(V40IDR0)NYB#QP7H]%AA<Q3(W]6S
M5-4XNDV]-<Y'6LT*BY P]3Y&Q3J(_CI&,HE*[0=FNNY3RGZZE++'I>POEE+V
MK[&2^ET:#T;SBA##S978UL\T$S9@=2?7\=7_?O/B[.D7*R1%+0X(M5)J/(E/
M[HYF5A_A1R3XP#]$:HUHMN3>5//>F>VU,CDG#I'7%]O8)4CF0R,&*V0A8V?)
M&ORJH2SIU&"#^@D:G7_SYJV1=%R!XWHJR+TNVQ:>[+(OMX183.TQF>T&,ZK\
M.2)%R1LC/]$G&8[?O!=Z3T'#2()&@8M,-Y*06.\<6>&(03$Z+^3/Z"P.^&7[
MBJ4(MC(\ GG!?!*?&+K^@L/$F28='I@$[S@Q'LZY35?%G-N4$@V2?Z7=C$;8
MC$>1.O-ZX-%+'N @PD1W6.:K,;5WP.$X(UT)>) /Z^#Y^;=^RG5)*Y +DB%/
MF6GP)6!MF,1%O5A51*A,.%>M1,M"TYT$9V)F&$:(LNLD=R"+V.7/LN!JSWH[
M*IAM'7,$,ILJA?OW/9+_4"Y;RXS4I.:?SZU*3;6\>:OD\J[J0?J$<*,3K?:D
M-HLM<INF7&M"'?;(_]_G#:Q:^-*; O=Y)C*-:G6: @+0G.6=Q>[\P^J41W2,
M8!%+9#WP$.'(@FW54O\>89<[4:WC><(+UML3;T":6O(,Z4VX7"0VW+K+Z^ZU
MZU$F1.JN<C&V9X[]D)J@K$ 9S4V%@"6(JV\*]R@H-L![<_A>G< *O0;NU5-5
MV9ZQHM.!LUHEN!N*9H\L4Y+ASF]LU1BW?D(PV0C"QJ>8$O\["28R,41#QQM)
MWJ-3G1G<)PJA)YXX==6\4QA]<H#=J9FS6+;Y-I8X%2HQ0>F<F%D1H?6)NKSF
MU(>^S!* RUF!.8R.?'3=+NA%E VS^,'>HA#2YB]J$.8$EV;\154C]F(3"Q<P
MKHLW;\^>U]=GSS)RI%HP'_EV=5,W^^U-N77\S@0_B: -)HLU@+;*+"(FH-U+
M!"\7DP'; RA*[Y]@L='2$\,",P)@&A;'Z!D"8& %VJ<"L]P<JJW ^/?PQ9/O
M"]$AD(4*=C?\@,.:F!XD.T3W<:C9,&*9,*7GA:>GABL(AU @LT%;P=X3_Y"A
M&Z^&PY#V!(\O^.@56PF'.YTO952='@^""=+;J+Z8"EL,]QHSV8J7_G@,TARV
M0OJLWKQJ7?<%DPUC#A<A5<&WA*A$>-+K 59-"@\ND>Y(,HA9A*DSD!!XV!;-
M6@_8[,A-D"7K.N.Y@V\+%PFC/92*4Z&345XA$9](V)#ZUL %P_;I&3Z.@U M
MDCR2*FR=^ &P)JU7G.F-AKT=)Z:#(;%KF%?EP=C+:!&VC)M,OM 5Y"Y2)$(J
M8BS[M",?"1U5;C"5 R,R0ZT+D9+=*?.EE_:$(+(A";O)HX0J1*YU6^6+^86!
M&X"U4D0S3T?5ZOQ%&)Q6F\32I/)(JQE!&MVWZ8P*@2JK(LB&=KSXCWS[CE0!
M1"@9<='%-B/T!/F72&;.9)SXIRP*GL\L8UBBO*?W2&G#RYW.N1Q=U+O=DQ5!
MIUWA+*.&:;DZC9)T:OFD*+:#5$<A)!<\!J)-T*I38\UUQ@&RRS=.%J.D_(5U
MX)%#KPUX^M@JR*%;A>@ ]L@TL!U-!0PCRL,3CF;FV1GQ(.SHNR)O4 H-]B.6
MNW4H?(H+/X?>*?!*YX=U&WEFM[Z&5U@C6%9[,XDKL6Z%^8E?L7;@NUE'2\,/
M0J+5C&/+'1=4F-N@_);NW*#$V(!;]+%OR^_$"YURGH)M$2[.B7O$M6Y4,C\9
MC" J; ^S8YX<1;)2L.%94-O \@=4Y&R$3>,&"_*4B9Q/4KG:<KVF'.:4M(!R
M9W3ZM<F[#S:TWZG405F:J^PXMY%M@= )U&MJ-U28MSJHK)K&D"468RJK,VX6
MX 2=H!4>^S+$8]V$YV4/TQK ZM>4,]]R_V^Q&BB0BN?#8O,$X$GX6-4KFR 1
M)CG>^]GB"4]JL"A1\!07G5DQ%$-EUX)M)K9#[4]J%IV%%5/EW<7)UK7WW@W2
M^S^4/F$.I,CF,^UG)C*YL9YI4ITAHFGO<IIBBD&@&Q_6VK]/\?+94KP<%2\_
M>[(4+W^UQ<LI QM2#(BZOZJ)0QR#DF#B1(AV']0Q_)NX,E^G'21DIP)1'[8'
ML;04(3"+"PG\J4*.@;W-7#K6EP@ZY1XC[6J2++M3+22YZXUJ%PO&&!UUM&FK
MRZ*^;')D2 II5@Q\U()B7_JACRW(,[7=B009]PO67'8IL7JRD7KM#(P&>?F5
M?[:OX#JX%BSN%"<[!:?X+(?60PTEQ^'JSH3:+;4V?W^AHK#[BQR=S315>OP$
M\3JYW-=K9"L=Y$+'2T7[5UB;X;K>7QLB1J&50]XW72>$BAYH"8\RUD2Y><3>
M!6+=BCF( VNL%UR4XA7+8Y]V1;A*JRF%K@YWE!_N+U^;#>C?5E\1M21,,5*\
M'O=T)D/$K'7_ER/5^_ " JB>\Y)XK0N(P$]M2??YRL;Q/,%4OHE#>65#H0L^
M^_,W$F#MXER\UGA/ROD/;\]^.28";N?:,FU,$6G]($S(WTE.N*R"!A<$>!"<
M+*.QO;M#^HG5)0%H;PIB5^.P0O7*N7EQXAXJ5G93^+1E(K[+WPG)N#S53M*A
MJK<V[JB\BJ9@U9[:KC@P&"]]IG:.S31'[&_>%4QHRH2(@9]X%K[KM-$'BSX6
MND<[B?.]Q.NHYAH?M&_'>9R("PT++G36 ?C27OOP98>Y!4QP%B-*93D\'V\U
M!?9%H5+>X+ORDE+LO@EI8*I'DD,FY(G''%$+;IFCFF24T3/AF-J49)J\U_Z!
MR"P>2UNF#(E59]Q*!Z$VC>L:#:M/S)DNC&OX"W;%7-K/74C'<V ["^D8F1%#
M9\UCS0=M?S!N2:>;EJXPS5X5E8T^BQT%@;3!JDI4HF@BD\:$3Y]\JB?KV[Q9
MYV 3SE[]L"^HC4E!"ZX_P-V>C5GDRFL0=, 3<>SA&3:XVW%N2"J\; YSH^6T
MT75!4!*FO=RH(/C[&,Q8B-@6:"OE1'<.:DBN3^" L9TFI+@ !%304H]68MEJ
M$H")@^:D%HPZ@40NH-'#01 @@;/..^(C$ 1?1YX!&SQ9>/AM7 /8XU*/9R)A
MO.?5I7:/QD-ZLJD!C$NM2"ER"-#0N<[&I,)A29<8I!-0I\FE!:K<S*'J'[75
M_&:\_2@;!:%+IZ?-Y(K)A3V1ZVGP'=_,Q[G"N78Z^,ZS)T^_R(8$D;>[)^%]
M=QLJT8ZN@X8WC[OXE FU\MJI@/D]R#UJ]SU0).#2C!\#)G-'OBLX,$ESD36(
M8SR4K4VPKE5IMM:]51[<GG!OPQ!-' [B6:+T[5VA31)&\"R0L^^N)GTT_QZ(
M%LD2ZCM+9][@*;?%.P8^QMA633EA^IJ*ZKILZDI(E X'$JG#BW/C6S]M,3T)
ML"\X?Y1_S,N*4DSU+B0RM!'(2GB3@D*/':,:./SNJ#^.TH=@&Z@C4LE XJ&P
M>E?5-_MBBTV+="$M7#G?%7W&>!7,9V)@\J\" Z%-W3"[K7@$A;]V4BN0%R,Z
M5^J![O+V2L[5[>JC=?K$*U998'<B3AA5@\C=\ _G-3NDVPQ+):4V?;/K2]R*
MDZ\A\B;BLB'G17>0U3,GWW,EW93;H&M(V9"\UY^<>A]1$3[JT8.;#=Y83QA,
M&!&VQY,!&J_=C^]Y(@=[L#_]HL9WD6*Z?< ?H!13-'SBOPOSEU@^<E+V?IM'
M)J+H_BO/*;M(;NN)2B[*58H5B%7>D]N8\?I^ZSM+(T%&Y&72F]%&H#P/?"^7
M#!];A.L28PJS?V2_*J1&=YUKW\/NPGU5<*9LD=M;=M7/L*M&SH2LX[:X;(K+
MZ+?U@D39$WY&5"]@M0Y7;92;)!"/9M4CN3,%%;XJBX$:(BMYU_"N1$* F3N0
M@U$CVTXUB$!IDT%LBAT1R/BE'QS<[)[W6?;?LO\^A%/-08K=H::.L!XH4KB/
MWC ?=S\D?!?#S7G'T-[OAC=YP_1^N,7Z9G.%98>C\?$PFX0\!RT>49O%R PQ
M"# *A09A9+O=$B*L04$+9N^-)RZ%-Y;ST8,]\? 937&3IX!93/3F,A7Y(B&Z
M[/!?\H35H]&EWU@\H=[7EZ?8 ON==<!*?VV\#F[";[Z36HS#8AO5IP2&WB%5
M2;>)Q-/[V8<_K3XJ/\;MU9!^-%:4G<&@/5HD68!IEX*KM3APR?%3*"IM(GQU
M*F^B=&2!,%&Y&>M^J-/N5. S[K/(#U(9)4L@"5H_'"<X_%$)3R+?4J8:ESR;
M>"X:,4R]?LEN9"P[_-996E1&"9]/Y.KQ2T0+M3]1C!'/ ,YO,$(WIHPRRL 3
M$17G'/XE"C]6<BBV:<:$'@V>#6UDCX11KG-D[JGH,=;YYEU_%(AP>K-#795=
MW2@?UD?E]<=6&?!(QW29ZD0EI'OIC;'NTM:[[B9/\1J4Z-MS/8?.AZ07!B;5
M)[(6+=U_7T/BDP6[-L:N/5VP:[_)#>(P;IK13%*FUH$>\G5-D@0(''!-6!.5
M!3".17%@CRWQ=E-O6%QF8P@]D7O=],BU&TE#C5=#-(L\RW<P=&W4#*AN$5A0
M7B"\D(@9,H0.%8VTTY^,K)' N4=S+=&<UN)D0,S]N@S9N(BUPOK5+>6KIU\H
MD^7<M)(;4VZC^&%L"E7* 63.ZQ!K/#6/</_J##,"R6]__,N:?R\>]?S^\\Q4
MA@_\FAPQVK_UFIX].5^EC5I:4^CNW$(KVD)A*,J6C]^V(VS7B'.=[YF-GU 8
M\0E<'TARR<G2GSC$7/H+KO2'TEAX%*4KVE=EW7UNJP;"[&S0>0-W""=G4(=%
M*"!^$E4!A&@EO._\T5B[LNN[8JI2\]C+[A=[3/M=7ED#X;JX[)$Z.HS;V(?=
MI).P.OQ#"NJ)(@)V(<6[L:+9'=<,;)C_#;@+&X<HP(#EA'V_+:P^SAA!JH+&
M_D0>'&,)8:6&BW;( 5]PBJ20Z]?-.P%)(2(E>]\QNH5/=(^Z\#7@4RL2!%A5
M-',O9W)?C!AJ9'<K6!+?%/;S411C8+3SU5>,NLF&0H-%F!BEKJ()(*5[H^<K
MHL:(N+($L#D'-?(X-(4(47E9GCJ2QLQ<8'):AN85W@QEQ?Q"F\:=4'9.046X
M7?)RHFTIJJ$[^9.[  :)Q^!:CW;EGAE\AQ@*@2(%#Y_[<0"GU03 *:42O:Z1
M(8>>4'#IB&-!P+B**@36J5S 3G-6]_4<^_&G3SX%)VC726T4F=ZPX>M-L<F/
M96?RD9AMRK2= K;_=7G-J=Z.7:'&1*NI^K3K&_"VK@@ 1 !BP20ZBR,PM:1[
M06%7[V'#8MH9#4F'F0ZV+(I<'F.8YD&*1/2T#>\)H%PA@-)IB[-DPHTJ)A F
MZ% TQ*IZV=0WU*A"S;>1H$Y<%C>'0OE7/-QSO2\PE)\K?#<HTI=$,C4-5Q6?
M5Y*:ZA8I@[D^+%&?7>:7'*7E6DC!A;.M-[UI_>II)WS?]UX31L].A4OITR3K
M>04N<4'\MD(>6"K]H'L5!:]A?^YNB:2C*^(HK%TZBWTC<!=^+J/='DO:UL>.
MK!?V?Q1RA-,A&'G%R?O0>2!WF%*OFY.'\X>[I\$> %[PL76.@DVAJV"U/C.9
M82F&G&UC"=(4HM1T%-O=%&'75[0*: ^V-O)A[I,($FE J!>00C<<I-86PVX"
M5#L/> POI ^(5'>Y#RA+@(AE^T[SF"4CUPOB:WOO'6%K6!LGS+GCU1\&JQ]/
MS5V3'\1A>3_8=-FZ D7>1@,!>WFX^P2?-M-E_*.Z+A[W4:I-1$8 ZFFGK"41
MA<]:ZOO#,-X@G1.\0]R!L+HN33"MI5VAO=LJ>K[TM;#3\A*LY!YW(.R+>M.<
MX @DK<@F/Q9]5VZ"[V_7?D^<^SUV=LID9JOGW[X\N^@__Z^V/^)3??8I5B/A
MW^RVH(F&[8![RDYI?%?,TA:YJ4H5A\2+MI:.,>,?%5>9-+Q'XI1+EA?GWDF?
M$-NB6OFV4+G*6%'!V\\-V&YZZZWXND'GX^7;;'7QM[<<,;Y^808=G),3$J@8
M#@Y9L>A:0K=!G*<%%LS*]I!@B^ DC!V(6B==ES8(&)UP8@3>.C3/G +<GXBL
M4L@+!J/@=QO+CN G7(NI8D"#]3CL1D.-@I'B6E) LM7@,Y3HNX*UV^5-5"MY
M6S)AINQO50<;,#E0R8W+G!"ETBFA;\*G;W%0HX5::@H,L10PV#":]_&3U+'O
M-GV(Y$1S%*WN=.-!*2X=_!#D\#0]^LEF;/$]6[A'RV*+H@%_)$]S@HABS!4M
M+SE23.M4XJ)**&1L#EO6]&S0<0B'J:U.)I0C.]J54NB4@(0XEWVHBF>LID22
M,FM,7C B7!>?OY=L[+#/UT29Q!D#,B3S8S/[<YN1D7[JUG]=Z*UQ1$W!/'78
MZ8[('#P7+NO]-N3[NBJ<ZM(>$[^HRN!?B .W,U6MM3(UFH]FXBCIB#K49<%4
M*_,#CB&5*MRP+J_FMU7E" O"FRML&V98'G&X-!S;-"R92@LQ-\):S'6,B$YB
M\\+P36W348=!@IU8XG"J>-DQ+$+<'^^3,VO/K%'-1>QF>&#3Y0N28Z+P1_2D
M$H7Q#PE!?Y_2\:=+Z7A<.GZVE(X_[&;^&>\0IKNFA NE<*.G@BU1?)+B*3U]
M)%/*N<;CLB9WB#A&T&_JZEJ0,\9]=*U]HA32*_&K"FRMVZ*YYDS&@%0J<$Y5
M\IT0L"G5YY$XPW"$T@4U[$-4SBD6)TT%F)%Y $;=%G<-D$-]%[(@M6IQHH%?
MY8>C9/P&[%M#*XAPT9Q*)>PV3A!GV57!V[A!CF"ZKA)]B_>3"ZDA84:+0,:U
M-SFO$5L596ZL$6ILT[5K_-=DN#^8N.K55'C*&X(<L76]CW R9'#8;/I#OV=.
M>'ZY2+0?^]F0(?(,RS*\8K&R]$[U/.+?C#)YA]0T,Z^>]JS77.;D(7\+GMZQ
M*:_^08E645;HG+)!5_]0;ABG:9RXT\N;:D<>,U+59[*OSB36H.[(-N0FD[ U
MMOQ)O8.;1#Z0P<]D!]C#E#;U30XA?U6#YP*^3V?CU.3E33'*J>NUPL >),1[
MRL:A#+K(+2,SP)LH2O5Y(S='<S-#[A$A):F27V2Y>>0[+#V;W"P. [#Y$TK+
MA,2]D'-XP(A41-@>&7#>HIFC3!)'IQ";J1(.'F=MR7ZX/Q=XP5!V '\==%<.
MTH9&PWIOJDYF-BI^R'&9\H-_]>(B6WW[\C7\]Z_P&&#2G^=5OLUAFK^&WWWY
M\L(X;8(+&WQ4P\-BNGFFYVC[ELG#X.2A2K!4"#S]-6G<8X>#,CC8L34(V D9
M4L6G"--V8H+L0T]?_.29)D>2 UAFE/>5'NE"4,GW'YW 2J8<[+QT&]\=N6E]
M-!)7B8V)*"@,VLJ#O'2#18@B*<%UV!T0B<X)@JNXQ>]'<)5JA3P>0S!DG!(]
MFVN41\8(GS8.':HGST*;<GL.UIVB2,37["LM.<@VE)6P+IB%5(CBUTIZ.D\A
M.N?N+9GGZ"%%1<@VE4,*L5@DA*A#_$4AN)+4V&3WH'9%PXSE+X8"I;2N@W<5
M/'W" >G$&Z^E=.MWK?GR]L5"?:0$K" 0'%W$N/FC<0]SQMT!0*-UGTY?<7Z(
M/#SO],B,Q6G"NT]?(5":3!@AZ4XDG'XZ2F((Z1!;3]42_5>&]B$QQ\8PCG?Q
M61IY/6'%<$' [8]U%:H>YKVF3/.&%"U<0HW1$S%OBT#)IO"-/W.SDYX_.AVQ
M&='K2/&Y$E"/U8%4O?O!*>U(  8S?9G,,[$O<J?-5IOY"E*X8[;XH:4R&O&I
M@S9H('&-]V+5T^_AJNVV7+BSYP(R)LF/!(.;@OW[:=-QX&,%R7;\@EM(/I9F
MR?<:@8,\KHM+=C'L2!N:/J'*5YEPY6,B]8 I*[;T["^+])=:I$GE28*P,6]6
MR^Q2_?:T0@$J^-L1L5O+PET6[@,OW&UQP#81%K9G-KQ![(=A1[YC#RYBP! 5
MQW_(L%JL/"F=@A*X$:MFH> ('5A6\+*"'W(%^UB"03*:&U+B7,K]*[$@@9?;
M3N3[-#^T<;$>Q;_BT2Z+=5FL#S$""G(1:WM).7*3FS<@VX02T++VEK7W(&O/
M!461YY6 WT>4I3*:%5RCE-6:4?)<UN>R/G^"]:E$.#[II]G$H2X]^:<-IKS5
MOXPK-4F)BL%U894_UOFR3-K.I;S\4 CX;BCSV-1=O:E_+<O]/M"[/RS0NS'T
M[I,%>O=@T+O%V'ZPQM:E0]$ %JTTD+BF]5Q$G935&/Z!UC1;5=A==G<=BO#P
M=&DRV=S4R/ICWN5HS><0+G2*V:S; AM@%$""\&Y/?A<O.5$X_G78Z66G?.@[
M)7$>HF],Q<<A\G06L#I?9E^6Z;),'S(-1DI/*AX<>P6% D,5#O.A>XM.-[$0
MQ5;ZP1%AO!QR[5G_>"'*71;U0X6$YF:4HACMU[,"-9/"F"F@#(MNQ342_%0"
M%\H'RS8C:AU"E<1=PHVM[[<]6/.MJ8]']DLZQJ;097YAJM$/ ECR70K")6 6
M@[6"@K4$A)O? =$Z)9IKQ/R6\/8X'I;HU/I$@4]EL6<;>TP-!>GY?PC2N")N
M6N[UL#R"=NQYB%MN=%*\* 0UN2TV",G%7,,:OB:D,QZ7)\RWCQV"]"VK*O85
M4B.2;)8 G .W%[%:6$P:S9U7^&XN^Y*W+C6/H  > 8XS#V=5EA5. <T=;PB6
M.Y2=B"@Y/JN9'EBJ[>_VQ4:;IV7$YZL+O \/T2_D7K[#]YD?!R$(F-6/*=%4
MSZ+.D0C:V,#?_*4U/G"8L*O^X D_BPY6=TOK%A^JB%_\ZYLOG\=O[BA3=H98
M>FD4]QM#D/D(\4-N&^P*+P]D_QH''U5$A.29AS[(8U_OWPR5>,G<D!*PH$'C
MY&6*U-=^ _WUR+$CKLXY<'46<:9&]R&8>0)_(KEW\HV@3#.(SU="[P'>F#ON
MN\*@_VV^IR(7[-I>F^%R!?_7[104F&\B$/)QJT.PJ;%ID23 \-CG%O1JTU#O
M!9MH6J#MOKY9;>N;:F)>$FN<,)0+%1 _]_=%?<3\P[^*,(9<$W)W, 5DB71V
M(K6=SHM*B2KGROMV2#C"UKLZ)&YMD$BG^V"OJE#\L% N(<,>+43B).CJC&BD
MX,5H/U@*8&X&^W_XJLPTHU;N@6D2Y,IR1%:RH*<@I[/= X_$IKAFCPDE[03#
MKXP,&=$O<U.8K'C6MCR#,PW)B"GA]F'U8]P1R_V,0XA]#9=]CD3/A?%_FI5T
M9Q_2:LJ\LV:/-DA-=9M.]H9Q.TY4TQ1L]:#)C1DM^73'UMFK>LMMI]:Q\V,&
M1::)1'N*2.@A5VROT(K"(J,F(S1+>&G?=Q8L4@/G!SO-8>81>M.J=/([:DXY
MP."XN8-K'.C[[<MW: =NQYM3DPG='>:KYJZW2(MEO'B!D<&TXD]*R69MY I3
M@\.WPZ:  GVVICZ3/L@SXA5I._@+34[BL,-X,/#(D Q%&!?_K=7A Y:Y=Y*9
M]+0C,;QUOPM;NN[N,+&[.;1EXA>[,1W8+M)^3&;U <0Q_KB46<=EUD^7,NMO
M<H/(X?A&XTM55A*1M[8OP@1)V1SK@K.#CG.,BX.. 7O*D%$3'/X.C/EET1E/
M9<+D0.I9>-"Z[F+V[2U,YJ.#N;>:T5-1\%N50@&")Z$HU!7S9^O@2?ZS;L+(
MM)^*;J6-5B=<5I%&X3W= ]]Z-5P8'X[?]BO(P4\FR.^7E)_XZB^=I?])AR0,
M$[Q7O ]*THHN/+F/*YJ0#0HIY%+J7\I-/T&Y:3[^@34+BX\XZ96_@WJRLOD
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M^TI;/-JJXK)&OUSEIDU2,&%4D:@TQNXXJ.&]EWVS[)N'&$&:$&!PE,^[P.:
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M(:TKMV$%*W]' :U$LPOJ<UFK#S8"EL8Z]@R/(J.*;&2D:?#HH9T)L )1D(H
M"4<"17:(3F%A&H([2IE H8R1C') M$55":5CG*)F9?,!/E<+WY%"<\D<\H5I
M<K2LT!-1I8F12!CH1&(N*?8[;33'4GL+V[A=FOT\A8HJ//31H$04[7@A7+CT
M N'5;*(3;$  P7TQ4V>BW:GY28.Q\CM7IMW]!'+';513^EZM&[IACG+BCIM-
MB'A)#<7P/L'P/IYX&]<3!LTVI.=P&; %;[MZ\XY7#I]'@L4R -("CF0S\5I?
MX2"3C6S1ROTX4&T4LS .KN(:H64%"^5\]6KT.];X(5'(-34VVW)@C)N#M%D"
M(40X4K;:UBUF]%J4>+OLK@A.VW#&\I3YE(R3Q>[;PH1JB1!^+,T[POF0"KKV
MNFAJ_CP0DKR[JOO+J_L"!V/.X^X\T;TU>\/]-7L),4G84M;93"6&DIV,18U;
M7ZG)<N@[9([0? (Y1N!&?EETHZN\%>1\427][-PM/.@/\FMGRN;(^DM!4 B:
M0G@3T7:"X3%PE)(),YXWGS1_MZ 1$<<M!4VSC\=^O2\WBEU-#JCP8/:/2(['
MF,=[V\#SD/"'=E>E:(E-"HW.JFNF4[\6#:VRLU3C;L\5 VH!6YD^#&+CQHV0
MR-",@H8GEM^FWV,XS*+8^;KNTU5)R-8)?"@)(4S;=W9%"*&/:V)?Y!Q7YX*C
M5M.&[/RN7V@*J&UW0@4Y/..8AU] K@[)?[NJ;)BHZ#TJQ^-GIL&^A\/"2R?P
MTG')OR0U*%PQ;;'IA?3_-^4XC)V"F6$D0_W=?[^)JWQ=;ZD! FV\GEJ3*O.L
M)$&'5CQ9 KX?TCFR62]6RE<Y.IO6!9H\RCO8%:2[2\[DFV)%9/MM5QSEEASO
MQ+,L/2G=+;) !O*&5@<>54I,7I+R)E_'[6^_--"5@<!B4VJ&SJTB8:N79 @?
M-_!I/(PI#H.#D=4L;_"8!K<FO^1C=6+,/Y?-^-EV[ =AG#@J:@DFA]IEW&=(
M$B(5G3%P+3K@X*6P=C>*9::-I11@$IX<OLIRF-HAJ,HDU(^:N>\,!8'@<#CR
M$8;KB+V9HF%AFSN_''+DR!8**^Q8:Q!:PC^3CQM/9]*F3+L98_C,JAUI<*ZZ
M2</@'.XCX;1.0031ITS?OS7+^6_(ILBZZE:G CT?\-:XP(NBI]X'$Y5X3JL,
MU=-F6,_]ZQGJ%]\W7S(64V_51-?[:VDL+2L,*M @0BB1L=%%=5/4Y5(U8?XD
MJPQU8E>=I;/=IM* )?'[ZV8+MM-64SMM64?4!TV+2?JRL"V+E)9KH7M.(G<2
MG"KKP6^C6"-WHV(_6+8"2X%Q8X,>+9_CY-RFQH?W-[RNMJXJ/(AA3 <8LS1,
M!C5[U!A9">V^-V'98&W?8@O3#CA=_4,!Z@9EZMH>LXQ[.#A1%PS#PL04P@&>
M-Q8Z35$$3%[\?/77^J8@V3D.IS$H7-/Y,!"UU@YUUR(N,Q&XH'>KP5?9"I^.
MY4)@\DR)>2<[7-K!8W>%35YG/"C2 K,%$V)HS!- ;IN$P&*P\6K:!>65$OJC
M-"(+DX*!=Y/CA1;#353B@B?L6%"RJE4B*7!GO)4RTW5UZ^5%Y(E* #Q:<KH2
MC8G!4:49 Q) 8YNTXU-^&Q+SMQVS(K0K;A-N"[!_S-E7I&(HFE/&KTXJ7:P2
M*162%]SO'ZT1^S'RRW]8H)MCZ.8G"W3SM[%!- KY!S)]; I?0HM\BF!YN1Y#
MY^OT^6Z,(J=XMD=S.98YC(53,8AJT]2CL+-BO]1-HAYO N$<NNB4\< B9U2I
M+%OB0-B?XMN\+NB4I-<]>L6'_/MZY,*Y%XK][G OY-J:_<QH183H[=W4S7Y[
M4VY98*D1S\&U"E-+]8P/.;7&1">75;GV)ZL?4\_W?A]=-+A1(#=-?; !&%84
M386/(+($T73V#9'E;-A9Q*JR!Y7"K\BF>Y$=<8HFRLW!AB0C\&7HI$G\M77(
MZWLB=C-,"RO.-M_D$,J5&V24AK_WDL'W[&>2'W("E5)%"%X/5=6$85R7,+'_
MTNP9JQ!S3TE4'";AS6-.Y1/P.[IB8P#BZ$K.>XXBFRQ7"S/ZQ1.NNHSKT3HP
M3D OJ=V8,F$P()7J"1.NNE3FD5)*#FX]:;PT#O@'HLB(Q88XA*)KL\X9.]J[
M OU;*GJTK; M# A4'#E4!;YI26];.(ZXH 8Q>-4:JX E?RR^89V\I$+4"*R1
M]=I7KP;/!G\,M%^D3!)K(PIG?%C O9B/TK2=B5TG/Y;;_2FH'"013 S'4S<>
MBN(A];'L,WQSMM6XI WQ71T1-,>Z9;O.7I:/TI!(BE-\3MX27O]_DEP=(6D@
M7I$X9U17>NR;[Z7+@ZD:9*V"ML&_']H9*8CHDNJYC2NOPNN%*VWD0*$\5%>V
M!=,+BTVFG.LM1O(($;,5$0M2JLV"6.T)VJ3,B?].O. V&V0F!D&IKN-M?;YZ
M62 #BI"Q;/[9E[SHC$HO/<C#^""'R>VE2X.[572Q8_QJ[%0R0UR(@0?#"(?5
MUYGU+S?-U>A)#';+^>JM? 2I>WA#P^SN3V<M:C@YC\)JK_34Z).N4X(_=]6,
M4P,;K"SOD06KH7K0+4<?)1W9R\&!>,%0&X+6GI/D0Y)KPP(.K1#*G&D*@_-E
M^-,_>UC*NQ+IF$@G%8<N;[7*>2@QA9:%Q)(,Z)7@C6H'4-I9PY5*TK@<KB_'
MRDZH%P29D]_E>0>9TXGTJQO,#5/1/%'ES;101FKVC\?PN*@L13QEX&O".R<9
M;)9LY9\R-.FP3<&KH^,)([BS=^7FW3I'2-H.7DHA]%=4)?7=6,?\1,L!7FC5
MPEI#2)-^")W#C6!-"C!VF,3G/^V:O&>@=K[&8BK57NLF*)^04\<>?7M4HW6J
MZSS/T55-M-33@S$!86P:\G$PVUO)A\.FO(:8$IP*& IYP,Q& 683_?C\@-)M
MF0/)Y'O&$'*)B[JJ<5NR*FSKM;\+T<Y8(E,^$_\:WS8:3=1M]&NL#4YH^8A0
M& 3@E0?<YA!969:R*<B]J[:YA1."^#IJY=QE.@?AUCP21LNC_(D +E_J>,T7
MMCCR!',WKDV"T]>JB^S6;^;S'775KL:0Q>N\0;:LL"M@FB2Z)7J5R4WE4%<9
MF7X$*D6"3B8FU$M=X+[__V3?K]["1_JN2#_R%=F"YVP++L"DA$2-VLQ!VU=X
M'$RC*O2 HK]1D8[P7)D<Q[QU.SQ-6K/AW*$Q78S!6(6S%V;L4PWJR<8Z0_^)
MF8H#Q,3YNNZNDB?W0;$0,-*TT_NS921N4_! NO/5&V7(Q%?:$Y6M,[?C-^G,
MWXS%X_B=Q@?.0GVS,)PMS2@_IF/\UJUOT*=V>FNR"RBA1]5)$(NQ\;N*EN2>
M#W^LQ'')'DL4FY)W;HWI6_H75^RBR!F< !Q<'/I*+.&LZT+ CYQ+C_#/=_"G
M3/J[^HUP1]_D#<,^R,##$5RQ>R@<N7QVP& :YE\30#=WAXDCR9\Z0B!QE3.[
M\I8S%H-#I]YE="!<UC6#THOFNMS %^)AHR92+-(AWQ9J$^QU7"4G(IHTZV!_
M2;WQXACQ#R6B)N1M"  'G:5M7;0"">/F-HHHQ8'!-[0OMI?6(7/[2L!'P>3M
MCI*%E+G#LZBLD;45@1*88* YT?O@M)0=!5GR.6+F'&!["V]7*71J2=N.TT;L
M=#K@, 03A];-:RLA'_Z-.X/BO?3!\%R]X^F00)+RGWAFB[]+&'TX4/L]L;W3
M0'9<K,>SR,B%V4T<GHM+<^MBHQ_:1B=Q&.5;:>F!82XH!K909>CYW;).S9=Y
M3G]^J==Z;=?Z6WYC@1.C1P0P2WT06@! H_ZO@E+^DL.@Z\'WVFY?K!G  +L'
M0OE5EQ^4H""+Z%K?D*LV3,^3Z>,G'C+HYN,7Z%AI"$1/CTVY%_ECP>?"M$N7
MZ;32#M>05E/74P:!<L>,C96_&\<A$9!<U^46.=6EBY!RH]6&>,7!,JWW"M46
M%1M\B:?Y\?VJS,D'RZ/UQP6,,09C?+J ,983=SEQ)T]<*>=]4RE6\G7==+Y=
MZV*SJ?O*?H4'*JS4IU]\\<?51\)N^]=O7E]<"+OMQW=%5,4/VIB!B27PG@_'
M3DXR_A/"'=K-%9PS#-'4G,_)APSKHBIV96>A0SRK!B=5*QJ4? =WA0/>FZH>
MDI =G$PSF:+\WPU"VH<--WY5Q^9B$SY8FT![F.I2^8$5642SQ@P$]H>R0_==
MK$ZB,_DEN'WU0<IGIFTAWT-[$>W$=U\^_ZL:BDP=\[+!["@7NES%55IM"<QS
MD'C4G,K$]X?GVW)"V]<O4$X&2QJP G)*3[-.Q=5D)IY_JU1[3*]CG]OLBQS3
M.%=UK[@F'C:XW4?!:UM+,43W]:9TQ!M\V[9?Z^"P\DV.-U@2G-08Z0LZXB!=
M\=+7@6]!]:Y0TF)/VAV4AXD1!;8,;[F.29M,'JATKTT:ZFG(U&F2[V"F'>A>
MTL19+$;1HV+9ZU"VK20<WN>>"['08J%^"J_EM55C7G,DVZ[>:CGF@H!XQ-K6
M^AI$A(20IN'.MJ9 BK8%;<(,\1>$993^$]8ZA V,ERK:B31GV:KT\%[SG)K"
MS"Q_J0G6YU?E?ML4%9K!IY_]N9WPP-BGX6)6=!**'Y#QAVT?AM]5Q5NP*1#<
MIN[+\X(U&W&4ED?]/_GA^.<XDK=J;]0P/W_YUMPW;S%B3\Y1ISD6GLDN[&0N
MF>H (WTK::X^ M\-7HAPD7$Y9UMO&!5"=J.E'IDC!$Q%U_!/QWH+QI-^8/MY
M53;U4<SFQVR0BIS;SYQH98*GF'J ^J:"H5Z5#./C+F!I*T=B<+P=$:IAPB<^
M@C^A<"%0#9+6+ZP+Q-& __@7K'X2I@1.F6=/GCW+YE<=G6;:A>2IS>4E4@;\
M'F]@8N[E,".AIVC067=H=2K8P8U53#BF2@*RP^15V$&SHDFFK#6=B 99X;\*
MKIE?4@XG'=)Q\$9IN^1J>. RLH:_*1_NXBM-/W!V*+<W<(2*5%KZ]#@KB,IL
M!9*+Y1;;:E@!7S$"C'Z^*=:(Q9&-XXY*FVG=- L7V>_^^\((\/?<5^U89A M
MPW5:XD*IJ[,(/<&Y)$% ;@+#S:BQS;"HNU4R&J0/02BL"P@1*P_['K_*UE2*
M1>NFSK?47 U18'TL@K%]P*8Z#8(X5R,1.A/:P1@L,B0NH\ ,Y\&E&DE1[41F
M*#J1FN8MT0[3QO9UG$!CE6HX16-'+.-L^3G)75,>Z=L:.0G1==*V;SBKX*Y[
MGM9G3YY\@N0Z)3.ZP7& ?AI8\:^IAVV/!#)@5?"$"')"K+[N2^9*0FO_.KWO
MR]3P,'B5+3>XE3UCR@1<B([SMI!#D:K[$!8C1!G//7YFYX?+50RA$!I?^Z>"
MX=TS<<#&9-?;B551?/2X:UL]TF@$23O$85U>]L+,1!^[@1<0RC95BTCG6I,"
M^AGIT*338-1?H]]SAIR_#*][<(&4F]-VCU4J'@\H;]K,_*]F*FAY#0 \P? Q
M6,7H$4]&DXWT4XI74]PU55LB>,UOW0A@0X?#5CMX3/N^%;88EAIMK9''05+"
M")*B()O;2](".U[#*D=/@BZK01Z.R[9Y-)[1"#WV=?&M@R9,S4^HZN$?89]A
MYS&;7W-WT,FDKBTBTF=&S"I1:,;M:)U"D8R*/74**Z:PFCE1LIU"<O:DH*>_
M@35(.,D]91R1,5!MC"MXNWK###F5?$>\-(.QU3L8XXKK>MB@1KX2PN&Q5WX/
MCN >/UXWUJM44N@!)KDMJ;6<="GE3&5,&2Y$Y>6"'09^TAX.[DLDT=.'E]N?
MK[Z4QF[J?2"WR8CH](G#'>0E[-K.&-"[$%_T7<UYI&V6;4<(,W2%L1%&!5(W
M=B)J5WHV.2?)R>_?D0S7H&:#QQU,('H2[MG"J+=!<[N$F8T/1N5:GF9Y/ND9
M,'3<8/G907W'E*&+$B+4)'HPL<S,-!1./Q@+QDWD.R+Y\G4!ZV+GP23#S>CW
MR@Q,,K@0S'UZ"*PFWH#$M2#P*7EL9&N5])2VCT!6MHZ6"4/'75%MF=J)?^N_
MF05JC"AWCDDE$\H#HGA 6CV*E(7D!"?U77&*:'_IY:7N""P42.J+=AP[0'-R
MK;)2"4P;\ EPR:0,/G'P"6\!8X*TT;$I+Z]84AOOIE.RB;0-B<ZN<056 UEF
M.R$#/B^-W;@WZ3C-DE/6A+*D*\,=JX8%AQF\K!NV %G$9="QF\5M%T]>YG^@
M%I#RR A6F(5Q>L1W7\Y#Q.X-4<_NB4]G<"_LY Z\/Y/_3@#*F<*?/;1>N"HQ
M'&7I[@&+#W^]2,U)Y,8P[?9XFQ$G9)$J&X]Z/!7L/<.YTG?479CN:#)XY,KO
MRW<X>@4+<X_ ;* 79@(\2MG7U62 -[@:GW'.2*0C^PJV&BQIV)5-TX,K\=I,
M+]B61^LK_1@^CL\6",@8 O*'!0+RF]P@$DQ\8Z:0>RHM@8L,K]S1K[6^!'E'
M/NK-%1Q1-P6UEG)E;%L[HXWHN+JOMH*U$Z)JYWL.'5VV=,3LE+9D!->&E4E
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M05@A:6)A"MQDZ3T@.B(SY\T,_78JF""4*AP(=(-YT"BQ>(MC42)1@_\ZFT*
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MW:6C09BD"#T^F]RF^/7#49I&\O_?2N<:H)84L]L0R*M?F*3V>0=@O7-UN3T
M3.UXXQ"H^DPG7O(X21-/UEK=>,[TJ]OAI-L\]3#SG([_P-_Q[P7/4[-+)>0\
M->!&<+&O9RI -3V_'VE,W3<(@@ 3P6+$O;5Z#V!_AB(N C^P@AH#)P@2,5;#
MR; KS-SAD&9U2B.9SBXG@.F'>! .V9HA'L-Q/0MWLNV4YA%8WC1(%0@\K\S
M^"^":7=IF0E%!NJBI )=[G&?4(N*WEGF6E5H$DA,X2(!Q B@RL.>I>;C3C1+
MY&TR4+< ="DC\KS"^\9AI;+UH'9#K486]QIKDV]^5T%FR \D7?_WPC=@_V3
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MDV:"6.+-)U!<!<8^34QDA8U^B8"CC>L2F*B# UB%+$A@,PXS<S6P?85.C#6
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M'SOLQR.48$(9HPOF28=O._@=S>V]3@W)I\#!\/)SQ9G-T*IP:1B[& G?4!8
MI"&B-P4IQD(I00C<-B)N) ?<*M#@5E;#%PP(I'+MNQ:QV)QV;%KT? "&'$=D
MX*Q$81;Q;\B0<^LCK2=M?Y0*@M]"5I [$4SU7>T\BE^5>QY@@V@2'[ZDZU4@
MZ)V0.J'<E\HF&\'TKPS,F_R";D"+C"\9E6N.OYY>Y/8-62XLWDQC(-"$<)Y]
M/\T ^N[M2;?SZ>.%_-_/O\K_T8R@B)G0.?MXTK6R6/!0Z2(!@9)MV:RL":8
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M#1EUTLR</>H8F.^5ZXR-4V"?F1-,[3,5V^6:0UWN.Y[ TX3R"<9J".KAY"E
M:_X<9)#7+4_W5]T@NV=+#325X#(\&F442KV<&B&S>O$\HQ>,:D%=.6ZA,N>8
MG:5U9OZH 1?,#,3YC[= E("M2L-: 6Z!X_)Y6U,!)<P)GJXS-=A8FGW44Z *
MII-4CZV"BV:#V(U@R]J!KN?/^IS;,'I4Q<L5]!<FL(8.UQG@;6'\'0D^Z-P0
M:CC00H/&KGZ)^ MF!,+^O@[WURI4%!Q"R+6SY'YVS;-][> /P"#!C8"H_ZD-
MV<L8EN2-=#5")9M+RQ+)C4T*-K-#Q+W?4GOM;FYH0]C#;AH+R2P+[$7K^WD,
MD*79=J" D/6DM:NQNB'I'EARY"^H9PE%F<"L"Y!*C")KS(:Q57$X:*2A\S+;
MD!,U8 =P?"%T3J;C:T! &M)! &)TI?QDU5P<&FHII[D<SOA:5(1XCUJ]6 @.
MJ+\6HFR"&M.SRO8B%VF@(4O@$M,U>ND.QEEY:EX!U#MHFF#O2?.B<+95I%M1
MR,Z0&M,VC6V$I^.='P^PC<PW)U6:Y."V?O)T-+0O[II1#YJ-8EB=G/^L @2:
M#T)&H7/"IL!&%?8P*-Q[IZ5!(SDD,,NO0S7HK1]406) ?G*0,W:2*6T.ZQ:@
M9QOG7V%7#>>IAFOA\2Z^W+PST9.0-@@=S;Q(QWKDIQ3Z6)0#"G#9(@K9#AP<
M, #G0TQ@-<<4JW$Z*9XVS0E:1CVO$]%D7U+>*8;?P_9>],1S R3H0EWSV \S
MF>!BJ4:GBLZK2@R>6RV3!6 Y=P\5XHX]60Y#;L)OIH+RE0>6:=Y#$_33"U!?
MF#^IWF+Z;L1!#5R,;>"RDUJ!J*A=(!Z=CF@D"IX"8 -R=61\$P7W(6$#T4M,
MBQ@C5\0@-&A?8!&E-;D'F(!8U7XR@2"$X.3+][P.BX&\>J7_-\VI@R#K\F6/
MD2.)B=QD>@Y-:@#:1D3H9GPJ:#C%X0141*)5T?PH]@X@YI'HS-*I:O6NX"Q8
MNZ&WEM+>T.$&BZF@Y[N 4R#-K/(]% J]Y< .*>X&^V:N<P:8U+B7W&C.V)=(
MUFYAI1(:Y#N#ET: >C0</L:C",-X<(IM8CC3?FO,IQ9!'67F\RDE4PWCK*I-
M.%K'VXWSZ0PMX82V@1V=\#U0TEN>M-.(<R5T=<(^SRNFPXYFO=V1)8S9@*$]
MP*\:X!B68VVOG0$7Y=#KJJ'\\C"&\-0'5LH7#5+N/H1IBV.S@3M5E5,O O20
M2>^&,V=X,.T0K0*995S*16&S@C:\6 )LUF[;H%9M4.NU#6J;<4 T=:$G8:FL
M.B)KT-486*X*3%U27J]@=VS>>+)B>GBH6Z5K09/J9-_\*D.@>EQ01G _<H95
M5?(ALE4:1MW2K:\RSY0>JKCHUK7$M",@5X0D(U1;=&Z5P .M604#=?@:7;@E
M5?^L L*TD;]!]U$3TRHS!,2'\NL$SL][4-A8*=5>Z4XB,[?<K6AI7)YQXCN]
MM'EIHA*$/UKQVY\"IG8T,]327R+MQ/DE=8)4-R'AO*MJWL,GPP"F\9FC7V!X
MIX:^^8T#'R(5.F!F8ELY\H!N$$<B<_,=Q)<'KLNU DM3C[41RY&M!_)IYO/F
M:Q3OH(/U5F9F)%;&K@9C_[,,9*72_$5>":&+:<]\=ET$F5.10@;YDQS2?]3J
M5J+&L=Q"RT*E"E:::D+V/)C."XZ%#$(CFP,22VG:VN6*Q,%"BZ""0 P#[?.!
M(\A8^.-IN="BJ[]=V!U_S A@E:HPAC!11\J@L)2C\FP5)/0M".Z \J"9+XG5
M>5_ ^V ,/$ESXHMPPE?E'I--E XM/9%@]PT1Q4,9&1C9FTR+@"/T&!\)^!0C
MAC_@FZ=RPY2R5W-2$XQ'I\XBE-CQ<%J461Y<PZ RC8CK(]\8;R'$*%%'*<O@
M:V/Q>CUIMLT7N$.ZB<<T=T9$"NM11FO';C ]PGT\G+O$3+^"]C;6XVO"'1+3
MA/X31S*EPU) !H&N_$%L<AW5)P=<$T=W6SXDD69[5&C,<ZQ)D74A^BLV%\9N
M2N6STE-6.0Q0DF#Z?)1BMH%T*QG2 :&0UU1]"0='IR!N4X[\-,VG_:=HUQ8]
M7B;A7$+3'Z39!*%2 J?FW-63M!8S2^D3"IC>3L'SS^%(AA0(1W< V&-0JCB;
M[8Y=A18<56"CRC!D(PEOJN7<@@^KS$T(])J:9L.SYV!7P+*B$R@R(6\TW8VL
MKE[C-01XEWJ,CI.CG$ROC3(#?@XPZD%CCI5H,^LGOQIB<$IHR2^6ZG<C)98W
M8,03T03R;[ZD._?D\+?#)4I'W]R1#GLQNO'%; +WX$C-F"/T$+*"%-)^]X[H
M&\9R/V_E'PQ!F>FRY_IY@'@VW"2$N32N"B.N^!!)B$VBK=1Y@9>%R!@D),[R
M@O)K7/'5!RRGI(O)RT[8GH#>4U8P\*U$FCWP&-AP-"G5 ,6$%$J $JVR<DTN
MSKLZ;676&TYJ$$;I!(P6_(K!(/'14*" 1S-:H\*N(A863J7?IN!0L*CPX=RO
MMCHS>2]5E9_%'P.?<S12[!)L&TB#[704ZL 8ZCU?-%>V(Z8FEJS".EF664M'
M>'$$V1M:1C'010):TY8V@/@^Y39#&B&'ZZ+@[&U &49RNSR[SEC]5O80F5.(
MS<=4,[0FY)1&C(RJZL"96#SP:?RMF<!TL72.\'+& P]_#G")VYTS)"\?>LV.
MW%OE=Z;4_L+5*#4?:T-;$7B?O'/X)'<-)AG8"?HU+@",= 1TBD';U9S[5%'0
MR.MA+$*(EP!/S1SBKM?!T_ 0)=8U*RA3K9#3W*!)8),9/SJP'VT[@_(^DWLA
MM[/*EZEM3&I0+5QX+#3F;FAB$+,,*:G<3*JZ!-.$+6G7<$AP &$QJPWYXOCG
M%,;J"48T@3H;U+V$JO=0MAM:O<#J69, ""@.:4(Z,#/I1Y0I2M!0LX)T2;.Z
M'73OH!JCHA)E>UR'&CXWU<U@3M"*AHD+3/I56YMAUIJ0%/095\CBJA\WU*Q#
MBJ456CX]&X2XIO8>&0J[B>NU:P8/3=,,%,%\"Y,<*6351!YPD8]"\ADF(/A+
MK-)*Z& MR].J7TU^:"S_P0=%N_ *'L;<M!=LAZ3 GR'0AWQ"YQR%Z/S(M^Z7
MJXO/YWS;_@GIIZX%=F?RL2&G8J*.)L0)67P7JBK)73K0_[T%55!.!'3A,!=;
M> .B /\5_XRF$XV*R"$K!W\>BWMVE9"<-\,$.*8$!/@M.5)?<PK1^C$(!99<
M*D7):U/;H"F4G6.C.GK='P[)C,'9372Y2&%?4=C#6X9^CUG_KB4391:T;5"5
M6]5[J6^5KCN_UZU*B5C&Z7T9*;>4$L4N",M$II4$J4J:.%@,;+P-,W@XTT-3
MIII))\,FSK&;A4JLKH$75]>513TN3H9,E- %?G&#+LHK:.Z3NSA5SI)]#MS4
MG=UY$MB53B+Z1DQ#>)]YZ@6=;U*U#&XX'@<JE=+V"P5;-*,V#RNHA=R*47)]
M_@/K^ZWH41^A7-_<J+Z.;>ARHXKZ+M)62P!CLE@(NJ^'(F1HYJ'KS@;.[<$5
MS*I[LMVYPFD&S4)4JF[+<-'Z;JVGZL=JT$&93)-U(O<IN!:PD4F89>D]N%I6
MB@/_X%8@\[8VM:-2BSMV9I73TXC00R>77)1ISEI4)MM@"Q*X18B2>Z%+W'B0
MX7F8!9YFSLBA-QPJ'44,LLM-4E?<\:\M&V8'2TT$AO"82]Y4FZ<N&KL@#OE&
M,ZIB@0&'FHB7CK5@GQ3G41#!&Q(BTX)L/)"*WJ69Z6;>AEI?CI7( E@L"$$4
M;D](&&F./XLIPC5!%1H'CL%XO;A?A<DSU$^E*RV/'VJ$E=475B8V)Y:6)_BJ
MJA#$;S2(L\%T?"<8/UP=@^N9G<<T-:K !@W6;\;,@;JF1;-S:;)EK)G*_+Y6
M%VR1GH"]MB>@VA/0;WL"-O* N+#"E"?3C9K,[A0@TV9N#_3J'F4*E$?QT UM
M5,["NH_DQ14"3FO$;<[<U5QJ5-3^&8@33I3I!#SK8%#&L,8(.QYT@#!6E\.&
M3'5(62T1:>-*V/G?)D"P:#4D4/^H%291JY=V!.BJ,AF:. OP2V2 ]-'.D\/[
M*X$,'(WK,I7BN&H8URGY13CI/\T*W4%L#1NZ@/16R5F!B)"3FN*(Q -((CB1
M[;3G>>IN>N)&S66I)1:0/E%-^F:T%"]I9W[F,=)(N+O-R!A/@3&&.G\]YJ<Y
M+^:ZCO/3R=B(K5)I\WI80 ,TV6Z1LI: 5(K@3,/>1R(?9/$U!: <K/["37O,
M&_3>6NW@@E=;98YY@T^2!/;B4D!]'1[T#DA/>CM;?Z&:AF$WNSH[A=]_Q&)0
M_[@KC4:_M]WY,N&.6I35&70O+9 .]'/*R"'.-Z;JM*.FFG2]ZV>3B5H:$>:Y
M?"^>&'630#<A,$BX X#:00(* *>=?BZ=TH/=,Z_3GV%S_6M\QVG < S9&CPH
MX'JS3QX%W*SL I P2F>ILY;S'5@V!?3@\K"HTB-ER\$SA4TO'Z(Q#I/ST2%[
MB6D2Z$#&O0/#K/^2#IT3L$>E#H G!(@VJI*38;:QOU K SS6A&YO!V?EF.Q9
M'6)VI*_X59X@=4!0^W9J'?OM 1[ ''TK?/#/'.L6/FNB7R7SX8"JQ)"=J."'
M:+X]ZC,7>:&GX2IFHV0.F.6*OZ8<V.CG8[NZ!=;FJQ+K#H @=:,HD\VT+8>:
MS,/KQ\9OYAUS.Z%*^7QGY!:SH-K0Z,EC^6:!>;/J5:QGU%37CK-@RNQ52N&1
M6C/S1.N&9<V-5*!+3$X!,3#(4TKD\T^\1.TE W4P^=$'&\OS.=.*P2OM++=(
MZKP]2*;_T/:L@K)GQ:VQD&#4K$LVJ>8T&<*X7*FOT#WY;9\H!2C<OJ!;]$IM
ME]188?Q>;<427RMHB&QNW'GHWR8]D"2?>!M?QTSXJWL!T9><6I;J04T XPKW
M V1G3"'$B !U7#[=43S$C'#!J7FT'X7\P0W>"O*#4:K=^E)EI5S!#'  ";FW
MJ']CWO,YF:8T^\%X@>LY>3@6B-</-T3.W5?W>L[(/,7)W 4/M_5Y"KP3:$F*
MK69:W5Y2V4C5XF2Z40%E!;Y$>H\CCHVHI14N'16EH=LPY_L39J9T7RG-2BOI
M%'L@66EN+1NET4G=Q:4:47 /S3=Z.A)62#? 5].[5DS&0VGWB55@&:IY.>2+
M^$91ABYB6 E"AAI*'WJADF058>!V*3KT(;X:QZ6B, WL@2*GX(#F\S3X,W;I
M6O$S%XK )PHL\!%/3<E;5B._XT%]MM114WMCV4H-O#GZ*<:!VW?P:F]%3T$6
M#, T+G+KE@Q,CF-^,[Q;5;D6Y9;KCMMR/4U,[H,R\.Z^V_U,&D[+C)@.TZE)
M\5#;J9W:CX>EHCEF8#I8@M9M.D^K9O-T:$B5#/>$A5-Y!*!^UE[Q=,67C28;
M*4:!*!]LITHK?#7:AS!H5:'V<TK7!]H(>IP"\Y%Q%NT0C,=. 4+*E-$5T;-I
MTW>C.2M$>#JD;]=Q+"LC$*;R"P]2*41T>W1GF((P>@PYF%.S>G*FVG%P9IEQ
M]0J$U/+@Q!;WHQDO*61Z>W."*<+A_C75Z,G)))TYDA&YB,FHT*[H\(^&%Z3M
M3ZG?%%J\="M"P-_#>\H/4=\*N*Y2\AO*B]*#M9+1)?JPMGRTF>@9M $C)%^B
M*] @#E9M.*),M;!+JM*KK/(J6AHDG_#&:-'C<G84!Z/<C.W@9#"08:M\1<C(
M1B*?Q(IHETC3'ANT\'ADEO<PG5"YO]HS,<\C=II9+-#/Q &SM?I7:-NA%]R*
MQKL$SP'3]CEECMG?+V4XW6,)T@>/YCL!=)'A,Z@_P.D*J+8$Z#XA:K_D=H+1
MK-1]K&A<R3\.[)JZ2>*I5G'=[\L74)*PVX>Y(?_NF^7CAGB<]:%WP66Q,U3V
M($)@0W#K6]*&?[B>=:P9B&C*B%HPV#,CRV,>_GK\H274FO?;6G.UUKS;UIHW
M\H 8L"^VNV[/,EA%BMKIJJ.I4_LB!^I/Y.D8%%87*]MX]L.-#PXW\\ED(J2-
M_"4-L\A<_FS0N0)K&7-N=\ZPUCQ.DXD\/D)WX&>4@-?LN3=9B@B(> E2 .,R
M4X,WQ![)(X^T:N=0Y+2N7'0U";4H!-]6E25X2=1\5 1TJ(B""E[7=1I9$TM.
MWB+DN7FL:ML)$YC^DKM5,N;4'S860 09YV-H$J8:BOA&+;.5!MN'.FJMOD3U
M(].W2SU6\M:3*\7Y!;NO]H'\1#>HMC/:?U[M<M-]L,K_,"W#&/I+OS<BONJT
M7 2@1QGJ#&PA2-+.* 4W-<#K6W7N:6^^TG8'A6S5[F: ;'D$ %5&C:!9FD.Q
M;TEU8H!<DJX'+ 88INW.[Y KD:^F>,SM>*%4U:"2N.Z^F#_SI1V*)#7^D&;/
MQ#YO^<UJ7LBNW4'<+4.'D1EDX=-/6@/S4X+*6O>A<2ZL46SB@[>, DV%D8L*
M\\H(IUM:NNK*21\Z*"^>A9"-DX?R14<BA  D5#T7TK>Z#2<YH?#.;[9,_-M\
M1<KB]JG:,^L/%W8 3Z^*#?1J/2R^0.9593!@"=Q0Q&J$+0?4SBRNY0)WN4M[
M*LTL@F-;&6;*<>I<MU5]QJ-.24TN.$MS1" @H<<2/Q :=)8>&@0+AP:=-C18
M$O(.MN0,T\R.GFE<]H&RD8)S-]7DO#3K9>T)$L)4\RT\;X%!-,?T&O=[6@5/
M2+.@W!+ALVQMSE+#UUB3<24DFP '#BP,F[LTCL@!M7.-]J626]@H#V?Q2JIA
MX$#Q&E6I/&X&"W2'N0 _A7/CI4D>, 2(](]C3 2)$2<&*30TH._SU((&R#O:
M9P7N%XN/X.'>$MN#H.X@/8K*W@%=R3>Z^RF:)=*'&,"'0T=4AISMVM#I>H&E
M>S^*OT(UMT )N5^.Z3843 F:Q!(H@R$G^&RLJ-]<6V?40KOAA"1YAWKD@DHH
M=D+J:3K M\JC,ZE2::<Y76!Z*!5[K2I_'3S\UXR&B\,<$'982ZI[+ L%/ZNP
M9UFS?'V7H"<W1$1"/4L\EX/.V[PC4LU6OW(C]+DR:<)!)ZQ[H-K&L,)MZ8E4
M'IYETU-$L1D)5973:I5@N_/6% ,H :_ -3/I@V?12.2Y^4)I&N-"X;MRK= Y
M,M9!8>8%1@,!PB%3-4=5E-J?@\,SZEK#1/9/H4@G!:=;C01(P'\!R*A\ I!8
MZ/B#O0S>ERPH$P58;=75^H%U@=N:^4A&7N?8W5':./ECFF"Y.=#K#:X=C2-)
M2Q2+H5L9U8U#3P(]\G%W5 SV[\9:!V9*<>9L412. 4+6 ?S*! C)OZ'1RJ)(
MLT3,5&MA9RA,#F(0DL) )S%UK)M%Y"%/@+FZP8LR*/4G..VH!E7U&@,DA6.5
M&@)[6W9TAFAQ\@)[ O7(&?7]S2E&8#.@[3=#G(Q#:]QX>YT+'NBV/^5G]E H
MPTHO2P.TB$$P* &=0U2-\[85HHQ@WEZ>J(Y/U85)+;D5@A"@T=6 81YJ$'N-
M=(7.TWK*:1>;9(>CZ6O[PV76CBHLX^.*ZIX#Q<:A+^3 P=5PM-H0N B#ZJ2Q
MU@P$D=W?F8NB,'!KSH%GFY!F!/N;HSU39)(!94/P 48G%%*2LS76DVG8DE17
MX5[+GZ2S<$3<--H;P!-EL:^Z:"(5CI)7>S$N4HHY:$LQU5+,7EN*V8P#HA,2
MCY2..PJ#/D J)S.&3<AHV,8 ]@=L3<X7EC1])M Q7C\VHU K.:2VTQS1QB#3
MI7(?W,J/S"O*[I]BX:5S);<7H$\#0$*0QJQ-.)"O_U8EV C')=>T:?X\4C7Q
M9_J:<4,[D.X'J!ZZB@R!L1H&N)7>"$%&C%.-SV9BTRP>.W65U"&28[R[>$AD
M&$RU)H/Q6:YJ=W<BQXXOU?+#(862@"+T1-Q@8<LBG^"4N1-\5\8AC)(%<Y6,
MD_0NDW*U5.0V[#@4=&4EY_DJ#;%BNGJT"X;S60XCFD441S@&W+."@Y#=CB;#
M(Y)XK()>3TNT:=KO\;*UZ;$/O8%:L "=4&IW'<UP+@3YT!Y<&+EP3M;8[=ZS
MB5"D0H<62U>NH?KF?G> KJ!NQQW-[*:F4KY<!E^J?\J\HWXUP,CC2A:N+BD6
M;):*$>5F2C&,!6,Z".UJ5XO5=G1<4I.GC>BX>.+8X.P0.6'=^?5X;YHG[MH&
MT;9!M:W>;E,\"RPJ.011BS&*PCJ(FMM5)$) F1BE@RD>-ALI2;K4"FS(<K0=
MM$4,,JG4<0,5F 1^K!.*@70C$)VV#,'5J93Y$*F/$/\@FH0)>"+%'M) 0?DE
ME"DTLK37($,3RS]/(QC]!R41":X91$<!3Y([,]"4N9X*ODTF81QI5#($5J*$
M)L!V>L&[1,SH,C"SK8$1<X#[A*0_\^O<,>X @"% UB%PLI94\C>/4PKJMC5X
M]*NC]$O'B&4UL=&5??H>9K-N8.FYC;]N@9C=Q03Q$!D7PX-CR;CH%EXR<C&B
MG2,[&4YR,M, (H^ <N@.7F,^GS!UU('#MA=,N(-XD+Q3>,* #DD3.-B_ZIP)
MFV$IF^+U:+IS\KB8AGI^AY(&[M$"T>@60/BT:[D8::(:G4EZ-]_LK59TK9N$
MRSQ\MQ*>8R'\Z%3*T"OH!$?5MH-/CJB8@G$B?BM)-4?P\$&Q.ZI_9VA(J"@U
M2ODJ=!>D!QFRZL.:(R*2ACW A!J"=R!V<+)E;>90*#-H?3TYHZ,9M6A NH=&
M8J\!RVI(V5FEJCE-[:K\&[Y_M^I?8%K+\C HLV/NS^=B3[S.[@JW2,TC@"XZ
M/^0&.QK^A68LPR*TD=4(X!VH)LL86^2+LI?;=3D4V44T-*L84;:\*#K.T\1Y
M4P7T48"[<-,-%/0;CY9/Q !2@+D*!-^]/3'1@B:R4[]]=).JF5AS.UG0H@%,
M><CWP-3[4$'3F1O751P&RH:W> L"7& P=FK-/<.KJ Y.^--+# O)9)UH0+O>
M\=$>!D"_ =E@Y_?PFUSRX$1UZW%?G?W+CODE,_P9 VG$0VGE]T\GA#%^)RSH
M7.C?0>N3Y*%F0K)?<P2> ]V:@8_$#EX;=J4*N6$N4WM.S,B%5P:/<')=GA/!
M7C^%9R*V@Y,YV\#-??B#B*^A,;O8:@WT\ER+68HTS$5:D +U]NQET?%3A+-6
M0](MI7"@2J-9 /K$W\='GA[..$OP&>Z:4HC6B)3/_H<SY=D%&X[T+3Q[C5<O
M58^<W[C\GW&A]96?;)&_N+,O&A@]L=;,!)NE9DFXXKB10GR#6D9.3F8D?WR#
M:5++DV+HE6!R&^9<JYJC#,X7AQ/%4@@WOG%[(A%&D!;S?5K7(%QD(.UPJ-9/
M773$F3GK:T#-\^',<;/L&,0"/2EY8^@;3- W5V-F>C:M&A01')CT"'5TA*5C
M%>G#,P77[,Q4>Y+.T6V&Y-<@V?)/0\6+(!</P?^53A?(3"^7/!Y1]Y[<^3'G
MJA0IK5T8=S^H528=2(^V(U=F\)4;*@QXC=W2HPEOE1AJ(GHF"F-%*3A12AH\
M8&6\5)ETFN=:F < 9/SKB0!I >DN6P95PS(?BG/OGGE<MG"F\6JL*\F#XF*Z
MH:T>8J/*)LI>A'Z]ZW)EFKC<YX@L^_I_(??N]#9$Z%RSTZ/P7C'EQ3@W@&%5
MH''=K6YW[A<R%"M$\5WE5WFPW;UUZC02O$TXDC-.O[PG11(."@4^F%N=;]H>
M$<5!)+;D)75C]8HA7\L8@JLX'_'0QB5^K?6LJ^D$K+=TN6"470;-F+(DG E&
M/Z:IQ >LM6X?@+9CG@T@'%M(C \X[WTOPJ\B89 ETZFE8E*"5K*^P<3KCJ$/
M#!4[.L$ZA\M0X=1JI,8S;+)YVZ;I:)N2Z5UJ3"X1PW&0#=LQP#QR9#\NX,>5
MIRG<DY)B^P:C=1#W>S*#3BF+_CJ2CCIE6!2HMPV1<I.A*4-A182))1YQ8N,>
M8.ZH:YK/+10W_%;*'=G@-W3&!WC^826<.1&88%$#V/@YVKDYZXFW):,(I@X&
M%LX2@W=J/]D GYD9;XK:^?N<?5'ME-H:ZR$G8[IL?!GV?@/7^S6COS0UX6S4
M@N @+Y0,8'M1 Y/UO!Z*P[:'HMI#L=_V4*Q$/P_7?T8>(E0V,T"BS!"H&O:<
M$:120LRP8KC(?::A;N4),OS?'BK_ ^^N%OPE/3HS2:S\!<V;XXX[6.# <\%M
M@7>V0CIK][K*:Q/_5#H&P#:P=9O>=ZU.:KN<8K=+VR-E 7*54#US+D@CW?0/
M>](>5F N$U;$YR%&Z6R@B8/LP_,9+3L.HR6W_CB4E@")]3@;98EK,GB<C1+;
MM5,8<U,ML8^047H@1FDH!IM 3>]G^7 RWK?0W"5*47)HKZ3"<&D]G+=4*ZC$
MLM)+-@VF2P7AI<$,'!K,,KVU,Z)8@0/OE()ZC5X&?C].@T-" 1](#Q<:Y2<F
MNF3(O]'(0,CSZ_$(2S8C/>)'A6L7>@DSA);N*0P@P#&$(4H@^YA'H&QF@@WU
M1VF:&=KT;5H/9XI330)?HV](TY8:,P^KM-0B0*$4)[FIDA]:Z0FK<9FA]SCS
M:HV5DEE7?V$3N]!\M$,W8D]-6CT>BN2H#&[[B+U_)3%S!5[.GI6P\:*<TT=#
M"_< *TC[/V4M-2J+24I09?AO=PI8-1#!=@G]K5F;L> ;UD:\LLRZ"]R<BR2F
MM+NF]\&#"4<'>AP -I7^%H9$V$Z[0VMIA>)=\RC:-W$YJPA_IK"W NL7IC6-
M3*]/] Y:X+%0G1-SWD1\0\[VR#,)U?5<I0'\R ;T=2<,RN/:!"#-Z\1BCK%;
MQ*:C+K(91=SXE.H94+7;::Z8N;2H#K:3?#7EP)CI.0ZNY2&X3[.O&M;6.[%4
M0FVC%+^]OF0_*T<PF(/Z:,\3E:;S'_:GW'0T/YWGCO+R:5:CL<BVJ,=CX<^+
M6TSX\&VA'$5^2\4?0CY.CCGB0F0*.V# R1:T+A[_P*-+U\@T%UB(9*7&:P=2
M$.'B$/--#: 1C#A*IQ+Z4+9!7!R-?*R714WEQ:Z7/ F1!WV<)J0@>KB+=QQ]
M#\B;<*[OH;$V7#0>OC,\LWKBW>8GL02LODTWJ(RT/\8^=DU8R3DREO.KF;5^
M?;>FO[&?<UUL'Y1NQ:.9PB#1HX2 I&QP#.E@:#92+V%N>TE::?U(@ G Y"2=
M;*M-5=4YL;OM$1!0<H!5<ES5GA_\"S2YV'YAU[A49&#:N@,[KC3%,SK#T!A!
MLV=SPU2+*?GSK8U:Q!5Q'@,?C:8*A^JG6F9/*?L]D LZ ;N8W/SW#SL_X+_S
M23A0_WZVF/=Q5-S"1W?^_0?(E_U7D:DO@=9(<&J4V$4Z^8%3:D6D/L1_7Q*^
MB.9_L$\96BEU8HN[-0S'\H3_])C ^-D\_I>@]X-G'A\<'LN'PC?^['VVWP M
M30+V2$KS ^/P*\5>!+>&W@>U>E*5P$)YMEN;KJ>%^2P1+<N-,)RJ:I+3A=_0
MOLT] 9M6F%HLBBLUS.DLF?R?#/?_#2H:*U^K_JWZ/RK!O3VQC69=T[T/XRPO
M]&&@J15-5%!2; __U_P4Z$(*[TYC&U?-WS.>X_N 5$S!4('597(H_DA[G-KC
MM*[C!&1[7I75?8C*%RNS7.=^: YU $,&AYAW)""(##E@'RL@(N^)@&]JCT1[
M));L8'ESXS;KW4.<T]&45%EX*;<1*3$ND%')@G)Y+/9IE;Q5\F5($(.ST='
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MR"G\B]*O=K*!=M\\$PA#$H7_HI%X39\+(@AD7<:@R^%\Q/DM(I<YX[#@D(@
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M'&\_<*($6JFNA7,!6G<M%UNQ3P,ZJ%?8UWX<YQT6+PR)IKBJG W4TOFZK/Z
M<-TUK*OCT#@ LGQ6 X/H:J.<(*#7TV] &(R0<F]WODSDSV@<."1D(0NH$WVG
M\J$DVD@^<X%&P1TR51\=IA&"PE29.FFMY,G/$ 1=L:H9C/@(J-KCZZG2;\3C
MT1%%F.?0"L<<?E0-T:@Y/BCVMX]8%+4+&G=7'O4_6-8P CW13#2, @(7'1*2
MPG+)\":#0X>?Q^[F0-.TWFD&,VV@X2N2*2!IFR-J2X<G&$2;PJZ8AVUW+HR1
MJRXX"8^#'*$%0AR4%U]O,QAV:YU1>^R_K&R;/(-Q!%BIDW!FT0O1@QF%!S;*
MC(9-4*WIK_+ W2H_:C[P@T1B@*! 9KC,7AUBS1JZ/@I-B$1B N+)OV35MR(
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M#7,O'[:_U]TYV@T>>,F]XV[OX, @+SW[1=&GY7L;''CR)2=9BDS"S-"J9 J
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MC+[#_;S!_Y7+Z#W;SP, 6/TZ^MR7)P,!++\U?B%Q7Z ]>@%+]!*H  L<])>
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M*SV7RQ]5ZO?;E-"*#^>"C&C+;I?O]]N4T(H=VE4<SS8EM'*'MC8'M$T)-?"
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M#AX..G)S6 V,[OS,Z57:#?$HSY';FQ!$:8#C'#O[=MS#DH3=7J4^I@&4<MS
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MM@[WZ24'?%D,B/T,)\!L^Q=-,B@,N_\=ZPIX M[[4SXZ %3E%-=.0-7G=II
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MY\>U[;7P_.7H]'3\O+0U0Y7Z'HMNOX4MQJ9DV8Y<]AT!$-6WM<#J1OMR/,&
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M9>)LPN3/,<]\=AK7^4>#\5>$_&/#_P!02P,$%     @ NX9H4T^)RZ_D!
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MT@X]['4>!_(_\]"W]?@OZ/"5_NX[6;V9UT6VMJ#*,6=K^5H%I_OLS?V(4HA
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M,"YX<V102P$"% ,4    " "[AFA3I>35^4<7  !4. $ %0
M@ &2*0  8VQN;BTR,#(Q,#DS,%]C86PN>&UL4$L! A0#%     @ NX9H4^O4
MF&MT;P  [10' !4              ( !#$$  &-L;FXM,C R,3 Y,S!?9&5F
M+GAM;%!+ 0(4 Q0    ( +N&:%/%]2>>"!4! +4X#@ 5              "
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M96EN8RYH=&U02P$"% ,4    " "[AFA32*52>=\&  !S*   &P
M    @ %S!P4 9C$P<3 Y,C%E>#,Q+3)?8VQE;F5I;F,N:'1M4$L! A0#%
M  @ NX9H4T^)RZ_D!   KA(  !L              ( !BPX% &8Q,'$P.3(Q
M97@S,BTQ7V-L96YE:6YC+FAT;5!+ 0(4 Q0    ( +N&:%/'^?W^Y00  &$3
M   ;              "  :@3!0!F,3!Q,#DR,65X,S(M,E]C;&5N96EN8RYH
8=&U02P4&      H "@"R @  QA@%

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
